cluster,concept,cuis
-10,> $nmbr$  < = $nmbr$,
-10,< = $nmbr$ . $nmbr$ %,
-10,< = $nmbr$ %,
-10,< = $nmbr$,
-10,> - $nmbr$ . $nmbr$,
-10,< - $nmbr$ . $nmbr$,
-10,x $nmbr$ = $nmbr$  p = $nmbr$ - $nmbr$,
-10,x $nmbr$ = $nmbr$ - l  p = $nmbr$ - $nmbr$,
-10,x $nmbr$ = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,
-10,x $nmbr$  n ( % ),
-10,x ? = l - $nmbr$  p = $nmbr$ - $nmbr$,
-10,x ? = $nmbr$ - l  p = $nmbr$ - $nmbr$,
-10,x ? = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,
-10,v $nmbr$ ( n = $nmbr$,
-10,t ( n = $nmbr$  $nmbr$ ),C2986835
-10,q $nmbr$ w ( n = $nmbr$ ),
-10,q $nmbr$ w ( n $nmbr$ $nmbr$ ),
-10,q $nmbr$ ( n   = $nmbr$ ),
-10,q $nmbr$ - q $nmbr$,
-10,q ( q $nmbr$ \,
-10,e $nmbr$ / s $nmbr$ ( n = $nmbr$ ),C3846405
-10,e $nmbr$ ( n = $nmbr$ ),
-10,e $nmbr$ + a $nmbr$,
-10,b + a ( n = $nmbr$ ),
-10,a $nmbr$ . $nmbr$ ± $nmbr$ a . $nmbr$,
-10,a $nmbr$ c > s . $nmbr$ - s . $nmbr$ %,
-10,a $nmbr$ c > $nmbr$ . $nmbr$ %,
-10,a $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %,
-10,a $nmbr$ c  %,
-10,a $nmbr$ c < $nmbr$ . $nmbr$ %,
-10,a / c,
-10,a,
-10,$nmbr$ ( $nmbr$ j ) z $nmbr$ ( $nmbr$ . e,
-10,$nmbr$ - $nmbr$ y  n ( % ),
-10,$nmbr$ . $nmbr$ ± b . b,
-10,$nmbr$ q $nmbr$ w ( n = $nmbr$ ),
-10,$nmbr$ c . t,
-10,$nmbr$ - $nmbr$ ( s $nmbr$ - $nmbr$ ) t,C0718146
-10,> $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
-10,< $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
-10,- $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$  - c ) . $nmbr$ r,C0722969
-10,< $nmbr$ . $nmbr$ ( % ),
-10,> $nmbr$ . $nmbr$ ( % ),
-10,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
-10,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),
-10,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ),
-10,( % ) ( $nmbr$ - $nmbr$ ),
-10,( % ) ( $nmbr$ . $nmbr$ ),
-10,$nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ %,
-10,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),
-10,$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),
-10,$nmbr$  $nmbr$ - < $nmbr$ . $nmbr$,
-10,$nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
-10,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ %,
-10,$nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ ),
-10,$nmbr$ . $nmbr$ + $nmbr$ . $nmbr$,
-10,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$,
-10,> $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,
-10,$nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,
-10,> $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,
-10,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,
-10,> $nmbr$ y . n ( % ),
-10,> $nmbr$ y  n ( % ),
-10,> = $nmbr$ ( % ),
-10,> = $nmbr$ * ( % ),
-10,< $nmbr$ ( % ),
-10,^ $nmbr$ y  n ( % ),
-10,< $nmbr$ y  n ( % ),
-10,< $nmbr$ { % ),
-10,a $nmbr$ c ( % ),
-10,> $nmbr$ ( % ),
-10,$nmbr$ - < $nmbr$ . $nmbr$,
-10,$nmbr$ . $nmbr$ % ( $nmbr$ ),
-10,$nmbr$ ( $nmbr$ . $nmbr$ ),
-10,$nmbr$ - $nmbr$ . $nmbr$,
-10,> $nmbr$ - $nmbr$ - $nmbr$,
-10,$nmbr$ ( $nmbr$ e < $nmbr$ % ),
-10,$nmbr$ ( $nmbr$ . $nmbr$ % ),
-10,$nmbr$ ( $nmbr$  $nmbr$ ),
-10,$nmbr$ / $nmbr$ ( $nmbr$ ),
-10,$nmbr$ e < $nmbr$ %,
-10,> $nmbr$  < $nmbr$,
-10,^ $nmbr$,
-10,£ $nmbr$,
-10,« = $nmbr$,
-10,> $nmbr$ - $nmbr$,
-10,y $nmbr$,
-10,> = $nmbr$,
-10,< $nmbr$ . $nmbr$,
-10,b,
-10,x / n *,
-10,> $nmbr$ . $nmbr$,
-10,$nmbr$ . $nmbr$ %,
-10,> $nmbr$ . $nmbr$ %,
-10,> = $nmbr$ y,
-10,> $nmbr$ - < $nmbr$,
-10,$nmbr$ - < $nmbr$ ( % ),
-10,£ $nmbr$ %,
-10,c,
-10,≥ $nmbr$,
-10,%,
-10,> $nmbr$ y ( n = $nmbr$ ),
-10,$nmbr$ — < $nmbr$,
-10,> = $nmbr$ . $nmbr$,
-10,$ $nmbr$ %,
-10,e,
-10,$nmbr$ y,
-10,< $nmbr$ y,
-10,m / f,C1306057
-10,$nmbr$ - $nmbr$,
-10,\ $nmbr$,
-10,$nmbr$ e $nmbr$,
-10,> $nmbr$ < $nmbr$,
-10,» $nmbr$ y,
-10,$nmbr$ . $nmbr$,
-10,< $nmbr$ - $nmbr$,
-10,$nmbr$ - < $nmbr$ y,
-10,< $nmbr$ %,
-10,« $nmbr$ - $nmbr$,
-10,= $nmbr$,
-10,v ( n = $nmbr$ ),
-10,$nmbr$ ( $nmbr$ % ),
-10,< $nmbr$ y ( n = $nmbr$ ),
-10,$nmbr$ / $nmbr$,
-10,$nmbr$ ( < $nmbr$ % ),
-10,$nmbr$ §,
-10,$nmbr$ - < $nmbr$,
-10,> $nmbr$,
-10,w,
-10,. $nmbr$,
-10,a $nmbr$,
-10,$ $nmbr$,
-10,$nmbr$ - < $nmbr$ %,
-10,a $nmbr$ c,
-10,≤ $nmbr$ . $nmbr$ %,
-10,$nmbr$ < - $nmbr$,
-10,> $nmbr$ y,
-10,≥ $nmbr$ %,
-10,^ $nmbr$ - $nmbr$,
-10,$nmbr$ % - $nmbr$ %,
-10,< $nmbr$ . $nmbr$ %,
-10,\ $nmbr$ %,
-10,≤ $nmbr$ %,
-10,$nmbr$,
-10,> $nmbr$ $nmbr$,
-10,x / n,
-10,$nmbr$ +,
-10,< $nmbr$ » < $nmbr$ y,
-10,$nmbr$ % $nmbr$,
-10,< $nmbr$,
-10,> $nmbr$ %,
-10,$nmbr$ $nmbr$,
-10,> $nmbr$ % $nmbr$,
-10,$nmbr$ ( > $nmbr$ % ),
-10,≤ $nmbr$,
-10,% $nmbr$ - $nmbr$,
-10,之 $nmbr$,
-10,$nmbr$ . $nmbr$ - < $nmbr$,
-10,$nmbr$ % c . i .,C1547546
-10,= $nmbr$ ’ ),
-10,£ $nmbr$ . $nmbr$ % * *,
-10,a a ( $nmbr$ ( % ),
-10,$nmbr$ e < $nmbr$ %  n ( % ),
-10,$nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
-10,$nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ ),
-10,e $nmbr$ + a $nmbr$ -,
-10,$nmbr$  $nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
-10,( % ) $nmbr$ - $nmbr$,
1834,r $nmbr$ + ezio ( n = $nmbr$ ),C0687673
1834,r $nmbr$ ( n = $nmbr$ ),C0687673
1833,d / mi / idr / st,C0036056;C0073187;C0332173;C3272372;C3810814;C4484261
1833,d / mi / idfvst,C0073187;C0332173;C3810814;C4484261
1833,d $nmbr$ % ( n / n ),C0073187;C0332173;C4484261
1833,d,C0073187;C0332173;C4484261
1833,$nmbr$ or $nmbr$ d / wk,C0073187;C0332173;C0332174;C0439230;C4484261
1832,ze + statin,C0360714
1832,atorvastatin $nmbr$ mg ( zi = $nmbr$ ),C0024671;C0026410;C0043476;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
1832,[ zi = $nmbr$ ] $nmbr$ ( $nmbr$ . $nmbr$ ),C0043476
1832,$nmbr$ ( $nmbr$ . $nmbr$ ) / $nmbr$ z ( $nmbr$ ze ),
1831,feno + eze,
1831,feno $nmbr$ mg / eze $nmbr$ mg ( n = $nmbr$ ),C1319635
1831,eze / simva ( n = $nmbr$ ),
1831,eze / simva $nmbr$ / $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1831,eze / simva $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1831,eze / simva  $nmbr$ / $nmbr$ mg dr = $nmbr$ ),C0013014;C0024671;C0026410;C0031831;C0439269;C1707664;C1960952;C2346927;C2348314;C3540849;C4321396;C4521761
1831,eze / simva  $nmbr$ / $nmbr$ mg dn = $nmbr$ c $nmbr$ ),C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761
1831,eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ),C1319635;C1333964;C1707618
1831,eze / simva,
1830,no . of patients ind / gly sfc,C0017890;C0030705;C0523677;C4049864;C4521536
1830,ind / glyb n = $nmbr$,C1415124;C4049864
1830,ind / gly n = $nmbr$,C0017890;C0523677;C4049864
1830,ind / gly ( n = $nmbr$ ),C0017890;C0523677;C4049864
1830,ind / gly $nmbr$ / $nmbr$ pg o . d . n = $nmbr$,C0017890;C0523677;C2827928;C4049864
1830,ind / gly,C0017890;C0523677;C4049864
1830,ind + gly ( n = $nmbr$ ),C0017890;C0523677;C4049864
1830,gly $nmbr$ μ g bid,C0017890;C0439267;C0523677
1830,gly,C0017890;C0523677
1829,other glp - $nmbr$ receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1829,hazard ratio glp - $nmbr$ analogue vs placebo [ $nmbr$ % cl ],C0018301;C0032042;C0243071;C0596019;C1422069;C1425391;C1539338;C1696465;C1706408;C2350813;C2985465
1829,glp - $nmbr$ receptor agonists,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1829,glp - $nmbr$ receptor agonist ( other than study drug ),C0013175;C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1829,glp - $nmbr$ receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1829,glp - $nmbr$ analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
1828,gmr,C1522544;C1704695
1828,gfr as assessed by mdrd,C0017654;C1424601;C1516048;C3839656
1828,gfr > $nmbr$,C0017654;C1424601
1828,gfr < $nmbr$,C0017654;C1424601
1828,gfr $nmbr$ - $nmbr$,C0017654;C1424601
1828,gfr $nmbr$ $nmbr$,C0017654;C1424601
1828,estimated gfr — no . ( % ) ^ |,C0017654;C0750572;C1424601
1828,estimated gfr — no . ( % ) $nmbr$,C0017654;C0750572;C1424601
1828,estimated gfr ^,C0017654;C0750572;C1424601
1828,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1828,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1828,estimated gfr  mean ( sd )  mlvmin per $nmbr$ . $nmbr$ m ^ *,C0017654;C0369637;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
1828,esrd or $nmbr$ % dedine in gfr,C0017654;C0022661;C0035078;C1424601;C2316810
1828,esrd or $nmbr$ % decline in gfr,C0017654;C0022661;C0035078;C1424601;C2316810
1827,l . l ± $nmbr$ . $nmbr$,C3539687
1827,l ( < l ),C3539687
1827,< $nmbr$ . $nmbr$ l - g / l,C0439267;C3539687
1827,$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ l ),C3539687
1827,$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ ),C3539687
1827,$nmbr$ l ( l $nmbr$ ),C3539687
1827,$nmbr$ . l ( $nmbr$ l . $nmbr$ ),C3539687
1827,$nmbr$ . l ( $nmbr$ . l ),C3539687
1827,$nmbr$ . $nmbr$ ± l . l,C3539687
1827,$nmbr$ . $nmbr$ ( $nmbr$ l . l ),C3539687
1827,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - l . l ),C3539687
1826,l vs . c,C0439394;C1706495;C3642217
1826,l compared wit,C0043197;C0439394;C1706495;C1707455;C3642217
1826,l / c,C0439394;C1706495;C3642217
1826,l . i ( $nmbr$ . $nmbr$ ),C0021966;C0221138;C0439394;C1706495;C3642217
1826,l ( % ),C0439394;C1706495;C3642217
1826,l $nmbr$ - $nmbr$ vs placebo,C0032042;C0439394;C1696465;C1706408;C1706495;C3642217
1826,l $nmbr$ - $nmbr$ vs l $nmbr$ - $nmbr$ - $nmbr$,C0439394;C1706495;C3642217
1826,l $nmbr$,C0439394;C1706495;C3642217
1826,l,C0439394;C1706495;C3642217
1826,( l ) t,C0439394;C1706495;C3642217
1825,positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,C0016327;C0741132;C1320283
1825,natalizumab ( n = $nmbr$ ) f,C0016327;C1172734
1825,la grade b  n ( % ) f,C0016327;C1881342
1825,f emale,C0016327
1825,f * >,C0016327
1825,f,C0016327
1825,ancestry ( % ) f,C0016327
1825,accp bleeding risk at inclusion  no . ( % ) f,C0007637;C0016327;C1512693;C3251812
1825,? f ? n,C0016327
1825,$nmbr$ f $nmbr$ q % ),C0016327
1825,$nmbr$ f $nmbr$ l % $nmbr$,C0016327
1825,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % f,C0016327
1824,o - oi $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0029118;C0029434;C0483204
1824,o $nmbr$,C0483204
1824,o,C0483204
1824,> o - $nmbr$ - i - i,C0021966;C0221138;C0483204
1824,- o $nmbr$ o ( - $nmbr$ - loto - $nmbr$ - $nmbr$ ),C0483204
1824,$nmbr$ o / $nmbr$ o $nmbr$ ( $nmbr$ - $nmbr$ % ),C0483204
1824,$nmbr$ . $nmbr$ ( $nmbr$ . o - $nmbr$ . o ),C0483204
1824,$nmbr$ - $nmbr$ { o - $nmbr$ - $nmbr$ - o $nmbr$ ),C0483204
1824,$nmbr$ - $nmbr$ ( o - $nmbr$ s - o - $nmbr$ ),C0483204
1824,$nmbr$ - $nmbr$ ( o - $nmbr$ s - i - $nmbr$ ),C0021966;C0221138;C0483204
1824,$nmbr$ - $nmbr$ ( o - $nmbr$ o - o - $nmbr$ ),C0483204
1824,$nmbr$ - $nmbr$ ( o - $nmbr$ i - o - $nmbr$ ),C0021966;C0221138;C0483204
1824,$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ o ),C0483204
1824,$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ ),C0483204
1824,$nmbr$ - $nmbr$ ( o - $nmbr$ - i - o $nmbr$ ),C0021966;C0221138;C0483204
1824,$nmbr$ - $nmbr$ ( o - $nmbr$ - i - $nmbr$ ),C0021966;C0221138;C0483204
1824,$nmbr$ - $nmbr$ ( o $nmbr$ o - i - i $nmbr$ ),C0021966;C0221138;C0483204
1824,$nmbr$ - $nmbr$ ( o $nmbr$ - o - $nmbr$ ),C0483204
1824,$nmbr$ ( o - o $nmbr$ - o - $nmbr$ ),C0483204
1824,$nmbr$ ( o - $nmbr$ - o - $nmbr$ ),C0483204
1824,$nmbr$ $nmbr$ ( o - $nmbr$ - i - o $nmbr$ ),C0021966;C0221138;C0483204
1823,p valuey,C0369773;C2603361
1823,p valuer,C0369773;C0401806;C2603361
1823,p valuej ',C0369773;C2603361
1823,p valued,C0369773;C1522609;C2603361
1823,p valuec,C0369773;C2603361
1823,p valueb,C0369773;C2603361
1823,p valuea,C0369773;C2603361
1823,p vaiue,C0369773;C2603361
1823,p inleraclion,C0369773;C2603361
1823,p for i,C0021966;C0221138;C0369773;C2603361
1823,p blockersubgroup,C0369773;C2603361
1823,p blocker before admission,C0184666;C0369773;C0809949;C2603361
1823,p blocker,C0369773;C2603361
1823,p . o ),C0369773;C2603361
1823,p - valuec,C0369773;C2603361
1823,p - valueb,C0369773;C2603361
1823,p - valuea,C0369773;C2603361
1823,p - val . ( $nmbr$ ),C0042285;C0369773;C0523975;C2603361
1823,p - interactio n,C0369773;C2603361
1823,p - inte faction,C0369773;C2603361
1823,p - heterogeneity,C0019409;C0242960;C0369773;C2603361
1823,p - for interaetion,C0369773;C2603361
1823,p - blocking agents  selective,C0036576;C0233660;C0332206;C0369773;C0450442;C1254351;C1521826;C1707391;C2603361
1823,p - blocker intake at randomisation ( n = $nmbr$ o ),C0034656;C0369773;C1512806;C2603361
1823,p - blocker intake at randomisation ( n = $nmbr$ ),C0034656;C0369773;C1512806;C2603361
1823,p - blocker,C0369773;C2603361
1823,p +,C0369773;C2603361
1823,p *,C0369773;C2603361
1823,p $nmbr$ z $nmbr$ ( n = $nmbr$ ),C0369773;C2603361
1823,p $nmbr$ y $nmbr$ antagonists,C0243076;C0369773;C2603361
1823,p $nmbr$ y $nmbr$ antagonist,C0231491;C0369773;C2603361
1823,p  regional difference *,C0369773;C0682132;C2603361
1823,p  regional difference,C0369773;C0682132;C2603361
1823,p,C0369773;C2603361
1823,* p for heterogeneity of treatment effect between tertiles > $nmbr$ . $nmbr$ .,C0019409;C0242960;C0369773;C1518681;C2603361
1822,ppci ( n = $nmbr$ ),
1822,ppci,
1822,pnorpci,
1822,fpci vs . ppci in men,C0025266
1821,fpg,
1821,baseline fpg  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
1821,baseline fpg,C0168634;C1442488
1820,ratio fp / sal : sal ( $nmbr$ % ci ),C0008107;C0016704;C0036140;C0037494;C0206136;C0456603;C1419068;C1419906;C1547037;C3259781;C3541238;C3541412
1820,fp versus no ics,C0016704;C0815320;C1419068;C1419906;C3541238;C3541412;C4551720
1820,fp ( n   = $nmbr$  $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
1820,fp ( n [ $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
1820,fp ( n = $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
1820,fp $nmbr$ mg,C0016704;C0024671;C0026410;C0439269;C1419068;C1419906;C1960952;C2346927;C3541238;C3541412;C4321396;C4521761
1820,fp,C0016704;C1419068;C1419906;C3541238;C3541412
1819,prostate cancer,C0376358;C0600139;C2984325;C3541264
1819,prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
1819,previous cancer — no . ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
1819,previous cancer  n ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
1819,previous cancer,C0006826;C0205156;C0998265;C1306459;C1552607
1819,pancreatic cancer,C0235974;C0346647;C2984259
1819,no prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
1819,no adk / e cancer,C0006826;C0998265;C1306459;C1412243
1819,no active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1819,medical history : cancer,C0006826;C0262926;C0998265;C1306459;C1704706
1819,cancer — no . ( % ),C0006826;C0998265;C1306459
1819,cancer §,C0006826;C0998265;C1306459
1819,cancer n ( % ),C0006826;C0998265;C1306459
1819,cancer medications,C0006826;C0013227;C0802604;C0998265;C1306459;C2598133;C4284232
1819,cancer * *,C0006826;C0998265;C1306459
1819,cancer *,C0006826;C0998265;C1306459
1819,cancer ( n = $nmbr$ ),C0006826;C0998265;C1306459
1819,cancer  fatal and nonfatal,C0006826;C0998265;C1302234;C1306459;C1705232
1819,cancer,C0006826;C0998265;C1306459
1819,all cancer,C0006826;C0998265;C1306459
1819,active or previous cancer,C0006826;C0205156;C0205177;C0998265;C1306459;C1552607;C3853793;C3888249
1819,active cancer — no . ( % ),C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1819,active cancer at randomization  n ( % ),C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
1819,active cancer at randomization,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
1819,active cancer at randomisation,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
1819,active cancer at baseline,C0006826;C0168634;C0205177;C0998265;C1306459;C1442488;C3853793;C3888249
1819,active cancer at any timeb,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1819,active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1819,ac tve cancer,C0001246;C0003354;C0006826;C0998265;C1306459;C1412573;C2000891;C3539770
1818,non - colorectal cancer,C0009402;C0346629;C1518422;C1527249;C2984278;C3542412
1818,golden - $nmbr$ and - $nmbr$,
1818,golden - $nmbr$,
1818,concern,C2699424
1818,colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
-10,oxcarbazepine,C0069751
1816,caffeine users  n ( % ),C3532939
1816,caffeine user  n ( % ),C3532939
1816,caffeine user,C3532939
1816,caffeine consumption *,C0948365
1816,caffeine consumption ( yes ) ( n ),C0948365;C1549445;C1705108;C1710701
1816,caffeine,C0006644;C0236734
1815,not - japan n = $nmbr$  $nmbr$,C0022341;C1518422
1815,not - japan,C0022341;C1518422
1815,japan n = $nmbr$,C0022341
1815,japan and south korea,C0022341;C0022773
1815,japan,C0022341
1815,calima japan ( n = $nmbr$ ),C0022341
1815,asia ( excluding japan ),C0003980;C0022341;C0332196;C2828389
1814,no . japanese,C0376247;C1556094
1814,japanese subpopulation,C0376247;C1257890;C1556094
1814,japanese subgroup ( n = $nmbr$ ),C0376247;C1079230;C1515021;C1556094
1814,japanese,C0376247;C1556094
1813,overallb,
1813,overall quality of life,C3641830
1813,korea  republic of,C0022773
1813,( ofl ),
1812,otherj ^ :,
1812,other forms of atherosclerosis ’,C0003850;C0004153;C0348078;C0376315
1812,other forms of atherosclerosis ^,C0003850;C0004153;C0348078;C0376315
1812,other forms of,C0348078;C0376315
1812,history of other medical conditions  n ( % ),C0012634;C0262926;C0348080;C1705253;C3864998
1811,† includes patients originally randomized to placebo who were switched to secukinumab per the study designs .   ‡ aes that occurred in at least $nmbr$ . $nmbr$ % of the patients in the any secukinumab group during the $nmbr$ ‐ week placebo ‐ controlled period and events with an eair of at least $nmbr$ . $nmbr$ cases per $nmbr$ patient ‐ years in the any secukinumab group during the entire treatment period . events listed according to preferred term in the medical dictionary for regulatory activities ( meddra version $nmbr$ . $nmbr$ )  sorted in descending order of eair in the any secukinumab group for the entire treatment period . the entire treatment period for safety data was from baseline to week $nmbr$ visit of the last patient enrolled in these studies . ae  adverse event  as  ankylosing spondylitis  eair  exposure adjusted incidence rates    n  number of randomized patients  sae  serious adverse event  urti  upper respiratory tract infection .,C0012113;C0021149;C0030705;C0032042;C0034656;C0035171;C0036043;C0038013;C0039798;C0041912;C0087111;C0168634;C0205386;C0220856;C0220905;C0274281;C0332157;C0332174;C0332257;C0333052;C0374505;C0439230;C0439234;C0439531;C0439751;C0441471;C0441655;C0441833;C0444667;C0456081;C0680240;C0687744;C0745732;C0868928;C0871208;C0877248;C0947630;C1140263;C1257890;C1412268;C1442488;C1511726;C1512346;C1519255;C1519504;C1521828;C1522326;C1533148;C1533734;C1547177;C1547401;C1552866;C1622657;C1696465;C1704735;C1705169;C1705187;C1705428;C1705429;C1706408;C1707719;C1709305;C1709637;C1948053;C2347664;C2360800;C2607870;C2699274;C2700399;C2983265;C2986888;C3179547;C3245479;C3272378;C3538994;C3541888;C3714741;C3815594;C3887670;C3887704;C4553214;C4684790
1811,“ off ”,
1811,previous number of ciu / csu medications,C0205156;C0578870;C1552607;C1718138
1811,off omt ( n = $nmbr$ ),
1811,off omt,
1811,number of “ off ” periods,C0237753;C0439531;C0449788;C1948053
1811,number of treated patients,C1522326;C2360800
1811,number of patients with fractures,C0016658;C2360800
1811,number of patients with events,C0441471;C2360800;C3541888
1811,number of patients with dose available,C0178602;C0470187;C0869039;C1114758;C2360800
1811,number of patients with,C2360800
1811,number of patients ( % ) or mean ± sd,C0444504;C2347634;C2348143;C2360800;C2699239
1811,number of patients,C2360800
1811,number of medications  n ( % ),C1718138
1811,number of individuals,C1549735
1811,number ( % ) of patients,C2360800
1810,numbers of events ( % ) :,C4330837
1810,number of treated lesions ( per patient ),C0030705;C0449791;C1522326
1810,number of treated lesions,C0449791;C1522326
1810,number of lesions  n ( % ) a,C0449791
1810,number of events ( annualised rate [ % ] ),C0871208;C1521828;C4330837
1810,number of events  event per $nmbr$ person - years,C0027361;C0439234;C2347489;C4330837
1810,number of events,C4330837
1809,extent of disease — no . / total no . ( % ) § ^ |,C0439175;C0439810;C0449279;C4553144
1809,extent of disease  n ( % ),C0449279;C4553144
1809,extent of disease  %,C0449279;C4553144
1809,extent of disease,C0449279;C4553144
1809,dates of recruitment,C0011008;C2348077;C2949735
1809,angiographic extent of disease,C0002978;C0449279;C4553144
1808,exlertl ot disease,C0012634;C1318464;C1418208;C1705587
1808,$nmbr$ . $nmbr$ ± l . ot,C0439394;C1318464;C1418208;C1705587;C1706495;C3642217
1807,effect of covariates on slopes,C0807955;C1280500;C1518681;C2348382
1807,covariates,
1807,covariate,
1807,ap - value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group .,C0002680;C0023779;C0039798;C0087111;C0168634;C0441833;C0687744;C0814908;C1257890;C1280500;C1442488;C1518681;C1519504;C1522326;C1522609;C1533734;C1705169;C1705428;C1705429;C2348382;C3538994;C3887704;C3887950
1806,median blood eosinophil count ( cells per pl ) t,C0200638;C0549183;C0876920;C2347635;C2348144;C2939193;C3897966;C4049765
1806,local eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205276;C0750879;C3897966;C4049765
1806,eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0750879;C3897966;C4049765
1806,eosinophil count ( cells / pl )  median ( range ) c,C0007584;C0007634;C0200638;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3897966;C4049765
1806,eosinophil counf cells pl ',C0682547;C3897966;C4049765
1806,eos count ( cells / pl ),C0007584;C0007634;C0750480;C1623465;C1705566;C1861303;C3897966;C4049765
1806,biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl ) t,C0005516;C0005773;C0007584;C0007634;C0014467;C0200638;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C3897966;C4049765;C4321237;C4522209
1806,baseline eosinophil < $nmbr$ cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
1806,baseline eosinophil $nmbr$ cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
1806,> $nmbr$ cells / pl,C0007584;C0007634;C3897966;C4049765
1806,< $nmbr$ cells / pl,C0007584;C0007634;C3897966;C4049765
1806,/ pl $nmbr$ $nmbr$,C3897966;C4049765
1806,( cells per pl ) t,C0007584;C0007634;C3897966;C4049765
1805,neutrophils  $nmbr$ / nl,C0027778;C0027950;C0560008;C3892223
1805,monocytes  $nmbr$ / nl,C0026473;C0027778;C0560008;C3892223
1805,leukocytes  $nmbr$ / nl,C0023516;C0027778;C0560008;C3892223
1804,proximal gl tract  n ( % ),C0018229;C0205107;C1185740;C1423073;C1427674;C4489236
1804,involved gl areas,C0018229;C1423073;C1427674;C1879646
1804,hemoglobin ( gl ' ),C0018229;C0019046;C1423073;C1427674
1804,bsl hb  gl - $nmbr$,C0018229;C0019046;C1423073;C1427674;C1549954
1803,positive hla - b $nmbr$ status  n ( % ),C0439178;C0449438;C1426226;C1446409;C1514241;C2825490;C3812269
1803,positive for hla - b $nmbr$  n ( % ),C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
1803,hla ‐ b $nmbr$ positive    n   ( % ),C0439178;C1426226;C1446409;C1514241;C2825490;C3812269
1803,hla - b $nmbr$  n ( % ) ⁎ ⁎,C1426226
1803,hla - b $nmbr$,C0019737;C0550853;C1415561
1802,mean platelet volume  fl,C0200665;C0344388;C1300812;C1708024
1802,history of atrial fibrillation or fl utter,C0729790;C1300812;C1708024
1802,fl ( $nmbr$ b ),C1300812;C1708024
1802,fl ( $nmbr$ . $nmbr$ ),C1300812;C1708024
1801,mean ( s . d . ) hbalc  mmol / mol,C0444504;C2347634;C2348143;C3829066
1801,hbalc £ $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
1801,hbalc £ $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
1801,hbalc £ $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
1801,hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
1801,hbalc > $nmbr$ - < $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
1801,hbalc < medan,
1801,hbalc < $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
1801,hbalc < $nmbr$ % ( < $nmbr$ mmol / mol )  n ( % ),C3829066
1801,hbalc < $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
1801,hbalc < $nmbr$ %,
1801,hbalc ( mmol / mol ),C3829066
1801,hbalc  mmol / mol,C3829066
1801,hbalc  median ( ql  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
1801,hbalc,
1800,psaqol,
1800,pdqol scale,C0175659;C0349674;C1947916
1799,hrqol,C4279947;C4300252
1799,health - related quality of life,C4279947
1798,right ventriculardysfunction atinclusion,C0205090;C0444532
1798,right,C0205090;C0444532
1798,r ight coronary,C0018787;C0205090;C0684010;C2603358
1798,r ight coronar y artery,C0003842;C0205090;C0226004;C0684010;C2603358
1798,r $nmbr$,C0205090;C0684010;C2603358
1798,r,C0205090;C0684010;C2603358
1798,canvas - r,C0205090;C0684010;C2603358;C3281223
1797,hfpef ( ef n $nmbr$ )  ( % ),
1797,ef b $nmbr$ %,
1797,ef > $nmbr$ % hfpef ( n = $nmbr$  $nmbr$ % ),
1797,ef > $nmbr$ % ( n = $nmbr$  $nmbr$ ),
1797,ef > $nmbr$ %,
1797,ef < $nmbr$ % n = $nmbr$,
1797,ef < $nmbr$ % ( n = $nmbr$  $nmbr$ ),
1797,ef $nmbr$ - $nmbr$ . $nmbr$ % ( n $nmbr$ $nmbr$ ),
1797,ef $nmbr$ - $nmbr$ % hfmref ( n = $nmbr$  $nmbr$ % ),
1797,ef $nmbr$ - $nmbr$ %,
1797,ef  %,
1797,dysfunction  ef = erectile function  iief = i,C0021966;C0030847;C0031843;C0031847;C0221138;C0277785;C0542341;C0700205;C1705273;C3641331;C3887504;C3887505
1796,reduced ef,C0392756
1796,hf without known reduced ef ( n = $nmbr$ ),C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1796,hf without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1796,hf ' without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1796,ef > $nmbr$ % ( n $nmbr$ $nmbr$ ),
1796,ef < $nmbr$ % ( n $nmbr$ $nmbr$ ),
1795,ref §,C1425988
1795,ref .,C1425988
1795,previous cd related surgery ( ref ) a,C0007928;C0034283;C0038894;C0038895;C0205156;C0439849;C0445223;C0543467;C1274039;C1425988;C1552607;C4552032
1795,nothfref,
1795,no history of extra - intestinal manifestations of ibd ( ref ),C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1425988;C1705255;C1883702;C2004062
1795,history of bowel resection ( ref ),C0019664;C0019665;C0262512;C0262926;C0741614;C1425988;C1705255;C2004062
1795,hfref ( n = $nmbr$ ),
1795,hfref,
1795,ef < $nmbr$ % hfref ( n = $nmbr$  $nmbr$ % ),
1795,( ref ),C1425988
1795,( e ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1795,( d ) aza treatment ( ref ),C0004482;C0039798;C0073187;C0087111;C0332173;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704;C4484261
1795,( c ) ' ' kza treatment ( ref ),C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1795,( b ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1795,( a ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1795,$nmbr$ . $nmbr$ ( ref . ),C1425988
1795,$nmbr$ ( ref ),C1425988
1794,prior electrical cardioversion for af ( n = $nmbr$ $nmbr$ ),C0013778;C0332152;C0344434;C0542380;C2826257;C4049859
1794,prior af ablation  n ( % ),C0332152;C0344434;C0547070;C1261381;C2826257;C4049859
1794,previous af,C0205156;C0344434;C1552607;C4049859
1794,maf,
1794,black / af rican american,C0085756;C0344434;C4049859
1794,af pattern,C0344434;C0449774;C4049859
1794,af alone,C0205171;C0344434;C0439044;C0679994;C4049859
1794,af,C0344434;C4049859
-10,qids - sr $nmbr$,C4331197
1792,rivaroxaban $nmbr$ . $nmbr$ mg bid + aspirin $nmbr$ mg od,C0004057;C0229089;C0439164;C1319635;C1512019;C1739768;C3273373;C3665488
1792,idegasp bid,
1792,bid,
1792,$nmbr$ μ g bid ( n = $nmbr$ ),C0439267
1791,number of arterial beds involved,C0003842;C0004916;C0221464;C0237753;C0449788;C1314939
1791,> $nmbr$ beds,C0004916
1791,< $nmbr$ beds,C0004916
1790,prior cvd,C0007222;C0332152;C2826257
1790,prior cardiovascular disease,C0007222;C0332152;C2826257
1790,patients with no prior cvd ( primary,C0007222;C0030705;C0205225;C0332152;C0439612;C0439631;C2826257
1790,patients with established cv disease aged > $nmbr$ years .,C0007222;C0030705;C0443211;C1272684;C1510829
1790,no prior cvd,C0007222;C0332152;C2826257
1790,no cvd,C0007222
1790,no cardiovascular disorder $nmbr$ ',C0007222
1790,no cardiovascular disease ( n = $nmbr$ ),C0007222
1790,n ( % ) patients with risk faetors for cv disease aged > $nmbr$,C0001779;C0001792;C0007222;C0030705;C0035647;C0369718;C0441922;C1999167;C4552904
1790,lisinopril cvd total,C0007222;C0065374;C0439175;C0439810
1790,established cardiovascular disease,C0007222;C0443211;C1272684
1790,established atherosclerotic cv disease §,C0007222;C0333482;C0443211;C1272684
1790,cvd without ml ^ troke,C0007222;C0439526;C1705224;C3887665
1790,cvd without ml / stroke,C0007222;C0038454;C0439526;C1705224;C3887665;C4554100
1790,cvd without miatroke,C0007222
1790,cvd  total,C0007222;C0439175;C0439810
1790,cvd,C0007222
1790,cv disease,C0007222
1790,cardiovascular disorder  n ( % ),C0007222
1790,cardiovascular disorder,C0007222
1790,cardiovascular disease n ( % ),C0007222
1790,cardiovascular disease history ‡,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1790,cardiovascular disease history  n ( % ) *,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1790,cardiovascular disease history,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1790,cardiovascular disease *,C0007222
1790,cardiovascular disease ( n = $nmbr$ ),C0007222
1790,cardiovascular disease,C0007222
1790,baseline cardiovascular disease,C0007222;C0168634;C1442488
1790,any cardiovascular disease history  n ( % ),C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1790,any cardiovascular disease,C0007222
1790,> $nmbr$ cv risk factors ^ or established atherosclerotic cv disease,C0007222;C0035648;C0333482;C0443211;C1272684;C1553898;C3538987;C4048877;C4318503
1790,$nmbr$ - $nmbr$ with cv disease ( n = $nmbr$ ),C0007222
1790,$nmbr$ - $nmbr$  cv disease ( n = $nmbr$  $nmbr$ ),C0007222
1789,roflumilast ( n = $nmbr$  $nmbr$ ),C0965618
1789,apremilast,C1678805
1788,reteplase,C0256103
1788,gliclazide ( modified release ) 一 no . ( % ) ^,C0017631;C1709058;C4544813
1787,history of elms  n ( % ),C0019664;C0019665;C0262512;C0262926;C0330531;C1705255;C2004062;C2980688
1787,elms  n ( % ),C0330531;C2980688
1787,$nmbr$ — $nmbr$ nlmw,
1786,> $nmbr$ to < $nmbr$ cells / mm ’,C0007584;C0007634;C4330985;C4554674
1786,> $nmbr$ to < $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
1786,> $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
1786,< $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
1786,$nmbr$ to < $nmbr$ cells,C0007584;C0007634
1785,s $nmbr$ gallop  n ( % ),C2986823
1785,s $nmbr$ ( n = $nmbr$ ),C2986823
1785,$nmbr$ < $nmbr$ s ) n $nmbr$ ( $nmbr$ . $nmbr$ ),C2986823
1784,« s $nmbr$ - $nmbr$,C0565930;C2603362
1784,| : s blocker,C0565930;C2603362
1784,s £ $nmbr$,C0565930;C2603362
1784,s fs $nmbr$,C0565930;C1517317;C2603362;C3814419
1784,s . e .,C0565930;C2603362
1784,s ( s $nmbr$,C0565930;C2603362
1784,s $nmbr$ yrs,C0565930;C2603362
1784,s $nmbr$ - $nmbr$ - s $nmbr$ . $nmbr$ %,C0565930;C2603362
1784,s $nmbr$ ( $nmbr$ . s ),C0565930;C2603362
1784,s $nmbr$ %,C0565930;C2603362
1784,s $nmbr$,C0565930;C2603362
1784,s,C0565930;C2603362
1784,= s $nmbr$,C0565930;C2603362
1784,$nmbr$ s f $nmbr$ ),C0016327;C0565930;C2603362
1784,$nmbr$ s . $nmbr$ ± s . $nmbr$,C0565930;C2603362
1784,$nmbr$ ( $nmbr$ s . s ),C0565930;C2603362
1783,second year !,C0205436;C0439234;C0439508;C0457385;C0565930;C1561503;C1705190
1783,second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
1783,second loading dose,C0205436;C0457385;C0565930;C1561503;C1705190;C3714444
1783,second - generation stent,C0038257;C0079411;C0205436;C0457385;C0565930;C1561503;C1705190;C3146294
1783,second ( n = $nmbr$ ),C0205436;C0457385;C0565930;C1561503;C1705190
1783,no second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
1782,short form $nmbr$ ( sf - $nmbr$ ),C0037712;C2964478
1782,sf ‐ $nmbr$ pcs  ls mean change ± se,C0023668;C0036919;C0037712;C0392747;C0443172;C0444504;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952
1782,sf ‐ $nmbr$ health survey,C0018762;C0037712
1782,sf - $nmbr$ v $nmbr$ pcs  mean [ sd ],C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239
1782,sf - $nmbr$ v $nmbr$ mcs  mean [ sd ],C0037712;C0444504;C2347634;C2348143;C2699239
1782,sf - $nmbr$ summary scores,C0037712;C0449820;C1552616;C1706244;C4050231
1782,sf - $nmbr$ score,C0037712;C0449820;C4050231
1782,sf - $nmbr$ pcs score,C0037712;C0449820;C1864389;C1882368;C4050231
1782,sf - $nmbr$ pcs  mean ± sd,C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239
1782,sf - $nmbr$ pcs  ls mean change from baseline   ±   se,C0023668;C0036919;C0037712;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952
1782,sf - $nmbr$ pcs,C0037712;C1864389;C1882368
1782,sf - $nmbr$ mcs score,C0037712;C0449820;C4050231
1782,sf - $nmbr$ mcs  mean ± sd,C0037712;C0444504;C2347634;C2348143;C2699239
1782,sf - $nmbr$ mcs,C0037712
1782,sf - $nmbr$ ( health transition score ),C0037712;C0376627;C0449820;C4050231
1782,sf $nmbr$ - pcs,C0037712;C1864389;C1882368
1781,density lipoprotein  csf =,C0023820;C0178587;C3540512;C3889436
1781,csii,
1781,csf cholesterol,C0008377;C3540512;C3889436
1781,csf,C3540512;C3889436
-10,uvb,C0454530;C0564461
1779,tvr,
1779,ischemic tvr,C0475224
1779,avr,C0449217
1778,jvp > $nmbr$ cm,
1778,jvp ( 〉 $nmbr$ cm ),
1778,jvp $ $nmbr$ cm h $nmbr$ o,C0455483
1778,jvp  ( % ),
1778,jvd $ $nmbr$ cm h $nmbr$ o  %,C0425687;C0455483
1777,qualifying cv event  n ( % ),C0441471;C1514624;C3538987;C4019010;C4048877;C4318503
1777,prior cv history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
1777,prior cv history,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
1777,prior cv event at randomization !,C0034656;C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
1777,prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
1777,previous cv events,C0205156;C0441471;C1552607;C3538987;C3541888;C4048877;C4318503
1777,previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
1777,non cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
1777,non - cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
1777,no prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
1777,no previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
1777,no cv event ( n = $nmbr$  $nmbr$ ),C0441471;C3538987;C4019010;C4048877;C4318503
1777,no ascvd + additional cv risk factors  n ( % ),C0035648;C1524062;C1553898;C3538987;C3665365;C4048877;C4318503
1777,incidence rate of cv events  n ( % ),C0441471;C1708485;C3538987;C3541888;C4048877;C4318503
1777,hospitalization for heart failure or cv death,C0011065;C1306577;C3538987;C3898876;C4048877;C4082313;C4318503;C4552775
1777,hospitalization for heart failure or cv,C3538987;C3898876;C4048877;C4318503
1777,heart failure hospitalisation or cv death,C0011065;C1306577;C3538987;C3898876;C4048877;C4082313;C4318503;C4552775
1777,first cv hospitalization,C0019993;C0205435;C1279901;C3538987;C4048877;C4318503
1777,expanded cv endpoint,C0205229;C2349179;C2826544;C3538987;C4048877;C4318503
1777,estimated cv risk at baseline,C0168634;C1442488;C1519101;C3538987;C4048877;C4318503
1777,cv risk factors and history,C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503
1777,cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
1777,cv risk factor - no . ( % ),C0035648;C3538987;C4048877;C4318503
1777,cv risk factor,C0035648;C3538987;C4048877;C4318503
1777,cv mortality,C0026565;C0026566;C3538987;C4048877;C4318503
1777,cv historya,C3538987;C4048877;C4318503
1777,cv endpoints n ( % ),C2349179;C3538987;C4048877;C4318503
1777,cv disease history  no . ( % ) §,C0007222;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C2004062;C3538987;C4048877;C4318503
1777,cv,C3538987;C4048877;C4318503
1777,baseline cv medications  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
1777,baseline cv medications,C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
1777,baseline ( geometric mean  cv ),C0168634;C1442488;C2986759;C3538987;C4048877;C4318503
1777,ascvdor > $nmbr$ cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
1777,any cv history / risk factors  n ( % ),C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503
1777,> $nmbr$ additional cv risk factors $nmbr$,C0035648;C1524062;C1553898;C3538987;C4048877;C4318503
1776,st - segment depression > $nmbr$ . $nmbr$ mv on admission  %,C0457453;C0520887;C1454484;C1705503;C4281602
1776,st - segment depression > $nmbr$ . $nmbr$ mv,C0520887;C1454484;C1705503;C4281602
1776,st - segment depression < $nmbr$ . $nmbr$ mv  %,C0520887;C1454484;C1705503;C4281602
1776,sokolow – lyon voltage ( mv ),C0598352;C1454484;C1705503;C4281602
1776,sokoiow - lyon voitage  mv,C1454484;C1705503;C4281602
1776,cornell voltage duration ( mv × ms ),C0449238;C0598352;C1454484;C1705503;C2349943;C2926735;C3539704;C3713294;C4281602
1775,no mvd ( n - $nmbr$  $nmbr$ ),C1417507;C3272839
1775,mvd ( n - $nmbr$  $nmbr$ ),C1417507;C3272839
1774,use of concomitant lipid - lowering therapy - no . ( % ),C0521115;C0585943;C1524063
1774,statin and / or other lipid - lowering agent therapy,C0039798;C0086440;C0087111;C0360714;C0450442;C0585943;C1254351;C1363945;C1521826
1774,lipid ‐ lowering therapies  n ( % ),C0585943
1774,lipid lowering therapy,C0585943
1774,lipid - lowering therapy — no . ( % ),C0585943
1774,lipid - lowering therapy - no . ( % ),C0585943
1774,lipid - lowering therapy,C0585943
1774,lipc,C1416867
1774,hyperlipidaemia therapy use  n ( % ) * no lipid - lowering agent therapy,C0020473;C0039798;C0042153;C0086440;C0087111;C0428465;C0450442;C0457083;C0585943;C1254351;C1363945;C1521826;C1947944;C4555212
1774,concomitant lipid - lowering therapy ( any ),C0521115;C0585943
1774,concomitant lipid - lowering therapy  n ( % ),C0521115;C0585943
1774,background lipid - lowering therapy,C0585943;C1706907
1774,any other lipid ‐ lowering therapy  n ( % ),C0585943
1773,without lipid - lowering agents,C0086440
1773,with lipid - lowering agents,C0086440
1773,revascularisation but no antiplatelets  lipid - lowering agents  or p blockers,C0086440;C0369773;C0581603;C2603361
1773,revascularisation + antiplatelets + lipid - lowering agents + p blockers,C0086440;C0581603
1773,other lipid lowering drugs,C0086440
1773,non - smokers receiving lipid lowering drugs  ( $nmbr$ blockers  and either an ace inhibitor or angiotension receptor blocker,C0003015;C0086440;C0337672;C0597357;C1514756;C3844638;C4541021;C4554605
1773,non - smokers receiving lipid - lowering drugs  p blockers  and either an ace inhibitor or angiotension receptor blocker,C0003015;C0086440;C0337672;C0597357;C1514756;C3844638;C4541021;C4554605
1773,non - smokers receiving lipid - lowering drugs  p blockers,C0086440;C0337672;C1514756;C4554605
1773,lipid lowering drugs,C0086440
1773,lipid lowering agents,C0086440
1773,lipid lowering agent n ( % ),C0086440
1773,lipid disorder,C0154251
1773,lipid - lowering drugs  n ( % ),C0086440
1773,lipid - lowering drugs,C0086440
1773,lipid - lowering drug * *,C0086440
1773,lipid - lowering drug,C0086440
1773,lipid - lowering agents ( % ),C0086440
1773,lipid - lowering agents,C0086440
1773,lipid - lowering agent §,C0086440
1773,lipid - lowering agent,C0086440
1773,fibrate or other lipid - lowering agent,C0086440
1773,blockers,
1773,any lipid - lowering agent use,C0042153;C0086440;C0457083;C1947944
1773,any lipid - lowering agent,C0086440
1773,^ - blockers,
1772,select lipids and lipoproteins,C0023779;C0023820;C1707391
1772,other lipid - modifying drug use at study entry  n ( % ),C0013175;C0013227;C0023779;C0042153;C0242510;C0392747;C0457083;C0557651;C0869040;C1254351;C1705654;C1947944;C2603343
1772,metabolic syndrome $nmbr$ baseline lipids  mg / dl,C0023779;C0168634;C0439269;C0524620;C1442488
1772,mean lipid values  mg / dl,C0023779;C0042295;C0439269;C0444504;C2347634;C2348143
1772,lipids — mg / dl,C0023779;C0439269
1772,lipids,C0023779
1772,lipid values  mmol / l,C0023779;C0042295;C1532563
1772,lipid values  mean ( sd ),C0023779;C0042295;C0444504;C2347634;C2348143;C2699239
1772,lipid values,C0023779;C0042295
1772,lipid profile,C0023779;C1979963;C2003903
1772,lipid modifiers,C0023779;C4284280
1772,lipid concentrations total cholesterol ( mmol / l ),C0023779;C0086045;C0201950;C0543421;C1532563
1772,lipid concentrations,C0023779;C0086045
1772,lipid - lowerinq druq,C0023779
1772,lipid,C0023779
1772,drinking  n ( % ) lipid values  mmol / l,C0001948;C0023779;C0042295;C0684271;C1532563
1772,baseline lipids  mg / dl,C0023779;C0168634;C0439269;C1442488
1772,baseline lipid profile  mg / dl  mean ( sd ),C0023779;C0168634;C0439269;C0444504;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239
1771,losmapimod ( n = $nmbr$ ),C3272847
1771,losmapimod,C3272847
1771,blisibimod ( n = $nmbr$ ),C3713826
1770,dyslipidemia — no . { % ),C0242339
1770,dyslipidemia — no . ( % ) |,C0242339
1770,dyslipidemia — no . ( % ),C0242339
1770,dyslipidemia $nmbr$,C0242339
1770,dyslipidemia  n ( % ),C0242339
1770,dyslipidemia,C0242339
1770,dyslipidaemiat,
1770,dyslipidaemiaj,
1770,dyslipidaemia 本,C0242339
1770,dyslipidaemia — no . ( % ),C0242339
1770,dyslipidaemia including hypercholesterol — no . ( % ),C0242339;C0332257
1770,dyslipidaemia and hypertension  n ( % ),C0020538;C0242339;C1963138
1770,dyslipidaemia  n ( % ),C0242339
1770,dyslipidaemia,C0242339
1770,baseline dyslipidemia,C0168634;C0242339;C1442488
1769,lp ( a ) §,C0065058;C1439335;C4553379
1769,lp ( a ) ( μ mol / l ),C0065058;C0347982;C1439335;C4553379
1769,lp ( a ) ( week $nmbr$ ),C0065058;C0332174;C0439230;C1439335;C4553379
1769,lp ( a ) ( pmol / l ),C0065058;C0439284;C1439335;C4553379
1769,lipoprotein ( a ) ( nmol / l ),C0065058;C0125953;C0439282;C1096202;C1439335
1769,lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C0439269;C1096202;C1439335
1769,lipoprotein ( a )  median ( ql  q $nmbr$ )  nmol / l,C0065058;C0125953;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
1769,lipoprotein ( a )  median ( qi  q $nmbr$ )  nmol / l,C0065058;C0125953;C0376586;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
1769,change in lp ( a ),C0065058;C0392747;C0443172;C1439335;C1705241;C4319952;C4553379
1769,baseline lipoprotein ( a ) ( nmol / l )  median ( iqr ),C0065058;C0125953;C0168634;C0439282;C0549183;C0876920;C1096202;C1439335;C1442488;C2347635;C2348144;C2939193
1768,range iga modified $nmbr$ score  n ( % ),C0392747;C0449820;C1514721;C2348147;C2825347;C3542016;C3889737;C4050231
1768,iga mod $nmbr$ score  n ( % ),C0011860;C0449820;C2825347;C4050231
1768,iga $nmbr$ / $nmbr$,C2825347
1767,placebo → golimumab $nmbr$ mg / $nmbr$ mga  b,C0024671;C0026410;C0032042;C0065879;C0439269;C1696465;C1706408;C1960952;C2346927;C2353893;C4321396;C4521761
1767,hscrp > $nmbr$ . $nmbr$ mga .,C0065879
1767,hscrp < $nmbr$ . $nmbr$ mga . $nmbr$ ( $nmbr$ . $nmbr$ x $nmbr$ ( $nmbr$ . $nmbr$ ),C0065879
1767,$nmbr$ / $nmbr$ mga ( n = $nmbr$ ),C0065879
1766,sua < $nmbr$ . $nmbr$,
1766,spga > $nmbr$,
1766,ptga ⁎ ⁎ ⁎,
1766,ptga  $nmbr$ - $nmbr$,
1766,mean ( sd ) ptga vas *,C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561
1766,baseline sua  mean ± sd mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
1766,baseline spga  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1765,sbp > $nmbr$ mnn hg,C0025424;C0085805;C0428257;C2347108;C2347109;C2348272
1765,bloodpressure  mean ( sd )  m m hg,C0025424;C0428257;C0428886;C1709500;C2347108;C2347109;C2348272;C2699239
1764,symptomatic infarct swelling,C0013604;C0021308;C0038999;C0231220
1764,swollen,C0038999
1764,question $nmbr$ ( pain / swelling in joints other than neck / back / hips ),C0003862;C0004600;C0013604;C0019552;C0027530;C0038999;C0205095;C0460009;C1522634;C1995000;C3159206
1764,number of swollen joints ( $nmbr$ assessed ),C0038999;C0449813;C1516048
1764,number of swollen joints ( $nmbr$ - $nmbr$ )  mean ( sd ),C0038999;C0444504;C0449813;C2347634;C2348143;C2699239
1764,number of swollen joints ( $nmbr$ - $nmbr$ ),C0038999;C0449813
1763,statin + fibrate or niacin,C0027996;C0360714;C1142562
1763,statin + fibrate or,C0360714
1763,other statin,C0360714
1763,other !,
1763,other,
1763,or,
1763,no statin vs statin alone vs any statin plus other llt,C0205171;C0360714;C0439044;C0679994;C2347090
1763,any statin + other llt,C0360714;C2347090
1763,any other llts ( other than statin ),C0360714;C2347090
1763,any llt other than statins  n ( % ) b,C0360714;C2347090
1762,• iii : death from cv causes  nonfatal mi  hospitalization for ua  all revascularization > $nmbr$ days  nonfatal stroke,C0011065;C0015127;C0019993;C0038454;C0041580;C0042014;C0439070;C0439228;C0581603;C1306577;C1314792;C1524003;C1705160;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
1762,• any stroke,C0038454;C4554100
1762,• $nmbr$ : death from any cause  major coronary event  or nonfatal stroke,C0011065;C0015127;C0038454;C0205082;C0205164;C0741923;C1306577;C1524003;C4082313;C4318856;C4521762;C4552775;C4554100
1762,toast classification of qualifying stroke ( % ),C0038454;C1514624;C1710306;C4521230;C4554100
1762,toast classification of qualifying stroke  no . ( % ),C0038454;C1514624;C1710306;C4521230;C4554100
1762,toast classification of qualifying stroke,C0038454;C1514624;C1710306;C4521230;C4554100
1762,time from qualifying stroke to randomization,C0034656;C0038454;C0040223;C1514624;C3541383;C4554100
1762,time from onset of qualifying stroke to randomization,C0034656;C0038454;C0449244;C1514624;C4554100
1762,stroke — no . / total no . ( % ),C0038454;C0439175;C0439810;C4554100
1762,stroke — no . ( % ),C0038454;C4554100
1762,stroke thought due to atherothrombotic disease,C0012634;C0038454;C0039869;C0678226;C4319827;C4554100
1762,stroke subtype  n ( % ),C0038454;C0449560;C4554100
1762,stroke subtype,C0038454;C0449560;C4554100
1762,stroke ortiab,C0038454;C4554100
1762,stroke ortia,C0038454;C4554100
1762,stroke or transient ischemic attack,C0007787;C0038454;C0917805;C4554100
1762,stroke or tia — no . ( % ),C0007787;C0038454;C0917805;C1054154;C4554100
1762,stroke or tia,C0007787;C0038454;C0917805;C1054154;C4554100
1762,stroke or systemic embolism,C0013922;C0038454;C0205373;C1704212;C4554100
1762,stroke or systemic,C0038454;C0205373;C4554100
1762,stroke or se ( s / se ),C0036919;C0038454;C4554100
1762,stroke or,C0038454;C4554100
1762,stroke of any etiology,C0015127;C0038454;C1314792;C1524003;C4554100
1762,stroke n = $nmbr$,C0038454;C4554100
1762,stroke n ( % ),C0038454;C4554100
1762,stroke at entry ( vs transient ischemic attack ),C0007787;C0038454;C0917805;C1705654;C4554100
1762,stroke at entry,C0038454;C1705654;C4554100
1762,stroke any,C0038454;C4554100
1762,stroke and tia  n ( % ),C0007787;C0038454;C0917805;C1054154;C4554100
1762,stroke / transient ischemic attack,C0007787;C0038454;C0917805;C4554100
1762,stroke / se,C0036919;C0038454;C4554100
1762,stroke / non -,C0038454;C1518422;C4554100
1762,stroke / m $nmbr$,C0038454;C0369637;C0441923;C4554100
1762,stroke / embolism,C0013922;C0038454;C1704212;C4554100
1762,stroke  total,C0038454;C0439175;C0439810;C4554100
1762,stroke  n ( % ),C0038454;C4554100
1762,stroke,C0038454;C4554100
1762,sensorimotor stroke,C0038454;C4554100
1762,qualifying stroke,C0038454;C1514624;C4554100
1762,pure sensory stroke,C0038454;C0445254;C2247561;C4554100
1762,prior stroke or transient ischemic attack,C0007787;C0038454;C0332152;C0917805;C2826257;C4554100
1762,previous stroke 一 no . ( % ),C0038454;C0205156;C1552607;C4554100
1762,previous stroke — no . ( % ) concomitant treatment — no . ( % ),C0038454;C0039798;C0087111;C0205156;C0521115;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704;C4554100
1762,previous stroke — no . ( % ),C0038454;C0205156;C1552607;C4554100
1762,previous stroke ortransient ischaemic attack ( % ),C0038454;C0205156;C0745413;C1552607;C4554100
1762,previous stroke ortia $nmbr$ - $nmbr$,C0038454;C0205156;C1552607;C4554100
1762,previous stroke ortia,C0038454;C0205156;C1552607;C4554100
1762,previous stroke or transient ischemic attack — no . / total,C0007787;C0038454;C0205156;C0439175;C0439810;C0917805;C1552607;C4554100
1762,previous stroke or transient ischemic attack  no . / total no . ( % ),C0007787;C0038454;C0205156;C0439175;C0439810;C0917805;C1552607;C4554100
1762,previous stroke or tl a $nmbr$ - $nmbr$,C0038454;C0205156;C0220928;C1552607;C4554100
1762,previous stroke or tl a,C0038454;C0205156;C0220928;C1552607;C4554100
1762,previous stroke or tia  n ( % ),C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1762,previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1762,previous stroke *,C0038454;C0205156;C1552607;C4554100
1762,previous stroke  n ( % ),C0038454;C0205156;C1552607;C4554100
1762,previous stroke,C0038454;C0205156;C1552607;C4554100
1762,previous clinical stroke or transient ischemic attack ( % ),C0007787;C0038454;C0205156;C0205210;C0917805;C1552607;C4554100
1762,previous clinical stroke or tia,C0007787;C0038454;C0205156;C0205210;C0917805;C1054154;C1552607;C4554100
1762,no stroke n = $nmbr$ $nmbr$,C0038454;C4554100
1762,no stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
1762,no stroke ( n = $nmbr$ ),C0038454;C4554100
1762,no previous stroke ortia,C0038454;C0205156;C1552607;C4554100
1762,no previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1762,no . of strokes / no . of patients in category ( and % ),C0030705;C0038454;C0683312;C3889287
1762,no . of strokes ( % ),C0038454
1762,no . ( % ) of patients with stroke,C0030705;C0038454;C4554100
1762,new stroke *,C0038454;C0205314;C4554100
1762,months from qualifying stroke *   ( % ),C0038454;C0439231;C1514624;C4554100
1762,hx mi or stroke,C0038454;C0262926;C3810814;C3814444;C4554100
1762,history of stroke or tia — no . ( % ),C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100
1762,hemispheric stroke n = $nmbr$,C0038454;C0205139;C4554100
1762,disabling stroke,C0038454;C4554100
1762,death or disabling stroke,C0011065;C0038454;C1306577;C4082313;C4552775;C4554100
1762,cvd without mi or stroke ( n = $nmbr$ ),C0007222;C0038454;C3810814;C4554100
1762,cvd / mi / stroke / urgent vascular hospitalization,C0005847;C0007222;C0019993;C0038454;C0439609;C1558950;C1801960;C3272275;C3810814;C4554100
1762,cvd / mi / stroke,C0007222;C0038454;C3810814;C4554100
1762,cerebrovascular accident / tia,C0007787;C0038454;C0917805;C1054154
1762,cerebrovascular accident,C0038454
1762,atherothrombotic stroke  n ( % ),C0038454;C4554100
1762,any stroke ( n = $nmbr$ ),C0038454;C4554100
1762,any stroke,C0038454;C4554100
1762,all strokes *,C0038454;C4554100
1762,all strokes  n ( % ),C0038454;C0369718;C0441922;C4554100
1762,all strokes,C0038454;C4554100
1762,all stroke,C0038454;C4554100
1762,a stroke,C0038454;C4554100
1762,$nmbr$ days stroke ( ischemic ),C0038454;C0439228;C0475224;C4554100
1761,rotigotine n = $nmbr$,C1700683;C4318637
1761,rotigotine ( n = $nmbr$ ),C1700683;C4318637
1761,rosiglitazone versus metformin,C0025598;C0289313
1761,rosiglitazone versus glyburide,C0017628;C0289313
1761,rosiglitazone ( n = $nmbr$ ),C0289313
1761,rosiglitazone,C0289313
1761,p value for heterogeneity （ rosiglitazone versus glyburide ）,C0017628;C0019409;C0242960;C0289313;C1709380
1760,pioglitazone pts / n ( % ),C0071097;C1419129;C2698747
1760,pioglitazone events / n ( % ),C0071097;C0441471;C3541888
1760,pioglitazone dose  mean ( sd )  mg,C0024671;C0026410;C0071097;C0178602;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1760,pioglitazone ( n = $nmbr$ ),C0071097
1760,pioglitazone ( n = $nmbr$  $nmbr$ ),C0071097
1760,pioglitazone,C0071097
1759,eplerenone ( n   = $nmbr$ ),C0961485
1759,canrenone ( n z $nmbr$ ),C0006882
1758,ras - aldosterone inhibitor ^,C0002006;C0002007;C0034678;C0525678;C1514727
1758,aldosterone inhibitor,C0002007
1758,aldosterone antagonists ( e . g . spironolactone ),C0002007;C0037982;C2757004
1758,aldosterone antagonists,C0002007;C2757004
1758,aldosterone antagonist,C0002007;C2757004;C3536833
1757,peri - op amiodarone : no ( n = $nmbr$ ),C0002598;C0347985;C0369718;C0441922
1757,no amiodarone,C0002598
1757,dronedarone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0766326
1757,dronedarone ( n = $nmbr$ ),C0766326
1757,dronedarone,C0766326
1757,amiodarone vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl ),C0002598;C0032042;C0596019;C1696465;C1706408;C2985465
1757,amiodarone vs . placebo,C0002598;C0032042;C1696465;C1706408
1757,amiodarone use at baseline,C0002598;C0042153;C0168634;C0457083;C1442488;C1947944
1757,amiodarone ote at baseline,C0002598;C0168634;C1442488
1757,amiodarone ( n = $nmbr$ ),C0002598
1757,amiodarone ( n  % ),C0002598
1757,amiodarone  n ( % ),C0002598
1757,amiodarone,C0002598
1757,* hypercholesterolemia was defined as a low - density lipoprotein cholesterol level at enrollment of more than $nmbr$ mg per deciliter ( $nmbr$ . $nmbr$ mmol per liter ) after an overnight fast . † nonsustained ventricular tachycardia was defined as $nmbr$ or more consecutive ventricular beats at a heart rate of more than $nmbr$ beats per minute . ‡ to convert weight to kilograms  divide by $nmbr$ . $nmbr$ . § to convert values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ¶ data for follow - up medication were available for $nmbr$ patients ( amiodarone  $nmbr$  placebo  $nmbr$  and icd  $nmbr$ ) . ace de - notes angiotensin - converting enzyme  and arb angiotensin ii – receptor blocker . ¿ p < $nmbr$ . $nmbr$ for the comparison among the groups,C0002598;C0005910;C0010294;C0011198;C0013227;C0015663;C0017480;C0018827;C0020443;C0021122;C0022709;C0023824;C0030705;C0032042;C0040363;C0041260;C0042295;C0043100;C0205172;C0332849;C0369773;C0425583;C0439209;C0439241;C0439300;C0439385;C0439583;C0441833;C0441889;C0456079;C0456962;C0470187;C0475211;C0521942;C0567349;C0589120;C0687744;C0750194;C0871208;C1257890;C1305866;C1316572;C1317574;C1452534;C1511726;C1516879;C1519504;C1521828;C1522133;C1522565;C1522577;C1547707;C1552839;C1561535;C1696073;C1696465;C1704685;C1704788;C1705104;C1705428;C1705429;C1706408;C1707455;C1707491;C1719797;C1883351;C2347285;C2348885;C2603361;C2911648;C2919575;C2946261;C2985769;C3244316;C3245479;C3274571;C3536793;C3539106;C3541240;C3714741;C3888021;C3888198;C4284014;C4284232
1756,t - jj ( $nmbr$ - $nmbr$ ),C2603360
1756,t $nmbr$ d,C2603360
1756,t,C2603360
1756,fibrinolytic agent — no . ( % ) : t,C0016018;C2603360
1756,$nmbr$ . ' ^ / $nmbr$ t $nmbr$ c } u,C0439148;C2603360
1756,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % t,C2603360
1755,ra,C3538806;C4048756
1755,patients without ra  as  or psa ( n = $nmbr$  $nmbr$ ),C0030705;C3538806;C3810537;C3813209;C4048756
1755,patients with ra  as  or psa ( n = $nmbr$ ),C0030705;C3538806;C3810537;C3813209;C4048756
1755,no . of patients with ra,C0030705;C3538806;C4048756
1755,months since ra was first diagnosed  mean ( sd ),C0011900;C0205435;C0439231;C0444504;C1279901;C2347634;C2348143;C2699239;C3538806;C4048756
1755,all - baricitinib ra ( n = $nmbr$ ) *,C3538806;C4044947;C4048756
1754,epa / aa ratio,C0282379;C0456603;C1235746;C1547037;C1882141;C4554792
1754,aa / g,C0282379;C0439267;C1235746;C1882141;C4554792
1754,aa  mol %,C0027960;C0282379;C0324740;C0439189;C1235746;C1456781;C1824986;C1882141;C3665593;C4554792
1754,aa,C0282379;C1235746;C1882141;C4554792
1753,numab,
1753,dmab ( n = $nmbr$ ),C0012411
1753,body mass index ( kg / ma ),C0005893;C0022718;C0024443;C0439209;C0578022;C1305855;C3887485;C4054209
1753,azl - ma,C0024443;C3887485
1753,> = $nmbr$ kg / ma $nmbr$,C0022718;C0024443;C0439209;C3887485;C4054209
1753,< $nmbr$ kg / ma $nmbr$,C0022718;C0024443;C0439209;C3887485;C4054209
1752,symptomatic pad of lower extremities *,C0023216;C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
1752,risk factors for pad,C0035648;C0182158;C0332568;C1553898;C3540603;C3669270;C3814046;C4319657
1752,pad symptoms ( % ),C0182158;C0332568;C0683368;C1457887;C3540603;C3669270;C3814046;C4319657
1752,pad lower extremities,C0023216;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1752,pad details  n ( % ),C0182158;C0332568;C0369718;C0441922;C1522508;C1561567;C3540603;C3669270;C3814046;C4319657
1752,pad at baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
1752,pad ( n - $nmbr$  $nmbr$ ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1752,pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1752,no pad baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
1752,no pad ( n - $nmbr$  $nmbr$ ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1751,vas ( $nmbr$ - $nmbr$ ),C0042815;C3536884;C3827561
1751,ptga ( $nmbr$ - $nmbr$ cm vas ),C0042815;C3536884;C3827561
1751,physician global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
1751,physician global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C3536884;C3827561;C4050369
1751,physician global assessment ( $nmbr$ - $nmbr$ mm vas ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
1751,physician ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd ),C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4050369;C4330985;C4554674
1751,physician ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4050369
1751,physician ' s assessment of disease activity ( vas )  mm,C0031831;C0042815;C0456681;C0804815;C1261322;C1292728;C1516048;C3536884;C3827561
1751,patient global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm ),C0042815;C3536884;C3827561;C4054228;C4330985;C4554674
1751,patient global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C3536884;C3827561;C4054228
1751,patient global assessment ( $nmbr$ - $nmbr$ mm vas ),C0042815;C3536884;C3827561;C4054229;C4330985;C4554674
1751,patient ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4054229
1751,pain ( vas ),C0042815
1751,mean ( sd ) pain vas *,C0042815;C0444504;C2347634;C2348143;C2699239
1751,general health vas  $nmbr$ - $nmbr$ mm,C0042815;C0424575;C3536884;C3827561;C4018875;C4330985;C4554674
1751,baseline skin pain vas  mean ( sd ),C0042815;C0168634;C0241136;C0444099;C0444504;C1123023;C1442488;C1963195;C2347634;C2348143;C2699239;C3536884;C3827561;C4520765
1751,activity ( $nmbr$ - $nmbr$ vas ),C0042815;C0205177;C0439167;C0441655;C1561536;C3536884;C3668946;C3827561;C4049938;C4049939
1751,( $nmbr$ - $nmbr$ - cm vas ),C0042815;C3536884;C3827561
1750,physician ' s ga  $nmbr$ - $nmbr$ mmvas,C0016993;C0031831;C0804815
1750,patient ' s ga  $nmbr$ - $nmbr$ mm vas,C0016993;C0030705;C0042815;C3536884;C3827561;C4330985;C4554674
1750,ga / a,C0016993
1750,ga,C0016993
1750,a / ga,C0016993
1749,tah ( n = $nmbr$ ),C0404079
1749,ta ( n = $nmbr$ ),C0039297;C1506978;C1705538;C3272501;C4553364
1749,ta,C0039297;C1506978;C1705538;C3272501;C4553364
1749,less than $nmbr$ mm hg,C0439092;C0439475
1749,less than $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439092;C0439445;C0441923
1749,less than $nmbr$ kg / m $nmbr$,C0439092;C1532718
1749,less than $nmbr$ . $nmbr$ %,C0439092
1749,less than $nmbr$ %,C0439092
1749,less than $nmbr$,C0439092
1748,total stent length - mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
1748,total stent length ( mm )  mean ± sd,C0038257;C0439175;C0439810;C0444504;C1444754;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
1748,total stent length  mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
1748,total stent length,C0038257;C0439175;C0439810;C1444754;C1706316
1748,laa length,C1444754;C1706316
1747,oral medications,C0304289
1747,oral contraceptives,C0009905
1747,oral anticoagulants,C0354604
1747,oral anticoagulant — no . / total no . ( % ),C0354604;C0439175;C0439810
1747,oral anticoagulant n ( % ),C0354604
1747,oral anticoagulant drugs  n ( % ),C0354604
1747,oral anticoagulant drugs,C0354604
1747,oral anticoagulant agent,C0354604
1747,oral anticoagulant  n ( % ),C0354604
1747,oral anticoagulant,C0354604
1746,oral β - adrenergics  n ( % ),C0001637;C0442027;C4521986
1746,oral treprostinil ( n = $nmbr$ ),C0442027;C1145760;C4521986
1746,oral blood glucose - lowering drug $nmbr$ ( $nmbr$ . $nmbr$ ),C0005802;C0013227;C0017725;C0018938;C0441994;C0442027;C1254351;C2003888;C4521986
1746,oral blood glucose - lowering,C0005802;C0441994;C0442027;C2003888;C4521986
1746,oral antidiabetic drugs / insulin ( % / % ),C0021641;C0029167;C0175795;C0304289;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
1746,oral antidiabetic drugs,C0029167;C0175795;C0304289;C0442027;C0935929;C4521986
1746,oral antidiabetes monotherapya  n ( % ),C0442027;C4521986
1746,oral ( % ),C0442027;C4521986
1746,oral,C0442027;C4521986
1746,concomitant oral glucose - lowering agents  zz ( % ),C0017725;C0441994;C0442027;C2003888;C2347310;C2347852;C4521986
1746,baseline prednisone or oral prednisone equivalent daily dose,C0032952;C0168634;C0205163;C0439185;C0442027;C1442488;C2348070;C4521986
1745,patent foramen ovale,C0016522;C0344724
1745,ovary,C0029939;C0227898
1744,other oral hypoglycemic drug ( s ),C0359086
1744,oral hypoglycemics hormone replacement,C0282402;C0359086
1744,oral hypoglycemics,C0359086
1744,oral hypoglycemic drug,C0359086
1744,oral hypoglycemic agentsj,C0359086
1744,oral hypoglycemic agents,C0359086
1744,oral hypoglycemic agent,C0359086
1744,oral hypoglycemic,C0359086
1744,oral antihyperglycaemic  n ( % ),C0359086
1743,teaes reported by ≥ $nmbr$ % patients in the overall brv group    n   ( % ),C0030705;C0155502;C0282416;C0441848;C1561607;C1709908
1743,qveral,
1743,overally,
1743,overall ® $nmbr$ . $nmbr$,C0282416;C1561607
1743,overall vero population,C0032659;C0282416;C1257890;C1561607
1743,overall treatment effect,C0282416;C1518681;C1561607
1743,overall population ( n = $nmbr$ ),C0032659;C0282416;C1257890;C1561607
1743,overall population ( n - $nmbr$ ),C0032659;C0282416;C1257890;C1561607
1743,overall population,C0032659;C0282416;C1257890;C1561607
1743,overall pad,C0182158;C0282416;C0332568;C1561607;C3540603;C3669270;C3814046;C4319657
1743,overall n = $nmbr$  $nmbr$,C0282416;C1561607
1743,overall effect,C0282416;C1280500;C1518681;C1561607;C2348382
1743,overall ctd,C0282416;C1335071;C1442905;C1561607
1743,overall a phase population,C0032659;C0205390;C0282416;C1257890;C1561607;C1710475
1743,overall ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0282416;C1561607
1743,overall ( pp ) ( n = $nmbr$ ),C0030375;C0063017;C0282416;C1561607;C4319755
1743,overall ( per protocol ) ( n = $nmbr$ ),C0282416;C1561607;C1698058
1743,overall ( n = u $nmbr$ ),C0282416;C0439148;C1561607
1743,overall ( n = $nmbr$ vs $nmbr$ ),C0282416;C1561607
1743,overall ( n = $nmbr$ ),C0282416;C1561607
1743,overall ( n = $nmbr$  $nmbr$ ),C0282416;C1561607
1743,overall ( itt ) ( n = $nmbr$ ),C0282416;C1561607
1743,overall ( $nmbr$  $nmbr$ ),C0282416;C1561607
1743,overall $nmbr$,C0282416;C1561607
1743,overall  qvai $nmbr$ - sfc,C0282416;C1561607;C4521536
1743,overall  n = $nmbr$,C0282416;C1561607
1743,overall,C0282416;C1561607
1743,overaii ( n = $nmbr$ ),
1743,overaii,
1743,omeprazole,C0028978
1743,metrex overall modified intention - to - treat population ? :,C0032659;C0087111;C0162425;C0282416;C0392747;C1257890;C1283828;C1292734;C1522326;C1561607;C3889737
1743,calima overall ( n = $nmbr$ ),C0282416;C1561607
1743,brv overalla ( n = $nmbr$ ),C0155502
1743,brv overall ( n = $nmbr$ ),C0155502;C0282416;C1561607
1743,brv overall,C0155502;C0282416;C1561607
1742,infarct on brain imaging 丰,C0011923;C0079595;C0751955
1742,infarct on brain imaging ^,C0011923;C0079595;C0751955
1742,brazil,C0006137
1741,non - frail,C0871754;C1518422
1741,frail,C0871754
1741,fragile,C0302113
1740,stratified log - rank   p   value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
1740,stratified log - rank p value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
1740,log rank p - value,C0667477;C0699794;C1708728;C1709380;C2986775
1740,log - rank p value,C0667477;C0699794;C1708728;C1709380;C2986775
1740,log - rank,C0667477;C0699794;C1708728;C2986775
1740,cmann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
1740,amann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
1739,strain ( % ),C0080194;C0456178;C1518614;C2987481
1739,brain volume  cm ',C1113695
1739,brain volume  cm $nmbr$,C1113695
1738,regular ppi use,C0042153;C0205272;C0358591;C0457083;C0871125;C1947944;C3811894
1738,ppi use ( p = $nmbr$ . $nmbr$ t ),C0042153;C0358591;C0369773;C0457083;C0871125;C1947944;C2603361;C3811894
1738,ppi use ( p = $nmbr$ - $nmbr$ t ),C0042153;C0358591;C0369773;C0457083;C0871125;C1947944;C2603361;C3811894
1738,ppi use,C0042153;C0358591;C0457083;C0871125;C1947944;C3811894
1738,ppi,C0358591;C0871125;C3811894
1738,pi,C0122626;C0429863;C3537219;C3539772
1738,phi ( n = $nmbr$ ),C1333690;C1704947;C1706536;C2975867;C4084801
1738,phi ( n - $nmbr$ ),C1333690;C1704947;C1706536;C2975867;C4084801
1738,pgi - s  n ( % ) y :,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
1738,noppi,
1738,nontrial ppi,C0358591;C0871125;C3811894
1738,non - study ppi use,C0042153;C0358591;C0457083;C0557651;C0871125;C1518422;C1947944;C2603343;C3811894
1738,no regular ppi use,C0042153;C0205272;C0358591;C0457083;C0871125;C1947944;C3811894
1738,combinations of aspirin and ppi use ( p = $nmbr$ . $nmbr$ t ),C0004057;C0042153;C0358591;C0453882;C0457083;C0871125;C1947944;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3811894;C3854036
1737,pb,C1415801;C3819255
1737,median feno ( ppb ) f,C0016327;C0549183;C0876920;C1415800;C2347635;C2348144;C2939193
1737,mean ( sd ) feno  ppb,C0444504;C1415800;C2347634;C2348143;C2699239
1737,high feno subgroup ( > $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ ),C0205250;C1079230;C1299351;C1415800;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
1737,feno — ppb,C1415800
1737,> $nmbr$ to < $nmbr$ ppb,C1415800
1737,> $nmbr$ ppb,C1415800
1737,< $nmbr$ ppb,C1415800
1736,tenecteplase and pci ( n = $nmbr$ ),C0872913;C4049621
1736,single vessel pci,C0005847;C0037179;C0087136;C0205171;C4049621
1736,ret / abx - facil . pci,C0389252;C4049621
1736,prerandomization pci,C4049621
1736,pre - randomization pci,C0034656;C0332152;C0740175;C2257086;C3669034;C4049621
1736,poci ( n = $nmbr$ ),
1736,poci,
1736,pci — no . { % ),C4049621
1736,pci — no . ( % ),C4049621
1736,pci revascularization,C0581603;C4049621
1736,pci orcabg,C4049621
1736,pci :,C4049621
1736,pci ( % ),C4049621
1736,pci  n ( % ),C4049621
1736,pci,C4049621
1736,no pci or cabg — no . ( % ),C0010055;C4049621
1736,no pci,C4049621
1736,multivessel pci,C4049621
1736,interval study drug to pci,C0013175;C1272706;C1552654;C1552713;C4049621
1736,history of pci — no . / total no . ( % ) : t,C0019664;C0019665;C0262512;C0262926;C0439175;C0439810;C1705255;C2004062;C2603360;C4049621
1736,glycoprotein ilb / iiia inhibitor before pci ],C0017968;C1999216;C4049621;C4697913
1736,facilitated pci ( n = $nmbr$ ),C4049621
1736,combo - facilitated pci,C4049621
1736,clopidogrel dose on / before pci,C0070166;C0178602;C0869039;C1114758;C4049621
1736,before pci,C4049621
1736,and after pci  median ( iqr )  d,C0549183;C0876920;C2347635;C2348144;C2939193;C4049621
1736,after pci,C4049621
1736,abx - facil . pci,C4049621
1736,abciximab - facilitated pci ( n = $nmbr$ ),C0288672;C4049621
1736,$nmbr$ vessel pci,C0005847;C4049621
1735,subpopulation analyses according to bmi,C0578022;C0680240;C1514228
1735,screening bmi ( kg / m $nmbr$ ),C0220908;C0220909;C0578022;C1532718;C1698960;C1710031;C1710032;C1710477;C2348164
1735,risk factors bmi ( kg / m $nmbr$ )  mean + sd,C0035648;C0444504;C0578022;C1532718;C1553898;C2347634;C2348143;C2699239
1735,obese ( bmi £ $nmbr$ ),C0028754;C0578022
1735,normal weight ( bmi < $nmbr$ ),C0005910;C0043100;C0578022;C1305866;C1705104;C2712185;C4229017
1735,normal ( bmi < $nmbr$ ),C4229017
1735,mean ± s . d . bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
1735,mean bmi ( kg / m $nmbr$ ) ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,mean bmi ( $nmbr$ % ci ),C0008107;C0444504;C0578022;C2347634;C2348143;C3259781
1735,mean bmi  kg / m $nmbr$ ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,mean bmi  kg / m $nmbr$ ( s . d . ),C0022718;C0439209;C0444504;C0578022;C1512018;C2347634;C2348143;C4054209
1735,mean bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
1735,mean bmi,C0444504;C0578022;C2347634;C2348143
1735,mean baseline bmi,C0168634;C0444504;C0578022;C1442488;C2347634;C2348143
1735,mean ( sd ) bmi ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,mean ( s . d . ) bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
1735,bms,
1735,bmit,
1735,bmij,
1735,bmia,
1735,bmi — mean ( sd ) ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,bmi £ $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi   kg · m − $nmbr$,C0578022;C1532718
1735,bmi o $nmbr$ kg / m $nmbr$  n ( % ),C0578022;C1532718
1735,bmi kg · m − $nmbr$,C0578022;C1532718
1735,bmi category ( kg / m $nmbr$ ),C0578022;C0683312;C1532718;C3889287
1735,bmi category ( % ),C0578022;C0683312;C3889287
1735,bmi category  no . ( % ),C0578022;C0683312;C3889287
1735,bmi category,C0578022;C0683312;C3889287
1735,bmi categories  n ( % ),C0578022;C0683312
1735,bmi a $nmbr$,C0578022
1735,bmi ^,C0578022
1735,bmi [ kg / m $nmbr$ ],C0578022;C1532718
1735,bmi > = $nmbr$ kg / m $nmbr$,C0578022;C1532718
1735,bmi > = $nmbr$,C0578022
1735,bmi > $nmbr$ — no . { % ) $,C0578022
1735,bmi > $nmbr$ — no . ( % ) f,C0016327;C0578022
1735,bmi > $nmbr$ obese,C0028754;C0578022
1735,bmi > $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi > $nmbr$ kg / m $nmbr$ *,C0578022;C1532718
1735,bmi > $nmbr$ kg / m $nmbr$  n ( % ),C0578022;C1532718
1735,bmi > $nmbr$ kg / m $nmbr$,C0578022;C1532718
1735,bmi > $nmbr$ ( % ),C0578022
1735,bmi > $nmbr$  n ( % ),C0578022
1735,bmi > $nmbr$,C0578022
1735,bmi < = $nmbr$,C0578022
1735,bmi < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi < $nmbr$ kg / m $nmbr$,C0578022;C1532718
1735,bmi < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi < $nmbr$,C0578022
1735,bmi : > $nmbr$ . $nmbr$ kg / m $nmbr$,C0578022;C1532718
1735,bmi : < $nmbr$ . $nmbr$ kg / m $nmbr$,C0578022;C1532718
1735,bmi - kg / m $nmbr$,C0578022;C1532718
1735,bmi ( median  iqr )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
1735,bmi ( kg = m $nmbr$ ),C0578022;C1532718
1735,bmi ( kg / m ’ ),C0578022;C1532718
1735,bmi ( kg / m ^ )  mean ± s . d .,C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C0578022;C1275571;C1513009;C2347634;C2348143;C4054209
1735,bmi ( kg / m ^ ),C0578022;C1532718
1735,bmi ( kg / m ),C0578022;C1532718
1735,bmi ( kg / m $nmbr$ ) mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,bmi ( kg / m $nmbr$ ) cardiovascular history,C0578022;C1532718;C1880008
1735,bmi ( kg / m $nmbr$ ) cardiac parameters,C0018787;C0449381;C0578022;C1522601;C1532718
1735,bmi ( kg / m $nmbr$ ) a,C0578022;C1532718
1735,bmi ( kg / m $nmbr$ ) [ mean - sd ],C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,bmi ( kg / m $nmbr$ ) : mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,bmi ( kg / m $nmbr$ ) *,C0578022;C1532718
1735,bmi ( kg / m $nmbr$ )  mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,bmi ( kg / m $nmbr$ )  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,bmi ( kg / m $nmbr$ ),C0578022;C1532718
1735,bmi ( kg / ( m ) $nmbr$ ),C0578022;C1532718
1735,bmi ( . kg / m - ) *,C0578022;C1532718
1735,bmi $nmbr$ - < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi $nmbr$ - < $nmbr$ kg / m - ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi $nmbr$ - < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi $nmbr$ - < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
1735,bmi $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,C0578022
1735,bmi $nmbr$ - $nmbr$ - $nmbr$ $nmbr$,C0578022
1735,bmi $nmbr$ $nmbr$ - $nmbr$ $nmbr$,C0578022
1735,bmi $nmbr$,C0578022
1735,bmi  x $nmbr$ kg / m $nmbr$,C0578022;C1532718
1735,bmi  no . ( % ),C0578022
1735,bmi  n ( % ),C0578022
1735,bmi  median ( iqr ),C0549183;C0578022;C0876920;C2347635;C2348144;C2939193
1735,bmi  mean  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
1735,bmi  kg per m $nmbr$,C0578022;C1532718
1735,bmi  kg / m ’,C0578022;C1532718
1735,bmi  kg / m ^  mean ( sd ) ’,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,bmi  kg / m $nmbr$  n,C0578022;C1532718
1735,bmi  kg / m $nmbr$  median ( iqr ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
1735,bmi  kg / m $nmbr$  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1735,bmi  kg / m $nmbr$,C0578022;C1532718
1735,bmi,C0578022
1735,bm i < $nmbr$,C0006416;C0021966;C0221138
1735,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0439230;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
1735,baseline bmi ( kg / m ^ ),C0168634;C0578022;C1442488;C1532718
1735,baseline bmi ( kg / m $nmbr$ ),C0168634;C0578022;C1442488;C1532718
1735,baseline bmi,C0168634;C0578022;C1442488
1735,> $nmbr$ years bmi,C0439234;C0578022
1735,( a ) bmi subgroups,C0578022;C1079230
1735,$nmbr$ < bmi < $nmbr$,C0578022
1734,• j . the body - mass index is the weight in kilograms divided by the square of the,C0005893;C0005910;C0043100;C0205120;C0332849;C0439209;C0578022;C1305855;C1305866;C1552595;C1705104
1734,the test for heterogeneity ( interaction ) indicates whether the treatment effect varied significantly among the sub - groups . the hochberg method was applied to each of the two comparisons of the treatment groups . bmi denotes body - mass index ( the weight in kilograms divided by the square of the height in meters ) .,C0005893;C0005910;C0019409;C0022885;C0025663;C0039593;C0039798;C0043100;C0087111;C0205120;C0205448;C0242960;C0332849;C0392366;C0439209;C0441074;C0441833;C0449851;C0456984;C0489786;C0542339;C0578022;C0687744;C0871511;C1257890;C1264637;C1305855;C1305866;C1515976;C1518681;C1519504;C1522326;C1533734;C1552595;C1552839;C1704675;C1705104;C1705169;C1705428;C1705429;C1707455;C3538994;C3831328;C3887704;C4048755;C4318744
1734,median body mass index  kg / m $nmbr$ ( range ),C0005893;C0549183;C0578022;C0876920;C1305855;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016
1734,median body mass index  kg / m $nmbr$ ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
1734,mean body mass index ( sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,mean body mass index ( kg / m $nmbr$ ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1734,mean body mass index ( kg / m $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1734,mean body mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1734,mean body - mass index ( = sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,mean body - mass index  kg / m $nmbr$   ( sd ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,mean body - mass index  kg / m $nmbr$ ( sd ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,mean body - mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1734,mean ( sd ) body mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index subgroups,C0005893;C0578022;C1079230;C1305855
1734,body mass index mean kg / m $nmbr$ ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index group ( kg / m $nmbr$ ) ≥ $nmbr$ kg / m $nmbr$ — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0578022;C0687744;C1257890;C1305855;C1519504;C1705428;C1705429;C1709500;C4054209
1734,body mass index category  no . ( % ) l,C0005893;C0439394;C0578022;C0683312;C1305855;C1706495;C3642217;C3889287
1734,body mass index blood pressure — mmhg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
1734,body mass index ^,C0005893;C0578022;C1305855
1734,body mass index [ kg / m $nmbr$ ]  mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index > $nmbr$ — no . ( % ) f,C0005893;C0016327;C0578022;C1305855
1734,body mass index > $nmbr$ t,C0005893;C0578022;C1305855
1734,body mass index > $nmbr$ kg / m  n ( % ),C0005893;C0578022;C1305855;C1532718
1734,body mass index > $nmbr$  n ( % ),C0005893;C0578022;C1305855
1734,body mass index :,C0005893;C0578022;C1305855
1734,body mass index / mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1734,body mass index - mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1734,body mass index - kg / m $nmbr$ t,C0005893;C0578022;C1305855;C1532718
1734,body mass index +,C0005893;C0578022;C1305855
1734,body mass index *,C0005893;C0578022;C1305855
1734,body mass index ( kgm _ $nmbr$ ),C0005893;C0578022;C1305855
1734,body mass index ( kg / m “ ) ^,C0005893;C0578022;C1305855;C1532718
1734,body mass index ( kg / m ’ ) ^,C0005893;C0578022;C1305855;C1532718
1734,body mass index ( kg / m ^ ) ^,C0005893;C0578022;C1305855;C1532718
1734,body mass index ( kg / m ),C0005893;C0578022;C1305855;C1532718
1734,body mass index ( kg / m $nmbr$ ) baseline systolic blood,C0005767;C0005768;C0005893;C0039155;C0168634;C0229664;C0578022;C1305855;C1442488;C1532718
1734,body mass index ( kg / m $nmbr$ ) - mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index ( kg / m $nmbr$ ) * ',C0005893;C0578022;C1305855;C1532718
1734,body mass index ( kg / m $nmbr$ )  mean ( sd ) c,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
1734,body mass index ( bmi )  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1734,body mass index $nmbr$,C0005893;C0578022;C1305855
1734,body mass index  median  ( $nmbr$ th — $nmbr$ th percentiles )  kg / m $nmbr$,C0005893;C0039725;C0039738;C0549183;C0578022;C0876920;C1264641;C1305855;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
1734,body mass index  mean ± sd ( kg / m $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  mean kg / m ^ ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  mean + sd ( kg / m ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  mean ( sd ) t,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1734,body mass index  mean ( sd ) kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  mean ( sd ) d,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1734,body mass index  mean ( sd ) [ range ] a,C0005893;C0444504;C0578022;C1305855;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
1734,body mass index  mean ( sd ) ( kg m ) $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  mean ( sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1734,body mass index  kg / rn \ mean ( sd ),C0005893;C0022718;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819
1734,body mass index  kg / m ’,C0005893;C0578022;C1305855;C1532718
1734,body mass index  kg / m ^ mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  kg / m ^ ( meanisd ),C0005893;C0578022;C1305855;C1532718
1734,body mass index  kg / m ^,C0005893;C0578022;C1305855;C1532718
1734,body mass index  kg / m $nmbr$   ( sd ),C0005893;C0578022;C1305855;C1532718;C2699239
1734,body mass index  kg / m $nmbr$ ( sd ),C0005893;C0578022;C1305855;C1532718;C2699239
1734,body mass index  kg / m $nmbr$ ( mean ± sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  kg / m $nmbr$  median ( q $nmbr$  q $nmbr$ ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
1734,body mass index  kg / m $nmbr$  mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  kg / m $nmbr$  mean + sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  kg / m $nmbr$  mean ( sd ) §,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  kg / m $nmbr$  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body mass index  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1734,body mass index  * kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1734,body mass index  %,C0005893;C0578022;C1305855
1734,body mass index,C0005893;C0578022;C1305855
1734,body - mass index ”,C0005893;C0578022;C1305855
1734,body - mass index — no . ( % ) : i :,C0005893;C0021966;C0221138;C0578022;C1305855
1734,body - mass index — no . ( % ) $,C0005893;C0578022;C1305855
1734,body - mass index §,C0005893;C0578022;C1305855
1734,body - mass index categories — no . ( % ) : c,C0005893;C0578022;C0683312;C1305855
1734,body - mass index ^ :,C0005893;C0578022;C1305855
1734,body - mass index ^,C0005893;C0578022;C1305855
1734,body - mass index \ kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1734,body - mass index > $nmbr$  n ( % ),C0005893;C0578022;C1305855
1734,body - mass index > $nmbr$,C0005893;C0578022;C1305855
1734,body - mass index : ! :,C0005893;C0578022;C1305855
1734,body - mass index - kg / m $nmbr$  median ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
1734,body - mass index - ! ',C0005893;C0578022;C1305855
1734,body - mass index *,C0005893;C0578022;C1305855
1734,body - mass index ) -,C0005893;C0578022;C1305855
1734,body - mass index ) ',C0005893;C0578022;C1305855
1734,body - mass index ),C0005893;C0578022;C1305855
1734,body - mass index ( kg / m   $nmbr$ ),C0005893;C0578022;C1305855;C1532718
1734,body - mass index ( kg / m - ),C0005893;C0578022;C1305855;C1532718
1734,body - mass index ( kg / m ' ),C0005893;C0578022;C1305855;C1532718
1734,body - mass index ( kg / m $nmbr$ ) t,C0005893;C0578022;C1305855;C1532718
1734,body - mass index ( kg / m $nmbr$ ) *,C0005893;C0578022;C1305855;C1532718
1734,body - mass index ( kg / m $nmbr$ ) ( mean  sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body - mass index ( kg / m $nmbr$ )  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1734,body - mass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
1734,body - mass index ( kg / cm $nmbr$ ),C0005893;C0578022;C1305855;C4054689
1734,body - mass index $,C0005893;C0578022;C1305855
1734,body - mass index  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1734,body - mass index  kq / nrn,C0005893;C0578022;C1305855;C1425210
1734,body - mass index  !,C0005893;C0578022;C1305855
1734,body - mass index,C0005893;C0578022;C1305855
1734,bmi ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),C0578022
1734,baseline body mass index,C0005893;C0168634;C0578022;C1305855;C1442488
1733,fibrous  mm ’,C0016059;C0439709;C4330985;C4554674
1733,fibrous,C0016059;C0439709
1733,fibrofatty  mm ^,C4330985;C4554674
1733,fibrofatty,
1733,fibrates,C1449704;C3540783
1732,study population,C2348561
1732,placebo - control study,C0683952
1732,overall study population,C0282416;C1561607;C2348561
1731,temporary discontinuation of study drug,C0013175;C0205374;C0457454;C1444662;C1548539;C3245481;C4552847
1731,teaes leading to discontinuation of study drug,C0013175;C0332152;C0457454;C1444662;C1522538;C4552847
1731,study drug,C0013175
1731,median duration of study - drug administration,C0013175;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
1731,leading to study drug discontinuation,C0013175;C0040363;C0041260;C0332152;C0457454;C1444662;C1522538;C1883351;C4552847
1731,duration of study - drug administration — hr,C0013175;C2348354
1730,this study,C0557651;C2603343
1730,study druga,C0557651;C2603343
1730,study $nmbr$ . $nmbr$,C0557651;C2603343
1730,study $nmbr$,C0557651;C2603343
1730,study,C0557651;C2603343
1730,six - study placebo - controlled set,C0036849;C0205452;C0557651;C1442518;C1705195;C1706408;C2603343
1730,related to study druga,C0040363;C0041260;C0439849;C0445223;C0557651;C1883351;C2603343
1730,pool of fh i and ii studies,C0337051;C0557651;C0947630;C1260386;C1509144;C2349200;C2603343
1730,permanently stopped study drug because of adverse events,C0041755;C0557651;C1272691;C2603343
1730,no inducer at core study entry,C0444669;C0557651;C1167518;C1705654;C1706352;C1882467;C2603343;C3274653;C3898767
1730,induction study treatment,C0205263;C0557651;C0857127;C1521826;C2603343;C4049995
1730,included in this study ( n = $nmbr$ ),C0332257;C0557651;C2603343
1730,in extension study,C0231448;C0557651;C1880641;C2603343
1730,enrolled from re - cover study — no . ( % ),C0180153;C0556581;C0557651;C1999244;C2603343;C2986904;C3888055;C4684790
1730,duration of treatment in the healing study  n,C0043240;C0205249;C0444921;C0557651;C2603343
1730,duration antiplatelet use as % of study duration ( sd ),C0557651;C1881378;C2603343;C2699239;C2826775
1730,concurrent treatment at study entry — no . ( % ) * *,C0009247;C0039798;C0087111;C0205420;C0557651;C0679827;C1521826;C1522326;C1533734;C1705169;C1705654;C2603343;C3161471;C3538994;C3887704
1729,tzd,
1729,met / tzd,C0428210;C1550543;C4317104
1729,met / su / tzd,C0038642;C0428210;C1550543;C1705534;C4317104
1729,did not meet atopy and ige $nmbr$ - $nmbr$ ku / lcriteriaa ( n = $nmbr$  $nmbr$ ),C0022804;C0392707;C1337080;C1518422;C1532717;C1550543;C1881335;C3539705
1729,> $nmbr$ % and < $nmbr$ %,
1728,woscops,
1728,patients with evaluable endoscopy,C0014245;C2986511
1728,endoscopy subscore  n ( % ),C0014245
1728,endoscopy subscore,C0014245
1728,colonoscopy,C0009378;C1548837
1727,std n ( n / loopy ),C0181687;C0445022
1727,overall n ( n / loopy ),C0181687;C0282416;C0445022;C1561607
1727,loop at last follow - up,C0445022;C0589120;C1522577;C1704685;C3274571
1727,loop,C0445022
1727,glargine n ( n / loopy ),C0181687;C0445022;C0907402
1726,prior copd medicationa  n ( % ),C0024117;C0332152;C1412502;C2826257;C3714496
1726,prior copd medication,C0013227;C0024117;C0332152;C1412502;C2826257;C3244316;C3714496;C4284232
1726,previous respiratory disease other than copd — no . ( % ),C0024117;C0035204;C0035242;C0205156;C1412502;C1552607;C3714496
1726,previous copd treatment  n ( % ) *,C0024117;C0039798;C0087111;C0205156;C1412502;C1522326;C1533734;C1552607;C1705169;C3538994;C3714496;C3887704
1726,patients with prior copd - related,C0024117;C0030705;C0332152;C0439849;C0445223;C1412502;C2826257;C3714496
1726,overall night - time copd symptom severity scorec,C0024117;C0240526;C0282416;C1319166;C1412502;C1561607;C3714496
1726,no previous copd medication,C0013227;C0024117;C0205156;C1412502;C1552607;C3244316;C3714496;C4284232
1726,mean copd duration  y ( sd ),C0024117;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1726,mean ( sd ) duration of copd  years,C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1726,grade $nmbr$ ( moderate copd )  n ( % ),C0024117;C0205081;C0441800;C0919553;C1412502;C1881878;C3244287;C3714496;C4049705;C4049706;C4085643;C4321335
1726,duration of copd — yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1726,duration of copd — days ^,C0024117;C0439228;C0449238;C1412502;C2926735;C3714496
1726,duration of copd ( yr ) f,C0016327;C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1726,duration of copd ( yr ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1726,duration of copd ( years )  mean ( sd ),C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1726,duration of copd ( years ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1726,duration of copd  yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1726,duration of copd  years,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1726,duration of copd  y,C0024117;C0449238;C1412502;C2926735;C3714496
1726,duration of copd,C0024117;C0449238;C1412502;C2926735;C3714496
1726,data are mean ( sd ) or number ( % ) . bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . lvef = left ventricular ejection fraction . hf = heart failure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter de ﬁ brillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .,C0010055;C0011198;C0014442;C0017480;C0018801;C0021122;C0024117;C0030705;C0032042;C0042508;C0085805;C0155626;C0162589;C0205091;C0237753;C0428772;C0428883;C0443246;C0444504;C0449788;C0470187;C0488055;C0488728;C0521942;C0815017;C0871470;C0965129;C1305855;C1306620;C1452534;C1511726;C1532338;C1552822;C1696465;C1706408;C2347634;C2348143;C2699239;C3245479;C3541240;C3714741;C3888198;C4284014;C4521602
1726,copd — no . ( % ) medication use,C0024117;C0240320;C1412502;C3714496
1726,copd type,C0024117;C0332307;C1412502;C1547052;C3714496
1726,copd population ( n = $nmbr$ ),C0024117;C0032659;C1257890;C1412502;C3714496
1726,copd or asthma  ( % ),C0004096;C0024117;C1412502;C2984299;C3714496
1726,copd or asthma,C0004096;C0024117;C1412502;C2984299;C3714496
1726,copd medication at study entry,C0013175;C0024117;C1412502;C1705654;C3714496
1726,copd duration  y,C0024117;C0449238;C1412502;C2926735;C3714496
1726,copd ( n = $nmbr$ ),C0024117;C1412502;C3714496
1726,copd ( % ),C0024117;C1412502;C3714496
1726,copd    n   ( % ),C0024117;C1412502;C3714496
1726,copd,C0024117;C1412502;C3714496
1726,clinical copd phenotype ^,C0024117;C0031437;C0205210;C1285572;C1412502;C3714496
1726,chronic obstructive pulmonary disease — no . ( % ),C0024117
1726,chronic obstructive pulmonary disease  n ( % ),C0024117
1726,chronic obstructive pulmonary disease,C0024117
1726,chronic obstructive lung disease,C0024117
1726,augment copd,C0024117;C0205217;C1412502;C3714496
1726,any copd medication,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
-10,computed tomographic angiography,C1536105
1724,time from randomization to coronary angiography — hr,C0034656;C0040223;C0085532;C1548829;C3541383
1724,normal coronary angiography,C0853522
1724,coronary angiography — no . ( % ),C0085532;C1548829
1724,coronary angiography during the index hospital stay,C0002978;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546;C3489408
1724,coronary angiography,C0085532;C1548829
1723,randomization to angiography,C0002978;C0034656
1723,randomization - to - angiography distribution time,C0002978;C0034656;C0681683
1723,randomization - to - angiography,C0002978;C0034656
1723,intravenous anticoagulant prior to pre - pci angiography,C0002978;C0003280;C0332152;C0348016;C0740175;C0848112;C2257086;C3536711;C3669034;C4049621
1723,interval from randomization to angiography,C0002978;C0034656;C1272706;C1552654;C1552713
1723,glycoprotein iib / iiia inhibitor use before angiography,C0002978;C0016011;C0042153;C0457083;C1947944;C1999216
1723,diagnostic angiography,C0002978
1723,contrast angiography,C0002978;C0009924;C1979874
1723,angiography — no . ( % ),C0002978
1723,angiography and revascularization,C0002978;C0581603
1723,angiography,C0002978
1723,additional angiography,C0002978;C1524062
1723,> $nmbr$ ( ml ) additional angiography,C0002978;C0439526;C1524062;C1705224;C3887665
1722,prior angioplasty,C0162577;C0332152;C1548817;C2826257
1722,previous angioplasty  n ( % ),C0162577;C0205156;C1548817;C1552607
1722,peripheral angioplasty,C0162577;C0205100;C1548817
1722,cabg or angioplasty,C0010055;C0162577;C1548817
1722,angioplasty,C0162577;C1548817
1721,previous balloon angioplasty  n ( % ),C0002996;C0002997;C0205156;C1552607
1721,previous balloon angioplasty,C0002996;C0002997;C0205156;C1552607
1721,balloon angioplasty — no . ( % ),C0002996;C0002997
1721,balloon angioplasty plus abciximab,C0002996;C0002997;C0288672;C0332287
1721,balloon angioplasty,C0002996;C0002997
-10,lymphadenopathy,C0497156;C4282165
1719,retinopathy — no . ( % ),C0035309;C1962966
1719,retinopathy — %,C0035309;C1962966
1719,retinopathy,C0035309;C1962966
1719,micro - / macro - albuminuria  ckd and / or retinopathy,C0001925;C0035309;C0085672;C1553035;C1561643;C1962966;C2984010;C3811161;C4049106
1718,peripheral sensory neuropathy,C0151313;C4554142
1718,peripheral neuropathy,C0031117
1718,neuropathy — no . ( % ),C0442874
1718,neuropathy,C0442874
1718,myopathyt,
1718,myopathy,C0026848
1718,autonomic neuropathy,C0259749
-10,radionuclide ventriculography,C0017200;C0034610
1716,spiralcomputedtomographyangiography,
1716,duplex ultrasonography,C3825392
1715,nice secondary prevention onlyb,C0679699;C4087029
1715,nice primary prevention onlyb,C0033144;C4087029
1715,gissi prevention $nmbr$ / $nmbr$ - $nmbr$ / $nmbr$,C0199176;C1706420;C2700409
1714,interruption ( n = $nmbr$ ),C0332453;C1512900
1714,interruption,C0332453;C1512900
1714,history of percutaneous coronary intervention,C1320647;C4554713
1714,$nmbr$ early intervention ( n = $nmbr$ ),C0242687;C1964029
1713,vka  only reason,C0205171;C0392360;C1720467
1713,redon,
1713,pci indication,C0392360;C3146298;C4049621
1713,patient ' s preference not to take vka  only reason * *,C0040363;C0041260;C0205171;C0376409;C0392360;C1515187;C1518422;C1720467;C1883351
1713,indication for stent,C0038257;C0392360;C3146298
1713,indication for pci,C0392360;C3146298;C4049621
1713,indication for index pci,C0392360;C0600653;C0918012;C1552854;C1637833;C2986546;C3146298;C4049621
1713,indication,C0392360;C3146298
1712,steroid - sparing remission *,C0038317;C0544452;C0687702
1712,steroid - free remission,C0038317;C0332296;C0544452;C0687702;C1880497;C1996904
1712,remission in overall population,C0032659;C0282416;C0544452;C0687702;C1257890;C1561607
1712,remission component of variable,C0439828;C0449432;C0544452;C0687702;C1705248;C4553760
1712,remission by : baseline steroid doses,C0038317;C0168634;C0178602;C0544452;C0687702;C1442488
1712,remission  n ( % ),C0544452;C0687702
1712,remission,C0544452;C0687702
1712,asdas inactive disease  %,C0544452
1711,no regular consumption,C0009830;C0205272;C1947907
1711,constitutional,C1511487
1711,constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
1710,priorother ( predefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
1710,priorother ( not predefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1518422;C1705253;C3864998
1710,prespecified medical conditions  n ( % ) f,C0012634;C0016327;C0199168;C0205476;C0348080;C1705253;C3864998
1710,presenting condition  n ( % ),C0012634;C0348080;C0449450;C1705253;C3864998
1710,medical conditions  no . ( % ),C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
1710,known thrombophilic condition — no . ( % ),C0012634;C0205309;C0348080;C0398623;C1705253;C3864998
1710,currentother ( notpredefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
1710,current other ( predefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C0521116;C1705253;C1705970;C3864998
1710,contusion,C0009938
1710,condition $nmbr$ ( $nmbr$ . $nmbr$ ),C0012634;C0348080;C1705253;C3864998
1710,coexisting conditions — no . ( % ),C0012634;C0348080;C1705253;C3864998
1710,coexisting conditions,C0679225
1710,any condition,C0012634;C0348080;C1705253;C3864998
1709,time from randomization to study - drug initiation — hr,C0013175;C0013227;C0034656;C0040223;C0040227;C0589507;C1158830;C1254351;C1704686;C2349982;C3541383
1709,time from randomization to study - drug administration — hr,C0013175;C0034656;C0040227;C0150270;C0206209;C2349982;C3469597
1709,time from acs to randomization ( median  iqr ),C0034656;C0040223;C0549183;C0742343;C0876920;C2347635;C2348144;C2939193;C3541383;C4318612
1709,time from acs to randomization,C0034656;C0040223;C0742343;C3541383;C4318612
1709,randomization to arterial sheath insertion,C0003842;C0021107;C0034656;C0221464;C0227952;C0441587;C1512796;C1883719
1709,randomization to,C0034656
1709,randomization - to -,C0034656
1709,history of diagnosed hypertension prior to randomization  n ( % ),C0011900;C0034656;C0455527
1709,days from acs to randomization,C0034656;C0439228;C0742343;C4318612
1709,$nmbr$ tol ( n = $nmbr$ ),
1708,medication prior to admission  ( % ),C0013227;C0184666;C0332152;C0809949;C3244316;C4284232
1708,interval pain onset to admission,C0184666;C0809949;C1272706;C1507009;C1552654;C1552713
1708,$nmbr$ b ( $nmbr$ b to > $nmbr$ a ),
1708,$nmbr$ b ( $nmbr$ b to $nmbr$ a ),
1707,immobilization — no . ( % ),C0020944;C4048292
1707,immobilization at randomization  n ( % ),C0020944;C0034656;C4048292
1707,immobilization,C0020944;C4048292
1707,immobazaton,
1706,tni ultrapositive ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$,C0077401;C0439294;C0456615
1706,tni ultrapositive  ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$,C0077401;C0439294;C0456615
1706,apolipoprotein b ( g / l ),C0003593;C0439294;C0456615
1706,apolipoprotein b  mean ( sd )  g / l,C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239
1706,> $nmbr$ . $nmbr$ - g / l,C0439294;C0456615
1706,$nmbr$ . $nmbr$ ( g . l ),C0439294;C0456615
1705,use of parenteral antithrombotic agents — no . ( % ),C0030547;C1524063;C1704311;C4522267
1705,antithrombotic agents  n ( % ),C1704311
1705,antithrombotic agents,C1704311
1705,antithrombotic / coagulant,C0009117
1705,antithrombotic,
1705,$nmbr$ prolonged antithrombotic pretreatment ( n = $nmbr$ ),C0439590;C1550147;C2709094;C3539075;C3539076
1704,short - acting anticholinergics,C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
1704,baseline short - acting anticholinergics  n ( % ),C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
1704,baseline short - acting anticholinergics,C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
1704,anticholinergics,C0242896;C3537307;C3540711
1704,anticholinergic use  n ( % ),C0042153;C0242896;C0457083;C1947944;C3537004
1704,anticholinergic drug,C0242896
1704,anticholinergic,C0242896;C3537004
1703,time from symptom onset to start of fibrinolytic therapy — hr,C0040044;C0040223;C0040363;C0041260;C0439659;C0449244;C1457887;C1883351;C3541383;C3854129;C4086878
1703,time from onset of symptoms to start of fibrinolytic therapy — hr,C0040044;C0040363;C0041260;C0439659;C1320528;C1883351
1703,time from fibrinolytic therapy to study - drug administration — no . / total no . ( % ),C0013175;C0013216;C0040044;C0040223;C0040227;C0150270;C0206209;C0439175;C0439810;C0557651;C1611232;C2349982;C2603343;C3469597;C3541383;C3665478
1703,thrombolytic therapy,C0040044
1703,fibrinolytics,C0040044
1703,fibrinolytic therapy — no . ( % ),C0040044
1703,fibrinolytic,C0040044
1702,tonic – clonic,C3543842
1702,tonic,C3543842
1702,functional assessment of chronic illness,C0008679;C0278372
1702,clonic,
1701,patients without chronic,C0030705;C0205191
1701,patients with chronic,C0030705;C0205191
1701,in patients with a history of chronic angina who have presented with an acute,C0002962;C0205178;C0205191;C0449450;C0679831
1701,chronic cvd,C0007222;C0205191
1701,chronic cox $nmbr$ inhibitors,C0085387;C0205191
1701,chronic bronchitist,C0205191
1701,cholecystitis chronic,C0008325;C0205191;C1963083;C4553186
1700,nordic countries,C0036273
1700,nordic,C0331873
1700,hordic,
1700,aortic valve disease ( n = $nmbr$ $nmbr$ ),C1260873;C4553103
1700,aortic - valve replacement,C0003506
1700,aortic,C0003483
1699,abdominal aortic — no . ( % ),C0003484
1699,$nmbr$ mortis,
1698,risk factors for atherosclerosis,C0003850;C0004153;C0035648;C1553898
1698,qualifying type of atherosclerosis — no . ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
1698,qualifying type of atherosclerosis  n ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
1698,qualifying atherosclerosis,C0003850;C0004153;C1514624
1698,large - artery atherosclerosis,C0003850;C0004153;C0226003
1698,high risk with atherosclerotic vascular disease *,C0004153;C0332167;C3272283;C4050568;C4319571
1698,established atherosclerotic cardiovascular disease — no . { % ),C0004153;C0443211;C1272684
1698,established atherosclerotic cardiovascular disease,C0004153;C0443211;C1272684
1698,atherosclerotic vascular disease — no .,C0004153
1698,atherosclerotic vascular disease  n ( % ) §,C0004153
1698,atherosclerotic cardiovascular disease *,C0004153
1698,atherosclerotic cardiovascular disease,C0004153
1698,atherosclerosis ^  n ( % ),C0003850;C0004153
1698,atherosclerosis,C0003850;C0004153
1698,arteriosclerosis,C0003850
1697,other atherosclerotic event,C0333482;C0441471;C4019010
1697,other atherosclerotic cvdd  e,C0333482;C1859330
1697,other atherosclerotic cvd st depression on,C0007222;C0333482;C0520887
1697,other atherosclerotic cvd * *,C0007222;C0333482
1697,other atherosclerotic cvd,C0007222;C0333482
1697,other atherosclerotic,C0333482
1697,atherosclerotic cvdj,C0333482
1697,atherosclerotic cvd §,C0007222;C0333482
1697,atherosclerotic cvd,C0007222;C0333482
1696,rosuvastain + fenofibric acid   n   =   $nmbr$,C0060179
1696,rosuvastain + fenofibric acid $nmbr$ = $nmbr$,C0060179
1696,fenofibric acid   n   =   $nmbr$,C0060179
1696,fenofibric acid + moderate - dose statin,C0060179;C0360714;C1709056
1696,fenofibric acid $nmbr$ = $nmbr$,C0060179
1696,fenofibric acid,C0060179
1696,fenofibric,
1696,drosuvastatin + fenofibric acid vs . fenofibric acid monotherapy .,C0060179
1695,gemfibrozil ( n = $nmbr$,C0017245
1695,gemfibrozil,C0017245
1694,aerobic exercise,C0001701
1694,aerobic activity,C0001701
1693,notable abnormalities,C0000768;C0000769;C4288581
1693,concordant stress test abnormalities,C0000768;C0000769;C0015260;C3494508;C4553529
1692,subscale  and $nmbr$ to $nmbr$ for the function subscale  normalized scores can range from $nmbr$ to $nmbr$ . scores for the health assessment question -,C0031843;C0040363;C0041260;C0175637;C0449820;C0459443;C0542341;C0700205;C1514721;C1522634;C1705273;C1882115;C1883351;C2348147;C3542016
1692,normalized,C1882115
1691,oral aminosalicylates,C0368663;C0442027;C4521986
1691,no aminosalicylates  n,C0368663
1691,concomitant aminosalicylates  n [ % ] concomitant corticosteroids  n [ % ] mayo score  mean [ sd ],C0001617;C0368663;C0444504;C0449820;C0454788;C0521115;C1077578;C2347634;C2348143;C2699239;C3539185;C3540725;C3540726;C3540727;C4050231
1691,aminosalicylates * *,C0368663
1691,aminosalicylates  n,C0368663
1691,aminosalicylates,C0368663
1691,aminosalicylate,C0368663;C2825094
1691,$nmbr$ - aminosalicylates ’ i  i ‘,C0021966;C0221138;C0368663
1691,$nmbr$ - aminosalicylates | | | |,C0368663
1691,$nmbr$ - aminosalicylates {,C0368663
1690,poor compliance / noncompliance,C0032646;C0376405;C0457432
1690,noncompliant,C0457432
1690,non - compliance,C0376405;C0457432
1689,nonblack ( n = $nmbr$ )  adjusted hazard ratio *,C0456081;C2985465
1689,nonblack ( n = $nmbr$ ),
1689,nonblack,
1688,not at goal,C0018017;C1518422;C1571704
1688,goal,C0018017;C1571704
1688,distance to ldl - c goal,C0012751;C0018017;C1571704
1688,at ldl - c ( bq ) goal * at baseline - no . ( % ),C0018017;C0168634;C0560038;C1442488;C1571704;C3541236
1688,at goal,C0018017;C1571704
1688,% to goal,C0018017;C1571704
1687,ldl - c goal attainment,C0680230
1687,dual bp / ldl - c goal attainment,C0037623;C0205173;C0680230;C1415692;C1554184;C1708288;C4318478
1687,bp goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
1686,getgoal - s,
1686,getgoal - l - asia,C0003980
1685,total ldl - c *,C0439175;C0439810
1685,total body ( without head ),C0018670;C0229960;C1706305
1685,total body,C0229960
1685,total bleeds,C0232100
1685,total bleeding,C0232100
1685,ldl *,
1684,total bilirubin > $nmbr$ x uln $nmbr$,C0005437;C0368753;C1519815
1684,total bilirubin  mg / dl,C0005437;C0368753;C0439269
1683,mitral regurgitation  n ( % ),C0026266
1683,mitral regurgitation  ( % ),C0026266
1683,mitral insufficiency  n ( % ),C0026266
1683,mitral insufficiency,C0026266
1683,italy ( n = $nmbr$ ),C0022277
1683,italy,C0022277
1682,nonfatal mi + fatal chdt,C1302234;C1705232;C3810814
1682,non - fatal mi,C1302234;C1518422;C1705232;C3810814
1682,mi ( fatal / nonfatal ),C1302234;C1705232;C3810814
1682,fatal or nonfatal myocardial infarction,C0027051;C0428953;C1302234;C1705232;C2926063;C3810814;C4552959
1682,fatal or non - fatal myocardial infarction,C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959
1682,fatal chd and nonfatal mia,C0280604;C1302234;C1417154;C1705232;C3542407
1682,fatal / nonfatal mi  n ( % ),C1302234;C1705232;C3810814
1682,fatal & nonfatal ccvd,C1302234;C1705232
1682,fatal,C1302234;C1705232
1682,disabling or fatal stroke,C0038454;C1302234;C1705232;C4554100
1682,disabling or fatal,C1302234;C1705232
1682,cv death  non - fatal mi or non - fatal stroke,C0011065;C0038454;C1302234;C1306577;C1518422;C1705232;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
1682,chd ( nonfatal mi + fatal chd ),C0280604;C1302234;C1705232;C3542407;C3810814
1681,oil,C0028908;C0032085;C1517288;C3541397
1681,fish oil ( n = $nmbr$ ),C0016157
1681,fish oil,C0016157
1681,- oil,C0028908;C0032085;C1517288;C3541397
1680,mean percentage change from baseline to final visit,C0168634;C0205088;C0392747;C0439165;C0443172;C0444504;C0545082;C1442488;C1512346;C1546485;C1549488;C1561533;C1705241;C2347634;C2348143;C2826704;C3853528;C4319952
1680,final mean  mg / dl,C0205088;C0439269;C0444504;C1546485;C2347634;C2348143;C3853528
1680,final mean,C0205088;C0444504;C1546485;C2347634;C2348143;C3853528
1680,final a $nmbr$ c ( % ),C0205088;C1546485;C3853528
1680,final ( mg / dl ),C0205088;C0439269;C1546485;C3853528
1680,final,C0205088;C1546485;C3853528
1680,change from baseline to final apbm,C0168634;C0205088;C0392747;C0443172;C1442488;C1546485;C1705241;C3853528;C4319952
1679,triglycerides  mmol / lf,C0041004;C0439190;C1416933;C2986618;C4554443
1679,serum creatinine  umol / lf,C0201976;C0439194;C0600061;C1416933;C2986618;C4554443
1679,$nmbr$ . $nmbr$ ± $nmbr$ . lf,C1416933;C2986618;C4554443
1679,$nmbr$ % clf,C3540486;C4553190
1678,total cholesterol > $nmbr$ - $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1678,total cholesterol > $nmbr$ ' $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1678,total cholesterol < $nmbr$ - $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1678,total cholesterol < $nmbr$ $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1678,total cholesterol  mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1678,ldl cholesterol  mmol / lt,C0023376;C0023824;C0202117;C0230426;C0439190;C3887647;C4521399
1678,hdl cholesterol  mmol / lt,C0023376;C0023822;C0230426;C0392885;C0439190;C3887647;C4521399
1678,fpg  mmol / lt,C0023376;C0230426;C0439190;C3887647;C4521399
1678,$nmbr$ . $nmbr$ ± o . lt,C0023376;C0230426;C0483204;C3887647;C4521399
1677,time from ld to pci  min  median ( q $nmbr$ – q $nmbr$ ),C0040223;C0549183;C0694649;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3541383;C3813700;C4049621
1677,ld,C0694649
1677,cg / ld,C0043444;C0694649;C1567075;C3540479
1677,< $nmbr$ . $nmbr$ ld,C0694649
1677,$nmbr$ mg ld,C0024671;C0026410;C0439269;C0694649;C1960952;C2346927;C4321396;C4521761
1676,normal ( ≤   uln ) n   =   $nmbr$,C0205307;C0231683;C0439166;C1519815;C2347086;C4553972
1676,cpk > $nmbr$ times uln,C0040223;C1519815;C1632851
1676,ast > $nmbr$ x uln on two consecutive visits,C0205448;C0545082;C1415181;C1512346;C1519815;C1707491;C3891303
1676,alt or ast > $nmbr$ x uln $nmbr$,C1266129;C1415181;C1519815;C3891303;C4553172
1676,alt and / or ast > $nmbr$ times uln consecutive #,C0040223;C1266129;C1415181;C1519815;C1632851;C1707491;C3891303;C4553172
1676,alt > $nmbr$ x uln on two consecutive visits,C0205448;C0545082;C1266129;C1512346;C1519815;C1707491;C4553172
1676,alt  ast  or both > $nmbr$ x uln,C1519815;C3831581
1676,> $nmbr$ uln,C1519815
1675,ck > $nmbr$ xuln,C0009212;C0010287;C1872855
1675,ck > $nmbr$ x uln $nmbr$,C0009212;C0010287;C1519815;C1872855
1675,< $nmbr$ xuln,
1674,cardiac rhythm disorders,C0264886
1674,cardiac rhythm disorder at baseline no,C0168634;C0264886;C1442488
1674,cardiac rhythm,C0232187
1673,sinus rhythm at baseline,C0168634;C0232201;C1442488
1673,sinus rhythm,C0232201
1672,mixed chronic bronchitis and emphysema,C0008677;C0013990;C0034067;C0205430;C3160715
1672,emphysema ( n = $nmbr$ ),C0013990;C0034067
1672,emphysema ( itt ) ( n = $nmbr$ ),C0013990;C0034067
1672,emphysema ( % ),C0013990;C0034067
1672,emphysema,C0013990;C0034067
1672,centrilobular emphysema,C0221227
1671,psycholeptics,C3653516
1671,psychogenic,C0458006
1671,psychoactivesd,
1670,non - ischemic,C0475224;C1518422
1670,non - ischaemic cause,C0015127;C0475224;C1518422;C1524003
1670,non - ischaemic ( n = $nmbr$ o $nmbr$ ),C0475224;C1518422
1670,non - ischaemic ( n = $nmbr$ ),C0475224;C1518422
1670,non - ischaemic,C0475224;C1518422
1670,ischemic outcomes,C0475224;C1274040
1670,ischemic cause,C0015127;C0475224;C1524003
1670,ischemic,C0475224
1670,ischaemic skin lesions,C0037284;C0475224
1670,ischaemic cause,C0015127;C0475224;C1524003
1670,ischaemic ( n = $nmbr$ l $nmbr$ ),C0475224
1670,ischaemic ( n = $nmbr$ ),C0475224
1670,ischaemic  n ( % ),C0475224
1670,ischaemic,C0475224
1669,• ischemic stroke,C0948008
1669,prior ischemic stroke,C0332152;C0948008;C2826257
1669,previous ischemic stroke ortia,C0205156;C0948008;C1552607
1669,previous ischemic stroke / tia ( n = $nmbr$  $nmbr$ . $nmbr$ % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
1669,previous ischemic stroke  n ( % ),C0205156;C0948008;C1552607
1669,post - acute ischemic stroke,C0205178;C0475224;C0687676;C0751956;C0948008;C1704687;C3469826
1669,nonfatal ischemic stroke,C0948008
1669,no previous ischemic stroke / tia ( n = $nmbr$ $nmbr$  $nmbr$ . $nmbr$ % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
1669,minor ischaemic stroke,C0026193;C0205165;C0948008
1669,ischemic stroke with hemnrrhnaic cnnversinn,C0948008
1669,ischemic stroke subtype,C0449560;C0948008
1669,ischemic stroke ( % ),C0948008
1669,ischemic stroke,C0948008
1669,ischaemic stroke  n ( % ),C0948008
1669,ischaemic stroke,C0948008
1669,cvdeath  ml  or ischemic stroke,C0439526;C0948008;C1705224;C3887665
1669,cv death  ml  ischemic stroke  hosp . for hf  cor . revasc .  ua,C0011065;C0018488;C0018787;C0041580;C0042014;C0056331;C0378365;C0439526;C0948008;C1306577;C1313497;C1538440;C1705224;C3273279;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
1669,cv death  ml  ischemic stroke,C0011065;C0439526;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
1669,all ischemic stroke,C0948008
1668,severe recurrent ischemia,C0022116;C0205082;C1455761;C2945760;C4050465;C4050466;C4321499
1668,recurrent ischemia - urgent revascularization,C0022116;C0439609;C0581603;C1455761;C2945760;C3272275;C4321499
1668,recurrent ischemia,C0022116;C1455761;C2945760;C4321499
1668,rec . ischemia requiring revasc,C0022116;C0378365;C1424025;C2606415;C4321499
1668,rec . ischemia leading to hosp,C0022116;C0332152;C1424025;C1522538;C2606415;C4321499
1668,rec . ischemia leading to hasp,C0022116;C0332152;C1424025;C1522538;C2606415;C4321499
1668,rec . ischemia,C0022116;C1424025;C2606415;C4321499
1668,no p value for ischemia ischemia hr ( $nmbr$ % ci ) interaction,C0008107;C0022116;C1704675;C1709380;C3259781;C4321499
1668,no ischemia ( n = $nmbr$  $nmbr$ ),C0022116;C4321499
1668,ischemia on cecg ( n = $nmbr$  $nmbr$ ),C0022116;C4321499
1668,ischemia on cecg ( % ),C0022116;C4321499
1668,ischemia driven revascularization,C0022116;C0581603;C4321499;C4683688
1668,ischemia - driven revascularization,C0022116;C0581603;C4321499;C4683688
1668,ischemia,C0022116;C4321499
1668,global ischemia ( % ) * *,C0022116;C0205246;C2348867;C4321499
1668,global ischemia,C0022116;C0205246;C2348867;C4321499
1668,effect of ranolazine compared with placebo on angina and recurrent ischemia,C0002962;C0022116;C0032042;C0073633;C1280500;C1455761;C1518681;C1696465;C1706408;C1707455;C2348382;C2945760;C4321499
1668,anti - ischaemia agents *,C0022116;C0040616;C4321499
1667,haq score ( $nmbr$ – $nmbr$ scale ),C0102923;C0175659;C0349674;C0449820;C0451208;C1947916;C4050231
1667,haq score,C0102923;C0449820;C0451208;C4050231
1667,haq pain score,C0102923;C0451208;C0582148
1667,haq alternative disability score,C0102923;C0231170;C0449820;C0451208;C1523987;C4050231
1667,haq,C0102923;C0451208
1666,total hands score,C0018563;C0439175;C0439810;C0449820;C1552914;C4050231
1666,hands,C0018563;C1552914
1666,hand,C0018563;C1552914
1665,mean score on haq - di §,C3533236;C3826998;C4321476
1665,health assessment questionnaire - disability index,C4321476
1665,haq di score ( range $nmbr$ - $nmbr$ )  mean ± sd,C0444504;C0449820;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4050231;C4321476
1665,haq di score ( $nmbr$ - $nmbr$ ),C0449820;C3826998;C4050231;C4321476
1665,haq di ( range $nmbr$ - $nmbr$ ),C1514721;C2348147;C3542016;C3826998;C4321476
1665,haq di,C3826998;C4321476
1665,haq - di scoreff,C3826998;C4321476
1665,haq - di scored,C0449820;C3826998;C4321476
1665,haq - di score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C3826998;C4050231;C4321476
1665,haq - di score ( $nmbr$ - $nmbr$ ),C0449820;C3826998;C4050231;C4321476
1665,haq - di score,C0449820;C3826998;C4050231;C4321476
1665,haq - di mcide,C3826998;C4321476
1665,haq - di improvement from baseline to week $nmbr$,C0168634;C0332174;C0439230;C1442488;C2986411;C3826998;C4321476
1665,haq - di improvement > $nmbr$ . $nmbr$,C2986411;C3826998;C4321476
1665,haq - di * *,C3826998;C4321476
1665,haq - di *,C3826998;C4321476
1665,haq - di ( range $nmbr$ - $nmbr$ ),C1514721;C2348147;C3542016;C3826998;C4321476
1665,haq - di ( $nmbr$ - $nmbr$ ),C3826998;C4321476
1665,haq - di  range $nmbr$ - $nmbr$  mean ( sd ),C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4321476
1665,haq - di  number ( % ),C0237753;C0449788;C3826998;C4321476
1665,haq - di,C3826998;C4321476
1665,change in haq - di ( mean ) t,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3826998;C4319952;C4321476
1665,assessment of physical function ( $nmbr$ - $nmbr$  haq - di ),C0031809;C0031843;C0516981;C0542341;C0700205;C1261322;C1516048;C1705273;C3826998;C4049916;C4321476
1665,( haq - di  $nmbr$ - $nmbr$ ),C3826998;C4321476
1665,% with haq - di decrease > $nmbr$ . $nmbr$,C0392756;C0547047;C3826998;C4321476
1664,ipah / hpah,C0152171;C0340543;C0637939;C1150929
1664,ipah  hpah  hiv  drug or toxin induced,C0013227;C0019682;C0019699;C0040549;C0152171;C0205263;C0340543;C0637939;C1150929;C1254351;C4522020
1664,hi ) ah ( % ),C0018619;C0239849;C1412082;C1412316;C1431594;C1836672;C4552857
1663,time from pah diagnosis months,C0011900;C0030123;C0556969;C1704338;C1704656;C3203102;C4284467
1663,pooled pah - mctd and pah,C0026272;C0030123;C1709595;C2349200;C3203102;C4284467;C4522255
1663,pah - ssc,C0030123;C3203102;C3897657;C4284467
1663,pah - sle,C0024141;C0030123;C3203102;C4284467
1663,pah - mctd / ctd - other,C0026272;C0030123;C1335071;C1442905;C3203102;C4284467
1663,pah - ctd,C0030123;C1335071;C1442905;C3203102;C4284467
1662,subcutaneous unfractionated heparin,C0353681
1662,subcutaneous injections,C0021499
1662,subcutaneous ( n = $nmbr$ ),C0443315
1662,mucocutaneous,
1661,prior percutaneous coronary intervention — no . / total no . ( % ),C0332152;C0439175;C0439810;C1532338;C2826257
1661,prior percutaneous coronary intervention — no . ( % ),C0332152;C1532338;C2826257
1661,prior percutaneous coronary intervention  n ( % ),C0332152;C1532338;C2826257
1661,prior percutaneous coronary intervention,C0332152;C1532338;C2826257
1661,previous percutaneous coronary intervention  %,C0205156;C1532338;C1552607
1661,previous percutaneous coronary intervention,C0205156;C1532338;C1552607
1661,percutaneous coronary revascularization,C1532338
1661,percutaneous coronary intervention §,C1532338
1661,percutaneous coronary intervention n ( % ),C1532338
1661,percutaneous coronary intervention done *,C1532338
1661,percutaneous coronary intervention  n ( % ),C1532338
1661,percutaneous coronary intervention,C1532338
1661,index percutaneous coronary intervention,C0600653;C0918012;C1532338;C1552854;C1637833;C2986546
1660,othert,
1660,other supraventricular tachycardia,C0039240;C1963244;C3815188
1660,nutraceuticals  n ( % ),C1518478
1660,any llt other than nutraceuticals  n ( % ),C1518478;C2347090
-10,cutoffs,C1442160
1658,other bph - luts therapy,C0005001;C0039798;C0087111;C0574785;C1363945;C1704272
1658,luts severity,C0439793;C0522510;C0574785
1658,luts = lower urinary tract symptoms  is =,C0574785
1658,luts / bph characteristics,C0005001;C0574785;C1521970;C1704272
1658,is domain luts severity ( % ),C0439793;C0522510;C0574785;C1880389;C1883221;C3541951
1658,bph - luts severity,C0005001;C0439793;C0522510;C0574785;C1704272
1658,baseline luts severity * :,C0168634;C0439793;C0522510;C0574785;C1442488
1658,baseline luts severity  n ( % ) :,C0168634;C0439793;C0522510;C0574785;C1442488
1657,subsets,C1515021
1657,subset of patients on metformin,C0025598;C0030705;C1515021
1657,subset of patients not on metformin,C0025598;C0030705;C1515021;C1518422
1657,other climate subset,C0008946;C1515021
1657,hot climate subset,C0178683;C1515021
1656,musculoskeletal stiffness,C0427008;C0497254;C2707260
1656,musculoskeletal,C0497254;C2707260
1655,total subjects,C0439175;C0439810;C0681850;C1550501;C1706203;C2349001;C2697811
1655,subjects with prevalent vertebral fracture  n ( % ) prevalent vertebral fracture,C0033105;C0080179;C0220900;C0681850;C1550501;C1706203;C2349001;C2697811
1655,subjects who did receive labd prior to the study,C0332152;C0396059;C0557651;C0681850;C1514756;C1550501;C1706203;C2349001;C2603343;C2697811
1655,subjects who did not receive labd prior to the study,C0332152;C0396059;C0557651;C0681850;C1514756;C1518422;C1550501;C1706203;C2349001;C2603343;C2697811
1655,subjects randomized,C0034656;C0681850;C1550501;C1706203;C2349001;C2697811;C3815594
1655,subjects n,C0369718;C0441922;C0681850;C1550501;C1706203;C2349001;C2697811
1655,subjects ( n ),C0369718;C0441922;C0681850;C1550501;C1706203;C2349001;C2697811
1655,subjects,C0681850;C1550501;C1706203;C2349001;C2697811
1655,subject disposition  n ( % ),C0681850;C0743223;C1550501;C1705555;C1706203;C2349001;C2697811
1655,subject completion status  n ( % ),C0205197;C0449438;C0681850;C0805732;C1550501;C1554962;C1706203;C2348577;C2349001;C2697811;C3891295
1655,number of subjects in analysis,C0002778;C0237753;C0449788;C0681850;C0936012;C1524024;C1550501;C1706203;C2349001;C2697811
1655,number of subjects,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
1655,no . of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
1655,n events / n subjects,C0369718;C0441471;C0441922;C0681850;C1550501;C1706203;C2349001;C2697811;C3541888
1655,mrf subjects,C0312443;C0681850;C1412879;C1550501;C1706203;C2349001;C2697811
1655,male subjects ( n = $nmbr$  $nmbr$ ),C0086582;C0369718;C0441922;C0681850;C1550501;C1706180;C1706203;C1706428;C1706429;C2349001;C2697811
1655,in therapeutic range for warfarin subjects,C0043031;C0460097;C0681850;C1550501;C1706203;C2349001;C2697811
1655,female subjects ( n = $nmbr$ ),C0043210;C0086287;C0369718;C0441922;C0681850;C1550501;C1705497;C1705498;C1706203;C2349001;C2697811
1655,diabetic subjects  n = $nmbr$,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
1655,cvd subjects,C0007222;C0681850;C1550501;C1706203;C2349001;C2697811
1655,concomitant medications in > $nmbr$ % of subjects  no . ( % ),C0013227;C0521115;C0681850;C0802604;C1550501;C1706203;C2349001;C2598133;C2697811;C4284232
1655,all subjects - n,C0369718;C0441922;C0681850;C1550501;C1706203;C2349001;C2697811
1655,all subjects,C0681850;C1550501;C1706203;C2349001;C2697811
1655,( $nmbr$ subjects ),C0681850;C1550501;C1706203;C2349001;C2697811
1654,exacerbations requiring oral steroids / antibiotics ( past year ) ( % ),C0003232;C0003237;C0038317;C0442027;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710;C4086268;C4086728;C4521986
1654,antibiotics * *,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
1653,daily activities / social functioning,C0037395;C0871707
1653,daily activities,C0871707
1652,table $nmbr$ . characteristics of the patients at baseline . *,C0039224;C0168634;C0815172;C1442488;C1706074
1652,subject characteristics,C0681884;C1519021;C1706465
1652,patients with specific disease characteristics  n ( % ),C0030705;C0205369;C0599878;C1552740
1652,patients with specific disease characteristics,C0030705;C0205369;C0599878;C1552740
1652,patients ' characteristics,C0815172
1652,patient characteristics at randomization,C0034656;C0815172
1652,patient characteristics,C0815172
1652,lesion characteristics,C1286326
1652,disease characteristics *,C0599878
1652,disease characteristics,C0599878
1652,demographic / disease characteristics at baseline,C0011298;C0012634;C0168634;C0599878;C0683970;C1442488;C4684572
1652,characteristicsa,
1652,characteristica,
1652,anatomic complexity characteristics,C0439855;C0502371;C1704241
1651,stricturing,C1261287
1651,stenosis > $nmbr$ %,C0678234;C1261287;C2632116
1651,prior known stenosis > $nmbr$ %,C0205309;C0332152;C0678234;C1261287;C2632116;C2826257
1651,prior angiography showing stenosis ≥ $nmbr$ %  n   =   $nmbr$   $nmbr$ a,C0002978;C0332152;C0678234;C1261287;C1547282;C2632116;C2826257
1651,prior angiography showing stenosis > $nmbr$ %  n = $nmbr$ °,C0002978;C0332152;C0678234;C1261287;C1547282;C2632116;C2826257
1651,percent stenosis [ investigator ],C0035173;C0439165;C0678234;C1261287;C2632116
1651,percent stenosis [ core lab ],C0439165;C0678234;C1261287;C2632116;C4684837
1651,no . of vessels with > $nmbr$ % stenosis,C0005847;C0678234;C1261287;C2632116
1651,no . of coronary vessels with > $nmbr$ % diameter stenosis,C0010075;C0678234;C1261287;C1301886;C2632116
1651,maximal diameter stenosis,C0205289;C0678234;C0806909;C1261287;C1301886;C2632116;C4049713
1651,ica stenosis $nmbr$ % - $nmbr$ % f,C0016327;C0201519;C0678234;C1261287;C2632116
1651,diameter stenosis  mean ( sd )  %,C0552409;C0678234;C1261287;C2632116;C2699239
1651,% stenosis ( investigator ),C0035173;C0678234;C1261287;C2632116
1651,% stenosis ( core lab ),C0678234;C1261287;C2632116;C4684837
1651,% stenosis  as assessed by investigator,C0035173;C0678234;C1261287;C1516048;C2632116
1650,time to first inhaled corticosteroid ( % ),C0001617;C0004048;C0040223;C0205435;C1279901;C3536709;C3541383
1650,required corticosteroid and / or antibiotic ( without hospitalization ),C0001617;C0003232;C0019993;C1514873;C3536709
1650,refractory to corticosteroids  n ( % ),C0001617;C0205269;C3539185;C3540725;C3540726;C3540727
1650,receiving concomitant corticosteroids,C0001617;C0521115;C1514756;C3539185;C3540725;C3540726;C3540727
1650,prior corticosteroid treatment,C0001617;C1514463;C3536709
1650,patients taking oral corticosteroids at baseline  n ( % ),C0001617;C0030705;C0168634;C0442027;C1442488;C1515187;C3539185;C3540725;C3540726;C3540727;C4521986
1650,patients receiving corticosteroids at baseline,C0001617;C0030705;C0168634;C1442488;C1514756;C3539185;C3540725;C3540726;C3540727
1650,patients not receiving corticosteroids at baseline,C0001617;C0030705;C0168634;C1442488;C1514756;C1518422;C3539185;C3540725;C3540726;C3540727
1650,oral corticosteroids,C0001617;C0442027;C3539185;C3540725;C3540726;C3540727;C4521986
1650,oral corticosteroid use at enrolmentt,C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
1650,oral corticosteroid use at baseline,C0001617;C0168634;C0239126;C0442027;C1442488;C1527415;C3536709;C4521986
1650,oral corticosteroid use  n ( % ),C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
1650,oral corticosteroid,C0001617;C0442027;C3536709;C4521986
1650,no corticosteroids or immunosuppressants,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727
1650,no corticosteroid + no imm  n,C0001617;C0205470;C3536709
1650,no corticosteroid  no imm,C0001617;C0205470;C3536709
1650,no corticosteroid,C0001617;C3536709
1650,no baseline corticosteroids,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
1650,neither corticosteroid nor immunosuppressant,C0001617;C0021081;C3536709
1650,inhaled corticosteroids,C0001617;C0004048;C3539185;C3540725;C3540726;C3540727
1650,inhaled corticosteroid - yes  n ( % ),C0001617;C0004048;C1549445;C1705108;C1710701;C3536709
1650,inhaled corticosteroid,C0001617;C0004048;C3536709
1650,immy ( without corticosteroid )  n,C0001617;C3536709
1650,immunosuppressant ( with or without corticosteroid ),C0001617;C0021081;C3536709
1650,imm + corticosteroid  n,C0001617;C0205470;C3536709
1650,imm ( without corticosteroid ),C0001617;C0205470;C3536709
1650,dmard or corticosteroid,C0001617;C0242708;C3536709
1650,current oral corticosteroid use,C0001617;C0239126;C0442027;C0521116;C1527415;C1705970;C3536709;C4521986
1650,corticosteroidsa,
1650,corticosteroids only,C0001617;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727
1650,corticosteroids and immunosuppressants,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727
1650,corticosteroids and antimalarials only,C0001617;C0003374;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727
1650,corticosteroids . immunosuppressants . and antimalarials,C0001617;C0003374;C0021081;C3539185;C3540725;C3540726;C3540727
1650,corticosteroids ( excluding budesonide ),C0001617;C0054201;C0332196;C2828389;C3539185;C3540725;C3540726;C3540727
1650,corticosteroids ' $nmbr$,C0001617;C3539185;C3540725;C3540726;C3540727
1650,corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
1650,corticosteroid or immunosuppressant,C0001617;C0021081;C3536709
1650,corticosteroid and immunosuppressant,C0001617;C0021081;C3536709
1650,corticosteroid + imm,C0001617;C0205470;C3536709
1650,corticosteroid ( without imm )  n,C0001617;C0205470;C3536709
1650,corticosteroid ( without imm ),C0001617;C0205470;C3536709
1650,corticosteroid ( with or without immunosuppressants ),C0001617;C0021081;C3536709
1650,corticosteroid,C0001617;C3536709
1650,concomitant use of corticosteroids,C0001617;C0521115;C1524063;C3539185;C3540725;C3540726;C3540727
1650,concomitant oral corticosteroids  n ( % ) * *,C0001617;C0442027;C0521115;C3539185;C3540725;C3540726;C3540727;C4521986
1650,catecholamines or corticosteroids without hospitalization,C0001617;C0007412;C0019993;C3539185;C3540725;C3540726;C3540727
1650,baseline corticosteroids *,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
1650,b ) those on inhaled corticosteroids and long - acting bronchodilators as previous treatment use .,C0001617;C0004048;C0006280;C0039798;C0042153;C0079613;C0087111;C0205156;C0205166;C0457083;C1522326;C1533734;C1552607;C1704930;C1705169;C1706317;C1869853;C1947944;C3538994;C3539185;C3540725;C3540726;C3540727;C3887704;C3890007;C4048375
1650,any ( including corticosteroid ),C0001617;C0332257;C3536709
1650,> $nmbr$ corticosteroids or immunosuppressants,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727
1649,time to first oral or systemic corticosteroid ( % ),C0040223;C0205435;C0442027;C1279901;C3541383;C4053960;C4521986
1649,systemic corticosteroids — no . ( % ),C4053960
1649,systemic corticosteroids  n ( % ) a,C4053960
1649,systemic corticosteroids  n ( % ),C4053960
1649,rate of oral or systemic corticosteroid,C0442027;C0871208;C1521828;C4053960;C4521986
1649,oral or other systemic corticosteroid,C0442027;C4053960;C4521986
1648,steroids § §,C0038317
1648,steroids ( other ),C0038317
1648,steroids ( n = $nmbr$ vs $nmbr$ ),C0038317
1648,steroids ( inhaled ) a,C0004048;C0038317
1648,steroids  n ( % ),C0038317
1648,other steroids,C0038317
1648,no steroids ( n = $nmbr$ vs $nmbr$ ),C0038317
1647,dutasteride ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0754659
1647,dutasteride ( n = $nmbr$ ),C0754659
1647,dutasteride,C0754659
1647,combined ( dutasteride / ta msu losi n ),C0024776;C0039297;C0205195;C0754659;C1412759;C1506978;C1705538;C3272501;C4553364
1646,statini,
1646,statin therapy,C1278454
1646,standard therapy ( n = $nmbr$ ),C2936643
1646,standard therapy,C2936643
1646,prerandomization statin therapy,C1278454
1646,combined therapy vsta msu iosin,C0024776;C0033972;C1412759
1646,combined therapy vsdutasteride,C0033972
1646,combined therapy ( / v = $nmbr$ )  $nmbr$ / $nmbr$,C0033972
1645,tertiary endpoints :,C0205372;C2349179
1645,tertiary end points,C0205372;C2349179
1645,tertiary amines,C3653356
1645,tertiary,C0205372
1644,toward,
1644,third yeart,C0205437
1644,third heart sound  n ( % ),C0232237;C0232278
1644,third heart sound,C0232237;C0232278
1644,slowest third,C0205437;C0439834
1644,one - third radius,C0034627;C0205437;C0205447;C1306504
1644,in thirds,C0205437
1644,distal one - third of radius,C0034627;C0205437;C0205447;C0450168;C0588207;C1306504
1643,residual deep - vein thrombosis  no . ( % ),C0149871;C1609982
1643,previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis,C0042487
1643,patients with deep - vein thrombosis only,C0030705;C0149871;C0205171;C1720467
1643,isolated deep - vein thrombosis,C0149871;C0205409;C1548221
1643,deep vein thrombosis only,C0149871;C0205171;C1720467
1643,deep - vein thrombosis only,C0149871;C0205171;C1720467
1643,deep - vein thrombosis ( % ),C0149871
1643,deep - vein thrombosis,C0149871
1642,direct thrombin inhibitors,C0003440;C3541936
1642,antithrombin,C0003438;C0003440;C4521254
1641,thrombus aspiration done per lesion †,C0087086;C0220787;C0221198;C0302148;C0349707;C0700198;C1272695;C1546698;C2712334;C2827071;C3146237
1641,thrombus aspiration,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
1641,thrombus - containing lesion,C0087086;C0221198;C0302148;C0332256;C1546698;C2700400;C3146237
1641,new or suspected thrombus,C0087086;C0205314;C0302148;C0332147;C0750491;C3146237
1641,increased - risk for thrombotic cardiovascular,C0007226;C0087086;C3887460;C4699158
1641,anti - thrombotics,C0087086
1640,low risk and more symptoms ( group b ),C0205172;C0683368;C1457887;C3272281;C3538919;C4522078
1640,high risk and more symptoms ( group d ),C0205172;C0332167;C0441838;C0683368;C1457887;C3272283;C4050568;C4319571
1640,group d,C0441838
1640,group c,C0441837
1640,group b,C4522078
1640,group a,C0441835;C4522145
1640,gold group c,C0018026;C0441837;C1304897
1640,gold group a,C0018026;C0441835;C1304897;C4522145
1639,glycaemic control group,C0005802;C0009932
1639,events / control group,C0009932;C0441471;C3541888
1639,control group,C0009932
1638,total group ( n = $nmbr$ ),C0439175;C0439810;C0441848
1638,rate - control group ( n = $nmbr$ ),C0441848;C0489879
1638,racial group  n ( % ),C0034510;C0441848;C1706779;C3669213;C3853635
1638,pioglitazone group ( n = $nmbr$ ),C0071097;C0441848
1638,no epa group n = $nmbr$,C0441848
1638,group c ( n = $nmbr$ ),C0441848
1638,group b ( n = $nmbr$ ),C0441848
1638,group a ( n = $nmbr$ ),C0441848
1638,etoricoxib group ( n = $nmbr$ $nmbr$ ),C0441848;C0972314
1638,epa group n = $nmbr$,C0441848
1638,diclofenac group ( n = $nmbr$ $nmbr$ ),C0012091;C0441848
1638,colesevelam hydrochloride group ( n = $nmbr$ ),C0441848;C0541154
1638,certolizumab group ( n = $nmbr$ ),C0441848;C1872109
1638,c group ( n = $nmbr$ ),C0441848
1638,benazepril - hydrochlorothiazide group ( n = $nmbr$ ),C0441848;C0717481
1638,benazepril - amlodipine group ( n = $nmbr$ ),C0051696;C0053091;C0441848
1638,antiplatelet - only group ( n = $nmbr$ ),C0205171;C0441848;C1720467
1638,antiplatelet - onl group ( n = $nmbr$ ),C0441848
1637,tpm subgroup  n = $nmbr$,C0076829;C1079230;C1515021
1637,the plot shows hazard ratios and $nmbr$ % confidence intervals for the primary outcome  with patients stratified according to eight sub - groups prespecified in the statistical analysis plan . no heterogeneity was observed for these subgroups .,C0009667;C0019409;C0205225;C0205363;C0205454;C0242960;C0270724;C0439612;C0439631;C0441833;C0542339;C0599880;C0680240;C0687744;C0871424;C1079230;C1257890;C1264637;C1301732;C1441672;C1519504;C1547282;C1547647;C1552839;C1705428;C1705429;C2985465
1637,subgroupt,
1637,subgroups,C1079230
1637,subgroup_level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
1637,subgroup p valuef,C1079230;C1515021
1637,subgroup overall,C0282416;C1079230;C1515021;C1561607
1637,subgroup no .,C1079230;C1515021
1637,subgroup name / level,C0027365;C0441889;C0456079;C1079230;C1515021;C1547383;C1547707;C2946261;C4522128
1637,subgroup levels,C0441889;C1079230;C1515021
1637,subgroup level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
1637,subgroup based on :,C1079230;C1515021;C1527178;C1705938
1637,subgroup $nmbr$,C1079230;C1515021
1637,subgroup,C1079230;C1515021
1637,secondary prevention subgroup,C0679699;C1079230;C1515021
1637,renal subgroup,C0022646;C1079230;C1515021
1637,renal function subgroups,C0232804;C1079230
1637,primary prevention subgroup,C0033144;C1079230;C1515021
1637,prespecified subgroups,C1079230
1637,p  subgroup *,C0369773;C1079230;C1515021;C2603361
1637,outcome_subgroup,C1079230;C1274040;C1515021
1637,m $nmbr$ subgroup,C0369637;C0441923;C1079230;C1515021
1637,latin american subgroup,C1079230;C1515021;C1553378
1637,genetic subgroup,C0017296;C0314603;C1079230;C1515021
1637,female subgroup,C0043210;C0086287;C1079230;C1515021;C1705497;C1705498
1637,diuretic subgroup,C0012798;C1079230;C1515021
1637,baseline subgroup,C0168634;C1079230;C1442488;C1515021
1637,baseline mtss subgroup,C0168634;C1079230;C1442488;C1515021
1637,baseline hba $nmbr$ c subgroup,C0019016;C0168634;C1079230;C1442488;C1515021;C1825777;C3538758
1637,asubset of the ≥ $nmbr$ years subgroup .,C0439234;C1079230;C1515021
1637,additional antihypertensive subgroup,C0003364;C1079230;C1515021;C1524062
1637,( subgroup ),C1079230;C1515021
1636,subgroup analyses,C2986480
1636,prespecified subgroup analyses,C2986480
1636,additional subgroup analyses,C1524062;C2986480
1635,tamong those enrolling via bnp stratum . the study - qualifying bnp or,C0054015;C0557651;C1095989;C1417808;C1514624;C2603343;C2982014
1635,nptercile $nmbr$ ( bnp $nmbr$ - $nmbr$ pg / ml  nt - probnp $nmbr$ - $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0439297;C1095989;C1317554;C1417808;C2825907;C2982014;C4284038
1635,np tercile $nmbr$ ( bnp > $nmbr$ pg / ml  nt - probnp > $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038
1635,np tercile $nmbr$ ( bnp < $nmbr$ pg / ml  nt - probnp < $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038
1635,normal bnp  ^ $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ ),C0054015;C0205307;C0231683;C0439166;C0439297;C1095989;C1417808;C2347086;C2982014;C4553972
1635,nesiritide ( n = $nmbr$ ),C0054015
1635,nesiritide  % z,C0054015
1635,median bnp ( iqr ) – pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
1635,mean ( $nmbr$ th to $nmbr$ thquartile ) bnp ( pg / ml ),C0039725;C0039738;C0054015;C0439297;C0444504;C1095989;C1417808;C1420718;C2347634;C2348143;C2982014;C4282123;C4285344
1635,elevated bnp ( $nmbr$ pg / ml )  %,C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
1635,elevated bnp  > $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ ),C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
1635,elevated bnp,C0054015;C0205250;C1095989;C1417808;C2982014;C3163633
1635,bnp — pg / ml  i,C0021966;C0023806;C0030827;C0054015;C0072225;C0221138;C0439297;C1095989;C1266240;C1417808;C2982014
1635,bnp — pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
1635,bnp o $nmbr$ pg / ml or nt pro - bnp o $nmbr$ pg / ml  n ( % ),C0033382;C0054015;C0439297;C0523852;C1095989;C1417808;C2982014;C2987124;C4284038
1635,bnp indicates brain natriuretic peptide  and nyha  new york heart association .,C0004083;C0018787;C0027976;C0054015;C0439849;C0596306;C0699792;C1095989;C1275491;C1417808;C2982014
1635,bnp > $nmbr$ pg / ml or nt pro - bnp > $nmbr$ pg / ml  n ( % ),C0033382;C0054015;C0439297;C0523852;C1095989;C1417808;C2982014;C2987124;C4284038
1635,bnp > $nmbr$ pg / ml n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
1635,bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
1635,bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
1635,bnp > $nmbr$ pg / ml  n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
1635,bnp < $nmbr$ pg / ml n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
1635,bnp / nt - probnp,C0054015;C0669479;C0754710;C1095989;C1417808;C2982014
1635,bnp ( pg / ml ) h,C0030827;C0033727;C0054015;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C1095989;C1266240;C1417808;C1705224;C2827929;C2982014;C3887665;C4528284
1635,bnp ( pg / ml ),C0054015;C0439297;C1095989;C1417808;C2982014
1635,bnp ( n = $nmbr$ ),C0054015;C1095989;C1417808;C2982014
1635,bnp  pg / mlt,C0030827;C0054015;C0072225;C1095989;C1266240;C1417808;C2982014;C4553833
1635,bnp  pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
1635,bnp  median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
1635,bnp  * median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
1635,bnp,C0054015;C1095989;C1417808;C2982014
1634,tr jet velocity ( m / sec ),C0108801;C0336862;C0439493;C0439830;C1539482;C1547053;C1705610;C1872943;C3811249;C3811250;C3814152
1634,m $nmbr$ s,C0439493;C1513009
1633,treatment comparison ( mg / day ) t,C0039798;C0087111;C0439422;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
1633,treatment comparison,C0039798;C0087111;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
1633,pairwise comparison,C1707455
1633,l compared wi,C0043193;C0439394;C1520135;C1706495;C1707455;C3642217
1633,comparison with baseline ( mean,C0168634;C0444504;C1442488;C1707455;C2347634;C2348143
1633,comparison with baseline,C0168634;C1442488;C1707455
1633,comparison,C1707455
1633,ci  confidence interval  esrd  end - stage renal disease  n / n  number of patients who had an event / total number of patients . aadjusted with terms including treatment ( losartan or placebo )  geographic region  genotype  and the treatment  genotype interaction . bp value for treatment  genotype interaction ( i . e .  comparison of the losartan treatment effect between the $nmbr$ genotype groups ) .,C0008107;C0009667;C0017431;C0017446;C0022661;C0030705;C0032042;C0037623;C0039798;C0087111;C0126174;C0205147;C0233324;C0332257;C0441471;C0441833;C0683454;C0687744;C1257890;C1280500;C1415692;C1515273;C1517526;C1518681;C1519504;C1522326;C1522609;C1533734;C1552839;C1696465;C1704675;C1705169;C1705313;C1705428;C1705429;C1706408;C1707455;C1708288;C2348382;C2360800;C2826302;C3259781;C3538994;C3887704;C4019010;C4288115;C4318478
1633,a compared wi,C0043193;C1520135;C1707455
1633,a compared w,C1707455
1632,total comparators ( n = $nmbr$ ),C0439175;C0439810;C1707454;C4553389;C4553390
1632,total comparators  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C1707454;C3541888;C4553389;C4553390
1632,favors comparator,C0309049;C1707454;C4553389;C4553390
1632,comparator,C1707454;C4553389;C4553390
1631,renal composite *,C0022646;C0205199;C1547335
1631,primary composite endpoint ‡,C0205199;C1547335;C2986535
1631,primary composite end point ‡,C0205199;C1547335;C2986535
1631,primary composite end point,C0205199;C1547335;C2986535
1631,disease - progression composite outcome !,C0205199;C0242656;C0449258;C0679250;C1274040;C1335499;C1547335;C1947900;C3542417;C4552808
1631,cromoglicate,C0010347
1631,composite vascular endpoint,C0005847;C0205199;C1547335;C1558950;C1801960;C2349179;C2826544
1631,composite of doubling of serum creatinine  end - stage kidney disease  or death from renal causes,C0007465;C0022646;C0022658;C0201976;C0205088;C0205173;C0205199;C0600061;C1547335;C1705764
1631,composite ocular end point ^,C0015392;C0042789;C0205199;C0700042;C1299003;C1547335;C2349179;C2826544;C4521296
1631,composite microvascular end point *,C0205199;C0443258;C1547335;C2349179;C2826544
1631,composite endpoint ( a $nmbr$ c < $nmbr$ . $nmbr$ %  bp,C0037623;C0205199;C1415692;C1547335;C1708288;C2349179;C2826544;C4318478
1631,composite endpoint,C0205199;C1547335;C2349179;C2826544
1631,composite,C0205199;C1547335
1631,components of primary composite end point — secondary end points,C0205199;C1547335;C1882460;C4528314
1631,( composite endpoint ),C0205199;C1547335;C2349179;C2826544
1630,hospitalized without airway compromise,C0701159;C4055482
1630,airway compromise,C4055482
1629,implanted pacemaker,C0848753
1629,impacts,C1825598;C4049986
1628,implanted cardioverter defibrillator,C0021102;C0810516;C2828363
1628,implanted cardioverter - defibrillator,C0021102;C0810516;C2828363
1628,implantable cardioverter - defibrillator n ( % ),C0162589;C2825184
1628,implantable cardioverter - defibrillator,C0162589;C2825184
1628,data are mean ( sd ) or number ( % ) . pufa = polyunsaturated fatty acids  bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . nyha = newyork heart association . lvef = left ventricular ejection fraction . hf = heartfailure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter defibrillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .,C0004083;C0005823;C0010055;C0012000;C0018787;C0018801;C0021122;C0022709;C0024117;C0030705;C0032042;C0032615;C0085805;C0155626;C0162589;C0185098;C0205042;C0237753;C0428772;C0439849;C0444504;C0449788;C0470187;C0488055;C0488728;C0521942;C0536221;C0596306;C0699792;C0815017;C0871470;C1264633;C1271104;C1272641;C1275491;C1305855;C1306620;C1511726;C1532338;C1554103;C1696465;C1706408;C2347634;C2348143;C2699239;C2733342;C2825184;C3245479;C3714741;C3813197;C3888198;C4281799
1627,subjects with imputed value for end ‐ of ‐ treatment body weight,C0039798;C0087111;C0681850;C1522326;C1522609;C1533734;C1550501;C1705169;C1706203;C2349001;C2697811;C2699638;C2983672;C3538994;C3887704
1627,imputed,C2699638
1627,bocf - iike imputation ( random . ) ( n = $nmbr$ ),C0034656;C0439605;C2699638;C2984917
1626,serum potassium level  mean ( sd )  meq / l,C0302353;C0439375;C0444504;C0543465;C2347634;C2348143;C2699239
1626,serum potassium  meq / l,C0302353;C0439375;C0543465
1626,eos serum k +  meq / l,C0302353;C0439375;C1623465;C1861303
1626,elevated bun ( > $nmbr$ . $nmbr$ meq / l ),C0151539;C0439375
1626,baseline : > $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
1626,baseline : > $nmbr$ . $nmbr$ meq / l eos : < $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
1626,baseline : < $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ or < $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
1626,$nmbr$ mq / kq *,C0024853
1625,ssomgdayp . eq .,C0205163;C0439185
1625,eq - $nmbr$ dprofile - mobility  n ( % ),C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
1625,eq - $nmbr$ d mobility,C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
1625,eq - $nmbr$ d ( visual analog score ),C0205163;C0234621;C0243071;C0439185;C0449820;C4050231
1625,eq $nmbr$ da health index status score,C0011318;C0018759;C0205163;C0439185;C0449820;C0600653;C0918012;C1552854;C1637833;C2986546;C3668815;C4050231
1625,< $nmbr$ mgday p . eq .,C0205163;C0439185
1624,dual therapy,C0039798;C0087111;C0205173;C1363945;C1554184
1624,dual antiplatelet therapy,C0205173;C1096021;C1554184
1624,dual antiplatelet,C0205173;C1554184
1623,plasma dha  mean ( sd ) weight  %,C0005910;C0032105;C0043100;C0142831;C0444504;C1305866;C1550098;C1705104;C2347634;C2348143;C2348308;C2699239;C4521445
1623,dha ( n = $nmbr$ ),C0142831;C2348308
1622,radiate,C0332301
1622,ohs graduate,C0268353;C0588053;C1547183;C1861455
1622,hs graduate / ged,C0588053;C1547183;C1880947
1621,vte at day $nmbr$ +,C0332173;C0439228;C0439505;C0630906
1621,use of rescue albuterol  puffs / day *,C0001927;C0332173;C0439228;C0439505;C1524063;C1533107
1621,treatment duration before randomization — days,C0034656;C0439228;C0444921;C3259042
1621,treatment duration  days,C0439228;C0444921;C3259042
1621,treatment before randomization — days,C0034656;C0039798;C0087111;C0439228;C1522326;C1533734;C1705169;C3538994;C3887704
1621,time from onset of symptoms to randomization — days,C0034656;C0439228;C1320528
1621,time from index acs event to randomisation ( days ),C0034656;C0040223;C0439228;C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4019010;C4318612
1621,time from event to randomization — days,C0034656;C0040223;C0439228;C0441471;C3541383;C4019010
1621,subacute ( $nmbr$ - $nmbr$ days ),C0205365;C0439228
1621,slo days,C0439228;C1416602;C3539661
1621,saba puffs per day at baseline,C0168634;C0332173;C0439228;C0439505;C1442488;C1533107
1621,recent use of allopurinol ( within $nmbr$ days of,C0002144;C0332185;C0439228;C1524063
1621,recent cardioversion ( within $nmbr$ days before randomization ) — no . ( % ),C0013778;C0034656;C0332185;C0439228
1621,recent cardioversion ( within $nmbr$ days before randomization ) —,C0013778;C0034656;C0332185;C0439228
1621,patient status after wake - up  % of days patient woke :,C0439228;C0442696;C0449437;C0585034;C1170730
1621,no . of days to randomization — median ( iqr ),C0034656;C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1621,medications at discharge or day $nmbr$  if earlier ( % ),C0332173;C0439228;C0439505;C0806915;C1279919
1621,medication within $nmbr$ days before enrolment,C0013227;C0439228;C1516879;C1696073;C3244316;C3888021;C4284232
1621,median duration of study - drug administration ( iqr ) — days,C0013175;C0439228;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
1621,median ( days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1621,mean ( sd ) extent of exposure  days,C0274281;C0332157;C0439228;C0439792;C0444504;C2347634;C2348143;C2699239
1621,insulin dose — lu / day,C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
1621,insulin dose ( lu / day ),C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
1621,infarction > $nmbr$ days previously,C0021308;C0439228
1621,infarction $nmbr$ - $nmbr$ days,C0021308;C0439228
1621,infarct ion w ithin previous $nmbr$ day s,C0021308;C0022023;C0205156;C0332173;C0439228;C0439505;C1552607;C1700702
1621,index stroke > $nmbr$ days before randomization — no . ( % ),C0034656;C0439228;C0456712
1621,hospital stay ( days ),C0439228;C3489408
1621,hospital stay  days,C0439228;C3489408
1621,exposure to study drug — days,C0013175;C0332157;C0439228
1621,every day,C0332173;C0439228;C0439505
1621,ended > $nmbr$ days before trial entry,C0008976;C0439228;C1272693;C1705654;C2746065
1621,elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) : ! :,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
1621,elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) $,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
1621,days with heartburna ( days ),C0439228
1621,day $nmbr$ oral glucocorticoid use — no . { % ),C0017710;C0042153;C0332173;C0439228;C0439505;C0442027;C0457083;C1947944;C4521986
1621,conversion to sinus rhythm in < $nmbr$ days,C0439228;C1321500
1621,change from baseline in rescue medication use ( puffs per day ),C0168634;C0240320;C0332173;C0392747;C0439228;C0439505;C0443172;C1442488;C1533107;C1705241;C4319952
1621,baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$ - q $nmbr$ ),C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352
1621,baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$  q $nmbr$ ),C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352
1621,aspirin < $nmbr$ day,C0004057;C0332173;C0439228;C0439505
1621,as - needed inhalations / day,C0004048;C0332173;C0354922;C0439228;C0439505;C1879745;C1883728
1621,absolute time spent “ on ”  h / day,C0033727;C0332173;C0369286;C0439228;C0439505;C0439546;C0441932;C0564385;C0680968;C4528284
1621,a ngina > $nmbr$ day s previously *,C0332173;C0439228;C0439505
1621,^ $nmbr$ days,C0439228
1621,> = medion ( $nmbr$ days ),C0439228
1621,> = median ( $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1621,> = $nmbr$ days,C0439228
1621,> $nmbr$ days warfarin,C0043031;C0439228
1621,> $nmbr$ days ( % ),C0439228
1621,> $nmbr$ days,C0439228
1621,> $nmbr$ / day,C0332173;C0439228;C0439505
1621,< median ( $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1621,< $nmbr$ days ( n = $nmbr$ ),C0439228
1621,< $nmbr$ days ( % ),C0439228
1621,< $nmbr$ days,C0439228
1621,( iqr ) — days,C0439228
1621,$nmbr$ — $nmbr$ days,C0439228
1621,$nmbr$ or $nmbr$ days,C0439228
1621,$nmbr$ days new mi or definite acute st,C0036056;C0205178;C0205314;C0439228;C0439544;C1704787;C3272372;C3810814
1621,$nmbr$ days new mi,C0205314;C0439228;C3810814
1621,$nmbr$ days,C0439228
1621,$nmbr$ day l,C0332173;C0439228;C0439505
1621,$nmbr$ / day,C0332173;C0439228;C0439505
1621,$nmbr$ - day mortality,C0026565;C0026566;C0332173;C0439228;C0439505
1621,$nmbr$ - day cce,C0332173;C0439228;C0439505
1621,$nmbr$ - $nmbr$ days ( % ),C0439228
1621,$nmbr$ - $nmbr$ days,C0439228
1621,$nmbr$ - $nmbr$ / day,C0332173;C0439228;C0439505
1620,treatment ( de vs warfarin ) by thrombophilia interaction,C0011198;C0017480;C0039798;C0043031;C0087111;C0398623;C1522326;C1533734;C1704675;C1705169;C3538994;C3541240;C3887704
1620,hemoglobin ( gm / dl ),C0017480;C0019046;C3642216;C3854019
1620,germany,C0017480
1620,de ( n = $nmbr$ ),C0011198;C0017480;C3541240
1620,de $nmbr$ n = $nmbr$,C0011198;C0017480;C3541240
1620,de $nmbr$ mg bid ( n - $nmbr$  $nmbr$ ),C0011198;C0017480;C0024671;C0026410;C0439269;C1960952;C2346927;C3541240;C4321396;C4521761
1620,de,C0011198;C0017480;C3541240
1619,treatment during or after catheterization,C0007430;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1619,or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) < $nmbr$ . $nmbr$,
1619,or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$,
1619,fibrinolytic agents before or after entry,C0016018;C1705654
1618,on or after e ^ andomization,
1618,after $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
1618,$nmbr$ hr after glucose challenge,C3840385
1617,leader,
1617,laser or vitrectomy,C0023089;C0042903;C0458142;C1023865;C1706315
1617,greater than or equal to $nmbr$ mm hg,C0205163;C0439093;C0439475
1617,greater than or equal to $nmbr$ %,C0205163;C0439093
1617,$nmbr$ or greater,C1704243
1616,othera,
1616,other teaes,
1616,other ischaemic heart disease ( non - infarction ),C0010054;C0021308;C0151744;C1518422
1616,other antihyperglycemic agents  not listed,C0020616;C0745732;C1518422;C3272378
1616,other *,
1616,other ( $nmbr$ . $nmbr$ % ) t,C2603360
1616,other ',
1615,tnfi ( no other bdmard taken ) t  n ( % ),C1883727;C2986835
1615,other bdmards ( no tnfi taken ) t  n ( % ),C1883727;C2986835
1615,other bdmard §,
1614,testing order,C0039593;C0392366;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
1614,hder *,C3898895
1613,nontraumatic leg or foot amputation,C0023216;C0188605;C1140621
1613,lower limbs,C0023216
1613,lower limb fractures,C0016658;C0023216
1613,lower limb fracture,C0016658;C0023216;C0441994;C0596838;C1548802;C2003888
1613,lower - limb arterial — no . ( % ),C0003842;C0023216;C0221464
1612,other blood glucose - lowering agents,C0005802;C0441994;C0450442;C1254351;C1521826;C2003888
1612,other : :,
1612,lower than normal range — % ^,C0086715;C0441994;C1548802;C2003888
1612,lower tertile : b $nmbr$ . $nmbr$,C0441994;C1548802;C2003888
1612,lower,C0441994;C1548802;C2003888
1612,distal lower,C0205108;C0441994;C1548802;C2003888;C4522154
1611,liver disorder,C0023895
1611,hepatic disorders,C0023895
1611,acute rheumatic disorders,C0001314
1610,neurocognitive disorders,C0029227;C4041080
1610,gastrointestinal disorders,C0017178
1610,gastrointestinal ( gi ) disorders,C0017178;C1708130;C3539617;C4050121
1609,pacific islander,C0242191
1609,other pacific islander,C0242191
1609,islander,
1609,bladder,C0005682;C4319531
1609,asian or pacific islander,C0078988;C0242191
1609,asian / pacific islander  n ( % ),C0078988;C0242191
1608,mucolytics,C0026698
1608,mucolytic agent,C0026698
1607,myoclonic,
1607,juvenile myoclonic epilepsy,C0270853
1606,pathological q waves,C0429090
1606,pathologic q waves — no . ( % ),C0429090
1606,pathologic q waves  n ( % ),C0429090
1606,hematologic,C0018943;C0205488
1606,haematological,C0018943;C0200627
1605,troponin t,C0077404;C1420827
1605,troponin ( - ),C0041199
1605,elevated troponin — %,C0041199;C0205250;C3163633
1605,elevated troponin t ( > $nmbr$ . $nmbr$ / xg / l ),C0017209;C0077404;C0205250;C1292284;C1420827;C1421532;C3163633
1605,elevated troponin ( > $nmbr$ . $nmbr$ pg / l ),C0041199;C0205250;C0439278;C3163633
1605,elevated troponin ( > $nmbr$ . $nmbr$ mg / l )  %,C0041199;C0205250;C0439268;C3163633
1605,elevated troponin,C0041199;C0205250;C3163633
1604,cryptogenic localization - related,C0332240;C0439849;C0445223;C0475264;C1744691
1604,cryptogenic,C0332240
1603,troponin ( + ),C0041199
1603,troponin $nmbr$ at baseline *,C0041199;C0168634;C1442488
1603,troponin $nmbr$ at baseline,C0041199;C0168634;C1442488
1603,troponin,C0041199
1603,positive troponin or ck - mb,C0010290;C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
1602,result,C1274040;C1546471;C2825142
1602,outcomes during accord,C0680240;C1274040
1602,outcomes,C1274040
1602,outcome severity,C0439793;C0522510;C1274040
1602,outcome according to stage of cancer — no . / total no . ( % ),C0027646;C0439175;C0439810;C0680240;C1274040
1602,outcome according to primary cancer site — no . / total no . ( % ),C0439175;C0439810;C0680240;C0872338;C1274040
1602,outcome according to no . of risk factors for vte,C0035648;C0630906;C0680240;C1274040;C1553898
1602,outcome - variant,C0205419;C1274040
1602,outcome ( n  % },C1274040
1602,outcome,C1274040
1602,other outcomes,C1274040
1602,microvascular outcome,C0443258;C1274040
1602,exploratory kidney and microvascular outcomes,C0022646;C0227665;C0443258;C1274040
1602,clinical outcome,C0205210;C1274040
1602,characteristic / outcome,C1274040;C1521970
1602,baseline outcomes,C0168634;C1274040;C1442488
1602,ancova result,C0814908;C1274040;C1546471;C2825142
1602,adverse outcome,C1274040
1601,trough fevi l,C0429706;C0444506;C0849974;C1561566;C4528367
1601,proportion of patients with trough fevi > $nmbr$ ml above baseline  n ( % ),C0030705;C0168634;C0429706;C0439526;C0444506;C0849974;C1442488;C1561566;C1705224;C1709707;C3887665;C4528367
1601,prebronchodilator fevi — liters,C0429706;C0475211;C0849974;C1561566;C2599602;C4528367
1601,prebronchodilator fevi ( % predicted ),C0681842;C0849974;C1561566;C1882327;C2599602;C4528367
1601,pre - bronchodilator fevi change,C0392747;C0443172;C0849974;C1561566;C1705241;C2599602;C4319952;C4528367
1601,post - bronchodilator fevi $nmbr$ % predicted,C0681842;C0849974;C1561566;C1882327;C2599594;C4528367
1601,post - bronchodilator fevi  n ( % ),C0429706;C0849974;C1561566;C2599594;C4528367
1601,mean ( sd ) fevi / evc  %,C0013903;C0429706;C0429711;C0444504;C0849974;C1414479;C1561566;C2347634;C2348143;C2699239;C4528367
1601,mean ( sd ) fevi  ml,C0429706;C0439526;C0444504;C0849974;C1561566;C1705224;C2347634;C2348143;C2699239;C3887665;C4528367
1601,fevi percent predicted ( % ),C0429706;C0439165;C0681842;C0849974;C1561566;C1882327;C4528367
1601,fevi auc $nmbr$ - $nmbr$ l,C0376690;C0429706;C0849974;C1561566;C4528367
1601,fevi $nmbr$ l,C0429706;C0849974;C1561566;C4528367
1601,fevi  l *,C0429706;C0849974;C1561566;C4528367
1601,fevi  l,C0429706;C0849974;C1561566;C4528367
1601,fevi  % predicted *,C0681842;C0849974;C1561566;C1882327;C4528367
1601,adjusted mean ( se ) trough fevi  ml,C0036919;C0429706;C0439526;C0444504;C0444506;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367
1601,$nmbr$ ( fevi ^ $nmbr$ % pred ),C0032952;C0044955;C0849974;C1561566;C4528367
1601,$nmbr$ ( fevi $nmbr$ - < $nmbr$ % pred ),C0032952;C0044955;C0849974;C1561566;C4528367
1600,pre - bronchodilator fevi / fvc  %,C0802741;C2599602;C3815113
1600,mean ( sd ) fevi / fvc  %,C0444504;C0802741;C2347634;C2348143;C2699239;C3815113
1600,fevi / fvc ( % ),C0802741;C3815113
1599,trough fev $nmbr$,C0444506;C3714541
1599,severe ( fev  < $nmbr$ % predicted ),C0205082;C0681842;C1882327;C3714541;C4050465;C4050466
1599,screening fev $nmbr$   % predicted,C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164;C3714541
1599,screening % predicted fev $nmbr$,C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164;C3714541
1599,ratio of fev $nmbr$ to fvc ( % ),C0456603;C1547037;C3714541
1599,ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
1599,prebronchodilator fev $nmbr$ / fvc,C2599602;C3714541
1599,prebronchodilator fev $nmbr$ ( l ) t,C2599602;C3714541
1599,prebronchodilator fev $nmbr$ ( l ),C2599602;C3714541
1599,prebronchodilator fev $nmbr$ ( %,C2599602;C3714541
1599,prebronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1599,prebronchodilator fev $nmbr$  l,C2599602;C3714541
1599,prebronchodilator fev $nmbr$  % predicted,C0681842;C1882327;C2599602;C3714541
1599,pre fev $nmbr$,C0332152;C0740175;C2257086;C3669034;C3714541
1599,pre - bronchodilator mean ( sd ) fev $nmbr$  . l,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1599,pre - bronchodilator fev $nmbr$ / fvc ratio *,C0456603;C1547037;C2599602;C3714541
1599,pre - bronchodilator fev $nmbr$ / fvc ( % ),C2599602;C3714541
1599,pre - bronchodilator fev $nmbr$  l *,C2599602;C3714541
1599,pre - bronchodilator fev $nmbr$,C2599602;C3714541
1599,pre - bronchodilation fvc,C0439566;C3714541
1599,pre - bronchodilation fev $nmbr$,C0439566;C3714541
1599,postdose fev / fvc at screening,C0220908;C0220909;C0439568;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
1599,postbronchodilator fev $nmbr$ / fvc  %,C2599594;C3714541
1599,postbronchodilator fev $nmbr$  l,C2599594;C3714541
1599,post fev $nmbr$,C0687676;C1704687;C3469826;C3714541
1599,post - bronchodilator percent of predicted fev $nmbr$  % ( sd ),C1882327;C2599594;C2699239;C3714541
1599,post - bronchodilator fev $nmbr$ / fvc ratio  mean ( sd ),C0444504;C0456603;C1547037;C2347634;C2348143;C2599594;C2699239;C3714541
1599,post - bronchodilator fev $nmbr$  % predicted  mean ( sd ) c,C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
1599,post - bronchodilation fvc,C0439576;C3714541
1599,post - bronchodilation fev $nmbr$,C0439576;C3714541
1599,post - albuterol % predicted fev $nmbr$ mean ( sd ) e,C0001927;C0444504;C0681842;C0687676;C1704687;C1882327;C2347634;C2348143;C2699239;C3469826;C3714541
1599,percent of predicted fev $nmbr$,C1882327;C3714541
1599,mild ( fev  > $nmbr$ % predicted ),C0681842;C1882327;C2945599;C3714541
1599,mean prebronchodilator fev $nmbr$ ( sd )  % predicted,C0444504;C0681842;C1882327;C2347634;C2348143;C2599602;C2699239;C3714541
1599,mean postbronchodilatora fev $nmbr$  % predicted ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
1599,mean fvc ± sd,C0444504;C2347634;C2348143;C2699239;C3714541
1599,mean ( sd ) postbronchodilator fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1599,mean ( sd ) postbronchodilator fev $nmbr$ % predicted,C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
1599,mean ( sd ) post - bronchodilator fev $nmbr$ percentage predicted,C0439165;C0444504;C0681842;C1549488;C1561533;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
1599,mean ( sd ) fev $nmbr$ postbronchodilator  l,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1599,mean ( sd ) fev $nmbr$ ( l ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1599,mean ( sd ) fev $nmbr$ ( l ) post - bronchodilator,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1599,mean ( sd ) % predicted normal fev $nmbr$,C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2699239;C3714541;C4553972
1599,mean % predicted fvc ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
1599,iv : fev $nmbr$ < $nmbr$ % predicted,C0022326;C0681842;C1882327;C3714541;C4265176
1599,iii : fev $nmbr$ > $nmbr$ % - < $nmbr$ % predicted,C0439070;C0681842;C1705160;C1882327;C3714541
1599,gold grades $nmbr$ - $nmbr$ ( percent - predicted fev ( )  n,C0018026;C0439165;C0441800;C0681842;C0919553;C1304897;C1882327;C3244287;C3714541
1599,fvc ∗,C3714541
1599,fvc — liters,C0475211;C3714541
1599,fvc change,C0392747;C0443172;C1705241;C3714541;C4319952
1599,fvc > $nmbr$ % predicted,C0681842;C1882327;C3714541
1599,fvc < $nmbr$ % predicted,C0681842;C1882327;C3714541
1599,fvc ( liters ),C0475211;C3714541
1599,fvc ( l ) *,C3714541
1599,fvc ( l ),C3714541
1599,fvc ( % predicted ),C0681842;C1882327;C3714541
1599,fvc % predicted !  t,C0681842;C1882327;C2603360;C3714541
1599,fvc  l,C3714541
1599,fvc  % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
1599,fvc  % predicted,C0681842;C1882327;C3714541
1599,fvc,C3714541
1599,fevt : fvc ratio — % |,C0016529;C0456603;C1547037;C3714541
1599,fev_ ( l ) :,C3714541
1599,fev $nmbr$ — liters,C0475211;C3714541
1599,fev $nmbr$   at baseline ( randomization ) ∗,C0034656;C0168634;C1442488;C3714541
1599,fev $nmbr$ reversibilityz ( pre / post salbutamol )  %,C0001927;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
1599,fev $nmbr$ reversibilityz ( pre / post ipratropium )  %,C0027235;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
1599,fev $nmbr$ reversibility  pre - / post - albuterol  %,C0001927;C0332152;C0449261;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
1599,fev $nmbr$ prebronchodilator [ l ]  mean ± sd,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1599,fev $nmbr$ prebronchodilator [ % pn ]  mean ± sd,C0219433;C0444504;C1549735;C2347634;C2348143;C2599602;C2699239;C3541307;C3714541;C4049640;C4049767
1599,fev $nmbr$ pre - bronchodilator ( l )  mean ( sd ) c,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1599,fev $nmbr$ post - bronchodilator,C2599594;C3714541
1599,fev $nmbr$ percent predicted ( sd ),C0439165;C0681842;C1882327;C2699239;C3714541
1599,fev $nmbr$ at baseline,C0168634;C1442488;C3714541
1599,fev $nmbr$ : fvc ratio,C0456603;C1547037;C3714541
1599,fev $nmbr$ / fvc ratio *,C0456603;C1547037;C3714541
1599,fev $nmbr$ / fvc ratio  % ( sd ),C0456603;C1547037;C2699239;C3714541
1599,fev $nmbr$ / fvc ratio  %,C0456603;C1547037;C3714541
1599,fev $nmbr$ / fvc prebronchodilatort,C3714541
1599,fev $nmbr$ / fvc prebronchodilator  mean ± sd,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1599,fev $nmbr$ / fvc at baseline ( randomization ) ( % ) ∗,C0034656;C0168634;C1442488;C3714541
1599,fev $nmbr$ / fvc ( post salbutamol ),C0001927;C0687676;C1704687;C3469826;C3714541
1599,fev $nmbr$ / fvc %,C3714541
1599,fev $nmbr$ / fvc  % a,C3714541
1599,fev $nmbr$ / fvc  % *,C3714541
1599,fev $nmbr$ / fvc,C3714541
1599,fev $nmbr$ ( pre - albuterol )  l,C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
1599,fev $nmbr$ ( post - albuterol )  l,C0001927;C0687676;C1704687;C3469826;C3714541
1599,fev $nmbr$ ( liters ),C0475211;C3714541
1599,fev $nmbr$ ( l ),C3714541
1599,fev $nmbr$ ( % predicted ),C0681842;C1882327;C3714541
1599,fev $nmbr$ % predicted ≥ $nmbr$ %,C0681842;C1882327;C3714541
1599,fev $nmbr$ % predicted at baseline,C0168634;C0681842;C1442488;C1882327;C3714541
1599,fev $nmbr$ % predicted < $nmbr$ %,C0681842;C1882327;C3714541
1599,fev $nmbr$ % predicted ( sd ),C0681842;C1882327;C2699239;C3714541
1599,fev $nmbr$ % predicted ( post salbutamol ),C0001927;C0681842;C0687676;C1704687;C1882327;C3469826;C3714541
1599,fev $nmbr$ % predicted  post - albuterol  %,C0001927;C0681842;C0687676;C1704687;C1882327;C3469826;C3714541
1599,fev $nmbr$ % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
1599,fev $nmbr$ % predicted,C0681842;C1882327;C3714541
1599,fev $nmbr$ % pred . ( post - albuterol )  %,C0001927;C0032952;C0044955;C0687676;C1704687;C3469826;C3714541
1599,fev $nmbr$  pre - albuterol  l,C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
1599,fev $nmbr$  post - albuterol  l,C0001927;C0687676;C1704687;C3469826;C3714541
1599,fev $nmbr$  mean  l,C0444504;C2347634;C2348143;C3714541
1599,fev $nmbr$  mean  % predicted,C0444504;C0681842;C1882327;C2347634;C2348143;C3714541
1599,fev $nmbr$  litres ( pre salbutamol )  mean ( sd ),C0001927;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541
1599,fev $nmbr$  litres ( pre ipratropium )  mean ( sd ),C0027235;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541
1599,fev $nmbr$  litres ( post ipratropium )  mean ( sd ),C0027235;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
1599,fev $nmbr$  l prebronchodilator fev $nmbr$  % predicted,C0681842;C1882327;C2599602;C3714541
1599,fev $nmbr$  l *,C3714541
1599,fev $nmbr$  l,C3714541
1599,fev $nmbr$  % predicteda,C3714541
1599,fev $nmbr$  % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
1599,fev $nmbr$  % predicted,C0681842;C1882327;C3714541
1599,fev $nmbr$,C3714541
1599,fev  at baseline,C0168634;C1442488;C3714541
1599,fev  > $nmbr$ % predicted,C0681842;C1882327;C3714541
1599,fev  < $nmbr$ % predicted,C0681842;C1882327;C3714541
1599,fev  % predicted,C0681842;C1882327;C3714541
1599,fev,C3714541
1599,change from baseline in % predicted fev $nmbr$,C0168634;C0392747;C0443172;C0681842;C1442488;C1705241;C1882327;C3714541;C4319952
1599,c $nmbr$ ml decrease in trough fev $nmbr$,C0392756;C0439526;C0444506;C0547047;C1705224;C3714541;C3887665
1599,baseline post - bronchodilator % predicted fev  > $nmbr$ % and no concurrent tiotropium,C0168634;C0205420;C0213771;C0681842;C1442488;C1882327;C2599594;C3714541
1599,baseline post - bronchodilator % predicted fev  > $nmbr$ % and concurrent tiotropium use,C0042153;C0168634;C0205420;C0213771;C0457083;C0681842;C1442488;C1882327;C1947944;C2599594;C3714541
1599,baseline fvc  l,C0168634;C1442488;C3714541
1599,baseline fev $nmbr$ % predicted,C0168634;C0681842;C1442488;C1882327;C3714541
1599,baseline fev $nmbr$ #,C0168634;C1442488;C3714541
1599,baseline fev $nmbr$  median ( range )  l,C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3714541
1599,baseline fev $nmbr$  l *,C0168634;C1442488;C3714541
1599,baseline fev $nmbr$,C0168634;C1442488;C3714541
1599,baseline fev  ( l ),C0168634;C1442488;C3714541
1599,baseline % predicted fev $nmbr$,C0168634;C0681842;C1442488;C1882327;C3714541
1599,absolute decline in fvc > $nmbr$ % predicted or death  n ( % ),C0011065;C0205344;C0681842;C1306577;C1882327;C3714541;C4082313;C4552775
1599,absolute decline in fvc > $nmbr$ % predicted,C0205344;C0681842;C1882327;C3714541
1599,% predicted ” fev  at baseline  % *,C0168634;C0681842;C1442488;C1882327;C3714541
1599,% predicted prebronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C0681842;C1882327;C2347634;C2348143;C2599602;C2699239;C3714541
1599,% predicted post - bronchodilator fev  ( sd ) ml,C0439526;C0681842;C1705224;C1882327;C2599594;C2699239;C3714541;C3887665
1599,% predicted fev ^,C0681842;C1882327;C3714541
1599,% predicted fev $nmbr$,C0681842;C1882327;C3714541
1599,% predicted fev,C0681842;C1882327;C3714541
1598,oral fi - blockers,C0442027;C4050619;C4521986
1598,fh ii,C1854107
1598,fh $nmbr$,
1598,% fhg,
1598,$nmbr$ . $nmbr$ ( fi . $nmbr$ ),C4050619
1597,ff – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C3259781;C4554348
1597,ff / vi $nmbr$ / $nmbr$ gg ( n = $nmbr$  $nmbr$ ),C0017454;C0018370;C0205999;C4554348
1597,ff / vi $nmbr$ % ( $nmbr$ %  $nmbr$ % ),C0205999;C4554348
1597,ff / vi,C0205999;C4554348
1597,ff - blocker,C4554348
1597,ff - $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C4554348
1597,ff $nmbr$   µ g,C0439267;C4554348
1597,ff $nmbr$ pgod,C4554348
1597,ff $nmbr$ gg ( n = $nmbr$  $nmbr$ ),C0017454;C0018370;C4554348
1597,ff $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C4554348
1597,ff $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C3259781;C4554348
1597,difference ff / vi versus uc  %,C0205999;C1705241;C1705242;C4554348
1597,bdp / ff / g ( n = $nmbr$ ),C0004906;C0439267;C1422585;C1538710;C4554348
1596,sinus tracts / perforation  ' ^ n ( % ),C0544791;C0549099;C0854572;C1185740;C1881710
1596,patients without draining fistulae at baseline [ n = $nmbr$ ],C0030705;C0168634;C0544791;C1442488
1596,patients with draining fistulae at baseline [ n = $nmbr$ ],C0030705;C0168634;C0544791;C1442488
1596,number of draining fistulae per patient  n,C0030705;C0237753;C0449788;C0544791
1596,no draining fistulas *,C0544791
1596,draining fistulae  n ( % ),C0544791
1595,patients with fistulas at baseline,C0016169;C0030705;C0168634;C1442488
1595,fistula at baseline  n ( % ),C0016169;C0168634;C1442488
1595,fistula  ' n ( % ),C0016169
1594,r - tpa,C0032143
1594,alteplase group ( n = $nmbr$ ),C0032143;C0441848
1594,alteplase ( n = $nmbr$ ),C0032143
1594,alteplase,C0032143
1593,type ic,C0020750;C0332307;C1547052;C4554818
1593,partial evolving to secondarily generalized ( ic ),C0020750;C0205246;C0332253;C0728938;C1550516;C4554818
1593,early ichaem ic stroke,C0020750;C0038454;C1279919;C4554100;C4554818
1593,$nmbr$ to $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
1592,transient ischemic attack ( % ) type of lacunar syndrome ( % ),C0007787;C0332307;C0917805;C1547052;C3178801
1592,transient ischemic attack,C0007787;C0917805
1592,transient ischaemic attack — no . ( % ),C0007787;C0917805
1592,transient ischaemic attack,C0007787;C0917805
1592,tia  n ( % ),C0007787;C0917805;C1054154
1592,tia,C0007787;C0917805;C1054154
1592,stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
1592,stroke ( vs tia ),C0007787;C0038454;C0917805;C1054154;C4554100
1592,previous transient ischemic attack,C0007787;C0205156;C0917805;C1552607
1592,previous tia or stroke,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1592,previous tia,C0007787;C0205156;C0917805;C1054154;C1552607
1592,previous stroke or tia ( n = $nmbr$ ),C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1592,previous stroke or tia ( % ),C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1592,previous stroke or tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1592,no previous stroke or tia ( n = $nmbr$ ),C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1592,no history of tia / stroke,C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100
1592,ischemic stroke ( vs . tia ),C0007787;C0917805;C0948008;C1054154
1592,hx stroke / tia,C0007787;C0038454;C0262926;C0917805;C1054154;C3814444;C4554100
1592,history of tia / stroke,C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100
1592,hemispheric tia n = $nmbr$,C0007787;C0205139;C0917805;C1054154
1591,nc group ( n = $nmbr$ ),C0027964;C0028407;C0067895;C0265987;C0441848
1591,nc,C0027964;C0028407;C0067895;C0265987
1590,uac =,
1590,bmi  kg / m $nmbr$ uac  no . ( % ),C0578022;C1532718
1589,uc duration  y  mean ( range ),C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2926735;C3542016
1589,uc ( n   =   $nmbr$ ),
1589,tjc ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1589,tjc  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1589,tjc  $nmbr$ - $nmbr$,
1589,tjc,
1589,sjc ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1589,sjc  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1589,sjc  $nmbr$ - $nmbr$,
1589,sjc,
1589,baseline tjc  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
1589,baseline sjc  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
1588,udy entry,C1705654
1588,statin use at study entry  n ( % ),C0360714;C0869040;C1705654
1588,remission at maintenance - trial entry — no . ( % ),C0008976;C0024501;C0544452;C0687702;C1705654
1588,entry hip fracture location  n ( % ),C1705654;C3260017
1588,controllertreatment before entry *,C1705654
1588,at entry,C1705654
1587,etn  no,C0014758;C0717758
1587,etanercept ( n = $nmbr$ ),C0717758
1587,etanercept,C0717758
1586,snp,C0752046;C1527094
1586,ntbnp ( n = $nmbr$ ),
1586,bnp / ntbnp ( n = $nmbr$ ),C0054015;C1095989;C1417808;C2982014
1585,— no . ( % ),
1585,thromboaspiration — no . ( % ),
1585,omega - $nmbr$ fa intake $nmbr$ nd third,C0205437;C1512806;C1719844
1585,no p - blocker intake at randomisation ( n = $nmbr$ ),C0034656;C0369773;C1512806;C2603361
1585,no . ( % ),
1585,nd,
1585,$nmbr$ nd > $nmbr$ . $nmbr$ / < $nmbr$ . $nmbr$,
1584,statins used during follow - up,C0360714;C0589120;C1273517;C1522577;C1704685;C3274571
1584,potassium - sparing at last follow - up,C0032821;C0202194;C0304475;C0589120;C0597277;C1522577;C1704685;C3274571;C3714637
1584,fracture during follow - up,C0016658;C0589120;C1522577;C1704685;C3274571
1584,follow - up,C0589120;C1522577;C1704685;C3274571
1584,end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
1584,at end of follow - up — no . / total no . ( % ),C0439175;C0439810;C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
1584,at end of follow - up — no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
1584,at end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
1583,ufh only,C0205171;C1720467
1583,ufh,
1582,pump,C0182537
1582,proton pump inhibitors,C0358591;C1384478;C3540020
1582,proton pump inhibitor use,C0042153;C0358591;C0457083;C1947944;C3536754;C4521480
1582,proton pump inhibitor ( n  % ),C0358591;C3536754;C4521480
1582,proton pump inhibitor,C0358591;C3536754;C4521480
1582,proton - pump inhibitors,C0358591;C1384478;C3540020
1582,proton - pump inhibitor,C0358591;C3536754;C4521480
1582,on pump,C3842462
1582,on - pump,C3842462
1582,off pump,C0182537;C1518543
1582,off - pump,C0182537;C1518543
1581,unadjusted p value,C1439367;C1709380
1581,unadjusted p - value for interaction,C1439367;C1704675;C1709380
1581,unadjusted hr .,C1439367
1581,unadjusted hr ( $nmbr$ % ci ) for $nmbr$ standard deviation increment,C0008107;C0871420;C1439367;C1705117;C3259781
1581,unadjusted hr ( $nmbr$ % ci ) for $nmbr$ sd increment,C0008107;C1439367;C1705117;C2699239;C3259781
1581,unadjusted hr ( $nmbr$ % ci ) a,C0008107;C1439367;C3259781
1581,unadjusted hr,C1439367
1581,unadjusted,C1439367
1581,score ( > $nmbr$ ) at $nmbr$ monthsb unadjusted or,C0449820;C1439367;C4050231
1581,or ( unadjusted ),C1439367
1580,p value for adjusted hr,C0456081;C1709380
1580,black ( n = $nmbr$ )  adjusted hazard ratio *,C0005680;C0027567;C0085756;C0439541;C0456081;C2985465
1580,adjustedaor,
1580,adjustedahr,
1580,adjusted *   hr,C0456081
1580,adjusted,C0456081
1579,“ relative risk of outcome in acei group iw control group . bbaseline variables for models included : logarithm of age  reciprocal of serum creatinine  sbp  up excretion  treatment assignment and terms for studies $nmbr$  $nmbr$ $nmbr$ and $nmbr$ ( see footnotes of table $nmbr$ ) . other baseline variables considered for analysis ( p < $nmbr$ . $nmbr$ in univariate analysis ) included dp mean arterial pressure  type of antihypertensive regimen in the control group  planned duration of follow - up  whether or not the investigators were blinded  whether or not dietary advice was given and the year of publication .,C0001779;C0002778;C0003364;C0009932;C0034036;C0034037;C0035173;C0039224;C0039798;C0040808;C0042789;C0085805;C0087111;C0150108;C0168634;C0201976;C0204932;C0221102;C0232108;C0233324;C0242492;C0243148;C0332257;C0332307;C0439234;C0439508;C0439828;C0441833;C0444504;C0504085;C0600061;C0683962;C0687744;C0750591;C0936012;C0947630;C1257890;C1272641;C1274040;C1442162;C1442488;C1515273;C1516050;C1518422;C1519504;C1522326;C1524024;C1531217;C1533734;C1547052;C1550141;C1550718;C1704324;C1705169;C1705313;C1705428;C1705429;C1706074;C1882911;C1882979;C1947903;C1947971;C2347634;C2348143;C2587213;C2699704;C2825232;C2826302;C2945654;C2986775;C3161035;C3244317;C3274648;C3538994;C3887704;C4288391;C4553389
1579,use of antihypertensive drugs,C0003364;C1524063
1579,types of antihypertensive medications at $nmbr$ year   †,C0003364;C0332307;C0439234;C0439508
1579,type of antihypertensive medication use among patients using antihypertensive medications  n ( % ),C0003364;C0030705;C0332307;C1524063;C1547052
1579,taking antihypertensive medication at baseline  no . ( % ) e,C0003364;C0168634;C1442488;C1515187
1579,prior antihypertensive medication  n ( % ),C0003364;C0332152;C2826257
1579,previous antihypertensive treatment — no . ( % ),C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1579,previous antihypertensive treatment,C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1579,patients on antihypertensive medications  n ( % ) | |,C0003364;C0030705
1579,other blood pressure - lowering drugs,C0003364
1579,other blood - pressure drug,C0003364
1579,other antihypertensive medications,C0003364
1579,other antihypertensive drug,C0003364
1579,other antihypertensive agents,C0003364
1579,other antihypertensive,C0003364
1579,other anti - hypertensives,C0003364
1579,other anti - hypertensive,C0003364
1579,or taking antihypertensive medication,C0003364;C1290952
1579,one antihypertensive medication,C0003364;C0205447
1579,on antihypertensive treatment  n ( % ),C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1579,on antihypertensive medication at baseline  n ( % ) ‡,C0003364;C0168634;C1442488
1579,number of antihypertensive medications at study entry,C0003364;C0557651;C1705654;C1718138;C2603343
1579,number of antihypertensive medications  n ( % ),C0003364;C1718138
1579,medications antihypertensive drugs,C0003364;C0013227;C0802604;C2598133;C4284232
1579,mean number of antihypertensive medications at $nmbr$ year   *,C0003364;C0439234;C0439508;C0444504;C1718138;C2347634;C2348143
1579,hypertension ( bp > $nmbr$ / $nmbr$ mmhg or using antihypertensive medication ),C0003364;C0020538;C0037623;C0439475;C1415692;C1524063;C1708288;C1963138;C4318478
1579,baseline anti - hypertensive usea,C0003364;C0168634;C1442488
1579,any antihypertensive drug,C0003364
1579,any antihypertensive agent,C0003364
1579,any anti - hypertensive agent,C0003364
1579,antihypertensives ' *,C0003364
1579,antihypertensives  n ( % ),C0003364
1579,antihypertensives,C0003364
1579,antihypertensive use,C0003364;C0042153;C0457083;C1947944
1579,antihypertensive treatments,C0003364;C0087111
1579,antihypertensive treatment  n ( % ),C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1579,antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1579,antihypertensive medication use  n ( % ),C0003364;C0042153;C0457083;C1947944
1579,antihypertensive medication or,C0003364
1579,antihypertensive medication ),C0003364
1579,antihypertensive medication $nmbr$ ',C0003364
1579,antihypertensive medication,C0003364
1579,antihypertensive drugs,C0003364
1579,antihypertensive drug  %,C0003364
1579,antihypertensive agents *,C0003364
1579,antihypertensive agents ( n per patient ),C0003364;C0030705
1579,antihypertensive agents  n ( % ),C0003364
1579,antihypertensive agents,C0003364
1579,antihypertensive agent use,C0003364;C0042153;C0457083;C1947944
1579,antihypertensive,C0003364
1579,anti - hypertensives,C0003364
1579,anti - hypertensive,C0003364
1579,> $nmbr$ antihypertensive medications,C0003364
1579,$nmbr$ antihypertensive medication,C0003364
1578,death or absolute fvc decrease > $nmbr$ %,C0011065;C0205344;C0392756;C0547047;C1306577;C3714541;C4082313;C4552775
1578,absolute fvc decrease > $nmbr$ %,C0205344;C0392756;C0547047;C3714541
1578,absolute decrease > $nmbr$ %,C0205344;C0392756;C0547047
1578,absolute change,C1549031
1578,absolute ( l ),C0205344
1578,absolute  litres,C0205344;C0475211
1577,hospitalization for acute limb ischemia,C0019993;C0205178;C2945695
1577,acute reaction,C0205178;C0443286
1577,acute and delayed reaction,C0205178;C0205421;C0443286;C1545665;C3272602
1577,acute ( < $nmbr$ hr ),C0205178
1576,prosper,
1576,hormone - refractory prostate carcinoma,C1328504
1575,prostate volume ( ml ),C0439526;C1441416;C1705224;C3887665
1575,prostate volume ( cm $nmbr$ ),C1441416
1574,valproate,C0080356
1574,inappropriate,C1548788;C3537135;C3542467
1573,time since prior alendronate use  n ( % ),C0040223;C0042153;C0102118;C0332152;C0457083;C1947944;C2826257;C3541383
1573,still taking alendronate at study entry  n ( % ),C0102118;C0557651;C1515187;C1705654;C2603343
1573,risedronate n / n ( % ),C0246719
1573,risedronate ( n   =   $nmbr$ ),C0246719
1573,risedronate ( n = $nmbr$ ),C0246719
1573,current alendronate use,C0042153;C0102118;C0457083;C0521116;C1705970;C1947944
1573,alendronate ( n = $nmbr$ ),C0102118
1573,alendronate,C0102118
1572,aspartate aminotransferase increased,C0004002;C0205217;C0442805
1572,aspartate aminotransferase  u / l,C0004002;C0439339
1572,alanine aminotransferase or aspartate aminotransferase > $nmbr$ x upper limit of normal ( n = $nmbr$ ),C0001899;C0004002;C0057041;C1415274;C1519815;C3887708
1572,alanine aminotransferase increased,C0001899;C0057041;C0205217;C0442805;C1415274;C3887708
1572,alanine aminotransferase  u / l,C0001899;C0057041;C0439339;C1415274;C3887708
1571,subgoup_name,C0027365;C1547383;C4522128
1571,characteristic_name,C0027365;C1521970;C1547383;C4522128
1570,physical and cognitive examination : ! :,C0031809;C0205485;C1509143;C1516691;C4321457
1570,impaired cognitive,C0338656
1570,cognitive functioning,C0392334;C0392335
1570,cognitive,C1516691
1569,unstable angina ( biomarker negative ),C0002965;C0005516;C0205160;C1513916;C2825415;C2825491;C3853545
1569,troponin negative ( n = $nmbr$ ),C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
1569,rf and acpa negative $nmbr$,C0035448;C0201660;C0205160;C0748398;C1513916;C1525410;C1547111;C1706063;C2825415;C2825491;C3853545
1569,rf and acpa negative  n ( % ),C0035448;C0201660;C0205160;C0748398;C1513916;C1525410;C1547111;C1706063;C2825415;C2825491;C3853545
1569,patients with negative anti - dsdna,C0030705;C0205160;C0741099;C1513916;C2825415;C2825491;C3853545
1569,negative ctnl ( n = $nmbr$  $nmbr$ ),C0205160;C1513916;C2825415;C2825491;C3853545
1569,negative ( < $nmbr$ . $nmbr$ )  n ( % ),C0205160;C1513916;C2825415;C2825491;C3853545
1569,negative,C0205160;C1513916;C2825415;C2825491;C3853545
1569,anti - gad negative ( n = $nmbr$ ),C0205160;C0270549;C0432633;C1414925;C1513916;C2825415;C2825491;C3853545
1569,anti - gad negative,C0205160;C0270549;C1414925;C1513916;C2825415;C2825491;C3853545
1568,ularitide n / n ( % ),C0077910
1568,ularitide ( n = $nmbr$ ),C0077910
1568,dulaglutide $nmbr$ . $nmbr$ mgf,C1366394;C3179549;C3712803;C3887684
1567,sustain $nmbr$ : semaglutide vs . sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C0443318;C1565750;C1960952;C2346927;C2732140;C3885068;C4321396;C4521761
1567,semaglutide exposure  nmol / l,C0274281;C0332157;C0439282;C3885068
1567,semaglutide ( n = $nmbr$ ),C3885068
1567,semaglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3885068;C4321396;C4521761
1567,semaglutide,C3885068
1566,pramlintide,C0537551
1566,n ( % ) liraglutide $nmbr$ placebo,C0032042;C0369718;C0441922;C1456408;C1696465;C1706408
1566,liraglutide n ( % ),C1456408
1566,liraglutide ( « = $nmbr$ ),C1456408
1566,liraglutide ( n = $nmbr$ ),C1456408
1566,liraglutide ( n = $nmbr$  $nmbr$ ),C1456408
1566,liraglutide ( $nmbr$ . $nmbr$ mg ) ± oad,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1566,liraglutide $nmbr$ . $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1566,liraglutide $nmbr$ . $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
1566,liraglutide $nmbr$ . $nmbr$ mg ls means ( n ),C0023668;C0024671;C0026410;C0439269;C1456408;C1704970;C1960952;C2346927;C4321396;C4521761
1566,liraglutide $nmbr$ . $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C1456408
1566,liraglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1566,liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$  $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1566,liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1566,liraglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1566,liraglutide $nmbr$ - $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
1566,liraglutide $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1566,liraglutide,C1456408
1565,progestins,C0033306
1565,country : argentina ( n = $nmbr$ ),C0003761;C0454664;C1504311;C1511538
1565,argentina,C0003761;C1504311
1564,infarction ( yr ) history of congestive heart failure ( % ),C0021308;C0439234;C0455531;C0742742
1564,history of congestive heart failure,C0455531;C0742742
1564,congestive heart,C0018787;C0742742
1564,congestion *,C0700148;C2826600
1564,any history of congestive heart failure,C0455531;C0742742
1563,univariate logistic modela,C0242415
1563,multivariate logistic modelb,C0242415
1563,logistic regression,C0206031
1563,bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828;C0441722;C0443221
1563,aunivariate logistic regression .,C0206031
1562,premature treatment discontinuation,C0039798;C0087111;C0151526;C0205252;C0457454;C1444662;C1522326;C1533734;C1705169;C3538994;C3887704;C4018905;C4552847
1562,premature discontinuation,C0151526;C0205252;C0457454;C1444662;C4018905;C4552847
1562,discontinued,C1444662
1562,discontinuations teaes,C0457454
1562,discontinuations,C0457454
1562,discontinuation of lama prior to baseline  n ( % ),C0168634;C0457454;C0999593;C1416775;C1442488;C1444662;C4552847
1561,data are mean ± standard deviation for continuous variables and number ( % ) for categoric variables . p,C0237753;C0439828;C0444504;C0449788;C0549178;C0683312;C0871420;C1442989;C1511726;C1828170;C2347634;C2348143;C2828392;C3245479;C3714741;C3889287
1561,continuous,C0549178
1561,continued thienopyridine n = $nmbr$ subjects,C0549178;C0681850;C1120149;C1550501;C1706203;C2349001;C2697811
1561,continued thienopyridine n ( % ),C0549178;C1120149
1561,continued thienopyridine ( n = $nmbr$ ),C0549178;C1120149
1561,continued thienopyridine ( n $nmbr$ $nmbr$ ),C0549178;C1120149
1561,continued thienopyridine %,C0549178;C1120149
1561,continue thienopyridine n = $nmbr$,C0549178;C1120149
1561,$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ) ( continued ),C0549178
1561,$nmbr$ ( $nmbr$ . $nmbr$ ) ( continued ),C0549178
1560,other †,
1560,other countries,C0454664
1560,country  n ( % ),C0454664;C1511538
1560,country,C0454664;C1511538
1560,black region or country ( % ),C0005680;C0017446;C0027567;C0085756;C0205147;C0439541;C0454664;C1511538
1559,southern hemisphere,C0205139;C1710133
1559,south or central american,C0238914;C1710133
1559,south or central america,C0007674;C1710133
1559,south  n ( % ),C1710133
1559,central / south,C0205099;C1710133;C1879652
1558,sacral and / or lumbar,C0024090;C0036037
1558,lumbar epidural,C0581283
1558,lumbar,C0024090
1558,general and lumbar epidural,C0205246;C0581283;C3812897;C3891294;C4521767
1557,number of co - aeds  n ( % ),C0180309;C0237753;C0449788;C3245499
1557,colombia,C3245499
1556,numbera,
1556,number ste  t > $nmbr$,C0237753;C0449788;C1420459;C3811127
1556,number resulting in hospital admission,C0184666;C0237753;C0449788;C0678226
1556,number resulting in emergency department visit,C0237753;C0332294;C0449788;C0545082;C0553618;C0562508;C1512346;C1704729;C2826704
1556,number resulting in ed visit,C0237753;C0332294;C0449788;C0545082;C1512346;C2826704;C3538926
1556,number of vessels disease,C0042373;C0237753;C0449788
1556,number of prior csdmards  n ( % ),C0237753;C0332152;C0449788;C2826257
1556,number of prior aeds    n   ( % ),C0180309;C0237753;C0332152;C0449788;C2826257
1556,number of prior aeds  n ( % ) b,C0180309;C0237753;C0332152;C0449788;C2826257
1556,number of prior aeds  n ( % ),C0180309;C0237753;C0332152;C0449788;C2826257
1556,number of prior aeds,C0180309;C0237753;C0332152;C0449788;C2826257
1556,number of previous reported aeds,C0180309;C0205156;C0237753;C0449788;C0684224;C0700287;C1552607;C4319718
1556,number of previous dmards,C0205156;C0237753;C0242708;C0449788;C1552607
1556,number of previous anti - tnf treatments for psa  n ( % ),C0087111;C0205156;C0237753;C0449788;C1448177;C1552607;C3810537;C3813209
1556,number of people ( n ),C0027361;C0237753;C0449788
1556,number of participants with an event,C0237753;C0441471;C0449788;C0679646;C4019010
1556,number of participants,C0237753;C0449788;C0679646
1556,number of exacerbations in the $nmbr$ months before screening,C0220908;C0220909;C0237753;C0439231;C0449788;C1698960;C1710031;C1710032;C1710477;C2348164;C4086268
1556,number of e,C0237753;C0449788
1556,number of copd exacerbations within $nmbr$ months  mean ( sd ),C0237753;C0439231;C0444504;C0449788;C0740304;C2347634;C2348143;C2699239
1556,number of concomitant csdmards  n ( % ),C0237753;C0449788;C0521115
1556,number of concomitant aedsc,C0237753;C0449788;C0521115
1556,number of antihypertensive agent reported,C0003364;C0237753;C0449788;C0684224;C0700287;C4319718
1556,number of antidiabetes drugs at screening  n ( % ),C0013227;C0220908;C0220909;C0237753;C0449788;C1698960;C1710031;C1710032;C1710477;C2348164;C3687832
1556,number insulin glargine,C0237753;C0449788;C0907402
1556,number ( % ) reporting migraine on $nmbr$ - month questionnaire,C0034394;C0149931;C0237753;C0332177;C0439231;C0449788;C0700287
1556,number ( % ),C0237753;C0449788
1556,number,C0237753;C0449788
1556,missing — number / n ( % ),C0237753;C0449788;C1551393;C1705492;C3272743
1556,female sex — number ( % ),C0086287;C0237753;C0449788
1556,> q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
1556,> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
1556,> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
1556,> q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
1556,> q $nmbr$ ( $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
1556,> $nmbr$ months — number / n ( % ),C0237753;C0439231;C0449788
1556,< q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
1556,< q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
1556,< $nmbr$ months — number / n ( % ),C0237753;C0439231;C0449788
1555,limb amputation,C0002689
1555,limb ( sd ),C0015385;C2699239
1555,limb,C0015385
1554,upper limbs,C1140618
1554,upper limb fractures,C0016658;C1140618
1554,upper limb fracture,C0178316
1554,upper limb,C1140618
1553,≥ $nmbr$ a ( n = $nmbr$ ),C0369718;C0441922
1553,us n = $nmbr$,C0369718;C0441922
1553,us ( n = $nmbr$ ),C0369718;C0441922
1553,type b $nmbr$ / c lesions  n ( % ),C0221198;C0369718;C0441922;C1546698;C4264484
1553,total phase $nmbr$ pooled ( n = $nmbr$ ),C0205390;C0369718;C0439175;C0439810;C0441922;C1709595;C1710475;C2349200;C4522255
1553,tophi present  n ( % ),C0150312;C0221248;C0369718;C0441922;C0449450
1553,patients analyzed  n,C0030705;C0369718;C0441922;C0936012
1553,non - us ( n = $nmbr$ ),C0369718;C0441922;C1518422
1553,neither n = $nmbr$  $nmbr$,C0369718;C0441922
1553,n_,C0369718;C0441922
1553,n t % ),C0369718;C0441922
1553,n observed,C0369718;C0441922;C1441672
1553,n o,C0369718;C0441922
1553,n events / n at risk,C0369718;C0441471;C0441922;C1444641;C3541888
1553,n analysed,C0369718;C0441922
1553,n = $nmbr$ t,C0369718;C0441922
1553,n = $nmbr$ lesions,C0221198;C0369718;C0441922;C1546698
1553,n = $nmbr$,C0369718;C0441922
1553,n =,C0369718;C0441922
1553,n / r,C0205090;C0369718;C0441922;C0684010;C2603358
1553,n / n   ( % ),C0369718;C0441922
1553,n / n ( % ),C0369718;C0441922
1553,n / n $nmbr$ / $nmbr$,C0369718;C0441922
1553,n / n,C0369718;C0441922
1553,n .,C0369718;C0441922
1553,n - $nmbr$ pufa events / patients ( % ),C0030705;C0032615;C0369718;C0441471;C0441922;C3541888
1553,n - $nmbr$ pufa ( n = $nmbr$ ),C0032615;C0369718;C0441922
1553,n - $nmbr$ pufa,C0032615;C0369718;C0441922
1553,n - $nmbr$ fatty acit,C0369718;C0441922
1553,n - $nmbr$ fatty acids slope lsm ± se ( mm / year ),C0015684;C0036919;C0369718;C0439234;C0439508;C0441922;C0807955;C4330985;C4554674
1553,n - $nmbr$ fatty acids - placebo lsm ( $nmbr$ % cl ),C0015684;C0032042;C0369718;C0441922;C0596019;C1696465;C1706408
1553,n - $nmbr$ fatty acids ( n = $nmbr$ ),C0015684;C0369718;C0441922
1553,n - $nmbr$ fatty acids,C0015684;C0369718;C0441922
1553,n - $nmbr$ - pufa ( n = $nmbr$ ),C0032615;C0369718;C0441922
1553,n + v ( n = $nmbr$ ),C0369718;C0441922
1553,n *,C0369718;C0441922
1553,n ( lesions ),C0221198;C0369718;C0441922;C1546698
1553,n ( iqr ),C0369718;C0441922
1553,n ( % ) unless otherwise specified,C0205369;C0369718;C0441922
1553,n ( % ),C0369718;C0441922
1553,n %,C0369718;C0441922
1553,n $nmbr$ yrs,C0369718;C0441922
1553,n $nmbr$ / n $nmbr$,C0369718;C0441922
1553,n $nmbr$,C0369718;C0441922
1553,n,C0369718;C0441922
1553,ll  n ( % ),C0369718;C0441922
1553,igehigh ( > i $nmbr$ ku / l  n = i  $nmbr$ ),C0021966;C0221138;C0369718;C0439340;C0441922
1553,duration of as  n ( % ),C0369718;C0441922;C0449238;C2926735
1553,diabetics • no ( n = $nmbr$  $nmbr$ ),C0241863;C0369718;C0441922
1553,diabetics - no ( n = $nmbr$  $nmbr$ ),C0241863;C0369718;C0441922
1553,clinical and patient reported outcomes  % ( observed n ) unless otherwise indicated,C0205210;C0369718;C0441922;C1441672;C1444656;C2987124
1553,a $nmbr$ n = $nmbr$,C0369718;C0441922
1553,a $nmbr$ / $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1553,a $nmbr$ + ezio a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),C0369718;C0441922
1553,> $nmbr$ . $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
1553,> $nmbr$ . $nmbr$  n ( % ),C0369718;C0441922
1553,> $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
1553,> $nmbr$ ( n = $nmbr$ l $nmbr$ ),C0369718;C0441922
1553,> $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1553,> $nmbr$ % ( n = $nmbr$ ),C0369718;C0441922
1553,> $nmbr$ %  n ( % ),C0369718;C0441922
1553,> $nmbr$  n ( % ),C0369718;C0441922
1553,< $nmbr$ . $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
1553,< $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
1553,< $nmbr$ ( n z $nmbr$ ),C0369718;C0441922
1553,< $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1553,< $nmbr$ % ( n = $nmbr$ ),C0369718;C0441922
1553,< $nmbr$ %  n ( % ),C0369718;C0441922
1553,< $nmbr$  n ( % ),C0369718;C0441922
1553,( n = l $nmbr$ ),C0369718;C0441922
1553,( n = $nmbr$ l $nmbr$ ),C0369718;C0441922
1553,( n = $nmbr$ ) ( n = $nmbr$ ),C0369718;C0441922
1553,( n = $nmbr$ )  ' ( n = $nmbr$ ),C0369718;C0441922
1553,( n = $nmbr$ ),C0369718;C0441922
1553,( n = $nmbr$,C0369718;C0441922
1553,( n $nmbr$ $nmbr$ ),C0369718;C0441922
1553,$nmbr$ n qi,C0369718;C0376586;C0441922
1553,$nmbr$ n / n,C0369718;C0441922
1553,$nmbr$ - $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1553,$nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
1553,$nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1553,$nmbr$ ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
1553,$nmbr$ ( n $nmbr$ $nmbr$ ),C0369718;C0441922
1553,$ $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1553,$ $nmbr$ %  n ( % ),C0369718;C0441922
1552,uas $nmbr$,
1552,uae ( p  g / min ),C0560021;C1519789
1552,in - clinic uask,C0002424;C0150312;C0332285;C0442592;C1707101
1552,in - clinic uas $nmbr$,C0002424;C0150312;C0332285;C0442592;C1707101
1551,spinal,C0521329
1551,mean lumbar spine t score,C0024091;C3533236;C3887615
1551,lumbar spine bmd t - score,C0024091;C0449820;C3887615;C4050231
1551,lumbar spine bmd t -,C0024091;C3887615
1551,lumbar spine,C0024091;C3887615
1551,flex baseline bmd t - score at lumbar spine ( meanisd ),C0024091;C0168634;C0449820;C1442488;C3887615;C4050231
1550,usa and canada,C0006823;C0041703
1550,usa / canada,C0006823;C0041703
1550,usa ( n = $nmbr$ ),C0041703
1550,usa ( n = $nmbr$  $nmbr$ ),C0041703
1550,usa,C0041703
1550,united states or canada,C0006823;C0041703
1550,united states and canada,C0006823;C0041703
1550,united states ( n   = $nmbr$  $nmbr$ ),C0041703
1550,united states,C0041703
1550,umied,
1550,region united states,C0017446;C0041703;C0205147
1550,non usa,C0041703;C1518422
1549,necrosis  n ( % ) a,C0027540;C1334928
1549,cross - clamp,C0175721;C1883710;C2828360;C3810601
1548,necrotic core  mm ^,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653;C4330985;C4554674
1548,necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
1548,core laboratory percent stenosis,C0022877;C0439165;C0444669;C0678234;C1167518;C1261287;C1706352;C1882467;C2632116;C3244292;C3274653;C4283904
1548,% stenosis  as assessed by core laboratory,C0022877;C0444669;C0678234;C1167518;C1261287;C1516048;C1706352;C1882467;C2632116;C3244292;C3274653;C4283904
1547,ultrasound carotid arteries,C0948945
1547,carotid revascularization,C0581603;C0741968
1547,carotid infarct,C0021308;C0741968
1547,carotid endarterectomy,C0014099
1547,carotid artery — no . ( % ),C0007272;C0162859
1547,carotid artery diseaset,C0007272;C0162859
1547,carotid,C0741968
1547,> $nmbr$ % stenosis of coronary  carotid  or lower extremity arteries,C0007282;C0018787;C0226415;C0242231;C0741968
1546,severitya,
1546,severity of copda  combined assessment of copd  n ( % ),C0024117;C0205195;C0439793;C0522510;C1261322;C1412502;C1516048;C3714496
1546,severity of copd — no . ( % ) f,C0016327;C0024117;C0439793;C0522510;C1412502;C3714496
1546,severity of copd *  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
1546,severity of copd  n ( % ) *,C0024117;C0439793;C0522510;C1412502;C3714496
1546,severity of copd  combined assessment  n ( % ),C0024117;C0205195;C0439793;C0522510;C1261322;C1412502;C1516048;C3714496
1546,severity of copd  ( gold $nmbr$ )  %,C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
1546,severity of copd,C0024117;C0439793;C0522510;C1412502;C3714496
1546,nice classification of copd severity of obstruction  n ( % ) [ $nmbr$ ],C0008902;C0008903;C0024117;C0028778;C0439793;C0522510;C0678229;C1412502;C1882136;C3714496;C4087029
1546,copd severityy,C0024117;C1412502;C3714496
1546,copd severitya    n   ( % ),C0024117;C1412502;C3714496
1546,copd severity : severe / very severe,C0024117;C0439793;C0442824;C0522510;C1412502;C2984081;C3714496
1546,copd severity : mild / moderate,C0024117;C0439793;C0522510;C1299392;C1412502;C3714496
1546,copd severity ( gold $nmbr$ ),C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
1546,copd severity  n ( % ) a,C0024117;C0439793;C0522510;C1412502;C3714496
1546,copd severity  n ( % ) *,C0024117;C0439793;C0522510;C1412502;C3714496
1546,copd severity  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
1546,copd severity  %,C0024117;C0439793;C0522510;C1412502;C3714496
1546,copd severity,C0024117;C0439793;C0522510;C1412502;C3714496
1546,copd disease severity,C0024117;C0521117;C1412502;C3714496
1545,patients with baseline crp concentration £ $nmbr$ mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
1545,patients with baseline crp concentration < $nmbr$ mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
1545,hs - crp mg / l,C0439268;C3890735;C4048285
1545,hs - crp j $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
1545,hs - crp _ = $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
1545,hs - crp > $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
1545,hs - crp < $nmbr$ . $nmbr$ nlg l,C3890735;C4048285
1545,hs - crp < $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
1545,hs - crp < $nmbr$ . $nmbr$ g / l,C0439294;C0456615;C3890735;C4048285
1545,hs - crp ( mg / l ),C0439268;C3890735;C4048285
1545,hs - crp ( mg / l  median ),C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1545,hs - crp ( median  iqr )  mg / l,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1545,hs - crp  mg / l,C0439268;C3890735;C4048285
1545,hs - crp,C3890735;C4048285
1545,crp   ≤   uln,C1519815;C3890735;C4048285
1545,crp   >   uln,C1519815;C3890735;C4048285
1545,crp concentration > $nmbr$ mg / l  n ( % ) \,C0086045;C0439268;C1446561;C3827302;C3890735;C4048285
1545,crp ( mg / l ) ( cv ),C0439268;C3538987;C3890735;C4048285;C4048877;C4318503
1545,crp ( mg / l ),C0439268;C3890735;C4048285
1545,crp,C3890735;C4048285
1545,crj,
1545,baseline hs - crp tertiles ( mg / i ],C0021966;C0024671;C0026410;C0168634;C0221138;C0439269;C1442488;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
1545,baseline high - sensitivity crp,C0168634;C1441604;C1442488;C3890735;C4048285
1545,baseline crp < $nmbr$ mg / l,C0168634;C0439268;C1442488;C3890735;C4048285
1545,baseline crp,C0168634;C1442488;C3890735;C4048285
1545,baseline asdas - crp,C0168634;C1442488;C3890735;C4048285
1545,asdas - crp   <   $nmbr$ . $nmbr$,C3890735;C4048285
1545,asdas - crp δ   ≥   $nmbr$ . $nmbr$,C3890735;C4048285
1545,asdas - crp *,C3890735;C4048285
1545,> $nmbr$ mg / dl baseline high - sensitivity crp,C0168634;C0439269;C1441604;C1442488;C3890735;C4048285
1544,ticagrelor $nmbr$ mg vs . placebo hr ( $nmbr$ % ci ),C0008107;C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C1999375;C2346927;C3259781;C4321396;C4521761
1544,rr ^ ( $nmbr$ % ci ),C0008107;C3259781;C4554402
1544,rr ( $nmbr$ % ci ) c,C0008107;C3259781;C4554402
1544,rr ( $nmbr$ % ci ) *,C0008107;C3259781;C4554402
1544,rr ( $nmbr$ % ci ),C0008107;C3259781;C4554402
1544,rr $nmbr$ - $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$  $nmbr$ ) ’,
1544,rr,
1544,hr ‡,
1544,hr vs placebo ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1706408;C3259781
1544,hr and $nmbr$ % ci *,C0008107;C3259781
1544,hr * or rr † ( $nmbr$ % ci ),C0008107;C3259781;C4554402
1544,hr ( $nmbr$ % ci ) “,C0008107;C3259781
1544,hr ( $nmbr$ % ci ) *,C0008107;C3259781
1544,hr ( $nmbr$ % ci )  univariate cox proportional - hazard regression,C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781
1544,hr ( $nmbr$ % ci )  multivariate cox proportional - hazard regression,C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781
1544,hr ( $nmbr$ % ci ),C0008107;C3259781
1544,hr $nmbr$ % ci,C0008107;C3259781
1544,esrd only rr ( ci ) “,C0008107;C0022661;C0035078;C0205171;C1720467;C2316810;C3259781;C4554402
1544,doubling of baseline serum creatinine or esrd rr ( ci ) “,C0008107;C0022661;C0035078;C0168634;C0201976;C0205173;C0600061;C1442488;C1705764;C2316810;C3259781;C4554402
1544,cox hr ( $nmbr$ % ci ),C0008107;C1565830;C3259781
1544,cmh rr ( $nmbr$ % ci ),C0008107;C3259781;C4554402
1543,patients with only mrf hr ( $nmbr$ % cl ),C0030705;C0205171;C0312443;C0596019;C1412879;C1720467
1543,mrf,C0312443;C1412879
1542,western europe hr ( $nmbr$ % cl ),C0043129;C0596019
1542,rrr ( $nmbr$ % cl ),C0596019
1542,rrr,
1542,rr reduction  $nmbr$ / $nmbr$ ( $nmbr$ / $nmbr$ cl ),C0301630;C0392756;C0596019;C1293152;C4551656;C4554402
1542,rr ( cl ),C0596019;C4554402
1542,rr ( $nmbr$ % cl ) p value,C0596019;C1709380;C4554402
1542,rr ( $nmbr$ % cl ) [ / ’ value ],C0596019;C1522609;C4554402
1542,rr ( $nmbr$ % cl ),C0596019;C4554402
1542,patients with prior ml hr ( $nmbr$ % cl ),C0030705;C0332152;C0439526;C0596019;C1705224;C2826257;C3887665
1542,patients with ascvd but no prior ml hr ( $nmbr$ % cl ),C0030705;C0332152;C0439526;C0596019;C1705224;C2826257;C3665365;C3887665
1542,hr vs control ( $nmbr$ % cl ) *,C0243148;C0596019;C1550141;C1882979;C2587213;C3274648;C4553389
1542,hr ( enl vs lcz ) ( $nmbr$ % cl ),C0596019
1542,hr ( $nmbr$ s % a ),
1542,hr ( $nmbr$ % cl ) *,C0596019
1542,hr ( $nmbr$ % c ! ),
1542,hr  ( $nmbr$ % cl ),C0596019
1541,soe or sue,
1541,or : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )  p = $nmbr$ . $nmbr$,C0369773;C2603361
1541,intravenous inotropes or vasopressors ( % ),C0042397;C0348016;C1258199
1541,barc types $nmbr$  $nmbr$  or $nmbr$,C0332307
1541,barc $nmbr$ - $nmbr$,
1540,laba or lamab n = $nmbr$,
1540,conieosieroids and / or $nmbr$ - mp,C0024944
1540,$nmbr$ or $nmbr$  n ( % ),C0369718;C0441922
1539,three or more drugs,C0013227;C0205172;C0205449;C3687832
1539,one or more medications,C0013227;C0205172;C0205447;C0802604;C2598133;C4284232
1539,one or more exacerbations,C0205172;C0205447;C4086268
1539,one or more blood pressure medications  n ( % ),C0005823;C0013227;C0033095;C0205172;C0205447;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
1539,no new a or and no more than $nmbr$ new bilag b domain score  %,C0205172;C0205314;C0449820;C1880389;C1883221;C3541951;C4050231
1539,college graduate or more,C0205172;C0682187
1539,$nmbr$ yrs or more,C0205172
1539,$nmbr$ years or more,C0205172;C0439234
1539,$nmbr$ or more,C0205172
1539,$nmbr$ . $nmbr$ or more,C0205172
1539,$nmbr$ . $nmbr$ % or more,C0205172
1538,using hrt or raloxifene at baseline ( % ),C0168634;C0244404;C0282402;C1442488;C1524063
1538,or raloxifene,C0244404
1538,benzodiazepine or bzra ‡,C0005064;C3536850;C4048284
1537,ors ( $nmbr$ % cis ) :,C0069590;C1504308;C1742862;C1963718
1537,$nmbr$ or $nmbr$,
1537,$nmbr$ ( or $nmbr$  if female only ),C0043210;C0086287;C0205171;C1705497;C1705498;C1720467
1536,right ventricular dysfunction — no . / total no . ( % ) §,C0242707;C0439175;C0439810;C1556315
1536,right ventricular dysfunction  n / n ( % ) j,C0242707;C1556315
1536,erectile dysfunction,C0242350;C1961100
1535,severe dysfunction,C3274777
1535,moderate dysfunction ( crcl $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C3274776
1535,moderate dysfunction,C3274776
1534,utis,C0042029
1534,uti,C0042029;C0077906;C1412376
1534,urinary tract infection,C0042029;C0262655;C4554638
1534,events consistent with uti,C0042029;C0077906;C0332290;C0441471;C1412376;C3541888
1533,social functioning,C0037395
1533,social function,C0037395
1533,physical functioning,C0516981;C4049916
1533,physical function,C0516981;C4049916
1533,opaqb physical function score,C0031843;C0449820;C0516981;C0542341;C0700205;C1705273;C4049916;C4050231;C4483112
1532,renal function : creatinine clearance,C0232804;C0812399
1532,renal function : ! : n ( % ),C0232804
1532,renal function *,C0232804
1532,renal function ( egfr ) according to mdrd  n ( % ),C0232804;C0680240;C1739039;C3811844;C3812682;C3839656
1532,renal function  bn ( % ),C0005005;C0034700;C0232804;C1706574;C4551963
1532,renal function,C0232804
1532,deterioration in renal function ( investigator reported ),C0035173;C0232804;C0684224;C0700287;C0868945;C4319718
1532,baseline renal function ( eclcr ),C0168634;C0232804;C1442488
1531,physical function ( $nmbr$ - $nmbr$  short form - $nmbr$ subscale ),C0031843;C0348078;C0376315;C0516981;C0542341;C0597240;C0700205;C0700329;C1282927;C1522492;C1705273;C1806781;C2350002;C2964478;C4049916;C4255237
1531,nyha functional classification — no . ( % ) i,C0021966;C0205245;C0221138;C0542341;C1275491;C2700217
1531,nyha functional classification — no . ( % ),C0205245;C0542341;C1275491;C2700217
1531,nyha functional class i,C0205245;C0542341;C1882084;C2700217
1531,nyha functional class at screening,C0205245;C0220908;C0220909;C0542341;C1698960;C1710031;C1710032;C1710477;C1882083;C2348164;C2700217
1531,nyha functional class at randomization,C0034656;C0205245;C0542341;C1882083;C2700217
1531,nyha functional class ( % ),C0205245;C0542341;C1882083;C2700217
1531,nyha functional class $nmbr$,C0205245;C0542341;C1882083;C2700217
1531,nyha functional class  n ( % ),C0205245;C0542341;C1882083;C2700217
1531,nyha functional class,C0205245;C0542341;C1882083;C2700217
1531,lv function > $nmbr$ . $nmbr$ and < $nmbr$ . $nmbr$  n ( % ) medications  n ( % of patients ),C0013227;C0023128;C0030705;C0031843;C0369718;C0441922;C0542341;C0700205;C0731033;C0802604;C1705273;C1881413;C2598133;C4284232
1531,lv function,C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
1531,inhibitors — no . { % ) se - $nmbr$ physical functioning score ^ ^,C0036919;C0205245;C0243077;C0542341;C4483112;C4552744
1531,haemodynamics and lv function,C0019010;C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413;C4281788
1531,functional outcome ( mrs $nmbr$ - $nmbr$ ),C0205245;C0542341;C1274040;C1522706;C2349188;C2700217;C3714939;C3854213
1531,function subscale,C0031843;C0542341;C0700205;C1705273
1531,emotional function,C0013987;C0031843;C0542341;C0700205;C0849912;C1705273
1530,symptoms of atrial fibrillation in the $nmbr$ months before randomization — no . ( % ),C0004238;C0034656;C0344434;C0439231;C0683368;C1457887;C1963067
1530,symptoms of atrial fibrillation in the $nmbr$ months before randomiza -,C0004238;C0344434;C0439231;C0683368;C1457887;C1963067
1530,significant worsening in kccq clinical score ( > $nmbr$ ) at $nmbr$ months $nmbr$,C0332271;C0439231;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
1530,s $nmbr$ months,C0439231;C0565930;C2603362
1530,ppi use within $nmbr$ months of randomization,C0034656;C0358591;C0439231;C0871125;C1524063;C3811894
1530,poor outcome at $nmbr$ months,C0439231;C3806166
1530,months ( log - transformed ),C0439231;C1510411;C1708728;C2986775
1530,mi > $nmbr$ months *,C0439231;C3810814
1530,mi < $nmbr$ months *,C0439231;C3810814
1530,kccq ( $nmbr$ months ),C0439231;C3476798
1530,fall in last $nmbr$ months ( % ),C0085639;C0238715;C0439231;C4553726
1530,duration of prior alendronate use  months,C0102118;C0332152;C0439231;C1881378;C2826257;C2826775
1530,duration of previous use of vka  months,C0205156;C0439231;C1552607;C1881378;C2826775
1530,duration of metformin therapy ( months ),C0025598;C0439231;C0444917
1530,duration of dementia symptoms  months,C0011265;C0436359;C0439231;C0497327
1530,copd medication taken for at least $nmbr$ months before study entry,C0013227;C0024117;C0439231;C0557651;C1412502;C1705654;C1883727;C2603343;C3244316;C3714496;C4284232
1530,change in sbp ( $nmbr$ months ),C0085805;C0392747;C0439231;C0443172;C1705241;C4319952
1530,change in nt - probnp at $nmbr$ months ( log - transformed ),C0392747;C0439231;C0443172;C0669479;C0754710;C1510411;C1705241;C1708728;C2986775;C4319952
1530,blood eosinophil count > $nmbr$ / mm $nmbr$ in $nmbr$ months before screening — no . ( % ),C0005767;C0005768;C0014467;C0200638;C0220908;C0220909;C0229664;C0439231;C0750480;C0750879;C1698960;C1705566;C1710031;C1710032;C1710477;C2348164;C4330985;C4554674
1530,^ $nmbr$ months,C0439231
1530,> $nmbr$ months ( n = $nmbr$  $nmbr$ ),C0439231
1530,> $nmbr$ months  n ( % ),C0439231
1530,> $nmbr$ months,C0439231
1530,< $nmbr$ months in - $nmbr$ kill,C0162388;C0439231;C0681205;C1550555
1530,< $nmbr$ months  n ( % ),C0439231
1530,< $nmbr$ months,C0439231
1530,$nmbr$ – $nmbr$ months,C0439231
1530,$nmbr$ tob $nmbr$ months  n ( % ),C0439231;C1420851
1530,$nmbr$ tob $nmbr$ months,C0439231;C1420851
1530,$nmbr$ montlts,
1530,$nmbr$ months,C0439231
1530,$nmbr$ - < $nmbr$ months  n ( % ),C0439231
1530,$nmbr$ - $nmbr$ months fn = $nmbr$ . $nmbr$ ),C0439231;C1570610
1530,$nmbr$ - $nmbr$ months ( n = $nmbr$ ),C0439231
1530,$nmbr$ - $nmbr$ months  n ( % ),C0439231
1530,$nmbr$ - $nmbr$ months,C0439231
1529,intensified ( n 二 $nmbr$ ),
1529,intensified $nmbr$ months ( n - $nmbr$ ),C0439231
1528,montelukast ( n = $nmbr$ ),C0298130
1528,monteiukast vs placebo,C0032042;C1696465;C1706408
1528,monteiukast ( n = $nmbr$ ),
1528,monteiukast,
1527,panel b,C0441833;C1706365;C1999270
1527,panel a,C0441833;C1706365;C1999270
1527,device group,C1706365
1526,vascular disease ( % of group ),C0042373;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,treatment group  on - treatment il - $nmbr$ threshold,C0020898;C0021764;C0022271;C0039798;C0087111;C0441833;C0449864;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
1526,total group,C0439175;C0439810;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,table_group,C0039224;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1706074
1526,subject group,C0441833;C0681850;C0687744;C1257890;C1519504;C1550501;C1705428;C1705429;C1706203;C2349001;C2697811
1526,statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,salmeterol - fluticasone group,C0441833;C0687744;C0939232;C1257890;C1519504;C1705428;C1705429
1526,risk factors ( % of group ),C0035648;C0441833;C0687744;C1257890;C1519504;C1553898;C1705428;C1705429
1526,randomized group by subgroup interaction,C0034656;C0441833;C0687744;C1079230;C1257890;C1515021;C1519504;C1704675;C1705428;C1705429;C3815594
1526,randomization groups $nmbr$ and $nmbr$,C0034656;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
1526,randomization group,C0034656;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,previous coronary procedure ( % of group ),C0018787;C0018821;C0205156;C0441833;C0687744;C1257890;C1279986;C1519504;C1552607;C1705428;C1705429;C2986530
1526,p value between groups,C0441833;C0441849;C0687744;C1257890;C1519504;C1522609;C1552839;C1705428;C1705429;C1709380
1526,no statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,no . of diseased vessels ( % of group ),C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,indacaterol - glycopyrronium group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1722260;C3814772
1526,hbaic group ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
1526,group — no . ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,group dif . ( $nmbr$ ),C0441833;C0687744;C0812246;C1257890;C1519504;C1705428;C1705429;C1710304
1526,group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,for combined hemoglobin groups,C0019046;C0205195;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
1526,ezetimibe / simvastatin group,C0441833;C0687744;C1257890;C1519504;C1532737;C1705428;C1705429
1526,experimental treatment group,C0441833;C0687744;C0949266;C1257890;C1519504;C1705428;C1705429;C2585119
1526,dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2348066
1526,coronary procedure ( % of group ),C0018787;C0018821;C0441833;C0687744;C1257890;C1279986;C1519504;C1705428;C1705429;C2986530
1526,certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1872109
1526,bmi group — no . ( % ),C0441833;C0578022;C0687744;C1257890;C1519504;C1705428;C1705429
1526,aga group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1526,( % of group ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1525,the square of the height in meters . patient ' s and physician ' s global assessment scores can range from $nmbr$ to $nmbr$ . scores for the western,C0030705;C0205120;C0441074;C0449820;C0489786;C1514721;C1552595;C1705493;C2348147;C3542016;C4050369
1525,physician global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4050369
1525,physician global assessment of disease,C0012634;C4050369
1525,physician ' s global assessment of dis -,C0451119;C1444662;C1970187;C4050369
1525,physician ' s global assessment . mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239;C4050369
1525,physician ' s global assessment !,C4050369
1525,physician ' s global assessment,C4050369
1525,pga subscore,C0016410;C3541266;C4050369
1525,pga score ( range ),C0016410;C0449820;C1514721;C2348147;C3541266;C3542016;C4050231;C4050369
1525,pga score  mean ( sd ),C0016410;C0444504;C0449820;C2347634;C2348143;C2699239;C3541266;C4050231;C4050369
1525,pga  $nmbr$ - $nmbr$,C0016410;C3541266;C4050369
1525,no worsening in pga  %,C0016410;C0332271;C1457868;C1546960;C3541266;C4050369
1525,mean pga score ± sd,C0016410;C2699239;C3533236;C3541266;C4050369
1525,mean ( sd ) pga vas *,C0016410;C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3541266;C3827561;C4050369
1524,ptca or pci,C2936173;C4049621
1524,ptca / cabg,C0010055;C2936173
1524,ptca,C2936173
1524,prior ptca or cabg,C0010055;C0332152;C2826257;C2936173
1524,previous ptca,C0205156;C1552607;C2936173
1524,percutaneous transluminal coronary angioplasty,C2936173
1524,history of pci / ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C2936173;C4049621
1524,cabg or ptca / pci,C0010055;C2936173;C4049621
1524,cabg or ptca ( % ),C0010055;C2936173
1524,both ptca and cabg,C0010055;C2936173
1523,phakic,
1523,participation in phase a,C0205390;C0679823;C1710475
1523,double - dummy phase * *,C0205390;C1710475;C4684647
1523,aphasia,C0003537
1522,ulpasi $nmbr$,
1522,tpasi $nmbr$,
1522,pasia,
1522,pasi score > $nmbr$ *,C0449820;C4050231;C4528685
1522,pasi score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1947916;C4050231;C4528685
1522,pasi score ( $nmbr$ - $nmbr$ ) d,C0449820;C4050231;C4528685
1522,pasi score ( $nmbr$ - $nmbr$ ),C0449820;C4050231;C4528685
1522,pasi score $nmbr$,C0449820;C4050231;C4528685
1522,pasi score ! * *,C0449820;C4050231;C4528685
1522,pasi score  $nmbr$ - $nmbr$ *,C0449820;C4050231;C4528685
1522,pasi score,C0449820;C4050231;C4528685
1522,pasi response by baseline mtx use  no . / total no . ( % ) * pasi $nmbr$,C0025677;C0042153;C0168634;C0439175;C0439810;C0457083;C0871261;C1417487;C1442488;C1704632;C1706817;C1947944;C2911692;C4528685
1522,pasi ^ i,C0021966;C0221138;C4528685
1522,pasi < $nmbr$ *,C4528685
1522,pasi *,C4528685
1522,pasi $nmbr$ a,C4528685
1522,pasi $nmbr$  no . / total no . ( % ) $nmbr$,C0439175;C0439810;C4528685
1522,pasi $nmbr$,C4528685
1522,pasi,C4528685
1522,median pasi score { range ) ' i  i ',C0021966;C0221138;C0449820;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4050231;C4528685
1522,llpasi $nmbr$,
1522,baseline pasi score,C0168634;C0449820;C1442488;C4050231;C4528685
-10,erysipelas,C0014733
1520,physician ' s judgment that vka inappropriate ],C0022423;C0031831;C0804815;C1548788;C3537135;C3542467
1520,physician ' s judgment that vka inappropriate,C0022423;C0031831;C0804815;C1548788;C3537135;C3542467
1520,physician ' s judgment that vka,C0022423;C0031831;C0804815
1520,physician,C0031831;C0804815
1520,bone erosion ( judged by physician )  n ( % ),C0031831;C0221191;C0587240;C0804815
1519,study $nmbr$ - item short - form general health survey ( sf - $nmbr$ ) can range from $nmbr$ to $nmbr$ for the physical component and from $nmbr$ to $nmbr$ for the mental,C0031809;C0037712;C0040363;C0041260;C0205485;C0229992;C0348078;C0376315;C0449432;C0557651;C1282927;C1509143;C1514721;C1522492;C1551338;C1705248;C1806781;C1883351;C2348147;C2350002;C2603343;C3481509;C3542016;C4255237;C4554251
1519,sf - $nmbr$ physical component summaryjj,C0031809;C0037712;C0205485;C0449432;C1509143;C1705248
1519,physical examinations,C0031809
1519,physical examination,C0031809;C1744699
1519,physical component summary,C0031809;C0205485;C0449432;C1509143;C1552616;C1705248;C1706244
1519,physical component,C0031809;C0205485;C0449432;C1509143;C1705248
1519,physical characteristics,C0031809;C0205485;C1509143;C1521970
1519,and physical examination,C0031809;C1744699
1518,pr / virgin islands  n ( % ),C0042752;C0279759;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
1518,n / pyr,C0369718;C0441922
1518,$nmbr$ . $nmbr$ per $nmbr$ pyr,
1518,$nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per $nmbr$ pyr pyr,
1518,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ pyr,
1518,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ . $nmbr$ per $nmbr$ pyr $nmbr$ pyr,
1518,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per pyr $nmbr$ pyr,
1517,standard care n ( % ) / $nmbr$ py,C0030428;C1442989;C1947933;C2828392;C3538810
1517,py = $nmbr$ . $nmbr$ ),C0030428;C3538810
1517,py = $nmbr$ ),C0030428;C3538810
1517,py *,C0030428;C3538810
1517,pa,C0030428;C3541314
1517,no pa,C0030428;C3541314
1517,insulin glargine n ( % ) / $nmbr$ py,C0030428;C0907402;C3538810
1517,$nmbr$ events  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),C0030428;C0441471;C3538810;C3541888
1517,$nmbr$ event  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),C0030428;C0441471;C3538810;C4019010
1517,$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ } pty = $nmbr$,
1517,$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$,
1517,$nmbr$ . $nmbr$ per $nmbr$ py,C0030428;C3538810
1517,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$,
1516,symptomatic pe,C0070939;C0231220;C1880476;C4284304
1516,sco . ’ ita ' rojs dvt . ' pe,C0022277;C0070939;C0149871;C1880476;C2926618;C2986561;C3899446;C4284304
1516,ruled out non - fatal pe with or,C0070939;C0439787;C0849355;C1302234;C1446409;C1518422;C1705232;C1880476;C4284304
1516,pre ' rtous eptscde ( s } d dvt / pe,C0070939;C0149871;C0332152;C0740175;C1880476;C2257086;C2926618;C3669034;C3899446;C4284304
1516,pe ± dvt,C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
1516,pe with / without dvt,C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
1516,pe only,C0070939;C0205171;C1720467;C1880476;C4284304
1516,pe associated with dvt at diagnosis,C0011900;C0070939;C0149871;C0332281;C1704338;C1704656;C1880476;C2926618;C3899446;C4284304
1516,pe and dvt,C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
1516,pe ( with or without dvt ),C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
1516,pe,C0070939;C1880476;C4284304
1516,neither pe nor dvt,C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
1516,initial symptomatic pe,C0070939;C0205265;C0231220;C1279901;C1555582;C1705685;C1880476;C4284304
1516,index events : pe ± dvt n ( % ),C0070939;C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2926618;C2986546;C3541888;C3899446;C4284304
1516,extent of index pe ' ( n  % of pe patients ),C0030705;C0070939;C0439792;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4284304
1516,death  with pe not,C0011065;C0070939;C1306577;C1518422;C1880476;C4082313;C4284304;C4552775
1516,causes of dvt or pe — no . ( % ) ^ |,C0015127;C0070939;C0149871;C1314792;C1880476;C2926618;C3899446;C4284304
1516,causes of dvt or pe  n ( % ),C0015127;C0070939;C0149871;C1314792;C1880476;C2926618;C3899446;C4284304
1516,cause of dvt or pe — no . ( % ),C0015127;C0070939;C0149871;C1524003;C1880476;C2926618;C3899446;C4284304
1515,stroke or pvd  ( % ),C0038454;C0085096;C4521226;C4554100
1515,pvd,C0085096;C4521226
1515,puva,C0853073;C1704892
1514,vdz / pla n = $nmbr$,C0456170
1514,pla « = $nmbr$,C0456170
1514,pla n = $nmbr$,C0456170
1514,pla,C0456170
1514,atio - pla,C0456170
1513,pt . years = $nmbr$,C0032743;C0439234;C0699718
1513,pt,C0032743;C0699718
1513,patients entering pt period n = $nmbr$,C0030705;C0032743;C0439531;C0699718;C1522196;C1948053
1513,event / patients ( $nmbr$ / pt - y ),C0030705;C0032743;C0441471;C0699718;C4019010
1513,diet diet + pravastatin event / patients ( $nmbr$ ooo / pt - y ),C0012155;C0012159;C0030705;C0032743;C0085542;C0441471;C0699718;C1519433;C2983588;C3668949;C4019010
1512,pts,C1419129;C2698747
1512,placebo pts / n ( % ),C0032042;C1419129;C1696465;C1706408;C2698747
1512,no . pts,C1419129;C2698747
1512,# pts,C1419129;C2698747
1511,ntprobnp ( pg / ml ),C0439297;C0669479;C0754710
1511,nt - probnp ， pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
1511,nt - probnp — pg / ml * *,C0439297;C0669479;C0754710
1511,nt - probnp — pg / ml,C0439297;C0669479;C0754710
1511,nt - probnp ( pg / ml ) h,C0030827;C0033727;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C0669479;C0754710;C1266240;C1705224;C2827929;C3887665;C4528284
1511,nt - probnp ( pg / ml ) ( q $nmbr$ - q $nmbr$ ),C0439297;C0669479;C0754710
1511,nt - probnp ( pg / ml ),C0439297;C0669479;C0754710
1511,nt - probnp $nmbr$ pmol - l - $nmbr$,C0439284;C0669479;C0754710
1511,nt - probnp  pmol / l ^,C0439284;C0669479;C0754710
1511,nt - probnp  pmol / l,C0439284;C0669479;C0754710
1511,nt - probnp  pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
1511,nt - probnp  pg / ml,C0439297;C0669479;C0754710
1511,nt - pro bnp,C0669479;C0754710
1511,nt - pro - bnp — pmol / literf,C0439192;C0669479;C0754710
1511,nt - pro - bnp — pmol / liter - j -,C0439192;C0475211;C0669479;C0754710
1511,nt - pro - bnp,C0669479;C0754710
1511,n - terminal pro - bnp — pg / ml §,C0439297;C0669479
1510,versus tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
1510,versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
1510,versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ - $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
1510,versus olodaterol $nmbr$ pg,C0030827;C0072225;C1266240;C2934193
1510,tiotropium + olodaterol $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
1510,tiotropium + olodaterol $nmbr$ / $nmbr$,C4032878
1510,tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
1510,olodaterol sgg,C2934193
1510,olodaterol $nmbr$ pg,C0030827;C0072225;C1266240;C2934193
1510,olodaterol $nmbr$ m g,C0456715;C2934193
1510,olodaterol $nmbr$ jig,C2934193
1510,olodaterol $nmbr$ gg ( n = $nmbr$ ),C0017454;C0018370;C2934193
1510,olodaterol,C2934193
1509,indacaterol n = $nmbr$,C1722260
1509,indacaterol group ( n = $nmbr$ ),C0441848;C1722260
1509,indacaterol / glycopyrronium $nmbr$ / $nmbr$   μ g o . d .,C0439417;C1722260;C3814772
1509,indacaterol - glycopyrronium group ( n = $nmbr$ ),C0441848;C1722260;C3814772
1509,indacaterol + tiotropium ( n [ $nmbr$ ),C0213771;C1722260
1509,indacaterol $nmbr$ ug versus placebo,C0032042;C0041573;C0439211;C1696465;C1706408;C1722260
1509,indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug,C0041573;C0439211;C1722260
1509,indacaterol $nmbr$ ug ( n = $nmbr$ ),C0041573;C0439211;C1722260
1508,salmeterol ( n [ $nmbr$ ),C0073992
1508,salmeterol ( n = $nmbr$ ),C0073992
1508,salmeterol $nmbr$ gg bid,C0017454;C0018370;C0073992
1508,salmeterol,C0073992
1508,formoterol $nmbr$   μ g ( n   =   $nmbr$ ),C0060657;C0439267
1508,formoterol $nmbr$ gg bid,C0017454;C0018370;C0060657
1508,formoterol $nmbr$ gg ( n = $nmbr$ ),C0017454;C0018370;C0060657
1507,oxypurinol ( n = $nmbr$ ),C0030086
1507,allopurinolt,
1507,allopurinol $nmbr$ mg ( n = $nmbr$ ) +,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1507,allopurinol $nmbr$ / $nmbr$ mg n = $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1507,allopurinol $nmbr$ / $nmbr$ mg daily n = $nmbr$,C0002144;C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1507,allopurinol,C0002144
1506,lansoprazole ( n = $nmbr$ ),C0050940
1506,dexlansoprazole mr ( n = $nmbr$ ),C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
1506,dexlansoprazole mr $nmbr$ mg qd,C0024485;C0024671;C0026410;C0332173;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
1506,dexlansoprazole mr $nmbr$ mg  n = $nmbr$,C0024485;C0024671;C0026410;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
1506,dexlansoprazole mr,C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
1505,total cholesterol : hdl - c ratio,C0439175;C0439810;C0523558
1505,total cholesterol - to - hdl cholesterol ratio,C0428619
1505,tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424;C3715113
1505,tolal choleslerol,
1505,hdlcholesterol,
1504,total cholesterol — mg / dl,C0201950;C0439269;C0543421
1504,total cholesterol ^,C0201950;C0543421
1504,total cholesterol > $nmbr$ mg / dl,C0201950;C0439269;C0543421
1504,total cholesterol - mg / dl * *,C0201950;C0439269;C0543421
1504,total cholesterol *,C0201950;C0543421
1504,total cholesterol ( sd )  mg / dl,C0201950;C0439269;C0543421;C2699239
1504,total cholesterol ( mmol / l ) :,C0201950;C0543421;C1532563
1504,total cholesterol ( mmol / l )  mean ( sd ),C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239
1504,total cholesterol ( mmol / l ),C0201950;C0543421;C1532563
1504,total cholesterol ( mmo $nmbr$ / $nmbr$ ),C0201950;C0543421
1504,total cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0030705;C0201950;C0439269;C0444504;C0470187;C0543421;C2347634;C2348143;C2699239
1504,total cholesterol ( mg / dl ),C0201950;C0439269;C0543421
1504,total cholesterol $nmbr$ > $nmbr$ mg / dl,C0201950;C0439269;C0543421
1504,total cholesterol $nmbr$ < $nmbr$ mg / dl,C0201950;C0439269;C0543421
1504,total cholesterol  mmol / l 本,C0201950;C0543421;C1532563
1504,total cholesterol  mmol / l ( sd ),C0201950;C0543421;C1532563;C2699239
1504,total cholesterol  mmol / l  mean ( sd ),C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239
1504,total cholesterol  mmol / l,C0201950;C0543421;C1532563
1504,total cholesterol  mg / dl ^,C0201950;C0439269;C0543421
1504,total cholesterol  mg / dl  mean ( sd ),C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
1504,total cholesterol  mg / dl  ^,C0201950;C0439269;C0543421
1504,total cholesterol  mg / dl,C0201950;C0439269;C0543421
1504,total cholesterol  mean ( sd )  mg / dl,C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
1504,total cholesterol  mean ( sd ),C0201950;C0444504;C0543421;C2347634;C2348143;C2699239
1504,total cholesterol  %,C0201950;C0543421
1504,total cholesterol,C0201950;C0543421
1504,total cholesterohhdl cholesterol ratio,C0201950;C0456603;C0543421;C1547037
1504,median total cholesterol  mmol / l,C0201950;C0543421;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1504,cholesterol  mg / dl total,C0201950;C0439269;C0543421
1504,baseline total cholesterol,C0168634;C0201950;C0543421;C1442488
1503,p - sitosterol / total c ( | imol / mmol ),C0037215;C0220914;C0369773;C0439175;C0439190;C0439810;C2603361
1503,p - sitosterol / lathosterol,C0037215;C0064673;C0220914;C0369773;C2603361
1503,cilostazol,C0055729
1503,( $nmbr$ - sitosterol ( p . mol / l ),C0037215;C0220914;C0347982
1502,lathosterol / total c ( | imol / mmol ),C0064673;C0439175;C0439190;C0439810
1502,lathosterol ( jimol / l ),C0064673
1502,csf lathosterol ( | jlg / cll ),C0023434;C0064673;C3540512;C3889436
1502,alathosterol ( % ),
1501,totalhdl cholesterol ratio,C0008377;C0456603;C1547037
1501,terol  hdl - c  high - density lipoprotein cholesterol,C0023822
1501,kdl cholesterol ( mmol / ),C0008377;C0439190
1501,high density lipoprotein cholesterol - mg / dl * *,C0023822;C0439269
1501,high density lipoprotein cholesterol  mg / dl ^,C0023822;C0439269
1501,high - density lipoprotein cholesterol — mg / dl,C0023822;C0439269
1501,high - density lipoprotein cholesterol mean ( mg / dl ± sd ),C0023822;C0439269;C0444504;C2347634;C2348143;C2699239
1501,high - density lipoprotein cholesterol  mg / dl,C0023822;C0439269
1501,high - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl,C0023822;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1501,hdl cholesterol — mg / dl,C0023822;C0392885;C0439269
1501,hdl cholesterol §,C0023822;C0392885
1501,hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
1501,hdl cholesterol ^ :,C0023822;C0392885
1501,hdl cholesterol > $nmbr$ - $nmbr$ mmol / l,C0023822;C0392885;C1532563
1501,hdl cholesterol < $nmbr$ mg / dl *,C0023822;C0392885;C0439269
1501,hdl cholesterol < $nmbr$ - $nmbr$ mmol / l,C0023822;C0392885;C1532563
1501,hdl cholesterol *,C0023822;C0392885
1501,hdl cholesterol ( sd )  mg / dl,C0023822;C0392885;C0439269;C2699239
1501,hdl cholesterol ( mmol / l ) :,C0023822;C0392885;C1532563
1501,hdl cholesterol ( mmol / l ) ( median  iqr ),C0023822;C0392885;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1501,hdl cholesterol ( mmol / l )  mean ( sd ),C0023822;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
1501,hdl cholesterol ( mmol / l ),C0023822;C0392885;C1532563
1501,hdl cholesterol ( mg / dl ),C0023822;C0392885;C0439269
1501,hdl cholesterol  mmol / 冲,C0023822;C0392885;C0439190
1501,hdl cholesterol  mmol / l *,C0023822;C0392885;C1532563
1501,hdl cholesterol  mmol / l  men  mean ± sd,C0023822;C0025266;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
1501,hdl cholesterol  mmol / l,C0023822;C0392885;C1532563
1501,hdl cholesterol  mg / dl,C0023822;C0392885;C0439269
1501,hdl cholesterol  ( mmol / l ),C0023822;C0392885;C1532563
1501,hdl cholesterol,C0023822;C0392885
1501,hdl - cholesterol ( mmol / l ),C0023822;C0392885;C1532563
1501,hdl - cholesterol ( mg / dl ),C0023822;C0392885;C0439269
1501,hdl - cholesterol  mmol / le,C0023190;C0023822;C0392885;C0439090;C0439190;C1423767;C2697858
1501,hdl - cholesterol  mmol / l,C0023822;C0392885;C1532563
1501,hdl - cholesterol,C0023822;C0392885
1501,hba $nmbr$ c — % cholesterol — mmol / l,C0008377;C0019016;C1532563;C1825777;C3538758
1501,cholesterol — mmol / liter,C0008377;C0439190;C0475211
1501,cholesterol ( mmol / l ),C0008377;C1532563
1501,cholesterol ( % ),C0008377
1501,cholesterol  mmol / l,C0008377;C1532563
1501,cholesterol  ( . $nmbr$ . $nmbr$ mmol / l )  n ( % ),C0008377;C1532563
1501,cholesterol,C0008377
1501,baseline high - density lipoprotein cholesterol ( mg / dl ),C0023822;C0168634;C0439269;C1442488
1501,aldl cholesterol,C0008377
1501,abbreviations : chd  coronary heart disease  cl  confidence interval  ml  myocardial infarction  rr  relative risk . ^ defined as a composite end point comprising the first of any of these events : nonfatal ml  nonfatal stroke  or cardiovascular death . tp value for interaction < . $nmbr$ for major cardiovascular event . no other interactions are significant . ^ calculated as weight in kilograms divided by the square of height in meters . § hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . | | hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl_ ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . ^ diabetes defined by self - report . # calculated using the framingham risk score among $nmbr$ $nmbr$ women who provided a blood sample at baseline .,C0000723;C0005767;C0005768;C0005910;C0007226;C0008377;C0009667;C0010068;C0011065;C0011847;C0011849;C0011900;C0020473;C0020538;C0021308;C0027061;C0031831;C0033095;C0035647;C0036183;C0038454;C0039155;C0043100;C0043210;C0168634;C0178913;C0201950;C0205082;C0205120;C0205164;C0205199;C0205250;C0205435;C0229664;C0237881;C0242492;C0332849;C0428465;C0428883;C0439209;C0439269;C0439475;C0439526;C0441074;C0441471;C0444686;C0444930;C0449820;C0460139;C0475209;C0489786;C0543421;C0596019;C0681906;C0750502;C0804815;C1279901;C1299351;C1305849;C1305866;C1306345;C1306577;C1320716;C1441506;C1442488;C1522564;C1522609;C1524063;C1532563;C1546944;C1547335;C1552595;C1704675;C1704788;C1705104;C1705224;C1706378;C1963138;C1999230;C2700149;C2700400;C2700446;C2746065;C2924612;C3166866;C3539106;C3541334;C3541888;C3887460;C3887512;C3887665;C3889660;C4050231;C4082313;C4284008;C4318856;C4321237;C4521762;C4522209;C4552775;C4552904;C4554100;C4554402;C4555212
1501,> $nmbr$ . $nmbr$ hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
1501,- hdl cholesterol,C0023822;C0392885
1500,visit $nmbr$ ldl cholesterol strata,C0023824;C0202117;C0545082;C1512346;C2826704
1500,mean ( s . d . ) measured ldl cholesterol,C0023824;C0202117;C0444504;C0444706;C2347634;C2348143;C3541902
1500,mean ( s . d . ) calculated ldl cholesterol,C0023824;C0202117;C0444504;C0444686;C1441506;C2347634;C2348143
1500,low - density lipoprotein cholesterol  %,C0023824
1500,ldl cholesterol mean,C0023824;C0202117;C0444504;C2347634;C2348143
1500,ldl cholesterol level,C0023824;C0201950;C0202117;C0428466;C0441889;C0456079;C1547707;C2946261
1500,ldl cholesterol ^ :,C0023824;C0202117
1500,ldl cholesterol,C0023824;C0202117
1500,ldl cholesicrol ( minol / l ),
1500,ldl - cholesterol ( mmol / ),C0023824;C0202117;C0439190
1500,ldl - cholesterol (,C0023824;C0202117
1500,ldl - cholesterol  mmol / lf,C0023824;C0202117;C0439190;C1416933;C2986618;C4554443
1500,ldl - cholesterol,C0023824;C0202117
1500,ldl $nmbr$ - c,
1500,data are presented as mean sd . * n $nmbr$ for ldl cholesterol . † n $nmbr$ for ldl cholesterol . ‡ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . § signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . ¶ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ .,C0002778;C0002780;C0023824;C0042295;C0168634;C0202117;C0369718;C0441922;C0444504;C0449450;C0565965;C0871881;C0936012;C1442488;C1511726;C1524024;C1705242;C1711260;C2347634;C2348143;C2348152;C2699239;C3245479;C3714741
1500,baseline ldl cholesterol ( derived ),C0023824;C0168634;C0202117;C1441547;C1442488;C3245521
1500,baseline ldl cholesterol,C0023824;C0168634;C0202117;C1442488
1500,atrial fibrillation ldl cholesterol level,C0004238;C0023824;C0202117;C0344434;C0441889;C0456079;C1547707;C1963067;C2946261
1500,- ldl cholesterol,C0023824;C0202117
1500,* the $nmbr$ substrata with baseline ( bl ) ldl cholesterol $nmbr$ to $nmbr$ mg / dl and $nmbr$ to $nmbr$ mg / dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg / dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg / dl . † bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg / dl for men and $nmbr$ or $nmbr$ mg / dl for women . bars indicate se . bmi body mass index  e ezetimibe $nmbr$ mg  hdl - c hdl cholesterol  ldl - c ldl cholesterol  tg triglycerides,C0005918;C0006413;C0023822;C0023824;C0024671;C0025266;C0026410;C0036919;C0040363;C0041260;C0043210;C0168634;C0202117;C0205195;C0332257;C0337445;C0368910;C0392885;C0439269;C0441833;C0687744;C0687760;C0700321;C1142985;C1257890;C1305855;C1442160;C1442488;C1519504;C1552663;C1704759;C1705428;C1705429;C1707156;C1881534;C1883351;C1960952;C2346927;C2360800;C2827109;C3274014;C3541345;C3642216;C3715113;C3889135;C4321396;C4521761
1500,* data are given as percentage of subjects unless otherwise specified . ptca indicates percutaneous transluminal coronary angioplasty  cabg  coronary artery bypass graft  ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by square of height in meters )  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  fpg  fasting plasma glucose  and fpi  fasting plasma insulin . tto convert cholesterol values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert triglycerides to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpg to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpi to picomoles per liter  multiply by $nmbr$ . $nmbr$ .,C0003842;C0005910;C0008377;C0010055;C0015663;C0022709;C0023821;C0023824;C0040363;C0041004;C0041061;C0041260;C0042295;C0043100;C0185098;C0202042;C0205120;C0205369;C0226004;C0332849;C0439165;C0439192;C0439194;C0439209;C0441074;C0444686;C0455280;C0475211;C0489786;C0681850;C0857690;C1305855;C1305866;C1441506;C1442162;C1511726;C1549488;C1550501;C1550718;C1552595;C1561533;C1705104;C1706203;C1719797;C1883351;C1947971;C2349001;C2697811;C2911648;C2936173;C3244317;C3245479;C3714741
1499,chylomicron triglycerides,C0008731;C0041004;C1325761
1499,chylomicron cholesterol,C0008377;C0008731;C1325761
1498,no history of hypertension ( n = $nmbr$ ),C0455527
1498,hyperlipidmemia,
1498,hypercholesterolemiat,
1498,history of systemic hypertension,C0205373;C0455527
1498,history of hypertension — no . ( % ),C0455527
1498,history of hypertension for $nmbr$ mo or more,C0026544;C0205172;C0332177;C0455527
1498,history of hypertension ^  %,C0455527
1498,history of hypertension . no . ( % ),C0455527
1498,history of hypertension - n ( % ),C0455527
1498,history of hypertension *,C0455527
1498,history of hypertension ( n = $nmbr$ ),C0455527
1498,history of hypertension ( a ) c,C0455527
1498,history of hypertension ( % ),C0455527
1498,history of hypertension  no . ( % ),C0455527
1498,history of hypertension  n ( % ),C0455527
1498,history of hypertension,C0455527
1498,history of hyperlipidemia ( % ),C4695788
1498,history of hypercholesterolemia  n ( % ),C1533076
1498,history of hypercholesterolemia,C1533076
1498,history of diagnosed hypertension n ( % ),C0011900;C0455527
1497,csf $nmbr$ s - hydroxy -,C0700307;C3540512;C3889436
1497,a $nmbr$ s - hydroxy -,C0700307
1496,lv hypertrophy  n ( % ),C0149721
1496,lelt ventricular hypertrophy *,C0340279
1496,left ventricular hypertrophy — no . ( % ),C0149721;C3484363
1496,left ventricular hypertrophy on echo,C0058928;C0149721;C1655045;C3484363
1496,left ventricular hypertrophy * *,C0149721;C3484363
1496,left ventricular hypertrophy ( % ),C0149721;C3484363
1496,left ventricular hypertrophy  n ( % ),C0149721;C3484363
1496,left ventricular hypertrophy,C0149721;C3484363
1496,hypertension and left ventricular hypertrophy,C0020538;C0149721;C1963138;C3484363
1495,hypertrophy per ecg ( n = $nmbr$ $nmbr$ ),C0020564;C1623258
1495,hypertrophy  n ( % ),C0020564
1494,prior history of cardiovascular disease  n ( % ),C0332152;C0455539;C2826257
1494,pinteraction for treatment and history of heart failure,C0039798;C0087111;C0455531;C1522326;C1533734;C1705169;C3538994;C3887704
1494,no history of heart failure at baseline,C0168634;C0455531;C1442488
1494,history of postmenopausal fracture *,C0232970;C1272071
1494,history of osteoporotic fracture  n ( % ) a,C4075937
1494,history of heart failure — no . { % ),C0455531
1494,history of heart failure — no . ( % ),C0455531
1494,history of heart failure at baseline,C0168634;C0455531;C1442488
1494,history of heart failure  no . ( % ),C0455531
1494,history of heart failure  n ( % ),C0455531
1494,history of heart failure,C0455531
1494,history of falls,C1561668;C2919132
1494,history of clinical fracture ( > $nmbr$ years ),C0205210;C0439234;C1272071
1494,history of cerebrovascular disease — no . { % ),C0585890
1494,history of cerebrovascular disease,C0585890
1494,history of cardiovascular disease — no . { % ),C0455539
1494,history of cardiovascular disease — no . ( % ) ^ |,C0455539
1494,history of cardiovascular disease — no . ( % ),C0455539
1494,history of cardiovascular disease,C0455539
1494,family history of premature coronary heart disease,C0151526;C0205252;C0260520;C1313980;C2317524;C4018905
1494,family history of coronary artery disease,C2317524
1493,no history of migraine,C0455512
1493,no history of cancer,C0455471
1493,no family history of chd ( n = $nmbr$  $nmbr$ ),C0241889;C0280604;C3542407
1493,history of pvd  no . ( % ),C4534349
1493,history of pvd  n ( % ),C4534349
1493,history of pvd,C4534349
1493,history of cancer,C0455471
1493,family history of vte,C0241889;C0630906
1493,family history of venous thromboembolism ( % ),C0015576;C0042449;C0241889;C0348013;C0455533;C1704727;C1997614
1493,family history of premature chdj,C0151526;C0205252;C0241889;C4018905
1493,family history of premature chd * *,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
1493,family history of premature chd,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
1493,family history of premature,C0151526;C0205252;C0241889;C4018905
1493,family history of chd ( n = $nmbr$  $nmbr$ ),C0241889;C0280604;C3542407
1493,family history of cancerf,C0241889
1493,family history of cancera,C0241889
1493,family history ^,C0241889
1493,family history  n ( % ),C0241889
1492,patient ' s history of :,C0679831;C1369882
1492,paternal history  n ( % ),C0424909
1492,medical history  n ( % of patients ),C0679831;C1369882;C1609576
1492,maternal history  n ( % ),C0559473
1492,history of intermittent claudication and abi < $nmbr$ - $nmbr$ or substantial peripheral arterial stenosis > $nmbr$ %,C0205267;C1328319;C2315493;C3888326;C4025272
1492,history of claudication,C2315493
1492,history of cardiac arrhythmia,C3494593
1492,history of atrial fibrillation or flutter treatment at randomisation,C0016385;C0034656;C0039798;C0087111;C0729790;C1522326;C1533734;C1705169;C2242390;C3538994;C3887704
1492,history of atrial fibrillation or flutter,C0016385;C0729790;C2242390
1492,history of atrial fibrillation and / or flutter,C0016385;C0729790;C2242390
1492,history of atrial fibrillation  type 一 no . ( % ),C0332307;C0729790;C1547052
1492,history of atrial fibrillation  n ( % ),C0729790
1492,history of atrial fibrillation,C0729790
1491,positive family history of type $nmbr$ diabetes ( % ),C0332307;C0439178;C1313937;C1446409;C1514241;C1547052;C2825490;C3812269
1491,ol / l ),
1491,history of diabetes mellitus ( n = $nmbr$ ),C0455488
1491,history of diabetes mellitus  no . ( % ),C0455488
1491,history of diabetes mellitus  n ( % ),C0455488
1491,history of diabetes mellitus,C0455488
1491,family history ol diabetes ?,C1313937
1491,family history of diabetes — no . ( % ),C1313937
1491,family history of diabetes mellitus — no . { % ),C0260526;C1313937
1491,family history of diabetes mellitus — no . ( % ),C0260526;C1313937
1491,family history of diabetes ( - ),C1313937
1491,family history of diabetes ( + ),C1313937
1491,family history of diabetes ( % ) *,C1313937
1490,medical and lifestyle history,C0019664;C0019665;C0023676;C0199168;C0205476;C0262512;C0262926;C1705255;C2004062
1490,lifestyle modifications,C0870811;C2960841
1490,lifestyle behaviours,C0004927;C0023676;C0677505
1490,lifestyle behaviors,C0004927;C0023676;C0677505
1490,lifestyle,C0023676
1489,very elderly patients ( n - $nmbr$ ),C0442824;C0870602;C2984081
1489,non ‐ elderly,C0001792;C1518422;C1999167
1489,non - elderly ( < $nmbr$ years ),C0001792;C0439234;C1518422;C1999167
1489,elderly patients ( n — $nmbr$ ),C0870602
1489,elderly,C0001792;C1999167
1488,daily iglar dose at week $nmbr$ ( u ),C0560588;C2348070
1488,daily dose of study medication prescribed,C0013175;C0278329;C2348070
1488,daily,C0332173
1488,baseline insulin daily dose / kg,C0021641;C0022718;C0168634;C0332173;C0366513;C0439209;C1442488;C1533581;C1579433;C2348070;C3714501;C4054209
1488,average daily dose,C1510992;C2348070;C2825518
1487,patients with early cd ( n = $nmbr$ ),C0007928;C0030705;C0034283;C1279919;C4552032
1487,overall early - morning copd symptom severity scorec,C0024117;C0282416;C0332170;C1279919;C1319166;C1412502;C1561607;C3714496
1487,non - early crohn ' s disease,C0010346;C1279919;C1518422
1487,early use intended,C0042153;C0457083;C1279919;C1283828;C1551357;C1947944
1487,early routine,C0205547;C1279919
1487,early eptifibatide,C0253563;C1279919
1487,early crohn ' s disease *,C0010346;C1279919
1487,early clopidogrel intended,C0070166;C1279919;C1283828;C1551357
1487,early - start group ( n = $nmbr$ ),C0439659;C0441848;C1279919
1487,early - eptifibatide group ( n = $nmbr$ ),C0253563;C0441848;C1279919
1487,early ( n = $nmbr$ ),C1279919
1487,early  n ( % ),C1279919
1487,early,C1279919
1487,$nmbr$ mg / day early - start,C0439422;C0439659;C1279919
1486,hgb  g / dl < $nmbr$ men  < $nmbr$ women,C0019029;C0019046;C0025266;C0043210;C0439267;C0518015;C1424337
1486,hgb  g / dl,C0019029;C0019046;C0439267;C0518015;C1424337
1486,hemoglobin 一 g / dl,C0019046;C0439267;C1319312;C3642216
1486,hemoglobin — g / dl,C0019046;C0439267;C1319312;C3642216
1486,hemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
1486,hemoglobin  g / dl,C0019046;C0439267;C1319312;C3642216
1486,hb decrease ≥ $nmbr$ g / dl,C0019046;C0392756;C0439267;C0547047;C3642216;C3843510
1486,hb  g / dl,C0019046;C0439267;C3642216;C3843510
1486,haemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
1486,glu $nmbr$ asp g . t,C0125690;C0439267
1486,g - blockers,C0439267
1486,g + c,C0439267
1486,creatinine clearance by c - g ( ml / min ),C0151280;C0439267
1486,baseline trig > $nmbr$ millycerides g / dl,C0168634;C0202236;C0439267;C1442488;C1519533
1486,baseline hemoglobin  median ( iqr  g / dl ),C0019046;C0168634;C0439267;C0549183;C0876920;C1319312;C1442488;C2347635;C2348144;C2939193;C3642216
1486,$nmbr$ μ g ( n = $nmbr$ ),C0439267
1486,$nmbr$ a . g,C0439267
1485,very g ood / ex cellent,C0439267;C0442824;C2984081;C4267693
1485,g,C0439267
1485,aclidinium $nmbr$   μ g bid ( n   =   $nmbr$ ),C0439267;C2699757
1485,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) b,C0439267;C2699757
1485,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) a,C0439267;C2699757
1485,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ),C0439267;C2699757
1484,sedentary,C0205254
1484,secondary pci,C0027627;C0175668;C0205436;C4049621
1484,secondary p,C0027627;C0175668;C0205436
1484,secondary outcomes,C0027627;C0175668;C0205436;C1274040
1484,secondary outcome,C0027627;C0175668;C0205436;C1274040
1484,secondary nonresponse,C0027627;C0175668;C0205436
1484,secondary kidney composite outcome,C0022646;C0027627;C0175668;C0205199;C0205436;C0227665;C1274040;C1547335
1484,secondary ip,C0027627;C0175668;C0205436;C1308226;C4049997
1484,secondary iii *,C0027627;C0175668;C0205436;C0439070;C1705160
1484,secondary end points iii,C0027627;C0175668;C0205436;C0439070;C1705160;C2349179
1484,secondary end points ii,C0027627;C0175668;C0205436;C1710602;C2349179;C4082587
1484,secondary end points $nmbr$,C0027627;C0175668;C0205436;C2349179
1484,secondary end points,C0027627;C0175668;C0205436;C2349179
1484,secondary dvt . ' fe,C0027627;C0149871;C0175668;C0205436;C2926618;C3848561;C3899446
1484,secondary *,C0027627;C0175668;C0205436
1484,secondary ( change in total updrs score from baseline to final visit in phase $nmbr$ ),C0027627;C0168634;C0175668;C0205088;C0205436;C0392747;C0439175;C0439810;C0443172;C0449820;C0545082;C1442488;C1512346;C1705241;C2826704;C3639721;C4050231;C4319952
1484,secondary ' outcomes,C0027627;C0175668;C0205436;C1274040
1484,secondary # $nmbr$,C0027627;C0175668;C0205436
1484,key secondary end points,C0027627;C0175668;C0205436;C2349179
1483,selected key secondary efficacy endpoints,C1280519;C1707391;C1707887;C4528314
1483,secondary endpoints :,C4528314
1482,standard therapyy ( n = $nmbr$ ),C1442989;C2828392
1482,standard control ( n = $nmbr$ ) no . of patients ( percent ),C0030705;C0243148;C0439165;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
1482,standard control,C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
1482,standard care n ( % ),C1442989;C1947933;C2828392
1482,standard care allocation,C1442989;C1706778;C1947933;C2828392
1482,standard care ( n = $nmbr$ ),C1442989;C1947933;C2828392
1482,standard care,C1442989;C1947933;C2828392
1482,standard bp lowering  < $nmbr$ mm hg ( n = $nmbr$ ),C0037623;C0439475;C0441994;C1415692;C1442989;C1708288;C2003888;C2828392;C4318478
1482,standard allocation,C1442989;C1706778;C2828392
1482,standard ( n = $nmbr$ ),C1442989;C2828392
1482,standard ( $nmbr$ ),C1442989;C2828392
1482,standard,C1442989;C2828392
1482,size ( cm $nmbr$ ) ( mean ± standard deviation ),C0444504;C0456389;C0871420;C1442989;C1828170;C2347634;C2348143;C2828392
1482,sd  standard,C1442989;C2699239;C2828392
1482,number standard care,C0237753;C0449788;C1442989;C1947933;C2828392
1482,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . * p < $nmbr$ . $nmbr$ vs . ng . † p < $nmbr$ . $nmbr$ vs . ng .,C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0205251;C0221099;C0439165;C0444504;C0455280;C0549183;C0580545;C0596620;C0684224;C0700287;C0871420;C0876920;C1154908;C1442989;C1444656;C1511726;C1549488;C1550472;C1561533;C1706005;C1711350;C1828170;C2347634;C2347635;C2348143;C2348144;C2828392;C2939193;C3245479;C3714741;C3890211;C4048187;C4319718;C4321351;C4522223
1482,a mini - mental state examination  insulin glargine vs standard care,C0451306;C0907402;C1442989;C1947933;C2828392
1482,$nmbr$ standard ( n = $nmbr$ ),C1442989;C2828392
1481,urgent cor revasc,C0018787;C0056331;C0378365;C0439609;C3272275
1481,treated vessel - native coronary,C0005847;C0018787;C0302891;C1522326
1481,symptomatic heart fail,C0018787;C0231175;C0231220
1481,prior cardiac surgery  n ( % ),C0018787;C0018821;C0332152;C0455610;C0524727;C1522601;C2826257
1481,pre - operative cardiac medications *,C0018787;C1522601;C1882154;C2347660
1481,native coronary,C0018787;C0302891
1481,major coronary,C0018787;C0205082;C0205164;C4318856;C4521762
1481,hospitaiization for heart faiiure,C0018787
1481,heart failurea,C0018787
1481,family history of premature heart disease,C0018787;C0151526;C0205252;C0850707;C4018905
1481,family history of coronary disease,C0018787;C0850707
1481,documented asymptomatic cardiac ischemiac,C0018787;C0231221;C1301725;C1522601;C1609436
1481,coronary,C0018787
1481,cor revasc,C0018787;C0056331;C0378365
1481,cardiac stretch,C0018787;C0600080;C1522601
1481,cardiac parameters,C0018787;C0449381;C1522601
1481,cardiac mediations,C0018787;C0680727;C1522601
1481,cardiac failurec,C0018787;C1522601
1481,cardiac enzyates raised,C0018787;C0442818;C1522601
1481,cardiac diseasec,C0018787;C1522601
1481,cardiac and echocardiography parameters,C0013516;C0018787;C0449381;C1522601
1481,cardiac,C0018787;C1522601
-10,very good or excellent,C1548784;C1961136;C3641222
-10,large / very large,C0442824;C0549177;C2984081
1478,very high vs . normalb,C0442804;C4321397
1478,very high ( >   $nmbr$ xuln ) n   =   $nmbr$,C0442804;C4321397
1478,very high,C0442804;C4321397
1478,coronary heart disease  n ( % ) cardiovascular risk ( per protocol )  n ( % ) very high,C0007226;C0442711;C0442804;C1277690;C1507394;C1522729;C1698058;C2348563;C2599718;C3715209;C3887460;C4282383;C4321397
1477,nonobese ( < $nmbr$ kg / nr ),C0022718;C0027496;C0439209;C3844738;C4054209
1477,> $nmbr$ ky / nr,C0027496;C3844738
1477,< $nmbr$ ky / nr,C0027496;C3844738
1476,time since diagnosis — mo,C0011900;C0026544;C0040223;C0332177;C1704338;C1704656;C3541383
1476,smoking ( during the previous month ),C0332177;C0439231;C2114448
1476,placebo monthly ( n = $nmbr$ ),C0032042;C0332177;C1696465;C1706408
1476,pci > $nmbr$ month ago,C0332177;C0439231;C4049621
1476,one or more requiring hospitalization in $nmbr$ mo before screening — no . ( % ) $nmbr$,C0019993;C0026544;C0205172;C0205447;C0220908;C0220909;C0332177;C1698960;C1710031;C1710032;C1710477;C2348164
1476,no . in the $nmbr$ mo before screening,C0026544;C0220908;C0220909;C0332177;C1698960;C1710031;C1710032;C1710477;C2348164
1476,monthly,C0332177
1476,month $nmbr$,C0332177;C0439231
1476,median duration of chf — mo,C0018802;C0026544;C0332177;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1476,lvef within $nmbr$ mo  %,C0026544;C0332177;C0428772;C0488728
1476,left ventricular ejection fraction within previous $nmbr$ mo — no . / total no . ( % ) $nmbr$,C0026544;C0205156;C0332177;C0428772;C0439175;C0439810;C0488728;C1552607
1476,left ventricular ejection fraction within previous $nmbr$ mo |,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
1476,heart failure $nmbr$ month before admission,C0018801;C0018802;C0184666;C0332177;C0439231;C0809949;C4554158
1476,heart failure $nmbr$ mo before admission,C0018801;C0018802;C0026544;C0184666;C0332177;C0809949;C4554158
1476,hba $nmbr$ c month $nmbr$ ( % ),C0019016;C0332177;C0439231;C1825777;C3538758
1476,fall in last $nmbr$ mo,C0026544;C0085639;C0238715;C0332177;C4553726
1476,exacerbations in previous $nmbr$ mo ( n )  mean ( sd ),C0026544;C0205156;C0332177;C0444504;C1552607;C2347634;C2348143;C2699239;C4086268
1476,exacerbations in past $nmbr$ mo — no . ( % ),C0026544;C0332177;C1444637;C4086268;C4284302
1476,exacerbation within previous $nmbr$ mo  no . ( % ),C0026544;C0205156;C0332177;C1552607;C4086268
1476,exacerbation within $nmbr$ mo  %,C0026544;C0332177;C4086268
1476,duration of macular edema  mo,C0024440;C0026544;C0271051;C0332177;C0449238;C2926735
1476,duration of initial anticoagulation  mean ( sd )  mo,C0003281;C0026544;C0205265;C0332177;C0444504;C0449238;C1279901;C1555582;C1705685;C2347634;C2348143;C2699239;C2917212;C2919015;C2926735;C3537050
1476,duration of full - dose warfarin therapy before enrollment ( mo ),C0026544;C0332177;C0366686;C0443225;C0444917;C1516879;C1696073;C3888021
1476,duration of disease — mo,C0026544;C0332177;C0872146
1476,change in hba $nmbr$ c $nmbr$ to month $nmbr$ ( % ),C0019016;C0332177;C0392747;C0439231;C0443172;C1705241;C1825777;C3538758;C4319952
1476,ccsc at $nmbr$ month before enrollment,C0332177;C0439231;C1516705;C1516879;C1696073;C3888021
1476,atenolol use at $nmbr$ month,C0004147;C0042153;C0332177;C0439231;C0457083;C1947944
1476,at least $nmbr$ / mo,C0026544;C0332177
1476,antiplatelet within $nmbr$ mo before randomization,C0026544;C0034656;C0332177
1476,> $nmbr$ month n = $nmbr$,C0332177;C0439231
1476,> $nmbr$ mo,C0026544;C0332177
1476,< $nmbr$ month n = $nmbr$,C0332177;C0439231
1476,< $nmbr$ mo  n ( % ),C0026544;C0332177
1476,< $nmbr$ mo,C0026544;C0332177
1476,$nmbr$ to < $nmbr$ mo,C0026544;C0332177
1476,$nmbr$ or $nmbr$ d / mo,C0026544;C0073187;C0332173;C0332177;C4484261
1476,$nmbr$ month l,C0332177;C0439231
1476,$nmbr$ mo - $nmbr$ y,C0026544;C0332177
1476,$nmbr$ mo  mean ( sd ) x,C0026544;C0332177;C0444504;C2347634;C2348143;C2699239
1476,$nmbr$ mo,C0026544;C0332177
1476,$nmbr$ - month follow - up median ( iq range ),C0332177;C0439231;C0549183;C0589120;C0876920;C1514721;C1522577;C1704685;C2347635;C2348144;C2348147;C2939193;C3274571;C3542016
1476,$nmbr$ - < $nmbr$ mo  n ( % ),C0026544;C0332177
1476,$nmbr$ - $nmbr$ mo,C0026544;C0332177
1476,$nmbr$ - $nmbr$ / month,C0332177;C0439231
1475,£ $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1475,£ $nmbr$ min,C0702093;C1524029;C3813700
1475,£ $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1475,time to treatment initiation ( min ),C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
1475,time to treatment initiation ( min,C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
1475,time to treatment ( min ) t,C0702093;C1524029;C3494202;C3813700
1475,time to balloon / needle  min *,C0027551;C0040223;C0336867;C0441144;C0702093;C1524029;C1882041;C3541383;C3813700
1475,time to admission  min,C0702093;C1524029;C3813700;C3854258;C3854259
1475,time from sx onset to baseline ecg  min,C0168634;C0449244;C0702093;C1442488;C1519428;C1524029;C1623258;C3539997;C3813700;C3815196
1475,symptoms onset to first balloon inflation  min,C0021398;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700;C4086878
1475,stiffness ( min ),C0427008;C0702093;C1524029;C3813700
1475,range : min  max,C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1475,range ( min  max ),C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1475,range  ( min  max ),C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1475,randomization to first balloon inflation  min,C0021398;C0034656;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700
1475,qrs > $nmbr$ msec $nmbr$ - min walk test,C0439223;C0702093;C1524029;C3813700;C4277740
1475,pra  median ( min  max )  ng / ml / h,C0033727;C0369286;C0441932;C0549183;C0564385;C0633231;C0702093;C0876920;C1141951;C1419788;C1524029;C1533072;C2347635;C2348144;C2827900;C2939193;C3274822;C3669212;C3813700;C4050009;C4283900;C4528284
1475,pifr l / min,C0702093;C1524029;C3813700
1475,pefpm   ( l / min ) ∗,C0702093;C1524029;C3813700
1475,pefam   ( l / min ) ∗,C0702093;C1524029;C3813700
1475,pef at baseline  l_ / min,C0030771;C0168634;C0702093;C1442488;C1518922;C1524029;C1542834;C3813700
1475,pasi [ c ]  median ( min - max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C4528685
1475,on - pump time : < l : $nmbr$ hrs : min ( n = $nmbr$ ),C0040223;C0702093;C1524029;C1568891;C3541383;C3813700;C3842462
1475,normal ( £ $nmbr$ ml / minute ),C0205307;C0231683;C0439166;C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347086;C2347166;C3887665;C4553972
1475,mtss  median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1475,morning stiffness duration  min,C0449238;C0457086;C0702093;C1524029;C2926735;C3813700
1475,min – max,C0702093;C1524029;C3813700
1475,min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0441923;C0702093;C1524029;C3813700
1475,min - ’,C0702093;C1524029;C3813700
1475,min - max,C0702093;C1524029;C3813700
1475,min  max,C0702093;C1524029;C3813700
1475,median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1475,mean score ( min  max range ),C0702093;C1514721;C1524029;C2348147;C3533236;C3542016;C3813700
1475,mean duration of surgery ± sd  min,C0038894;C0038895;C0444504;C0449238;C0543467;C0702093;C1274039;C1524029;C2347634;C2348143;C2699239;C2926735;C3813700
1475,jsn  median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1475,iduration of symptoms > $nmbr$ min,C0683368;C0702093;C1457887;C1524029;C3813700
1475,heart rates ( beats / minutes ),C0018810;C0439232;C0700321;C0702093;C1282918;C2347166
1475,heart rate 一 beats / min,C0018810;C0702093;C1524029;C3813700
1475,heart rate — beats / min,C0018810;C0702093;C1524029;C3813700
1475,heart rate at rest — beats / min,C0018810;C0035253;C0702093;C1524029;C1622890;C3813700
1475,heart rate at rest in the supine position ( beats / min ),C0018810;C0035253;C0038846;C0702093;C1524029;C1622890;C3813700
1475,heart rate ( min − $nmbr$ ),C0018810;C0702093;C1524029;C3813700
1475,heart rate ( beats / min ),C0018810;C0702093;C1524029;C3813700
1475,heart rate  min_ $nmbr$ ( mean ),C0018810;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
1475,heart rate  beats / min,C0018810;C0702093;C1524029;C3813700
1475,heart rate  / min,C0018810;C0702093;C1524029;C3813700
1475,esr ( mm / h )  median ( min - max ),C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284
1475,esr ( mm / h )  median ( min  max ),C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284
1475,erosion score  median ( min  max ),C0333307;C0449820;C0549183;C0702093;C0876920;C1524029;C1880549;C1959609;C2347635;C2348144;C2939193;C3813700;C3887524;C4050231
1475,egfr  ml / minute / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439232;C0439526;C0441923;C0700321;C0702093;C1282918;C1705224;C1739039;C2347166;C3811844;C3812682;C3887665
1475,duration of symptoms > $nmbr$ min,C0436359;C0702093;C1524029;C3813700
1475,crp ( mg / l )  median ( min  max ),C0439268;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C3890735;C4048285
1475,cross - damp time : < l : llhrs : min ( n = $nmbr$ ),C0040223;C0205381;C0702093;C1524029;C2828360;C3541383;C3813700;C3891560
1475,baseline pos frequency per $nmbr$ days  median ( min  max ),C0168634;C0549183;C0585290;C0702093;C0876920;C1262869;C1442488;C1524029;C2347635;C2348144;C2939193;C3496112;C3496399;C3813700
1475,baseline in - check * ’ pifr ( l / min ),C0168634;C0702093;C1283174;C1442488;C1524029;C1555524;C3813700;C4321547
1475,baseline heart rate ( beat / min ),C0168634;C0425583;C0702093;C0871208;C1442488;C1521828;C1524029;C3813700
1475,[ min  max ],C0702093;C1524029;C3813700
1475,> $nmbr$ to < $nmbr$ ml / min / l $nmbr$ nr,C0027496;C0702093;C1524029;C1635169;C3813700;C3844738
1475,> $nmbr$ months  median ( min  max ),C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1475,> $nmbr$ min,C0702093;C1524029;C3813700
1475,> $nmbr$ mi / min,C0702093;C1524029;C3810814;C3813700
1475,> $nmbr$ beats / min,C0702093;C1524029;C3813700
1475,> $nmbr$ : $nmbr$ hrs : min ( n = $nmbr$ ),C0702093;C1524029;C1568891;C3813700
1475,> $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1475,< $nmbr$ months  median ( min  max ),C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1475,< $nmbr$ ml / minute ),C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1475,< $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1475,< $nmbr$ min,C0702093;C1524029;C3813700
1475,< $nmbr$ mi / min,C0702093;C1524029;C3810814;C3813700
1475,< $nmbr$ beats / min,C0702093;C1524029;C3813700
1475,< $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1475,( min ) *,C0702093;C1524029;C3813700
1475,( < $nmbr$ ml / minute ) *,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1475,$nmbr$ to < $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1475,$nmbr$ min / time ),C0040223;C0702093;C1524029;C3541383;C3813700
1475,$nmbr$ min,C0702093;C1524029;C3813700
1475,$nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1475,$nmbr$ - min walk distance m,C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
1475,$nmbr$ - min walk distance  ft,C0429886;C0702093;C1524029;C1881534;C3813700;C3890579
1475,$nmbr$ - lead ecg heart rate  beats / min,C0018810;C0179504;C0702093;C1524029;C3813700
1475,$nmbr$ - $nmbr$ min,C0702093;C1524029;C3813700
1474,timi minor bleeding,C0019080;C0026193;C0205165
1474,timi minor,C0026193;C0205165
1474,timi major or minor bleeding,C0019080;C0026193;C0205082;C0205164;C0205165;C4318856;C4521762
1474,minor bleeding,C0019080;C0026193;C0205165
1474,minor bleed,C0019080;C0026193;C0205165
1474,minor,C0026193;C0205165
1474,acuity minor,C0026193;C0205165;C0750509
1474,acuity - bleeding major / minor,C0019080;C0750509;C4441842
1474,> $nmbr$ mon ( n = $nmbr$ ),
1474,< $nmbr$ mon ( n = $nmbr$ ),
1474,$nmbr$ ( mono ),C1551432;C1551969
1473,updrs iii ( motor ),C0439070;C1513492;C1705160;C1705994;C3639721
1473,updrs  part iii ( motor ),C0439070;C0449719;C1513492;C1705160;C1705994;C1709471;C3639721
1473,pure motor hemiparesis,C0018989;C1513492;C1705994;C2247561
1473,motor weakness,C1513492;C1705994;C3714552
1473,motor updrs subscore ( baseline )  mean ( sd ),C0168634;C0444504;C1442488;C1513492;C1705994;C2347634;C2348143;C2699239;C3639721
1473,motor,C1513492;C1705994
1472,timi non - cabg major,C0010055;C0205082;C0205164;C1518422;C4318856;C4521762
1472,timi major or,C0205082;C0205164;C4318856;C4521762
1472,timi major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
1472,timi major,C0205082;C0205164;C4318856;C4521762
1472,previous major bleeding,C0019080;C0205082;C0205156;C0205164;C1552607;C4318856;C4521762
1472,net clinical benefit : on - treatment vte or major bleeding,C0019080;C0039798;C0087111;C0205082;C0205164;C0630906;C0814225;C1456447;C1516635;C1522326;C1533734;C1705169;C3538994;C3853572;C3887704;C3887809;C3890893;C4318856;C4521762;C4684590
1472,minor / major,C0026193;C0205082;C0205164;C0205165;C4318856;C4521762
1472,major st depression or t - wave,C0036056;C0041696;C0205082;C0205164;C0429103;C0520887;C1269683;C3272372;C4318856;C4521762
1472,major st depression or,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
1472,major secondary end pointf,C0027627;C0175668;C0205082;C0205164;C0205436;C0444930;C2746065;C4318856;C4521762
1472,major macrovascular events,C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
1472,major gl bleeding,C0018229;C0019080;C0205082;C0205164;C1423073;C1427674;C4318856;C4521762
1472,major gastro - intestinal bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
1472,major cvd /,C0007222;C0205082;C0205164;C4318856;C4521762
1472,major cv event,C0205082;C0205164;C0441471;C3538987;C4019010;C4048877;C4318503;C4318856;C4521762
1472,major coronary event,C0205082;C0205164;C0741923;C4318856;C4521762
1472,major coronary disease event ( fatal / non - fatal mi ),C0010068;C0012634;C0205082;C0205164;C0441471;C0741923;C1302234;C1518422;C1705232;C1956346;C3810814;C4019010;C4318856;C4521762
1472,major clinical response,C0205082;C0205164;C4055223;C4318856;C4521762
1472,major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
1472,major cardiovascular event *,C0205082;C0205164;C1320716;C4318856;C4521762
1472,major cardiovascular event,C0205082;C0205164;C1320716;C4318856;C4521762
1472,major cardiovascular,C0007226;C0205082;C0205164;C3887460;C4318856;C4521762
1472,major bleeding events *,C0019080;C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
1472,major bleeding ( mb ),C0019080;C0024853;C0205082;C0205164;C4318856;C4521762
1472,major bleeding $nmbr$ to $nmbr$,C0019080;C0205082;C0205164;C4318856;C4521762
1472,major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
1472,major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
1472,major and crnm bleeds,C0019080;C0205082;C0205164;C4318856;C4521762
1472,major amputationsb,C0205082;C0205164;C4318856;C4521762
1472,major adverse cardiovascular events,C0007226;C0205082;C0205164;C0877248;C1705413;C3887460;C4318856;C4521762
1472,major / crnm bleed,C0019080;C0205082;C0205164;C4318856;C4521762
1472,major,C0205082;C0205164;C4318856;C4521762
1472,intracranial disease of major artery 寸,C0205082;C0205164;C0524466;C0852949;C4318856;C4521762
1472,intracranial disease of major artery disease t,C0012634;C0205082;C0205164;C0752138;C4318856;C4521762
1472,hospitalization in previous year with management of heart failure as major component — no . ( % ),C0001554;C0018801;C0018802;C0019993;C0205082;C0205156;C0205164;C0376636;C0439234;C0439508;C0449432;C1273870;C1552607;C1705248;C3273539;C4318856;C4521762;C4554158
1472,history of major cardiovascular disease  n ( % ),C0205082;C0205164;C0455539;C4318856;C4521762
1472,gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
1472,gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
1472,combined major macrovascular events .,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
1472,b major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
1472,as major component — no . ( % ),C0205082;C0205164;C0449432;C1705248;C4318856;C4521762
1472,amputationsa,
1472,all major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
1472,acuity major or,C0205082;C0205164;C0750509;C4318856;C4521762
1472,acuity major,C0205082;C0205164;C0750509;C4318856;C4521762
1472,> $nmbr$ % stenosis of major artery  n ( % ),C0038449;C0205082;C0205164;C4318856;C4521762
1472,- major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
1471,mssbp ± sd  mmhg,C0439475;C2699239
1471,mssbp > $nmbr$ mmhg,C0439475
1471,mssbp / msdbp,
1471,mssbp  mmhg ( sd ),C0439475;C2699239
1471,mssbp,
1471,msdbp ± sd  mmhg,C0439475;C2699239
1471,msdbp  mmhg ( sd ),C0439475;C2699239
1471,msdbp,
1471,changes from baseline in mssbp and msdbp are shown as least - squares mean sem . * p $nmbr$ . $nmbr$ vs $nmbr$ y .,C0023189;C0168634;C0392747;C0443172;C0444504;C1442488;C1547282;C2347634;C2348143
1471,bmi ¼ body mass index  hctz ¼ hydrochlorothiazide  msdbp ¼ mean sitting diastolic blood pressure  mssbp ¼ mean sitting systolic blood pressure  sd ¼ standard deviation,C0020261;C0277814;C0444504;C0488055;C0871420;C0871470;C1305855;C1306620;C1319894;C2347634;C2348143;C2584297;C2699239;C4050224
1471,baseline mssbp ( mmhg )  mean ± sd,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1471,baseline msdbp ( mmhg )  mean ± sd,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1470,mean blood pressure  mmhg ( s . d . j,C0428886;C0488053;C2347155
1470,> = $nmbr$ mmhq,
1469,visit $nmbr$ sbp  mm hg,C0085805;C0439475;C0545082;C1512346;C2826704
1469,untreated at baseline  mm hg : sbp  mean ( sd ),C0085805;C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1469,untreated at baseline  mean ( sd )  mm hg,C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1469,treated at baseline  mm hg : sbp  mean ( sd ),C0085805;C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239
1469,systolic — mm hg,C0039155;C0439475
1469,systolic — mean ( sd ) ( mm hg ),C0039155;C0439475;C0444504;C2347634;C2348143;C2699239
1469,systolic pulmonary arterial pressure  mean ( sd )  mm hg,C0024109;C0039155;C0439475;C0444504;C0871470;C1168098;C2347634;C2348143;C2699239;C2707265;C2709248;C4522268
1469,systolic pressure — mm hg,C0439475;C0871470
1469,systolic pressure  mm hg,C0439475;C0871470
1469,systolic bp ( mmhg ) *,C0439475;C0871470
1469,systolic bp ( mmhg ),C0439475;C0871470
1469,systolic bp ( mm hg ),C0439475;C0871470
1469,systolic bp  mmhg ( sd ),C0439475;C0871470;C2699239
1469,systolic bp  mmhg  mean ± sd,C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1469,systolic bp  mmhg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1469,systolic bp  mmhg,C0439475;C0871470
1469,systolic bp  mm   hg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1469,systolic bp  mm hg ( mean ) nyha class,C0039155;C0439475;C0444504;C0488053;C0871470;C1882083;C2347634;C2348143
1469,systolic bp  mm hg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1469,systolic bp  mm hg,C0439475;C0871470
1469,systolic blood pressurea  mm hg,C0005767;C0005768;C0039155;C0229664;C0439475
1469,systolic blood pressure — mmhg,C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure — mm hg,C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure mmhg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1469,systolic blood pressure [ mmhg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0439475;C0488055;C0871470;C1306620;C1704675
1469,systolic blood pressure > $nmbr$ mm hg — no . ( % ),C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure > $nmbr$ mm hg or diastolic blood pressure > $nmbr$ mm hg,C0428883;C0439475;C0488055;C0871470;C1305849;C1306620
1469,systolic blood pressure > $nmbr$ mm hg or diastolic,C0012000;C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure > $nmbr$ mm hg  n ( % ),C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure > $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure < $nmbr$ mm hg and diastolic blood pressure < $nmbr$ mm hg,C0428883;C0439475;C0488055;C0871470;C1305849;C1306620
1469,systolic blood pressure < $nmbr$ mm hg and diastolic,C0012000;C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure - mmhg,C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure ( mmhg )  mean ± sd,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1469,systolic blood pressure ( mm hg )  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1469,systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure  mmhg *,C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure  mmhg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1469,systolic blood pressure  mm   hg,C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure  mm hg ^,C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure  mm hg < $nmbr$,C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure  mm hg ( sd ),C0439475;C0488055;C0871470;C1306620;C2699239
1469,systolic blood pressure  mm hg  mean ± sd,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1469,systolic blood pressure  mm hg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1469,systolic blood pressure  mm hg,C0439475;C0488055;C0871470;C1306620
1469,systolic blood pressure  mean ( sd )  mm hg,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1469,systolic blood pressure  ( mm hg ),C0439475;C0488055;C0871470;C1306620
1469,systolic ( mmhg ),C0039155;C0439475
1469,systolic ( mm hg ),C0039155;C0439475
1469,sl $nmbr$ mm hg,C0439475
1469,sitting systolic blood pressure ( mm hg ),C0277814;C0439475;C0488055;C0871470;C1306620;C2584297;C4050224
1469,sitting diastolic blood pressure ( mm hg ),C0439475;C1319894
1469,sitting blood pressure — mmhg,C0439475;C0580946
1469,sbp > $nmbr$ mm hg,C0085805;C0439475
1469,sbp < $nmbr$ mm hg,C0085805;C0439475
1469,sbp  mm   hg,C0085805;C0439475
1469,sbp  mm hg,C0085805;C0439475
1469,s $nmbr$ mmhg,C0439475;C0565930;C2603362
1469,receiving antihypertensive treatment  n ( % ) blood pressure  mm hg  mean ( sd ),C0003364;C0039798;C0087111;C0428886;C0439475;C1514756;C1522326;C1533734;C1705169;C2699239;C3538994;C3887704
1469,nob systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
1469,nighttime mean dbp ( abpm ) at week $nmbr$  mmhg,C0240526;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
1469,n ( % ) blood pressure - mean ( sd ) mm hg,C0369718;C0428886;C0439475;C0441922;C2699239
1469,mssbp < $nmbr$ mmhg,C0439475
1469,mssbp ( mm hg ),C0439475
1469,mssbp  mm hg,C0439475
1469,msdbp ( mm hg ),C0439475
1469,msdbp  mm hg,C0439475
1469,mm hg,C0439475
1469,mean — mm hg,C0439475;C0444504;C2347634;C2348143
1469,mean ± sd msdbp  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239
1469,mean systolic bp  mmhg  mean = sd,C0439475;C0444504;C0871470;C2347634;C2348143;C2699239
1469,mean systolic blood pressure ( sd )  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1469,mean systolic blood pressure  mm hg ( sd ),C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1469,mean systolic blood pressure  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
1469,mean sd mssbp  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239
1469,mean pulmonary artery pressure  mm hg,C0439475;C3854605
1469,mean diastolic blood pressure ( sd )  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143;C2699239
1469,mean diastolic blood pressure  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143
1469,mean bp ( mmhg ),C0037623;C0439475;C0444504;C1415692;C1708288;C2347634;C2348143;C4318478
1469,mean blood pressure  mm hg,C0428886;C0439475;C0488053
1469,mean ( s . d . ) systolic blood pressure  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
1469,mean ( s . d . ) diastolic blood pressure  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143
1469,map ( mmhg ),C0024779;C0439475;C1706473;C4050322
1469,iop  mm hg,C0439475;C0578862
1469,diastolic — mm hg,C0012000;C0439475
1469,diastolic — mean ( sd ) ( mm hg ),C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
1469,diastolic pressure  mm hg,C0428883;C0439475
1469,diastolic blood pressurea  mmhg,C0005767;C0005768;C0012000;C0229664;C0439475
1469,diastolic blood pressure — mm hg,C0428883;C0439475;C1305849
1469,diastolic blood pressure mmhg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1469,diastolic blood pressure > $nmbr$ mm hg,C0428883;C0439475;C1305849
1469,diastolic blood pressure - mmhg,C0428883;C0439475;C1305849
1469,diastolic blood pressure ( mmhg ),C0428883;C0439475;C1305849
1469,diastolic blood pressure ( mm hg ) :,C0428883;C0439475;C1305849
1469,diastolic blood pressure ( mm hg )  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1469,diastolic blood pressure  mmhg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1469,diastolic blood pressure  mmhg,C0428883;C0439475;C1305849
1469,diastolic blood pressure  mm   hg,C0428883;C0439475;C1305849
1469,diastolic blood pressure  mm hg ^,C0428883;C0439475;C1305849
1469,diastolic blood pressure  mm hg ( sd ),C0428883;C0439475;C1305849;C2699239
1469,diastolic blood pressure  mm hg  mean ± sd,C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1469,diastolic blood pressure  mm hg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1469,diastolic blood pressure  ( mm hg ),C0428883;C0439475;C1305849
1469,diastolic ( mmhg ),C0012000;C0439475
1469,diastolic ( mm hg ),C0012000;C0439475
1469,diastolic  mean ( sd )  mm hg,C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
1469,daytime mean dbp ( abpm ) at week $nmbr$  mmhg,C0332169;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
1469,change in bp  mm hg,C0439475;C1268766
1469,change from baseline  mmhg,C0168634;C0392747;C0439475;C0443172;C1442488;C1705241;C4319952
1469,blood pressure systolic  mm hg,C0005823;C0039155;C0439475;C1271104;C1272641
1469,blood pressure in mm hg  mean ( sd ),C0428886;C0439475;C0488053;C2699239
1469,blood pressure : systolic / diastolic ( mm hg ) ( mean  sd ),C0439475;C0444504;C2347634;C2348143;C2699239;C2704328
1469,blood pressure ( mm hg ) systolic,C0005823;C0039155;C0439475;C1271104;C1272641
1469,blood pressure  mmhg  mean ( sd ),C0428886;C0439475;C2699239
1469,blood pressure  mm hg  mean ( sd ),C0428886;C0439475;C2699239
1469,blood pressure  mean ± sd mm hg,C0428886;C0439475;C2699239
1469,blood pressure  mean ( sd ) [ range ]  mm hg,C0428886;C0439475;C1514721;C2348147;C2699239;C3542016
1469,blood pressure  mean ( sd )  mm hg systolic,C0039155;C0428886;C0439475;C2699239
1469,blood pressure  mean ( sd )  mm hg,C0428886;C0439475;C2699239
1469,bl mean ( mmhg ),C0005918;C0006413;C0439475;C0444504;C1552663;C2347634;C2348143;C2827109
1469,baseline systolic blood pressure ( mm hg ),C0439475;C4274438
1469,baseline systolic blood pressure  mean ( sd )  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239;C4274438
1469,baseline sitting sbp  $nmbr$ mm hg,C0085805;C0168634;C0277814;C0439475;C1442488;C2584297;C4050224
1469,baseline sedbp  mean ( sd )  mm hg §,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1469,baseline sbp ( mm hg ),C0085805;C0168634;C0439475;C1442488
1469,baseline mssbp / msdbp  mm hg,C0168634;C0439475;C1442488
1469,baseline diastolic blood pressure ( mm hg ),C0439475;C4274392
1469,baseline diastolic blood pressure  mean ( sd )  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239;C4274392
1469,baseline  mm hg,C0168634;C0439475;C1442488
1469,at home systolic pressure > $nmbr$ mm hg,C0439475;C0871470;C4534363
1469,at home systolic pressure < $nmbr$ mm hg,C0439475;C0871470;C4534363
1469,at home diastolic pressure > $nmbr$ mm hg,C0428883;C0439475;C4534363
1469,at home diastolic pressure < $nmbr$ mm hg,C0428883;C0439475;C4534363
1469,at clinic systolic pressure > $nmbr$ mm hg,C0002424;C0439475;C0442592;C0871470
1469,at clinic systolic pressure < $nmbr$ mm hg,C0002424;C0439475;C0442592;C0871470
1469,at clinic diastolic pressure > $nmbr$ mm hg,C0002424;C0428883;C0439475;C0442592
1469,at clinic diastolic pressure < $nmbr$ mm hg,C0002424;C0428883;C0439475;C0442592
1469,apasp ( per mmhg ),C0439475
1469,^ numbers do not always sum to group totals due to missing information for some variables . fbody mass index was calculated as weight in kilograms divided by the square of height in meters . ^ hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . § hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . | | diabetes was defined by self - report .,C0005910;C0011847;C0011849;C0011900;C0020443;C0020473;C0020538;C0025424;C0031831;C0043100;C0201950;C0205120;C0237753;C0332849;C0428257;C0428465;C0428883;C0439175;C0439209;C0439269;C0439475;C0439810;C0439828;C0441074;C0441833;C0444686;C0449788;C0488055;C0489786;C0543421;C0577559;C0577573;C0600653;C0678226;C0681906;C0687744;C0804815;C0871470;C0918012;C1096155;C1257890;C1305849;C1305866;C1306372;C1306620;C1441506;C1515051;C1518422;C1519504;C1522133;C1532563;C1552595;C1552854;C1637833;C1704788;C1705104;C1705428;C1705429;C1963138;C2003902;C2347108;C2347109;C2348272;C2700446;C2986546;C3146286;C3152252;C3539106;C3539882;C3812891;C4283905;C4330985;C4524803;C4554674;C4555212
1469,^ $nmbr$ mm hg,C0439475
1469,> = $nmbr$ mmhg,C0439475
1469,> = $nmbr$ - < $nmbr$ mmhg,C0439475
1469,> $nmbr$ to < $nmbr$ mm hg,C0439475
1469,> $nmbr$ mmhg,C0439475
1469,> $nmbr$ mm hg — no . ( % ),C0439475
1469,> $nmbr$ mm hg,C0439475
1469,> $nmbr$ / > $nmbr$ mm hg,C0439475
1469,> $nmbr$ . $nmbr$ mm hg,C0439475
1469,> $nmbr$ - < $nmbr$ mmhg,C0439475
1469,< $nmbr$ mmhg,C0439475
1469,< $nmbr$ mm hg — no . ( % ),C0439475
1469,< $nmbr$ mm hg heart rate,C0018810;C0439475
1469,< $nmbr$ mm hg,C0439475
1469,< $nmbr$ / < $nmbr$ mm hg,C0439475
1469,< $nmbr$ / $nmbr$ mm hg +,C0439475
1469,< $nmbr$ / $nmbr$ mm hg,C0439475
1469,< $nmbr$ . $nmbr$ mm hg diastolic blood pressure,C0428883;C0439475;C1305849
1469,< $nmbr$ . $nmbr$ mm hg,C0439475
1469,$nmbr$ to < $nmbr$ mmhg,C0439475
1469,$nmbr$ to < $nmbr$ mm hg — no . { % ),C0439475
1469,$nmbr$ to < $nmbr$ mm hg,C0439475
1469,$nmbr$ to $nmbr$ mm hg,C0439475
1469,$nmbr$ o - i $nmbr$ mm hg,C0021966;C0221138;C0439475;C0483204
1469,$nmbr$ mmhg,C0439475
1469,$nmbr$ mm hg,C0439475
1469,$nmbr$ l $nmbr$ mmhg,C0439394;C0439475;C1706495;C3642217
1469,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmhg,C0439475
1469,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mm hg,C0439475
1469,$nmbr$ - $nmbr$ / $nmbr$ - $nmbr$ mm hg,C0439475
1468,somnolence,C0013144;C2830004;C4553740
1468,relative risk ( $nmbr$ % confidence interval ),C0009667;C0242492
1468,abbreviations : egfr = estimated glomerular filtration rate  imt = intimal medial thickness  lv = left ventricular . * two - sample comparison t - tests were calculated based on log - transformed variables . * * geometric mean with $nmbr$ % confidence interval in parenthesis .,C0000723;C0009667;C0023128;C0162864;C0205098;C0205448;C0225897;C0334121;C0370003;C0439828;C0444686;C0731033;C0871472;C1256463;C1280412;C1441506;C1510411;C1527178;C1704614;C1705938;C1707455;C1708728;C1739039;C1881413;C2347026;C2986759;C2986775;C3811844;C3812682;C4318736
1468,$nmbr$ % confidence interval,C0009667
1467,incidencea,
1467,incidence of each outcome,C0021149;C0220856;C1274040
1467,incidence ^,C0021149;C0220856
1467,incidence *,C0021149;C0220856
1467,incidence  ° / o ( $nmbr$ / $nmbr$ cl ),C0021149;C0220856;C0596019
1467,incidence  %,C0021149;C0220856
1467,event incidence / n,C0021149;C0220856;C0441471;C4019010
1467,event / patients in group ( incidence / $nmbr$ person - year ),C0021149;C0027361;C0030705;C0220856;C0439234;C0439508;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2347489;C4019010
1467,cumulative incidence lyear,C0021149;C0220856;C1511559
1467,cumulative incidence $nmbr$ years,C0021149;C0220856;C0439234;C1511559
1467,$nmbr$ - year cumulative incidence  % ( ci ),C0008107;C0021149;C0220856;C0439234;C0439508;C1511559;C3259781
1466,sbp  difference,C0085805;C1705241;C1705242
1466,risk difference,C0035647;C1705241;C1705242;C4552904
1466,percentage difference ( $nmbr$ % cl ),C0439165;C0596019;C1549488;C1561533;C1705241;C1705242
1466,mean arterial pressure  difference,C0428886;C1705241;C1705242
1466,lsm difference,C1705241;C1705242
1466,laba + ics versus indzgly lsm difference ( $nmbr$ % cl ),C0596019;C0815320;C1705241;C1705242;C4551720
1466,group difference,C0441833;C0687744;C1257890;C1519504;C1705241;C1705242;C1705428;C1705429
1466,estimated treatment difference ( % ),C0039798;C0087111;C0750572;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
1466,estimated means and treatment differences ( % ),C0039798;C0087111;C0750572;C1522326;C1533734;C1704970;C1705169;C1705241;C1705242;C3538994;C3887704
1466,estimated means and difference,C0750572;C1704970;C1705241;C1705242
1466,estimated difference %,C0750572;C1705241;C1705242
1466,estimated difference,C0750572;C1705241;C1705242
1466,differencevs . pbof,
1466,difference vs pbo ( $nmbr$ % ci ),C0008107;C0031962;C1705241;C1705242;C3259781
1466,difference vs . pbof mean ( s . e . ) t,C0444504;C1705241;C1705242;C2347634;C2348143
1466,difference in sbp between treatment,C0039798;C0085805;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
1466,difference in means ( $nmbr$ % cl ),C0596019;C1704970;C1705241;C1705242
1466,difference in means,C1704970;C1705241;C1705242
1466,difference in change,C0392747;C0443172;C1705241;C1705242;C4319952
1466,difference from baselinea,C1705241;C1705242
1466,difference ( tiotropium - placebo ) ml ( $nmbr$ % ci ),C0008107;C0032042;C0213771;C0439526;C1696465;C1705224;C1705241;C1705242;C1706408;C3259781;C3887665
1466,difference ( % ),C1705241;C1705242
1466,difference $nmbr$,C1705241;C1705242
1466,difference,C1705241;C1705242
1466,absolute risk difference ( ci )  % *,C0008107;C0035647;C1519101;C1549031;C1705241;C1705242;C3259781;C4552904
1466,absolute risk difference ( $nmbr$ % cl ),C0035647;C0596019;C1519101;C1549031;C1705241;C1705242;C4552904
1466,* plus - minus values are means ± sd . there were no significant differences ( at,C0042295;C0237881;C0332288;C0750502;C1546944;C1704970;C1705241;C1705242;C2699239
1466,% - point difference ( $nmbr$ % ci ) c,C0008107;C1552961;C1705241;C1705242;C2347617;C3259781;C3714763
1466,$nmbr$ % ci for difference,C0008107;C1705241;C1705242;C3259781
1465,medication adherence,C2364172
1465,adherence > $nmbr$ %,C1510802
1464,type of reference treatment strategy,C0455708;C0679199;C1514811;C1706462
1464,referent,C1706462
1464,reference,C1514811;C1706462
1464,no ( reference ),C1514811;C1706462
1464,< $nmbr$ mg dl ( reference ),C0439269;C1514811;C1706462
1464,< $nmbr$ kg  mj ( reference ),C0022718;C0439209;C0439254;C1514811;C1706462;C4054209;C4284025
1464,$nmbr$ . $nmbr$ ( referent ),C1706462
1464,$nmbr$ . $nmbr$ ( reference ),C1514811;C1706462
1463,sonti amenca,
1463,region north america,C0017446;C0028405;C0205147
1463,region - north america,C0017446;C0028405;C0205147
1463,region  north america,C0017446;C0028405;C0205147
1463,north america n z $nmbr$,C0028405
1463,north america / oceania,C0028405;C0282279;C4085681
1463,north america *,C0028405
1463,north america ( plus america and new zealand ),C0027978;C0028405;C0324547;C0332287
1463,north america ( n = $nmbr$ ),C0028405
1463,north america ( % ),C0028405
1463,north america,C0028405
1463,n america,C0002454;C0369718;C0441922
1463,latin and north america,C0028405
1463,geographic region - north america,C0017446;C0028405
1463,america,C0002454
1462,mexico  central / south america,C0007674;C0025885;C0037713;C0205099;C1710133;C1879652
1462,mexico,C0025885
1461,region latin american,C0017446;C0205147;C1553378
1461,native american or alaskan native,C0238611;C0282204;C0302891;C1515945
1461,native american or alaska native,C0282204;C0682125;C1515945
1461,native american / alaskan,C0238611;C0282204;C0596070;C0682125;C1515945
1461,native american,C0282204;C1515945
1461,mexican,C0240339
1461,latin ameriea,
1461,latin american,C1553378
1461,latin america hr ( $nmbr$ % cl ),C0023122;C0596019
1461,latin america ( n = $nmbr$ ),C0023122
1461,latin america,C0023122
1461,latin,
1461,indian ( american ) or alaskan native,C0238611;C0302891;C0596070;C1524069
1461,hispanic american,C0019576
1461,hispanic / latin american,C0019576
1461,american,C0596070
1460,vka experienced,C0237607;C0596545
1460,prior vka experience,C0237607;C0332152;C0596545;C2826257
1460,oac experienced  bn   ( % ),C0005005;C0034700;C0237607;C0596545;C1706574;C4551963
1460,experienced,C0237607;C0596545
1460,experience ( n  % ),C0237607;C0596545
1460,experience,C0237607;C0596545
1460,clinic research experience  n ( % ),C0008972;C0237607;C0596545
1460,cdmard experience  n ( % ),C0237607;C0596545
1459,vldm n = $nmbr$,
1459,vildagliptin + metformin ( vldm ),C0025598;C1570906
1459,metformin ( hdm ),C0025598
1459,hdm n = $nmbr$,
1458,hd edoxaban vs warfarin,C0043031;C2975435
1458,hd ( n = $nmbr$ ),
1457,tiotropium $nmbr$ gg qd,C0017454;C0018370;C0213771;C0332173
1457,qd,C0332173
1457,no vhd,
1457,indacaterol $nmbr$ gg qd,C0017454;C0018370;C0332173;C1722260
1457,d  mitral stenosis vhd ( n = $nmbr$ ),C0026269;C0073187;C0264766;C0332173;C4484261
1457,b  vhd ( n = $nmbr$ ),
1457,a  no vhd ( n = $nmbr$ $nmbr$ ),
1456,unacceptable side effects,C0001688;C0877248;C0879626;C1883420
1456,unacceptable adverse events,C0877248;C1705413;C1883420
1456,gall bladder adverse event ( n = $nmbr$ ),C0016976;C0877248
1456,any early adverse event,C0877248;C1279919
1456,adverse event,C0877248
1455,sle markers  n ( % ),C0005516;C0024141
1455,elevated biomarkers and st - segment changes,C0005516;C0205250;C0232326;C3163633
1455,biomarker levels,C0005516;C0441889
1454,teaes ( > $nmbr$ % in any treatment group ) *,C0374505
1454,teaes ( > $nmbr$ % in any treatment group ),C0374505
1454,any teaes,
1454,any teae,
1454,all treatments,C0087111
1454,all,
1453,volume depletion - related aes,C0439849;C0445223;C0546884;C1412268;C2699274
1453,tier $nmbr$ aes,C1412268;C2699274
1453,other selected aes,C1412268;C1707391;C2699274
1453,osmotic diuresis - related aes,C0232823;C0439849;C0445223;C1412268;C2699274
1453,most common aes ‡,C0205214;C0205393;C1412268;C1522138;C2699274;C3245511
1453,most common aes in any group,C0205214;C0205393;C0441833;C0687744;C1257890;C1412268;C1519504;C1522138;C1705428;C1705429;C2699274;C3245511
1453,investigator - reported aes,C0035173;C0684224;C0700287;C1412268;C2699274;C4319718
1453,gallbladder - related aes,C0016976;C0439849;C0445223;C1412268;C2699274
1453,fatal aes,C1302234;C1412268;C1705232;C2699274
1453,any aes  n ( % ),C1412268;C2699274
1453,any aes,C1412268;C2699274
1453,aes related to,C0040363;C0041260;C0439849;C0445223;C1412268;C1883351;C2699274
1453,aes leading to dose reduction of study drugb,C0178602;C0557651;C0861063;C0869039;C1114758;C1412268;C2603343;C2699274
1453,aes in ≥ $nmbr$ japanese patients in a study arm  n ( % ) §,C0030705;C0376247;C0446516;C0557651;C1412268;C1556094;C2603343;C2699274;C3715044;C4553528
1453,aes *,C1412268;C2699274
1453,> $nmbr$ aes,C1412268;C2699274
1452,ongoing atopic or allergic condition — no . { % ),C0392707;C0549178;C0851444
1452,allergic disease by historyb  n ( % ),C0020517;C0851444
1452,alleles,C0002085
1451,ulcers / gangrene,C0017086;C0041582
1451,ulcer  n ( % ) a,C0041582;C3887532
1451,ulcer,C0041582;C3887532
1451,or ulcerations  ® n ( % ),C0041582
1451,irregular or ulcerated ica plaquef,C0041582;C0201519;C0205271;C3887532
1451,irregular or ulcerated ica p ) laque : [ :,C0041582;C0201519;C0205271;C3887532
1450,verapamil sr strategy ( n = $nmbr$  $nmbr$ ),C0679199;C1527129
1450,verapamil sr n = $nmbr$ no . ( % ),C1527129
1450,verapamil sr n = $nmbr$,C1527129
1450,verapamil sr ( no . = $nmbr$ ),C1527129
1450,verapamil sr,C1527129
1450,verapamil - sr strategy,C0679199;C1527129
1450,verapamil - sr ( « = $nmbr$ $nmbr$ ),C1527129
1450,verapamil ( n  % ),C0042523
1450,use of verapamil or quinidine,C0034414;C0042523;C1524063
1450,diltiazem or verapamil,C0012373;C0042523
1449,varespladib ( n = $nmbr$ ),C2713485
1449,varespladib,C2713485
1448,vorapaxar placebo,C0032042;C1696465;C1706408;C2974521
1448,vorapaxar no . ( $nmbr$ - y km % ),C2974521;C3887676
1448,vorapaxar n = $nmbr$,C2974521
1448,vorapaxar group ( n = $nmbr$ ),C0441848;C2974521
1448,vorapaxar event rate ( n = $nmbr$ )  %,C0441471;C0871208;C1521828;C2974521;C4019010
1448,vorapaxar ( n = $nmbr$ . $nmbr$ ),C2974521
1448,vorapaxar ( n = $nmbr$ )  n ( % ),C2974521
1448,vorapaxar ( n = $nmbr$ ),C2974521
1448,vorapaxar ( n = $nmbr$ $nmbr$ ),C2974521
1448,vorapaxar ( n = $nmbr$  $nmbr$ ),C2974521
1448,vorapaxar $nmbr$ - y,C2974521
1448,vorapaxar,C2974521
1447,pyrexia,C0015967
1447,proximal to the splenic flexure,C0205107;C0227387;C4489236
1447,proximal gi tract,C0017189;C0205107;C4489236
1447,proximal gastrointestinal tract,C0017189;C0205107;C0521362;C4489236
1447,proximal - mainleft,C0205107;C4489236
1447,proximal,C0205107;C4489236
1446,paroxysmal atrial fibrillation — no . ( % ),C0235480;C4050122
1446,paroxysmal af,C0235480
1446,paroxysmal ( n  % ),C0205311
1446,paroxysmal !,C0205311
1446,paroxysmal  n ( % ),C0205311
1446,paroxysmal,C0205311
1446,history of paroxysmal atrial fibrillation  n ( % ),C0205311;C0729790
1446,history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
1445,pre - procedure,C3272300
1445,post - procedure,C3272301
1445,other diagnostic procedure *,C0430022;C1546908
1444,systoiic biood pressure  mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
1444,question $nmbr$ ( discomfort from any areas tender to touch / pressure ),C0033095;C0152054;C0205146;C0234234;C0439815;C0460139;C0702221;C1306345;C1522634;C2364135;C4284008;C4319729
1444,pressure ( mm hg ),C0033095;C0439475;C0460139;C1306345;C4284008
1444,pressure,C0033095;C0460139;C1306345;C4284008
1444,diastoiic biood pressure  mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
1444,any blood pressure medications ( % ),C0005823;C0013227;C0033095;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
-10,czech repumc,C0337799
-10,puerperium,C0034042;C0086839;C1879329
1441,rectum and sigmoid colon only,C0034896;C0205171;C0227391;C1720467
1441,rectum,C0034896
1440,rib,C0035561
1440,primary ep ( cvd / mi / ri ),C0007222;C0035487;C0205225;C0439612;C0439631;C1826843;C1880476;C3810814;C4321526
1440,( ri = $nmbr$ ),C0035487;C1826843
1439,subgroup w . r . t . re - cover,C0180153;C0232024;C0556581;C1079230;C1515021;C1999244;C2986904;C3888055
1439,re - medy,C0556581;C2986904
1438,time to rx,C0040223;C1425688;C1521941;C2709207;C3541383
1438,any new anti - hyperglycemic rx,C0205314;C1425688;C1521941;C2709207
-10,qmaxi rn l / s,C2827110;C3540639;C4281819
1436,> $nmbr$ rd quartile,C0694666;C2828255;C4553350
1436,> $nmbr$ nd and < $nmbr$ rd quartile,C0694666;C2828255;C4553350
1436,$nmbr$ rd tertile ( > $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) d,C0439190;C0439269;C0475219;C0567349;C0694666;C2348885;C3642216;C4553350
1436,$nmbr$ rd > $nmbr$ . $nmbr$,C0694666;C4553350
1435,seropositive ( rf + ve and / or acpa + ve ) subgroup,C0035448;C0042469;C0201660;C0521143;C0748398;C1079230;C1515021;C1525410;C1547111;C1706063;C3714652;C4321495
1435,rheumatoid factor - positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
1435,rheumatoid factor !,C0035448;C0201660
1435,rf positive — number ( % ),C0035448;C0201660;C0748398;C1547111;C3812269
1435,rf positive and acpa negative  n ( % ),C0035448;C0201660;C0205160;C0439178;C0748398;C1446409;C1513916;C1514241;C1525410;C1547111;C1706063;C2825415;C2825490;C2825491;C3812269;C3853545
1435,rf positive ( > $nmbr$ iu / ml )  n ( % ),C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1435,rf positive  no . ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1435,rf positive  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1435,rf positive  %,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1435,rf positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1435,rf negative and acpa positive  n ( % ),C0035448;C0201660;C0205160;C0439178;C0748398;C1446409;C1513916;C1514241;C1525410;C1547111;C1706063;C2825415;C2825490;C2825491;C3812269;C3853545
1435,rf and acpa positive  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1525410;C1547111;C1706063;C2825490;C3812269
1435,rf - positive  > $nmbr$ iu / ml  %,C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1435,rf ( mg / dl ),C0035448;C0201660;C0439269;C0748398;C1547111
1435,rf ( mg / dl  per unit ),C0024671;C0026410;C0035448;C0201660;C0439148;C0439269;C0439453;C0748398;C1509845;C1519795;C1532632;C1547111;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C4321396;C4521761
1435,rf ( iu / ml ),C0035448;C0201660;C0439458;C0748398;C1547111
1435,rf  % positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1435,positive for rheumatoid factor — no . ( % ) : t,C0035448;C0201660;C0439178;C1446409;C1514241;C2603360;C2825490;C3812269
1435,% rf +,C0035448;C0201660;C0748398;C1547111
1434,waist circumference women : > $nmbr$ in ( $nmbr$ cm ) men : > $nmbr$ in ( $nmbr$ cm ) tc $nmbr$ c $nmbr$ mg / dl,C0025266;C0039411;C0040642;C0041405;C0041698;C0043210;C0439269;C0455829;C1824670;C3272447;C4522122
1434,tk,C0041405;C0220928;C4050092
1434,tc : hdlc,C0039411;C0040642;C0041405;C0041698;C1704429;C1824670;C3272447;C4522122
1434,tc / hdl - c ratio,C0039411;C0040642;C0041405;C0041698;C0456603;C1547037;C1824670;C3272447;C3715113;C4522122
1434,tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3715113;C4522122
1434,tc ( mmol / l ),C0039411;C0040642;C0041405;C0041698;C1532563;C1824670;C3272447;C4522122
1434,tc ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C0439269;C1824670;C3272447;C4522122
1434,tc  mmol / l ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3642216;C3898312;C4522122
1434,tc,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
1434,baseline tc  mg / dl,C0039411;C0040642;C0041405;C0041698;C0168634;C0439269;C1442488;C1824670;C3272447;C4522122
1434,= ezetimibe  tc = triglycerides  hdl - c = lg / dl l > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having,C0023128;C0039411;C0040363;C0040642;C0041260;C0041405;C0041698;C0062152;C0439190;C0694651;C1142985;C1824670;C1883351;C3272447;C3642216;C4522122
1433,weight ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0552346;C0876920;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
1433,weight  median ( $nmbr$ th — $nmbr$ th percentiles )  kg,C0022718;C0039725;C0039738;C0439209;C0549183;C0552346;C0876920;C1420718;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344
1433,weight  kg  median ( $nmbr$ th  $nmbr$ th ),C0005910;C0022718;C0039725;C0039738;C0043100;C0439209;C0549183;C0876920;C1305866;C1420718;C1705104;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344
1433,uacr  mg / g  median ( $nmbr$ th − $nmbr$ th percentile ),C0039725;C0039738;C0549183;C0876920;C1264641;C1300563;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1433,time from onset of pain to randomization  median ( $nmbr$ th — $nmbr$ th percentiles )  n,C0030193;C0034656;C0039725;C0039738;C0449244;C0518090;C0549183;C0876920;C1264641;C1420718;C1962977;C2347635;C2348144;C2939193;C2984058;C4085210;C4085211;C4085212;C4282123;C4285344;C4553004;C4554132
1433,th c,C0039725;C0039738;C1420718;C4282123;C4285344
1433,th ( $nmbr$ % ),C0039725;C0039738;C1420718;C4282123;C4285344
1433,median ( $nmbr$ th  $nmbr$ th percentile ),C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1433,euroscore logistic  median ( $nmbr$ th  $nmbr$ th % ) £,C0039725;C0039738;C0242415;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344
1433,euroscore additive  median ( $nmbr$ th  $nmbr$ th % ) §,C0039725;C0039738;C0442796;C0549183;C0876920;C1420718;C1550602;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344
1433,age ( y )  median ( $nmbr$ th to $nmbr$ th percentiles ),C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1433,age  y ( $nmbr$ th  $nmbr$ th percentiles ),C0001779;C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
1433,age  median ( $nmbr$ th — $nmbr$ th percentiles )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1433,age  median ( $nmbr$ th - $nmbr$ th percentiles )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1433,age  median ( $nmbr$ th  $nmbr$ th )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1433,$nmbr$ th — $nmbr$ th percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
1433,$nmbr$ th : $nmbr$ . $nmbr$ - $nmbr$ pmol / l,C0039725;C0039738;C0439284;C1420718;C4282123;C4285344
1433,$nmbr$ th - $nmbr$ th percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
1432,any type  according to daily dose * *,C0332307;C0680240;C1547052;C2348070
1432,$nmbr$ % ( oto $nmbr$ ),
1432,$nmbr$ % ( ito $nmbr$ ),C0022283
1432,$nmbr$ % ( - ito $nmbr$ ),C0022283
1431,due to drug - relateda ae,C0013227;C1254351;C3887670
1431,due to ae,C3887670
1431,discontinuations due to ae,C0457454;C0678226;C3887670
1431,$nmbr$ to $nmbr$ y  n ( % ),
1430,tj ( $nmbr$ - $nmbr$ ),C0039247
1430,tj ( $nmbr$ % ),C0039247
1430,sou ti africa,C0001737;C0039247;C0040302;C1553045;C1704756
1430,- $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ § ti,C0039247;C0040302;C1553045;C1704756
1429,unadjusteda beta ( se ),C0036919;C0330390;C0439096;C2004068
1429,randomized to receive beta carotene,C0034656;C0040363;C0041260;C0053396;C0696105;C1514756;C1883351;C3815594
1429,beta receptor antagonist,C0330390;C0439096;C2004068;C4543207
1429,beta bloekers,C0330390;C0439096;C2004068
1429,beta - carotene ( n = $nmbr$  $nmbr$ ),C0053396;C0696105
1429,beta - carotene,C0053396;C0696105
1429,beta $nmbr$ selective,C0036576;C0330390;C0439096;C1707391;C2004068
1429,adjustedb  c beta ( se ),C0036919;C0330390;C0439096;C2004068
1428,both adalimumab groups ( n = $nmbr$ ) baseline cd - related antibiotic use,C0003232;C0007928;C0034283;C0042153;C0168634;C0369718;C0439849;C0441833;C0441922;C0445223;C0457083;C0687744;C1122087;C1257890;C1442488;C1519504;C1552839;C1705428;C1705429;C1947944;C4552032
1428,both ( % ),
1428,both,
1428,> $nmbr$ and / or > $nmbr$ moderate or severe deformity  or both ( n = $nmbr$ ),C0000768;C0205081;C0205082;C0221430;C0302142;C0369718;C0441922;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
1427,pci data,C1511726;C3245479;C3714741;C4049621
1427,number of patients with available data,C0470187;C1511726;C2360800;C3245479;C3714741
1427,no ef data | |,C1511726;C3245479;C3714741
1427,laboratory data  mean ( sd ),C0022877;C0444504;C1511726;C2347634;C2348143;C2699239;C3244292;C3245479;C3714741;C4283904
1427,laboratory data,C0022877;C1511726;C3244292;C3245479;C3714741;C4283904
1427,fpg data ',C1511726;C3245479;C3714741
1427,ecg and imaging data,C0011923;C0079595;C1511726;C1623258;C3245479;C3714741
1427,data  ' ' n,C1511726;C3245479;C3714741
1427,baseline data,C0168634;C1442488;C1511726;C3245479;C3714741
1427,available data,C0470187;C1511726;C3245479;C3714741
1427,at c data,C1511726;C3245479;C3714741
1427,angiographic data and treatment :,C0002978;C0039798;C0087111;C1511726;C1522326;C1533734;C1705169;C3245479;C3538994;C3714741;C3887704
1427,angiographic data,C0002978;C1511726;C3245479;C3714741
1427,* data are expressed as median ± sd  except,C0549183;C0876920;C1511726;C2347635;C2348144;C2699239;C2939193;C3245479;C3714741
1427,* data are expr,C1511726;C3245479;C3714741
1426,transient monocular blindness,C0149793
1426,acenocoumaroi,
1425,immunomodulatory agents,C0005525
1425,immunomodulators,C0001551;C0005525;C1527392
1424,no glucocorticoids or immunosuppressants,C0017710;C0021081;C3540777;C3540778
1424,no concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0042153;C0332152;C0457083;C0521115;C1448177;C1947944;C2826257
1424,no baseline immunosuppressant use,C0021081;C0042153;C0168634;C0457083;C1442488;C1947944
1424,neither glucocorticoids nor immunosuppressive agents,C0017710;C0021081;C3540777;C3540778
1424,immunosuppressive use  n ( % ),C0021081;C0042153;C0457083;C1947944
1424,immunosuppressive agents only,C0021081;C0205171;C1720467
1424,immunosuppressants onlyff,C0021081
1424,immunosuppressants only,C0021081;C0205171;C1720467
1424,immunosuppressants,C0021081
1424,immunosuppressant use  %,C0021081;C0042153;C0457083;C1947944
1424,immunosuppressant ^ ^,C0021081
1424,immunosuppressant ^,C0021081
1424,glucocorticoids plus immunosuppressive agents,C0017710;C0021081;C3540777;C3540778
1424,glucocorticoids combined with immunosuppressive agents,C0017710;C0021081;C0205195;C3540777;C3540778
1424,glucocorticoids and immunosuppressants,C0017710;C0021081;C3540777;C3540778
1424,corticosteroids and immunosuppressants only,C0001617;C0021081;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727
1424,concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0042153;C0332152;C0457083;C0521115;C1448177;C1947944;C2826257
1424,both adalimumab groups ( n = $nmbr$ ) baseline immunosuppressant use,C0021081;C0042153;C0168634;C0369718;C0441833;C0441922;C0457083;C0687744;C1122087;C1257890;C1442488;C1519504;C1552839;C1705428;C1705429;C1947944
1424,any immunosuppressive agent,C0021081
1423,• death from any cause,C0007465
1423,time to first cv hospitalization or death from any cause,C0007465;C0019993;C0040223;C0205435;C1279901;C3538987;C3541383;C4048877;C4318503
1423,nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
1423,death from any cause,C0007465
1423,cause of death unknown,C0007465;C0439673;C3541433;C4050014;C4050444
1423,by cause of death,C0007465;C4050444
1422,crude analysis  n ( % ),C0002778;C0936012;C1524024
1422,crude,
1421,transaminases increased,C0002594;C0205217;C0442805;C0919834
1421,pancreas,C0030274
1421,ocs maintained / increased,C0205217;C0442805;C1314677
1421,increased waist circumference,C0205217;C0442805;C0455829
1421,increased risk for thrombotic cardiovascular event ^  n ( % ),C0087086;C0205217;C0442805;C1273410
1421,ggt increased,C0205217;C0442805;C1415053
1421,alt increased,C0205217;C0442805;C1266129;C4553172
1420,smoking status current smoker ( n = $nmbr$ ),C1519386;C3173209;C3241966
1420,smoking history : current smoker,C1519384;C3173209;C3241966
1420,smoking : current smoker,C0037369;C0453996;C1881674;C3173209;C3241966
1420,former or current smokers ( % ),C0205156;C0750523;C3173209;C3241966
1420,ex - / current smoker,C0337671;C0521116;C1704625;C1705970;C3173209;C3241966;C4555205
1420,currentd,
1420,current tobacco smoker ( % ) qualifying event ( % ),C0040329;C0086707;C0441471;C0521116;C0740009;C1514624;C1705970;C3173209;C3241966;C4019010;C4505217
1420,current tobacco smoker,C0040329;C0086707;C0521116;C0740009;C1705970;C3173209;C3241966;C4505217
1420,current smokers *,C3173209;C3241966
1420,current smokers ( n = $nmbr$ ),C3173209;C3241966
1420,current smokers ( itt ) ( n = $nmbr$ ),C3173209;C3241966
1420,current smokers ( % ),C3173209;C3241966
1420,current smokers    n   ( % ),C3173209;C3241966
1420,current smokers  n ( % ) medicai history  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3173209;C3241966
1420,current smokers  n ( % ),C3173209;C3241966
1420,current smokers  %,C3173209;C3241966
1420,current smokers,C3173209;C3241966
1420,current smoker — no . { % ),C3173209;C3241966
1420,current smoker »,C3173209;C3241966
1420,current smoker at screeninga  n ( % ),C3173209;C3241966
1420,current smoker at screening  n ( % ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3173209;C3241966
1420,current smoker at baseline    n   ( % ),C0168634;C1442488;C3173209;C3241966
1420,current smoker : ex - smoker ( % ),C3173209;C3241966
1420,current smoker ( n z $nmbr$ ),C3173209;C3241966
1420,current smoker ( n = $nmbr$ ),C3173209;C3241966
1420,current smoker ( n = $nmbr$  $nmbr$ ) former smoker ( n = $nmbr$  $nmbr$ ),C0205156;C0750523;C3173209;C3241966
1420,current smoker ( n = $nmbr$  $nmbr$ ),C3173209;C3241966
1420,current smoker ( > $nmbr$ cigarettes / day ) — no . ( % ),C0332173;C0439228;C0439505;C0677453;C3173209;C3241966
1420,current smoker ( % ),C3173209;C3241966
1420,current smoker  n [ % ],C3173209;C3241966
1420,current smoker  n / n ( % ),C3173209;C3241966
1420,current smoker  n ( % },C3173209;C3241966
1420,current smoker  n ( % of patients ),C0030705;C3173209;C3241966
1420,current smoker  n ( % ),C3173209;C3241966
1420,current smoker  %,C3173209;C3241966
1420,current smoker,C3173209;C3241966
1420,current drinker,C0556297
1420,current cigarette smoker or within past year,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423;C4086728
1420,current cigarette smoker  n ( % ),C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
1420,current cigarette smoker,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
1420,current / past smoker,C1444637;C3173209;C3241966;C4284302
1420,> $nmbr$ . $nmbr$ bpm current smoker,C3173209;C3241966
1419,strokezsee,
1419,any recurrent stroke,C2242682
1419,all recurrent strokes,C1836785
1418,concurrent prednisolone,C0032950;C0205420
1418,concurrent illness,C0205420;C0221423
1417,smoking — current,C0037369;C0453996;C0521116;C1705970;C1881674
1417,smoking status current,C0521116;C1519386;C1705970
1417,smoking ( current ),C0037369;C0453996;C0521116;C1705970;C1881674
1417,smoking  % current,C0037369;C0453996;C0521116;C1705970;C1881674
1417,postmenopausal  current hormone therapy use,C0019932;C0042153;C0232970;C0279025;C0457083;C0521116;C1705970;C1947944;C2827774;C4521914
1417,postmenopausal  current hormone,C0019932;C0232970;C0521116;C1705970;C4521914
1417,history of currently treated hypertension  n ( % ),C0455527;C0521116;C1522326
1417,currently,C0521116
1417,current use of hormone therapy,C0019932;C0279025;C0521116;C1524063;C1705970;C2827774;C4521914
1417,current tobacco abuse  n ( % ),C0040336;C0521116;C1705970
1417,current smoking *,C0037369;C0453996;C0521116;C1705970;C1881674
1417,current smoking ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
1417,current smoking  n ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
1417,current smoking  %,C0037369;C0453996;C0521116;C1705970;C1881674
1417,current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
1417,current prescribed medications,C0521116;C1705970;C3166216;C3202967
1417,current or prior smoking  %,C0037369;C0332152;C0453996;C0521116;C1705970;C1881674;C2826257
1417,current or previous atrial fibrillation,C0004238;C0205156;C0344434;C0521116;C1552607;C1705970;C1963067
1417,current nonsmokers,C0337672;C0521116;C1705970;C4554605
1417,current n z $nmbr$,C0521116;C1705970
1417,current inhaler +,C0021461;C0521116;C1705970;C1881212;C4319647
1417,current inhaled corticosteroid use,C0004048;C0239126;C0521116;C1705970
1417,current enthesitis  n ( % ) ’,C0521116;C1282952;C1705970
1417,current dactylitis  n,C0239161;C0521116;C1705970
1417,current corticosteroid use  n,C0239126;C0521116;C1705970
1417,current cigarette use  n ( % ),C0521116;C0694535;C1705970
1417,current cigarette use,C0521116;C0694535;C1705970
1417,current cigarette  n ( % ),C0521116;C0677453;C1704760;C1705970;C3890423
1417,current bone disease,C0005940;C0521116;C1705970
1417,current angina ( % ),C0002962;C0521116;C1705970
1417,current angina,C0002962;C0521116;C1705970
1417,current alcohol drinking  n ( % ),C0001948;C0521116;C0556297;C1705970
1417,current ( n   = $nmbr$  $nmbr$ ),C0521116;C1705970
1417,current ( % ),C0521116;C1705970
1417,current ( $nmbr$ + cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
1417,current (  $nmbr$ cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
1417,current  n ( % ),C0521116;C1705970
1417,current,C0521116;C1705970
1416,current medication — no . ( % ),C0746467
1416,current medication  n ( % ),C0746467
-10,chest discomfort,C0235710
1414,left circumflex coronary artery,C0226037
1414,left circumflex artery  n ( % ),C0226037
1414,left circumflex artery,C0226037
1414,left circumflex  n ( % ),C0205091;C0443246;C1552822;C1880089
1414,left circumflex,C0205091;C0443246;C1552822;C1880089
1414,circumflex,C1880089
1413,waist circumference — cmj,C0455829
1413,waist circumference — cm,C0455829
1413,waist circumference s $nmbr$ ( men ) or > $nmbr$ cm ( women ),C0025266;C0043210;C0455829
1413,waist circumference .,C0455829
1413,waist circumference ( cm ) : mean ± sd,C0444504;C0455829;C2347634;C2348143;C2699239
1413,waist circumference ( cm ),C0455829
1413,waist circumference  mean ( sd )  in,C0444504;C0455829;C2347634;C2348143;C2699239
1413,waist circumference  mean ( sd )  cm,C0444504;C0455829;C2347634;C2348143;C2699239
1413,waist circumference  cm mean ( sd ),C0444504;C0455829;C2347634;C2348143;C2699239
1413,waist circumference  cm ( sd ),C0455829;C2699239
1413,waist circumference  cm  mean ( sd ),C0444504;C0455829;C2347634;C2348143;C2699239
1413,waist circumference  cm,C0455829
1413,waist circumference  ( cm ),C0455829
1413,waist circumference,C0455829
1413,mean ± sd waist circumference  cm,C0444504;C0455829;C2347634;C2348143;C2699239
1412,no atopy ( n = $nmbr$ ),C0392707;C3539705
1412,met atopy and ige $nmbr$ - $nmbr$ ku / l criteria  ( n = $nmbr$ ),C0243161;C0392707;C0428210;C0439340;C1550543;C3539705;C4317104
1412,dermatitis atopic,C0011603;C0392707
1412,atopy ( specific ige ) c  n ( % ),C0205369;C0392707;C1552740;C3539705
1412,atopy ( n = $nmbr$  $nmbr$ ),C0392707;C3539705
1412,atopic at baseline : yes,C0168634;C0392707;C1442488;C1549445;C1705108;C1710701
1412,atopic,C0392707
1412,atonic,C0541791
1411,atv n ( % ),C0210243;C0674679;C1145759;C1334862
1411,atv $nmbr$ mg study protocol,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1507394;C1960952;C2346927;C2348563;C2599718;C4321396;C4521761
1411,atv $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
1411,atv $nmbr$ mg,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
1410,> lto £ $nmbr$ symptom days per week,C0677547;C1457887;C3854129
1410,> lto < $nmbr$ ( n = $nmbr$ ),
1410,> $nmbr$ days to $nmbr$ year ( n = $nmbr$ ),C0556972
1409,waist : hip ratio,C0205682
1409,waist - to - hip ratio,C0205682
1409,waist - to - hip  female,C0019552;C0022122;C0043210;C0086287;C0230097;C1505163;C1705497;C1705498;C3538851;C4284725
1409,waist - hip ratio,C0205682
1409,body - mass index  !  waist - to - hip ratio,C0005893;C0205682;C0578022;C1305855
1409,* $nmbr$ to < $nmbr$ y,
1408,ssz + mtx ( n = $nmbr$ ),C0025677;C1417487
1408,pbo + mtx to mtx,C0025677;C0031962;C1417487
1408,pbo + mtx n = $nmbr$,C0025677;C0031962;C1417487
1408,pbo + mtx ^ mtx,C0025677;C0031962;C1417487
1408,pbo + mtx,C0025677;C0031962;C1417487
1408,other ^,
1408,nonbiologic disease - modifying drug other than methotrexate : :,C0025677;C0392747;C4036059
1408,non - mtx csdmards,C0025677;C1417487;C1518422
1408,non - mtx,C0025677;C1417487;C1518422
1408,no mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
1408,no mtx at baseline,C0025677;C0168634;C1417487;C1442488
1408,mtx use at randomization  n ( % ),C0025677;C0034656;C0042153;C0457083;C1417487;C1947944
1408,mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
1408,mtx plus infliximab,C0025677;C0332287;C0666743;C1417487
1408,mtx only,C0025677;C0205171;C1417487;C1720467
1408,mtx naive or free,C0025677;C0332296;C1417487;C1880497;C1996904
1408,mtx n = $nmbr$,C0025677;C1417487
1408,mtx at baseline  n ( % ),C0025677;C0168634;C1417487;C1442488
1408,mtx at baseline,C0025677;C0168634;C1417487;C1442488
1408,mtx + othetcsdmards,C0025677;C1417487
1408,mtx + other csomards,C0025677;C1417487
1408,mtx + other csdmards,C0025677;C1417487
1408,mtx + non - mtx,C0025677;C1417487;C1518422
1408,mtx ( n = $nmbr$ ),C0025677;C1417487
1408,mtx ( n ),C0025677;C1417487
1408,mtx,C0025677;C1417487
1408,methotrexate user,C0025677;C1548600;C1706077
1408,methotrexate plus other csdmardfl,C0025677
1408,methotrexate,C0025677
1408,lef + mtx ( n = $nmbr$ ),C0025677;C1417487
1408,hcq + mtx ( n = $nmbr$ ),C0020336;C0025677;C1417487
1408,etn + mtx ( n = $nmbr$ ),C0014758;C0025677;C0717758;C1417487
1408,etn $nmbr$ mg + mtx n = $nmbr$,C0014758;C0024671;C0025677;C0026410;C0439269;C0717758;C1417487;C1960952;C2346927;C4321396;C4521761
1408,csdmards + mtx ( n = $nmbr$ ),C0025677;C1417487
1408,csdmard otherthan methotrexate,C0025677
1408,concomitant use of mtx to week $nmbr$,C0025677;C0332174;C0439230;C0521115;C1417487;C1524063
1408,concomitant mtx —,C0025677;C0521115;C1417487
1408,concomitant mtx use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1417487;C1947944
1408,concomitant methotrexate  n ( % ),C0025677;C0521115
1408,concomitant csdmards other than methotrexate  n ( % ),C0025677;C0521115
1408,$nmbr$ non - mtx,C0025677;C1417487;C1518422
1407,ldl - cz,C0206578
1407,ez / simva n = $nmbr$ n ( % ),C0206578
1407,ez / simva < % >,C0206578
1407,ez / simva $nmbr$ mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
1407,ez / simva $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
1407,ez / simva,C0206578
1407,czech republic,C0206578
1407,all ez / simva,C0206578
1407,a $nmbr$ + ez n = $nmbr$ a $nmbr$ n = $nmbr$,C0206578
1407,a $nmbr$ + ez n = $nmbr$,C0206578
1407,a $nmbr$ + ez $nmbr$ a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),C0206578;C0369718;C0441922
1407,a $nmbr$ + ez $nmbr$,C0206578
1406,week $nmbr$ czp dose combined ( n   =   $nmbr$ ),C0054841;C0178602;C0205195;C0332174;C0369718;C0439230;C0441922;C0869039;C1114758;C1861828;C1872109
1406,week $nmbr$ czp dose combined,C0054841;C0178602;C0205195;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
1406,czp combined arms ( n = $nmbr$ ),C0054841;C0205195;C0206655;C0446516;C1861828;C1872109;C2681631;C3715044;C4553528
1406,czp baseline,C0054841;C0168634;C1442488;C1861828;C1872109
1406,czp + mtx to mtx,C0025677;C0054841;C1417487;C1861828;C1872109
1406,czp + mtx n = $nmbr$,C0025677;C0054841;C1417487;C1861828;C1872109
1406,czp + mtx ^ mtx,C0025677;C0054841;C1417487;C1861828;C1872109
1406,czp + mtx,C0025677;C0054841;C1417487;C1861828;C1872109
1406,certolizumab pegol ( n = $nmbr$ ),C1872109
1405,values were reported for $nmbr$ patients in the spironolactone group and $nmbr$,C0037982;C0042295;C0441833;C0588446;C0687744;C1257890;C1519504;C1705428;C1705429
1405,spironolactone ( n = $nmbr$ ),C0037982
1405,spironolactone  n ( % ),C0037982
1405,spironolactone,C0037982
1405,outcomes by treatment ( spironolactone vs placebo ),C0032042;C0037982;C0085415;C1696465;C1706408
1405,mra ( spironolactone or eplerenone ),C0037982;C0243032;C0961485;C1609165;C3891069
1405,in the spironolactone group and $nmbr$ patients in the placebo group .,C0030705;C0032042;C0037982;C0441833;C0687744;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
1404,glucosamine + chondroitin sulfate,C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
1404,chondroitin sulfate ( n = $nmbr$ ),C0008466
1404,chondroitin sulfate,C0008466
1404,chondroitin,C0008454
1403,no methotrexate  hydroxychloroquine  or sulfasalazine treatment,C0020336;C0025677;C0036078;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1403,hydroxychloroquine treatment §,C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1403,hydroxychloroquine,C0020336
1403,chloroquine,C0008269
1402,whiteb,
1402,white race — no . { % ) - i -,C0007457;C0021966;C0034510;C0043157;C0220938;C0221138;C1706779;C3853635
1402,white race — no . { % ) ' i ',C0007457;C0021966;C0034510;C0043157;C0220938;C0221138;C1706779;C3853635
1402,white race — no . { % ) $,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1402,white race — no . / total no . ( % ) f,C0007457;C0016327;C0034510;C0043157;C0220938;C0439175;C0439810;C1706779;C3853635
1402,white race — no . / total no . ( % ) $,C0007457;C0034510;C0043157;C0220938;C0439175;C0439810;C1706779;C3853635
1402,white race — no . ( % ) f,C0007457;C0016327;C0034510;C0043157;C0220938;C1706779;C3853635
1402,white race — no . ( % ) : t,C0007457;C0034510;C0043157;C0220938;C1706779;C2603360;C3853635
1402,white race — no . ( % ) :,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1402,white race  n ( % ),C0007457;C0043157
1402,white race  %,C0007457;C0043157
1402,white non - hispanic - n ( % ),C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
1402,white non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
1402,white mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1402,white : black : other,C0005680;C0007457;C0027567;C0043157;C0085756;C0220938;C0439541
1402,white / other,C0007457;C0043157;C0220938
1402,white ( n — $nmbr$ ),C0007457;C0043157;C0220938
1402,white ( n   = $nmbr$  $nmbr$ ),C0007457;C0043157;C0220938
1402,white ( n = $nmbr$ ),C0007457;C0043157;C0220938
1402,white ( n = $nmbr$  $nmbr$ ),C0007457;C0043157;C0220938
1402,white ( $nmbr$ . $nmbr$ % ),C0007457;C0043157;C0220938
1402,white  non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
1402,white  no . ( % ),C0007457;C0043157;C0220938
1402,white  n / n ( % ),C0007457;C0043157;C0220938
1402,white  n ( % ),C0007457;C0043157;C0220938
1402,white  %,C0007457;C0043157;C0220938
1402,white,C0007457;C0043157;C0220938
1402,w hite,
1402,race_white  %,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1402,race - non - white,C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635
1402,race  non - white,C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635
1402,race  no . ( % ) white,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1402,non white,C0007457;C0043157;C0220938;C1518422
1402,non - white raceb,C0007457;C0043157;C0220938;C1518422
1402,non - white race,C0007457;C0043157;C1518422
1402,non - white,C0007457;C0043157;C0220938;C1518422
1402,non - hispanic white,C0007457;C0043157;C0220938;C1518424
1402,asian / black / white / hispanic / other ( % ) clinical parameters,C0005680;C0007457;C0027567;C0043157;C0078988;C0085756;C0205210;C0220938;C0439541;C0449381;C1533017;C1533018;C1533020;C1533021
1401,while,
1401,race - nonwhite,C0034510;C1706779;C3853635
1401,race  while,C0034510;C1706779;C3853635
1401,race  % nonwhite,C0034510;C1706779;C3853635
1401,nonwhite race — no . ( % ) ejection fraction,C0034510;C0489482;C1706779;C2700378;C3853635
1401,nonwhite race !,C0034510;C1706779;C3853635
1401,nonwhite race,C0034510;C1706779;C3853635
1401,nonwhite,
1400,sita / pio $nmbr$ / $nmbr$,C0030800;C2347712
1400,sita $nmbr$ + pio $nmbr$,C0030800;C2347712
1400,sita $nmbr$,
1400,= sia,C1225105;C1551538
1399,type ia,C0020980;C0332307;C0694634;C1547052;C1947960
1399,simple partial ( ia ),C0020980;C0205352;C0694634;C0728938;C1550516;C1947960
1399,austral ia / new zealand,C0020980;C0027978;C0324547;C0694634;C1947960
1398,type ib,C0332307;C1547052;C2744579;C3890035;C4283819
1398,ib ( $nmbr$ . $nmbr$ ),C2744579;C3890035;C4283819
1398,complex partial ( ib ),C0439855;C0728938;C1550516;C1704241;C2744579;C3890035;C4283819
1398,class ib,C0456387;C1518526;C1705943;C2744579;C3890035;C4283819
1397,tnfi - ir,C0022065;C0022071;C1448132
1397,tnf - ir,C0022065;C0022071;C1448132;C1448177
1397,mtx ir,C0022065;C0022071;C0025677;C1417487;C1448132
1397,mtx - ir,C0022065;C0022071;C0025677;C1417487;C1448132
1397,homa - ir score,C0022065;C0022071;C0449820;C1448132;C4050231
1397,homa - ir index — median ( iqr ),C0022065;C0022071;C0549183;C0600653;C0876920;C0918012;C1448132;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546
1397,homa - ir index,C0022065;C0022071;C0600653;C0918012;C1448132;C1552854;C1637833;C2986546
1397,homa - ir ( mu / l ^ mmol / l ),C0022065;C0022071;C0439190;C0439342;C1448132
1397,homa - ir ( % ) b,C0022065;C0022071;C1448132
1397,homa - ir  mean ( sd ) ( mu / l $ mmol / l ) b,C0022065;C0022071;C0439190;C0439342;C0444504;C1448132;C2347634;C2348143;C2699239
1397,homa - ir,C0022065;C0022071;C1448132
1397,dmard - ir / anti - tnf - ir,C0022065;C0022071;C0242708;C1448132;C1448177
1397,dmard - ir,C0022065;C0022071;C0242708;C1448132
1397,dmard - biologic ir,C0005515;C0022065;C0022071;C0205460;C0242708;C1448132
1397,bdmard - ir,C0022065;C0022071;C1448132
1397,anti - tnf ir,C0022065;C0022071;C1448132;C1448177
1397,anti - tnf - ir patients,C0022065;C0022071;C0030705;C1448132;C1448177
1396,denotes angiotensin - converting enzyme .,C0022709;C1452534
1396,converting enzyme inhibitor,C0014432;C0919438;C4521603
1396,angiotension converting enzyme - inhibitor,C0014432;C0919438;C4521603
1396,angiotensin - eonverting enzyme inhibitors / angiotensin reeeptor bloekers,C0003018;C0014432;C1152555;C2756995;C4521302
1396,angiotensin - eonverting enzyme inhibitors,C0003018;C0014432;C1152555;C2756995;C4521302
1396,ace = angiotensin - converting enzyme . arb = angiotensin receptor blockers .,C0022709;C0597357;C3888198
1395,coenzyme q $nmbr$ p  g / ml #,C0041536;C1300565
1395,coenzyme q $nmbr$  ^ g / ml #,C0041536;C1300565
1395,coenzyme q $nmbr$,C0041536
1395,all with coenzyme q $nmbr$ ( n = $nmbr$  $nmbr$ ),C0041536
1395,$nmbr$ coenzyme q $nmbr$ subgroups for time to first hospitalization ( number of patients variable ) .,C0019993;C0040223;C0041536;C0205435;C0439828;C1079230;C1279901;C2360800;C3541383;C4553760
1394,time from end of fit  years ( meanisd ),C0036572;C0439234;C1522314;C2349186;C4048158;C4553125
1394,seizure worry,C0036572;C0233481;C1959629;C4553401
1394,seizure types reported during baselinee,C0036572;C0332307;C0684224;C0700287;C1959629;C4319718;C4553401
1394,convulsion,C0036572;C4048158
1394,cluster seizures,C0036572;C1555715;C1704332
1393,laparoscopic cholecystectomy,C0162522
1393,cholecystectomy ( n = $nmbr$ ),C0008320
1392,cholesterol absorption inhibitor ( ezetimibe ),C0000854;C0003277;C1142985;C1999216;C2347023;C2347080;C2698776;C2825050;C2945742
1392,cabgorptca,
1391,hvpercholesterolemia,
1391,heterozygous familial hypercholesterolemia †,C0342882
1391,heterozygous familial hypercholesterolemia,C0342882
1390,reported high cholesterol ' !,C0020443;C0684224;C0700287;C1522133;C4319718
1390,hypertension — no . ( % ) hypercholesterolemia — no . ( % ),C0020443;C0020538;C1522133;C1963138
1390,hypercholesterolemia 一 no . ( % ),C0020443;C1522133
1390,hypercholesterolemia — no . ( % ) *,C0020443;C1522133
1390,hypercholesterolemia — no . ( % ),C0020443;C1522133
1390,hypercholesterolemia *,C0020443;C1522133
1390,hypercholesterolemia ( > $nmbr$ mg / dl ),C0020443;C0439269;C1522133
1390,hypercholesterolemia ( % ),C0020443;C1522133
1390,hypercholesterolemia  no . ( % ),C0020443;C1522133
1390,hypercholesterolemia  n ( % ),C0020443;C1522133
1390,hypercholesterolemia,C0020443;C1522133
1390,hypercholesterolaemia ( % ),C0020443;C1522133
1390,hypercholesterolaemia,C0020443;C1522133
1390,elevated cholesterol,C0020443
1390,duration of hypercholesterolaemia  mean ± sd ( year ),C0020443;C0439234;C0439508;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
1390,acholesterol ( % ),
1389,tender joint count ( $nmbr$ - $nmbr$ possible joints ),C0022417;C0240094;C0332149;C0392905;C0750480;C1705566;C1705910;C2362652;C4554549;C4696258
1389,tender - or painful - joint count ( of $nmbr$ joints assessed ) — no .,C0003862;C0234234;C0750480;C1516048;C1705566
1389,eosinoohil count,C0750480;C1705566
1389,enthesitis count,C0750480;C1282952;C1705566
1389,dactylitis count ( $nmbr$ - $nmbr$ )  mean ( sd ),C0239161;C0444504;C0750480;C1705566;C2347634;C2348143;C2699239
1389,dactylitis count,C0239161;C0750480;C1705566
1389,< $nmbr$ with no historical count > $nmbr$,C0750480;C1552658;C1552723;C1705566;C2004062
1389,< $nmbr$ with historical count > $nmbr$,C0750480;C1552658;C1552723;C1705566;C2004062
1389,< $nmbr$ regardless of historical count,C0750480;C1552658;C1552723;C1705566;C2004062
1388,rs - cough & sputumc,C0010200;C0035970;C1961131;C3274924;C3714753;C3813325;C4084725;C4084726;C4084727
1388,cough ( investigator reported ),C0010200;C0035173;C0684224;C0700287;C1961131;C3274924;C4084725;C4084726;C4084727;C4319718
1388,cough  n ( % ),C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
1388,cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
1388,any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
1387,use $nmbr$ - asa compounds,C0004057;C0042153;C0205198;C0457083;C1706082;C1947944;C3853627
1387,no use of $nmbr$ - asa compounds,C0004057;C0205198;C1524063;C1706082;C3853627
1387,$nmbr$ - asa compounds  n ( % ),C0004057;C0205198;C1706082;C3853627
1387,$nmbr$ - aminosalicylic compounds — no . ( % ),C0205198;C1706082
1386,components,C0449432
1386,chads $nmbr$ components  n ( % ),C0007928;C0449432;C1413373
1385,threatened abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
1385,pfo closure group ( n = $nmbr$ ),C0185003;C0441848;C1521802
1385,pfo closure,C0185003;C1521802
1385,closure,C0185003;C1521802
1385,abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
1384,cyclosporine ( n = $nmbr$ ),C0010592;C0010594
1384,cyclosporin,C0010592;C0010594
1383,whole cohort,C0009247;C0444667;C0599755
1383,total cohort,C0009247;C0439175;C0439810;C0599755
1383,secondary - prevention cohort,C0009247;C0599755;C0679699
1383,primary - prevention cohort,C0009247;C0033144;C0599755
1383,itt cohort  overall study period,C0009247;C0282416;C0439531;C0557651;C0599755;C1561607;C1948053;C2603343
1383,full cohort,C0009247;C0443225;C0599755
1383,entire evaluable cohort,C0009247;C0439751;C0444667;C0599755;C1516986
1383,entire cohort gender,C0009247;C0079399;C0439751;C0444667;C0599755;C1522384
1383,entire cohort,C0009247;C0439751;C0444667;C0599755
1383,cohort $nmbr$ ( n = $nmbr$ ) f,C0009247;C0016327;C0599755
1383,cohort $nmbr$ ( n = $nmbr$ ),C0009247;C0599755
1383,cohort,C0009247;C0599755
1382,residence in asia  n ( % ),C0003980;C0237096
1382,region  asia / paafic,C0003980;C0017446;C0205147
1382,pacific,
1382,geo graphic region : asia,C0003980;C0017446;C0017454;C0205147
1382,east asia,C0015631
1382,asia pacific or other,C0003980
1382,asia pacific and south africa,C0003980;C0037712
1382,asia pacific and other,C0003980
1382,asia pacific ( n = $nmbr$ ),C0003980
1382,asia pacific,C0003980
1382,asia and pacific islands,C0003980;C0030168
1382,asia / pacific / other,C0003980
1382,asia / pacific ( % ),C0003980
1382,asia / pacific,C0003980
1382,asia - pacific region and south africa,C0003980;C0017446;C0037712;C0205147
1382,asia - pacific hr ( $nmbr$ % cl ),C0003980;C0596019
1382,asia - pacific and south africa,C0003980;C0037712
1382,asia - pacific,C0003980
1382,asia ( n = $nmbr$ ),C0003980
1382,asia ( n = $nmbr$  $nmbr$ ),C0003980
1382,asia #,C0003980
1382,asia  pacific and other,C0003980
1382,asia,C0003980
1381,saudi arabia,C0036243
1381,sa acs,C0036243;C0038702;C0742343;C1539696;C1825840;C3539736;C4318612;C4521691
1381,sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
1380,with higher classes indicating greater limitations on physical activity owing to,C0015259;C0026606;C0205250;C0449295;C0456387;C1518526;C1704243;C1705943;C4019422
1380,walk for exercise ( % ),C0015259;C0080331;C1522704
1380,walk for exercise,C0015259;C0080331;C1522704
1380,some physical activity,C0015259;C0026606
1380,physical activity §,C0015259;C0026606
1380,physical activity  kcal / wk < $nmbr$,C0015259;C0026606;C0332174;C0439230;C0439259
1380,physical activity  kcal / wk *,C0015259;C0026606;C0332174;C0439230;C0439259
1380,physical activity  kcal / wk,C0015259;C0026606;C0332174;C0439230;C0439259
1380,exercise times per week  ( minimum,C0015259;C0456698;C1522704;C1524031;C1552614;C2826545
1380,exercise status,C0015259;C0449438;C1522704
1380,exercise at least weekly ( a ),C0015259;C0332174;C1522704
1380,exercise > once weekly ?,C0015259;C0558293;C1522704
1380,exercise > once weekly,C0015259;C0558293;C1522704
1380,exercise ( % ),C0015259;C1522704
1380,exercise  n ( % ),C0015259;C1522704
1380,exercise,C0015259;C1522704
1380,daily exercise ( % ),C0015259;C0332173;C1522704
1379,serum sodium — meq / liter,C0439152;C0475211;C0523891
1379,serum sodium . meq / l,C0439375;C0523891
1379,serum sodium  meq / l,C0439375;C0523891
1379,pravastatin sodium,C0700474
1378,sodium - glucose cotransporter $nmbr$ inhibitor,C0017725;C0037473;C0597484;C1999216;C3541959;C3714642
1378,sodium  meq / l,C0037473;C0439375;C0597484;C3541959;C3714642
1378,sodium,C0037473;C0597484;C3541959;C3714642
1377,statin potency medium ( n = $nmbr$ ),C0009458;C0360714;C0439536;C1705217;C3244283;C3245505;C4085196;C4522282;C4522283
1377,small / medium,C0009458;C0439536;C0700321;C1705217;C3244283;C4085196;C4522282;C4522283
1377,medium - or low - intensity statin,C0009458;C0360714;C0439536;C0596836;C1705217;C3244283;C4085196;C4522282;C4522283
1377,medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
1377,low to medium microalbuminuria ( n = $nmbr$ ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
1377,low - medium microalbuminuria ( n = $nmbr$ ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
1376,minimum — maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1376,minimum — maxim um,C0024968;C1524031;C1552614;C2826545
1376,minimum : maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1376,minimum / maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1376,minimum - maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1376,minimum  maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1376,minimum,C1524031;C1552614;C2826545
1376,median ( minimum – maximum ) focal seizure frequency / $nmbr$   days at baseline,C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0806909;C0871396;C0876920;C1442488;C1524031;C1552614;C1552615;C1561548;C1705502;C2347635;C2348144;C2826545;C2826546;C2939193;C3898838;C4321352
1376,mean of maximum cimt  mean ( sd )  mm,C0444504;C0806909;C1552615;C2347634;C2348143;C2699239;C2826546;C4330985;C4554674
1376,maximum cimt a med an,C0806909;C1552615;C2826546;C4321267
1376,maximum,C0806909;C1552615;C2826546
1376,average of maximum far wall cimt ( mm ),C0205108;C0677535;C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
1376,average of maximum common carotid cimt ( mm ),C0205214;C0741968;C0806909;C1510992;C1522138;C1552615;C2825518;C2826546;C3245511;C4330985;C4554674
1376,average maximum common and bifurcation cimt ( mm ),C0184906;C0205214;C0806909;C1510992;C1522138;C1552615;C2825518;C2826546;C3146289;C3245511;C4330985;C4554674
1376,average maximum cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
1376,( minimum - maximum ) focal seizure fre - quency / $nmbr$ days at baseline,C0168634;C0439228;C0751495;C0806909;C1414819;C1442488;C1524031;C1552614;C1552615;C2826545;C2826546
1375,calcium channel,C0006685
1375,calcium - channel inhibitor,C0006685;C1999216
1375,calcium - channel blockersubgroup,C0006685
1375,calcium - channel blockerf,C0006685
1375,belgium,C0004950
1374,non - calcium antagonist strategy ( ncas ) ( events / n ),C0006684;C0441471;C0679199;C1413309;C1518422;C3541888;C3813543
1374,non - calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C0006684;C0679199;C1518422
1374,calcium channel antagonists  n ( % ),C0006684;C2757014
1374,calcium antagonists  n ( % ),C0006684
1374,calcium antagonists,C0006684
1374,calcium antagonist — no . ( % ),C0006684
1374,calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C0006684;C0679199
1374,calcium antagonist strategy ( cas ) ( events / n ),C0006684;C0441471;C0679199;C3541888
1374,calcium antagonist,C0006684
1374,calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611
1374,calcium - channel antagonists,C0006684;C2757014
1374,aniagonisi,
1373,taking calcium supplements at baseline  n ( % ),C0006675;C0006726;C0168634;C0242295;C1442488;C1515187;C1947943;C2348609;C2936886;C3540037;C3714611
1373,serum albumin - adjusted calcium ( mg / dl ),C0006675;C0006726;C0036773;C0439269;C0456081;C0728877;C2936886;C3540037;C3714611
1373,dense calcium  mm ’,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611;C4330985;C4554674
1373,dense calcium,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611
1373,calcium supplements,C0006675;C0006726;C0242295;C1947943;C2348609;C2936886;C3540037;C3714611
1373,calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
1373,calcium ( mmol / l ),C0006675;C0006726;C1532563;C2936886;C3540037;C3714611
1373,calcium  mmol $nmbr$ $nmbr$,C0006675;C0006726;C0439190;C2936886;C3540037;C3714611
1372,with tiotropium,C0213771
1372,versus tiotropium $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
1372,versus tiotropium $nmbr$ . $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
1372,tiotropiumc,
1372,tiotropium vs . salmeterol,C0073992;C0213771
1372,tiotropium group ( n = $nmbr$ ),C0213771;C0441848
1372,tiotropium + placeb ( n [ $nmbr$ ),C0213771
1372,tiotropium ( nz $nmbr$ ),C0027978;C0213771
1372,tiotropium ( n z $nmbr$ ),C0213771
1372,tiotropium ( n = $nmbr$ ),C0213771
1372,tiotropium $nmbr$   μ g ( n   =   $nmbr$ ),C0213771;C0439267
1372,tiotropium $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
1372,tiotropium $nmbr$ meg ( n = $nmbr$ ),C0024489;C0025175;C0072225;C0213771
1372,tiotropium $nmbr$ m g,C0213771;C0456715
1372,tiotropium $nmbr$ . $nmbr$ μ g ( n   = $nmbr$ ),C0213771;C0439267
1372,tiotropium $nmbr$ . $nmbr$   μ g ( n   =   $nmbr$ ),C0213771;C0439267
1372,tiotropium $nmbr$ . $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
1372,tiotropium,C0213771
1372,patients using concurrent tiotropium,C0030705;C0205420;C0213771;C1524063
1372,non - tiotropium,C0213771;C1518422
1372,lama ( tiotropium )  b   n ( % ),C0213771;C0999593;C1416775
1372,formoterol tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0060657;C0213771;C1518422
1372,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ ),C0213771;C1518422
1372,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ $nmbr$,C0213771;C1518422
1371,potassium — mmol / liter,C0032821;C0202194;C0304475;C0439190;C0475211;C0597277;C3714637
1371,potassium — mg / dl,C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
1371,potassium supplement,C0304475
1371,potassium - sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C1516879;C1696073;C3714637;C3888021
1371,potassium ( mmol / l ),C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
1371,potassium ( mg / dl ),C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
1371,potassium ( meql )  mean + sd  available for $nmbr$ patients,C0030705;C0032821;C0202194;C0304475;C0444504;C0470187;C0597277;C2347634;C2348143;C2699239;C3714637
1371,potassium ( meq / l ),C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
1371,potassium  mmol / l,C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
1371,potassium  meq / l,C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
1371,potassium  meq / dl  mean,C0032821;C0202194;C0304475;C0444504;C0597277;C1532568;C2347634;C2348143;C3714637
1371,potassium  mean ( sd )  meq / l,C0032821;C0202194;C0304475;C0439375;C0444504;C0597277;C2347634;C2348143;C2699239;C3714637
1371,potassium,C0032821;C0202194;C0304475;C0597277;C3714637
1371,hyperkalemia ‡   ( potassium ≥ $nmbr$ . $nmbr$ mmol / l ),C0020461;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4552983
1370,p - value for east asian versus non - east asian *,C0078988;C1518422;C1707877;C1709380
1370,non - east asianf,C1518422;C1707877
1370,non - east asian §,C0078988;C1518422;C1707877
1370,non - asian ( n = $nmbr$ $nmbr$ ),C0078988;C1518422
1370,non - asian,C0078988;C1518422
1370,east asian,C0078988;C1707877
1370,aslan,
1369,other asian,C0078988
1369,black or asian,C0005680;C0027567;C0078988;C0085756;C0439541
1369,asians ( n = $nmbr$ ),C0078988
1369,asian *,C0078988
1369,asian ( n — $nmbr$ ),C0078988
1369,asian ( n   = $nmbr$ ),C0078988
1369,asian ( n = $nmbr$ ),C0078988
1369,asian ( n = $nmbr$  $nmbr$ ),C0078988
1369,asian ( $nmbr$ . $nmbr$ % ),C0078988
1369,asian  n ( % ),C0078988
1369,asian,C0078988
1368,on aspirin at baseline,C0004057;C0168634;C1442488
1368,on $nmbr$,
1368,baseline use of adm  n ( % ),C0168634;C0215825;C1442488;C1524063;C4521767
1368,baseline numberf of adm classes  n ( % ),C0168634;C0215825;C0456387;C1442488;C1518526;C1705943;C4019422;C4521767
1368,atrial fibrillation on baseline ecg  n ( % ),C0168634;C0344434;C1442488
1368,af on baseline ecg  n ( % ),C0168634;C0344434;C1442488;C1623258;C4049859
1367,dose of aspirin,C4696290
1367,aspirin dose  mg / d,C0439422;C4696290
1367,aspirin dose,C4696290
1367,aspirin at any dose,C4696290
1367,aspirin + dipyridamole ( n = $nmbr$ ),C0732279
1367,aspirin + dipyridamole,C0732279
1366,without aspirin ( n = $nmbr$  $nmbr$ ),C0004057
1366,with aspirin ( n = $nmbr$  $nmbr$ ),C0004057
1366,spirono ( n = $nmbr$ ),
1366,no aspirin,C0004057
1366,long - term aspirin,C0004057;C0443252
1366,initial aspirin — no . ( % ),C0004057;C0205265;C1279901;C1555582;C1705685
1366,aspirin or thienopyridines ( % ),C0004057;C1120149;C2936588
1366,aspirin but no ppi,C0004057;C0358591;C0871125;C3811894
1366,aspirin and ppi,C0004057;C0358591;C0871125;C3811894
1366,aspirin and other antiplatelet,C0004057
1366,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0004057;C0205171;C0439044;C0679994
1366,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0004057;C0205171;C0439044;C0679994
1366,aspirin alone ( n = $nmbr$ ),C0004057;C0205171;C0439044;C0679994
1366,aspirin alone ( n / n ),C0004057;C0205171;C0439044;C0679994
1366,aspirin alone,C0004057;C0205171;C0439044;C0679994
1366,aspirin / antiplatelet,C0004057
1366,aspirin - erdp clopidogrel no . of patients / total no .,C0004057;C0030705;C0070166;C0439175;C0439810
1366,aspirin - erdp ( n = $nmbr$  $nmbr$ ),C0004057
1366,aspirin ( n = $nmbr$ ) no . of participants with events ( % ),C0004057;C0441471;C0679646;C3541888
1366,aspirin ( n = $nmbr$ $nmbr$ ),C0004057
1366,aspirin ( n = $nmbr$  $nmbr$ ),C0004057
1366,aspirin ( n  % ),C0004057
1366,aspirin ( % ),C0004057
1366,aspirin  no . ( % ),C0004057
1366,aspirin  n ( % ),C0004057
1366,aspirin,C0004057
1366,$nmbr$ aspirin ( n = $nmbr$ $nmbr$ ),C0004057
1365,resistant htn n = $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
1365,resistant htn : spiro n = $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
1365,resistant htn : placebo n = $nmbr$,C0020538;C0032042;C0332325;C1514892;C1550464;C1696465;C1706408;C2827757
1365,prior hypertension yes,C0020538;C0332152;C1549445;C1705108;C1710701;C1963138;C2826257
1365,prior hypertension,C0020538;C0332152;C1963138;C2826257
1365,prior htn ( n = $nmbr$  $nmbr$ ),C0020538;C0332152;C2826257
1365,no resistant htn n = $nmbr$  $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
1365,no prior htn ( n = $nmbr$  $nmbr$ ),C0020538;C0332152;C2826257
1365,no htn,C0020538
1365,htn,C0020538
1365,high blood pressure,C0020538;C2926615
1365,elevated blood pressure,C0020538;C0497247
1364,treated hypertension :,C0020538;C1522326;C1963138
1364,treated for hypertension  %,C0020538;C1522326;C1963138
1364,systemic hypertension,C0020538
1364,systemic arterial hypertension  n ( % ),C0020538
1364,reported hypertension *,C0020538;C0684224;C0700287;C1963138;C4319718
1364,previous hypertension,C0020538;C0205156;C1552607;C1963138
1364,patient - reported hypertension — no . { % ),C0020538;C0030705;C0684224;C0700287;C1963138;C4319718
1364,participant - reported hypertension — no . { % ),C0020538;C0679646;C0684224;C0700287;C1963138;C2698741;C4319718;C4554048
1364,no hypertension ( n = $nmbr$ ),C0020538;C1963138
1364,no hypertension,C0020538;C1963138
1364,medical history of hypertension,C0020538;C0199168;C0205476;C0262926;C0455527;C1963138
1364,isoiated systoiic hypertension *,C0020538;C1963138
1364,hypertension 本,C0020538;C1963138
1364,hypertension 一 no . ( % ),C0020538;C1963138
1364,hypertension — no . / total no . ( % ),C0020538;C0439175;C0439810;C1963138
1364,hypertension — no . ( % ) |,C0020538;C1963138
1364,hypertension — no . ( % ),C0020538;C1963138
1364,hypertension § yes,C0020538;C1549445;C1705108;C1710701;C1963138
1364,hypertension §,C0020538;C1963138
1364,hypertension serum lipid values,C0020538;C0042295;C0428462;C1963138
1364,hypertension n ( % ),C0020538;C1963138
1364,hypertension history,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C1963138;C2004062
1364,hypertension ^,C0020538;C1963138
1364,hypertension : no ( n = $nmbr$ ),C0020538;C0369718;C0441922;C1963138
1364,hypertension / yes,C0020538;C1549445;C1705108;C1710701;C1963138
1364,hypertension *,C0020538;C1963138
1364,hypertension ( n 二 $nmbr$ ),C0020538;C1963138
1364,hypertension ( > $nmbr$ / $nmbr$ mm hg or taking,C0020538;C0439475;C1515187;C1963138
1364,hypertension ( % ) : t,C0020538;C1963138
1364,hypertension ( % ),C0020538;C1963138
1364,hypertension $nmbr$ ( % ),C0020538;C1963138
1364,hypertension !,C0020538;C1963138
1364,hypertension    n   ( % ),C0020538;C1963138
1364,hypertension  treated,C0020538;C1522326;C1963138
1364,hypertension  no . / total no . ( % ) medications in use at baseline  no . / total no . ( % ),C0013227;C0020538;C0042153;C0150312;C0168634;C0332285;C0439175;C0439810;C0457083;C0802604;C1442488;C1707101;C1947944;C1963138;C2598133;C4284232
1364,hypertension  n / n ( % ),C0020538;C1963138
1364,hypertension  n ( % ) yes,C0020538;C1549445;C1705108;C1710701;C1963138
1364,hypertension  n ( % ),C0020538;C1963138
1364,hypertension  * n ( % ),C0020538;C1963138
1364,hypertension  ( % ),C0020538;C1963138
1364,hypertension  %,C0020538;C1963138
1364,hypertension,C0020538;C1963138
1364,hyperlension,
1364,hyper - tension,C0020538;C1963138
1364,hvpertension,
1364,grade of hypertension,C0020538;C0441800;C0919553;C1963138;C3244287
1364,duration of hypertension ( years ),C0020538;C0439234;C0449238;C1963138;C2926735
1364,duration of hypertension ( months ),C0020538;C0439231;C0449238;C1963138;C2926735
1364,duration of hypertension  y,C0020538;C0449238;C1963138;C2926735
1364,duration of hypertension  n ( % ),C0020538;C0449238;C1963138;C2926735
1364,arterial hypertension — no . ( % ),C0020538
1364,arterial hypertension *,C0020538
1364,arterial hypertension  no . ( % ),C0020538
1364,arterial hypertension  n ( % ),C0020538
1364,arterial hypertension,C0020538
1364,( including hypertension ),C0020538;C0332257;C1963138
1363,symptomatic ich,C0019191;C0231220;C3272597;C3281105
1363,nd not due to swelling or ich,C0013604;C0019191;C0038999;C0678226;C1518422;C3272597;C3281105
1363,ich,C0019191;C3272597;C3281105
1363,gusto moderate bleeding / ich,C0019080;C0019191;C0205081;C1881878;C3272597;C3281105;C4049705;C4049706;C4085643;C4321335
1362,itch nrs $nmbr$ - $nmbr$ ( v = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1362,itch nrs $nmbr$ - $nmbr$ ( at = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1362,itch nrs $nmbr$ - $nmbr$ ( a ' = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1362,itch nrs $nmbr$ - $nmbr$ ( . \ ' = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1362,itch nrs $nmbr$ ( v = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1362,itch nrs,C0033774;C1422257;C2240043;C4050142
1361,previous ischemic heart disease — no . ( % ),C0010054;C0151744;C0205156;C1552607
1361,myocardial ischaemia,C0010054;C0151744
1361,ischemic heart disease indicator no ( n = $nmbr$ l ),C0010054;C0021212;C0151744;C0369718;C0441922;C1235732;C1522602
1361,ischemic heart disease *,C0010054;C0151744
1361,ischemic heart disease ( % ),C0010054;C0151744
1361,ischemic heart disease  no . ( % ),C0010054;C0151744
1361,ischemic heart disease  n ( % ),C0010054;C0151744
1361,ischemic heart disease  ( % ),C0010054;C0151744
1361,ischemic heart disease  %,C0010054;C0151744
1361,ischemic heart disease,C0010054;C0151744
1361,ischaemic heart disease or cerebrovascular disorder  n ( % ),C0007820;C0010054;C0151744
1361,ischaemic heart disease  n ( % ),C0010054;C0151744
1361,ischaemic heart disease,C0010054;C0151744
1361,ihd,C0151744
1361,combined ischaemic heart disease and / or cerebrovascular disorder *,C0007820;C0010054;C0151744;C0205195
1360,relative risk comparing icd therapy and placebo,C0021122;C0032042;C0039798;C0087111;C0242492;C1363945;C1696465;C1706408;C1707455
1360,relative risk ( $nmbr$ % cl ) comparing icd therapy and placebo using a linear interaction term in the model ( shfmxicd ) *,C0021122;C0023732;C0032042;C0039798;C0087111;C0233324;C0242492;C0596019;C1363945;C1515273;C1524063;C1696465;C1704675;C1705313;C1706408;C1707455;C2826302
1360,pacemaker or icd,C0021122;C0030163;C0810633;C1546728;C3275122;C3853703
1360,icd vs . placebo,C0021122;C0032042;C1696465;C1706408
1360,icd  n ( % ),C0021122
1360,icd  %,C0021122
1360,icd,C0021122
1360,aicd  ( % ),C0972395;C2611803;C3537205;C3546309
1360,acd,C4554601
1359,without concomitant ics,C0521115;C0815320;C4551720
1359,with ics  n ( % ),C0815320;C4551720
1359,with concomitant ics,C0521115;C0815320;C4551720
1359,use of ics at baseline  %,C0168634;C0815320;C1442488;C1524063;C4551720
1359,use of ics,C0815320;C1524063;C4551720
1359,total ics dose at entry  / xg / d,C0017209;C0815320;C1292284;C1421532;C1705654;C2986497;C4551720
1359,other ics versus no ics,C0815320;C4551720
1359,other ics,C0815320;C4551720
1359,non - ics +,C0815320;C1518422;C4551720
1359,no laba  no ics  n ( % ),C0815320;C4551720
1359,no ics,C0815320;C4551720
1359,mean ics use at enrolment ( pg ) *,C0030827;C0042153;C0072225;C0444504;C0457083;C0815320;C1266240;C1516879;C1696073;C1947944;C2347634;C2348143;C3888021;C4551720
1359,laba   +   ics,C0815320;C4551720
1359,laba plus ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0332287;C0815320;C1696465;C1706408;C4551720
1359,laba plus ics  n ( % ),C0332287;C0815320;C4551720
1359,laba / ics use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C0815320;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164;C4551720
1359,laba  no ics  n ( % ),C0815320;C4551720
1359,icsf,
1359,ics users at screening,C0220908;C0220909;C0815320;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
1359,ics users at baseline  n ( % ),C0168634;C0815320;C1442488;C1706077;C4551720
1359,ics users at baseline  %,C0168634;C0815320;C1442488;C1706077;C4551720
1359,ics users  n ( % ),C0815320;C1706077;C4551720
1359,ics users,C0815320;C1706077;C4551720
1359,ics use no,C0042153;C0457083;C0815320;C1947944;C4551720
1359,ics use at screeningg  n ( % ),C0042153;C0457083;C0815320;C1947944;C4551720
1359,ics use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C0815320;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164;C4551720
1359,ics use at screening,C0042153;C0220908;C0220909;C0457083;C0815320;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164;C4551720
1359,ics use at baseline : no,C0042153;C0168634;C0457083;C0815320;C1442488;C1947944;C4551720
1359,ics use  %,C0042153;C0457083;C0815320;C1947944;C4551720
1359,ics use,C0042153;C0457083;C0815320;C1947944;C4551720
1359,ics usage,C0457083;C0815320;C4551720
1359,ics subset,C0815320;C1515021;C4551720
1359,ics plus laba,C0815320;C4551720
1359,ics nonusers  n ( % ),C0815320;C4551720
1359,ics non - users at screening,C0220908;C0220909;C0815320;C1518422;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
1359,ics non - users,C0815320;C1518422;C1706077;C4551720
1359,ics no laba,C0815320;C4551720
1359,ics : no,C0815320;C4551720
1359,ics / laba subset,C0815320;C1515021;C4551720
1359,ics # #,C0815320;C4551720
1359,ics  no laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0815320;C1696465;C1706408;C4551720
1359,ics  no laba  n ( % ),C0815320;C4551720
1359,ics  n ( % ),C0815320;C4551720
1359,ics  mg / day,C0439422;C0815320;C4551720
1359,ics,C0815320;C4551720
1359,gold grade $nmbr$ and ics users at screening,C0018026;C0220908;C0220909;C0441800;C0815320;C0919553;C1304897;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C3244287;C4551720
1359,gold grade $nmbr$ and ics non - users at screening,C0018026;C0220908;C0220909;C0441800;C0815320;C0919553;C1304897;C1518422;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C3244287;C4551720
1359,fp versus other ics,C0016704;C0815320;C1419068;C1419906;C3541238;C3541412;C4551720
1359,discontinuation of ics / laba prior to baseline  n ( % ),C0168634;C0457454;C0815320;C1442488;C1444662;C4551720;C4552847
1359,calima overalldhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ),C0014467;C0168634;C0178602;C0815320;C1442488;C2699156;C2986497;C4551720
1359,baseline post - bronchodilator % predicted fev  > $nmbr$ % and no prior ics use,C0042153;C0168634;C0332152;C0457083;C0681842;C0815320;C1442488;C1882327;C1947944;C2599594;C2826257;C3714541;C4551720
1359,baseline ics use : no,C0042153;C0168634;C0457083;C0815320;C1442488;C1947944;C4551720
1359,baseline ics use  n ( % ),C0042153;C0168634;C0369718;C0441922;C0457083;C0815320;C1442488;C1947944;C4551720
1359,baseline ics dose  n ( % ),C0168634;C0178602;C0815320;C0869039;C1114758;C1442488;C4551720
1359,baseline ics > $nmbr$ pg per day ( fluticasone propionate dpi or equivalent ) and laba,C0117996;C0168634;C0205163;C0439185;C0815320;C1442488;C2827928;C4551720
1359,baseline ics,C0168634;C0815320;C1442488;C4551720
1359,+ ics / + laba nz $nmbr$,C0027978;C0815320;C4551720
1358,£ $nmbr$ % bsa psoriasis  no . ( % ),C0033860
1358,without psoriasis ( zi = $nmbr$ ),C0033860;C0043476
1358,without psoriasis ( zi = $nmbr$  $nmbr$ ),C0033860;C0043476
1358,without psoriasis ( n = $nmbr$ ),C0033860
1358,without psoriasis ( n = $nmbr$  $nmbr$ ),C0033860
1358,with psoriasis ( zi = $nmbr$ ),C0033860;C0043476
1358,with psoriasis ( n = $nmbr$ ),C0033860
1358,scalp psoriasis  n ( % ),C0406326
1358,psoriasis covering > $nmbr$ % bsa  n ( % ) §,C0033860;C0180153;C0439844
1358,psoriasis characteristics,C0033860;C1521970
1358,psoriasis bsa > $nmbr$ %  n ( % ),C0033860
1358,psoriasis body surface area > $nmbr$ %,C0005902;C0033860
1358,psoriasis affecting > $nmbr$ % of body - surface,C0033860;C0392760;C0489451;C1314939
1358,psoriasis > $nmbr$ % of bsa,C0033860
1358,psoriasis ( n =,C0033860
1358,psoriasis,C0033860
1358,previous exposure to systemic psoriasis therapyb ( yes )  n ( % ),C0033860;C0205156;C0205373;C0332157;C1549445;C1552607;C1705108;C1710701
1358,previous exposure to non - biologic systemic psoriasis therapyb ( yes )  n ( % ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1518422;C1549445;C1552607;C1705108;C1710701
1358,previous exposure to biologic systemic psoriasis therapyb ( yes )  n ( % ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1549445;C1552607;C1705108;C1710701
1358,patients without psoriasis ( n = $nmbr$ ),C0030705;C0033860
1358,patients with psoriasis > $nmbr$ % of body surface area,C0017446;C0030705;C0033860;C0205146;C0489451
1358,patients with psoriasis ( n = $nmbr$ ),C0030705;C0033860
1358,patients with psoriasis ( bsa ≥   $nmbr$ % ),C0030705;C0033860
1358,patients with > $nmbr$ % bsa psoriasis skin involvement  n ( % ),C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
1358,facial psoriasis  n ( % ),C1276112
1358,dlqi ( patients with £ $nmbr$ % bsa psoriasis ),C0030705;C0033860;C3899393
1358,bsa > $nmbr$ %  n ( % ) t,
1357,time from psoriatic arthritis diagnosis [ a ]  years,C0003872;C0011900;C0040223;C0439234;C1704338;C1704656;C3541383
1357,psoriatic arthropathy,C0003872
1357,psoriatic arthritis pain ],C0003872;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4317006;C4553004;C4554132
1357,psoriatic arthritis  %,C0003872
1357,psoriatic arthritis,C0003872
1357,organic,C0747055
1357,number of previous anti - tnf treatments for psoriatic arthritis,C0003872;C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
1356,severe oa symptoms at baselined,C0029408;C0436345;C3887876
1356,osteoarthritis,C0029408
1356,oa,C0029408;C3887876
1356,less severe oa symptoms at baseline,C0029408;C0168634;C0436345;C0439092;C0547044;C1442488;C3887876
1356,duration of osteoarthritis symptoms — yr,C0029408;C0436359;C0439234
1355,selena - sledai mean score ( sd ),C0451528;C2699239;C3533236
1355,selena - sledai > $nmbr$  %,C0451528
1355,sdai < $nmbr$ t,C3871128
1355,sdai < $nmbr$ . $nmbr$ *,C3871128
1355,sdai ( $nmbr$ - $nmbr$ ),C3871128
1355,sdai  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3871128
1355,sdai,C3871128
1355,mean selena - sledai score ± sd,C0444504;C0449820;C0451528;C2347634;C2348143;C2699239;C4050231
1355,mean ( sd ) sdai *,C0444504;C2347634;C2348143;C2699239;C3871128
1354,total basdai score  mean ( sd ),C0439175;C0439810;C0444504;C0449820;C1998004;C2347634;C2348143;C2699239;C4050231
1354,total basdai  mean ( sd ),C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239
1354,baseline basdai,C0168634;C1442488;C1998004
1354,basdai ⁎ ⁎,C1998004
1354,basdai responses at week $nmbr$,C0332174;C0439230;C0871261;C1998004
1354,basdai $nmbr$  n ( % ),C1998004
1354,basdai $nmbr$  %,C1998004
1353,vka ( n   = $nmbr$ ),
1353,previous vka use ( stratified randomization ),C0042153;C0205156;C0457083;C1552607;C1947944;C4687737
1353,previous vka use,C0042153;C0205156;C0457083;C1552607;C1947944
1352,vka at randomization,C0034656
1352,vka,
1352,no vka at randomization,C0034656
1351,glycemic status f,C0016327;C1320980
1351,glycemic status,C1320980
1351,glycemic indexes,C1136206
1350,glyburide dose duringthe study ( mg ),C0017628;C0024671;C0026410;C0178602;C0439269;C0557651;C0869039;C1114758;C1960952;C2346927;C2603343;C4321396;C4521761
1350,glyburide ( n = $nmbr$ ),C0017628
1350,glyburide,C0017628
1349,glycemic variability  mmol / lc,C0005802;C0439190;C2827666
1349,glycemic characteristics,C0005802;C1521970
1349,blood glucose lowering treatment,C0005802;C0017725;C0039798;C0087111;C0441994;C0596197;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704
1349,blood glucose - lowering treatments  n ( % ),C0005802;C0017725;C0087111;C0441994;C0596197;C2003888
1349,blood glucose,C0005802
1348,use of oral glucocorticoids,C0017710;C0442027;C1524063;C3540777;C3540778;C4521986
1348,use of inhaled glucocorticoids at baseline,C0004048;C0017710;C0168634;C1442488;C1524063;C3540777;C3540778
1348,systemic glucocorticoid use at randomization  n ( % ),C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
1348,systemic glucocorticoid use at randomisation,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
1348,postoperative nsaid or glucocorticoid use post - randomisation characteristic * *,C0003211;C0017710;C0032790;C0034656;C0042153;C0457083;C0687676;C1521970;C1704687;C1947944;C3469826;C3536840
1348,postoperative nsaid or glucocorticoid use,C0003211;C0017710;C0032790;C0042153;C0457083;C1947944;C3536840
1348,postoperative glucocorticoid use post - randomisation characteristic * *,C0017710;C0032790;C0034656;C0042153;C0457083;C0687676;C1521970;C1704687;C1947944;C3469826
1348,postoperative glucocorticoid use,C0017710;C0032790;C0042153;C0457083;C1947944
1348,oral glucocorticoid use at baseline — no . ( % ) : t,C0017710;C0168634;C1442488;C1527415;C2603360
1348,oral glucocorticoid use,C0017710;C1527415
1348,no glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
1348,glucocorticoids only,C0017710;C0205171;C1720467;C3540777;C3540778
1348,glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
1348,glucocorticoids *,C0017710;C3540777;C3540778
1348,glucocorticoids,C0017710;C3540777;C3540778
1348,glucocorticoid ],C0017710
1348,glucocorticoid,C0017710
1348,any glucocorticoid *,C0017710
1347,baseline microalbumin : < $nmbr$,C0168634;C0201838;C1442488;C2362049
1347,albumin measurements ^ ^,C0201838
1346,without tamsulosin,C0257343
1346,with tamsulosin,C0257343
1346,tamsulosin ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0257343
1346,tamsulosin ( n = $nmbr$ ),C0257343
1346,tamsulosin $nmbr$ . $nmbr$ mg vs . placebo,C0024671;C0026410;C0032042;C0257343;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
1346,tamsulosin $nmbr$ . $nmbr$ mg vs . $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1346,tamsulosin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1346,tamsulosin,C0257343
1345,previous metformin use  %,C0025598;C0042153;C0205156;C0457083;C1552607;C1947944
1345,plus metformin,C0025598;C0332287
1345,overall cohort ( post hoc analysis excluding metformin users ),C0025598;C0086027;C0282416;C0332196;C0687676;C1561607;C1704687;C1706077;C2828389;C3469826
1345,on metformin ir or metformin xr $nmbr$   mg / d,C0022065;C0022071;C0025598;C0038976;C0043309;C0439422;C1448132;C1707968;C1962945
1345,no metformin use,C0025598;C0042153;C0457083;C1947944
1345,no metformin,C0025598
1345,metformin 一 no . ( % ),C0025598
1345,metformin • pioglitazone,C1635037
1345,metformin — no . ( % ),C0025598
1345,metformin ± other oral anti - dm drugs,C0011816;C0025598;C0029167;C0175795;C0304289;C3250443
1345,metformin use  n ( % ),C0025598;C0042153;C0457083;C1947944
1345,metformin use,C0025598;C0042153;C0457083;C1947944
1345,metformin open - label *,C0025598;C1709323
1345,metformin monotherapy,C0025598
1345,metformin ? pioglitazone,C1635037
1345,metformin ( n = $nmbr$ ),C0025598
1345,metformin ( n $nmbr$ $nmbr$ ),C0025598
1345,metformin  n ( % ),C0025598
1345,metformin,C0025598
1345,merformin,
1345,linagliptin / metformin,C3264599
1345,baseline metformin,C0025598;C0168634;C1442488
1344,with lowest hba $nmbr$ cd,C0007928;C0019016;C0034283;C1708760;C1825777;C3538758;C4552032
1344,with lowest bwb,C1708760
1344,lowest activated clotting,C0005778;C1328723;C1708760;C1879547
1344,lowest,C1708760
1343,low molecular weight heparin,C0019139;C3536766
1343,low molecular weight ( lmw ) heparin before randomisation,C0019139;C0034656;C3536766
1343,low - molecular weight heparin or intravenous unfractionated heparin,C0019139;C0354566;C3536766
1343,low - molecular - weight heparin — no . ( % ),C0019139;C3536766
1343,low - molecular - weight heparin only,C0019139;C0205171;C1720467;C3536766
1343,low - molecular - weight heparin,C0019139;C3536766
1343,lmwh within $nmbr$ days before randomization — no . / total no . ( % ),C0019139;C0034656;C0439175;C0439228;C0439810;C3536766
1343,lmwh,C0019139;C3536766
1342,lm $nmbr$ bid ( n = $nmbr$ ),C1261082;C1551056
1342,lm $nmbr$ $nmbr$,C1261082;C1551056
1342,left main coronary artery  n ( % ),C1261082
1342,left main coronary artery,C1261082
1341,ileum only  n ( % ),C0020885;C0205171;C1720467
1341,ileum only,C0020885;C0205171;C1720467
1341,ileum,C0020885
1340,womac pain score,C0582148
1340,upper abdominal pain,C0232492
1340,spain ( n = $nmbr$ ),C0037747
1340,spain,C0037747
1340,shoulder pain,C0037011
1340,scores for global and pain assessments §,C0030198;C0205246;C0449820;C2348867
1340,oropharyngeal pain,C2363731;C4554669
1340,$nmbr$ % decrease in womac pain score,C0392756;C0547047;C0582148
1339,sf - $nmbr$ bodily pain  mean change from baselinee,C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952
1339,sf - $nmbr$ bodily pain  mean change from baselineb,C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952
1339,rest pain,C0234253
1339,intensity of rest pain ( mmvas )  mean ± sd,C0035253;C0234253;C0444504;C0522510;C1320357;C1622890;C2347634;C2348143;C2699239;C4085211
1339,bodily pain,C3890602
1338,time from onset of pain to randomization — hr,C0030193;C0034656;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1338,time from onset of pain to randomization  median ( iqr )  h,C0030193;C0033727;C0034656;C0369286;C0441932;C0449244;C0518090;C0549183;C0564385;C0876920;C1962977;C2347635;C2348144;C2939193;C2984058;C4085210;C4085211;C4085212;C4528284;C4553004;C4554132
1338,patient assessment of pain ( $nmbr$ - $nmbr$ mm )  mean ( sd ),C0030193;C0030198;C0030705;C0444504;C0518090;C0679830;C1962977;C2347634;C2348143;C2699239;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
1338,patient ' s assessment of pain !,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1338,patient ' s assessment of pain,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1338,pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1338,pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1338,ontario and mcmaster universities osteoarthritis index ( womac ) can range from $nmbr$ to $nmbr$ for the pain subscale  $nmbr$ to $nmbr$ for the stiffness,C0029040;C0029408;C0030193;C0041740;C0427008;C0518090;C0600653;C0918012;C1514721;C1552854;C1637833;C1962977;C2348147;C2984058;C2986546;C3542016;C4085210;C4085211;C4085212;C4553004;C4554132
1338,eq - $nmbr$ d - $nmbr$   l  no pain or discomfortf,C0030193;C0205163;C0439185;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1338,eq - $nmbr$ d - $nmbr$   l  no pain or discomfortc,C0030193;C0205163;C0439185;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1337,total back pain score ( $nmbr$ – $nmbr$   mm scale )  mean   ±   sd,C0004604;C0175659;C0349674;C0444504;C1947916;C1963071;C2347634;C2348143;C2699239;C2964552;C4330985;C4553945;C4554674
1337,total back pain  mean ( sd ),C0004604;C0439175;C0439810;C0444504;C1963071;C2347634;C2348143;C2699239;C4553945
1337,question $nmbr$ ( neck / back / hip pain ),C0004600;C0004604;C0007859;C0019552;C0019559;C0022122;C0027530;C0205095;C0460009;C1505163;C1522634;C1963071;C1963180;C1995000;C3159206;C3538851;C4284725;C4551516;C4553909;C4553945
1337,pin /,C0175718;C1168556;C1704584
1337,neck pain,C0007859;C1963180;C4553909
1337,back pain,C0004604;C1963071;C4553945
1336,patient - reported outcomes,C2987124
1336,patient - reported outcome measures,C4277735
1335,reported in ecrf,C0684224;C0700287;C4319718;C4551412
1335,not reported in ecrf,C0684224;C0700287;C1518422;C4319718;C4551412
1335,in,
1334,taking statins  n ( % ) a,C0360714;C1515187
1334,patients taking mtx  no . ( % ),C0025677;C0030705;C1417487;C1515187
1334,patients taking mtx  n ( % ),C0025677;C0030705;C1417487;C1515187
1333,patients with eot data  n,C2707520
1333,* patient characterization data are reproduced from morrow et al . ( $nmbr$ ) .,C0040028;C0202311;C1880022;C2707520
1332,taiwan,C0039260
1332,previously taken tnfi  %,C1883727
1332,previously taken methotrexate  %,C0025677;C1883727
1332,previously taken dmards other than methotrexate  %,C0025677;C0242708;C1883727
1331,native hawaiian or other pacific islander,C0242191;C0337920
1331,native hawaiian or other pacific,C0337920
1331,native hawaiian or,C0337920
1331,native hawaiian / pacific islander,C0242191;C0337920
1331,native hawaiian / other,C0337920
1331,hawaiian pacific islander,C0242191;C0337920
1331,hawaiian / pacific islander,C0242191;C0337920
1331,hawaiian / pacific,C0337920
1330,watchman ( n = $nmbr$ ),C0335390
1330,device = watchman filter,C0180860;C0335390
1329,white or caucasian  n ( % ),C0007457;C0043157;C0220938
1329,white / caucasian,C0043157
1329,race  % caucasian,C0007457;C0034510;C0043157;C1706779;C3853635
1329,noncaucasian,
1329,non - caucasian simva ( „ = $nmbr$ },C0007457;C0043157;C1518422
1329,non - caucasian simva ( n = $nmbr$ ),C0007457;C0043157;C1518422
1329,non - caucasian simva,C0007457;C0043157;C1518422
1329,non - caucasian eze / simva ( „ = $nmbr$ },C0007457;C0043157;C1518422
1329,non - caucasian eze / simva ( n = $nmbr$ ),C0007457;C0043157;C1518422
1329,non - caucasian eze / simva,C0007457;C0043157;C1518422
1329,non - caucasian,C0007457;C0043157;C1518422
1329,causaslan,
1329,caucasians ( n = $nmbr$ ),C0007457;C0043157
1329,caucasians,C0007457;C0043157
1329,caucasiana ( % ),
1329,caucasian simva ( „ = $nmbr$ },C0007457;C0043157
1329,caucasian simva ( n = $nmbr$ ),C0007457;C0043157
1329,caucasian race ( % ),C0007457
1329,caucasian race,C0007457
1329,caucasian n = $nmbr$  $nmbr$,C0007457;C0043157
1329,caucasian eze / simva ( „ = $nmbr$ },C0007457;C0043157
1329,caucasian eze / simva ( n = $nmbr$ ),C0007457;C0043157
1329,caucasian eze / simva,C0007457;C0043157
1329,caucasian ethnicity,C0007457;C0015031;C0043157;C0243103
1329,caucasian ( % ),C0007457;C0043157
1329,caucasian $nmbr$,C0007457;C0043157
1329,caucasian  n ( % ) *,C0007457;C0043157
1329,caucasian  n ( % ),C0007457;C0043157
1329,caucasian  %,C0007457;C0043157
1329,caucasian,C0007457;C0043157
1328,levosimendan ( n   = $nmbr$ ),C0246904
1328,concomitant use of bosentan  n ( % ),C0252643;C0521115;C1524063
1328,bosentan use :,C0042153;C0252643;C0457083;C1947944
1328,bosentan ( n = $nmbr$ ),C0252643
1328,bosentan,C0252643
1327,use of supplemental oxygen  n ( % ),C4067893;C4554557
1327,supplementary oxygen,C0030054
1327,supplemental oxygen,C4534306
1326,hypoglycaemiad  %,
1326,documented symptomatic chdb,C0231220;C1301725;C1609436
1326,documented mi,C1301725;C1609436;C3810814
1326,documented hypoglycaemiac,C1301725;C1609436
1326,angina with documented ischemia,C0002962;C0022116;C1301725;C1609436;C4321499
1325,phospholipid omega - $nmbr$ levels : < $nmbr$ % ( n = $nmbr$ ),C0031676;C0202177;C0441889;C1719844
1325,omega - $nmbr$ fa intake $nmbr$ st third,C0036056;C0205437;C1512806;C1719844;C3272372
1325,omega - $nmbr$ fa intake $nmbr$  d third,C0205437;C1512806;C1719844
1325,omega - $nmbr$ fa ( n = $nmbr$ ),C1719844
1325,omega - $nmbr$ fa,C1719844
1324,diclofenac ( n = $nmbr$ ),C0012091
1324,diclofenac ( n = $nmbr$ $nmbr$ ),C0012091
1324,diclofenac ( n = $nmbr$  $nmbr$ ),C0012091
1324,diclofenac $nmbr$ mg ( n = $nmbr$ ) n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . n . . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1324,diclofenac $nmbr$ mg  n = $nmbr$  n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1324,diclofenac,C0012091
1323,£ $nmbr$ ( men ) / £ $nmbr$ ( women ),C0025266;C0043210
1323,womens,
1323,women — no . ( % ),C0043210
1323,women t,C0043210
1323,women / men [ % ],C0025266;C0043210
1323,women / men  %,C0025266;C0043210
1323,women - no . ( % ),C0043210
1323,women ( n = $nmbr$ ) events,C0043210;C0441471;C3541888
1323,women ( n = $nmbr$ )  n / n ( % ),C0043210
1323,women ( n = $nmbr$ ),C0043210
1323,women ( n ( % ) ),C0043210
1323,women ( % ),C0043210
1323,women  no . ( % ),C0043210
1323,women  n ( % ) *,C0043210
1323,women  n ( % ),C0043210
1323,women  %,C0043210
1323,women,C0043210
1323,woman,C0043210;C4281745
1323,p value ( men versus women ),C0025266;C0043210;C1709380
1323,no . women,C0043210
1323,history of gestational diabetes mellitus — no . ( % of women ),C0043210;C2183115
1323,hdl cholesterol < $nmbr$ ( men ) or < $nmbr$ mg / dl ( women ),C0023822;C0025266;C0043210;C0392885;C0439269
1323,gmi ( women ),C0043210
1323,gender  women n  % ),C0043210;C0079399;C1522384
1323,fpci vs . ppci in women,C0043210
1323,all women,C0043210
1323,< $nmbr$ ( men ) / < $nmbr$ ( women ),C0025266;C0043210
1323,( women only ),C0043210;C0205171;C1720467
1323,$nmbr$ - $nmbr$ ( women ),C0043210
1322,statin ( open ),C0175566;C0360714
1322,open — no . ( % ),C0175566
1322,open triple ( n = $nmbr$ ),C0175566;C0205174
1322,open,C0175566
1321,daily bowel movements,C0011135;C0332173
1321,bowel stricturing  ' n ( % ),C0267465
1321,bowel function,C0011135
1320,unadjusted model hr  $nmbr$ % ci  p value,C0008107;C1439367;C1709380;C3161035;C3259781;C3274659;C3714583;C3853906
1320,risk model endpoint,C0035647;C2349179;C2826544;C3161035;C3274659;C3714583;C3853906;C4552904
1320,risk marker and model,C1519104;C3161035;C3274659;C3714583;C3853906
1320,model $nmbr$ §,C3161035;C3274659;C3714583;C3853906
1320,model $nmbr$ t,C3161035;C3274659;C3714583;C3853906
1320,model $nmbr$ +,C3161035;C3274659;C3714583;C3853906
1320,model $nmbr$,C3161035;C3274659;C3714583;C3853906
1320,model  n,C3161035;C3274659;C3714583;C3853906
1320,crude model hr ( $nmbr$ % ci ),C0008107;C3161035;C3259781;C3274659;C3714583;C3853906
-10,proctosigmoiditis,C0033252
1318,seropositivity status  n,C0449438;C0521143
1318,seropositivity,C0521143
1317,eligibility stratum,C0013893;C1548635
1317,eligibility strata,C0013893;C1548635
1317,eligibility risk factorsa,C0013893;C0035647;C1548635;C4552904
1317,eligibility risk factors ’ ),C0013893;C0035648;C1548635;C1553898
1317,eligibility risk factors — n ( % ) :,C0013893;C0035648;C1548635;C1553898
1317,eligibility risk factors :,C0013893;C0035648;C1548635;C1553898
1317,eligibility risk factors /,C0013893;C0035648;C1548635;C1553898
1317,eligibility risk factors !,C0013893;C0035648;C1548635;C1553898
1317,eligibility risk factors  no . ( % ) t,C0013893;C0035648;C1548635;C1553898;C2603360
1317,eligibility risk factors  % t ascvo,C0013893;C0035648;C1548635;C1553898
1317,eligibility risk factors,C0013893;C0035648;C1548635;C1553898
1317,* eligibility risk factors  n ( % ) *,C0013893;C0035648;C1548635;C1553898
1316,reversibility to salbutamol  %,C1271924
1316,fevi reversibility — %,C3830088
1315,screening absolute reversibility fev $nmbr$  ml,C0205344;C0220908;C0220909;C0439526;C0449261;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C3714541;C3887665
1315,screening % reversibility fev $nmbr$,C0220908;C0220909;C0449261;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
1315,saba reversibility,C0449261
1315,reversibility ’ ' %,C0449261
1315,reversibility — %,C0449261
1315,reversibility to salbutamolc  d  mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2699239
1315,reversibility to,C0449261
1315,reversibility stratum *,C0449261
1315,reversibility s $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
1315,reversibility of fev $nmbr$ ( % ),C0449261;C3714541
1315,reversibility [ % ]  median ( range ),C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1315,reversibility > $nmbr$ % ( n = $nmbr$ ),C0449261
1315,reversibility > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
1315,reversibility < $nmbr$ % ( n = $nmbr$ ),C0449261
1315,reversibility < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
1315,reversibility : > $nmbr$ - < $nmbr$ %,C0449261
1315,reversibility : > $nmbr$ %,C0449261
1315,reversibility : < $nmbr$ %,C0449261
1315,reversibility *,C0449261
1315,reversibility ( b $nmbr$ - agonist )  %  mean ( sd ) $nmbr$,C0444504;C0449261;C2347634;C2348143;C2699239;C2987634
1315,reversibility ( anticholinergic )  %  mean ( sd ) $,C0242896;C0444504;C0449261;C2347634;C2348143;C2699239;C3537004
1315,reversibility ( % predicted fev $nmbr$ ) *,C0449261;C0681842;C1882327;C3714541
1315,reversibility ( % ) t,C0449261
1315,reversibility ( % )  median ( range ) c,C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1315,reversibility ( % ),C0449261
1315,reversibility %,C0449261
1315,reversibility  %,C0449261
1315,reversibility,C0449261
1315,postbronchodilator fev $nmbr$ reversibility  %,C0449261;C2599594;C3714541
1315,post - bronchodilator fev i reversibility  % b,C0021966;C0221138;C0449261;C2599594;C3714541
1315,post - bronchodilator fev $nmbr$ reversibility  % a,C0449261;C2599594;C3714541
1315,post - bronchodilator fev $nmbr$ reversibility  %,C0449261;C2599594;C3714541
1315,post - bronchodilator fev  reversibility,C0449261;C2599594;C3714541
1315,mean reversibility ( % ),C0444504;C0449261;C2347634;C2348143
1315,mean ( sd ) postbronchodilator fev $nmbr$ reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
1315,mean ( sd ) % reversibility fev $nmbr$ at,C0444504;C0449261;C2347634;C2348143;C2699239;C3714541
1315,fev $nmbr$ reversibility  % b,C0449261;C3714541
1315,fev $nmbr$ reversibility  % *,C0449261;C3714541
1315,fev $nmbr$ % reversibility ( sd ),C0449261;C2699239;C3714541
1315,fev $nmbr$ % reversibility,C0449261;C3714541
1315,bronchial reversibility %,C0205039;C0449261;C1442216
1315,albuterol reversibility  %,C0001927;C0449261
1315,airway reversibility  mean  %,C0178987;C0444504;C0449261;C0458827;C2347634;C2348143
1315,airway reversibility  %,C0178987;C0449261;C0458827
1315,airflow reversibility — no . ( % ) |,C0231999;C0449261
1315,absolute reversibility in fev $nmbr$  ml *,C0205344;C0439526;C0449261;C1705224;C3714541;C3887665
1315,% reversibility in fev ^ at,C0449261;C3714541
1315,% reversibility,C0449261
1315,% bronchial reversibility ( sd ),C0205039;C0449261;C1442216;C2699239
1314,nationality,C0027473
1314,ecg abnormality at entry,C0522055;C1705654
1314,any electrocardiographic abnormality — no . ( % ),C0522055
1313,obesityj,
1313,abdominal obesity *,C0311277
1313,abdominal obesity,C0311277
1312,vitality,C0424589
1312,shfm annual mortality,C0026565;C0026566;C0332181
1312,overall mortality,C0026565;C0026566;C0282416;C1561607
1312,or morbidity and mortality,C0026538;C0026565;C0026566;C0220880
1312,non - cvd mortality,C0007222;C0026565;C0026566;C1518422
1312,non - cardiovascular mortality,C0007226;C0026565;C0026566;C1518422;C3887460
1312,mortality outcomes,C0026565;C0026566;C1274040
1312,mortality,C0026565;C0026566
1312,cvd mortality,C0007222;C0026565;C0026566
1312,cardiovascular mortality or mi,C0007226;C0026565;C0026566;C3810814;C3887460
1312,cardiovascular mortality ( per $nmbr$ person - years ),C0007226;C0026565;C0026566;C0027361;C0439234;C2347489;C3887460
1312,cardiovascular mortality  mi  or revascularization,C0007226;C0026565;C0026566;C0581603;C3810814;C3887460
1312,cardiovascular mortality,C0007226;C0026565;C0026566;C3887460
1312,cardiovascuiar mortaiity,
1312,all - causa mortality,C0026565;C0026566;C3903827
1311,si . gni . fi . canr ecg changes  positive biomarkers  and age < $nmbr$ vrs,C0001779;C0005516;C0392747;C0439178;C0443172;C0458261;C1446409;C1514241;C1623258;C1705241;C2825490;C3273608;C3812269;C4050619;C4319952
1311,bi ( $nmbr$ . $nmbr$ ),
1311,age is > $nmbr$ vrs  significant ecg changes  and no positive bi . omark . ers,C0001779;C0237881;C0439178;C0458261;C0750502;C0855329;C1446409;C1514241;C1546944;C1704489;C2825490;C2931783;C3273608;C3812269
1311,age is > $nmbr$ vrs  positive biomarkers  and no si . gni . fi . canr ecg changes,C0001779;C0005516;C0392747;C0439178;C0443172;C0458261;C1446409;C1514241;C1623258;C1705241;C2825490;C3273608;C3812269;C4050619;C4319952
1311,- bi -,
1311,$nmbr$ ( $nmbr$ si,
1310,wrist,C0043262;C1322271
1310,hip  wrist  or spine *,C0019552;C0022122;C0037949;C0043262;C1322271;C1505163;C2752558;C3538851;C4284725
1309,whitea,C1021495
1309,white hispanic - n ( % ),C1533020;C1533021
1309,white hispanic,C1533020;C1533021
1308,patients with > $nmbr$ % bsa,C0030705
1308,patients with $ $nmbr$ % bsa at baseline  no .,C0030705;C0168634;C1442488
1308,bsa ( % ),
1308,bsa  % *,
1307,yaa,
1307,laa ostium,C0444567
1307,laa closure ( n = $nmbr$ ),C0185003;C1521802
1307,laa closure ( n - $nmbr$ ),C0185003;C1521802
1307,laa closure,C0185003;C1521802
1307,laa,
1306,chajdsrvasc $nmbr$ - $nmbr$,
1306,cardiovascu lar subg roup,C0276828;C1419115;C3814448
1305,sabaa,
1305,previous ics / labd,C0205156;C0396059;C0815320;C1552607;C4551720
1305,percentage of patients using ics or ics / laba on entry,C0030705;C0439165;C0815320;C1524063;C1549488;C1561533;C1705654;C4551720
1305,lamad,
1305,labaa,
1305,laba / lama / ics,C0815320;C0999593;C1416775;C4551720
1305,laba / ics #,C0815320;C4551720
1305,laba + ics n = $nmbr$,C0815320;C4551720
1305,laba + ics ( free or fixed - dose combination ),C0178602;C0205195;C0332296;C0443218;C0815320;C0869039;C1114758;C1880497;C1947911;C1996904;C2827483;C3714578;C3811910;C4551720
1305,laba + ics,C0815320;C4551720
1305,laba  n ( % ),
1305,laba,
1305,icsa plus laba  n ( % ),C0332287
1305,icsa,
1305,ics ? laba ( free or fdc ),C0332296;C0340427;C0815320;C1413520;C1880497;C1996904;C3539652;C4551720
1305,ics / lama,C0815320;C0999593;C1416775;C4551720
1305,ics / labd,C0396059;C0815320;C4551720
1305,ics / laba,C0815320;C4551720
1305,ics + laba,C0815320;C4551720
1305,- ics / + laba n z $nmbr$,C0815320;C4551720
1305,+ ics / + laba n z $nmbr$,C0815320;C4551720
1304,univariable or ( $nmbr$ % ci )  p value *,C0008107;C1709380;C3259781
1304,univariable,
1304,multivariable adjusted model hr ( $nmbr$ % ci ),C0008107;C0456081;C3161035;C3259781;C3274659;C3714583;C3853906
1304,multivariable adjusted hr ( $nmbr$ % ci ),C0008107;C0456081;C3259781
1304,multivariable,
1303,lavolta ii,C1710602;C4082587
1303,lavolta $nmbr$,
1302,week $nmbr$  % ( n ) | | or for cana vs pbo ( $nmbr$ % ci ) §,C0008107;C0031962;C0332174;C0439230;C1418845;C3259781
1302,week $nmbr$  % ( n ) $nmbr$ or for cana vs pbo ( $nmbr$ % ci ) | |,C0008107;C0031962;C0332174;C0439230;C1418845;C3259781
1302,week $nmbr$  % ( n ) # or for cana vs pbo ( $nmbr$ % ci ) | |,C0008107;C0031962;C0332174;C0439230;C1418845;C3259781
1302,pooled non - canvas studies ( n = $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C0369718;C0441922;C0557651;C0947630;C1319635;C1418845;C1518422;C1709595;C2349200;C2603343;C3281223;C4522255
1302,overall population ( n = $nmbr$ $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C0032659;C0282416;C1257890;C1319635;C1418845;C1518422;C1561607
1302,or for cana vs pbo ( $nmbr$ % ci ) §,C0008107;C0031962;C1418845;C3259781
1302,or for cana vs pbo ( $nmbr$ % ci ) | |,C0008107;C0031962;C1418845;C3259781
1302,non - cana ( n = $nmbr$ ),C1418845;C1518422
1302,canvas ( n = $nmbr$ ) : placebo ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C0032042;C1319635;C1418845;C1696465;C1706408;C3281223
1302,canvas,C3281223
1302,cana $nmbr$ ( n = $nmbr$ ),C1418845
1302,cana,C1418845
1302,all cana,C1418845
1301,united states  canada,C0006823;C0041703
1301,saaca,
1301,laaca,
1301,canada or united states,C0006823;C0041703
1301,canada,C0006823
1300,samac,
1300,sama $nmbr$,C1075468
1300,sama  b   n ( % ),C1075468
1300,sama,C1075468
1300,previous treatment with a laba and / or lama  n ( % ) c,C0039798;C0087111;C0205156;C0999593;C1416775;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1300,lama use  n ( % ),C0042153;C0457083;C0999593;C1416775;C1947944
1300,lama +,C0999593;C1416775
1300,lama,C0999593;C1416775
1300,laba or lama ’,C0999593;C1416775
1300,laba or lama,C0999593;C1416775
1300,laba / lama,C0999593;C1416775
1300,current lama use,C0042153;C0457083;C0521116;C0999593;C1416775;C1705970;C1947944
1300,ama 士 s . e .,C0002461;C0279755;C2825862
1299,place of randomization,C0034656;C0442504;C1533810;C1704765;C1882509
1299,place !,C0442504;C1533810;C1704765;C1882509
1299,plac,C0048838
1299,inhixanab $nmbr$ mgikg versus piacom,
1298,peace ( n = $nmbr$ ),C0680443
1298,pace  no . ( $nmbr$ ),C0287990;C1552930;C4048252
1297,yearl,
1297,smoking history ( pack - years ) ∗,C1277691;C1519384
1297,smoking history ( pack - years ),C1277691;C1519384
1297,smoking history  pack - years,C1277691;C1519384
1297,smoking consumption pack - years,C0425291;C1277691
1297,sack,
1297,pack years,C1277691
1297,pack - years smoked,C0037366;C0439994;C1277691;C1881674
1297,number of pack years,C0237753;C0449788;C1277691
1297,number of pack - years,C0237753;C0449788;C1277691
1297,nicotine pack - years,C0028040;C1277691
1297,estimated number of pack - years,C0237753;C0449788;C0750572;C1277691
1296,lack of efficacy with > $nmbr$ bdmard,C0235828
1296,lack of efficacy with > $nmbr$ anti - interleukin $nmbr$,C0021764;C0235828;C1527200
1296,lack of efficacy,C0235828
1296,lack of effectiveness,C0235828
1296,laci ( n = $nmbr$ ),C1420705;C3273314;C4281721
1296,laci,C1420705;C3273314;C4281721
1296,b lack,C0332268
1295,history of a transient ischaemic attack,C0455536
1295,attain,
1295,attack ( % ),C0277793;C1261512;C1304680
1294,time between index acs and randomization — days,C0034656;C0040223;C0439228;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
1294,time between index acs and randomization ( days ),C0034656;C0040223;C0439228;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
1294,qualifying acs event — no . ( % ),C0441471;C0742343;C1514624;C4019010;C4318612
1294,prior ml ( before index acs ),C0332152;C0439526;C0600653;C0742343;C0918012;C1552854;C1637833;C1705224;C2826257;C2986546;C3887665;C4318612
1294,previous pci ( before index acs ),C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4049621;C4318612
1294,previous cabg ( before index acs ) *,C0010055;C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4318612
1294,pcr after acs,C0032520;C0742343;C3853643;C4050242;C4318612
1294,nste acs,C0742343;C4318612
1294,nste - acs,C0742343;C4318612
1294,no acs,C0742343;C4318612
1294,myocardial infarction before index acs — no . ( % ),C0027051;C0428953;C0600653;C0742343;C0918012;C1552854;C1637833;C2926063;C2986546;C3810814;C4318612;C4552959
1294,index acs — no . ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
1294,index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
1294,index acs ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
1294,hospitalization for acs,C0019993;C0742343;C4318612
1294,days between acs and rand,C0439228;C0742343;C1555436;C4318612
1294,before index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
1294,acs treatment,C0039798;C0087111;C0742343;C1522326;C1533734;C1705169;C3538994;C3887704;C4318612
1294,acs presentation,C0449450;C0742343;C4318612
1294,acs event,C0441471;C0742343;C4019010;C4318612
1294,acs ( n = $nmbr$  $nmbr$ ),C0742343;C4318612
1294,acs ( n - $nmbr$  $nmbr$ ),C0742343;C4318612
1294,acs,C0742343;C4318612
1293,uncontrolled : acq - $nmbr$ > $nmbr$ . $nmbr$,C0205318;C2919686
1293,acq score  mean,C0444504;C0449820;C2347634;C2348143;C2919686;C4050231
1293,acq - $nmbr$ scoret,C2919686
1293,acq - $nmbr$ score 本,C0449820;C2919686;C4050231
1293,acq - $nmbr$ score *,C0449820;C2919686;C4050231
1293,acq - $nmbr$ score ' ! ',C0449820;C2919686;C4050231
1293,acq - $nmbr$ score  mean ( sd ) e,C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231
1293,acq - $nmbr$ score,C0449820;C2919686;C4050231
1293,acq $nmbr$ score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231
1293,acq $nmbr$ score,C0449820;C2919686;C4050231
1293,( sd ) l / min acq - $nmbr$ score  mean ( sd ),C0444504;C0449820;C0702093;C1524029;C2347634;C2348143;C2699239;C2919686;C3813700;C4050231
1292,hematocrit  %,C0018935;C0518014
1292,baseline hematocrit  median ( iqr ),C0018935;C0168634;C0518014;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1291,exact - pro total score  mean ( sd ),C0033382;C0444504;C0523852;C2347634;C2348143;C2699239;C2828393;C2964552;C2987124;C4050514
1291,exact ( b ),C2828393;C4050514
1290,total cataract extraction,C0007389;C0185115;C0439175;C0439810;C0684295;C3665439
1290,total cataract,C3665439
1290,cataract removal,C0007389
1290,cataract,C0086543;C4555209
1289,upper respiratory tract inflammation,C0877266
1289,upper respiratory tract infection $nmbr$ ( $nmbr$ . $nmbr$ ),C0041912
1289,upper respiratory tract infection,C0041912
1289,trait,C0599883
1288,vertebrobasilar infarct,C0021308;C0545733
1288,q waves in the infarct territory at baseline *  %,C0021308;C0168634;C0429089;C1301808;C1305738;C1442488;C2983136
1288,q wave in the infarct territory at baseline *  %,C0021308;C0168634;C0429089;C1301808;C1305738;C1442488;C2983136
1288,prior infarction,C0021308;C0332152;C2826257
1288,nonfatal myocardiail infarction,C0021308
1288,nonfatai myocardiai infarction,C0021308
1288,no infarct visible,C0021308;C0205379
1288,myocardiai infarction,C0021308
1288,infarct territory ( % ),C0021308;C1301808;C2983136
1288,infarct size,C0021308;C0456389
1288,atherothrombotic infarction  n ( % ),C0021308
1288,any relevant infarct,C0021308;C2347946
1288,any infarct,C0021308
1287,± sd .,C2699239
1287,years ( sd ),C0439234;C2699239
1287,week o ( baseline ) mean 士 sd,C0168634;C0332174;C0439230;C0444504;C1442488;C2347634;C2348143;C2699239
1287,week $nmbr$ mean 士 sd,C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
1287,week $nmbr$ mean ( sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
1287,week $nmbr$ ( mean  sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
1287,vital signs  mean ( sd ),C0150404;C0444504;C0518766;C2347634;C2348143;C2699239
1287,vessel size  mean ( sd )  mm,C0005847;C0444504;C0456389;C2347634;C2348143;C2699239;C4330985;C4554674
1287,treated at baseline  mean ( sd )  mm hg,C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239
1287,total periventricular wml score  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C2964552
1287,total macular volume  mean ( sd )  mm $nmbr$,C0332574;C0444504;C0449468;C2347634;C2348143;C2699239;C4330985;C4554674
1287,time from parkinson ’ s disease diagnosis in months  mean ( sd ),C0011900;C0030567;C0040223;C0439231;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383
1287,systolic pressure at ankle level ( mmhg )  mean ± sd,C0003086;C0003087;C0039155;C0439475;C0441889;C0444504;C0445074;C0456079;C0871470;C1547707;C2347634;C2348143;C2699239;C2946261
1287,systolic blood pressure  mean ( sd )  mm hga,C0039155;C0428886;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239;C4330985;C4554674
1287,systolic ( mean  sd ),C0039155;C0444504;C2347634;C2348143;C2699239
1287,systolic  mean ( sd )  mm hg h,C0025424;C0039155;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239
1287,symptom score ( sd ),C2699239;C3476546
1287,sf - $nmbr$ v $nmbr$ domain scores  mean [ sd ],C0037712;C0444504;C0449820;C1880389;C1883221;C2347634;C2348143;C2699239;C3541951;C4050231
1287,sesbp ( mmhg ) [ mean _sd ] a,C0439475;C0444504;C2347634;C2348143;C2699239
1287,sesbp ( mmhg ) [ mean - sd ] d,C0439475;C0444504;C2347634;C2348143;C2699239
1287,sedbp ( mmhg ) [ mean_ sd ] a,C0439475;C0444504;C2347634;C2348143;C2699239
1287,sedbp ( mmhg ) [ mean _sd ] d,C0439475;C0444504;C2347634;C2348143;C2699239
1287,seated sbp  mean ( sd )  mmhg,C0085805;C0277814;C0439475;C0444504;C1283233;C2347634;C2348143;C2699239
1287,sd or %,C2699239
1287,sd,C2699239
1287,scsbp  mean ( sd )  mmhge,C0444504;C2347634;C2348143;C2699239
1287,scdbp  mean ( sd )  mmhgf,C0444504;C2347634;C2348143;C2699239
1287,sbp ( mmhg )  mean ± sd,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1287,sbp ( mmhg )  mean ( sd ),C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1287,sbp ( mmghg )  mean ( sd ),C0085805;C0444504;C2347634;C2348143;C2699239
1287,sbp  mean ± sd ( mmhg ),C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1287,sbp  mean = sd  mmhg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1287,sbp  mean ( sd )  mmhg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1287,pulmonary function tests ( post - bronchodilator )  mean ( sd ),C0024119;C0444504;C2347634;C2348143;C2598152;C2599594;C2699239
1287,ppbc score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1287,post - bronchodilator reversibility fev $nmbr$ ( % ) mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
1287,post - bronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1287,post - bronchodilator fev $nmbr$  l  mean ( sd ) c,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1287,post - bronchodilator fev $nmbr$  l  mean ( sd ),C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1287,patient global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
1287,patient ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd ),C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4054228;C4330985;C4554674
1287,patient ' s global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
1287,oab - q score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C3641332;C4050231
1287,number of patients ( % ) or mean 士 sd,C0444504;C2347634;C2348143;C2360800;C2699239
1287,mean 土 sd ( n ),C0444504;C2347634;C2348143;C2699239
1287,mean ± sd bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,mean ± sd $nmbr$ - h adbp  mm hg,C0033727;C0168370;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1287,mean ± sd  n ( % ),C0444504;C2347634;C2348143;C2699239
1287,mean   ±   sd,C0444504;C2347634;C2348143;C2699239
1287,mean ucsd - sobq score * ( sd ),C2699239;C3533236
1287,mean total ipss ( sd ),C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1287,mean stent diameter per lesion  mm ( sd ) †,C0038257;C0221198;C0552409;C1546698;C2699239;C4330985;C4554674
1287,mean sd $nmbr$ - h asbp  mm hg,C0033727;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1287,mean fev $nmbr$  l ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1287,mean diastolic bp  mmhg  mean = sd,C0428883;C0439475;C0444504;C2347634;C2348143;C2699239
1287,mean bmi ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
1287,mean a ± sd ( mmhg ),C0439475;C0444504;C2347634;C2348143;C2699239
1287,mean ( ± sd ) baseline score,C0168634;C1442488;C2699239;C3533236
1287,mean ( sd ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239
1287,mean ( sd ) post - bronchodilator fev $nmbr$ reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
1287,mean ( sd ) post - bronchodilator fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1287,mean ( sd ) post - bronchodilator,C0444504;C2347634;C2348143;C2599594;C2699239
1287,mean ( sd ) nonstudy eye e - etdrs visual acuity letter score,C0015392;C0042812;C0700042;C1096774;C2360551;C2699239;C3533236
1287,mean ( sd ) improvement from baseline to week $nmbr$ in basdai questions *,C0168634;C0332174;C0439230;C0444504;C1442488;C1522634;C1998004;C2347634;C2348143;C2699239;C2986411
1287,mean ( sd ) improvement from baseline to week $nmbr$ in basdai,C0168634;C0332174;C0439230;C0444504;C1442488;C1998004;C2347634;C2348143;C2699239;C2986411
1287,mean ( sd ) fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2699239;C3714541
1287,mean ( sd ) fev $nmbr$  l,C0444504;C2347634;C2348143;C2699239;C3714541
1287,mean ( sd ) eevi  ml,C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665
1287,mean ( sd ) e - etdrs visual acuity letter score ( snellen equivalent ),C0042812;C0183370;C0205163;C0439185;C1096774;C2360551;C2699239;C3533236
1287,mean ( sd ) change from pre - to post - bronchodilator fevi  nil,C0332152;C0442734;C0444504;C0687676;C0740175;C1704687;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034
1287,mean ( sd ) bmi,C0444504;C0578022;C2347634;C2348143;C2699239
1287,mean ( sd ) baseline scores,C0168634;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C4050231
1287,mean ( sd ) baseline,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1287,mean ( sd ) aqlq,C0444504;C2347634;C2348143;C2699239;C4055434
1287,mean ( sd )  y,C0444504;C2347634;C2348143;C2699239
1287,mean ( sd )  mmhg,C0439475;C0444504;C2347634;C2348143;C2699239
1287,mean ( sd )  kg / m $nmbr$,C0444504;C1532718;C2347634;C2348143;C2699239
1287,mean  sd,C0444504;C2347634;C2348143;C2699239
1287,left ventricular ejection fraction  mean ( sd )  %,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
1287,ldl - c in mmol / l ( mean ± sd for baseline [ n ]  mean ± se for week $nmbr$ [ n ] ),C0036919;C0168634;C0332174;C0439230;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
1287,jsn  mean ± sd,C0444504;C2347634;C2348143;C2699239
1287,iuss score  mean ( sd ),C0439453;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1287,ipss ( mean ± sd ),C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1287,ibdq domain scores  mean [ sd ],C0444504;C0449820;C1880389;C1883221;C2347634;C2348143;C2699239;C3541951;C4050231
1287,ibdq  mean ± sd,C0444504;C2347634;C2348143;C2699239
1287,hrql mean ( sd ),C0444504;C2347634;C2348143;C2699239
1287,hours from clopidogrel loading  mean ( sd ),C0070166;C0439227;C0444504;C1708715;C2347634;C2348143;C2699239
1287,homa - ir  mean ( sd ),C0022065;C0022071;C0444504;C1448132;C2347634;C2348143;C2699239
1287,heart rate ( sd ),C0018810;C2699239
1287,heart rate ( b . p . m . )  mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
1287,heart rate  mean ± sd ( b . p . m . ),C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
1287,heart rate  mean ( sd ) [ range ]  beats / min,C0018810;C0444504;C0702093;C1514721;C1524029;C2347634;C2348143;C2348147;C2699239;C3542016;C3813700
1287,heart rate  mean ( sd )  beats / min,C0018810;C0444504;C0702093;C1524029;C2347634;C2348143;C2699239;C3813700
1287,heart rate  mean ( sd ),C0018810;C0444504;C2347634;C2348143;C2699239
1287,heart rate  beats / min  mean ± sd,C0018810;C0444504;C0702093;C1524029;C2347634;C2348143;C2699239;C3813700
1287,heart rate  b . p . m . mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
1287,hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo subtracted change ( se ),C0008107;C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0040363;C0041260;C0168634;C0230347;C0392747;C0443172;C0444504;C0456081;C1442488;C1696465;C1705241;C1706408;C1719767;C1825777;C1883351;C2346906;C2347634;C2348143;C2348589;C2699239;C3259781;C3538758;C3829066;C4319952;C4553351
1287,hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % ( > $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se ),C0008107;C0019016;C0023031;C0023749;C0027960;C0030705;C0032042;C0036919;C0168634;C0230347;C0324740;C0392747;C0439189;C0443172;C0444504;C0456081;C1442488;C1456781;C1696465;C1705241;C1706408;C1719767;C1824986;C1825777;C1960955;C2346906;C2347634;C2348143;C2348589;C2699239;C3259781;C3538758;C3665593;C4319952;C4553351
1287,haq - di total score  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C2964552;C3826998;C4321476
1287,haq - di ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
1287,haq - di  mean [ sd ],C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
1287,haq - di  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
1287,gout history  mean ± sd years,C0018099;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239
1287,fvc  l  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1287,fsn score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1287,fpi  mean ( sd )  pu / rnff,C0018387;C0444504;C2347634;C2348143;C2699239
1287,fpi  mean ( sd )  pu / mlt,C0018387;C0444504;C2347634;C2348143;C2699239;C4553833
1287,fev $nmbr$ / fvc  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1287,fev $nmbr$ / fvc  %  mean ( sd ) $nmbr$,C0444504;C2347634;C2348143;C2699239;C3714541
1287,fev $nmbr$ ( l )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1287,fev $nmbr$  mean ( sd ) pre - bd fev $nmbr$ / fvc,C0005126;C0332152;C0444504;C0740175;C2257086;C2344255;C2347634;C2348143;C2699239;C3669034;C3714541;C4050145
1287,fev $nmbr$  l  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1287,femoral neck t - score ( mean = sd ),C0015815;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1287,erosion score  mean ± sd,C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231
1287,erosion score  mean $nmbr$ sd,C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231
1287,ejection fraction — mean ± sd,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
1287,ejection fraction  mean ( sd )  %,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
1287,dietary calcium intake  mean ( sd )  mg / d,C0439422;C0444504;C0489458;C2347634;C2348143;C2699239
1287,diastolic bp  mmhg  mean ± sd,C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
1287,diastolic ( mean  sd ),C0012000;C0444504;C2347634;C2348143;C2699239
1287,dha intake on food frequency questionnaire  mean ( sd )  mg / d,C0034394;C0142831;C0439422;C0444504;C1286336;C1512806;C2347634;C2348143;C2348308;C2699239;C2986698
1287,data are number of patients ( % ) or mean ( sd )  unless otherwise indicated . cabg = coronary - artery bypass grafting . ptca = percutaneous transluminal coronary angioplasty  ldl = low - density lipoprotein . hdl = high - density lipoprotein . iqr = i nterquarti le range  hmg coa ri = $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a reductase inhibitor . bmi = body - mass index  which is weight in kg divided by the square of height in metres  * median ( iqr ) .,C0005910;C0009235;C0010055;C0021966;C0022718;C0023190;C0023821;C0023823;C0035487;C0043100;C0047420;C0162577;C0189695;C0205120;C0221138;C0332849;C0439090;C0439209;C0444504;C0475209;C0489786;C0522520;C0522523;C0545743;C0549183;C0597153;C0700307;C0876920;C1305855;C1305866;C1423767;C1444656;C1511726;C1514721;C1522231;C1548817;C1552595;C1655741;C1705104;C1826843;C2347634;C2347635;C2348143;C2348144;C2348147;C2360800;C2697858;C2699239;C2936173;C2939193;C3245479;C3542016;C3714741;C4054209
1287,cumulative nsaid score  mean   ±   sd,C0003211;C0444504;C0449820;C1511559;C2347634;C2348143;C2699239;C3536840;C4050231
1287,comorbidity score  mean ( sd ) t,C0009488;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1287,chads $nmbr$ score  mean ± sd,C0007928;C0444504;C0449820;C1413373;C2347634;C2348143;C2699239;C4050231
1287,chads $nmbr$ score  mean ( ± sd ),C0007928;C0444504;C0449820;C1413373;C2347634;C2348143;C2699239;C4050231
1287,chads $nmbr$  mean ± sd,C0007928;C0444504;C1413373;C2347634;C2348143;C2699239
1287,bw  mean ( sd )  kg,C0005910;C0006041;C0022718;C0439209;C0444504;C2347634;C2348143;C2699239;C2986891;C4054209
1287,bsa ( % )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1287,bone erosion score  mean ( sd ),C0444504;C0449820;C0587240;C2347634;C2348143;C2699239;C4050231
1287,bmi in kg / m $nmbr$  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,bmi ( kg / m ^ )  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,bmi ( kg / m $nmbr$ ) mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,bmi ( kg / m $nmbr$ ) ( mean ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,bmi ( kg / m $nmbr$ )  mean ( sd ) a,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,bmi  mean ± sd,C0444504;C0578022;C2347634;C2348143;C2699239
1287,bmi  mean ( sd ) b,C0444504;C0578022;C2347634;C2348143;C2699239
1287,bmi  mean ( sd )  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,bmi  mean ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
1287,bmi  kg / m ^  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,bmi  kg / m $nmbr$  mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,bmi  kg / m $nmbr$  mean + sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1287,blood oxygenation  mean ± sd,C0005767;C0005768;C0229664;C0231940;C0282636;C0444504;C2347634;C2348143;C2699239
1287,bii ( mean ± sd ),C0444504;C1413059;C2347634;C2348143;C2699239
1287,basmi ( linear )  mean ( sd ),C0205132;C0444504;C2347634;C2348143;C2699239
1287,baseline total ipss  mean ( sd ),C0168634;C0439175;C0439810;C0444504;C1019118;C1442488;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1287,baseline sesbp  mean ( sd )  mm hg §,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1287,baseline pssi score  mean ( sd ),C0168634;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C4050231
1287,baseline ppasi score  mean ( sd ),C0168634;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C4050231
1287,baseline pasi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C4528685
1287,baseline mean fev $nmbr$ ( sd )  ml,C0168634;C0439526;C0444504;C1442488;C1705224;C2347634;C2348143;C2699239;C3714541;C3887665
1287,baseline mean ( sd )  % [ mmol / mol ],C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3829066
1287,baseline mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1287,baseline hbi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1287,baseline characteristics  mean ( sd ) a,C0444504;C2347634;C2348143;C2699239;C4684572
1287,baseline bsa  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1287,baseline bii  mean ( sd ),C0168634;C0444504;C1413059;C1442488;C2347634;C2348143;C2699239
1287,baseline . mean _ sd . mg / mg,C0168634;C0444504;C1319635;C1442488;C2347634;C2348143;C2699239
1287,baseline ( mean  sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1287,baseline  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1287,aqlq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434
1287,aqlq ( s ) + $nmbr$ score  mean ( sd ) c  f,C0016327;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434
1287,albuterol use ( sd )  puffs / day,C0001927;C0042153;C0332173;C0439228;C0439505;C0457083;C1533107;C1947944;C2699239
1287,[ sd ],C2699239
1287,( sd ),C2699239
1287,( mean ± sd ),C0444504;C2347634;C2348143;C2699239
1287,( mean + . sd ),C0444504;C2347634;C2348143;C2699239
1286,sun - $nmbr$ ( $nmbr$ ),C0038817;C0376223
1286,su monotherapy,C0038642;C1705534
1286,su / tzd,C0038642;C1705534
1286,su / met,C0038642;C0428210;C1550543;C1705534;C4317104
1286,su  n ( % ),C0038642;C1705534
1286,su,C0038642;C1705534
1286,metformin ? su,C0025598;C0038642;C1705534
1286,metformin + su + tzd,C0025598;C0038642;C1705534
1286,metformin + su,C0025598;C0038642;C1705534
1286,baseline su dose > $nmbr$ / $nmbr$ maximal,C0038642;C0168634;C0178602;C0205289;C0806909;C0869039;C1114758;C1442488;C1705534;C4049713
1286,baseline su dose < $nmbr$ / $nmbr$ maximal,C0038642;C0168634;C0178602;C0205289;C0806909;C0869039;C1114758;C1442488;C1705534;C4049713
1285,soc,
1285,so $nmbr$ %,C0037640
1285,so,C0037640
1285,evolocumab + soc ( n = $nmbr$ ),C3529352
1284,abl - sc n / n,C0023139;C0282380;C1704928;C3890208
1284,abl - sc mean,C0023139;C0282380;C0444504;C1704928;C2347634;C2348143;C3890208
1284,abaloparatide - sc  n ( % ),C0282380;C4042342
1283,women  qva $nmbr$ - sfc,C0043210;C4521536
1283,sfc ( n   = $nmbr$  $nmbr$ ),C4521536
1283,sfc ( n [ $nmbr$ ),C4521536
1283,sfc ( n = $nmbr$ ),C4521536
1283,sfc $nmbr$ mg / $nmbr$ mg,C1319635;C4521536
1283,sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
1283,sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
1283,sfc,C4521536
1283,severe cord * : qvai $nmbr$ - sfc,C0205082;C1550235;C1706500;C3489532;C4050465;C4050466;C4521536
1283,moderate cord * : qva $nmbr$ - sfc,C0205081;C1550235;C1706500;C1881878;C3489532;C4049705;C4049706;C4085643;C4321335;C4521536
1283,men : qvai $nmbr$ - sfc,C0025266;C4521536
1283,ics users : qvai $nmbr$ - sfc,C0815320;C1706077;C4521536;C4551720
1283,ics non - users : qvai $nmbr$ - sfc,C0815320;C1518422;C1706077;C4521536;C4551720
1283,annualized rate ind / gly sfc,C0017890;C0523677;C0871208;C1521828;C4049864;C4521536
1283,age > $nmbr$ : qvai $nmbr$ - sfc,C0001779;C4521536
1283,age < $nmbr$ : qvai $nmbr$ - sfc,C0001779;C4521536
1282,≥ $nmbr$ sae,C1519255;C1622657;C4553214
1282,saes,C1519255;C1622657;C4553214
1282,due to sae,C1519255;C1622657;C4553214
1282,due to drug - relateda sae,C0013227;C1254351;C1519255;C1622657;C4553214
1282,drug - related saes,C0013227;C0439849;C0445223;C1254351;C1519255;C1622657;C4553214
1282,because of sae,C1519255;C1622657;C4553214
1282,any sae,C1519255;C1622657;C4553214
1281,sabae,
1281,saba §,
1281,saba ( inhaled )  c   n ( % ),C0004048
1281,saba,
1280,traditional nsaid use,C0003211;C3536840;C3897349
1280,traditional nsaid,C0003211;C0443324;C1548559;C3536840
1280,prior nsaid use,C0003211;C0042153;C0332152;C0457083;C1947944;C2826257;C3536840
1280,prior nsaid  n ( % ) a,C0003211;C0332152;C2826257;C3536840
1280,other nsaids,C0003211
1280,nsaid   at   least   once,C0003211;C3536840
1280,nsaid,C0003211;C3536840
1280,non - steroidal anti - inflammatory drugs,C0003211
1280,never nsaid,C0003211;C2003901;C3536840
1280,cox - $nmbr$ selective nsaid use,C0003211;C0036576;C0042153;C0457083;C1565830;C1707391;C1947944;C3536840
1280,cox - $nmbr$ selective nsaid,C0003211;C0036576;C1565830;C1707391;C3536840
1280,chronic non - steroidal antiinflammatory drugs,C0003211;C0205191
1280,abbreviations : bmi  body mass index  cabg  coronary artery bypass graft  nsaids  nonsteroidal anti - inflammatory drugs  pci  percutaneous coronary interventions . * values expressed as number ( percentage ) unless otherwise indicated . percentages may not equal $nmbr$ due to rounding . fhistory of or currently taking antidiabetic or lipid - lowering medications . ^ history of or currently have elevated serum creatinine level but less than $nmbr$ mg / dl_ ( < $nmbr$ pmol / l ) . § patients with a history of skin  prostate  and other cancers with long survival expectancy were not excluded . | | lnsulin and / or oral hypoglycemics . ildata for women only ( n = $nmbr$ for calcium antagonist strategy and n = $nmbr$ for non - calcium antagonist strategy ) .,C0000723;C0003211;C0006684;C0006826;C0010055;C0023779;C0033572;C0038952;C0042295;C0043210;C0205163;C0205166;C0205171;C0205250;C0220921;C0237753;C0332196;C0332490;C0359086;C0369718;C0439092;C0439165;C0441922;C0441994;C0444099;C0449788;C0521116;C0600061;C0678226;C0679138;C0679199;C0679831;C0935929;C0998265;C1123023;C1305855;C1306459;C1444656;C1515187;C1518422;C1532338;C1549488;C1553893;C1554077;C1561533;C1706317;C1720467;C2003888;C2828389;C3146286;C3163633;C3642216;C3898174;C4520765
1279,underlying disease,C0012634;C4067746
1279,uc disease durslion,C0012634
1279,site of disease — no . ( % ),C0012634;C2945843
1279,serious gi disorder,C0012634;C0205404;C1708130;C3539617;C4050121
1279,priorvascular disease  %,C0012634
1279,priorbone disease,C0012634
1279,prior disease - modifying drugs resulting in inadequate response — mean no . / patient,C0012634;C0013227;C0030705;C0205412;C0332152;C0332294;C0392747;C0439856;C0444504;C0871261;C1704632;C1706817;C2347634;C2348143;C2826257;C2911692;C3687832
1279,prior disease,C0012634;C0332152;C2826257
1279,previous disease — no . ( % ) f,C0012634;C0016327;C0205156;C1552607
1279,previous disease and drug use,C0012634;C0205156;C0242510;C1552607
1279,previous disease :,C0012634;C0205156;C1552607
1279,polyvascular disease and type $nmbr$ diabetes ( n = $nmbr$ ),C0012634;C1320657
1279,polyvascular disease and no type $nmbr$ diabetes ( n = $nmbr$ ),C0012634;C1320657
1279,polyvascular disease * ( n = $nmbr$ ),C0012634
1279,polyvascular disease ( n = $nmbr$ ),C0012634
1279,peripherai arteriai disease,C0012634
1279,no polyvascular disease * ( n = $nmbr$ $nmbr$ ),C0012634
1279,no polyvascular disease ( n = $nmbr$ $nmbr$ ),C0012634
1279,no multivessel disease,C0012634
1279,multivessel disease 一 no . ( % ),C0012634
1279,multivessel disease — no . ( % ),C0012634
1279,multivessel disease  no . ( % ),C0012634
1279,multivessel disease  n ( % ),C0012634
1279,multivessel disease,C0012634
1279,most frequent gi disorders,C0012634;C0205393;C0332183;C1708130;C3539617;C4050121
1279,microvascular disease *,C0012634;C0443258
1279,microvascular disease  n ( % ),C0012634;C0443258
1279,mer ’ s disease assessment,C0012634;C0673013;C1261322;C1516048;C3810521;C4281714
1279,macrovascular disease  n ( % ),C0012634
1279,established atherosclerotic disease — no . { % ),C0012634;C0333482;C0443211;C1272684
1279,established atherosclerotic disease,C0012634;C0333482;C0443211;C1272684
1279,disorders ( soc ),C0012634
1279,disease localization ' ’  n ( % ),C0012634;C0475264;C1744691
1279,disease localization  n ( % ),C0012634;C0475264;C1744691
1279,disease hare . no . ( % ) i,C0012634;C0021966;C0221138;C0242372;C1425660
1279,disease extent  n ( % ),C0012634;C0439792
1279,disease,C0012634
1279,coronarv arterv disease,C0012634
1279,clinical atherosclerotic disease *,C0012634;C0205210;C0333482
1279,cerebrovascuiar disease,C0012634
1279,atherosclerotic disease *,C0012634;C0333482
1279,atherosclerotic disease ( % ),C0012634;C0333482
1279,any disease,C0012634
1279,albuminuria and previous maerovaseular disease plus established renal disease ( egfr $nmbr$ - $nmbr$ ml / min / l $nmbr$ in - with an uacr > $nmbr$ mg / g or egfr $nmbr$ - < $nmbr$ ml / inin / l $nmbr$ in - with any uacr mg / g ),C0001925;C0012634;C0022658;C0205156;C0332287;C0443211;C0702093;C1272684;C1300563;C1524029;C1552607;C1635169;C1739039;C3811844;C3812682;C3813700
1279,$nmbr$ - $nmbr$ with cv risk but not disease ( n = $nmbr$ ),C0012634;C0035647;C1518422;C3538987;C4048877;C4318503;C4552904
1279,$nmbr$ - $nmbr$  risk  not disease ( n = $nmbr$  $nmbr$ ),C0012634;C0035647;C1518422;C4552904
1278,patients with cardiac disorders  n ( % ) §,C0012634;C0018799;C0030705;C0741926
1278,patients with cardiac disorders  n ( % ) c,C0012634;C0018799;C0030705;C0741926
1278,no cardiac disease,C0018799
1278,no apparent heart disease,C0018799;C0750489
1278,isehemie heart disease,C0018799
1278,cardiac disorders ( soc ),C0018799
1278,cardiac disorder  n ( % ) §,C0018799
1278,cardiac disorder,C0018799
1278,cardiac disease,C0018799
1277,sex : female,C0086287
1277,sex ( female ),C0086287
1277,sex  female    n   ( % ),C0086287
1277,sex  female  n ( % ),C0086287
1277,sex  female  %,C0086287
1277,sex  female,C0086287
1277,sex  % female,C0086287
1277,number of females n ( % ),C0086287;C0237753;C0449788
1277,number of ( % ) females,C0086287;C0237753;C0449788
1277,gender ( female : male  % ),C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
1277,femalesex,
1277,females only,C0086287;C0205171;C1720467
1277,females ( n = $nmbr$ ),C0086287
1277,females ( itt ) ( n = $nmbr$ ),C0086287
1277,females  n ( % ),C0086287
1277,females  > $nmbr$ . $nmbr$,C0086287
1277,females  > $nmbr$,C0086287
1277,females  < $nmbr$ . $nmbr$,C0086287
1277,females  < $nmbr$,C0086287
1277,females  %,C0086287
1277,females,C0086287
1277,femaleb,
1277,female — no . ( % ),C0043210;C0086287;C1705497;C1705498
1277,female sex — no . { % ),C0086287
1277,female sex — no . ( % ),C0086287
1277,female sex — %,C0086287
1277,female sex ( % ),C0086287
1277,female sex  no . / total ( % ),C0086287;C0439175;C0439810
1277,female sex  no . ( % ),C0086287
1277,female sex  n ( % ),C0086287
1277,female sex  %,C0086287
1277,female sex,C0086287
1277,female n ( % ),C0043210;C0086287;C1705497;C1705498
1277,female gender n ( % ),C0086287
1277,female gender ( % ),C0086287
1277,female gender,C0086287
1277,female eze / simva ( „ = $nmbr$ },C0043210;C0086287;C1705497;C1705498
1277,female eze / simva ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1277,female - n ( % ),C0043210;C0086287;C1705497;C1705498
1277,female ( n — $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1277,female ( n   = $nmbr$  $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1277,female ( n z $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1277,female ( n = lll $nmbr$ ),C0043210;C0086287;C1261077;C1705497;C1705498
1277,female ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1277,female ( n = $nmbr$  $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1277,female ( % ),C0043210;C0086287;C1705497;C1705498
1277,female $nmbr$,C0043210;C0086287;C1705497;C1705498
1277,female  no . ( % ),C0043210;C0086287;C1705497;C1705498
1277,female  no ( % ),C0043210;C0086287;C1705497;C1705498
1277,female  n ( % ),C0043210;C0086287;C1705497;C1705498
1277,female  %,C0043210;C0086287;C1705497;C1705498
1277,female,C0043210;C0086287;C1705497;C1705498
1277,eze / simva ( „ = $nmbr$ },
1277,eze,
1277,caleitonin  ng / l  females mean ± sd,C0086287;C0439297;C0444504;C2347634;C2348143;C2699239
1276,years male gender  n ( % ),C0086582;C0439234;C1706180
1276,sexa male,C0086582;C1706180;C1706428;C1706429
1276,sex : male ( n = $nmbr$ ),C0086582
1276,sex : male,C0086582
1276,sex ( male / female ) ( n ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1276,sex ( male / female ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1276,sex ( male ) - no . ( % ),C0086582
1276,sex ( male )  n ( % ),C0086582
1276,sex ( male )  %,C0086582
1276,sex ( male ),C0086582
1276,sex ( male  % ),C0086582
1276,sex  n ( % ) male,C0086582
1276,sex  male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1276,sex  male  no . ( % ),C0086582
1276,sex  male  n ( % ),C0086582
1276,sex  male,C0086582
1276,sex  % male,C0086582
1276,overall  male : female,C0043210;C0086287;C0086582;C0282416;C1561607;C1705497;C1705498;C1706180;C1706428;C1706429
1276,males [ n ( % ) ],C0086582
1276,males ( n = $nmbr$ ),C0086582
1276,males ( itt ) ( n = $nmbr$ ),C0086582
1276,males ( % ),C0086582
1276,males  n ( % ),C0086582
1276,males  > $nmbr$ . $nmbr$,C0086582
1276,males  > $nmbr$,C0086582
1276,males  < $nmbr$ . $nmbr$,C0086582
1276,males  < $nmbr$,C0086582
1276,males  %,C0086582
1276,males,C0086582
1276,male sex 一 no . ( % ),C0086582
1276,male sex — no . { % ),C0086582
1276,male sex — no . / total no . ( % ),C0086582;C0439175;C0439810
1276,male sex — no . ( % ) race — no . ( % ) ) :,C0034510;C0086582;C1706779;C3853635
1276,male sex — no . ( % ) medical history — no . / total no . ( % ),C0086582;C0262926;C0439175;C0439810;C1704706
1276,male sex — no . ( % ) f,C0016327;C0086582
1276,male sex — no . ( % ),C0086582
1276,male sex — %,C0086582
1276,male sex ^,C0086582
1276,male sex \ no . ( % ),C0086582
1276,male sex ( % ),C0086582
1276,male sex  no . / total no . ( % ),C0086582;C0439175;C0439810
1276,male sex  no . ( % ),C0086582
1276,male sex  n [ % ],C0086582
1276,male sex  n ( % ),C0086582
1276,male sex  ( % ),C0086582
1276,male sex  %,C0086582
1276,male sex,C0086582
1276,male nyha class,C0086582;C1706180;C1706428;C1706429;C1882083
1276,male gender ( % ),C0086582;C1706180
1276,male gender    n   ( % ),C0086582;C1706180
1276,male gender  n ( % ),C0086582;C1706180
1276,male gender,C0086582;C1706180
1276,male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1276,male / female,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1276,male - no . ( % ),C0086582;C1706180;C1706428;C1706429
1276,male *  n ( % ),C0086582;C1706180;C1706428;C1706429
1276,male ( n   = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1276,male ( n z $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1276,male ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1276,male ( n = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1276,male ( n - $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1276,male ( % ),C0086582;C1706180;C1706428;C1706429
1276,male    n   ( % ),C0086582;C1706180;C1706428;C1706429
1276,male  no ( % ),C0086582;C1706180;C1706428;C1706429
1276,male  n / n ( % ),C0086582;C1706180;C1706428;C1706429
1276,male  n ( % ),C0086582;C1706180;C1706428;C1706429
1276,male  n,C0086582;C1706180;C1706428;C1706429
1276,male  % ( n ),C0086582;C1706180;C1706428;C1706429
1276,male  %,C0086582;C1706180;C1706428;C1706429
1276,male,C0086582;C1706180;C1706428;C1706429
1276,genital mycotic infections male $nmbr$,C0086582;C0740330;C1706180;C1706428;C1706429
1276,gender male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1276,gender : male    n   ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1276,gender - male  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1276,gender ( male / female ) ( number ),C0043210;C0079399;C0086287;C0086582;C0237753;C0449788;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
1276,gender ( male )  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1276,gender ( % ) male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
1276,gender  n [ % ] male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1276,gender  n ( % ) male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1276,gender  male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
1276,gender  male ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1276,gender  male  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1276,gender  male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1276,female / male ( % ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1276,caleitonin  ng / l  males mean ± sd,C0086582;C0439297;C0444504;C2347634;C2348143;C2699239
1276,[ cm { female ) / cm { male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1276,[ cm ( female ) / cm ( male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1275,never used lev,C0023556;C1273517;C2003901
1275,lev - naive,C0023556
1275,lev - exposed,C0023556;C0332157
1275,lev ( n   =   $nmbr$ ),C0023556
1274,triacylglycerol  mmol / le,C0023190;C0041004;C0439090;C0439190;C1423767;C2697858
1274,total cholesterol  mmol / le,C0023190;C0201950;C0439090;C0439190;C0543421;C1423767;C2697858
1274,fema le,C0023190;C0439090;C1423767;C2697858
1273,white race — no . ( % ) y left ventricular ejection fraction — %,C0007457;C0034510;C0043157;C0220938;C0428772;C0488728;C1706779;C3853635
1273,values are mean ± sd  median [ quartile range ]  or % . ace indicates angiotensin - converting enzyme  arb  angiotensin receptor blocker  bnp  b - type natriuretic peptide  bp  blood pressure  bun  blood urea nitrogen  lvef  left ventricular ejection fraction  and nt - probnp  n - terminal pro - b - type natriuretic peptide .,C0005823;C0022709;C0033382;C0042295;C0054015;C0205088;C0332307;C0428772;C0444504;C0488728;C0523852;C0549183;C0597357;C0600137;C0876920;C1095989;C1144709;C1291218;C1317554;C1417808;C1452534;C1514721;C1547052;C1705314;C1705315;C2347634;C2347635;C2348143;C2348144;C2348147;C2699239;C2709270;C2825907;C2828255;C2939193;C2982014;C2987124;C3537020;C3542016;C3683557;C3888198;C4284014;C4284038
1273,nyha ll / lll patients with lvef < $nmbr$ . $nmbr$ at baseline,C0030705;C0168634;C0428772;C0488728;C1261077;C1275491;C1442488
1273,mean lvef,C0428772;C0444504;C0488728;C2347634;C2348143
1273,lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ a,C0428772;C0488728
1273,lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ ) a,C0428772;C0488728
1273,lvef within $nmbr$ months  %,C0428772;C0439231;C0488728
1273,lvef ^ $nmbr$ . $nmbr$ and nyha class ii  iii at baseline,C0168634;C0428772;C0439070;C0488728;C1442488;C1705160;C1710602;C1882085;C1882086;C4082587
1273,lvef > $nmbr$ %,C0428772;C0488728
1273,lvef < $nmbr$ . $nmbr$,C0428772;C0488728
1273,lvef < $nmbr$ %  n = $nmbr$ $nmbr$ ) “,C0428772;C0488728
1273,lvef < $nmbr$ %,C0428772;C0488728
1273,lvef ( u ),C0428772;C0439148;C0488728
1273,lvef ( mean ± sd ),C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
1273,lvef ( % )  mean ± sd,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
1273,lvef ( % ),C0428772;C0488728
1273,lvef  %,C0428772;C0488728
1273,lvef,C0428772;C0488728
1273,left ventricular ejection fraction — no . / total no . ( % ),C0428772;C0439175;C0439810;C0488728
1273,left ventricular ejection fraction — % §,C0428772;C0488728
1273,left ventricular ejection fraction — %,C0428772;C0488728
1273,left ventricular ejection fraction < $nmbr$ %,C0428772;C0488728
1273,left ventricular ejection fraction ( % ),C0428772;C0488728
1273,left ventricular ejection fraction  median ( iqr )  %,C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193
1273,left ventricular ejection fraction  % af history,C0019664;C0019665;C0262512;C0262926;C0344434;C0428772;C0488728;C1705255;C2004062;C4049859
1273,left ventricular ejection fraction  % *,C0428772;C0488728
1273,left ventricular ejection fraction  %,C0428772;C0488728
1273,left ventricular ejection fraction,C0428772;C0488728
1273,history of hf or lvef b $nmbr$ % with index event  no . ( % ),C0018488;C0019664;C0019665;C0262512;C0262926;C0428772;C0441471;C0488728;C0600653;C0918012;C1313497;C1538440;C1552854;C1637833;C1705255;C2004062;C2986546;C3273279;C4019010
1273,hf or lvef < $nmbr$ % associated with index event,C0018488;C0332281;C0428772;C0441471;C0488728;C0600653;C0918012;C1313497;C1538440;C1552854;C1637833;C2986546;C3273279;C4019010
1273,heart failure or lvef < $nmbr$ % associated with index acs event,C0018801;C0018802;C0332281;C0428772;C0441471;C0488728;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612;C4554158
1273,heart failure  lvef < $nmbr$ %  or both,C0018801;C0018802;C0428772;C0488728;C4554158
1273,continuous lvef $nmbr$ treatment interaction,C0039798;C0087111;C0428772;C0488728;C0549178;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
1273,baseline lvef  %,C0168634;C0428772;C0488728;C1442488
1273,baseline lvef,C0168634;C0428772;C0488728;C1442488
1273,alvef ( per $nmbr$ % ),
1272,lvh by minnesota code  no . ( % ),C0009219;C0026183;C0149721;C0805701;C3889831
1272,lvh by minnesota code,C0009219;C0026183;C0149721;C0805701;C3889831
1272,lvh by echocardiography,C0013516;C0149721
1272,lvh by echocardiogram,C0013516;C0149721;C2243117
1272,lvh - n = $nmbr$,C0149721
1272,lvh + n = $nmbr$,C0149721
1272,lvh ( from echocardiogram ),C0013516;C0149721;C2243117
1272,lvh,C0149721
1272,history of lvh on echocardiogram,C0013516;C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062;C2243117
1271,lv systolic dysfunction  n ( % ),C0023128;C0731033;C0749225;C1881413
1271,lv heart structure,C0018787;C0023128;C0731033;C1881413
1271,lv ejection fractionb,C0023128;C0302131;C0336969;C0731033;C0812388;C1881413
1271,lv ejection fraction > $nmbr$ % and < $nmbr$ %,C0023128;C0489482;C0731033;C1881413;C2700378
1271,lv ejection fraction ( % ),C0023128;C0489482;C0731033;C1881413;C2700378
1271,lv ejection fraction  % ( n = $nmbr$ ),C0023128;C0489482;C0731033;C1881413;C2700378
1271,lv ejection fraction,C0023128;C0489482;C0731033;C1881413;C2700378
1271,lv diastolic dysfunction  n ( % ),C0023128;C0520863;C0731033;C1881413
1271,latvia,C0023128
1270,ultra,C0728475
1270,lira,C1555441
1269,la diameter,C0023031;C0023749;C0230347;C1301886;C2346906;C4553351
1269,fev $nmbr$  la,C0023031;C0023749;C0230347;C2346906;C3714541;C4553351
1268,years since last gout flare,C0018099;C0439234;C1517205;C1517741;C3540542
1268,at least $nmbr$ severe flare,C0205082;C1517205;C3540542;C4050465;C4050466
1268,at least $nmbr$ flare,C1517205;C3540542
1267,class l / ll heart failure,C0018801;C0018802;C0456387;C1518526;C1705943;C4554158
1267,$nmbr$ . $nmbr$ ( ll . $nmbr$ ),
1266,lda  %,C4553195
1266,lb,
1266,glycoprotein llb / llla receptor inhibitor,C0017968;C0597357;C1999216
1266,glycoprotein llb / llla inhibitors,C0017968;C0243077
1266,glycoprotein llb / llia inhibitor,C0017968;C1999216
1266,glycoprotein llb / illa inhibitor,C0017968;C1999216
1266,ascot - lla,C0718674
1266,> $nmbr$ lb,
1266,< $nmbr$ lb,
1265,other llt use,C0042153;C0457083;C1947944;C2347090
1265,allhat - llt,C2347090
1264,p value ( int ),C1709380;C3272375
1264,p int . f,C0016327;C0369773;C2603361;C3272375
1264,p [ int ],C0369773;C2603361;C3272375
1264,p . b “ int,C1539794;C3272375
1264,p . b * int,C1539794;C3272375
1264,p - value ( int ),C1709380;C3272375
1264,p - int .,C0369773;C2603361;C3272375
1264,p - int,C0369773;C2603361;C3272375
1264,int . p *,C3272375
1263,nt - probnp pg / mla ( iqr ),C0030827;C0072225;C0599973;C0669479;C0754710;C1266240
1263,iqr,
1262,imt ( mm ),C0334121;C1704614;C4318736;C4330985;C4554674
1262,imt ( $nmbr$ ),C0334121;C1704614;C4318736
1262,carotid imt,C0334121;C0741968;C1704614;C4318736
1261,immunologic,C0152036;C0205470
1261,imm only,C0205171;C0205470;C1720467
1261,imm,C0205470
1260,umec $nmbr$ . $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
1260,tio $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
1260,sfc $nmbr$ / $nmbr$ | ig bid n = $nmbr$,C0021027;C0305052;C0360506;C4521536
1260,qva $nmbr$ $nmbr$ / $nmbr$ | ig od n = $nmbr$,C0021027;C0229089;C0305052;C0360506;C0439164;C1512019;C3273373;C3665488
1260,olodaterol $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0021027;C0305052;C0360506;C1518422;C4032878
1260,olodaterol $nmbr$ $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0021027;C0305052;C0360506;C1518422;C4032878
1260,igl ( n = $nmbr$ ),C0021037;C0314619;C2247518
1260,igg ( > $nmbr$ . $nmbr$ g / l )  %,C0439294;C0456615
1260,ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
1260,ff / vi $nmbr$ / $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0205999;C0305052;C0360506;C4554348
1260,ff $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506;C4554348
1260,air + ig ( n = $nmbr$ ),C0001861;C0021027;C0305052;C0360506;C3536832
1260,a . beuralizuinab $nmbr$ ing q $nmbr$ w,
1259,who / idf ifg,C1334085;C1708411
1259,igt or ifg,C1334085;C1708411
1259,igt / ifg,C1334085;C1708411
1259,ifg and igt,C1334085;C1708411
1259,ifg / igt,C1334085;C1708411
1259,ifg,C1334085;C1708411
1259,baseline ifg ( fpg $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l ) - n,C0168634;C1334085;C1442488;C1532563;C1708411
1259,ada ifg,C1060325;C1334085;C1708411;C3811629
1258,ivc ( n = $nmbr$ ),C4085887
1258,class iv only,C0205171;C0441888;C1720467;C2698970
1258,class iv glomerulonephritis,C0017658;C0441888;C2698970
1258,class iv,C0441888;C2698970
1257,total diuretic dose ( iv + oral ) on day $nmbr$  mg,C0012798;C0022326;C0439422;C0442027;C2986497;C4265176;C4521986
1257,nyha lll - iv,C0022326;C1261077;C1275491;C4265176
1257,nyha class iii or iv ( n = $nmbr$ ),C0022326;C1882086;C4265176
1257,nyha class iii or iv  n ( % ),C0022326;C1882086;C4265176
1257,lll / iv,C0022326;C1261077;C4265176
1257,lll - iv,C0022326;C1261077;C4265176
1257,killip class ii - iv  n ( % ),C0022326;C1710602;C2697845;C2697847;C4082587;C4265176
1257,iv ( n z $nmbr$ ),C0022326;C4265176
1257,iv ( $nmbr$ ),C0022326;C4265176
1257,iv,C0022326;C4265176
1257,iii or iv,C0022326;C0439070;C1705160;C4265176
1257,iii and iv ejection fraction,C0022326;C0439070;C0489482;C1705160;C2700378;C4265176
1257,iii and iv,C0022326;C0439070;C1705160;C4265176
1257,iii / iv,C0022326;C0439070;C1705160;C4265176
1257,iii - iv,C0022326;C0439070;C1705160;C4265176
1257,iii & iv,C0022326;C0439070;C1705160;C4265176
1257,ii - iv ( % ),C0022326;C1710602;C4082587;C4265176
1257,ii - iv,C0022326;C1710602;C4082587;C4265176
1257,ii ( $nmbr$ ),
1257,gold iii - iv,C0018026;C0022326;C0439070;C1304897;C1705160;C4265176
1257,dual iv,C0022326;C0205173;C1554184;C4265176
1257,class ll - iv,C0022326;C0456387;C1518526;C1705943;C4265176
1257,class iv / iv - v,C0022326;C0457166;C1880098;C4265176
1257,ciass ll - iv,C0022326;C4265176
1257,angina class iii or iv — no . ( % ),C0022326;C0264677;C4265176
1257,angina class iii or iv prior,C0022326;C0264677;C0332152;C2826257;C4265176
1256,ifx treatment,C0020823;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1256,ifx + aza ( n = $nmbr$ ),C0004482;C0020823
1256,ifx ( n = $nmbr$ ),C0020823
1256,combination treatment ifx + aza,C0004482;C0020823;C0039798;C0087111;C0205195;C1522326;C1533734;C1705169;C1947911;C3538994;C3811910;C3887704
1256,$nmbr$ ix,C0015491
1255,idm,C0270221
1255,id genotype,C0009450;C0017431;C0600091;C1441613
1255,id ( n = $nmbr$ ),C0009450;C0600091;C1441613
1255,id,C0009450;C0600091;C1441613
1255,( id,C0009450;C0600091;C1441613
1254,time since ipf diagnosisa  mean years ( sd ),C0034069;C0040223;C0439234;C0444504;C1800706;C2347634;C2348143;C2699239;C3541383
1254,ipf,C0034069;C1800706
1253,of variation )  iu,C0049272;C0205419;C0439453;C0694756
1253,iu,C0049272;C0439453;C0694756
1253,insulin glargine dose at screening visit  iu,C0049272;C0178602;C0220908;C0220909;C0366513;C0439453;C0545082;C0694756;C0869039;C0907402;C1114758;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
1253,dose ( iu ),C0049272;C0178602;C0439453;C0694756;C0869039;C1114758
1252,iee at baseline : < $nmbr$ iu / l,C0168634;C0439457;C1442488
1252,> $nmbr$ to < $nmbr$ iu / l,C0439457
1252,> $nmbr$ iu / l,C0439457
1251,w eight ( k g ),C0205454;C0439267;C0597277;C1708601
1251,no body weight at randomization ( ixrs ),C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
1251,body weiqht,C0242821;C0460148;C1268086;C4082212
1251,body weighta  kg,C0022718;C0242821;C0439209;C0460148;C1268086;C4054209;C4082212
1251,body weight at randomization,C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
1251,body height ( cm ),C0005890;C0487985
1251,> $nmbr$ kg body weight at randomization,C0005910;C0022718;C0034656;C0242821;C0439209;C0460148;C1268086;C1305866;C2985844;C4054209;C4082212
1250,yes ( % ) weight [ kg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0005910;C0022718;C0043100;C0439209;C1305866;C1549445;C1704675;C1705104;C1705108;C1710701;C4054209
1250,weight — no . ( % ),C0005910;C0043100;C1305866;C1705104
1250,weight — kg cardiovascular history — no . ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C1880008;C4054209
1250,weight — kg ( median ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1250,weight of < $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1250,weight in kg  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1250,weight group  no . ( % ),C0005910;C0043100;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429
1250,weight category,C0005910;C0043100;C0683312;C1305866;C1705104;C3889287
1250,weight ab  %,C0005910;C0043100;C1305866;C1705104
1250,weight ^,C0005910;C0043100;C1305866;C1705104
1250,weight > $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1250,weight < $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1250,weight < $nmbr$ . $nmbr$ kg  n,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1250,weight < $nmbr$,C0005910;C0043100;C1305866;C1705104
1250,weight - kg  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1250,weight ( range ) ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1514721;C1705104;C2348147;C3542016;C4054209
1250,weight ( median [ iqr ] )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1250,weight ( kg }  median ( min  max },C0005910;C0043100;C0549183;C0876920;C1305866;C1532757;C1705104;C2347635;C2348144;C2939193
1250,weight ( kg ) bmi ( kg / m $nmbr$ ),C0005910;C0043100;C0369637;C0441923;C0578022;C1305866;C1319635;C1705104
1250,weight ( kg ) *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1250,weight ( kg )  median ( m / n  max ),C0005910;C0043100;C0549183;C0876920;C1305866;C1532718;C1705104;C2347635;C2348144;C2939193
1250,weight ( kg )  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1250,weight $nmbr$ - $nmbr$,C0005910;C0043100;C1305866;C1705104
1250,weight $nmbr$ +,C0005910;C0043100;C1305866;C1705104
1250,weight $ $nmbr$ . $nmbr$ kg  n,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1250,weight $ $nmbr$ . $nmbr$ kg  < $nmbr$ . $nmbr$ kg  n,C0005910;C0043100;C1305866;C1319635;C1705104
1250,weight # $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1250,weight  median ( iqr )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1250,weight  median ( interquartile range )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C1711350;C2347635;C2348144;C2939193;C4054209
1250,weight  mean ( sd ) lbs .,C0005910;C0043100;C0439219;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C3161851
1250,weight  mean ( sd )  kgb,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239
1250,weight  lbs,C0005910;C0043100;C0439219;C1305866;C1705104;C3161851
1250,weight  kg duration of pah  n ( % ),C0005910;C0022718;C0030123;C0043100;C0439209;C0449238;C1305866;C1705104;C2926735;C3203102;C4054209;C4284467
1250,weight  kg $nmbr$,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1250,weight  kg  median ( range ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1514721;C1705104;C2347635;C2348144;C2348147;C2939193;C3542016;C4054209
1250,weight,C0005910;C0043100;C1305866;C1705104
1250,per body weight  u / kg,C0005910;C1300561;C1305866
1250,male sex — no . ( % ) weight — no . ( % ),C0005910;C0043100;C0086582;C1305866;C1705104
1250,healthy weight,C0005910;C0043100;C1305866;C1705104;C3898900
1250,electrophysiological study — no . ( % ) weight — ibj,C0005910;C0043100;C0850293;C1305866;C1705104
1250,dose / weight ( iu / kg ),C0005910;C0043100;C0178602;C0439463;C0869039;C1114758;C1305866;C1705104
1250,data are number of patients ( % ) or hazard ratio ( $nmbr$ % cl )  p values are forthe test of heterogeneity . cad = coronary artery disease . bmi = body - mass index  which is weight in kg divided by the square of height in metres . ldl = low - density lipoprotein . hdl = high - density lipoprotein . there is a deficit of clinical data in some patients with the events .,C0005910;C0018787;C0019409;C0022718;C0022885;C0023820;C0023821;C0030705;C0039593;C0042295;C0043100;C0162429;C0178587;C0205120;C0205251;C0242960;C0332849;C0392366;C0439209;C0441471;C0456984;C0475209;C0489786;C0596019;C0852949;C1305855;C1305866;C1504769;C1511726;C1515976;C1516606;C1550472;C1552595;C1705104;C2239547;C2360800;C2985465;C2987487;C3245479;C3541888;C3714741;C3813548;C3831328;C3890211;C4048187;C4054209;C4284121;C4318744;C4321351;C4522223
1250,body weight reduction > $nmbr$ %,C0005910;C0242821;C0301630;C0392756;C0460148;C1262477;C1268086;C1293152;C1305866;C4082212;C4551656
1250,body weight index ( kg / m $nmbr$ ),C0005910;C0600653;C0918012;C1305866;C1532718;C1552854;C1637833;C2986546
1250,body weight at randonization { ixrs ),C0005910;C1305866
1250,body weight *,C0005910;C1305866
1250,body weight ( kg )  mean ( sd ),C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
1250,body weight ( kg )  mean ( s . d . ),C0005910;C0444504;C1275571;C1305866;C2347634;C2348143
1250,body weight  mean ± sd  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
1250,body weight  %,C0005910;C1305866
1250,body weight,C0005910;C1305866
1250,> $nmbr$ ( n  % ) weight  kg,C0005910;C0022718;C0043100;C0369718;C0439209;C0441922;C1305866;C1705104;C4054209
1249,height — cm,C0489786
1249,height loss ( cm ),C0424641
1249,height loss,C0424641
1249,height ( cm ) ( mean ± sd ),C0444504;C0489786;C2347634;C2348143;C2699239
1249,height ( cm )  mean ( sd ) a,C0444504;C0489786;C2347634;C2348143;C2699239
1249,height ( cm )  mean ( s . e . ),C0439392;C0444504;C0489786;C2347634;C2348143
1249,height ( cm ),C0489786
1249,height '  cm,C0489786
1249,height  mean ( sd )  cm,C0444504;C0489786;C2347634;C2348143;C2699239
1249,height  inches,C0439204;C0489786
1249,height  cm *,C0489786
1249,height  cm ( mean ± s . d . ),C0439392;C0444504;C0489786;C2347634;C2348143
1249,height  cm  mean ( sd ),C0444504;C0489786;C2347634;C2348143;C2699239
1249,height  cm,C0489786
1249,baseline height ( cm ),C0168634;C0489786;C1442488
1248,overweight ( bmi £ $nmbr$ to < $nmbr$ ),C0497406;C0578022
1248,overweight ( bmi = $nmbr$ - $nmbr$ . $nmbr$ ),C0497406;C0578022
1248,overweight ( $nmbr$ to < $nmbr$ kg / m $nmbr$ ),C0497406;C1532718
1248,overweight,C0497406
1248,lisinopril vs chlorthalidone overweight,C0008294;C0065374;C0497406
1248,bmi $nmbr$ – $nmbr$ overweight,C0497406;C0578022
1248,$nmbr$ - $nmbr$ . $nmbr$ : overweight,C0497406
1248,$nmbr$ - $nmbr$ - $nmbr$  overweight,C0497406
1247,p value ( cangrelor versus clopidogrel in women ),C0043210;C0070166;C1121991;C1709380
1247,p value ( cangrelor versus clopidogrel in men ),C0025266;C0070166;C1121991;C1709380
1247,cangrelor n / n ( % ),C1121991
1247,cangrelor clopidogrel no . of events / total no . ( % ),C0070166;C0439175;C0439810;C0441471;C1121991;C3541888
1247,cangrelor ( n = $nmbr$ ) n / n ( % ),C1121991
1247,cangrelor ( n = $nmbr$ ),C1121991
1247,cangrelor  %,C1121991
1247,cangrelor,C1121991
1246,ticagrelor in ‐ hosp ( n = $nmbr$ ),C1999375
1246,prehospital ticagrelor ( n = $nmbr$ ),C1999375
1246,in hospital ticagrelor,C0019994;C1510665;C1999375
1246,in - hospital ticagrelor ( n = $nmbr$ ),C0019994;C1510665;C1999375
1245,posterior circulation,C0005775;C0205095;C1516559
1245,inferior or posterior,C0205095;C0542339;C0678975
1245,inferior / posterior,C0205095;C0542339;C0678975
1245,inferior ( n  % ),C0542339;C0678975
1245,inferior ( % ),C0542339;C0678975
1245,inferior,C0542339;C0678975
1245,anterior circulation,C0005775;C0205094;C1516559
1244,not anterior,C0205094;C1518422
1244,non - anterior,C0205094;C1518422
1244,infarct location anterior,C0021308;C0205094;C0450429;C1515974;C4284930;C4284931
1244,anterior { % ),C0205094
1244,anterior or non - anterior ml,C0205094;C0439526;C1518422;C1705224;C3887665
1244,anterior ( n  % ),C0205094
1243,nonanterior,
1243,left anterior descending coronary artery,C0226032
1243,left anterior descending artery  n ( % ),C0226032
1243,left anterior descending artery,C0226032
1243,left anterior descending  n ( % ),C0205386;C0441998;C1547177
1243,left anterior descending,C0205386;C0441998;C1547177
1243,l eft anterior descending coronary artery,C0226032;C0439394;C0451214;C1706495;C3642217
1243,l eft anterior descending,C0205094;C0205386;C0439394;C0451214;C1547177;C1706495;C3642217
1243,anterior,C0205094
1242,time - to - first infusion,C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
1242,time - to - first - infusion from hip surgery ( days )  n ( % ),C0040223;C0205435;C0439228;C0574032;C0596706;C1279901;C1827465;C3541383
1242,no . of infusions,C0574032
1242,median infusions — no . ( range ),C0549183;C0574032;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1242,glyceryl trinitrate infusion,C0017887;C0574032;C1827465
1242,core study to first infusion,C0205435;C0444669;C0557651;C0574032;C1167518;C1279901;C1706352;C1827465;C1882467;C2603343;C3274653
1242,c $nmbr$ e $nmbr$ fab bolus and infusion ( n = $nmbr$ ),C0574032;C1186706;C1511237;C1705509;C1827465;C3812160
1242,bolus and infusion,C0574032;C1186706;C1511237;C1705509;C1827465;C3812160
1242,and infusion,C0574032;C1827465
1241,transfusions,C0005841;C0199960;C1879316
1241,transfusion ≥ $nmbr$ units rbcs or whole blood,C0005841;C0014792;C0199960;C0229664;C0370231;C0439148;C1519795;C1546552;C1608383;C1879316;C3853603
1241,transfusion,C0005841;C0199960;C1879316
1241,blood transfusion,C0005841;C0281867
1241,any blood transfusion,C0005841;C0281867
1241,any blood product transfusion,C0005841;C0199960;C0281867;C0456388;C1514468;C1547007;C1704444;C1879316
1240,tnfi naive,
1240,tnfi - naive,
1240,acei vs . non - acei,C1518422
1240,acei,
1240,# of prior tnfi among non - tnfi naive,C0332152;C1518422;C2826257
1239,non – small - cell lung cancer,C0007131;C2984258;C3539721
1239,non - carrier ( n = $nmbr$ ),C2986416
1239,cancert,
1238,no known frtrontxtfufoc cond aon,C0205309;C1856054;C2826243;C4597943
1238,known tiromtcch * c ccndifeon,C0205309
1238,known t ' rc - iitoji cccndilon,C0205309;C1167159;C1419366
1237,omega - $nmbr$ fatty acids,C0015684;C1719844
1237,omega - $nmbr$ fatty acid ( n = $nmbr$ ),C0015684;C1719844
1237,omega - $nmbr$ fatty acid,C0015684;C1719844
1237,number omega - $nmbr$ number placeb fatty acid,C0015684;C0237753;C0449788;C1719844
1237,fatty acid profile,C0015684;C1979963;C2003903
1237,fatty acid group ( n = $nmbr$ ),C0015684;C0441848
1237,a mini - mental state examination  omega - $nmbr$ fatty acids vs placebo,C0015684;C0032042;C0451306;C1696465;C1706408;C1719844
1236,thromboaspiration,
1236,fatty acid composition,C0015684;C0486616;C1555710
1235,therapy - fatigue ( facit - f  $nmbr$ - $nmbr$ ),C0015672;C0039798;C0087111;C1363945;C3272505;C3463815;C4050243;C4554645
1235,taci ( n = $nmbr$ ),C0666480;C1425349;C4284230
1235,taci,C0666480;C1425349;C4284230
1235,paci ( n = $nmbr$ ),C1165245
1235,paci,C1165245
1235,facit - f,C3272505
1234,zoledronic acid arm,C0257685;C0446516;C3715044;C4553528
1234,zoledronic acid ( n = $nmbr$ ),C0257685
1234,zoledronic acid,C0257685
1234,serum uric acid  n,C0455272;C0700634
1234,bempedoic acid ( n = $nmbr$ ),C3659310
1234,bempedoic,
1234,baseline mean serum uric acid  pmol / l ( sd ),C0168634;C0439284;C0444504;C0455272;C0700634;C1442488;C2347634;C2348143;C2699239
1233,cad and abi < $nmbr$ - $nmbr$ §,C1328319;C1504769;C2239547;C3813548;C3888326;C4284121
1233,baseline abi  affected limb,C0015385;C0168634;C0392760;C1314939;C1328319;C1442488;C3888326
1233,ankle / brachial index,C1328319;C3888326
1233,ankle - brachial index £ $nmbr$ . $nmbr$,C1328319;C3888326
1233,ankle - brachial index < $nmbr$ . $nmbr$ — no . ( % ),C1328319;C3888326
1233,ankle - brachial index < $nmbr$ . $nmbr$,C1328319;C3888326
1233,abi > $nmbr$ . $nmbr$,C1328319;C3888326
1233,abi < $nmbr$ . $nmbr$,C1328319;C3888326
1233,abi # $nmbr$ . $nmbr$,C1328319;C3888326
1233,abi,C1328319;C3888326
1232,perindopril - indapamide,C1273169
1232,pctindopnl - indapamide ( n = $nmbr$ ),C0021186
1231,lce — l - dopa / carbidopa / entacapone  lc — l - dopa / carbidopa  pd — parkinson disease  updrs — rating scale  adl — activities of daily living  pdq - $nmbr$ — parkinson disease questionnaire .,C0001288;C0030567;C0034394;C0165921;C0353697;C0441655;C0681889;C1420005;C1423759;C1521736;C3273355;C3639721;C4552744
1231,l - dopa / carbidopa - l - dopa / carbidopa / entacapone,C0165921;C0353697
1231,entacapone,C0165921
1230,pdq - $nmbr$,
1230,paod,
1230,mean duration of pd  yr,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C4553228;C4553229
1230,duration of procedure,C2346509
1230,duration of pd  y,C0449238;C2926735;C4553228;C4553229
1230,duration of paod ( years )  mean ± sd,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1229,non - dihydropyridine ccbs,C0006684;C0012315;C0220821;C1518422
1229,dihydropyridine,C0012315;C0220821
1228,dipyridamole alone,C0012582;C0205171;C0439044;C0679994
1228,dipyridamole,C0012582
1227,without dyspnoea,C0013404;C1963100
1227,with dyspnoea,C0013404;C1963100
1227,no dyspnoea ( n = $nmbr$ ),C0013404;C1963100
1227,mmrc dyspnea scale score : t : t,C0013404;C1963100;C3826977;C4049715
1227,mmrc dyspnea scale  n ( % ),C0013404;C0175659;C0349674;C1947916;C1963100;C3826977
1227,dyspnoea ( n = $nmbr$ ),C0013404;C1963100
1227,dyspnea t,C0013404;C1963100
1227,dyspnea  frequent / continuous,C0013404;C0332183;C0549178;C1963100
1227,dyspnea  % ( frequent / continuous ),C0013404;C0332183;C0549178;C1963100
1227,dyspnea,C0013404;C1963100
1227,clopidogrel dyspnoea vs no dyspnoea *,C0013404;C0070166;C1963100
1227,cangrelor dyspnoea vs no dyspnoea *,C0013404;C1121991;C1963100
1226,pnd,C1417807;C1956415;C4552608
1226,paroxysmal nocturnal dyspnea,C1956415
1225,rivaroxaban plus aspirin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0004057;C0332287;C1739768
1225,rivaroxaban plus aspirin ( n = $nmbr$ ),C0004057;C0332287;C1739768
1225,rivaroxaban plus aspirin ( $nmbr$ % cl ),C0004057;C0332287;C0596019;C1739768
1225,rivaroxaban plus,C1739768
1225,rivaroxaban + aspirin,C0004057;C1739768
1225,rivaroxaban +,C1739768
1225,rivaroxaban ( n   = $nmbr$ ),C1739768
1225,rivaroxaban ( n = $nmbr$ ),C1739768
1225,rivaroxaban $nmbr$ mg,C0024671;C0026410;C0439269;C1739768;C1960952;C2346927;C4321396;C4521761
1225,rivaroxaban,C1739768
1225,low - dose rivaroxaban plus aspirin ( n = $nmbr$ ),C0332287;C1739768;C2608320
1225,low - dose rivaroxaban + aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1739768;C2608320
1225,low - dose rivaroxaban + aspirin ( n / n ),C1739768;C2608320
1224,apixaban vs . placebo,C0032042;C1696465;C1706408;C1831808
1224,apixaban dose ( or matching placebo ),C0032042;C0150103;C0178602;C0869039;C1114758;C1696465;C1706408;C1708943;C1831808
1224,apixaban ( n = $nmbr$ ),C1831808
1224,apixaban,C1831808
1223,tolvaptan ( n = $nmbr$ ),C1176308
1223,tolvaptan,C1176308
1223,placebo tolvaptan ( $nmbr$ mg ) ( n $nmbr$ $nmbr$ ) ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0032042;C0439269;C1176308;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
1222,fluvastatin ( n = $nmbr$ ),C0082608
1222,fluvastatin $nmbr$ mg,C0024671;C0026410;C0082608;C0439269;C1960952;C2346927;C4321396;C4521761
1221,plasma triglyceride — mg / dl,C0032105;C0041004;C0439269;C1550098;C4521445
1221,plasma lipoproteins  mmol / l,C0023820;C0032105;C1532563;C1550098;C4521445
1221,plasma creatine  mg / dl,C0010286;C0032105;C0439269;C1550098;C4521445
1220,lower dose edoxaban regimen,C0441994;C1548802;C2003888;C2348331;C2975435
1220,low - dose edoxaban ( n = $nmbr$ ),C0445550;C1708745;C2975435
1220,low - dose edoxaban,C0445550;C1708745;C2975435
1220,hr with edoxaban ( $nmbr$ % ci ),C0008107;C2975435;C3259781
1220,higher dose edoxaban regimen,C0205250;C2348331;C2975435
1220,edoxaban n = $nmbr$ n / n ( % ),C2975435
1220,edoxaban n = $nmbr$,C2975435
1220,edoxaban n / n  rate ( % ),C0871208;C1521828;C2975435
1220,edoxaban ( n = $nmbr$ ),C2975435
1220,edoxaban,C2975435
1219,doxazosin group,C0114873;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1219,doxazosin,C0114873
1218,rv and pulmonary vascular,C0035190;C0459963;C1508661;C3889272
1218,endovascular — no . ( % ),C0524425
1218,endovascular,C0524425
1217,ventricular tachycardia or fibrillation,C0042514;C0232197;C0344428;C1963247;C4554446
1217,ventricular tachyarrhythmias,C3827656
1216,lacunar infarction  n ( % ),C0333559
1216,lacunar,C0241970;C1459585
1215,glomerular,C0022663;C0268731
1215,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C3811844
1215,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area §,C0017446;C0205146;C0369637;C0439445;C0441923;C0489451;C3811844
1215,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
1215,estimated glomerular filtration rate §,C3811844
1215,estimated glomerular filtration rate | |,C3811844
1215,estimated glomerular filtration rate ^,C3811844
1215,estimated glomerular filtration rate < $nmbr$,C3811844
1215,estimated glomerular filtration rate - ml / min / $nmbr$ . $nmbr$ m $nmbr$ tt,C0369637;C0439445;C0441923;C1452561;C3811844;C4554543
1215,estimated glomerular filtration rate - ml / min  median ( iqr ) ',C0439445;C0549183;C0876920;C2347635;C2348144;C2939193;C3811844
1215,estimated glomerular filtration rate  n ( % ),C3811844
1215,estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ) §,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143;C2699239;C3811844
1215,estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
1214,patients with microvascular complications  n ( % ),C0009566;C0030705;C0443258;C1171258
1214,microvascular complicationsb,C0443258
1214,microvascular complications  n ( % ) ’,C0009566;C0443258;C1171258
1213,• urgent coronaiy revascularization > $nmbr$ days,C0439228;C0439609;C0581603;C3272275
1213,with revascularisation,C0581603
1213,urgent revascularisation due to unstable angina,C0002965;C0439609;C0581603;C0678226;C3272275
1213,revascularization in $nmbr$ days,C0439228;C0581603
1213,revascularization during index hospitalization  %,C0019993;C0581603;C0600653;C0918012;C1552854;C1637833;C2986546
1213,revascularization,C0581603
1213,revascularisation  n ( % ),C0581603
1213,prior revascularization ( n = $nmbr$  $nmbr$ ),C0332152;C0581603;C2826257
1213,prior revascularization ( % ),C0332152;C0581603;C2826257
1213,prior revascularization,C0332152;C0581603;C2826257
1213,peripheral arterial revascularization,C0003842;C0205100;C0221464;C0581603
1213,no revascularisation,C0581603
1213,no prior revascularization ( n = $nmbr$  $nmbr$ ),C0332152;C0581603;C2826257
1213,arterial revascularization,C0003842;C0221464;C0581603
1213,any revascularization,C0581603
1213,any peripheral revascularization,C0205100;C0581603
1213,$nmbr$ days urgent revascularization,C0439228;C0439609;C0581603;C3272275
1212,with rehospitalization  urgent coronary revascularization,C0439609;C0877341;C3272275
1212,urgent revascularizati on,C0439609;C3272275
1212,urgent coronary revascularization,C0439609;C0877341;C3272275
1212,cvd / mi / stroke / urgent coronary revascularization,C0007222;C0038454;C0439609;C0877341;C3272275;C3810814;C4554100
1211,vora,
1211,korean,C1556095
1211,korea,C0022771
1211,forearm fracture,C1305215
1211,forearm,C0016536
1211,distal forearm,C0588203
1210,median fecal calprotectin — mg / kg gi areas involved — no . ( % ),C0015733;C0205146;C0439272;C0549183;C0876920;C0950624;C1314939;C1335798;C1366582;C1708130;C2347635;C2348144;C2939193;C3539617;C4050121;C4319729
1210,involved intestinal area  n ( % ),C0021853;C1879646
1210,intestinal area involved — no . ( % ),C0017446;C0021853;C0205146;C1314939
1210,intestinal area involved  n ( % ) $,C0017446;C0021853;C0205146;C0369718;C0441922;C1314939
1210,colonic area involved,C0009368;C0017446;C0205146;C1314939
1210,areas,C0205146;C4319729
1210,agea,
1210,affected body - surface area > $nmbr$ % — no . { % ),C0005902;C0205148;C0392760;C1314939;C1879646
1209,olmesartan along with diuretic ( n - $nmbr$ ),C0012798;C1098320
1209,olmesartan ( n = $nmbr$ ),C1098320
1209,irbesartan ( n = $nmbr$ ),C0288171
1209,irbesartan,C0288171
1208,other - candesartan,C0717550
1208,candesartan group ( n = $nmbr$ ),C0441848;C0717550
1208,candesartan $nmbr$ / $nmbr$,C0717550
1208,candesartan,C0717550
1208,aceis  angiotensin - converting enzyme inhibitors  c  candesartan  des  drug - eluting stent  egfr  estimated glomerular filtration rate  hdl  high - density lipoprotein  ldl  low - density lipoprotein  nc  non - candesartan .,C0003015;C0011702;C0013227;C0017654;C0023821;C0023823;C0027964;C0028407;C0038257;C0067895;C0265987;C0717550;C0750572;C1254351;C1518422;C1561549;C1739039;C2757044;C3811844;C3812682;C4551552
1207,serum creatinine concentration and randomization to losartan,C0010294;C0034656;C0086045;C0126174;C0201976;C0600061;C0683149;C1446561;C1561535;C3827302
1207,p ( losartan versus placebo ),C0032042;C0126174;C0369773;C1696465;C1706408;C2603361
1207,losartan plus placebo ( n = $nmbr$ ),C0032042;C0126174;C0332287;C1696465;C1706408
1207,losartan n = $nmbr$,C0126174
1207,losartan + placebo,C0032042;C0126174;C1696465;C1706408
1207,losartan ( n = $nmbr$ ),C0126174
1207,losartan ( n = $nmbr$  $nmbr$ ),C0126174
1207,losartan  n / n ( % ),C0126174
1207,losartan,C0126174
1207,atenolol - losartan,C0004147;C0126174
1207,adjusted hr losartan vs atenolol *,C0004147;C0126174;C0456081
1207,adjusted $nmbr$ risk reduction losartan vs placebo ( $nmbr$ % cl ),C0032042;C0126174;C0456081;C0596019;C1137094;C1696465;C1706408
1206,valsartan n / n,C0216784
1206,valsartan / hctz ( n = $nmbr$ ),C0020261;C0216784
1206,valsartan / hctz  n / n ( % ),C0020261;C0216784
1206,valsartan / hctz,C0020261;C0216784
1206,valsartan ( n = $nmbr$ ),C0216784
1206,valsartan  n / n ( % ),C0216784
1206,valsartan  n ( % ),C0216784
1206,valsartan,C0216784
1206,sacubitril / valsartan ( n = $nmbr$ ),C4033631
1206,sacubitril / valsartan,C4033631
1206,hazard ratio ( $nmbr$ % cl ) valsartan vs . placebo,C0032042;C0216784;C0596019;C1696465;C1706408;C2985465
1206,amlodipine and valsartan,C0051696;C0216784
1205,telmisartan group ( n = $nmbr$ ),C0248719;C0441848
1205,telmisartan ( n = $nmbr$ ),C0248719
1205,telmisartan ( n = $nmbr$  $nmbr$ ),C0248719
1205,telmisartan,C0248719
1205,randomization to placebo or telmisartan,C0032042;C0034656;C0248719;C1696465;C1706408
1204,legend,C2729544
1204,any dynamic st - segment shift,C0333051;C0429029;C0729333;C2347509
1203,self - reported descent  n ( % ),C0205386;C0369718;C0441922;C0680043;C0681906;C2700446
1203,descent,C0205386;C0680043
1203,african descent,C0027567;C0205386;C0680043
1202,requiring assistance,C0018896;C1269765
1202,events requiring assistance,C0018896;C0441471;C1269765;C3541888
1202,$nmbr$ = help needed  still independent,C0027552;C0085862;C0686904;C1269765;C1290940;C1299583;C1552861
1201,fixed triple ( n = $nmbr$ ),C0205174;C0443218;C2827483;C3714578
1201,adhere,C3714578
1200,verifynow pru - defined hpr ( % patients ),C0030705;C1337105;C1704788;C3539106
1200,vasp pri - defined hpr ( % patients ),C0030705;C0034044;C0255567;C1337105;C1421428;C1704788;C1826843;C3539106;C3539761;C3539762
1200,other defined,C1704788;C3539106
1200,lta ( max response to $nmbr$ pm adp ) defined hpr ( % patients ),C0030266;C0030705;C0523452;C1337105;C1704788;C2611142;C3539106;C4049155
1199,none or diet,C0012155;C0012159;C1519433;C2983588;C3668949
1199,hr is < $nmbr$ if pravastatin is better than diet alone,C0012155;C0012159;C0085542;C0205171;C0332272;C0439044;C0679994;C1519433;C2983588;C3668949;C4522046
1199,diet plus pravastatin group ( n = $nmbr$ ),C0012155;C0012159;C0085542;C0332287;C0441848;C1519433;C2983588;C3668949
1199,diet only,C0012155;C0012159;C0205171;C1519433;C1720467;C2983588;C3668949
1199,diet group ( n = $nmbr$ ),C0012155;C0012159;C0441848;C1519433;C2983588;C3668949
1199,diet group,C0012155;C0012159;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
1199,diet diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1199,diet and exercise,C0012155;C0012159;C0015259;C1519433;C1522704;C2983588;C3668949
1199,diet alone,C0012155;C0012159;C0205171;C0439044;C0679994;C1519433;C2983588;C3668949
1199,diet - i - pravastatin ( n = $nmbr$ ),C0012155;C0012159;C0021966;C0085542;C0221138;C1519433;C2983588;C3668949
1199,diet + pravastatin group,C0012155;C0012159;C0085542;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
1199,diet + pravastatin ( n = $nmbr$ ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1199,diet + pravastatin $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1199,diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1199,diet ( n 二 $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
1199,diet ( n = $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
1199,diet $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
1199,diet,C0012155;C0012159;C1519433;C2983588;C3668949
1198,safety variable,C0036043;C0439828;C1705187;C4553760
1198,safety : non - cabg - related bleeding,C0010055;C0019080;C0036043;C0439849;C0445223;C1518422;C1705187
1198,safety    n   ( % ) b,C0036043;C1705187
1198,safety  %,C0036043;C1705187
1198,primary safety outcome -,C0036043;C0205225;C0439612;C0439631;C1274040;C1705187
1197,spirometry,C0037981
1197,spirometric values at baseline,C0037981;C0042295;C0168634;C0183441;C1442488
1197,baseline spirometry,C0037981;C0168634;C1442488
1196,left atrial diameter : < $nmbr$ mm ( n = $nmbr$ ),C0225860;C0225861;C1301886;C4330985;C4554674
1196,left atrial diameter  mm ( sd ),C0225860;C0225861;C1301886;C2699239;C4330985;C4554674
1196,left atrial diameter,C0225860;C0225861;C1301886
1196,left atrial anteroposterior diameter — mm,C0225860;C0225861;C1301886;C4330985;C4554674
1196,degree of stenosis  % of diameter,C1301886;C4034225
1195,type ii diabetes,C0011860
1195,mod / sev exacerbation rates,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
1195,mod / sev exacerbation rate,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
1195,diabetes type ii  n ( % ),C0011860
1194,sample size ( n ),C0242618
1194,sample size  n ( % ) by treatment,C0037793;C0039798;C0087111;C0242618;C0456389;C1522326;C1533734;C1705169;C3538994;C3887704
1194,sample size  n,C0242618
1194,sample size,C0242618
1194,effect size ^,C0814843
1194,effect size !,C0814843
1193,us site,C0205145;C1515974;C2825164
1193,u . s . sites,C0041703;C0205145
1193,u . s . site,C0041703;C0205145;C1515974;C2825164
1193,sites,C0205145
1193,site,C0205145;C1515974;C2825164
1193,internal carotid artery sites,C0007276;C0205145
1193,fractures ( site not specified ),C0016658;C0205145;C0205369;C1515974;C1518422;C2825164
1193,disease site — no . of patients ( % ) |,C0012634;C0030705;C0205145;C1515974;C2825164
1193,disease site — no . ( % ) ^,C0012634;C0205145;C1515974;C2825164
1193,disease site  n [ % ],C0012634;C0205145;C1515974;C2825164
1193,critical site,C0205145;C1511545;C1515974;C2825164
1193,common carotid artery sites,C0007272;C0162859;C0205145
1193,carotid bulb sites,C0007281;C0205145
1193,any site,C0205145;C1515974;C2825164
1193,$nmbr$ carotid artery sites,C0007272;C0162859;C0205145
1192,platelet  $nmbr$ / l,C0456525
1192,other antiplatelet agents  n ( % ),C0085826
1192,other antiplatelet agents,C0085826
1192,other antiplatelet,
1192,other anti - platelet agents,C0005821;C0040616
1192,other $nmbr$,
1192,aspirin or other antiplatelet agents,C0004057;C0085826
1192,aspirin or other antiplatelet agent,C0004057;C0085826
1192,aspirin / other antiplatelet agents  n ( % ),C0004057;C0085826
1191,use of antiplatelet agents — no . / total no . ( % ),C0085826;C0439175;C0439810;C1524063
1191,use of antiplatelet agents ^,C0085826;C1524063
1191,use of antiplatelet agents  n ( % ),C0085826;C1524063
1191,previous use of antiplatelet drugs,C0085826;C0205156;C1524063;C1552607;C2963157
1191,previous chronic use of antiplatelet drugs,C0085826;C0205156;C0205191;C1524063;C1552607;C2963157
1191,other antiplatelet agent 一 no . ( % ),C0085826
1191,aspirin orother antiplatelet drug,C0004057;C0013227;C0085826;C1254351
1191,aspirin or other antiplatelet drug,C0004057;C0085826
1191,asa or antiplatelet agent,C0004057;C0085826;C3853627
1191,antiplateletsa,
1191,antiplatelets agents,C0085826
1191,antiplatelets  any,
1191,antiplatelet drugs,C0085826;C2963157
1191,antiplatelet drug,C0085826
1191,antiplatelet agents ( % ),C0085826
1191,antiplatelet agents,C0085826
1191,antiplatelet agent n ( % ),C0085826
1191,antiplatelet agent,C0085826
1191,> $nmbr$ . $nmbr$ mg / liter antiplatelet agents,C0024671;C0026410;C0085826;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
1190,placebo / open - label abatacept,C0032042;C1619966;C1696465;C1706408;C1709323
1190,placebo - abatacept $nmbr$ / $nmbr$ - abatacept $nmbr$ / $nmbr$,C0032042;C1619966;C1696465;C1706408
1190,abatacept ‡,C1619966
1190,abatacept ~ $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
1190,abatacept plus mtx ( n = $nmbr$ ),C0025677;C1417487;C1619966
1190,abatacept monotherapy ( n = $nmbr$ ),C1619966
1190,abatacept / open - label abatacept,C1619966;C1709323
1190,abatacept ( n = $nmbr$ * ),C1619966
1190,abatacept $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
1190,abatacept $nmbr$ / — $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
1190,abatacept $nmbr$ / $nmbr$ ( n = $nmbr$ ),C1619966
1190,abatacept,C1619966
1189,intravenous vasodilators ( % ),C0443081
1189,intravenous vasoactive drugs  % y,C0683092;C1980011
1189,intravenous study drug administered — no . ( % ),C0013175;C0348016;C0557651;C0683092;C1521801;C2603343
1189,intravenous dobutamine,C0012963;C0348016
1189,intravenous anticoagulant during hospitalization,C0003280;C0019993;C0348016;C0848112;C3536711
1189,intravenous anticoagulant during hospitalisation *,C0003280;C0019993;C0348016;C0848112;C3536711
1189,intravenous ( n = $nmbr$ ),C0348016
1188,without antiplatelets,
1188,with antiplatelets,
1188,treatment with antiplatelet drugs,C3469597
1188,teaes,
1188,nsteacs,
1188,drug - related teaes *,C0013227;C0439849;C0445223;C1254351
1188,drug - related teaes $nmbr$,C0013227;C0439849;C0445223;C1254351
1188,drug - related teaes,C0013227;C0439849;C0445223;C1254351
1188,antidiabetes drug usage [ % ( n ) ],C0242510
1187,parameters at baseline,C0168634;C0449381;C1442488
1187,parameters,C0449381
1187,other lipid parameters,C0023779;C0449381
1187,lipid parameters,C0023779;C0449381
1187,hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0030705;C0168634;C0449381;C1442488;C4281788;C4684790
1187,glycaemic parameters,C0005802;C0449381
1187,biometric parameters,C0005544;C0449381;C2718322
1186,parameter mean ± s . d .,C0444504;C0549193;C1704769;C2347634;C2348143;C2350001
1186,parameter at baseline,C0168634;C0549193;C1442488;C1704769;C2350001
1186,parameter / variable,C0439828;C0549193;C1704769;C2350001;C4553760
1186,parameter ( mg / dl ),C0439269;C0549193;C1704769;C2350001
1186,parameter  n ( % ),C0549193;C1704769;C2350001
1186,parameter  % ( $nmbr$ % ci ),C0008107;C0549193;C1704769;C2350001;C3259781
1186,parameter,C0549193;C1704769;C2350001
1186,efficacy parameter,C0549193;C1280519;C1704769;C1707887;C2350001
1186,baseline parameter,C0168634;C0549193;C1442488;C1704769;C2350001
1186,$nmbr$ parameter,C0549193;C1704769;C2350001
1185,placebo - linagliptin,C0032042;C1696465;C1706408;C2746078
1185,linagliptin ( n z $nmbr$ ),C2746078
1185,linagliptin ( n = $nmbr$ ) ',C2746078
1185,linagliptin ( n = $nmbr$ ),C2746078
1185,linagliptin  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C2746078;C3541888
1185,linagliptin,C2746078
1185,incidence rate difference  linagliptin - placebo ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408;C1708485;C2746078
1185,comparator - linagliptin,C1707454;C2746078;C4553389;C4553390
1184,sitagliptin ± oad,C1565750
1184,sitagliptin no . / total no .,C0439175;C0439810;C1565750
1184,sitagliptin n = $nmbr$,C1565750
1184,sitagliptin ( n = $nmbr$ ),C1565750
1184,sitagliptin $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C4321396;C4521761
1184,sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ $nmbr$ - h postprandial plasma glucose ( ppg ) ( mmol / l ),C0202042;C0376674;C0455280;C1418888;C1565750;C2827804
1184,sitagliptin $nmbr$,C1565750
1184,sitagliptin,C1565750
1184,canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C2974540;C4321396;C4521761
1183,with alogliptin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1183,with alogliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1183,with alogliptin $nmbr$ . $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1183,with alogliptin $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1183,vildagliptin ( n = $nmbr$ ),C1570906
1183,vildagliptin $nmbr$ mg qd n = $nmbr$,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1183,vildagliptin $nmbr$ mg qd,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1183,vildagliptin $nmbr$ mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1183,vildagliptin $nmbr$ mg daily,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1183,vildagliptin $nmbr$ mg bid n = $nmbr$,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1183,vildagliptin $nmbr$ mg bid,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1183,vildagliptin,C1570906
1183,saxagliptin ( n = $nmbr$ ),C1611934
1183,saxagliptin ( n = $nmbr$  $nmbr$ ),C1611934
1183,saxagliptin ( % ),C1611934
1183,saxagliptin $nmbr$ mg ( n z $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1183,saxagliptin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1183,saxagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1183,saxagliptin $nmbr$ . $nmbr$ mg ( n z $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1183,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1183,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1183,saxagliptin $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1183,saxagliptin,C1611934
1183,saxagiiptin,
1183,alogliptin ( n = $nmbr$ ),C1958126
1183,alogliptin  n ( % ),C1958126
1183,alogliptin,C1958126
1183,allogliptin,
1182,empagllflozln,
1182,empagllflozin,
1182,empagliflozin n with event / n,C0441471;C3490348;C4019010
1182,empagliflozin ( n   =   $nmbr$ ),C3490348
1182,empagliflozin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C3490348
1182,empagliflozin ( n = $nmbr$ ),C3490348
1182,empagliflozin $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C3490348
1182,empagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
1182,empagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
1182,empagliflozin,C3490348
1182,$nmbr$ mg empagliflozin,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
1181,canagliflozin dose,C0178602;C0869039;C1114758;C2974540
1181,canagliflozin ( n = $nmbr$ ),C2974540
1181,canagliflozin,C2974540
1181,canagiiflozin,
1180,sotagliflozin ( n = $nmbr$ ),C3896939
1180,sotagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3896939;C4321396;C4521761
1180,sotagliflozin,C3896939
1180,ertugliflozin $nmbr$   mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin $nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin $nmbr$ mg vs placebo / glirneplride,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin $nmbr$ mg vs placebo / glinepiride,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0032042;C0061323;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin $nmbr$ mg vs placebo / giimepiride,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin $nmbr$ mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1180,ertugliflozin,C4079805
1180,dapagliflozint,
1180,dapagliflozin ( n = $nmbr$ ),C2353951
1180,dapagliflozin $nmbr$ mg + insulin ( n   = $nmbr$ ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
1180,dapagliflozin $nmbr$ mg + insulin ( n = $nmbr$ ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
1180,dapagliflozin  n *,C2353951
1180,dapagliflozin,C2353951
1180,dapaglifloiin  n *,
1179,serum haemoglobin a $nmbr$ c concentration ( % )  mean ( sd ),C0019020;C0444504;C0683149;C2347634;C2348143;C2699239;C3889898
1179,hemoglobin level  %,C0019029;C1314664
1179,hemoglobin concentration — g / liter,C0019029;C0086045;C0439267;C0475211;C1314664;C1318517;C1319312;C1446561;C3827302
1179,hemoglobin a ^ c  %,C0019020;C3889898
1179,hemoglobin a $nmbr$ c ( % ),C0019020;C3889898
1179,hemoglobin a $nmbr$ c  %,C0019020;C3889898
1179,hemoglobin a $nmbr$ c,C0019020;C3889898
1179,hemoglobin - a $nmbr$ c ( % ) ' • ■ * *,C0019020;C3889898
1179,glycated hemoglobin  n ( % ),C0062408;C3666909
1179,ct  calcitonin  cv  cardiovascular  egfr  estimated glomerular filtration rate  hbalc  glycated hemoglobin  h $nmbr$  histamine $nmbr$  iqr  interquartile range  n  number of patients  sd  standard deviation .,C0006668;C0007226;C0017654;C0019588;C0033727;C0062408;C0369286;C0441932;C0564385;C0750572;C0871420;C1561549;C1711350;C1739039;C2360800;C2699239;C3538987;C3666909;C3811844;C3812682;C3887460;C4048877;C4318503;C4528284
1178,hemoglobin ( g r $nmbr$ ),C0205090;C0684010;C1319312;C2603358
1178,hemoglobin ( g $nmbr$ ! ),C1319312
1178,hemoglobin  g / dlf,C1319312
1178,hemoglobin  g $nmbr$ $nmbr$,C1319312
1178,for baseline hemoglobin < $nmbr$ g $nmbr$ ',C0168634;C1319312;C1442488
1178,for baseline hemoglobin $nmbr$ g $nmbr$ ’,C0168634;C1319312;C1442488
1177,hemoglobin category,C0019046;C0683312;C3889287
1177,hemoglobin aj ^ ( % ),C0004486;C0019046;C0230613
1177,hemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
1177,hemoglobin  mg / dl,C0019046;C0439269
1177,hemoglobin  g / l,C0019046;C0439267;C0439294;C0456615;C0635222
1177,hemoglobin,C0019046
1177,haemoglobin ( mg / dl ),C0019046;C0439269
1177,haemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
1177,haemoglobin  mg / dl,C0019046;C0439269
1177,glyeated haemoglobin,C0019046
1177,baseline hemoglobin aj ^ values,C0004486;C0019046;C0042295;C0168634;C0230613;C1442488
1176,patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode ofdiabetic ketoacidosis *,C0017853;C0030705;C1859860
1176,mean glycated hemoglobin reduction during characteristic follow - up ( $nmbr$ % ci ) percent,C0017853;C0439165;C0444504;C0520870;C0589120;C1521970;C1522577;C1704685;C2347634;C2348143;C3274571
1176,glycosylated hemoglobin  %,C0017853
1176,glycated hemoglobin — % -,C0017853
1176,glycated hemoglobin — %,C0017853
1176,glycated hemoglobin | |,C0017853
1176,glycated hemoglobin < median,C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
1176,glycated hemoglobin - % ’,C0017853
1176,glycated hemoglobin ( % ),C0017853
1176,glycated hemoglobin  standardized level — %,C0017853;C0441889;C0456079;C1547707;C2946261
1176,glycated hemoglobin  median ( iqr ),C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
1176,glycated hemoglobin  %  mean ( sd ),C0017853;C0444504;C2347634;C2348143;C2699239
1176,glycated hemoglobin  %,C0017853
1176,glycated hemoglobin,C0017853
1176,glycated haemoglobin ( % ),C0017853
1176,glycated haemoglobin  %,C0017853
1176,baseline glycated hemoglobin ( % ),C0017853;C0168634;C1442488
1175,glycohemoglobin  %  mean ( sd ),C0202054;C0444504;C0696092;C2347634;C2348143;C2699239
1175,glycohemoglobin  %,C0202054;C0696092
1175,glycated hemoglobin level,C0202054
1175,glycated hemoglobin  nonstandardized level — %,C0202054
1174,modmy al randcnxzaton,C0202311
1174,iglar dose at randomization ( u / day ),C0034656;C0178602;C0456683;C0869039;C1114758
1174,iglar,
1174,ali,
1173,patients randomly assigned,C0030705;C1516050;C1552601
1173,indzgly,
1173,all randomly assigned,C1516050;C1552601
1172,enalapril + aliskiren dm = $nmbr$ non - dm = $nmbr$,C0011816;C0014025;C1120110;C1518422;C3250443
1172,aliskiren dm = $nmbr$ non - dm = $nmbr$,C0011816;C1120110;C1518422;C3250443
1172,aliskiren / valsartan ( n = $nmbr$ ),C2733073
1172,aliskiren ( n = $nmbr$ ),C1120110
1172,aliskiren ( dm - vs . dm + ),C0011816;C1120110;C3250443
1172,aliskiren,C1120110
1171,sulphonamides  urea derivatives,C0038760;C0041942;C0243072
1171,adamantane derivatives,C3653470
1170,mycophenolate ( any derivative ),C0883242;C1527240
1170,dilatative  n ( % ),C0002940;C0012359;C0700124;C1322279
1170,dilatative,C0002940;C0012359;C0700124;C1322279
1169,elective surgery,C0206058
1169,elective procedure,C0747973
1169,elective peripheral revascularization,C0205100;C0206058;C0439608;C0581603
1168,use of anti - hypertensive agents  n ( % ) *,C0432633;C0450442;C0857121;C1254351;C1521826;C1524063
1168,normotensive ( n = $nmbr$ ),C2712122
1168,hypertensive  n ( % ),C0857121
1168,hypertensive,C0857121
1168,anti - hypertensive treatment history  n ( % ),C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0432633;C0857121;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
1167,non - extensive,C0205231;C1518422
1167,no extensive colitis  n,C0009319;C0205231;C1963084
1167,extenswe,
1167,extensive colitisy,C0205231
1167,extensive colitis or pancolitis,C0009319;C0205231;C0868908;C1963084
1167,extensive colitis  n,C0009319;C0205231;C1963084
1167,extensive colitis,C0009319;C0205231;C1963084
1167,extensive  n ( % ),C0205231
1167,extensive,C0205231
1166,placebo - ezetimibe $nmbr$ / simvastatin $nmbr$ - fenofibrate $nmbr$ - ezetimibe $nmbr$ / simvastatin $nmbr$ / ezetimibe $nmbr$,C0032042;C0033228;C1532737;C1696465;C1706408
1166,ezetimibe / simvastatin - double dose statin - rosuvastatin,C0178602;C0205173;C0360714;C0869039;C0965129;C1114758;C1532737;C1705764;C1705765
1166,ezetimibe / simvastatin,C1532737
1166,ezetimibe + simvastatin ( n = $nmbr$ * ),C1532737
1166,ezetimibe + simvastatin ( n = $nmbr$  $nmbr$ * ),C1532737
1166,chd  coronary heart disease  eze / simva  ezetimibe / simvastatin combination tablet  fpg  fasting plasma glucose  pvd  peripheral vascular disease,C0010068;C0015663;C0039225;C0074554;C0085096;C0202042;C0455280;C1532737;C1705223;C4319774
1165,statins / ezetimibe,C0360714;C1142985
1165,statin with ezetimibe,C0360714;C1142985
1165,statin or ezetimibe,C0360714;C1142985
1165,statin and / or ezetimibe,C0360714;C1142985
1165,statin + ezetimibe { n = $nmbr$  $nmbr$ ),C0360714;C1142985
1165,statin + ezetimibe ( n = $nmbr$ . $nmbr$ ),C0360714;C1142985
1165,statin + ezetimibe  n ( % ),C0360714;C1142985
1165,statin + ezetimibe,C0360714;C1142985
1165,ezetimibe $nmbr$ mg + statin ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0360714;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
1165,ezetimibe  n ( % ),C1142985
1165,ezetimibe,C1142985
1164,sensitive responders ( n = $nmbr$ ),C0020517;C0332324;C1522640
1164,sensitive responder ( n = $nmbr$ ),C0020517;C0332324;C1522640
1164,sensitive,C0020517;C0332324;C1522640
1164,hypersensitivity  n ( % ),C0020517;C0520946
1164,highly sensitive responders ( n = $nmbr$ ),C0439822
1164,highly sensitive responder ( n = $nmbr$ ),C0439822
1164,highly sensitive,C0439822
1163,troponin positive ( n = $nmbr$ ),C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
1163,shared epitope  a % positive,C0003316;C0237876;C0439178;C1446409;C1514241;C1522138;C2825490;C3812269
1163,rheumatoid factor positive §  n ( % ),C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
1163,rheumatoid factor positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
1163,rheumatoid factor or acpa positive  or both,C0035448;C0201660;C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1163,rheumatoid factor and acpa positive,C0035448;C0201660;C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1163,rf or acpa positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1525410;C1547111;C1706063;C2825490;C3812269
1163,positive vs . negative,C0205160;C0439178;C1446409;C1513916;C1514241;C2825415;C2825490;C2825491;C3812269;C3853545
1163,positive troponin i or t  no . ( % ),C0077401;C0439178;C1446409;C1514241;C2603360;C2825490;C3812269
1163,positive for rheumatoid factor  anti - cyclic citrullinated peptide antibodies  or both — % ff,C0003241;C0035448;C0201660;C0439178;C0439596;C0741132;C1320283;C1446409;C1511572;C1514241;C2825490;C3812269;C4505301;C4554348
1163,positive ctnl ( n = $nmbr$ ),C0439178;C1446409;C1514241;C2825490;C3812269
1163,positive atopic status,C0392707;C0439178;C0449438;C1446409;C1514241;C2825490;C3812269
1163,positive,C0439178;C1446409;C1514241;C2825490;C3812269
1163,low complement / anti - dsdna positive ( n = $nmbr$ ),C0012854;C0311474;C0432633;C0439178;C1446409;C1514241;C2825490;C3812269;C3897137
1163,hla - b $nmbr$ positive at baseline  n ( % ),C0019737;C0168634;C0439178;C0550853;C1415561;C1442488;C1446409;C1514241;C2825490;C3812269
1163,hla - b $nmbr$ positive  n ( % ),C0439178;C1426226;C1446409;C1514241;C2825490;C3812269
1163,gad positive — no . ( % ) ^,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
1163,anticyclic citrullinated peptide positive ^  n ( % ),C0439178;C1320283;C1446409;C1514241;C2825490;C3812269
1163,anti - gad positive ( n = $nmbr$ ),C0270549;C0432633;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
1163,anti - gad positive,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
1163,anti - dsdna positive,C0439178;C0741099;C1446409;C1514241;C2825490;C3812269
1163,anti - ccp positive ( > $nmbr$ u / ml )  n ( % ),C0432633;C0439178;C0439340;C1446409;C1514241;C1525410;C1704514;C1880521;C2825490;C2945590;C3812269
1163,anti - ccp positive,C0439178;C1446409;C1514241;C2825490;C3812269;C4318437
1163,angina or positive stress test,C0002962;C0015260;C0439178;C1446409;C1514241;C2825490;C3494508;C3812269
1163,age is > $nmbr$ vrs  significant ecg changes  and positive biomarkers,C0001779;C0005516;C0237881;C0439178;C0458261;C0750502;C0855329;C1446409;C1514241;C1546944;C2825490;C3273608;C3812269
1163,acpa positive ( > $nmbr$ iu / ml )  n ( % ),C0439178;C0439458;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1163,acpa positive  no . ( % ),C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1163,acpa positive  n ( % ),C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1163,acpa positive  %,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1163,acpa positive,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1163,* * positive stress test,C0015260;C0439178;C1446409;C1514241;C2825490;C3494508;C3812269
1162,torsemide,C0076840
1162,furosemide equivalent  mg / kg,C0016860;C0205163;C0439185;C0439272
1162,furosemide,C0016860
1161,lacosamide,C0893761
1161,glucosamine + chondroitin sulfate ( n = $nmbr$ ),C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
1161,glucosamine ( n = $nmbr$ ),C0017718
1161,glucosamine,C0017718
1160,bumetanide,C0006376
1160,budesonide — no . ( % ),C0054201
1160,budesonide { symptom days a week ),C0054201;C0332174;C0439228;C0439230;C1457887;C3854129
1160,budesonide mmx $nmbr$ mg  ( n = $nmbr$ ),C0024671;C0026410;C0054201;C0439269;C1960952;C2346927;C4321396;C4521761
1160,budesonide ( symptom days a week ),C0054201;C0332174;C0439228;C0439230;C1457887;C3854129
1160,budesonide ( n = $nmbr$ ),C0054201
1160,budesonide $nmbr$ ^ g ( n = $nmbr$ ),C0054201;C0439267
1160,budesonide  n ( % ),C0054201
1160,budesonide,C0054201
1159,budesonide - formoterol ( n = $nmbr$ ),C1276807
1159,budesonide - formoterol $nmbr$ ^ g + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C1276807;C1319635
1159,budesonide - formoterol $nmbr$ + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C0439267;C1276807
1159,budesonide - budesonide / formoterol,C1276807
-10,leflunomide,C0063041
1157,glinide 一 no . ( % ),C2266929
1157,glinide,C2266929
1157,flecainide,C0016229
1156,nateglinide n / n,C0903898
1156,nateglinide and repaglinide,C0246689;C0903898
1156,nateglinide ( n = $nmbr$ ),C0903898
1156,meglitinides ( glinides ),C0065880;C1579432;C3537178
1156,meglitinide,C0065880
1155,placebo + glimepiride,C0032042;C0061323;C1696465;C1706408
1155,glipizide ( n = $nmbr$ ),C0017642
1155,glipizide,C0017642
1155,glimepiride,C0061323
1155,ertuglrflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0032042;C0061323;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
1155,eduglinozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0032042;C0061323;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
1154,fasting c - peptide ( nmol / l ) c,C0006558;C0015663;C0439282
1154,c peptide  nmol / l * ',C0006558;C0439282
1154,c - peptide tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0006558;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952
1154,c - peptide,C0006558
1153,glucagon - like peptide - $nmbr$ receptor agonist,C0014361;C4543206
1153,glucagon - like peptide - $nmbr$ agonist,C0014361;C2987634
1152,hscrp at baseline,C0168634;C1442488
1152,hscrp,
1152,b - blockers at baseline,C0168634;C1442488
1152,( $nmbr$ - blockers,
1151,lc  n = $nmbr$,
1151,hbalc tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952
1151,hbalc > $nmbr$ %,
1151,baseline ldl - c > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc,C0168634;C0439190;C1442488
1151,baseline ldl - c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc,C0168634;C0439190;C1442488
1151,baseline hbalc > $nmbr$ % to < $nmbr$ %,C0168634;C1442488
1150,nsclc,C0007131
1150,muscle twitching,C0015644;C0231530
1150,muscle spasms,C0037763
1149,val / hctz ( n = $nmbr$ ),C0020261;C0042285;C0523975
1149,v alsartan / hctz  n ( % ),C0020261
1149,v / hctz ( n = $nmbr$ ),C0020261
1149,v / hctz,C0020261
1149,telmisartan / amlodipine - telmisartan / amlodipine / hydrochlorothiazide,C0020261;C0051696;C0939233;C2733369
1149,om $nmbr$ mg / hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0028971;C1319635;C1705272
1149,om $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0028971;C1319635;C1705272
1149,om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
1149,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
1149,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg *,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
1149,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
1149,olmesartan medoxomil $nmbr$ mg / hctz $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0020261;C0386393;C1319635
1149,olmesartan $nmbr$ - olmesartan $nmbr$ / hydrochlorothiazide $nmbr$ . $nmbr$,C0020261;C1098320
1149,hydrochlorothiazide,C0020261
1149,hydochlorothiazide ( n = $nmbr$ ),
1149,hctz = hydrochlorothiazide . * based on wilcoxon $nmbr$ - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / $nmbr$ tests for categorical variables . t data were missing for some patients .,C0001779;C0005767;C0005768;C0005893;C0012000;C0020261;C0022885;C0030705;C0039155;C0039593;C0229664;C0242931;C0370003;C0392366;C0439828;C0456984;C0578022;C0871472;C1305855;C1515051;C1515976;C1527178;C1551393;C1705492;C1705938;C2347026;C3272743;C3831328;C4318744;C4684582
1149,hctz = hydrochlorothiazide . * based on a ' / _ $nmbr$ test  t data were missing for some patients .,C0020261;C0022885;C0030705;C0039593;C0242356;C0392366;C0456984;C0993637;C1515976;C1551393;C1705492;C3272743;C3831328;C4318744
1149,hctz - hydrochlorothiazide . * data were missing for some patients .,C0020261;C0030705;C1511726;C1551393;C1705492;C3245479;C3272743;C3714741
1149,hctz * ( n = $nmbr$ ),C0020261
1149,hctz *,C0020261
1149,hctz,C0020261
1149,aml / hctz ( n = $nmbr$ ),C0020261;C0023465;C0023467
1149,aml $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C1319635
1149,aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0023465;C0023467;C1319635
1149,aml $nmbr$ mg + hctz $nmbr$ mg,C0020261;C0023465;C0023467;C1319635
1148,morning peak expiratory flow — liters / min,C0332170;C0475211;C0702093;C1518922;C1524029;C3813700
1148,morning,C0332170
1148,coping,C0009967
1147,smoking history — no . ( % ),C1519384
1147,smoking history ( ever ),C1519384;C3887636
1147,smoking history    n   ( % ),C1519384
1147,smoking history  r ( % ),C0205090;C0684010;C1519384;C2603358
1147,smoking history  n ( % ),C1519384
1147,smoking history,C1519384
1147,history of smoking,C1519384
1146,walking,C0080331;C4283795;C4321241;C4321242
1146,some walking,C0080331;C4283795;C4321241;C4321242
1146,physical activity ( hours walking / wk ),C0015259;C0026606;C0080331;C0332174;C0439227;C0439230;C4283795;C4321241;C4321242
1145,wssng,
1145,other or missing data,C4684714
1145,missing data — no . / total no . ( % ),C0439175;C0439810;C4684714
1145,missing data,C4684714
1144,unknown or missing,C0439673;C1551393;C1705492;C3272743;C3541433;C4050014
1144,unknown / missing,C0439673;C1551393;C1705492;C3272743;C3541433;C4050014
1144,other / missing,C1551393;C1705492;C3272743
1144,missing hb at yr $nmbr$,C0019046;C0439234;C1551393;C1705492;C3272743
1144,missing *,C1551393;C1705492;C3272743
1144,missing  n ( % ) a,C1551393;C1705492;C3272743
1144,missing,C1551393;C1705492;C3272743
1144,data missing or no drug given,C0013227;C1254351;C1442162;C1511726;C1550718;C1551393;C1705492;C1947971;C3244317;C3245479;C3272743;C3714741
1144,data missing,C1511726;C1551393;C1705492;C3245479;C3272743;C3714741
1144,* subgroups were defined on the basis of variables assessed before randomization . the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization . to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$  to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ci denotes confidence interval  ldl low - density lipoprotein  and hdl high - density lipoprotein . tests for heterogeneity of treatment effect were undertaken across each of the subgroups . in addition  we performed tests for interaction between treatment and the following continuous base - line variables : age  total  ldl  and hdl cholesterol  and triglyceride levels . there was no evidence of significant heterogeneity of treat - ment effect in any prespecified subgroup ( p » $nmbr$ . $nmbr$ ) . † data were missing for three patients  two in the placebo group and one in the pravastatin group .,C0001779;C0008107;C0008377;C0009667;C0019409;C0022885;C0023820;C0023821;C0030705;C0032042;C0034656;C0039593;C0039798;C0040363;C0041004;C0041260;C0042295;C0084844;C0085542;C0087111;C0168634;C0178587;C0205251;C0205447;C0205448;C0205449;C0205450;C0231290;C0237881;C0242960;C0332282;C0332287;C0392366;C0428460;C0428475;C0439175;C0439190;C0439230;C0439810;C0439828;C0441833;C0444706;C0456984;C0475211;C0549178;C0687744;C0750502;C0884358;C1079230;C1257890;C1280500;C1292734;C1442488;C1510992;C1511726;C1515021;C1515976;C1516048;C1518681;C1519504;C1522326;C1527178;C1532563;C1533734;C1538994;C1546944;C1550472;C1551393;C1696465;C1704675;C1704788;C1705169;C1705428;C1705429;C1705492;C1706408;C1719797;C1874451;C1882932;C1883351;C1883712;C2348382;C2825518;C2911648;C3245479;C3259781;C3272743;C3538994;C3539106;C3541902;C3714741;C3715113;C3831328;C3887511;C3887704;C3890211;C4048187;C4318744;C4321351;C4522223
1143,post - fibrinolysis angioplasty ( n = $nmbr$ ),C0016017;C0162577;C0687676;C1305868;C1548817;C1704687;C3469826
1143,fibrinolysist,
1143,fibrinolysis ( n = $nmbr$ ),C0016017;C1305868
1142,fibrinogen ( pmol / l ) c,C0016006;C0439284;C1167394;C2587184;C3540039
1142,fibrinogen  g / l,C0016006;C0439294;C0456615;C1167394;C2587184;C3540039
1142,fibrinogen,C0016006;C1167394;C2587184;C3540039
1141,inclusion findings ( % ),C0007637;C1512693;C2607943;C2926606;C3539655
1141,electrocardiographic findings — no . ( % ),C0438154
1141,electrocardiographic findings at randomization,C0034656;C0438154
1141,ecg findings at baseline — no . ( % ),C0168634;C0438154;C1442488
1141,ecg findings,C0438154
1141,angiographic findings | |,C0002978;C2607943;C2926606;C3539655
1141,additional radiographic findings at week $nmbr$,C0332174;C0439230;C0444708;C1524062;C2607943;C2926606;C3539655
1140,swollen joints ( $nmbr$ - joint count )  mean ± sd,C0444504;C0451521;C2347634;C2348143;C2699239
1140,swollen joint count of $nmbr$ joints,C0451521
1140,swollen joint count ( range $nmbr$ - $nmbr$ joints ),C0451521;C1514721;C2348147;C3542016
1140,swollen joint count ( n / $nmbr$ ),C0451521
1140,swollen joint count ( $nmbr$ — $nmbr$  per swollen joint ),C0451521
1140,swollen joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
1140,swollen joint count ( $nmbr$ joints )  mean ( sd ) ’,C0444504;C0451521;C2347634;C2348143;C2699239
1140,swollen joint count ( $nmbr$ joints )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
1140,swollen joint count ( $nmbr$ joints ),C0451521
1140,swollen joint count ( $nmbr$ - $nmbr$ possible joints ),C0332149;C0451521;C1705910;C2362652
1140,swollen joint count ( $nmbr$ - $nmbr$ joints ),C0451521
1140,swollen joint count ( $nmbr$ - $nmbr$ ),C0451521
1140,swollen joint count ( $nmbr$ )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
1140,swollen joint count  of $nmbr$,C0451521
1140,swollen joint count,C0451521
1140,swollen - joint count ( of $nmbr$ joints assessed ) — no .,C0451521;C1516048
1140,swollen - joint count ( of $nmbr$ joints ),C0451521
1140,swollen - joint count  of $nmbr$ joints examined,C0332128;C0451521
1140,mean ( sd ) swollen joint count *,C0444504;C0451521;C2347634;C2348143;C2699239
1139,tender joints ( $nmbr$ - joint count )  mean ± sd,C0444504;C0451530;C2347634;C2348143;C2699239
1139,tender joint count of $nmbr$ joints,C0451530
1139,tender joint count ( range $nmbr$ - $nmbr$ joints ),C0451530;C1514721;C2348147;C3542016
1139,tender joint count ( n / $nmbr$ ),C0451530
1139,tender joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
1139,tender joint count ( $nmbr$ joints )  mean ( sd ) ’,C0444504;C0451530;C2347634;C2348143;C2699239
1139,tender joint count ( $nmbr$ joints )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
1139,tender joint count ( $nmbr$ joints ),C0451530
1139,tender joint count ( $nmbr$ - $nmbr$ joints ),C0451530
1139,tender joint count ( $nmbr$ - $nmbr$ ),C0451530
1139,tender joint count ( $nmbr$ - $nmbr$  per tender joint ),C0451530
1139,tender joint count ( $nmbr$ )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
1139,tender joint count  of $nmbr$,C0451530
1139,tender joint count,C0451530
1139,tender - joint count ( of $nmbr$ joints ),C0451530
1139,tender - joint count  of $nmbr$ joints examined,C0332128;C0451530
1139,mean ( sd ) tender joint count *,C0444504;C0451530;C2347634;C2348143;C2699239
1138,tender and swollen joints — mean no . : :,C0152031;C0234234;C0444504;C2347634;C2348143
1138,swollen joints > $nmbr$  n ( % ),C0152031
1138,joint swelling  effusion  or both on clinical examination — no . ( % ),C0013604;C0013687;C0031809;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335
1138,joint swelling  effusion  or both on clinical examination,C0013604;C0013687;C0031809;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335
1138,joint swelling,C0152031
1137,tjc ( / $nmbr$ joints ),C0022417;C0392905
1137,tjc ( $nmbr$ joints )  mean ( sd ),C0022417;C0392905;C0444504;C2347634;C2348143;C2699239
1137,tjc ( $nmbr$ joints ),C0022417;C0392905
1137,sjc ( / $nmbr$ joints ),C0022417;C0392905
1137,sjc ( $nmbr$ joints )  mean ( sd ),C0022417;C0392905;C0444504;C2347634;C2348143;C2699239
1137,sjc ( $nmbr$ joints ),C0022417;C0392905
1136,patients with end point,C0030705;C2349179;C2826544
1136,other prespecified end points,C2349179
1136,other end points,C2349179
1136,mean change in radiographic end points,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
1136,main accord endpoint,C0205225;C0680240;C1542147;C2349179;C2826544
1136,endpoints,C2349179
1136,endpointc,
1136,endpoint rate,C0871208;C1521828;C2349179;C2826544
1136,endpoint *,C2349179;C2826544
1136,endpoint,C2349179;C2826544
1136,end points,C2349179
1136,end point,C2349179;C2826544
1136,end - point ( sd ),C2349179;C2699239;C2826544
1136,coronary endpoint,C0018787;C2349179;C2826544
1136,coronary end point,C0018787;C2349179;C2826544
1136,combined end points,C0205195;C2349179
1136,combined end point,C0205195;C2349179;C2826544
1136,bleeding end points,C0019080;C2349179
1136,all randomized coronary end point,C0018787;C0034656;C2349179;C2826544;C3815594
1136,additional endpoints,C1524062;C2349179
1135,oct center point thickness  pm,C0030266;C0205099;C1280412;C1552961;C2347617;C3714763;C3810851;C3828732;C4049155
1135,mean change from baseline  % ‐ points,C0168634;C0392747;C0443172;C0444504;C1442488;C1552961;C1705241;C2347617;C2347634;C2348143;C3714763;C4319952
1135,( points ),C1552961;C2347617;C3714763
1134,time point,C2348792
1134,pint,C0560012;C3811619;C3890014;C3890556
1134,p value ( vs . previous time point ),C0205156;C1552607;C1709380;C2348792
1133,spine *,C0037949;C2752558
1133,spine,C0037949;C2752558
1133,post erior - anterior spine,C0037949;C0205094;C0687676;C1704687;C2752558;C3469826
1132,£ $nmbr$ m b ' m in,C1709500
1132,ppci in - $nmbr$,
1132,pain in extremity,C0030196;C4553007
1132,in - stent restenosis of des,C0011702;C3272317;C4551552
1132,in - stent restenosis,C3272317
1132,in - h,C0033727;C0369286;C0441932;C0564385;C4528284
1132,dapaglifloz . in  n,
1132,dactylitis in > $nmbr$ digit,C3863761
1131,“ on ” without troublesome dyskinesia,C0013384
1131,“ on ” with troublesome dyskinesia,C0013384
1131,ocn,C1412791;C2347392
1131,absolute time spent “ on ” without troublesome dyskinesia  h / day,C0013384;C0033727;C0332173;C0369286;C0439228;C0439505;C0439546;C0441932;C0564385;C0680968;C4528284
1131,absolute time spent “ on ” with troublesome dyskinesia  h / day,C0013384;C0033727;C0332173;C0369286;C0439228;C0439505;C0439546;C0441932;C0564385;C0680968;C4528284
1130,valdecoxib,C0913246
1130,rofecoxib,C0762662
1130,etoricoxib dose,C0178602;C0869039;C0972314;C1114758
1130,etoricoxib ( n = $nmbr$ ),C0972314
1130,etoricoxib ( n = $nmbr$ $nmbr$ ),C0972314
1130,etoricoxib ( n = $nmbr$  $nmbr$ ),C0972314
1130,etoricoxib $nmbr$ mg n = $nmbr$ n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . . ( . % . . ) . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1130,etoricoxib $nmbr$ mg  n = $nmbr$  n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1130,etoricoxib,C0972314
1130,celecoxib ( n = $nmbr$ ),C0538927
1130,celecoxib,C0538927
1129,lvh by electrocardiogram  n ( % ),C0013798;C0149721;C1547122;C1623258
1129,lvh by electrocardiogram,C0013798;C0149721;C1547122;C1623258
1129,lvh ( from electrocardiogram ),C0013798;C0149721;C1547122;C1623258
1129,history of lvh on electrocardiogram,C0013798;C0019664;C0019665;C0149721;C0262512;C0262926;C1547122;C1623258;C1705255;C2004062
1129,electrocardiography,C0013798;C1623258
1129,electrocardiograph results  no . ( % ),C0013798;C0180600;C1274040;C1546471;C1623258;C2825142
1129,electrocardiogram,C0013798;C1547122;C1623258
1129,ecg abnormality ( resting )  %,C0035253;C1512899;C1623258;C1704258
1129,ecg,C1623258
1128,uc [ gemini $nmbr$ ] ‘,
1128,uc,
1128,surgical technique,C0683469
1128,other uc - related gi surgical procedure,C0439849;C0445223;C0543467;C1708130;C3539617;C4050121
1127,mean bdi focal score ( sd ),C0006448;C0205234;C0451022;C2699239;C3533236;C3714938;C3889415
1127,focal,C0205234
1127,bdi focal score $nmbr$,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
1127,bdi focal score,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
1127,> $nmbr$ % focal seizure frequency responders,C0149775;C0205234;C0376249;C0439603;C0751495;C0871396;C1561548;C1705502;C3898838;C4321352
-10,atypical absence,C0595948
1125,topical prescription,C0033080;C0332237;C1521941
1125,topical non - prescription,C0033080;C0332237;C1518422;C1521941
1125,topical,C0332237
1125,nitrate ( oral or topical ),C0028125;C0332237;C0442027;C0699857;C3848573;C4521986
-10,puerto rican,C0034043
1123,rca  n ( % ),
1123,rca,
1123,mca,C0149566
1123,$nmbr$ degree of ica stenosis 丰,C0201519;C4034225
1122,primary / key efficacy endpoint,C1280519;C1707887;C1709665;C2349179;C2826544
1122,peripheral limb vascular efficacy,C0015385;C0150936;C0947487;C1280519;C1707887
1122,overall efficacy,C0282416;C1280519;C1561607;C1707887
1122,efficacy variable,C0439828;C1280519;C1707887;C4553760
1122,efficacy endpoints *,C1280519;C1707887;C2349179
1122,efficacy endpoint,C1280519;C1707887;C2349179;C2826544
1122,efficacy end points,C1280519;C1707887;C2349179
1122,efficacy and safety : net adverse clinical events *,C0036043;C0205210;C0877248;C1280519;C1456447;C1705187;C1705413;C1707887;C3853572;C3887809;C3890893
1122,efficacy    n   ( % ) a,C1280519;C1707887
1122,efficacy,C1280519;C1707887
1122,combined efficacy and safety endpoint,C0036043;C0205195;C1280519;C1705187;C1707887;C2349179;C2826544
-10,colesevelam ( n = $nmbr$ ),C0541155
1120,the american college of rheumatology ) .,C0035452;C0557806;C0596070
1120,some college / tech,C0557806;C1826596
1120,some college,C0557806
1119,volume change  mm ^,C0392747;C0443172;C0449468;C1690016;C1705102;C1705241;C2700258;C4319952;C4330985;C4554674
1119,voided volume  ml,C0042034;C0439526;C0449468;C1552835;C1690016;C1705102;C1705224;C2700258;C3887665
1119,normalized volume measures,C0079809;C0242485;C0449468;C1690016;C1705102;C1879489;C1882115;C2700258
1119,median change in atheroma volume  %,C0264956;C0392747;C0443172;C0449468;C0549183;C0876920;C1690016;C1705102;C1705241;C2347635;C2348144;C2700258;C2939193;C4319952
1119,contrast volume > $nmbr$ ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1119,contrast volume > $nmbr$ ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1119,contrast volume ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1119,contrast volume  ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1119,contrast volume,C0009924;C0449468;C1690016;C1705102;C1979874;C2700258
1118,pulse pressure ( mmhg ),C0439475;C0949236
1118,pulse pressure ( mm hg ),C0439475;C0949236
1118,pulse pressure,C0949236
1118,pollent s $nmbr$,
1118,pollent < $nmbr$,
1118,pollen exposure,C0032385;C0274281;C0332157;C0795585;C1320238
1118,mean pulse pressure  mmhg ( s . d . ) “,C0232117;C0391850;C0444504;C0445074;C0949236;C1947910;C2347155;C2347634;C2348143
1117,sitting pulse  bpma,C0232117;C0277814;C0391850;C1947910;C2584297;C4050224
1117,pulse — beats / min,C0232117;C0391850;C0702093;C1524029;C1947910;C3813700
1117,pulse ( beats / min ) cholesterol ( mmol / l ),C0008377;C0232117;C0391850;C1947910;C2827896
1117,pulse  beats / min,C0232117;C0391850;C0702093;C1524029;C1947910;C3813700
1116,quality of life,C0034380;C0518214
1116,qol due to urinary symptoms,C0426359;C0518214;C0678226
1116,qol,C0518214
1116,mean ipss qol ( sd ),C0444504;C0518214;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1116,ipss qol ( ls,C0023668;C0518214;C1019118;C1998280;C2827405;C3811063
1116,ipss qol,C0518214;C1019118;C1998280;C2827405;C3811063
1116,disease and quality - of - life scores  mean ( sd ),C0012634;C0034380;C0444504;C0449820;C0518214;C2347634;C2348143;C2699239;C4050231
1116,disease and quality - of - life scores,C0012634;C0034380;C0449820;C0518214;C4050231
1116,baseline disease and quality - of - life scores,C0012634;C0034380;C0168634;C0449820;C0518214;C1442488;C4050231
1115,wrist fracture,C0435630;C4553927
1115,thoracic cage fractures,C0016658;C0222762
1115,skull  and facial bone fractures,C0015455;C0016658;C0037303;C2951888
1115,radius fracture,C0034628
1115,prior nonvertebral fracture at age > $nmbr$ years,C0016658;C0332152;C1510829;C2826257
1115,prior nonvertebral fracture,C0016658;C0332152;C2826257
1115,prior clinical fracture ( since age $nmbr$ ),C0001779;C0016658;C0205210;C0332152;C2826257
1115,nonvertebral fractures,C0016658
1115,nonvertebral fracture,C0016658
1115,no fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1115,humerus fracture,C0020162
1115,hip + other nonvertebral fractures,C0016658;C0019552;C0022122;C1505163;C3538851;C4284725
1115,hand fracture,C0435632
1115,fractures,C0016658
1115,fracture history ( predefined )  n ( % ),C0016658;C0019664;C0019665;C0262512;C0262926;C0369718;C0441922;C1705255;C2004062
1115,fracture history  n ( % ),C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1115,fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1115,fracture,C0016658
1115,foot fracture,C0272774
1115,femur fracture,C0015802
1115,fas,
1115,e major non - vertebral fragility fractures ( fas ),C0016658;C0205082;C0205164;C0302113;C0549207;C1518422;C4318856;C4521762
1115,d non - vertebral fragility fractures ( fas ),C0016658;C0073187;C0302113;C0332173;C0549207;C1518422;C4484261
1115,clinical fracture,C0016658;C0205210
1115,c clinical fractures ( fas ),C0016658;C0205210
1115,bone fracture due to fall,C0016658;C0085639;C0238715;C0678226;C4553726
1115,bone fracture,C0016658
1114,pelvic fractures,C0149531
1114,hip fracture only,C0019557;C0149531;C0205171;C1720467;C4552776
1114,hip fracture + > $nmbr$,C0019557;C0149531;C4552776
1114,hip fracture,C0019557;C0149531;C4552776
1113,vertebral fracture and / or t score s - $nmbr$ . $nmbr$,C0080179;C0449820;C0718146;C4050231
1113,vertebral fracture and / or t score - $nmbr$ . $nmbr$,C0080179;C3854607
1113,vertebral fracture,C0080179
1113,tibia fracture,C0040185
1113,spinal fractures,C0080179;C0518450
1113,prevalent vertebral fracture status,C0033105;C0080179;C0220900;C0449438
1113,prevalent vertebral fracture  n ( % ),C0033105;C0080179;C0220900
1113,prevalent vertebral fracture,C0033105;C0080179;C0220900
1113,patella fracture,C0159849
1113,number of prevalent vertebral fractures,C0033105;C0080179;C0220900;C0237753;C0449788
1113,fibula fracture,C0149699
1113,clinical vertebral fractures,C0080179;C0205210
1113,clavicle fracture,C0159658
1113,ankle fracture,C0159877;C4552974
1112,stratification factors,C1514984
1112,stratification factor : menopausal status  n ( % ),C1513126;C1514984
1112,predictive factor,C0683956
1112,factor xa inhibitor,C2825027;C4553708
1112,factor v leiden or prothrombin mutation,C0380964;C0584960;C1414509;C1610621;C3542419
1112,factor v leiden ( % ),C0380964;C0584960;C1414509;C3542419
1111,temporary factors,C0205374;C1521761;C1548539;C2827422;C3245481
1111,risk factor for venous thromboembolism  no . ( % ),C1521761;C2827422;C3495424;C3496592
1111,hospital factor # $nmbr$,C0019994;C1510665;C1521761;C2827422
1111,factors that confer a,C1521761;C2827422
1111,factor at baseline,C0168634;C1442488;C1521761;C2827422
1111,factor *,C1521761;C2827422
1111,factor,C1521761;C2827422
1111,baseline factor,C0168634;C1442488;C1521761;C2827422
1110,surgical technique post - randomisation characteristic * *,C0034656;C0683469;C0687676;C1521970;C1704687;C3469826
1110,patient characteristic,C0030705;C1521970
1110,medical characteristics,C0199168;C0205476;C1521970
1110,infarct characteristics,C0021308;C1521970
1110,feature,C1521970;C1706388;C2346469;C2348519
1110,e ( characteristic n,C1521970
1110,demographic characteristic,C0011298;C1521970
1110,characteristics of pulmonary embolism at inclusion,C0007637;C0034065;C1512693;C1521970
1110,characteristics *,C1521970
1110,characteristics,C1521970
1110,characteristic †,C1521970
1110,characteristic at baseline,C0168634;C1442488;C1521970
1110,characteristic age — yr,C0001779;C0439234;C1521970
1110,characteristic age,C0001779;C1521970
1110,characteristic ^,C1521970
1110,characteristic *,C1521970
1110,characteristic ( a ),C1521970
1110,characteristic  no . ( % ),C1521970
1110,characteristic,C1521970
1110,baseline feature,C0168634;C1442488;C1521970;C1706388;C2346469;C2348519
1110,baseline characteristic,C0168634;C1442488;C1521970
1110,anthropometric characteristics,C0003188;C1521970
1110,angiographic features,C0002978;C1521970;C1706388;C2346469;C2348519
1110,angiographic characteristics  no . ( % ),C0002978;C1521970
1109,three - point mace,C0205449;C0349381;C0949745;C1445339;C1552961;C2347617;C3714763
1109,secondary mace endpoint,C0349381;C0949745;C1445339;C4528314
1109,primary outcome ( $nmbr$ - point mace ),C0205225;C0349381;C0439612;C0439631;C0949745;C1274040;C1445339;C1552961;C2347617;C3714763
1109,primary mace endpoint,C0349381;C0949745;C1445339;C2986535
1109,mae,C0286540;C4085238
1109,mace category  n ( % ) [ ir ],C0022065;C0022071;C0349381;C0683312;C0949745;C1445339;C1448132;C3889287
1109,mace +,C0349381;C0949745;C1445339
1109,mace,C0349381;C0949745;C1445339
1109,hard mace,C0018599;C0349381;C0949745;C1445339
1109,first mace,C0205435;C0349381;C0949745;C1279901;C1445339
1109,expanded mace,C0205229;C0349381;C0949745;C1445339
1109,b mace,C0349381;C0949745;C1445339
1109,adjudicated mace $nmbr$,C0349381;C0949745;C1445339
1109,$nmbr$ - polnt mace,C0349381;C0949745;C1445339
1109,$nmbr$ - point mace ( $nmbr$ - point mace plus hospitalization for unstable angina ),C0002965;C0019993;C0349381;C0949745;C1445339;C1552961;C2347617;C3714763
1109,$nmbr$ - point mace,C0349381;C0949745;C1445339;C1552961;C2347617;C3714763
1108,macce ( % ) abciximab placebo,C0032042;C0288672;C1696465;C1706408
1108,macce ( % ),
1108,macce,
1107,white race — no . { % ) t,C0007457;C0034510;C0043157;C0220938;C1706779;C2603360;C3853635
1107,racec  n ( % ),C4287599
1107,race — no . { % ) - i -,C0021966;C0034510;C0221138;C1706779;C3853635
1107,race — no . { % ) ' i ',C0021966;C0034510;C0221138;C1706779;C3853635
1107,race — no . / total no . ( % ) f,C0016327;C0034510;C0439175;C0439810;C1706779;C3853635
1107,race — no . ( % ) 卞,C0034510;C1706779;C3853635
1107,race — no . ( % ) |,C0034510;C1706779;C3853635
1107,race — no . ( % ) f,C0016327;C0034510;C1706779;C3853635
1107,race — no . ( % ) : t,C0034510;C1706779;C2603360;C3853635
1107,race — no . ( % ) : c,C0034510;C1706779;C3853635
1107,race — no . ( % ) ' (,C0034510;C1706779;C3853635
1107,race — no . ( % ),C0034510;C1706779;C3853635
1107,race §,C0034510;C1706779;C3853635
1107,race white,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race or ethnic group — no . ( % ) : t,C0015031;C0034510;C1706779;C1879937;C2603360;C3853635
1107,race or ethnic group  no . ( % ),C0015031;C0034510;C1706779;C1879937;C3853635
1107,race or ethnic background — no . ( % ) f,C0015031;C0016327;C0034510;C1706779;C3853635
1107,race nonwhitet,C0034510;C1706779;C3853635
1107,race n ( % ),C0034510;C1706779;C3853635
1107,race : white,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race : non - white,C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635
1107,race :,C0034510;C1706779;C3853635
1107,race / ethnicity chinese,C0008120;C0015031;C0034510;C0152035;C0243103;C1706779;C3853635
1107,race / ethnicity  zz ( % ),C0015031;C0034510;C0243103;C1706779;C2347310;C3853635
1107,race / ethnicity  %,C0015031;C0034510;C0243103;C1706779;C3853635
1107,race / ethnicity,C0015031;C0034510;C0243103;C1706779;C3853635
1107,race - white ( n = $nmbr$  $nmbr$ ),C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race - non - white ( n = $nmbr$  $nmbr$ ),C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635
1107,race - no . ( % ),C0034510;C1706779;C3853635
1107,race - n ( % ),C0034510;C1706779;C3853635
1107,race *,C0034510;C1706779;C3853635
1107,race ( white  n [ % ] ),C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race ( p = o - $nmbr$ ),C0034510;C1706779;C3853635
1107,race ( non - white ) ( % ),C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635
1107,race ( % white ),C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race ( % ) white,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race ( % ) *,C0034510;C1706779;C3853635
1107,race ( % ) ) ',C0034510;C1706779;C3853635
1107,race ( % ) $,C0034510;C1706779;C3853635
1107,race ( % ),C0034510;C1706779;C3853635
1107,race $nmbr$,C0034510;C1706779;C3853635
1107,race    n   ( % ),C0034510;C1706779;C3853635
1107,race  zz ( % ),C0034510;C1706779;C2347310;C3853635
1107,race  white ( % ),C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race  white    n   ( % ),C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race  white  n ( % ),C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race  nonwhite,C0034510;C1706779;C3853635
1107,race  no . / total ( % ),C0034510;C0439175;C0439810;C1706779;C3853635
1107,race  no . ( % ) c,C0034510;C1706779;C3853635
1107,race  no . ( % ) b,C0034510;C1706779;C3853635
1107,race  no . ( % ) *,C0034510;C1706779;C3853635
1107,race  no . ( % ),C0034510;C1706779;C3853635
1107,race  n ( % ],C0034510;C1706779;C3853635
1107,race  n ( % ) ’,C0034510;C1706779;C3853635
1107,race  n ( % ) y,C0034510;C1706779;C3853635
1107,race  n ( % ) white,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race  n ( % ) t,C0034510;C1706779;C3853635
1107,race  n ( % ) b,C0034510;C1706779;C3853635
1107,race  n ( % ) a,C0034510;C1706779;C3853635
1107,race  n ( % ) :,C0034510;C1706779;C3853635
1107,race  n ( % ) +,C0034510;C1706779;C3853635
1107,race  n ( % ) *,C0034510;C1706779;C3853635
1107,race  n ( % ),C0034510;C1706779;C3853635
1107,race  asian  n ( % ),C0034510;C0078988;C1706779;C3853635
1107,race  * ’ n ( % ),C0034510;C1706779;C3853635
1107,race  % white,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1107,race  % of patients,C0030705;C0034510;C1706779;C3853635
1107,race  %,C0034510;C1706779;C3853635
1107,race,C0034510;C1706779;C3853635
1107,other race  n ( % ),C0034510;C1706779;C3853635
1107,other race,C0034510;C1706779;C3853635
1107,nonblack race — no . ( % ) f,C0016327;C0034510;C1706779;C3853635
1107,nonblack race — no . ( % ) - j -,C0034510;C1706779;C3853635
1107,female sex — no . ( % ) race — no . ( % ) f,C0016327;C0034510;C0086287;C1706779;C3853635
1107,female sex  n ( % ) race  n ( % ),C0034510;C0086287;C1706779;C3853635
1107,female race white,C0007457;C0034510;C0043157;C0043210;C0086287;C0220938;C1705497;C1705498;C1706779;C3853635
1107,female race / ethnicity,C0015031;C0034510;C0043210;C0086287;C0243103;C1705497;C1705498;C1706779;C3853635
1107,female  n ( % ) race  n ( % ),C0034510;C0043210;C0086287;C1705497;C1705498;C1706779;C3853635
1107,$ race was determined by the investigator during the patient ' s interview .,C0034510;C0035173;C0521095;C0683518;C1706779;C3853635
1106,number and % of participants with events  and incidence rate per $nmbr$ person - year,C0027361;C0237753;C0439234;C0439508;C0441471;C0449788;C0679646;C1708485;C2347489;C3541888
1106,no . ( % ) with event [ incidence rate per $nmbr$ patient - y ],C0030705;C0441471;C1708485;C4019010
1106,incidence rate *,C1708485
1106,incidence rate ( per $nmbr$ person - yr ),C0027361;C0439234;C1708485;C2347489
1106,incidence rate ( n ) a,C1708485
1106,incidence rate ( n ),C1708485
1106,incidence rate,C1708485
1106,$nmbr$ - y incidence rate ( se ) per $nmbr$ participants,C0036919;C0679646;C1708485
1105,preoperative heart rate ( beats per minute ),C0018810;C0439385;C0445204
1105,heart rate — bpm,C0018810
1105,heart rate ( bpm ) *,C0018810
1105,heart rate ( bpm ),C0018810
1105,heart rate ( bpm $nmbr$ ) *  * *,C0018810
1105,heart rate ( beats per minute ),C0018810;C0439385
1105,heart rate ( beats per min ),C0018810;C0439385
1105,heart rate ( b . p . m . ),C0018810;C0369637;C0441923
1105,heart rate  beats per minute,C0018810;C0439385
1105,heart rate  beats per min,C0018810;C0439385
1105,heart rate,C0018810
1105,baseline heart rate ( beats / min ),C0018810;C0168634;C0702093;C1442488;C1524029;C3813700
1105,baseline heart rate,C0018810;C0168634;C1442488
1104,ramus,C3538818
1104,rales  n ( % ),C0034642;C0240859
1104,rales  ( % ),C0034642;C0240859
1104,rales,C0034642;C0240859
1104,pulmonary rales  n ( % ),C0034642
1104,pulmonary rales,C0034642
1103,w event ( rate ),C0441471;C0871208;C1521828;C4019010
1103,vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1103,rates per $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
1103,rates,C0871208;C1521828
1103,rate ‡,C0871208;C1521828
1103,rate †,C0871208;C1521828
1103,rate per $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
1103,rate per $nmbr$ - patient - years ( control vs alirocumab ) i,C0021966;C0030705;C0221138;C0243148;C0439234;C0871208;C1521828;C1550141;C1882979;C2587213;C3274648;C3491162;C4553389
1103,rate per $nmbr$ - patient - years ( control vs alirocumab ) *,C0030705;C0243148;C0439234;C0871208;C1521828;C1550141;C1882979;C2587213;C3274648;C3491162;C4553389
1103,rate of sares,C0871208;C1521828
1103,rate of non - progression ( defined as cfb in mtss £ $nmbr$ . $nmbr$ )  n / n ( % ) *,C0009002;C0871208;C1521828;C1704788;C1824728;C3539106;C3839460
1103,rate of non - progression ( defined as cfb in mtss £ $nmbr$ )  n / n ( % ) *,C0009002;C0871208;C1521828;C1704788;C1824728;C3539106;C3839460
1103,rate in all participants  % / y,C0679646;C0871208;C1521828
1103,rate difference ( events / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C1705241;C1705242;C3541888
1103,rate / $nmbr$ pyo,C0033809;C0871208;C1521828
1103,rate / $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
1103,rate * ( n ),C0871208;C1521828
1103,rate *,C0871208;C1521828
1103,rate ( % per year ),C0439234;C0439508;C0871208;C1521828
1103,rate ( % / year ),C0439234;C0439508;C0871208;C1521828
1103,rate  % / y,C0871208;C1521828
1103,rate,C0871208;C1521828
1103,ranotazine vs . placebo km failure rate,C0032042;C0231174;C0680095;C0871208;C1521828;C1696465;C1706408;C3887676
1103,overall event rate,C0282416;C0441471;C0871208;C1521828;C1561607;C4019010
1103,overal event rate,C0441471;C0871208;C1521828;C4019010
1103,no vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1103,no . of events ( rate ),C0441471;C0871208;C1521828;C3541888
1103,n event ( rate ),C0369718;C0441471;C0441922;C0871208;C1521828;C4019010
1103,n ( $nmbr$ yr km event rate  % ),C0369718;C0439234;C0441471;C0441922;C0871208;C1521828;C3887676;C4019010
1103,km rates { % ) p / s,C0234833;C0722388;C0871208;C1521828;C3887676
1103,km rates { % ) e / s,C0871208;C1521828;C3887676
1103,km rate ( % ),C0871208;C1521828;C3887676
1103,km event rate ( % ),C0441471;C0871208;C1521828;C3887676;C4019010
1103,kaplan - meier rates  % i i,C0021966;C0221138;C0871208;C1521828
1103,kaplan - meier rates  %,C0871208;C1521828
1103,k ( rate ),C0597277;C0871208;C1521828;C1708601
1103,health - care use rate ( peryear ),C0814514;C0871208;C1521828
1103,filtration rate $nmbr$ - $nmbr$,C0016107;C0871208;C1521828
1103,exacerbation rate per year,C0439234;C0439508;C0871208;C1521828;C4086268
1103,exacerbation rate in the previous year ( range ),C0205156;C0439234;C0439508;C0871208;C1514721;C1521828;C1552607;C2348147;C3542016;C4086268
1103,event rates per $nmbr$ patient - years ( $nmbr$ % ci ),C0008107;C0030705;C0439234;C0441471;C0871208;C1521828;C3259781;C4019010
1103,event rates  %,C0441471;C0871208;C1521828;C4019010
1103,event rate ( per $nmbr$ person years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
1103,event rate ( per $nmbr$ person - years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
1103,event rate ( per $nmbr$,C0441471;C0871208;C1521828;C4019010
1103,event rate ( % / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1103,event rate ( % / vr ),C0441471;C0871208;C1521828;C3476815;C4019010
1103,event rate ( % ) of primary endpoints,C0441471;C0871208;C1521828;C2986535;C4019010
1103,event rate,C0441471;C0871208;C1521828;C4019010
1103,crude rate,C0871208;C1521828
1103,baseline monthly pos seizure rate,C0036572;C0168634;C0332177;C0871208;C1262869;C1442488;C1521828;C1959629;C3496112;C3496399;C4553401
1103,annual exacerbation rate,C0332181;C0871208;C1521828;C4086268
1103,annual asthma exacerbation rates,C0332181;C0349790;C0871208;C1521828
1103,adjusted exacerbation rate { per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
1103,adjusted exacerbation rate ( per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
1103,> $nmbr$ % responder rate  n ( % ),C0871208;C1521828
1103,* rate is number of events per $nmbr$ patient - years of follow - up . fthe p value for number of patients from log - rank  for total number of hospitalizations from permutation test . ^ by treatment comparing the,C0022885;C0030705;C0039593;C0039798;C0087111;C0392366;C0439175;C0439234;C0439810;C0456984;C0589120;C0667477;C0699794;C0871208;C1515976;C1521828;C1522326;C1522577;C1533734;C1704685;C1705169;C1707455;C1708728;C1709380;C1882348;C2360800;C2986775;C3274571;C3538994;C3831328;C3887704;C4086639;C4318744;C4330837
1103,$nmbr$ yr . km rate,C0439234;C0871208;C1521828;C3887676
1103,$nmbr$ - yr rate / $nmbr$ participants,C0439234;C0679646;C0871208;C1521828
1103,$nmbr$ - y kaplan - meier rate ( $nmbr$ % ci ),C0008107;C0871208;C1521828;C3259781
1102,respiratory rate ( breaths / min ),C0231832;C0439386;C0489258
1102,respiratory rate  breaths / min,C0231832;C0439386;C0489258
1102,breakfastb,
1101,raee,
1101,glomerular filtration rate §,C0017654;C1561549
1101,glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ ma,C0017654;C0024443;C0439445;C1561549;C3887485
1100,white race — number ( % ),C0007457;C0043157;C0237753;C0449788
1100,white race ( n = $nmbr$ $nmbr$ ),C0007457;C0043157
1100,white race,C0007457;C0043157
1100,racey  z,
1100,racea white,C0007457;C0043157;C0220938
1100,racea,
1099,赛 $nmbr$ years,C0439234
1099,〉 $nmbr$ years,C0439234
1099,■ $nmbr$ years,C0439234
1099,≥ $nmbr$ years,C0439234
1099,≥ $nmbr$ to < $nmbr$ years,C0439234
1099,≥ $nmbr$ . $nmbr$ years,C0439234
1099,≥ $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ years,C0439234
1099,≤ $nmbr$   year,C0439234;C0439508
1099,≤ $nmbr$ years,C0439234
1099,» $nmbr$ yr,C0439234
1099,» $nmbr$ years,C0439234
1099,£ $nmbr$ yr,C0439234
1099,£ $nmbr$ years,C0439234
1099,£ $nmbr$ to < $nmbr$ years,C0439234
1099,years with gouty arthritis,C0003868;C0439234
1099,years with gout  mean ± sd,C0018099;C0439234;C0444504;C2347634;C2348143;C2699239
1099,years with gout,C0018099;C0439234
1099,years since symptom onset,C0439234;C4086878
1099,years since pd diagnosis  mean ± sd,C0011900;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C4553228;C4553229
1099,years since pah diagnosis,C0011900;C0030123;C0439234;C1704338;C1704656;C3203102;C4284467
1099,years since menopause,C0025320;C0439234;C0567312
1099,years since diagnosis  mean,C0011900;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143
1099,years since diagnosis,C0011900;C0439234;C1704338;C1704656
1099,years of follow - up  mean ( sd ) [ maximum ],C0439234;C0444504;C0589120;C0806909;C1522577;C1552615;C1704685;C2347634;C2348143;C2699239;C2826546;C3274571
1099,years of education  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1099,years duration oa,C0029408;C0439234;C0449238;C2926735;C3887876
1099,years [ range ],C0439234;C1514721;C2348147;C3542016
1099,years ),C0439234
1099,years  n ( % ) smoking  n ( % ) current,C0037369;C0439234;C0453996;C0521116;C1705970;C1881674
1099,years,C0439234
1099,year from randomization,C0034656;C0439234;C0439508
1099,year - $nmbr$,C0439234;C0439508
1099,year $nmbr$,C0439234;C0439508
1099,year  n ( % ),C0439234;C0439508
1099,x $nmbr$ years,C0439234
1099,women > $nmbr$ years,C0043210;C0439234
1099,women < $nmbr$ years,C0043210;C0439234
1099,vorapaxar placebo $nmbr$ - yr . km % rate,C0032042;C0439234;C0871208;C1521828;C1696465;C1706408;C2974521;C3887676
1099,vorapaxar placebo $nmbr$ - yr %,C0032042;C0439234;C1696465;C1706408;C2974521
1099,ukpds $nmbr$ - year risk score > $nmbr$ %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
1099,ukpds $nmbr$ - year risk score < $nmbr$ %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
1099,type $nmbr$ diabetes duration  years,C0439234;C0449238;C1320657;C2926735
1099,type $nmbr$ diabetes duration  mean ( sd )  years,C0439234;C0444504;C0449238;C1320657;C2347634;C2348143;C2699239;C2926735
1099,time since start of fit  years ( meanisd ),C0036572;C0040223;C0439234;C0439659;C1711239;C2349186;C3541383;C4048158;C4553125
1099,time since start insulin ( years ),C0021641;C0040223;C0439234;C0439659;C1533581;C1579433;C1711239;C3541383;C3714501
1099,time since rheumatoid arthritis diagnosis  years,C0003873;C0011900;C0040223;C0439234;C1704338;C1704656;C3541383
1099,time since psoriasis diagnosis  years $nmbr$,C0011900;C0033860;C0040223;C0439234;C1704338;C1704656;C3541383
1099,time since psa diagnosis ( years )  mean ( sd ),C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383;C3810537;C3813209
1099,time since pah diagnosisc ( years ),C0030123;C0040223;C0439234;C3203102;C3541383;C4284467
1099,time since first copd diagnosis ( years ),C0011900;C0024117;C0040223;C0205435;C0439234;C1279901;C1412502;C1704338;C1704656;C3541383;C3714496
1099,time since epilepsy diagnosis ( years ),C0011900;C0014544;C0040223;C0439234;C1704338;C1704656;C3541383
1099,time since diagnosis of sle  years,C0011900;C0024141;C0040223;C0439234;C1704338;C1704656;C3541383
1099,time since diagnosis of psa ( years )  mean ( sd ),C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383;C3810537;C3813209
1099,time since diagnosis of pah years #,C0011900;C0030123;C0040223;C0439234;C1704338;C1704656;C3203102;C3541383;C4284467
1099,time since diagnosis of osteoarthritis — yr,C0011900;C0029408;C0040223;C0439234;C1704338;C1704656;C3541383
1099,time since diagnosis of ln  years,C0011900;C0040223;C0439234;C0861352;C1428884;C1704338;C1704656;C3541383;C3714709
1099,time since diagnosis of diabetes ( years ) ( median  iqr ),C0011847;C0011849;C0011900;C0040223;C0439234;C0549183;C0876920;C1704338;C1704656;C2347635;C2348144;C2939193;C3541383
1099,time since diagnosis of copd  years,C0011900;C0024117;C0040223;C0439234;C1412502;C1704338;C1704656;C3541383;C3714496
1099,time since diagnosis  years,C0011900;C0040223;C0439234;C1704338;C1704656;C3541383
1099,time since bph diagnosis ( years ),C0005001;C0011900;C0040223;C0439234;C1704272;C1704338;C1704656;C3541383
1099,time since as diagnosis ( years )  mean   ±   sd,C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383
1099,ticagrelor $nmbr$ mg $nmbr$ yr km %,C0024671;C0026410;C0439234;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
1099,t $nmbr$ dm duration ( years ),C0011816;C0439234;C0449238;C2603360;C2926735;C3250443
1099,t $nmbr$ d duration  years,C0439234;C0449238;C2603360;C2926735
1099,surgical repair of vsd or pda > $nmbr$ - year duration,C0013274;C0018818;C0226047;C0374711;C0439234;C0439508;C0449238;C2926735;C4282128
1099,standard care slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C1442989;C1947933;C2828392;C4330985;C4554674
1099,ss years,C0439234;C2699257;C3891295;C4551874
1099,smoking index — pack - yr §,C0037369;C0439234;C0453996;C0600653;C0918012;C1552854;C1637833;C1881674;C1968515;C2825051;C2828395;C2986546
1099,smoking history ( pack - yr ),C0439234;C1519384;C1968515;C2825051;C2828395
1099,s $nmbr$ years ( n = $nmbr$ ),C0439234;C2986823
1099,s $nmbr$ years,C0439234;C0565930;C2603362
1099,recurrent infections ( > $nmbr$ per year ),C0239998;C0439234;C0439508
1099,ra duration ( years )  mean ( s . e . ),C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3538806;C4048756
1099,psoriasis duration ( years )  mean ( sd ),C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1099,psoriasis duration  years,C0033860;C0439234;C0449238;C2926735
1099,psoriasis duration  mean ± sd  years,C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1099,psa duration ( years )  mean ( sd ),C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3810537;C3813209
1099,psa duration ( years ),C0439234;C0449238;C2926735;C3810537;C3813209
1099,psa duration  years,C0439234;C0449238;C2926735;C3810537;C3813209
1099,prior years taking warfarin,C0043031;C0332152;C0439234;C1515187;C2826257
1099,person - years,C0027361;C0439234;C2347489
1099,persistent anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i $nmbr$,C0019046;C0021966;C0221138;C0439234;C0741008;C1319635;C1549954
1099,percentage with disease duration < $nmbr$ years,C0439165;C0439234;C0872146;C1549488;C1561533
1099,patients with an event per $nmbr$ patient - years,C0030705;C0439234;C0441471;C4019010
1099,patients per $nmbr$ patient - years,C0030705;C0439234
1099,patient years,C0030705;C0439234
1099,patient - years ) hr ( unadjusted ),C0030705;C0439234;C1439367
1099,participants with an event per $nmbr$ patient - years,C0030705;C0439234;C0441471;C0679646;C4019010
1099,p value ( aged > $nmbr$ vs . < $nmbr$ years ),C0001779;C0001792;C0439234;C1709380;C1999167
1099,older than $nmbr$ years,C0439234;C0580836
1099,of t $nmbr$ dm ( years ),C0011816;C0439234;C2603360;C3250443
1099,number ol ( % ) patients > $nmbr$ years,C0030705;C0237753;C0439234;C0449788
1099,number of patients > $nmbr$ years ( % ),C0439234;C2360800
1099,number of hospitalizations in last year prior to baseline,C0168634;C0332152;C0439234;C0439508;C1442488;C1517741;C4086639
1099,number of copd exacerbations in the previous year    n   ( % ),C0205156;C0237753;C0439234;C0439508;C0449788;C0740304;C1552607
1099,number of copd exacerbations in the previous year  n ( % ),C0205156;C0237753;C0439234;C0439508;C0449788;C0740304;C1552607
1099,number of clinically significant asthma exacerbations in last year prior to baseline,C0168634;C0237753;C0237881;C0332152;C0349790;C0439234;C0439508;C0449788;C0750502;C1442488;C1517741;C1546944
1099,number of ( % ) patients > $nmbr$ years,C0439234;C2360800
1099,no . of participants per $nmbr$ patient - yr,C0030705;C0439234;C0679646
1099,no . of pack - yr,C0439234;C1968515;C2825051;C2828395
1099,no . of events / patients % / yr,C0030705;C0439234;C0441471;C3541888
1099,no . of cardiovascular events ( cardiovascular events / $nmbr$ person - years ),C0027361;C0439234;C1320716;C2347489
1099,no . / $nmbr$ person - yr,C0027361;C0439234;C2347489
1099,necessitating hospitalization in previous year — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
1099,n / n ( % / yr ),C0369718;C0439234;C0441922
1099,myocardial infarction / cabg / pci < $nmbr$ years,C0010055;C0027051;C0428953;C0439234;C2926063;C3810814;C4049621;C4552959
1099,median duration of symptoms ( range )  yr,C0436359;C0439234;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1099,median disease duration — yr,C0439234;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
1099,median ( q $nmbr$ : q $nmbr$ ) duration of insulin use  years,C0021641;C0439234;C0549183;C0876920;C1533581;C1579433;C1881378;C2347635;C2348144;C2826775;C2939193;C3714501
1099,median ( q $nmbr$ : q $nmbr$ ) duration of diabetes  years,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1099,median ( interquartile range ) — yr,C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
1099,mean — yr age group — no . ( % ),C0027362;C0439234;C0444504;C2347634;C2348001;C2348143
1099,mean — yr,C0439234;C0444504;C2347634;C2348143
1099,mean ± sd ( yr ),C0439234;C0444504;C2347634;C2348143;C2699239
1099,mean ± s . d . duration of diabetes  years,C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
1099,mean years since menopause,C0025320;C0439234;C0444504;C0567312;C2347634;C2348143
1099,mean time since diagnosis ( years ),C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C3541383
1099,mean duration offollow - up ( years ) *,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
1099,mean duration of disease  years,C0439234;C0444504;C0872146;C2347634;C2348143
1099,mean ( sd ) [ range ] duration of epilepsy  years,C0014544;C0439234;C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2699239;C2926735;C3542016
1099,mean $nmbr$ - year cvd risk *,C0007222;C0035647;C0439234;C0439508;C0444504;C2347634;C2348143;C4552904
1099,less than $nmbr$ year,C0439092;C0439234;C0439508
1099,known duration of diabetes  yr,C0011847;C0011849;C0205309;C0439234;C0449238;C2926735
1099,interval of > $nmbr$ yr since diagnosis of type $nmbr$ diabetes — no . ( % ),C0011847;C0011849;C0011900;C0439234;C1272706;C1320657;C1550351;C1552654;C1552713;C1704338;C1704656
1099,interquartile range — yr,C0439234;C1711350
1099,insulin glargine slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C0907402;C4330985;C4554674
1099,incidence rate per $nmbr$ person years,C0027361;C0439234;C1708485;C2347489
1099,incidence rate per $nmbr$ person - years,C0027361;C0439234;C1708485;C2347489
1099,incidence rate no . ( / $nmbr$ person - years ),C0027361;C0439234;C1708485;C2347489
1099,incidence [ n / n ( rate per $nmbr$ person - years ) ],C0027361;C0439234;C1708485;C2347489
1099,incidence  $nmbr$ person - year,C0021149;C0027361;C0220856;C0439234;C0439508;C2347489
1099,history of falls in year before randomization,C0034656;C0439234;C0439508;C1561668;C2919132
1099,history of clinical fracture ( > $nmbr$ years old ),C0205210;C0439234;C0580836;C1272071
1099,heart failure $nmbr$ yr before admission,C0018801;C0018802;C0184666;C0439234;C0809949;C4554158
1099,framingham $nmbr$ - year cv risk score,C0035647;C0439234;C0439508;C0449820;C3166866;C3538987;C4048877;C4050231;C4318503;C4552904
1099,formal education  years,C0439234;C0681344
1099,follow - up in - trial at $nmbr$ yr,C0008976;C0439234;C0589120;C1522577;C1704685;C3274571
1099,first year *,C0205435;C0439234;C0439508;C1279901
1099,eze / simva - $nmbr$ yr km rale ( % ),C0034642;C0439234;C3887676
1099,exacerbations in the year before study,C0439234;C0439508;C0557651;C2603343;C4086268
1099,exacerbations in the prev . year : $nmbr$,C0439234;C0439508;C1552852;C4086268
1099,exacerbations in previous year requiring hospitalization and / or ed visit  n ( % ),C0019993;C0205156;C0439234;C0439508;C0545082;C1512346;C1552607;C2826704;C3538926;C4086268
1099,exacerbations in previous year requiring hospitalization  n ( % ),C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
1099,exacerbations in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1099,exacerbation in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1099,evenls per $nmbr$  $nmbr$ palienl - years,C0439234
1099,elderly ( > $nmbr$ years ),C0001792;C0439234;C1999167
1099,education in years  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1099,education in years  mean,C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143
1099,education > $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
1099,education < $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
1099,education ( years ),C0013621;C0013622;C0013658;C0039401;C0439234
1099,education $nmbr$ - $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
1099,education  years  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1099,education  mean ( sd ) years,C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1099,ed > $nmbr$ yr  no . ( % ),C0439234;C3538926
1099,duration — yr,C0439234;C0449238;C2926735
1099,duration since diagnosis ( years ),C0011900;C0439234;C0449238;C1704338;C1704656;C2926735
1099,duration ofdiabetes — yr,C0439234;C0449238;C2926735
1099,duration of t $nmbr$ d ( years ),C0439234;C0449238;C2926735
1099,duration of rheumatoid arthritis  year,C0003873;C0439234;C0439508;C0449238;C2926735
1099,duration of rat  years,C0034693;C0034721;C0439234;C0449238;C2926735
1099,duration of ra  mean ± sd years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3538806;C4048756
1099,duration of psoriasis ( years )  mean ( sd ),C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1099,duration of psoriasis  years,C0033860;C0439234;C0449238;C2926735
1099,duration of hypercholesterolemia ( yr ),C0020443;C0439234;C0449238;C1522133;C2926735
1099,duration of hypercholesterolemia  mean ± sd ( years ),C0020443;C0439234;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
1099,duration of heart failure ( years ),C0018801;C0018802;C0439234;C0449238;C2926735;C4554158
1099,duration of epilepsy  years  mean ( sd ),C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1099,duration of epilepsy  years,C0014544;C0439234;C0449238;C2926735
1099,duration of epilepsy  mean ( sd )  years,C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1099,duration of disease ( years ),C0439234;C0872146
1099,duration of disease  years,C0439234;C0872146
1099,duration of diabetes — yr,C0011847;C0011849;C0439234;C0449238;C2926735
1099,duration of diabetes in years  median ( iqr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1099,duration of diabetes > $nmbr$ years,C0011847;C0011849;C0439234;C0449238;C2926735
1099,duration of diabetes < $nmbr$ years,C0011847;C0011849;C0439234;C0449238;C2926735
1099,duration of diabetes ( years ) t,C0011847;C0011849;C0439234;C0449238;C2926735
1099,duration of diabetes ( years )  mean ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1099,duration of diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
1099,duration of diabetes  years  median ( iqr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1099,duration of diabetes  years  mean ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1099,duration of diabetes  years,C0011847;C0011849;C0439234;C0449238;C2926735
1099,duration of coronary artery disease — yr,C0018787;C0439234;C0449238;C0852949;C2926735
1099,duration of as  years,C0439234;C0449238;C2926735
1099,duration dm in dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
1099,duration diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
1099,duration alendronate use  years ( meanisd ),C0042153;C0102118;C0439234;C0449238;C0457083;C1947944;C2926735
1099,duration > $nmbr$ years  n ( % ),C0439234;C0449238;C2926735
1099,duration > $nmbr$ to < $nmbr$ years  n ( % ),C0439234;C0449238;C2926735
1099,duration < $nmbr$ year  n ( % ),C0439234;C0439508;C0449238;C2926735
1099,dm duration  years,C0011816;C0439234;C0449238;C2926735;C3250443
1099,disease duration > $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
1099,disease duration ( years )  mean ± s . d .,C0439234;C0444504;C0872146;C2347634;C2348143
1099,disease duration ( years ),C0439234;C0872146
1099,disease duration $nmbr$ to b $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
1099,disease duration  years : median ( range ),C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1099,disease duration  years,C0439234;C0872146
1099,disease duration  median ( range ) years,C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1099,difference ( glargine - standard care ) lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0907402;C1442989;C1705241;C1705242;C1947933;C2828392;C4330985;C4554674
1099,diagnosis — yr,C0011900;C0439234;C1704338;C1704656
1099,diagnosis ( years ),C0011900;C0439234;C1704338;C1704656
1099,diabetes duration ( years ) *,C0011847;C0011849;C0439234;C0449238;C2926735
1099,diabetes duration  years ^,C0011847;C0011849;C0439234;C0449238;C2926735
1099,diabetes duration  median ( iqr )  years,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1099,dabigatran $nmbr$ mg $nmbr$ mg % per yr,C0439234;C1319635;C2348066
1099,cv event  years,C0439234;C0441471;C3538987;C4019010;C4048877;C4318503
1099,copd exacerbations during the previous year,C0205156;C0439234;C0439508;C0740304;C1552607
1099,copd exacerbation history in the previous year  n ( % ),C0019664;C0019665;C0205156;C0262512;C0262926;C0439234;C0439508;C0740304;C1552607;C1705255;C2004062
1099,copd duration  mean ( sd )  yr *,C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1099,characteristic age mean ± sd — yr,C0001779;C0439234;C0444504;C1521970;C2347634;C2348143;C2699239
1099,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  hr  hazard ratio  k ( rate )  # of events per $nmbr$ patient - years of follow - up  yr  year . multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates .,C0009667;C0019046;C0022661;C0030705;C0036773;C0042027;C0168634;C0201976;C0229671;C0439234;C0441471;C0456603;C0589120;C0596019;C0597277;C0600061;C0683312;C0728877;C0871208;C1442488;C1521828;C1522577;C1524119;C1546774;C1547037;C1549954;C1550100;C1565830;C1704685;C1708601;C2362049;C2985465;C3161035;C3274571;C3274659;C3541888;C3714583;C3853906;C3889287
1099,baseline to year $nmbr$,C0168634;C0439234;C0439508;C1442488
1099,baseline if have $nmbr$ yr follow - up *,C0168634;C0439234;C0589120;C1442488;C1522577;C1704685;C3274571
1099,at $nmbr$ years,C0439234
1099,asthma duration ( sd )  years,C0004096;C0439234;C0449238;C2699239;C2926735;C2984299
1099,aspirin group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years ),C0004057;C0027361;C0439234;C0441848;C2347489
1099,ard per $nmbr$ $nmbr$ patient - years ( $nmbr$ % ci ),C0008107;C0030705;C0439234;C1817569;C1826411;C3259781
1099,ard ( $nmbr$ % cl ) per $nmbr$ patient - years,C0030705;C0439234;C0596019;C1817569;C1826411
1099,all - cause mortality at $nmbr$ year,C0015127;C0026565;C0026566;C0439234;C0439508;C0444868;C1524003;C3539085
1099,all - cause mortality ( per $nmbr$ person - years ),C0015127;C0026565;C0026566;C0027361;C0439234;C0444868;C1524003;C2347489;C3539085
1099,age at menopause ( yr ),C0439234;C1625754;C1629609
1099,age at asthma diagnosis years,C0004096;C0439234;C1828181;C2984299;C3173302
1099,age  yr  mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
1099,admission for hf in previous year  n ( % ),C0018488;C0184666;C0205156;C0439234;C0439508;C0809949;C1313497;C1538440;C1552607;C3273279
1099,admission for hf in previous year,C0018488;C0184666;C0205156;C0439234;C0439508;C0809949;C1313497;C1538440;C1552607;C3273279
1099,a $nmbr$ years,C0439234
1099,> year $nmbr$,C0439234;C0439508
1099,> l $nmbr$ years,C0439234;C0439394;C1706495;C3642217
1099,> is years,C0439234
1099,> = medan ( $nmbr$ year - old ),C0439234;C0439508;C0580836
1099,> = $nmbr$ yr,C0439234
1099,> = $nmbr$ years and < $nmbr$ years,C0439234
1099,> = $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ ),C0032042;C0439234;C1611934;C1696465;C1706408
1099,> = $nmbr$ years ( n = $nmbr$ ),C0439234
1099,> = $nmbr$ years,C0439234
1099,> = $nmbr$ yea ' s,
1099,> $nmbr$   years,C0439234
1099,> $nmbr$ yr — no . { % ),C0439234
1099,> $nmbr$ yr — no . ( % ),C0439234
1099,> $nmbr$ yr — %,C0439234
1099,> $nmbr$ yr warfarin experience,C0043031;C0237607;C0439234;C0596545
1099,> $nmbr$ yr since menopause,C0025320;C0439234;C0567312
1099,> $nmbr$ yr from the united states,C0041703;C0439234
1099,> $nmbr$ yr ( n = $nmbr$ ),C0439234
1099,> $nmbr$ yr ( % ),C0439234
1099,> $nmbr$ yr  n ( % ),C0439234
1099,> $nmbr$ yr,C0439234
1099,> $nmbr$ yearstos is years,C0439234
1099,> $nmbr$ years vs .   ≤   $nmbr$ years,C0439234
1099,> $nmbr$ years to < $nmbr$ years ( n = $nmbr$ ),C0439234
1099,> $nmbr$ years to < $nmbr$ years,C0439234
1099,> $nmbr$ years simva ( „ = $nmbr$ },C0439234
1099,> $nmbr$ years simva ( n = $nmbr$ ),C0439234
1099,> $nmbr$ years simva,C0439234
1099,> $nmbr$ years old,C0439234;C0580836
1099,> $nmbr$ years n z $nmbr$,C0439234
1099,> $nmbr$ years eze / simva baseline ldl - c,C0168634;C0439234;C1442488
1099,> $nmbr$ years eze / simva ( „ = $nmbr$ },C0439234
1099,> $nmbr$ years eze / simva ( n = $nmbr$ ),C0439234
1099,> $nmbr$ years education,C0013621;C0013622;C0013658;C0039401;C0439234
1099,> $nmbr$ years ( n = $nmbr$ ),C0439234
1099,> $nmbr$ years ( % ),C0439234
1099,> $nmbr$ years $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0439234
1099,> $nmbr$ years  n ( % ),C0439234
1099,> $nmbr$ years,C0439234
1099,> $nmbr$ year,C0439234;C0439508
1099,> $nmbr$ to   ≤   $nmbr$ years vs .   ≤   $nmbr$ years,C0439234
1099,> $nmbr$ to < = $nmbr$ years  n ( % ),C0439234
1099,> $nmbr$ to < $nmbr$ yr,C0439234
1099,> $nmbr$ to < $nmbr$ years,C0439234
1099,> $nmbr$ to $nmbr$   years,C0439234
1099,> $nmbr$ to $nmbr$ years,C0439234
1099,> $nmbr$ and < $nmbr$ years,C0439234
1099,> $nmbr$ - < $nmbr$ years,C0439234
1099,> $nmbr$ - $nmbr$ yr,C0439234
1099,> $nmbr$ - $nmbr$ years,C0439234
1099,< median ( $nmbr$ year - old ),C0439234;C0439508;C0549183;C0580836;C0876920;C2347635;C2348144;C2939193
1099,< l $nmbr$ years,C0439234;C0439394;C1706495;C3642217
1099,< = $nmbr$ yr,C0439234
1099,< = $nmbr$ year  n ( % ),C0439234;C0439508
1099,< $nmbr$ yr — no . ( % ),C0439234
1099,< $nmbr$ yr since menopause,C0025320;C0439234;C0567312
1099,< $nmbr$ yr of education — no . ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
1099,< $nmbr$ yr ( n = $nmbr$ ),C0439234
1099,< $nmbr$ yr,C0439234
1099,< $nmbr$ years simva ( n = $nmbr$ },C0439234
1099,< $nmbr$ years simva ( n = $nmbr$ ),C0439234
1099,< $nmbr$ years simva,C0439234
1099,< $nmbr$ years n z $nmbr$,C0439234
1099,< $nmbr$ years eze / simva ( n = $nmbr$ },C0439234
1099,< $nmbr$ years eze / simva ( n = $nmbr$ ),C0439234
1099,< $nmbr$ years eze / simva,C0439234
1099,< $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ ),C0032042;C0439234;C1611934;C1696465;C1706408
1099,< $nmbr$ years ( n = $nmbr$ ),C0439234
1099,< $nmbr$ years ( % ),C0439234
1099,< $nmbr$ years  n ( % ),C0439234
1099,< $nmbr$ years,C0439234
1099,< $nmbr$ year,C0439234;C0439508
1099,< $nmbr$ yea ' s,
1099,< $nmbr$ . $nmbr$ years,C0439234
1099,( years ),C0439234
1099,% / yr,C0439234
1099,% / year,C0439234;C0439508
1099,$nmbr$ — < $nmbr$ years,C0439234
1099,$nmbr$ — $nmbr$ years,C0439234
1099,$nmbr$ yr km % ( n ),C0439234;C3887676
1099,$nmbr$ yr,C0439234
1099,$nmbr$ years or older,C0439234;C0580836
1099,$nmbr$ years ( n = $nmbr$ ),C0439234
1099,$nmbr$ years  n ( % ),C0439234
1099,$nmbr$ years,C0439234
1099,$nmbr$ year or more,C0205172;C0439234;C0439508
1099,$nmbr$ to < $nmbr$ yr — no . { % ),C0439234
1099,$nmbr$ to < $nmbr$ yr — no . ( % ),C0439234
1099,$nmbr$ to < $nmbr$ yr,C0439234
1099,$nmbr$ to < $nmbr$ years,C0439234
1099,$nmbr$ to $nmbr$ yr,C0439234
1099,$nmbr$ to $nmbr$ years,C0439234
1099,$nmbr$ moto < $nmbr$ yr  n ( % ),C0439234
1099,$nmbr$ mo to $nmbr$ yr,C0026544;C0332177;C0439234
1099,$nmbr$ e $nmbr$ years,C0439234
1099,$nmbr$ = $nmbr$ yr — no . ( % ),C0439234
1099,$nmbr$ - yr km mortality rate,C0026565;C0205848;C0439234;C3887676
1099,$nmbr$ - yr %,C0439234
1099,$nmbr$ - year risk of chd  % # < $nmbr$ . $nmbr$,C0439234;C0439508;C1282512
1099,$nmbr$ - year risk of chd  % #,C0439234;C0439508;C1282512
1099,$nmbr$ - year risk for chd,C0439234;C0439508;C1282512
1099,$nmbr$ - year predicted risk ( % ) of,C0035647;C0439234;C0439508;C0681842;C1882327;C4552904
1099,$nmbr$ - year mortality,C0026565;C0026566;C0439234;C0439508
1099,$nmbr$ - year km %,C0439234;C0439508;C3887676
1099,$nmbr$ - year framingham chd risk ( % ) $nmbr$ mean / sd ),C0439234;C0439508;C0444504;C1282512;C2347634;C2348143;C2699239;C3166866
1099,$nmbr$ - year framingham chd risk  %,C0439234;C0439508;C1282512;C3166866
1099,$nmbr$ - year framingham chd risk,C0439234;C0439508;C1282512;C3166866
1099,$nmbr$ - < $nmbr$ years,C0439234
1099,$nmbr$ - $nmbr$ yr — no . ( % ),C0439234
1099,$nmbr$ - $nmbr$ yr ( % ),C0439234
1099,$nmbr$ - $nmbr$ yr,C0439234
1099,$nmbr$ - $nmbr$ years,C0439234
1099,$nmbr$ $nmbr$ years  n ( % ),C0439234
1099,$ $nmbr$ years ( n = $nmbr$ ),C0439234
1099,$ $nmbr$ years,C0439234
1099,$ $nmbr$ and  $nmbr$ years,C0439234
1099,# $nmbr$ year,C0439234;C0439508
1098,teaes of special interest,C0205555;C0543488
1098,special interest categories,C0205555;C0543488;C0683312
1098,social interaction,C0037420
1098,interact !,
1097,interval from symptom onset to qualifying ecg obtained in the er — hr,C1272706;C1301820;C1514624;C1552654;C1552713;C1623258;C3810541;C3811131;C4086878
1097,interval from onset of symptoms,C1272706;C1552654;C1552713;C4086878
1097,interval between clinical evaluation and initiation oftreatment — no . ( % ),C0205210;C0589507;C1158830;C1261322;C1272706;C1552654;C1552713;C1704686;C2826267;C4084924
1097,interval between clinical evaluation and initiation of treatment — no . ( % ),C0039798;C0087111;C0205210;C0589507;C1158830;C1261322;C1272706;C1522326;C1533734;C1552654;C1552713;C1704686;C1705169;C2826267;C3538994;C3887704;C4084924
1097,hazard ratio ( $nmbr$ % confi dence interval ),C1272706;C1552654;C1552713;C2985465
1096,p value ( inter ),C0205103;C1548610;C1709380
1096,p inter,C0205103;C0369773;C1548610;C2603361
1096,p for inter - act,C0079613;C0205103;C0369773;C1548610;C1704930;C1869853;C2603361;C3890007;C4048375
1096,p - inter,C0205103;C0369773;C1548610;C2603361
1096,p ( inter - action ),C0205103;C0369773;C0441472;C1548610;C2603361;C3266814
1096,p ( inter ),C0205103;C0369773;C1548610;C2603361
1096,long - acting  intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
1096,intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
1096,intermediate - acting,C0205103;C1550465;C2827755;C3889971
1096,intermediate ( $nmbr$ - $nmbr$ ),C0205103;C1550465;C2827755;C3889971
1096,intermediate ( $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205103;C1550465;C2827755;C3889971
1096,intermediate ( $nmbr$ )  %,C0205103;C1550465;C2827755;C3889971
1096,intermediate,C0205103;C1550465;C2827755;C3889971
1096,inter p - value,C0205103;C1548610;C1709380
1096,inter . p - value,C0205103;C1548610;C1709380
1096,inter .,C0205103;C1548610
1096,dabigatran $nmbr$ vs . warfarin p ( inter ),C0043031;C0205103;C1548610;C2348066
1095,nintedanib ( n   =   $nmbr$ ),C2930789
1095,nintedanib ( n = $nmbr$ ),C2930789
1095,maintenance dose,C3714445
1095,ics dose of stable maintenance treatment ( μ g ) ∗  †,C0039798;C0087111;C0178602;C0205360;C0439267;C0814469;C0815320;C0869039;C1114758;C1522326;C1533734;C1547311;C1705169;C3538994;C3714445;C3887704;C4551720
1094,statin intolerance $nmbr$  n ( % ),C0231199;C0360714;C1744706;C2355652
1094,previous intolerance of infliximab  n ( % ) *,C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
1094,patients with previous loss of response to and intolerance of infliximab *,C0030705;C0205156;C0231199;C0666743;C0871261;C1517945;C1552607;C1704632;C1706817;C1744706;C2355652;C2911692
1094,patients with previous intolerance of infliximab,C0030705;C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
1094,intolerance ®,C0231199;C1744706;C2355652
1094,intolerance ',C0231199;C1744706;C2355652
1094,intolerance,C0231199;C1744706;C2355652
1094,inadequate response or intolerance to > $nmbr$ anti - tnfdrug,C0205412;C0231199;C0439856;C0871261;C1704632;C1706817;C1744706;C2355652;C2911692
1093,potential injection site reactions,C0151735;C3245505
1093,injection - site reaction  n ( % ),C0151735;C4551923
1093,infections and infestations,C0851341;C3714514
1093,infections,C3714514
1093,infected  n ( % ) a,C0439663
1093,acute infection without septic shock,C0036983;C0275518
1092,uncertain,C0087130;C4085655
1092,uncerlain,
1092,ischemic stroke ( incl . uncertain ),C0087130;C0948008;C4085655
1092,( incl . uncertain ),C0087130;C0268281;C1418854;C4085655
1091,t wave inversion,C0520888
1091,t - wave inversion,C0520888
1091,symmetric t wave inversions,C0332516;C0520888;C2699744
1091,symmetric t - wave inversions,C0332516;C0520888;C2699744
1091,st - segment depression or t - wave inversion on ecg,C0021943;C0021945;C0429104;C0520887;C0520888;C1623258;C1705687;C2349984
1091,st - depression and t - wave inversion,C0520887;C0520888
1091,major st depression or t - wave inversion,C0036056;C0041696;C0205082;C0205164;C0520887;C0520888;C1269683;C3272372;C4318856;C4521762
1091,inversion,C0021943;C0021945;C1705687;C2349984
1090,patients with fingernail involvement,C0030705;C0222001;C1314939
1090,organ system involvement  no . ( % ),C0460002;C1314939
1090,no ststm,
1090,no . fingernails,C0222001
1090,no . ( % ) of patients with fingernail involvement,C0030705;C0222001;C1314939
1089,specific risk of bleeding ^,C0205369;C1552740;C3251812
1089,risk of bleeding,C3251812
1089,noliecervrig,
1089,noirecerving,
1088,life - threatening bleeding  disabling stroke  and death,C0011065;C0019080;C0038454;C1306577;C1546953;C2826244;C3537125;C4082313;C4552775;C4554100
1088,life - threatening bleed,C0019080;C1546953;C2826244;C3537125
1088,life - threatening,C1546953;C2826244;C3537125
1087,undeterminedc,
1087,undetermined etiology  n ( % ),C0478157
1087,undetermined etiology,C0478157
1087,stroke of undetermined cause,C0015127;C0038454;C1524003
1086,undetermined,C0205258;C3536725;C4082977
1086,patients who received indeterminate results on test for antibodies to infliximabt,C0003241;C0030705;C0205258;C0456984;C1514756
1086,indeterminate nfs - $nmbr$ . $nmbr$ < nfs < $nmbr$ . $nmbr$ ! n = $nmbr$ ),C0205258;C1513839
1086,indeterminate ! !,C0205258
1085,generalized,C0205246
1085,general andthoracic epidural,C0205246;C0228134;C0812144;C3812897;C3891294;C4521767
1085,general alone,C0205171;C0205246;C0439044;C0679994;C3812897;C3891294;C4521767
1085,general allergic events,C0205246;C0441471;C0700624;C3541888;C3812897;C3891294;C4521767
1085,general,C0205246;C3812897;C3891294;C4521767
1084,gene / chr / snp,C0017337;C0043459;C0752046;C1527094;C1861559;C3890034;C4050175
1084,gene,C0017337
1083,gertder,
1083,gender n ( % ),C0079399;C1522384
1083,gender female,C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
1083,gender [ n ( % ) ],C0079399;C1522384
1083,gender :,C0079399;C1522384
1083,gender - n ( % ),C0079399;C1522384
1083,gender ( m / f )  ( % ),C0079399;C1306057;C1522384
1083,gender    n   ( % ),C0079399;C1522384
1083,gender  no . ( % ),C0079399;C1522384
1083,gender  n ( % ],C0079399;C1522384
1083,gender  n ( % ),C0079399;C1522384
1083,gender  female  n ( % ),C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
1083,gender  % of patients,C0030705;C0079399;C1522384
1083,gender  %,C0079399;C1522384
1083,gender,C0079399;C1522384
1083,gendar,
1083,eze / simva gender,C0079399;C1522384
1083,> $nmbr$  n ( % ) gender  n ( % ),C0079399;C0369718;C0441922;C1522384
1082,tender,C0234234
1082,number of tender joints ( $nmbr$ assessed ),C0234234;C0449813;C1516048
1082,number of tender joints ( $nmbr$ - $nmbr$ )  mean ( sd ),C0234234;C0444504;C0449813;C2347634;C2348143;C2699239
1082,number of tender joints ( $nmbr$ - $nmbr$ ),C0234234;C0449813
1081,p  net difference,C0369773;C1456447;C1705241;C1705242;C2603361;C3853572;C3887809;C3890893
1081,net ep $nmbr$,C1456447;C1880476;C3853572;C3887809;C3890893;C4321526
1081,net composite,C0205199;C1456447;C1547335;C3853572;C3887809;C3890893
1081,net clinical benefit *,C1456447;C3853572;C3887809;C3890893;C4684590
1081,net adverse clinical events at day $nmbr$,C0205210;C0332173;C0439228;C0439505;C0877248;C1456447;C1705413;C3853572;C3887809;C3890893
1080,knees ( n ),C0022742
1080,knee,C0022742;C0022745;C1963703
1080,below - knee popliteal crural,C0022742;C0022745;C0023216;C0442037;C0542339;C1140621;C1552829;C1963703
1080,below - knee popliteal,C0022742;C0022745;C0442037;C0542339;C1552829;C1963703
1079,new or worsentna neohrodathv,C0205314
1079,new or worsenina neohrodathv,C0205314
1079,new des ( n = $nmbr$ ),C0011702;C0205314;C4551552
1078,odds ratio,C0028873
1078,estimated response rate and odds ratio,C0028873;C0237629;C0750572
1078,estimated odds ratio,C0028873;C0750572
1078,dd ( n = $nmbr$ ),C3538867;C3814791
1078,dd,C3538867;C3814791
1077,fluticasone propionate / salmeterol fdc,C0340427;C1413520;C1622832;C3539652
1077,fdc $nmbr$ / $nmbr$   μ g ( n   =   $nmbr$ ),C0340427;C0439267;C1413520;C3539652
1077,budesonide / formoterol fdc,C0340427;C1276807;C1413520;C3539652
1076,ada impaired fasting glucose,C1060325;C1272092;C3811629
1076,ada $nmbr$ / $nmbr$ n [ $nmbr$,C1060325;C3811629
1076,ada $nmbr$ / $nmbr$ ( n [ $nmbr$ ),C1060325;C3811629
1076,ada  yes,C1060325;C1549445;C1705108;C1710701;C3811629
1076,ada  no,C1060325;C3811629
1075,adas — cog score,C0449820;C3539026;C4050231
1075,adas - cog score *,C0449820;C3539026;C4050231
1075,adas - cog,C3539026
1074,gaviscon da ( n = $nmbr$ ),C0011318;C0061146;C3668815
1074,abbreviations : da  disc area  e - etdrs  electronic early treatment diabetic retinopathy study  iop  intraocular pressure  oct  optical coherence tomography .,C0000723;C0011318;C0011884;C0013850;C0017446;C0021888;C0180459;C0205146;C0920367;C1547561;C1556138;C1705370;C2348299;C3161471;C3668815;C4281784
1074,> $nmbr$ da of capillary nonperfusion in the eyec,C0006901;C0011318;C0935624;C3668815
1073,vdz n = \ $nmbr$,
1073,vdz n = $nmbr$,
1073,vdz / vdz [ n = $nmbr$ ],
1073,vdz / pbo [ n = $nmbr$ ],C0031962
1072,feno  $nmbr$ dn = $nmbr$ ),C1333964;C1707618
1072,eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ) ',C1319635;C1333964;C1707618
1071,tg  mmol / l [ mg / dl ],C0337445;C3642216;C3898312
1071,ldl - c  mmol / l ( mg / dl ),C3642216;C3898312
1071,hdl - c  mmol / l ( mg / dl ),C3642216;C3715113;C3898312
1071,fpg  mmol / l ( mg / dl ),C3642216;C3898312
1071,albumin ( mg / dl ),C0001924;C0439269
1071,albumin  g / dl,C0001924;C0439267
1070,adl subscale ( range  $nmbr$ - $nmbr$ ) *,C0001288;C1420005;C1514721;C2348147;C3542016
1070,adl,C0001288;C1420005
1070,adcs - adl score *,C0449820;C3641947;C4050231
1070,adcs - adl,C3641947
1069,ldl - c ( calculated ) *,C0444686;C1441506
1069,fc - ldl - c  friedewald - calculated,C0444686;C1441506;C2983605
1069,ap = $nmbr$ . $nmbr$  bp $nmbr$ . $nmbr$  cp = $nmbr$ . $nmbr$ . * the study - speci ﬁ c bp targets were sbp $nmbr$ mm hg and dbp $nmbr$ mm hg ( or sbp $nmbr$ mm hg and dbp $nmbr$ mm hg in those with dm ) . the ldl - c target was $nmbr$ mg / dl or $nmbr$ mg / dl  depending on risk factor status at baseline in accordance with ncep atp iii guidelines . odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site . an interaction between treatment effect and dm status was observed for bp goal attainment ( p = $nmbr$ . $nmbr$ ) and dual bp / ldl - c goal attainment ( p = $nmbr$ . $nmbr$ ) among patients with or without dm calculated based on a mixed - effects linear model ( not adjusted for differences in baseline values ) . abbreviations : bp  blood pressure  dbp  diastolic blood pressure  dm  diabetes mellitus  ldl - c  low - density lipoprotein cholesterol  ncep atp iii  national cholesterol education program – adult treatment panel iii  or  odds ratio  sbp  systolic blood pressure,C0000723;C0001675;C0002680;C0005767;C0005768;C0005823;C0006938;C0011816;C0011849;C0023732;C0025424;C0025663;C0028873;C0030705;C0033095;C0035648;C0037623;C0039155;C0039798;C0042295;C0065055;C0085805;C0086858;C0087111;C0162791;C0168634;C0178587;C0205145;C0205173;C0205198;C0205246;C0205251;C0205430;C0220845;C0229664;C0282423;C0332257;C0332516;C0428257;C0428883;C0439070;C0439269;C0439475;C0441833;C0444686;C0445247;C0449438;C0449851;C0456081;C0460139;C0536221;C0552449;C0557651;C0680230;C0681850;C0725813;C0750572;C0871511;C1280500;C1306345;C1415692;C1441506;C1441672;C1442488;C1515974;C1518422;C1518681;C1521840;C1522326;C1527178;C1533734;C1550472;C1550501;C1552866;C1554184;C1704640;C1704675;C1705160;C1705169;C1705241;C1705242;C1705938;C1706082;C1706203;C1706365;C1706450;C1706515;C1708288;C1709380;C1999270;C2347108;C2347109;C2348272;C2349001;C2603343;C2697811;C2700399;C2744579;C2825164;C2825575;C2946465;C2986546;C3160715;C3245503;C3250443;C3538994;C3813197;C3887704;C3887950;C3890211;C4048187;C4050020;C4050026;C4068104;C4281799;C4284008;C4318478;C4319583;C4321351;C4330985;C4522223;C4552600;C4553629;C4554674
1068,ldl : hdl ratio,C0428621
1068,ldl / hdl cholesterol ratio  mean ( sd ) §,C0008377;C0428621;C0444504;C2347634;C2348143;C2699239
1068,ldl - to - hdl cholesterol ratio  mean ( sd ),C0008377;C0428621;C0444504;C1171408;C2347634;C2348143;C2699239
1068,ldl - csmedian,
1068,ldl - c > median,C0549183;C0876920;C2347635;C2348144;C2939193
1068,ldl - c : hdl - c ratio,C0428621
1068,ldl - c / hdl - c ratio  mean ( sd ),C0428621;C0444504;C2347634;C2348143;C2699239
1068,ldl - c / hdl - c ratio,C0428621
1068,ldl - c ( median  iqr )  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1068,ldl - c,
1068,lcl,C3658298
1067,ldu - c,
1067,ldlc,C1416822
1067,baseline ldlc level ( n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mgzdl,C0168634;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1067,baseline fc - ldl - c,C0168634;C1442488;C2983605
1066,vldl cholesterol,C0023826;C0523560
1066,vldl - c,C0523560
1066,vldl,C0523560
1066,serum ldl cholesterol,C0428474
1066,ratio of ldl to hdl cholesterol,C0023822;C0392885;C0456603;C1547037
1066,ldl cholesterolt,
1066,ldl cholesterohhdl cholesterol ratio,C0023824;C0202117;C0456603;C1547037
1066,ldl choleslerol,
1066,ldl  - c,
1066,ldl,
1065,inconsistent fao ( n [ $nmbr$ ),C0016457;C0442809
1065,$nmbr$ - $nmbr$ fo - $nmbr$ - o - q ^ i,C0021966;C0221138
1065,$nmbr$ - $nmbr$ fo - $nmbr$ $nmbr$ - $nmbr$ ^,
1065,$nmbr$ $nmbr$ fo $nmbr$ - $nmbr$ $nmbr$ ),
1064,metrex modified intention - to - treat population with an eosinophilic phenotypey,C0032659;C0087111;C0162425;C0333930;C0392747;C1257890;C1283828;C1292734;C1522326;C3889737
1064,metreo modified intention - to - treat population §,C0032659;C0087111;C0162425;C0392747;C1257890;C1283828;C1292734;C1522326;C3889737
1064,ization — no . ( % ),
1064,intention to treat,C0040363;C0041260;C0087111;C0162425;C1283828;C1292734;C1522326;C1883351
1064,intent - to - treatb,C0162425;C1283828;C1550453
1064,intent - to - treat population  n ( % ),C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
1064,intent - to - treat population,C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
1064,individual intended study duration — no . ( % ),C0027361;C0237401;C0489652;C1283828;C1551357
1063,no prior pci,C0332152;C2826257;C4049621
1063,no . of prior bdmards,C0332152;C2826257
1063,leading to discontinuation,C0332152;C0457454;C1444662;C1522538;C4552847
1063,any ae leading to discontinuation  n ( % ),C0332152;C0457454;C1444662;C1522538;C3887670;C4552847
1063,aes leading to discontinuation of study drugb,C0332152;C0457454;C0557651;C1412268;C1444662;C1522538;C2603343;C2699274;C4552847
1063,aes leading to,C0332152;C1412268;C1522538;C2699274
1063,adverse events leading to premature treatment discontinuation,C0039798;C0087111;C0151526;C0205252;C0332152;C0457454;C0877248;C1444662;C1522326;C1522538;C1533734;C1705169;C1705413;C3538994;C3887704;C4018905;C4552847
1063,> $nmbr$ b ( $nmbr$ b to $nmbr$ a ),
1063,> $nmbr$ aes leading to discontinuation,C0332152;C0457454;C1412268;C1444662;C1522538;C2699274;C4552847
1063,< $nmbr$ — no . { % ),
1063,- $nmbr$ . $nmbr$ to - $nmbr$ cm,
1063,$nmbr$ to < $nmbr$ ( n z $nmbr$ ),C0369718;C0441922
1063,$nmbr$ to < $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1063,$ $nmbr$ to  $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1062,some,
1062,geographic distribution - no . ( % ),C0681686
1062,edss stratification . no . ( % ),C0451246;C1514983;C3887783
1062,edss stratification  no . ( % ),C0451246;C1514983;C3887783
1062,$nmbr$ = some restrictions  no help needed,C0027552;C0443288;C0686904;C1269765;C1552861
1061,use of other medications — no . ( % ),C0240320
1061,other  no . ( % ),
1061,no immomtedion,
1061,no hemoconcentration hemoconcentration,C0549409;C0854379
1061,history of amputation — no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
1061,history of amputation  no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
1061,amputation — no . ( % ),C0002688;C0332840;C1546539
1061,> $nmbr$ y  no . ( % ),
1060,region 一 no . ( % ),C0017446;C0205147
1060,region — no . { % ),C0017446;C0205147
1060,region — no . ( % ),C0017446;C0205147
1060,region - no . ( % ),C0017446;C0205147
1060,region  no . / total ( % ),C0017446;C0205147;C0439175;C0439810
1060,region  no . ( % ) c,C0017446;C0205147
1060,region  no . ( % ),C0017446;C0205147
1060,previous antiarrhythmic treatment — no . ( % ),C0003195;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3537142;C3538994;C3887704
1060,other ® region — no . ( % ),C0017446;C0205147
1060,no treatment or antihistamines only,C0019590;C0039798;C0087111;C0205171;C1522326;C1533734;C1705169;C1720467;C3538994;C3887704
1060,no ?,
1060,no .,
1060,geographic region — no . ( % ),C0017446
1060,enrollment by region  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
1059,primary end point  no . of events / total no . ( % ),C0439175;C0439810;C0441471;C2986535;C3541888
1059,no . of events / total no . ( % ),C0439175;C0439810;C0441471;C3541888
1059,no . of events / total no . $nmbr$ % ),C0439175;C0439810;C0441471;C3541888
1059,no . of events / total,C0439175;C0439810;C0441471;C3541888
1059,no . of events,C0441471;C3541888
1059,no . of,
1059,no . evenls,
1059,management of event — no . ( % ),C0001554;C0376636;C0441471;C1273870;C3273539;C4019010
1059,< $nmbr$ — no . ( % ),
1059,$nmbr$ no . of events,C0441471;C3541888
1058,eo severity by la classification at baseline ( baseline of the healing study )  n ( % ),C0043240;C0168634;C0205249;C0332120;C0439793;C0522510;C0557651;C1442488;C1881447;C2603343
1058,eo,C0332120
1057,low renin ( pra < $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ ),C0633231;C0855389;C1141951;C1419788;C1533072;C3274822;C3669212;C4050009;C4283900
1057,lo ( lo - lo ),C0206579;C1232424
1057,$nmbr$ . $nmbr$ ( lo . i ),C0021966;C0206579;C0221138;C1232424
1057,$nmbr$ . $nmbr$ ( lo - $nmbr$ . $nmbr$ ),C0206579;C1232424
1056,wml load at follow - up mri stratified by baseline severity of wml load,C0024485;C0168634;C0205363;C0439793;C0522510;C0589120;C1442488;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
1056,wml load at follow - up mri,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
1056,wml load at baseline mri,C0024485;C0168634;C1442488;C1550025;C1704782;C1708715;C1824234;C3890166
1056,late load,C0205087;C1550025;C1704782;C1708715
1056,early load,C1279919;C1550025;C1704782;C1708715
1055,carvedilol  % ( n ),C0054836
1055,carvedilol,C0054836
1055,bmi  body mass index  hrt  hormone replacement therapy  lvh  left ventricular hypertrophy  nsaids  nonsteroidal anti - inflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ahistory of and / or currently taking lipid - lowering or antidiabetic medications . bp < $nmbr$ . $nmbr$ for verapamil sustained - release ( sr ) vs . atenolol . chistory of or currently have elevated serum creatinine but less than $nmbr$ mg / dl . dblood pressure control defined as < $nmbr$ / $nmbr$ or < $nmbr$ / $nmbr$ in patients with diabetes or a history of renal insufficiency .,C0003211;C0004147;C0007787;C0011847;C0011849;C0012634;C0019664;C0019665;C0023779;C0030685;C0030705;C0033095;C0035078;C0037623;C0042523;C0085096;C0149721;C0150936;C0201976;C0205091;C0205250;C0243148;C0262512;C0262926;C0282402;C0340279;C0391871;C0439092;C0439180;C0439269;C0441994;C0443246;C0443318;C0460139;C0521116;C0600061;C0680255;C0753208;C0935929;C0947487;C1283071;C1305855;C1306345;C1415692;C1515187;C1550141;C1552822;C1565489;C1704788;C1705255;C1708288;C1709991;C1882979;C1963578;C2003888;C2004062;C2587213;C3163633;C3274648;C3539106;C3813610;C3890900;C3891546;C4284008;C4318478;C4521226;C4553389
1055,atenolol n = $nmbr$ no . ( % ),C0004147
1055,atenolol n = $nmbr$,C0004147
1055,atenolol *,C0004147
1055,atenolol ( « = $nmbr$ $nmbr$ ),C0004147
1055,atenolol ( no . = $nmbr$ ),C0004147
1055,atenolol ( n = $nmbr$ ),C0004147
1055,atenolol ( n = $nmbr$  $nmbr$ ),C0004147
1055,atenolol,C0004147
1055,atenoioi ( n = $nmbr$ ),
1054,lleocolon,
1054,ileum or colon,C0009368;C0020885;C3888384
1054,ileum and colon  n ( % ),C0009368;C0020885;C3888384
1054,ileum and colon  ' n ( % ),C0009368;C0020885;C3888384
1054,ileum and colon,C0009368;C0020885;C3888384
1054,ileocolonic ( both ileum and colon ),C0009368;C0020885;C3888384
1054,ileocolon,
1054,colon or rectum,C0009368;C0034896;C3888384
1054,colon only  n ( % ),C0009368;C0205171;C1720467;C3888384
1054,colon only  ' n ( % ),C0009368;C0205171;C1720467;C3888384
1054,colon only,C0009368;C0205171;C1720467;C3888384
1054,colon,C0009368;C3888384
1054,all of the colon,C0009368;C3888384
1053,history of alcohol use,C0551571;C0552479
1053,current alcohol  n ( % ),C0001962;C0001975;C0521116;C1705970
1053,alcohol usef  n ( % ),C0001962;C0001975
1053,alcohol useb,C0001962;C0001975
1053,alcohol abuse,C0085762;C4050601
1053,alcohol ^,C0001962;C0001975
1053,alcohol > $nmbr$ / wk,C0001962;C0001975;C0332174;C0439230
1053,alcohol < = $nmbr$ / wk,C0001962;C0001975;C0332174;C0439230
1053,alcohol,C0001962;C0001975
1052,alcohol users  n ( % ),C0556297
1052,alcohol > $nmbr$ drinks per week,C0332174;C0439230;C0556297
1051,previously untreated isolated systolic hypertension,C0332155;C0745133
1051,isolated systolic hypertension ⁎,C0745133
1051,isolated systolic hypertension ^,C0745133
1051,isolated systolic hypertension  n ( ' % >,C0745133
1051,isolated systolic hypertension  n ( % ) “,C0745133
1051,isolated systolic hypertension,C0745133
1050,hypertensiont,
1050,dyslipidaemia and hypertensiont,C0242339
1049,perfusion defectsatinclusion,C0031001;C4281794
1049,no reperfusion,C0035124;C0684253
1049,acute reperfusion,C0035124;C0205178;C0684253
1048,symptomatic hypotension with sbp < $nmbr$ mm   hg,C0020649;C0085805;C0231220;C0439475;C3163620
1048,symptomatic hypotension ( sbp < $nmbr$ mmhg ),C0020649;C0085805;C0231220;C0439475;C3163620
1048,symptomatic hypotension,C0020649;C0231220;C3163620
1048,orthostatic hypotension,C0020651
1048,hypotension  n ( % ),C0020649;C3163620
1048,hypotension,C0020649;C3163620
1047,proportions  n ( % ),C1709707
1047,proportion of responders n / n ( % ),C1709707
1047,proportion of > = $nmbr$ % responder rates,C0871208;C1521828;C1709707
1047,proportion,C1709707
1047,propafenone,C0033429
1047,mean proportion ( % ),C0444504;C1709707;C2347634;C2348143
1047,estimated proportions ( % ) and odds ratios,C0028873;C0750572;C1709707
1046,patients with radiographic erosion  n / n ( % ),C0030705;C0333307;C0444708;C1880549;C1959609;C3887524
1046,erosion score ( $nmbr$ – $nmbr$ scale ),C0175659;C0333307;C0349674;C0449820;C1880549;C1947916;C1959609;C3887524;C4050231
1046,erosion score ( $nmbr$ - $nmbr$ ),C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
1046,erosion score,C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
1046,erosion  mean ± sd,C0333307;C0444504;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524
1046,erosion,C0333307;C1880549;C1959609;C3887524
1046,change in erosion score ( mean ),C0333307;C0392747;C0443172;C1705241;C1880549;C1959609;C3533236;C3887524;C4319952
1046,baseline erosion,C0168634;C0333307;C1442488;C1880549;C1959609;C3887524
1046,> $nmbr$ erosion  n ( % ),C0333307;C1880549;C1959609;C3887524
1045,prior diagnosis - no . ( % ),C0332132
1045,previous hypersensitivity reaction — no . ( % ),C0020517;C0205156;C1552607
1045,previous events  no . ( % ),C0205156;C0441471;C1552607;C3541888
1045,previous diagnosis,C0332132
1045,previous antiparkinson medication  no . ( % ),C0003405;C0205156;C1552607
1045,no previous diagnosis of diabetes mellitus,C0011849;C0332132
1045,no . of previous csdmards  n ( % ),C0205156;C1552607
1045,no . of previous biologic dmards — no . ( % ),C0205156;C1552607;C4055380
1045,no . *,
1044,yes previous revascularization,C0205156;C0581603;C1549445;C1552607;C1705108;C1710701
1044,smoking status ( previous ) ( n ),C0205156;C1519386;C1552607
1044,severe episodes in previous year — no . / patient,C0030705;C0205082;C0205156;C0332189;C0439234;C0439508;C1552607;C4050465;C4050466
1044,reason for discontinuation of previous tnfa inhibitor,C0205156;C0392360;C0457454;C1444662;C1448177;C1552607;C1710304;C1999216;C4552847
1044,previous vte — no . ( % ),C0205156;C0630906;C1552607
1044,previous vte n ( % ),C0205156;C0630906;C1552607
1044,previous vte  n ( % ),C0205156;C0630906;C1552607
1044,previous vte,C0205156;C0630906;C1552607
1044,previous venous thromboembolism — no . ( % ),C0205156;C1552607;C1861172
1044,previous vascular disease,C0042373;C0205156;C1552607
1044,previous use of systemic steroids for ciu / csu,C0205156;C0205373;C0281991;C0578870;C1552607
1044,previous use of systemic steroids  n ( % ),C0205156;C0205373;C0281991;C1552607
1044,previous use of other biologic agents in addition to tne,C0005515;C0205156;C1524063;C1552607;C3896585
1044,previous use of nonbiologic systemic therapy  n ( % ),C0205156;C1515119;C1524063;C1552607
1044,previous use of niacin or niaspan §,C0027996;C0205156;C1142562;C1161310;C1524063;C1552607
1044,previous use of biologic systemic therapy  n ( % ),C0005515;C0005527;C0205156;C0205373;C0205460;C1515119;C1524063;C1552607
1044,previous use of amiodarone,C0002598;C0205156;C1524063;C1552607
1044,previous treatment failure — no . ( % ) § * *,C0162643;C0205156;C0235828;C0521983;C1547544;C1552607
1044,previous tnf - antagonist use  n ( % ),C0042153;C0205156;C0231491;C0457083;C1448177;C1552607;C1947944
1044,previous therapy,C0039798;C0087111;C0205156;C1363945;C1552607
1044,previous therapies  n ( % ),C0087111;C0205156;C1552607
1044,previous systemic treatment  n ( % ),C0205156;C0678812;C1552607
1044,previous statin use,C0042153;C0205156;C0360714;C0457083;C1552607;C1947944
1044,previous segments resection ( s ) *,C0205156;C1552607;C2987624
1044,previous segmental resection — no . ( % ),C0205156;C1552607;C2987624
1044,previous revascularization,C0205156;C0581603;C1552607
1044,previous receipt of therapy against tnf - a — no . ( % ),C0039798;C0087111;C0205156;C1363945;C1448177;C1552607;C1710304
1044,previous pde $nmbr$ inhibitors,C0031638;C0205156;C1552607
1044,previous pci or cabg,C0010055;C0205156;C1552607;C4049621
1044,previous pci / cabg  n ( % ),C0010055;C0205156;C1552607;C4049621
1044,previous pci ( % total ),C0205156;C0439175;C0439810;C1552607;C4049621
1044,previous pci  n ( % ),C0205156;C1552607;C4049621
1044,previous pci,C0205156;C1552607;C4049621
1044,previous myocardiaunfarction,C0205156;C1552607
1044,previous infliximab therapy — no . of patients ( % ) * *,C0030705;C0205156;C1552607;C4076075
1044,previous infliximab therapy | |,C0205156;C1552607;C4076075
1044,previous infarction ( % of group ),C0021308;C0205156;C0441833;C0687744;C1257890;C1519504;C1552607;C1705428;C1705429
1044,previous infarction,C0021308;C0205156;C1552607
1044,previous htn  n ( % ),C0020538;C0205156;C1552607
1044,previous heart failure — no . ( % ),C0018801;C0018802;C0205156;C1552607;C4554158
1044,previous heart failure,C0018801;C0018802;C0205156;C1552607;C4554158
1044,previous episode of heart failure,C0018801;C0018802;C0205156;C0332189;C1552607;C4554158
1044,previous dmards use  n ( % ),C0042153;C0205156;C0242708;C0369718;C0441922;C0457083;C1552607;C1947944
1044,previous diabetes mellitus,C0011849;C0205156;C1552607
1044,previous diabetes,C0011847;C0011849;C0205156;C1552607
1044,previous cvd ^,C0007222;C0205156;C1552607
1044,previous congestive heart failure — no . ( % ),C0018802;C0205156;C1552607
1044,previous congestive heart failure ( % ),C0018802;C0205156;C1552607
1044,previous congestive heart failure,C0018802;C0205156;C1552607
1044,previous chronic kidney disease,C0205156;C1552607;C1561643;C4553188
1044,previous chf — no . ( % ),C0018802;C0205156;C1552607
1044,previous chf  n ( % ),C0018802;C0205156;C1552607
1044,previous chf,C0018802;C0205156;C1552607
1044,previous cardiovascular disease !,C0007222;C0205156;C1552607
1044,previous cancerc,C0205156;C1552607
1044,previous cabg surgery,C0010055;C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
1044,previous cabg  n ( % ),C0010055;C0205156;C1552607
1044,previous cabg,C0010055;C0205156;C1552607
1044,previous bdmard received,C0205156;C1514756;C1552607
1044,previous anti - tnf therapy  n [ % ],C0205156;C0279936;C0432633;C1552607
1044,previous analgesic products n ( % ),C0002771;C0205156;C1552607
1044,previous ami  n ( % ),C0205156;C1552607;C4319936
1044,previous ami,C0205156;C1552607;C4319936
1044,previous $nmbr$ ari use,C0042153;C0205156;C0457083;C1412533;C1552607;C1947944;C4521376
1044,previous $nmbr$ - ari use ( % ),C0042153;C0205156;C0457083;C1412533;C1552607;C1947944;C4521376
1044,previous,C0205156;C1552607
1044,number of previous tnfa inhibitors,C0205156;C0237753;C0243077;C0449788;C1448177;C1552607;C1710304
1044,no previous dmard therapy,C0039798;C0087111;C0205156;C0242708;C1363945;C1552607
1044,no . of previous venous thromboembolic events,C0205156;C1552607;C1861172;C1997614;C3160733
1044,moderate or severe exacerbations in the previous year ( range ),C0205081;C0205082;C0205156;C0439234;C0439508;C1514721;C1552607;C1881878;C2348147;C3542016;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335
1044,hospitalization in previous year with management of heart failure,C0001554;C0018801;C0018802;C0019993;C0205156;C0376636;C0439234;C0439508;C1273870;C1552607;C3273539;C4554158
1044,exacerbations in the previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1044,cardioversion in previous $nmbr$ wk,C0013778;C0205156;C0332174;C0439230;C1552607
1044,> $nmbr$ previous venous thromboembolisms ( % ),C0205156;C1552607;C1997614
1044,> $nmbr$ in previous,C0205156;C1552607
1043,postmenopausal and no ht,C0018510;C0232970;C0677607
1043,postmenopausal and current ht,C0018510;C0232970;C0521116;C0677607;C1705970
1043,poslmenopausal  no ht,C0018510;C0677607
1043,poslmenopausal  ht,C0018510;C0677607
1043,menopause and ht,C0018510;C0025320;C0567312;C0677607
1043,menopause and hrt,C0025320;C0282402;C0567312
1042,premenopausal  %,C0279752
1042,premenopausal,C0279752
1042,menopausal status and hormone therapy use premenopausal,C0042153;C0279025;C0279752;C0457083;C1513126;C1947944
1042,female : premenopausal,C0043210;C0086287;C0279752;C1705497;C1705498
1041,postmenopausal hormone use,C0019932;C0042153;C0232970;C0457083;C1947944;C4521914
1041,postmenopausal ( % ),C0232970
1041,postmenopausal  never or past hormone therapy use,C0042153;C0232970;C0279025;C0457083;C1444637;C1947944;C2003901;C4284302
1041,postmenopausal,C0232970
1041,post - menopausal ( a ),C0232970
1041,peri - or postmenopausal,C0232970;C0347985
1041,female participants who are ≥ $nmbr$ years postmenopausal,C0043210;C0086287;C0232970;C0439234;C0679646;C1705497;C1705498
1041,female : ≥ $nmbr$ years postmenopausal,C0043210;C0086287;C0232970;C0439234;C1705497;C1705498
1041,female : perimenopausal or < $nmbr$ years postmenopausal,C0043210;C0086287;C0232970;C0439234;C0849668;C1705497;C1705498;C3839366
-10,personal relationships,C1552027
1039,perianal or anus,C0003461;C0442158
1039,perianal gi tract,C0017189;C0442158
1039,perianal  n ( % ),C0442158
1038,new vertebral fracture at $nmbr$ months,C0080179;C0205314;C0439231
1038,new or worsening vertebral fracture at $nmbr$ months,C0080179;C0205314;C0332271;C0439231;C1457868;C1546960
1038,mfns ( n = $nmbr$ ),
1038,b pooled new and worsened vertebral fractures ( mfas ),C0080179;C0205314;C1457868;C1549796;C1549980;C1709595;C2349200;C4084902;C4522255
1038,a new vertebral fractures ( mfas ),C0080179;C0205314;C1549796;C1549980
1037,male patients *,C0150904
1037,male patients  n ( % ),C0150904
1037,female sex  n ( % of patients ),C0009253;C0030705;C0036864;C0043210;C0079399;C0086287;C0150831;C0150905;C0804628;C1314687;C1522384;C1705497;C1705498
1037,female patients ^,C0150905
1037,female patients  n ( % ),C0150905
1037,femaie,
1036,supplementary table $nmbr$ . change from baseline in urine albumin - to - creatinine ratio by hba $nmbr$ c at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria .,C0019016;C0030705;C0039224;C0168634;C0392747;C0443172;C0455271;C0730345;C1318330;C1442488;C1705241;C1706074;C1825777;C3538758;C4319952
1036,patients with normoalbuminuria at baseline,C0030705;C0168634;C1442488
1036,patients with macroalbuminuria at baseline,C0030705;C0168634;C1442488
1036,normoalbuminuria §,
1035,worldwide black patients,C0005680;C0027567;C0030705;C0085756;C0439541
1035,vents / patients,C0030705
1035,u . s . black patients,C0005680;C0027567;C0030705;C0041703;C0085756;C0439541
1035,remaining patients,C0030705;C1527428
1035,randomised patients ( n ),C0030705
1035,race  white  n ( % of patients ),C0007457;C0030705;C0034510;C0043157;C0220938;C1706779;C3853635
1035,proportion of patients who achieved acr $nmbr$ n / n ( % ),C0030705;C1412134;C1515941;C1709707
1035,previous bowel resection performed — no . of patients ( % ),C0030705;C0205156;C0741614;C0884358;C1552607
1035,previous acute hypersensitivity reaction to infliximab — no . of patients ( % ),C0030705;C0205156;C0413234;C0666743;C1552607
1035,percentage patients reaching target,C0030705;C0439165;C1521840;C1549488;C1561533;C2584321;C2986546
1035,percent of patients,C0030705;C0439165
1035,patients without prevalent kidney disease at baseline,C0022646;C0030705;C0168634;C0227665;C0683921;C1442488
1035,patients without diabetesb,C0030705
1035,patients without,C0030705
1035,patients with uncomplicated events ( p = o - $nmbr$ 十 ),C0030705;C0441471;C0443334;C3541888
1035,patients with uncomplicated events,C0030705;C0441471;C0443334;C3541888
1035,patients with pulmonary embolism,C0030705;C0034065
1035,patients with prior dmard use  n ( % ) a,C0030705;C0042153;C0242708;C0332152;C0457083;C1947944;C2826257
1035,patients with prevalent kidney disease at baseline,C0022646;C0030705;C0168634;C0227665;C0683921;C1442488
1035,patients with pneumonia event  n ( % ) #,C0030705;C0032285;C0441471;C4019010
1035,patients with perianal fistulae  n [ % ],C0030705;C0267561
1035,patients with nail psoriasis ( mnapsi > $nmbr$ ),C0030705;C0406322
1035,patients with level > $nmbr$ pg / ml,C0030705;C0439297;C0441889;C0456079;C1547707;C2946261
1035,patients with improvement $ $nmbr$ . $nmbr$,C0030705;C2986411
1035,patients with event / patients analyzed,C0030705;C0441471;C0936012;C4019010
1035,patients with event / patients analysed,C0030705;C0441471;C4019010
1035,patients with event / analyzed,C0030705;C0441471;C0936012;C4019010
1035,patients with event ( n  % ),C0030705;C0441471;C4019010
1035,patients with endpoin t  n ( % ),C0030705;C2986835
1035,patients with digits with dactylitis  n ( % ),C0030705;C0239161;C0582802
1035,patients with diabetic nephropathy,C0011881;C0030705;C1442864
1035,patients with diabetesb,C0030705
1035,patients with dactylitisa,C0030705
1035,patients with at least one concomitant disease | |,C0030705;C0205447;C0243087
1035,patients with at least one concomitant disease *,C0030705;C0205447;C0243087
1035,patients with any clinical event,C0030705;C0205210;C0441471;C4019010
1035,patients with any clinical,C0030705;C0205210
1035,patients with > $nmbr$ co - aeds,C0030705;C0180309;C3245499
1035,patients with $nmbr$ co - aeds,C0030705;C0180309;C3245499
1035,patients with $nmbr$ co - aed,C0030705;C0887457;C3245499
1035,patients who used insulin pump,C0030705;C1140609;C1273517
1035,patients who had ulcerations at,C0030705;C0041582
1035,patients who did not use insulin pump,C0030705;C0042153;C0457083;C1140609;C1518422;C1947944
1035,patients treated with statins ( n = $nmbr$ ),C0030705;C0332293;C0360714
1035,patients treated with atenoloi ( n = $nmbr$ ),C0030705;C0332293
1035,patients receiving immunotherapy  no . ( % ),C0005525;C0021083;C0030705;C1514756
1035,patients receiving immunosuppressive agents at baseline,C0021081;C0030705;C0168634;C1442488;C1514756
1035,patients receiving enl  no . ( % ),C0030705;C1514756
1035,patients randomised  n,C0030705;C0369718;C0441922
1035,patients not treated with statins ( n = $nmbr$ ),C0030705;C0332293;C0360714;C1518422
1035,patients not receiving immunosuppressive agents at baseline,C0021081;C0030705;C0168634;C1442488;C1514756;C1518422
1035,patients n,C0030705
1035,patients assessed,C0030705;C1516048
1035,patients > $nmbr$ y *,C0030705
1035,patients > $nmbr$ y,C0030705
1035,patients > $nmbr$ %,C0030705
1035,patients < $nmbr$ y *,C0030705
1035,patients < $nmbr$ y,C0030705
1035,patients < $nmbr$ %,C0030705
1035,patients / events n,C0030705;C0441471;C3541888
1035,patients ( n ),C0030705
1035,patients    n   ( % ),C0030705
1035,patients  no .,C0030705
1035,patients  n / n ( % ) a,C0030705
1035,patients  n ( % ),C0030705
1035,patients  n,C0030705
1035,patients,C0030705
1035,patient presentation,C0030705;C0449450
1035,patient,C0030705
1035,of patients,C0030705
1035,obese patients  ! n ( % ),C0028754;C0030705
1035,nyha class ( when patient was last in stable condition before admission )  %,C0030705;C0184666;C0677946;C0809949;C1517741;C1882083;C3538874
1035,nyha class ( when patient was last in stable condition,C0030705;C0677946;C1517741;C1882083;C3538874
1035,number of events / patients,C0030705;C0441471;C2360800;C3541888;C4330837
1035,no . patients with,C0030705
1035,no . patients ( % ),C0030705
1035,no . of patients with events ( % ),C0030705;C0441471;C3541888
1035,no . of patients with as,C0030705
1035,no . of patients ( % ),C0030705
1035,no . of patients,C0030705
1035,no . of hospitalised patients,C0030705
1035,n ( % of patients ),C0030705;C0369718;C0441922
1035,male sex — no . of patients ( % ),C0030705;C0086582
1035,laba use  % patients,C0030705;C0042153;C0457083;C1947944
1035,itt patients  n ( % ),C0030705
1035,intensive control ( n = $nmbr$ ) no . of patients ( percent ),C0030705;C0162425;C0243148;C0439165;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
1035,for patients using personal cgm,C0030705;C1519021;C1524063
1035,for patients not using personal cgm,C0030705;C1518422;C1519021;C1524063
1035,all randomized patients ( range ),C0030705;C0034656;C1514721;C2348147;C3542016;C3815594
1035,all randomized patients,C0030705;C0034656;C3815594
1035,all patients with opg n - $nmbr$,C0030705;C1262886;C1336645;C1412836;C1710303
1035,all patients with fistulas ( n = $nmbr$ ),C0016169;C0030705
1035,all patients n = $nmbr$ $nmbr$,C0030705
1035,all patients n = $nmbr$,C0030705
1035,all patients ( « = $nmbr$ $nmbr$ ),C0030705
1035,all patients ( p = $nmbr$ . $nmbr$ ),C0030705
1035,all patients ( p < $nmbr$ . $nmbr$ ),C0030705
1035,all patients ( n   =   $nmbr$ ) b,C0030705
1035,all patients ( n = $nmbr$ ),C0030705
1035,all patients ( n = $nmbr$  $nmbr$ ),C0030705
1035,all patients ( n $nmbr$ $nmbr$ ),C0030705
1035,all patients  n =,C0030705
1035,all patients,C0030705
1035,all mn - na ï ve patients,C0026327;C0026405;C0030705;C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
1035,> $nmbr$ %  n ( % of patients ),C0030705;C0369718;C0441922
1035,( $nmbr$ patients ),C0030705
1035,( $nmbr$ . $nmbr$ % )  values were not collected for $nmbr$ patients ( $nmbr$ . $nmbr$ % ) who were enrolled,C0030705;C0042295;C1516695;C1516698;C1518422;C4684790
1035,% patients with no progression,C0030705;C0242656;C0449258
1035,% patients,C0030705
1035,% of patients $nmbr$ . $nmbr$ $nmbr$ . $nmbr$,C0030705
1035,$nmbr$ %  n ( % of patients ),C0030705;C0369718;C0441922
-10,philippines,C0031529
1033,total no . of events / total no . of participants,C0439175;C0439810;C0441471;C0679646;C3541888
1033,total no . of events / participants,C0439175;C0439810;C0441471;C0679646;C3541888
1033,total no . of events ( % of participants ) / total no . of participants,C0439175;C0439810;C0441471;C0679646;C3541888
1033,peri - operative cabg participants :,C0010055;C0347985;C0679646;C1882154
1033,participants without hf at baseline,C0018488;C0168634;C0679646;C1313497;C1442488;C1538440;C3273279
1033,participants with hf at baseline,C0018488;C0168634;C0679646;C1313497;C1442488;C1538440;C3273279
1033,participants n,C0679646
1033,participants at baseline  n,C0168634;C0679646;C1442488
1033,participants  no . ( % ),C0679646
1033,participants  n,C0679646
1033,participants,C0679646
1033,normal cognitive function ( spmsq < $nmbr$ ) . n - $nmbr$ . $nmbr$ n ( % ) participants with the event of interest,C0009240;C0392335;C0441471;C0679646;C1276356;C4019010;C4050130
1033,nonblack participants,C0679646
1033,no . of participants with events ( % ),C0441471;C0679646;C3541888
1033,no . of participants ( % ),C0679646
1033,no . of participants,C0679646
1033,no . ( % ) of participants,C0679646
1033,n participants,C0369718;C0441922;C0679646
1033,impaired cognitive function ( spmsq > $nmbr$ ) . n - $nmbr$ n ( % ) participants with the event of interest,C0009240;C0221099;C0392335;C0441471;C0543488;C0679646;C4019010;C4050130
1033,characteristics no . of participants,C0679646;C1521970
1033,by gfr stratum tor all participants  ml / min per $nmbr$ . $nmbr$ m ^ !,C0017654;C0076836;C0369637;C0439445;C0441923;C0679646;C1199517;C1419603;C1424601;C3539732
1033,by gfr stratum for all participants  ml / min per $nmbr$ . $nmbr$ m ’ !,C0017654;C0369637;C0439445;C0441923;C0679646;C1424601
1033,all participants ^ ^ ( n = $nmbr$ / $nmbr$ ),C0679646
1033,all participants * ( n = $nmbr$ / $nmbr$ ),C0679646
1033,all participants ( n = $nmbr$ ),C0679646
1033,all participants  mm hg : sbp  mean ( sd ),C0085805;C0439475;C0444504;C0679646;C2347634;C2348143;C2699239
1033,all participants,C0679646
1033,$nmbr$ % participants,C0679646
1032,multivitamins,C0301532;C3714835
1032,multivitamin use yes,C0042153;C0301532;C0457083;C1549445;C1705108;C1710701;C1947944
1032,multivitamin use ( current ),C0042153;C0301532;C0457083;C0521116;C1705970;C1947944
1032,multivitamin use,C0042153;C0301532;C0457083;C1947944
1031,sustain $nmbr$ : semaglutide vs . placebo,C0032042;C0443318;C1696465;C1706408;C2732140;C3885068
1031,sustain $nmbr$ : semaglutide vs . iglar,C0443318;C2732140;C3885068
1031,sustain $nmbr$,C0443318;C2732140
1031,sustain,C0443318;C2732140
1031,octave sustain,C0443318;C2732140
1030,mean lixi dose ± sd ( lg / day ),C0023128;C0178602;C0332173;C0439228;C0439505;C0444504;C0694651;C0869039;C1114758;C2347634;C2348143;C2699239
1030,mean ( s . d . ) ldl particle size  nm,C0203634;C0312860;C0444504;C2347634;C2348143;C3641256;C3890923
1030,lixi,
1030,ldi - b > $nmbr$ ( n = $nmbr$ ),
1030,ldi $nmbr$,
1030,ldi  mean [ sd ] b,C0444504;C2347634;C2348143;C2699239
1030,ldi  mean ( sd ) a,C0444504;C2347634;C2348143;C2699239
1029,napsit,
1029,mnapsi  mean [ sd ] d,C0444504;C2347634;C2348143;C2699239
1029,mnapsi  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1029,mnapsi,
1029,basfi *,
1029,basfi  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1028,apolipoprotein b tx difference vs pbo  ls mean % change from baseline ( se ),C0003593;C0023668;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952
1028,apolipoprotein b ^,C0003593
1028,apolipoprotein b,C0003593
1028,apolipoprotein a - i *,C0085201;C1677784
1028,apolipoprotein a - i,C0085201;C1677784
1028,apolipoprotein a $nmbr$ ( g / l ),C0003592;C0439294;C0456615;C0523508
1028,apolipoprotein a,C0003592;C0523508
1028,apolipoprotein,C0003591
1028,apolipoproiein b ( mij / $nmbr$ ),
1028,apolipoproiein a $nmbr$ ( tng / $nmbr$ ),
1028,= placebo  eze = ezetimibe  erol  apo = apolipoprotein  metabolic syndrome  patients were eans and percentage changes are,C0003591;C0030705;C0032042;C0392747;C0439165;C0443172;C0524620;C1142985;C1549488;C1561533;C1696465;C1706408
1027,periostin ( ng / ml ),C0219433;C0439275;C1424662;C3812270
1027,periostin,C0219433;C1424662;C3812270
1027,low periostin subgroup (  $nmbr$ ng / ml ) ( n = $nmbr$ ),C0205251;C0219433;C0439275;C1079230;C1424662;C1515021;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
1026,ulcerative colitis,C0009324
1026,mouth ulceration,C0149745
1026,concomitant medications for ulcerative colitis — no . ( % ),C0009324;C0013227;C0521115;C0802604;C2598133;C4284232
1026,any ulcerative colitis medication,C0009324;C0013227;C3244316;C4284232
1025,penetrating no . of resections  n ( % ),C0015252;C0205321
1025,penetrating disease  %,C0012634;C0205321
1025,penetrating,C0205321
1024,monitoring treatment,C0039798;C0087111;C0150369;C1283169;C1522326;C1533734;C1705169;C3538994;C3887704
1024,monitoring group ( n = $nmbr$ ),C0150369;C0441848;C1283169
1024,monitoring ( n = $nmbr$ ),C0150369;C1283169
1023,vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
1023,nausea and / or vomiting adverse events,C0027497;C0042963;C0877248;C1705413;C1963179;C1963281;C2984057;C3829611;C3898969;C4084766;C4084767;C4084768;C4084769;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
1022,use of concomitant lipid - lowering treatment,C0023779;C0039798;C0087111;C0441994;C0521115;C1522326;C1524063;C1533734;C1705169;C2003888;C3538994;C3887704
1022,remodeling,
1022,prior urate lowering therapies  n ( % ),C0441994;C0729829;C0935936;C1514463;C2003888
1022,lipid lowering medication use,C0023779;C0240320;C0441994;C2003888
1022,lipid lowering,C0023779;C0441994;C2003888
1022,lipid - lowering,C0023779;C0441994;C2003888
1022,glucose - lowering drug,C0013227;C0017725;C0441994;C1254351;C2003888
1021,stratum i,C0021966;C0221138
1021,revive i,C0021966;C0221138
1021,previous pde $nmbr$ - i therapy  no . ( % ),C0021966;C0039798;C0087111;C0205156;C0221138;C1363945;C1552607
1021,pre - bronchodilator fev i ( l ),C0021966;C0221138;C2599602;C3714541
1021,pde - $nmbr$ i monotherapy,C0021966;C0221138
1021,pde - $nmbr$ i,C0021966;C0221138
1021,other ' i ',C0021966;C0221138
1021,lvef — no . ( % )  i,C0021966;C0221138;C0428772;C0488728
1021,infliiimab i,C0021966;C0221138
1021,i u - uj,C0021966;C0221138;C0439148
1021,i idl cholesterol ( mg / dl ),C0021966;C0123167;C0221138;C0439269;C0523559;C0619865
1021,i amiodarone,C0002598;C0021966;C0221138
1021,i . $nmbr$ i ( $nmbr$ . $nmbr$ - i . $nmbr$ ),C0021966;C0221138
1021,i . $nmbr$ ( $nmbr$ . $nmbr$ - i . $nmbr$ ),C0021966;C0221138
1021,i - ^ w « - i - $nmbr$,C0021966;C0221138
1021,i ( $nmbr$ . i ),C0021966;C0221138
1021,i % $nmbr$,C0021966;C0221138
1021,i $nmbr$ ± i $nmbr$,C0021966;C0221138
1021,i $nmbr$ ± $nmbr$ i,C0021966;C0221138
1021,i $nmbr$ i ± i $nmbr$,C0021966;C0221138
1021,i $nmbr$ i ( i $nmbr$ . $nmbr$ ),C0021966;C0221138
1021,i $nmbr$ i $nmbr$ ± $nmbr$,C0021966;C0221138
1021,i $nmbr$ i,C0021966;C0221138
1021,i $nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$,C0021966;C0221138
1021,i $nmbr$ ( i $nmbr$ . i ),C0021966;C0221138
1021,i $nmbr$ ( i $nmbr$ . $nmbr$ ),C0021966;C0221138
1021,i,C0021966;C0221138
1021,ffa / i,C0015688;C0021966;C0221138
1021,dual i extension - end of trial hba $nmbr$ c,C0008976;C0019016;C0021966;C0205173;C0221138;C0231448;C0444930;C1554184;C1825777;C1880641;C2746065;C3538758
1021,dual i extension,C0021966;C0205173;C0221138;C0231448;C1554184;C1880641
1021,antithrombotic ! i,C0021966;C0221138
1021,albumin - to - creatinine ratio ' i  /,C0021966;C0221138;C0486293;C1318293
1021,> i,C0021966;C0221138
1021,- f $nmbr$ . $nmbr$ ( - i - $nmbr$ . $nmbr$ ),C0016327;C0021966;C0221138
1021,- b - i —,C0021966;C0221138
1021,- b - i -,C0021966;C0221138
1021,$nmbr$ — — bh — i,C0004684;C0004952;C0021966;C0221138;C1412800;C2986890;C4284594;C4321407
1021,$nmbr$ tq - fi ' i,C0021966;C0221138;C3555502;C4050619
1021,$nmbr$ t i,C0021966;C0221138;C2603360
1021,$nmbr$ i $nmbr$ ( $nmbr$ i . $nmbr$ ),C0021966;C0221138
1021,$nmbr$ . i $nmbr$ ( $nmbr$ . $nmbr$ i - $nmbr$ . $nmbr$ ),C0021966;C0221138
1021,$nmbr$ . $nmbr$ to . $nmbr$ . i . iot,C0006196;C0021966;C0221138
1021,$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ) a,C0021966;C0221138
1021,$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0021966;C0221138
1021,$nmbr$ . $nmbr$ ( i $nmbr$ . s ),C0021966;C0221138
1021,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . i $nmbr$ i ),C0021966;C0221138
1021,$nmbr$ - i,C0021966;C0221138
1021,$nmbr$ ( $nmbr$ i . i ),C0021966;C0221138
1020,trial completers,C0008976
1020,trial $nmbr$,C0008976
1020,trial,C0008976
1020,time in trial,C0008976;C0040223;C0150312;C0332285;C1707101;C3541383
1020,pooled trials * n = $nmbr$,C0008976;C1709595;C2349200;C4522255
1020,non - trial treatment during hospital stay,C0008976;C0039798;C0087111;C1518422;C1522326;C1533734;C1705169;C3489408;C3538994;C3887704
1020,non - trial p blocker,C0008976;C1518422
1020,non - trial antiplatelet,C0008976;C1518422
1020,no in - trial stroke n = $nmbr$  $nmbr$,C0008976;C0038454;C0150312;C0332285;C1707101;C4554100
1020,lipid trial participantss,C0008976;C0023779
1020,lipid trial participantsk,C0008976;C0023779
1020,end of trial,C0008976;C0444930;C2746065
1020,enact - $nmbr$ trial rerandomization to natalizumab ( n = $nmbr$ ),C0008976;C1172734
1020,enact - $nmbr$ trial,C0008976
1020,dual iv - end of trial hba $nmbr$ c,C0008976;C0019016;C0205173;C0444930;C0444972;C1554184;C1825777;C2746065;C3538758
1020,dual ii - end of trial hba $nmbr$ c,C0008976;C0019016;C0205173;C0444930;C0444967;C1554184;C1825777;C2746065;C3538758
1020,completed trial,C0008976;C0205197;C3854010
1020,all trials,C0008976
1019,ure,
1019,pre - specified trial endpoints,C0008976;C2349179;C2826245
1019,cure trial,C0008976;C1880198
1018,variables .,C0439828
1018,variables *,C0439828
1018,variables $nmbr$,C0439828
1018,variables,C0439828
1018,variable ' ! ',C0439828;C4553760
1018,variable,C0439828;C4553760
1018,values were calculated using t tests for continuous variables and chi - square,C0042295;C0439828;C0444686;C0549178;C0871472;C1441506;C1524063;C1552646
1018,stratification variables,C0439828;C1514983
1018,diary variables  mean ( sd ),C0376660;C0439828;C0444504;C2347634;C2348143;C2699239
1018,continuous variables  mean ( sd ) ^,C0439828;C0444504;C0549178;C2347634;C2348143;C2699239
1018,continuous variables  mean ( sd ),C0439828;C0444504;C0549178;C2347634;C2348143;C2699239
1018,categorical variables . no . ( % ) * ’,C0439828;C0683312;C3889287
1018,categorical variables,C0439828;C0683312;C3889287
1018,baseline variable,C0168634;C0439828;C1442488;C4553760
1018,adjusted for all baseline variables and interaction between acei and baseline upb,C0168634;C0439828;C0456081;C1442488;C1704675
1018,adjusted for all baseline variables $nmbr$,C0168634;C0439828;C0456081;C1442488
1018,action tested is between the continuous variable and treatment .,C0039798;C0087111;C0392366;C0439828;C0441472;C0549178;C1522326;C1533734;C1705169;C3266814;C3538994;C3887704;C4553760
1017,quintile ( n ),C1508496
1017,quintile $nmbr$ ( $nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ % ) ( n = $nmbr$ ),C1508496
1017,quintile  range  mg / dl,C0439269;C1508496;C1514721;C2348147;C3542016
1017,quicki,
1016,suit quartile $nmbr$ ( b $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
1016,suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
1016,suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
1016,estradiol quartiles,C0014912;C2828255
1015,teriparatide n / n ( % ),C0070093
1015,teriparatide ( n   =   $nmbr$ ),C0070093
1015,interquartile range height — cm,C0489786;C1711350
1015,interquartile range,C1711350
1015,bmi = body mass index  bnp = brain natriuretic peptide  dbp = diastolic blood pressure  gfr = glomerular filtration rate  hr = heart rate  iqr = interquartile range  kccq = kansas city cardiomyopathy questionnaire  n = number  nt = n - terminal  nyha = new york heart association  sbp = systolic blood pressure,C0004083;C0005767;C0005768;C0005823;C0012000;C0017654;C0018787;C0018810;C0027976;C0033095;C0039155;C0054015;C0085805;C0205088;C0229664;C0237753;C0332126;C0439849;C0449788;C0460139;C0536221;C0596306;C0699792;C1095989;C1271104;C1272641;C1275491;C1305855;C1306345;C1417808;C1424601;C1449832;C1561549;C1705314;C1705315;C1711350;C2982014;C3476086;C3476798;C3813197;C3889152;C4050156;C4281799;C4283901;C4284008;C4284038
1015,* interquartile range,C1711350
1015,( interquartile range ) ( mm ),C1711350;C4330985;C4554674
1014,sleeping problems in the past $nmbr$ weeks ( % ),C0700201;C2987125
1014,restriction in normal activities in the past $nmbr$ weeks,C0443288;C2987125;C4697852
1014,night - time awakenings in past $nmbr$ weeks prior to baseline,C0168634;C0860510;C1442488;C2987125
1014,night - time awakenings in past $nmbr$ weeks ( sd ) *,C0860510;C2699239;C2987125
1014,angina ( past $nmbr$ weeks ),C0002962;C2987125
1013,weekly iss {,C0332174;C1740819;C1845118
1013,weekly iss $nmbr$,C0332174;C1740819;C1845118
1013,weekly,C0332174
1013,patients with weekly iss mid response  n ( % ) v,C0030705;C0332174;C0871261;C1704632;C1706817;C1740819;C1845118;C2911692
1013,median ( $nmbr$ % ci ) time to weekly iss mid response up to week $nmbr$ ( wk ) f,C0008107;C0016327;C0034746;C0332174;C0439230;C0549183;C0876920;C1740819;C1845118;C2347635;C2348144;C2939193;C3259781
1013,change from baseline to week $nmbr$ in weekly iss,C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C1740819;C1845118;C4319952
1013,baseline weekly iss,C0168634;C0332174;C1442488;C1740819;C1845118
1012,weeks,C0439230
1012,week   $nmbr$,C0332174;C0439230
1012,week and,C0332174;C0439230
1012,week - $nmbr$ changea,C0332174;C0439230;C4349366
1012,week $nmbr$ — mg / liter ^,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
1012,week $nmbr$ — mg / liter,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
1012,week $nmbr$ responders  ( n = $nmbr$ ),C0332174;C0439230
1012,week $nmbr$ overall population,C0032659;C0282416;C0332174;C0439230;C1257890;C1561607
1012,week $nmbr$ outcomes,C0332174;C0439230;C1274040
1012,week $nmbr$ outcome,C0332174;C0439230;C1274040
1012,week $nmbr$ crp,C0332174;C0439230;C3890735;C4048285
1012,week $nmbr$ a,C0332174;C0439230
1012,week $nmbr$ / et,C0040028;C0332174;C0439230
1012,week $nmbr$ - baseline,C0168634;C0332174;C0439230;C1442488
1012,week $nmbr$ * ’ ’,C0332174;C0439230
1012,week $nmbr$ *,C0332174;C0439230
1012,week $nmbr$ ( non - ee responders ),C0332174;C0439230;C1518422
1012,week $nmbr$ ( mmol / l ),C0332174;C0439230;C1532563
1012,week $nmbr$ ( itt population ),C0032659;C0332174;C0439230;C1257890
1012,week $nmbr$ ( geometric mean  cv ),C0332174;C0439230;C2986759;C3538987;C4048877;C4318503
1012,week $nmbr$ ( before ee ),C0332174;C0439230
1012,week $nmbr$ % of patients,C0030705;C0332174;C0439230
1012,week $nmbr$  % ( n ) §,C0332174;C0439230
1012,week $nmbr$  % ( n ) j,C0332174;C0439230
1012,week $nmbr$  % ( n ) ^,C0332174;C0439230
1012,week $nmbr$  % ( n ) * *,C0332174;C0439230
1012,week $nmbr$  % ( n ) $nmbr$,C0332174;C0439230
1012,week $nmbr$  % ( n ) #,C0332174;C0439230
1012,week $nmbr$  % ( n ),C0332174;C0439230
1012,week $nmbr$,C0332174;C0439230
1012,week,C0332174;C0439230
1012,treated patients with baseline and $nmbr$ post - baseline ef ﬁ cacy measurement  bp value for treatment group comparison ( proactive intervention vs usual care ) was calculated based on a $nmbr$ - sample t test for continuous variables and chi - square test for categorical variables  cbp values were measured at baseline ( week $nmbr$ )  whereas information on all of the other variables listed was collected during screening . abbreviations : bmi  body mass index  bp  blood pressure  chd  coronary heart disease  crucial  cluster randomized usual care vs caduet investigation assessing long - term - risk  dbp  diastolic blood pressure  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  sd  standard deviation  sbp  systolic blood pressure  tc  total cholesterol  tg  triglyceride .,C0000723;C0005823;C0008041;C0011849;C0012641;C0018787;C0023822;C0030705;C0034656;C0035647;C0037623;C0039411;C0039798;C0040642;C0041004;C0041405;C0041698;C0042295;C0065055;C0085805;C0087111;C0168634;C0184661;C0201950;C0205251;C0220825;C0220908;C0220909;C0237403;C0242485;C0280604;C0332174;C0332293;C0370003;C0374505;C0428883;C0439230;C0439828;C0441833;C0443252;C0444686;C0444706;C0488055;C0543421;C0549178;C0683312;C0687676;C0687744;C0745732;C0871420;C0871470;C0871472;C0886296;C1149372;C1257890;C1261322;C1273869;C1305855;C1306620;C1330119;C1415692;C1419788;C1441506;C1442488;C1516048;C1516695;C1516698;C1519504;C1522326;C1522609;C1527178;C1533716;C1533734;C1550472;C1552578;C1698960;C1704687;C1705169;C1705428;C1705429;C1705938;C1705981;C1707455;C1708288;C1710031;C1710032;C1710477;C1824670;C1947933;C2347026;C2348164;C2699239;C2986530;C3272378;C3272447;C3274822;C3469826;C3538928;C3538994;C3539643;C3541902;C3542407;C3815594;C3887704;C3887980;C3889287;C3890211;C4048187;C4318478;C4321351;C4522122;C4522223;C4552904
1012,total cholesterol ( week $nmbr$ ),C0201950;C0332174;C0439230;C0543421
1012,tdi total score ( week $nmbr$,C0205976;C0332174;C0439230;C2674784;C2964552;C3714807
1012,tcz - sc $nmbr$ mg every other week ( n = $nmbr$ ),C0024671;C0026410;C0282380;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
1012,sgrq total score ( week,C0332174;C0439230;C2964552
1012,responders of three - item end point at $nmbr$ weeks *,C0205449;C0439230;C1551338;C2349179;C2826544;C4554251
1012,received an oral aha within $nmbr$ weeks prior to screening,C0050451;C0220908;C0220909;C0439230;C0442027;C0772110;C1514756;C1698960;C1710031;C1710032;C1710477;C2348164;C4521986
1012,ratio to baseline in eosinophil count at week $nmbr$  geometric mean ( se on loge scale ) cells / ll,C0007584;C0007634;C0036919;C0168634;C0175659;C0200638;C0332174;C0349674;C0439230;C0456603;C0750879;C1442488;C1547037;C1947916;C2697934;C2986759
1012,randomized  double - blind reversal phase ( baseline = week $nmbr$ ),C0013072;C0034656;C0168634;C0205390;C0332174;C0439230;C0443290;C1442488;C1710475;C3815594
1012,randomised patients with basdai assessment at baseline and week $nmbr$  n,C0168634;C0332174;C0439230;C0679830;C1442488;C1998004
1012,pt baseline ( week $nmbr$ ),C0032743;C0168634;C0332174;C0439230;C0699718;C1442488
1012,proportion of patients in corticosteroid - free clinical remission at week $nmbr$,C0001617;C0030705;C0205210;C0332174;C0332296;C0439230;C0544452;C0687702;C1709707;C1880497;C1996904;C3536709
1012,percent change from baseline at week $nmbr$,C0332174;C0439230;C3272907
1012,patients with dactylitis at week $nmbr$  n ( % ),C0030705;C0239161;C0332174;C0439230
1012,pasi # $nmbr$ at week $nmbr$,C0332174;C0439230;C4528685
1012,p $nmbr$ min twice / week,C0332174;C0369773;C0439230;C0702093;C1524029;C1720725;C1948050;C2603361;C3813700
1012,open - label phase ( baseline = week $nmbr$ ),C0168634;C0205390;C0332174;C0439230;C1442488;C1709323;C1710475
1012,night - time awakenings / week,C0332174;C0439230;C0860510
1012,mtx ≥ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1012,mtx £ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1012,mtx sio mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1039355;C1417487;C1960952;C2346927;C4321396;C4521761
1012,mtx exposure ( mg / week ),C0024671;C0025677;C0026410;C0274281;C0332157;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1012,ldl particle size ( week $nmbr$ ),C0332174;C0439230;C3641256
1012,ldl particle numbers ( week $nmbr$ ),C0237753;C0332174;C0439230;C0449788;C2612459
1012,ixekizumab every $nmbr$ weeks ( n = $nmbr$ ),C0439230;C3489764
1012,hdl cholesterol ( week $nmbr$ ) a,C0023822;C0332174;C0392885;C0439230
1012,habitual fish intake : < $nmbr$ servings / wk ( n = $nmbr$ ),C0205353;C0332174;C0439230;C0556216;C1519269
1012,evaluable for acr $nmbr$ at week $nmbr$  n,C0332174;C0439230;C1412134;C1515941;C1516986
1012,endpoint week $nmbr$,C0332174;C0439230;C2349179;C2826544
1012,dose ratio at week $nmbr$ ( $nmbr$ % cl ),C0178602;C0332174;C0439230;C0456603;C0596019;C0869039;C1114758;C1547037
1012,disease activity outcomes ( itt population ) week $nmbr$,C0032659;C0205177;C0332174;C0439167;C0439230;C0441655;C0679250;C1257890;C1274040;C1292728;C1561536;C3542417;C3668946;C4049938;C4049939
1012,db baseline ( week $nmbr$ ),C0168634;C0332174;C0439230;C1418892;C1442488
1012,daytime symptoms more than twice per week,C0332169;C0332174;C0439230;C0683368;C1457887;C1720725;C1948050
1012,concomitant use of nsaids to week $nmbr$,C0003211;C0332174;C0439230;C0521115;C1524063
1012,complete clinical response at week $nmbr$,C0205197;C0332174;C0439230;C3853530;C4055223;C4283785
1012,clinical efficacy at week $nmbr$,C0087113;C0332174;C0439230
1012,change to   week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1012,change to week $nmbr$ *,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1012,change to week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1012,change in fev $nmbr$ at week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C3714541;C4319952
1012,change from baseline to week $nmbr$ in weekly size of largest hive score,C0042109;C0168634;C0221232;C0332174;C0392747;C0439230;C0443172;C0443228;C0449820;C0456389;C1442488;C1705241;C4050231;C4319952
1012,change from baseline to week $nmbr$ in dlqi scorez,C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C3899393;C4319952
1012,change from baseline to week $nmbr$,C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C4319952
1012,cfb at week $nmbr$,C0009002;C0332174;C0439230;C1824728
1012,calculated ldl cholesterol ( week $nmbr$ ),C0023824;C0202117;C0332174;C0439230;C0444686;C1441506
1012,at weeks $nmbr$ and $nmbr$,C0439230
1012,at week $nmbr$,C0332174;C0439230
1012,at six weeks,C0205452;C0439230
1012,apob ( week $nmbr$ ),C0003593;C0332174;C0439230;C3252643
1012,acr $nmbr$ week $nmbr$ responders  ( n = $nmbr$ ),C0332174;C0439230;C1412134;C1515941
1012,> $nmbr$ weeks,C0439230
1012,> $nmbr$ servings / wk ( n = $nmbr$ ),C0332174;C0439230;C1519269
1012,> $nmbr$ / week,C0332174;C0439230
1012,> $nmbr$ - $nmbr$ mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
1012,< $nmbr$ weeks,C0439230
1012,< $nmbr$ week,C0332174;C0439230
1012,- - week $nmbr$ - -,C0332174;C0439230
1012,( week ),C0332174;C0439230
1012,% change from baseline to week $nmbr$,C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C4319952
1012,$nmbr$ wk,C0332174;C0439230
1012,$nmbr$ week to $nmbr$ month,C0332174;C0332177;C0439230;C0439231
1012,$nmbr$ week,C0332174;C0439230
1012,$nmbr$ min twice / week,C0332174;C0439230;C0702093;C1524029;C1720725;C1948050;C3813700
1012,$nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
1012,$nmbr$ / week,C0332174;C0439230
1012,$nmbr$ - wk kaplan - meier rate  %,C0332174;C0439230;C0871208;C1521828
1012,$nmbr$ - $nmbr$ / week ( n = $nmbr$ ) $nmbr$ - $nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
1012,$nmbr$ - $nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
1012,$nmbr$ - $nmbr$ / week,C0332174;C0439230
1011,parenteral anticoagulation,C0003281;C0030547;C2917212;C2919015;C3537050;C4522267
1011,intended duration of anticoagulation,C0003281;C0449238;C1283828;C1551357;C2917212;C2919015;C2926735;C3537050
1011,antimalarial,C0003374;C3536844;C4552582
1010,rvalue for interaction,C1704675
1010,rvalue,
1010,pvaluefor interaction $nmbr$ - $nmbr$,C1704675
1010,interaction p - valuef,C1704675
1010,interaction j $nmbr$ - valuet,C1704675
1010,interaction : treatment by psoriasis p valueb,C1704675;C3258078
1009,type of atrial fibrillation — no . / total no . ( % ),C0004238;C0332307;C0344434;C0439175;C0439810;C1547052;C1963067
1009,type of atrial fibrillation - n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1009,type of atrial fibrillation ( n = $nmbr$ $nmbr$ ),C0004238;C0332307;C0344434;C1547052;C1963067
1009,type of atrial fibrillation ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1009,type of atrial fibrillation  no . / total no . ( % ),C0004238;C0332307;C0344434;C0439175;C0439810;C1547052;C1963067
1009,type of atrial fibrillation  n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1009,type of atrial fibrillation,C0004238;C0332307;C0344434;C1547052;C1963067
1009,rate of atrial fibrillation,C0004238;C0344434;C0871208;C1521828;C1963067
1009,no atrial fibrillation,C0004238;C0344434;C1963067
1009,history of atrial fibrillation / flutter  ( % ),C0016385;C0232197;C0729790;C1998417;C2242390
1009,history of atrial fibrillation / flutter,C0016385;C0232197;C0729790;C1998417;C2242390
1009,first episode of atrial fibrillation ( vs . recurrent episode ) — no . ( % ) f,C0004238;C0016327;C0205435;C0332189;C0344434;C0443287;C1279901;C1963067
1009,fibrillation / flutter ),C0016385;C0232197;C2242390
1009,ecg atrial fibrillation  n ( % ),C0004238;C0344434;C1623258;C1963067
1009,duration of last qualifying episode of atrial fibrillation > $nmbr$ days,C0004238;C0332189;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
1009,current atrial fibrillation or flutter on ecg,C0004238;C0016385;C0344434;C0521116;C1623258;C1705970;C1963067;C2242390
1009,atrial flutter / fibrillation,C0155709
1009,atrial flutter,C0004239;C0344423;C1963068
1009,atrial fibrillation — no . / total no . ( % ),C0004238;C0344434;C0439175;C0439810;C1963067
1009,atrial fibrillation — no . ( % ),C0004238;C0344434;C1963067
1009,atrial fibrillation type  n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1009,atrial fibrillation pattern,C0004238;C0344434;C0449774;C1963067
1009,atrial fibrillation or flutter — no . ( % ),C0004238;C0016385;C0344434;C1963067;C2242390
1009,atrial fibrillation or flutter ( ecg ) §,C0004238;C0016385;C0344434;C1623258;C1963067;C2242390
1009,atrial fibrillation or flutter,C0004238;C0016385;C0344434;C1963067;C2242390
1009,atrial fibrillation onset,C0004238;C0206132;C0332162;C0344434;C1963067
1009,atrial fibrillation alone ),C0004238;C0205171;C0344434;C0439044;C0679994;C1963067
1009,atrial fibrillation / flutter  n ( % ),C0155709
1009,atrial fibrillation / flutter,C0155709
1009,atrial fibrillation / atrial flutter  %,C0155709
1009,atrial fibrillation . no . ( % ),C0004238;C0344434;C1963067
1009,atrial fibrillation ( % ),C0004238;C0344434;C1963067
1009,atrial fibrillation !,C0004238;C0344434;C1963067
1009,atrial fibrillation    n   ( % ),C0004238;C0344434;C1963067
1009,atrial fibrillation  n ( % ),C0004238;C0344434;C1963067
1009,atrial fibrillation  %,C0004238;C0344434;C1963067
1009,atrial fibrillation,C0004238;C0344434;C1963067
1009,arial flutter or fibrillation,C0016385;C0232197;C2242390
1009,af or atrial flutter 卞,C0004239;C0344423;C0344434;C1963068;C4049859
1009,af or atrial flutter !,C0004239;C0344423;C0344434;C1963068;C4049859
1009,> $nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo,C0004238;C0026544;C0205156;C0332177;C0332189;C0344434;C1552607;C1963067
1008,naive ( n = $nmbr$ ),
1008,iv inotropic drug,C1971835
1008,drug naive,C0013227;C1254351
1007,serum k + level and drug treatment,C0150270;C0302353;C0441889;C0456079;C1547707;C2946261;C3469597
1007,on drug treatment ( % ),C0150270;C3469597
1007,days of study - drug administration ( % ) * * $nmbr$ day,C0150270;C2826182;C3469597
1007,concomitant drug treatment,C0150270;C0521115;C3469597
1007,administration of study drug ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1254351;C1533734;C2603343;C3161471;C3469597
1006,stool frequency subscore,C0015733;C0183622;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
1006,sotalol,C0037707
1006,socalone ( n = $nmbr$ ),
1005,symbol digit score,C0449820;C0582802;C0679214;C1698987;C3241971;C4050231
1005,digit symbol substitution,C0582802;C0679214;C1555721;C1698987;C1706204;C3241971
1005,b digit symbol substitution  insulin glargine vs standard care,C0291665;C0582802;C0679214;C0907402;C1442989;C1555721;C1698987;C1706204;C1947933;C2828392;C3241971
1004,total sample = $nmbr$ ( % ),C0370003;C0439175;C0439810;C2347026
1004,sample sizea,C0370003;C2347026
1004,no . of events / sample size i i,C0021966;C0221138;C0370003;C0441471;C0456389;C2347026;C3541888
1004,no . of events / sample size,C0370003;C0441471;C0456389;C2347026;C3541888
1004,atwo ‐ sample t ‐ test .,C0370003;C0871472;C2347026
1003,stable angina — no . ( % ),C0340288
1003,stable angina ( n = $nmbr$  $nmbr$ ),C0340288
1003,stable angina ( n - $nmbr$  $nmbr$ ),C0340288
1003,stable angina  n ( % ),C0340288
1003,stable angina,C0340288
1003,rankin scale ≥ $nmbr$,C0451405
1003,histor y of stable angina,C0340288
1003,chronic stable angina,C0340288
1002,• unstable angina,C0002965
1002,• hospitalization for unstable angina,C0002965;C0019993
1002,urgent revascularization because of unstable angina,C0002965;C0439609;C0581603;C3272275
1002,unstableangina,
1002,unstable anginat,C0443343;C1883468
1002,unstable anginad,C0443343;C1883468
1002,unstable angina §,C0002965
1002,unstable angina requiring hospitalization,C0002965;C0019993
1002,unstable angina > $nmbr$ mo ago,C0002965;C0026544;C0332177
1002,unstable angina *,C0002965
1002,unstable angina  n ( % ),C0002965
1002,unstable,C0443343;C1883468
1002,uncodable,
1002,hospitalization for unstable angina,C0002965;C0019993
1002,histor y of unstable angina,C0002965
1002,cvd  mi  stroke  or recurrent ischemia - urgent revascularization  or hospitalization for unstable angina,C0002965;C0007222;C0019993;C0022116;C0038454;C0439609;C0581603;C1455761;C2945760;C3272275;C3810814;C4321499;C4554100
1002,* * * unstable angina,C0002965
1001,probable stent thrombosis,C0033204;C0332148;C3897493
1001,probable,C0033204;C0332148
1001,heritable,C0439660
1000,octi & mate $nmbr$,C0682323;C1260875
1000,octi,
1000,mate !,C0682323;C1260875
1000,mate,C0682323;C1260875
1000,companion : wake - up stroke,C0031268;C0038454;C0335343;C0682323;C1170730;C4554100
1000,companion : $nmbr$ - $nmbr$ hours,C0031268;C0335343;C0439227;C0682323
999,empty,C1880497
999,corticosteroid - free remissioni,C0001617;C0332296;C1880497;C1996904;C3536709
998,romania,C0035826
998,iief - ef domain score  visit $nmbr$ y,C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231
998,iief - ef domain score  visit $nmbr$ * *,C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231
998,ef domain,C1880389;C1883221;C3541951
998,coumadin,C0699129
998,bilag a  b or c domain score  n ( % ),C0449820;C1440044;C1880389;C1883221;C3541951;C3845933;C4050231
997,other combination,C0205195;C1947911;C3811910
997,medication taken alone or in combination,C0013227;C0205171;C0205195;C0439044;C0679994;C1883727;C1947911;C3244316;C3811910;C4284232
997,continuation ( n = $nmbr$ ),
997,continuation,
997,combined trials,C0008976;C0205195
997,combined statin and other lipid - lowering agent use,C0042153;C0086440;C0205195;C0360714;C0457083;C1947944
997,combined n = $nmbr$,C0205195
997,combined macro + micro,C0085672;C0205195;C1553035;C2984010;C3811161;C4049106
997,combined insulin / oral hypoglycaemic agent use,C0205195;C0240016;C0359086
997,combined fatal / nonfatal outcomes,C0205195;C0206277
997,combined cvd,C0007222;C0205195
997,combined ( n = $nmbr$ ),C0205195
997,combined $nmbr$ - year cvd,C0007222;C0205195;C0439234;C0439508
997,combined,C0205195
997,combinationf,
997,combination - facilitated pci ( n = $nmbr$ ),C0205195;C1947911;C3811910;C4049621
997,combination - facilitated pci ( % ),C0205195;C1947911;C3811910;C4049621
997,combination ( n = $nmbr$ ),C0205195;C1947911;C3811910
997,combination,C0205195;C1947911;C3811910
996,total ! by baseline diabetic status,C0168634;C0241863;C0439175;C0439810;C0449438;C1442488
996,non - diabetics ( n = $nmbr$ ),C0241863;C1518422
996,non - diabetics,C0241863;C1518422
996,non - diabetic subjects  n = $nmbr$,C0241863;C0681850;C1518422;C1550501;C1706203;C2349001;C2697811
996,non - diabetic patients,C0241863;C1829939
996,non - diabetic ( n = $nmbr$ ),C0241863;C1518422
996,non - diabetic,C0241863;C1518422
996,diabetics ( n = $nmbr$ ),C0241863
996,diabetics,C0241863
996,diabeticb,
996,diabetic treatments !,C0087111;C0241863
996,diabetic therapy use  n ( % ) * no therapy,C0039798;C0042153;C0087111;C0241863;C0457083;C1363945;C1947944
996,diabetic status  n ( % ),C0241863;C0449438
996,diabetic status,C0241863;C0449438
996,diabetic patients,C0030705;C0241863
996,diabetic participants !,C0241863;C0679646
996,diabetic participants,C0241863;C0679646
996,diabetic no,C0241863
996,diabetic ( no ),C0241863
996,diabetic $nmbr$,C0241863
996,diabetic  n ( % ),C0241863
996,diabetic,C0241863
996,by gfr stratum tor diabetic participants  ml / min per $nmbr$ . $nmbr$ m ’ §,C0017654;C0076836;C0241863;C0369637;C0439445;C0441923;C0679646;C1199517;C1419603;C1424601;C3539732
996,by gfr stratum for diabetic participants  mt / min per $nmbr$ . $nmbr$ m ’ §,C0017654;C0241863;C0369637;C0441923;C0679646;C0702093;C1424601;C1524029;C3813700
996,by baseline diabetic status,C0168634;C0241863;C0449438;C1442488
996,brandomization was stratified by diabetic status .,C0205363;C0241863;C0449438
995,previous oral antidiabetic medication use  n ( % ),C0205156;C0935929;C1527415;C1552607
995,no oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
995,no antidiabetic drug,C0935929
995,insulin + oral antidiabetic medication ( s ),C0021641;C0175795;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
995,duration of oral antidiabetic treatment  y  mean ( sd ),C0442027;C0444504;C0444921;C0935929;C2347634;C2348143;C2699239;C4521986
995,antidiabetic medications,C0935929
995,antidiabetic medication | |,C0935929
995,antidiabetic medication,C0935929
995,antidiabetic drug ‘ i “ j ‘,C0021966;C0221138;C0935929
995,antidiabetic drug,C0935929
995,antidiabetic agents,C0935929
995,antidiabetic agent,C0935929
995,antidiabetic,C0935929
995,> $nmbr$ oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
995,$nmbr$ oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
994,potassium - sparing diuretic,C0304490;C3536751
994,acitretin,C0050559
993,thiazide diuretics,C0012802
993,thiazide diuretic *,C0012802;C3536861
993,thiazide diuretic,C0012802;C3536861
993,loop or thiazide diuretic ^,C0012802;C0445022;C3536861
993,loop or thiazide diuretic : ! :,C0012802;C0445022;C3536861
993,loop or thiazide diuretic #,C0012802;C0445022;C3536861
993,loop or thiazide diuretic,C0012802;C0445022;C3536861
993,diuretic thiazide,C0012802
993,any thiazide diuretic,C0012802;C3536861
992,randomly assigned to diuretic,C0012798;C1516050;C1552601
992,other diuretic,C0012798
992,no - diuretics group ( n = $nmbr$ ),C0012798;C0441848
992,diuretics group ( n = $nmbr$ ),C0012798;C0441848
992,diuretics ^,C0012798
992,diuretics * *,C0012798
992,diuretics ( % ),C0012798
992,diuretics  n ( % ),C0012798
992,diuretics  %,C0012798
992,diuretics,C0012798
992,diureticff,
992,diuretic use at baseline,C0012798;C0042153;C0168634;C0457083;C1442488;C1947944
992,diuretic use,C0012798;C0042153;C0457083;C1947944
992,diuretic n ( % ),C0012798
992,diuretic drugs ( excluding antialdosterone ),C0012798;C0013227;C0332196;C2828389;C3687832
992,diuretic drugs  n ( % ),C0012798;C0013227;C3687832
992,diuretic drugs,C0012798;C0013227;C3687832
992,diuretic agents ( excluding antialdosterone ),C0012798;C0332196;C0450442;C1254351;C1521826;C2828389
992,diuretic agents,C0012798;C0450442;C1254351;C1521826
992,diuretic agent,C0012798;C0450442;C1254351;C1521826
992,diuretic ( any ),C0012798
992,diuretic,C0012798
992,diurciic,
992,cluster $nmbr$ : reversible  no diuretic ( n = $nmbr$ ),C0012798;C0205343;C1555715;C1704332
992,cluster $nmbr$ : diuretic ( n = $nmbr$ ),C0012798;C1555715;C1704332
992,baseiine diuretic,C0012798
991,use of loop diuretics  n ( % ),C0354100;C1524063
991,use of loop diuretics,C0354100;C1524063
991,total intravenous loop diuretics  mg,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C1960952;C2346927;C4321396;C4521761
991,loop diureties,C0445022
991,loop diuretics,C0354100
991,loop diuretic use,C0042153;C0354100;C0457083;C1947944;C3536704
991,loop diuretic,C0354100;C3536704
991,intravenous loop diuretics !,C0348016;C0354100
991,diureties,
990,digoxin or digitalis glycoside,C0012253;C0012265
990,digoxin / digitalis glycoside,C0012253;C0012265
990,digitalis glycoside,C0012253
990,digitalis  n ( % ),C0012252;C0304520
990,digitalis,C0012252;C0304520
990,digital clubbing  n ( % ),C0009080;C0149651
989,previous use of digoxin,C0012265;C0205156;C1524063;C1552607
989,previous digoxin use ( % ),C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
989,previous digoxin use,C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
989,no digoxin scd  no . ( % / y ),C0012265
989,no digoxin n = $nmbr$ $nmbr$ ( $nmbr$ % ),C0012265
989,digoxin or digitalis preparations,C0012265;C0304520
989,digoxin or digitalis preparation,C0012265;C0304520
989,digoxin n = $nmbr$ ( $nmbr$ % ),C0012265
989,digoxin n ( % ),C0012265
989,digoxin at enrollment,C0012265;C1516879;C1696073;C3888021
989,digoxin  n ( % ),C0012265
989,digoxin  ( % ),C0012265
989,digoxin  % ( n ),C0012265
989,digoxin  %,C0012265
989,digoxin,C0012265
988,item,C1551338;C4554251
988,fasting free fatty acids ( ^ mol / liter ),C0015663;C0015688;C0347982
988,> $nmbr$ ^ mol / liter — no . ( % ),C0347982
987,triglycerides — mmol / liter,C0041004;C0439190;C0475211
987,serum triglycerides — pmol / liter,C0439192;C0475211;C0542495
987,serum triglycerides — mmol / liter,C0439190;C0475211;C0542495
987,serum sodium — mmol / liter,C0439190;C0475211;C0523891
987,serum potassium 一 mmol / liter,C0302353;C0439190;C0475211;C0543465
987,serum potassium — mmol / liter,C0302353;C0439190;C0475211;C0543465
987,serum creatinine — pmol / liter,C0201976;C0439192;C0475211;C0600061
987,serum cholesterol — mmol / liter,C0439190;C0475211;C0587184
987,plasma glucose — mmol per liter,C0202042;C0439190;C0455280;C0475211
987,plasma glucose $nmbr$ hr after glucose load — mmol / liter,C0202042;C0439190;C0455280;C0475211;C1550025;C1704782;C1708715
987,glucose — mmol / liter,C0017725;C0439190;C0475211
987,free fatty acids — mmol / liter,C0015688;C0439190;C0475211
987,fasting plasma glucose — mmol / liter,C0015663;C0202042;C0439190;C0455280;C0475211
987,fasting blood glucose — mmol / liter,C0428568;C0439190;C0475211;C1261430
987,> $nmbr$ / tmol / liter — no . ( % ),C0475211
987,> $nmbr$ . $nmbr$ pmol / liter hscrp level,C0439192;C0441889;C0456079;C0475211;C1547707;C2946261
987,> $nmbr$ . $nmbr$ pmol / liter,C0439192;C0475211
987,> $nmbr$ . $nmbr$ mmol / liter,C0439190;C0475211
987,< $nmbr$ . $nmbr$ pmol / liter,C0439192;C0475211
987,< $nmbr$ . $nmbr$ mmol / liter triglyceride level,C0428475;C0439190;C0475211
987,< $nmbr$ . $nmbr$ mmol / liter,C0439190;C0475211
986,d - dimer levelsatinclusion,C0060323
986,d - dimer ( ng / ml ),C0060323;C0439275
985,other / mixed ( n = $nmbr$ ),C0205430;C3160715
985,mixed hispanic,C0086409;C0205430;C3160715
985,mixed ( n = $nmbr$ ),C0205430;C3160715
985,mixed ( itt ) ( n = $nmbr$ ),C0205430;C3160715
985,mixed,C0205430;C3160715
985,lisrs,
985,ixeq $nmbr$ w  n = $nmbr$,
985,insulin lispro mix $nmbr$ / lispro mix $nmbr$ - insulin glargine / insulin lispro,C0205430;C0293359;C0907402;C1421951;C1720722;C4553942
985,insulin lispro mix $nmbr$,C0205430;C0293359;C1421951;C1720722;C4553942
984,planned conservative therapy subgroup,C0459914;C1079230;C1301732;C1515021
984,observation,C0302523;C0700325;C1964257;C3889687
984,conservative,
983,naire can range from $nmbr$ to $nmbr$ for the alternative disability portion and from $nmbr$ to $nmbr$ for the pain portion . scores for the medical outcomes,C0030193;C0040363;C0041260;C0199168;C0205476;C0231170;C0449719;C0449820;C0518090;C1274040;C1514721;C1523987;C1883351;C1962977;C2348147;C2984058;C3542016;C4050231;C4085210;C4085211;C4085212;C4553004;C4554132
983,alternative disability,C0231170;C1523987
982,obstructive subscore,C0549186
982,chronic obstructive pulmonary,C0024109;C0205191;C0549186;C2707265;C2709248;C4522268
981,strategy,C0679199
981,rerapamil - sr strategy ( n = $nmbr$ ),C0679199;C0753208;C1709991;C3813610;C3890900;C3891546
981,planned treatment strategy,C0599880;C0679199
981,intent of conservative strategy  %,C0162425;C0679199;C1283828;C1550453
981,conservative strategy ( n = $nmbr$  $nmbr$ ),C0679199
981,atenolol strategy ( n = $nmbr$ ),C0004147;C0679199
981,atenolol strategy ( n = $nmbr$  $nmbr$ ),C0004147;C0679199
981,atenolol strategy,C0004147;C0679199
980,stating,C1301808;C1442792;C3148680
980,state,C1301808;C1442792;C3148680
980,ipeated - measures state examinatioi,C0079809;C1301808;C1442792;C1879489;C3148680
980,disease characteristics  n ( % )  unless otherwise stated,C0599878;C1301808;C1442792
979,laboratory measurements,C0681902
979,laboratory examination,C0260877
979,clinical and laboratory measurements,C0205210;C0681902
979,catscorecategory  n ( % ),
978,symptom onset to arrival in catheterization laboratory,C0007430;C0022877;C1555577;C1706079;C3244292;C4086878;C4283904
978,randomization to arrival in catheterization laboratory,C0007430;C0022877;C0034656;C1555577;C1706079;C3244292;C4283904
978,laboratory variables at baseline,C0022877;C0168634;C0439828;C1442488;C3244292;C4283904
978,laboratory variables,C0022877;C0439828;C3244292;C4283904
978,laboratory values at admission ( median and iqr ),C0022877;C0042295;C0184666;C0549183;C0809949;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
978,laboratory values,C0022877;C0042295;C3244292;C4283904
978,laboratory measures,C0022877;C0079809;C0242485;C1879489;C3244292;C4283904
978,laboratory evaluations,C0022877;C0220825;C3244292;C4283904
978,laboratory determinations,C0022877;C0680730;C3244292;C4283904
978,dbp > $nmbr$ or sbp > $nmbr$ mm hg laboratory determinations,C0022877;C0085805;C0439475;C0536221;C0680730;C3244292;C3813197;C4281799;C4283904
978,catheterization laboratory in center,C0007430;C0022877;C0205099;C3244292;C4283904;C4534362
978,catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
978,baseline laboratory values  median ( iqr ) d,C0022877;C0042295;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C3244292;C4283904
977,inspiratory capacity ( l ),C0021610;C0802663
977,chronic respiratory failure,C0264492
977,acute respiratory insufficiency,C0865850
976,respiratory medication ( % ),C0418986
976,previous medication for respiratory disease — no . ( % ),C0012634;C0013227;C0035204;C0035242;C0205156;C0418986;C1552607;C3244316;C4284232
976,( b ) concomitant respiratory medications [ n ( % ) ],C0418986;C0521115
975,unadjusted hazard ratio ( $nmbr$ % cl ),C0596019;C1439367;C2985465
975,unadjusted hazard ratio ( $nmbr$ % ci ),C0008107;C1439367;C2985465;C3259781
975,tio ( n $nmbr$ $nmbr$ ),
975,tio,
975,selexipag vs placebo hazard ratio ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1706408;C2000145;C2985465
975,primary and secondary prevention subgroups  adjusted for age  gender  hypertension  diabetes mellitus  and smoking . hr indicates hazard ratio  $nmbr$ % cl  $nmbr$ % confidence interval  tia  transient ischemic attack .,C0007787;C0011849;C0020538;C0037369;C0079399;C0205225;C0237529;C0439612;C0439631;C0453996;C0596019;C0679699;C1079230;C1272706;C1522384;C1552654;C1552713;C1704725;C1704726;C1881674;C1963138;C2985465;C4300468
975,hazard ratio with low ( $nmbr$ % cl ),C0205251;C0596019;C1550472;C2985465;C3890211;C4048187;C4321351;C4522223
975,hazard ratio with high ( $nmbr$ % cl ),C0205250;C0596019;C1299351;C2700149;C2985465;C3887512;C3889660;C4321237;C4522209
975,hazard ratio with,C2985465
975,hazard ratio vs . placebo,C0032042;C1696465;C1706408;C2985465
975,hazard ratio for event ( $nmbr$ % ci ),C0008107;C0441471;C2985465;C3259781;C4019010
975,hazard ratio and $nmbr$ % confidence interval,C0009667;C2985465
975,hazard ratio [ $nmbr$ % cl ],C0596019;C2985465
975,hazard ratio [ $nmbr$ % ci ],C0008107;C2985465;C3259781
975,hazard ratio * ( and $nmbr$ % ci ),C0008107;C2985465;C3259781
975,hazard ratio ( $nmbr$ % confidence interval ) *,C0009667;C2985465
975,hazard ratio ( $nmbr$ % confidence interval ),C0009667;C2985465
975,hazard ratio ( $nmbr$ % cl ],C0596019;C2985465
975,hazard ratio ( $nmbr$ % cl ) nateglinide vs . placebo,C0032042;C0596019;C0903898;C1696465;C1706408;C2985465
975,hazard ratio ( $nmbr$ % cl ) *,C0596019;C2985465
975,hazard ratio ( $nmbr$ % cl ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),C0596019;C2985465
975,hazard ratio ( $nmbr$ % cl ),C0596019;C2985465
975,hazard ratio ( $nmbr$ % ci ) vs . placebo,C0008107;C0032042;C1696465;C1706408;C2985465;C3259781
975,hazard ratio ( $nmbr$ % ci ) for adjudicated type $nmbr$ diabetes,C0008107;C1320657;C2985465;C3259781
975,hazard ratio ( $nmbr$ % ci ) - j -,C0008107;C2985465;C3259781
975,hazard ratio ( $nmbr$ % ci ) *,C0008107;C2985465;C3259781
975,hazard ratio ( $nmbr$ % c,C2985465
975,hazard ratio $nmbr$ ),C2985465
975,hazard ratio $nmbr$,C2985465
975,hazard ratio  umec / vi vs . tio ( $nmbr$ % ci ),C0008107;C0205999;C2985465;C3259781
975,hazard ratio,C2985465
975,hazard . ratio . ( $nmbr$ % ci ) . . . . . . . . . .,C0008107;C2985465;C3259781
975,genotype - specific treatment effect hazard ratio ( $nmbr$ % ci ),C0008107;C0017431;C0205369;C1518681;C1552740;C2985465;C3259781
975,bp : blood pressure  ci : confidence interval  esrd : end - stage renal disease  hr  hazard ratio . all patients ( except patients with other race ) were included with missing covariates imputed . event : no . of patients with esrd  rate : event rate per $nmbr$ years of follow - up  pre - specified : a cox model with treatment group and region as covariates and baseline proteinuria level ( o or x $nmbr$ g / g ) as strata  adjusted : a multivariate cox model with treatment group  time - varying systolic and diastolic bp as covariates . pre - specified analysis and adjusted for time - varying bp,C0002778;C0005823;C0008107;C0009667;C0012634;C0017446;C0022646;C0022661;C0030705;C0033687;C0034510;C0035078;C0037623;C0039155;C0039798;C0040223;C0087111;C0168634;C0205088;C0205147;C0332257;C0332283;C0428883;C0439234;C0441471;C0441833;C0441835;C0441889;C0456079;C0456081;C0679845;C0687744;C0871208;C0936012;C1257890;C1319635;C1415692;C1442488;C1519504;C1521828;C1522326;C1524024;C1533734;C1547707;C1551393;C1565830;C1705169;C1705428;C1705429;C1705492;C1706779;C1708288;C1719822;C1962972;C2316810;C2699638;C2826245;C2946261;C2985465;C3161035;C3259781;C3272743;C3274659;C3538994;C3541383;C3714583;C3853635;C3853906;C3887704;C4019010;C4281991;C4318478;C4522145;C4554346
975,adjusted ⁎ hazard ratio ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
975,adjusted hazard ratio ≠ ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
975,adjusted hazard ratio ‡ ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
975,adjusted hazard ratio § ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
975,adjusted hazard ratio *,C0456081;C2985465
975,adjusted hazard ratio ( $nmbr$ % cl ) *,C0456081;C0596019;C2985465
975,adjusted hazard ratio ( $nmbr$ % ci ) †,C0008107;C0456081;C2985465;C3259781
975,adiusted hazard ratio *,C2985465
974,ratet n ( % ),
974,ratet ( $nmbr$ % cl ),C0596019
974,ratet,
974,odds ratio and $nmbr$ % cl,C0028873;C0596019
974,odds ratio adj ( $nmbr$ % cl ),C0001552;C0028873;C0596019;C2826286
974,odds ratio ( $nmbr$ % cl ),C0028873;C0596019
973,waisthip ratio,C0205682;C0456603;C1547037
973,ratio,C0456603;C1547037
973,rate ratio { $nmbr$ % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
973,rate ratio mepo / pbo ( $nmbr$ % ci ),C0008107;C0031962;C0456603;C0871208;C1521828;C1547037;C3259781
973,rate ratio ( $nmbr$ % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
973,rate ratio ( $nmbr$ % ci ),C0008107;C0456603;C0871208;C1521828;C1547037;C3259781
973,rate ratio,C0456603;C0871208;C1521828;C1547037
973,pepsinogen i / ii ratio,C0030915;C0456603;C0523817;C1547037
973,iglarlixi ( n   =   $nmbr$ ),
973,iglarlixi ( fixed - ratio combination ),C0205195;C0443218;C0456603;C1547037;C1947911;C2827483;C3714578;C3811910
973,iglarlixi,
973,hzard ratio,C0456603;C1547037
973,hscrp ( post - baseline / baseline ratio )  ls mean   ±   se,C0023668;C0036919;C0168634;C0444504;C0456603;C0687676;C1442488;C1547037;C1704687;C2347634;C2348143;C3469826
973,e / a ratio,C0456603;C1547037
973,cardiothoracic ratio > $nmbr$ . $nmbr$,C0456603;C1547037;C4055270
973,cardiothoracic ratio,C0456603;C1547037;C4055270
972,multiple ( $nmbr$ + ) chd risk,C0439064;C1282512
972,chda,
972,chd risk equivalents  n ( % ),C0439185;C1282512;C4049980
971,vhd,
971,c  right - sided vhd ( n = $nmbr$ ),C0205090;C0444532
970,repaired chd,C0205340;C0280604;C3542407
970,other chd,C0280604;C3542407
970,no chd simva ( „ = $nmbr$ ),C0280604;C3542407
970,no chd simva ( n = $nmbr$ ],C0280604;C3542407
970,no chd simva,C0280604;C3542407
970,no chd eze / simva ( n = $nmbr$ ),C0280604;C3542407
970,no chd eze / simva $nmbr$ = $nmbr$ },C0280604;C3542407
970,no chd eze / simva,C0280604;C3542407
970,no chd at baseline,C0168634;C0280604;C1442488;C3542407
970,no chd,C0280604;C3542407
970,known chd,C0205309;C0280604;C3542407
970,history ot chd  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1318464;C1418208;C1705255;C1705587;C2004062;C3542407
970,history ol chd at baselines,C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
970,history of chd at baseline §,C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1442488;C1705255;C2004062;C3542407
970,history of chd at baseline d  g,C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C0439267;C1442488;C1705255;C2004062;C3542407
970,history of chd at baseline  no . ( % ),C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1442488;C1705255;C2004062;C3542407
970,history of chd at baseline,C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1442488;C1705255;C2004062;C3542407
970,history of chd  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
970,history of chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
970,history chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
970,family history ot chd  n ( % ),C0241889;C0280604;C1318464;C1418208;C1705587;C3542407
970,combined chd,C0205195;C0280604;C3542407
970,chd status §,C0280604;C0449438;C3542407
970,chd status,C0280604;C0449438;C3542407
970,chd simva ( „ = $nmbr$ ),C0280604;C3542407
970,chd simva $nmbr$ = $nmbr$ ],C0280604;C3542407
970,chd simva,C0280604;C3542407
970,chd risk - no . ( % ),C0035647;C0280604;C3542407;C4552904
970,chd history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
970,chd eze / simva ( „ = $nmbr$ ),C0280604;C3542407
970,chd eze / simva ( n = $nmbr$ ],C0280604;C3542407
970,chd eze / simva,C0280604;C3542407
970,chd disease death,C0011065;C0012634;C0280604;C1306577;C3542407;C4082313;C4552775
970,chd deaths,C0011065;C0280604;C1306577;C3542407
970,chd death,C0011065;C0280604;C1306577;C3542407;C4082313;C4552775
970,chd at baseline,C0168634;C0280604;C1442488;C3542407
970,chd + cl all,C0280604;C0596019;C3542407
970,chd *  n ( % ),C0280604;C3542407
970,chd  total,C0280604;C0439175;C0439810;C3542407
970,chd  n ( % ),C0280604;C3542407
970,chd,C0280604;C3542407
970,> $nmbr$ mg / dl chd status,C0280604;C0439269;C0449438;C3542407
970,* p < $nmbr$ . $nmbr$ for between - treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean ± standard error simva = simvastatin  eze = ezetimibe  chd = coronary heart disease,C0009247;C0012634;C0018787;C0023189;C0039798;C0074554;C0087111;C0178602;C0280604;C0369773;C0439751;C0444504;C0444667;C0445247;C0599755;C0869039;C1114758;C1142985;C1511726;C1522326;C1533734;C1705169;C1705241;C1705242;C1710181;C2347634;C2348143;C2603361;C3245479;C3538994;C3542407;C3714741;C3887704
969,chlor,C0308648
969,chl,C0019829
969,aml vs . chl,C0019829;C0023465;C0023467
968,charm,C0849759
968,chajdsj - vasc > $nmbr$,
968,chajdsj - vasc $nmbr$ - $nmbr$,
968,chajdsa - vasc $nmbr$ - $nmbr$,
968,cha $nmbr$ ds $nmbr$ vasc score ( % ),C0449820;C1420648;C3714751;C4050231
968,cha $nmbr$ ds $nmbr$ vasc score,C0449820;C1420648;C3714751;C4050231
968,cha $nmbr$ ds $nmbr$ - vasc score ( median  iqr ),C0449820;C0549183;C0876920;C1420648;C2347635;C2348144;C2939193;C3714751;C4050231
968,cha $nmbr$ ds $nmbr$ - vasc score    n   ( % ),C0449820;C1420648;C3714751;C4050231
968,cha $nmbr$ ds $nmbr$ - vasc score  mean ± sd,C0444504;C0449820;C1420648;C2347634;C2348143;C2699239;C3714751;C4050231
968,cha $nmbr$ ds $nmbr$ - vasc score,C0449820;C1420648;C3714751;C4050231
968,cha $nmbr$ ds $nmbr$ - vasc > $nmbr$,C1420648;C3714751
968,cha $nmbr$ ds $nmbr$ - vasc < $nmbr$,C1420648;C3714751
968,cha $nmbr$ ds $nmbr$ - vasc $nmbr$ - $nmbr$,C1420648;C3714751
968,cha $nmbr$ ds $nmbr$ - vasc $nmbr$ $nmbr$,C1420648;C3714751
968,cha $nmbr$ ds $nmbr$ - vasc $ $nmbr$,C1420648;C3714751
968,cha $nmbr$ ds $nmbr$ - vasc # $nmbr$,C1420648;C3714751
968,cha $nmbr$ ds $nmbr$ - vasc  mean ± sd,C0444504;C1420648;C2347634;C2348143;C2699239;C3714751
968,cha $nmbr$ ds $nmbr$ - vasc,C1420648;C3714751
968,baseline cha $nmbr$ ds $nmbr$ - vascb  c,C0168634;C1420648;C1442488;C3714751
967,without ckd ( $nmbr$ ),C1561643
967,with ckd standard ( n = $nmbr$ ),C1442989;C1561643;C2828392
967,with ckd intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453;C1561643
967,with ckd ( $nmbr$ ),C1561643
967,stage > $nmbr$ chronic kidney disease ( % ),C0205390;C1300072;C1306673;C1561643;C4553188
967,no moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
967,no ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
967,no ckd n,C1561643
967,no ckd ( % ),C1561643
967,no ckd,C1561643
967,no - ckd standard ( n = $nmbr$ ),C1442989;C1561643;C2828392
967,no - ckd intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453;C1561643
967,moderate ckd at randomization,C0034656;C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
967,moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
967,gfr ( ckd - epi ),C0017654;C0162734;C1424601;C1561643;C4281721
967,cvd  ckd,C0007222;C1561643
967,ckdc  n ( % ),
967,ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
967,ckd prognosis by kdigo ' ',C0033325;C1561643;C3854082
967,ckd n,C1561643
967,ckd at baseline,C0168634;C1442488;C1561643
967,ckd *,C1561643
967,ckd  n ( % ) t,C1561643
967,ckd,C1561643
967,chronic renal insufficiency  %,C0403447;C1561643
967,chronic renal insufficiency,C0403447;C1561643
967,chronic renal failure  n ( % ),C0022661;C1561643;C2316810
967,chronic renal failure,C0022661;C1561643;C2316810
967,chronic renal disease — no . ( % ),C0022661;C1561643
967,chronic renal disease,C0022661;C1561643
967,chronic kidney disease †,C1561643;C4553188
967,chronic kidney disease ( % ),C1561643;C4553188
967,chronic kidney disease  no . ( % ) t,C1561643;C2603360;C4553188
967,chronic kidney disease  n ( % ),C1561643;C4553188
967,chronic kidney disease,C1561643;C4553188
967,change from baseline stage $nmbr$ ckd,C0168634;C0597205;C0679846;C1442488;C1561643
967,baseline - ckd - epi,C0162734;C0168634;C1442488;C1561643;C4281721
966,non - black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422;C2699257;C3891295;C4551874
966,non - black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422;C2699257;C3891295;C4551874
966,non - black race ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
966,non - black,C0005680;C0027567;C0085756;C0439541;C1518422
966,blaic > $nmbr$ . $nmbr$ %,
966,blaic < $nmbr$ . $nmbr$ %,
966,blaek / afriean - ameriean,
966,blaek,
966,black race — no . / total no . ( % ) f,C0005680;C0016327;C0027567;C0034510;C0085756;C0439175;C0439541;C0439810;C1706779;C3853635
966,black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680;C2699257;C3891295;C4551874
966,black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ) ■ -,C0005680;C2699257;C3891295;C4551874
966,black race ( n = $nmbr$ vs $nmbr$ ),C0005680
966,black race  n ( % ),C0005680
966,black race,C0005680
966,black and other,C0005680;C0027567;C0085756;C0439541
966,black / african,C0337824
966,black /,C0005680;C0027567;C0085756;C0439541
966,black ( n = $nmbr$ ),C0005680;C0027567;C0085756;C0439541
966,$nmbr$ fe black *,C0005680;C0027567;C0085756;C0439541;C3848561
965,locf ),C2825507
965,left bundle - branch block,C0023211;C0344420;C2828132
965,bundle branch block,C0006384;C1879286
965,$nmbr$ locf ),C2825507
964,patients receiving lcz  no . ( % ),C0030705;C1514756
964,lcz $nmbr$ treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
964,lcz $nmbr$ ( n = $nmbr$ ),
964,lcz $nmbr$,
964,lce  n = $nmbr$,C1423759;C3273355
963,β - blocker,
963,| ? > - blocker ( n  % ),
963,| ? ) - blocker  %,
963,renin - angiotensin - aldosterone system blocker,C0086907
963,b - blockers,
963,angiotensin receptor blocker yes,C0034787;C1549445;C1622222;C1705108;C1710701
963,angiotensin receptor blocker and / or ace,C0034787;C1452534;C1622222;C4284014
963,angiotensin receptor blocker,C0034787;C1622222
963,angiotensin - receptor blocker,C0034787;C1622222
963,angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C0034787;C1452534;C1622222
963,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker use ( mitt population ),C0003015;C0032659;C0034787;C0042153;C0457083;C1257890;C1622222;C1947944;C2757044;C3536837;C4541021
963,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C0034787;C1622222;C2757044;C3536837;C4541021
963,angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,C0003015;C0034787;C1622222;C2757044;C3536837;C4541021
963,aldosterone blockers,C0002006
963,aldosterone blocker  %,C0002006
963,aldosterone blocker,C0002006
963,ace - i or angiotensin receptor blocker,C0021966;C0034787;C0221138;C1452534;C1622222;C4284014
963,/ $nmbr$ - blocker,
963,( i - blocker,C0021966;C0221138
963,( a blocker,
963,( $nmbr$ - blocker,
963,$nmbr$ blocker before admission,C0184666;C0809949
962,receptor blockers  n ( % ) baseline lipid and apolipoprotein levels,C0003591;C0023779;C0168634;C0441889;C0597357;C1442488
962,receptor blockers  n ( % ),C0597357
962,receptor blockers,C0597357
962,receptor blocker,C0597357
962,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C0597357;C2757044
962,and either an ace inhibitor or angiotension receptor blocker,C0003015;C0597357;C3844638;C4541021
962,$nmbr$ blockers,
962,$nmbr$ - blockers,
961,prior a - blocker use,C0042153;C0332152;C0457083;C1947944;C2826257
961,preoperative use p - blocker,C0042153;C0445204;C0457083;C1947944
961,preoperative p - blocker use yes,C0042153;C0445204;C0457083;C1549445;C1705108;C1710701;C1947944
961,p - blocker use,C0042153;C0369773;C0457083;C1947944;C2603361
961,no . previous alpha - blocker use,C0001641;C0042153;C0205156;C0457083;C1552607;C1947944
961,alpha blockers,C0001641
961,alpha - blockers,C0001641
961,alpha - blocker,C0001641
961,alpha $nmbr$ blockers,C0001641
961,a - blockers,
961,^ - blocker,
961,$nmbr$ blocker,
960,β - blockers,
960,without p blockers,C0369773;C2603361
960,with p blockers,C0369773;C2603361
960,randomly assigned to calcium channel blocker,C0006684;C1516050;C1552601;C3536851;C4521885
960,p blockers ( % ),C0369773;C2603361
960,p blockers,C0369773;C2603361
960,p blocker *,C0369773;C2603361
960,p - blockers ( % ),C0369773;C2603361
960,p - blockers  n ( % ),C0369773;C2603361
960,p - blockers,C0369773;C2603361
960,p - blocker yes,C0369773;C1549445;C1705108;C1710701;C2603361
960,p - blocker ( % ),C0369773;C2603361
960,j $nmbr$ - blocker  % ( n ),
960,dihydropyridine calcium - channel blocker,C2945601
960,caleium ehannel bloekers ( ccb ),C0006684
960,calcium channel blockers  n ( % ),C0006684;C2757014
960,calcium channel blockers,C0006684;C2757014
960,calcium channel blocker ( % ),C0006684;C3536851;C4521885
960,calcium channel blocker,C0006684;C3536851;C4521885
960,calcium - channel blockers ( % ),C0006684;C2757014
960,calcium - channel blockers,C0006684;C2757014
960,calcium - channel blocker *,C0006684;C3536851;C4521885
960,calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885
960,calcium - channel blocker,C0006684;C3536851;C4521885
960,ca - channel blockers  n ( % ),C0870261;C3887642
960,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol  tg  triglycerides . * includes agents acting on the renin - angiotensin system  beta blocking agents  calcium channel blockers  and diuretics . † median values [ standard deviation for medians calculated by ( q $nmbr$ q $nmbr$ ) / $nmbr$ . $nmbr$ ] . § includes cardiac glycosides  antiarrhythmics class i and iii  vasodilators used in cardiac diseases and other cardiac preparations . ‡ expressed as g / l .,C0001645;C0003195;C0003591;C0003594;C0006684;C0008377;C0011849;C0012634;C0012798;C0017977;C0018787;C0023821;C0023824;C0035096;C0039411;C0040642;C0041004;C0041405;C0041698;C0042295;C0042402;C0079613;C0201950;C0202117;C0332257;C0428473;C0439070;C0439294;C0441885;C0444686;C0450442;C0456615;C0543421;C0549183;C0871420;C0876920;C1254351;C1273517;C1319793;C1441506;C1521826;C1521827;C1522601;C1552866;C1704930;C1705160;C1824670;C1869853;C2347635;C2348144;C2698967;C2700399;C2757014;C2939193;C2984247;C3272447;C3541930;C3715113;C3812761;C3890007;C4048375;C4522122
960,= calcium channel blocker  bmi = body,C0006684;C0242821;C0460148;C0578022;C1268086;C3536851;C4082212;C4521885
960,( e - blocker,
960,( : > blockers,
959,β ‐ blocker,
959,β blockers,
959,β blocker,
959,without beta blocker,C0001645
959,with beta blocker,C0001645
959,use of beta - blockers,C0001645;C1524063
959,use of beta - blocker,C0001645;C1524063
959,peri - op beta - blockers : no ( n = $nmbr$ ),C0001645;C0347985;C0369718;C0441922
959,no betablocker use,C0001645;C0042153;C0457083;C1947944
959,j $nmbr$ - blocker,
959,blocker,
959,betablocker use,C0001645;C0042153;C0457083;C1947944
959,betablocker,C0001645
959,beta blockers,C0001645
959,beta blocker users,C0001645;C1706077
959,beta blocker use ( % ),C0001645;C0042153;C0457083;C1947944
959,beta blocker use,C0001645;C0042153;C0457083;C1947944
959,beta blocker  n ( % ),C0001645
959,beta blocker  %,C0001645
959,beta blocker,C0001645
959,beta - blockers through hospital discharge or day $nmbr$ — %,C0001645;C0332173;C0439228;C0439505;C0586003
959,beta - blockers ( all )  n ( % ),C0001645;C0369718;C0441922
959,beta - blockers  n ( % ),C0001645
959,beta - blockers  ( % ),C0001645
959,beta - blockers,C0001645
959,beta - blocker — no . / total no . ( % ),C0001645;C0439175;C0439810
959,beta - blocker use at randomization,C0001645;C0034656;C0042153;C0457083;C1947944
959,beta - blocker use at baseline,C0001645;C0042153;C0168634;C0457083;C1442488;C1947944
959,beta - blocker use,C0001645;C0042153;C0457083;C1947944
959,beta - blocker n ( % ),C0001645
959,beta - blocker at last follow - up |,C0001645;C0589120;C1522577;C1704685;C3274571
959,beta - blocker at enrollment,C0001645;C1516879;C1696073;C3888021
959,beta - blocker ( except sotalol ),C0001645;C0037707
959,beta - blocker % target dose,C0001645;C0178602;C0869039;C1114758;C1521840;C2986546
959,beta - blocker !,C0001645
959,beta - blocker  %,C0001645
959,beta - blocker,C0001645
959,beta - adrenergic blocker,C0001645;C2757061;C3536830
959,b - blockers  n ( % ),
959,/ $nmbr$ - blockers,
959,( $nmbr$ blocker,
959,$nmbr$ - blocker,
958,tdi e ' ( septal ) ( cm / sec ),C0205976;C0439392;C0442004;C2674784;C3714807
958,ae ' ( per cm / s ),C0439392;C3887670
957,om $nmbr$ /,C0028971;C1705272
957,new om,C0028971;C0205314;C1705272
957,- ° - $nmbr$  wom -,
956,triglycerides  mmolt $nmbr$ ( gm * ),C0017480;C0041004;C3854019
956,lgm ( n = $nmbr$ ),
956,im on ] y,
956,igm ( n = $nmbr$ ),C1706005
956,igm,
956,gm,C0017480;C3854019
956,bmi : body mass index  dbp : diastolic blood pressure  gm : geometric mean  sbp : systolic blood pressure . the analysis was based on observed data without imputation on missing values . asubgroup of patients in whom $nmbr$ h urine was collected ( see materials and methods section ) .,C0002778;C0017480;C0025663;C0025664;C0030705;C0033727;C0039155;C0042036;C0042037;C0042295;C0042789;C0085805;C0152060;C0369286;C0428883;C0428886;C0441932;C0444504;C0449829;C0449851;C0488053;C0488055;C0520510;C0564385;C0700320;C0871470;C0936012;C1305855;C1306620;C1441672;C1511726;C1516695;C1516698;C1522472;C1524024;C1527178;C1551393;C1552923;C1705191;C1705492;C1705938;C1947903;C2347634;C2348143;C2699638;C2963137;C3245479;C3272743;C3714523;C3714741;C3854019;C4528284
956,( gm ),C0017480;C3854019
955,without t $nmbr$ dm n = $nmbr$,C0011816;C2986835;C3250443
955,without dm ( n = $nmbr$ i $nmbr$ * ),C0011816;C0021966;C0221138;C0369718;C0441922;C3250443
955,without dm,C0011816;C3250443
955,with t $nmbr$ dm n = $nmbr$,C0011816;C2986835;C3250443
955,with dm,C0011816;C3250443
955,t $nmbr$ dm,C0011816;C2603360;C3250443
955,prior dm,C0011816;C0332152;C2826257;C3250443
955,previous mi and t $nmbr$ dm,C0011816;C0205156;C1552607;C2603360;C3250443;C3810814
955,previous dm  n ( % ),C0011816;C0205156;C1552607;C3250443
955,previous dm,C0011816;C0205156;C1552607;C3250443
955,patients without dm ( n = $nmbr$ ),C0011816;C0030705;C3250443
955,patients without dm ( n = $nmbr$  $nmbr$ ),C0011816;C0030705;C3250443
955,patients with possible new dm at randomization ( fpg > $nmbr$ - $nmbr$ ),C0011816;C0030705;C0034656;C0205314;C0332149;C1705910;C2362652;C3250443
955,patients with dm vs . patients without dm,C0011816;C0030705;C3250443
955,patients with dm ( n = $nmbr$ ),C0011816;C0030705;C3250443
955,p value for dm vs . no dm,C0011816;C3250443;C4086240
955,oral anti - dm drug status  no . ( % ),C0011816;C0029167;C0175795;C0304289;C0449438;C3250443
955,non - insulin treated dm,C0011816;C0021641;C1518422;C1522326;C1533581;C1579433;C3250443;C3714501
955,non - dm,C0011816;C1518422;C3250443
955,no prior dm,C0011816;C0332152;C2826257;C3250443
955,no dm ( n = $nmbr$ ),C0011816;C3250443
955,no dm ( n = $nmbr$  $nmbr$ ),C0011816;C3250443
955,no dm,C0011816;C3250443
955,new dm,C0011816;C0205314;C3250443
955,neither t $nmbr$ dm nor mets,C0011816;C0812270;C1705694;C2603360;C2939420;C3250443
955,mets w / o t $nmbr$ dm,C0011816;C0812270;C1705694;C2939420;C3250443
955,dm or diabetic complications,C0011816;C0342257;C3250443
955,dm or ckd *,C0011816;C1561643;C3250443
955,dm medication  n ( % ) c,C0011816;C0013227;C3244316;C3250443;C4284232
955,dm ( n = $nmbr$ ),C0011816;C3250443
955,dm ( n = $nmbr$  $nmbr$ ),C0011816;C3250443
955,dm  n ( % ),C0011816;C3250443
955,dm,C0011816;C3250443
955,diff_measure ( dm added this as table had multiple headings ),C0011816;C0039224;C0079809;C0242485;C0439064;C1524062;C1706074;C3250443
955,concomitant oral anti - dm drugs  no . ( % ) a,C0011816;C0029167;C0175795;C0304289;C0521115;C3250443
954,pm  n ( % ),C0030266;C4049155
954,hr ( bpm ),
954,hr  bpm ( sd ),C2699239
954,hr  bpm,
954,csf a ( $nmbr$ ( pm ),C0030266;C3540512;C3889436;C4049155
954,> $nmbr$ bpm ( n = $nmbr$ l $nmbr$ ),
954,> $nmbr$ . $nmbr$ bpm,
953,serum albumin concentration  g / l,C0001924;C0036773;C0086045;C0229671;C0439294;C0456615;C0486291;C0683149;C0728877;C1446561;C1546774;C1550100;C3827302
953,serum albumin  g / l,C0036773;C0439294;C0456615;C0728877
953,serum albumin  g / dl,C0036773;C0439267;C0728877
953,serum albumin  g $nmbr$ $nmbr$,C0036773;C0439267;C0728877
953,serms,C0732611
952,serum creatinine — mg / dl §,C0201976;C0439269;C0600061
952,serum creatinine — mg / dl | |,C0201976;C0439269;C0600061
952,serum creatinine — mg / dl,C0201976;C0439269;C0600061
952,serum creatinine level,C0600061
952,serum creatinine > $nmbr$ pmol / l . n ( % ) |,C0201976;C0439284;C0600061
952,serum creatinine > $nmbr$ mmol / l  n ( % ),C0201976;C0600061;C1532563
952,serum creatinine > $nmbr$ / xmol / l  n ( % ) | |,C0201976;C0600061
952,serum creatinine . mg / dl,C0201976;C0439269;C0600061
952,serum creatinine - mean ( sd  n ),C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
952,serum creatinine ( pmol / l )  mean ( sd ),C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
952,serum creatinine ( mmol / l ),C0201976;C0600061;C1532563
952,serum creatinine ( mg / dl ),C0201976;C0439269;C0600061
952,serum creatinine ( gmol / ),C0201976;C0600061
952,serum creatinine  ≥ $nmbr$ . $nmbr$ mg / dl,C0201976;C0439269;C0600061
952,serum creatinine  μ mol / l,C0201976;C0347982;C0600061
952,serum creatinine  mg / dl  mean ( sd ),C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
952,serum creatinine  mg / dl,C0201976;C0439269;C0600061
952,serum creatinine  mean ( sd ) mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
952,serum creatinine  mean ( sd )  pmol / l,C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
952,serum creatinine  mean ( sd )  mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
952,serum creatinine  limo $nmbr$ $nmbr$,C0201976;C0600061
952,serum creatinine  gmol / l |,C0201976;C0600061
952,serum creatinine  gmol / ' l  mean ( sd ),C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
952,serum creatinine  ^ mol / l,C0201976;C0347982;C0600061
952,serum creatinine  / xmol / l | |,C0201976;C0600061
952,serum creatinine,C0201976;C0600061
952,second serum creatinine,C0201976;C0205436;C0457385;C0565930;C0600061;C1561503;C1705190
952,preoperative serum creatinine > $nmbr$ pmol / l,C0201976;C0439284;C0445204;C0600061
952,mean serum creatinine  mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143
952,increase in serum creatinine,C0201976;C0442805;C0600061
952,first serum creatinine,C0201976;C0205435;C0600061;C1279901
952,doubling of serum creatinine,C0201976;C0205173;C0600061;C1705764
952,composite endpoint of doubling of serum creatinine  esrd,C0022661;C0035078;C0201976;C0205173;C0205199;C0600061;C1547335;C1705764;C2316810;C2349179;C2826544
952,acute increase in serum creatinine,C0010294;C0201976;C0205178;C0442805;C0600061;C1546542;C1561535
951,serum values ^,C0042295;C0229671;C1546774;C1550100
951,serum values,C0042295;C0229671;C1546774;C1550100
951,serum trap - $nmbr$ b ( u / liter ),C0184047;C0229671;C0439148;C0475211;C1336677;C1546774;C1550100;C1566918;C1706005;C1710330;C3887583
951,serum pepsinogen i / iit,C0077923;C0229671;C0523816;C1546774;C1550100
951,serum p $nmbr$ np ( ^ g / liter ),C0065827;C0229671;C0439267;C0475211;C1546774;C1550100;C1706141;C3887659
951,serum n - propeptide of type $nmbr$ collagen,C0009325;C0229671;C0332307;C1546774;C1547052;C1550100;C1709708;C1875696
951,serum gastrint  pg / ml,C0229671;C0439297;C1546774;C1550100
951,serum ctx i ( ng / ml ),C0229671;C0439275;C0631180;C1546774;C1550100
951,serum ctx - $nmbr$  ng / ml  median ( iqr ),C0010377;C0229671;C0439275;C0549183;C0631180;C0876920;C1546774;C1550100;C2347635;C2348144;C2939193;C3539598
951,serum ctx ( ng / ml ),C0010377;C0229671;C0439275;C0631180;C1546774;C1550100;C3539598
951,serum c - terminal telopeptide of,C0229671;C1546774;C1550100;C1707271
951,serum bone - specific alkaline,C0205369;C0229671;C0262950;C1546774;C1550100;C1552740;C1979842
951,serum $nmbr$ - hydroxyvitamin d  ng / ml,C0020337;C0229671;C0439275;C1546774;C1550100
951,serum,C0229671;C1546774;C1550100
951,patients with serum $nmbr$ ( oh ) d ≥   $nmbr$ . $nmbr$ and <   $nmbr$   ng / ml    n / n   ( % ),C0030705;C0220853;C0229671;C0439275;C1546774;C1550100
951,median serum periostin ( ng / ml ) t,C0219433;C0229671;C0439275;C0549183;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
951,mean total serum psa,C0229671;C0444504;C1546774;C1550100;C2347634;C2348143;C2986589
951,mean total serum ige ( sd )  iu / ml,C0229671;C0439175;C0439458;C0439810;C0444504;C1546774;C1550100;C2347634;C2348143;C2699239
950,two arm,C0205448;C0446516;C3715044;C4553528
950,treatment arm ( zoledronate ) ( % ),C0392938;C1522541
950,treatment arm,C1522541
950,three arm,C0205449;C0446516;C3715044;C4553528
950,s arm,C0446516;C0565930;C2603362;C3715044;C4553528
950,by treatment arm,C1522541
950,arm,C0446516;C3715044;C4553528
949,short term ^,C0443303
949,short term ( n = $nmbr$ ) +,C0443303
949,preferred term  %,C1709637;C2347664
948,evolocumab ( n = $nmbr$ ),C3529352
948,evolocumab ( $nmbr$ mg ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
948,evolocumab $nmbr$ mg monthly ( n = $nmbr$ ),C0024671;C0026410;C0332177;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
948,evolocumab $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0439230;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
948,evolocumab,C3529352
948,alirocumab n = $nmbr$,C3491162
948,alirocumab ( n = $nmbr$ ),C3491162
948,alirocumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
948,alirocumab $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
948,alirocumab,C3491162
948,aiirocumab ( n = $nmbr$ ),
948,aiirocumab,
947,veflonzumao,
947,resllzumab,
947,reslizumab ( n = $nmbr$ ),C1869620
947,reslizumab $nmbr$ . $nmbr$   mg / kg ( n   = $nmbr$ ),C0439272;C1869620
947,reslizumab $nmbr$ . $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1869620
947,reslizumab,C1869620
947,benralizumab q $nmbr$ w ( n = $nmbr$ ),C2982078
947,benralizumab q $nmbr$ w ( n - $nmbr$ ),C2982078
947,benralizumab $nmbr$ mg q $nmbr$ w ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
947,benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
947,benralizumab,C2982078
947,b reslizumab $nmbr$ . $nmbr$ mg / kg n / n,C0439272;C1869620
947,b . benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
947,a reslizumab $nmbr$ . $nmbr$ mg / kg n / n,C0439272;C1869620
946,rituximab ( $nmbr$ x $nmbr$ mg ) + mtx ( n = $nmbr$ ),C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
946,rituximab ( $nmbr$ x $nmbr$ mg ) + mtx,C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
946,rituximab  n = $nmbr$,C0393022
946,rituximab,C0393022
-10,jejunum,C0022378
944,secukinumab $nmbr$   mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
944,secukinumab $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
944,secukinumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
944,secukinumab,C3179547
944,placebo secukinumab $nmbr$ mg,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C3179547;C4321396;C4521761
944,any secukinumab ( n   = $nmbr$ ),C3179547
943,vedolizumab n = $nmbr$,C2742797
943,vedolizumab cohort $nmbr$ ( n = $nmbr$ ),C0009247;C0599755;C2742797
943,vedolizumab,C2742797
943,mepolizumab group,C0441833;C0687744;C0969324;C1257890;C1519504;C1705428;C1705429
943,mepolizumab,C0969324
943,evomab + soc,
943,evomab ( n = $nmbr$ ),
943,evomab,
943,denosumab ( n = $nmbr$ ) n ( % ),C1690432
943,denosumab ( n = $nmbr$ ),C1690432
943,denosumab,C1690432
942,dupilumab $nmbr$,C3660996
942,both adalimumab groups ( n = $nmbr$ ) no baseline cd - related antibiotic use,C0003232;C0007928;C0034283;C0042153;C0168634;C0369718;C0439849;C0441833;C0441922;C0445223;C0457083;C0687744;C1122087;C1257890;C1442488;C1519504;C1552839;C1705428;C1705429;C1947944;C4552032
942,both adalimumab groups ( n = $nmbr$ ),C0369718;C0441833;C0441922;C0687744;C1122087;C1257890;C1519504;C1552839;C1705428;C1705429
942,adalimumab group ( n = $nmbr$ ) t,C0036669;C1122087
942,adalimumab croup  n / n ( % ),C0010380;C1122087
942,adalimumab ( n = $nmbr$ ),C1122087
942,adalimumab,C1122087
941,golimumab combined ( n = $nmbr$ ),C0205195;C2353893
941,golimumab $nmbr$ mg / $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
941,golimumab $nmbr$ mg ( n = $nmbr$ ) †,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
941,golimumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
941,golimumab $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
941,golimumab,C2353893
941,combined golimumab groups,C0205195;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C2353893
940,tocilizumab ( n = $nmbr$ ),C1609165
940,tocilizumab,C1609165
940,prior therapy with omalizumab : yes,C0966225;C1514463;C1549445;C1705108;C1710701
940,omalizumab ( lsm ),C0966225
940,omalizumab,C0966225
939,renal insufficiency — no . ( % ),C0035078;C1565489
939,renal insufficiency or failure,C0035078;C0231174;C0680095;C1565489
939,renal insufficiency / failure,C0035078;C0231174;C0231179;C0680095;C1565489;C1963154
939,renal insufficiency *,C0035078;C1565489
939,renal insufficiency $nmbr$,C0035078;C1565489
939,renal insufficiency,C0035078;C1565489
939,renal failure,C0035078;C1963154
939,death due to renal failure ®,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
939,death due to renal failure or sustained esrd,C0011065;C0022661;C0035078;C0443318;C0678226;C1306577;C1963154;C2316810;C4082313;C4552775
938,renal parameters,C0022646;C0449381
938,renal impairmentt,C0022646
938,renal impairmentf,C0022646
938,renal functionc  n ( % ),C0022646
938,renal functionb,C0022646
938,renal functiona,C0022646
938,renal events,C0022646;C0441471;C3541888
938,renal,C0022646
938,primary renal endpoint or death,C0011065;C0022646;C1306577;C2986535;C4082313;C4552775
938,primary renal endpoint,C0022646;C2986535
937,severe renal impairment,C0205082;C1565489;C4050465;C4050466
937,renal impairment *,C1565489
937,renal impairment  n ( % ),C1565489
937,renal impairment,C1565489
937,renal dysfunction,C1565489;C3279454
937,non - endstage renal dysfunction *,C0205088;C1518422;C1565489;C3279454
937,non - end - stage renal dysfunction,C0205088;C1518422;C1565489;C3279454
937,no renal dysfunction,C1565489;C3279454
937,moderate renal impairment  n ( % ) *,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
937,moderate renal impairment,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
937,mild to moderate renal impairment *,C1299392;C1565489
937,level of renal impairment ',C0441889;C0456079;C1547707;C1565489;C2946261
937,level of renal impairment,C0441889;C0456079;C1547707;C1565489;C2946261
937,impaired renal function †,C1565489
937,impaired renal function §,C1565489
937,history of impaired renal function  no . ( % ),C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
937,history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
936,medal,C0524670
936,beyond popliteal pedal,C0016504;C0442037;C0687080
935,wegu,
935,emotional well - being,C2984554;C3641833
934,peripheral artery revascularization without amputation,C0002688;C0332840;C0489868;C0581603;C1546539
934,peripheral artery diseasef,C0489868
934,peripheral artery diseaseb,C0489868
934,peripheral artery disease 一 no . ( % ),C1704436;C4025272
934,peripheral artery disease — no . ( % ),C1704436;C4025272
934,peripheral artery disease details,C1522508;C1561567;C1704436;C4025272
934,peripheral artery disease - -,C1704436;C4025272
934,peripheral artery disease *,C1704436;C4025272
934,peripheral artery disease,C1704436;C4025272
934,peripheral artery,C0489868
934,peripheral arterial stenosis,C4025272
934,peripheral - artery stenosis,C4025272
934,peripheral - artery disease — no . ( % ),C1704436;C4025272
934,peripheral - artery disease ( % ),C1704436;C4025272
934,peripheral - artery disease,C1704436;C4025272
934,only peripheral artery disease,C0205171;C1704436;C1720467;C4025272
934,history of peripheral artery disease — no . { % ),C0489868;C0683519;C0730226;C0850708;C0944983
934,history of peripheral artery disease,C0489868;C0683519;C0730226;C0850708;C0944983
934,baseline peripheral artery disease,C0168634;C1442488;C1704436;C4025272
933,values expressed as mean sd or number ( percent ) . * two patients were missing values for body mass index . † other forms of atherosclerosis are peripheral arterial disease  abdom - inal aortic aneurysm  symptomatic carotid artery disease  transient isch - emic attack  and stroke . ‡ family history of premature chd de ﬁ ned as chd in male ﬁ rst - degree relative aged $nmbr$ years or female ﬁ rst - degree relative $nmbr$ years . § blood pressure $nmbr$ / $nmbr$ mm hg  on antihypertensive medication  or diagnosis of hypertension based on medical history . n number of randomly assigned patients  ncep atp national cholesterol education program adult treatment panel .,C0001675;C0001779;C0001792;C0003364;C0003486;C0003850;C0004153;C0005823;C0005893;C0007273;C0008377;C0011198;C0011900;C0015576;C0017480;C0019664;C0019665;C0020538;C0030688;C0030705;C0038454;C0040704;C0042295;C0043210;C0080103;C0085096;C0086287;C0086582;C0151526;C0205252;C0205345;C0205374;C0205448;C0231220;C0237753;C0262512;C0262926;C0277793;C0280604;C0340629;C0348078;C0376315;C0439165;C0439234;C0439475;C0441833;C0441889;C0444504;C0449286;C0449788;C0542560;C0578022;C0679841;C1261512;C1271104;C1272641;C1304680;C1305855;C1425219;C1516050;C1518340;C1527178;C1547039;C1551393;C1552601;C1704338;C1704436;C1704656;C1704727;C1705255;C1705492;C1705497;C1705498;C1705938;C1706180;C1706365;C1706428;C1706429;C1706450;C1963138;C1999167;C1999270;C2004062;C2347634;C2348088;C2348143;C2699239;C2744579;C3245503;C3272743;C3541240;C3542407;C4018905;C4552600;C4554100
933,qualifying peripheral arterial disease,C0085096;C1514624;C1704436
933,prior peripheral arterial disease,C0085096;C0332152;C1704436;C2826257
933,peripheral vascular disease  n ( % ),C0085096
933,peripheral vascular disease,C0085096
933,peripheral artery occlusive disease ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ ),C0205390;C1300072;C1306673;C1306889
933,peripheral artery occlusive disease,C1306889
933,peripheral arterial disease — no . ( % ) §,C0085096;C1704436
933,peripheral arterial disease — no . ( % ),C0085096;C1704436
933,peripheral arterial disease §,C0085096;C1704436
933,peripheral arterial disease ( n = $nmbr$ $nmbr$ ),C0085096;C1704436
933,peripheral arterial disease  n ( % ),C0085096;C1704436
933,peripheral arterial disease,C0085096;C1704436
933,cerebrovascular or peripheral arterial disease    n   ( % ),C0085096;C1704436;C1880018
933,cerebrovascular or peripheral arterial disease  n ( % ),C0085096;C1704436;C1880018
933,cerebrovascular or peripheral arterial disease,C0085096;C1704436;C1880018
933,any peripheral arterial disease,C0085096;C1704436
933,any established peripheral arterial disease,C0085096;C0443211;C1272684;C1704436
932,urgent peripheral revascularization,C0205100;C0439609;C0581603;C3272275
932,peripheral vasodilators,C0724804
932,peripheral revascularization ( n = $nmbr$ ),C0205100;C0581603
932,peripheral revascularization,C0205100;C0581603
932,peripheral revascularisation,C0205100;C0581603
932,peripheral,C0205100
932,no peripheral revascularization ( n = $nmbr$  $nmbr$ ),C0205100;C0581603
932,history of peripheral vascular disease,C1881056
931,lateral,C0205093
931,bilateral disease ( % ) ' j ' ' j ',C1511113
930,vilanterol  n = $nmbr$,C2935023
930,fluticasone furoate and vilanterol ( n = $nmbr$ ),C1948374;C2935023
929,intracerebral,C0442111
929,chd plus cerebral infarction,C0007785;C0280604;C3542407
929,chd + cerebral infarction,C0007785;C0280604;C3542407
929,cerebral thrombosis,C0079102;C0151945;C0795687
929,cerebral ischemia,C0007785;C0917798
929,cerebral infarction,C0007785
929,cerebral hemorrhage,C2937358
929,cerebral embolism,C0007780
929,cerebral,
928,northamerica,
928,nonvertebral,
928,morphometric vertebral,C0200760;C0549207
928,hip + nonvertebral + vertebral,C0019552;C0022122;C0549207;C1505163;C3538851;C4284725
927,neuraxial anaesthesia,C0002903;C0002912;C0002930;C3714787;C4049933
927,neuraxial alonee,C3714787
927,central nervous system,C3540014;C3714787
926,treatment after randomization  in the single - dummy phase — days ],C0034656;C0037179;C0039798;C0087111;C0087136;C0205171;C0205390;C0439228;C1522326;C1533734;C1705169;C1710475;C3538994;C3887704
926,thienopyridine alone,C0205171;C0439044;C0679994;C1120149
926,single,C0037179;C0087136;C0205171
926,rivaroxaban alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0205171;C0439044;C0679994;C1739768
926,rivaroxaban alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C1739768
926,previous ics alone,C0205156;C0205171;C0439044;C0679994;C0815320;C1552607;C4551720
926,pci alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C4049621
926,methotrexate alone ^,C0025677;C0205171;C0439044;C0679994
926,metformin alone,C0025598;C0205171;C0439044;C0679994
926,lived alone,C0205171;C0439044;C0679994;C1548795;C1634625;C2982691
926,ics alone,C0205171;C0439044;C0679994;C0815320;C4551720
926,heparin alone ( n = $nmbr$ ),C0019134;C0205171;C0439044;C0679994;C0770546
926,fluticasone alone ( n = $nmbr$ ),C0082607;C0205171;C0439044;C0679994
926,bivalirudin alone ( n = $nmbr$ ),C0168273;C0205171;C0439044;C0679994
926,basal alone,C0205112;C0205171;C0439044;C0679994
926,alone,C0205171;C0439044;C0679994
926,$nmbr$ ( except for female alone ),C0043210;C0086287;C0205171;C0439044;C0679994;C1705497;C1705498
925,unfractionated only,C0205171;C1720467
925,unfractionated heparin only,C0019134;C0205171;C1720467;C2825026
925,type of surgery cabg only,C0010055;C0038894;C0038895;C0205171;C0332307;C0543467;C1274039;C1547052;C1720467
925,t - wave inversion only,C0205171;C0520888;C1720467
925,sulphonylureas only,C0038766;C0205171;C1720467
925,statin only ( n = $nmbr$  $nmbr$ ),C0205171;C0360714;C1720467
925,statin only  n ( % ),C0205171;C0360714;C1720467
925,statin only,C0205171;C0360714;C1720467
925,st - depression only,C0205171;C0520887;C1720467
925,pulmonary embolism only,C0034065;C0205171;C1720467
925,ptca only,C0205171;C1720467;C2936173
925,previous lev only,C0023556;C0205156;C0205171;C1552607;C1720467
925,previous labd only,C0205156;C0205171;C0396059;C1552607;C1720467
925,pioglitazone only,C0071097;C0205171;C1720467
925,oral hypoglycemic drugs only,C0205171;C0359086;C1720467
925,oral hypoglycaemics only,C0205171;C0359086;C1720467
925,oad only,C0205171;C1720467
925,monotherapy $nmbr$,
925,metformin only,C0025598;C0205171;C1720467
925,medical management only — no . { % ),C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
925,medical management only,C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
925,lieum only  n ( % ),C0205171;C1720467
925,legs only,C0205171;C1140621;C1720467
925,lama ( only monotherapy ),C0205171;C0999593;C1416775;C1720467
925,laba ( only monotherapy ),C0205171;C1720467
925,jbs - $nmbr$ secondary prevention only $nmbr$,C0175692;C0205171;C0679699;C0795841;C1416527;C1720467
925,jbs - $nmbr$ primary prevention only $nmbr$,C0033144;C0175692;C0205171;C0795841;C1416527;C1720467
925,immunosuppressants and antimalarials only,C0003374;C0021081;C0205171;C1720467
925,image only,C0205171;C1704254;C1704922;C1720467;C3542466
925,handihaler only  n,C0205171;C1720467
925,enoxaparin only,C0205171;C0206460;C1720467
925,depressed only,C0205171;C0344315;C0549249;C1720467
925,class v only,C0205171;C0457166;C1720467;C1880098
925,cabg only,C0010055;C0205171;C1720467
925,basal only,C0205112;C0205171;C1720467
925,aspirin only ( n = $nmbr$  $nmbr$ ),C0004057;C0205171;C1720467
925,aspirin only,C0004057;C0205171;C1720467
925,antimalarials only,C0003374;C0205171;C1720467
925,$nmbr$ ( only $nmbr$ distal ),C0205108;C0205171;C1720467;C4522154
924,range ed etiology ( n ),C0015127;C1314792;C1514721;C1524003;C2348147;C3538926;C3542016
924,pah origin / cause,C0015127;C1418251;C1524003
924,pah etiology :,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
924,pah etiology,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
924,other determined etiology,C0015127;C0521095;C1314792;C1524003
924,other cause  n ( % ),C0015127;C1524003
924,other cause,C0015127;C1524003
924,non - ischaemic aetiology,C0015127;C0475224;C1314792;C1518422;C1524003
924,neohrodathv . and all - cause mortalitv,C0015127;C1524003
924,main etiology of heart failure,C0015127;C0018801;C0018802;C0205225;C1314792;C1524003;C1542147;C4554158
924,ischemic heart failure etiology,C0015127;C0018801;C0018802;C0475224;C1314792;C1524003;C4554158
924,ischemic etiology ( % ),C0015127;C0475224;C1314792;C1524003
924,ischemic etiology  %,C0015127;C0475224;C1314792;C1524003
924,ischemic etiology,C0015127;C0475224;C1314792;C1524003
924,ischemic aetiology  n ( % ),C0015127;C0475224;C1314792;C1524003
924,ischemic aetiology,C0015127;C0475224;C1314792;C1524003
924,ischaemic etiology n ( % ),C0015127;C0475224;C1314792;C1524003
924,ischaemic aetiology,C0015127;C0475224;C1314792;C1524003
924,etiology ( % ),C0015127;C1314792;C1524003
924,etiology    n   ( % ),C0015127;C1314792;C1524003
924,etiology  n ( % ),C0015127;C1314792;C1524003
924,etiology,C0015127;C1314792;C1524003
924,ed etiology  no . ( % ),C0015127;C1314792;C1524003;C3538926
924,diabetes etiology,C0011847;C0011849;C0015127;C1314792;C1524003
924,combined major macrovascular events  neohrodathv . and all - cause mortalitv ■,C0015127;C0205082;C0205164;C0205195;C0441471;C1524003;C3541888;C4318856;C4521762
924,any cause,C0015127;C1524003
924,all randomized all - cause mortality or hospitalization for worsening hf ^,C0015127;C0018488;C0019993;C0026565;C0026566;C0034656;C0332271;C0444868;C1313497;C1457868;C1524003;C1538440;C1546960;C3273279;C3539085;C3815594
924,all randomized all - cause mortality,C0015127;C0026565;C0026566;C0034656;C0444868;C1524003;C3539085;C3815594
924,all cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
924,all - cause mortality or hf hospitalization ^,C0015127;C0018488;C0019993;C0026565;C0026566;C0444868;C1313497;C1524003;C1538440;C3273279;C3539085
924,all - cause mortality or hf hospitalization,C0015127;C0018488;C0019993;C0026565;C0026566;C0444868;C1313497;C1524003;C1538440;C3273279;C3539085
924,all - cause mortality ( no . of events ),C0015127;C0026565;C0026566;C0441471;C0444868;C1524003;C3539085;C3541888
924,all - cause mortality ( n = $nmbr$ ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
924,all - cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
924,all - cause mortalitv,C0015127;C1524003
924,all - cause hospitalization,C0015127;C0019993;C1524003
924,all - cause,C0015127;C1524003
924,aetiology of pah,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
924,aetiology,C0015127;C1314792;C1524003
924,acute stroke of other determined cause,C0015127;C0521095;C0751956;C1524003
923,six - minute walk distance  m,C0012751;C0369637;C0441923;C3900196
923,rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C0871208;C1521828
923,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ level — no . ( % ),C0369637;C0439445;C0441889;C0441923;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
923,mab,C0003250;C0369637
923,m o nito ring treatment,C0039798;C0087111;C0369637;C0441923;C0521164;C1260969;C1522326;C1533734;C1705169;C1882954;C3538994;C3887704
923,m being,C0369637;C0441923
923,m,C0369637;C0441923
923,k - m % n,C0369637;C0441923;C0597277;C1708601
923,k - m %,C0369637;C0441923;C0597277;C1708601
923,glomerular filtration rate  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C1561549
923,estimated glomerular filtration rate < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
923,estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . / total no . ( % ) §,C0369637;C0439175;C0439445;C0439810;C0441923;C3811844
923,estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ : i : §,C0021966;C0023806;C0221138;C0369637;C0439445;C0441923;C0702093;C1524029;C3811844;C3813700
923,estimated glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C3811844
923,estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$ *,C0369637;C0439445;C0441923;C3811844;C3839656
923,estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844;C3839656
923,estimated glomerular filtration rate ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844;C3839656
923,estimated glomerular filtration rate  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
923,death or $nmbr$ mwd decrease > $nmbr$ m,C0011065;C0369637;C0392756;C0441923;C0547047;C1306577;C4082313;C4552775
923,baseline mwd  m,C0168634;C0369637;C0441923;C1442488
923,baseline $nmbr$ - min walk distance m,C0168634;C0369637;C0429886;C0441923;C0702093;C1442488;C1524029;C3813700
923,azl - m / cld ( n = $nmbr$ ),C0369637;C0441923
923,azl - m + hctz ( n = $nmbr$ ),C0020261;C0369637;C0441923
923,azl - m + cldb,C0369637;C0441923
923,azl - m $nmbr$ mg + cld $nmbr$ mg,C0369637;C0441923;C1319635
923,azl - m $nmbr$ mg $nmbr$ - cld $nmbr$ mg ( n = l $nmbr$ ),C0369637;C0441923;C2827881
923,azl - m,C0369637;C0441923
923,> $nmbr$ to < $nmbr$ iiil / iiim / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0441923
923,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % ),C0369637;C0439445;C0441923
923,> $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
923,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . { % ),C0369637;C0439445;C0441923
923,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % ),C0369637;C0439445;C0441923
923,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ nt - pro - bnp,C0369637;C0439445;C0441923;C0669479;C0754710
923,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
923,. $nmbr$ . $nmbr$ ml / s / m $nmbr$ ( $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % ),C0369637;C0439445;C0441923
923,$nmbr$ to < $nmbr$ m um in,C0369637;C0441923
923,$nmbr$ mwt ( m ),C0369637;C0441923
923,$nmbr$ mwd decrease > $nmbr$ m,C0369637;C0392756;C0441923;C0547047
923,$nmbr$ mwd  m,C0369637;C0441923
923,$nmbr$ mw distance  m,C0012751;C0024548;C0026385;C0369637;C0441923;C0556966
923,$nmbr$ - minute walk distance — m,C0369637;C0429886;C0439232;C0441923;C0700321;C0702093;C1282918;C2347166
923,$nmbr$ - min walk distance ( m ),C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
922,method of identification ofstenosis ( % ),C1301921
922,mestizos,C0682082
921,without mets,C0812270;C1705694;C2939420
921,with mets,C0812270;C1705694;C2939420
921,presence of mets ( % ) a,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
921,presence of mets,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
921,non - mets,C0812270;C1518422;C1705694;C2939420
921,no dysglycaemia or mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C0812270;C1705694;C1960636;C2939420
921,no dysglycaemia or mets,C0812270;C1705694;C1960636;C2939420
921,mets  n ( % ),C0812270;C1705694;C2939420
921,mets,C0812270;C1705694;C2939420
921,i without mets ( n = $nmbr$ ),C0021966;C0221138;C0812270;C1705694;C2939420
921,i with mets ( n = $nmbr$ ),C0021966;C0221138;C0812270;C1705694;C2939420
921,dysglycaemia or mets,C0812270;C1705694;C1960636;C2939420
920,height in meters .,C0441074;C0489786
920,> = $nmbr$ meters,C0441074
920,< $nmbr$ meters,C0441074
919,neither ics nor laba,C0815320;C4551720
919,neither,
918,venous insufficiency,C0042485
918,jugular venous distention > $nmbr$ cm,C0425687
918,jugular venous distension  n ( % ),C0425687
917,venous graft,C0042449;C0181074;C0332835;C0348013;C1961139
917,venous,C0042449;C0348013
917,history of recurrent venous thromboembolism,C0042449;C0348013;C0455533;C1455761;C2945760
916,sirius,
916,serious teaes,C0205404
916,serious infections,C0205404;C3714514
916,serious decline in kidney function *,C0205404;C0232804
916,serious decline in kidney function $nmbr$,C0205404;C0232804
916,serious aes,C0205404;C1412268;C2699274
916,serious ae,C0205404;C3887670
916,serious,C0205404
916,any serious teaes,C0205404
916,any serious ae  n ( % ),C0205404;C3887670
916,> $nmbr$ serious aes,C0205404;C1412268;C2699274
915,stent thrombosis arc definite / probable,C0033204;C0332148;C0439544;C1704787;C3897493
915,disseminated tuberculosis,C0152915
915,definite stent thrombosis,C0439544;C1704787;C3897493
915,definite / probable stent thrombosis,C0033204;C0332148;C0439544;C1704787;C3897493
915,definite,C0439544;C1704787
914,patients without clinically evident vascular disease,C0030705;C0042373;C3887511
914,patients with clinically evident vascular disease,C0030705;C0042373;C3887511
914,evidence or thombus  n ( % ),C3887511
914,clinically evident vascular disease,C0042373;C3887511
913,very severe n z $nmbr$,C3641272;C4050419
913,very severe copd,C0024117;C1412502;C3641272;C3714496;C4050419
913,very severe ( itt ) ( n = $nmbr$ ),C3641272;C4050419
913,very severe ( gold $nmbr$ ),C0018026;C1304897;C3641272;C4050419
913,very severe  gold $nmbr$,C0018026;C1304897;C3641272;C4050419
913,very severe,C3641272;C4050419
913,severe or very severe smoking status,C0205082;C1519386;C3641272;C4050419;C4050465;C4050466
913,severe or very severe copd,C0024117;C0205082;C1412502;C3641272;C3714496;C4050419;C4050465;C4050466
913,severe or very severe,C0205082;C3641272;C4050419;C4050465;C4050466
913,extreme tortuosity,C0205403;C0333076;C3641272;C4085555
913,$nmbr$ - $nmbr$ ( very severe ),C3641272;C4050419
912,prior or new diabetes,C0011847;C0011849;C0205314;C0332152;C2826257
912,prior gestational diabetes,C0085207;C0332152;C2826257
912,prior diabetes,C0011847;C0011849;C0332152;C2826257
912,diabetese,
912,diabetesc,
912,comorbid diseasesa diabetesb,C0009488
911,progression to diabetes,C1735364
911,diabetesf,
911,amputation due to diabetes — no . ( % ),C0598284;C0678226
910,prediabeticb,
910,prediabetese,
910,prediabetes — no . ( % ) $nmbr$,C0362046
910,prediabetes  n ( % ),C0362046
910,prediabetes  %,C0362046
910,pre – diabetes mellitus  n = $nmbr$,C0362046
910,pre – diabetes mellitus,C0362046
910,ifg / prediabetes ^,C0362046;C1334085;C1708411
910,baseline prediabetes,C0168634;C0362046;C1442488
909,without diabetes,C0011847;C0011849
909,with diabetes,C0011847;C0011849
909,undiagnosed diabetes mellitus  n = $nmbr$,C0011849;C1408353
909,undiagnosed diabetes mellitus,C0011849;C1408353
909,undiagnosed diabetes ( n = $nmbr$ ),C0011847;C0011849;C1408353
909,time since diagnosis of type $nmbr$ diabetes,C0011847;C0011849;C0011900;C0040223;C1320657;C1550351;C1704338;C1704656;C3541383
909,time since diagnosis of diabetes — no . ( % ),C0011847;C0011849;C0011900;C0040223;C1704338;C1704656;C3541383
909,time since diagnosis of diabetes  n ( % ),C0011847;C0011849;C0011900;C0040223;C1704338;C1704656;C3541383
909,time since diagnosis of diabetes,C0011847;C0011849;C0011900;C0040223;C1704338;C1704656;C3541383
909,short ( < $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0439234;C0439593
909,reported diabetes mellitus,C0011849;C0684224;C0700287;C4319718
909,postbaseline new - onset diabetes - n ( % ),C0011847;C0011849;C0746890
909,people without diabetes n = $nmbr$,C0011847;C0011849;C0027361
909,people with diabetes n = $nmbr$,C0011847;C0011849;C0027361
909,patients without diabetes mellitus ( n = $nmbr$ ),C0011849;C0030705
909,patients without diabetes,C0011847;C0011849;C0030705
909,patients with diabetes mellitus ( n = $nmbr$ ),C0011849;C0030705
909,patients with diabetes mellitus,C0011849;C0030705
909,patients with diabetes,C0011847;C0011849;C0030705
909,other ( % ) diabetes ( interaction : p = $nmbr$ . $nmbr$ ),C0011847;C0011849;C1704675
909,non - diabetes,C0011847;C0011849;C1518422
909,no diabetes mellitus,C0011849
909,no diabetes ( p = . o $nmbr$ ),C0011847;C0011849
909,no diabetes ( p = . $nmbr$ ),C0011847;C0011849
909,no diabetes ( n = $nmbr$  $nmbr$ ),C0011847;C0011849
909,no diabetes ( n - $nmbr$  $nmbr$ ),C0011847;C0011849
909,no diabetes,C0011847;C0011849
909,new diabetes — no . ( % ),C0011847;C0011849;C0205314
909,new diabetes,C0011847;C0011849;C0205314
909,new - onset diabetes §,C0011847;C0011849;C0746890
909,new - onset diabetes,C0011847;C0011849;C0746890
909,n o diabetes,C0011847;C0011849;C0369718;C0441922
909,mellitus,
909,median duration of diabetes ( yr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
909,long ( i $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0021966;C0221138;C0439234;C0439591
909,long ( > $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0439234;C0439591
909,laboratory values in patients with history of diabetes,C0011847;C0011849;C0019664;C0019665;C0022877;C0030705;C0042295;C0262512;C0262926;C1705255;C2004062;C3244292;C4283904
909,individuals without diabetes  n = $nmbr$  $nmbr$,C0011847;C0011849;C0027361;C0237401
909,individuals with t $nmbr$ dm ( scale diabetes ),C0011816;C0011847;C0011849;C0027361;C0175659;C0237401;C0349674;C1947916;C3250443
909,individuals with diabetes  n = $nmbr$,C0011847;C0011849;C0027361;C0237401
909,hx of diabetes  n ( % ),C0011847;C0011849;C0262926;C3814444
909,history of diabetes requiring drugs,C0011847;C0011849;C0019664;C0019665;C0020616;C0262512;C0262926;C1553893;C1705255;C2004062
909,history of diabetes :,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
909,history of diabetes - n ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
909,history of diabetes ( n = $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
909,history of diabetes ( a ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
909,high risk of diabetes,C0011847;C0011849;C0332167
909,duration of diabetes — yr ^,C0011847;C0011849;C0439234;C0449238;C2926735
909,duration of diabetes microvascular disease — no . ( % ),C0011847;C0011849;C0443258;C0872146
909,duration of diabetes mellitus  y  mean ( sd ) §,C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
909,duration of diabetes mellitus  y,C0011849;C0449238;C2926735
909,duration of diabetes mellitus  median ( iqr )  y,C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
909,duration of diabetes mellitus,C0011849;C0449238;C2926735
909,duration of diabetes by tertiles,C0011847;C0011849;C0449238;C2926735
909,duration of diabetes < $nmbr$ yrs,C0011847;C0011849;C0449238;C2926735
909,duration of diabetes ( years )  mean  ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
909,duration of diabetes ( y ),C0011847;C0011849;C0449238;C2926735
909,duration of diabetes ( months ),C0011847;C0011849;C0439231;C0449238;C2926735
909,duration of diabetes  yrs,C0011847;C0011849;C0449238;C2926735
909,duration of diabetes  y  mean ( sd ),C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
909,duration of diabetes  y,C0011847;C0011849;C0449238;C2926735
909,duration of diabetes  median ( iqr ),C0011847;C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
909,duration of diabetes  mean ( sd )  y,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
909,duration of diabetes,C0011847;C0011849;C0449238;C2926735
909,drugs used in diabetes  n ( % ),C0011847;C0011849;C0013227;C1273517;C3687832
909,drugs used in diabetes,C0011847;C0011849;C0013227;C1273517;C3687832
909,diagnosis of diabetes  n ( % ),C0011847;C0011849;C0011900;C1704338;C1704656
909,diagnosed diabetes ( n = $nmbr$ ),C0011847;C0011849;C0011900
909,diabetesz,
909,diabetes — no . ( % ),C0011847;C0011849
909,diabetes | |,C0011847;C0011849
909,diabetes with target organ disease *,C0011847;C0011849;C0012634;C0178784;C1521840;C2986546
909,diabetes treatment,C0011847;C0011849;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
909,diabetes t,C0011847;C0011849
909,diabetes present $nmbr$ ( $nmbr$ . $nmbr$ ),C0011847;C0011849;C0150312;C0449450
909,diabetes n ( % ),C0011847;C0011849
909,diabetes mellitust,C0011847;C0011849
909,diabetes mellitus 一 no . ( % ),C0011849
909,diabetes mellitus — no . / total no . ( % ),C0011849;C0439175;C0439810
909,diabetes mellitus — no . ( % ),C0011849
909,diabetes mellitus n = $nmbr$  $nmbr$,C0011849
909,diabetes mellitus duration ( sd )  y,C0011849;C0449238;C2699239;C2926735
909,diabetes mellitus duration  y ( sd ),C0011849;C0449238;C2699239;C2926735
909,diabetes mellitus duration  y,C0011849;C0449238;C2926735
909,diabetes mellitus [ n ( % ) ],C0011849
909,diabetes mellitus :,C0011849
909,diabetes mellitus ( % ),C0011849
909,diabetes mellitus !,C0011849
909,diabetes mellitus  § n ( % ),C0011849
909,diabetes mellitus  no . / total no . ( % ),C0011849;C0439175;C0439810
909,diabetes mellitus  no . ( % ),C0011849
909,diabetes mellitus  n = $nmbr$,C0011849
909,diabetes mellitus  n / n ( % ),C0011849
909,diabetes mellitus  n ( % ),C0011849
909,diabetes mellitus  ( % ),C0011849
909,diabetes mellitus  %,C0011849
909,diabetes mellitus,C0011849
909,diabetes melitus,C0011847;C0011849
909,diabetes history  mean ( sd )  years,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239
909,diabetes durationa < median,C0011847;C0011849;C0549183;C0876920;C2347635;C2348144;C2939193
909,diabetes duration subgroups,C0011847;C0011849;C0449238;C1079230;C2926735
909,diabetes duration mean ± sd,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
909,diabetes duration ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
909,diabetes duration ( y ),C0011847;C0011849;C0449238;C2926735
909,diabetes duration ( known )  % of patients,C0011847;C0011849;C0030705;C0205309;C0449238;C2926735
909,diabetes duration  years ( mean ± sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
909,diabetes duration  years,C0011847;C0011849;C0439234;C0449238;C2926735
909,diabetes duration  ycars “,C0011847;C0011849;C0449238;C2926735
909,diabetes duration  y,C0011847;C0011849;C0449238;C2926735
909,diabetes duration  n ( % ),C0011847;C0011849;C0449238;C2926735
909,diabetes duration,C0011847;C0011849;C0449238;C2926735
909,diabetes classificationa,C0011847;C0011849
909,diabetes at randomization,C0011847;C0011849;C0034656
909,diabetes and untreated hypertension,C0011847;C0011849;C0745134
909,diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849;C0359086;C0521116
909,diabetes absent $nmbr$ ( $nmbr$ . $nmbr$ ),C0011847;C0011849;C0332197;C4285062
909,diabetes ^,C0011847;C0011849
909,diabetes - related medication use    n   ( % ),C0011847;C0011849;C0240320;C0439849;C0445223
909,diabetes *,C0011847;C0011849
909,diabetes ( p = . oo $nmbr$ ),C0011847;C0011849
909,diabetes ( p = . o $nmbr$ ),C0011847;C0011849
909,diabetes ( p = . $nmbr$ ),C0011847;C0011849
909,diabetes ( n [ % ] ) *,C0011847;C0011849
909,diabetes ( n = $nmbr$ ),C0011847;C0011849
909,diabetes ( n - $nmbr$  $nmbr$ ),C0011847;C0011849
909,diabetes ( % ),C0011847;C0011849
909,diabetes $nmbr$ ( % ),C0011847;C0011849
909,diabetes $nmbr$,C0011847;C0011849
909,diabetes  no . ( % ) c,C0011847;C0011849
909,diabetes  no . ( % ),C0011847;C0011849
909,diabetes  n ( % ),C0011847;C0011849
909,diabetes  * n ( % ),C0011847;C0011849
909,diabetes  %,C0011847;C0011849
909,diabetes,C0011847;C0011849
909,dabetes,
909,current cvd / diabetes  n ( % ),C0007222;C0011847;C0011849;C0521116;C1705970
909,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol,C0003591;C0003594;C0008377;C0011849;C0023824;C0039411;C0040642;C0041405;C0041698;C0392885;C0428471;C1824670;C3272447;C3715113;C4522122
909,all without diabetes ( n = $nmbr$ ),C0011847;C0011849
909,all with diabetes ( n = $nmbr$ ),C0011847;C0011849
909,( scale diabetes ),C0011847;C0011849;C0175659;C0349674;C1947916
-10,dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830
907,years since diagnosis of type $nmbr$ diabetes  n ( % ),C0011847;C0011849;C0011900;C0439234;C1320657;C1550351;C1704338;C1704656
907,type $nmbr$ diabetes 一 no . ( % ),C1320657
907,type $nmbr$ diabetes — no . { % ) §,C1320657
907,type $nmbr$ diabetes — no . ( % ) §,C1320657
907,type $nmbr$ diabetes — no . ( % ),C1320657
907,type $nmbr$ diabetes mellitusa,C1320657
907,type $nmbr$ diabetes mellitus ’,C1320657
907,type $nmbr$ diabetes mellitus ' $nmbr$ ',C1320657
907,type $nmbr$ diabetes mellitus  n ( % ),C1320657
907,type $nmbr$ diabetes mellitus,C1320657
907,type $nmbr$ diabetes meiiitus,C1320657
907,type $nmbr$ diabetes history  n ( % ),C0019664;C0019665;C0262512;C0262926;C1320657;C1705255;C2004062
907,type $nmbr$ diabetes . n ( % ),C1320657
907,type $nmbr$ diabetes *,C1320657
907,type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ ),C1320657
907,type $nmbr$ diabetes  no . ( % ),C1320657
907,type $nmbr$ diabetes  n ( % ) d,C1320657
907,type $nmbr$ diabetes  n ( % ),C1320657
907,type $nmbr$ diabetes,C1320657
907,time since diagnosis of type $nmbr$ diabetes mellitus,C0011900;C0040223;C1320657;C1704338;C1704656;C3541383
907,time since diagnosis of type $nmbr$ diabetes - no . ( % ),C0011847;C0011849;C0011900;C0040223;C1320657;C1550351;C1704338;C1704656;C3541383
907,no type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ ),C1320657
907,known duration of type $nmbr$ diabetes ( years ),C0205309;C0439234;C0449238;C1320657;C2926735
907,known duration of type $nmbr$ diabetes,C0205309;C0449238;C1320657;C2926735
907,duration of type $nmbr$ diabetes mellitus ( years ),C0439234;C0449238;C1320657;C2926735
907,duration of type $nmbr$ diabetes mellitus  years,C0439234;C0449238;C1320657;C2926735
907,duration of type $nmbr$ diabetes categories  n ( % ),C1320657;C1547660
907,duration of type $nmbr$ diabetes ( years ),C0439234;C0449238;C1320657;C2926735
907,duration of type $nmbr$ diabetes  years,C0439234;C0449238;C1320657;C2926735
907,duration of type $nmbr$ diabetes,C0449238;C1320657;C2926735
907,diabetes mellitus ( type $nmbr$ or $nmbr$ ),C1320657
907,diabetes mellitus ( type $nmbr$ )  n ( % ),C1320657
906,option,C1518601;C1550456
906,location of ml,C0439526;C0450429;C1515974;C1705224;C3887665;C4284930;C4284931
906,location of infarction — no . ( % ) §,C0021308;C0450429;C1515974;C4284930;C4284931
906,location of infarction,C0021308;C0450429;C1515974;C4284930;C4284931
906,location of disease  n ( % ),C0012634;C0450429;C1515974;C4284930;C4284931
906,location of crohn ' s disease  %,C0010346;C0450429;C1515974;C4284930;C4284931
906,location  n ( % ),C0450429;C1515974;C4284930;C4284931
906,location,C0450429;C1515974;C4284930;C4284931
906,lesion location,C0221198;C0450429;C1515974;C1546698;C4284930;C4284931
906,infarct related artery location,C0003842;C0021308;C0226004;C0439849;C0445223;C0450429;C1515974;C4284930;C4284931
906,infarct location — no . / total no . ( % ),C0021308;C0439175;C0439810;C0450429;C1515974;C4284930;C4284931
906,infarct location ( interactsn $ : p = $nmbr$ . $nmbr$ ),C0021308;C0450429;C1515974;C4284930;C4284931
906,infarct location,C0021308;C0450429;C1515974;C4284930;C4284931
906,geographical location  n ( % ),C4545686
906,ethnicity  location,C0015031;C0243103;C0450429;C1515974;C4284930;C4284931
906,disease location ( % ) *,C0012634;C0450429;C1515974;C4284930;C4284931
906,disease location  %,C0012634;C0450429;C1515974;C4284930;C4284931
906,discontinu - ation,
906,anterior infarct location,C0340293;C0450429;C1515974;C2349195;C4284930;C4284931
905,omega $nmbr$ allocation,C1706778;C1719844
905,n - $nmbr$ allocation,C0369718;C0441922;C1706778
904,uplift ® population,C0032659;C1257890
904,subpopulation,C1257890
904,safety population  n ( % ),C0032659;C0036043;C1257890;C1705187
904,safety population,C0032659;C0036043;C1257890;C1705187
904,populations :,C0032659;C1257890
904,population,C0032659;C1257890
904,patient population,C0030705;C0032659;C1257890
904,overall pea population,C0030738;C0032659;C0069964;C0070939;C0282416;C1257890;C1262903;C1561607;C3257529
904,overall freedom population ( n = $nmbr$ ),C0016694;C0032659;C0282416;C1257890;C1561607
904,open - label population,C0032659;C1257890;C1709323
904,indian subpopulation,C1257890;C1524069
904,global trial population,C0008976;C0032659;C0205246;C1257890;C2348867
904,full population,C0032659;C0443225;C1257890
904,d population,C0032659;C0073187;C0332173;C1257890;C4484261
904,ctd population subgroup,C0032659;C1079230;C1257890;C1335071;C1442905;C1515021
904,boost intensify premix i ( global patient population ),C0021966;C0030705;C0032659;C0205246;C0221138;C1257890;C1511253;C1874596;C2348867
904,boost intensify all ( pan - asian patient population ),C0030705;C0032659;C0078988;C0085999;C1257890;C1511253;C1874596;C3887654
904,^ ≥ $nmbr$ % incidence in any treatment group in the overall safety population .,C0021149;C0032659;C0036043;C0220856;C0282416;C0374505;C1257890;C1561607;C1705187
903,uc disease duration ( y ),C0872146
903,prothrombin mutation ( % ),C1610621
903,mean disease duration  years,C0439234;C0444504;C0872146;C2347634;C2348143
903,mean disease duration  y ( sd ),C0444504;C0872146;C2347634;C2348143;C2699239
903,mean ( sd ) disease duration  years,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
903,duration of disease — yr ^ mean,C0439234;C0444504;C0872146;C2347634;C2348143
903,duration of disease — yr : t,C0439234;C0872146
903,duration of disease — yr,C0439234;C0872146
903,duration of disease since,C0872146
903,duration of disease before baseline,C0168634;C0872146;C1442488
903,duration of disease ( yr ),C0439234;C0872146
903,duration of disease ( y )  median ( min  max },C0549183;C0702093;C0872146;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
903,duration of disease  y,C0872146
903,duration of disease  n ( % ),C0872146
903,duration of disease  median,C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
903,disease duration b $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
903,disease duration [ year ]  mean ± sda,C0276477;C0439234;C0439508;C0444504;C0872146;C1428349;C1553165;C2347634;C2348143
903,disease duration > $nmbr$ years  $nmbr$ [ % ] disease activity ‘ s,C0205177;C0439167;C0439234;C0441655;C0449238;C0872146;C1292728;C1561536;C2926735;C3668946;C4049938;C4049939
903,disease duration : < baseline mean,C0168634;C0444504;C0872146;C1442488;C2347634;C2348143
903,disease duration ( yr )  mean ± sd,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
903,disease duration ( yr ),C0439234;C0872146
903,disease duration ( y )  median ( m / n  max ),C0369637;C0441923;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
903,disease duration  year ( median ),C0439234;C0439508;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
903,disease duration  y  mean ± sd,C0444504;C0872146;C2347634;C2348143;C2699239
903,disease duration  y,C0872146
903,disease duration  mean yr ( sd ),C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
903,disease duration  mean [ sd ] years,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
903,disease duration,C0872146
903,disease characteristics duration of psoriatic arthritis — yr,C0003872;C0439234;C0449238;C0599878;C0872146;C1521970;C2926735
902,years of education *,C0013621;C0013622;C0013658;C0039401;C0439234
902,education — no . ( % ),C0013621;C0013622;C0013658;C0039401
902,education level,C0013621;C0013658
902,education > $nmbr$ yr ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
902,education > $nmbr$ y,C0013621;C0013622;C0013658;C0039401
902,education < $nmbr$ y,C0013621;C0013622;C0013658;C0039401
902,education *,C0013621;C0013622;C0013658;C0039401
902,education ( % ),C0013621;C0013622;C0013658;C0039401
902,education $nmbr$ to $nmbr$ y,C0013621;C0013622;C0013658;C0039401
902,education  yrs  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
902,education  y  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
902,education  y,C0013621;C0013622;C0013658;C0039401
902,education  mean ( sd )  ya,C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
902,education  mean ( sd )  y,C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
902,education,C0013621;C0013622;C0013658;C0039401
902,age of completion of highest education  years ( sd ),C0013621;C0013622;C0013658;C0039401;C0205197;C1510829;C1522410;C1554962;C2699239
901,t $nmbr$ dm duration  y,C0011816;C0449238;C2603360;C2926735;C3250443
901,symptom duration  months,C0439231;C0449238;C1457887;C2926735;C3854129
901,symptom duration,C0449238;C1457887;C2926735;C3854129
901,ra symptom duration — year,C0439234;C0439508;C0449238;C1457887;C2926735;C3538806;C3854129;C4048756
901,ra symptom duration < $nmbr$ months — number ( % ),C0237753;C0439231;C0449238;C0449788;C1457887;C2926735;C3538806;C3854129;C4048756
901,ra duration ( months ) *,C0439231;C0449238;C2926735;C3538806;C4048756
901,pci duration in min ( median  iqr ),C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
901,pci duration,C0449238;C2926735;C4049621
901,median crohn ' s disease duration  y ( range ),C0010346;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
901,mean ( sd ) duration of t $nmbr$ dm  y,C0011816;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3250443
901,mean ( s . d . ) duration of t $nmbr$ dm  years,C0011816;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3250443
901,known duration of t $nmbr$ dm  y,C0011816;C0205309;C0449238;C2926735;C3250443
901,known duration,C0205309;C0449238;C2926735
901,extended - duration enoxaparin ( n = $nmbr$ ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
901,extended - duration enoxaparin  n / n ( % ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
901,duration of ulcerative colitis,C0009324;C0449238;C2926735
901,duration of t $nmbr$ dm > $nmbr$ years,C0011816;C0439234;C0449238;C2926735;C3250443
901,duration of t $nmbr$ dm < $nmbr$ years,C0011816;C0439234;C0449238;C2926735;C3250443
901,duration of t $nmbr$ dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
901,duration of t $nmbr$ dm ( % ),C0011816;C0449238;C2926735;C3250443
901,duration of t $nmbr$ dm  years,C0011816;C0439234;C0449238;C2926735;C3250443
901,duration of t $nmbr$ dm  y,C0011816;C0449238;C2926735;C3250443
901,duration of t $nmbr$ dm,C0011816;C0449238;C2926735;C3250443
901,duration of t $nmbr$ d  y,C0449238;C2926735
901,duration of study - drug infusion,C0392877;C0449238;C0557651;C2603343;C2926735
901,duration of ra ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
901,duration of ra ( time from symptom onset )  years,C0040223;C0439234;C0449238;C2926735;C3538806;C3541383;C4048756;C4086878
901,duration of ra,C0449238;C2926735;C3538806;C4048756
901,duration of pci — min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
901,duration of pci ( min )  median,C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
901,duration of pci  min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
901,duration of morning,C0332170;C0449238;C2926735
901,duration of dm - years,C0011816;C0439234;C0449238;C2926735;C3250443
901,duration of chf ( months ),C0018802;C0439231;C0449238;C2926735
901,duration of assigned regimen before surgery post - randomisation characteristic * *,C0034656;C0038894;C0038895;C0040808;C0449238;C0543467;C0687676;C1274039;C1516050;C1521970;C1552601;C1704687;C2926735;C2945654;C3469826
901,duration of assigned regimen before surgery post - randomisation characteristic *,C0034656;C0038894;C0038895;C0040808;C0449238;C0543467;C0687676;C1274039;C1516050;C1521970;C1552601;C1704687;C2926735;C2945654;C3469826
901,duration of assigned regimen before surgery,C0038894;C0038895;C0040808;C0449238;C0543467;C1274039;C1516050;C1552601;C2926735;C2945654
901,duration of,C0449238;C2926735
901,duration,C0449238;C2926735
901,dm duration,C0011816;C0449238;C2926735;C3250443
901,crohn ' s disease duration,C0010346;C0449238;C2926735
901,cornell voltage - duration product ( mmxmsec ) *,C0449238;C0598352;C1514468;C1704444;C2926735
901,af duration  n ( % ),C0344434;C0449238;C2926735;C4049859
900,severe exacerbations  itt population  n ( % ),C0032659;C0205082;C1257890;C4050465;C4050466;C4086268
900,moderate / severe exacerbations  itt population  n ( % ),C0032659;C0205081;C0205082;C1257890;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335
900,mitt population ( n = $nmbr$ ),C0032659;C1257890
900,mitt population,C0032659;C1257890
900,joint damage outcomes ( mitt population ),C0010957;C0022417;C0032659;C0392905;C1257890;C1274040;C1706309;C1883709
900,itt population  n,C0032659;C1257890
900,itt population,C0032659;C1257890
900,itt,
900,asian itt population total ( n = $nmbr$ ),C0032659;C0078988;C0439175;C0439810;C1257890
899,symptomatic localization - related,C0231220;C0439849;C0445223;C0475264;C1744691
899,infarct localization  n ( % ),C0021308;C0475264;C1744691
899,infarct localization,C0021308;C0475264;C1744691
899,infarct localisation,C0021308;C0475264;C1744691
898,medications at discharge,C0806915
898,medication effects,C1319171
898,cardiac medications at discharge  %,C0018787;C0806915;C1522601
897,cardiovascular medications  %,C0007220
897,cardiovascular medications,C0007220
897,cardiovascular medication usage,C0007220;C0457083
897,baseline concomitant cardiovascular medications,C0007220;C0168634;C0521115;C1442488
897,baseline cardiovascular medications  n ( % ),C0007220;C0168634;C1442488
897,baseline cardiovascular medication  c n ( % ),C0007220;C0168634;C1442488
897,baseline cardiovascular medication,C0007220;C0168634;C1442488
897,antihypertensive  antianginal  and other cardiovascular medications,C0003364;C0007220;C1874267;C3537168
896,laboratory investigations,C0022877;C1261322;C3244292;C4283904
896,investigations,C1261322
896,additional investigations,C2359834
895,prior amputation,C0002688;C0332152;C0332840;C1546539;C2826257
895,major amputations at week $nmbr$,C0002688;C0205082;C0205164;C0332174;C0439230;C4318856;C4521762
895,amputations  n ( % ),C0002688
895,amputation,C0002688;C0332840;C1546539
894,• ml without st - segment elevation,C0439526;C0520886;C1705224;C3887665
894,• ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
894,time from randomization to pci ( st - elevation mi )  min,C0034656;C0040223;C0520886;C0702093;C1524029;C3541383;C3810814;C3813700;C4049621
894,st segment elevation,C0520886
894,st elevation,C0520886
894,st - segment elevation mi,C0520886;C3810814
894,st - segment elevation,C0520886
894,st - elevation mi,C0520886;C3810814
894,non - st - segment elevation mi,C0520886;C1518422;C3810814
894,non - st - segment elevation acs,C0520886;C0742343;C1518422;C4318612
894,non - st - segment elevation,C0520886;C1518422
894,non - st - elevation ml,C0439526;C0520886;C1518422;C1705224;C3887665
894,ml without st - segment elevation !,C0439526;C0520886;C1705224;C3887665
894,ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
893,lm bifurcation treated,C0184906;C1261082;C1522326;C1551056;C3146289
893,lm bifurcation not treated,C0184906;C1261082;C1518422;C1522326;C1551056;C3146289
893,bifurcation per lesion ‡,C0184906;C0221198;C1546698;C3146289
893,bifurcation lesion with side branch ≥ $nmbr$ . $nmbr$ mm stented,C0038257;C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
893,bifurcation lesion with side branch $ $nmbr$ . $nmbr$ mm stented,C0038257;C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
893,bifurcation lesion,C0184906;C0221198;C1546698;C3146289
893,bifurcation  n ( % ),C0184906;C3146289
893,bifurcation,C0184906;C3146289
892,score distribution : < $nmbr$,C0449820;C0520511;C1704711;C4050231
892,score distribution :,C0449820;C0520511;C1704711;C4050231
892,distribution — no . { % ),C0520511;C1704711
892,distribution — no . ( % ),C0520511;C1704711
892,distribution time,C0040223;C0520511;C1704711;C3541383
892,distribution of metformin dose at randomization  n ( % ),C0025598;C0034656;C0178602;C0520511;C0869039;C1114758;C1704711
892,bmi distribution  n ( % ),C0520511;C0578022;C1704711
892,a $nmbr$ c distribution ( % ),C0520511;C1704711
891,one or more copd exacerbations ( n / n [ % ] ),C0205172;C0205447;C0740304
891,copd exacerbation : no,C0740304
890,mean number of clinically significant asthma exacerbations †,C0237753;C0237881;C0349790;C0444504;C0449788;C0750502;C1546944;C2347634;C2348143
890,asthma exacerbations,C0349790
889,s $nmbr$ exacerbations,C0565930;C2603362;C4086268
889,patients with > $nmbr$ exacerbations resulting in hospital admission,C0030705;C0184666;C0678226;C4086268
889,patients with > $nmbr$ exacerbations resulting in emergency department visit,C0030705;C0332294;C0545082;C0553618;C0562508;C1512346;C1704729;C2826704;C4086268
889,patients with > $nmbr$ exacerbations resulting in ed visit,C0030705;C0332294;C0545082;C1512346;C2826704;C3538926;C4086268
889,patients with > $nmbr$ exacerbation in previous $nmbr$ months,C0030705;C0205156;C0439231;C1552607;C4086268
889,patients having exacerbation,C0030705;C4086268
889,p ) atients with > $nmbr$ exacerbations resulting in emergency department visit,C0332294;C0369773;C0545082;C0553618;C0562508;C1512346;C1704729;C2603361;C2826704;C4086268
889,number of patients with exacerbations in the previous $nmbr$ months  n ( % ),C0205156;C0439231;C1552607;C2360800;C4086268
889,number of exacerbations in the past $nmbr$ months,C0237753;C0449788;C4086268;C4331910
889,number of exacerbations in the last $nmbr$ months  mean ± sd,C0237753;C0444504;C0449788;C2347634;C2348143;C2699239;C4086268;C4331910
889,number of exacerbations in the last $nmbr$ months,C0237753;C0449788;C4086268;C4331910
889,number of exacerbations in previous $nmbr$   months,C0205156;C0237753;C0439231;C0449788;C1552607;C4086268
889,number of exacerbations in previous $nmbr$ months,C0205156;C0237753;C0439231;C0449788;C1552607;C4086268
889,number of exacerbations in last $nmbr$ months,C0237753;C0449788;C4086268;C4331910
889,number of exacerbations $nmbr$ months before randomisation,C0034656;C0237753;C0439231;C0449788;C4086268
889,number of exacerbations,C0237753;C0449788;C4086268
889,number of exacerbation in the previous $nmbr$ months  n ( % ),C0205156;C0237753;C0439231;C0449788;C1552607;C4086268
889,hospitalized for an exacerbation,C0701159;C4086268
889,hospitalized exacerbation rates,C0701159;C0871208;C1521828;C4086268
889,exacerbations in the past $nmbr$ months n,C4086268;C4331910
889,exacerbations,C4086268
889,exacerbation historyh  n ( % ),C4086268
889,> $nmbr$ exacerbations,C4086268
889,> $nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C0369637;C0441923;C1552852;C4086268
889,$nmbr$ exacerbations,C4086268
889,$nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C0369637;C0441923;C1552852;C4086268
889,$nmbr$ exacerbation,C4086268
889,$ $nmbr$ exacerbations,C4086268
888,| interactior $nmbr$ p,
888,time to randomisation [ hours ] ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0040223;C0439227;C1704675;C3541383
888,pinteraction = $nmbr$ . $nmbr$,
888,pinteraction,
888,pfor interaction,C1151635;C1704675
888,p   values for interaction,C1704675;C1709380
888,p value for interaction - dosage with dabigatran  $nmbr$ mg,C0024671;C0026410;C0178602;C0439269;C1704675;C1709380;C1960952;C2346927;C2348066;C2986497;C4321396;C4521761
888,p value for interaction  dosage with dabigatran  $nmbr$ mg,C0024671;C0026410;C0178602;C0439269;C1704675;C1709380;C1960952;C2346927;C2348066;C2986497;C4321396;C4521761
888,p vaiue ( interaction ),C0369773;C1704675;C2603361
888,p lace of randomization ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0280109;C0369773;C0453991;C1704675;C2603361
888,p interaction women vs men,C0025266;C0043210;C0369773;C1704675;C2603361
888,p interaction = $nmbr$ . $nmbr$,C0369773;C1704675;C2603361
888,p interaction,C0369773;C1704675;C2603361
888,p for interaction between rhtn and no rhtn and treatmenta,C0369773;C1704675;C2603361
888,p for interaction *,C0369773;C1704675;C2603361
888,p for interaction,C0369773;C1704675;C2603361
888,p : interaction,C0369773;C1704675;C2603361
888,p / interaction,C0369773;C1704675;C2603361
888,p . interaction,C0369773;C1704675;C2603361
888,p - interaction,C0369773;C1704675;C2603361
888,p $nmbr$ interaction,C0369773;C1704675;C2603361
888,p  interaction !,C0369773;C1704675;C2603361
888,lue for interaction,C1704675
888,interactior p - value,C1709380
888,interaction pf,C1704675;C3815179
888,interaction p vaiue,C1704675
888,interaction p = $nmbr$ . $nmbr$,C1704675
888,interaction p - vaiue,C1704675
888,interaction p,C1704675
888,interaction - p,C1704675
888,interaction $nmbr$,C1704675
888,interaction,C1704675
888,egfr_p_interaction,C1704675;C1739039;C3811844;C3812682
888,/ ’ interaction,C1704675
887,section $nmbr$ c,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
887,section $nmbr$ b,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
887,section $nmbr$ a,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
887,method of assessing ejection fraction,C0025663;C0302131;C0336969;C0449851;C0812388;C0871511;C1264633;C1516048
887,fraction ( % ),C1264633;C1554103
887,ejection fraction group,C0441833;C0489482;C0687744;C1257890;C1519504;C1705428;C1705429;C2700378
887,ejection fraction category,C0489482;C0683312;C2700378;C3889287
887,ejection fraction based on local reading,C0034754;C0205276;C0489482;C1527178;C1705179;C1705938;C2700378;C4284139
887,ejection fraction : < $nmbr$ % ( n = $nmbr$ ),C0489482;C2700378
887,ejection fraction *,C0489482;C2700378
887,ejection fraction ( % ),C0489482;C2700378
887,ejection fraction  percent ( sd ),C0439165;C0489482;C2699239;C2700378
887,ejection fraction  % nyha class  n ( % ),C0489482;C1882083;C2700378
887,ejection fraction  %,C0489482;C2700378
887,ejection fraction,C0489482;C2700378
886,rosuvastatin   n   =   $nmbr$,C0965129
886,rosuvastatin of patients ( rate ),C0030705;C0871208;C0965129;C1521828
886,rosuvastatin n = $nmbr$,C0965129
886,rosuvastatin n ( rate ) *,C0871208;C0965129;C1521828
886,rosuvastatin n ( rate ) $nmbr$,C0871208;C0965129;C1521828
886,rosuvastatin n ( rate ),C0871208;C0965129;C1521828
886,rosuvastatin events / patients ( % ),C0030705;C0441471;C0965129;C3541888
886,rosuvastatin + fenofibric acid,C0060179;C0965129
886,rosuvastatin +,C0965129
886,rosuvastatin ( n = $nmbr$ . $nmbr$ ),C0965129
886,rosuvastatin ( n = $nmbr$ ),C0965129
886,rosuvastatin ( n = $nmbr$  $nmbr$ ),C0965129
886,rosuvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
886,rosuvastatin $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
886,rosuvastatin  n ( rate ),C0871208;C0965129;C1521828
886,rosuvastatin  n ( % ),C0965129
886,rosuvastatin  events / patients ( % ),C0030705;C0441471;C0965129;C3541888
886,rosuvastatin,C0965129
886,rosuva  rosuvastatin  sd  standard deviation  t $nmbr$ dm  type $nmbr$ diabetes mellitus .,C0011816;C0011849;C0332307;C0871420;C0965129;C1320657;C1547052;C2699239;C3250443
886,i rosuvastatin ( n = $nmbr$ ),C0021966;C0221138;C0965129
886,dose of rosuvastatin,C0178602;C0869039;C0965129;C1114758
886,crosuvastatin + fenofibric acid vs . rosuvastatin monotherapy .,C0060179;C0965129
886,copd - rosuvastatin ( n = $nmbr$ ),C0024117;C0965129;C1412502;C3714496
886,copd - rosuvastatin ( $nmbr$ pt ) n . ( % ),C0024117;C0032743;C0699718;C0965129;C1412502;C3714496
886,$nmbr$ mg  rosuvastatin $nmbr$ mg .,C0965129;C1319635
885,z\tonastaiin,
885,dose of atorvastatin,C0178602;C0286651;C0869039;C1114758
885,concomitant atorvastatin dose  mg,C0024671;C0026410;C0178602;C0286651;C0439269;C0521115;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
885,atv  atorvastatin  ldl - c  low - density lipoprotein cholesterol . * p - values pertain to treatment - by - stratum interaction test for stratum or treatment - by - subgroup interaction test for subgroups . ' multiplicity adjustments were not applied to this predefined subgroup analysis of ldl - c goal attainment   [ expressed as number of patients reaching ldl - c goal at week $nmbr$ / number of patients above goal at baseline  ^ treatment stratum was defined by intake of atv $nmbr$ or $nmbr$ mg .,C0018017;C0022885;C0023824;C0024671;C0026410;C0039593;C0039798;C0087111;C0168634;C0210243;C0237455;C0286651;C0332174;C0376209;C0392366;C0439230;C0439269;C0449822;C0456081;C0456984;C0674679;C0680230;C1079230;C1145759;C1334862;C1442488;C1512806;C1515021;C1515976;C1518422;C1522326;C1533734;C1571704;C1704675;C1704788;C1705169;C1709380;C1960952;C2346927;C2360800;C2584321;C2945673;C2986480;C3538994;C3539106;C3831328;C3887704;C4048755;C4318744;C4321396;C4521761
885,atorvastatinb,
885,atorvastatin { n = $nmbr$  $nmbr$ ),C0286651
885,atorvastatin monotherapy ( n = $nmbr$ * ),C0286651
885,atorvastatin factorial study,C0286651;C2826344
885,atorvastatin dose,C0178602;C0286651;C0869039;C1114758
885,atorvastatin ( n = $nmbr$  $nmbr$ ),C0286651
885,atorvastatin $nmbr$ mg + ezetimibe $nmbr$ mg ( n = $nmbr$ ),C0286651;C1142985;C1319635
885,atorvastatin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
885,atorvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
885,atorvastatin $nmbr$ mg,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
885,atorvastatin  n ( % ),C0286651
885,atorvastatin,C0286651
885,aiorvasiaiin,
884,metastatic disease,C0027627;C2939419;C2939420
884,metastatic,C0036525;C1522484;C4085632
884,epistaxis,C0014591;C4554627
883,prosthetic,
883,benign prostatic hyperplasia,C1704272
883,alprostadil n / n %,C0002335
883,alprostadil n / n,C0002335
883,alprostadil ( n = $nmbr$ ),C0002335
882,pravastatin vs usual care,C0085542;C1947933;C3538928
882,pravastatin n = $nmbr$,C0085542
882,pravastatin ( n = $nmbr$ >,C0085542
882,pravastatin ( n = $nmbr$ ),C0085542
882,pravastatin $nmbr$ mg,C0024671;C0026410;C0085542;C0439269;C1960952;C2346927;C4321396;C4521761
882,pravastatin,C0085542
882,i moderate  $nmbr$ mg of pravastatin ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0085542;C0205081;C0221138;C0439269;C1881878;C1960952;C2346927;C4049705;C4049706;C4085643;C4321335;C4321396;C4521761
882,clow - potency stratum : simvastatin $nmbr$ mg  pravastatin $nmbr$ mg  fluvastatin $nmbr$ mg  atorvastatin $nmbr$ mg  high - potency stratum : simvastatin $nmbr$ mg  atorvastatin,C0074554;C0082608;C0085542;C0205250;C0286651;C1299351;C1319635;C2700149;C2985073;C3245505;C3887512;C3889660;C4321237;C4522209
882,atorvastatin - pravastatin,C0085542;C0286651
881,migraine with aura,C0154723
881,epilepsy with grand mal seizures on awakening,C0014549;C0494475;C1720052
880,without revascularsation,
880,without ( n = $nmbr$ $nmbr$ ),C0369718;C0441922
880,migraine without aura,C0338480
879,withdrew consent,C1511481;C1554192;C2349954;C2923685
879,withdrawals  n / n ( % ),C1710677;C2349954;C2825032;C3812880;C4049634
878,with an sfua,
878,with ( n = $nmbr$ ),C0369718;C0441922
878,patients with specific disease characteris -,C0205369;C0683521;C1552740
878,patients with remission,C1277626
877,treated with losartan ( n = $nmbr$ ),C0126174;C0332293
877,treated with laba  %,C0332293
877,treated with atenolol ( n = $nmbr$ ),C0004147;C0332293
877,table $nmbr$ . characteristics of patients treated with losartan and atenolol *,C0004147;C0039224;C0126174;C0332293;C0815172;C1706074
877,patients treated with losartan ( n = $nmbr$ ),C0030705;C0126174;C0332293
876,without an sfua,
876,or ( itt ) ( n = $nmbr$ ),
876,associated with hiv infection,C0019693;C0332281
876,associated with drug or toxin exposure,C0013227;C0040537;C0332281;C1254351
876,associated with drug / toxin,C0013221;C0332281
876,associated with ctd,C0332281;C1335071;C1442905
876,associated with corrected - congenital shunts,C0009678;C0205202;C0232180;C0332281;C0542331;C1442858;C1744681
876,associated with corrected,C0205202;C0332281
876,associated with an atrial septal defect,C0018817;C0332281
875,regular alcohol consumption per week  no . ( % ),C0001948;C0205272;C0332174;C0439230
875,no alcohol consumption  on average,C0001948;C1510992;C2825518
875,drinking  n ( % ),C0001948;C0684271
875,drinking,C0001948;C0684271
875,current weekly alcohol use ( % ),C0001948;C0332174;C0521116;C1705970
875,current alcohol use  n ( % ),C0001948;C0521116;C1705970
875,alcohol use ( > $nmbr$ drink / wk ),C0001948;C0042153;C0332174;C0439230;C0452428;C0457083;C0556297;C1947944
875,alcohol use ( % ),C0001948
875,alcohol use ( %  > $nmbr$ / day ),C0001948;C0332173;C0439228;C0439505
875,alcohol use  n ( % ),C0001948
875,alcohol use,C0001948
875,alcohol intake never / rarely,C0001948;C0522498;C2003901
875,alcohol intake ( a ),C0001948
875,alcohol intake ( + ) ( % ),C0001948
875,alcohol intake  drinks / week,C0001948;C0332174;C0439230;C0452428
875,alcohol intake,C0001948
875,alcohol consumption at baseline,C0001948;C0168634;C1442488
875,alcohol consumption > once weekly,C0001948;C0558293
875,alcohol consumption *,C0001948
875,alcohol consumption ( yes ) ( n ),C0001948;C1549445;C1705108;C1710701
875,alcohol consumption ( % ) < $nmbr$ drink / dav,C0001948;C0009830;C0452428;C0556297;C1947907
875,alcohol consumption ( % ),C0001948
875,alcohol consumption !,C0001948
875,alcohol consumption  no . ( % ),C0001948
875,alcohol consumption  n ( % ),C0001948
875,alcohol consumption,C0001948
875,alcohol  % with > $nmbr$ drink / d,C0001948;C0556297
874,solifenacin ( n = $nmbr$ ),C1099677
874,sildenafil ( n = $nmbr$ ),C0529793
873,simvastatin monotherapy ( n = $nmbr$  $nmbr$ * ),C0074554
873,simvastatin ( n = $nmbr$ . $nmbr$ ),C0074554
873,simvastatin ( n = $nmbr$ ),C0074554
873,simvastatin ( n = $nmbr$  $nmbr$ ),C0074554
873,simvastatin $nmbr$ mg ( n = $nmbr$ ) *,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
873,simvastatin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
873,simvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
873,simvastatin $nmbr$ mg,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
873,simvastatin  n ( % ),C0074554
873,simvastatin,C0074554
873,pooled simvastatin factorial studies,C0074554;C1709595;C2349200;C2826344;C4522255
873,placebo / simvastatin,C0032042;C0074554;C1696465;C1706408
873,placebo + $nmbr$ mg / d of simvastatin,C0032042;C0074554;C0439422;C1696465;C1706408
873,patients on atorvastatin  rosuvastatin  or simvastatin at,C0030705;C0074554;C0286651;C0965129
873,exetimibe / simvastatin,C0074554
873,atorvastatin $nmbr$ mg and simvastatin $nmbr$ - $nmbr$ mg ( zi = $nmbr$ ),C0024671;C0026410;C0043476;C0074554;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
872,use of statins,C0360714;C1524063
872,use of statin at any follow - up visit ( % ),C0360714;C0589121;C1524063
872,treatment with statins,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
872,statins 一 no . ( % ),C0360714
872,statins  no . ( % ),C0360714
872,statins  n ( % ),C0360714
872,statins,C0360714
872,statin without other llt,C0360714;C2347090
872,statin with other llt,C0360714;C2347090
872,statin with niacin,C0027996;C0360714;C1142562
872,statin use at baseline,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
872,statin use  n ( % ),C0042153;C0360714;C0457083;C1947944
872,statin usage,C0360714;C0457083
872,statin treatment,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
872,statin potency stratum  n ( % ),C0360714;C3245505
872,statin medication,C0013227;C0360714;C3244316;C4284232
872,statin intolerant *,C0231200;C0360714
872,statin during admission,C0184666;C0360714;C0809949
872,statin alone,C0205171;C0360714;C0439044;C0679994
872,statin + er niacin ( n = $nmbr$ ),C0027996;C0360714;C1142562;C3810541;C3811131
872,statin ( s ),C0360714
872,statin ( n = $nmbr$ ),C0360714
872,statin ( n - $nmbr$ ),C0360714
872,statin ( % ),C0360714
872,statin  n ( % ),C0360714
872,statin  % ( n ),C0360714
872,statin,C0360714
872,stalin,
872,prevention )  n ( % ) patients on llt ( other than statin )  n ( % ),C0030705;C0199176;C0360714;C1706420;C2347090;C2700409
872,peri - op statins : no ( n = $nmbr$ ),C0347985;C0360714;C0369718;C0441922
872,patients receiving statin,C0030705;C0360714;C1514756
872,patients not receiving statin,C0030705;C0360714;C1514756;C1518422
872,non high dose statin ( n = $nmbr$  $nmbr$ ),C0360714;C0444956;C1518422
872,non - statin ( n = $nmbr$ ),C0360714;C1518422
872,no statin during admission,C0184666;C0360714;C0809949
872,no statin ( + / - llt ),C0360714;C2347090
872,no statin,C0360714
872,moderate - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081855
872,moderate - intensity statin,C0360714;C4081855
872,ltt other than statin,C0360714
872,llv wlalil $nmbr$ statin,C0360714
872,history of statin use,C0019664;C0019665;C0262512;C0262926;C0360714;C1524063;C1705255;C2004062
872,high - dose statin pretreatment ( n = $nmbr$ ),C0360714;C0444956;C1550147;C2709094;C3539075;C3539076
872,eze + statin n = $nmbr$,C0360714
872,eze + statin,C0360714
872,baseline statin use,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
872,baseiine statin,C0360714
872,any statin versus no statin at randomization,C0034656;C0360714
872,any statin ( with / without llt ),C0360714;C2347090
872,any statin,C0360714
872,all patients on maximally tolerated statin ± other llt,C0030705;C0360714;C2347090
872,a . overall and subgroups bv statin potency - -,C0085166;C0282416;C0360714;C1079230;C1511278;C1561607;C3245505
871,niacini,
871,niacin + statin,C0027996;C0360714;C1142562
871,niacin ( n = $nmbr$ ),C0027996;C1142562
871,niacin  n ( % ),C0027996;C1142562
871,niacin,C0027996;C1142562
871,extended - release niacin plus statin ( n = $nmbr$ ),C0027996;C0332287;C0360714;C1142562;C1707968
870,rivastigmine ( n = $nmbr$ ),C0649350
870,rivastigmine,C0649350
870,histamine - $nmbr$ - receptor antagonist,C0019590;C4521896
870,anti - histamines,C0019590
869,vitamin e,C0042874;C3714803
869,randomized to receive vitamin e,C0034656;C0040363;C0041260;C0042874;C1514756;C1883351;C3714803;C3815594
869,i vitamin e ( n = $nmbr$ ),C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
869,i vitamin e,C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
869,$nmbr$ vitamin e ( n = $nmbr$ $nmbr$ ),C0042874;C3714803
869,$nmbr$ vitamin e,C0042874;C3714803
868,vitamin k antagonists,C3653316
868,vitamin k antagonist naive,C1096489;C2267235
868,vitamin k antagonist experiencedk ( n = $nmbr$ $nmbr$ ),C1096489;C2267235
868,vitamin k antagonist experienced  n ( % ),C0237607;C0369718;C0441922;C0596545;C1096489;C2267235
868,vitamin k antagonist ( e . g . warfarin / coumarol ),C0043031;C1096489;C2267235
868,vitamin k antagonist,C1096489;C2267235
868,vitamin c,C0003968;C2349136;C3714687;C4522080
868,previous use of vitamin k antagonist for > $nmbr$ days — no . ( % ),C0205156;C0439228;C1096489;C1524063;C1552607;C2267235
867,vitamins,C0042890;C3540032;C3714649
867,other plain vitamin preparations,C0042890
866,vitamin d §,C0014695;C0042866;C2936842;C3537249;C3714503
866,serum vitamin d ( nmol / l ),C0014695;C0042866;C0229671;C0439282;C1546774;C1550100;C2936842;C3537249;C3714503
866,daily dose of vitamin d ( iu / day ),C0014695;C0042866;C0439465;C2348070;C2936842;C3537249;C3714503
866,baseline vitamin - d,C0014695;C0042866;C0168634;C1442488;C2936842;C3537249;C3714503
866,$nmbr$ ( oh ) vitamin d ( ng / ml ),C0014695;C0042866;C0220853;C0439275;C2936842;C3537249;C3714503
865,white not of hispanic origin,C0007457;C0043157;C0079946;C0086409;C0220938;C0439659;C1518422;C1518424;C1550512
865,not hispanic or latino ( n — $nmbr$ ),C0086528;C1518424
865,not hispanic or latino ( n = $nmbr$ ),C0086528;C1518424
865,not hispanic or latino,C0086528;C1518424
865,not hispanic / latino ( n = $nmbr$  $nmbr$ ),C0086528;C1518424
865,not hispanic / latino,C0086528;C1518424
865,not hispanic,C1518424
865,non - hispanic or latino,C0086528;C1518424
865,non - hispanic and latino,C0086528;C1518424
865,non - hispanic / latino,C0086528;C1518424
865,non - hispanic  non - latino,C0086528;C1518424
865,non - hispanic,C1518424
865,hispanic — no . ( % ),C0086409
865,hispanic or non - hispanic ethnic group — no . ( % ) f,C0015031;C0016327;C0086409;C1518424;C1879937
865,hispanic ethnic group — no . { % ) ’ i ',C0015031;C0021966;C0086409;C0221138;C1879937
865,hispanic ethnic group — no . / total no . ( % ) ‘ j ‘,C0015031;C0086409;C0439175;C0439810;C1879937
865,hispanic ethnic group — no . ( % ) f,C0015031;C0016327;C0086409;C1879937
865,hispanic ethnic group — no . ( % ) : t,C0015031;C0086409;C1879937;C2603360
865,hispanic ethnic group  n ( % ),C0015031;C0086409;C0441848;C0680174
865,hispanic / non - hispanic,C0086409;C1518422
865,hispanic ( n = $nmbr$ l $nmbr$ ),C0086409
865,hispanic ( n = $nmbr$ ),C0086409
865,hispanic  n ( % ),C0086409
865,hispanic,C0086409
865,ethnicity  not hispanic / latino    n   ( % ),C0015031;C0086528;C0243103;C1518424
865,black hispanic - n ( % ),C1533017;C1533018
865,black hispanic,C1533017;C1533018
865,black  non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
865,biack non - hispanic,C1518424
865,biack hispanic,C0086409
865,biack,
865,american hispanic ( n   = $nmbr$ ),C0086409;C0596070
864,unfractionated heparin — no . ( % ),C0019134;C2825026
864,unfractionated heparin within $nmbr$ hr before randomization — no . / total no . ( % ),C0019134;C0034656;C0439175;C0439810;C2825026
864,unfractionated heparin before randomisation,C0019134;C0034656;C2825026
864,unfractionated heparin ( n = $nmbr$ ),C0019134;C2825026
864,unfractionated heparin ( n = $nmbr$  $nmbr$ ),C0019134;C2825026
864,unfractionated heparin,C0019134;C2825026
864,unfractionated,
864,non - pci intravenous unfractionated heparin,C0354566;C1518422;C4049621
864,neither unfractionated heparin nor low - molecular - weight heparin,C0019134;C0019139;C2825026;C3536766
864,intravenous heparin,C0354566
864,both unfractionated heparin and low - molecular - weight heparin,C0019134;C0019139;C2825026;C3536766
863,neither uh or lmw heparin,C0019134;C0770546
863,initial heparin treatment duration on or after randomization,C0019134;C0034656;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
863,initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
863,heparin plus gpi ( n = $nmbr$  $nmbr$ ),C0019134;C0332287;C0770546;C1415351
863,heparin plus a gpi ( n = $nmbr$ ),C0019134;C0770546;C1415351
863,heparin only,C0019134;C0205171;C0770546;C1720467
863,heparin dose regimen,C0019134;C0770546;C2348331
863,heparin,C0019134;C0770546
863,bivalirudin - heparin plus gpi,C0019134;C0168273;C0770546;C1415351
863,additional heparin,C0019134;C0770546;C1524062
863,> = $nmbr$ day s initial heparin treatment duration,C0019134;C0205265;C0332173;C0439228;C0439505;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
863,> = $nmbr$ ^ initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
862,unfractionated heparin or enoxaparin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ ),C0016011;C0019134;C0206460;C0243077;C0332287;C2825026
862,semuloparin ( n = $nmbr$ ),C2700104
862,enoxaparin / vka n / n ( % ) $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0206460
862,enoxaparin / vka,C0206460
862,enoxaparin ( n = $nmbr$ ),C0206460
862,enoxaparin ( n = $nmbr$  $nmbr$ ),C0206460
862,enoxaparin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0206460;C0439269;C1960952;C2346927;C4321396;C4521761
862,enoxaparin,C0206460
861,nyhaiiioriv,
861,nonaspirin antiplatelet agent,C0085826;C0722138
861,nonaspirin antiplatelet,C0722138
860,no nadroparin ( n = $nmbr$ ),C0206232
860,nadroparin vs control,C0206232;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
860,nadroparin ( n = $nmbr$ ),C0206232
860,nadroparin,C0206232
860,dalteparin ( n = $nmbr$ ),C0206461
859,total time of fondaparinux treatment before,C0039798;C0040223;C0087111;C0439175;C0439810;C1098510;C1522326;C1533734;C1705169;C3538994;C3541383;C3887704
859,heparins and fondaparinux,C0019134;C1098510
859,heparin  fondaparinux or brvalirudin use between - oex event,C0019134;C0042153;C0441471;C0457083;C0770546;C1098510;C1947944;C4019010
859,fondaparinux — no . ( % ),C1098510
859,fondaparinux ( n = $nmbr$ ),C1098510
859,fondaparinux ( n = $nmbr$  $nmbr$ ),C1098510
859,fondaparinux,C1098510
859,commercially available fondaparinux,C0470187;C1098510
858,warfarin naive,C0043031
858,warfarin n = $nmbr$ n / n ( % ),C0043031
858,warfarin n = $nmbr$,C0043031
858,warfarin n / n  rate ( % ),C0043031;C0871208;C1521828
858,warfarin group ( n = $nmbr$ ),C0043031;C0441848
858,warfarin group,C0043031;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
858,warfarin at enrollment,C0043031;C1516879;C1696073;C3888021
858,warfarin ( s $nmbr$ % cl ),C0043031;C0596019
858,warfarin ( n = $nmbr$ )  n ( % / y ),C0043031
858,warfarin ( n = $nmbr$ ),C0043031
858,warfarin ( n - $nmbr$  $nmbr$ ),C0043031
858,warfarin ( % ),C0043031
858,warfarin % ( n / n ),C0043031
858,warfarin  no . ( % ),C0043031
858,warfarin,C0043031
858,warf,C0043031
858,vs . warfarin,C0043031
858,ttr ( warfarin arm only ),C0032923;C0043031;C0205171;C0446516;C1421224;C1720467;C3715044;C4553528
858,re - cover $nmbr$ warfarin,C0043031;C0180153;C0556581;C1999244;C2986904;C3888055
858,previous warfarin use  no . ( % ),C0042153;C0043031;C0205156;C0457083;C1552607;C1947944
858,previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0007787;C0038454;C0042153;C0043031;C0205156;C0457083;C0917805;C1552607;C1947944;C4554100
858,median time in therapeutic range for warfarin recipients  %,C0040223;C0043031;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C1709854;C2347635;C2348144;C2939193;C3541383
858,low - dose edoxaban vs warfarin,C0043031;C0445550;C1708745;C2975435
858,ld edoxaban vs warfarin,C0043031;C0694649;C2975435
858,hr vs . warfarin ( $nmbr$ % ci ),C0008107;C0043031;C3259781
858,edoxaban warfarin,C0043031;C2975435
858,edoxaban vs . warfarin,C0043031;C2975435
858,d $nmbr$ vs warfarin rr ( $nmbr$ % ci  p value ),C0008107;C0043031;C0073187;C0332173;C1709380;C3259781;C4484261;C4554402
858,d $nmbr$ vs warfarin,C0043031;C0073187;C0332173;C4484261
857,tofacitinib $nmbr$ mg two times a day,C0024671;C0026410;C0332173;C0439228;C0439269;C0439505;C1948050;C1960952;C2346927;C2930696;C4321396;C4521761
857,tofacitinib $nmbr$ mg bid [ n = $nmbr$ |,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
857,tofacitinib $nmbr$ mg bid ( n   = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
857,tofacitinib $nmbr$ mg bid ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
857,tofacitinib $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
857,tofacitinib  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
857,tofacitinib,C2930696
856,anacetrapib ( n = $nmbr$ ),C2604745
856,anacetrapib ( n = $nmbr$  $nmbr$ ),C2604745
856,anacetrapib $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
856,anacetrapib $nmbr$ mg ( n - $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
856,anacetrapib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
855,tadalafil $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
855,tadalafil $nmbr$ mg mean change ( sd ),C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1176316;C1705241;C1960952;C2346927;C2347634;C2348143;C2699239;C4319952;C4321396;C4521761
855,tadalafil $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
855,tadalafil $nmbr$ mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
855,tadalafil $nmbr$ . $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
855,tadalafil $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
855,tadalafil $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
855,tadalafil,C1176316
854,tnl ultrapositive > $nmbr$ . $nmbr$ pg / l  $nmbr$ = $nmbr$,C0439278;C1540071
854,ag + gg,C0002037;C0017454;C0018370;C0051080;C0152305;C3888235
854,ag,C0002037;C0051080;C0152305;C3888235
853,sal ( n   = $nmbr$  $nmbr$ ),C0036140;C0037494;C0206136
853,sal ( n = $nmbr$ ),C0036140;C0037494;C0206136
853,sal $nmbr$ pg ( n = $nmbr$ ),C0030827;C0036140;C0037494;C0072225;C0206136;C1266240
853,sal $nmbr$ mg,C0024671;C0026410;C0036140;C0037494;C0206136;C0439269;C1960952;C2346927;C4321396;C4521761
853,fp / sal $nmbr$ / $nmbr$ pg ( n = $nmbr$ ),C0016704;C0030827;C0036140;C0037494;C0072225;C0206136;C1266240;C1419068;C1419906;C3541238;C3541412
852,rvw,
852,row §,C1552840;C1552846
852,row * n = $nmbr$,C1552840;C1552846
852,row,C1552840;C1552846
852,low - density lipoprotein choles -,C0023823
852,low - density lipoprotein ^,C0023823
852,low - density lipoprotein  mg / dl,C0023823;C0439269
852,low - density lipoprotein,C0023823
852,analysis compared with the pretreatment condition ( baseline )  n  ldl = low - density lipoprotein  csf = cerebrospinal fluid .,C0002778;C0007806;C0012634;C0023823;C0168634;C0348080;C0936012;C1442488;C1524024;C1550147;C1705253;C1707455;C2709094;C3539075;C3539076;C3864998
851,scale — cognitive portion  ldl — low -,C0175659;C0205251;C0349674;C0449719;C1516691;C1550472;C1947916;C3890211;C4048187;C4321351;C4522223
851,periostin low,C0205251;C0219433;C1424662;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
851,patients with low ( < $nmbr$ mg / dl ) c $nmbr$,C0030705;C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
851,nfs < - $nmbr$ . $nmbr$ ( low ),C0205251;C1550472;C1555018;C3890211;C4048187;C4321351;C4522223
851,moderate / low,C0205081;C0205251;C1550472;C1881878;C3890211;C4048187;C4049705;C4049706;C4085643;C4321335;C4321351;C4522223
851,low ’,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low { < $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223
851,low subgroup,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
851,low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low perceived social support only,C0030971;C0037438;C0205171;C0205251;C0748877;C1540833;C1550472;C1720467;C3669642;C3890211;C4048187;C4321351;C4522223
851,low or moderate,C0205081;C0205251;C1550472;C1881878;C3890211;C4048187;C4049705;C4049706;C4085643;C4321335;C4321351;C4522223
851,low normal ( n = $nmbr$ ),C0205251;C0205307;C0231683;C0439166;C1550472;C2347086;C3890211;C4048187;C4321351;C4522223;C4553972
851,low nfs nfs < - $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205251;C1513839;C1550472;C3890211;C4048187;C4321351;C4522223
851,low nafld fibrosis score ( nfs < - $nmbr$ . $nmbr$ ),C0205251;C0400966;C1550472;C1555018;C1954436;C1954437;C3890211;C4048187;C4321351;C4522223
851,low feno subgroup (  $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ ),C0205251;C1079230;C1415800;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
851,low eosinophil subgroup (  $nmbr$ / ml ) ( n = $nmbr$ ),C0014467;C0205251;C0439526;C1079230;C1515021;C1550472;C1705224;C3887665;C3890211;C4048187;C4321351;C4522223
851,low c $nmbr$ / c $nmbr$ and anti - dsdna,C0012854;C0205251;C0311474;C1550472;C3890211;C4048187;C4321351;C4522223
851,low c $nmbr$ ( < $nmbr$ mg / dl )  %,C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
851,low c $nmbr$ ( < $nmbr$ . $nmbr$ g / l ),C0205251;C0439294;C0456615;C1550472;C3890211;C4048187;C4321351;C4522223
851,low - molecular - weight only,C0026385;C0041667;C0205171;C0205251;C1521991;C1550472;C1720467;C3890211;C4048187;C4321351;C4522223
851,low - molecular - weight,C0026385;C0041667;C0205251;C1521991;C1550472;C3890211;C4048187;C4321351;C4522223
851,low - ceiling diuretic,C0012798;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low ( no risk factor ),C0035648;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low ( n = $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low ( > $nmbr$ . $nmbr$ and < $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low ( < $nmbr$ % ) baseline hbalc,C0168634;C0205251;C1442488;C1550472;C3890211;C4048187;C4321351;C4522223
851,low ( < $nmbr$ % ) baseline hba $nmbr$ c,C0019016;C0168634;C0205251;C1442488;C1550472;C1825777;C3538758;C3890211;C4048187;C4321351;C4522223
851,low ( < $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low ( $nmbr$ - $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low ( $nmbr$ - $nmbr$ )  %,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low ( $nmbr$ - $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low  %,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,fgf - $nmbr$ low / egfr > $nmbr$,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
851,fgf - $nmbr$ low / egfr < $nmbr$,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
851,fgf - $nmbr$ low / > $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
851,fgf - $nmbr$ low / < $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
851,eosinophil low,C0014467;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,depressed and low perceived social support,C0030971;C0037438;C0205251;C0344315;C0549249;C0748877;C1540833;C1550472;C3669642;C3890211;C4048187;C4321351;C4522223
851,bl updrs : low,C0005918;C0006413;C0205251;C1550472;C1552663;C2827109;C3639721;C3890211;C4048187;C4321351;C4522223
851,biomarker low,C0005516;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
851,$nmbr$ low ( n = $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
850,igelow ( n = $nmbr$  $nmbr$ ),
850,igelow ( < i $nmbr$ ku / l  n = i  $nmbr$ ),C0021966;C0221138;C0369718;C0439340;C0441922
850,igelow ( < $nmbr$ ku / l  n = $nmbr$  $nmbr$ ),C0439340
849,eosinophils £ $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils £ $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ^ ^ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ^ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils > $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils > $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils < $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils < $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / l ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils $nmbr$ % ( n - $nmbr$ ),C0014467;C0200638
849,eosinophils $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
849,eosinophils,C0014467;C0200638
849,calima japandhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ) y,C0014467;C0168634;C0178602;C0815320;C1442488;C2699156;C2986497;C4551720
849,blood eosinophils count,C0014467;C0750480;C1705566
849,blood eosinophils  mean ( range )  cells / mlb,C0005773;C0007584;C0007634;C0014467;C0200638;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
849,blood eosinophils  cells / ml,C0014467;C2699156
849,blood eosinophil proportion ( % ),C0014467;C1709707
849,blood eosinophil count  geometric mean ( sd loge scale ) cells / ll,C0007584;C0007634;C0014467;C0175659;C0349674;C0750480;C1705566;C1947916;C2697934;C2699239;C2986759
849,blood eosinophil,C0014467
848,median blood eosinophil count  cells per pla,C0200638;C0456170;C0549183;C0876920;C2347635;C2348144;C2939193
848,local eosinophil count [ cells / µ l ]  median ( range ),C0200638;C0205276;C0347983;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
848,local eosinophil count [ cells / ml ]  median ( range ),C0200638;C0205276;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2699156;C2939193;C3542016
848,local eosinophil count,C0200638;C0205276;C0750879
848,eosinophil count,C0200638;C0750879
848,blood eosinophil count — cells / mm ’,C0005773;C0200638;C0750879;C4330985;C4554674
848,blood eosinophil count cells / mm $nmbr$ no .,C0005773;C0200638;C0750879;C4330985;C4554674
848,blood eosinophil count > $nmbr$ / mm $nmbr$ at screening — no . ( % ),C0200638;C0750879;C1511226;C4330985;C4554674
848,blood eosinophil count ( $nmbr$ cells per l ),C0200638
847,losartan plus lisinopril ( n = $nmbr$ ),C0065374;C0126174;C0332287
847,losartan + lisinopril,C0065374;C0126174
847,lisinopril ( n = $nmbr$ ),C0065374
847,lisinopril,C0065374
847,ii lisinopril i,C0021966;C0065374;C0221138;C1710602;C4082587
847,i lisinopril ( n = $nmbr$ ),C0021966;C0065374;C0221138
847,$nmbr$ lisinopril,C0065374
846,killip class — no . / total no . ( % ) i,C0021966;C0221138;C0439175;C0439810;C1881332
846,killip class — no . ( % ) i,C0021966;C0221138;C1881332
846,killip class lll - iv,C1261077;C2697847
846,killip class iv at randomization,C0034656;C2697847
846,killip class i — no . ( % ),C2697844
846,killip class at admission — no . / total no . ( % ),C0184666;C0439175;C0439810;C0809949;C1881332
846,killip class > ii ( % ),C2697845
846,killip class > i  %,C2697844
846,killip class > $nmbr$  no . ( % ),C1881332
846,killip class *,C1881332
846,killip class ( interaction : p = $nmbr$ . $nmbr$ ),C1704675;C1881332
846,killip class $nmbr$ / $nmbr$,C1881332
846,killip class $nmbr$,C1881332
846,killip class  n ( % ) i,C0021966;C0221138;C0369718;C0441922;C1881332
846,killip class  n ( % ),C1881332
846,killip class,C1881332
846,baseline killip class,C0168634;C1442488;C1881332
846,< $nmbr$ baseline killip class,C0168634;C1442488;C1881332
845,who functional class ii / iii,C0205245;C0439070;C0441886;C0441887;C0542341;C1705160;C1710602;C2698968;C2698969;C2700217;C4082587
845,iorii ( n z $nmbr$ ),
845,iiiv,
845,class iii,C0441887;C2698969
845,class ii ( b - blockers ),C0441886;C2698968
845,class ii,C0441886;C2698968
845,class > ii,C0441886;C2698968
845,> ii,
845,> $nmbr$ : obese class iii,C1319441
845,$nmbr$ - $nmbr$ . $nmbr$ : obese class ii,C3853263
844,diastolic fmmhff ' ),C0012000
844,diastolic  treated at baseline,C0012000;C0168634;C1442488;C1522326
844,diastolic  total,C0012000;C0439175;C0439810
844,diastolic,C0012000
843,idiopathica,
843,idiopathic / familial,C0015576;C0241888;C0332240
843,idiopathic,C0332240
842,diastolic bp ( mmhg ) *,C0428883;C0439475
842,diastolic bp ( mmhg ),C0428883;C0439475
842,diastolic bp ( mm hg ),C0428883;C0439475
842,diastolic bp  mmhg ( sd ),C0428883;C0439475;C2699239
842,diastolic bp  mmhg,C0428883;C0439475
842,diastolic bp  mm   hg  mean ( sd ),C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
842,diastolic bp  mm hg  mean ( sd ),C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
842,diastolic bp  mm hg,C0428883;C0439475
842,diastolic bp,C0428883
842,diastolic blood pressure subgroups,C0428883;C1079230;C1305849
842,diastolic blood pressure ( mm hg ) medications,C0013227;C0428883;C0439475;C0802604;C1305849;C2598133;C4284232
842,diastolic blood pressure ( mm hg ),C0428883;C0439475;C1305849
842,diastolic blood pressure  mm hq,C0428883;C1305849;C4330985;C4554674
842,diastolic blood pressure  mm hg  median ( range ),C0428883;C0439475;C0549183;C0876920;C1305849;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
842,diastolic blood pressure  mm hg,C0428883;C0439475;C1305849
842,diastolic blood pressure  and lp ( a ),C0065058;C0428883;C1305849;C1439335;C4553379
842,diastolic blood pressure,C0428883;C1305849
841,time since diagnosis of t $nmbr$ dm  y  n ( % ),C0011816;C0011900;C0040223;C1704338;C1704656;C3250443;C3541383
841,time since diagnosis of t $nmbr$ dm,C0011816;C0011900;C0040223;C1704338;C1704656;C3250443;C3541383
841,time since diagnosis of pah — yrf,C0011900;C0030123;C0040223;C1704338;C1704656;C3203102;C3541383;C4284467
841,time since diagnosis of diabetesa  n ( % ),C0011900;C0040223;C1704338;C1704656;C3541383
841,time since diagnosis of ciu / csuf ( y ),C0011900;C0040223;C0578870;C1704338;C1704656;C3541383
841,time since diagnosis of ciu / csu ( years ) $nmbr$,C0011900;C0040223;C0439234;C0578870;C1704338;C1704656;C3541383
841,since diagnosis,C0011900;C1704338;C1704656
841,qualifying diagnosis,C0011900;C1514624;C1704338;C1704656
841,presenting history or diagnosis — no . ( % ),C0011900;C0019664;C0019665;C0262512;C0262926;C0449450;C1704338;C1704656;C1705255;C2004062
841,presenting diagnosis,C0011900;C0449450;C1704338;C1704656
841,predominant cardiac diagnosis — no . ( % ),C0011900;C0018787;C1522601;C1542147;C1704338;C1704656
841,inclusion diagnosis,C0007637;C0011900;C1512693;C1704338;C1704656
841,first diagnosed,C0011900;C0205435;C1279901
841,diagnosis of hefh  n ( % ),C0011900;C1704338;C1704656
841,diagnosis of allergic rhinitis,C0011900;C1334103;C1704338;C1704656;C2607914;C4552864
841,diagnosis at presentation — no . ( % ),C0011900;C0449450;C1704338;C1704656
841,diagnosis at presentation,C0011900;C0449450;C1704338;C1704656
841,diagnosed  y,C0011900
841,age when diabetes first diagnosed — yr,C0001779;C0011847;C0011849;C0011900;C0205435;C0439234;C1279901
841,af first diagnosis > $nmbr$ years  n ( % ),C0011900;C0205435;C0344434;C0439234;C1279901;C1704338;C1704656;C4049859
840,with highest bwa,C0006041;C1522410
840,highest killip classiciation pre - pci,C0332152;C0740175;C1522410;C2257086;C3669034;C4049621
840,highest,C1522410
839,hhf ( n = $nmbr$ ),
839,first hhf,C0205435;C1279901
839,cv death or first hhf,C0011065;C0205435;C1279901;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
838,less than high school,C0439092;C0599395;C0683862;C0870649
838,high - school graduate or ged,C0870649;C1549971;C1880947
838,high - school graduate,C0870649;C1549971
837,very high risk,C0035647;C0332167;C0442804;C0442824;C2984081;C3272283;C4050568;C4319571;C4321397;C4552904
837,qualifying high - risk features — %,C0332167;C1514624;C1521970;C1706388;C2346469;C2348519;C3272283;C4050568;C4319571
837,moderately high risk without atherosclerotic vascular disease *,C0004153;C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
837,moderately high risk,C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
837,higher risk ( n = $nmbr$ ),C0332167;C3272283;C4050568;C4319571
837,high risk without atherosclerotic vascular disease +,C0004153;C0332167;C3272283;C4050568;C4319571
837,high risk for diabetes *,C0011847;C0011849;C0205250;C0332167;C1171304;C1299351;C2700149;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
837,high risk and fewer symptoms ( group c ),C0205388;C0332167;C0441837;C0683368;C1457887;C3272283;C4050568;C4319571
837,high risk *  %,C0332167;C3272283;C4050568;C4319571
837,high risk ( ri ≥ $nmbr$ ),C0035487;C0332167;C1826843;C3272283;C4050568;C4319571
837,high risk ( receiving treatment for ) :,C0039798;C0087111;C0332167;C1514756;C1522326;C1533734;C1705169;C3272283;C3538994;C3887704;C4050568;C4319571
837,high risk ( n $nmbr$ $nmbr$ ),C0332167;C3272283;C4050568;C4319571
837,high risk ( ? ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
837,high risk ( > $nmbr$ ),C0332167;C3272283;C4050568;C4319571
837,high risk ( - ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
837,high risk ( $nmbr$ - $nmbr$ ),C0332167;C3272283;C4050568;C4319571
837,high risk,C0332167;C3272283;C4050568;C4319571
837,high fracture risk stratum,C0016658;C0332167;C3272283;C4050568;C4319571
837,high cv risk,C0332167;C3272283;C3538987;C4048877;C4050568;C4318503;C4319571
837,high cardiovascular risk  n ( % ) ^,C0007226;C0332167;C3272283;C3887460;C4050568;C4319571
837,high - risk cvd  n ( % ),C0007222;C0332167;C3272283;C4050568;C4319571
837,high - risk criterion,C0243161;C0332167;C3272283;C4050568;C4319571
837,high - risk clinical features,C0332167;C0683325;C3272283;C4050568;C4319571
837,high - risk,C0332167;C3272283;C4050568;C4319571
837,high ( > $nmbr$ risk factor ),C0035648;C0205250;C0332167;C1299351;C1521761;C2700149;C2827422;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
837,group d ( high risk  more symptoms )  n ( % ),C0332167;C0441848;C0683368;C1457887;C3272283;C4050568;C4319571
837,> $nmbr$ ( high risk ),C0332167;C3272283;C4050568;C4319571
837,$nmbr$ or $nmbr$ high cardiovascular risk categories,C0007226;C0332167;C0683312;C3272283;C3887460;C4050568;C4319571
837,$nmbr$ or $nmbr$ high - risk categories,C0332167;C0683312;C3272283;C4050568;C4319571
836,no high - intensity statin,C0360714;C4081854
836,high ‐ intensity statins ‡,C0360714;C4081854
836,high intensity,C4081854
836,high - intensity statin vs medium - or low - intensity statin at randomization,C0009458;C0034656;C0360714;C0439536;C0596836;C1705217;C3244283;C4081854;C4085196;C4522282;C4522283
836,high - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081854
836,high - intensity statin *,C0360714;C4081854
836,high - intensity statin,C0360714;C4081854
835,high density lipoprotein ( mg / dl ),C0023821;C0439269
835,high - density lipoprotein ],C0023821
835,high - density lipoprotein  mg / dl,C0023821;C0439269
835,high - density lipoprotein,C0023821
834,total aim ‐ high study,C0205250;C0439175;C0439810;C0557651;C1299351;C1947946;C2603343;C2700149;C2744535;C2948600;C3540471;C3540472;C3887512;C3889660;C3890193;C4321237;C4522209
834,periostin high,C0205250;C0219433;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
834,p - value low vs . high nfs ^,C0205250;C0205251;C1299351;C1550472;C1555018;C1709380;C2700149;C3887512;C3889660;C3890211;C4048187;C4321237;C4321351;C4522209;C4522223
834,nfs > $nmbr$ . $nmbr$ ( high ),C0205250;C1299351;C1555018;C2700149;C3887512;C3889660;C4321237;C4522209
834,ige high ( > $nmbr$ ku / l  n = $nmbr$  $nmbr$ ),C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,highjj,
834,high vs . normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high vs . normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high tt > $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205250;C1299351;C1452561;C2700149;C3887512;C3889660;C4321237;C4522209;C4554543
834,high trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high titre ( > $nmbr$ times of uln )  n ( % ),C0040223;C0205250;C0475208;C1299351;C1519815;C1632851;C2700149;C3887512;C3889660;C4321237;C4522209
834,high subgroup,C0205250;C1079230;C1299351;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
834,high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high periostin subgroup ( > $nmbr$ ng / ml ) ( n = $nmbr$ ),C0205250;C0219433;C0439275;C1079230;C1299351;C1424662;C1515021;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
834,high on - treatment platelet reactivity *,C0005821;C0039798;C0087111;C0205250;C0443286;C1299351;C1522326;C1533734;C1705169;C2700149;C3538994;C3887512;C3887704;C3889660;C4321237;C4522209
834,high nfs nfs > $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205250;C1299351;C1513839;C2700149;C3887512;C3889660;C4321237;C4522209
834,high nafld fibrosis score ( nfs > $nmbr$ . $nmbr$ ),C0205250;C0400966;C1299351;C1555018;C1954436;C1954437;C2700149;C3887512;C3889660;C4321237;C4522209
834,high microalbuminuria to macroalbuminuria ( n = $nmbr$ ),C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high crp or esr,C0205250;C1299351;C2700149;C3811131;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
834,high crp and esr,C0205250;C1299351;C2700149;C3811131;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
834,high - dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl ( n = $nmbr$ ),C0005773;C0007584;C0007634;C0014467;C0168634;C0178602;C0200638;C0205250;C0815320;C1299351;C1442488;C2700149;C2986497;C3887512;C3889660;C3897966;C4049765;C4321237;C4522209;C4551720
834,high - dosage ics plus laba with baseline blood eosinophils > $nmbr$ cells per pl ( n = $nmbr$ ),C0005773;C0007584;C0007634;C0014467;C0168634;C0178602;C0200638;C0205250;C0815320;C1299351;C1442488;C2700149;C2986497;C3887512;C3889660;C3897966;C4049765;C4321237;C4522209;C4551720
834,high - dosage ics plus laba with baseline blood eosinophils < $nmbr$ cells per pl ( n = $nmbr$ ),C0005773;C0007584;C0007634;C0014467;C0168634;C0178602;C0200638;C0205250;C0815320;C1299351;C1442488;C2700149;C2986497;C3887512;C3889660;C3897966;C4049765;C4321237;C4522209;C4551720
834,high *,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( n = $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( i $nmbr$ % ) baseline hba $nmbr$ c,C0019016;C0021966;C0168634;C0205250;C0221138;C1299351;C1442488;C1825777;C2700149;C3538758;C3887512;C3889660;C4321237;C4522209
834,high ( >   uln and   ≤   $nmbr$ xuln ) ( n   =   $nmbr$ ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( > uln ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( > $nmbr$ . $nmbr$ u / ml ),C0205250;C0439340;C1299351;C1880521;C2700149;C2945590;C3887512;C3889660;C4321237;C4522209
834,high ( > $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( > $nmbr$ )  %,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( > $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( > $nmbr$ % ) baseline hbalc,C0168634;C0205250;C1299351;C1442488;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( > $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( $nmbr$ - $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high ( $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high  %,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,fgf - $nmbr$ high / egfr > $nmbr$,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
834,fgf - $nmbr$ high / egfr < $nmbr$,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
834,fgf - $nmbr$ high / > $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
834,fgf - $nmbr$ high / < $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
834,eosinophil high,C0014467;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
834,education  high school or higher,C0205250;C0683862
834,college degree or higher,C0205250;C0441889;C0449286;C0542560;C0557806;C2348088
834,bl updrs : high,C0005918;C0006413;C0205250;C1299351;C1552663;C2700149;C2827109;C3639721;C3887512;C3889660;C4321237;C4522209
834,biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl )  na,C0005516;C0005773;C0007584;C0007634;C0014467;C0200638;C0205250;C0219433;C0439275;C0597484;C1272460;C1299351;C1424662;C1546968;C1879645;C2700149;C3812270;C3887512;C3889660;C3897966;C4049765;C4049872;C4321237;C4522209;C4552882
834,biomarker high,C0005516;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
833,hscrp §,
833,hcru ( a ),
833,elevated hscrp > $nmbr$ mg / l  n ( % ),C0205250;C0439268;C3163633
833,elevated hscrp,C0205250;C3163633
832,white  n ( % ) medical history  n ( % ),C0007457;C0043157;C0220938;C0262926;C1704706
832,vascular history  %,C0005847;C0019664;C0019665;C0262512;C0262926;C1558950;C1705255;C1801960;C2004062
832,uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,selective vascular history,C0005847;C0019664;C0019665;C0036576;C0262512;C0262926;C1558950;C1705255;C1707391;C1801960;C2004062
832,seizure history  n ( % ),C0019664;C0019665;C0036572;C0262512;C0262926;C1705255;C1959629;C2004062;C4553401
832,risk factors and medical history,C0035648;C0262926;C1553898;C1704706
832,revascularization history,C0019664;C0019665;C0262512;C0262926;C0581603;C1705255;C2004062
832,prior treatment history $nmbr$,C0019664;C0019665;C0262512;C0262926;C1514463;C1705255;C2004062
832,plus – minus values are means ± sd . cabg denotes coronary - artery by - pass graft  ptca percutaneous transluminal coronary angioplasty  and ace angiotensin - converting enzyme . hypertension and diabetes were de - fined by clinical history . a more complete list of base - line characteristics is given in rubins et al . $nmbr$ † nitrates includes all preparations except as - needed nitroglycerin . ‡ any antianginal drug includes any nitrate ( as defined above )  calcium - channel blocker  or beta - blocker . § the body - mass index is the weight in kilograms divided by the square of the height in meters . ¶ to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$ . to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ .,C0001645;C0005893;C0005910;C0006448;C0006539;C0006684;C0008377;C0010055;C0011198;C0011847;C0011849;C0013227;C0017480;C0017887;C0019664;C0019665;C0020538;C0022709;C0028125;C0030125;C0040028;C0040363;C0041004;C0041260;C0042295;C0043100;C0181074;C0202311;C0205042;C0205120;C0205172;C0205197;C0205210;C0205232;C0252873;C0262512;C0262926;C0332257;C0332288;C0332835;C0332849;C0439190;C0439209;C0441074;C0475211;C0489786;C0578022;C0687757;C0699857;C0745732;C0885378;C1254351;C1305855;C1305866;C1442162;C1452534;C1521827;C1532563;C1550718;C1552595;C1552866;C1704788;C1704970;C1705104;C1705255;C1719797;C1820373;C1874267;C1879745;C1883351;C1883728;C1947971;C1961139;C1963138;C2004062;C2699239;C2700399;C2828386;C2911648;C2936173;C3244317;C3272378;C3536851;C3537168;C3539106;C3541240;C3812761;C3848573;C3853530;C3854028;C4283785;C4284014;C4321248;C4521885;C4522126;C4684572
832,pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
832,participants without a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
832,participants with a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
832,parental history of mii,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062
832,parental history of mi before age $nmbr$ y,C0001779;C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062;C3810814
832,other medical history — no . / total no . ( % ),C0262926;C0439175;C0439810;C1704706
832,other medical history — no . ( % ),C0262926;C1704706
832,other medical history  no . ( % ),C0262926;C1704706
832,oad history  years,C0019664;C0019665;C0262512;C0262926;C0439234;C1705255;C2004062
832,no history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
832,no history of mi ( n = $nmbr$  $nmbr$ ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
832,no history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
832,no history of diabetes ( n = $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,no history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
832,no history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
832,medical history — no . / total no . ( % ),C0262926;C0439175;C0439810;C1704706
832,medical history — no . ( % ),C0262926;C1704706
832,medical history — %,C0262926;C1704706
832,medical history of diabetic retinopathy §,C0011884;C0262926
832,medical history before index acute coronary syndrome — no . { % ),C0262926;C0600653;C0918012;C0948089;C1552854;C1637833;C1704706;C2986546
832,medical history at randomization — no . ( % ),C0034656;C0262926;C1704706
832,medical history and risk factors — no . ( % ),C0035648;C0262926;C1553898;C1704706
832,medical history and risk factors ( % ),C0035648;C0262926;C1553898;C1704706
832,medical history and risk factors  no . / total ( % ) *,C0035648;C0262926;C0439175;C0439810;C1553898;C1704706
832,medical history and risk factors,C0035648;C0262926;C1553898;C1704706
832,medical history . no . ( % ),C0262926;C1704706
832,medical history ( % ),C0262926;C1704706
832,medical history    n   ( % ),C0262926;C1704706
832,medical history  no . ( % ),C0262926;C1704706
832,medical history  n ( % ),C0262926;C1704706
832,medical history,C0262926;C1704706
832,hx cabg,C0010055;C0262926;C3814444
832,htn hx,C0020538;C0262926;C3814444
832,history pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
832,history ol mi or stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100
832,history of vte * *,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
832,history of vte,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
832,history of venous,C0019664;C0019665;C0042449;C0262512;C0262926;C0348013;C1705255;C2004062
832,history of upper gi events ( perforations  ulcers and bleeding ) n ( % ),C0019080;C0019664;C0019665;C0041582;C0203057;C0262512;C0262926;C0441471;C0549099;C1705255;C2004062;C3541888
832,history of upper,C0019664;C0019665;C0262512;C0262926;C1282910;C1705255;C2004062
832,history of tia or stroke,C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100
832,history of tia  n ( % ),C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
832,history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of stroke †,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
832,history of stroke or transient ischemic attack,C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1705255;C2004062;C4554100
832,history of stroke or tia - n ( % ),C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100
832,history of stroke or tia,C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100
832,history of stroke at baseline,C0019664;C0019665;C0038454;C0168634;C0262512;C0262926;C1442488;C1705255;C2004062;C4554100
832,history of stroke / see / tia  n ( % ),C0007787;C0019664;C0019665;C0038454;C0042789;C0262512;C0262926;C0917805;C1054154;C1705255;C1947903;C2004062;C4554100
832,history of stroke / see / tia,C0007787;C0019664;C0019665;C0038454;C0042789;C0262512;C0262926;C0917805;C1054154;C1705255;C1947903;C2004062;C4554100
832,history of stroke * *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
832,history of stroke *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
832,history of stroke ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
832,history of stroke $nmbr$,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
832,history of stroke  n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
832,history of stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
832,history of second prior mi  n ( % ),C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
832,history of pci with stenting,C0019664;C0019665;C0038257;C0262512;C0262926;C1705255;C2004062;C2348535;C4049621
832,history of pci  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
832,history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
832,history of parental myocardial,C0019664;C0019665;C0027061;C0030551;C0262512;C0262926;C1522564;C1705255;C2004062
832,history of pad,C0019664;C0019665;C0182158;C0262512;C0262926;C0332568;C1705255;C2004062;C3540603;C3669270;C3814046;C4319657
832,history of oxygen use - yes  n ( % ),C0019664;C0019665;C0030054;C0262512;C0262926;C1524063;C1549445;C1705108;C1705255;C1710701;C2004062
832,history of or current cardiac disorders  %,C0018799;C0019664;C0019665;C0262512;C0262926;C0521116;C1705255;C1705970;C2004062
832,history of omalizumab treatment :,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
832,history of omalizumab treatment,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
832,history of non - hemor - rhagic stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1518422;C1705255;C2004062;C4554100
832,history of nicotine use,C0019664;C0019665;C0028040;C0262512;C0262926;C1524063;C1705255;C2004062
832,history of more than $nmbr$ prior mi ( % ),C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3810814
832,history of ml or stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665;C4554100
832,history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C0948008;C1705224;C1705255;C2004062;C3887665
832,history of mi or stroke history of coronary,C0018787;C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100
832,history of mi or stroke d,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100
832,history of mi or stroke  no . ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100
832,history of mi or stroke  n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100
832,history of mi or stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100
832,history of mi ( n = $nmbr$  $nmbr$ ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
832,history of mi  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
832,history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
832,history of major bleeding,C0019080;C0019664;C0019665;C0205082;C0205164;C0262512;C0262926;C1705255;C2004062;C4318856;C4521762
832,history of macroalbuminuriat  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0948008;C1705255;C2004062
832,history of htn  %,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C2004062
832,history of high cholesterol ( a ) $nmbr$,C0019664;C0019665;C0020443;C0262512;C0262926;C1522133;C1705255;C2004062
832,history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
832,history of h pylori eradication *,C0019664;C0019665;C0079488;C0262512;C0262926;C1705255;C2004062
832,history of extra - intestinal manifestations of ibd,C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1705255;C1883702;C2004062
832,history of dyslipidemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
832,history of dyslipidaemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
832,history of diabetes { p = $nmbr$ * $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of diabetes nyha class,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C1882083;C2004062
832,history of diabetes ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of diabetes,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of cvd  n ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of cvd,C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
832,history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
832,history of coronary,C0018787;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of copd,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
832,history of chronic hf,C0018488;C0019664;C0019665;C0205191;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
832,history of chf - n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of chf  nyha class ii or iii — no . ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C0439070;C1705160;C1705255;C1882085;C2004062
832,history of chf  n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of cardiovascular events,C0019664;C0019665;C0262512;C0262926;C0441471;C1320716;C1705255;C1880008;C2004062;C3541888
832,history of cad / mi,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3810814;C3813548;C4284121
832,history of cad,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
832,history of cabg  n ( % ),C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history of bowel resections  n ( % ),C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
832,history of atrial arrhythmia  n ( % ),C0019664;C0019665;C0085611;C0262512;C0262926;C1705255;C2004062
832,history of amputation  n ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
832,history of amputation,C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
832,history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
832,history of > $nmbr$ previous vte ( excluding index event ),C0019664;C0019665;C0205156;C0262512;C0262926;C0332196;C0441471;C0600653;C0630906;C0918012;C1552607;C1552854;C1637833;C1705255;C2004062;C2828389;C2986546;C4019010
832,history of ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history mi or stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100
832,history coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
832,history coronary,C0018787;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history congestive heart failure,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,history ( pack - years ),C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
832,history  pack - years,C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
832,history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,diabetic history ( years ) x,C0019664;C0019665;C0241863;C0262512;C0262926;C0439234;C1705255;C2004062
832,copd history yrs,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
832,copd exacerbation history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0740304;C1705255;C2004062
832,clinical history — no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
832,clinical history  no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
832,clinical history  n ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
832,clinical history,C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
832,chf history,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,cardiovascular risk factors and medical history,C0262926;C0850624;C1704706
832,cardiac history  %,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
832,cardiac history,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
832,cad history and risk factors  n ( % ),C0019664;C0019665;C0035648;C0262512;C0262926;C1504769;C1553898;C1705255;C2004062;C2239547;C3813548;C4284121
832,cabg history,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,baseline copd exacerbation history  * n ( % ),C0019664;C0019665;C0168634;C0262512;C0262926;C0740304;C1442488;C1705255;C2004062
832,atherosclerotic vascular disease history †,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,atherosclerotic vascular disease history  no . ( % ) ‡,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,atherosclerotic vascular disease history  n ( % ) t,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,any cvd history ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
832,all participants history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
831,hiv,C0019682;C0019699
831,hip circumference — cm,C0562350
830,waist - to - hip  male,C0019552;C0022122;C0086582;C0230097;C1505163;C1706180;C1706428;C1706429;C3538851;C4284725
830,total hip or knee replacement,C0019552;C0022122;C0086511;C0439175;C0439810;C1505163;C3538851;C4284725
830,total hip bmi ) t - score,C0019552;C0022122;C0578022;C1505163;C2964552;C3538851;C4284725
830,total hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
830,total - hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
830,hip + $nmbr$ vertebral fractures,C0019552;C0019557;C0022122;C0080179;C0549207;C1505163;C3538851;C4284725
830,hip  femur,C0015811;C0019552;C0022122;C1505163;C3538851;C4284725
830,hip,C0019552;C0022122;C1505163;C3538851;C4284725
-10,hub,C0063034;C1414372;C1708389
828,aspirin < $nmbr$ hours,C0004057;C0439227
828,$nmbr$ - hour postload glucose,C0017725;C0439227;C0564385
828,$nmbr$ - hour masbp  mm hg,C0439227;C0439475;C0564385
828,$nmbr$ - hour madbp  mm hg,C0439227;C0439475;C0564385
828,$nmbr$ - $nmbr$ hours,C0439227
827,use of medication from randomization through $nmbr$ hr — no . / total no . ( % ),C0013227;C0034656;C0439175;C0439810;C1524063;C3244316;C4284232
827,hr ( b . p . m . ),C0369637;C0441923
827,hr ( adjusteda ),
827,> $nmbr$ hr,
827,$nmbr$ hr prandial glucose ' * ’,C0017725;C1998602;C4553624
827,$nmbr$ - $nmbr$ hr,
826,erythrocyte sedimentation rate — mm / hr | |,C1176468;C1619634;C4330985;C4554674
826,< $nmbr$ hr,
825,hr $nmbr$ . $nmbr$,
825,hr,
825,hc,C0020268;C0262499;C1413512
825,duration of infusion — hr,C0449238;C0574032;C1827465;C2926735
825,duration of infusion during medical management — hr,C0001554;C0199168;C0205476;C0376636;C0449238;C0574032;C1273870;C1827465;C2926735;C3273539
825,duration of infusion before pci — hr,C0449238;C0574032;C1827465;C2926735;C4049621
825,duration of infusion before cabg — hr,C0010055;C0449238;C0574032;C1827465;C2926735
825,duration of infusion after pci — hr,C0449238;C0574032;C1827465;C2926735;C4049621
825,duration of clopidogrel pretreatment — hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
825,direction of hr,C0449738
824,without hx of hf,C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
824,stroke / m l / hf hospitalization,C0018488;C0019993;C0038454;C0456616;C1313497;C1538440;C3273279;C4554100
824,recurrent hf hospitalization,C0018488;C0019993;C1313497;C1455761;C1538440;C2945760;C3273279
824,recurrent hf,C0018488;C1313497;C1455761;C1538440;C2945760;C3273279
824,prior hf n = $nmbr$,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
824,prior hf ( n = $nmbr$  $nmbr$ ),C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
824,previous hf hospitalization  n ( % ),C0018488;C0019993;C0205156;C1313497;C1538440;C1552607;C3273279
824,previous hf,C0018488;C0205156;C1313497;C1538440;C1552607;C3273279
824,pharmacological therapy for hf,C0013217;C0018488;C1313497;C1538440;C3273279
824,no prior hf n = $nmbr$,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
824,no prior hf hospitalization ( n   = $nmbr$  $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
824,no prior hf ( n = $nmbr$  $nmbr$ ),C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
824,no hx of hf ( n = $nmbr$ ),C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
824,new hf medication,C0013227;C0018488;C0205314;C1313497;C1538440;C3244316;C3273279;C4284232
824,ischemic hf etiology,C0015127;C0018488;C0475224;C1313497;C1314792;C1524003;C1538440;C3273279
824,ischemic hf  % ( n ),C0018488;C0475224;C1313497;C1538440;C3273279
824,hospitalized hf !,C0018488;C0701159;C1313497;C1538440;C3273279
824,hospitalized hf,C0018488;C0701159;C1313497;C1538440;C3273279
824,hospitalization for hf previous year  ( % ),C0018488;C0019993;C0205156;C0439234;C0439508;C1313497;C1538440;C1552607;C3273279
824,hosp . worsening hf,C0018488;C0332271;C1313497;C1457868;C1538440;C1546960;C3273279
824,hosp . for hf,C0018488;C1313497;C1538440;C3273279
824,history of hf hospitalization,C0018488;C0551577;C1313497;C1538440;C3273279
824,hf symptoms and signs,C0018488;C0220912;C0220913;C0311392;C0683368;C1313497;C1457887;C1538440;C3273279
824,hf symptomatic improvement,C0018488;C0231220;C1313497;C1538440;C2986411;C3273279
824,hf symptom unchanged,C0018488;C0442739;C1313497;C1457887;C1538440;C2346711;C3273279;C3854129
824,hf signs and symptoms,C0018488;C0220912;C0220913;C0311392;C0683368;C1313497;C1457887;C1538440;C3273279
824,hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
824,hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
824,hf hosp .,C0018488;C1313497;C1538440;C3273279
824,hf duration  y  n ( % ),C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
824,hf cause,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279
824,hf  total,C0018488;C0439175;C0439810;C1313497;C1538440;C3273279
824,hf  lvd  or both,C0018488;C1313497;C1538440;C3273279
824,hf,C0018488;C1313497;C1538440;C3273279
824,heart failure ( hf )  ( % ),C0018488;C0018801;C0018802;C1313497;C1538440;C3273279;C4554158
824,enrolment through hf,C0018488;C1313497;C1516879;C1538440;C1696073;C3273279;C3888021
824,duration of hf  y,C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
824,congestive hf,C0018488;C0742742;C1313497;C1538440;C3273279
824,clinical features of hf,C0018488;C0683325;C1313497;C1538440;C3273279
824,cardiovascular death or hospitalized hf,C0007226;C0011065;C0018488;C0701159;C1306577;C1313497;C1538440;C3273279;C3887460;C4082313;C4552775
824,all ~ cause mort / hf hosp .,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279;C3815322
824,all cause mortality or hosp . for worsening hf hs - crp < $nmbr$ . $nmbr$ mg / l,C0015127;C0018488;C0026565;C0026566;C0332271;C0439268;C0444868;C1313497;C1457868;C1524003;C1538440;C1546960;C3273279;C3539085;C3890735;C4048285
823,reduced hdl cholesterol,C0151691
823,non ‐ hdl cholesterol,C0729627;C1535899
823,non - hdl cholesterol j,C0729627;C1535899
823,non - hdl cholesterol / apob ( ratio ),C0003593;C0456603;C0729627;C1518422;C1535899;C1547037;C2938854;C3252643
823,non - hdl cholesterol ( week $nmbr$ ),C0332174;C0439230;C0729627;C1535899
823,non - hdl cholesterol ( mmol / l ),C0729627;C1532563;C1535899
823,non - hdl cholesterol ( mg / dl ),C0439269;C0729627;C1535899
823,non - hdl cholesterol,C0729627;C1535899
823,low hdl cholesterol * |,C0151691
823,low hdl cholesterol,C0151691
823,low hdl - c,C0151691
823,hl 土 $nmbr$ . $nmbr$,C1453952;C4085347
823,elevated non - hdl cholesterol,C0205250;C0729627;C1535899;C3163633
822,non - hdlc concentration,C0086045;C1446561;C1518422;C1704429;C3827302
822,non - hdlc,C1518422;C1704429
822,ldlc : hdlc,C1416822;C1704429
821,total cholesterol / hdl - c,C0023822;C0201950;C0439175;C0439810;C0543421;C3715113
821,total c / hdl - c ratio * *,C0439175;C0439810;C0456603;C1547037;C3715113
821,total - c : hdl - c,C0439175;C0439810;C3715113
821,ratio of ldl to hdl,C0456603;C1547037;C3715113
821,non - hdl choleslerol,C1518422;C3715113
821,non - hdl - c in $nmbr$ classes,C0456387;C1518422;C1518526;C1705943;C3715113;C4019422
821,non - hdl - c / hdl - c,C1518422;C3715113
821,non - hdl - c *,C1518422;C3715113
821,non - hdl - c ( mmol / l ),C1518422;C1532563;C3715113
821,non - hdl - c ( mmol / l  mean ),C0444504;C1518422;C1532563;C2347634;C2348143;C3715113
821,non - hdl - c  mmol / l  mean ( sd ),C0444504;C1518422;C1532563;C2347634;C2348143;C2699239;C3715113
821,non - hdl - c  mmol / l,C1518422;C1532563;C3715113
821,non - hdl - c  mean ( sd )  rng / dl,C0444504;C1518422;C2347634;C2348143;C2699239;C3642216;C3715113
821,non - hdl - c  mean ( sd ),C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
821,non - hdl - c,C1518422;C3715113
821,non - hdl,C1518422;C3715113
821,ldl - c : hdl - c,C3715113
821,ldl - c / hdl - cx,C3715113
821,ldl - c / hdl - c,C3715113
821,hdl — male,C0086582;C1706180;C1706428;C1706429;C3715113
821,hdl — female,C0043210;C0086287;C1705497;C1705498;C3715113
821,hdl choleslerol,C3715113
821,hdl - cy,C0010622;C0332298;C2239193;C3715113
821,hdl - cd,C0007928;C0034283;C3715113;C4552032
821,hdl - c at baseline .,C0168634;C1442488;C3715113
821,hdl - c ( mmol / l ),C1532563;C3715113
821,hdl - c  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239;C3715113
821,hdl - c  mmol / l,C1532563;C3715113
821,hdl - c,C3715113
821,hdl *,C3715113
821,hdl ( mmol / l ),C1532563;C3715113
821,hdl $nmbr$ - c,C3715113
821,hdl $nmbr$,C3715113
821,hdl,C3715113
821,baseline non - hdl - ca,C0168634;C1442488;C1518422;C3715113;C3887642
821,baseline hdl - c in $nmbr$ classes,C0168634;C0456387;C1442488;C1518526;C1705943;C3715113;C4019422
821,baseline hdl - c,C0168634;C1442488;C3715113
820,with highest hba $nmbr$ cc,C0008318;C0019016;C1522410;C1825777;C3538758;C3538933
820,week $nmbr$ hba $nmbr$ c  mean ( s . e . ),C0019016;C0332174;C0439230;C0444504;C1825777;C2347634;C2348143;C3538758
820,subpopulation analyses according to baseline hba $nmbr$ c,C0002778;C0019016;C0168634;C0441837;C0680240;C0936012;C1442488;C1524024;C1825777;C3538758
820,subgroup analysis : change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category,C0019016;C0168634;C0332174;C0392747;C0439230;C0443172;C0683312;C1442488;C1705241;C1825777;C2986480;C3538758;C3889287;C4319952
820,screening hba $nmbr$ c ( % ),C0019016;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C1825777;C2348164;C3538758
820,qualifying hba $nmbr$ c ( % ),C0019016;C1514624;C1825777;C3538758
820,proportion ( $nmbr$ % ci ) adjusted for baseline hba $nmbr$ c  %,C0008107;C0019016;C0168634;C0456081;C1442488;C1709707;C1825777;C3259781;C3538758
820,pen - label empagliflozin $nmbr$ mg ( baseline hba $nmbr$ c > $nmbr$ % ),C0019016;C0024671;C0026410;C0168634;C0181496;C0439269;C1424886;C1442488;C1825777;C1960952;C2346927;C2827499;C3273588;C3490348;C3538758;C4319659;C4321396;C4521761;C4522130;C4551445
820,patients with possible new dm at randomization ( hba $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ % ),C0011816;C0019016;C0030705;C0034656;C0205314;C0332149;C1705910;C1825777;C2362652;C3250443;C3538758
820,mean ± s . d . hba $nmbr$ c,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
820,mean hba $nmbr$ c ± s . d .  %,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
820,mean hba $nmbr$ c  %,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
820,mean ( sd ) hba $nmbr$ c level  %,C0019016;C0441889;C0444504;C0456079;C1547707;C1825777;C2347634;C2348143;C2699239;C2946261;C3538758
820,mean ( s . d . ) baseline hba $nmbr$ c  %,C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
820,hemoglobin a    ( % ),C0019016
820,hbau  %,
820,hba „ ( % ),C0019016;C1825777;C3538758
820,hba ] c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
820,hba $nmbr$ ca  % ( mmol / mol ),C0019016;C1825777;C3538758;C3829066;C3887642
820,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ % without gi adverse reactions,C0019016;C0559546;C1708130;C1825777;C3538758;C3539617;C4050121
820,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
820,hba $nmbr$ c   baseline ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
820,hba $nmbr$ c   at randomization,C0019016;C0034656;C1825777;C3538758
820,hba $nmbr$ c   ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
820,hba $nmbr$ c   ( % ),C0019016;C1825777;C3538758
820,hba $nmbr$ c subgroups,C0019016;C1079230;C1825777;C3538758
820,hba $nmbr$ c strata,C0019016;C1825777;C3538758
820,hba $nmbr$ c levels,C0019016;C0441889;C1825777;C3538758
820,hba $nmbr$ c in patients with baseline hba $nmbr$ c < $nmbr$ % ( < $nmbr$ mmol / l )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se ),C0008107;C0019016;C0023031;C0023749;C0027960;C0030705;C0032042;C0036919;C0168634;C0230347;C0324740;C0392747;C0439189;C0443172;C0444504;C0456081;C1442488;C1456781;C1696465;C1705241;C1706408;C1719767;C1824986;C1825777;C1960955;C2346906;C2347634;C2348143;C2348589;C2699239;C3259781;C3538758;C3665593;C4319952;C4553351
820,hba $nmbr$ c distribution at baseline  n ( % ),C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
820,hba $nmbr$ c distribution at baseline,C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
820,hba $nmbr$ c distribution,C0019016;C0520511;C1704711;C1825777;C3538758
820,hba $nmbr$ c category  n ( % ),C0019016;C0683312;C1825777;C3538758;C3889287
820,hba $nmbr$ c category,C0019016;C0683312;C1825777;C3538758;C3889287
820,hba $nmbr$ c categories  n ( % ),C0019016;C0683312;C1825777;C3538758
820,hba $nmbr$ c at week $nmbr$,C0019016;C0332174;C0439230;C1825777;C3538758
820,hba $nmbr$ c at baseline :,C0019016;C0168634;C1442488;C1825777;C3538758
820,hba $nmbr$ c at baseline  %,C0019016;C0168634;C1442488;C1825777;C3538758
820,hba $nmbr$ c at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
820,hba $nmbr$ c at $nmbr$ weeks *,C0019016;C0439230;C1825777;C3538758
820,hba $nmbr$ c \n,C0019016;C1825777;C3538758
820,hba $nmbr$ c > = $nmbr$ %,C0019016;C1825777;C3538758
820,hba $nmbr$ c > $nmbr$ · $nmbr$ %,C0019016;C1825777;C3538758
820,hba $nmbr$ c > $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
820,hba $nmbr$ c > $nmbr$ % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
820,hba $nmbr$ c > $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
820,hba $nmbr$ c > $nmbr$ %,C0019016;C1825777;C3538758
820,hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
820,hba $nmbr$ c < = $nmbr$ %,C0019016;C1825777;C3538758
820,hba $nmbr$ c < $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
820,hba $nmbr$ c < $nmbr$ % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
820,hba $nmbr$ c < $nmbr$ % ( n - $nmbr$ ),C0019016;C1825777;C3538758
820,hba $nmbr$ c < $nmbr$ %,C0019016;C1825777;C3538758
820,hba $nmbr$ c ( sd )  %,C0019016;C1825777;C2699239;C3538758
820,hba $nmbr$ c ( n ),C0019016;C1825777;C3538758
820,hba $nmbr$ c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
820,hba $nmbr$ c ( change from baseline ),C0019016;C0168634;C0392747;C0443172;C1442488;C1705241;C1825777;C3538758;C4319952
820,hba $nmbr$ c ( % patients < $nmbr$ . $nmbr$ % ),C0019016;C0030705;C1825777;C3538758
820,hba $nmbr$ c ( % ) *,C0019016;C1825777;C3538758
820,hba $nmbr$ c ( % )  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
820,hba $nmbr$ c ( % ),C0019016;C1825777;C3538758
820,hba $nmbr$ c % ( range ),C0019016;C1514721;C1825777;C2348147;C3538758;C3542016
820,hba $nmbr$ c $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
820,hba $nmbr$ c $nmbr$ - < = $nmbr$ %,C0019016;C1825777;C3538758
820,hba $nmbr$ c $nmbr$ % - < $nmbr$ % ( n - $nmbr$ ),C0019016;C1825777;C3538758
820,hba $nmbr$ c $ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C1825777;C3538758;C3829066
820,hba $nmbr$ c  n,C0019016;C1825777;C3538758
820,hba $nmbr$ c  mmol / mole,C0019016;C1825777;C3538758;C3829066
820,hba $nmbr$ c  mmol / mold,C0019016;C0369241;C0439190;C1825777;C3538758
820,hba $nmbr$ c  mmol / mol,C0019016;C1825777;C3538758;C3829066
820,hba $nmbr$ c  median ( sd )  %,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2699239;C2939193;C3538758
820,hba $nmbr$ c  mean = sd  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
820,hba $nmbr$ c  mean ( sd )  % [ mmol / mol ],C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066
820,hba $nmbr$ c  mean ( sd )  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
820,hba $nmbr$ c  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
820,hba $nmbr$ c  baseline mean hba $nmbr$ c  % ( sd ),C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C2699239;C3538758
820,hba $nmbr$ c  > $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
820,hba $nmbr$ c  < $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
820,hba $nmbr$ c  ( % ),C0019016;C1825777;C3538758
820,hba $nmbr$ c  % §,C0019016;C1825777;C3538758
820,hba $nmbr$ c  % d,C0012358;C0019016;C1825777;C3538758
820,hba $nmbr$ c  % *,C0019016;C1825777;C3538758
820,hba $nmbr$ c  % ( sd ),C0019016;C1825777;C2699239;C3538758
820,hba $nmbr$ c  % ( mean ± sd ) [ range ],C0019016;C0444504;C1514721;C1825777;C2347634;C2348143;C2348147;C2699239;C3538758;C3542016
820,hba $nmbr$ c  % ( mean $nmbr$ sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
820,hba $nmbr$ c  %  n ( % ) b,C0019016;C1825777;C3538758
820,hba $nmbr$ c  %  mean ± sd,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
820,hba $nmbr$ c  %  mean ( sd ) b,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
820,hba $nmbr$ c  %  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
820,hba $nmbr$ c  %,C0019016;C1825777;C3538758
820,hba $nmbr$ c  $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
820,hba $nmbr$ c,C0019016;C1825777;C3538758
820,hba  c ( % ),C0019016;C1825777;C3538758
820,hba  % $nmbr$ c,C0019016;C1825777;C3538758
820,hba   ( % ),C0019016;C1825777;C3538758
820,change from baseline in hba $nmbr$ c ( % ),C0019016;C0168634;C0392747;C0443172;C1442488;C1705241;C1825777;C3538758;C4319952
820,baseline hba ^ c,C0019016;C0168634;C1442488;C1825777;C3538758
820,baseline hba $nmbr$ c in $nmbr$ classes,C0019016;C0168634;C0456387;C1442488;C1518526;C1705943;C1825777;C3538758;C4019422
820,baseline hba $nmbr$ c concentration,C0019016;C0086045;C0168634;C1442488;C1446561;C1825777;C3538758;C3827302
820,baseline hba $nmbr$ c ^,C0019016;C0168634;C1442488;C1825777;C3538758
820,baseline hba $nmbr$ c > $nmbr$ . $nmbr$ %,C0019016;C0168634;C1442488;C1825777;C3538758
820,baseline hba $nmbr$ c < $nmbr$ . $nmbr$ %,C0019016;C0168634;C1442488;C1825777;C3538758
820,baseline hba $nmbr$ c ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
820,baseline hba $nmbr$ c  n ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
820,baseline hba $nmbr$ c  mean ( s . e . ),C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
820,baseline hba $nmbr$ c  %,C0019016;C0168634;C1442488;C1825777;C3538758
820,baseline hba $nmbr$ c,C0019016;C0168634;C1442488;C1825777;C3538758
820,any hba $nmbr$ c,C0019016;C1825777;C3538758
820,% hba $nmbr$ c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
820,$nmbr$ % < hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
820,$nmbr$ % < hba $nmbr$ c < = $nmbr$ %,C0019016;C1825777;C3538758
-10,bisphosphonates,C0012544;C3541401
818,isolated upper gastrointestinal disease behavior  n ( % ),C0004927;C0205409;C0810300;C1548221;C2707008
818,isolated pulmonary embolism,C0034065;C0205409;C1548221
818,isolated impaired glucose tolerance — no .,C0205409;C0271650;C1548221
818,isolated igt,C0205409;C1548221
817,vasodilator therapy,C0039798;C0042402;C0087111;C1363945;C3537240
817,vasodilator,C0042402;C3537240
817,other vasodilators §,C0042402
817,other vasodilator,C0042402;C3537240
817,iv vasodilator,C0022326;C0042402;C3537240;C4265176
817,both iv vasodilator and inotrope,C0022326;C0042402;C1258199;C3537240;C4265176
817,alpha - blocker / other vasodilator,C0001641;C0042402;C3537240
816,non - ischaemic dilated cardiomyopathy,C1518422;C1960867
816,ischaemic dilated cardiomyopathy,C1960867
816,hypertrophic cardiomyopathy,C0007194;C4551472
816,dilated cardiomyopathy,C0007193;C2984282
816,combined cardiac failure  cardiomyopathy or other cardiac disorders,C0018799;C0018801;C0018802;C0205195;C0878544
816,cardiomyopathy,C0878544
815,rhabdomyolysis or myopathy,C0026848;C0035410;C4552660
815,rhabdomyolysis ( n = $nmbr$ ),C0035410;C4552660
815,rhabdomyolysis  myopathy  or myalgia with ck elevation > $nmbr$ x uln,C0009212;C0010287;C0026848;C0035410;C0231528;C0439775;C0702240;C1519815;C1872855;C4552646;C4552660
815,rhabdomyolysis  myopathy  or elevated creatine phosphokinase > $nmbr$ x upper limit of normal ( n = $nmbr$ ),C0010286;C0026848;C0035410;C0205250;C1427255;C1519815;C3163633;C4552660
815,rhabdomyolysis,C0035410;C4552660
814,α - glucosidase inhibitor,C1512211
814,pde $nmbr$ inhibitors,C0031638
814,pde $nmbr$ inhibitor monotherapy,C0031638
814,monoamine oxidase b inhibitors,C2917290;C3653412
814,era and pde $nmbr$ inhibitors,C0031638;C1521863;C3495919
814,a - glucosidase inhibitors ' $nmbr$,C1512211
814,a - glucosidase inhibitors,C1512211
814,a - glucosidase inhibitor,C1512211
813,sglt - $nmbr$ inhibitors ^,C3665045
813,renin inhibitors,C2917241;C3653375
813,renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920
813,renin inhibitor,C1960108;C3537174;C4521920
813,renin - angiotensin inhibitors,C0003018;C2917241;C3653375;C4521302
813,platelet aggregation inhibitors excluding heparin,C0019134;C0032177;C0332196;C0770546;C2828389
813,platelet aggregation inhibitors  n ( % ),C0032177
812,renin – angiotensin system inhibitor,C0035096;C1999216;C2984247
812,renin - angiotensin system inhibitor use,C0035096;C0042153;C0457083;C1947944;C1999216;C2984247
812,raas inhibitor use,C0042153;C0457083;C1947944;C1999216
812,raas inhibitor,C1999216
812,p $nmbr$ y $nmbr$ inhibitor maintenance,C0024501;C0369773;C1999216;C2603361
812,p $nmbr$ y $nmbr$ inhibitor loading dos,C0369773;C1428722;C1708715;C1999216;C2603361
812,p $nmbr$ y $nmbr$ inhibitor,C0369773;C1999216;C2603361
812,other sglt - $nmbr$ inhibitor,C1999216
812,inhibitor,C1999216
812,gpifo ' llia inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
812,gpifeellla inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
811,use of ace inhibitor,C0003015;C1524063;C4541021
811,dipeptidyl peptidase - $nmbr$ inhibitor,C0003015;C2757044;C3536837
811,dipeptidyl peptidase $nmbr$ inhibitors,C0003015
811,dipeptidyl peptidase $nmbr$ inhibitor,C0003015;C2757044;C3536837
811,current use of an ace inhibitor,C0003015;C0521116;C1524063;C1705970;C4541021
811,angiotensin - converting enzyme inhibitors ^,C0003015;C2757044
811,angiotensin - converting enzyme inhibitors,C0003015;C2757044
811,angiotensin - converting enzyme inhibitor / angiotensin receptor blocker,C0003015;C0597357;C2757044;C3536837;C4541021
811,angiotensin - converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
811,angiotensin - converting - enzyme inhibitor or angiotensin -,C0003015;C0003018;C2757044;C3536837;C4521302;C4541021
811,angiotensin - converting - enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
811,ace inhibitors through hospital discharge or day $nmbr$ — %,C0003015;C0332173;C0439228;C0439505;C0586003
811,ace inhibitors / sartans,C0003015;C1563745
811,ace inhibitors,C0003015
811,ace inhibitor — no . ( % ),C0003015;C4541021
811,ace inhibitor use ( % ),C0003015;C0042153;C0457083;C1947944;C4541021
811,ace inhibitor or arb use,C0003015;C0042153;C0457083;C1947944;C3888198;C4541021
811,ace inhibitor or angiotensin ii receptor,C0003011;C0003015;C4541021
811,ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % ),C0003015;C0034787;C0439175;C0439810;C1622222;C4541021
811,ace inhibitor monotherapy,C0003015;C4541021
811,ace inhibitor  n ( % ),C0003015;C4541021
811,ace inhibitor  %,C0003015;C4541021
811,ace inhibitor,C0003015;C4541021
811,ace - inhibitors  n ( % ),C0003015
811,ace - inhibitors,C0003015
811,ace - inhibitor use,C0003015;C0042153;C0457083;C1947944;C4541021
810,p - gp inhibitor,C3898062
810,gp llb / llla inhibitors,C0243077;C1705010;C3811116
809,tnf inhibitors,C0243077;C1448177
809,raas inhibitors,C0243077
809,non - tnf inhibitors,C0243077;C1448177;C1518422
809,no . of previous tne inhibitors,C0205156;C0243077;C1552607;C3896585
808,no ilb / iiia inhibitors,C0243077;C4697913
808,ilb / iiia inhibitors,C0243077;C4697913
808,ijb ^,
808,gpiib / iiia receptor inhibitor,C0016011;C0597357;C1999216
808,gpiib - iiia inhibitors,C0016011;C0243077
808,gp iib / iiia inhibitors,C0016011;C0243077
808,gp iib / iiia inhibitor used,C0016011;C1273517;C1999216
808,gp iib / iiia inhibitor before pci — no . ( % ),C0016011;C1999216;C4049621
808,glycoprotein iib / iiia inhibitort,C0016011
808,glycoprotein iib / iiia inhibitors,C0016011;C0243077
808,glycoprotein iib / iiia inhibitor,C0016011;C1999216
808,bail ‐ out use of glycoprotein iib / iiia inhibitors,C0016011;C0175673;C0243077;C1524063
807,potent phosphorylated glycoprotein inhibitor use,C0017968;C0042153;C0457083;C1947944;C1999216;C3245505
807,glycoprotein iib / iiiareceptorinhibitor,C0017968
806,received first loading dose,C0205435;C1279901;C1514756;C3714444
806,no ipst ( n = $nmbr$  $nmbr$ ),
806,no ipst,
806,missing data initial diagnosis — no .,C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685;C4684714
806,ipst ( n = $nmbr$ ),
806,ipst,
806,initial timi flow grade $nmbr$,C0205265;C0441800;C0919553;C1279901;C1555582;C1705685;C3244287;C3272266
806,initial timi flow,C0205265;C1279901;C1555582;C1705685;C3272266
806,initial heparin — no . ( % ) §,C0019134;C0205265;C0770546;C1279901;C1555582;C1705685
806,initial diagnosis — no . ( % ),C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685
806,first loading dose,C0205435;C1279901;C3714444
806,first - recorded event  no . ( and % ) of patients,C0030705;C0034869;C0205435;C0441471;C1279901;C3853788;C4019010
806,first - generation stentt,C0079411;C0205435;C1279901;C3146294
806,first ( n = $nmbr$ ),C0205435;C1279901
806,criterion reached first  n ( % ),C0205435;C0243161;C1279901;C2584321;C4321250
806,components of the first cid,C0205435;C0449432;C1279901;C1707433
805,micral test result,C0456984;C0587081
805,labs at randomization,C0034656;C0587081
805,laboratory findings,C0587081
805,> $nmbr$ microg / l,
805,< $nmbr$ microg / l,
804,tirofiban ( n = $nmbr$ ),C0247025
804,irofiban,
804,heparin ± tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0770546
804,heparin plus tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0332287;C0770546
804,heparin + tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0770546
803,simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg ( n = $nmbr$ /,C0033228;C0074554;C0332287;C1319635
803,fenofibrate ( n = $nmbr$ ),C0033228
802,non - fibrin - specific,C0015982;C0205370
802,fibrin - specilic,C0015982
802,fibrin - specific,C0015982;C0205369;C1552740
801,minority,C0026192
801,ethnic minority group — no . ( % ),C0015031;C0026192;C0680174;C1879937
800,evening mealb,C0587117
800,evening,C0587117
799,selexipag patients / events n,C0030705;C0441471;C2000145;C3541888
799,selexipag ( n = $nmbr$ ),C2000145
799,selexipag,C2000145
798,use of inhaled glucocorticoids at screening — no . ( % ),C0004048;C0017710;C0220908;C0220909;C1524063;C1698960;C1710031;C1710032;C1710477;C2348164;C3540777;C3540778
798,theophylline use at screening,C0220908;C0220909;C0241361;C1698960;C1710031;C1710032;C1710477;C2348164
798,screening visit,C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
798,screening and baseline lung function characteristics,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C4684572
798,screening ( visit $nmbr$ ),C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
798,screening  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
798,screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
798,risk factor ( predefined ) for falling at screening  n ( % ),C0000921;C0035648;C0085639;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
798,pre - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602
798,post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
798,post - bronchodilator fev $nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541
798,patients with > $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening,C0184666;C0220908;C0220909;C0439231;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C3810541;C3811131;C4086268
798,patients with > $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening,C0019994;C0030673;C0220908;C0220909;C0439231;C1510665;C1698960;C1710031;C1710032;C1710477;C2348164;C4086268
798,oad at screening  n ( % ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
798,modified rankin scale at screening  $nmbr$ - $nmbr$,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2984908;C3854213
798,mean blood pressure at screening visit ( mm hg ),C0220908;C0220909;C0428886;C0439475;C0488053;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
798,lama use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
798,lama use at screening,C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
798,laba use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
798,laba use at screening,C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
798,laba - inhaled glucocorticoid use at screening,C0004048;C0017710;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
798,inhaled glucocorticoid use at screening,C0004048;C0017710;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
798,fev $nmbr$   at screening ∗,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
798,devices for heart failure at screening visit,C0018787;C0018801;C0018802;C0025078;C0025080;C0220819;C0220908;C0220909;C0231174;C0545082;C0680095;C0699733;C1512346;C1698960;C1710031;C1710032;C1710477;C2024216;C2348164;C2826704;C4554158
798,current smoker  n ( % ) post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3173209;C3241966
798,at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
798,aspirin use before screening — no . { % ),C0004057;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
798,> $nmbr$ per pl in $nmbr$ months before screening,C0220908;C0220909;C0439231;C1698960;C1710031;C1710032;C1710477;C2348164;C3897966;C4049765
798,> $nmbr$ per pl at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3897966;C4049765
798,> $nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
797,smokingb,
797,smoking habit  n ( % ),C4505437
797,current cigarette smoking  no . ( % ),C0239059;C0521116;C0700219;C1705970
797,current cigarette smoking,C0239059;C0521116;C0700219;C1705970
797,cigarette smoking in the past year,C0239059;C0700219;C4086728
797,cigarette smoking  n ( % ),C0239059;C0700219
797,cigarette smoking,C0239059;C0700219
796,smoking status — no . { % ),C1519386
796,smoking status — no . ( % ),C1519386
796,smoking status at screening  n ( % ),C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
796,smoking status at screening,C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
796,smoking status . no . ( % ),C1519386
796,smoking status *,C1519386
796,smoking status ( ongoing ) ( n ),C0549178;C1519386
796,smoking status ( % ),C1519386
796,smoking status  no . ( % ),C1519386
796,smoking status  n [ % ] ®,C1519386
796,smoking status  n ( % ) *,C1519386
796,smoking status  n ( % ),C1519386
796,smoking status,C1519386
796,cigarette smoking status,C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
796,cigarette - smoking status — no . ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
796,cigarette - smoking status ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
796,baseline smoking status,C0168634;C1442488;C1519386
-10,streptokinase,C0038418
794,use of compression stockings  no . ( % ),C0038348;C1524063
794,compression stockings,C0038348
793,no clinical or lesion rfs for st,C0036056;C0205210;C0221198;C0341703;C1546698;C3272372
793,durable clinical responseg,C0205210
793,durable clinical remissionh,C0205210
793,clinical responsed,C0205210
793,clinical remissione,C0205210
793,clinical or lesion rf for st,C0035448;C0036056;C0201660;C0205210;C0221198;C0748398;C1546698;C1547111;C3272372
793,clinical details,C0205210;C1522508
793,clinical criteria $nmbr$,C0205210;C0243161
793,clinical and patient - reported characteristics at baseline and randomization,C0034656;C0205210;C0588446;C4684572
793,clinical,C0205210
793,any clinical or lesion rf for st,C0035448;C0036056;C0201660;C0205210;C0221198;C0748398;C1546698;C1547111;C3272372
792,non - cortical,C0001613;C0007776;C0022655;C1518422
792,cortical only,C0001613;C0007776;C0022655;C0205171;C1720467
791,clinical endpoint,C2347784
791,clinical dementia rating score,C4304227
790,clinical presentation of vte at initial diagnosis — no . ( % ),C0011900;C0205265;C0630906;C1279901;C1555582;C1704338;C1704656;C1705685;C2708283
790,clinical presentation,C2708283
789,selected clinical characteristics — no . / total no . ( % ),C0439175;C0439810;C0683325;C1707391
789,selected clinical characteristics  n ( % ),C0683325;C1707391
789,selected clinical characteristics,C0683325;C1707391
789,other clinical characteristics,C0683325
789,demographics and clinical characteristics,C0011298;C0683325;C1704791
789,clinical characteristics ( % ),C0683325
789,clinical characteristics  n ( % ),C0683325
789,clinical characteristics,C0683325
788,timi clinically significant,C0237881;C0750502;C1546944
788,significant worsening in kccq clinical,C0205210;C0237881;C0332271;C0750502;C1457868;C1546944;C1546960;C3476798
787,women ethnic origin,C0015031;C0043210
787,white ethnicity,C0007457;C0015031;C0043157;C0220938;C0243103
787,white ethnic origin,C0007457;C0015031;C0043157;C0220938
787,while ethnic origin,C0015031
787,sex ( male ) ethnic origin,C0015031;C0086582
787,race or ethnicity  n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
787,race or ethnicity,C0015031;C0034510;C0243103;C1706779;C3853635
787,race or ethnic origin,C0015031;C0034510;C1706779;C3853635
787,race or ethnic group — no . { % ) ■ ' ( white,C0007457;C0015031;C0034510;C0043157;C0220938;C1706779;C1879937;C3853635
787,race or ethnic group — no . f,C0015031;C0016327;C0034510;C1706779;C1879937;C3853635
787,race or ethnic group — no . / total no . ( % ) f,C0015031;C0016327;C0034510;C0439175;C0439810;C1706779;C1879937;C3853635
787,race or ethnic group — no . ( % ) f,C0015031;C0016327;C0034510;C1706779;C1879937;C3853635
787,race or ethnic group ( % ) f,C0015031;C0016327;C0034510;C0441840;C0680174;C1706779;C1879937;C3853635
787,race or ethnic group ( % ),C0015031;C0034510;C1706779;C1879937;C3853635
787,race or ethnic group  n ( % ) *,C0015031;C0034510;C0441848;C0680174;C1706779;C3853635
787,race or ethnic group,C0015031;C0034510;C1706779;C1879937;C3853635
787,race / ethnicity white,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1706779;C3853635
787,race / ethnicity n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
787,race / ethnicity  no . ( % ) *,C0015031;C0034510;C0243103;C1706779;C3853635
787,race / ethnicity  no . ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
787,race / ethnicity  n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
787,race / ethnicity  % white non - hispanic,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1518422;C1518424;C1533020;C1533021;C1706779;C3853635
787,othery ethnicity  n ( % ) *,C0015031;C0243103
787,othery ethnicity  n ( % ),C0015031;C0243103
787,male sex ( % ) race or ethnic group ( % ) f,C0015031;C0016327;C0034510;C0086582;C0441840;C0680174;C1706779;C1879937;C3853635
787,hispanic ethnicity  n ( % ),C0015031;C0086409;C0243103
787,hispanic ethnicity,C0015031;C0086409;C0243103
787,hispanic / latino ethnicity  n ( % ),C0015031;C0086409;C0086528;C0243103
787,hispanic / latino ethnicity,C0015031;C0086409;C0086528;C0243103
787,ethnieity,
787,ethnicity t,C0015031;C0243103
787,ethnicity - no . ( % ),C0015031;C0243103
787,ethnicity - - hispanic or latino,C0015031;C0086409;C0086528;C0243103
787,ethnicity ( % ),C0015031;C0243103
787,ethnicity $nmbr$ ',C0015031;C0243103
787,ethnicity  no . ( % ),C0015031;C0243103
787,ethnicity  n ( % ) b,C0015031;C0243103
787,ethnicity  n ( % ) :,C0015031;C0243103
787,ethnicity  n ( % ) *,C0015031;C0243103
787,ethnicity  n ( % ),C0015031;C0243103
787,ethnicity  hispanic / latino  n ( % ),C0015031;C0086409;C0086528;C0243103
787,ethnicity  %,C0015031;C0243103
787,ethnicity,C0015031;C0243103
787,ethnic origin white,C0007457;C0015031;C0043157;C0220938
787,ethnic origin *,C0015031
787,ethnic origin  n ( % ),C0015031
787,ethnic origin,C0015031
787,ethnic group — no . ( % ) ',C0015031;C1879937
787,ethnic group ( % ),C0015031;C1879937
787,ethnic group,C0015031;C1879937
787,ethnic background,C0015031
787,age  mean ( sd )  y ethnicity  no . ( % ),C0001779;C0015031;C0243103;C0444504;C2347634;C2348143;C2699239
787,* plus - minus values are means 士 sd . race or ethnic group was self - determined . the body - mass index is the weight in kilograms divided by,C0005893;C0005910;C0015031;C0034510;C0036595;C0042295;C0043100;C0332288;C0332849;C0439209;C0578022;C1305855;C1305866;C1704970;C1705104;C1706779;C1879937;C2699239;C3853635
786,urti,
786,single vessel coronary artery disease †,C0581374
786,single vessel coronary artery disease *,C0581374
786,single vessel coronary artery disease $nmbr$,C0581374
786,multi - vessel coronary artery disease,C1299432
786,ischemic coronary artery disease,C0852149
786,history of coronary artery disease — no . { % ),C1881055
786,history of coronary artery disease - n ( % ),C1881055
786,history of coronary artery disease,C1881055
786,coronar y artery disease,C0852949
786,coronaiy artery disease,C0852949
785,non - lad artery,C0003842;C0226004;C1518422
785,lad artery,C0003842;C0226004
785,imaged artery,C0003842;C0226004;C1704254;C1704922;C3542466
784,carrier ( n = $nmbr$ ),C0007294;C0560175;C1325398;C1706209;C3273162
784,apolipoprotein e carrier,C0003595;C0007294;C0560175;C1325398;C1706209;C3273162
784,apoe   ε $nmbr$ carrier,C0003595;C0007294;C0523511;C0560175;C1325398;C1412481;C1706209;C3273162
784,apoe e $nmbr$ carriers  no . ( % ),C0003595;C0007294;C0523511;C1412481
784,ala carriers,C0007294;C0523459;C3888236
783,prevalence of each metabolic syndrome criterion,C0033105;C0220900;C0243161;C0524620
783,entry criteria ( % ),C0243161;C1705654
783,entry criteria,C0243161;C1705654
783,cv entry criteria,C0243161;C1705654;C3538987;C4048877;C4318503
783,criterion,C0243161
783,by who / simon broome criteria,C0243161;C0443058
782,total  adjusted weight of $nmbr$ . $nmbr$ for gastrointestinal bleeding,C0005910;C0017181;C0043100;C0439175;C0439810;C0456081;C1305866;C1705104
782,gastrointestinal bleeding,C0017181
782,gastroenteritis,C0017160
781,upper gastrointestinal tract,C3203348
781,upper gastrointestinal,C3203348
781,history of upper gastrointestinal event,C0019664;C0019665;C0262512;C0262926;C0441471;C1705255;C2004062;C3203348;C4019010
780,vasoprotectives,C0304533
780,fecal calprotectin — pg / g * *,C0015733;C0950624;C1335798;C1366582;C1638318
779,angiotensin receptor blockers,C0521942;C0815017
779,angiotensin receptor,C0034787;C1622222
779,angiotensin receptive blocker,C0003018;C0544683;C4521302
779,angiotensin ll - receptor blocker,C0003018;C0597357;C4521302
779,angiotensin ll - receptor antagonist — no . ( % ),C0003018;C4521302;C4543207
779,angiotensin il - receptor blocker,C0003018;C0020898;C0021764;C0022271;C0034787;C1149183;C1622222;C4521302
779,angiotensin ii receptor blockers,C0521942;C2757003
779,angiotensin ii receptor blocker,C0521942;C3536793
779,angiotensin - receptor,C0034787;C1622222
779,angiotensin -,C0003018;C4521302
779,angiogenesis,C0302600;C1519670
779,ace inhibitors or angiotensin receptor blockers,C0003015;C0521942;C0815017
779,ace inhibitors or angiotensin - receptor blockers ^,C0003015;C0521942;C0815017
779,ace inhibitors or angiotensin - receptor blockers,C0003015;C0521942;C0815017
779,ace inhibitor or angiotensin receptor blocker,C0003015;C0034787;C1622222;C4541021
779,ace inhibitor or angiotensin ii receptor blocker,C0003015;C0521942;C3536793;C4541021
778,urticaria,C0042109;C1559188
778,other / multiracial,C1881928
778,multiracial or other,C1881928
778,multiracial  n ( % ),C1881928
778,multiracial,C1881928
777,prior exposure to levetiracetam,C0274281;C0332152;C0332157;C0377265;C2826257;C3693636
777,levetiracetam,C0377265;C3693636
776,bivalirudin used during pci,C0168273;C1273517;C4049621
776,bivalirudin used,C0168273;C1273517
776,bivalirudin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ ),C0016011;C0168273;C0243077
776,bivalirudin only,C0168273;C0205171;C1720467
776,bivalirudin ( n = $nmbr$ ),C0168273
776,bivalirudin ( n = $nmbr$  $nmbr$ ),C0168273
776,bivalirudin,C0168273
775,re - cover $nmbr$ dabigatran,C0180153;C0556581;C1999244;C2348066;C2986904;C3888055
775,hazard ratio with dabigatran  $nmbr$ mg ( $nmbr$ % cl ),C0024671;C0026410;C0439269;C0596019;C1960952;C2346927;C2348066;C2985465;C4321396;C4521761
775,favors dabigatran,C0309049;C2348066
775,factors dabigatran event incidence / n,C0021149;C0220856;C0441471;C1521761;C2348066;C2827422;C4019010
775,factors dabigatran,C1521761;C2348066;C2827422
775,dabigatran ( n = $nmbr$ ),C2348066
775,dabigatran  $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2348066;C4321396;C4521761
775,dabigatran,C2348066
775,$nmbr$ mg dabigatran ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
775,$nmbr$ mg dabigatran,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
774,placebo - ideglira,C0032042;C1696465;C1706408;C4308663
774,ideglira - ideg - lira,C1555441;C4308663
774,ideglira - ideg,C4308663
774,ideglira,C4308663
774,ideg,
773,cgi - s  n ( % ) z :,C4526016
773,bpearson ' s chi ‐ square test .,C0008041
772,china / tjapan,C0008115
772,china / japan,C0008115;C0022341
772,china,C0008115
771,mean ( ± sd ) change from,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2699239;C4319952
771,mean ( sd ) change from pre - to post - bronchodilator fevi  ml,C0332152;C0439526;C0444504;C0687676;C0740175;C1704687;C1705224;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034;C3887665
771,mean ( sd ) change from pre - to post - bronchodilator fev $nmbr$  l,C0332152;C0392747;C0443172;C0444504;C0687676;C0740175;C1704687;C1705241;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3669034;C3714541;C4319952
771,change from pre - to,C0332152;C0392747;C0443172;C0740175;C1705241;C2257086;C3669034;C4319952
770,chinese subgroup,C0008120;C0152035;C1079230;C1515021
770,chinese,C0008120;C0152035
769,prior congestive heart failure yes,C0018802;C0332152;C1549445;C1705108;C1710701;C2826257
769,prior congestive heart failure,C0018802;C0332152;C2826257
769,prior chf  %,C0018802;C0332152;C2826257
769,prior chf,C0018802;C0332152;C2826257
769,first hospitalization for chf or cv death,C0011065;C0018802;C0019993;C0205435;C1279901;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
769,chf on losartan ( % ),C0018802;C0126174
769,chf ( % ),C0018802
769,chf,C0018802
768,pulmonary congestion ( cxr ),C0006888;C0039985;C0242073
768,chest x - ray,C0039985
767,total psa ‐ modified shs,C0392747;C2986589;C3889737
767,second primary ( estimated change in total updrs score from baseline to wk $nmbr$ ),C0168634;C0205225;C0205436;C0332174;C0392747;C0439175;C0439230;C0439612;C0439631;C0439810;C0443172;C0449820;C0457385;C0565930;C0750572;C1442488;C1561503;C1705190;C1705241;C3639721;C4050231;C4319952
767,retinal severity change,C0035298;C0392747;C0439793;C0443172;C0522510;C1705241;C4319952
767,rec . ischemia due to ecg changes,C0022116;C0392747;C0443172;C0678226;C1424025;C1623258;C1705241;C2606415;C4319952;C4321499
767,percent change,C0392747;C0439165;C0443172;C1705241;C4319952
767,patients with enthesitis at week $nmbr$ radiographic progression § change from baseline to week $nmbr$ in psa - modified total shs score,C0030705;C0168634;C0242656;C0332174;C0392747;C0439175;C0439230;C0439810;C0443172;C0444708;C0449258;C0449820;C1282952;C1442488;C1705241;C3810537;C3813209;C3889737;C4050231;C4319952
767,patients with change from baseline in total psa ‐ modified shs ≤ $nmbr$,C0030705;C0168634;C0392747;C0443172;C1442488;C1705241;C2986589;C3889737;C4319952
767,pain vas  mean change from baselined,C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
767,pain vas  mean change from baselinea,C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
767,nominal change,C0392747;C0443172;C1705241;C4319952
767,no incident dm or change in fg > $nmbr$,C0011816;C0016703;C0392747;C0439214;C0443172;C1551358;C1705241;C2348814;C3250443;C4319952
767,no change,C0392747;C0443172;C1705241;C4319952
767,modified total sharp score * *,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
767,modified total sharp score,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
767,modified has - bled score  mean ± sd,C0019080;C0392747;C0444504;C0449820;C2347634;C2348143;C2699239;C3889737;C4050231
767,modified has - bled > $nmbr$,C0019080;C0392747;C3889737
767,modified has - bled < $nmbr$,C0019080;C0392747;C3889737
767,modified has - bled $ $nmbr$,C0019080;C0392747;C3889737
767,modified has - bled,C0019080;C0392747;C3889737
767,mean change in sgrq,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
767,mean change in fev $nmbr$,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3714541;C4319952
767,mean change in acq score,C0392747;C0443172;C1705241;C2919686;C3533236;C4319952
767,mean change from baseline in the number of,C0168634;C0237753;C0392747;C0443172;C0444504;C0449788;C1442488;C1705241;C2347634;C2348143;C4319952
767,mean change from baseline in fev $nmbr$ % predicted  % ( sd ) *,C0168634;C0392747;C0443172;C0444504;C0681842;C1442488;C1705241;C1882327;C2347634;C2348143;C2699239;C3714541;C4319952
767,mean change from baseline bp at week $nmbr$,C0168634;C0332174;C0392747;C0439230;C0443172;C0444504;C0488053;C1268766;C1442488;C1705241;C2347634;C2348143;C4319952
767,mean change at week $nmbr$,C0332174;C0392747;C0439230;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
767,mean change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
767,mean - sd change in pre - bronchodilator fev $nmbr$  l,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2599602;C2699239;C3714541;C4319952
767,mean % change in fn bmd,C0392747;C0443172;C0444504;C1570610;C1705241;C2347634;C2348143;C4319952
767,lyear mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
767,ls mean change from baseline ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
767,ls mean change from baseline $nmbr$,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
767,ls mean change from baseline,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
767,low - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023668;C0023824;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952
767,lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se ),C0023668;C0031962;C0036919;C0041403;C0065058;C0125953;C0168634;C0392747;C0443172;C0444504;C1096202;C1439335;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952
767,incident dm or change in,C0011816;C0392747;C0443172;C1551358;C1705241;C3250443;C4319952
767,high - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023668;C0023822;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952
767,fasting plasma glucose ( change from baseline ),C0168634;C0392747;C0443172;C0583513;C1442488;C1705241;C4319952
767,ecg changes ( % ) t,C0392747;C0443172;C1623258;C1705241;C2603360;C4319952
767,due to ecg changes,C0392747;C0443172;C1623258;C1705241;C4319952
767,changes in shs,C0392747;C0443172
767,changes in serum creatinine  pmol / l,C0201976;C0392747;C0439284;C0443172;C0600061
767,change to week $nmbr$ * ’ ’,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
767,change in tc,C0039411;C0040642;C0041405;C0041698;C0392747;C0443172;C1705241;C1824670;C3272447;C4319952;C4522122
767,change in retinal pathology,C0030664;C0035298;C0205469;C0392747;C0443172;C0677042;C1705241;C4319952
767,change in psa ‐ modified shs  baseline to week $nmbr$,C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C3810537;C3813209;C3889737;C4319952
767,change in nt - probnp at $nmbr$,C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
767,change in mtss ( mean ),C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
767,change in ldl ‐ c,C0392747;C0443172;C1705241;C4319952
767,change in hdl ‐ c,C0392747;C0443172;C1705241;C3715113;C4319952
767,change in hbalc after $nmbr$ weeks etd ( $nmbr$ % cl ),C0392747;C0439230;C0443172;C0596019;C1180255;C1705241;C4319952
767,change in das $nmbr$ > $nmbr$ . $nmbr$,C0051767;C0057671;C0392747;C0443172;C1705241;C4319952
767,change in das $nmbr$ - esr ( mean ) i physical function outcomes week $nmbr$,C0021966;C0051767;C0057671;C0221138;C0332174;C0392747;C0439230;C0443172;C0444504;C0516981;C1274040;C1705241;C2347634;C2348143;C3811131;C4049916;C4319952
767,change from baseline in sgrq,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
767,change from baseline in fevj ( mb ),C0024853;C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
767,change from baseline in acq - $nmbr$ score,C0168634;C0392747;C0443172;C0449820;C1442488;C1705241;C2919686;C4050231;C4319952
767,change from baseline in acq - $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C2919686;C4319952
767,change from baseline in,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
767,change from baseline at week $nmbr$,C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C4319952
767,change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
767,change from,C0392747;C0443172;C1705241;C4319952
767,change at week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
767,change $nmbr$,C0392747;C0443172;C1705241;C4319952
767,change,C0392747;C0443172;C1705241;C4319952
767,body weight ( change from baseline ),C0005911;C0168634;C0392747;C0443172;C1303013;C1442488;C1705241;C4319952
767,before a change to the enrollment form was implemented in august $nmbr$ . bnp,C0054015;C0348078;C0376315;C0392747;C0443172;C1095989;C1417808;C1516879;C1522492;C1696073;C1705241;C2982014;C3831448;C3888021;C4255237;C4319952;C4520547
767,basdai  mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952
767,at c change ( % ) *,C0392747;C0443172;C1705241;C4319952
767,% change from baseline  mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
767,% change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
767,% change ( meantse ),C0392747;C0443172;C1705241;C4319952
767,% change ( meanlse ),C0392747;C0443172;C1705241;C4319952
767,% change,C0392747;C0443172;C1705241;C4319952
767,$nmbr$ year mean change from baseline,C0168634;C0392747;C0439234;C0439508;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
766,charlson comorbidity index  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4546361
766,charlson comorbidity index,C4546361
766,charlson comobility score  n ( % ),C0449820;C4050231
766,charlson,
765,comorbidity  no . ( % ),C0009488
765,comorbidities other than diabetes,C0009488;C0011847;C0011849
765,comorbidities ( % ),C0009488
765,comorbidities  no . ( % ),C0009488
765,comorbidities  n ( % ) a,C0009488
765,comorbidities  %,C0009488
765,comorbidities,C0009488
765,comorbidites  n ( % ),
765,comorbid illnesses,C0009488;C0221423
765,comorbid conditionsb,C0009488
765,co - morbidities  n ( % ),C0009488
765,co - morbidities  a n ( % ),C0009488;C0369718;C0441922
765,co - morbidities,C0009488
764,prior exposure to carbamazepine,C0006949;C0006950;C0274281;C0332152;C0332157;C0682993;C2826257
764,cbz - naive,C0006949
764,cbz - exposed,C0006949;C0332157
764,carbamazepine,C0006949;C0006950;C0682993
763,native latin,C0302891
763,american ‐ indian / alaska native,C0002460;C0682125
763,american indian or alaskan native,C0002460;C0238611;C0302891
763,american indian or alaska native  :,C0002460;C0682125
763,american indian or alaska native,C0002460;C0682125
763,american indian / alaskan native  n ( % ),C0002460;C0238611;C0302891;C0886378;C1524069
763,american indian / alaskan native,C0002460;C0238611;C0302891
763,american indian / alaska native,C0002460;C0682125
763,alaska native,C0682125
762,pharmaco - invasive n = $nmbr$,C0205281;C1334278
762,pharmaco - invasive ( n = $nmbr$ ),C0205281;C1334278
762,invasive,C0205281;C1334278
762,intent of early invasive strategy  %,C0162425;C0205281;C0679199;C1279919;C1283828;C1334278;C1550453
762,early invasive strategy ( n = $nmbr$  $nmbr$ ),C0205281;C0679199;C1279919;C1334278
762,early invasive *,C0205281;C1279919;C1334278
762,early invasive $nmbr$,C0205281;C1279919;C1334278
-10,oxidative stress,C0242606
760,relative wall thickness,C0080103;C0205345;C0677535;C1280412;C1547039
760,relative decrease > $nmbr$ %,C0080103;C0205345;C0392756;C0547047;C1547039
759,sustain $nmbr$ : semaglutide vs . exenatide er $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0167117;C0439269;C0443318;C1960952;C2346927;C2732140;C3810541;C3811131;C3885068;C4321396;C4521761
759,lixisenatide ( n = $nmbr$ o ),C2973895
759,lixisenatide ( n = $nmbr$ ),C2973895
759,lixisenatide,C2973895
759,exenatide ± oad,C0167117
759,exenatide no . of events / total no . ( % ),C0167117;C0439175;C0439810;C0441471;C3541888
759,exenatide n = $nmbr$,C0167117
759,exenatide lar,C0167117;C1419115;C3814448
759,exenatide er,C0167117;C3810541;C3811131
759,exenatide,C0167117
758,thiazides,C0541746
758,thiazide users,C0541746;C1706077
758,thiazide at enrollment,C0541746;C1516879;C1696073;C3888021
758,thiazide,C0541746
757,timi ≥ $nmbr$ and spoke and time ≤ $nmbr$ h,C0033727;C0040223;C0369286;C0441932;C0564385;C3541383;C4528284
757,timi ≥ $nmbr$ and spoke,
757,time to first sare * ( % ),C0040223;C0205435;C1279901;C3541383
757,time to first morbidity / mortality event up to the end of the treatment periodd,C0026538;C0026565;C0026566;C0039798;C0040223;C0087111;C0205435;C0220880;C0441471;C0444930;C0547043;C1279901;C1522326;C1533734;C1705169;C2746065;C3538994;C3541383;C3887704;C4019010
757,time to first exacerbation,C0040223;C0205435;C1279901;C3541383;C4086268
757,time since primary diagnosis,C0040223;C0332137;C0801658;C3541383
757,time since most recent myocardial,C0027061;C0040223;C0332185;C1522564;C3541383
757,time since first luts ( years ),C0040223;C0205435;C0439234;C0574785;C1279901;C3541383
757,time since cabg,C0010055;C0040223;C3541383
757,time since asthma diagnosis years,C0004096;C0011900;C0040223;C0439234;C1704338;C1704656;C2984299;C3541383
757,time since asthma diagnosis [ years ]  median ( range ),C0004096;C0011900;C0040223;C0439234;C0549183;C0876920;C1514721;C1704338;C1704656;C2347635;C2348144;C2348147;C2939193;C2984299;C3541383;C3542016
757,time since asthma diagnosis ( years ),C0004096;C0011900;C0040223;C0439234;C1704338;C1704656;C2984299;C3541383
757,time since asthma,C0004096;C0040223;C2984299;C3541383
757,time in therapeutic range before inclusion,C0007637;C0040223;C0087111;C0302350;C0460097;C1512693;C1554109;C3541383
757,time in therapeutic range  median ( iqr )  %,C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383
757,time in therapeutic range,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
757,time from randomization to cabg — hr,C0010055;C0034656;C0040223;C3541383
757,time from qualifying mi  yrs,C0040223;C1514624;C3541383;C3810814
757,time from qualifying mi  %,C0040223;C1514624;C3541383;C3810814
757,time from most recent qualifying,C0040223;C0332185;C1514624;C3541383
757,time from first eval,C0040223;C0205435;C1279901;C1707957;C2698624;C3541383
757,time ( sec ) *,C0040223;C0565930;C3541383
757,spoke,
757,percentage of time in therapeutic inr range  mean ( sd ),C0040223;C0439165;C0444504;C0460097;C0525032;C1549488;C1561533;C1704538;C2347634;C2348143;C2699239;C3541383
757,percent work time missed due to asthma,C0004096;C0040223;C0043227;C0439165;C0678226;C1705492;C2984299;C3541383
757,percent of the time that inr was in the therapeutic range,C0040223;C0439165;C0460097;C0525032;C1704538;C3541383
757,mean time to first oral dose postsurgeryh  hr,C0040223;C0178602;C0205435;C0442027;C0444504;C0869039;C1114758;C1279901;C2347634;C2348143;C3541383;C4521986
757,mean time since asthma,C0004096;C0040223;C0444504;C2347634;C2348143;C2984299;C3541383
757,ecg at time of qualifying symptoms,C0040223;C0683368;C1457887;C1514624;C1623258;C3541383
757,at any time,C0040223;C3541383
756,time since last dose of,C0946444
756,time intervals  h,C0033727;C0369286;C0441932;C0564385;C0872291;C4528284
756,time intervals,C0872291
756,time from last dose of p $nmbr$ y $nmbr$ inhibitor  days,C0439228;C0946444;C1999216
755,tpm - naive,C0076829
755,tpm - exposed,C0076829;C0332157
755,topiramate,C0076829
755,assigned to topiramate,C0040363;C0041260;C0076829;C1516050;C1552601;C1883351
754,womac stiffness score,C0427008;C0449820;C4050231
754,stiffness subscale,C0427008
754,question $nmbr$ ( morning stiffness since arising ),C0332284;C0457086;C1522634;C4019053;C4318616
754,question $nmbr$ ( length of morning stiffness since arising ),C0332284;C0457086;C1444754;C1522634;C1706316;C4019053;C4318616
753,voiding subscore,C0042034;C4067975
753,rectal bleeding subscore {,C0018932;C0267596
753,rectal bleeding subscore,C0018932;C0267596
753,mean ipss  voiding subscore ( sd ),C0042034;C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063;C4067975
753,irritative subscore,C0441723;C1706307;C2700617
753,ipss voiding subscore,C0042034;C1019118;C1998280;C2827405;C3811063;C4067975
752,sulphonylureas,C0038766
752,sulphonylurea,C0038766;C3536898
752,sulfonylureasb,
752,sulfonylureas,C0038766;C3653359
752,sulfonylureaa,
752,sulfonylurea — no . ( % ),C0038766;C3536898
752,sulfonylurea use at baseline,C0038766;C0042153;C0168634;C0457083;C1442488;C1947944;C3536898
752,sulfonylurea derivatives,C0038766
752,sulfonylurea based,C0038766;C1527178;C1705938;C3536898
752,sulfonylurea,C0038766;C3536898
752,other sulfonylurea 一 no . ( % ),C0038766;C3536898
752,on sulfonylurea,C0038766;C3536898
752,non - sulfonylurea secretagogues,C0038766;C1518422;C3536898;C4704833
752,metformin + sulphonylureas,C0025598;C0038766
752,insulin + sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
752,insulin + metformin + sulphonylureas,C0021641;C0025598;C0038766;C1533581;C1579433;C3714501
752,duration of sulphonylurea use ( months )  mean ± s . d .,C0038766;C0439231;C0444504;C1881378;C2347634;C2348143;C2826775;C3536898
752,any sulfonylurea,C0038766;C3536898
751,st george ' s respiratory questionnaire total score !,C0439175;C0439810;C3472502
751,score on st . george ' s respiratory questionnaire ^ ^,C3472502
751,score on asthma control questionnaire * *,C4706265
750,mean aqlq total score t,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236;C4055434
750,aqlq ( s ) + $nmbr$ scorets,C4055434
749,physical component score ( pcs ),C0449432;C1705248;C1864389;C1882368;C4483112
749,pcs score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1864389;C1882368;C1947916;C4050231
749,pcs score,C0449820;C1864389;C1882368;C4050231
749,lithe,
749,iwqol - lite physical score ( arbitrary units ),C0439183;C4483112
748,— $nmbr$ . $nmbr$ < fn t - score < — $nmbr$ . $nmbr$,C0449820;C1570610;C4050231
748,— $nmbr$ . $nmbr$ < fn t - score,C0449820;C1570610;C4050231
748,womac score,C0449820;C4050231
748,womac function score,C0031843;C0449820;C0542341;C0700205;C1705273;C4050231
748,weekly size of largest hives score {,C0042109;C0332174;C0443228;C0449820;C0456389;C4050231
748,weekly number of hives score {,C0042109;C0237753;C0332174;C0449788;C0449820;C4050231
748,weekly number of hives score $nmbr$,C0042109;C0237753;C0332174;C0449788;C0449820;C4050231
748,vadas score *,C0449820;C4050231
748,updrs score,C0449820;C3639721;C4050231
748,tlmi risk score,C0035647;C0449820;C4050231;C4552904
748,timi score,C0449820;C4050231
748,timi risk score — no . / total no . ( % ) f,C0016327;C0035647;C0439175;C0439810;C0449820;C4050231;C4552904
748,timi risk score — no . ( % ) : t,C0035647;C0449820;C2603360;C4050231;C4552904
748,timi risk score — %,C0035647;C0449820;C4050231;C4552904
748,timi risk score > $nmbr$  %,C0035647;C0449820;C4050231;C4552904
748,timi risk score *,C0035647;C0449820;C4050231;C4552904
748,timi risk score ( interaction : p = $nmbr$ . $nmbr$ ),C0035647;C0449820;C1704675;C4050231;C4552904
748,timi risk score !,C0035647;C0449820;C4050231;C4552904
748,timi risk score  %,C0035647;C0449820;C4050231;C4552904
748,timi risk score,C0035647;C0449820;C4050231;C4552904
748,tim $nmbr$ nsk score,C0449820;C1313407;C3541335;C3711667;C3827754;C3890185;C4050231;C4319633
748,target nail napsi score ( $nmbr$ – $nmbr$ scale ),C0027342;C0175659;C0349674;C0449820;C1432728;C1521840;C1947916;C2986546;C3538766;C4050231
748,stroke risk score,C0449820;C1277291;C4050231
748,st - segment deviation timi risk score  %,C0012727;C0035647;C0036056;C0205419;C0429029;C0429066;C0441635;C0449820;C1114722;C1116089;C1705236;C3272372;C4050231;C4552904
748,sss score,C0037052;C0449820;C0723181;C4050231
748,significant worsening in kccq clinical score ( ≥ $nmbr$ ) at $nmbr$ mo †,C0026544;C0332177;C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
748,shs ( $nmbr$ - $nmbr$  per $nmbr$ score ),C0449820;C4050231
748,score 一 no . ( % ),C0449820;C4050231
748,score on modified rankin scale — no . ( % ) §,C0449820;C2984908;C3854213;C4050231
748,score on modified rankin scale ( ' % / ',C0449820;C2984908;C3854213;C4050231
748,score of > $nmbr$ . $nmbr$ — %,C0449820;C4050231
748,score of $ $nmbr$  no . ( % ),C0449820;C4050231
748,score of # $nmbr$  no . ( % ),C0449820;C4050231
748,score > $nmbr$ . $nmbr$,C0449820;C4050231
748,score > $nmbr$ %  % of patients,C0030705;C0449820;C4050231
748,score $nmbr$ . $nmbr$,C0449820;C4050231
748,score $nmbr$ - $nmbr$,C0449820;C4050231
748,score  no . ( % ),C0449820;C4050231
748,score  %,C0449820;C4050231
748,score,C0449820;C4050231
748,schwab & england score,C0014282;C0449820;C4050231
748,rope score * *,C0449820;C1563164;C4050231
748,rope score,C0449820;C1563164;C4050231
748,rentrop score,C0449820;C4050231
748,patients with mild pain ( womac pain score  $nmbr$ - $nmbr$ ),C0030705;C0278138;C0449820;C0582148;C2945599;C4050231;C4522280
748,nvf at flex baseline - $nmbr$ < flex fn t - score,C0168634;C0449820;C1442488;C1570610;C4050231
748,npi - $nmbr$ score *,C0449820;C1412208;C1549728;C3539727;C4050231
748,normalized womac score,C0449820;C1882115;C4050231
748,nihss score,C0449820;C1697238;C4050231
748,napsi score ( $nmbr$ - $nmbr$ ) of target fingernail,C0222001;C0449820;C1521840;C2986546;C4050231
748,modified rankin score,C0392747;C0449820;C3889737;C4050231
748,modified rankin scale score,C0449820;C2984908;C3854213;C4050231
748,midas score,C0449820;C1309950;C1423498;C4049617;C4050231
748,mhis score,C0449820;C4050231
748,mcs score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1947916;C4050231
748,mcs score,C0449820;C4050231
748,ls t - score < — $nmbr$ . $nmbr$,C0023668;C0449820;C4050231
748,leeds enthesitis index ^ score > $nmbr$ — no . { % ),C0449820;C0451148;C4050231
748,kccq score,C0449820;C3476798;C4050231
748,karnofsky score 竺 $nmbr$,C0206065;C0449820;C4050231
748,karnofsky score < $nmbr$,C0206065;C0449820;C4050231
748,jsn score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1947916;C4050231
748,jsn score ( $nmbr$ - $nmbr$ ),C0449820;C4050231
748,jsn score  mean $nmbr$ sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
748,jsn score,C0449820;C4050231
748,joint space narrowing score  mean ( sd ),C0444504;C0449820;C1859695;C2347634;C2348143;C2699239;C4050231
748,joint space narrowing score,C0449820;C1859695;C4050231
748,ibdq score |,C0449820;C4050231
748,ibdq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
748,hit - $nmbr$ score,C0272285;C0332159;C0449820;C1708373;C4050231
748,gds score *,C0449820;C0451184;C1149049;C1418244;C4050231
748,fn t - score < — $nmbr$ . $nmbr$,C0449820;C1570610;C4050231
748,fn t - score < = - $nmbr$ . $nmbr$ ( % ),C0449820;C1570610;C4050231
748,flex fn f - score < - $nmbr$ . $nmbr$,C0016327;C0449820;C1570610;C4050231
748,flex baseline bmd t - score at femoral neck ( meanisd ),C0015815;C0168634;C0449820;C1442488;C4050231
748,first primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ ),C0205225;C0205435;C0332174;C0392747;C0439230;C0439612;C0439631;C0443172;C0449820;C1279901;C1705241;C3639721;C4050231;C4319952
748,femoral neck t - score,C0015815;C0449820;C4050231
748,femoral neck bmd t - score,C0015815;C0449820;C4050231
748,facit - f score,C0449820;C3272505;C4050231
748,edss score,C0449820;C0451246;C3887783;C4050231
748,crusade score,C0449820;C4050231
748,crusade bleeding score  mean ( sd ) ^,C0019080;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
748,crusade bleeding score,C0019080;C0449820;C4050231
748,crohn ' s disease activity index score ],C0449820;C0451071;C4050231
748,chf score ( u ),C0018802;C0439148;C0449820;C4050231
748,change from baseline to week $nmbr$ in weekly no . of hives score,C0042109;C0168634;C0332174;C0392747;C0439230;C0443172;C0449820;C1442488;C1705241;C4050231;C4319952
748,change from baseline in aqlq { s ) score,C0168634;C0392747;C0443172;C0449820;C1442488;C1705241;C4050231;C4055434;C4319952
748,cha $nmbr$ s $nmbr$ score,C0449820;C1420648;C4050231
748,ccq score § §,C0449820;C4050231
748,cadillac score,C0449820;C4050231
748,bii score,C0449820;C1413059;C4050231
748,baseline nihss score ( % ) #,C0168634;C0449820;C1442488;C1697238;C4050231
748,baseline nihss score  median ( range ),C0168634;C0449820;C0549183;C0876920;C1442488;C1514721;C1697238;C2347635;C2348144;C2348147;C2939193;C3542016;C4050231
748,baseline dyspnea index score,C0449820;C1511069;C4050231
748,baseline bmd t score at femoral neck,C0015815;C0168634;C0449820;C1442488;C4050231
748,aqlq score  mean,C0444504;C0449820;C2347634;C2348143;C4050231;C4055434
748,aqlq score,C0449820;C4050231;C4055434
748,aqlq ( si + $nmbr$ score ’,C0449820;C4050231;C4055434
748,aqlq ( s ) score,C0449820;C4050231;C4055434
748,aqlq ( s ) + $nmbr$ scored,C0449820;C4055434
748,aqlq ( s ) + $nmbr$ score : §,C0449820;C4050231;C4055434
748,admission grace score,C0184666;C0449820;C0809949;C4050231
748,accp score,C0449820;C4050231
748,abbreviations : ace  angiotensin - converting enzyme  iqr  interquartile range  ml  myocardial infarction . si conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * data are expressed as no . / total ( % ) unless otherwise specified . festimated using cockroft - gault equation . tthe timi risk score was used to categorize patients at low ( $nmbr$ - $nmbr$ )  intermediate ( $nmbr$ - $nmbr$ )  and high ( $nmbr$ - $nmbr$ ) risk . $nmbr$,C0000723;C0021308;C0022709;C0027061;C0030705;C0035647;C0040363;C0041260;C0205103;C0205250;C0205251;C0205369;C0439175;C0439390;C0439526;C0439810;C0439836;C0449820;C0552449;C0812399;C0871968;C1273517;C1299351;C1511726;C1514721;C1522564;C1524063;C1550465;C1550472;C1705224;C1719797;C1883351;C2348147;C2700149;C2827755;C2911648;C3245479;C3542016;C3714741;C3887512;C3887665;C3889660;C3889971;C3890211;C4048187;C4050231;C4321237;C4321351;C4522209;C4522223;C4552904
748,- $nmbr$ < flex fn f - score,C0016327;C0449820;C1570610;C4050231
748,- $nmbr$ . $nmbr$ < ls t - score < — $nmbr$ . $nmbr$,C0023668;C0449820;C4050231
748,- $nmbr$ . $nmbr$ < ls t - score,C0023668;C0449820;C4050231
748,- $nmbr$ . $nmbr$ < flex fn f - score < - $nmbr$,C0016327;C0449820;C1570610;C4050231
747,target vessel diameter,C0449618;C1301886
747,target vessel,C0449618
747,target - vessel revascularization,C0449618;C0581603
747,number of target vessels,C0237753;C0449618;C0449788
747,no . of target vessels,C0449618
747,large vessel atherosclerosis,C0003850;C0004153;C0225990
747,large vessel,C0225990
746,two - vessel disease,C0581375
746,triple - vessel disease  n ( % ),C0856738
746,three - vessel disease,C3272265
746,small vessel,C0225988
745,vessels with stenosis > $nmbr$ %,C0679403
745,stented vessels,C0183521
745,stented vessel,C0183521
745,non - stenotic vessels  n ( % ),C0679403;C1518422
745,> $nmbr$ vessels with > $nmbr$ % stenosis,C0679403
744,variable_level,C0439828;C0441889;C0456079;C1547707;C2946261;C4553760
744,troponin level,C0041199;C0441889;C0456079;C1547707;C2946261
744,risk factors and immobility level  n ( % ),C0035648;C0231441;C0441889;C0456079;C1547707;C1553898;C2946261
744,no active cancer center - level inr percent time,C0040223;C0205177;C0439165;C0441889;C0456079;C0525032;C1513817;C1547707;C1704538;C2946261;C3541383;C3853793;C3888249
744,mean — mm hg level — no . ( % ),C0439475;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
744,level — no . ( % ),C0441889;C0456079;C1547707;C2946261
744,level $nmbr$ immobility § | |,C0231441;C0441889;C0456079;C1547707;C2946261
744,level $nmbr$ immobility ^,C0231441;C0441889;C0456079;C1547707;C2946261
744,level $nmbr$,C0441889;C0456079;C1547707;C2946261
744,hscrp level,C0441889;C0456079;C1547707;C2946261
744,geometric anti - dsdna antibody binding level,C0441889;C0449829;C0456079;C1145667;C1167622;C1547707;C2355607;C2746079;C2946261
744,european quality of life - $nmbr$ dimensions - $nmbr$ level ( eq - $nmbr$ d ),C0034380;C0205163;C0239307;C0439185;C0439534;C0441889;C0456079;C0518214;C1535514;C1547707;C2946261
744,elevated natriuretic peptide level ( n = $nmbr$ ),C0205250;C0441889;C0456079;C1144709;C1547707;C2709270;C2946261;C3163633;C3537020
744,characteristic_level,C0441889;C0456079;C1521970;C1547707;C2946261
744,center level ttr,C0032923;C0205099;C0441889;C0456079;C1421224;C1547707;C2946261;C3810851
744,cardiac troponin t level > $nmbr$ . $nmbr$ pg / l,C0439278;C0441889;C0456079;C1547707;C2946261;C3538889
744,cardiac troponin t level  median ( iqr )  pg / l,C0439278;C0441889;C0456079;C0549183;C0876920;C1547707;C2347635;C2348144;C2939193;C2946261;C3538889
743,vessel treated  n,C0005847;C0369718;C0441922;C1522326
743,vascular territory # $nmbr$,C0005847;C1301808;C1558950;C1801960;C2983136
743,vascular intervention,C0005847;C0184661;C0886296;C1273869;C1558950;C1801960
743,vascular disordersb,C0005847;C1558950;C1801960
743,vascular accidents  n ( % ),C0000924;C0005847;C1558950;C1801960
743,vascular access site †,C0005847;C0205145;C0589360;C0750138;C1515974;C1558950;C1801960;C2825164
743,vascular,C0005847;C1558950;C1801960
743,urgent vascular hospitalization,C0005847;C0019993;C0439609;C1558950;C1801960;C3272275
743,treated vessel ( s ),C0005847;C1522326
743,treated vessel !,C0005847;C1522326
743,treated vessel,C0005847;C1522326
743,timi flow grade $nmbr$ of mi culprit vessel pre ‐ pci,C0005847;C0332152;C0441800;C0740175;C0919553;C2257086;C3244287;C3272266;C3669034;C3810814;C4049621
743,single vessel coronary artery diseasea,C0005847;C0265903
743,restenotic vessel,C0005847;C0333186
743,number of vessels treated  index pci,C0005847;C0237753;C0449788;C0600653;C0918012;C1522326;C1552854;C1637833;C2986546;C4049621
743,number of treated vessels ( per patient ),C0005847;C0030705;C0237753;C0449788;C1522326
743,number of treated vessels,C0005847;C0237753;C0449788;C1522326
743,number of diseased vessels  mean ( sd ),C0005847;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
743,no culprit vessel identified,C0005847;C0205396;C1550043
743,no . of vessels treated,C0005847;C1522326
743,no . of vessels,C0005847
743,no . of treated vessels,C0005847;C1522326
743,multi vessel ( or left main ),C0005847;C0205091;C0205225;C0439064;C0443246;C1542147;C1552822;C3266262
743,more than $nmbr$ vessels stented,C0005847;C0038257;C0205172
743,cvd / mi / stroke / revascularization / urgent vascular hospitalization,C0005847;C0007222;C0019993;C0038454;C0439609;C0581603;C1558950;C1801960;C3272275;C3810814;C4554100
743,culprit vessel,C0005847
743,any vascular diasease,C0005847;C1558950;C1801960
743,any vascular *   efficacy,C0005847;C1280519;C1558950;C1707887;C1801960
743,> $nmbr$ vessels treated,C0005847;C1522326
743,> $nmbr$ diseased vessels,C0005847
743,$nmbr$ vessels or left main,C0005847;C0205091;C0205225;C0443246;C1542147;C1552822
743,$nmbr$ vessels,C0005847
743,$nmbr$ vessel,C0005847
742,tnfi and other bdmardst  n ( % ),
742,otherx,
742,otherd,
742,other { n = $nmbr$ ),C0369718;C0441922
742,other vasculars,
742,other vascular disease ( cvd or pad )  %,C0007222;C0042373;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
742,other vascular disease,C0042373
742,other n ( % ),C0369718;C0441922
742,other * ( n = $nmbr$ ),C0369718;C0441922
742,other ( n — $nmbr$ ),C0369718;C0441922
742,other ( n   = $nmbr$ ),C0369718;C0441922
742,other ( n = $nmbr$ ),C0369718;C0441922
742,other ( n = $nmbr$  $nmbr$ ],C0369718;C0441922
742,other ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
742,other ( n  % ),C0369718;C0441922
742,other  n ( % ),C0369718;C0441922
742,extensive disease other,C0849867
742,dpi ( other than diskus )  n,C1553480
742,all other,
741,othersc,
741,others  n ( % ),C1955473;C3539125
741,others,C1955473;C3539125
741,otherc,
741,all others eteed for $nmbr$ mg edoxaban dose at,C1955473;C2975435;C3539125;C4086581
741,all others  n ( % ),C1955473;C3539125
741,all others,C1955473;C3539125
740,otherz,
740,otherf,
740,other osteoporosis medication,C0013227;C0029456;C3244316;C4284232;C4554622
740,other medication usage,C0013227;C0457083;C3244316;C4284232
740,other glucose - lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
740,other drugs — no . ( % ),C0013227;C3687832
740,other drugs,C0013227;C3687832
740,other * ’,
740,any other antihyperglycaemic drugs,C0013227;C0020616;C3687832
739,upper tertile : > $nmbr$ . $nmbr$,C1282910
739,upper,C1282910
739,none of the above,C1282910;C1552828
739,history of upper gl events ( perforations  ulcers  bleeding )  n ( % ),C0018229;C0019080;C0019664;C0019665;C0041582;C0262512;C0262926;C0369718;C0441471;C0441922;C0549099;C1282910;C1423073;C1427674;C1705255;C2004062;C3541888
739,any of the above,C1282910;C1552828
739,all of the above,C1282910;C1552828
738,one - vessel disease,C3275121
738,noneh,
738,none 一 no . ( % ),
738,none ( n = $nmbr$ ),C0369718;C0441922
738,none,
737,one vessel,C0005847;C0205447
737,one tnfi and,C0205447
737,one tnfi *,C0205447
737,one of the above,C0205447
737,one lesion,C0205447;C0221198;C1546698
736,time since psa onset  mean years ( sd ),C0040223;C0206132;C0332162;C0439234;C0444504;C2347634;C2348143;C2699239;C3541383;C3810537;C3813209
736,time since onset ( h ),C0033727;C0040223;C0206132;C0332162;C0369286;C0441932;C0564385;C3541383;C4528284
736,since onset,C0206132;C0332162
736,onset of chest pain,C0024902;C0206132;C0332162
736,onset $nmbr$ [ $nmbr$ ],C0206132;C0332162
736,age of onset < $nmbr$ years ( n = $nmbr$ ),C0206132;C0439234;C3175530
736,age of onset $nmbr$ years ( n = $nmbr$ ),C0206132;C0439234;C3175530
736,age of onset,C0206132;C3175530
736,age of asthma onset  years,C0004096;C0206132;C0439234;C2984299;C3175530
736,age at onset  y,C0206132;C3870509
736,age at disease onset  years *,C0012634;C0206132;C0439234;C3870509
736,age at disease onset  n ( % ) *,C0012634;C0206132;C3870509
735,lower - target group ( n = $nmbr$ ),C0441848;C0441994;C1521840;C1548802;C2003888;C2986546
735,higher - target group ( n = $nmbr$ ),C0205250;C0441848;C1521840;C2986546
735,average daily dose ( % of target ) *,C1510992;C1521840;C2348070;C2825518;C2986546
735,( % of target ) ∗,C1521840;C2986546
734,suit index  nmol / mmol,C0600653;C0918012;C1532564;C1533073;C1552854;C1637833;C2986546
734,qualifying index event as pe,C0070939;C0441471;C0600653;C0918012;C1514624;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
734,percutaneous coronary intervention or coronary - artery bypass grafting for index acute coronary syndrome — no . { % ),C0010055;C0600653;C0918012;C0948089;C1532338;C1552854;C1637833;C2986546
734,pci for index mi ( % ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814;C4049621
734,nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
734,mean slicc damage index score ± sd,C0010957;C0600653;C0918012;C1552854;C1637833;C1883709;C2699239;C2986546;C3533236
734,mean preoperative abpi of the index,C0444504;C0445204;C0600653;C0918012;C1552854;C1637833;C2347634;C2348143;C2986546
734,mass index,C0577559;C0577573;C0600653;C0918012;C1096155;C1306372;C1552854;C1637833;C2986546;C3152252;C3539882;C4283905
734,lv mass index ( g / m $nmbr$ - $nmbr$ ),C0455825;C0456715;C0600653;C0918012;C1552854;C1637833;C2986546
734,labs at the index acs event,C0441471;C0587081;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
734,interval after index event,C0441471;C0600653;C0918012;C1272706;C1552654;C1552713;C1552854;C1637833;C2986546;C4019010
734,insulinogenic index ( dinsulino_ $nmbr$ o min / dglucoseo - $nmbr$ o min ),C0600653;C0702093;C0918012;C1524029;C1552854;C1637833;C2986546;C3813700
734,indication for index procedure,C0600653;C0918012;C1552854;C1637833;C2315323;C2986546
734,index pe : event during,C0070939;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
734,index mi ( n - $nmbr$  $nmbr$ ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814
734,index inclusion acute coronary syndrome,C0007637;C0600653;C0918012;C0948089;C1512693;C1552854;C1637833;C2986546
734,index event subtype,C0441471;C0449560;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
734,index event  %,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
734,index diagnosis,C0011900;C0600653;C0918012;C1552854;C1637833;C1704338;C1704656;C2986546
734,index acute coronary syndrome — no . { % ),C0600653;C0918012;C0948089;C1552854;C1637833;C2986546
734,extent of index event,C0439792;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
734,extent of index dvt ' ( n  % of dvt patients ' ),C0030705;C0149871;C0439792;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
734,disposition index,C0600653;C0743223;C0918012;C1552854;C1637833;C1705555;C2986546
734,des type at index procedure,C0011702;C0455713;C0600653;C0918012;C1552854;C1637833;C2986546;C4551552
734,coronary angiography during the index hospitalization,C0002978;C0019993;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546
734,cornell index  pv,C0030840;C0032463;C0600653;C0918012;C1552854;C1637833;C2986546
734,composite physiologic index §,C0205199;C0205463;C0600653;C0918012;C1547335;C1552854;C1637833;C2986546
734,clinical indication at the index procedure  n ( % ),C0205210;C0600653;C0918012;C1552854;C1637833;C2315323;C2347896;C2986546
734,classification of index venous thromboembolism — no . ( % ),C0008902;C0008903;C0600653;C0678229;C0918012;C1552854;C1637833;C1997614;C2986546
734,charlson index ( % ),C0600653;C0918012;C1552854;C1637833;C2986546
734,at index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
734,at index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
734,angiography during index hospitalization,C0002978;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
733,reversible to bronchodilator  b %,C0006280;C0205343
733,reversible to albuterolc  d  n ( % ),C0205343
733,reversible ( % ),C0205343
733,reversible,C0205343
733,nonreversible,
733,non - reversible ( % ),C0205343;C1518422
733,cluster $nmbr$ : not reversible  no diuretic ( n = $nmbr$ ),C0012798;C0205343;C1518422;C1555715;C1704332
733,associated with transient or reversible risk factor,C0035648;C0040704;C0205343;C0205374;C0332281
732,measured at home with automated device,C0025080;C0205554;C0444706;C0699733;C3541902;C4534363
732,measured at clinic visit with usual device,C0008952;C0025080;C0444706;C0699733;C3538928;C3541902
732,measured at clinic visit with automated device §,C0008952;C0025080;C0205554;C0444706;C0699733;C3541902
732,devices,C0025080;C0220819;C0699733
732,device group ( n = $nmbr$ ),C0025080;C0441848;C0699733
731,recervng,
731,recervini },
731,receiving antihypertensive treatment -,C0003364;C0039798;C0087111;C1514756;C1522326;C1533734;C1705169;C3538994;C3887704
731,receiving antihypertensive,C0003364;C1514756
731,received pci,C1514756;C4049621
731,received antihypertensive within last $nmbr$ days  n ( % ),C0003364;C0439228;C1514756
731,received $nmbr$ prior biologic therapy  n,C0278947;C1514756
731,received $nmbr$ prior biologic therapies  n,C0278947;C1514756
731,patients who received positive results on test for antibodies to infliximabt,C0003241;C0030705;C1335447;C1514756
731,patients who received negative results on test for antibodies to infliximabt,C0003241;C0030705;C1334932;C1514756
731,patients who received $nmbr$ or $nmbr$ drugs,C0013227;C0030705;C1514756;C3687832
731,patients who received $nmbr$ drug,C0013227;C0030705;C1254351;C1514756
731,patients receiving mtx  n =,C0025677;C0030705;C1417487;C1514756
731,patients receiving mtx,C0025677;C0030705;C1417487;C1514756
731,patients not receiving mtx  n =,C0025677;C0030705;C1417487;C1514756;C1518422
731,not receiving,C1514756;C1518422
730,seizure reduction from baseline,C0036572;C0168634;C0301630;C0392756;C1293152;C1442488;C1959629;C4551656;C4553401
730,reduction of hba $nmbr$ c from baseline ≥ $nmbr$ . $nmbr$ %,C0019016;C0168634;C0301630;C0392756;C1293152;C1442488;C1825777;C3538758;C4551656
730,reduction in odds %,C0301630;C0392756;C1293152;C4551656
730,rate reduction ( % ),C0301630;C0392756;C0871208;C1293152;C1521828;C4551656
730,osteoprotegerin decreased,C0205216;C0392756;C0442797;C0538161;C1308614;C1336645
730,ocs reduced / stopped,C0392756;C1272691
730,% reduction,C0301630;C0392756;C1293152;C4551656
730,$nmbr$ ‐ point reduction in selena – sledai score  %,C0301630;C0392756;C0449820;C0451528;C1293152;C1552961;C2347617;C3714763;C4050231;C4551656
-10,= cerebrospinal fluid .,C0007806;C0007807
728,without cerebrovascular disease,C0007820
728,with cerebrovascular disease,C0007820
728,stroke or cerebrovascular disease,C0007820;C0038454;C4554100
728,prior cerebrovascular disease,C0007820;C0332152;C2826257
728,only cerebrovascular disease,C0007820;C0205171;C1720467
728,ischemic cerebrovascular disease  n ( % ),C0007820;C0475224
728,cerebrovascular disorders  n ( % ),C0007820
728,cerebrovascular disease n ( % ),C0007820
728,cerebrovascular disease  n ( % ),C0007820
728,cerebrovascular disease  %,C0007820
728,cerebrovascular disease,C0007820
728,cerebral vascular disease,C0007820
727,sri ‐ $nmbr$ response rate  %,C0237629;C1420401
727,n ( % ) responders,C0369718;C0441922
727,all responders  ( n = $nmbr$ ),
726,trough fvc response ( l ) !,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
726,trough fvc response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
726,trough fev | response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
726,trough fev $nmbr$   response,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
726,trough fev  response ( l ) i,C0021966;C0221138;C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
726,stratum $nmbr$ : inadequate response or intolerance to > $nmbr$ bdmards of same moa or > $nmbr$ of multiple moa,C0205412;C0231199;C0439064;C0439856;C0445247;C0871261;C1704632;C1706817;C1744706;C2355652;C2911692;C4551881
726,stratum $nmbr$ : inadequate response or intolerance to $nmbr$ - $nmbr$ bdmards of same moa,C0205412;C0231199;C0439856;C0445247;C0871261;C1704632;C1706817;C1744706;C2355652;C2911692;C4551881
726,sri response  %,C0871261;C1420401;C1704632;C1706817;C2911692
726,previous loss of response to infliximab  n ( % ) *,C0205156;C0666743;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
726,previous loss of response to and intolerance of infliximab  n ( % ) *,C0205156;C0231199;C0666743;C0871261;C1517945;C1552607;C1704632;C1706817;C1744706;C2355652;C2911692
726,peak fev $nmbr$ ( $nmbr$ - $nmbr$ h )   response,C0033727;C0369286;C0441932;C0444505;C0564385;C0871261;C1704632;C1706817;C2911692;C3714541;C4528284
726,patients with previous loss of response to infliximab,C0030705;C0205156;C0666743;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
726,pasi response by baseline weight  no . / total no . ( % ) * pasi $nmbr$,C0439175;C0439810;C0871261;C1303013;C1704632;C1706817;C2911692;C4528685
726,pasi $nmbr$ response },C0871261;C1704632;C1706817;C2911692;C4528685
726,omeract - oarsi response,C0871261;C1704632;C1706817;C2911692
726,loss of response ‘ s,C0871261;C1517945;C1704632;C1706817;C2911692
726,loss of response ®,C0871261;C1517945;C1704632;C1706817;C2911692
726,loss of response : ! : : ! :,C0871261;C1517945;C1704632;C1706817;C2911692
726,loss of response,C0871261;C1517945;C1704632;C1706817;C2911692
726,inadequate response / intolerance to prior therapy  %,C0039798;C0087111;C0205412;C0231199;C0332152;C0439856;C0871261;C1363945;C1704632;C1706817;C1744706;C2355652;C2911692
726,inadequate response ' ’ ',C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
726,inadequate response ' ^,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
726,inadequate response,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
726,eular good response,C0205170;C0871261;C1704632;C1706817;C2911692
726,bronchodilator response  ml,C0006280;C0439526;C0871261;C1704632;C1705224;C1706817;C2911692;C3887665
725,medical treatment  n ( % ),C0679624
725,medical treatment,C0679624
725,hypertension requiring treatment,C0578998
725,hypertension requiring medical treatment,C0020538;C0679624;C1963138
725,hypertension  receiving treatment  n ( % ),C0578998;C1514756
725,conventional treatment ( n = $nmbr$ ),C2945704
725,conventional treatment,C2945704
724,≥ $nmbr$ teae,
724,insulin treatment  n ( % ),C0745343
724,insulin treatment,C0745343
724,abbreviations :   teae  treatment - emergent adverse event  gly  glycopyrrolate inhalation solution  bid  twice daily .,C0000723;C0017890;C0017970;C0523677;C0585361;C1154181;C4684800
723,naive : no,
723,naive ( no treatment for current flare ),C1517205;C2827774;C3540542
723,active treatment,C1704532
722,transient st elevation,C0040704;C0205374;C0520886
722,transient,C0040704;C0205374
722,prior transient ischaemic,C0040704;C0205374;C0332152;C0475224;C2826257
721,prevalent cvd,C0007222;C0033105;C0220900
721,fracture status prevalent vertebral fractured,C0016658;C0033105;C0220900;C0449438;C0549207;C4554413
720,sufficient,C0205410
720,j $nmbr$ coefficient,C1707429
720,coefficient,C1707429
719,persistent wrf ( n = $nmbr$ ),C0205322;C0332996
719,persistent or paroxysmal,C0205311;C0205322;C0332996
719,persistent faol ( n [ $nmbr$ ),C0205322;C0332996
719,persistent faod ( n [ $nmbr$ ),C0205322;C0332996
719,persistent af  n ( % ),C0205322;C0332996;C0344434;C4049859
719,persistent af,C0205322;C0332996;C0344434;C4049859
719,persistent *,C0205322;C0332996
719,persistent ( n  % ),C0205322;C0332996
719,persistent  n ( % ),C0205322;C0332996
719,persistent,C0205322;C0332996
719,persisent,
719,no persistent wrf ( n = $nmbr$  $nmbr$ ),C0205322;C0332996
719,long - standing persistent,C0205166;C0205322;C0231472;C0332996;C1706317
718,persistent or permanent immobilization,C0020944;C0205322;C0205355;C0332996;C4048292
718,persistent / permanent,C0205322;C0205355;C0332996
718,permanent users  n,C0205355;C1706077
718,permanent users,C0205355;C1706077
718,permanent af,C0205355;C0344434;C4049859
718,permanent ( n  % ),C0205355
718,permanent  n ( % ),C0205355
718,permanent,C0205355
717,treatment throughout study,C1521826;C3161471
717,study treatment — no . / total no . ( % ),C0439175;C0439810;C1521826
717,study treatment,C1521826
717,standard treatment ( n - $nmbr$ ),C4684780
717,prior treatment status,C0332152;C0449438;C0749659;C1514463;C2826257
717,previously failed anti - tnf treatment  no . ( % ),C0039798;C0087111;C0231175;C1448177;C1522326;C1533734;C1705169;C3538994;C3887704
717,previously,
717,previous treatment in the healing study  n ( % ),C0043240;C0205156;C0205249;C1521826;C1552607;C3161471
717,prestudy treatment status,C0749659
717,continued treatment study,C0549178;C3161471
716,treatment satisfaction,C3476649
716,rank based on treatment   =   placebo,C0032042;C0667477;C0699794;C1527178;C1696465;C1705938;C1706408;C4684449
716,planned treatment duration  n ( % ),C4528394
716,past treatment for paod,C2945691
716,on - treatment,C4684449
716,methotrexate treatment !,C0746573
715,with laba  n ( % ) pretreatment,C1550147;C2709094;C3539075;C3539076
715,pretreatment hdl - c,C1550147;C2709094;C3539075;C3539076;C3715113
715,pre - treatment [ n ( % ) ] c,C1550147;C2709094;C3539075;C3539076
715,no pretreatment,C1550147;C2709094;C3539075;C3539076
714,bb after randomisation,C0004739;C0034656;C0332297
714,bb,C0004739;C0332297
714,acei / arb and bb after randomisation,C0004739;C0034656;C0332297;C3888198
714,- < — ■ bb — - ►,C0004739;C0332297
713,subjects stratified by baseline pra,C0168634;C0205363;C0633231;C0681850;C1141951;C1419788;C1442488;C1550501;C1706203;C2349001;C2697811;C3274822;C3669212;C4283900
713,stratified by,C0205363
712,≥ $nmbr$ bpm ( n = $nmbr$ ),
712,pulse rate ( mean $nmbr$ h )  bpm *,C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
712,pulse rate ( bpm ),C0232117
712,pulse rate  bpm ( mean $nmbr$ h )  mean ( sd ) *,C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
712,heart rate at baseline ( bpm,C0018810;C0168634;C1442488
712,heart rate at baseline  bpm,C0018810;C0168634;C1442488
712,heart rate > $nmbr$ bpm,C0018810
712,heart rate < $nmbr$ bpm,C0018810
712,heart rate ( sd )  bpm blood pressure  mm hg,C0005823;C0018810;C0439475;C1271104;C1272641;C2699239
712,heart rate ( sd )  bpm,C0018810;C2699239
712,heart rate  mean ( sd )  bpm ( n = $nmbr$ $nmbr$ ),C0018810;C0444504;C2347634;C2348143;C2699239
712,heart rate  bpm  mean ( sd ),C0018810;C0444504;C2347634;C2348143;C2699239
712,heart rate  bpm,C0018810
712,> $nmbr$ bpm ( n = $nmbr$ ),
712,< $nmbr$ bpm ( n = $nmbr$ ),
712,< $nmbr$ . $nmbr$ bpm,
711,trough seated hr ( bpm ) a,C0277814;C0444506;C1283233
711,seated sbp  n,C0085805;C0277814;C1283233
710,obesity t,C0028754;C1963185
710,obesity * ( bm $nmbr$ > $nmbr$ kg / m $nmbr$ ),C0006416;C0028754;C1532718;C1963185
710,obesity *,C0028754;C1963185
710,obesity ( % ) §,C0028754;C1963185
710,obesity  % *,C0028754;C1963185
710,obesity,C0028754;C1963185
710,obese ( > $nmbr$ kg / m $nmbr$ ) b,C0028754;C1532718
710,obese ( > $nmbr$ kg / m $nmbr$ ),C0028754;C1532718
710,obese,C0028754
710,> $nmbr$  obesity class $nmbr$,C0028754;C0456387;C1518526;C1705943;C1963185
710,( scale obesity and prediabetes ),C0028754;C0175659;C0349674;C0362046;C1947916;C1963185
710,$nmbr$ - $nmbr$ - $nmbr$  obesity class $nmbr$,C0028754;C0456387;C1518526;C1705943;C1963185
709,volumetric bmd by qct,C0412669;C0445383
709,lost bmd,C0745777;C3815882
709,gained bmd,C1517378
708,form / bud,C0348078;C0376315;C1522492;C2700462;C2945744;C4255237
708,bud / fm $nmbr$ / $nmbr$ atg n = ^ $nmbr$,C2700462;C2945744;C3540627;C3815109
708,bud $nmbr$ ptg n = $nmbr$,C0039512;C1418830;C2700462;C2945744
707,timi - defined bleeding,C0019080;C1704788;C3539106
707,primary + gusto severe bleeding,C0019080;C0205082;C0205225;C0439612;C0439631;C4050465;C4050466
707,primary + gusto moderate or severe bleeding,C0019080;C0205081;C0205082;C0205225;C0439612;C0439631;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
707,has - bled score ’,C0019080;C0449820;C4050231
707,has - bled score > $nmbr$,C0019080;C0449820;C4050231
707,has - bled score,C0019080;C0449820;C4050231
707,has - bled > $nmbr$,C0019080
707,has - bled $nmbr$ - $nmbr$,C0019080
707,gusto severe bleed,C0019080;C0205082;C4050465;C4050466
707,gusto moderate / severe bleed,C0019080;C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
707,gusto - defined bleeding,C0019080;C1704788;C3539106
707,gusto - bleeding severe / moderate,C0019080;C1299393
707,fatal bleeding,C0019080;C1302234;C1705232
707,fatal bleed,C0019080;C1302234;C1705232
707,bleeding outcomes,C0019080;C1274040
707,bleeding events during the entire study,C0019080;C0439751;C0441471;C0444667;C0557651;C2603343;C3541888
707,bleeding events during first $nmbr$ days of treatmen,C0019080;C0205435;C0439228;C0441471;C1279901;C3541888
707,bleeding,C0019080
707,any timi bleeding,C0019080
707,any overt bleed,C0019080
707,any gusto bleeding,C0019080
707,any bleeding,C0019080
707,all bleeding,C0019080
707,all bleed,C0019080
707,acuity - defined bleeding,C0019080;C0750509;C1704788;C3539106
706,cyclo,C1172566
706,crcl < $nmbr$,C1846718
706,crcl $nmbr$ - $nmbr$,C1846718
706,crci > $nmbr$ - < $nmbr$,
706,crci > $nmbr$,
706,admission crcl,C0184666;C0809949;C1846718
706,> $nmbr$ years or < $nmbr$ crcl  n ( % ),C0439234;C1846718
706,> $nmbr$ crcl,C1846718
706,< $nmbr$ crcl  n ( % ),C1846718
706,< $nmbr$ crcl,C1846718
706,$nmbr$ - $nmbr$ crcl,C1846718
705,rs $nmbr$ ( cc ) & rs $nmbr$,C0008318;C0035970;C3538933;C3714753;C3813325
705,cc,C0008318;C3538933
704,olmesartan along with ccb ( n - $nmbr$ ),C0006684;C1098320
704,olmesartan / ccb - olmesartan / diuretic,C0006684;C0012798;C1098320
704,dihydropyridine ccbs,C0006684;C0012315;C0220821
704,ccbs  ( % ),C0006684
704,ccb,C0006684
704,baseiine ccb,C0006684
704,arb = angiotensin ii receptor blocker  ccb,C0006684;C0521942;C3536793;C3888198
704,arb - arb / ccb,C0006684;C3888198
704,arb + ccb ( n = $nmbr$ ),C0006684;C3888198
703,women  > $nmbr$ cm,C0043210
703,women  < $nmbr$ cm,C0043210
703,wc ( cm ),C0013123;C2825512
703,mean wall thickness ( cm ),C0677535;C4054557
703,< - $nmbr$ . $nmbr$ cm,
702,waist ( cm ),C0230097
702,pulmonary vascular resistance  dyne • s • cm $nmbr$,C0308914;C0456261;C0488644;C0600130
701,mean bmd ( = sd )  g / cm $nmbr$,C0439267;C0444504;C2347634;C2348143;C2699239
701,mean ( sd ) bmd in g / cm $nmbr$,C0439267;C0444504;C2347634;C2348143;C2699239
701,flex baseline bmd  mean ( sd )  g / cm $nmbr$,C0168634;C0439267;C0444504;C1442488;C2347634;C2348143;C2699239
701,flex baseline bmd  g / cm ^ ( meanisd ),C0168634;C0439267;C1442488
701,femoral neck bmd ( g / cm $nmbr$ ),C0015815;C0439267
701,femoral neck ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd ),C0015815;C0439267;C2699239
701,cm,
701,bone mineral density ( g / cm $nmbr$ )  mean ( sd ),C0005938;C0177804;C0439267;C0444504;C2347634;C2348143;C2699239
701,> - $nmbr$ cm,
701,> $nmbr$ cm,
701,> $nmbr$ - $nmbr$ cm,
701,< $nmbr$ cm,
701,( cm ),
700,urine p / cr,C0042036;C0042037;C0201975;C2963137;C3539604;C3711669;C4084730;C4553336;C4553337
700,steroid - free cr - $nmbr$,C0038317;C0201975;C0332296;C1880497;C1996904;C3539604;C3711669;C4084730;C4553336;C4553337
700,crpnonr ?,
700,cr imputation ( random . ) ( n = $nmbr$ ),C0034656;C0201975;C0439605;C2699638;C3539604;C3711669;C4084730;C4553336;C4553337
700,cr + mh + crpnorr,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
700,cr + crpnorr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
700,albuminuria < $nmbr$ gram / gram cr,C0001925;C0201975;C1319635;C3539604;C3711669;C4084730;C4553336;C4553337
699,prior surgery for cd  n [ % ],C0007928;C0034283;C0455610;C4552032
699,prior surgery for cd  n ( % ),C0007928;C0034283;C0455610;C4552032
699,patients with eligible ses - cd score,C0007928;C0030705;C0034283;C0449820;C1548635;C4050231;C4552032
699,chadsj > $nmbr$,
699,chadsj < $nmbr$,
699,chadsa < $nmbr$,
699,chads score  n ( % ),C0007928;C0369718;C0441922;C0449820;C1413373;C4050231
699,chads score,C0007928;C0449820;C1413373;C4050231
699,chads - $nmbr$ score,C0007928;C0449820;C1413373;C4050231
699,chads $nmbr$   score    n   ( % ),C0007928;C0369718;C0441922;C0449820;C1413373;C4050231
699,chads $nmbr$ scoret,C0007928;C1413373
699,chads $nmbr$ scoref,C0007928;C1413373
699,chads $nmbr$ scoreb,C0007928;C1413373
699,chads $nmbr$ score per outcome stroke or systemic embolism,C0007928;C0013922;C0038454;C0205373;C0449820;C1274040;C1413373;C1704212;C4050231;C4554100
699,chads $nmbr$ score > $nmbr$,C0007928;C0449820;C1413373;C4050231
699,chads $nmbr$ score *,C0007928;C0449820;C1413373;C4050231
699,chads $nmbr$ score $nmbr$ - $nmbr$  n ( % ),C0007928;C0369718;C0441922;C0449820;C1413373;C4050231
699,chads $nmbr$ score $nmbr$,C0007928;C0449820;C1413373;C4050231
699,chads $nmbr$ score  n ( % ),C0007928;C0369718;C0441922;C0449820;C1413373;C4050231
699,chads $nmbr$ score,C0007928;C0449820;C1413373;C4050231
699,chads $nmbr$ risk factors  n ( % ),C0007928;C0035648;C1413373;C1553898
699,chads $nmbr$ ^,C0007928;C1413373
699,chads $nmbr$ < $nmbr$,C0007928;C1413373
699,chads $nmbr$,C0007928;C1413373
699,chad $nmbr$ > $nmbr$,C0007928;C1413373
699,cd duration  y,C0007928;C0034283;C0449238;C2926735;C4552032
699,cd complications,C0007928;C0009566;C0034283;C1171258;C4552032
699,cd [ gemini $nmbr$ ] * ’,C0007928;C0034283;C4552032
699,baseline chads $nmbr$ a  c,C0007928;C0168634;C1413373;C1442488
699,> $nmbr$ ( n  % ) chads $nmbr$ score,C0007928;C0369718;C0441922;C0449820;C1413373;C4050231
698,prior cad,C0332152;C1504769;C2239547;C2826257;C3813548;C4284121
698,previous cad  n ( % ),C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
698,previous cad,C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
698,premature cad among family members,C0086282;C0151526;C0205252;C1504769;C2239547;C3813548;C4018905;C4284121
698,no cad / mi,C1504769;C2239547;C3810814;C3813548;C4284121
698,multivessel cad ( % ),C1504769;C2239547;C3813548;C4284121
698,multivessel cad  n ( % ),C1504769;C2239547;C3813548;C4284121
698,mi or cad,C1504769;C2239547;C3810814;C3813548;C4284121
698,family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
698,familv historv of cad,C1504769;C2239547;C3813548;C4284121
698,cad death,C0011065;C1306577;C1504769;C2239547;C3813548;C4082313;C4284121;C4552775
698,cad and / or crvd ( % ),C1504769;C2239547;C3813548;C4284121
698,cad *,C1504769;C2239547;C3813548;C4284121
698,cad,C1504769;C2239547;C3813548;C4284121
697,mean cdai score ( sd ),C0444504;C0449820;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706;C4050231
697,mean cdai score,C0444504;C0449820;C0683448;C1413248;C2347634;C2348143;C3273706;C4050231
697,mean ( sd ) cdai *,C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
697,cdai §,C0683448;C1413248;C3273706
697,cdai score §,C0449820;C0683448;C1413248;C3273706;C4050231
697,cdai score < $nmbr$,C0449820;C0683448;C1413248;C3273706;C4050231
697,cdai score  median ( min  max ),C0449820;C0549183;C0683448;C0702093;C0876920;C1413248;C1524029;C2347635;C2348144;C2939193;C3273706;C3813700;C4050231
697,cdai score  mean ± sda,C0276477;C0444504;C0449820;C0683448;C1413248;C1428349;C1553165;C2347634;C2348143;C3273706;C4050231
697,cdai score  mean ( s . d . ),C0444504;C0449820;C0683448;C1413248;C2347634;C2348143;C3273706;C4050231
697,cdai score,C0449820;C0683448;C1413248;C3273706;C4050231
697,cdai > $nmbr$  n [ % ],C0683448;C1413248;C3273706
697,cdai < $nmbr$ t,C0683448;C1413248;C3273706
697,cdai < $nmbr$ . $nmbr$ *,C0683448;C1413248;C3273706
697,cdai ( $nmbr$ - $nmbr$ ),C0683448;C1413248;C3273706
697,cdai  mean [ sd ],C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
697,cdai  mean ( sd ),C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
697,cdai,C0683448;C1413248;C3273706
697,baseline cdai score  mean ( sd ),C0168634;C0444504;C0449820;C0683448;C1413248;C1442488;C2347634;C2348143;C2699239;C3273706;C4050231
697,baseline cdai score  mean ( s . d . ),C0168634;C0444504;C0449820;C0683448;C1413248;C1442488;C2347634;C2348143;C3273706;C4050231
697,baseline cdai  mean ( sd ),C0168634;C0444504;C0683448;C1413248;C1442488;C2347634;C2348143;C2699239;C3273706
697,baseline cdai,C0168634;C0683448;C1413248;C1442488;C3273706
697,a decrease of > $nmbr$ points in the cdai score,C0392756;C0449820;C0547047;C0683448;C1413248;C2924612;C3273706;C4050231
696,cdr - sob,C0013404;C4521843
696,baseline cdr - sb ( n   = $nmbr$ + $nmbr$ ),C0038111;C0168634;C1442488;C3811240;C4521843
695,oam,
695,no oam,
695,atm - locus,C1708726;C3711796
695,atm - locm,C3711796
695,am △ 士 s . e .,C3813124;C3890196;C4520798
695,acm,C0001143;C1549040
694,total asthma symptom score :,C0004096;C2984299;C3533163
694,total asthma symptom score  mean ± sdz,C0004096;C0444504;C2347634;C2348143;C2984299;C3533163
694,total asthma symptom score  mean ± sd ‡,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
694,total asthma symptom score,C0004096;C2984299;C3533163
694,percent overall work impairment due to asthma,C0004096;C0043227;C0221099;C0282416;C0439165;C0678226;C0684336;C1561607;C2984299
694,percent impairment while working due to asthma,C0004096;C0043227;C0221099;C0439165;C0678226;C0684336;C2984299
694,percent activity impairment due to asthma,C0004096;C0221099;C0439167;C0678226;C0684336;C2984299
694,newly diagnosed asthma ( n ),C0004096;C0011900;C0750546;C2984299
694,median ( range ) duration of asthma ( years ),C0004096;C0439234;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
694,median ( range ) duration of asthma ( y ),C0004096;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
694,hospitalized for asthma  n ( % ) *,C0004096;C0701159;C2984299
694,duration of asthma — yr,C0004096;C0439234;C0449238;C2926735;C2984299
694,duration of asthma > $nmbr$ years,C0004096;C0439234;C0449238;C2926735;C2984299
694,duration of asthma ( years ),C0004096;C0439234;C0449238;C2926735;C2984299
694,duration of asthma  years,C0004096;C0439234;C0449238;C2926735;C2984299
694,duration of asthma  y,C0004096;C0449238;C2926735;C2984299
694,duration of asthma,C0004096;C0449238;C2926735;C2984299
694,asthma population ( n = $nmbr$ ),C0004096;C0032659;C1257890;C2984299
694,asthma,C0004096;C2984299
693,noncomplex anatomy ( n - $nmbr$  $nmbr$ ),C0002808;C0700276;C1384516
693,complex anatomy ( n - $nmbr$  $nmbr$ ),C0002808;C0439855;C0700276;C1384516;C1704241
693,anatomy,C0002808;C0700276;C1384516
692,treatments at randomisation,C0034656;C0087111
692,treatmentofpulmonary embolismpriorto randomization,C0034656
692,treatment randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
692,treatment at randomization — no . ( % ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
692,treatment at randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
692,treatment at randomisation,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
692,to randomization,C0034656
692,time to randomization from symptom onset,C0034656;C0040223;C3541383;C4086878
692,time to randomization,C0034656;C0040223;C3541383
692,time to randomisation from symptom onset ( h ),C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C3541383;C4086878;C4528284
692,time since randomization,C0034656;C0040223;C3541383
692,time of randomization ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0040223;C1704675;C3541383
692,time of randomization,C0034656;C0040223;C3541383
692,time from symptom onset to randomization,C0034656;C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
692,time from randomization to pci — hr,C0034656;C0040223;C3541383;C4049621
692,time from qualifying event to randomization,C0034656;C0040223;C0441471;C1514624;C3541383;C4019010
692,time from presentation to randomization — hr,C0034656;C0040223;C0449450;C3541383
692,time from longest event to randomisation,C0034656;C0040223;C0441471;C1522425;C3541383;C4019010
692,time from hospitalization to randomization — hr,C0019993;C0034656;C0040223;C3541383
692,thienopyridine at randomization,C0034656;C1120149
692,symptom onset to randomization,C0034656;C4086878
692,symptom onset - to - randomization,C0034656;C4086878
692,renal function at randomization,C0034656;C0232804
692,randomized treatments  n ( % ),C0034656;C0087111;C3815594
692,randomized to receiveaspirin,C0034656;C3815594
692,randomized to aspirin use,C0004057;C0034656;C0042153;C0457083;C1947944;C3815594
692,randomized patients,C0030705;C0034656;C3815594
692,randomized < $nmbr$ hr after presentation — %,C0034656;C0449450;C3815594
692,randomized,C0034656;C3815594
692,randomize,
692,randomization ),C0034656
692,randomization  n ( % ),C0034656
692,randomization,C0034656
692,randomisation scheme,C0034656;C1519193
692,randomisation,C0034656
692,radiographic characteristics at baseline and randomization,C0034656;C0444708;C4684572
692,patients randomized  no .,C0030705;C0034656;C3815594
692,patients randomized  n,C0030705;C0034656;C0369718;C0441922;C3815594
692,patients randomized,C0030705;C0034656;C3815594
692,participants randomized,C0034656;C0679646;C3815594
692,parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
692,other llt at randomization,C0034656;C2347090
692,on oac at time of randomisation  n ( % ),C0034656;C0040223;C3541383
692,number randomized,C0034656;C0237753;C0449788;C3815594
692,number of patients randomized,C0034656;C2360800;C3815594
692,no . randomized,C0034656;C3815594
692,nihss at randomization  $nmbr$ - $nmbr$,C0034656;C1697238
692,nihss at randomization,C0034656;C1697238
692,medications at timing of randomization  n ( % ),C0034656;C2359859
692,malignancy at randomization,C0006826;C0034656;C1306459;C4282132
692,mafcaiancy at randorrtzaton,
692,llt other than statin at randomization,C0034656;C0360714;C2347090
692,heparin at randomization,C0019134;C0034656;C0770546
692,edoxaban at randomization  n ( % ),C0034656;C2975435
692,coronary revascularization $nmbr$ days after randomization,C0034656;C0439228;C0877341
692,concomitant treatments at randomization,C0034656;C0087111;C0521115
692,at randomization,C0034656
692,aspirin dose at randomization,C0034656;C4696290
692,asastoppedat randomization  n,C0034656
692,antiplatelet at randomization,C0034656
692,all randomized women,C0034656;C0043210;C3815594
692,all randomized,C0034656;C3815594
692,- [ the null hypothesis is that there are no differences among subgroups  for age and time since randomization  the inter -,C0001779;C0034656;C0040223;C0205103;C1079230;C1548610;C1705241;C1705242;C3541383;C4684719
691,peripheral edema,C0085649
691,eczema,C0013595;C4553957
691,ankle edema,C0235439
690,physical exam oedema,C0013604;C0031809;C1717255
690,edema peripheral,C0013604;C0205100;C1717255
690,edema  peripheral,C0013604;C0205100;C1717255
690,edema  n ( % ),C0013604;C1717255
690,edema  ( % ),C0013604;C1717255
690,edema  % z,C0013604;C1717255
689,proportion of angioedema - free days from week $nmbr$ to week $nmbr$ x,C0002994;C0332174;C0332296;C0439228;C0439230;C1709707;C1880497;C1996904
689,angioedema ( adjudicated )  n ( % ),C0002994
688,pnorcabg,
688,normal renal function,C0232805
688,normal cognitive,C2712133
687,very high vs . normal,C0205307;C0231683;C0439166;C0442804;C2347086;C4321397;C4553972
687,size of left atrium normal — no . ( % ) £,C0205307;C0225860;C0231683;C0439166;C0456389;C2347086;C4553972
687,serum mg > $nmbr$ . $nmbr$ mmol / l ( normal mg / hvpermagnesemia ),C0205307;C0229671;C0231683;C0439166;C0439190;C1546774;C1550100;C2347086;C2827881;C4553972
687,percent of predicted normal value,C0205307;C0231683;C0439166;C1882327;C2347086;C4553972
687,normal troponin,C0041199;C0205307;C0231683;C0439166;C2347086;C4553972
687,normal study termination,C0205307;C0231683;C0439166;C0557651;C1549081;C1692758;C2347086;C2603343;C4553972
687,normal responders ( n = $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
687,normal responder ( n = $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
687,normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
687,normal left ventricular ejection fraction — no . ( % ) j,C0205091;C0205307;C0231683;C0428772;C0439166;C0443246;C0488728;C1535947;C1552822;C2347086;C4553972
687,normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
687,normal hba $nmbr$ c  n = $nmbr$,C0019016;C0205307;C0231683;C0439166;C1825777;C2347086;C3538758;C4553972
687,normal fasting glucose level ( n = $nmbr$ ),C0015663;C0202045;C0205307;C0231683;C0439166;C0522082;C2347086;C4553972
687,normal crp and,C0205307;C0231683;C0439166;C2347086;C3890735;C4048285;C4553972
687,normal baseline crp,C0168634;C0205307;C0231683;C0439166;C1442488;C2347086;C3890735;C4048285;C4553972
687,normal albuminuria ( uacr < $nmbr$ ),C0001925;C0205307;C0231683;C0439166;C2347086;C4553972
687,normal > $nmbr$ - $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
687,normal - high renin ( pra > $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ ),C0205307;C0231683;C0439166;C0633231;C0855390;C1141951;C1419788;C1533072;C2347086;C3274822;C3669212;C4050009;C4283900;C4553972
687,normal ( ≥ $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C2347086;C4553972
687,normal ( > $nmbr$ mlvmin per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0369637;C0439166;C0441923;C2347086;C4553972
687,normal ( > $nmbr$ ml / min ),C0205307;C0231683;C0439166;C0439445;C2347086;C4553972
687,normal ( > $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
687,normal ( < $nmbr$ . $nmbr$ u / ml ),C0205307;C0231683;C0439166;C0439340;C1880521;C2347086;C2945590;C4553972
687,normal  < $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
687,normal,C0205307;C0231683;C0439166;C2347086;C4553972
687,mild dysfunction or normal,C0205307;C0231683;C0439166;C2347086;C3274775;C4553972
687,medium normal ( n = $nmbr$ ),C0009458;C0205307;C0231683;C0439166;C0439536;C1705217;C2347086;C3244283;C4085196;C4522282;C4522283;C4553972
687,lowest normal ( n = $nmbr$ ),C0205307;C0231683;C0439166;C1708760;C2347086;C4553972
687,high normal ( n = $nmbr$ ),C0205250;C0205307;C0231683;C0439166;C1299351;C2347086;C2700149;C3887512;C3889660;C4321237;C4522209;C4553972
686,prior ml or abnormal angiogram,C0002978;C0205161;C0332152;C0439526;C1548816;C1705224;C2347472;C2699333;C2826257;C3887665;C3891555;C4255126
686,previous ml or abnormal angiogram,C0002978;C0205156;C0205161;C0439526;C1548816;C1552607;C1705224;C2347472;C2699333;C3887665;C3891555;C4255126
686,abnormal angiogram,C0002978;C0205161;C1548816;C2347472;C2699333;C3891555;C4255126
686,abnormal,C0205161;C2347472;C2699333
685,biguanides ¶,C0005382;C0360396;C3540012
685,biguanides ( metformin ),C0005382;C0025598;C0360396;C3540012
685,biguanides,C0005382;C0360396;C3540012
685,biguanide use at baseline,C0005382;C0042153;C0168634;C0457083;C1442488;C1947944;C3537187;C4317165
685,biguanide ( metformin ),C0005382;C0025598;C3537187;C4317165
685,biguanide,C0005382;C3537187;C4317165
684,prior migraine *,C0149931;C0332152;C2826257
684,prior migraine,C0149931;C0332152;C2826257
684,migraine — no . ( % ) $,C0149931
684,migraine severity score,C0149931;C0457451
684,migraine occurrence ( days / month ),C0149931;C0243132;C0556971;C1554210;C2745955
683,≥ $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %,
683,rankin grade,C0441800;C0919553;C3244287
683,nerd grade,C0441800;C0919553;C3244287
683,nerd,
683,modi fied la grade *,C0023031;C0023749;C0230347;C0342276;C0441800;C0919553;C2346906;C3244287;C4553351
683,mmrc grade  n ( % ),C0441800;C0919553;C3244287;C3826977
683,mmrc grade,C0441800;C0919553;C3244287;C3826977
683,mean mmrc grade  units ( sd ),C0439148;C0441800;C0444504;C0919553;C1519795;C2347634;C2348143;C2699239;C3244287;C3826977;C3853603
683,la grade a  n ( % ) f,C0016327;C0023031;C0023749;C0230347;C0369718;C0441800;C0441922;C0919553;C2346906;C3244287;C4553351
683,kellgren and lawrence radiographic reading grade $nmbr$ — no . ( % ),C0034754;C0441800;C0444708;C0919553;C1705179;C3244287;C4284139
683,grade > $nmbr$,C0441800;C0919553;C3244287
683,grade $nmbr$,C0441800;C0919553;C3244287
683,gold grade $nmbr$,C0018026;C0441800;C0919553;C1304897;C3244287
683,dyspnoea - mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
683,dyspnea – mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
683,baseline los angeles grade of eo  n ( % ),C0024015;C0168634;C0332120;C0441800;C0919553;C1442488;C3244287
683,adverse events ( any grade ),C0441800;C0877248;C0919553;C1705413;C3244287
682,screening prebronchodilator fev $nmbr$  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541
682,prebronchodilator fevj ( % predicted ),C0681842;C1882327;C2599602
682,prebronchodilator fev $nmbr$,C2599602;C3714541
682,prebronchodilator,C2599602
682,pre - bronchodilator screening fev $nmbr$ ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541;C3887665
682,pre - bronchodilator fvc ’ % pred,C0032952;C0044955;C2599602;C3714541
682,pre - bronchodilator fvc ( l ),C2599602;C3714541
682,pre - bronchodilator fevr l,C1708033;C2599602
682,pre - bronchodilator fevr % pred,C0032952;C0044955;C1708033;C2599602
682,pre - bronchodilator fevj,C2599602
682,pre - bronchodilator fev ^ ( l ),C2599602;C3714541
682,pre - bronchodilator fev $nmbr$ ( l ),C2599602;C3714541
682,pre - bronchodilator fev $nmbr$ ( % predicted normal ),C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C2599602;C3714541;C4553972
682,pre - bronchodilator fev  ( l ),C2599602;C3714541
682,pre - bronchodilator fev  % predicted,C0681842;C1882327;C2599602;C3714541
682,pre - bronchodilator fef $nmbr$ . $nmbr$ ( ml / s ) baseline blood eosinophil count,C0005767;C0005768;C0014467;C0168634;C0200638;C0229664;C0439390;C0750480;C0750879;C1442488;C1705566;C2599602
682,pre - bronchodilator,C2599602
682,percentage of predicted pre - bronchodilator fev ^,C0439165;C0681842;C1549488;C1561533;C1882327;C2599602;C3714541
682,fvc pre - bronchodilator,C2599602;C3714541
682,fev $nmbr$ pre - bronchodilator ( % predicted normal )  mean ( sd ) c  d,C0012358;C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2599602;C2699239;C3714541;C4553972
682,fev $nmbr$ pre - bronchodilator,C2599602;C3714541
682,fev $nmbr$ ( l ) pre - bronchodilator,C2599602;C3714541
682,baseline pre - bronchodilator fev $nmbr$  l,C0168634;C1442488;C2599602;C3714541
682,a prebronchodilator fevl ( % predicted ),C0681842;C1882327;C2599602
682,% predicted pre - bronchodilator fev $nmbr$  % *,C0681842;C1882327;C2599602;C3714541
681,spirometry after bronchodilation §,C0037981;C1371299;C3537072
681,before bronchodilation — liters §,C0475211;C1371299;C3537072
681,before bronchodilation,C1371299;C3537072
681,after bronchodilation,C1371299;C3537072
680,postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
680,postbronchodilator fev $nmbr$  % predicted,C0681842;C1882327;C2599594;C3714541
680,postbronchodilator $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C2599594
680,postbronchodilator,C2599594
680,post - bronchodilator screening fev $nmbr$ ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541;C3887665
680,post - bronchodilator ratio of fev $nmbr$ to fvc — %,C0456603;C1547037;C2599594;C3714541
680,post - bronchodilator fvc ( l ) a,C2599594;C3714541
680,post - bronchodilator fevx ( l ),C2599594
680,post - bronchodilator fev $nmbr$ — liters,C0475211;C2599594;C3714541
680,post - bronchodilator fev $nmbr$ — % of predicted value,C0681842;C1522609;C1882327;C2599594;C3714541
680,post - bronchodilator fev $nmbr$ ml,C0439526;C1705224;C2599594;C3714541;C3887665
680,post - bronchodilator fev $nmbr$ / fvc ( % ) a,C2599594;C3714541
680,post - bronchodilator fev $nmbr$ / fvc  %,C2599594;C3714541
680,post - bronchodilator fev $nmbr$ ( l ) a,C2599594;C3714541
680,post - bronchodilator fev $nmbr$ ( l ) *,C2599594;C3714541
680,post - bronchodilator fev $nmbr$ ( l ),C2599594;C3714541
680,post - bronchodilator fev $nmbr$ ( % predicted normal ) a,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C2599594;C3714541;C4553972
680,post - bronchodilator fev $nmbr$ ( % predicted * ),C0681842;C1882327;C2599594;C3714541
680,post - bronchodilator fev $nmbr$ % predictedb,C2599594;C3714541
680,post - bronchodilator fev $nmbr$  l *,C2599594;C3714541
680,post - bronchodilator fev $nmbr$  l,C2599594;C3714541
680,post - bronchodilator fev $nmbr$  % predicted of normal value,C0086715;C0681842;C1882327;C2599594;C3714541
680,post - bronchodilator fev $nmbr$  % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
680,post - bronchodilator fev $nmbr$  % predicted,C0681842;C1882327;C2599594;C3714541
680,post - bronchodilator fev  / fvc,C2599594;C3714541
680,post - bronchodilator fev  ( l ),C2599594;C3714541
680,post - bronchodilator fev  % predicted,C0681842;C1882327;C2599594;C3714541
680,post - bronchodilator fev   % predicted,C0681842;C1882327;C2599594;C3714541
680,post - bronchodilator,C2599594
680,fvc post - bronchodilator,C2599594;C3714541
680,fev $nmbr$ post - bronchodilator  % predicted normal,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C2599594;C3714541;C4553972
680,baseline post - bronchodilator fev $nmbr$   ( sd )  ml,C0168634;C0439526;C1442488;C1705224;C2599594;C2699239;C3714541;C3887665
680,baseline post - bronchodilator % predicted fev  > $nmbr$ % and prior ics use,C0042153;C0168634;C0332152;C0457083;C0681842;C0815320;C1442488;C1882327;C1947944;C2599594;C2826257;C3714541;C4551720
680,baseline post - bronchodilator % predicted fev  < $nmbr$ %,C0168634;C0681842;C1442488;C1882327;C2599594;C3714541
680,% predicted post - bronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
679,nebivolol ( n = $nmbr$ ),C0068475
679,metoprolol group ( n = $nmbr$ ),C0025859;C0441848
679,metoprolol ( n = $nmbr$ $nmbr$ ),C0025859
678,study protocol,C1507394;C2348563;C2599718
678,original dabigatran protocol,C0205313;C0442711;C1507394;C1522729;C2347409;C2348066;C2348563;C2599718;C3715209;C4282383
678,amended dabigatran protocol,C0442711;C1507394;C1522729;C1691222;C2348066;C2348563;C2599718;C3715209;C4282383
677,location of treatment center,C0039798;C0087111;C0205099;C1522326;C1533734;C1705169;C3538994;C3887704
677,centre,C0205099;C3810851
677,central eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
677,central eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
677,central eosinophil count,C0200638;C0205099;C0750879;C1879652
677,central / eastern,C0205099;C1707877;C1879652
677,center location,C0205099
677,center - level ihr percent time in therapeutic range for warfarin subjects,C0040223;C0043031;C0087111;C0205099;C0302350;C0439165;C0441889;C0456079;C0460097;C0681850;C1547707;C1550501;C1554109;C1706203;C2349001;C2697811;C2946261;C3541383;C3810851
677,center,C0205099;C3810851
676,ldl - c concentration,C0086045;C1446561;C3827302
676,hdlc - concentration,C0086045;C1446561;C1704429;C3827302
676,geometric c $nmbr$ concentration  mg / dl,C0086045;C0439269;C0449829;C1446561;C3827302
676,crp concentration > $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mg / l )  n ( % ),C0086045;C1446561;C2827881;C3642216;C3827302;C3890735;C4048285
676,blood leucocyte concentration ( $nmbr$ cells per l ),C0023516;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
676,blood eosinophil concentration  $nmbr$ cells per l,C0014467;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
675,rhythm - control group ( n = $nmbr$ ),C0243148;C0441848;C0871269;C1523018;C1550141;C1882979;C2587213;C3274648;C3828331;C4553389
675,proportion ( % ) of individuals • control alirocumab,C0027361;C0237401;C0243148;C1550141;C1709707;C1882979;C2587213;C3274648;C3491162;C4553389
675,good control ( < $nmbr$ ),C0205170;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
675,glycaemic control ( hba $nmbr$ c )  n ( % ),C0005802;C0019016;C0243148;C1550141;C1825777;C1882979;C2587213;C3274648;C3538758;C4553389
675,fair control ( $nmbr$ - $nmbr$ . $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C2911689;C3274648;C4553389
675,controls ( n = $nmbr$ ),C0243148;C0369718;C0441922;C1550141;C1882979;C2587213;C3274648;C4553389
675,controlled : acq - $nmbr$ < $nmbr$ . $nmbr$,C2587213;C2911690;C2919686
675,controlled $nmbr$ — no . ( % ),C2587213;C2911690
675,controlled,C2587213;C2911690
675,controlld,
675,control of sitting bp at week $nmbr$,C0037623;C0243148;C0277814;C0332174;C0439230;C1415692;C1550141;C1708288;C1882979;C2584297;C2587213;C3274648;C4050224;C4318478;C4553389
675,control n = $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
675,control group ( n = $nmbr$ ),C0243148;C0441848;C1550141;C1882979;C2587213;C3274648;C4553389
675,control baseline ( n - $nmbr$ ),C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
675,control = warfarin,C0043031;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
675,control ( nz $nmbr$ ),C0027978;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
675,control ( n z $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
675,control ( n = $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
675,control ( n - $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
675,control $nmbr$ months ( n - $nmbr$ ),C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389
675,control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
675,bp control,C0037623;C0243148;C1415692;C1550141;C1708288;C1882979;C2587213;C3274648;C4318478;C4553389
675,blood pressure control *,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
675,blood pressure control,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
675,baseline glycemic control,C0005802;C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
675,asthma control,C0004096;C0243148;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
675,asthma - control status at randomization — no . ( % ),C0004096;C0034656;C0243148;C0449438;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
675,active - control study,C0243148;C0557651;C1550141;C1706449;C1882979;C2347179;C2587213;C2603343;C3274648;C4553389
675,( % ) control ( $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
675,% asthma control days {  #,C0004096;C0243148;C0439228;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
674,tertile $nmbr$ ( > $nmbr$ . $nmbr$ pg / ml ) n - $nmbr$,C0439297
674,tertile $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pg / ml ) n = $nmbr$,C0439297
674,tertile $nmbr$,
674,terrible,C3827840
674,terlile $nmbr$,
673,terminal ileum,C0227327
673,disease location / type : terminal ileum,C0227327;C0450429;C0457464;C1515974;C4284930;C4284931
673,$nmbr$ rrmnl ),
672,western europe and israel,C0022271;C0043129
672,lymphocytes  $nmbr$ / + il,C0020898;C0021764;C0022271;C0024264;C4018897
672,israel,C0022271
672,il - $nmbr$ ( pg / ml ),C0020898;C0021764;C0022271;C0439297
672,il - $nmbr$  ng / l,C0020898;C0021764;C0022271;C0439297
672,il - $nmbr$,C0020898;C0021764;C0022271
672,canakinumab  $nmbr$ month on - treatment il - $nmbr$ above the median value ( ≥ $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ ),C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704
671,ppg  mmol / l,C1418888;C1532563
671,phosphorus  mmol $nmbr$ $nmbr$,C0031705;C0080014;C0439190;C3714498
671,fpg ( mmol / $nmbr$ ),C0439190
671,fpg  mmol / la,C0023031;C0023749;C0230347;C0439190;C2346906;C4553351
671,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
671,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
671,> $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
671,> $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
671,< $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
671,< $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
671,( mu / l $ mmol / l ) b,C0439190;C0439342
671,$nmbr$ - hour ppg  mmol / l,C0439227;C0564385;C1418888;C1532563
671,$nmbr$ - h ppg ( mmol / l ) *,C1418888;C2827804
671,$nmbr$ - h ppg ( mmol / l ),C1418888;C2827804
671,$nmbr$ - h pmg ( mmol / l ),C2827804
671,$nmbr$ - h pmg  mmol / l ( mean ± sd ),C0444504;C2347634;C2348143;C2699239;C2827804
670,£ $nmbr$ . $nmbr$ mmol / l,C1532563
670,women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0043210;C0439269;C1532563
670,triacylglycerol  mmol / l  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
670,total c ( mmol / l  mean ),C0439175;C0439810;C0444504;C1532563;C2347634;C2348143
670,tertile of total cholesterol at baseline  mean ( sd )  mmol / l,C0168634;C0201950;C0444504;C0543421;C1442488;C1532563;C2347634;C2348143;C2699239
670,sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ fasting plasma glucose ( fpg ) ( mmol / l ),C0015663;C0202042;C0455280;C1532563;C1565750
670,serum total cholesterol ( mmol / l )  mean ( sd ),C0444504;C0587184;C1287371;C1532563;C2347634;C2348143;C2699239
670,serum total cholesterol  mmol / l ( sd ),C0587184;C1287371;C1532563;C2699239
670,serum potassium : < $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ ),C0302353;C0543465;C1532563
670,serum potassium ( mmol / l ),C0302353;C0543465;C1532563
670,serum potassium  mean ( sd ) mmol / l,C0302353;C0444504;C0543465;C1532563;C2347634;C2348143;C2699239
670,serum potassium  > $nmbr$ . $nmbr$ mmol / l,C0302353;C0543465;C1532563
670,serum phosphate  mmol / l,C0036820;C1532563
670,serum mg < $nmbr$ . $nmbr$ mmol / l ( hypomagnesemia ),C0024671;C0026410;C0151723;C0229671;C0439190;C0439268;C0439269;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761;C4552839
670,serum hdl cholesterol ( mmol / l )  mean ( sd ),C0428472;C0444504;C1532563;C2347634;C2348143;C2699239
670,serum glucose ( mmol / l ),C0202041;C1532563;C3534430
670,serum calcium  mmol / l,C0036785;C0728876;C1532563
670,serum biochemistry potassium  mmol / l,C0005477;C0302353;C0543465;C1532563
670,potassium at admission  mmol / l - $nmbr$,C0032821;C0184666;C0202194;C0304475;C0597277;C0809949;C1532563;C3714637
670,phosphate ( mmol / l ),C0031603;C0031701;C1532563;C1601799
670,mmol / l [ n ],C1532563
670,mmol / l ),C1532563
670,mmol / l,C1532563
670,mg / dl fpg ( mmol / l ),C0439269;C1532563
670,mean fpg  mmol / l,C0444504;C1532563;C2347634;C2348143
670,mean change ‘ s in fasting blood glucose [ mg / dl ( mmol / l ) ],C0392747;C0428568;C0443172;C0444504;C1261430;C1532563;C1705241;C2347634;C2348143;C2827883;C3642216;C4319952
670,mean ( s . d . ) baseline fpg  mmol / l,C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
670,mdg ( mmol / l ),C0024443;C1417239;C1532563;C2986643
670,low - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023824;C0444504;C1532563;C2347634;C2348143;C2699239
670,lipoprotein ( a ) ( mmol / l ),C0065058;C0125953;C1096202;C1439335;C1532563
670,ldl cholesterol > $nmbr$ - $nmbr$ mmol / l,C0023824;C0202117;C1532563
670,ldl cholesterol < $nmbr$ - $nmbr$ mmol / l,C0023824;C0202117;C1532563
670,ldl cholesterol ( mmol / l ) :,C0023824;C0202117;C1532563
670,ldl cholesterol ( mmol / l ) ( median  iqr ),C0023824;C0202117;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
670,ldl cholesterol ( mmol / l )  mean ( sd ),C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
670,ldl cholesterol ( mmol / l ),C0023824;C0202117;C1532563
670,ldl cholesterol  mmol / l 丰,C0023824;C0202117;C1532563
670,ldl cholesterol  mmol / l *,C0023824;C0202117;C1532563
670,ldl cholesterol  mmol / l  mean ± sd,C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
670,ldl cholesterol  mmol / l  mean ( sd ) §,C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
670,ldl cholesterol  mmol / l,C0023824;C0202117;C1532563
670,ldl - cholesterol ( mmol / l ),C0023824;C0202117;C1532563
670,ldl - cholesterol  mmol / l,C0023824;C0202117;C1532563
670,ldl - c   *   ( mmol / l ),C1532563
670,ldl - c < $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563
670,ldl - c < $nmbr$ . $nmbr$ mmol / l,C1532563
670,ldl - c * ( mmol / l ),C1532563
670,ldl - c ( mmol / l ),C1532563
670,ldl - c ( mmol / l  mean ),C0444504;C1532563;C2347634;C2348143
670,ldl - c  mmol / l ( sd ),C1532563;C2699239
670,ldl - c  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
670,ldl - c  mmol / l,C1532563
670,ldl ( mmol / l ),C1532563
670,k ( mmol / l ),C0597277;C1532563;C1708601
670,k  mmol / l,C0597277;C1532563;C1708601
670,hyperkalaemia ( serum potassium > $nmbr$ . $nmbr$ mmol / l ),C0020461;C0302353;C0543465;C1532563;C4552983
670,high - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023822;C0444504;C1532563;C2347634;C2348143;C2699239
670,hdl - c > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563;C3715113
670,hdl - c ( mmol / l  mean ),C0444504;C1532563;C2347634;C2348143;C3715113
670,haemoglobin ( mmol / l ),C0019046;C0439190;C0635222;C1532563
670,glucose  mmol / l,C0017725;C1532563
670,free fatty acids ( mmol / l ),C0015688;C1532563
670,fpg ( range ) ( mmol / l ),C1514721;C1532563;C2348147;C3542016
670,fpg ( mmol / l )  mean ( sd ) 、,C0444504;C1532563;C2347634;C2348143;C2699239
670,fpg ( mmol / l )  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
670,fpg ( mmol / l ),C1532563
670,fpg  mmol / l ( mean ± sd ),C0444504;C1532563;C2347634;C2348143;C2699239
670,fpg  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
670,fpg  mmol / l,C1532563
670,fpg  mg / dl ( mmol / l ),C0439269;C1532563
670,fpg  median ( ql  q $nmbr$ )  mmol / l,C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
670,fpg  median ( q $nmbr$  q $nmbr$ )  mmol / l,C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
670,fpg  mean ( sd )  mmol / l,C0444504;C1532563;C2347634;C2348143;C2699239
670,fpg  mean ( sd )  mg / dl [ mmol / l ],C0439269;C0444504;C1532563;C2347634;C2348143;C2699239
670,fpg  ( mmol / l ),C1532563
670,ffa ( mmol / l ),C0015688;C1532563
670,fc > $nmbr$ mg / dl ( > _ $nmbr$ . $nmbr$ mmol / l ) or history of diabetes,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C0439269;C1532563;C1705255;C2004062;C2983605
670,fbg ( mmol / l ),C1532563
670,fbg  mmol / l,C1532563
670,fasting serum glucose  mmol / l  median ( q $nmbr$  q $nmbr$ ),C0015663;C0202041;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193;C3534430
670,fasting plasma glucose ( mmol / l ) $nmbr$,C0015663;C0202042;C0455280;C1532563
670,fasting plasma glucose ( mmol / l ),C0015663;C0202042;C0455280;C1532563
670,f - plasma glucose  mmol / l,C0016327;C0202042;C0455280;C1532563
670,elevated serum potassium  > $nmbr$ . $nmbr$ mmol / l,C0553704;C1532563
670,change  mg / dl ( mmol / l ),C0392747;C0439269;C0443172;C1532563;C1705241;C4319952
670,bun  mmol / l,C1532563
670,baseline normoglycaemia ( fpg < $nmbr$ . $nmbr$ mmol / l ) - n,C0168634;C0580545;C1442488;C1532563
670,baseline lipids  mean ± sd ( mmol / l ),C0023779;C0168634;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
670,baseline lipid parameters  mg / dl  mmol / l or g / l,C0023779;C0168634;C0439269;C0439294;C0449381;C0456615;C1442488;C1532563
670,baseline ( mmol / l ),C0168634;C1442488;C1532563
670,admission k  mmol / l,C0184666;C0597277;C0809949;C1532563;C1708601
670,[ $nmbr$ . $nmbr$ mmol / l ] ),C1532563
670,> $nmbr$ mmol / l,C1532563
670,> $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ) + +,C0439269;C1532563
670,> $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ ),C1532563
670,> $nmbr$ . $nmbr$ mmol / l,C1532563
670,> $nmbr$ - $nmbr$ mmol / l,C1532563
670,> $nmbr$ + $nmbr$ mmol / l,C1532563
670,> $nmbr$ ' $nmbr$ mmol / l,C1532563
670,< $nmbr$ mmol / l,C1532563
670,< $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563
670,< $nmbr$ . $nmbr$ mmol / l,C1532563
670,< $nmbr$ - $nmbr$ mmol / l,C1532563
670,( mmol / l ],C1532563
670,( mmol / l ),C1532563
670,( < $nmbr$ . $nmbr$ mmol / l ),C1532563
670,( $ $nmbr$ mg / dl [ $nmbr$ . $nmbr$ mmol / l ] ),C0439269;C1532563
670,$nmbr$ st tertile ( < = $nmbr$ mg / dl [ < = $nmbr$ . $nmbr$ mmol / l ] ) b,C0036056;C0439269;C1532563;C3272372
670,$nmbr$ nd tertile ( > $nmbr$ to < = $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ to < = $nmbr$ . $nmbr$ mmol / l ] ) c,C0439269;C1532563
670,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l,C1532563
670,$nmbr$ - $nmbr$ mmol / l,C1532563
669,unbound pcsk $nmbr$ ( nmol / l ),C0439282
669,testosterone level ( nmol / l ),C0428412;C0439282;C0523912
669,testosterone ( tt ) ( nmol / l ),C0039601;C0439282;C1452561;C4554543
669,testosterone ( nmol / l ),C0039601;C0439282
669,hscrp ( nmol / l ),C0439282
669,crp  nmol / l  median ( range ),C0439282;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
669,cholesterol ( nmol / l ),C0008377;C0439282
668,≥   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
668,≥ $nmbr$ . $nmbr$ % ( ≥ $nmbr$ mmol / mol ),C3829066
668,≤   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
668,mmol / mol,C3829066
668,mean hba $nmbr$ c  mmol / mol †,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066
668,ls mean ( $nmbr$ % ci )  mmol / mol,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781;C3829066
668,hbalc a $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
668,hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) at week $nmbr$,C0332174;C0439230;C3829066
668,hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
668,hbajc ( mmol / mol ) mean ± sd,C0444504;C2347634;C2348143;C2699239;C3829066
668,hbaj ( - ( %  mmol / mol ),C3829066
668,hba $nmbr$ c ( sd )  mmol / mol,C0019016;C1825777;C2699239;C3538758;C3829066
668,hba $nmbr$ c ( mmol / mol [ se ] ),C0019016;C0036919;C1825777;C3538758;C3829066
668,hba $nmbr$ c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ - $nmbr$ mmol / mol ),C0019016;C1825777;C3538758;C3829066
668,hba $nmbr$ c  mmol / mol ( mean ),C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066
668,hba $nmbr$ c  mmol / mol  median ( q $nmbr$  q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
668,hba $nmbr$ c  mmol / mol  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066
668,hba $nmbr$ c  ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
668,hba $nmbr$ c  % [ mmol / mol ],C0019016;C1825777;C3538758;C3829066
668,baseline hba $nmbr$ c ≥ $nmbr$ mmol / mol ( ≥ $nmbr$ . $nmbr$ % )  n ( % ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
668,baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % to < $nmbr$ . $nmbr$ % ( $nmbr$ – $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
668,baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
668,baseline hba $nmbr$ c ≤ median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
668,baseline hba $nmbr$ c > median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
668,baseline hba $nmbr$ c < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
668,alc ( mmol / mol ),C1424945;C3811058;C3829066
668,a $nmbr$ c ( mmol / mol ),C3829066
668,a $nmbr$ c  % ( mmol / mol ),C3829066
668,>   $nmbr$ – <   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
668,> = $nmbr$ . $nmbr$ % ( > = $nmbr$ mmol / mol ),C3829066
668,> = $nmbr$ % and < $nmbr$ % ( > = $nmbr$ and < $nmbr$ mmol / mol ),C3829066
668,> = $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
668,> $nmbr$ % ( > $nmbr$ mmol / mol ),C3829066
668,< $nmbr$ . $nmbr$ % ( < $nmbr$ mmol / mol ),C3829066
668,< $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
668,< $nmbr$ % ( < $nmbr$ mmol / mol ),C3829066
668,< $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
667,trigl yeerides * ( m mol / l ),C0027960;C0324740;C0347982;C0369637;C0439189;C0441923;C0456616;C1456781;C1824986;C3665593
667,serum creatinine  弘 mol 儿 | |,C0027960;C0201976;C0324740;C0439189;C0600061;C1456781;C1824986;C3665593
667,epa ( mol % ),C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
667,epa  mol %,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
666,fpi  m - u / ml ( pmol / l ),C0369637;C0439192;C0439284;C0439340;C0441923;C0456616;C1880521;C2945590
666,fpi  gu / ml ( pmol / l ),C0120446;C0439192;C0439284;C0439526;C1635169;C1705224;C3887515;C3887665
666,estradiol ( pmol / l ),C0014912;C0439284
666,estradiol ( e $nmbr$ ) ( pmol / l ),C0014912;C0439284
666,elevated creatinine ( > $nmbr$ pmol / l ),C0151578;C0439284;C0700225
666,$nmbr$ rd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0439284;C0694666;C4553350
666,$nmbr$ nd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0439284
665,fasting proinsulin ( pmol / l ),C0015663;C0033362;C0439284;C3813208
665,$nmbr$ - h postprandial proinsulin ( pmol / l ),C0033362;C0376674;C2827799;C3813208
664,el  n ( % ),C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
664,( $nmbr$ % ell ' ll  * non - hdl - c,C1427925;C1518422;C3273466;C3715113
664,( $nmbr$ % ell ' ll,C1427925;C3273466
664,$nmbr$ ± ll,
663,ll $nmbr$ ( $nmbr$ ),
663,l / ll,C0439394;C1706495;C3642217
663,insulin glargine ( n = $nmbr$ ll ),C0907402
663,- $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) * ll,
662,ll ( $nmbr$ ),
662,eosinophils ( cells / ll ) inclusion criteria  n ( % ),C0682547;C1512693
662,eosinophil count ( cells / microlitre ),C0200638;C0439378;C0750879
662,> $nmbr$ cells / ul,C0439378
662,< $nmbr$ cells / ul $nmbr$ $nmbr$,C0439378
661,squamous cell carcinoma,C0007137;C1302853
661,dynamic measure of β - cell function ( ϕ s ) ( change from baseline ) – assessed for mmtt subset only,C0007613;C0079809;C0168634;C0205171;C0242485;C0392747;C0443172;C0729333;C1442488;C1515021;C1516048;C1705241;C1720467;C4319952
661,^ $nmbr$ - cell function — % §,C0007613
660,ill -,C0231218
660,all noncompleters,
660,all completers ( n $nmbr$ $nmbr$ ),
660,all completers,
660,< $nmbr$ . $nmbr$ tng > cll,C0023434
659,white blood cell count  cellsx $nmbr$,C0023508;C0427512
659,white - cell count — x $nmbr$ _ $nmbr$ / liter,C0023508;C0427512;C0475211
659,blood leukocyte count ( $nmbr$ cells per l ),C0023508;C0023516;C0347983;C0427512
658,ucl,
658,treatment difference ( $nmbr$ % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
658,treatment difference % ( $nmbr$ % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
658,risk reduction ( $nmbr$ % cl ),C0596019;C1137094
658,risk ratio [ $nmbr$ % cl ],C0028873;C0242492;C0596019
658,relative risk ® ( $nmbr$ % cl ),C0242492;C0596019
658,relative risk ® ' ( $nmbr$ % cl ),C0242492;C0596019
658,relative risk vs . placebo ( $nmbr$ % cl ),C0032042;C0242492;C0596019;C1696465;C1706408
658,relative risk reduction ( $nmbr$ % cl ) percent,C0080103;C0205345;C0242492;C0301630;C0392756;C0439165;C0596019;C1137094;C1293152;C1547039;C4551656
658,relative risk reduction ( $nmbr$ % cl ),C0080103;C0205345;C0242492;C0301630;C0392756;C0596019;C1137094;C1293152;C1547039;C4551656
658,relative risk * ( $nmbr$ % cl ),C0242492;C0596019
658,relative risk ( $nmbr$ % cl ),C0242492;C0596019
658,ratio of hrs ( $nmbr$ % cl )  p for sex interaction,C0009253;C0036864;C0079399;C0456603;C0596019;C0804628;C1314687;C1522384;C1547037;C1568891;C1704675
658,pre - specified hr ( $nmbr$ % cl ),C0596019;C2826245
658,p ( $nmbr$ % cl ),C0369773;C0596019;C2603361
658,overall hr ( $nmbr$ % cl ),C0282416;C0596019;C1561607
658,orc ( $nmbr$ % cl ),C0596019;C1167125
658,oradj ( $nmbr$ % cl ),C0596019
658,or [ $nmbr$ % cl ],C0596019
658,or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),C0596019
658,or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ . $nmbr$ ),C0596019
658,or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ $nmbr$ ),C0596019
658,or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ ),C0596019
658,or ( $nmbr$ % cl ),C0596019
658,or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ — $nmbr$  $nmbr$ ),C0596019
658,or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),C0596019
658,north america hr ( $nmbr$ % cl ),C0028405;C0596019
658,mean difference ( $nmbr$ % cl ),C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
658,lsm difference ( $nmbr$ % cl ),C0596019;C1705241;C1705242
658,lsm ( $nmbr$ % cl ),C0596019
658,ls mean difference ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
658,ls - mean difference ® ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
658,least - squares mean difference ( $nmbr$ % cl ),C0023189;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
658,laba or lama ’ versus ind / gly lsm difference ( $nmbr$ % cl ),C0017890;C0523677;C0596019;C0999593;C1416775;C1705241;C1705242;C4049864
658,hr : $nmbr$ . $nmbr$ ( $nmbr$ % cl : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0596019
658,hr ( $nmbr$ % cl ) pvalue,C0596019
658,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ b ( $nmbr$  $nmbr$ . $nmbr$ ),C0596019
658,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ ),C0596019
658,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$  $nmbr$ . $nmbr$ ),C0596019
658,hr ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$  $nmbr$ ),C0596019
658,hr ( $nmbr$ % cl ),C0596019
658,hr $nmbr$ and $nmbr$ % cl,C0596019
658,hr $nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$ *,C0596019
658,hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$ ),C0596019
658,hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ ),C0596019
658,hr $nmbr$ % cl,C0596019
658,hr  $nmbr$ % cl,C0596019
658,hazard ratio or difference $nmbr$ * ( $nmbr$ % cl ) p - value,C0596019;C1705241;C1705242;C1709380;C2985465
658,hazard ratio or difference $nmbr$ ( $nmbr$ % cl ) p - value,C0596019;C1705241;C1705242;C1709380;C2985465
658,estimated mean $nmbr$ % cl,C0444504;C0596019;C0750572;C2347634;C2348143
658,estimate ( $nmbr$ % cl ),C0596019;C0750572
658,difference in ls mean $nmbr$ ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
658,difference ( $nmbr$ % cl ),C0596019;C1705241;C1705242
658,cl - $nmbr$ ],C0596019
658,cl $nmbr$ %,C0596019
658,change in pav  mean ( $nmbr$ % cl )  %,C0058890;C0392747;C0443172;C0444504;C0596019;C1705241;C2347634;C2348143;C4319952
658,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  k ( rate )  # of events per $nmbr$ patient - years of follow - up  rrr  relative risk reduction  yr  year . ^ treatment effect of losartan versus placebo . interaction test between treatment group and hemoglobin group ( < $nmbr$ or > $nmbr$ g i - $nmbr$ ) . cmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates . dmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin and change in hemoglobin at year $nmbr$ as covariates .,C0001924;C0009667;C0010294;C0019046;C0022661;C0022885;C0030705;C0032042;C0036773;C0039593;C0042027;C0080103;C0086706;C0126174;C0168634;C0201976;C0205345;C0229671;C0237455;C0242492;C0301630;C0374505;C0392366;C0392747;C0392756;C0439234;C0439508;C0441471;C0441833;C0443172;C0455271;C0456603;C0456984;C0486293;C0589120;C0596019;C0597277;C0600061;C0687744;C0728877;C0871208;C1137094;C1257890;C1293152;C1318330;C1442488;C1515976;C1518681;C1519504;C1521828;C1522577;C1524119;C1546774;C1547037;C1547039;C1549954;C1550100;C1561535;C1565830;C1626828;C1696465;C1704675;C1704685;C1705241;C1705428;C1705429;C1706408;C1708601;C1708728;C2986775;C3161035;C3274571;C3274659;C3541888;C3714583;C3831328;C3853906;C4281686;C4318744;C4319952;C4551656
658,adjusted or ( $nmbr$ % cl ),C0456081;C0596019
658,adjusted hr * ( $nmbr$ % cl ) pvalue,C0456081;C0596019
658,adjusted hr ( enl vs lcz ) ( $nmbr$ % cl ),C0456081;C0596019
658,adjusted hr ( $nmbr$ % cl ),C0456081;C0596019
658,adjusted $nmbr$ or ( $nmbr$ % cl ),C0456081;C0596019
658,adj . hr ( $nmbr$ % cl ) a,C0001552;C0596019;C2826286
658,[ $nmbr$ % cl ],C0596019
658,( %  $nmbr$ % cl ),C0596019
658,( $nmbr$ % cl ) interaction,C0596019;C1704675
658,( $nmbr$ % cl ),C0596019
658,% risk reduction ( $nmbr$ % cl ),C0596019;C1137094
658,$nmbr$ cl ),C0596019
658,$nmbr$ ( $nmbr$ cl ),C0596019
658,$nmbr$ % cl,C0596019
657,kl $nmbr$ ( % ),C1366480;C1416656;C1704887
657,hmgcoa rl,C0047420;C1419337;C3539667
656,cox bsl onlyc,C1549954;C1565830
656,cox bsl + yr $nmbr$ hbd,C0439234;C1549954;C1565830
655,diabetes bl,C0005918;C0006413;C0011847;C0011849;C1552663;C2827109
655,bl mean ( cm ),C0005918;C0006413;C0444504;C1552663;C2347634;C2348143;C2827109
655,bl h / y : unilateral,C0005918;C0006413;C0033727;C0205092;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
655,bl h / y : bilateral,C0005918;C0006413;C0033727;C0238767;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
655,bl bml > $nmbr$ kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
655,bl bml > $nmbr$ ke / m ^,C0005918;C0006413;C0022558;C0369637;C0441923;C1552663;C2827109
655,bl bml < $nmbr$ kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
655,bl bmioo kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
655,bl alc < $nmbr$ . $nmbr$ %,C0005918;C0006413;C1424945;C1552663;C2827109;C3811058
655,bl,C0005918;C0006413;C1552663;C2827109
655,\bl - sc n / n,C0005918;C0006413;C0282380;C1552663;C2827109
-10,caribbean,C0043122;C0206155;C1331005
653,cardiogenic shock during first $nmbr$ hr after randomization,C0034656;C0036980;C0205435;C1279901
653,cardiogenic shock,C0036980
652,nonischemic cardiomyopathy — no . ( % ),C0878544
652,nonischemic cardiomyopathy,C0878544
652,nonischemic,
652,non - ischaemic cardiomyopathy,C0349782;C1518422
652,ischemic cardiomyopathy,C0349782
652,ischaemic cardiomyopathy,C0349782
651,other cardiovascular risk factors,C0850624
651,nonglycemic cardiovascular risk factors,C0850624
651,major cerebrovascular,C0205082;C0205164;C1880018;C4318856;C4521762
651,cerebrovascular,C1880018
651,cardiovascular risk factors — no . { % ),C0850624
651,cardiovascular risk factors — no . / total no . ( % ),C0439175;C0439810;C0850624
651,cardiovascular risk factors and history — no . ( % ),C0019664;C0019665;C0262512;C0262926;C0850624;C1705255;C2004062
651,cardiovascular risk factors and history ( % ),C0019664;C0019665;C0262512;C0262926;C0850624;C1705255;C2004062
651,cardiovascular risk factors and history,C0019664;C0019665;C0262512;C0262926;C0850624;C1705255;C2004062
651,cardiovascular risk factors alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C0850624
651,cardiovascular risk factors  no . ( % ),C0850624
651,cardiovascular risk factors  n ( % ),C0850624
651,cardiovascular risk factors,C0850624
651,cardiovascular risk factor — no . { % ),C0850624
651,at least two cardiovascular risk factors,C0205448;C0850624
650,cardiovascular history 一 no . ( % ),C1880008
650,cardiovascular history — no . / total no . ( % ),C0439175;C0439810;C1880008
650,cardiovascular history — no . ( % ),C1880008
650,cardiovascular history,C1880008
649,secondary cardiovascular endpoint,C0007226;C3887460;C4528314
649,primary cardiovascular endpoint,C0007226;C2986535;C3887460
649,previous history of cardiovascular events,C0007226;C2004062;C3887460
649,no . of predictors of cardiovascular risk,C0007226;C0035647;C2698872;C3887460;C4552904
649,extended cardiovascular endpoint,C0007226;C0231448;C0231449;C0439792;C2349179;C2826544;C3887460
649,death from cardiovascular causes,C0007226;C0007465;C3887460
649,core cardiovascular endpoint,C0007226;C0444669;C1167518;C1706352;C1882467;C2349179;C2826544;C3274653;C3887460
649,cardiovascular status,C0007226;C0449438;C3887460
649,cardiovascular risk  n ( % ),C0007226;C0035647;C3887460;C4552904
649,cardiovascular risk,C0007226;C0035647;C3887460;C4552904
649,cardiovascular hospitalization,C0007226;C0019993;C3887460
649,cardiovascular hospitalisation §,C0007226;C0019993;C3887460
649,cardiovascular and respiratory,C0007226;C0521346;C1546767;C3887460
649,cardiovascular and oral hypoglycemic drugs - no . ( % ),C0007226;C0359086;C3887460
649,cardiovascular,C0007226;C3887460
649,any cardiovascular diseased,C0007226;C3887460
649,all cardiovascular,C0007226;C3887460
649,* per $nmbr$ participant years . composite of first occurrence death ( all cause )  nonfatal ml  or nonfatal stroke . cardiovascular death excluding those classified as “ unable to determine . ”,C0007226;C0008902;C0011065;C0015127;C0038454;C0040363;C0041260;C0205199;C0205435;C0243132;C0332196;C0439234;C0439526;C0566415;C0679646;C1279901;C1299582;C1306577;C1524003;C1547335;C1554210;C1705224;C1883351;C2698741;C2745955;C2828389;C3887460;C3887665;C4048706;C4082313;C4321405;C4552775;C4554048;C4554100
648,concomitant cardiovascular therapy — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
648,concomitant cardiovascular therapy ( taken > $nmbr$ days ),C0007226;C0439228;C0521115;C0587038;C1707479;C1883727;C3887460
648,concomitant cardiovascular therapy,C0007226;C0521115;C0587038;C1707479;C3887460
648,concomitant cardiovascular therapies — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
648,cardiovascular therapies — no . { % ),C0587038
647,prior myocardial infarction 一 no . ( % ),C0155668
647,prior myocardial infarction — no . { % ),C0155668
647,prior myocardial infarction — no . / total no . ( % ),C0155668;C0439175;C0439810
647,prior myocardial infarction — no . ( % ),C0155668
647,prior myocardial infarction yes,C0155668;C1549445;C1705108;C1710701
647,prior myocardial infarction ( % ),C0155668
647,prior myocardial infarction  no . / total no . ( % ),C0155668;C0439175;C0439810
647,prior myocardial infarction  n ( % ),C0155668
647,prior myocardial infarction  %,C0155668
647,prior myocardial infarction,C0155668
647,cardioembolic infarction  n ( % ),C0021308
647,cardioembolic,
647,anterior myocardial infarction — no . / total no . ( % ),C0340293;C0439175;C0439810
647,anterior myocardial infarction — no . ( % ),C0340293
647,angina class iii or iv prior myocardial infarction,C0022326;C0155668;C0264677;C4265176
647,> $nmbr$ prior myocardial infarction — no . ( % ),C0155668
646,years since myocardial infarction,C0027051;C0428953;C0439234;C2926063;C3810814;C4552959
646,type of myocardial infarction — no . ( % ),C0027051;C0332307;C0428953;C1547052;C2926063;C3810814;C4552959
646,time from qualifying myocardial infarction,C0027051;C0040223;C0428953;C1514624;C2926063;C3541383;C3810814;C4552959
646,suspected myocardial infarction,C0027051;C0332147;C0428953;C0750491;C2926063;C3810814;C4552959
646,qualifying myocardial infarction,C0027051;C0428953;C1514624;C2926063;C3810814;C4552959
646,previous stroke yes ( n  % ) previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C3841753;C4552959
646,previous myocardial infarction — no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
646,previous myocardial infarction ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
646,previous myocardial infarction  no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
646,previous myocardial infarction  n ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
646,previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
646,nonfatal myocardial infarction ®,C0027051;C0428953;C2926063;C3810814;C4552959
646,nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
646,non - fatal myocardial infarction,C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959
646,no previous myocardial infarction $nmbr$ / $nmbr$,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
646,no previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
646,no myocardial infarction at presentation ( n = $nmbr$ ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
646,myocardial infarction — no . ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
646,myocardial infarction §,C0027051;C0428953;C2926063;C3810814;C4552959
646,myocardial infarction within the previous $nmbr$ yr,C0027051;C0205156;C0428953;C0439234;C1552607;C2926063;C3810814;C4552959
646,myocardial infarction n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
646,myocardial infarction at presentation ( n = $nmbr$ ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
646,myocardial infarction :,C0027051;C0428953;C2926063;C3810814;C4552959
646,myocardial infarction / cabg / pci,C0010055;C0027051;C0428953;C2926063;C3810814;C4049621;C4552959
646,myocardial infarction ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
646,myocardial infarction  n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
646,myocardial infarction  ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
646,myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
646,investigator - determined myocardial infarction,C0027051;C0035173;C0428953;C2926063;C3810814;C4552959
646,histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
646,fatal myocardial infarction,C0027051;C0428953;C1302234;C1705232;C2926063;C3810814;C4552959
646,cardiovasculardeath / myocardial infarction / stroke,C0027051;C0038454;C0428953;C2926063;C3810814;C4552959;C4554100
646,cardiovasculardeath,
646,cardiovascular death or nonfatal myocardial infarction,C0007226;C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959
646,cardiovascular death  nonfatal myocardial infarction  nonfatal stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
646,b . myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
645,sudden cardiac death §,C0085298
645,noncardiovascular death,C0011065;C1306577;C4082313;C4552775
645,noncardiovascular,
645,cardiac death,C0376297
644,prior cardiac resynchronization therapy  n ( % ),C0332152;C1167956;C2826257
644,d includes cardiac glycosides  antiarrhythmics classes i and iii  vasodilators used in cardiac disease and other cardiac preparations .,C0003195;C0007158;C0018787;C0018799;C0042402;C0073187;C0332173;C0332257;C0439070;C0441885;C1273517;C1319793;C1521827;C1522601;C1552866;C1705160;C2698967;C2700399;C3812761;C4484261
644,cardiac therapy §,C3654025
644,cardiac therapy  n ( % ) d,C3654025
644,cardiac therapy,C3654025
644,cardiac resynchronization therapy n ( % ),C1167956
644,cardiac resynchronization therapy,C1167956
644,cardiac glycosides,C0007158
643,rvfac ( % ),
643,elevation of cardiac biomarker levels — no . / total no . ( % ),C0439175;C0439775;C0439810;C0441889;C0702240;C1271630
643,cardiac procedure :,C1279986
643,cardiac biomarker status !,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
643,cardiac biomarker elevation,C0439775;C0702240;C1271630
643,cardiac biomarker  n ( % ),C1271630
643,arvfac ( per $nmbr$ % ),
643,aborted cardiac arrest,C0018790;C1550015;C1609614;C4085625;C4318470;C4553105
-10,phenobarbital,C0031412
641,reinfarction,
641,prior myocardial intarction,C0027061;C0332152;C1522564;C2826257
641,parental history of myocardial infarction before age $nmbr$ y yes,C0001779;C0030551;C1275835;C1549445;C1705108;C1710701
641,parental history of myocardial infarction before age $nmbr$ y,C0001779;C0030551;C1275835
641,parental history of myocardial infarction before $nmbr$ yr of age ( % ),C0001779;C0030551;C0439234;C1275835
641,history of myocardial infarction ( % ),C1275835
641,history of myocardial infarction  n ( % ),C1275835
641,history of myocardial infarction,C1275835
641,history myocardial infarction,C0155668;C1275835
641,fatal or nonlatal myocardial inlarctlon,C0027061;C1302234;C1522564;C1705232
640,useofmedical therapyathospitaldischarge,
640,stenting plus medical therapy ( n = $nmbr$ ),C0038257;C0418981;C2348535
640,stent plus medical therapy,C0038257;C0418981
640,medical therapy only ( n = $nmbr$ ),C0205171;C0418981;C1720467
640,medical therapy only,C0205171;C0418981;C1720467
640,medical therapy before admission,C0184666;C0418981;C0809949
640,medical therapy alone,C0205171;C0418981;C0439044;C0679994
640,medical therapy ( n = $nmbr$ ),C0418981
640,medical therapy,C0418981
640,medical therapies,C0418981
639,medical historv,C0199168;C0205476
639,first medical contact — no . ( % ) §,C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666
639,first medical contact,C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666
638,minimal important change threshold ( improvement ) a,C0449864;C2986411;C3845594;C3898777;C4084912
638,medically important infectionsa,C3898777;C4084912
637,indian ( indian subcontinent ),C0454693
637,indian ( american ) or alaska native,C0596070;C0682125;C1524069
637,indian,C1524069
637,american indian or native alaskan,C0002460;C0682125
637,american indian or alaskan,C0002460;C0238611
637,american indian or alaska,C0001905;C0002460
637,american indian or,C0002460
637,american indian / native alaskan,C0002460;C0682125
637,american indian /,C0002460
637,american indian  alaskan native  or aboriginal canadian,C0002460;C0238611;C0238884;C0302891;C0935542
637,american indian,C0002460
636,rarertd antocagibtcn before andorrtzafon,
636,indomethacin,C0021246
635,≤ median,C0549183;C0876920;C2347635;C2348144;C2939193
635,£ median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
635,£ median ( $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
635,£ median,C0549183;C0876920;C2347635;C2348144;C2939193
635,years since mi ( median,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814
635,wt  second  median,C0205436;C0457385;C0549183;C0565930;C0876920;C1561503;C1705190;C1883559;C2347635;C2348144;C2700323;C2939193
635,waisvhip > = median,C0549183;C0876920;C2347635;C2348144;C2939193
635,waist / hip < median,C0019552;C0022122;C0230097;C0549183;C0876920;C1505163;C2347635;C2348144;C2939193;C3538851;C4284725
635,urine acr > = median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
635,urine acr < median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
635,urinary albumin / creatinine ratio  median mg / g ( range ),C0455271;C0549183;C0876920;C1300563;C1318330;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,triglycerides  median ( range ),C0041004;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,triglycerides  median ( q $nmbr$ : q $nmbr$ ),C0041004;C0549183;C0876920;C2347635;C2348144;C2939193
635,total ige levelx ( iu / ml )  median ( range ),C0439175;C0439458;C0439810;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,total cholesterol ( median  iqr )  mg / dl,C0201950;C0439269;C0543421;C0549183;C0876920;C2347635;C2348144;C2939193
635,tngtycerides a median,C0549183;C0876920;C2347635;C2348144;C2939193
635,tngtycerides < median,C0549183;C0876920;C2347635;C2348144;C2939193
635,tngtycendes a median,C0549183;C0876920;C2347635;C2348144;C2939193
635,tnglycendes < median,C0549183;C0876920;C2347635;C2348144;C2939193
635,time to end - of - study ivus  median ( iqr )  days,C0439548;C0444930;C0549183;C0557651;C0876920;C1456025;C2347635;C2348144;C2603343;C2746065;C2939193
635,time from symptom onset of ra  years  median,C0439234;C0549183;C0876920;C1320528;C2347635;C2348144;C2939193;C3538806;C4048756
635,time from study drug administration to coronary revascularization  median ( iqr )  h,C0013175;C0033727;C0040227;C0150270;C0206209;C0369286;C0441932;C0549183;C0564385;C0876920;C0877341;C2347635;C2348144;C2349982;C2939193;C3469597;C4528284
635,time from ra diagnosis  years  median,C0011900;C0549183;C0556970;C0876920;C1704338;C1704656;C2347635;C2348144;C2939193;C3538806;C4048756
635,time from hospital admission to pci  h  median ( q $nmbr$  q $nmbr$ ),C0019994;C0033727;C0040223;C0369286;C0441932;C0549183;C0564385;C0876920;C1510665;C1959907;C2347635;C2348144;C2939193;C3541383;C4049621;C4528284
635,time from  median ( iqr )  h,C0033727;C0040223;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C3541383;C4528284
635,tg ( mmol / l  median ),C0337445;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
635,tg  mmol / l ( mg / dl ) [ median ],C0337445;C0549183;C0876920;C2347635;C2348144;C2939193;C3642216;C3898312
635,tg  median ( sdy rng / cjl,C0337445;C0549183;C0876920;C1424906;C2347635;C2348144;C2939193
635,tg  median ( interquartile range ),C0337445;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
635,systolic blood pressure  mm hg  median ( range ),C0439475;C0488055;C0549183;C0871470;C0876920;C1306620;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,score on nih stroke scale — median ( iqr ),C0449820;C0549183;C0876920;C1697238;C2347635;C2348144;C2939193;C3484372;C4050231
635,score on modified rankin scale — median ( iqr ),C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C2984908;C3854213;C4050231
635,score on modified mini - mental state examination — median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193;C4304091
635,score improvement  baseline to week $nmbr$  median ( iqr ),C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411;C4050231
635,sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .,C0000545;C0003695;C0042295;C0085805;C0282379;C0428883;C0439175;C0439632;C0439810;C0441833;C0444504;C0456603;C0488055;C0536221;C0549183;C0578022;C0687744;C0871470;C0876920;C1235746;C1257890;C1306620;C1519504;C1547037;C1552839;C1705241;C1705242;C1705428;C1705429;C1709380;C1711350;C1882141;C1882932;C2316832;C2347634;C2347635;C2348143;C2348144;C2699193;C2939193;C3813197;C4281799;C4554792
635,sbp > median ( n = $nmbr$ ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
635,sbp < median ( n = $nmbr$ o $nmbr$ ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
635,sbp ( mm hg )  median ( iqr ),C0085805;C0439475;C0549183;C0876920;C2347635;C2348144;C2939193
635,s median,C0549183;C0565930;C0876920;C2347635;C2348144;C2603362;C2939193
635,pulse pressure ( median $nmbr$ . $nmbr$ ],C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
635,percent improvement  baseline to week $nmbr$  median ( iqr ),C0168634;C0332174;C0439165;C0439230;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411
635,pasi  median ( range ) * *,C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4528685
635,number of visits  median,C0549183;C0876920;C1549755;C2347635;C2348144;C2939193
635,nt - probnp  median pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
635,nt - probnp  median ( iqr )  pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
635,non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = $nmbr$  $nmbr$ ),C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
635,non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = $nmbr$  $nmbr$ ),C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
635,msfc timed $nmbr$ - foot walk test  median seconds,C0016504;C0347981;C0392761;C0457385;C0549183;C0876920;C2346504;C2347635;C2348144;C2348613;C2348704;C2939193;C4277740
635,months from mi — median ( iqr ),C0439231;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814
635,minutes from symptom onset to prehospital ecg  median ( iqr ),C0439232;C0549183;C0700321;C0702093;C0876920;C1282918;C1623258;C2347166;C2347635;C2348144;C2939193;C4086878
635,minutes from prehospital ecg to pci  median ( iqr ),C0439232;C0549183;C0700321;C0702093;C0876920;C1282918;C1623258;C2347166;C2347635;C2348144;C2939193;C4049621
635,minutes from pre - pci angiography to post - pci angiography  median ( iqr ),C0002978;C0332152;C0439232;C0549183;C0687676;C0700321;C0702093;C0740175;C0876920;C1282918;C1704687;C2257086;C2347166;C2347635;C2348144;C2939193;C3469826;C3669034;C4049621
635,medians ( iqr ),C0549183
635,median — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
635,median — vr,C0549183;C0876920;C2347635;C2348144;C2939193;C3476815
635,median §,C0549183;C0876920;C2347635;C2348144;C2939193
635,median time to event ( weeks ),C0040223;C0439230;C0441471;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383;C4019010
635,median time since diagnosis * ( range )  yr,C0011900;C0040223;C0439234;C0549183;C0876920;C1514721;C1704338;C1704656;C2347635;C2348144;C2348147;C2939193;C3541383;C3542016
635,median time delay ( interquartile range ) — min,C0522486;C0549183;C0702093;C0876920;C1524029;C1711350;C2347635;C2348144;C2939193;C3813700
635,median seconds,C0457385;C0549183;C0876920;C2347635;C2348144;C2939193
635,median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
635,median nt - probnp ( iqr ) – pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
635,median n - terminal probnp ( iqr ) — pg / ml,C0439297;C0549183;C0669479;C0876920;C2347635;C2348144;C2939193
635,median feno  ppba,C0549183;C0876920;C2347635;C2348144;C2939193
635,median egfr ( interquartile range ),C0549183;C0876920;C1711350;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
635,median duration oftype $nmbr$ diabetes ( iqr ) — yr,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
635,median delay ( h ) §,C0033727;C0205421;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
635,median daily dose - iu ™,C0049272;C0439453;C0549183;C0694756;C0876920;C2347635;C2348070;C2348144;C2939193
635,median change  %,C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952
635,median cardiac troponin t ( iqr ) 一 pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
635,median cardiac troponin t ( iqr ) — pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
635,median c - reactive protein — mg / dl ^,C0006560;C0439269;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
635,median albumin / creatinine ratio ( g / mg ),C0024671;C0026410;C0439267;C0439269;C0486293;C0549183;C0876920;C1318293;C1960952;C2346927;C2347635;C2348144;C2939193;C4321396;C4521761
635,median age ( iqr  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
635,median age  y ( range ),C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,median ( range ) total ige level ( iuml ~ ’ ) $nmbr$,C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1514721;C1547707;C2347635;C2348144;C2348147;C2939193;C2946261;C3542016
635,median ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,median ( q $nmbr$ – q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
635,median ( q $nmbr$ : q $nmbr$ ) total daily insulin dose $nmbr$,C0021641;C0549183;C0876920;C1533581;C1579433;C2347635;C2348070;C2348144;C2939193;C3714501
635,median ( q $nmbr$ : q $nmbr$ ) tgs,C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
635,median ( q $nmbr$ : q $nmbr$ ) lp ( a )  mg / dl,C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
635,median ( q $nmbr$ : q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
635,median ( q $nmbr$  q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
635,median ( iqr ) — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
635,median ( iqr ) cholesterol,C0008377;C0549183;C0876920;C2347635;C2348144;C2939193
635,median ( iqr ) change from baseline to week $nmbr$ in psa - modified total shs score,C0168634;C0332174;C0392747;C0439175;C0439230;C0439810;C0443172;C0449820;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C3810537;C3813209;C3889737;C4050231;C4319952
635,median ( iqr ) age  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
635,median ( iqr ) admission data,C0184666;C0549183;C0809949;C0876920;C1511726;C2347635;C2348144;C2939193;C3245479;C3714741
635,median ( iqr )  h,C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
635,median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
635,median ( iq range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,median ( interquartile range ),C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
635,median  y ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,median  range,C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,median  ml,C0439526;C0549183;C0876920;C1705224;C2347635;C2348144;C2939193;C3887665
635,median  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
635,median  iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
635,median  iqr,C0549183;C0876920;C2347635;C2348144;C2939193
635,median,C0549183;C0876920;C2347635;C2348144;C2939193
635,mean age  y  median ( range ),C0001779;C0444504;C0549183;C0876920;C1514721;C2347634;C2347635;C2348143;C2348144;C2348147;C2939193;C3542016
635,maximum cimt < median,C0549183;C0806909;C0876920;C1552615;C2347635;C2348144;C2826546;C2939193
635,lvef  %  median ( iqr ),C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193
635,lp ( a )  mg / dl  median ( q $nmbr$ : q $nmbr$ ),C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
635,lp ( a )  median ( q $nmbr$ : q $nmbr$ ),C0065058;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
635,less than the median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
635,less than median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
635,length of stent > median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
635,length of stent < median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
635,laboratory values at randomization ( median and iqr ),C0022877;C0034656;C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
635,laboratory parameters  median ( iqr ),C0022877;C0449381;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
635,insulin dose ( iu / day )  median,C0366513;C0439465;C0549183;C0876920;C2347635;C2348144;C2939193
635,insulin  median ( ql  q $nmbr$ )  pmol / l,C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
635,insulin  median ( q $nmbr$  q $nmbr$ )  pmol / l,C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
635,index event to randomization  median ( iqr )  h,C0033727;C0034656;C0369286;C0441471;C0441932;C0549183;C0564385;C0600653;C0876920;C0918012;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C4019010;C4528284
635,ige ( ku / l )  median ( range ) c,C0439340;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,hscrp ( mg / l )  median ( min – max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193
635,hscrp  mg / l  median ( min – max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193
635,hscrp  median ( min  max )  mg / l,C0549183;C0876920;C2347635;C2348144;C2827895;C2939193
635,homa_ir  median ( q $nmbr$  q $nmbr$ )  % / $nmbr$,C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
635,homa_ % b tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952
635,homa_ % b  median ( q $nmbr$  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
635,heart rate ( median $nmbr$ . $nmbr$ },C0018810;C0549183;C0876920;C2347635;C2348144;C2939193
635,hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193
635,hbalc in %  median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
635,hbalc > median,C0549183;C0876920;C2347635;C2348144;C2939193
635,hbalc < median,C0549183;C0876920;C2347635;C2348144;C2939193
635,hbak > median,C0549183;C0876920;C2347635;C2348144;C2939193
635,hbak < median,C0549183;C0876920;C2347635;C2348144;C2939193
635,hba < median,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
635,hba $nmbr$ c tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0019016;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C1825777;C2347635;C2348144;C2939193;C3538758;C4319952
635,hba $nmbr$ c in % ( median ( q $nmbr$  q $nmbr$ ) [ n ] ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
635,hba $nmbr$ c ( % ) ( median ( iqr ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
635,hba $nmbr$ c  median ( q $nmbr$ – q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
635,hba $nmbr$ c  median ( q $nmbr$  q $nmbr$ )  %,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
635,hba $nmbr$ c  %  median ( q $nmbr$  q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
635,fastng plasma glucose < median,C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
635,fasting tgs  median ( q $nmbr$ : q $nmbr$ ),C0015663;C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
635,fasting plasma glucose in mmol / l ( median ( q $nmbr$  q $nmbr$ ) [ n ] ),C0549183;C0583513;C0876920;C1532563;C2347635;C2348144;C2939193
635,fasting plasma glucose < median,C0015663;C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
635,duration of pci ( min )  median n ( iqr ),C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
635,duration from hospital admission to pci  h ( median  iqr ),C0019994;C0033727;C0369286;C0441932;C0449238;C0549183;C0564385;C0876920;C1510665;C1959907;C2347635;C2348144;C2926735;C2939193;C4049621;C4528284
635,difference  % median,C0549183;C0876920;C1705241;C1705242;C2347635;C2348144;C2939193
635,data represent number of patients ( % ) or mean ( standard deviation )  unless otherwise indicated . a self - reported information . bc physician - diagnosed diabetes or fasting plasma glucose ≥ $nmbr$ mg / dl or hemoglobin a $nmbr$ c ≥ $nmbr$ . $nmbr$ % . d physician - diagnosed hypertension or systolic blood pressure ≥ $nmbr$ mmhg or diastolic blood pressure ≥ $nmbr$ mmhg . median ( interquartile range ) . ldl  low - density lipoprotein  hdl  high - density lipoprotein  tg  triglyceride .,C0006041;C0011847;C0011849;C0011900;C0015663;C0019020;C0020538;C0023820;C0031831;C0062152;C0073187;C0178587;C0202042;C0205251;C0332173;C0337445;C0428883;C0439269;C0439475;C0444504;C0455280;C0488055;C0549183;C0681906;C0804815;C0871420;C0871470;C0876920;C1305849;C1306620;C1442989;C1444656;C1511726;C1533716;C1550472;C1711350;C1828170;C1882932;C1963138;C2347634;C2347635;C2348143;C2348144;C2360800;C2700446;C2828392;C2939193;C2984916;C3245479;C3714741;C3889898;C3890211;C4048187;C4321351;C4484261;C4522223
635,dactylitis score at baseline  median ( iqr ) week $nmbr$,C0168634;C0239161;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C4050231
635,crp median ( se )  rng / l,C0036919;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
635,crp [ mg / l ]  median,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
635,crp ( mg / l ) [ b ]  median ( min - max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
635,crp  median ( range ) mg / literl,C0024671;C0026410;C0439269;C0549183;C0876920;C1514721;C1960952;C2346927;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285;C4321396;C4521761
635,clinical variables  median ( iqr ),C0205210;C0439828;C0549183;C0876920;C2347635;C2348144;C2939193
635,change from baseline  median ( iqr ),C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952
635,c - reactive protein  median ( q $nmbr$  q $nmbr$ ),C0006560;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
635,c - reactive protein  median ( iqr )  mg / l,C0006560;C0439268;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
635,c - peptide  median ( ql  q $nmbr$ )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
635,c - peptide  median ( q $nmbr$  q $nmbr$ )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
635,body mass index ( median,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
635,body mass index  median ( iqr ) b,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
635,body mass index  median ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
635,bmi * ( kg / m $nmbr$ )  median ( q $nmbr$  q $nmbr$ ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
635,bmi ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0876920;C1420718;C1532718;C2347635;C2348144;C2923536;C2939193;C4282123;C4285344
635,bmi  median ( sd )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2699239;C2939193
635,below median,C0549183;C0876920;C2347635;C2348144;C2939193
635,baseline total pcsk $nmbr$ level by median,C0168634;C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C2347635;C2348144;C2939193;C2946261
635,baseline tg  ( mg / dl )  median ( iqr ),C0168634;C0337445;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
635,baseline tav - > = median ( n = $nmbr$  $nmbr$ ),C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
635,baseline tav - < median ( n = $nmbr$  $nmbr$ ),C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
635,baseline scales  median ( range ),C0168634;C0175659;C0222045;C0349674;C0549183;C0876920;C1442488;C1514721;C1947916;C2347635;C2348144;C2348147;C2939193;C3542016
635,baseline pav - > = median ( n = $nmbr$  $nmbr$ ),C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
635,baseline pav - < median ( n = $nmbr$  $nmbr$ ),C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
635,baseline median [ mg / l ],C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
635,baseline median ( iq range ),C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
635,baseline median  mg / dl,C0168634;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
635,baseline median,C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
635,baseline free pcsk $nmbr$ level by median,C0168634;C0332296;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C1880497;C1996904;C2347635;C2348144;C2939193;C2946261
635,at or above the median,C0549183;C0876920;C2347635;C2348144;C2939193
635,at or above median,C0549183;C0876920;C1282910;C1552828;C2347635;C2348144;C2939193
635,age in years  median ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
635,age > - median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
635,age < median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
635,age - years  median ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
635,age ( median [ iqr ] )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
635,age ( median  iqr )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
635,age  median ( iqr )  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
635,age  median ( iqr )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
635,age  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
635,a median,C0549183;C0876920;C2347635;C2348144;C2939193
635,a $nmbr$ c > = median,C0549183;C0876920;C2347635;C2348144;C2939193
635,a $nmbr$ c < median,C0549183;C0876920;C2347635;C2348144;C2939193
635,a $nmbr$ c < $nmbr$ . $nmbr$ % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
635,a $nmbr$ = $nmbr$ . $nmbr$ % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
635,^ median > median,C0549183;C0876920;C2347635;C2348144;C2939193
635,^ median,C0549183;C0876920;C2347635;C2348144;C2939193
635,> median ( $nmbr$ mm ),C0549183;C0876920;C2347635;C2348144;C2939193;C4330985;C4554674
635,> median ( $nmbr$ kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
635,> median ( $nmbr$ . $nmbr$ years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
635,> median ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
635,> median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
635,> median ( $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
635,> median ( $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
635,> median ( $nmbr$ % ),C0549183;C0876920;C2347635;C2348144;C2939193
635,> median $nmbr$ . $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
635,> median,C0549183;C0876920;C2347635;C2348144;C2939193
635,> = median,C0549183;C0876920;C2347635;C2348144;C2939193
635,< median { $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
635,< median ( $nmbr$ kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
635,< median ( $nmbr$ . $nmbr$ years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
635,< median ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
635,< median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
635,< median ( $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
635,< median $nmbr$ . $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
635,< median,C0549183;C0876920;C2347635;C2348144;C2939193
635,- median tg ( iqr ),C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
635,- median pulse pressure ( mm hg ) ( iqr ),C0439475;C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
635,* data reported as n ( % ) or median ( quartiles $nmbr$  $nmbr$ ) .,C0549183;C0684224;C0700287;C0876920;C1511726;C2347635;C2348144;C2828255;C2939193;C3245479;C3714741;C4319718
635,( median  h ),C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
635,& median,C0549183;C0876920;C2347635;C2348144;C2939193
635,% change ( median  q $nmbr$  q $nmbr$ ),C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952
634,no . of days to homa - ir testing — median ( iqr ),C0022065;C0022071;C0039593;C0392366;C0439228;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
634,homa > median,C0549183;C0876920;C2347635;C2348144;C2939193
634,homa . ir  median ( ql  q $nmbr$ )  % / $nmbr$,C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
634,homa . % b  median ( ql  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
634,homa - p,
634,homa - ir  median ( q $nmbr$  q $nmbr$ ),C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
634,homa - b,
634,homa,
633,zotarolimust,
633,zotarolimus - eluting,C1700035
633,zotarolimus,C1700035
633,sirolimus eluting stent,C0038257;C0072980
633,sirolimus - eluting stent use  n ( % ),C0038257;C0042153;C0072980;C0457083;C1947944
633,sirolimus - eluting,C0072980
633,sirolimus,C0072980
633,everolimus - eluting,C0541315
633,everolimus,C0541315
632,c $nmbr$ e $nmbr$ fab bolus ( n = $nmbr$ ),C1186706;C1511237;C1705509;C3812160
632,c $nmbr$ e $nmbr$ fab bolus,C1186706;C1511237;C1705509;C3812160
632,bolus of heparin given,C0019134;C0770546;C1186706;C1442162;C1511237;C1550718;C1705509;C1947971;C3244317;C3812160
632,bolus and corrections,C1186706;C1511237;C1705509;C1705565;C1947976;C3812160
632,bolus alone,C0205171;C0439044;C0679994;C1186706;C1511237;C1705509;C3812160
632,bolus administered — no . ( % ),C1186706;C1511237;C1521801;C1705509;C3812160
632,bolus,C1186706;C1511237;C1705509;C3812160
632,basal plus bolus,C0205112;C0332287;C1186706;C1511237;C1705509;C3812160
631,systemic embolism,C0013922;C0205373;C1704212
631,peripheral embolism,C0013922;C0205100;C1704212
631,non cns embolism,C0013922;C1518422;C1704212;C3714787
631,embolism,C0013922;C1704212
631,cns systemic embolism,C0013922;C0205373;C1704212;C3714787
630,pulmonary embolism ± deep vein thrombosis,C0034065;C0149871;C0226514;C0852030
630,pulmonary embolism,C0034065
630,previous deep - vein thrombosis or pulmonary embolism,C0034065;C0149871;C0205156;C1552607
630,neither deep - vein thrombosis nor pulmonary embolism §,C0034065;C0149871
630,neither deep - vein thrombosis nor pulmonary embolism ^,C0034065;C0149871
630,deep - vein thrombosis or pulmonary embolism — no . ( % ),C0034065;C0149871
630,both deep - vein thrombosis and pulmonary embolism,C0034065;C0149871
629,metabolism and nutrition,C0025519;C0025520;C0028707;C0392209;C0518896;C1442959
629,glucose metabolism,C0596620
629,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . ‡ p < $nmbr$ . $nmbr$ vs . non - epa . § p < $nmbr$ . $nmbr$ vs . non - epa,C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0205251;C0221099;C0439165;C0444504;C0455280;C0549183;C0580545;C0596620;C0684224;C0700287;C0871420;C0876920;C1154908;C1442989;C1444656;C1511726;C1518422;C1549488;C1550472;C1561533;C1706005;C1711350;C1828170;C2347634;C2347635;C2348143;C2348144;C2828392;C2939193;C3245479;C3714741;C3890211;C4048187;C4319718;C4321351;C4522223
628,undetermined  other  or cardioembolism,C0205258;C3536725;C4082977
628,thromboembolism,C0040038
628,cardioembolism,
627,table $nmbr$ . selected baseline characteristics of the study patients . *,C0030705;C0039224;C0168634;C0557651;C1442488;C1568011;C1706074;C1707391;C2603343;C4684572
627,p < $nmbr$ . $nmbr$ ) between the study groups in any of the baseline characteristics . ace,C0369773;C0441849;C0557651;C0681848;C1452534;C1959644;C2603343;C2603361;C4284014;C4684572
627,no baseline characteristics,C4684572
627,endpoint / baselinec,C2349179;C2826544
627,endpoint / baseline,C0168634;C1442488;C2349179;C2826544
627,baselinec,
627,baseline characteristics,C4684572
626,weight at baseline,C1303013
626,baseline body weight quartile,C1303013;C2828255
625,without hypertension at baseline to hypertension,C0020538;C0168634;C1442488;C1963138
625,without baseline vertebral fracture,C0080179;C0168634;C1442488
625,with baseline vertebral fracture,C0080179;C0168634;C1442488
625,vertebral fractures at baseline,C0080179;C0168634;C1442488
625,using alendronate at baseline ( % ),C0102118;C0168634;C1442488;C1524063
625,use at baseline  n,C0042153;C0168634;C0457083;C1442488;C1947944
625,use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944
625,uas $nmbr$ {,
625,triglycerides at baseline,C0041004;C0168634;C1442488
625,treated at baseline,C0168634;C1442488;C1522326
625,thienopyridine at baseline,C0168634;C1120149;C1442488
625,systolic  treated at baseline,C0039155;C0168634;C1442488;C1522326
625,supine after $nmbr$ minutes change from baseline,C0038846;C0168634;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1442488;C1705241;C2347166;C4319952
625,statin use at baseline :,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
625,standing after $nmbr$ minutes change from baseline,C0168634;C0231472;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1442488;C1705241;C2347166;C4319952
625,standing after $nmbr$ minute change from baseline,C0168634;C0231472;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1442488;C1705241;C2347166;C4319952
625,selected baseline medications,C0013227;C0168634;C0802604;C1442488;C1707391;C2598133;C4284232
625,seizure types reported during baseline  n ( % ) a,C0036572;C0168634;C0332307;C0684224;C0700287;C1442488;C1959629;C4319718;C4553401
625,seizure types reported during baseline  b n ( % ),C0036572;C0168634;C0332307;C0684224;C0700287;C1442488;C1959629;C4319718;C4553401
625,respiratory medication taken at baseline  n ( % ),C0168634;C0418986;C1442488;C1883727
625,remission by : baseline duration of steroid,C0038317;C0168634;C0814126;C1442488
625,randomised patients with > $nmbr$ % bsa psoriasis skin involvement at baseline,C0030705;C0033860;C0168634;C0444099;C1123023;C1314939;C1442488;C4520765
625,radiographic progression based on change from baseline > sdc,C0168634;C0242656;C0392747;C0443172;C0444708;C0449258;C1419891;C1442488;C1527178;C1705241;C1705938;C3273112;C4319952
625,ppi use at baseline,C0042153;C0168634;C0358591;C0457083;C0871125;C1442488;C1947944;C3811894
625,planned thienopyridine at baseline,C0168634;C1120149;C1301732;C1442488
625,percent atheroma volume at baseline,C0168634;C0264956;C1442488;C1690016;C3887614
625,patients without syndesmophytes at baseline,C0030705;C0168634;C0221690;C1442488
625,patients with syndesmophytes at baseline,C0030705;C0168634;C0221690;C1442488
625,pah therapy at baseline,C0030123;C0039798;C0087111;C0168634;C1363945;C1442488;C3203102;C4284467
625,one at baseline,C0168634;C0205447;C1442488
625,on steroid at baseline,C0038317;C0168634;C1442488
625,on statins at baseline,C0168634;C0360714;C1442488
625,ocs at baseline,C0168634;C1442488
625,normonatremic ( > $nmbr$ meq / l ) at baseline,C0168634;C0439375;C1442488
625,none at baseline,C0168634;C1442488
625,non - smokers ( at baseline ),C0168634;C0337672;C1442488;C4554605
625,no new jsn among patients with ≥ $nmbr$ uninvolved joint at baseline ¶,C0022417;C0030705;C0168634;C0205314;C0205429;C0392905;C1442488;C1706309
625,no new erosions among patients with ≥ $nmbr$ uninvolved joint at baseline ¶,C0022417;C0030705;C0168634;C0205314;C0205429;C0333307;C0392905;C1442488;C1706309;C1959609
625,no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
625,no hospitalization in the past $nmbr$ months prior to baseline ( ref ),C0019993;C0168634;C1425988;C1442488;C4331910
625,no aspirin at baseline,C0004057;C0168634;C1442488
625,nihss at baseline,C0168634;C1442488;C1697238
625,mmrc at baseline,C0168634;C1442488;C3826977
625,microalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C0730345;C1442488;C1522326
625,methotrexate use at baseline,C0025677;C0042153;C0168634;C0457083;C1442488;C1947944
625,methotrexate dose at baseline,C0025677;C0168634;C0178602;C0869039;C1114758;C1442488
625,mental activities updrs subscore ( baseline )  mean ( sd ),C0168634;C0229992;C0441655;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721
625,memantine use at baseline  no . ( % ),C0025242;C0042153;C0168634;C0457083;C1442488;C1947944
625,medication use at baseline — no . ( % ),C0168634;C0240320;C1442488
625,medication use at baseline - n ( % ),C0168634;C0240320;C1442488
625,medication use at baseline  n ( % ),C0168634;C0240320;C1442488
625,medication in use at the baseline,C0013227;C0042153;C0150312;C0168634;C0332285;C0457083;C1442488;C1707101;C1947944;C3244316;C4284232
625,median ( iqr ) mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use : weight,C0005910;C0025677;C0042153;C0043100;C0168634;C0332174;C0439230;C0441833;C0444504;C0457083;C0549183;C0687744;C0876920;C1257890;C1305866;C1417487;C1442488;C1519504;C1705104;C1705428;C1705429;C1947944;C2347634;C2347635;C2348143;C2348144;C2939193
625,mean change from baseline in acq overall score ( sd ) *,C0168634;C0282416;C0392747;C0443172;C0444504;C0449820;C1442488;C1561607;C1705241;C2347634;C2348143;C2699239;C2919686;C4050231;C4319952
625,mean change from baseline  %,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
625,mean baseline ucdai score,C0168634;C0444504;C0449820;C1442488;C2347634;C2348143;C4050231
625,mean baseline nasal congestion score,C0027424;C0168634;C1442488;C3533236;C4554631
625,mean baseline ldl - c ( mmol / l ),C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
625,mean baseline ei score,C0022067;C0168634;C0444504;C0449820;C1414370;C1442488;C2347634;C2348143;C2348481;C4050231
625,mean baseline ( n ),C0168634;C0444504;C1442488;C2347634;C2348143
625,mean arterial pressure  baseline,C0168634;C0428886;C1442488
625,macroalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C1442488;C1522326
625,low - dose aspirin use at baseline yes,C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944;C2608320
625,level of thyroperoxidase antibody at baseline,C0021965;C0168634;C0428536;C0441889;C0456079;C0487652;C1318460;C1364508;C1429427;C1442488;C1547707;C2946261;C3272921
625,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0168634;C0202117;C0220908;C0220909;C1442488;C1532563;C1698960;C1710031;C1710032;C1710477;C2348164
625,ldl - c in mmol / l ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] ),C0036919;C0168634;C0332174;C0392747;C0439230;C0443172;C0444504;C1442488;C1532563;C1705241;C2347634;C2348143;C2699239;C4319952
625,ldl - c at baseline :,C0168634;C1442488
625,killip at baseline,C0168634;C1442488
625,intensified baseline ( n - $nmbr$ ),C0168634;C1442488
625,in remission at maintenance study baseline,C0024501;C0168634;C0544452;C0557651;C0687702;C1442488;C2603343
625,improvement from baseline ≥   $nmbr$,C0168634;C1442488;C2986411
625,immunosuppressive agents at baseline,C0021081;C0168634;C1442488
625,icsusers atbaseline  n ( % ),
625,ics use at baseline : yes,C0042153;C0168634;C0457083;C0815320;C1442488;C1549445;C1705108;C1710701;C1947944;C4551720
625,ics use at baseline  n ( % ),C0042153;C0168634;C0457083;C0815320;C1442488;C1947944;C4551720
625,ics use at baseline,C0042153;C0168634;C0457083;C0815320;C1442488;C1947944;C4551720
625,hyponatremic ( < $nmbr$ meq / l ) at baseline,C0168634;C0439375;C0857122;C1442488
625,hypertension severity at baseline  n ( % ),C0168634;C1442488;C4013784
625,hypertension at baseline,C0020538;C0168634;C1442488;C1963138
625,hospitalization in the past $nmbr$ months prior to baseline,C0019993;C0168634;C1442488;C4331910
625,heart - rate group at baseline,C0018810;C0168634;C0441833;C0687744;C1257890;C1442488;C1519504;C1705428;C1705429
625,flex baseline bmd t score,C0168634;C0449820;C1442488;C4050231
625,femoral neck f - score at flex baseline,C0015815;C0016327;C0168634;C0449820;C1442488;C4050231
625,fbg baseline,C0168634;C1442488
625,draining cutaneous fistula at baseline  n ( % ),C0013103;C0168634;C0180499;C0423772;C1442488;C4265177
625,dmard at baseline,C0168634;C0242708;C1442488
625,difference $nmbr$ years - baseline *,C0168634;C0439234;C1442488;C1705241;C1705242
625,difference $nmbr$ years - baseline,C0168634;C0439234;C1442488;C1705241;C1705242
625,diabetic retinopathy at baseline,C0011884;C0168634;C1442488
625,diabetes duration at baseline,C0011847;C0011849;C0168634;C0449238;C1442488;C2926735
625,diabetes at baseline,C0011847;C0011849;C0168634;C1442488
625,csdmard use at baseline ^,C0042153;C0168634;C0457083;C1442488;C1947944
625,crohn ' s disease - related medication at baseline  n ( % ),C0010346;C0013227;C0168634;C0439849;C0445223;C1442488;C3244316;C4284232
625,creatinine > $nmbr$ x baseline,C0010294;C0168634;C1442488;C1561535
625,creatinine > $nmbr$ . $nmbr$ x baseline and above uln,C0010294;C0168634;C1282910;C1442488;C1519815;C1552828;C1561535
625,conventional synthetic dmard use at baseline,C0042153;C0168634;C0242708;C0439858;C0457083;C1442488;C1883254;C1947944
625,concentrations at baseline,C0086045;C0168634;C1442488
625,common study baseline,C0168634;C0205214;C0557651;C1442488;C1522138;C2603343;C3245511
625,coiticosieroids at baseline,C0168634;C1442488
625,changes at baseline,C0168634;C0392747;C0443172;C1442488
625,change in psa ‐ modified shs  baseline to week $nmbr$ ‡,C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C3810537;C3813209;C3889737;C4319952
625,change in femoral neck bmd from fit baseline to flex baseline,C0015815;C0036572;C0168634;C0392747;C0443172;C1442488;C1705241;C2349186;C4048158;C4319952;C4553125
625,change from baseline to week $nmbr$ in uas $nmbr$,C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C4319952
625,change from baseline to eos  uu / ml,C0168634;C0392747;C0439342;C0443172;C1442488;C1623465;C1705241;C1861303;C4319952
625,change from baseline in pre - bd,C0005126;C0168634;C0332152;C0392747;C0443172;C0740175;C1442488;C1705241;C2257086;C2344255;C3669034;C4050145;C4319952
625,change from baseline in post - bd,C0005126;C0168634;C0392747;C0443172;C0687676;C1442488;C1704687;C1705241;C2344255;C3469826;C4050145;C4319952
625,change from baseline *,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
625,change from baseline ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
625,change from baseline  adjusted mean ( $nmbr$ % ci )  %,C0008107;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
625,change from baseline  adjusted mean ( $nmbr$ % ci ),C0008107;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
625,c - reactive protein ( high - sensitivity assay )  mitt = modified intent - to - treat  pbo cholesterol  cl = confidence intervals  hdl - c = high - density lipoprotein cholest = national cholesterol education program adult treatment panel y patients with diabetes ( fc > _ $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having acteristics described in methods ( ncep atp iii definition )  + baseline values are rr d hs - crr for which medians are presented  * * p < $nmbr$ . $nmbr$  § p = $nmbr$ . $nmbr$  * p = $nmbr$ . $nmbr$ . nteractions were not statistically significant ( p > $nmbr$ . $nmbr$ ) .,C0001675;C0005507;C0006560;C0009667;C0011847;C0011849;C0023822;C0025663;C0025664;C0030705;C0031962;C0040363;C0041260;C0042295;C0065055;C0087111;C0150375;C0162425;C0168634;C0178587;C0205250;C0243073;C0369773;C0392747;C0439070;C0449450;C0449851;C0549183;C0596019;C0679841;C1273937;C1283828;C1292734;C1299351;C1413716;C1441604;C1442488;C1510438;C1522326;C1550452;C1550453;C1552738;C1704788;C1705160;C1706450;C1883351;C2603361;C2700149;C2744579;C2983605;C3245503;C3539107;C3642216;C3887512;C3888054;C3889660;C3889737;C3898312;C4048285;C4321237;C4522209;C4552600;C4554402
625,biomarkers at baseline,C0005516;C0168634;C1442488
625,baselineb,
625,baseline vfx,C0168634;C1442488
625,baseline vertebral fracture,C0080179;C0168634;C1442488
625,baseline uric acid,C0041980;C0168634;C1442488
625,baseline upgr > $nmbr$ gm / gm ( $nmbr$ mg / mmole ),C0017480;C0168634;C0567349;C1442488;C2348885;C3854019
625,baseline upgr  mg / mmole ( n = $nmbr$  $nmbr$  $nmbr$ ),C0168634;C0567349;C1442488;C2348885
625,baseline uas $nmbr$,C0168634;C1442488
625,baseline trl - c by quintiles,C0168634;C1442488;C1508496
625,baseline triglycerides by quintiles,C0041004;C0168634;C1442488;C1508496
625,baseline triglycerides,C0041004;C0168634;C1442488
625,baseline treatments  n ( % ) a,C0087111;C0168634;C1442488
625,baseline total pcsk $nmbr$ level,C0168634;C0439175;C0439810;C0441889;C0456079;C1442488;C1547707;C2946261
625,baseline tophusa,C0168634;C1442488
625,baseline therapy,C0039798;C0087111;C0168634;C1363945;C1442488
625,baseline tava,C0168634;C1442488
625,baseline t - score at femoral neck  n ( % ),C0015815;C0168634;C0449820;C1442488;C4050231
625,baseline steroids,C0038317;C0168634;C1442488
625,baseline statin usec,C0168634;C0360714;C0439224;C1442488
625,baseline statin,C0168634;C0360714;C1442488
625,baseline sitosterol / lathosterol,C0037215;C0064673;C0168634;C0220914;C1442488
625,baseline sitosterol / cholesterol,C0008377;C0037215;C0168634;C0220914;C1442488
625,baseline sitosterol,C0037215;C0168634;C0220914;C1442488
625,baseline shs ( $nmbr$ - $nmbr$ ),C0168634;C1442488
625,baseline sgrq score,C0168634;C0449820;C1442488;C4050231
625,baseline serum k +  meq / l,C0168634;C0302353;C0439375;C1442488
625,baseline serum calcium level  n ( % ),C0036785;C0168634;C0728876;C1442488
625,baseline rst - segment elevation  mm,C0168634;C0439775;C0441635;C0702240;C1425219;C1442488;C4330985;C4554674
625,baseline rst - segment,C0168634;C0441635;C1425219;C1442488
625,baseline ptga,C0168634;C1442488
625,baseline pos frequency per $nmbr$ days,C0168634;C0585290;C1262869;C1442488;C3496112;C3496399
625,baseline pfd  m,C0016065;C0168634;C0369637;C0441923;C1442488;C1839454;C2827389;C3889643
625,baseline pcsi < $nmbr$ a,C0168634;C1442488
625,baseline pava,C0135567;C0168634;C1442488
625,baseline of induction )  n ( % ),C0168634;C0205263;C0857127;C1442488
625,baseline of induction,C0168634;C0205263;C0857127;C1442488
625,baseline nihss,C0168634;C1442488;C1697238
625,baseline nih stroke scale — no . ( % ) ^,C0168634;C1442488;C1697238;C3484372
625,baseline medications ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
625,baseline medications  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
625,baseline medication,C0013227;C0168634;C1442488;C3244316;C4284232
625,baseline medical therapy  n ( % ),C0168634;C0418981;C1442488
625,baseline medical therapy,C0168634;C0418981;C1442488
625,baseline measurements,C0168634;C0242485;C1442488
625,baseline mean 士 sd,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
625,baseline mean mtss,C0168634;C0444504;C1442488;C2347634;C2348143
625,baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
625,baseline mdrd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
625,baseline mdrd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
625,baseline lipids  mean ± sd ( mmol / $nmbr$ ),C0023779;C0168634;C0439190;C0444504;C1442488;C2347634;C2348143;C2699239
625,baseline lipids,C0023779;C0168634;C1442488
625,baseline lipid therapy,C0023779;C0039798;C0087111;C0168634;C1363945;C1442488
625,baseline lipid and lipoprotein values,C0023779;C0023820;C0042295;C0168634;C1442488
625,baseline lipid and apolipoprotein levels,C0003591;C0023779;C0168634;C0441889;C1442488
625,baseline lipid / lipoprotem values,C0023779;C0042295;C0168634;C1442488
625,baseline lipid / lipoprotein values,C0042295;C0168634;C0443602;C1442488
625,baseline ldl - c strata  n ( ° / o ),C0168634;C1442488
625,baseline ldl - c :,C0168634;C1442488
625,baseline ldl - c,C0168634;C1442488
625,baseline hstni,C0168634;C1442488
625,baseline hbalc ’,C0168634;C1442488
625,baseline hbalc ^,C0168634;C1442488
625,baseline hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ),C0168634;C1442488;C3829066
625,baseline hbalc > $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$,C0168634;C1442488;C3829066
625,baseline hbalc > $nmbr$ %,C0168634;C1442488
625,baseline hbalc < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$,C0168634;C1442488;C3829066
625,baseline hbalc < $nmbr$ %,C0168634;C1442488
625,baseline hbalc,C0168634;C1442488
625,baseline hb < $nmbr$ g $nmbr$ $nmbr$ n = $nmbr$,C0062408;C0168634;C0439267;C1442488
625,baseline hb $nmbr$ g i $nmbr$ n = $nmbr$,C0062408;C0086706;C0168634;C1442488
625,baseline glycated,C0168634;C1442488;C3666909
625,baseline free pcsk $nmbr$ level,C0168634;C0332296;C0441889;C0456079;C1442488;C1547707;C1880497;C1996904;C2946261
625,baseline fecal caicrctectin,C0015733;C0168634;C1442488
625,baseline ezetimibe usec,C0168634;C0439224;C1142985;C1442488
625,baseline ecro < $nmbr$ mumin,C0168634;C1442488
625,baseline ecrcl k $nmbr$ to < $nmbr$ ml / min,C0168634;C0439445;C0597277;C1442488;C1708601
625,baseline ecrcl $nmbr$ $nmbr$ ml / min,C0168634;C0439445;C1442488
625,baseline ecrcl,C0168634;C1442488
625,baseline ecg with lvh  n ( % ),C0168634;C0232306;C1442488
625,baseline dmard use  n ( % ),C0042153;C0168634;C0242708;C0457083;C1442488;C1947944
625,baseline dlco . mmol kpa - ’ -,C0168634;C0263428;C0439190;C0439474;C1442488;C1516251
625,baseline dipeptidyl peptidase $nmbr$,C0022709;C0168634;C1442488
625,baseline diabetes mellitus therapy  n ( % ),C0168634;C0948092;C1442488
625,baseline diabetes,C0011847;C0011849;C0168634;C1442488
625,baseline demographics,C0011298;C0168634;C1442488;C1704791
625,baseline das $nmbr$  mean ( s . e . ),C0051767;C0057671;C0168634;C0444504;C1442488;C2347634;C2348143
625,baseline dad ( n   = $nmbr$ + $nmbr$ ),C0168634;C1442488;C3641946
625,baseline cv treatment  n ( % ) y,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
625,baseline cv treatment,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
625,baseline crohn ' s disease medications,C0010346;C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
625,baseline creatinine clearance,C0168634;C0812399;C1442488
625,baseline creatinine  median ( range ) mg / dl,C0010294;C0168634;C0439269;C0549183;C0876920;C1442488;C1514721;C1561535;C2347635;C2348144;C2348147;C2939193;C3542016
625,baseline concentration,C0086045;C0168634;C1442488;C1446561;C3827302
625,baseline cardiovascular assessment,C0007226;C0168634;C0846600;C1442488;C3887460;C4684571
625,baseline cardiac biomarkers elevated,C0168634;C0205250;C1442488;C2735101;C2735102;C3163633
625,baseline cardiac biomarkers,C0168634;C1442488;C2735101;C2735102
625,baseline bp  mean ( sd ) *,C0168634;C0488053;C1442488;C2699239
625,baseline bnp concentration ( pg / ml ),C0054015;C0086045;C0168634;C0439297;C1095989;C1417808;C1442488;C1446561;C2982014;C3827302
625,baseline basfi,C0168634;C1442488
625,baseline anti - hyperglycemic medications  n ( % ),C0013227;C0168634;C0432633;C0802604;C1442488;C2598133;C4284232
625,baseline anti - hyperglycemic medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
625,baseline albuminuria,C0001925;C0168634;C1442488
625,baseline albumin : < $nmbr$,C0001924;C0168634;C1442488
625,baseline adas - cog $nmbr$,C0168634;C1442488;C3539026
625,baseline acq - $nmbr$ score,C0168634;C0449820;C1442488;C2919686;C4050231
625,baseline a $nmbr$ c ( % ),C0168634;C1442488
625,baseline - adjusted hr,C0168634;C0456081;C1442488
625,baseline - - mdrd,C0168634;C1442488;C3839656
625,baseline ( sd ),C0168634;C1442488;C2699239
625,baseline ( n ),C0168634;C1442488
625,baseline % bsa involvement,C0168634;C1314939;C1442488
625,baseline $nmbr$ - mlnute walk distance :,C0168634;C0429886;C1442488
625,baseline $nmbr$ - h ppg,C0033727;C0168634;C0369286;C0441932;C0564385;C1418888;C1442488;C4528284
625,baseline  no . ( % ),C0168634;C1442488
625,baseline  % ( n ),C0168634;C1442488
625,baseline,C0168634;C1442488
625,available baseline blood specimen n,C0168634;C0178913;C0470187;C1442488
625,at baseline — no . ( % ),C0168634;C1442488
625,at baseline,C0168634;C1442488
625,asthma control test score at baseline,C0168634;C1442488;C2733224
625,aspirin use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
625,aspirin at baseline,C0004057;C0168634;C1442488
625,antihyperglycaemic medication at baseline,C0013227;C0020616;C0168634;C1442488;C3244316;C4284232
625,antiepileptic drug type at baseline,C0003299;C0168634;C0332307;C0457591;C1442488;C1547052;C3537002
625,antibody binding level at baseline,C0168634;C0428536;C0441889;C0456079;C1145667;C1149306;C1167622;C1442488;C1547707;C2946261
625,adjusted mean change from baseline ( $nmbr$ % ci )  % [ mmol / mol ],C0008107;C0168634;C0392747;C0439190;C0443172;C0444504;C0456081;C0948922;C1442488;C1705241;C2347634;C2348143;C3259781;C3829066;C4319952
625,adjusted mean change from baseline,C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
625,adjusted change from baseline mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
625,adjusted change from baseline,C0168634;C0392747;C0443172;C0456081;C1442488;C1705241;C4319952
625,activities of daily living updrs subscore ( baseline )  mean ( sd ),C0001288;C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721;C4050548
625,abdominal or perianal fistula at baseline  n ( % ),C0000726;C0168634;C0267561;C1442488
625,abbreviations : acei  angiotensin - converting enzyme inhibitor  arb  angiotensin receptor blocker  bpm  beats per minute  ccb  calcium channel blocker  msdbp  mean sitting diastolic blood pressure  mssbp  mean sitting systolic blood pressure . values are no . ( % ) unless otherwise indicated . amean ± sd . bmore severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg  less severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg . blood pressure at baseline is with monotherapy ( ie  before switch to amlodipine / valsar - tan therapy ) .,C0000723;C0003015;C0005767;C0005768;C0005823;C0006684;C0014122;C0022067;C0025424;C0039798;C0040363;C0041260;C0042295;C0051696;C0087111;C0168634;C0205082;C0229664;C0277814;C0302595;C0332152;C0428257;C0439092;C0439385;C0439453;C0439475;C0443150;C0444504;C0488055;C0547044;C0597357;C0871470;C1271104;C1272641;C1306620;C1319894;C1363945;C1442488;C1444656;C1537110;C1705850;C1707719;C1881173;C1883351;C2347108;C2347109;C2347634;C2348143;C2348272;C2584297;C2699239;C2757044;C3275241;C3536837;C3536851;C3888198;C4050224;C4050465;C4050466;C4330985;C4521885;C4541021;C4554371;C4554674
625,a from baselineb,
625,a from baseline,C0168634;C1442488
625,a $nmbr$ c at baseline ≥ $nmbr$ . $nmbr$ %,C0168634;C1442488
625,a $nmbr$ c at baseline < $nmbr$ . $nmbr$ %,C0168634;C1442488
625,> $nmbr$ years baseline ldl - c,C0168634;C0439234;C1442488
625,> $nmbr$ med at baseline cardiac disorder *,C0018799;C0168634;C1442488;C4321267
625,> $nmbr$ % blood eosinophils at baseline,C0014467;C0168634;C1442488
625,< $nmbr$ % blood eosinophils at baseline,C0014467;C0168634;C1442488
625,( baseline ),C0168634;C1442488
625,$nmbr$ med at baseline,C0168634;C1442488;C4321267
625,$nmbr$ baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
624,thrombocytopenia,C0040034;C0392386
624,profound thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C0040034;C0392386;C0439808
624,moderate thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C0040034;C0205081;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
624,mild thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C1856453
623,thrombophilia  no . ( % ) e,C0398623
623,thrombophilia,C0398623
623,known thrombophilia — no . ( % ),C0205309;C0398623
623,known thrombophilia,C0205309;C0398623
622,stent thrombosis or mi,C3810814;C3897493
622,stent thrombosis - related mi,C0439849;C0445223;C3810814;C3897493
622,stent thrombosis *,C3897493
622,stent thrombosis,C3897493
622,non stent thrombosis - related mi,C0439849;C0445223;C1518422;C3810814;C3897493
622,definite acute stent thrombosis,C0205178;C0439544;C1704787;C3897493
622,death or stent thrombosis,C0011065;C1306577;C3897493;C4082313;C4552775
622,death / q - ml / stent thrombosis,C0011065;C0439526;C1306577;C1705224;C3887665;C3897493;C4082313;C4552775
622,composite of death / mi / stro ke / urgent revasc / definit e acute stent thrombosis,C0011065;C0022558;C0155626;C0205199;C0378365;C0439609;C1306577;C1547335;C3272275;C3897493;C4082313;C4552775
622,acute stent thrombosis ( definite or probable ),C0033204;C0205178;C0332148;C0439544;C1704787;C3897493
622,acute stent thrombosis,C0205178;C3897493
621,use of pci or thrombolysis within one day of randomization,C0034656;C0520997;C1524063;C3844320;C4049621
621,thrombolysis,C0520997
621,pci / thrombolysis at randomization,C0034656;C0520997;C4049621
620,treatment with open - label perindopril,C0136123;C3640652
620,trandolapril ( n = $nmbr$ ),C0076891
620,trandolapril,C0076891
620,perindopril,C0136123
619,phenytoin,C0031507;C0202454
619,outcome and metabolizer phenotype,C0031437;C1274040;C1285572
619,metabolizer phenotype ( % ) §,C0031437;C1285572
618,genotyping,C1285573
618,by genotyping,C1285573
617,without metabolic syndrome,C0524620
617,with metabolic syndrome,C0524620
617,the metabolic syndrome ^,C0524620
617,syndrome  n ( % ),C0039082
617,specific syndromes,C0039082;C0205369;C1552740;C1558916
617,participants without metabolic syndrome,C0524620;C0679646
617,participants with metabolic syndrome,C0524620;C0679646
617,nonmetabolic syndrome ( n = $nmbr$ ),C0039082
617,no metabolic syndrome,C0524620
617,ncep atp - iii metabolic syndrome features  n ( % ),C0369718;C0439070;C0441922;C0524620;C1521970;C1705160;C1706388;C2346469;C2348519;C2744579;C4552600
617,metabolic syndromeb,C0311400;C1524026;C2707259
617,metabolic syndrome — no . ( % ) ^,C0524620
617,metabolic syndrome — no . ( % ) $nmbr$,C0524620
617,metabolic syndrome — no . ( % ) !,C0524620
617,metabolic syndrome w / o t $nmbr$ dm,C0011816;C0524620;C3250443
617,metabolic syndrome visit $nmbr$ low - density lipoprotein cholesterol strata,C0023824;C0524620;C0545082;C1512346;C2826704
617,metabolic syndrome characteristics  n ( % ),C0524620;C1521970
617,metabolic syndrome * n = $nmbr$,C0524620
617,metabolic syndrome *,C0524620
617,metabolic syndrome ( n = $nmbr$ ),C0524620
617,metabolic syndrome ( > $nmbr$ of $nmbr$ characteristics ),C0524620;C1521970
617,metabolic syndrome ( % ) b,C0524620
617,metabolic syndrome ( % ),C0524620
617,metabolic syndrome $nmbr$ *,C0524620
617,metabolic syndrome  n / n ( % ) *,C0524620
617,metabolic syndrome  n ( % ),C0524620
617,metabolic syndrome  ! n ( % ),C0524620
617,metabolic syndrome,C0524620
617,high - density lipoprotein cholesterol metabolic syndrome  patients were to,C0023822;C0030705;C0040363;C0041260;C0524620;C1883351
617,changes ( a ) in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172;C0449381;C0524620;C1705241;C2357172;C4319952
617,cardiovascular metabolic syndrome risk lactors,C0007226;C0035647;C0524620;C3887460;C4552904
617,cardiometabolic syndrome  ^ n ( % ),C0039082
616,syncope — no . ( % ),C0039070;C3541349;C4554644
616,syncope,C0039070;C3541349;C4554644
615,systolic bp at baseline :,C0168634;C0871470;C1442488
615,systolic bp,C0871470
615,systolic blood pressure subgroups,C0488055;C0871470;C1079230;C1306620
615,systolic blood pressure ^,C0488055;C0871470;C1306620
615,systolic blood pressure ( mmhg ),C0439475;C0488055;C0871470;C1306620
615,systolic blood pressure ( median $nmbr$ . $nmbr$ ),C0488055;C0549183;C0871470;C0876920;C1306620;C2347635;C2348144;C2939193
615,systolic blood pressure  mmhg,C0439475;C0488055;C0871470;C1306620
615,systolic blood pressure  mm hq,C0488055;C0871470;C1306620;C4330985;C4554674
615,systolic blood pressure,C0488055;C0871470;C1306620
615,nonglycemic cardiovascular risk factors systolic blood pressure — mmhg,C0439475;C0488055;C0850624;C0871470;C1306620
615,baseline systolic bp,C0168634;C0871470;C1442488
614,systolic  total,C0039155;C0439175;C0439810
614,systolic,C0039155
614,peak systolic pressure gradient,C0039155;C4687747
614,mean systolic pressure gradient,C0039155;C4687744
613,systemic symptoms,C0205373;C0683368;C1457887
613,symptoms and feelings,C0683368;C1457887;C1527305
613,symptoms,C0683368;C1457887
613,symptom bother,C1457887;C3854129
613,symptom - free days in the past $nmbr$ weeks ( % ),C0332296;C0439228;C0677547;C1444637;C1457887;C1880497;C1996904;C2987125;C3854129;C4284302
613,presenting signs and symptoms,C0220912;C0220913;C0311392;C0449450;C0683368;C1457887
613,placebo ( symptom days a week ),C0032042;C0332174;C0439228;C0439230;C1457887;C1696465;C1706408;C3854129
613,number of symptom days per week,C0237753;C0332174;C0439228;C0439230;C0449788;C1457887;C3854129
613,nocturnal symptoms in past week,C0240526;C0683368;C1457887;C2987125
613,no symptoms,C0683368;C1457887
613,no . of ' signs or symptoms of chff,C0220912;C0220913;C0311392;C0683368;C1457887
613,days with asthma symptoms / week,C0004096;C0677547;C0683368;C1457887;C2984299
613,class i or no symptoms,C0441885;C0683368;C1319793;C1457887;C2698967
613,class $nmbr$ or no symptoms,C0456387;C0683368;C1457887;C1518526;C1705943
613,baseline symptom days perweek,C0168634;C0439228;C1442488;C1457887;C3854129
613,asthma symptoms in the past $nmbr$ weeks,C0004096;C0683368;C1457887;C2984299;C2987125
613,> $nmbr$ symptom days per week,C0677547;C1457887;C3854129
613,$nmbr$ to $nmbr$ symptom days per week,C0677547;C1457887;C3854129
613,$nmbr$ = no symptoms,C0683368;C1457887
613,$nmbr$ = minor symptoms  no limitations,C0026193;C0205165;C0449295;C0683368;C1457887
612,symptom onset to hospitalization,C0019993;C4086878
612,symptom onset to hospital arrival  median ( iqr )  h,C0019994;C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C1510665;C1555577;C1706079;C2347635;C2348144;C2939193;C4086878;C4528284
612,symptom onset to hospital arrival  hours,C0019994;C0439227;C1510665;C1555577;C1706079;C4086878
612,symptom onset to hospital admission,C0184666;C4086878
612,symptom onset - to -,C4086878
612,symptom onset,C4086878
611,symptomaticb,
611,symptomatic remissionb n / n ( % ),C0231220
611,symptomatic padt,C0231220
611,symptomatic pad,C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
611,symptomatic hypoglycaemia,C0020615;C0231220;C4553659
611,symptomatic deep - vein thrombosis,C0149871;C0231220
611,symptomatic,C0231220
611,history of symptomatic,C0019664;C0019665;C0231220;C0262512;C0262926;C1705255;C2004062
610,dpp ‐ $nmbr$ inhibitors,C0243077;C1414174
610,dpp - $nmbr$ inhibitors,C0243077;C1414174
610,dpp - $nmbr$ inhibitor therapy,C0039798;C0087111;C1363945;C1414174;C1999216
610,dpp - $nmbr$ inhibitor,C1414174;C1999216
610,dpp - $nmbr$,C1414174
609,cyp $nmbr$ a $nmbr$ inhibitors,C0243077;C1418793;C2634343
609,cyp $nmbr$ a $nmbr$,C1418793;C2634343
608,treatment with any bp lowering drugs,C0037623;C0441994;C1415692;C1708288;C2003888;C3469597;C4318478
608,syst . bp ( mmhg ),C0037623;C0439475;C1415692;C1708288;C4318478
608,patientswith bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt,C0037623;C0168634;C0332126;C0439475;C1415692;C1442488;C1449832;C1708288;C3889152;C4050156;C4283901;C4284038;C4318478
608,patientswith bp  $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  n §,C0037623;C0168634;C0439475;C1415692;C1442488;C1708288;C4318478
608,patients with bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt,C0030705;C0037623;C0168634;C0332126;C0439475;C1415692;C1442488;C1449832;C1708288;C3889152;C4050156;C4283901;C4284038;C4318478
608,other bp drug,C0013227;C0037623;C1254351;C1415692;C1708288;C4318478
608,on bp medication  n ( % ),C0013227;C0037623;C1415692;C1708288;C3244316;C4284232;C4318478
608,intensive bp lowering  < $nmbr$ mm hg ( n = $nmbr$ ),C0037623;C0162425;C0439475;C0441994;C0522510;C1283828;C1415692;C1550453;C1708288;C2003888;C4318478
608,hba $nmbr$ c < $nmbr$ . $nmbr$ %  bp < $nmbr$ / $nmbr$ mm hg  ldl - c < $nmbr$ mg / dl,C0019016;C0037623;C0439269;C0439475;C1415692;C1708288;C1825777;C3538758;C4318478
608,bp variable  mm hg,C0037623;C0439475;C0439828;C1415692;C1708288;C4318478;C4553760
608,bp in pre - treated patients,C0030705;C0037623;C0332152;C0740175;C1415692;C1522326;C1708288;C2257086;C3669034;C4318478
608,bp goal at week $nmbr$,C0018017;C0037623;C0332174;C0439230;C1415692;C1571704;C1708288;C4318478
608,bp goal  no . ( % ),C0018017;C0037623;C1415692;C1571704;C1708288;C4318478
608,bp component ( mm hg ),C0037623;C0439475;C0449432;C1415692;C1705248;C1708288;C4318478
608,bp and fasting glucose results,C0015663;C0017725;C0037623;C1274040;C1415692;C1546471;C1708288;C2825142;C4318478
608,bp < $nmbr$ / $nmbr$  n ( % ),C0037623;C1415692;C1708288;C4318478
608,bp - lowering treatments  n ( % ),C0037623;C0087111;C0441994;C1415692;C1708288;C2003888;C4318478
608,bp - lowering treatment ( n = $nmbr$ ),C0037623;C0039798;C0087111;C0441994;C1415692;C1522326;C1533734;C1705169;C1708288;C2003888;C3538994;C3887704;C4318478
608,any bp - lowering agents ^,C0037623;C0441994;C0450442;C1254351;C1415692;C1521826;C1708288;C2003888;C4318478
607,trough seated sbp ( mmhg ) a,C0085805;C0277814;C0439475;C0444506;C1283233
607,seated sbp at $nmbr$ weeks  mmhg + * *,C0085805;C0277814;C0439230;C0439475;C1283233
607,seated sbp at $nmbr$ weeks  mmhg +,C0085805;C0277814;C0439230;C0439475;C1283233
607,sd of sbp,C0085805;C2699239
607,sbp ≥ $nmbr$ mmhg,C0085805;C0439475
607,sbp during the follow - up period ( mmhg ),C0085805;C0439475;C0439531;C0589120;C1522577;C1704685;C1948053;C3274571
607,sbp > $nmbr$ mmhg or dbp > $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
607,sbp > $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
607,sbp > $nmbr$ mmhg and / or dbp > $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
607,sbp > $nmbr$ mmhg,C0085805;C0439475
607,sbp > $nmbr$ mm hg and / or dbp > $nmbr$ mm hg $nmbr$ / $nmbr$,C0085805;C0439475;C0536221;C3813197;C4281799
607,sbp < $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
607,sbp < $nmbr$ mmhg and dbp < $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
607,sbp < $nmbr$ mmhg,C0085805;C0439475
607,sbp < $nmbr$ mm hg and dbp < $nmbr$ mm hg $nmbr$ / $nmbr$,C0085805;C0439475;C0536221;C3813197;C4281799
607,sbp / dbp ( mmhg ),C0085805;C0439475;C0536221;C3813197;C4281799
607,sbp / dbp $ $nmbr$ / $ $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
607,sbp . mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
607,sbp ( sd )  mm   hg,C0085805;C0439475;C2699239
607,sbp ( sd ),C0085805;C2699239
607,sbp ( office measurement )  mmhg,C0085805;C0242485;C0439475;C0442603
607,sbp ( mmhg ) < $nmbr$,C0085805;C0439475
607,sbp ( mmhg ) *,C0085805;C0439475
607,sbp ( mmhg ),C0085805;C0439475
607,sbp ( mm hg ),C0085805;C0439475
607,sbp ( mean over $nmbr$ h )  mmhg,C0033727;C0085805;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
607,sbp  systolic blood pressure  sd  standard deviation  dbp  diastolic blood pressure  b . p . m .  beats per minute  mi  myocardial infarction  tia  transient ischaemic attack .,C0007787;C0027051;C0085805;C0369637;C0428883;C0439385;C0441923;C0488055;C0871420;C0871470;C1306620;C2699239
607,sbp  mmhg,C0085805;C0439475
607,sbp  mm   hg ( sd ),C0085805;C0439475;C2699239
607,sbp  mm   hg,C0085805;C0439475
607,sbp  mm hg ( office measurement )  mean ( sd ),C0085805;C0242485;C0439475;C0442603;C0444504;C2347634;C2348143;C2699239
607,sbp  mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
607,sbp  mean ( sd )  mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
607,sbp  last,C0085805;C1517741
607,sbp,C0085805
607,nighttime mean sbp ( abpm ) at week $nmbr$  mmhg,C0085805;C0240526;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143
607,mean sitting sbp ( mmhg ),C0085805;C0277814;C0439475;C0444504;C2347634;C2348143;C2584297;C4050224
607,mean change in sbp from baseline  mmhg  mean ( sd ),C0085805;C0168634;C0392747;C0439475;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2699239;C4319952
607,daytime mean sbp ( abpm ) at week $nmbr$  mmhg,C0085805;C0332169;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143
607,change in sbp,C0085805;C0392747;C0443172;C1705241;C4319952
607,change from baseline in mean $nmbr$ - h sbp  mmhg,C0033727;C0085805;C0168634;C0369286;C0392747;C0439475;C0441932;C0443172;C0444504;C0564385;C1442488;C1705241;C2347634;C2348143;C4319952;C4528284
607,baseline sbp  mean ± sd  mm hg,C0085805;C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
607,baseline mean seated sbp  mm hg ( sd ),C0085805;C0168634;C0277814;C0439475;C0444504;C1283233;C1442488;C2347634;C2348143;C2699239
607,baseline mean ambulatory sbp  mm hg ( sd ) *,C0085805;C0168634;C0439475;C0439841;C0444504;C1442488;C2347634;C2348143;C2699239
607,ambulatory sbp  n,C0085805;C0439841
607,$nmbr$ < sbp < $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
606,tbp,
606,sbp at baseline,C0085805;C0168634;C1442488
606,sbp  baseline,C0085805;C0168634;C1442488
606,nbp,
606,baseline tbp,C0168634;C1442488
606,baseline sbp { p = o - $nmbr$ ),C0085805;C0168634;C1442488
606,baseline sbp,C0085805;C0168634;C1442488
606,baseline nbp,C0168634;C1442488
606,baseline $nmbr$ - hour mean sbp  mm hg,C0085805;C0168634;C0439227;C0439475;C0444504;C0564385;C1442488;C2347634;C2348143
606,adjusted for all baseline variables  interaction between acei and baseline up  and declines in sbp and up,C0085805;C0168634;C0439828;C0456081;C1442488;C1704675
605,visit $nmbr$ dbp  mm hg,C0439475;C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
605,trough seated dbp ( mmhg ) a,C0277814;C0439475;C0444506;C0536221;C1283233;C3813197;C4281799
605,seated dbp  mean ( sd )  mmhg,C0277814;C0439475;C0444504;C0536221;C1283233;C2347634;C2348143;C2699239;C3813197;C4281799
605,sbp / dbp mean,C0085805;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
605,mean sitting dbp ( mmhg ),C0277814;C0439475;C0444504;C0536221;C2347634;C2348143;C2584297;C3813197;C4050224;C4281799
605,mean $nmbr$ - h dbp +,C0033727;C0369286;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
605,dbp ≥ $nmbr$ mmhg,C0439475;C0536221;C3813197;C4281799
605,dbp mm hg,C0439475;C0536221;C3813197;C4281799
605,dbp during the follow - up period ( mmhg ),C0439475;C0439531;C0536221;C0589120;C1522577;C1704685;C1948053;C3274571;C3813197;C4281799
605,dbp < $nmbr$ mmhg,C0439475;C0536221;C3813197;C4281799
605,dbp . mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp ( sd )  mm   hg,C0439475;C0536221;C2699239;C3813197;C4281799
605,dbp ( sd ),C0536221;C2699239;C3813197;C4281799
605,dbp ( office measurement )  mmhg,C0242485;C0439475;C0442603;C0536221;C3813197;C4281799
605,dbp ( mmhg )  mean ( sd ),C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp ( mmhg ),C0439475;C0536221;C3813197;C4281799
605,dbp ( mmghg )  mean ( sd ),C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp ( mm hg )  median ( iqr ),C0439475;C0536221;C0549183;C0876920;C2347635;C2348144;C2939193;C3813197;C4281799
605,dbp ( mm hg ),C0439475;C0536221;C3813197;C4281799
605,dbp ( mean over $nmbr$ h )  mmhg,C0033727;C0369286;C0439475;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
605,dbp  mmhg,C0439475;C0536221;C3813197;C4281799
605,dbp  mm   hg ( sd ),C0439475;C0536221;C2699239;C3813197;C4281799
605,dbp  mm   hg,C0439475;C0536221;C3813197;C4281799
605,dbp  mm hg ( office measurement )  mean ( sd ),C0242485;C0439475;C0442603;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp  mm hg ( mean $nmbr$ h )  mean ( sd ),C0025424;C0428257;C0444504;C0456680;C0536221;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239;C3813197;C4281799
605,dbp  mm hg  mean ± sdc,C0439475;C0444504;C0536221;C1419891;C2347634;C2348143;C3273112;C3813197;C4281799
605,dbp  mm hg,C0439475;C0536221;C3813197;C4281799
605,dbp  mean ± sd ( mmhg ),C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp  mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp  mean ( sd )  mmhg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp  mean ( sd )  mm hg glycaemic parameters,C0005802;C0439475;C0444504;C0449381;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp  mean ( sd )  mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp  mean ( sd ),C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
605,dbp,C0536221;C3813197;C4281799
605,change from baseline in mean $nmbr$ - h dbp  mmhg,C0033727;C0168634;C0369286;C0392747;C0439475;C0441932;C0443172;C0444504;C0536221;C0564385;C1442488;C1705241;C2347634;C2348143;C3813197;C4281799;C4319952;C4528284
605,baseline sitting dbp  * mm hg,C0168634;C0277814;C0439475;C0536221;C1442488;C2584297;C3813197;C4050224;C4281799
605,baseline dbp ( mm hg ),C0168634;C0439475;C0536221;C1442488;C3813197;C4281799
605,baseline dbp  mean ± sd  mm hg,C0168634;C0439475;C0444504;C0536221;C1442488;C2347634;C2348143;C2699239;C3813197;C4281799
605,baseline dbp,C0168634;C0536221;C1442488;C3813197;C4281799
604,type of treatment  n ( % ),C0455708
604,type of intervention,C3274412
604,type of index event — no . ( % ),C0600653;C0918012;C1552854;C1561488;C1637833;C2986546
604,type of hospitalization,C3177060
604,type of event — no . ( % ),C1561488
604,type of event :,C1561488
604,type of event,C1561488
604,initial type of heparin treatment received,C0019134;C0205265;C0455708;C0770546;C1279901;C1514756;C1555582;C1705685
604,hope ( n = $nmbr$ ),C0392347
603,type of stent at index procedure,C0038257;C0184661;C0332307;C0600653;C0918012;C1547052;C1552854;C1637833;C2700391;C2986546;C3274430;C3539779
603,type of lipid - lowering regimen,C0023779;C0040808;C0332307;C0441994;C1547052;C2003888;C2945654
603,type of hospital care,C0259945;C0332307;C1547052
603,type of end point,C0332307;C1547052;C2349179;C2826544
603,type of des at index procedure,C0011702;C0184661;C0332307;C0600653;C0918012;C1547052;C1552854;C1637833;C2700391;C2986546;C3274430;C3539779;C4551552
603,type of des,C0011702;C0332307;C1547052;C4551552
603,type of concomitant statin by daily dose - no . ( % ),C0332307;C0360714;C0521115;C1547052;C2348070
603,type of concomitant statin by daily dose,C0332307;C0360714;C0521115;C1547052;C2348070
603,type of concomitant statin,C0332307;C0360714;C0521115;C1547052
603,type of af  n ( % ),C0332307;C0344434;C1547052;C4049859
603,type of af,C0332307;C0344434;C1547052;C4049859
603,type / no . of valves repaired / replaced mitral,C0184252;C0205340;C0332307;C0559956;C0746591;C1186983;C1299987;C1547052
603,type $nmbr$  n ( % ),C0332307;C1547052
603,type,C0332307;C1547052
603,stent type implanted,C0021102;C0038257;C0332307;C1547052;C2828363
603,stent type,C0038257;C0332307;C1547052
603,predominant type of heparin,C0019134;C0332307;C0770546;C1542147;C1547052
603,phosphodiesterase type $nmbr$ inhibitors,C0031638;C0332307;C1547052;C1656262;C3539996
603,outcome type,C0332307;C1274040;C1547052
603,des type,C0011702;C0332307;C1547052;C4551552
603,cardiac surgery type,C0018821;C0332307;C0524727;C1547052
603,af type — no . ( % ),C0332307;C0344434;C1547052;C4049859
603,af type,C0332307;C0344434;C1547052;C4049859
603,acs type,C0332307;C0742343;C1547052;C4318612
603,> $nmbr$ type,C0332307;C1547052
603,> $nmbr$ des type,C0011702;C0332307;C1547052;C4551552
602,known prothrombotic genotype,C0017431;C0205309
602,haplotype,C0018591
602,gentype,
602,genotype,C0017431
601,eastern european,C0239309
601,eastern europe and africa,C0001737;C0015177
601,eastern europe ( n   = $nmbr$  $nmbr$ ),C0015177
601,eastern europe ( n = $nmbr$ ),C0015177
601,eastern europe ( % ),C0015177
601,eastern europe  africa,C0001737;C0001741;C0015176;C0015177
601,eastern europe,C0015177
601,central and eastern europe,C0015177;C0205099;C1879652
600,western friroce,C1705493
600,western,C1705493
600,west europe,C0015176;C1705493
599,western europe plus other,C0043129;C0332287
599,western europe and other,C0043129
599,western europe and lebanon,C0023190;C0043129
599,western europe ( n   = $nmbr$  $nmbr$ ),C0043129
599,western europe ( n = $nmbr$ ),C0043129
599,western europe ( including south africa ),C0037712;C0043129;C0332257
599,western europe ( % ),C0043129
599,western europe  australia  new zealand  middle east,C0026068;C0043129;C4289954
599,western europe  australia  new zealand  and middle east,C0026068;C0043129;C4289954
599,western europe  australia  new zealand,C0043129;C4289954
599,western europe,C0043129
599,southern europe,C0037724
598,without previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
598,with previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
598,valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1704414;C3888056
598,type of surgery cabg,C0010055;C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
598,type of surgery,C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
598,surgery,C0038894;C0038895;C0543467;C1274039
598,recent surgery or trauma,C0038894;C0038895;C0043251;C0332185;C0543467;C1274039;C1510467;C3263723;C3714660;C4049136
598,prior pci or cabg surgery,C0010055;C0038894;C0038895;C0332152;C0543467;C1274039;C2826257;C4049621
598,planned valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1301732;C1704414;C3888056
598,operative procedure,C0543467;C0677612
598,no previous cd related surgery $nmbr$,C0007928;C0034283;C0038894;C0038895;C0205156;C0439849;C0445223;C0543467;C1274039;C1552607;C4552032
598,interventional or surgical procedures,C0184661;C0543467;C3274035
598,diuretic — no . ( % ) surgery,C0012798;C0038894;C0038895;C0543467;C1274039
598,crohn ’ s disease related surgery,C0010346;C0038894;C0038895;C0439849;C0445223;C0543467;C1274039
598,cardiac valve surgery : no ( n = $nmbr$ ),C0018821;C0018826;C0038894;C0038895;C0184252;C0369718;C0441922;C0524727;C0543467;C1186983;C1274039;C1704414;C3888056
598,cabg surgery,C0010055;C0038894;C0038895;C0543467;C1274039
597,study eye characteristics,C0015392;C0700042;C1568011
597,microvascular eye diseased,C0015392;C0443258;C0700042
596,major diabetic eye disease  n ( % ),C0205082;C0205164;C0342245;C4318856;C4521762
596,diabetic eye disease,C0342245
595,edge ii,C0205154;C1710602;C2697523;C4082587
595,edge,C0205154;C2697523
594,sertraline,C0074393;C0524265
594,postbaseline binding antibodies,C0003241;C1145667;C1167622
594,femoralneck t - scorebybaselinevfxstatus,
593,postprandial indices,C0376674;C4033634
593,$nmbr$ - h postprandial c - peptide ( ng / ml ),C0006558;C0376674;C2827809
592,treatment by egfr stage,C0815181;C1739039;C3811844;C3812682
592,sustained decrease of > $nmbr$ % in egfr ®,C0392756;C0443318;C0547047;C1739039;C3811844;C3812682
592,stage $nmbr$ ckd egfr > $nmbr$ ml / ( n = $nmbr$ ),C0205390;C0439526;C1300072;C1306673;C1561643;C1705224;C1739039;C3811844;C3812682;C3887665
592,normal or increased egfr,C0205217;C0205307;C0231683;C0439166;C0442805;C1739039;C2347086;C3811844;C3812682;C4553972
592,normal egfr ( $nmbr$ < egfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0168634;C0205250;C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C1299351;C1442488;C1739039;C2347086;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209;C4553972
592,normal ( egfr ≥ $nmbr$ )  n ( % ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
592,normal ( egfr > $nmbr$ ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
592,moderate impairment ( egfr $nmbr$ – $nmbr$ )  n ( % ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
592,moderate impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ ),C0205081;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
592,moderate impairment ( egfr $nmbr$ - $nmbr$ ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
592,moderate / severe reduction in egfr,C0205081;C0205082;C0301630;C0392756;C1293152;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335;C4551656
592,mild reduction in egfr,C0301630;C0392756;C1293152;C1739039;C2945599;C3811844;C3812682;C4551656
592,mdrd egfr geometric mean ( cv % )  a  b ml /,C0439526;C1705224;C1739039;C2986759;C3538987;C3811844;C3812682;C3839656;C3887665;C4048877;C4318503
592,estimated glomerular filtration rate — no . ( % ),C3811844
592,estimated glomerular filtration rate - no . ( % ) : :,C3811844
592,estimated glomerular filtration rate,C3811844
592,egfr ≥ $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr ‡ ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr   ≥ $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr   < $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr using cg / mdrd formulae  % of patients,C0012164;C0030705;C0043444;C0489829;C1524063;C1567075;C1705501;C1739039;C3540479;C3811844;C3812682;C3839656
592,egfr s $nmbr$ o ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr s $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr category ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % ),C0369637;C0439445;C0441923;C0683312;C1739039;C3811844;C3812682;C3889287
592,egfr category  n ( % ),C0683312;C1739039;C3811844;C3812682;C3889287
592,egfr category,C0683312;C1739039;C3811844;C3812682;C3889287
592,egfr and albuminuria,C0001925;C1739039;C3811844;C3812682
592,egfr > $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr > $nmbr$  n ( % ),C1739039;C3811844;C3812682
592,egfr > $nmbr$,C1739039;C3811844;C3812682
592,egfr < $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr < $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr < $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C1739039;C3811844;C3812682
592,egfr < $nmbr$  n ( % ),C1739039;C3811844;C3812682
592,egfr < $nmbr$,C1739039;C3811844;C3812682
592,egfr -,C1739039;C3811844;C3812682
592,egfr ( mumin / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0441923;C1739039;C3811844;C3812682
592,egfr ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr ( ml / min per $nmbr$ ^ $nmbr$ m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr ( ml / min per $nmbr$ - $nmbr$ m ^ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr ( ml / min per $nmbr$ - $nmbr$ kg / m ^ ),C0369637;C0439402;C0441923;C1739039;C3811844;C3812682
592,egfr ( ml / min per $nmbr$ + $nmbr$ m ”,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr ( mdrd )  n ( % ),C1739039;C3811844;C3812682;C3839656
592,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C1739039;C3811844;C3812682
592,egfr $nmbr$ - $nmbr$,C1739039;C3811844;C3812682
592,egfr  n ( % ) normal ( egfr > $nmbr$ ml / min / em ^ ),C0205307;C0231683;C0439166;C0439445;C1739039;C2347086;C3811844;C3812682;C4553972
592,egfr  ml • mn ' • $nmbr$ . $nmbr$ m $nmbr$,C0026327;C0026405;C0369637;C0439526;C0441923;C1705224;C1739039;C3811844;C3812682;C3887665;C4285072
592,egfr  ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr  ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  ‡,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
592,egfr,C1739039;C3811844;C3812682
592,ckd ( egfr < $nmbr$ b ),C1561643;C1739039;C3811844;C3812682
592,ckd ( egfr < $nmbr$ )  n ( % ),C1561643;C1739039;C3811844;C3812682
592,bp = blood pressure  egfr = estimated glomerular filtration rate ( men : $nmbr$ en : $nmbr$ x cr $nmbr$ . $nmbr$ x age $nmbr$ . $nmbr$ x $nmbr$ . $nmbr$ )  hdl = high - density lipoprotein .,C0001779;C0005823;C0014908;C0017654;C0023821;C0025266;C0201975;C0750572;C1417861;C1561549;C1739039;C2987294;C3539604;C3711669;C3811844;C3812682;C3889152;C4084730;C4553336;C4553337
592,baseline egfr ≥ $nmbr$ to < $nmbr$,C0168634;C1442488;C1739039;C3811844;C3812682
592,baseline egfr < $nmbr$,C0168634;C1442488;C1739039;C3811844;C3812682
592,baseline egfr ( ml / min per $nmbr$ « $nmbr$ m ’ ),C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
592,baseline egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
592,baseline egfr,C0168634;C1442488;C1739039;C3811844;C3812682
592,baseline ckd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
592,$nmbr$ — em,
-10,inguinal hernia repair,C0021446
590,hiatus hernia,C3489393
590,hiatal hernia ( yes ) ( n ),C1549445;C1705108;C1710701;C3489393
590,esophageal hiatal hernia *,C3489393
589,previous pneumonia,C0032285;C0205156;C1552607
589,pneumonia,C0032285
589,estonia,C0014908
589,bacterial pneumonia,C0004626
588,teaes in a $nmbr$ % of individuals,C0027361;C0237401
588,other individual and exploratory end points,C0027361;C0237401;C2349179
588,normoglycaemic individuals  n ( % ),C0027361;C0237401;C0580545
588,no . ( % ) of individuals *,C0027361;C0237401
588,individuals with type $nmbr$ diabetes  n ( % ),C0027361;C0237401;C1320657
588,individuals with prediabetes,C0027361;C0237401;C0362046
588,individuals with pre - diabetes  n ( % ),C0027361;C0237401;C0362046
588,individuals with normoglycaemia,C0027361;C0237401;C0580545
588,individual endpoints,C0027361;C0237401;C2349179
587,smi :,
587,meddra smq,C1140263
587,intended durat - sm of antccagubficn,C0036154;C1283828;C1551357;C4553627
586,simva n = $nmbr$ n ( % ),
586,simva ( „ = $nmbr$ },
586,simva ( n = $nmbr$ ),
586,simva ( % ),
586,simva,
586,male simva ( „ = $nmbr$ },C0086582;C1706180;C1706428;C1706429
586,male simva ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
586,male simva,C0086582;C1706180;C1706428;C1706429
586,male eze / simva ( „ = $nmbr$ },C0086582;C1706180;C1706428;C1706429
586,male eze / simva ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
586,male eze / simva,C0086582;C1706180;C1706428;C1706429
586,female simva ( „ = $nmbr$ },C0043210;C0086287;C1705497;C1705498
586,female simva ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
586,female simva,C0043210;C0086287;C1705497;C1705498
586,female eze / simva,C0043210;C0086287;C1705497;C1705498
586,caucasian simva,C0007457;C0043157
585,subdural / epidural,C0038541;C0228134;C0812144
585,structural heart disease — no . ( % ) f,C0016327;C1290384
585,structural heart disease §,C1290384
585,structural heart disease,C1290384
585,structural,C0678594
584,salbutamol  %,C0001927
584,post - salbutamol fev $nmbr$ / fvcb  mean ( sd ),C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
584,post - salbutamol fev $nmbr$ ( l ) b  mean ( sd ),C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
584,fev $nmbr$  litres ( post - salbutamol )  mean ( sd ),C0001927;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
583,variable demographic characteristics,C0439828;C0683970;C4553760
583,demographic features,C0683970
583,demographic feature,C0683970
583,demographic data,C4684639
583,demographic characteristics  mean ± sd unless otherwise indicated,C0444504;C0683970;C1444656;C2347634;C2348143;C2699239
583,demographic characteristics  mean ( sd )  unless otherwise stated,C0444504;C0683970;C1301808;C1442792;C2347634;C2348143;C2699239
583,demographic characteristics,C0683970
582,patient demographics age — yr,C0011298;C0439234;C1704791;C4698447
582,demography,C0011298
582,demographics age ( years ),C0011298;C1510829;C1704791
582,demographics age  years  mean ( sd ),C0011298;C0444504;C1510829;C1704791;C2347634;C2348143;C2699239
582,demographics,C0011298;C1704791
582,demographic variable,C0011298;C0439828;C4553760
582,demographic factors,C0011292;C0011298
582,demographic and medical variables,C0011298;C0199168;C0205476;C0439828
582,demographic and clinical characteristics,C0011298;C0683325
582,demographic and clinical,C0011298;C0205210
582,demographic $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C0011298
582,demographic,C0011298
582,( a ) demographics,C0011298;C1704791
581,• hemorrhagic stroke,C0553692
581,subarachnoid hemorrhage,C0038525
581,prior non - haemorrhagic stroke,C0332152;C0553692;C1518422;C2826257
581,primary hemorrhagic stroke,C0205225;C0439612;C0439631;C0553692
581,non ‐ haemorrhagic stroke — no . ( % ),C0038454;C0333275;C1518422;C4554100
581,ischemic stroke without hemorrhagic conversior,C0333275;C0475224;C0553692;C0948008
581,hemorrhagic stroke ( n = $nmbr$ ),C0553692
581,hemorrhagic stroke,C0553692
581,hemorrhagic,C0333275
581,haemorrhagic stroke — no . ( % ),C0553692
581,haemorrhagic stroke,C0553692
581,haemorrhagic,C0333275
580,south asian,C1519427
580,south asia,C0037723;C1519427
580,south american,C0425359
580,south america ( n = $nmbr$ ),C0037713
580,south america ( % ),C0037713
580,south america,C0037713
580,south africa / south america,C0001737;C0002454;C0037712;C0037713
580,south africa,C0037712
580,south ! central america,C0007674;C0037713;C0205099;C1710133;C1879652
580,latin america or south africa,C0023122;C0037712
580,central or south america,C0037713;C0205099;C1879652
580,central and south america and mexico,C0025885;C0037713;C0205099;C1879652
580,central and south america,C0037713;C0205099;C1879652
580,central america and south america,C0007674;C0037713
580,central / south america and mexico,C0007674;C0025885;C0037713;C0205099;C1710133;C1879652
580,central / south america,C0007674;C0037713;C0205099;C1710133;C1879652
579,north ameriea,C1709269
579,north american,C0425358;C2700615
579,north,C1709269
579,< $nmbr$ nwrrtn,
578,grip strength > = median,C0429271;C0549183;C0876920;C2347635;C2348144;C2598165;C2939193
578,grip strength < meidan,C0429271;C2598165
577,health state index score  uk algorithm,C0002045;C0041700;C0449820;C0600653;C0683314;C0918012;C1552854;C1553907;C1637833;C2986546;C4050231
577,algorithm $nmbr$,C0002045;C1553907
576,tertile $nmbr$ index pci performed,C0600653;C0884358;C0918012;C1552854;C1637833;C2986546;C4049621
576,resection performed — no . { % ),C0015252;C0728940;C0884358
576,resection performed  %,C0015252;C0728940;C0884358
576,pci performed,C0884358;C4049621
576,index pci performed,C0600653;C0884358;C0918012;C1552854;C1637833;C2986546;C4049621
575,thienopyridine drug at start of open - label period,C0439531;C1120149;C1709323;C1948053;C2348346
575,study period fatal pe,C0070939;C0439531;C0557651;C1302234;C1705232;C1880476;C1948053;C2603343;C4284304
575,placebo ‐ controlled period,C0439531;C1706408;C1948053
575,period i,C0021966;C0221138;C0439531;C1948053
575,overall study period,C0282416;C0439531;C0557651;C1561607;C1948053;C2603343
575,during overall study period,C0282416;C0439531;C0557651;C1561607;C1948053;C2603343
575,- recurrent vte during overall study period,C0282416;C0439531;C0557651;C0630906;C1455761;C1561607;C1948053;C2603343;C2945760
574,prior treatment — no . ( % ),C1514463
574,prior treatment — %,C1514463
574,prior treatment,C1514463
574,prior tnfi treatment,C1514463
574,prior tnf antagonist treatment - no,C0231491;C1448177;C1514463
574,prior therapy  %,C1514463
574,prior ms treatment with ifn - beta or glatiramer acetate . no . ( % ),C0015980;C0289884;C1514463;C2349943;C3539704;C3713294
574,prior ms treatment with ifn - beta or,C0015980;C1514463;C2349943;C3539704;C3713294
574,prior lipid - modifying therapy,C0023779;C0392747;C1514463
574,prior lev treatment    n   ( % ),C0023556;C1514463
574,prior lev treatment,C0023556;C1514463
574,prior anti - tnf treatment,C1448177;C1514463
574,no prior ms therapies,C1514463;C2349943;C3539704;C3713294
573,negative for helicobacter pylori — no . / total no . ( % ),C0439175;C0439810;C4688581
573,helicobacter pylori infection ( + ) ( n ),C0850666
573,helicobacter pylori - negative  n ( % ),C4688581
573,h pylori serology *,C0036745;C0079488;C0220911;C0455278
573,h . pylori infection,C0850666
572,pulmonary medications ( % ),C0013227;C0024109;C0802604;C2598133;C2707265;C2709248;C4284232;C4522268
572,pulmonary medication during baseline ! ',C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
572,pulmonary embolismb  n / n ( % ),C0024109;C2707265;C2709248;C4522268
572,pulmonary embolisma  n / n ( % ),C0024109;C2707265;C2709248;C4522268
572,proportion taking pulmonary medications ( % ) b,C0013227;C0024109;C0802604;C1515187;C1709707;C2598133;C2707265;C2709248;C4284232;C4522268
572,fvc ( l ) proportion taking pulmonary medications ( % ) b,C0013227;C0024109;C0802604;C1515187;C1709707;C2598133;C2707265;C2709248;C3714541;C4284232;C4522268
572,baseline pulmonary medications,C0013227;C0024109;C0168634;C0802604;C1442488;C2598133;C2707265;C2709248;C4284232;C4522268
572,baseline pulmonary medication  n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
572,baseline pulmonary medication  b n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
572,baseline pulmonary medication,C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
572,any pulmonary medication  n ( % ),C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
572,any pulmonary medication,C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
571,sleep,C0037313
571,on step - $nmbr$ drug  %,C0013227;C1254351;C1261552;C1704379;C1705117;C2825408;C3814463
571,. $nmbr$ step or incident vitrectomy or photocoagulation,C0023694;C0042903;C1261552;C1328010;C1551358;C1704379;C1705117;C2825408;C3814463
571,$nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
571,$nmbr$ or $nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
570,stemi ( % ),C1536220;C3538872
570,stemi,C1536220;C3538872
570,st - segment — elevation myocardial infarction,C1536220
570,st - segment elevation myocardial infarction,C1536220
570,st - segment - elevation myocardial infarction — no . ( % ),C1536220
570,st - elevation myocardial infarction,C1536220;C3538872
570,qualifying mi : stemi,C1514624;C1536220;C3538872;C3810814
570,prior stemi,C0332152;C1536220;C2826257;C3538872
570,no prior stemi,C0332152;C1536220;C2826257;C3538872
570,myocardial infarction without st - segment elevation — no . ( % ),C1536220
569,without stent,C0038257
569,with stent ^ l,C0038257
569,with stent,C0038257
569,with any stent,C0038257
569,vein graft stented,C0038257;C0042449;C0181074;C0332835;C1961139
569,vein bypass stented,C0038257;C0042449;C0741847
569,vein bypass graft stented,C0038257;C0398147
569,stent plus placebo,C0032042;C0038257;C0332287;C1696465;C1706408
569,stent plus abciximab,C0038257;C0288672;C0332287
569,stent length per lesion  mm,C0038257;C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
569,stent group ( n = $nmbr$ ),C0038257;C0441848
569,stent diameter < $nmbr$ mm,C0038257;C1301886;C4330985;C4554674
569,stent diameter $ $nmbr$ mm,C0038257;C1301886;C4330985;C4554674
569,stent / abciximab - stent / placebo,C0032042;C0038257;C0288672;C1696465;C1706408
569,stent ( n = $nmbr$ ),C0038257
569,stent,C0038257
569,prior stent,C0038257;C0332152;C2826257
569,previous stenting ( % previous pci ),C0038257;C0205156;C1552607;C2348535;C4049621
569,other stent,C0038257
569,number stent > $nmbr$,C0038257;C0237753;C0449788
569,number of stents implanted,C0021102;C0038257;C0237753;C0449788;C2828363
569,number of stents ( per patient ),C0030705;C0038257;C0237753;C0449788
569,number of stents,C0038257;C0237753;C0449788
569,number of stent = l or $nmbr$ or $nmbr$,C0038257;C0237753;C0449788
569,number of stent = $nmbr$,C0038257;C0237753;C0449788
569,no . of stents,C0038257
569,multivessel stenting,C0038257;C2348535
569,minimum stent diameter,C0038257;C4054490
569,mean total stent length per lesion  mm ( sd ) ‡,C0038257;C0221198;C0439175;C0439810;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
569,coronary angioplasty or stenting,C0002997;C0038257;C0190211;C2348535
569,biolimus a $nmbr$ - eluting stent ¶,C0038257
568,subgroup sex,C0009253;C0036864;C0079399;C0804628;C1079230;C1314687;C1515021;C1522384
568,sexy,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex — no . / total no . ( % ),C0009253;C0036864;C0079399;C0439175;C0439810;C0804628;C1314687;C1522384
568,sex — no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex m / f,C0009253;C0036864;C0079399;C0804628;C1306057;C1314687;C1522384
568,sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex ( women  n [ % ] ),C0009253;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
568,sex ( p = $nmbr$ ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex ( no . ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex ( interaction : p = $nmbr$ . $nmbr$ ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C1704675
568,sex ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex  no . ( % ) male,C0009253;C0036864;C0079399;C0086582;C0804628;C1314687;C1522384;C1706180;C1706428;C1706429
568,sex  no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex  no  ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex  n ( % ) b,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex  n ( % ) *,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex  n ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex  %,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,p interaction ( rx arm * sex ),C0009253;C0036864;C0079399;C0369773;C0446516;C0804628;C1314687;C1425688;C1521941;C1522384;C1704675;C2603361;C2709207;C3715044;C4553528
568,intercourse satisfac -,C0009253
568,assigned treatment by sex interaction,C0009253;C0036864;C0039798;C0079399;C0087111;C0804628;C1314687;C1516050;C1522326;C1522384;C1533734;C1552601;C1704675;C1705169;C3538994;C3887704
568,> $nmbr$ yrs sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
568,> $nmbr$ yr sex,C0009253;C0036864;C0079399;C0439234;C0804628;C1314687;C1522384
567,week $nmbr$ mean ( se ),C0036919;C0332174;C0439230;C0444504;C2347634;C2348143
567,triglycerides tx difference vs pbo  ls mean % change from baseline ( se ),C0023668;C0031962;C0036919;C0041004;C0041403;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952
567,sesbp,
567,sedbp,
567,se,C0036919
567,modified se - adl scale,C0001288;C0036919;C0175659;C0349674;C0392747;C1420005;C1947916;C3889737
567,mean ± se ) bii ( ls mean ± se ),C0023668;C0036919;C0444504;C1413059;C2347634;C2348143
567,mean ± se,C0036919;C0444504;C2347634;C2348143
567,mean change  % ( se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
567,mean ( se ) trough l,C0036919;C0444504;C0444506;C2347634;C2348143
567,mean ( se ) trough  l,C0036919;C0444504;C0444506;C2347634;C2348143
567,mean ( se ) auc ^ p l,C0036919;C0376690;C0444504;C2347634;C2348143
567,mean ( se ) auc $nmbr$ - $nmbr$  l,C0036919;C0376690;C0444504;C2347634;C2348143
567,mean ( se ) $nmbr$ - year rates per $nmbr$ population,C0036919;C0439234;C0439508;C0871208;C1521828;C2347634
567,mean ( se ),C0036919;C0444504;C2347634;C2348143
567,ls mean ± se,C0023668;C0036919;C0444504;C2347634;C2348143
567,ls mean difference ( se ),C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
567,ls mean change from baseline ( se )  %,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
567,ls mean change from baseline  ml ( se ) a,C0023668;C0036919;C0168634;C0392747;C0439526;C0443172;C0444504;C1442488;C1705224;C1705241;C2347634;C2348143;C3887665;C4319952
567,ls mean change ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
567,ls mean ( se ),C0023668;C0036919;C0444504;C2347634;C2348143
567,ls mean % change from baseline _ se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
567,ipss ( ls mean ± se ),C0023668;C0036919;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
567,in ibdq total score at week $nmbr$  mean [ se ],C0036919;C0332174;C0439175;C0439230;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
567,in - trial and post - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk,C0008976;C0036919;C0150312;C0332285;C0439175;C0439234;C0439508;C0439810;C0441471;C0687676;C0871208;C1264674;C1444641;C1521828;C1704687;C1707101;C3469826;C3541888;C4288115
567,hscrp  exp ls mean change ± se ‡,C0023668;C0036919;C0392747;C0443172;C0444504;C1417055;C1705241;C2347634;C2348143;C4319952
567,homajr tx difference vs pbo  median change from baseline ( se ) $nmbr$ lipid parameters,C0031962;C0036919;C0041403;C0168634;C0449381;C0549183;C0876920;C1158406;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193
567,homa_ir tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0022065;C0022071;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1448132;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952
567,fev $nmbr$ at week $nmbr$  mean ml ( se ) difference mepo - pbo ( $nmbr$ % ci ),C0031962;C0036919;C0332174;C0439230;C0444504;C1705241;C1705242;C2347634;C2348025;C2348143;C3714541
567,difference ( se ),C0036919;C1705241;C1705242
567,daytime nasal symptoms score change from baseline  mean ± se,C0036919;C0168634;C0231918;C0332169;C0392747;C0443172;C0444504;C0449820;C1442488;C1705241;C2347634;C2348143;C4050231;C4319952
567,das $nmbr$ - crp  ls mean change from baseline ( se ) §,C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952
567,cwt  mean ( se )  mm,C0036919;C0444504;C2347634;C2348143;C4330985;C4554674
567,change in sesbp  ls mean ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
567,change in sedbp  ls mean ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
567,change from baseline in morning pef during weeks $nmbr$ - $nmbr$  mean l / min ( se ),C0030771;C0036919;C0168634;C0332170;C0392747;C0439230;C0443172;C0444504;C0702093;C1442488;C1518922;C1524029;C1542834;C1705241;C2347634;C2348143;C3813700;C4319952
567,baseline mean ( se ),C0036919;C0168634;C0444504;C1442488;C2347634;C2348143
567,baseline insulin dose ( u = kg ) [ lsm ( se ) ],C0036919;C0168634;C0366513;C1300561;C1442488
567,baseline a $nmbr$ c ( % ) [ lsm ( se ) ],C0036919;C0168634;C1442488
567,basdai  ls mean change from baseline   ±   se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952
567,asqol  ls mean change ± se,C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
567,asqol  ls mean change from baseline   ±   se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
567,adjusted ∗   mean ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C2347634;C2348143;C3887665
567,adjusted mean change from baseline ( se ),C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
567,adjusted mean _ se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
567,adjusted mean ( se ) fevi auco_ $nmbr$  ml,C0036919;C0429706;C0439526;C0444504;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367
567,( se ] tf total - c,C0036919;C0439175;C0439810;C4048299;C4048587
567,( se ] tf hdl - c,C0036919;C3715113;C4048299;C4048587
567,( se ] tf,C0036919;C4048299;C4048587
567,( se ] t *,C0036919
567,( se ] t,C0036919
567,( se ] +,C0036919
567,( se ) t *,C0036919
567,( se ),C0036919
567,% change from baseline ls means ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C1442488;C1704970;C1705241;C4319952
567,% change ( mean ± se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
567,% ( se ),C0036919
567,$nmbr$ - y rate per $nmbr$ persons ( se )  n,C0027361;C0036919;C0871208;C1521828
566,screening  mean ( sd ) morning pef  mean,C0030771;C0220908;C0220909;C0332170;C0444504;C1518922;C1542834;C1698960;C1710031;C1710032;C1710477;C2347634;C2348143;C2348164;C2699239
566,pm pef ( sd )  l / min,C0030266;C0030771;C0702093;C1518922;C1524029;C1542834;C2699239;C3813700;C4049155
566,pef !,C0030771;C1518922;C1542834
566,am pef ( sd )  l / min,C0030771;C0702093;C1518922;C1524029;C1542834;C2699239;C3813700
565,extracranial carotid stenosis  n ( % ),C0007282;C0580586
565,carotid stenosis,C0007282
565,carotid artery stenosis  n ( % ),C0007282
565,aortic stenosis  n ( % ),C0003507
565,aortic stenosis,C0003507
565,> $nmbr$ y pathogenesis  n ( % ),C0543483;C0699748
564,osteoporosis drug,C0013227;C0029456;C1254351;C4554622
564,osteoporosis,C0029456;C4554622
-10,exercise category ( % ),C3669314
562,t - score categories lumbar spineb,C0024090;C0683312;C3854607
562,racial category *,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
562,racial category,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
562,qmax category  n ( % ) :,C0683312;C3889287
562,p value within category,C0683312;C1709380;C3889287
562,mean ± sd age ( y ) mean bmi category ( % ),C0001779;C0444504;C0578022;C0683312;C2347634;C2348143;C2699239;C3889287
562,key : fc = fasting glucose  bp = * this category did not include ar have $nmbr$ of the indicated charac,C0015663;C0017725;C0037623;C0332257;C0683312;C1415692;C1436327;C1444656;C1518422;C1552866;C1708288;C2700399;C2983605;C2986463;C3884535;C3889287;C4318478;C4521369
562,interaction between treatment and baseline bmi category,C0039798;C0087111;C0168634;C0578022;C0683312;C1442488;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704;C3889287
562,glycatedhemoglobin category  %,C0683312;C3889287
562,entry category,C0683312;C1705654;C3889287
562,dysglycemic categories  n ( % ),C0683312;C1960636
562,creatine clearance category $nmbr$ to < $nmbr$ ml / min $nmbr$ / $nmbr$,C0373595;C0439445;C0683312;C3889287
562,creatine clearance category,C0373595;C0683312;C3889287
562,category $nmbr$ and $nmbr$,C0683312;C3889287
562,category $nmbr$,C0683312;C3889287
562,category,C0683312;C3889287
562,cardiovascular disease risk category,C0683312;C1113685;C3889287
562,background csdmard category,C0683312;C1706907;C3889287
562,age category >,C0001779;C0683312;C3889287
562,age category ( years )  n ( % ),C0683312;C1510829;C3889287
562,age category ( % ),C0001779;C0683312;C3889287
562,age category  n ( % ) < $nmbr$ years,C0683312;C1510829;C3889287
562,age category  n ( % ) :,C0001779;C0683312;C3889287
562,age category  n ( % ),C0001779;C0683312;C3889287
562,age category,C0001779;C0683312;C3889287
562,/ \ge category,C0683312;C1292300;C3538705;C3889287
561,statin intensity per acc / ahac,C0175754;C0282160;C0360714;C0522510;C3541413
561,statin intensity $nmbr$ * $nmbr$,C0360714;C0522510
561,severity ofhypertension [ n ( % ) ] b,C0439793;C0522510
561,severity of hypertensionb,C0439793;C0522510
561,severity of heartburnb,C0439793;C0522510
561,severity of copda  airflow limitation  n ( % ),C0231999;C0439793;C0443288;C0449295;C0522510
561,severity of copd  airflow limitation  n ( % ),C0024117;C0231999;C0439793;C0443288;C0449295;C0522510;C1412502;C3714496
561,severity of airflow obstruction,C0028778;C0231999;C0439793;C0522510;C1882136
561,severity of airflow limitation,C0231999;C0439793;C0443288;C0449295;C0522510
561,severity n ( % ),C0439793;C0522510
561,severity,C0439793;C0522510
561,nocturnal heartburn severity,C0018834;C0240526;C0439793;C0522510
561,morning stiffness severity  $nmbr$ - $nmbr$ scale,C0175659;C0349674;C0439793;C0457086;C0522510;C1947916
561,lowzmedium intensity,C0522510
561,lntensityd,
561,intensive therapy ( n = $nmbr$ ),C0039798;C0087111;C0162425;C0522510;C1283828;C1363945;C1550453
561,intensive glycemia lowering,C0005802;C0162425;C0441994;C0522510;C1283828;C1550453;C2003888
561,intensive control,C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
561,intensive blood glucose control,C0162425;C0522510;C1283828;C1550453;C3267174
561,intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453
561,intensity of statin therapy at baseline — no . { % ),C0168634;C0522510;C1278454;C1442488
561,intensity of statin therapy,C0522510;C1278454
561,intensity $nmbr$,C0522510
561,intense physical activity,C0015259;C0026606;C0522510
561,intense,C0522510
561,hypertension severity,C0020538;C0439793;C0522510;C1963138
561,heartburn severity during the run - in periodt,C0018834;C0439793;C0522510;C3274438
561,ed severity * *  n ( % ) :,C0439793;C0522510;C3538926
561,ed severity  no . ( % ) a,C0439793;C0522510;C3538926
561,data presented as mean   ±   sd  unless otherwise specified    acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ]  gold $nmbr$ [ $nmbr$ ]    bon a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status  the mcid is a change of $nmbr$   units  on a scale of $nmbr$ – $nmbr$  with higher scores indicating more severe dyspnea  on a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status,C0018026;C0018759;C0175659;C0205172;C0205250;C0205369;C0243161;C0332271;C0349674;C0392747;C0439148;C0439793;C0443172;C0444504;C0449450;C0449820;C0522510;C1279889;C1304897;C1457868;C1511726;C1519795;C1527178;C1552041;C1705241;C1705938;C1947916;C2080700;C2347634;C2348143;C2699239;C2986536;C3245479;C3714741;C3853603;C4319952
561,baseline statin intensity,C0168634;C0360714;C0522510;C1442488
561,baseline ed severity * * :,C0168634;C0439793;C0522510;C1442488;C3538926
561,any severity,C0439793;C0522510
560,hrg,C1437978;C1705020
560,hmg - coa reductase inhibitors,C0360714;C2756999;C3539119
559,ra - beam,C0338248;C2347880;C3538806;C4048756;C4521565
559,beam   <   $nmbr$   mg / dl at week $nmbr$  n ( % ),C0332174;C0338248;C0439230;C0439269;C2347880;C4521565
558,menopausal status and hormone therapy use,C0042153;C0279025;C0457083;C1513126;C1947944
558,hormone therapy use,C0042153;C0279025;C0457083;C1947944
558,hormone therapy,C0279025
558,hormonal therapy — no . ( % ),C0279025
558,baseline use of hormone therapy ( % ),C0168634;C0279025;C1442488;C1524063
557,number of antihypertensive medications used  n ( % ) no antihypertensive therapy,C0003364;C0369718;C0441922;C0585941;C1273517;C1718138
557,antihypertensive therapy — no . ( % ),C0585941
557,antihypertensive therapy  n ( % ),C0585941
557,antihypertensive therapy,C0585941
557,anti - hypertensive therapy - no . ( % ),C0585941
557,anti - hypertensive therapy,C0585941
556,no diuretic therapy,C0948575
556,diuretic therapy,C0948575
556,diabetes therapy at baseline ( alone or in combination ),C0168634;C0205171;C0205195;C0439044;C0679994;C1442488;C1947911;C3274787;C3539002;C3811910
556,diabetes therapy  n ( % ),C3274787;C3539002
556,diabetes therapy,C3274787;C3539002
555,no antiplatelet therapy,C1096021
555,long - term antiplatelet therapy,C0443252;C1096021
555,estrogen therapy,C0279494
555,antiplatelet therapy §,C1096021
555,antiplatelet therapy dual,C0205173;C1096021;C1554184
555,antiplatelet therapy,C1096021
555,antiplatelet or anticoagulant therapy,C0150457
555,anticoagulant therapy,C0150457
554,pharmacotherapy,C0013216;C0013217
554,other drug therapy  n ( % ),C0013216;C0013217
554,macroalbuminuria — no . ( % ) drug therapy — no . ( % ),C0013216;C0013217
554,drug therapy  no . ( % ),C0013216;C0013217
554,drug therapy  n ( % ),C0013216;C0013217
554,drug therapy,C0013216;C0013217
553,statin monotherapy,C0360714
553,phototherapy previous systemic treatment  n ( % ),C0031765;C0205156;C0678812;C1552607
553,phototherapy,C0031765
553,monotherapy,
553,metforminmonotherapy,
553,glulisine monotherapy,
552,treatment stratum ^ :,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
552,treated lesions ‡,C0221198;C1522326
552,treated,C1522326
552,stratum,
552,patients treated for > $nmbr$ weeks ( % ),C0030705;C0439230;C1522326
552,patients treated and operated  n ( % ),C0030705;C1522326;C3242339
552,patients treated,C0030705;C1522326
552,patients ( treated set * )  n,C0030705;C0036849;C1442518;C1522326;C1705195
552,not treated,C1518422;C1522326
552,normoalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C1442488;C1522326
552,no . of treated lesions,C0221198;C1522326
552,lesions treated per patient,C0030705;C0221198;C1522326
552,coronary artery treated  no . ( % ),C0205042;C1522326
551,untreated at baseline,C0168634;C0332155;C1442488
551,untreated,C0332155
550,pvaluefor trend,C1521798;C4554533
550,pfor trend,C1151635;C1521798;C4554533
550,p trend,C0369773;C1521798;C2603361;C4554533
550,p j $nmbr$ * trend,C1518835;C1521798;C4554533
550,p for trend -,C0369773;C1521798;C2603361;C4554533
550,p for trend,C0369773;C1521798;C2603361;C4554533
550,heterogeneity or trend p vaiue,C0019409;C0242960;C1521798;C4554533
549,use of hormone replacement therapy ( a ),C0282402;C1524063
549,pre - menopausal without hormone replacement,C0206158;C0282402
549,pre - menopausal with hormone replacement,C0206158;C0282402
549,postmenopausal and no hrt,C0232970;C0282402
549,postmenopausal and current hrt,C0232970;C0282402;C0521116;C1705970
549,postmenopausal  no hrt,C0232970;C0282402
549,postmenopausal  current hrt,C0232970;C0282402;C0521116;C1705970
549,hrt use,C0042153;C0282402;C0457083;C1947944
549,hrt,C0282402
549,hormone replacement therapy use,C0042153;C0282402;C0457083;C1947944
549,hormone replacement therapy,C0282402
549,hormone replacement ! !,C0282402
549,hormone replacement,C0282402
548,itherchdt,
548,atherectomy,C0162513
548,> $nmbr$ or incident vitrectomy or photocoagulation,C0023694;C0042903;C1328010;C1551358
547,rarely,C0522498
547,none or seldom,C0522498
547,never / rarely,C0522498;C2003901
546,stratum ii,C1710602;C4082587
546,stratum *,
546,stratum  n ( % ),
546,randomization stratum,C0034656
545,statin with fibrate,C0360714
545,moderatex,
545,moderate - dose statin,C0360714;C1709056
545,fibrate,
545,fenofibric acid - i - moderate - dose statin,C0021966;C0060179;C0221138;C0360714;C1709056
544,risk factors and diabetes status ( % ),C0035648;C1317301;C1553898
544,polyvascular disease * and type $nmbr$ diabetes status,C0012634;C0332307;C0449438;C1317301;C1320657;C1547052
544,diabetes status  no . ( % ),C1317301
544,diabetes status  n ( % ),C1317301
544,diabetes status,C1317301
544,diabetes mellitus status,C1317301
544,biomarker status,C0449442
543,ugt induction status : per aeda  n ( % ),C0205263;C0449438;C0857127;C1420188;C4284131
543,status ( spmsq > $nmbr$,C0449438
543,status ( spmsq < $nmbr$,C0449438
543,smokinq status,C0449438
543,other glucose status,C0017725;C0449438
543,lev status  n ( % ),C0023556;C0449438
543,lev status,C0023556;C0449438
543,hormonal status,C0449438;C0458083
543,h . pylori status  n ( % ),C0079488;C0449438
543,frailty status,C0424594;C0449438
543,emotional status,C0013987;C0449438;C0849912
543,cortteosterom relrsclory status,C0449438
543,angina status — no . ( % ),C0002962;C0449438
543,aha status at screeningb  n ( % ),C0050451;C0449438;C0772110
543,aed inducer status,C0449438;C0887457;C3898767
542,stage iii,C0441771
542,stage ii,C0441767
542,stage $nmbr$ b : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441781;C0441923;C1739039;C3811844;C3812682
542,stage $nmbr$ b : > = $nmbr$ and < $nmbr$,C0441781
542,stage $nmbr$ b : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441781;C0441923
542,stage $nmbr$ b,C0441781
542,gold stage iii,C0018026;C0441771;C1304897
542,gold stage ii,C0018026;C0441767;C1304897
541,years modified hoehn and yahr stage  n ( % ),C0205390;C0392747;C0439234;C1300072;C1306673;C3889737
541,stage of pda,C0013274;C0205390;C0226047;C1300072;C1306673;C4282128
541,stage iv,C0022326;C0205390;C1300072;C1306673;C4265176
541,stage $nmbr$ a ckd cohort ( secondary analysis ),C0027627;C0086027;C0175668;C0205390;C0205436;C1300072;C1306673;C1561643
541,stage $nmbr$ a ckd cohort ( post hoc analysis excluding metformin users ),C0025598;C0086027;C0205390;C0332196;C0687676;C1300072;C1306673;C1561643;C1704687;C1706077;C2828389;C3469826
541,stage $nmbr$ a : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0205390;C0369637;C0439445;C0441923;C1300072;C1306673;C1739039;C3811844;C3812682
541,stage $nmbr$ a : > = $nmbr$ and < $nmbr$,C0205390;C1300072;C1306673
541,stage $nmbr$ a : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0205390;C0369637;C0439445;C0441923;C1300072;C1306673
541,stage $nmbr$ a,C0205390;C1300072;C1306673
541,stage $nmbr$ : > = $nmbr$,C0205390;C1300072;C1306673
541,stage $nmbr$ : < $nmbr$,C0205390;C1300072;C1306673
541,stage $nmbr$ ( four - variable modification of diet in kidney disease ),C0022658;C0086153;C0205390;C0205450;C0439828;C1300072;C1306673;C3671772;C4553760
541,stage $nmbr$ ( cockcroft - gault ),C0205390;C1300072;C1306673
541,stage $nmbr$,C0205390;C1300072;C1306673
541,retinopathy ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ ),C0035309;C0205390;C1300072;C1306673;C1962966
541,nkf stage,C0205390;C1300072;C1306673
541,hoehn and yahr stage ( range  $nmbr$ - $nmbr$ ),C0205390;C1300072;C1306673;C1514721;C2348147;C3542016
541,hoehn and yahr stage ( baseline )  mean ( sd ),C0168634;C0205390;C0444504;C1300072;C1306673;C1442488;C2347634;C2348143;C2699239
541,hoehn and yahr stage,C0205390;C1300072;C1306673
541,hoehn & yahr stage ( “ on ” )  n ( % ),C0205390;C1300072;C1306673
541,hoehn & yahr stage ( “ off ” )  n ( % ),C0205390;C1300072;C1306673
541,hoehn & yahr stage,C0205390;C1300072;C1306673
541,gold stage — no . ( % ) * *,C0018026;C0205390;C1300072;C1304897;C1306673
541,gold stage iv,C0018026;C0022326;C0205390;C1300072;C1304897;C1306673;C4265176
541,gold stage [ n ( % ) ],C0018026;C0205390;C1300072;C1304897;C1306673
541,gold stage ( % ) f,C0016327;C0018026;C0205390;C1300072;C1304897;C1306673
541,gold stage #,C0018026;C0205390;C1300072;C1304897;C1306673
541,gold stage  nf * ( % ),C0018026;C0205390;C1300072;C1304897;C1306673
541,gold stage  n ( % ),C0018026;C0205390;C1300072;C1304897;C1306673
541,gold stage  %,C0018026;C0205390;C1300072;C1304897;C1306673
541,gold stage,C0018026;C0205390;C1300072;C1304897;C1306673
541,estimated gfr renal function stage,C0017654;C0205390;C0232804;C0750572;C1300072;C1306673;C1424601
541,copd severity stage ( gold ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
541,copd severity ( gold stage ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
541,ckd stages,C1306673;C1561643
541,ckd stage $nmbr$ ( % ),C0205390;C1300072;C1306673;C1561643
541,ckd stage $nmbr$,C0205390;C1300072;C1306673;C1561643
540,total vdh - s score ( $nmbr$ - $nmbr$ ) ( n ),C2964552
540,total vdh - s score,C2964552
540,total sgrq mean total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
540,total score §,C2964552
540,total score on the sgrq - c  i,C0021966;C0221138;C2964552;C3826872
540,total score > $nmbr$,C2964552
540,total score < $nmbr$,C2964552
540,total score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C1947916;C2964552
540,total score,C2964552
540,total feet score,C0016504;C0347981;C2964552
540,source,C0449416;C1705919;C4521696
540,sgrq total score * *,C2964552
540,sgrq total score * ( units ),C0439148;C1519795;C2964552;C3853603
540,sgrq total score ( units ) : ! :,C0439148;C1519795;C2964552;C3853603
540,sgrq total score ( units ),C0439148;C1519795;C2964552;C3853603
540,sgrq total score $nmbr$,C2964552
540,sgrq total score  units,C0439148;C1519795;C2964552;C3853603
540,sgrq total score,C2964552
540,sgrq responder ( % ),
540,selena - sledai total score,C0451528;C2964552
540,mean sgrq total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
540,mean sgrq total score,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
540,iwqol - lite total score ( arbitrary units ) #,C0439183;C2964552
540,ibdq total score  mean [ sd ],C0444504;C2347634;C2348143;C2699239;C2964552
540,ibdq total score,C2964552
540,eacit - e total score ) |,C2964552
540,ccq total score,C2964552
540,c $nmbr$ - unit sgrq total score increase,C0439148;C0439453;C0442805;C1509845;C1519795;C1704753;C1880519;C2964552;C3853603
540,bdi total score ( baseline ),C0006448;C0168634;C0451022;C1442488;C2964552;C3714938;C3889415
540,baseline sgrq total score,C0168634;C1442488;C2964552
540,baseline ibdq total score  mean,C0168634;C0444504;C1442488;C2347634;C2348143;C2964552
540,acq - $nmbr$ total score ∗,C2919686;C2964552
540,( total ses - cd score at,C0007928;C0034283;C2964552;C4552032
539,storage subscore,C0337174;C1698986;C1753314
539,stomach,C0038351;C3714551
539,mean ipss  storage sub - score ( sd ),C0337174;C0542339;C1019118;C1264637;C1698986;C1753314;C1998280;C2699239;C2827405;C3533236;C3811063
539,ipss storage subscore,C0337174;C1019118;C1698986;C1753314;C1998280;C2827405;C3811063
538,trochanter,C0162370
538,subtrochanteric,
538,intertrochanteric,C0745355
537,nitratesf,
537,nitrates ( oral or topical ),C0028125;C0332237;C0442027;C0699857;C3848573;C4521986
537,nitrates ( % ),C0028125;C0699857;C3848573
537,nitrates  n ( % ),C0028125;C0369718;C0441922;C0699857;C3848573
537,nitrates  ( % ),C0028125;C0699857;C3848573
537,nitrates,C0028125;C0699857;C3848573
537,nitrate — no . ( % ),C0028125;C0699857;C3848573
537,nitrate use,C0028125;C0042153;C0457083;C0699857;C1947944;C3848573
537,nitrate ( oral or intravenous ),C0028125;C0348016;C0442027;C0699857;C3848573;C4521986
537,nitrate,C0028125;C0699857;C3848573
537,iv nitrates,C0022326;C0028125;C0699857;C3848573;C4265176
537,intravenous nitrates,C0028125;C0348016
536,no estimate,C0750572
536,estimated glomerular filtration,C0232809;C0750572
536,estimated gfr,C0017654;C0750572;C1424601
536,estimate,C0750572
536,combined estimated gfr and albuminuria status,C0001925;C0017654;C0205195;C0449438;C0750572;C1424601
536,baseline estimated gfr,C0017654;C0168634;C0750572;C1424601;C1442488
536,< $nmbr$ . $nmbr$ mmol / liter estimated gfr,C0017654;C0439190;C0475211;C0750572;C1424601
535,used,C1273517
535,spacer use during the study,C0221874;C0869040
535,gpi used during pci,C1273517;C1415351;C4049621
535,acei use,C0042153;C0457083;C1947944
535,acei  n ( % ),
534,user,C1548600;C1706077
534,statin users ( n = $nmbr$ ),C0360714;C1706077
534,statin users,C0360714;C1706077
534,statin non - users ( n = $nmbr$ ),C0360714;C1518422;C1706077
534,nonuser,
534,non - user $nmbr$,C1518422;C1548600;C1706077
534,low - dose corticosteroid user,C0001617;C0445550;C1548600;C1706077;C1708745;C3536709
534,laba users,C1706077
534,laba non - users,C1518422;C1706077
534,dmard user,C0242708;C1548600;C1706077
534,bivariate frailty model ( statin users vs non - users ),C0360714;C0424594;C1518422;C1706077;C3161035;C3274659;C3714583;C3853906
534,biologics user,C0005515;C0005522;C1548600;C1706077;C4553887
533,western eu  australia  new zealand,C0015179;C0027978;C0043128;C0324547;C1705493;C3665627;C4289954
533,european union,C0015179
533,eu,C0015179;C3665627
533,eastern eu,C0015179;C1707877;C3665627
-10,environmental stimuli,C0450025
531,timi flow ‡,C3272266
531,final timi flow grade post - ppci,C0205088;C0441800;C0687676;C0919553;C1546485;C1704687;C3244287;C3272266;C3469826;C3853528
531,final timi flow grade < $nmbr$,C0205088;C0441800;C0919553;C1546485;C3244287;C3272266;C3853528
531,final timi flow,C0205088;C1546485;C3272266;C3853528
530,timi ≥ $nmbr$,
530,timi major / minor bleeding,C0019080;C4441842
530,timi major / minor,C4441842
530,timi - bleeding major / minor,C0019080;C4441842
529,qualifying nstemi  n ( % ),C1514624;C3537184;C4255010
529,nstemi ( n = $nmbr$  $nmbr$ ),C3537184;C4255010
529,nstemi ( % ),C3537184;C4255010
529,nstemi,C3537184;C4255010
529,nste - mi,C3537184;C4255010
529,non — st - segment — elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
529,non - stemi,C3537184
529,non - st - segment elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
529,non - st - elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
528,moderate decrease ( $nmbr$ - < $nmbr$ mlymin per $nmbr$ . $nmbr$ m $nmbr$ ),C0205081;C0369637;C0392756;C0441923;C0547047;C1881878;C4049705;C4049706;C4085643;C4321335
528,lvmi ( $nmbr$,
528,alvmi ( per g / m $nmbr$ ),C0456715
528,> $nmbr$ mlymin,
528,< $nmbr$ mlymin,
528,< $nmbr$ mlmin ) $nmbr$,
528,$nmbr$ - < $nmbr$ mvmin,
527,overall dlqi score $nmbr$,C0282416;C0449820;C1561607;C3899393;C4050231
527,overall dlqi score,C0282416;C0449820;C1561607;C3899393;C4050231
527,mean dlqi score ( $nmbr$ % ci ),C0008107;C0444504;C0449820;C2347634;C2348143;C3259781;C3899393;C4050231
527,dlqi §,C3899393
527,dlqi score,C0449820;C3899393;C4050231
527,dlqi improvement from baseline to week $nmbr$,C0168634;C0332174;C0439230;C1442488;C2986411;C3899393
527,dlqi ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3899393
527,dlqi  $nmbr$ - $nmbr$ *,C3899393
527,dlqi,C3899393
527,baseline dlqi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3899393
526,patients with enthesitis ( lei > $nmbr$ ),C0023401;C0030705;C0428209;C1282952
526,li $nmbr$ ( $nmbr$ . $nmbr$ ),C0023617;C3495095
526,lei > $nmbr$ ( n = $nmbr$ ),C0023401;C0428209
526,lei $nmbr$,C0023401;C0428209
526,lei  mean [ sd ] c,C0023401;C0428209;C0444504;C2347634;C2348143;C2699239
526,lei  mean ( sd ),C0023401;C0428209;C0444504;C2347634;C2348143;C2699239
525,no gi bleed,C0019080;C1708130;C3539617;C4050121
525,gi bleed,C0019080;C1708130;C3539617;C4050121
525,$nmbr$ - gi,C1708130;C3539617;C4050121
524,who fc iii symptoms at baseline,C0168634;C0439070;C0683368;C1442488;C1457887;C1705160;C2983605
524,updrs total ( ii + iii ),C0439070;C0439175;C0439810;C1705160;C1710602;C3639721;C4082587
524,ncep atp iii risk factors,C0035648;C0439070;C1553898;C1705160;C2744579;C4552600
524,killip class ii  iii  or iv — %,C0022326;C0439070;C1705160;C1710602;C2697845;C2697846;C4082587;C4265176
524,iii ( n z $nmbr$ ),C0439070;C1705160
524,iii ( $nmbr$ ),C0439070;C1705160
524,iii,C0439070;C1705160
524,ii or iii,C0439070;C1705160
524,ii / iii,C0439070;C1705160;C1710602;C4082587
524,ii - iii,C0439070;C1705160;C1710602;C4082587
524,class iii / iii - v,C0439070;C0457166;C1705160;C1880098
524,class i or iii aad use in $nmbr$ months before enrollment,C0042153;C0439070;C0439231;C0441885;C0457083;C1319793;C1516879;C1696073;C1705160;C1947944;C2698967;C3888021
524,$nmbr$ ii ( $nmbr$ . $nmbr$ ),
523,re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
523,re - cover / re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
523,ii = $nmbr$,
523,ii $nmbr$ ( i $nmbr$ . $nmbr$ ),C0021966;C0221138;C1710602;C4082587
523,i or ii,C0021966;C0221138
523,i & ii : fev $nmbr$ > $nmbr$ % predicted,C0021966;C0221138;C0681842;C1710602;C1882327;C3714541;C4082587
523,i $nmbr$ ± $nmbr$ ii,C0021966;C0221138;C1710602;C4082587
523,enrolled from re - cover ii study — no . ( % ),C0180153;C0556581;C0557651;C1999244;C2603343;C2986904;C3888055;C4684790
523,asteria i / ii,C0021966;C0221138;C1093020;C1710602;C4082587
523,$nmbr$ . i ± ii . $nmbr$,C0021966;C0221138;C1710602;C4082587
523,$nmbr$ . $nmbr$ ± ii . $nmbr$,
522,ii . $nmbr$ ( $nmbr$ . $nmbr$ ) $nmbr$,
522,ii $nmbr$ ± $nmbr$,
522,angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
522,ace inhibitors or angiotensin ii blockers,C0003009;C0003015;C1366631;C3714928
522,ace inhibitors or angiotensin ii,C0003009;C0003015;C1366631;C3714928
521,who fc ii symptoms at baselinef,C0683368;C1457887;C1710602;C2983605;C4082587
521,who fc ii symptoms at baseline $nmbr$,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
521,who fc ii symptoms at baseline,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
521,updrs  part ii ( adl ),C0001288;C0449719;C1420005;C1709471;C1710602;C3639721;C4082587
521,sr ii b $nmbr$ - cjl $nmbr$,C0753208;C1709991;C1710602;C3813610;C3890900;C3891546;C4082587
521,revive ii,
521,period ii,C0439531;C1710602;C1948053;C4082587
521,lor ii,C1416897;C1416899;C1710602;C2986770;C4082587
521,ii lisinopril,C0065374;C1710602;C4082587
521,ii chiorthaiidone amiodipine,C1710602;C4082587
521,ii ( n = $nmbr$ ),C1710602;C4082587
521,ii $nmbr$ amlodipine - lisinopril - chlorthalidone chlorthalidone,C0008294;C0051696;C0065374;C1710602;C4082587
521,ii $nmbr$ ( ii . $nmbr$ ),C1710602;C4082587
521,ii,
521,i / ii,C0021966;C0221138;C1710602;C4082587
521,europe ii,C0015176;C1710602;C4082587
521,dual ii,C0205173;C1554184;C1710602;C4082587
521,> o - $nmbr$ - ii,C0483204;C1710602;C4082587
520,xi = ° - ° $nmbr$,C1720296
520,xi = oo  p = o - $nmbr$,C1720296
520,xi = o - $nmbr$  p = o - $nmbr$,C1720296
520,xi = l ’ $nmbr$  p = $nmbr$ - $nmbr$,C1720296
520,xi = $nmbr$ . $nmbr$,C1720296
520,xi = $nmbr$ - l  p = $nmbr$ - $nmbr$,C1720296
520,xi = $nmbr$ - $nmbr$  p = o - l,C1720296
520,xi = $nmbr$ - $nmbr$  p = $nmbr$ - l,C1720296
520,xi = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,C1720296
520,xi = $nmbr$ - $nmbr$  p = $nmbr$,C1720296
520,xi = $nmbr$ - $nmbr$,C1720296
520,xi = $nmbr$,C1720296
519,unadjusted or ( $nmbr$ % ci ) p value,C0008107;C1439367;C1709380;C3259781
519,treatment difference ( $nmbr$ % ci ),C0008107;C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3259781;C3538994;C3887704
519,treatment diff . vs tio ( $nmbr$ % ci ),C0008107;C0039798;C0087111;C1522326;C1533734;C1705169;C3259781;C3538994;C3887704
519,stratified hazard ratio ( $nmbr$ % ci ),C0008107;C0205363;C2985465;C3259781
519,relative risk { $nmbr$ % ci ),C0008107;C0242492;C3259781
519,relative risk ( $nmbr$ % ci ) ofprimary end point,C0008107;C0242492;C2349179;C2826544;C3259781
519,relative risk ( $nmbr$ % ci ),C0008107;C0242492;C3259781
519,ratio of hrs ( $nmbr$ % ci )  p for sex interaction,C0008107;C0009253;C0036864;C0079399;C0456603;C0804628;C1314687;C1522384;C1547037;C1568891;C1704675;C3259781
519,ratio mepo / pbo ( $nmbr$ % ci ),C0008107;C0031962;C0456603;C1547037;C3259781
519,ratio ( $nmbr$ % ci ) *,C0008107;C0456603;C1547037;C3259781
519,rate estimate ( $nmbr$ % ci ),C0008107;C0750572;C0871208;C1521828;C3259781
519,r | r ' ' ' ( $nmbr$ % ci ),C0008107;C0205090;C0684010;C2603358;C3259781
519,r elative risk ( $nmbr$ % ci ),C0008107;C0035647;C0205090;C0233492;C0684010;C2603358;C3259781;C4552904
519,placebo - adjusted mean difference in % hba $nmbr$ c ( $nmbr$ % ci  [ p value ] ),C0008107;C0019016;C0032042;C0444504;C0456081;C1696465;C1705241;C1705242;C1706408;C1709380;C1825777;C2347634;C2348143;C3259781;C3538758
519,pav  mean ( $nmbr$ % ci ),C0008107;C0058890;C0444504;C2347634;C2348143;C3259781
519,oradj ( $nmbr$ % ci ),C0008107;C3259781
519,or 、 ( $nmbr$ % ci ),C0008107;C3259781
519,or [ $nmbr$ % ci ],C0008107;C3259781
519,or ( $nmbr$ % ci ) a,C0008107;C3259781
519,or ( $nmbr$ % ci ),C0008107;C3259781
519,or $nmbr$ % ci,C0008107;C3259781
519,odds ‐ ratio ( $nmbr$ % ci ),C0008107;C0028873;C3259781
519,odds ratios ( $nmbr$ % ci ),C0008107;C0028873;C3259781
519,odds ratio versus placebo ( $nmbr$ % ci ),C0008107;C0028873;C0032042;C1696465;C1706408;C3259781
519,odds ratio ( $nmbr$ % ci ),C0008107;C0028873;C3259781
519,mmrm estimates  ls mean ( se )  [ $nmbr$ % ci ],C0008107;C0023668;C0036919;C0444504;C0750572;C2347634;C2348143;C3259781
519,median time to first exacerbation ( months [ $nmbr$ % ci ] ),C0008107;C0205435;C0549183;C0556969;C0876920;C1279901;C2347635;C2348144;C2939193;C3259781;C4086268
519,mean sf $nmbr$ score ( $nmbr$ % ci ),C0008107;C0037712;C3259781;C3533236
519,mean pasi score ( $nmbr$ % ci ),C0008107;C3259781;C3533236;C4528685
519,mean number of exacerbations ( per patient - year [ $nmbr$ % ci ] ),C0008107;C0030705;C0237753;C0439234;C0439508;C0444504;C0449788;C2347634;C2348143;C3259781;C4086268
519,mean ham - d score ( $nmbr$ % ci ),C0008107;C1570167;C3259781;C3533236;C3853311
519,mean eq - $nmbr$ d response ( $nmbr$ % ci ),C0008107;C0205163;C0439185;C0444504;C0871261;C1704632;C1706817;C2347634;C2348143;C2911692;C3259781
519,mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  % ‐ points,C0008107;C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1552961;C1705241;C1960952;C2346927;C2347617;C2347634;C2348143;C3259781;C3714763;C4319952;C4321396;C4521761
519,mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  %,C0008107;C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1705241;C1960952;C2346927;C2347634;C2348143;C3259781;C4319952;C4321396;C4521761
519,lsms difference ( $nmbr$ % ci ) $nmbr$,C0008107;C1705241;C1705242;C3259781
519,lsm ( $nmbr$ % ci ),C0008107;C3259781
519,ls means difference ( $nmbr$ % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
519,ls means difference ( $nmbr$ % ci ) $nmbr$,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
519,ls mean treatment difference ( $nmbr$ % ci ),C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
519,ls mean difference ( $nmbr$ % ci ),C0008107;C0023668;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
519,ls mean ( $nmbr$ % ci ) a,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
519,ls mean ( $nmbr$ % ci )  %,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
519,ls mean ( $nmbr$ % ci ),C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
519,ls - mean difference between treatment groups ( $nmbr$ % ci ),C0008107;C0023668;C0039798;C0087111;C0374505;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
519,ls - mean change from baseline ( $nmbr$ % ci ),C0008107;C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
519,ls - mean between - group difference ( $nmbr$ % ci ),C0008107;C0023668;C1705241;C1705242;C2347634;C3259781
519,least squares mean between - treatment difference ( $nmbr$ % ci ),C0008107;C0023189;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
519,least - squares mean difference ( $nmbr$ % ci ) *,C0008107;C0023189;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
519,hradjusted ( $nmbr$ % ci ) b,C0008107;C3259781
519,hradj ( $nmbr$ % ci ),C0008107;C3259781
519,hr [ $nmbr$ % ci ),C0008107;C3259781
519,hr ( $nmbr$ s % ci ),C0008107;C3259781
519,hr ( $nmbr$ % ci ) p   value,C0008107;C1709380;C3259781
519,hr ( $nmbr$ % ci ) p value for interaction *,C0008107;C1704675;C1709380;C3259781
519,hr  ( $nmbr$ % ci ),C0008107;C3259781
519,heart failure  ci  confidence interval .,C0008107;C0009667;C0018801;C0018802;C3259781;C4554158
519,hazard ratio for cardiovascular death  stroke  or myocardial infarction ( $nmbr$ % ci ),C0008107;C0011065;C0027051;C0428953;C1306577;C2926063;C2985465;C3259781;C3810814;C4082313;C4552775;C4552959
519,hazard ratio * ( $nmbr$ % ci ),C0008107;C2985465;C3259781
519,hazard ratio ( $nmbr$ % ci ) $nmbr$ with vs . without psoriasis,C0008107;C0033860;C2985465;C3259781
519,hazard ratio ( $nmbr$ % ci ),C0008107;C2985465;C3259781
519,harzard ratio ( $nmbr$ % ci ),C0008107;C0456603;C1547037;C3259781
519,harzar ratio ( $nmbr$ % ci ),C0008107;C0456603;C1547037;C3259781
519,from baseline ( $nmbr$ % ci ),C0008107;C0168634;C1442488;C3259781
519,etr : $nmbr$ . $nmbr$ [ $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$,C0008107;C3259781
519,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
519,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
519,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
519,etd ( % ) [ $nmbr$ % ci ],C0008107;C1180255;C3259781
519,etd ( $nmbr$ % ci ),C0008107;C1180255;C3259781
519,estimated difference ( $nmbr$ % ci ),C0008107;C0750572;C1705241;C1705242;C3259781
519,estimate ( $nmbr$ % ci ),C0008107;C0750572;C3259781
519,difference in ls means ( $nmbr$ % ci ) versus placebo,C0008107;C0023668;C0032042;C1696465;C1704970;C1705241;C1705242;C1706408;C3259781
519,difference in ls means ( $nmbr$ % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
519,difference in ls means ( $nmbr$ % ci ) $nmbr$,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
519,difference in ls means ( $nmbr$ % ci ),C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
519,difference in ls mean vs placebo ( $nmbr$ % ci )  mmol / mol,C0008107;C0023668;C0032042;C0444504;C1696465;C1705241;C1705242;C1706408;C2347634;C2348143;C3259781;C3829066
519,difference in ls mean vs placebo ( $nmbr$ % ci )  %,C0008107;C0023668;C0032042;C0444504;C1696465;C1705241;C1705242;C1706408;C2347634;C2348143;C3259781
519,difference ( $nmbr$ % ci ) *,C0008107;C1705241;C1705242;C3259781
519,difference ( $nmbr$ % ci  p value ),C0008107;C1705241;C1705242;C1709380;C3259781
519,d ( $nmbr$ % ci ),C0008107;C0073187;C0332173;C3259781;C4484261
519,coronary syndrome . ci = confidence interval  hr = hazard ratio .,C0008107;C0009667;C0018787;C0039082;C2985465;C3259781
519,cochranemantelehaenszel ( repeated $nmbr$ . $nmbr$ % ci ) c,C0008107;C0205341;C3259781
519,ci = confidence interval  na = not applicable or not analyzed .,C0008107;C0009667;C0597484;C0936012;C1272460;C1518422;C1546968;C1879645;C3259781;C4049872;C4552882
519,ci - aki risk score,C0008107;C0022660;C0035647;C0330978;C0449820;C3259781;C4050231;C4552904
519,atorvastatin ls means difference $nmbr$ mg ( $nmbr$ % ci ) a ( n = $nmbr$ ),C0008107;C0023668;C0024671;C0026410;C0286651;C0369718;C0439269;C0441922;C1704970;C1705241;C1705242;C1960952;C2346927;C3259781;C4321396;C4521761
519,annt or bnnh ( $nmbr$ % ci ),C0008107;C3259781
519,adjusted rate of pneumonia events ( per patient - year )  mean ( $nmbr$ % ci ),C0008107;C0030705;C0032285;C0439234;C0439508;C0441471;C0444504;C0456081;C0871208;C1521828;C2347634;C2348143;C3259781;C3541888
519,adjusted rate of hospitalized pneumonia events ( per patient - year )  mean ( $nmbr$ % ci ),C0008107;C0030705;C0032285;C0439234;C0439508;C0441471;C0444504;C0456081;C0701159;C0871208;C1521828;C2347634;C2348143;C3259781;C3541888
519,adjusted or ( $nmbr$ % ci ) c,C0008107;C0456081;C3259781
519,adjusted or ( $nmbr$ % ci ) b,C0008107;C0456081;C3259781
519,adjusted modelc hr  $nmbr$ % ci  p value,C0008107;C0456081;C1709380;C3259781
519,adjusted mean ± se ( $nmbr$ % ci ),C0008107;C0036919;C0444504;C0456081;C2347634;C2348143;C3259781
519,adjusted mean difference ( $nmbr$ % ci ),C0008107;C0444504;C0456081;C1705241;C1705242;C2347634;C2348143;C3259781
519,adjusted hr * ( $nmbr$ % ci ),C0008107;C0456081;C3259781
519,adjusted hr ( $nmbr$ % ci ) * comparing idm with bl,C0005918;C0006413;C0008107;C0270221;C0456081;C1552663;C1707455;C2827109;C3259781
519,adjusted hr ( $nmbr$ % ci ) * compared with no diabetes at bl or at year $nmbr$,C0005918;C0006413;C0008107;C0011847;C0011849;C0439234;C0439508;C0456081;C1552663;C1707455;C2827109;C3259781
519,adjusted hr ( $nmbr$ % ci ),C0008107;C0456081;C3259781
519,adjusted hr  $nmbr$ % ci,C0008107;C0456081;C3259781
519,adjusted * or ( $nmbr$ % ci ) p value,C0008107;C0456081;C1709380;C3259781
519,[ $nmbr$ % ci ] *,C0008107;C3259781
519,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) a - $nmbr$ . $nmbr$ %  * p = $nmbr$ . $nmbr$,C0008107;C3259781
519,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) * p = $nmbr$ . $nmbr$,C0008107;C3259781
519,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ),C0008107;C3259781
519,* ci denotes confidence interval .,C0008107;C0009667;C3259781
519,( mean difference  $nmbr$ % ci ),C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
519,( mean change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
519,( mean % difference  $nmbr$ % ci ),C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
519,( mean % change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
519,( ci ) b,C0008107;C3259781
519,( $nmbr$ % ci ] h,C0008107;C0033727;C0369286;C0441932;C0564385;C3259781;C4528284
519,( $nmbr$ % ci ] $nmbr$,C0008107;C3259781
519,( $nmbr$ % ci ) p value,C0008107;C1709380;C3259781
519,( $nmbr$ % ci ) c,C0008107;C3259781
519,( $nmbr$ % ci ) b,C0008107;C3259781
519,( $nmbr$ % ci ) a,C0008107;C3259781
519,( $nmbr$ % ci ),C0008107;C3259781
519,% difference  $nmbr$ % ci ),C0008107;C1705241;C1705242;C3259781
519,% change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C1705241;C3259781;C4319952
519,% ( $nmbr$ % ci ),C0008107;C3259781
519,$nmbr$ . $nmbr$ ( $nmbr$ % ci : $nmbr$ . $nmbr$  $nmbr$ . $nmbr$  n = $nmbr$ ),C0008107;C3259781
519,$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0008107;C3259781
519,$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ),C0008107;C3259781
519,$nmbr$ . $nmbr$ $nmbr$ % ci : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ p = $nmbr$ . $nmbr$,C0008107;C3259781
519,$nmbr$ % ci $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$,C0008107;C3259781
519,$nmbr$ % ci $nmbr$,C0008107;C3259781
519,$nmbr$ % ci,C0008107;C3259781
518,mdi / hfa  n,C0015458;C0993596;C1839839;C4049613
518,mdi,C0993596;C1839839;C4049613
518,gp mdi,C0993596;C1705010;C1839839;C3811116;C4049613
518,gff mdi,C0993596;C1839839;C4049613
518,ff mdi,C0993596;C1839839;C4049613;C4554348
517,mri substudy ( n = $nmbr$ ),C0024485;C1824234;C3890166
517,criteria for subcortical vad ( by mri )  %,C0024485;C0077973;C0243161;C0815275;C1824234;C3890166
516,• ii : death from coronary heart disease  nonfatal mi  coronary revascularization > $nmbr$ days,C0011065;C0018799;C0439228;C0545743;C0581603;C1306577;C1710602;C3810814;C4082313;C4082587;C4552775
516,• any mi,C3810814
516,type of mi ( % ),C0332307;C1547052;C3810814
516,type of mi,C0332307;C1547052;C3810814
516,time from randomization to pci ( non - st - elevation mi )  h,C0033727;C0034656;C0040223;C0369286;C0441932;C0520886;C0564385;C1518422;C3541383;C3810814;C4049621;C4528284
516,second prior mi,C0205436;C0332152;C0457385;C0565930;C1561503;C1705190;C2826257;C3810814
516,qualifying mi type,C0332307;C1514624;C1547052;C3810814
516,qualifying mi < $nmbr$ yrs prior,C0332152;C1514624;C2826257;C3810814
516,qualifying mi $ $nmbr$ yrs prior,C0332152;C1514624;C2826257;C3810814
516,qmi,
516,pvaluefor any mi versus no mi,C3810814
516,prior mi within $nmbr$ y  no . ( % ),C0332152;C2826257;C3810814
516,prior mi n = $nmbr$,C0332152;C2826257;C3810814
516,prior mi diagnosis :,C0332132;C3810814
516,prior mi ( n = $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
516,prior mi ( n - $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
516,prior mi  n / n ( % ),C0332152;C2826257;C3810814
516,prior mi  %,C0332152;C2826257;C3810814
516,prior mi,C0332152;C2826257;C3810814
516,prior history of mi or ischaemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0948008;C1705255;C2004062;C2826257;C3810814
516,previous mi — no . ( % ),C0205156;C1552607;C3810814
516,previous mi ( % ),C0205156;C1552607;C3810814
516,previous mi  n ( % ),C0205156;C1552607;C3810814
516,previous mi  %,C0205156;C1552607;C3810814
516,previous mi,C0205156;C1552607;C3810814
516,nonfatal mi ( n = $nmbr$ ),C3810814
516,non - st — elevation mi,C0520886;C1518422;C3810814
516,non - st - elevation mi,C0520886;C1518422;C3810814
516,nocad / mi,C3810814
516,no prior mi n = $nmbr$,C0332152;C2826257;C3810814
516,no prior mi ( n = $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
516,no prior mi,C0332152;C2826257;C3810814
516,no mi ( n - $nmbr$  $nmbr$ ),C3810814
516,no mi,C3810814
516,mi — no . ( % ),C3810814
516,mi *,C3810814
516,mi  n ( % ),C3810814
516,mi,C3810814
516,mhi,
516,large mi,C0549177;C3810814
516,inferior mi *  %,C0340305;C3542426
516,history of second prior mi,C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
516,fatal / nonfatal mi ( excluding silent mi ),C0332196;C0443304;C1302234;C1705232;C2828389;C3810814;C3816734
516,death  large mi,C0011065;C0549177;C1306577;C3810814;C4082313;C4552775
516,cvd or mi,C0007222;C3810814
516,cvd  mi  stroke  or recurrent ischemia - urgent revascularization,C0007222;C0022116;C0038454;C0439609;C0581603;C1455761;C2945760;C3272275;C3810814;C4321499;C4554100
516,cvd  mi  or stroke,C0007222;C0038454;C3810814;C4554100
516,cardiovascular death or nonfatal mi ( excluding silent mi ),C0007226;C0011065;C0332196;C0443304;C1306577;C2828389;C3810814;C3816734;C3887460;C4082313;C4552775
516,cardiovascular death  nonfatal mi ( excluding silent mi )  or stroke,C0007226;C0011065;C0038454;C0332196;C0443304;C1306577;C2828389;C3810814;C3816734;C3887460;C4082313;C4552775;C4554100
516,any mi ( n - $nmbr$  $nmbr$ ),C3810814
516,any mi,C3810814
516,anterior mi,C3536746
516,: mi  previous pci and chronic obstructive pulmonary disease .,C0024117;C0205156;C1552607;C3810814;C4049621
515,vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
515,vi - $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999
515,vi $nmbr$   µ g,C0205999;C0439267
515,vi $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0205999;C0439269;C1960952;C2346927;C4321396;C4521761
515,vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999
515,vi $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
515,vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
515,umec / vi $nmbr$ . $nmbr$ / $nmbr$ ( n $nmbr$ $nmbr$ ),C0205999
515,umec / vi $nmbr$ . $nmbr$ / $nmbr$,C0205999
515,ff / vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781;C4554348
515,ff / vi ( n   =   $nmbr$ ),C0205999;C4554348
515,ff / vi $nmbr$ mg / $nmbr$ mg ( n = $nmbr$ ),C0205999;C1319635;C4554348
515,ff / vi $nmbr$ / $nmbr$   µ g,C0205999;C0439267;C4554348
515,ff / vi $nmbr$ / $nmbr$ pg od,C0030827;C0072225;C0205999;C0229089;C0439164;C1266240;C1512019;C3273373;C3665488;C4554348
515,ff / vi $nmbr$ . $nmbr$,C0205999;C4554348
515,ff / vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999;C4554348
515,ff / vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781;C4554348
515,favors ff / vi favors placebo,C0032042;C0205999;C0309049;C1696465;C1706408;C4554348
515,$nmbr$ . $nmbr$ % vi . $nmbr$ . $nmbr$ %,C0205999
515,$nmbr$ . $nmbr$ % vi  $nmbr$ . $nmbr$ %,C0205999
514,work and school,C0036375;C0043227
514,network,C0150775;C1513822;C1705739;C1882071
513,never took alendronate,C0102118;C1515187;C2003901
513,- $nmbr$ - $nmbr$ ( - $nmbr$ - $nmbr$ too $nmbr$ ),
512,transfemoral,
512,femoral neckc,C0015811
512,femoral access — no . / total no . ( % ),C0015811;C0439175;C0439810;C0444454;C1554204
512,femoral access,C0015811;C0444454;C1554204
512,femoral,C0015811
512,catheter site — femoral,C0015811;C0449652
511,t - score at femoral neck,C0015815;C3854607
511,mean femoral neck t score,C0015815;C3533236
511,femoral neck,C0015815
511,at femoral neck  mean ( sd ),C0015815;C0444504;C2347634;C2348143;C2699239
510,total study population ( n = $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
510,total study population ( n = $nmbr$  $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
510,total study population,C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
510,total study itt population ( n = $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
510,total population n,C3258257
510,total population ( n = $nmbr$ ),C3258257
510,total population,C3258257
510,total ho population ( n = $nmbr$ ),C0019905;C1832110;C3258257;C3889614
510,total carmelina population,C3258257
509,total no . $nmbr$,C0439175;C0439810
509,total gadolinium - enhancing lesion count . no . ( % ),C0439175;C0439810;C0750480;C1333400;C1705566
509,total gadolinium - enhancing lesion count  no . ( % ),C0439175;C0439810;C0750480;C1333400;C1705566
509,no . ( % ) *,
509,no *,
509,cardiac - biomarker status 一 no . / total no . ( % ) $,C0005516;C0018787;C0439175;C0439810;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
509,cardiac - biomarker status — no . / total no . ( % ) $,C0005516;C0018787;C0439175;C0439810;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
509,antiplatelet — no . / total no . ( % ),C0439175;C0439810
509,antiplatelet — no . ( % ),
509,$nmbr$ - $nmbr$  no . / totalno . ( % ),
508,v total ( n = $nmbr$ ),C0439175;C0439810
508,treated with pci — no . / total no . ( % ),C0332293;C0439175;C0439810;C4049621
508,total sgrq score,C0439175;C0439810;C0449820;C4050231
508,total resolution of nail psoriasisd,C0027342;C0439175;C0439810;C1432728;C1514893;C1706463;C2699488;C3538766
508,total resolution of enthesitisc,C0439175;C0439810;C1514893;C1706463;C2699488
508,total resolution of dactylitisb,C0439175;C0439810;C1514893;C1706463;C2699488
508,total randomized  n,C0034656;C0439175;C0439810;C3815594
508,total randomized,C0034656;C0439175;C0439810;C3815594
508,total randomised ( n ),C0439175;C0439810
508,total patients n = $nmbr$,C0030705;C0439175;C0439810
508,total patients  n,C0030705;C0439175;C0439810
508,total patients,C0030705;C0439175;C0439810
508,total number of patients,C0439175;C0439810;C2360800
508,total number of events / participants,C0439175;C0439810;C0679646;C4330837
508,total no . of patients,C0030705;C0439175;C0439810
508,total no .,C0439175;C0439810
508,total n   =   $nmbr$,C0439175;C0439810
508,total n = $nmbr$ n ( % ),C0439175;C0439810
508,total n = $nmbr$,C0439175;C0439810
508,total n $nmbr$,C0439175;C0439810
508,total n,C0439175;C0439810
508,total mortality all,C0026565;C0026566;C0439175;C0439810
508,total mortality,C0026565;C0026566;C0439175;C0439810
508,total invasive cancer,C0439175;C0439810;C0677898
508,total ige — lu / ml,C0439175;C0439810;C2697941
508,total ige  geometric,C0439175;C0439810;C0449829
508,total hipc,C0439175;C0439810
508,total hip bmd ( g / cm $nmbr$ ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
508,total hip ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C2699239;C3538851;C4284725
508,total hip,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
508,total haq  $nmbr$ - $nmbr$,C0102923;C0439175;C0439810;C0451208
508,total deaths  n,C0011065;C0439175;C0439810;C1306577
508,total deaths,C0011065;C0439175;C0439810;C1306577
508,total death,C0011065;C0439175;C0439810;C1306577;C4082313;C4552775
508,total c,C0439175;C0439810
508,total antihypertensive use,C0003364;C0042153;C0439175;C0439810;C0457083;C1947944
508,total > atients,C0439175;C0439810
508,total - c,C0439175;C0439810
508,total *,C0439175;C0439810
508,total ( v = $nmbr$  $nmbr$ ),C0439175;C0439810
508,total ( n   =   $nmbr$ ),C0439175;C0439810
508,total ( n   = $nmbr$ ),C0439175;C0439810
508,total ( n [ $nmbr$ ),C0439175;C0439810
508,total ( n = $nmbr$ ),C0439175;C0439810
508,total ( n = $nmbr$ $nmbr$ ),C0439175;C0439810
508,total ( n = $nmbr$  $nmbr$ ) - -,C0439175;C0439810
508,total ( n = $nmbr$  $nmbr$ ),C0439175;C0439810
508,total ( n ),C0439175;C0439810
508,total ( n $nmbr$ $nmbr$ ),C0439175;C0439810
508,total $nmbr$,C0439175;C0439810
508,total !,C0439175;C0439810
508,total  n = $nmbr$ $nmbr$,C0439175;C0439810
508,total  n = $nmbr$,C0439175;C0439810
508,total,C0439175;C0439810
508,totai mortaiity,
508,tiotropium salmeterol no . of patients / total no .,C0030705;C0073992;C0213771;C0439175;C0439810
508,statin — no . / total no . ( % ),C0360714;C0439175;C0439810
508,standardized total hip bmd ( g / cm $nmbr$ ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
508,sgrq - c total scoreb,C0439175;C0439810;C3826872
508,previous cabg ( % total ),C0010055;C0205156;C0439175;C0439810;C1552607
508,patients total no .,C0030705;C0439175;C0439810
508,patients  no . / total no . ( % ),C0030705;C0439175;C0439810
508,oral study drug administered — no . / total no . ( % ),C0013175;C0439175;C0439810;C0442027;C1521801;C4521986
508,oral contraceptive pills — no . / total no . ( % ),C0009905;C0009906;C0029151;C0439175;C0439810
508,of patients meeting criterion / total no . of patients,C0030705;C0243161;C0439175;C0439810;C0556656
508,o total randomized,C0034656;C0439175;C0439810;C0483204;C3815594
508,nsaid use — no . / total no . ( % ),C0003211;C0042153;C0439175;C0439810;C0457083;C1947944;C3536840
508,normoalbuminuria — no . / total no . ( % ),C0439175;C0439810
508,no . of patients / total no . ( % ),C0030705;C0439175;C0439810
508,no . of panents . total no . $nmbr$ % ),C0439175;C0439810
508,no . / total no . ( % ) t,C0439175;C0439810;C2603360
508,no . / total no . ( % ),C0439175;C0439810
508,no . / total 	 no . ( % ),C0439175;C0439810
508,no . / total,C0439175;C0439810
508,medications in use at baseline — no . / total no . ( % ),C0013227;C0042153;C0150312;C0168634;C0332285;C0439175;C0439810;C0457083;C0802604;C1442488;C1707101;C1947944;C2598133;C4284232
508,medications at study entry — no . / total no . ( % ),C0013175;C0439175;C0439810;C1705654
508,medical therapy before randomization — no . / total no . ( % ),C0034656;C0418981;C0439175;C0439810
508,managed medically — no . / total no . ( % ),C0439175;C0439810;C1273870
508,macroalbuminuria — no . / total no . ( % ),C0439175;C0439810
508,long - term treatment with aspirin — no . / total no . ( % ),C0004057;C0023977;C0439175;C0439810
508,infusion administered — no . / total no . ( % ),C0439175;C0439810;C0574032;C1521801;C1827465
508,history of gi bleeding or ulcer — no . / total no . ( % ),C0017181;C0019664;C0019665;C0041582;C0262512;C0262926;C0439175;C0439810;C1705255;C2004062;C3887532
508,gastrointestinal area involved — no . / total no . ( % ),C0017446;C0205146;C0439175;C0439810;C0521362;C1314939
508,elevation of troponin levels — no . / total no . ( % ),C0041199;C0439175;C0439775;C0439810;C0441889;C0702240
508,diuretic — no . / total no . ( % ),C0012798;C0439175;C0439810
508,current alcohol use — no . / total no . ( % ),C0001962;C0001975;C0042153;C0439175;C0439810;C0457083;C0521116;C1705970;C1947944
508,colectomy ( partial or total ),C0009274;C0439175;C0439810;C0728938;C1550516
508,category — no . / total no . ( % ),C0439175;C0439810;C0683312;C3889287
508,between - treatment comparison of percentage change from baseline in total hip bmd,C0019552;C0022122;C0168634;C0439165;C0439175;C0439810;C1299575;C1442488;C1505163;C1549488;C1561533;C1707455;C3538851;C4284725
508,angiographic complications  site - reported — no . / total no . ( % ),C0002978;C0009566;C0205145;C0439175;C0439810;C0684224;C0700287;C1171258;C1515974;C2825164;C4319718
508,administration of study - drug bolus — no . / total no . ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0439175;C0439810;C0557651;C1186706;C1254351;C1511237;C1533734;C1705509;C2603343;C3161471;C3469597;C3812160
508,$nmbr$ — no . / total no . ( % ),C0439175;C0439810
508,$nmbr$ or $nmbr$ — no . / total no . ( % ),C0439175;C0439810
508,$nmbr$ or $nmbr$  no . / total no . ( % ),C0439175;C0439810
508,$nmbr$ - $nmbr$ — no . / total no . ( % ),C0439175;C0439810
508,$nmbr$  no . / total no . ( % ),C0439175;C0439810
507,• death from cv causes  major coronary event  or nonfatal stroke,C0011065;C0015127;C0038454;C0205082;C0205164;C0741923;C1306577;C1314792;C1524003;C3538987;C4048877;C4082313;C4318503;C4318856;C4521762;C4552775;C4554100
507,stroke non - fatal,C0038454;C1302234;C1518422;C1705232;C4554100
507,stroke ( fatal / nonfatal ),C0038454;C1302234;C1705232;C4554100
507,stroke  fatal and nonfatal,C0038454;C1302234;C1705232;C4554100
507,nonfatal stroke ®,C0038454;C4554100
507,nonfatal stroke ( n = $nmbr$ ),C0038454;C4554100
507,nonfatal stroke,C0038454;C4554100
507,nonfatal,
507,nondisabling  nonfatal stroke,C0038454;C4554100
507,non - fatal stroke,C0038454;C1302234;C1518422;C1705232;C4554100
507,in - trial nonfatal or fatal stroke n = $nmbr$  $nmbr$,C0008976;C0038454;C0150312;C0332285;C1302234;C1705232;C1707101;C4554100
507,fatal stroke,C0038454;C1302234;C1705232;C4554100
507,fatal or nonlatal stroke,C0038454;C1302234;C1705232;C4554100
507,fatal or nonfatal stroke,C0038454;C1302234;C1705232;C4554100
507,fatal or non - fatal stroke,C0038454;C1302234;C1518422;C1705232;C4554100
507,fatal and nonfatal stroke,C0038454;C1302234;C1705232;C4554100
507,fatal / nonfatal stroke  n ( % ),C0038454;C1302234;C1705232;C4554100
507,fatal / nonfatal stroke,C0038454;C1302234;C1705232;C4554100
507,fatal & nonfatal hospitalized stroke,C0038454;C0701159;C1302234;C1705232;C4554100
506,role physical,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
506,role emotional,C0013987;C0035820;C0849912;C1705810;C3871154
506,physical role,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
506,emotional role,C0013987;C0035820;C0849912;C1705810;C3871154
505,neutropenia,C0023530;C0027947;C0853697
505,leukopenia,C0023530;C0750394
505,europa ( n = $nmbr$ l $nmbr$ ),C0242751
505,eastern and central europe,C0682369;C1707877
505,central europe,C0682369
505,central / eastern europe and russia hr ( $nmbr$ % cl ),C0015177;C0035970;C0205099;C0596019;C0682369;C1707877;C1879652
505,central / eastern europe / russia,C0015177;C0035970;C0205099;C0682369;C1707877;C1879652
504,white / european,C0007457;C0043157;C0220938;C0239307;C1535514
504,non - european trial,C0008976;C0239307;C1518422;C1535514
504,non - european,C0239307;C1518422;C1535514
504,european trial,C0008976;C0239307;C1535514
504,european subcategories,C0239307;C1515010;C1535514
504,european,C0239307;C1535514
503,prior pacemaker  n ( % ),C0030163;C0332152;C0810633;C1546728;C2826257;C3275122;C3853703
503,pacemaker — no . ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
503,pacemaker  n ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
503,pacemaker  ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
503,pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
503,cardiac pacemaker — no . ( % ),C0030163;C0037189
503,biventricular pacemaker,C1719274
502,paracetamol,C0000970
502,acetaminophen,C0000970;C2917659
501,study drug loading days ( actual ) : $nmbr$ ( n = $nmbr$ ),C0013175;C0237400;C0439228;C1708715
501,actual ( l ),C0237400
500,paclitaxel - eluting stent use  n ( % ),C0038257;C0042153;C0144576;C0457083;C1947944
500,paclitaxel - eluting,C0144576
500,paclitaxel,C0144576
499,with long - acting j $nmbr$ - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
499,short - acting b $nmbr$ - agonists,C0079613;C0243192;C1282927;C1704930;C1806781;C1869853;C2350002;C2987634;C3890007;C4048375
499,short - acting,C0079613;C1282927;C1704930;C1806781;C1869853;C2350002;C3890007;C4048375
499,peak procedural act — sec,C0025664;C0079613;C0184661;C0444505;C0565930;C1704930;C1869853;C2700391;C3274430;C3538935;C3539779;C3890007;C4048375
499,long acting nitratef,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
499,long - acting or short - acting nitrates,C0028125;C0079613;C0205166;C1282927;C1704930;C1706317;C1806781;C1869853;C2350002;C3890007;C4048375
499,long - acting nitrates,C0028125;C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
499,long - acting nitrate agents,C0028125;C0079613;C0205166;C0450442;C0699857;C1254351;C1521826;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
499,long - acting nitrate,C0028125;C0079613;C0205166;C0699857;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
499,long - acting bronchodilator use at screening,C0006280;C0042153;C0079613;C0205166;C0220908;C0220909;C0457083;C1698960;C1704930;C1706317;C1710031;C1710032;C1710477;C1869853;C1947944;C2348164;C3890007;C4048375
499,long - acting b $nmbr$ - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
499,long - acting ^,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
499,long - acting,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
499,b - agonists ( short - acting ) a,C0079613;C0243192;C1282927;C1704930;C1806781;C1869853;C2350002;C2987634;C3890007;C4048375
499,b - agonists ( long - acting ) a,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
499,anti - cholinergics ( short - acting ) a,C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3890007;C4048375
499,anti - cholinergics ( long - acting ),C0079613;C0205166;C0242896;C1704930;C1706317;C1869853;C3890007;C4048375
499,act total score ≥   $nmbr$,C0079613;C1704930;C1869853;C2964552;C3890007;C4048375
499,act total score   ≥   $nmbr$ and / or improvement from baseline   ≥   $nmbr$,C0079613;C0168634;C1442488;C1704930;C1869853;C2964552;C2986411;C3890007;C4048375
499,act . $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
499,act - $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
-10,centrally acting sympathomimetics,C3653511
497,sexually active with female,C0043210;C0086287;C0241028;C1705497;C1705498
497,sexually active $nmbr$ ( % ),C0241028
497,sexually active,C0241028
496,reason for enrollment in active a — no . ( % ),C0150312;C0205177;C0332285;C0392360;C1516879;C1696073;C1707101;C3853793;C3888021;C3888249
496,reason for enrollment in active a,C0150312;C0205177;C0332285;C0392360;C1516879;C1696073;C1707101;C3853793;C3888021;C3888249
496,randomized to active yitamin e,C0034656;C0205177;C3815594;C3853793;C3888249
496,alive ( n = $nmbr$ ),C2584946;C4551704
496,active smoking,C0037369;C0205177;C0453996;C1881674;C3853793;C3888249
496,active pso wi $nmbr$ bsa > $nmbr$ %  n ( . % y,C0043193;C0205177;C1520135;C3853793;C3888249
496,active comparatorb,C0205177;C3853793;C3888249
496,active canakinumab ( n   =   $nmbr$  $nmbr$ ),C0205177;C2718773;C3853793;C3888249
496,active a,C0205177;C3853793;C3888249
496,active ( n = $nmbr$ ),C0205177;C3853793;C3888249
496,active,C0205177;C3853793;C3888249
-10,any acuity bleeding,C0333276
494,selena - sledai activity  n ( % ),C0205177;C0439167;C0441655;C0451528;C1561536;C3668946;C4049938;C4049939
494,activity limitation,C0205177;C0439167;C0441655;C0443288;C0449295;C1561536;C3668946;C4049938;C4049939
494,activity ( range $nmbr$ - $nmbr$ )  mean ± sd,C0205177;C0439167;C0441655;C0444504;C1514721;C1561536;C2347634;C2348143;C2348147;C2699239;C3542016;C3668946;C4049938;C4049939
494,activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
493,catheter access site,C0085590;C0444454;C0449652;C0589360;C1554204
493,arterial access site,C3272298
493,arterial access,C0003842;C0221464;C0444454;C1554204
493,arteriai access,C0444454;C1554204
493,access site,C0589360
492,randomised patients with dactylitis at baseline,C0030705;C0168634;C0239161;C1442488
492,patients with dactylitis at baseline  no .,C0030705;C0168634;C0239161;C1442488
492,patients with dactylitis  no . ( % ),C0030705;C0239161
492,patients with dactylitis,C0030705;C0239161
492,dactylitis severity score ) score > $nmbr$ — no . { % ),C0239161;C0449820;C0457451;C4050231
492,dactylitis score ( $nmbr$ – $nmbr$ scale ),C0175659;C0239161;C0349674;C0449820;C1947916;C4050231
492,dactylitis score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0239161;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
492,dactylitis score ( $nmbr$ - $nmbr$ ),C0239161;C0449820;C4050231
492,dactylitis score,C0239161;C0449820;C4050231
492,dactylitis  n ( % ),C0239161
492,dactylitis  % #,C0239161
492,dactylitis,C0239161
492,% improvement in dactylitis score at week $nmbr$  n,C0239161;C0332174;C0439230;C0449820;C2986411;C4050231
491,patient global assessment of disease,C0012634;C4054229
491,patient assessment of pain ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C0679830
491,patient assessment of disease activity  mm,C0679830;C1292728;C4330985;C4554674
491,patient assessment of arthritis pain  mm,C0679830;C4317006;C4330985;C4554674
491,patient ' s global assessment of response to therapy score,C0039798;C0087111;C0449820;C0871261;C1363945;C1704632;C1706817;C2911692;C4050231;C4054229
491,patient ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4054229
491,patient ' s global assessment of disease,C0012634;C4054229
491,patient ' s global assessment of,C4054229
491,patient ' s global assessment !,C4054229
491,patient ' s global assessment,C4054229
491,patient ' s assessment of pain ( $nmbr$ - $nmbr$ vas ),C0042815;C0679830
490,patients with measurement,C0030705;C0242485
490,measurements,C0242485
490,* determined by investigator to be possibly  probably or definitely related to study drug tmyopathy defined as cpk > $nmbr$ x uln with associated muscle symptoms with no other plausible etiology ^ consecutive defined as two or more measurements at least one week apart or one measurement < $nmbr$ days after the last dose of study drug ( presumed consecutive ) § two patients had incomplete data to assess chd status simva = simvastatin  eze = ezetimibe  ae = adverse event  alt = alanine aminotransferase  ast = aspartate aminotransferase  cpk = creatine phosphokinase  uln = upper limit of normal,C0010287;C0013175;C0015127;C0026845;C0030705;C0035173;C0040363;C0041260;C0074554;C0178602;C0205172;C0205448;C0242485;C0280604;C0332281;C0439849;C0445223;C0449438;C0521095;C0683368;C0750492;C0805162;C0869039;C0877248;C1114758;C1142985;C1266129;C1314792;C1415181;C1442452;C1457887;C1516048;C1519815;C1524003;C1704788;C1707491;C1883351;C2362652;C3242203;C3539106;C3542407;C3844320;C3887670;C3891303;C4083049;C4553172
489,preamendment,C1548596
489,postamendment,
489,before amendment ( % ),C0680532;C2346732
489,before amendment,C0680532;C2346732
489,after amendment ( % ),C0680532;C2346732
489,after amendment,C0680532;C2346732
488,temporal data and management strategy,C0001554;C0376636;C0442043;C0679199;C1273870;C1511726;C2362314;C3245479;C3273539;C3714741
488,primary management strategy,C0001554;C0205225;C0376636;C0439612;C0439631;C0679199;C1273870;C3273539
488,management distribution medical treatment,C0001554;C0030677;C0199168;C0205476;C0376636;C0520511;C0679624;C1273870;C1704711;C3273539
488,management distribution,C0001554;C0376636;C0520511;C1273870;C1704711;C3273539
488,acs management  no . ( % ),C0001554;C0376636;C0742343;C1273870;C3273539;C4318612
487,types of fibrinolytic agent,C0016018;C0332307
487,thrombolytic agents,C0016018
487,inotropic agent,C0304509
487,fibrinolytic agent given,C0016018;C1442162;C1550718;C1947971;C3244317
487,fibrinolytic agent before randomisation,C0016018;C0034656
486,use of antiarrhythmic agent,C0003195;C0301380;C1524063
486,class $nmbr$ antiarrhythmic agents,C0003195;C0301380;C0456387;C1518526;C1705943
486,antiarrhythmic agent,C0003195;C0301380
486,aget  y,
485,hypertension absent,C0020538;C0332197;C1963138;C4285062
485,factor absent,C0332197;C1521761;C2827422;C4285062
485,dm absent,C0011816;C0332197;C3250443;C4285062
485,absent ( < $nmbr$ mg / dl ),C0332197;C0439269;C4285062
485,absent,C0332197;C4285062
485,absence,C0332197;C1689985
484,three or more agents,C0205172;C0205449;C0450442;C1254351;C1521826
484,ras agents,C0034678;C0450442;C0525678;C1254351;C1521826
484,oral diabetic agent,C0241863;C0442027;C0450442;C1254351;C1521826;C4521986
484,oral agents use,C0042153;C0442027;C0450442;C0457083;C1254351;C1521826;C1947944;C4521986
484,oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
484,oral agent and / or insulin therapy,C0021641;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C1533581;C1579433;C3714501;C4521986
484,oral agent,C0442027;C0450442;C1254351;C1521826;C4521986
484,number of agents,C0237753;C0449788;C0450442;C1254351;C1521826
484,no . of agents,C0450442;C1254351;C1521826
484,ipah / fpah / drug and toxin,C0013227;C0040549;C0152171;C1254351;C1419079;C4522020
484,drug and insulint,C0013227;C1254351
484,conventional agents *,C0439858;C0450442;C1254351;C1521826
484,anyantianginal agent,C0450442;C1254351;C1521826
484,antihyperglycemic oral agent therapy,C0020616;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C4521986
484,antialdosterone agents,C0450442;C1254351;C1521826
484,anti ‐ platelet agents  n ( % ),C0005821;C0432633;C0450442;C1254351;C1521826
484,> $nmbr$ oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
484,> $nmbr$ and < $nmbr$,
483,no ocs use  no nasal polyps  pre - bd fvc s $nmbr$ % of predicted and age at diagnosis < $nmbr$ years,C0005126;C0027430;C0042153;C0332152;C0439234;C0457083;C0681842;C0740175;C1828181;C1882327;C1947944;C2257086;C2344255;C3173302;C3669034;C3714541;C4050145
483,aqe i $nmbr$,C0021966;C0221138
483,aqe ^ $nmbr$,
483,aqe < $nmbr$,
483,aqc < $nmbr$,
483,age at diagnosis s $nmbr$ years,C0439234;C1828181;C3173302
483,age at diagnosis of sle  years,C0024141;C0439234;C1828181;C3173302
483,age at diagnosis of ln  years,C0439234;C0861352;C1428884;C1828181;C3173302;C3714709
483,age at diagnosis < $nmbr$ years,C0439234;C1828181;C3173302
483,age at diagnosis  y,C1828181;C3173302
482,p between age groups,C0001779;C0027362;C0369773;C0441849;C1959644;C2603361
482,age groups,C0027362
481,subjects $ $nmbr$ years of age  n ( % ),C0681850;C1510829;C1550501;C1706203;C2349001;C2697811
481,subjects  $nmbr$ years of age  n ( % ),C0681850;C1510829;C1550501;C1706203;C2349001;C2697811
481,patients ' characteristics age ( years )  mean + sd,C0444504;C0815172;C1510829;C2347634;C2348143;C2699239
481,median age  years ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
481,mean ± s . d . age  years,C0444504;C1510829;C2347634;C2348143
481,mean age ± sd ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
481,mean age ± s . d .  years,C0444504;C1510829;C2347634;C2348143
481,mean age ( years ) race,C0034510;C0444504;C1510829;C1706779;C2347634;C2348143;C3853635
481,mean age ( years ) ( s . d . ),C0444504;C1510829;C2347634;C2348143
481,mean age ( years ),C0444504;C1510829;C2347634;C2348143
481,mean age ( years  sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,mean age ( sd )  years,C0444504;C1510829;C2347634;C2348143;C2699239
481,mean age  years ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
481,mean age  years ( range ),C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
481,mean age  years ( $nmbr$ % ci ),C0008107;C0444504;C1510829;C2347634;C2348143;C3259781
481,mean age  years,C0444504;C1510829;C2347634;C2348143
481,mean ( s . d . ) age  years,C0444504;C1510829;C2347634;C2348143
481,i $nmbr$ years of age,C0021966;C0221138;C1510829
481,age ≥ $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C0578022;C1510829;C1532718
481,age ≥ $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C0578022;C1510829;C1532718
481,age ≥ $nmbr$ years  n ( % ),C1510829
481,age ≥ $nmbr$ years,C1510829
481,age £ $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
481,age years geographic region,C0017446;C1510829
481,age years,C1510829
481,age s $nmbr$ years ( n = $nmbr$  $nmbr$ ),C1510829
481,age range ( years ),C1510829;C1514721;C2348147;C3542016
481,age range  years,C1510829;C1514721;C2348147;C3542016
481,age mean age  years sex,C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143
481,age in years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age in years  mean,C0444504;C1510829;C2347634;C2348143
481,age in years,C1510829
481,age group ( ≥ $nmbr$ years ) — no . ( % ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
481,age groiro : < $nmbr$ years,C1510829
481,age distribution  years  n ( % ),C0001782;C0439234;C0520511;C1510829;C1704711
481,age distribution  n ( % ),C0001782
481,age distribution,C0001782
481,age categories ( y )  n ( % ),C2916832
481,age categories  n ( % ),C2916832
481,age categories,C2916832
481,age at randomization ( years ),C0034656;C1510829
481,age at entry ( years ),C1510829;C1705654
481,age at enrolment  years,C1510829;C1516879;C1696073;C3888021
481,age at enrollment ( years ),C1510829;C1516879;C1696073;C3888021
481,age at baseline years,C0168634;C1442488;C1510829
481,age at baseline ( years ),C0168634;C1442488;C1510829
481,age [ years ] ( interaction : p = $nmbr$ . $nmbr$ ),C1510829;C1704675
481,age [ years ]  median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
481,age [ years ],C1510829
481,age > = $nmbr$ years old,C0580836;C1510829
481,age > = $nmbr$ years,C1510829
481,age > $nmbr$ years ( n = $nmbr$ ),C1510829
481,age > $nmbr$ years ( median ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
481,age > $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
481,age > $nmbr$ years $nmbr$,C1510829
481,age > $nmbr$ years  n ( % ),C1510829
481,age > $nmbr$ years  %,C1510829
481,age > $nmbr$ years,C1510829
481,age > $nmbr$ ( years ) t,C1510829
481,age < $nmbr$ years — no . ( % ),C1510829
481,age < $nmbr$ years old,C0580836;C1510829
481,age < $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C0578022;C1510829;C1532718
481,age < $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C0578022;C1510829;C1532718
481,age < $nmbr$ years ( n = $nmbr$ ),C1510829
481,age < $nmbr$ years ( n = $nmbr$  $nmbr$ ),C1510829
481,age < $nmbr$ years ( n =,C1510829
481,age < $nmbr$ years ( median ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
481,age < $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
481,age < $nmbr$ years $nmbr$,C1510829
481,age < $nmbr$ years  n ( % ),C1510829
481,age < $nmbr$ years,C1510829
481,age : > $nmbr$ years,C1510829
481,age : < $nmbr$ years ( n = $nmbr$ ),C1510829
481,age : < $nmbr$ years,C1510829
481,age . years,C1510829
481,age - years,C1510829
481,age - mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
481,age ( years ) a,C1510829
481,age ( years ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C1510829;C2347635;C2348144;C2939193;C4282123;C4285344
481,age ( years ) : mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
481,age ( years ) : > $nmbr$,C1510829
481,age ( years ) : < $nmbr$,C1510829
481,age ( years ) : $nmbr$ - < $nmbr$,C1510829
481,age ( years ) :,C1510829
481,age ( years ) - mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
481,age ( years ) - > = median ( n = $nmbr$  $nmbr$ ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
481,age ( years ) - < median ( n = $nmbr$  $nmbr$ ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
481,age ( years ) +,C1510829
481,age ( years ) *,C1510829
481,age ( years ) ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age ( years ) ( mean  sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age ( years )  median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
481,age ( years )  mean   ±   sd,C0444504;C1510829;C2347634;C2348143;C2699239
481,age ( years )  mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
481,age ( years )  mean ± s . d .,C0444504;C1510829;C2347634;C2348143
481,age ( years )  mean _ sd,C0444504;C1510829;C2347634;C2348143;C2699239
481,age ( years )  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age ( years )  mean ( s . d . ),C0444504;C1510829;C2347634;C2348143
481,age ( years ),C1510829
481,age ( years ( s . d . ) ),C1510829
481,age ( years  sd ),C1510829;C2699239
481,age ( range ) ( years ),C1510829;C1514721;C2348147;C3542016
481,age ( per $nmbr$ years ),C1510829
481,age ( median  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
481,age $nmbr$ years or more,C0205172;C1510829
481,age $nmbr$ years ( n = $nmbr$ ),C1510829
481,age $nmbr$ years,C1510829
481,age $nmbr$ - $nmbr$ years ( n = $nmbr$ ),C1510829
481,age $nmbr$ - $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
481,age $nmbr$ + years,C1510829
481,age $ $nmbr$ years § *,C1510829
481,age  years “,C1510829
481,age  years mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
481,age  years mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age  years mean ( s . d . ),C0444504;C1510829;C2347634;C2348143
481,age  years geographical distribution of patients,C0030705;C0681686;C1510829
481,age  years ^,C1510829
481,age  years : median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
481,age  years *,C1510829
481,age  years ( sd ),C1510829;C2699239
481,age  years ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age  years ( mean _ + sd ) sex  n ( % ) :,C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143;C2699239
481,age  years ( mean = sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age  years ( mean $nmbr$ sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age  years $nmbr$ ',C1510829
481,age  years  mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
481,age  years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age  years  mean ( range ),C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
481,age  years,C1510829
481,age  median years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
481,age  median ( range ) ( years ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
481,age  mean ± sd  years,C0444504;C1510829;C2347634;C2348143;C2699239
481,age  mean years ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age  mean = sd  years,C0444504;C1510829;C2347634;C2348143;C2699239
481,age  mean ( sd ) years  n ( % ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age  mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
481,age  mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age  mean ( sd )  years,C0444504;C1510829;C2347634;C2348143;C2699239
481,age  mean ( range ) years,C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
481,age  mean  years ( ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
481,age  ( years ),C1510829
481,age  $nmbr$ years,C1510829
481,> $nmbr$ years of age  n ( % ),C1510829
481,> $nmbr$ years of age,C1510829
481,< $nmbr$ years of age,C1510829
480,x cr $nmbr$ . $nmbr$ x age,C0001779;C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
480,unstable angina age,C0001779;C0002965
480,patients aged > $nmbr$ y  no  ( ss ),C0001779;C0001792;C0030705;C1999167;C2699257;C3891295;C4551874
480,p value for interaction ( age continuous ),C0001779;C0549178;C1704675;C1709380
480,min - max age,C0001779;C0702093;C1524029;C3813700
480,median age — yr §,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
480,median age — yr,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
480,median age [ interquartile range ] — yr,C0001779;C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
480,median age ( $nmbr$ %  $nmbr$ % )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
480,mean age 士 s . d .  year,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143
480,mean age — yr ( range ),C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
480,mean age — yr,C0001779;C0439234;C0444504;C2347634;C2348143
480,mean age ± s . d .  year,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143
480,mean age ( yrs ),C0001779;C0444504;C2347634;C2348143
480,mean age ( yr ),C0001779;C0439234;C0444504;C2347634;C2348143
480,mean age ( y ),C0001779;C0444504;C2347634;C2348143
480,mean age ( sd )  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
480,mean age ( sd )  y,C0001779;C0444504;C2347634;C2348143;C2699239
480,mean age ( range ) — yr,C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
480,mean age  yrs,C0001779;C0444504;C2347634;C2348143
480,mean age  y : ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
480,mean age  y ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
480,mean age  y,C0001779;C0444504;C2347634;C2348143
480,mean ( sd ) age  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
480,mean ( sd ) age  y race  n ( % ) *,C0001779;C0034510;C0444504;C1706779;C2347634;C2348143;C2699239;C3853635
480,mean ( sd ) age  y,C0001779;C0444504;C2347634;C2348143;C2699239
480,low - trauma fracture since age $nmbr$  n ( % ),C0001779;C0521170
480,infarction before age $nmbr$ ( a ),C0001779;C0021308
480,goncomitant treatment with age inhibitors / angiotensin,C0001779;C0003018;C0039798;C0087111;C0243077;C1522326;C1533734;C1705169;C3538994;C3887704;C4521302
480,family history of myocardial infarction prior to age $nmbr$  %,C0001779;C0455406
480,established cvd / chronic kidney disease ( age > $nmbr$ ) ^ * ’,C0001779;C0007222;C0443211;C1272684;C1561643;C4553188
480,established cvd ( age > $nmbr$ ),C0001779;C0007222;C0443211;C1272684
480,cvd risk factors ( age > $nmbr$ ) ^ “ ^,C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
480,cvd risk factors ( age > $nmbr$ ),C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
480,baseline age,C0001779;C0168634;C1442488
480,average age ( year ),C0001779;C0439234;C0439508;C1510992;C2825518
480,aged $nmbr$ y or older  n ( % ),C0001779;C0001792;C0580836;C1999167
480,ageadj,
480,age\\yr,C0001779;C0439234
480,age — yrf,C0001779
480,age — yr race — no . ( % ) f,C0001779;C0016327;C0034510;C0439234;C1706779;C3853635
480,age — yr,C0001779;C0439234
480,age — year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
480,age — y £,C0001779
480,age — y  meantsd,C0001779
480,age   ≥ $nmbr$   y  n ( % ),C0001779
480,age £ $nmbr$,C0001779
480,age yrs,C0001779
480,age yr  range,C0001779;C0439234;C1514721;C2348147;C3542016
480,age y  median ( range ),C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
480,age subgroups,C0001779;C1079230
480,age subgroup  y,C0001779;C1079230;C1515021
480,age s * $nmbr$ yr,C0001779;C0439234
480,age s $nmbr$,C0001779
480,age range  y,C0001779;C1514721;C2348147;C3542016
480,age range,C0001779;C1514721;C2348147;C3542016
480,age mean ( yrs ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
480,age groups  n ( % ),C0001779;C0441848
480,age group ( y ),C0001779;C0441858
480,age group  n ( % ),C0001779;C0441848
480,age b $nmbr$ y ( n = $nmbr$ ),C0001779
480,age at time of first seizure,C0001779;C0036572;C0040223;C0205435;C1279901;C1959629;C3541383;C4553401
480,age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
480,age at randomization,C0001779;C0034656
480,age at randomisation,C0001779;C0034656
480,age at lipid randomization ( y ),C0001779;C0034656;C0065033
480,age at completion of highest level of,C0001779;C0205197;C1554962;C4321237
480,age a $nmbr$,C0001779
480,age ^ $nmbr$,C0001779
480,age [ year ]  mean ± sda,C0001779;C0276477;C0439234;C0439508;C0444504;C1428349;C1553165;C2347634;C2348143
480,age > = $nmbr$ yrs,C0001779
480,age > = $nmbr$,C0001779
480,age > : $nmbr$,C0001779
480,age > $nmbr$ yrs *,C0001779
480,age > $nmbr$ yrs  %,C0001779
480,age > $nmbr$ yrs,C0001779
480,age > $nmbr$ yr 十,C0001779;C0439234
480,age > $nmbr$ yr — no . ( % ),C0001779;C0439234
480,age > $nmbr$ yr and st - segment changes,C0001779;C0232326;C0439234
480,age > $nmbr$ yr and elevated biomarkers,C0001779;C0005516;C0205250;C0439234;C3163633
480,age > $nmbr$ yr ( % ),C0001779;C0439234
480,age > $nmbr$ yr  elevated biomarkers  and st - segment changes,C0001779;C0005516;C0205250;C0232326;C0439234;C3163633
480,age > $nmbr$ yr,C0001779;C0439234
480,age > $nmbr$ y * *,C0001779
480,age > $nmbr$ y *,C0001779
480,age > $nmbr$ y ( n = $nmbr$ ),C0001779
480,age > $nmbr$ y ( % ),C0001779
480,age > $nmbr$ y  n / n ( % ),C0001779
480,age > $nmbr$ y  n ( % ),C0001779
480,age > $nmbr$ y  %,C0001779
480,age > $nmbr$ y,C0001779
480,age > $nmbr$ vears n = $nmbr$,C0001779
480,age > $nmbr$  y,C0001779
480,age > $nmbr$  %,C0001779
480,age > $nmbr$,C0001779
480,age >,C0001779
480,age < $nmbr$ yrs,C0001779
480,age < $nmbr$ yr or > $nmbr$ yr,C0001779;C0439234
480,age < $nmbr$ yr,C0001779;C0439234
480,age < $nmbr$ y ( n = $nmbr$ ),C0001779
480,age < $nmbr$ y,C0001779
480,age < $nmbr$ vears n = $nmbr$,C0001779
480,age < $nmbr$,C0001779
480,age :,C0001779
480,age . y,C0001779
480,age . . . . . . . . y ( n = $nmbr$ ),C0001779
480,age - interaction,C0001779;C1704675
480,age *,C0001779
480,age ( yrs )  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
480,age ( yrs )  mean *,C0001779;C0444504;C2347634;C2348143
480,age ( yrs ),C0001779
480,age ( yr ) *,C0001779;C0439234
480,age ( yr )  mean ( sd ) bmd t - score  mean ( sd ),C0001779;C0439234;C2699239;C3533236
480,age ( yr )  mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
480,age ( yr ),C0001779;C0439234
480,age ( yij,C0001779
480,age ( year )  mean ± sd,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239
480,age ( year ),C0001779;C0439234;C0439508
480,age ( y ) ∗,C0001779
480,age ( y ) [ mean - sd ],C0001779;C0444504;C2347634;C2348143;C2699239
480,age ( y )  median ( min  max },C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
480,age ( y )  median ( min  max ),C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
480,age ( y )  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
480,age ( y )  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
480,age ( y )  mean ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
480,age ( y ),C0001779
480,age ( sd )  y,C0001779;C2699239
480,age ( p = o - $nmbr$ ),C0001779
480,age ' ^ $nmbr$ yrs,C0001779
480,age ' $nmbr$ y ( n $nmbr$ ),C0001779
480,age & $nmbr$,C0001779
480,age $nmbr$ y,C0001779
480,age $nmbr$ - $nmbr$ yr  elevated biomarkers  and previous vascular,C0001779;C0005516;C0005847;C0205156;C0205250;C0439234;C1552607;C1558950;C1801960;C3163633
480,age $nmbr$ - $nmbr$ y ( n = $nmbr$ ),C0001779
480,age $nmbr$ - $nmbr$,C0001779
480,age $nmbr$ + y,C0001779
480,age $nmbr$ +,C0001779
480,age $nmbr$ * $nmbr$ yr,C0001779;C0439234
480,age $nmbr$ $nmbr$ y,C0001779
480,age $nmbr$,C0001779
480,age $ $nmbr$ yrs,C0001779
480,age # $nmbr$ yrs,C0001779
480,age  yt,C0001779;C1412122
480,age  yrs *,C0001779
480,age  yrs ( mean ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
480,age  yrs  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
480,age  yrs,C0001779
480,age  yr mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
480,age  yr  n ( % ),C0001779;C0439234
480,age  yr,C0001779;C0439234
480,age  yf $nmbr$ - $nmbr$,C0001779
480,age  year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
480,age  year,C0001779;C0439234;C0439508
480,age  ya,C0001779
480,age  y sex  no . ( % ),C0001779;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
480,age  y gender  n ( % ),C0001779;C0079399;C1522384
480,age  y < $nmbr$,C0001779
480,age  y . o .,C0001779
480,age  y ( sd ),C0001779;C2699239
480,age  y ( mean ± s . d . ),C0001779;C0444504;C2347634;C2348143
480,age  y  median ( q $nmbr$ – q $nmbr$ ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
480,age  y  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
480,age  y,C0001779
480,age  x,C0001779
480,age  n ( % ),C0001779
480,age  median ( interquartile range )  y,C0001779;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
480,age  mean ± sd ( year ),C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239
480,age  mean ± sd  y,C0001779;C0444504;C2347634;C2348143;C2699239
480,age  mean yr ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
480,age  mean yr,C0001779;C0439234;C0444504;C2347634;C2348143
480,age  mean ( sd ) [ range ]  y,C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
480,age  mean ( sd )  yrs,C0001779;C0444504;C2347634;C2348143;C2699239
480,age  mean ( sd )  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
480,age  mean ( sd )  yearsa,C0001779;C0444504;C2347634;C2348143;C2699239
480,age  mean ( sd )  y,C0001779;C0444504;C2347634;C2348143;C2699239
480,age  mean ( s . e . ),C0001779;C0444504;C2347634;C2348143
480,age  mean ( min - max ) ( yrs ),C0001779;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
480,age  mean  yrs ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
480,age  mean,C0001779;C0444504;C2347634;C2348143
480,age,C0001779
480,adults ( aged   ≥ $nmbr$ y )  no . ( % ),C0001675;C0001779;C0001792;C1999167
480,adolescents ( aged $nmbr$ - $nmbr$ y )  no . ( % ),C0001779;C0001792;C0205653;C1999167
480,> $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ ),C0001779
480,< $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ ),C0001779
480,( b ) age subgroups,C0001779;C1304659
479,§ classes on the canadian cardiovascular society ( ccs ) scale range from i to iv,C0007226;C0021966;C0022326;C0037455;C0175659;C0221138;C0238884;C0349674;C1514721;C1879987;C1947916;C2348147;C3542016;C3887460;C4265176
479,total updrs score ( range  $nmbr$ — $nmbr$ ) y,C0439175;C0439810;C0449820;C1514721;C2348147;C3542016;C3639721;C4050231
479,total updrs score ( range  $nmbr$ - $nmbr$ ) 卞,C0439175;C0439810;C0449820;C1514721;C2348147;C3542016;C3639721;C4050231
479,total scores ( total score range : $nmbr$ - $nmbr$ ),C1514721;C2348147;C2964552;C3542016
479,selena - sledai ( range u - $nmbr$ u $nmbr$ ) t,C0439148;C0451528;C1514721;C2348147;C3542016
479,seizure frequency during $nmbr$ ‐ week baseline  median ( range ),C0149775;C0168634;C0332174;C0439230;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
479,range race  n ( % ),C0034510;C1514721;C1706779;C2348147;C3542016;C3853635
479,range of sbp,C0085805;C1514721;C2348147;C3542016
479,range,C1514721;C2348147;C3542016
479,motor subscale ( range  $nmbr$ - $nmbr$ ),C1513492;C1514721;C1705994;C2348147;C3542016
479,median dose ( range ) b,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
479,median dose ( range ) ' ’,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
479,median ( range ) treatment duration  d,C0444921;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3259042;C3542016
479,median ( range ) duration of hospital stayi  d,C0019994;C0449238;C0549183;C0876920;C1510665;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
479,il - $nmbr$ range  ng / l,C0020898;C0021764;C0022271;C0439297;C1514721;C2348147;C3542016
479,hscrp range  mg / l,C0439268;C1514721;C2348147;C3542016
479,health assessment questionnaire ( $nmbr$ - $nmbr$ range ),C0451208;C1514721;C2348147;C3542016
479,duration of current flare  median ( range ) months ( n = $nmbr$  $nmbr$  $nmbr$ ),C0439231;C0449238;C0521116;C0549183;C0876920;C1514721;C1517205;C1705970;C2347635;C2348144;C2348147;C2926735;C2939193;C3540542;C3542016
479,( range ),C1514721;C2348147;C3542016
479,$nmbr$ . $nmbr$ range $nmbr$ - $nmbr$,C1514721;C2348147;C3542016
479,$nmbr$ . $nmbr$  range $nmbr$ - $nmbr$,C1514721;C2348147;C3542016
478,repaired s - p shunts,C0205340;C0232180;C0542331;C1442858
478,repaired congenital shunts,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
478,repaired congenital shunt,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
478,pfo with large shunt without atrial septal aneurysm,C0232180;C0521533;C0542331;C0549177;C1442858
478,pfo with large shunt and atrial septal aneurysm,C0232180;C0521533;C0542331;C0549177;C1442858
478,large shunt,C0232180;C0542331;C0549177;C1442858
478,congenital shunts,C0009678;C0232180;C0542331;C1442858;C1744681
478,assoc  with corrected congenital shunts,C0009678;C0205202;C0232180;C0542331;C1442858;C1744681
477,residual perfusion defect > $nmbr$ % on lung scan  no . ( % ),C1457869;C1518040;C1609982
477,lung infection,C0876973;C4552950
477,lung,C0024109
477,lunchb,
477,high - probability ventilation / perfusion lung scanning,C0024109;C0560738;C4699572
476,lung neoplasm malignant,C0024121;C0205282
476,> $nmbr$ / $nmbr$ lung fields,C0225759
475,pool of long term ( hefh patients only ) and high fh,C0030705;C0205171;C0205250;C0337051;C0443252;C1299351;C1509144;C1720467;C2349200;C2700149;C3887512;C3889660;C4321237;C4522209
475,long term *,C0443252
475,long term ( n = $nmbr$ ) +,C0443252
475,long - term warfarin ( n = $nmbr$ ),C0043031;C0443252
475,long - term warfarin ( n - $nmbr$ ),C0043031;C0443252
475,long - term vitamin k antagonist,C0443252;C1096489;C2267235
475,hong kong,C0019907;C2987742
474,total occlusion  n ( % ),C0001168;C0011382;C0028778;C0439175;C0439810;C0441597;C1110554;C1947917
474,small - artery occlusion ( lacune ),C0001168;C0011382;C0028778;C0226001;C0241970;C0264995;C0441597;C0700321;C1110554;C1947917
474,small - artery occlusion,C0001168;C0011382;C0028778;C0226001;C0264995;C0441597;C0700321;C1110554;C1947917
473,inclusion criteria — no . ( % ),C1512693
473,inclusion criteria,C1512693
473,cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
472,three or more lesions,C0205172;C0205449;C0221198;C1546698
472,t $nmbr$ lesion volume  mm ',C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674
472,t $nmbr$ lesion volume  mm $nmbr$,C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674
472,stents per lesion  n,C0038257;C0221198;C1546698
472,stented lesions,C0038257;C0221198
472,n ( stented lesions ),C0038257;C0221198;C0369718;C0441922
472,more than $nmbr$ lesions per vessel,C0005847;C0205172;C0221198;C1546698
472,mean stents per lesion ( sd ) ‡,C0038257;C0221198;C0444504;C1546698;C2347634;C2348143;C2699239
472,lesions b $nmbr$ / c,C0221198;C1546698
472,lesions,C0221198
472,lesion length ≥ $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
472,lesion length > $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
472,lesion length $ $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
472,lesion length  mean ( sd )  mm,C0221198;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
472,lesion ( s ),C0221198;C1546698
472,intervention in complex lesions,C0221198;C1292781
472,direct stenting per lesion ‡,C0038257;C0221198;C0439851;C1546698;C1947931;C2348535
472,complex lesions ^,C0221198;C0439855;C1704241
472,age > $nmbr$ gd lesion > $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
472,age > $nmbr$ gd lesion = $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
472,age < $nmbr$ gd lesion > $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
472,age < $nmbr$ gd lesion = $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
472,age / gd lesion,C0001779;C0221198;C1546698
472,> $nmbr$ lesions per vessel,C0005847;C0221198
471,regadenoson ( n = $nmbr$ ),C1698215
471,regadenoson,C1698215
471,readmission ( n = $nmbr$ ),C1548168;C4489276
471,no readmission ( n = $nmbr$ ),C1548168;C4489276
470,treatment before admission ( % ),C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
470,treatment after admission,C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
470,risk level at admission,C0184666;C0809949;C2923839
470,creatinine clearance at admission ( ml / min ),C0151280;C0184666;C0809949
470,before admission )  %,C0184666;C0809949
470,aspirin before admission,C0004057;C0184666;C0809949
469,st segment depression,C0520887
469,st depression or elevation,C0439775;C0520887;C0702240
469,st depression > $nmbr$ mm,C0520887;C4330985;C4554674
469,st depression ( without st elevation ),C0011570;C0011581;C0344315;C0439775;C0460137;C0520886;C0520887;C0702240;C4049644;C4084909;C4085311;C4553827
469,st - segment depression > $nmbr$ mm — no . ( % ),C0520887;C4330985;C4554674
469,st - segment depression > $nmbr$ mm,C0520887;C4330985;C4554674
469,st - segment depression,C0520887
469,no st depression or elevation,C0439775;C0520887;C0702240
469,no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
469,depression ®,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
469,depression ^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
469,depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
469,antidepressant,C0003289
468,linear regression,C0023733;C2346679
468,aggressive ( n = $nmbr$ ),C0001807;C0580822
468,aggressive ( $nmbr$ ),C0001807;C0580822
467,history of dyspepsia,C0013395;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4552968
467,dyspepsia,C0013395;C4552968
466,y es,C0013754;C0205944
466,esr,C3811131
466,das $nmbr$ - esr remission  %,C0051767;C0057671;C0544452;C0687702;C3811131
466,das $nmbr$ - esr remission,C0051767;C0057671;C0544452;C0687702;C3811131
466,das $nmbr$ - esr lda,C0051767;C0057671;C3811131;C4553195
466,das $nmbr$ - esr  mean ± sd das $nmbr$ - esr remission  %,C0051767;C0057671;C0444504;C0544452;C0687702;C2347634;C2348143;C2699239;C3811131
466,das $nmbr$ - esr  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
466,das $nmbr$ - esr,C0051767;C0057671;C3811131
466,das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ t,C0051767;C0057671;C3811131
466,das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ *,C0051767;C0057671;C3811131
466,das $nmbr$ - $nmbr$ ( esr ) $nmbr$,C0051767;C0057671;C3811131
466,das $nmbr$ - $nmbr$ ( esr ),C0051767;C0057671;C3811131
466,das $nmbr$ ( esr ),C0051767;C0057671;C3811131
465,with des,C0011702;C4551552
465,older des ( n = $nmbr$ ),C0011702;C0580836;C4551552
465,no des,C0011702;C4551552
465,des implantation for restenosis  n ( % ),C0011702;C0021107;C0029976;C0333186;C4551552
465,des ( % previous stenting ),C0011702;C0038257;C0205156;C1552607;C2348535;C4551552
465,des,C0011702;C4551552
464,yes  no,C1512698
464,non - metsyn,C1518422
464,metsyn,
464,ics use yes / no  %,C0042153;C0457083;C0815320;C1512698;C1947944;C4551720
464,ics use  yes / no %,C0042153;C0457083;C0815320;C1512698;C1947944;C4551720
464,ics use  yes / no  %,C0042153;C0457083;C0815320;C1512698;C1947944;C4551720
464,( yes / no ),C1512698
463,us,
463,non - us,C1518422
463,non - inhaled steroid use  n ( % ),C0586793;C1518422
463,non - black  us,C0005680;C0027567;C0085756;C0439541;C1518422
462,saphenous vein graft,C0729538
462,saphenous - vein graft,C0729538
462,graft occlusionsa,C0181074;C0332835;C1961139
462,graft  pci  percutaneous coronary intervention  tia  transient,C0007787;C0040704;C0181074;C0205374;C0332835;C0917805;C1054154;C1532338;C1961139
462,graft  n ( % ),C0181074;C0332835;C1961139
462,graft,C0181074;C0332835;C1961139
462,gait,C0016928
462,all grafts,C0181074;C0332835;C1527362;C1961139
461,prior bypass graft surgery,C0185098;C0455610
461,percentage unless otherwise noted . cabg indicates coronary artery bypass graft  lvh  left ventricular hypertrophy  nsaids  nonsteroidal antiinflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ‘ history of hypercholesterolemia or reporting use of lipid - lowering medications at baseline . thistory of or currently have elevated serum creatinine level < $nmbr$ mg / dl . tbased on participant history or review of chart .,C0003211;C0007787;C0010055;C0013227;C0019664;C0019665;C0020443;C0023779;C0042373;C0085096;C0149721;C0168634;C0205100;C0205250;C0229671;C0262512;C0262926;C0439165;C0439269;C0441889;C0441994;C0455536;C0456079;C0521116;C0541653;C0600061;C0679646;C0700225;C0700287;C0802604;C0917805;C1054154;C1260596;C1442488;C1522133;C1524063;C1546774;C1547707;C1549488;C1550100;C1561533;C1705255;C2003888;C2004062;C2598133;C2698741;C2946261;C3163633;C3671888;C4284232;C4288581;C4521226;C4554048
461,need for urgent coronary - artery bypass grafting,C0010055;C0027552;C0439609;C0686904;C3272275
461,multivessel coronary - artery bypass grafting,C0010055
461,granulating  n ( % ) a,
461,coronary bypass graft,C1260596
461,coronary artery bypass grafting n ( % ),C0010055
461,coronary artery bypass grafting,C0010055
461,coronary artery bypass graft — no . ( % ),C0010055;C1260596
461,coronary - artery bypass grafting §,C0010055
461,coronary - artery bypass grafting,C0010055
461,coronar y - artery bypass grafting,C0450140;C0741847
461,bypass graft §,C0185098
461,bypass graft,C0185098
461,arterial graft,C0450140
460,peak creatine kinase - mb  u / l,C0010290;C0439339;C0444505;C0523584
460,gamma glutamyltransferase  u / l,C0017040;C0439339
460,elevated creatine kinase mb ( > $nmbr$ u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
460,elevated creatine kinase - mb ( > $nmbr$ u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
460,alt ( units / l ),C0439339;C1266129;C4553172
460,alt  u / l,C0439339;C1266129;C4553172
459,idegasp – biasp $nmbr$,
459,biasp $nmbr$ bid,
459,biasp $nmbr$,
459,ast increased,C0205217;C0442805;C1415181;C3891303
459,ast  u / l,C0439339;C1415181;C3891303
459,asp,C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371
458,warfarin at last follow - up,C0043031;C0589120;C1522577;C1704685;C3274571
458,thiazide at last follow - up,C0541746;C0589120;C1522577;C1704685;C3274571
458,statin at last follow - up,C0360714;C0589120;C1522577;C1704685;C3274571
458,digoxin at last follow - up,C0012265;C0589120;C1522577;C1704685;C3274571
458,at,
458,arb at last follow - up,C0589120;C1522577;C1704685;C3274571;C3888198
458,ace inhibitor or arb at last follow - up,C0003015;C0589120;C1522577;C1704685;C3274571;C3888198;C4541021
458,ace inhibitor at last follow - up,C0003015;C0589120;C1522577;C1704685;C3274571;C4541021
457,within last $nmbr$ d,C1517741
457,mean arterial pressure  last,C0428886;C1517741
457,last infusion in the horizon - pft,C0024119;C0053122;C0279232;C0574032;C1517741;C1827465
456,smoking past,C0037369;C0453996;C1444637;C1881674;C4284302
456,smoking in past yr,C0037369;C0439234;C0453996;C1444637;C1881674;C4284302
456,past smoking,C0037369;C0453996;C1444637;C1881674;C4284302
456,past smoker  n ( % ),C0337664;C1444637;C4284302
456,past smoker,C0337664;C1444637;C4284302
456,past or nonsmoker ( n = $nmbr$ ),C0337672;C0425293;C1444637;C4284302;C4554605
456,past or nonsmoker,C0337672;C0425293;C1444637;C4284302;C4554605
456,past or never,C1444637;C2003901;C4284302
456,past or current angina pectoris,C0002962;C0521116;C1444637;C1705970;C4284302
456,past or current,C0521116;C1444637;C1705970;C4284302
456,past only,C0205171;C1444637;C1720467;C4284302
456,past cardiovascular history  no . ( % ),C0007226;C0332119;C1444637;C1880008;C3887460;C4284302
456,past,C1444637;C4284302
456,never or past,C1444637;C2003901;C4284302
456,intra - abdominal abscess ( past ),C0243001;C1444637;C4284302
456,current / past,C0521116;C1444637;C1705970;C4284302
456,bmi indicates body mass index  sbp  systolic blood pressure  dbp  lipoprotein ( a ) . ldl - c was calculated with the friedewald formula . ' hypertension and diabetes were based on physician diagnosis . ! smoker includes current and past smokers .,C0005893;C0011847;C0011849;C0011900;C0012164;C0020538;C0031831;C0065058;C0085805;C0125953;C0332257;C0337664;C0444686;C0488055;C0489829;C0521116;C0536221;C0578022;C0804815;C0871470;C1096202;C1305855;C1306620;C1439335;C1441506;C1444637;C1527178;C1552866;C1704338;C1704656;C1705501;C1705938;C1705970;C1963138;C2700399;C3813197;C4281799;C4284302
455,tcomparison of proportion of patients with nyha class lll / iv heart failure .,C0018801;C0018802;C0030705;C1261077;C1709707;C1882087;C4554158
455,nyha functional class iii ( % ),C0205245;C0542341;C1882086;C2700217
455,nyha functional class iii,C0205245;C0542341;C1882086;C2700217
455,nyha classes iii - iv,C0278962
455,nyha class iv,C1882087
455,nyha class iii / iv,C0278962
455,nyha class iii  % ( n ),C1882086
455,nyha class iii,C1882086
455,nyha class ii ( n = $nmbr$ l $nmbr$ ),C1882085
455,nyha class ii ( n = $nmbr$ ),C1882085
455,nyha class ii,C1882085
455,nyha class i,C1882084
455,nyha class > ii,C1882085
455,nyha class  n ( % ) ii,C1882085
455,killip ciass,
455,ciass i,C0021966;C0221138
455,ccs class §,C1879987
455,baseline heart failure severity nyha class i,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C1882084;C4554158
454,others  classes i and iiic,C0441885;C1319793;C1955473;C2698967;C3539125
454,heart failure ( class i — iii ),C0018801;C0018802;C0021966;C0221138;C0439070;C0441885;C0441887;C1319793;C1705160;C2698967;C2698969;C4554158
454,class i,C0441885;C1319793;C2698967
453,nyha_class,C1882083
453,nyha class — no . ( % ) $,C1882083
453,nyha class — no . ( % ),C1882083
453,nyha class within past month — no . / total no . ( % ),C0439175;C0439810;C1882083;C4331910
453,nyha class not reported,C0684224;C0700287;C1518422;C1882083;C4319718
453,nyha class $nmbr$ or higher,C0205250;C1882083
453,nyha class $nmbr$ - $nmbr$ : no { n = llll ),C0369718;C0441922;C1882083
453,nyha class  n ( % ) i,C0021966;C0221138;C0369718;C0441922;C1882083
453,nyha class  n ( % ),C1882083
453,nyha class  ( % ),C1882083
453,nyha class,C1882083
453,nyha chf class,C0018802;C1882083
453,new york heart association congestive heart failure class,C0018802;C1882083
453,new york heart association class,C1882083
452,who functional class — no . ( % ) : c,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
452,who functional class,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
452,renal biopsy class,C0194073;C0456387;C1518526;C1705943
452,modified braunwald class,C0392747;C0456387;C1518526;C1705943;C3889737
452,modified acc or aha lesion class b $nmbr$ or c,C0050451;C0175754;C0221198;C0282160;C0392747;C0456387;C0772110;C1518526;C1546698;C1705943;C3541413;C3889737
452,modified acc / aha lesion class b $nmbr$ or cj,C0007481;C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
452,modified acc / aha lesion class b $nmbr$ / c,C0050451;C0101856;C0221198;C0392747;C0456387;C0772110;C1518526;C1546698;C1705943;C3889737
452,modified acc - aha lesion class b $nmbr$ or c,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
452,kilip class,C0456387;C1518526;C1705943
452,heart failure ( class l - lll ),C0018801;C0018802;C0456387;C1261077;C1518526;C1705943;C4554158
452,egfr in $nmbr$ classes,C0456387;C1518526;C1705943;C1739039;C3811844;C3812682;C4019422
452,class ic,C0020750;C0456387;C1518526;C1705943;C4554818
452,class ia,C0020980;C0456387;C0694634;C1518526;C1705943;C1947960
452,class > $nmbr$,C0456387;C1518526;C1705943
452,class $nmbr$,C0456387;C1518526;C1705943
452,calculated ldl - c in $nmbr$ classes,C0444686;C0456387;C1441506;C1518526;C1705943;C4019422
452,borg dyspnea score who functional class  n ( % ),C0013404;C0205245;C0449820;C0456387;C0542341;C1518526;C1705943;C1963100;C2700217;C4050231
452,baseline who functional class,C0168634;C0205245;C0456387;C0542341;C1442488;C1518526;C1705943;C2700217
452,baseline who function class,C0031843;C0168634;C0456387;C0542341;C0700205;C1442488;C1518526;C1705273;C1705943
452,baseline trl - c in $nmbr$ classes,C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
452,baseline triglycerides in $nmbr$ classes,C0041004;C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
452,baseline lp ( a ) in $nmbr$ classes,C0065058;C0168634;C0456387;C1439335;C1442488;C1518526;C1705943;C4019422;C4553379
452,ara functional class — no . ( % ),C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
452,ara functional class,C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
452,angina class at baseline,C0002962;C0168634;C0456387;C1442488;C1518526;C1705943
452,age in $nmbr$ classes,C0001779;C0456387;C1518526;C1705943;C4019422
452,acc / aha lesion class b $nmbr$ or c  n ( % ),C0221198;C0456387;C1518526;C1546698;C1705943;C4072694
451,periprocedural anticoagulant,C0003280;C0848112;C3536711
451,aspirin or other antiplatelet or anticoagulant agent,C0003280;C0004057
451,any anticoagulant,C0003280;C0848112;C3536711
451,antithrombotic and anticoagulant medications,C0003280
451,antiplatelets or anticoagulants,C0003280
451,antiplatelets,
451,antiplatelet or anticoagulant,C0003280;C0848112;C3536711
451,antiplatelet agent or anticoagulant,C0003280;C0085826;C0848112;C3536711
451,antiplatelet,
451,anticoagulants,C0003280
451,anticoagulant — no . ( % ),C0003280;C0848112;C3536711
451,anticoagulant group ( n = $nmbr$ ),C0003280;C0441848;C0848112;C3536711
450,other anticoagulant,C0003280;C0848112;C3536711
450,concomitant anticoagulant  antithrombotic or nsaid  n ( % ),C0003211;C0003280;C0521115;C0848112;C3536711;C3536840
450,anticoagulant,C0003280;C0848112;C3536711
450,anti - coagulants - no . ( % ),C0848112
450,anti - coagulants,C0848112
449,piacebo ( n = $nmbr$ ) no . of participants with events ( % ),C0441471;C0679646;C3541888
449,piacebo,
449,nondiabetic participants !,C0679646
449,nondiabetic,
449,nondiabetes,
448,receiving concomitant nsaids and / or cox - $nmbr$ inhibitors,C0003211;C0085387;C0521115;C1514756
448,oads  n ( % ),
448,number of concomitant aeds  n ( % ),C0180309;C0237753;C0449788;C0521115
448,most common concomitant aeds  n ( % ),C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
448,most common concomitant aeds  d n ( % ),C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
448,concomitant oads  n ( % ),C0521115
448,concomitant aedsb    n   ( % ),C0521115
448,concomitant aedsb  n ( % ),C0521115
448,concomitant aedsa,C0521115
448,concomitant aeds  n ( % ),C0180309;C0521115
448,> - $nmbr$ . $nmbr$ and < - $nmbr$ . $nmbr$,
448,> $nmbr$ oads,
448,$nmbr$ oads,
447,no concomitant antiplatelet,C0521115
447,main concomitant treatments  no . ( % ),C0087111;C0205225;C0521115;C1542147
447,concomitant drugs  %,C0013227;C0521115;C3687832
447,concomitant drugs,C0013227;C0521115;C3687832
447,concomitant drug therapies  n ( % ),C0013216;C0521115
447,concomitant antiplatelet,C0521115
447,concomitant antihyperglycaemic drugs  n ( % ),C0013227;C0020616;C0521115;C3687832
447,concomitant,C0521115
446,use of concomitant lipid - modifying therapy,C0023779;C0392747;C1524063;C1707479
446,concomitant therapy  no . ( % ),C1707479
446,concomitant therapy  n [ % ],C1707479
446,concomitant therapy,C1707479
446,concomitant therapies n ( % ),C1707479
446,concomitant therapies at hospital discharge,C0586003;C1707479
446,concomitant lipid - modifying therapy — no . { % ),C0023779;C0392747;C1707479
446,baseline / concomitant therapies,C0168634;C1442488;C1707479
445,tion — no . ( % ),
445,tics — no . ( % ),C0040188;C0278076;C2169806;C3889970
445,no . copies gly $nmbr$ - glu $nmbr$ - $nmbr$ c,C0068000;C1948062
445,no ( n = $nmbr$ ),C0369718;C0441922
445,no ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
445,acecoumarol  no . ( % ),
445,$nmbr$ - $nmbr$ — no . ( % ),
444,inflotmas io mgluj versus piecew,C1046794;C3146236
444,$nmbr$ . $nmbr$ ( io . i ),C0021966;C0221138;C1046794;C3146236
444,$nmbr$ ( io - $nmbr$ % ),C1046794;C3146236
443,xho  p = o - $nmbr$,C4050013
443,ho active cancer,C0006826;C0019905;C0205177;C0998265;C1306459;C1832110;C3853793;C3888249;C3889614
443,ho,C0019905;C1832110;C3889614
442,no beta - blocker use,C0001645;C0042153;C0457083;C1947944
442,no beta - blocker,C0001645
442,glatiramer acetate  no . ( % ),C0289884
442,beta - blocker — no . ( % ),C0001645
442,acarbose 一 no . ( % ),C0050393
442,> $nmbr$ — no . { % ),
441,study medication — no . ( % ),C0013227;C0557651;C2603343;C3244316;C4284232
441,other — no . ( % ),
441,other lipid - modifying drug 一 no . ( % ),C0013227;C0023779;C0392747;C1254351
441,no glucose lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
441,no . a,
441,no ( % ),
441,medication use — no . { % ),C0013227;C0042153;C0457083;C1947944;C3244316;C4284232
441,medication use — no . ( % ) ^ |,C0013227;C0042153;C0457083;C1947944;C3244316;C4284232
441,medication use — no . ( % ),C0013227;C0042153;C0457083;C1947944;C3244316;C4284232
441,medication use  no . / total no . ( % ),C0013227;C0042153;C0439175;C0439810;C0457083;C1947944;C3244316;C4284232
440,£ $nmbr$ yo ( n = $nmbr$ ),C1413296
440,sso - $nmbr$,
440,no smoking,C0037369;C0453996;C1881674
440,no smo king,C1311076;C1364142;C1423784
440,no current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
440,current smoking — no . / total no . ( % ),C0037369;C0439175;C0439810;C0453996;C0521116;C1705970;C1881674
440,current smoking — no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
440,< $nmbr$ yo ( n = $nmbr$ ),C1413296
440,- $nmbr$ . $nmbr$ ± lno ^,
439,no antihypertensive medication,C0003364
439,no  no,
439,any blood - pressure - lowering drug 一 no . ( % ),C0003364
439,antihypertensive randomization  no . ( % ) a,C0003364;C0034656
439,antihypertensive medication  open - label  no . ( % ),C0003364;C1709323
439,> $nmbr$ antihypertensive medication  no . ( % ),C0003364
438,ppi but no aspirin,C0004057;C0358591;C0871125;C3811894
438,no ppi,C0358591;C0871125;C3811894
438,no aspirin or ppi,C0004057;C0358591;C0871125;C3811894
438,no . ( % ) ',
438,no $nmbr$  $nmbr$,
438,no,
438,drug therapy at admission 一 no . ( % ) aspirin,C0004057;C0013216;C0013217;C0184666;C0809949
438,drug therapy at admission — no . ( % ) aspirin,C0004057;C0013216;C0013217;C0184666;C0809949
438,aspirin 一 no . ( % ),C0004057
438,aspirin — no . ( % ),C0004057
437,pio $nmbr$,C0030800;C2347712
437,full po pulatio n,C0443225;C0946289
436,rro . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
436,rro $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),
436,pro / pro homozygotes,C0019904;C1120626
435,type $nmbr$ diabetes pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C1320657
435,score at week $nmbr$  mean ( se ) difference mepo - pbo ( $nmbr$ % ci ),C0008107;C0031962;C0036919;C0332174;C0439230;C1705241;C1705242;C3259781;C3533236
435,pbo to czp week $nmbr$ dose combined,C0031962;C0054841;C0178602;C0205195;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
435,pbo n = $nmbr$,C0031962
435,pbo n ( % ),C0031962
435,pbo / simva - $nmbr$ yr km rale ( % ),C0031962;C0034642;C0439234;C3887676
435,pbo - sc every other week ( n = $nmbr$ ),C0031962;C0282380;C0332174;C0439230
435,pbo - adjusted ls mean change ( se ),C0023668;C0031962;C0036919;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
435,pbo - adjusted ls mean change,C0023668;C0031962;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
435,pbo + statin n = $nmbr$,C0031962;C0360714
435,pbo + statin $nmbr$,C0031962;C0360714
435,pbo + statin,C0031962;C0360714
435,pbo ( n   =   $nmbr$ ),C0031962
435,pbo ( n = $nmbr$ ) vs,C0031962
435,pbo ( n = $nmbr$ ),C0031962
435,pbo ( n - $nmbr$ ),C0031962
435,pbo ( n $nmbr$ ),C0031962
435,pbo ( n $nmbr$ $nmbr$ ),C0031962
435,pbo  no . ( o / o ) ^ ’,C0031962;C0483204
435,pbo  no . ( % ) ^,C0031962
435,pbo  n = $nmbr$,C0031962
435,pbo,C0031962
435,neither pbo + statin eze + statin,C0031962;C0360714
435,mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C0812270;C1705694;C2939420
435,mepo ( n = $nmbr$ ),
435,insulin tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0021641;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1533581;C1579433;C1705241;C1705242;C2347635;C2348144;C2939193;C3714501;C4319952
435,ind + pbo ( n = $nmbr$ ),C0031962;C4049864
435,ifg pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C1334085;C1708411
435,fpg tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952
435,flex pbo ®,C0031962
435,difference vs pbo,C0031962;C1705241;C1705242
435,difference mepo - pbo ( $nmbr$ % ci ),C0008107;C0031962;C1705241;C1705242;C3259781
435,blood pressure  pbo y patients with diabe teristics ( ncep atp i,C0005823;C0021966;C0030705;C0031962;C0221138;C1271104;C1272641;C2744579;C4552600
434,time from symptoms onset to $nmbr$ st balloon inflation ( h ),C0021398;C0033727;C0036056;C0336867;C0369286;C0441144;C0441932;C0449244;C0564385;C0683368;C1318493;C1457887;C3272372;C4528284
434,time from symptom onset to balloon inflation,C0021398;C0040223;C0336867;C0441144;C0449244;C1318493;C1457887;C3541383;C3854129;C4086878
434,time from randomisation to $nmbr$ st balloon inflation ( h ),C0021398;C0033727;C0034656;C0036056;C0040223;C0336867;C0369286;C0441144;C0441932;C0564385;C1318493;C3272372;C3541383;C4528284
434,time from qualifying ecg to balloon inflation,C0021398;C0040223;C0336867;C0441144;C1318493;C1514624;C1623258;C3541383
434,o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0483204
434,o $nmbr$ o ( oo $nmbr$ - o - $nmbr$ o ),C0483204
434,antibodies to infliximab  n ( % ) * *,C3533054
434,- o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0483204
434,$nmbr$ - $nmbr$ ( o - $nmbr$ - $nmbr$ - oo ),C0483204
434,$nmbr$ ( oo $nmbr$ - o . $nmbr$ ),
433,time to treatment  h,C0033727;C0369286;C0441932;C0564385;C3494202;C4528284
433,time to treatment,C3494202
433,time to angiography — hr,C0002978;C0040223;C3541383
433,mean time to first subcutaneous injectiong  h in relation to surgery  hr,C0033727;C0038894;C0038895;C0040223;C0205435;C0369286;C0441932;C0443315;C0444504;C0543467;C0564385;C1274039;C1279901;C2347634;C2348143;C3541383;C4528284
433,door - to - balloon time — hr,C4296144
433,$nmbr$ to < $nmbr$ hr,
432,unrelated to effectiveness,C0445356;C1280519;C1704623;C4553491
432,no . needed to treat ( $nmbr$ % cl ) *,C0027552;C0040363;C0041260;C0087111;C0596019;C0686904;C1292734;C1522326;C1883351
432,creatinine clearance > $nmbr$ to < $nmbr$ ml / min — no . ( % ) f,C0016327;C0151280
432,- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to - $nmbr$ - $nmbr$ ),C0596019
432,- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0596019
432,$nmbr$ to < $nmbr$ — no . { % ),
432,$nmbr$ to < $nmbr$ cel,C0208736;C0346421;C0439237;C1413336
432,$nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0596019
432,$nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0596019
432,$nmbr$ ( $nmbr$ % cl $nmbr$ to $nmbr$ ),C0596019
431,三 $nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
431,≥ $nmbr$ to < $nmbr$ %,C0040363;C0041260;C1883351
431,randomized to receive aspirin yes,C0004057;C0034656;C0040363;C0041260;C1514756;C1549445;C1705108;C1710701;C1883351;C3815594
431,randomization to end of study,C0034656;C0040363;C0041260;C0444930;C0557651;C1883351;C2603343;C2746065
431,randomised to canakinumab $nmbr$ mg,C0024671;C0026410;C0040363;C0041260;C0439269;C1883351;C1960952;C2346927;C2718773;C4321396;C4521761
431,patients meeting the criteria to receive $nmbr$ mg of,C0024671;C0026410;C0030705;C0040363;C0041260;C0243161;C0439269;C0556656;C1514756;C1883351;C1960952;C2346927;C4321396;C4521761
431,patient ' s preference not to take vka  only reason,C0040363;C0041260;C0205171;C0376409;C0392360;C1515187;C1518422;C1720467;C1883351
431,patient ' s preference not to take,C0040363;C0041260;C0376409;C1515187;C1518422;C1883351
431,method used to diagnose the incident pulmonary embolism  no . ( % ),C0011900;C0025663;C0034065;C0040363;C0041260;C0449851;C0871511;C1273517;C1551358;C1883351
431,length of stay ( randomization to discharge  h ),C0012621;C0023303;C0030685;C0033727;C0034656;C0040363;C0041260;C0369286;C0441932;C0564385;C1883351;C2926602;C4528284
431,leading to study withdrawal,C0040363;C0041260;C0332152;C0557651;C1522538;C1710677;C1883351;C2349954;C2603343;C2825032;C3812880;C4049634
431,key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ $nmbr$ of the indicated char least - square means  except tc an note : all treatment by subgroup,C0015663;C0017725;C0023189;C0023823;C0036143;C0039411;C0039798;C0040363;C0040642;C0041004;C0041260;C0041405;C0041698;C0087111;C0327953;C0332257;C0683312;C1079230;C1316572;C1317574;C1436327;C1444656;C1515021;C1518422;C1522326;C1533734;C1552866;C1704970;C1705169;C1824670;C1883351;C2700399;C2744579;C2983605;C2986463;C3272447;C3538994;C3884535;C3887704;C3889287;C3890735;C4048285;C4521369;C4522122;C4552600
431,intention - to - treat without st - segment - elevation myocardial infarction,C0040363;C0041260;C0087111;C0162425;C1283828;C1292734;C1522326;C1536220;C1883351
431,intention - to - treat with st - segment - elevation myocardial infarction,C0040363;C0041260;C0087111;C0162425;C1283828;C1292734;C1522326;C1536220;C1883351
431,intention - to - treat,C0040363;C0041260;C0087111;C0162425;C1283828;C1292734;C1522326;C1883351
431,intent to use gp iib / iiia,C0016011;C0040363;C0041260;C0042153;C0162425;C0457083;C1283828;C1550453;C1883351;C1947944
431,intent to use glycoprotein iib / iiia inhibitor,C0016011;C0040363;C0041260;C0042153;C0162425;C0457083;C1283828;C1550453;C1883351;C1947944;C1999216
431,intent to use dti,C0040363;C0041260;C0042153;C0162425;C0457083;C1283828;C1537007;C1550453;C1883351;C1947944
431,intent to use direct thrombin,C0040018;C0040363;C0041260;C0042153;C0162425;C0439851;C0457083;C1283828;C1550453;C1883351;C1947931;C1947944
431,first disease - progression outcome to occur §,C0040363;C0041260;C0205435;C0242656;C0449258;C0679250;C1274040;C1279901;C1335499;C1709305;C1883351;C1947900;C2745955;C3542417;C4284875;C4552808
431,duration of total exposure to study treatment  weeks,C0039798;C0040363;C0041260;C0087111;C0439175;C0439230;C0439810;C0557651;C1522326;C1533734;C1705169;C1883351;C2603343;C2826870;C3538994;C3887704
431,cough ( leading to study drug discontinuation ),C0010200;C0013175;C0040363;C0041260;C0332152;C0457454;C1444662;C1522538;C1883351;C1961131;C3274924;C4084725;C4084726;C4084727;C4552847
431,any adverse event leading to study drug discontinuation  n ( % ),C0013175;C0040363;C0041260;C0332152;C0457454;C0877248;C1444662;C1522538;C1883351;C4552847
431,adherence to study regimen — no . ( % ) ff,C0040363;C0040808;C0041260;C0557651;C1510802;C1883351;C2603343;C2945654;C4554348
431,adherence to study regimen — no . ( % ),C0040363;C0040808;C0041260;C0557651;C1510802;C1883351;C2603343;C2945654
431,> - $nmbr$ . $nmbr$ to < - $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
431,> $nmbr$ to s $nmbr$ yrs,C0040363;C0041260;C1883351
431,> $nmbr$ to < $nmbr$ uln,C0040363;C0041260;C1519815;C1883351
431,> $nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
431,> $nmbr$ to $nmbr$,C0040363;C0041260;C1883351
431,> $nmbr$ . $nmbr$   vs . $nmbr$ . $nmbr$ to   ≤   $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
431,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
431,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
431,> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
431,> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
431,> $nmbr$ % to < $nmbr$ %,C0040363;C0041260;C1883351
431,$nmbr$ to less than $nmbr$,C0040363;C0041260;C1883351
431,$nmbr$ to < $nmbr$ mumin,
431,$nmbr$ to < $nmbr$ bpm ( n = $nmbr$ ),C0040363;C0041260;C1883351
431,$nmbr$ to < $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
431,$nmbr$ to < $nmbr$ ( % ),C0040363;C0041260;C1883351
431,$nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
431,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ to < $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
431,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ( % ),C0040363;C0041260;C1883351
431,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
431,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
431,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
431,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
431,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
431,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
-10,two - dimensional echocardiography,C0013524
429,two or more at baseline,C0168634;C0205172;C0205448;C1442488
429,two or more antihypertensive medications,C0003364;C0205172;C0205448
429,two or more,C0205172;C0205448
429,two of the above,C0205448
429,two lesions,C0205448;C0221198
429,two agents,C0205448;C0450442;C1254351;C1521826
429,two - sided p - value for hetero - geneity,C0205448;C0441987;C1709380
428,apobe,
428,apob : apoal ratio,C0003593;C0456603;C1547037;C3252643
428,apob : apoal,C0003593;C3252643
428,apob $nmbr$,C0003593;C3252643
428,apob  g / l,C0003593;C0439294;C0456615;C3252643
428,apob,C0003593;C3252643
428,apoal,
428,apo bt,
428,apo b *,C0003593;C3252643
428,apo b ( mg / dl ) - mean ± sd,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
428,apo b ( mg / dl ) * *,C0003593;C0439269;C3252643
428,apo b ( mg / dl ),C0003593;C0439269;C3252643
428,apo b ( g / l ),C0003593;C0439294;C0456615;C3252643
428,apo b  mg / dl,C0003593;C0439269;C3252643
428,apo b  mean ( sd )  mg / dl,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
428,apo b,C0003593;C3252643
428,apo - b,C0003593;C3252643
427,apob : apoa - l ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
427,apob : apoa - $nmbr$ ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
427,apob : apoa $nmbr$ ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
427,apob : apoa $nmbr$,C0003592;C0003593;C0523508;C3252643;C4553344;C4553379
427,apoa - $nmbr$  g / l,C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
427,apo b / apo a - l ratio ( mean ),C0003592;C0444504;C0456603;C0523508;C1447574;C1547037;C2347634;C2348143;C4521365;C4553344
427,apo b / apo a - l,C0003592;C0523508;C1447574;C4521365;C4553344
427,apo a $nmbr$ ( g / l ),C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
427,apo a $nmbr$  mean ( sd ),C0003592;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
427,< $nmbr$ . $nmbr$ mmol / liter apob : apoa - l ratio,C0003592;C0003593;C0456603;C0475211;C0523508;C1532563;C1547037;C3252643;C4553344;C4553379
426,apob : apoa - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
426,apob : apoa - i,C0003593;C0085201;C1677784;C3252643
426,apoa - i,C0085201;C1677784
426,apo b : apo a - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
426,apo a - l ( g / l ),C0628062
426,apo a - i ( mg / dl ) *,C0085201;C0439269;C1677784
426,apo a - i  mg / dl,C0085201;C0439269;C1677784
426,apo a - i,C0085201;C1677784
425,week $nmbr$ mayo endoscopy subscorea,C0014245;C0332174;C0439230;C0454788;C1077578
425,total mayo score $ | |,C0454788;C1077578;C2964552
425,total mayo score,C0454788;C1077578;C2964552
425,partial mayo score $ | |,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
425,partial mayo score  mean ( sd ),C0444504;C0449820;C0454788;C0728938;C1077578;C1550516;C2347634;C2348143;C2699239;C4050231
425,partial mayo score,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
425,partial mayo clinic scored,C0002424;C0442592;C0449820;C0454788;C0728938;C1077578;C1550516
425,mean mayo score ( sd ),C0454788;C1077578;C2699239;C3533236
425,mayo score ( mean ± sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
425,mayo score ( $nmbr$ - $nmbr$ ),C0449820;C0454788;C1077578;C4050231
425,mayo score  mean ( sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
425,mayo clinic scoreb,C0002424;C0442592;C0454788;C1077578
425,mayo clinic score §,C0002424;C0442592;C0449820;C0454788;C1077578;C4050231
425,mayo clinic score  mean ± sd,C0002424;C0442592;C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
425,mayo < $nmbr$  n,C0454788;C1077578
425,mayo $ $nmbr$  n,C0454788;C1077578
425,complete mayo clinic score  median ( min  max },C0002424;C0205197;C0442592;C0449820;C0454788;C0549183;C0702093;C0725685;C0876920;C1077578;C1524029;C2347635;C2348144;C2939193;C3813700;C3853530;C4050231;C4283785
425,baseline mayo score,C0168634;C0449820;C0454788;C1077578;C1442488;C4050231
425,baseline composite mayo clinic score,C0002424;C0168634;C0442592;C0454788;C1077578;C1442488;C4055211
424,smoking : ex - smoker,C0037369;C0337671;C0453996;C1881674;C4555205
424,smoker or ex - smoker  n ( % ),C0337664;C0337671;C4555205
424,prior smoker,C0337671
424,previous smokers,C0337671
424,previous smoker,C0337671
424,former smokers,C0337671
424,former smoker — no . { % ),C0337671
424,former smoker — no . ( % ),C0337671
424,former smoker ( n = $nmbr$ ),C0337671
424,former smoker ( n = $nmbr$  $nmbr$ ),C0337671
424,former smoker  n ( % ),C0337671
424,former smoker,C0337671
424,exsmoker,C0337671;C4555205
424,ex - smokers : qvai $nmbr$ - sfc,C0337671;C4521536;C4555205
424,ex - smokers ( n = $nmbr$ ),C0337671;C4555205
424,ex - smokers ( itt ) ( n = $nmbr$ ),C0337671;C4555205
424,ex - smokers $nmbr$,C0337671;C4555205
424,ex - smokers,C0337671;C4555205
424,ex - smoker / smoker  %,C0337671;C4555205
424,ex - smoker / current,C0337671;C0521116;C1705970;C4555205
424,ex - smoker ( n z $nmbr$ ),C0337671;C4555205
424,ex - smoker,C0337671;C4555205
424,current or former smoker,C0337671;C0521116;C1705970
424,b includes both ex - smokers and nonsmokers .,C0332257;C0337671;C0337672;C1552866;C2700399;C4554605;C4555205
423,smoking history : ex - smoker,C0337664;C1519384
423,smokers : qva $nmbr$ - $nmbr$ fc,C0337664;C2983605
423,smokers ( at baseline ),C0168634;C0337664;C1442488
423,smokers  no . ( % ),C0337664
423,smokers  n ( % ),C0337664
423,smokers  %,C0337664
423,smokers,C0337664
423,smoker at baseline,C0168634;C0337664;C1442488
423,smoker ( % ) a,C0337664
423,smoker ( % ),C0337664
423,smoker  n ( % ),C0337664
423,smoker  %,C0337664
423,smoker  ! n ( % ),C0337664
423,smoker,C0337664
423,present smoker,C0150312;C0337664;C0449450
423,noncurrent smoker,C0337664
423,ever - smoker,C0337664;C3887636
423,currently smoker,C0337664;C0521116
423,active smokers,C0205177;C0337664;C3853793;C3888249
423,active smoker,C0205177;C0337664;C3853793;C3888249
423,> $nmbr$ kg / m $nmbr$ smokers,C0337664;C1532718
422,nonsmoker  n ( % ),C0337672;C0425293;C4554605
422,nonsmoker,C0337672;C0425293;C4554605
422,non - smoker ( n = $nmbr$  $nmbr$ ),C0337672;C0425293;C4554605
422,non - smoker,C0337672;C0425293;C4554605
422,never smoker,C0425293
422,current smoker 一 no . ( % ),C3173209;C3241966
422,current smoker — no . of patients ( % ),C0030705;C3173209;C3241966
422,current smoker — no . / total no . ( % ),C0439175;C0439810;C3173209;C3241966
422,current smoker — no . ( % ) blood pressure — mm hg,C0005823;C0439475;C1271104;C1272641;C3173209;C3241966
422,current smoker — no . ( % ),C3173209;C3241966
422,current smoker  no . ( % ),C3173209;C3241966
422,current smoker  no ( % ),C3173209;C3241966
422,current nonsmoker,C0337672;C0425293;C0521116;C1705970;C4554605
422,current non - smoker,C0425311
422,$nmbr$ +  no . ( % ),
421,passive smoker,C0425309
421,cigarette smoker *,C0337667
421,cigarette smoker  no . ( % ),C0337667
421,cigarette smoker,C0337667
420,smoking pack year ( years ) fl,C0037369;C0439234;C0439508;C0453996;C1277691;C1300812;C1708024;C1881674
420,smoking pack year ( years ) ^,C0037369;C0439234;C0439508;C0453996;C1277691;C1881674
420,smoking pack - yearsb  n ( % ),C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
420,smoking pack - yearsa,C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
420,smoking pack - years,C0037369;C0453996;C1277691;C1881674
420,smoking in the past year,C0037369;C0453996;C1881674;C4086728
420,smoking classification  n ( % ),C0008902;C0008903;C0037369;C0453996;C0678229;C1881674
420,smoking * ( > $nmbr$ pack - years ),C0037369;C0453996;C1277691;C1881674
420,smoking *,C0037369;C0453996;C1881674
420,smoking ( a ),C0037369;C0453996;C1881674
420,smoking ( % ) laboratory parameters,C0022877;C0037369;C0449381;C0453996;C1881674;C3244292;C4283904
420,smoking ( % ),C0037369;C0453996;C1881674
420,smoking ' ! ',C0037369;C0453996;C1881674
420,smoking  n ( % ),C0037369;C0453996;C1881674
420,smoking  %,C0037369;C0453996;C1881674
420,smoking,C0037369;C0453996;C1881674
420,never smoked — no . ( % ),C0037366;C0439994;C1881674;C2003901
420,never smoked  n ( % ),C0037366;C0439994;C1881674;C2003901
420,never smoked,C0037366;C0439994;C1881674;C2003901
420,currently smokes,C0037366;C0037369;C0439994;C0521116;C1881674
419,tnfi - na ï ve  n ( % ),C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
419,tnfi - na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
419,tnf - na ï ve,C0042469;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
419,rando . in na * *,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
419,not rando . in na *,C0597484;C1272460;C1518422;C1546968;C1879645;C4049872;C4552882
419,na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
419,na ( mmol / l ),C0597484;C1272460;C1532563;C1546968;C1879645;C4049872;C4552882
419,na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
419,n / a,C1272460
419,n . a .,C1272460
419,insulin - na ' ive,C0021641;C0597484;C1272460;C1533581;C1546968;C1579433;C1879645;C3435805;C3714501;C4049872;C4552882;C4554334
419,anti ‐ tnf ‐ na ï ve    n   ( % ),C0042469;C0432633;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
419,a / v ( n = $nmbr$ ) v ( n = $nmbr$ ),C0560268;C1272460;C3887614
419,a / v ( n = $nmbr$ ),C1272460
419,a $nmbr$ c [ n ( % ) ],C1272460
419,a $nmbr$ + e $nmbr$ ( n = $nmbr$ ),C1272460
418,neoplasia  n ( % ),C0027651;C1882062
418,neoplasia,C0027651;C1882062
418,detected during tumor evaluation,C0027651;C0220825;C0442726;C1261322;C1511790;C1578706;C3273930
417,tenecteplase,C0872913
417,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C0003842;C0021107;C0035124;C0039798;C0040363;C0041260;C0087111;C0221464;C0227952;C0439659;C0441587;C0684253;C0872913;C1512796;C1522326;C1533734;C1705169;C1883351;C1883719;C3538994;C3887704;C4086878
416,pleased,C3829994;C4264468
416,elevated high - sensitivity crp — no . { % ) * *,C0742906;C1441604
416,elevated crp ( > ulnt )  n ( % ),C0742906
416,elevated crp  n ( % ),C0742906
416,elevated baseline crp,C0168634;C0742906;C1442488
415,elevated vs normalb,C0205250;C3163633
415,elevated vs . normalc,C0205250;C3163633
415,elevated vs . normalb,C0205250;C3163633
415,elevated cardiac markers — no . ( % ) : t,C0205250;C1271630;C2603360;C3163633
415,elevated cardiac markers,C0205250;C1271630;C3163633
415,elevated at wk $nmbr$ — no . ( % ) $nmbr$,C0205250;C0332174;C0439230;C3163633
415,elevated at wk $nmbr$ — no . ( % ) !,C0205250;C0332174;C0439230;C3163633
414,serious adverse events,C1519255
414,previous cardiovascular events,C0205156;C1320716;C1552607
414,previous cardiovascular event — no . ( % ),C0205156;C1320716;C1552607
414,previous cardiovascular event at randomization,C0034656;C0205156;C1320716;C1552607
414,previous cardiovascular event ( % ),C0205156;C1320716;C1552607
414,cardiovascular events,C1320716
414,adverse eventy,
413,recent cardiovascular eventf,C0007226;C0332185;C3887460
413,recent,C0332185
412,with events ( % ),C0441471;C3541888
412,warfarin events / n ( % / y ),C0043031;C0441471;C3541888
412,use of aspirin at time of qualifying event ( % ),C0004057;C0040223;C0441471;C1514624;C1524063;C3541383;C4019010
412,total events  n,C0439175;C0439810;C0441471;C3541888
412,time since qualifying event,C0040223;C0441471;C1514624;C3541383;C4019010
412,qualifying symptomatic event  n ( % ) a,C0231220;C0441471;C1514624;C4019010
412,qualifying events,C0441471;C1514624;C3541888
412,qualifying event — no . ( % ),C0441471;C1514624;C4019010
412,qualifying event,C0441471;C1514624;C4019010
412,procedures for index event,C0025664;C0184661;C0441471;C0600653;C0918012;C1552854;C1637833;C2700391;C2986546;C3538935;C4019010
412,probability  of event %,C0033204;C0441471;C4019010
412,prior to index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
412,previous cerebrovascular event,C0205156;C0441471;C1552607;C1880018;C4019010
412,presentation of index event,C0441471;C0449450;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
412,pneumonia events  n,C0032285;C0441471;C3541888
412,pervious cerebrovascular event,C0205326;C0441471;C1880018;C4019010
412,pciperformed for qualifying event,C0441471;C1514624;C4019010
412,pci postindex event,C0441471;C4019010;C4049621
412,pci or cabg surgery for index event,C0010055;C0038894;C0038895;C0441471;C0543467;C0600653;C0918012;C1274039;C1552854;C1637833;C2986546;C4019010;C4049621
412,pci for index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
412,patients with pneumonia events  n ( % ) #,C0030705;C0032285;C0441471;C3541888
412,patients with hospitalized pneumonia events  n ( % ),C0032285;C0441471;C0870668;C3541888
412,patients with complicated events ( p = $nmbr$ - $nmbr$ 十 ),C0030705;C0231242;C0441471;C3541888
412,patients with complicated events,C0030705;C0231242;C0441471;C3541888
412,other antithrombotic medication for index event — no . ( % ),C0013227;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3244316;C4019010;C4284232
412,ophthalmologic events,C0029087;C0205481;C0441471;C3541888
412,number ( % ) of patients with event,C0441471;C2360800;C4019010
412,no revascularization for index acs event  no . ( % ),C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
412,no revascularization for index acs event,C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
412,no of events womenmen *,C0441471;C3541888
412,no of events / total n ( % ),C0439175;C0439810;C0441471;C3541888
412,no . with event / total no . { % ),C0439175;C0439810;C0441471;C4019010
412,no . of patients / no . of events ( % ) $nmbr$ / $nmbr$ ( $nmbr$ ) $nmbr$ / $nmbr$ ( $nmbr$ ),C0030705;C0441471;C3541888
412,no . of patients / no . of events,C0030705;C0441471;C3541888
412,no . of events / totol no . ( % ),C0441471;C3541888
412,no . of events / patients,C0030705;C0441471;C3541888
412,no . of events / no . of patients,C0030705;C0441471;C3541888
412,neurologicai events,C0441471;C3541888
412,n events ( % ),C0369718;C0441471;C0441922;C3541888
412,morphine use for index event / pci,C0242000;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
412,km event ( % ) at $nmbr$ y,C0441471;C3887676;C4019010
412,index events : dvt n ( % ),C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3541888;C3899446
412,index events,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3541888
412,index event — no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
412,index event not confirmed,C0441471;C0521093;C0600653;C0750484;C0918012;C1518422;C1552854;C1637833;C2986546;C4019010
412,index event information,C0441471;C0600653;C0918012;C1533716;C1552854;C1637833;C2986546;C4019010
412,index event asymptomatic or unconfirmed,C0231221;C0441471;C0600653;C0918012;C1547326;C1552854;C1637833;C2986546;C4019010
412,index event  n / n ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
412,index event  n ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
412,index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
412,in - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk,C0008976;C0036919;C0150312;C0332285;C0439175;C0439234;C0439508;C0439810;C0441471;C0871208;C1264674;C1444641;C1521828;C1707101;C3541888;C4288115
412,icosapent ethyl ( events / n ( % ) ),C0058978;C0441471;C3541888
412,i no . of events,C0021966;C0221138;C0441471;C3541888
412,history of pci or cabg before index event,C0010055;C0019664;C0019665;C0262512;C0262926;C0441471;C0600653;C0918012;C1552854;C1637833;C1705255;C2004062;C2986546;C4019010;C4049621
412,history of ml before index event,C0019664;C0019665;C0262512;C0262926;C0439526;C0441471;C0600653;C0918012;C1552854;C1637833;C1705224;C1705255;C2004062;C2986546;C3887665;C4019010
412,history of chf before index event,C0018802;C0019664;C0019665;C0262512;C0262926;C0441471;C0600653;C0918012;C1552854;C1637833;C1705255;C2004062;C2986546;C4019010
412,heparin  ‘ ondaparinux or brvalirudin use between rxjex event,C0019134;C0042153;C0441471;C0457083;C0770546;C1947944;C4019010
412,gastrointestinal event,C0441471;C0521362;C4019010
412,frequency of events,C0376249;C0439603;C0441471;C0871396;C1561548;C1705502;C3541888;C3898838;C4321352
412,freqency of events,C0441471;C3541888
412,for treatment of index event,C0039798;C0087111;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C2986546;C3538994;C3887704;C4019010
412,fibrinolytic for qualifying event,C0040044;C0441471;C1514624;C4019010
412,events treatment ( $nmbr$ ),C0039798;C0087111;C0441471;C1522326;C1533734;C1705169;C3538994;C3541888;C3887704
412,events consistent with volume depletion,C0332290;C0441471;C0546884;C3541888
412,events consistent with genital infection,C0332290;C0441471;C0729552;C3541888
412,events / statin group,C0360714;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888
412,events / patient - year ( n ),C0030705;C0439234;C0439508;C0441471;C3541888
412,events / n,C0441471;C3541888
412,events ( % ),C0441471;C3541888
412,events  no .,C0441471;C3541888
412,events  n ( % / y ),C0441471;C3541888
412,events  n ( % ),C0441471;C3541888
412,events,C0441471;C3541888
412,event { n ( % ),C0441471;C4019010
412,event number,C0237753;C0441471;C0449788;C4019010
412,event during overall,C0282416;C0441471;C1561607;C4019010
412,event during on -,C0441471;C4019010
412,event / total,C0439175;C0439810;C0441471;C4019010
412,event ( p = $nmbr$ . $nmbr$ o + ),C0441471;C4019010
412,event ( % ),C0441471;C4019010
412,event  n ( % ),C0441471;C4019010
412,event,C0441471;C4019010
412,cvd events,C0007222;C0441471;C3541888
412,cumulative events,C0441471;C1511559;C3541888
412,composite events,C0205199;C0441471;C1547335;C3541888
412,catheterization performed for qualifying event,C0007430;C0441471;C0884358;C1514624;C4019010
412,biochemical events,C0205474;C0441471;C3541888
412,atients with event,C0441471;C4019010
412,at qualifying event,C0441471;C1514624;C4019010
412,at index event : no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
412,aspirin alone group no of events / total n ( % ),C0004057;C0439175;C0439810;C0441471;C2826346;C3541888
412,any event,C0441471;C4019010
412,antithrombotic drug use at time of event,C0013227;C0040223;C0441471;C1254351;C1524063;C3541383;C4019010
412,anatomical extent of qualifying event — no . ( % ) : t,C0220784;C0439792;C0441471;C1514624;C2603360;C4019010
412,anatomic extent of qualifying event  n ( % . ) x,C0220784;C0439792;C0441471;C1514624;C4019010
412,$nmbr$ events [ $nmbr$ . $nmbr$ ],C0441471;C3541888
412,$nmbr$ events,C0441471;C3541888
411,sd = standard deviation  bmi = body mass index  ed = erectile,C0030847;C0871420;C1305855;C2699239;C3538926
411,prior ed therapy,C1514463;C3538926
411,missing ed duration ( y ),C0449238;C1551393;C1705492;C2926735;C3272743;C3538926
411,educ ssy,
411,educ > $nmbr$ y,
411,educ $nmbr$ - $nmbr$ y,
411,edo,
411,eda  %,C0162359;C1539327;C3539920;C3887494
411,ed therapy,C0039798;C0087111;C1363945;C3538926
411,ed duration > $nmbr$ yr  n ( % ),C0439234;C0449238;C2926735;C3538926
411,ed duration,C0449238;C2926735;C3538926
411,ed characteristics,C1521970;C3538926
410,time to all - cause death up to end of the study,C0007465;C0015127;C0040223;C0444930;C0547043;C0557651;C1301931;C1524003;C2603343;C2746065;C3541383
410,study end concentration,C0086045;C0444930;C0557651;C1446561;C2603343;C2746065;C3827302
410,combined end poir,C0205195;C0444930;C2746065
409,era monotherapy,C1521863;C3495919
409,era and pde - $nmbr$ i,C0021966;C0221138;C1521863;C3495919
409,era,C1521863;C3495919
409,ebria,C1917247
408,no epa group no . of events ( % ),C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888
408,epa hr events ( % ),C0441471;C3541888
408,epa group no . of events ( % ),C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888
408,epa ( n = $nmbr$ ),
408,epa,
408,empa,C2699863
-10,entocort ec ( n = $nmbr$ ),C1170256
406,lvh on ecg,C0232306
406,lvh by echo or ecg,C0058928;C0149721;C1623258;C1655045
406,lvh by ecg or echocardiographyd,C0232306
406,lvh by ecg or echocardiography  no ( % ),C0013516;C0232306
406,lvh by ecg or echo . n ( % ),C0058928;C0232306;C1655045
406,lvh by ecg / echo,C0058928;C0232306;C1655045
406,lvh by ecg ( minnesota code ),C0009219;C0026183;C0232306;C0805701;C3889831
406,lvh by ecg,C0232306
406,lv hypertrophy per ecg,C0232306
406,ecg - lvh ( sokolow - lyon ),C0232306
406,ecg - lvh ( cornell ),C0232306
405,infrequent exacerbator,C0521114
405,influenza,C0021400;C0021403
404,frequent or continuous,C0332183;C0549178
404,frequent exacerbator,C0332183
403,insufficient,C0205412;C0231180;C0439856
403,inadequate response ( > $nmbr$ months mmf / ggs ),C0083765;C0205412;C0209368;C0439231;C0439856;C0871261;C1704632;C1706817;C2911692;C3848524
403,inadequate,C0205412;C0439856
402,treatment effect ( hr ),C1518681
402,main effect baseline hormone,C0019932;C0168634;C0205225;C1280500;C1442488;C1518681;C1542147;C2348382;C4521914
402,effect estimate,C0750572;C1280500;C1518681;C2348382
402,consistency of effect,C0332529;C1280500;C1518681;C1547017;C2348382
401,wafarin event incidence / n,C0021149;C0220856;C0441471;C4019010
401,wafarin,
400,hemoglobin ale *,C0019046;C0678386;C2632076
400,hemoglobin ale  %  median ( iqr ),C0019046;C0549183;C0678386;C0876920;C2347635;C2348144;C2632076;C2939193
400,hale,
400,flex aln ^,C0729594;C2681220
400,ale < $nmbr$,C0678386;C2632076
400,ale,C0678386;C2632076
399,previous labd alone,C0205156;C0205171;C0396059;C0439044;C0679994;C1552607
399,labd alone,C0205171;C0396059;C0439044;C0679994
399,laba alone,C0205171;C0439044;C0679994
399,laba ',
398,alpha glucosidase inhibitors,C1299007;C2756986;C3539108
398,alpha - glucosidase inhibitors,C1299007;C2756986;C3539108
398,agi,C1299007
397,notatincreased fall risk ( n - $nmbr$  $nmbr$ ),C1268740
397,at increased fall risk ( n - $nmbr$ ),C0085639;C0205217;C0238715;C0442805;C1268740;C4553726;C4699158
397,all mis *,C0687670;C1333208;C1412384;C3538735
397,all mis,C0687670;C1333208;C1412384;C3538735
396,hba $nmbr$ c ( % ) all countries,C0019016;C0454664;C1825777;C3538758
396,all teaes *,
396,all teaes,
396,all rosuva,
396,all patientsb,
396,all participantst ( n = $nmbr$ / $nmbr$ ),
396,all participantsa,
396,all n = $nmbr$ $nmbr$,C0369718;C0441922
396,all n = $nmbr$  $nmbr$,C0369718;C0441922
396,all n = $nmbr$,C0369718;C0441922
396,all itt sutajects,
396,all diabetesd,
396,all countries,C0454664
396,all ( n = $nmbr$ f ),C0016327;C0369718;C0441922
396,all ( n = $nmbr$ * ),C0369718;C0441922
396,all ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0369718;C0441922
396,all ( n = $nmbr$ ),C0369718;C0441922
396,all ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
395,mean alc  %,C0444504;C1424945;C2347634;C2348143;C3811058
395,baseline alc category,C0168634;C0683312;C1424945;C1442488;C3811058;C3889287
395,baseline alc < $nmbr$ . $nmbr$ %,C0168634;C1424945;C1442488;C3811058
395,alc group ( % ),C0441833;C0687744;C1257890;C1424945;C1519504;C1705428;C1705429;C3811058
395,alc at weeko ( % ),C1424945;C3811058
395,alc at week $nmbr$ ( % ),C0332174;C0439230;C1424945;C3811058
395,alc > = $nmbr$ . $nmbr$ %,C1424945;C3811058
395,alc > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %,C1424945;C3811058
395,alc < $nmbr$ . $nmbr$ % at baseline  n ( % ),C0168634;C1424945;C1442488;C3811058
395,alc < $nmbr$ . $nmbr$ %,C1424945;C3811058
395,alc ( % ),C1424945;C3811058
394,insulin and oral hypoglycemic drugs,C0021641;C0359086;C1533581;C1579433;C3714501
394,any oral hypoglycemic drug 一 no . ( % ),C0359086
394,any,
394,> $nmbr$ and < $nmbr$ %,
393,european or arab,C0239307;C0282540;C1535514;C1561448
393,aab $nmbr$ ( % ),
392,texcaps,
392,enrolled in the americas,C0002454;C0596070;C4684790
392,americas * *,C0002454;C0596070
392,americas ( n = $nmbr$ ),C0002454;C0596070
392,americas  excluding us,C0002454;C0332196;C0596070;C2828389
392,americas,C0002454;C0596070
392,afcaps /,
391,usual care ( n = $nmbr$ la ),C0023031;C0023749;C0230347;C1947933;C2346906;C3538928;C4553351
391,usual care ( n = $nmbr$ a ),C1947933;C3538928
391,usual care ( n = $nmbr$ ),C1947933;C3538928
391,usual care,C1947933;C3538928
391,p $nmbr$ vs usual care,C0369773;C1947933;C2603361;C3538928
391,care use,C0042153;C0457083;C1947933;C1947944
391,care,C1947933
391,cards,C2930619;C3275277
390,卞 at discharge .,C0012621;C0030685;C2926602
390,thienopyridine at discharge,C0012621;C0030685;C1120149;C2926602
390,therapy at discharge,C0012621;C0030685;C0039798;C0087111;C1363945;C2926602
390,medications during hospitalization or at discharge,C0012621;C0013227;C0019993;C0030685;C0802604;C2598133;C2926602;C4284232
390,discharge medication  n ( % ),C0012621;C0013227;C0030685;C2926602;C3244316;C4284232
390,concomitant drug therapy at discharge,C0012621;C0013216;C0013217;C0013227;C0030685;C0039798;C0087111;C0521115;C1254351;C1363945;C1707479;C2926602;C3850077
390,cardiac medications during indexhospitalization and / or discharge,C0012621;C0013227;C0018787;C0030685;C0802604;C1522601;C2598133;C2926602;C4284232
390,cardiac medications during index hospital stay and / or discharge,C0012621;C0013227;C0030685;C0428776;C0802604;C2598133;C2926602;C3489408;C4284232
390,and / or discharge,C0012621;C0030685;C2926602
389,treated with cabg — no . / total no . ( % ),C0010055;C0332293;C0439175;C0439810
389,prior coronary intervention or coronary artery bypass grafting,C0010055;C0018787;C0184661;C0332152;C0886296;C1273869;C2826257
389,prior coronary artery bypass surgery,C0010055;C0332152;C2826257
389,prior coronary artery bypass grafting,C0010055;C0332152;C2826257
389,prior coronary artery bypass graft surgery,C0010055;C0332152;C2826257
389,prior coronary artery bypass graft,C0010055;C0332152;C1260596;C2826257
389,prior cabg ( before index acs ),C0010055;C0332152;C0600653;C0742343;C0918012;C1552854;C1637833;C2826257;C2986546;C4318612
389,prior cabg  %,C0010055;C0332152;C2826257
389,prior cabg,C0010055;C0332152;C2826257
389,percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % ),C0010055;C1532338
389,pci = percutaneous coronary intervention . cabg = coronary - artery bypass graft . for hope > $nmbr$ mg / l  for europa > $nmbr$ mg / l or on a lipid - lowering treatment  for peace  data are mean ( sd ) . data are mean ( sd ) unless otherwise indicated .,C0010055;C0023779;C0039798;C0087111;C0184661;C0189695;C0242751;C0392347;C0441994;C0444504;C0522523;C0545743;C0680443;C0886296;C1273869;C1444656;C1511726;C1522326;C1533734;C1705169;C2003888;C2347634;C2348143;C2699239;C2827881;C3245479;C3538994;C3714741;C3887704;C4049621
389,no prior cabg,C0010055;C0332152;C2826257
389,history of cabg surgery  n ( % ),C0010055;C0455610
389,history of cabg surgery,C0010055;C0455610
389,data are expressed as n / total ( % ) unless otherwise speci ﬁ ed . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation  † at discharge . ace angiotensin - converting enzyme  cabg coronary artery bypass graft  ccsc canadian cardiovascular society classi ﬁ cation  mi myocardial infarction  pci percutaneous coronary intervention .,C0007226;C0007447;C0010055;C0012621;C0018787;C0022709;C0027051;C0030685;C0037455;C0040363;C0041260;C0184661;C0238884;C0439175;C0439453;C0439526;C0439810;C0439836;C0522523;C0552449;C0565930;C0750572;C0812399;C0886296;C1273869;C1511726;C1516705;C1705224;C1719797;C1883351;C2603362;C2911648;C2926602;C3245479;C3538926;C3714741;C3887460;C3887665;C4049621
389,coronary bypass surgery,C0010055
389,coronary bypass  n ( % ),C0010055
389,coronary artery bypass surgery,C0010055
389,coronary artery bypass graft  n ( % ),C0010055;C1260596
389,coronary artery bypass graft,C0010055;C1260596
389,coronary artery bypass,C0010055
389,cabg — no . { % ),C0010055
389,cabg — no . ( % ),C0010055
389,cabg surgery by no . of vessels $nmbr$,C0010055;C0042381;C3714645
389,cabg or pci,C0010055;C4049621
389,cabg > $nmbr$ month ago,C0010055;C0332177;C0439231
389,cabg :,C0010055
389,cabg ( % ),C0010055
389,cabg  n ( % ),C0010055
389,cabg,C0010055
389,ace = angiotensin - converting enzyme  cabg = coronary artery bypass graft  ccsc = canadian cardiovascular society classification  mi = myocardial infarction  pci = percutaneous coronary,C0010055;C0022709;C0027051;C0189695;C0545743;C3640258
388,race and ss at baseline,C0034510;C0168634;C1442488;C1706779;C2699257;C3853635;C3891295;C4551874
388,none ( cdmard - naive or past use at baseline ),C0042153;C0168634;C0457083;C1442488;C1444637;C1947944;C4284302
388,cdmard,
388,bdmard - naive,
388,> $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %,
387,avm ( n = $nmbr$ ),C0003857;C0279476
387,avm % △ ( se ),C0003857;C0036919;C0279476
386,s wave in v $nmbr$ ( mm ),C0456681;C4301968
386,q wave mi,C0861151
386,q - wave mi,C0861151
386,death / q - wave mi / idr,C0011065;C0861151;C1306577;C4082313;C4552775
386,death  q wave mi or ischemia - driven revasc,C0011065;C0022116;C0378365;C0861151;C1306577;C4082313;C4321499;C4552775;C4683688
385,q wave,C0429089;C1305738
385,non - q wave,C0429089;C1305738;C1518422
385,non - q - wave myocardial infarction,C0542269;C3537181
385,non - q - wave ml,C0429089;C0439526;C1305738;C1518422;C1705224;C3887665
384,transradial,
384,intracranial hemorrhage †,C0151699;C4554169
384,intracranial hemorrhage  n ( % ),C0151699;C4554169
384,intracranial hemorrhage,C0151699;C4554169
384,intracranial bleeding,C0151699
384,intracranial bleed,C0151699
384,intracranial,C0524466
384,extracranial,C0580586
383,intrathoracic or intraperitoneal surgery,C0038894;C0038895;C0442120;C0543467;C0595836;C1274039
383,intraperitoneal,C0442120
382,no antianginal drug,C0013227;C1254351;C1874267;C3537168
382,new anti - anginal therapy,C1874267;C3242274;C3537168
382,intensification of antianginal therapy,C1511484;C1874267;C3537168
382,any antianginal drug !,C0013227;C1254351;C1874267;C3537168
382,$nmbr$ antianginal drug,C0013227;C1254351;C1874267;C3537168
381,tachyarrhythmias  n ( % ),C0080203
381,supraventricular tachyarrhythmias ( incl . atrial,C0018792;C1698480;C3853833
381,no . ( % ) of patients with atrial tachyarrhythmia,C0018792;C0030705;C0080203
380,prior arrhythmias  n ( % ),C0003811;C0332152;C2826257
380,cardiac arrhythmia  n ( % ),C0003811;C0264886;C1560249
380,cardiac arrhythmia,C0003811;C0264886;C1560249
380,arrhythmias,C0003811
380,arrhythmia !,C0003811
380,arrhythmia,C0003811
379,previous use of antiarrhythmic drugs,C0003195;C0205156;C1524063;C1552607
379,other antiarrhythmics ^,C0003195
379,any prerandomization failure of an antiarrhythmic drug — no . ( % ),C0003195;C0231174;C0301380;C0680095
379,antiarrhythmics,C0003195
379,antiarrhythmic therapy,C0003195;C0039798;C0087111;C1363945;C3537142
379,antiarrhythmic drugs    n   ( % ),C0003195
379,antiarrhythmic drug,C0003195;C0301380
379,antiarrhythmic,C0003195;C3537142
379,anti arrhythmic,C0003195;C3537142
378,rheumatoid arthritis,C0003873
378,polyarticular arthritis  no rheumatoid nodules,C0035450;C0162323
378,duration of rheumatoid arthritis — yr,C0003873;C0439234;C0449238;C2926735
378,duration of rheumatoid arthritis ( years ),C0003873;C0439234;C0449238;C2926735
378,arthritis mutilans,C0702102
378,arthralgia,C0003862;C4551938
377,normoalbuminuria — no . ( % ),
377,normoalbuminuria  no . ( % ),
377,normoalbuminuria,
377,micro / macroalbuminuria,C0085672;C1553035;C3811161;C4049106
377,micro / macroaibuminuria,C0085672;C1553035;C3811161;C4049106
377,micro - or macroalbuminuria  no . ( % ),C0085672;C1553035;C3811161;C4049106
377,micro - or macroalbuminuria  n ( % ) §,C0085672;C1553035;C3811161;C4049106
377,macroalbuminuriaf,
377,macroalbuminuria  n ( % ),
377,macroalbuminuria,
377,history of microalbuminuria — no . ( % ),C3532606
376,patients with microalbuminuria at baseline,C0030705;C0168634;C0730345;C1442488
376,or no microalbuminuria or macroalbuminuria,C0730345
376,normoalbuminuria or microalbuminuria,C0730345
376,microalbuminuria — no . / total no . ( % ),C0439175;C0439810;C0730345
376,microalbuminuria — no . ( % ),C0730345
376,microalbuminuria or proteinuria,C0033687;C0730345;C1962972;C4554346
376,microalbuminuria or macroalbuminuria §,C0730345
376,microalbuminuria or macroalbuminuria,C0730345
376,microalbuminuria ( uacr $nmbr$ – $nmbr$ ),C0730345
376,microalbuminuria  n ( % ),C0730345
376,microalbuminuria,C0730345
376,macroalbuminuria ( uacr > $nmbr$ ),
376,and microalbuminuria or macroalbuminuria,C0730345
375,progression of albuminuria,C0001925;C0242656;C0449258
375,micro - albuminuria,C0001925;C0085672;C1553035;C3811161;C4049106
375,macro - albuminuria,C0001925;C2984010
375,any albuminuria — no . ( % ),C0001925
375,any albuminuria,C0001925
375,albuminuria_p_interaction,C0001925;C1704675
375,albuminuria progression,C0001925;C0242656;C0449258
375,albuminuria ( g / g ),C0001925;C1319635
375,albuminuria,C0001925
374,reteplase / abciximab - facilitated pci ( n = $nmbr$ ),C0256103;C0288672;C4049621
374,abciximab vs . primary,C0205225;C0288672;C0439612;C0439631
374,abciximab no . / total ( % ),C0288672;C0439175;C0439810
374,abciximab - facilitated pci,C0288672;C4049621
374,abciximab ( n = $nmbr$ ),C0288672
374,abciximab,C0288672
374,$nmbr$ abciximab ( n = $nmbr$ ),C0288672
373,rate ratio ( lebrikizumab vs placebo  $nmbr$ % cl ),C0032042;C0456603;C0596019;C0871208;C1521828;C1547037;C1696465;C1706408;C2981360
373,rate difference ( lebrikizumab - placebo ),C0032042;C0871208;C1521828;C1696465;C1705241;C1705242;C1706408;C2981360
373,lebrikizumab ( n = $nmbr$ ),C2981360
372,canakinumab  il - $nmbr$ top tertilec,C0020898;C0021764;C0022271;C1704458;C2718773
372,canakinumab  il - $nmbr$ middle tertile,C0020898;C0021764;C0022271;C0444598;C0549183;C1552826;C2718773
372,canakinumab  il - $nmbr$ lowest tertile,C0020898;C0021764;C0022271;C1708760;C2718773
372,canakinumab  $nmbr$ - month on - treatment il - $nmbr$ below the median value ( < $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ ),C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704
372,canakinumab,C2718773
372,anakinra,C0245109
372,all canakinumab,C2718773
371,ustekinumab ® ( n = $nmbr$ ),C1608841
371,ustekinumab combined,C0205195;C1608841
371,ustekinumab ' ’ ( n = $nmbr$ ),C1608841
371,ustekinumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1608841;C1960952;C2346927;C4321396;C4521761
371,ustekinumab,C1608841
371,ustekinu,
371,usteki,
371,uistekinumab,
370,geographic site  %,C0017446
370,geographic region — number ( % ),C0017446;C0237753;C0449788
370,geographic region ?,C0017446
370,geographic region,C0017446
370,geographic location,C0017446
370,area of retinal thickening within the grid  mean ( sd )  dab,C0017446;C0086162;C0205146;C0444504;C1081457;C1302690;C1415284;C2347634;C2348143;C2348395;C2699239;C2825313;C4522144
370,area of retinal hemorrhage within the grid  mean ( sd )  dab,C0017446;C0035317;C0086162;C0205146;C0444504;C1081457;C1415284;C2347634;C2348143;C2348395;C2699239;C2825313;C4522144
370,area of fluorescein leakage within the grid  mean ( sd )  dab,C0017446;C0086162;C0205146;C0444504;C1081457;C1415284;C2347634;C2348143;C2348395;C2699239;C2825313;C4476700;C4522144
370,area,C0017446;C0205146
369,reqion,
369,regiont,
369,regions  n ( % ),C0017446;C0205147
369,region ofthe world,C0017446;C0205147;C2700280
369,region ofenrollment — %,C0017446;C0205147
369,region of world — no . ( % ),C0017446;C0205147;C2700280
369,region of the world,C0017446;C0205147;C2700280
369,region of residence ( p = $nmbr$ $nmbr$ ),C0017446;C0205147;C0237096
369,region of enrollment — no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
369,region of enrollment  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
369,region of enrollment  n ( % ) +,C0017446;C0205147;C1516879;C1696073;C3888021
369,region of enrollment,C0017446;C0205147;C1516879;C1696073;C3888021
369,region n ( % ),C0017446;C0205147
369,region :,C0017446;C0205147
369,region - n ( % ),C0017446;C0205147
369,region *,C0017446;C0205147
369,region ( us ),C0017446;C0205147
369,region ( pooled ),C0017446;C0205147;C1709595;C2349200;C4522255
369,region ( % ),C0017446;C0205147
369,region    n   ( % ),C0017446;C0205147
369,region  n ( % ) a,C0017446;C0205147
369,region  n ( % ),C0017446;C0205147
369,region  latin america,C0017446;C0023122;C0205147
369,region  europe union,C0015179;C0017446;C0205147
369,region  %,C0017446;C0205147
369,region,C0017446;C0205147
369,p  treatment - by - region interaction,C0017446;C0039798;C0087111;C0205147;C0369773;C1522326;C1533734;C1704675;C1705169;C2603361;C3538994;C3887704
369,grouped region,C0017446;C0205147;C0439745;C4319846
369,geographical region ( % ),C0017446
369,geographical region  n ( % ),C0017446
369,geographical region,C0017446
369,geographic region ^,C0017446
369,geographic region - other,C0017446
369,geographic region  n ( % ),C0017446
369,geographic region  %,C0017446
368,± standard deviation . triglyceride,C0041004;C0871420
368,triglycerides — mmol / l,C0041004;C1532563
368,triglycerides — mg / dl | |,C0041004;C0439269
368,triglycerides — mg / dl ^,C0041004;C0439269
368,triglycerides — mg / dl,C0041004;C0439269
368,triglycerides > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ),C0041004;C0439269;C1532563
368,triglycerides > $nmbr$ mg / dl,C0041004;C0439269
368,triglycerides > $nmbr$ - $nmbr$ mmol / l,C0041004;C1532563
368,triglycerides < $nmbr$ - $nmbr$ mmol / l,C0041004;C1532563
368,triglycerides - mg / dl * *,C0041004;C0439269
368,triglycerides * *,C0041004
368,triglycerides * ( mg / dl ),C0041004;C0439269
368,triglycerides *,C0041004
368,triglycerides ( week $nmbr$ ) a,C0041004;C0332174;C0439230
368,triglycerides ( mmol / l ) :,C0041004;C1532563
368,triglycerides ( mmol / l ) ( median  iqr ),C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
368,triglycerides ( mmol / l )  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
368,triglycerides ( mmol / l ),C0041004;C1532563
368,triglycerides ( mg / dl ) * *,C0041004;C0439269
368,triglycerides ( mg / dl ),C0041004;C0439269
368,triglycerides ( median  iqr )  mg / dl,C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
368,triglycerides $nmbr$ nd third,C0041004;C0205437
368,triglycerides $nmbr$  d third,C0041004;C0205437
368,triglycerides $ $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0041004;C0439269;C1532563
368,triglycerides  mmol / l ®,C0041004;C1532563
368,triglycerides  mmol / l §,C0041004;C1532563
368,triglycerides  mmol / l  mean ± sd,C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
368,triglycerides  mmol / l  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
368,triglycerides  mmol / l,C0041004;C1532563
368,triglycerides  mg / l,C0041004;C0439268
368,triglycerides  mg / dl ^,C0041004;C0439269
368,triglycerides  mg / dl  median ( q $nmbr$ : q $nmbr$ ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
368,triglycerides  median ( ql  q $nmbr$ )  mmol / l,C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
368,triglycerides  median ( qi  q $nmbr$ )  mmol / l,C0041004;C0376586;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
368,triglycerides  median ( iqr )  mg / dl,C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
368,triglycerides  * mmol / l,C0041004;C1532563
368,triglycerides,C0041004
368,triglyceride a,C0041004
368,triglyceride ( mmol / l ) t,C0041004;C1532563
368,triglyceride ( mmol / l ) * blood pressure,C0005823;C0041004;C1271104;C1272641;C1532563
368,triglyceride ( mmol / l ),C0041004;C1532563
368,triglyceride ( mg / dl ) d,C0041004;C0439422;C3642216
368,triglyceride ( mg / dl ) $nmbr$,C0041004;C0439269
368,triglyceride ( median : mg / dl ) a [ $nmbr$ - $nmbr$ percentile ],C0041004;C0439269;C0549183;C0876920;C1264641;C2347635;C2348144;C2939193
368,triglyceride ( median  mg / dl ) - $nmbr$ [ $nmbr$ - $nmbr$ percentile |,C0041004;C0439269;C0549183;C0876920;C1264641;C2347635;C2348144;C2939193
368,triglyceride  mmol / l,C0041004;C1532563
368,triglyceride,C0041004
368,tg  triglycerides . * median values ( standard deviation for medians ) .,C0041004;C0042295;C0399532;C0549183;C1442989;C2828392
368,pretreatment triglycerides,C0041004;C1550147;C2709094;C3539075;C3539076
368,median triglyceride ( mg / dl ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
368,fasting triglycerides — mg / dl,C0015663;C0041004;C0439269
368,fasting triglycerides > $nmbr$ mg / dl *,C0015663;C0041004;C0439269
368,fasting triglycerides  mg / dl,C0015663;C0041004;C0439269
368,fasting triglycerides  mean ( sd )  mg / dl,C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
368,fasting triglycerides,C0015663;C0041004
368,deviation  tg  triglyceride .,C0012727;C0041004;C0205419;C1705236
368,baseline triglycerides > $nmbr$ mg / dl and,C0041004;C0168634;C0439269;C1442488
368,baseline triglycerides < $nmbr$ mg / dl,C0041004;C0168634;C0439269;C1442488
368,- triglycerides,C0041004
368,$nmbr$ . $nmbr$ mg / dl triglycerides ^,C0041004;C0439269
367,no . of previous anti - tnf drugs — no . ( % ),C0013227;C0205156;C1448177;C1552607;C3687832
367,no . of drugs,C0013227;C3687832
367,lowering drugs,C0013227;C0441994;C2003888;C3687832
367,lipid - modulating drug,C0013227;C0023779;C0443264;C1254351
367,investigator - defined drug - related aes,C0013227;C0035173;C0439849;C0445223;C1254351;C1412268;C1704788;C2699274;C3539106
367,immunomodulatory drugs,C0013227;C3687832
367,glycemic drugs,C0005802;C0013227;C3687832
367,epilepsy drug,C0013227;C0014544;C1254351
367,drugs and toxins,C0013227;C0040549;C3687832
367,drug ‐ relateda,C0013227;C1254351
367,drug eluting,C0013227;C1254351
367,drug - relateda,C0013227;C1254351
367,drug - eluting,C0013227;C1254351
367,blood glucose - lowering drugs  excluding insulin  n ( % ),C0005802;C0013227;C0017725;C0018938;C0021641;C0332196;C0441994;C1533581;C1579433;C2003888;C2828389;C3687832;C3714501
367,because of drug ‐ relateda   sae,C0013227;C1254351;C1519255;C1622657;C4553214
367,because of drug ‐ relateda   ae,C0013227;C1254351;C3887670
367,annanginal drugs ( $nmbr$ / l / s » $nmbr$ ) ^,C0013227;C3687832
367,> $nmbr$ drug - related aes *,C0013227;C0439849;C0445223;C1254351;C1412268;C2699274
367,> $nmbr$ drug - related,C0013227;C0439849;C0445223;C1254351
367,$nmbr$ antianginal drugs,C0013227;C1874267;C3537168;C3687832
366,use of medications for pah — no . ( % ),C0013227;C0030123;C0802604;C1524063;C2598133;C3203102;C4284232;C4284467
366,use of medication for pah,C0013227;C0030123;C1524063;C3203102;C3244316;C4284232;C4284467
366,use of medication at baseline — no . ( % ),C0013227;C0168634;C1442488;C1524063;C3244316;C4284232
366,use of cardiac medication *,C0013227;C0018787;C1522601;C1524063;C3244316;C4284232
366,use of blood pressure lowering medication *,C0013227;C0020649;C1524063;C3244316;C4284232
366,systemic sle medications  n ( % ),C0013227;C0024141;C0205373;C0802604;C2598133;C4284232
366,selected medications — no . ( % ),C0013227;C0802604;C1707391;C2598133;C4284232
366,prior use of osteoporosis medications  n ( % ),C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
366,prior use of osteoporosis medications,C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
366,prior medications,C0013227;C0332152;C0802604;C2598133;C2826257;C4284232
366,previous medications  n ( % ),C0013227;C0205156;C0802604;C1552607;C2598133;C4284232
366,periprocedural medications — no . / total no . ( % ),C0013227;C0439175;C0439810;C0802604;C2598133;C4284232
366,periprocedural medications — no . / total no .,C0013227;C0439175;C0439810;C0802604;C2598133;C4284232
366,periprocedural medications  n ( % ),C0013227;C0802604;C2598133;C4284232
366,periprocedural medications,C0013227;C0802604;C2598133;C4284232
366,patients receiving any uc medication  n ( % ),C0013227;C0030705;C1514756;C3244316;C4284232
366,other medications,C0013227;C0802604;C2598133;C4284232
366,other lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
366,op concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
366,no . of previous ciu / csu medications  mean ( median ),C0013227;C0205156;C0444504;C0549183;C0578870;C0802604;C0876920;C1552607;C2347634;C2347635;C2348143;C2348144;C2598133;C2939193;C4284232
366,no . of previous ciu / csu medications,C0013227;C0205156;C0578870;C0802604;C1552607;C2598133;C4284232
366,medications — no . { % ) * *,C0013227;C0802604;C2598133;C4284232
366,medications — no . ( % ),C0013227;C0802604;C2598133;C4284232
366,medications through day $nmbr$,C0013227;C0332173;C0439228;C0439505;C0802604;C2598133;C4284232
366,medications taken at time of randomization statins,C0013227;C0034656;C0040223;C0360714;C0802604;C1883727;C2598133;C3541383;C4284232
366,medications on admission  %,C0013227;C0457453;C0802604;C2598133;C4284232
366,medications in use at baseline — no . ( % ),C0013227;C0042153;C0150312;C0168634;C0332285;C0457083;C0802604;C1442488;C1707101;C1947944;C2598133;C4284232
366,medications in use at baseline  n ( % ),C0013227;C0042153;C0150312;C0168634;C0332285;C0457083;C0802604;C1442488;C1707101;C1947944;C2598133;C4284232
366,medications for crohn ' s disease taken at baseline — no . ( % ),C0010346;C0013227;C0168634;C0802604;C1442488;C1883727;C2598133;C4284232
366,medications before admission,C0013227;C0184666;C0802604;C0809949;C2598133;C4284232
366,medications at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
366,medications at the time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
366,medications at randomization,C0013227;C0034656;C0802604;C2598133;C4284232
366,medications at coronary angiography,C0013227;C0085532;C0802604;C1548829;C2598133;C4284232
366,medications at baselinet,C0013227;C0802604;C2598133;C4284232
366,medications at baseline  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
366,medications . no . ( % ),C0013227;C0802604;C2598133;C4284232
366,medications *,C0013227;C0802604;C2598133;C4284232
366,medications ( % ),C0013227;C0802604;C2598133;C4284232
366,medications  no . ( % ),C0013227;C0802604;C2598133;C4284232
366,medications  n ( % of patients ),C0013227;C0030705;C0802604;C2598133;C4284232
366,medications  n ( % ),C0013227;C0802604;C2598133;C4284232
366,medications  n,C0013227;C0802604;C2598133;C4284232
366,medications,C0013227;C0802604;C2598133;C4284232
366,medication — no . ( % ),C0013227;C3244316;C4284232
366,medication useb,C0013227;C3244316;C4284232
366,medication continued into double - blind treatment period,C0013072;C0013227;C0039798;C0087111;C0439531;C0549178;C1522326;C1533734;C1705169;C1948053;C3244316;C3538994;C3887704;C4284232
366,medication at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
366,medication at time of randomization,C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
366,medication at randomization  n ( % ),C0013227;C0034656;C3244316;C4284232
366,medication at randomization  %,C0013227;C0034656;C3244316;C4284232
366,medication at randomization,C0013227;C0034656;C3244316;C4284232
366,medication at entry ( % ),C0013227;C1705654;C3244316;C4284232
366,medication $nmbr$ ( $nmbr$ . $nmbr$ ),C0013227;C3244316;C4284232
366,medication  n ( % ),C0013227;C3244316;C4284232
366,medication,C0013227;C3244316;C4284232
366,mean no . agents ( sd ) other medications,C0013227;C0444504;C0450442;C0802604;C1254351;C1521826;C2347634;C2348143;C2598133;C2699239;C4284232
366,lipids medications,C0013227;C0023779;C0802604;C2598133;C4284232
366,lipid medication  n ( % ),C0013227;C0023779;C3244316;C4284232
366,lipid - lowering medications ^,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
366,lipid - lowering medications,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
366,lipid - lowering medication ( % ),C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
366,lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
366,iop - lowering medication,C0013227;C0441994;C0578862;C2003888;C3244316;C4284232
366,glucose - lowering medications,C0013227;C0017725;C0441994;C0802604;C2003888;C2598133;C4284232
366,glucose - lowering medication,C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
366,diabetes medication,C0011847;C0011849;C0013227;C3244316;C4284232
366,cv medication  % of patients,C0013227;C0030705;C3244316;C3538987;C4048877;C4284232;C4318503
366,cv medication,C0013227;C3244316;C3538987;C4048877;C4284232;C4318503
366,concurrent medications,C0013227;C0205420;C0802604;C2598133;C4284232
366,concurrent medication,C0013227;C0205420;C3244316;C4284232
366,concomitant pd medications at baseline  n ( % ) c  d,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232;C4553228;C4553229
366,concomitant medications — no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
366,concomitant medications at baseline,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232
366,concomitant medications after randomization,C0013227;C0034656;C0521115;C0802604;C2598133;C4284232
366,concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
366,concomitant medications  no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
366,concomitant medications  n ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
366,concomitant medications  * n ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
366,concomitant medications  %,C0013227;C0521115;C0802604;C2598133;C4284232
366,concomitant medications,C0013227;C0521115;C0802604;C2598133;C4284232
366,concomitant medication — no . { % ) | ace inhibitor,C0003015;C0013227;C0521115;C3244316;C4284232;C4541021
366,concomitant medication — no . ( % ),C0013227;C0521115;C3244316;C4284232
366,concomitant medication | |,C0013227;C0521115;C3244316;C4284232
366,concomitant medication after randomisation,C0013227;C0034656;C0521115;C3244316;C4284232
366,concomitant medication ( > $nmbr$ % ),C0013227;C0521115;C3244316;C4284232
366,concomitant medication ( % ),C0013227;C0521115;C3244316;C4284232
366,concomitant medication  no . ( % ),C0013227;C0521115;C3244316;C4284232
366,concomitant medication  n [ % ],C0013227;C0521115;C3244316;C4284232
366,concomitant medication  n ( % ) d,C0013227;C0521115;C3244316;C4284232
366,concomitant medication  n ( % ),C0013227;C0521115;C3244316;C4284232
366,concomitant medication,C0013227;C0521115;C3244316;C4284232
366,concomitant asthma medications  n ( % ),C0004096;C0013227;C0521115;C0802604;C2598133;C2984299;C4284232
366,comorbidities and concomitant medications,C0009488;C0013227;C0521115;C0802604;C2598133;C4284232
366,comorbidities / concomitant medications,C0009488;C0013227;C0521115;C0802604;C2598133;C4284232
366,cardiac medications during index hospitalization — no . ( % ),C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
366,cardiac medications during index hospitalization  %,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
366,cardiac medications during index hospitalization,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
366,blood - pressure medications at randomization — no . / total no . ( % ),C0005823;C0013227;C0033095;C0034656;C0439175;C0439810;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
366,baseline medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
366,baseline antihyperglycemic medications  n ( % ),C0013227;C0020616;C0168634;C0802604;C1442488;C2598133;C4284232
366,aspirin / antiplatelet medication,C0004057;C0013227;C0085826;C3244316;C4284232
366,any medication,C0013227;C3244316;C4284232
366,antithrombotic medications  n ( % ),C0013227;C0802604;C2598133;C4284232
366,antihyperglycemic medications,C0013227;C0020616;C0802604;C2598133;C4284232
366,antianginal medications,C0013227;C0802604;C1874267;C2598133;C3537168;C4284232
366,anti - arthritic medications,C0013227;C0802604;C2598133;C4284232
366,acute medication intake ( days / month ),C0013227;C0205178;C0556971;C1512806;C3244316;C4284232
366,> $nmbr$ glucose - lowering medication . no . ( % ),C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
366,> $nmbr$ concomitant medication,C0013227;C0521115;C3244316;C4284232
365,type of drug - eluting stent  n ( % ),C0038257;C0332307;C0457591;C1322815;C1547052
365,received drug - eluting stent,C1322815;C1514756
365,non - drug - eluting stent,C1322815;C1518422
365,drug eluting stent,C1322815
365,drug - eluting stent — no . ( % ),C1322815
365,drug - eluting stent implanted — no . ( % ),C0021102;C1322815;C2828363
365,drug - eluting stent implanted ( at least one ),C0021102;C0205447;C1322815;C2828363
365,drug - eluting stent implanted,C0021102;C1322815;C2828363
365,drug - eluting stent  n ( % ),C1322815
365,drug - eluting stent,C1322815
365,at least one drug - eluting stent,C0205447;C1322815
364,stent placement,C0522776
364,stent implanted — no . ( % ),C0522776
364,stent implanted,C0522776
363,not hispanie / latino,C0086528;C1518422
363,latino,C0086528
363,hispanie / latino,C0086528
363,hispanic or latino ethnic groupf,C0015031;C0086409;C0086528;C0680174
363,hispanic or latino ethnic groupb,C0015031;C0086409;C0086528;C0680174
363,hispanic or latino ethnic group *,C0015031;C0086409;C0086528;C1879937
363,hispanic or latino ethnic group !,C0015031;C0086409;C0086528;C1879937
363,hispanic or latino ( n — $nmbr$ ),C0086409;C0086528
363,hispanic or latino ( n = $nmbr$ ),C0086409;C0086528
363,hispanic or latino,C0086409;C0086528
363,hispanic / latino ( n = $nmbr$ ),C0086409;C0086528
363,hispanic / latino,C0086409;C0086528
363,ethnicitya hispanic or latino,C0086409;C0086528
362,tnf inhibitor,C1448177;C1999216
362,tnf antagonist - naive ®,C0231491;C1448177
362,tnf antagonist - naive subgroup ( n - $nmbr$ ),C0231491;C1079230;C1448177;C1515021
362,tnf antagonist - naive ' ’,C0231491;C1448177
362,tnf - naivea,C1448177
362,tnf - naive patientsa,C1448177
362,tnf - failurea,C1448177
362,prior tnf inhibitor exposure  no . ( % ),C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
362,prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
362,prior biologic therapy ( including anti - tnfs ),C0278947;C0332257;C1448177
362,no prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
362,naive,
362,history of tnf antagonist treatment failure — no . ( % ) * *,C0019664;C0019665;C0162643;C0231491;C0235828;C0262512;C0262926;C0521983;C1448177;C1547544;C1705255;C2004062
362,anti - tnf agent ( s ),C0221141;C0313162;C0450442;C1254351;C1448177;C1521826
362,anti - tnf - naive patients $nmbr$,C0030705;C1448177
362,anti - tnf - naive patients,C0030705;C1448177
362,anti - tnf - naive  n ( % ),C0432633;C1448177
362,anti - tnf - experienced patients,C0030705;C1448177
362,anti - tnf,C1448177
361,injectable anti ‐ hyperglycaemic  n ( % ),C0432633;C1272883
361,anti ‐ hyperglycaemic agent  n ( % ),C0432633;C1321567
361,anti - anaemics,C0857322
360,anti - p $nmbr$,
360,anti - ccp antibody positive  n ( % ),C0432633;C0741132;C1525410;C1704514
360,anti - ccp antibody positive,C0741132;C4318437
360,anti - ccp antibody - positive  n ( % ),C0432633;C0741132;C1525410;C1704514
360,anti - ccp antibody ( u /,C0003241;C0003242;C0021027;C0439148;C1167408;C1525410;C1704514;C3665580;C4318437
360,anti - ccp antibodies *,C0003241;C1525410;C1624602;C1704514;C4318437
359,xanthinesg,
359,xanthines $nmbr$,C0043318;C3541955
359,xanthines  b   n ( % ),C0043318;C3541955
359,xanthines,C0043318;C3541955
359,xanthine,C0043314;C0043318
359,methylxanthines,C0066447
359,current xanthine derivative use,C0042153;C0043314;C0043318;C0457083;C0521116;C1527240;C1705970;C1947944
358,normai fasting giucose levei ( n = $nmbr$ ),C0015663
358,impaired fasting glucosex,C0015663;C0221099
358,impaired fasting giucose levei ( n = $nmbr$ ),C0015663;C0221099
358,glucose  non - fasting or random ( nmol / l ),C0015663;C0017725;C0034656;C0439282;C0439605;C1518422
358,fasting plasma insulin — mu / liter,C0015663;C0028971;C0347978;C0475211;C0857690;C3714918
358,fasting lipids ( mmol / $nmbr$ ),C0015663;C0023779;C0439190
358,fasting lipid levels  mmol / l,C0015663;C0428460;C1532563
358,fasting indices,C0015663;C4033634
358,fasting glucose *,C0015663;C0017725
358,fasting glucose ( mmol / l ),C0015663;C0017725;C1532563
358,fasting glucose  mmol / l  mean ± sd,C0015663;C0017725;C0444504;C1532563;C2347634;C2348143;C2699239
358,fasting glucose,C0015663;C0017725
358,fasting,C0015663
358,fastest third,C0015663;C0205437;C0456962;C2985769
358,faster aspart ( mealtime ),C0015663;C0123677;C0456962;C0587119;C2985769
358,faster aspart,C0015663;C0123677;C0456962;C2985769
358,elevated fasting glucose,C0015663;C0017725;C0205250;C3163633
357,multi - racial,C0034510;C0439064;C1706779;C3266262;C3669213;C3853635
357,glacial $nmbr$,
357,brachial,C0445456
356,radial access — no . / total no . ( % ),C0439175;C0439810;C0442038;C0444454;C0920847;C1554204
356,radial access site,C0442038;C0589360;C0920847
356,radial access,C0442038;C0444454;C0920847;C1554204
356,radial,C0442038;C0920847
355,familial,C0015576;C0241888
355,diagnosis of heterozygous familial hypercholester,C0011900;C0015576;C0019425;C0241888;C1704338;C1704656
354,placebo * ( add on to basal insulin ),C0032042;C0650607;C1696465;C1706408;C1883712
354,faster aspart   +   basal,C0015663;C0123677;C0205112;C0456962;C2985769
354,basal insulin doset,C0650607
354,basal insulin dose at run - in ( u / day ),C0178602;C0205112;C0366513;C0456683;C0650607;C0869039;C1114758;C3274438
354,basal insulin analogue dose * ( coefficient,C0178602;C0205112;C0243071;C0366513;C0650607;C0869039;C1114758;C1707429;C2825028
354,basal insulin analogue : insulin,C0205112;C0243071;C0650607;C2825028
354,basal insulin,C0650607
354,basal,C0205112
353,no nasal polyps,C0027430
353,nasal polyps at baseline : yes,C0027430;C0168634;C1442488;C1549445;C1705108;C1710701
353,nasal polyps  n ( % ),C0027430
353,nasal polyps,C0027430
353,nasal polyposis or chronic rhinosinusitis — no . { % ),C0027430;C0149516
353,either ocs use  nasal polyps  pre - bd fvc < $nmbr$ % of predicted or age at diagnosis sl $nmbr$ years,C0005126;C0027430;C0042153;C0332152;C0439234;C0457083;C0681842;C0740175;C1828181;C1882327;C1947944;C2257086;C2344255;C3173302;C3669034;C3714541;C3844638;C4050145
352,medial - distal - diag,C0205098;C0205108;C0348026;C4522154
352,distal anastomosis ( % ),C0448964
352,distal,C0205108;C4522154
351,septal anomaly — no . ( % ),C0332447;C0442004;C1704258
351,e / e ' ( septal ),C0442004
350,mental status ( baseline spmsq scores )  n ( % ),C0168634;C0278060;C0369718;C0441922;C0449820;C1442488;C4050231
350,mental status,C0278060
350,mental component summary,C0229992;C0449432;C1552616;C1705248;C1706244
350,mental component score ( mcs ),C0229992;C0449432;C0449820;C1705248;C4050231
350,mental component,C0229992;C0449432;C1705248
350,mental,C0229992
350,mensa,
349,dermal,C0221928;C1522447
349,dental procedure,C0011331
348,bare metal stent  n ( % ),C2825200
348,bare metal stent,C2825200
348,bare metal,C0025552
348,bare - metal stent — no . ( % ),C2825200
348,bare - metal stent,C2825200
348,bare - metal,C0025552
348,all bare metal stents,C2825200
347,≥ $nmbr$ . $nmbr$ % and < $nmbr$ . $nmbr$ %,
347,seronegative ( rf - ve and acpa - ve ) subgroup,C0035448;C0042469;C0201660;C0521144;C0748398;C1079230;C1515021;C1525410;C1547111;C1706063;C3714652;C4321495
347,dopa and dopa derivativese,C0013023
346,propionic acid derivatives,C0033482;C0695274;C3540752
346,ethacrynic acid,C0014963
346,ampd $nmbr$,
346,acid,C0001128;C0202406
345,hazard ratiof ( $nmbr$ % ci ),C0008107;C0598697;C3259781
345,hazard ratiof,C0598697
345,hazard interaction,C0598697;C1704675
345,hazard inleraction,C0598697
345,hazard,C0598697
344,other ascvd  no . ( % ),C3665365
344,other ascvd,C3665365
344,oascvd,
344,no ascvd,C3665365
344,ascvd no prior ml,C0332152;C0439526;C1705224;C2826257;C3665365;C3887665
344,ascvd including tia,C0007787;C0332257;C0917805;C1054154;C3665365
344,ascvd as per protocol,C1698058;C3665365
344,ascvd * . n ( % ),C3665365
344,ascvd  n ( % ),C3665365
344,ascvd  b no . ( % ),C3665365
344,ascvd,C3665365
343,scd ( % ),
343,non - lad,C1518422
343,lad,
343,digoxin scd  no . ( % / y ),C0012265
342,sustained esrd  death due to kidney failure  or sustained decrease of > $nmbr$ % in egfr from baseline,C0011065;C0022661;C0035078;C0168634;C0392756;C0443318;C0547047;C0678226;C1306577;C1442488;C1739039;C2316810;C3811844;C3812682;C4082313;C4552775
342,or esrd,C0022661;C0035078;C2316810
342,esrd or death,C0011065;C0022661;C0035078;C1306577;C2316810;C4082313;C4552775
342,esrd on losartan ( % ),C0022661;C0035078;C0126174;C2316810
342,esrd *,C0022661;C0035078;C2316810
342,esrd ',C0022661;C0035078;C2316810
342,esrd,C0022661;C0035078;C2316810
342,erd *  n ( % ),
342,end - stage renal disease,C0022661;C2316810
342,composite of $nmbr$ % reduction in egfr  end - stage kidney disease  or death from renal causes,C0007465;C0022646;C0022661;C0205199;C0301630;C0392756;C1293152;C1547335;C1739039;C2316810;C3811844;C3812682;C4551656
341,gastroduodenum,C0391900
341,gastroduodenal,C0450199
340,women taking estrogen,C0014939;C0043210;C1515187;C2936882;C4542544
340,no estrogen,C0014939;C2936882;C4542544
340,estrogens,C0014939;C3537250;C3541386;C3714615
340,estrogen supplementation -,C0014939;C0242297;C2936882;C4542544
340,estrogen supplementation,C0014939;C0242297;C2936882;C4542544
340,estrogen ( ' % ? ),C0014939;C2936882;C4542544
340,estrogen,C0014939;C2936882;C4542544
339,us site of enrollment,C1516879;C1696073;C2945843;C3888021
339,time from symptom onset to enrollment,C0040223;C0449244;C1457887;C1516879;C1696073;C3541383;C3854129;C3888021;C4086878
339,time from hospital admission to enrollment,C0019994;C0040223;C1510665;C1516879;C1696073;C1959907;C3541383;C3888021
339,thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
339,symptom onset to enrollment,C1516879;C1696073;C3888021;C4086878
339,statin at enrollment,C0360714;C1516879;C1696073;C3888021
339,primary enrollment diagnoses  n ( % ),C0332137;C0801658;C1516879;C1696073;C3888021
339,pre - enrollment antihyperglycemic therapy,C0020616;C1516879;C1696073;C1882440;C3888021
339,other medications at enrollment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
339,medications at enrolment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
339,medications at enrollment  n ( % ) :,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
339,medication at enrollment — no . ( % ),C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
339,medication after enrolment,C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
339,loop at enrollment,C0445022;C1516879;C1696073;C3888021
339,hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
339,enrollment to randomization,C0034656;C1516879;C1696073;C3888021
339,enrollment in lmwh substudy,C0019139;C1516879;C1696073;C3536766;C3888021
339,enrollment in lmwh,C0019139;C1516879;C1696073;C3536766;C3888021
339,ace inhibitor at enrollment,C0003015;C1516879;C1696073;C3888021;C4541021
338,naproxen,C0027396
338,improved,C0184511;C0332272;C1561611;C4084203
338,ibuprofen,C0020740
337,western europe / australia / israel,C0004340;C0015176;C0022271;C0043128;C0043129
337,western europe / australia,C0004340;C0015176;C0043128;C0043129
337,western europe  israel  australia  or south africa,C0004340;C0015176;C0022271;C0037712;C0043128;C0043129
337,w europe,C0015176
337,w est europe,C0015176;C3811127;C3890902
337,w . europe,C0015176
337,region  europe,C0015176;C0017446;C0205147
337,non europe,C0015176;C1518422
337,geographic region - europe,C0015176;C0017446
337,europe n z $nmbr$,C0015176
337,europe i,C0015176;C0021966;C0221138
337,europe and canada,C0006823;C0015176
337,europe and australia,C0004340;C0015176
337,europe / lsrael,C0015176
337,europe ( zone $nmbr$ ),C0015176;C1710706
337,europe ( plus south africa ),C0015176;C0037712;C0332287
337,europe ( non - eu ),C0015176;C0015179;C1518422;C3665627
337,europe ( including south africa ),C0015176;C0037712;C0332257
337,europe ( eu ),C0015176;C0015179;C3665627
337,europe $nmbr$ ¶,C0015176
337,europe $nmbr$ +,C0015176
337,europe $nmbr$ ( n = $nmbr$ ),C0015176
337,europe $nmbr$ ( n = $nmbr$  $nmbr$ ),C0015176
337,europe $nmbr$,C0015176
337,europe  israel  or australia,C0004340;C0015176;C0022271
337,europe,C0015176
337,enrope + sonth afriea,
337,east europe,C0015176;C1707877
337,e europe,C0015176
337,e . europe,C0015176
336,stroke or see,C0038454;C0042789;C1947903;C4554100
336,stroke / see,C0038454;C0042789;C1947903;C4554100
336,stroke  see  or death,C0011065;C0038454;C0042789;C1306577;C1947903;C4082313;C4552775;C4554100
336,stroke  see  or cv death,C0011065;C0038454;C0042789;C1306577;C1947903;C3538987;C4048877;C4082313;C4318503;C4552775;C4554100
336,old stroke *,C1536121
336,ischemic stroke or see,C0042789;C0948008;C1947903
336,cvd / stroke / see,C0007222;C0038454;C0042789;C1947903;C4554100
335,unprovoked vte n ( % ),C0630906
335,unprovoked,
335,provoked,C1444748
334,nt - probnp values were reported in $nmbr$ of $nmbr$ patients enrolled in this stratum,C0042295;C0588446;C0669479;C0754710;C4684790
334,enrolled into osler,C4684790
334,> $nmbr$ enroll,
334,< $nmbr$ enroll,
333,diet controlled or no,C0743195
333,diet - controlled ( % ),C0743195
332,uncontrolled on oad ( s ),C0205318
332,uncontrolled on basal insulin,C0205318;C0650607
332,uncontrolled,C0205318
331,western europe  australia  new zealand  middle eai,C0043129;C0444598;C0549183;C1552826;C4289954
331,tertile $nmbr$ : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),
331,tertile $nmbr$ ( n = $nmbr$ ),
331,middle third,C0442050
331,middle tertile : > $nmbr$ . $nmbr$ to b $nmbr$ . $nmbr$,C0444598;C0549183;C1552826
331,middle tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C0444598;C0549183;C1514721;C1552826;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
331,middle,C0444598;C0549183;C1552826
331,$nmbr$ mgrdl,
330,other / multiple,C0439064
330,multiple tnfi and other bdmards §,C0439064
330,multiple tnfi *,C0439064
330,multiple diagnoses,C0011900;C0439064
330,multiple,C0439064
329,renal function  normal - mild,C0205307;C0231683;C0232804;C0439166;C2347086;C2945599;C4553972
329,normalfunction or mild impairment,C0221099;C0684336;C2945599
329,normal or mild ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205307;C0231683;C0439166;C2347086;C2945599;C3641331;C4553972
329,normal function or mild impairment,C0221099;C0684336;C2945599;C4296962
329,normal / mild ckd,C0205307;C0231683;C0439166;C1561643;C2347086;C2945599;C4553972
329,mildly impaired,C0221099;C0750532;C2945599
329,mild teaes,C2945599
329,mild impairment ( £ $nmbr$ to,C0221099;C0684336;C2945599
329,mild impairment ( egfr $nmbr$ – $nmbr$ )  n ( % ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
329,mild impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ ),C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C2945599;C3811844;C3812682
329,mild impairment ( egfr $nmbr$ - $nmbr$ ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
329,mild impairment ( $nmbr$ to < $nmbr$ ),C0221099;C0684336;C2945599
329,mild impairment ( $nmbr$ to $nmbr$ ml / min ),C0221099;C0439445;C0684336;C2945599
329,mild impairment  < $nmbr$ to < $nmbr$,C0221099;C0684336;C2945599
329,mild impairment,C0221099;C0684336;C2945599
329,mild ed severe ed,C0205082;C2945599;C3538926;C4050465;C4050466
329,mild ed,C2945599;C3538926
329,mild ( n = $nmbr$ ),C2945599
329,mild ( n $nmbr$ = $nmbr$ ) $nmbr$,C2945599
329,mild ( iief - ef $nmbr$ - $nmbr$ ),C2945599;C3641331
329,mild ( gold $nmbr$ ),C0018026;C1304897;C2945599
329,mild ( > $nmbr$ to < $nmbr$ ),C2945599
329,mild ( < $nmbr$ ),C2945599
329,mild ( $nmbr$ - $nmbr$ ),C2945599
329,mild,C2945599
329,< mild,C2945599
329,$nmbr$ - $nmbr$ ( mild ),C2945599
328,sustained mucosal healingc n / n ( % ),C0026724;C0443318
328,sustained mucosal healingc,C0026724;C0443318
328,mucosal healingf,C0026724
328,mucosal healingc n / n ( % ),C0026724
327,complete ulcer healing at week $nmbr$,C0205197;C0332174;C0333293;C0439230;C0725685;C3853530;C4283785
327,complete healinga,C0205197;C0725685;C3853530;C4283785
326,health habits,C0679786
326,health assessment questionnaire score,C2960025
326,headache,C0018681;C4553197
325,self - rated health status,C0018759;C0036588;C0871208;C1551994
325,mental health,C0025353
325,health practices,C0018684;C0237607;C3245512
325,general health ( self - reported ),C0424575;C0681906;C2700446;C4018875
325,general health  self - reported,C0424575;C0681906;C2700446;C4018875
325,general health,C0424575;C4018875
325,$nmbr$ mentis,
324,sudden death,C0011071;C1964022;C4554103
324,early death,C1836407
323,vascular death,C0005847;C0011065;C1306577;C1558950;C1801960;C4082313;C4552775
323,stroke deaths,C0011065;C0038454;C1306577;C4554100
323,s / se  mb or death,C0011065;C0024853;C0036919;C0565930;C1306577;C2603362;C4082313;C4552775
323,patients with pneumonia resulting in death  n ( % ),C0011065;C0030705;C0032285;C0332294;C1306577;C4082313;C4552775
323,or death,C0011065;C1306577;C4082313;C4552775
323,noncardiac death,C0011065;C1306577;C4082313;C4552775
323,non - cvd deaths,C0007222;C0011065;C1306577;C1518422
323,no . of deaths,C0011065;C1306577
323,net clinical benefit : cv death  mi  stroke  gusto moderate / severe bleeding,C0011065;C0019080;C0038454;C0205081;C0205082;C1306577;C1456447;C1881878;C3538987;C3810814;C3853572;C3887809;C3890893;C4048877;C4049705;C4049706;C4050465;C4050466;C4082313;C4085643;C4318503;C4321335;C4552775;C4554100;C4684590
323,malignancy death,C0006826;C0011065;C1306459;C1306577;C4082313;C4282132;C4552775
323,macce ( death  mi  stroke ),C0011065;C0038454;C1306577;C3810814;C4082313;C4552775;C4554100
323,leading to death,C0011065;C0332152;C1306577;C1522538;C4082313;C4552775
323,hf hospitalization or cardiovascular death,C0007226;C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3887460;C4082313;C4552775
323,hazard ratio for cardiovascular death,C0007226;C0011065;C1306577;C2985465;C3887460;C4082313;C4552775
323,exploratory cardiovascular and death outcomes,C0007226;C0011065;C1274040;C1306577;C3887460;C4082313;C4552775
323,drug discontinuation not due to death,C0011065;C0013227;C0457454;C0678226;C1254351;C1306577;C1444662;C1518422;C4082313;C4552775;C4552847
323,deaths  n ( % ),C0011065;C1306577
323,deaths,C0011065;C1306577
323,death or myocardial infarction,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
323,death or mi at $nmbr$ days,C0011065;C0439228;C1306577;C3810814;C4082313;C4552775
323,death or ich,C0011065;C0019191;C1306577;C3272597;C3281105;C4082313;C4552775
323,death from,C0011065;C1306577;C4082313;C4552775
323,death *,C0011065;C1306577;C4082313;C4552775
323,death ( all cause ),C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
323,death ( all - cause ),C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
323,death  n ( % ),C0011065;C1306577;C4082313;C4552775
323,death,C0011065;C1306577;C4082313;C4552775
323,dead ( n = $nmbr$ ),C0011065
323,data are reported as n ( % ) . event rates in parentheses are kaplan - meier estimates ( % ) at $nmbr$ year . * cardiovascular ( cv ) death  myocardial infarction ( mi )  or recurrent ischemia . † cv death  mi  or severe recurrent ischemia,C0007226;C0011065;C0022116;C0027051;C0205082;C0428953;C0439234;C0439508;C0441471;C0684224;C0700287;C0871208;C1306577;C1455761;C1511726;C1521828;C1720943;C2926063;C2945760;C3245479;C3538987;C3714741;C3810814;C3887460;C4019010;C4048877;C4050465;C4050466;C4082313;C4318503;C4319718;C4321499;C4552775;C4552959
323,cvd deaths,C0007222;C0011065;C1306577
323,cvd death,C0007222;C0011065;C1306577;C4082313;C4552775
323,cv death or ml,C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
323,cv death or hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
323,cv death or hf hospitalization n,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
323,cv death or hf hosp .,C0011065;C0018488;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
323,cv death n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
323,cv death / mi / stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
323,cv death / hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
323,cv death + hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
323,cv death  myocardial infarction  stroke,C0011065;C0027051;C0038454;C0428953;C1306577;C2926063;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4552959;C4554100
323,cv death  ml or ischemic stroke,C0011065;C0439526;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
323,cv death  ml  or stroke,C0011065;C0038454;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775;C4554100
323,cv death  ml  ischemic stroke  hospitalization for unstable angina  revascularization or heart failure,C0002965;C0011065;C0018801;C0018802;C0019993;C0439526;C0581603;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775;C4554158
323,cv death  mi  stroke  recurrent ischemia,C0011065;C0022116;C0038454;C1306577;C1455761;C2945760;C3538987;C3810814;C4048877;C4082313;C4318503;C4321499;C4552775;C4554100
323,cv death  mi  stroke  or urgent coronary revascularization,C0011065;C0038454;C0439609;C0877341;C1306577;C3272275;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
323,cv death  mi  stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
323,cv death  mi  or stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
323,cv death  mi  or ischemic stroke,C0011065;C0948008;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
323,cv death  mi  ischemic stroke  hospitalization for hf  coronary revascularization  ua,C0011065;C0018488;C0019993;C0041580;C0042014;C0376297;C0581603;C0877341;C0948008;C1306577;C1313497;C1538440;C3273279;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
323,cv death  mi  ischemic stroke,C0011065;C0948008;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
323,cv death,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
323,composite of death / mi / urg ent revasc,C0011065;C0205199;C0378365;C0919420;C1306577;C1367721;C1547335;C1705448;C3810814;C3889152;C4082313;C4552775
323,cardiovascular death ®,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
323,cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775
323,cardiovascular death or heart failure hospitalization,C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775
323,cardiovascular death and hospital admission for heart failure,C0007226;C0011065;C0018801;C0018802;C0184666;C1306577;C3887460;C4082313;C4552775;C4554158
323,cardiovascular death / myocardial infarction / stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
323,cardiovascular death *,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
323,cardiovascular death ( n = $nmbr$ ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
323,cardiovascular death !,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
323,cardiovascular death  nonfatal myocardial infarction  or nonfatal stroke,C0007226;C0011065;C0027051;C0038454;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959;C4554100
323,cardiovascular death  myocardial infarction  or stroke,C0007226;C0011065;C0027051;C0038454;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959;C4554100
323,cardiovascular death  mi  or stroke,C0007226;C0011065;C0038454;C1306577;C3810814;C3887460;C4082313;C4552775;C4554100
323,cardiovascular death,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
323,any death,C0011065;C1306577;C4082313;C4552775
323,all death,C0011065;C1306577;C4082313;C4552775
323,all - cause death n,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
323,all - cause death / stroke / see,C0011065;C0015127;C0038454;C0042789;C1306577;C1524003;C1947903;C4082313;C4552775;C4554100
323,all - cause death,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
323,a cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775
322,severe / moderate,C1299393
322,pfo with mild - to - moderate shunt and atrial septal aneurysm,C0232180;C0521533;C0542331;C1299392;C1442858
322,moderate - to - severe copd exacerbation,C0740304;C1299393
322,mild to moderate,C1299392
322,mild - < moderate,C1299392
322,gusto severe / moderate,C1299393
321,severe or moderate,C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
321,renal function  moderate,C0205081;C0232804;C1881878;C4049705;C4049706;C4085643;C4321335
321,pedal edema  slight / moderate / marked,C0205081;C0522501;C0574002;C1706089;C1881878;C2937276;C2945599;C4049705;C4049706;C4050469;C4085643;C4321335
321,patients with moderate - to - severe pain ( womac pain score  $nmbr$ - $nmbr$ ),C0030705;C0205081;C0205082;C0278140;C0449820;C0582148;C1881878;C4049705;C4049706;C4050231;C4050465;C4050466;C4085643;C4321335;C4521229
321,moderatez,
321,moderatey,
321,moderately impaired,C0205081;C0221099;C1881878;C4085643;C4321491
321,moderate ’,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate severity,C0205081;C0439793;C0522510;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate severe ( n = $nmbr$ ) ( n = $nmbr$ ),C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
321,moderate risk ( $nmbr$ - $nmbr$ ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
321,moderate risk,C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
321,moderate or severe impairment,C0205081;C0205082;C0221099;C0684336;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
321,moderate or severe copd exacerbations,C0205081;C0205082;C0740304;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
321,moderate or less airflow limitation,C0205081;C0231999;C0439092;C0443288;C0449295;C0547044;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate n z $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate impairment ( $nmbr$ to < $nmbr$ ),C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate impairment ( $nmbr$ to $nmbr$ ml / min ),C0205081;C0221099;C0439445;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate impairment  < $nmbr$ to < $nmbr$,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate impairment,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate disease activity : > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$  n ( % ),C0012634;C0205081;C1292728;C1513375;C1881878;C3833417;C4049705;C4049706;C4085643;C4321335
321,moderate disease,C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate copdb [ n z $nmbr$ ],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate copd,C0024117;C0205081;C1412502;C1881878;C3714496;C4049705;C4049706;C4085643;C4321335
321,moderate chronic kidney disease,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335;C4553188
321,moderate - to -,C0040363;C0041260;C0205081;C1881878;C1883351;C4049705;C4049706;C4085643;C4321335
321,moderate - < severe,C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
321,moderate ( s $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate ( n = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate ( n $nmbr$ = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
321,moderate ( iief - ef $nmbr$ - $nmbr$ ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
321,moderate ( > $nmbr$ to < $nmbr$ ),C0040363;C0041260;C0205081;C1881878;C1883351;C4049705;C4049706;C4085643;C4321335
321,moderate ( > $nmbr$ and < $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate ( > $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205081;C0369637;C0439445;C0441923;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate ( $nmbr$ risk factor ),C0035648;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate ( $nmbr$ - $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate ( $nmbr$ % < fev  < $nmbr$ % predicted ),C0205081;C0681842;C1881878;C1882327;C3714541;C4049705;C4049706;C4085643;C4321335
321,moderate ( $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate  n ( % ) a,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,mild or moderate copd,C0024117;C0205081;C1412502;C1881878;C2945599;C3714496;C4049705;C4049706;C4085643;C4321335
321,gusto moderate or severe bleeding,C0019080;C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
321,gusto moderate or severe,C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
321,gusto moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,death  mi  idr  st  or gusto moderate / severe bleeding,C0011065;C0019080;C0036056;C0205081;C0205082;C1306577;C1881878;C3272372;C3810814;C4049705;C4049706;C4050465;C4050466;C4082313;C4085643;C4321335;C4552775
321,> $nmbr$ - $nmbr$ ( moderate risk ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
321,< $nmbr$ and no moderate or severe deformity ( n = $nmbr$ ),C0000768;C0205081;C0205082;C0221430;C0302142;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
321,$nmbr$ - $nmbr$ ( moderate ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
321,$nmbr$ ( moderate disease ),C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
320,renal disease ),C0022658
320,renal disease,C0022658
320,previous renal disease  n ( % ),C0022658;C0205156;C1552607
320,nephropathy,C0022658
320,established renal disease *,C0022658;C0443211;C1272684
320,contrast nephropathy risk score,C0009924;C0022658;C0035647;C0449820;C1979874;C4050231;C4552904
320,albuminuria and previous maerovaseular disease without established renal disease,C0001925;C0012634;C0022658;C0205156;C0443211;C1272684;C1552607
319,respiratory - related ^,C0439849;C0445223;C0521346;C1546767
319,ipf - related,C0034069;C0439849;C0445223;C1800706
319,infarct - related vessel ( % ),C0005847;C0021308;C0439849;C0445223
319,hospitalisation related to exacerbation  n ( % ),C0019993;C0439849;C0445223;C4086268
319,history of asthma - related intubation — no . ( % ),C0021925;C0439849;C0445223;C0455544
319,bph - related health status,C0005001;C0018759;C0439849;C0445223;C1704272
319,asthma - related health -,C0004096;C0018684;C0439849;C0445223;C2984299
318,vte / vte - related deathsb  n / n ( % ),C0439849;C0445223;C0630906
318,vte / vte - related deathsa  n / n ( % ),C0439849;C0445223;C0630906
318,deathsb,
318,any vte or vte - related death — no . ( % ),C0425043;C0630906
318,any vte - related death,C0425043;C0630906
317,delighted,C3830544
317,delayed reaction,C0205421;C0443286;C1545665;C3272602
317,delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
317,delayed - start group ( n = $nmbr$ ),C0205421;C0439659;C0441848;C1545665;C3272602
317,delayed - eptifibatide group ( n = $nmbr$ ),C0205421;C0253563;C0441848;C1545665;C3272602
317,delayed,C0205421;C1545665;C3272602
317,$nmbr$ mg / day early - start - delayed start,C0205421;C0439422;C0439659;C1279919;C1545665;C3272602
317,$nmbr$ mg / day early - start - delayed - start,C0205421;C0439422;C0439659;C1279919;C1545665;C3272602
317,$nmbr$ mg / day delayed - start,C0205421;C0439422;C0439659;C1545665;C3272602
316,smoking ( ever ),C0037369;C0453996;C1881674
316,never smoking,C0037369;C0453996;C1881674;C2003901
316,never drink,C0452428;C2003901
316,never,C2003901
316,ever,
315,vka naxve,
315,vka naive  n ( % ),
315,vka naive,
315,uncover - $nmbr$,
315,rarely / never,C4035880
315,never been on a vka,C2003901
315,ever been on a vka,
314,triglyceride level,C0428475
314,doubling of creatinine level,C0205173;C0428279;C1705764
314,creatinine level,C0428279
314,calcium level,C0201925;C0428302
313,severely impaired,C0205082;C0221099
313,severe to end - stage impairment ( $nmbr$ ml / min ),C0205082;C0205088;C0221099;C0439445;C0684336;C4050465;C4050466
313,severe teaes,C0205082;C4050465;C4050466
313,severe or worse airflow limitation,C0205082;C0231999;C0332271;C0443288;C0449295;C1279889;C1457868;C4050465;C4050466
313,severe oab subgroup,C0205082;C1079230;C1515021;C4050465;C4050466
313,severe n z $nmbr$,C0205082;C4050465;C4050466
313,severe impairment ( egfr < $nmbr$ ml / min / m ^ ),C0205082;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
313,severe impairment ( egfr < $nmbr$ )  n ( % ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
313,severe impairment ( egfr < $nmbr$ ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
313,severe impairment ( < $nmbr$ ),C0205082;C0221099;C0684336;C4050465;C4050466
313,severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
313,severe hyperkalemiac,C0205082;C4050465;C4050466
313,severe hyperkalemia ‘ s,C0020461;C0205082;C4050465;C4050466;C4552983
313,severe hyperkalemia ' s,C0020461;C0205082;C4050465;C4050466;C4552983
313,severe exacerbations,C0205082;C4050465;C4050466;C4086268
313,severe ed,C0205082;C3538926;C4050465;C4050466
313,severe copdc [ n z $nmbr$ ],C0205082;C4050465;C4050466
313,severe copd,C0024117;C0205082;C1412502;C3714496;C4050465;C4050466
313,severe aes,C0205082;C1412268;C2699274;C4050465;C4050466
313,severe / very severea,C0205082;C0442824;C2984081;C4050465;C4050466
313,severe / lite threatening,C0205082;C4050465;C4050466
313,severe / life ttireatening,C0205082;C0376558;C4050465;C4050466
313,severe / life threatening,C0205082;C1546953;C2826244;C3537125;C4050465;C4050466
313,severe - very severe,C0205082;C0442824;C2984081;C4050465;C4050466
313,severe ( n $nmbr$ = $nmbr$ ),C0205082;C4050465;C4050466
313,severe ( itt ) ( n = $nmbr$ ),C0205082;C4050465;C4050466
313,severe ( iief - ef < $nmbr$ ),C0205082;C3641331;C4050465;C4050466
313,severe ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205082;C3641331;C4050465;C4050466
313,severe ( > $nmbr$ ),C0205082;C4050465;C4050466
313,severe ( < $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205082;C0369637;C0439445;C0441923;C4050465;C4050466
313,severe  n ( % ) b,C0205082;C4050465;C4050466
313,severe,C0205082;C4050465;C4050466
313,risk of moderate / severe exacerbations,C0205082;C0332166;C4050465;C4050466;C4086268
313,renal function  severe,C0205082;C0232804;C4050465;C4050466
313,patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode of severe hypoglycemia *,C0017853;C0020615;C0030705;C0205082;C0332189;C4050465;C4050466;C4553659
313,patients with glycated hemoglobin < $nmbr$ . $nmbr$ % and no severe hypoglycemia or diabetic ketoacidosis,C0011880;C0017853;C0020615;C0030705;C0205082;C4050465;C4050466;C4553659
313,or severe,C0205082;C4050465;C4050466
313,no severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
313,no . of moderate or severe exacerbations in previous,C0205081;C0205082;C0205156;C1552607;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335
313,more severe ^,C0205082;C0205172;C4050465;C4050466
313,more severe,C0205082;C0205172;C4050465;C4050466
313,moderate or severe decrease in gfr { < $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0017654;C0205081;C0205082;C0369637;C0392756;C0439526;C0441923;C0547047;C1417190;C1424601;C1705224;C1881878;C3815103;C3887665;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
313,moderate / severe exacerbations  patient subgroups  n ( % ),C0030705;C0205081;C0205082;C1079230;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335
313,moderate / severe exacerbation,C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335
313,less severe $nmbr$,C0205082;C0439092;C0547044;C4050465;C4050466
313,less severe,C0205082;C0439092;C0547044;C4050465;C4050466
313,gusto severe or,C0205082;C4050465;C4050466
313,gusto severe,C0205082;C4050465;C4050466
313,gusto moderate / severe bleeding,C0019080;C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
313,gusto moderate / severe,C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
313,grade $nmbr$ ( severe copd )  n ( % ),C0024117;C0205082;C0441800;C0919553;C1412502;C3244287;C3714496;C4050465;C4050466
313,first severe asthma exacerbation,C0205082;C0205435;C0349790;C0581126;C1279901;C4050465;C4050466;C4086268
313,death / mi / idr / st / gusto - defined moderate or severe bleeding,C0011065;C0019080;C0036056;C0205081;C0205082;C1306577;C1704788;C1881878;C3272372;C3539106;C3810814;C4049705;C4049706;C4050465;C4050466;C4082313;C4085643;C4321335;C4552775
313,a severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
313,$nmbr$ - $nmbr$ ( severe ),C0205082;C4050465;C4050466
312,type of vessel involved,C1282017;C1314939
312,nail involvement  %,C0027342;C1314939;C1432728;C3538766
312,involved gastrointestinal,C0521362;C1314939
312,gastrointestinal area involved  n / total n ( % ),C0017446;C0205146;C0369718;C0439175;C0439810;C0441922;C0521362;C1314939
312,dip involvement  ! n ( % ),C1314939;C3539618
311,no . ( % ) of patients with ≥ $nmbr$ % bsa affected,C0030705;C0392760;C1314939
311,mean involved bsa  % ( $nmbr$ % ci ),C0008107;C0444504;C1314939;C2347634;C2348143;C3259781
311,bsa involved  % $nmbr$,C1314939
311,bsa affected  mean ± sd  %,C0392760;C0444504;C1314939;C2347634;C2348143;C2699239
311,bsa affected  %,C0392760;C1314939
-10,ttf - fv,C1332112;C1705840;C4087167
309,op  vfx,
309,op  no vfx,
309,no op  vfx,
309,no op  no vfx,
309,and vfx status,C0449438
309,> - $nmbr$ . $nmbr$ - vfx,
309,> - $nmbr$ . $nmbr$ + vfx,
309,< - $nmbr$ . $nmbr$ - vfx,
309,< - $nmbr$ . $nmbr$ + vfx,
308,— b - h —,C0033727;C0369286;C0441932;C0564385;C4528284
308,within $nmbr$ h after,C0033727;C0369286;C0441932;C0564385;C4528284
308,within $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
308,use of h $nmbr$ bloekers  n ( % ),C0033727;C0369286;C0441932;C0564385;C1524063;C4528284
308,urgency episodes / $nmbr$ h,C0033727;C0332189;C0369286;C0439609;C0441932;C0564385;C4528284
308,time to randomization ( h ),C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C3541383;C4528284
308,time sample drawn ( h ),C0033727;C0040223;C0369286;C0370003;C0441932;C0564385;C2347026;C3541383;C4528284
308,time from symptoms to randomization  h,C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C0683368;C1457887;C3541383;C4528284
308,time from onset to randomization  h  mean ± sd,C0033727;C0034656;C0369286;C0441932;C0444504;C0449244;C0564385;C2347634;C2348143;C2699239;C4528284
308,time from onset to medication  h  mean ± sd,C0013227;C0033727;C0369286;C0441932;C0444504;C0449244;C0564385;C2347634;C2348143;C2699239;C3244316;C4284232;C4528284
308,symptom onset to pci  h,C0033727;C0369286;C0441932;C0564385;C4049621;C4086878;C4528284
308,ptca < $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C2936173;C4528284
308,non - cabg related bleeding at $nmbr$ h,C0010055;C0019080;C0033727;C0369286;C0439849;C0441932;C0445223;C0564385;C1518422;C4528284
308,nocturia episodes / $nmbr$ h,C0028734;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
308,migraine duration ( h ),C0033727;C0149931;C0369286;C0441932;C0449238;C0564385;C2926735;C4528284
308,micturitions / $nmbr$ h,C0033727;C0042034;C0369286;C0441932;C0564385;C4528284
308,incontinence episodes / $nmbr$ h,C0021167;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
308,i - h,C0021966;C0033727;C0221138;C0369286;C0441932;C0564385;C4528284
308,h,C0033727;C0369286;C0441932;C0564385;C4528284
308,fev auc i $nmbr$ h,C0021966;C0033727;C0221138;C0369286;C0376690;C0441932;C0564385;C3714541;C4528284
308,fev $nmbr$ auc $nmbr$ mine $nmbr$ h,C0033727;C0369286;C0376690;C0441932;C0564385;C3714541;C4528284
308,duration of symptoms  h,C0033727;C0369286;C0436359;C0441932;C0564385;C4528284
308,b + h ( n = $nmbr$ ),C0033727;C0369286;C0441932;C0564385;C4528284
308,> = $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
308,> $nmbr$ to < $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
308,> $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
308,> $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
308,< $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
308,< $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
308,$nmbr$ — e - h,C0033727;C0369286;C0441932;C0564385;C4528284
308,$nmbr$ to < $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
308,$nmbr$ . $nmbr$ f $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ h,C0016327;C0033727;C0369286;C0441932;C0564385;C4528284
308,$nmbr$ - $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
307,〉 $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
307,≥ $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,≥ $nmbr$ ml / min,C0439445
307,• ? sd ml / min,C0439445;C2699239
307,£ $nmbr$ ml / min,C0439445
307,stage i ( gfr > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) and stage v ( gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) were not considered because they included only $nmbr$ and $nmbr$ patient  respectively . chf  congestive,C0007591;C0017654;C0018802;C0021966;C0023806;C0030705;C0205171;C0221138;C0332257;C0369637;C0439445;C0441766;C0441777;C0441923;C0456533;C0702093;C0742742;C0750591;C1424601;C1518422;C1524029;C1720467;C3813700
307,stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml / min ( n = $nmbr$ ),C0205390;C0439445;C1300072;C1306673;C1561643;C1739039;C3811844;C3812682
307,stage $nmbr$ : > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
307,stage $nmbr$ : < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
307,stage $nmbr$ : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
307,s $nmbr$ ml / min,C0439445;C0565930;C2603362
307,renal impairment ( crcl < $nmbr$ ml / min ),C0439445;C1565489;C1846718
307,renal function < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,renal function ( ml / min ),C0232804;C0439445
307,renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  according to mdrd )  n ( % ),C0232804;C0369637;C0439445;C0441923;C0680240;C1739039;C3811844;C3812682;C3839656
307,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C0030705;C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
307,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,patients with egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C0030705;C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
307,patients with egfr $nmbr$ > $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,outcome according to renal function level ( in ml / min ),C0022646;C0232804;C0439445;C0441889;C0456079;C0680240;C0935587;C1274040;C1547707;C2946261
307,normal or increased baseline gfr ( > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0168634;C0205217;C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C0442805;C1424601;C1442488;C2347086;C4553972
307,normal or high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to low egfr ( < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0168634;C0205250;C0205251;C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C1299351;C1442488;C1550472;C1739039;C2347086;C2700149;C3811844;C3812682;C3887512;C3889660;C3890211;C4048187;C4321237;C4321351;C4522209;C4522223;C4553972
307,normal function ( crcl > $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C4296962
307,moderate or severe decrease in gfr ( < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0205081;C0205082;C0369637;C0392756;C0439445;C0441923;C0547047;C1424601;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
307,mildlydecreased baseline gfr ( $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
307,mild or no dysfunction ( crcl > $nmbr$ ml / min  n = $nmbr$ $nmbr$  [ $nmbr$ . $nmbr$ % ] ),C0031847;C0277785;C0439445;C1846718;C2945599;C3887504;C3887505
307,mild dysfunction ( crcl > $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C3274775
307,mild decrease ( $nmbr$ - < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0392756;C0439445;C0441923;C0547047;C2945599
307,mild ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0369637;C0439445;C0441923;C2945599
307,median — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193
307,median — ml / min,C0439445;C0549183;C0876920;C2347635;C2348144;C2939193
307,median crcl — ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
307,mean ± sd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
307,mean ( sd ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
307,mean ( s . d . ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C3811844;C3812682
307,mdrd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
307,mdrd - egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
307,interquartile range — ml / min,C0439445;C1711350
307,greater than or equal to $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0205163;C0369637;C0439093;C0439445;C0441923
307,gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C1424601
307,gfr ( ml / min per $nmbr$ . $nmbr$ nr ),C0017654;C0027496;C0439445;C1424601;C3844738
307,gfr ( mdrd ) ( ml / min / $nmbr$ - $nmbr$ m $nmbr$ ),C0017654;C0369637;C0439445;C0441923;C1424601;C3839656
307,estimated gfr — ml / min / $nmbr$ . $nmbr$ m ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
307,estimated gfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
307,estimated gfr at baseline  ml • min $nmbr$,C0017654;C0168634;C0439445;C0750572;C1424601;C1442488
307,estimated gfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
307,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
307,estimated gfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
307,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) lipid baseline lipid profile,C0017654;C0023779;C0168634;C0369637;C0439445;C0441923;C0750572;C1424601;C1442488;C1979963;C2003903
307,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
307,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
307,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
307,estimated gfr  ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$ ( sd ) a,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601;C2699239
307,estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$   of body - surface area,C0017446;C0017654;C0205146;C0369637;C0439445;C0441923;C0489451;C0750572;C1424601
307,estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
307,estimated gfr  ml / min,C0017654;C0439445;C0750572;C1424601
307,estimated gfr  < $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$  n ( % ) a,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
307,estimated creatinine clearance — ml / min §,C0439445;C0750572;C0812399
307,estimated creatinine clearance — ml / min  i,C0021966;C0023806;C0221138;C0439445;C0702093;C0750572;C0812399;C1524029;C3813700
307,estimated creatinine clearance < $nmbr$ ml / min *,C0439445;C0750572;C0812399
307,estimated creatinine clearance ( ml / min ),C0439445;C0750572;C0812399
307,egfrmdrd ， ml - min - $nmbr$ - $nmbr$ . $nmbr$ m_ $nmbr$,C0369637;C0439445;C0441923
307,egfrmdrd < $nmbr$ ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$  n ( % ),C0369637;C0439445;C0441923
307,egfrmdrd  ml / min / $nmbr$ . $nmbr$ m $nmbr$ bsa,C0369637;C0439445;C0441923
307,egfrmdrd  ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$,C0369637;C0439445;C0441923
307,egfr — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr — ml / min / $nmbr$ . $nmbr$ m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr £ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr via mdrd ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
307,egfr in ml / min / $nmbr$ . $nmbr$ m ^  median ( iqr ),C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
307,egfr from the mdrd equation ( sd )  ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C0369637;C0439445;C0441923;C0552449;C1739039;C2699239;C3811844;C3812682;C3839656
307,egfr crcl ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
307,egfr crcl < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
307,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  mean [ se ] ),C0036919;C0071744;C0369637;C0439445;C0441923;C0444504;C1413772;C1739039;C2347634;C2348143;C3811844;C3812682
307,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] ),C0036919;C0071744;C0369637;C0439445;C0441923;C1413772;C1739039;C2986759;C3811844;C3812682
307,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0010294;C0369637;C0439445;C0441923;C1561535;C1739039;C3811844;C3812682
307,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] ),C0010294;C0036919;C0369637;C0439445;C0441923;C1561535;C1739039;C2986759;C3811844;C3812682
307,egfr at baseline  $nmbr$ ml / min ( % ) b,C0168634;C0439445;C1442488;C1739039;C3811844;C3812682
307,egfr > = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
307,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr > $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr > $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
307,egfr > $nmbr$ ml / min,C0439445;C1739039;C3811844;C3812682
307,egfr > $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
307,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
307,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
307,egfr < $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr < $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
307,egfr < $nmbr$ ml / min,C0439445;C1739039;C3811844;C3812682
307,egfr < $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr < $nmbr$  ml / min / m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr +  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mean ± sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
307,egfr ( ml / min per $nmbr$ - $nmbr$ m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ) t,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ [ mdrdequation ] ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
307,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr ( ml / min / $nmbr$ - $nmbr$ mz ),C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
307,egfr ( ml / min ),C0439445;C1739039;C3811844;C3812682
307,egfr ( median  iqr )  ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
307,egfr ( mdrd )  ml min − $nmbr$ $nmbr$ . $nmbr$   m − $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
307,egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
307,egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
307,egfr ( ckd - epi  cystatinc )  ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0162734;C0369637;C0439445;C0441923;C1561643;C1739039;C3811844;C3812682;C4281721
307,egfr ( ckd - epi  cystatin c )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0071744;C0162734;C0369637;C0439445;C0441923;C1413772;C1561643;C1739039;C3811844;C3812682;C4281721
307,egfr $nmbr$ – $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ’,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
307,egfr $nmbr$ to < $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
307,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
307,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr  ml min $nmbr$ $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
307,egfr  ml / min / m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr  ml / min / bsa,C0439445;C1739039;C3811844;C3812682
307,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( sd ),C0369637;C0439445;C0441923;C1739039;C2699239;C3811844;C3812682
307,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682;C3839656
307,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
307,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ± sd,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
307,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
307,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr  ml / min ( mdrd ),C0439445;C1739039;C3811844;C3812682;C3839656
307,egfr  ml / min,C0439445;C1739039;C3811844;C3812682
307,egfr  median ( sd )  ml / min,C0439445;C0549183;C0876920;C1739039;C2347635;C2348144;C2699239;C2939193;C3811844;C3812682
307,egfr  mean = sd  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
307,egfr  mean ( sd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
307,egfr  * ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,ecrcl < $nmbr$ ml / min,C0439445
307,ecrcl  ml / min,C0439445
307,ecfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C0369637;C0439445;C0441923
307,ecfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,creatinine clearance — ml / min,C0439445;C0812399
307,creatinine clearance < $nmbr$ ml / min ( % ),C0439445;C0812399
307,creatinine clearance < $nmbr$ ml / min,C0439445;C0812399
307,creatinine clearance ( ml / min )  mean ± sd,C0439445;C0444504;C0812399;C2347634;C2348143;C2699239
307,creatinine clearance ( ml / min ),C0439445;C0812399
307,creatinine clearance  ml / min - $nmbr$ *,C0439445;C0812399
307,creatinine clearance  ml / min,C0439445;C0812399
307,creatine clearance  ml / min,C0373595;C0439445
307,creat clearance > $nmbr$ ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
307,creat clearance < $nmbr$ ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
307,crcl of $nmbr$ - $nmbr$ ml min '  n ( % ),C0439445;C1846718
307,crcl at randomization - ml / min,C0034656;C0439445;C1846718
307,crcl at randomization  ml / min,C0034656;C0439445;C1846718
307,crcl at baseline < $nmbr$ ml / min,C0168634;C0439445;C1442488;C1846718
307,crcl at baseline  ml / min,C0168634;C0439445;C1442488;C1846718
307,crcl > $nmbr$ ml / min,C0439445;C1846718
307,crcl > $nmbr$ - < $nmbr$ ml / min,C0439445;C1846718
307,crcl < $nmbr$ ml / min,C0439445;C1846718
307,crcl ( sd ) ml / min,C0439445;C1846718;C2699239
307,crcl ( ml / min ) at randomization,C0034656;C0439445;C1846718
307,crcl ( ml / min ),C0439445;C1846718
307,crcl  ml / min mean ( sd ),C0439445;C0444504;C1846718;C2347634;C2348143;C2699239
307,crcl  ml / min,C0439445;C1846718
307,crcl  median ( iqr )  ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
307,crcl  mean  ml / min ( ± sd ),C0439445;C0444504;C1846718;C2347634;C2348143;C2699239
307,chronic kidney disease stage : egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0007591;C0439445;C0456533;C1561643;C1739039;C3811844;C3812682;C4553188
307,cgfrby ckd - epi  ml / min / $nmbr$ . $nmbr$ m $nmbr$  median ( iqr ),C0162734;C0369637;C0439445;C0441923;C0549183;C0876920;C1561643;C2347635;C2348144;C2939193;C4281721
307,cgfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,baseline gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
307,baseline gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
307,baseline egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
307,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ c,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
307,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
307,baseline egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
307,baseline ecrq $nmbr$ $nmbr$ to < $nmbr$ ml / min,C0168634;C0439445;C1442488
307,baseline crcl  ml / min,C0168634;C0439445;C1442488;C1846718
307,baseline ckd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
307,^ $nmbr$ ml / min,C0439445
307,> l : $nmbr$ hrs : min ( n = $nmbr$ ),C0439393;C1568891
307,> = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,> = $nmbr$ l_ / min,C0439393
307,> = $nmbr$ l / min,C0439393
307,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
307,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,> $nmbr$ to < $nmbr$ ml / min,C0439445
307,> $nmbr$ to < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C0040363;C0041260;C0369637;C0439445;C0441923;C1739039;C1883351;C3811844;C3812682
307,> $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C0369637;C0439445;C0441923
307,> $nmbr$ ml min ) $nmbr$,C0439445
307,> $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
307,> $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
307,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,> $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445
307,> $nmbr$ ml / min ( n = $nmbr$ ),C0439445
307,> $nmbr$ ml / min,C0439445
307,> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
307,< = $nmbr$ ml / min,C0439445
307,< $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m  $nmbr$,C0369637;C0439445;C0441923
307,< $nmbr$ ml / min — %,C0439445
307,< $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
307,< $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
307,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,< $nmbr$ ml / min / $nmbr$  $nmbr$ m ^,C0369637;C0439445;C0441923
307,< $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,< $nmbr$ ml / min ( n = $nmbr$ ),C0439445
307,< $nmbr$ ml / min,C0439445
307,< $nmbr$ l / min,C0439393
307,< $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,( $nmbr$ - $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
307,( $ $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
307,(  $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
307,$nmbr$ – ≤ $nmbr$ ml / min,C0439445
307,$nmbr$ – < $nmbr$ ml / min,C0439445
307,$nmbr$ to o $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0483204
307,$nmbr$ to < $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C0369637;C0439445;C0441923
307,$nmbr$ to < $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
307,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
307,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,$nmbr$ to < $nmbr$ ml / min / $nmbr$ - $nmbr$,C0439445
307,$nmbr$ to < $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,$nmbr$ to < $nmbr$ ml / min ( n = $nmbr$ $nmbr$ ),C0439445
307,$nmbr$ to < $nmbr$ ml / min,C0439445
307,$nmbr$ to $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
307,$nmbr$ ml / min,C0439445
307,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,$nmbr$ - < $nmbr$ ml / min,C0439445
307,$nmbr$ - $nmbr$ ml min ) $nmbr$,C0439445
307,$nmbr$ - $nmbr$ ml min  $nmbr$,C0439445
307,$nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
307,$nmbr$ - $nmbr$ ml / min,C0439445
307,$nmbr$ - $nmbr$ ( < $nmbr$ ml / min ),C0439445
307,$nmbr$ ( $nmbr$ to < $nmbr$ ml / min ),C0439445
307,$nmbr$ ( $ $nmbr$ ml / min ),C0439445
306,women men,C0025266;C0043210
306,sex ( women  men ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
306,sex ( men / women ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
306,sex  men / women  %,C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
306,sex  men ( % ),C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
306,ratio of women to men — %,C0025266;C0043210;C0456603;C1547037
306,p ( women vs men ),C0025266;C0043210;C0369773;C2603361
306,p $nmbr$ interaction women vs men,C0025266;C0043210;C0369773;C1704675;C2603361
306,no of events women men *,C0025266;C0043210;C0441471;C3541888
306,no . men,C0025266
306,ment,C0084844;C1538994
306,men without ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0025266;C3538926
306,men with ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0025266;C3538926
306,men : women ( % ),C0025266;C0043210
306,men : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0025266;C0439269;C1532563
306,men / women,C0025266;C0043210
306,men ( n 二 $nmbr$ ),C0025266
306,men ( n [ % ] ),C0025266
306,men ( n = $nmbr$ vs $nmbr$ ),C0025266
306,men ( n = $nmbr$ )  n / n ( % ),C0025266
306,men ( n = $nmbr$ ),C0025266
306,men ( n = $nmbr$ $nmbr$ ),C0025266
306,men ( n  % ),C0025266
306,men ( % ),C0025266
306,men    n   ( % ),C0025266
306,men  total ( n 二 $nmbr$ ),C0025266;C0439175;C0439810
306,men  total ( n = $nmbr$ ),C0025266;C0439175;C0439810
306,men  no . ( % ),C0025266
306,men  n ( % ) *,C0025266
306,men  n ( % ),C0025266
306,men  > $nmbr$ cm,C0025266
306,men  < $nmbr$ cm,C0025266
306,men  %,C0025266
306,men,C0025266
306,low hdl - c ( for men < $nmbr$   mg / dl / for women < $nmbr$   mg / dl ),C0025266;C0043210;C0151691;C0439269
306,high hdl - c ( for men ≥ $nmbr$   mg / dl / for women ≥ $nmbr$   mg / dl ),C0025266;C0043210;C0205250;C0439269;C1299351;C2700149;C3715113;C3887512;C3889660;C4321237;C4522209
306,hemoglobin ( < $nmbr$ men  ， : : $nmbr$ women ),C0019046;C0025266;C0043210
306,hdl < $nmbr$ / $nmbr$ mg / dl ( $nmbr$ . $nmbr$ / $nmbr$ . $nmbr$ mmol / l ) for men / women,C0025266;C0043210;C3642216;C3715113;C3898312
306,gmi ( men ),C0025266
306,gender    n   ( % men ),C0025266;C0079399;C1522384
306,chd men,C0025266;C0280604;C3542407
306,chd + cerebrovascular disease men $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0007820;C0025266;C0280604;C3542407
306,all men,C0025266
306,( _ > $nmbr$ . $nmbr$ mmol / l ) hdl - c women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ) men : < $nmbr$ mg / dl,C0025266;C0043210;C3539687;C3715113;C3898312
306,$nmbr$ - $nmbr$ ( men ),C0025266
305,smmse < $nmbr$,
305,smmse,
305,mmse score *,C0449820;C0451306;C4050231
305,mmse score,C0449820;C0451306;C4050231
305,mmse > $nmbr$,C0451306
305,mmse = mini - mental state examination  adas — cog = alzhei -,C0451306;C3539026
305,mmse < $nmbr$,C0451306
305,mmse ( points ),C0451306;C1552961;C2347617;C3714763
305,mmse $nmbr$ - $nmbr$,C0451306
305,mini - mental state examination  mean ( sd ) d,C0444504;C0451306;C2347634;C2348143;C2699239
305,mini - mental state examination,C0451306
305,mean mmse score,C0451306;C3533236
305,> < $nmbr$ . $nmbr$  < $nmbr$ . $nmbr$  r < mmse = mini - mental,C0205090;C0229992;C0445542;C0451306;C0684010;C2603358
304,recent treatment ( < $nmbr$ months mmf / ggs ),C0039798;C0083765;C0087111;C0209368;C0332185;C0439231;C1522326;C1533734;C1705169;C3538994;C3848524;C3887704
304,mycophenolate mofetil - cyclophosphamide,C0010583;C0209368
304,mycophenolate mofetil,C0209368
304,mmf ( n = $nmbr$ ),C0083765;C0209368;C3848524
303,mn population  n,C0026327;C0026405;C0032659;C1257890;C4285072
303,mn population,C0026327;C0026405;C0032659;C1257890;C4285072
303,mn - na ï ve population,C0026327;C0026405;C0032659;C0042469;C0597484;C1257890;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
303,cardiac index  l • mn ' • m $nmbr$,C0026327;C0026405;C0369637;C0428776;C0441923;C4285072
303,all non - mn,C0026327;C0026405;C1518422;C4285072
302,mh + crpnorr,C0026514;C2930980
302,cr + mh,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
301,titre ( u / ml ) t,C0439340;C0475208;C1880521;C2945590
301,serum total ige  iu / ml,C0439458;C1441420
301,anti - dsdna ( > $nmbr$ iu / ml )  %,C0439458;C0741099
300,type of ml  no . ( % ),C0332307;C0439526;C1547052;C1705224;C3887665
300,treatment of the index ml,C0039798;C0087111;C0439526;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1705224;C2986546;C3538994;C3887665;C3887704
300,quartiles of fgf - $nmbr$ ( ru / ml ),C0016026;C0035970;C0439526;C0919505;C1425796;C1705224;C2828255;C3887665
300,pvr volume  ml  mean ( sd ),C0242852;C0439526;C0444504;C0449468;C0456261;C1419141;C1690016;C1705102;C1705224;C2347634;C2348143;C2699239;C2700258;C3887665
300,pvr  ml,C0242852;C0439526;C0456261;C1419141;C1705224;C3887665
300,pv  ml,C0030840;C0032463;C0439526;C1705224;C3887665
300,prior ml / stroke,C0038454;C0332152;C0439526;C1705224;C2826257;C3887665;C4554100
300,prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
300,prior history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C0948008;C1705224;C1705255;C2004062;C2826257;C3887665
300,prior history ml or stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665;C4554100
300,previous ml ( interaction : p = $nmbr$ . $nmbr$ ),C0205156;C0439526;C1552607;C1704675;C1705224;C3887665
300,previous ml ( before index acs ),C0205156;C0439526;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C1705224;C2986546;C3887665;C4318612
300,previous ml,C0205156;C0439526;C1552607;C1705224;C3887665
300,placebo  $nmbr$ . $nmbr$ ml ( n = $nmbr$ ),C0032042;C0439526;C1696465;C1705224;C1706408;C3887665
300,patients with > $nmbr$ % ■ $nmbr$ ml increase in fev $nmbr$ post - bronchodilator ( % ),C0030705;C0439526;C0442805;C1705224;C2599594;C3714541;C3887665
300,normal or increased gfr ( > $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0017654;C0205217;C0205307;C0231683;C0369637;C0439166;C0439526;C0441923;C0442805;C1417190;C1424601;C1705224;C2347086;C3815103;C3887665;C4553972
300,nontatal ml,C0439526;C1705224;C3887665
300,nonfatal ml,C0439526;C1705224;C3887665
300,non - fatal ml,C0439526;C1302234;C1518422;C1705224;C1705232;C3887665
300,no prior ml or stroke,C0038454;C0332152;C0439526;C1705224;C2826257;C3887665;C4554100
300,no prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
300,ml c,C0439526;C1705224;C3887665
300,ml ),C0439526;C1705224;C3887665
300,ml,C0439526;C1705224;C3887665
300,mild decrease in gfr ( $nmbr$ - $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0017654;C0369637;C0392756;C0439526;C0441923;C0547047;C1417190;C1424601;C1705224;C2945599;C3815103;C3887665
300,lvesv ( ml ),C0439526;C1705224;C3887665
300,lvedv ( ml ),C0439526;C1705224;C3887665
300,lav ( ml ),C0019682;C0439526;C1705224;C3887665
300,history of ml at baseline,C0019664;C0019665;C0168634;C0262512;C0262926;C0439526;C1442488;C1705224;C1705255;C2004062;C3887665
300,history of ml,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
300,high eosinophil subgroup ( > $nmbr$ / ml ) ( n = $nmbr$ ),C0014457;C0439526;C1079230;C1515021;C1705224;C3887665
300,fvc  ml,C0439526;C1705224;C3714541;C3887665
300,fatal chd + nonfatal ml,C0280604;C0439526;C1302234;C1705224;C1705232;C3542407;C3887665
300,fatal and nonfatal ml,C0439526;C1302234;C1705224;C1705232;C3887665
300,fatal / nonfatal ml,C0439526;C1302234;C1705224;C1705232;C3887665
300,decline #   ml · yr − $nmbr$,C0439234;C0439526;C1705224;C3887665
300,contrast used ( ml ) *,C0009924;C0439526;C1273517;C1705224;C1979874;C3887665
300,characteristics of the index ml,C0439526;C0600653;C0918012;C1521970;C1552854;C1637833;C1705224;C2986546;C3887665
300,alvesv ( per ml ),C0439526;C1705224;C3887665
300,alvedv ( per ml ),C0439526;C1705224;C3887665
300,alav ( per ml ),C0439526;C1705224;C3887665
300,adjusted rate of fev $nmbr$   decline ( se )  ml / yr,C0036919;C0439234;C0439526;C0456081;C0871208;C1521828;C1705224;C3714541;C3887665
300,> = $nmbr$ ml / mln,C0439526;C1417190;C1705224;C3815103;C3887665
300,> $nmbr$ ml,C0439526;C1705224;C3887665
300,< $nmbr$ ml,C0439526;C1705224;C3887665
300,* nonfatal ml,C0439526;C1705224;C3887665
300,$nmbr$ to < $nmbr$ ml per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439526;C0441923;C1705224;C3887665
300,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ) §,C0439526;C1705224;C3887665
300,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ),C0439526;C1705224;C3887665
300,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n - $nmbr$ / $nmbr$ ),C0439526;C1705224;C3887665
300,$nmbr$ - $nmbr$ ml / rain,C0034640;C0439526;C1705224;C3887665
299,urine qmax  ml / s,C0042036;C0042037;C0439390;C2963137
299,qmax ( ml / s ),C0439390
299,qmax  ml / s  mean ( sd ),C0439390;C0444504;C2347634;C2348143;C2699239
299,qmax  ml / s,C0439390
299,> $nmbr$ ml / s,C0439390
299,< $nmbr$ ml / s,C0439390
298,mean ( sd ) esr  mm / h *,C0444504;C0456680;C2347634;C2348143;C2699239;C3811131
298,esr ( mm / h )  mean ( sd ),C0444504;C0456680;C2347634;C2348143;C2699239;C3811131
298,esr ( mm / h ),C0456680;C3811131
298,erythrocyte sedimentation rate ( mm / h ),C0456680;C1176468;C1619634
297,triglyceride ( mm,C0041004;C4330985;C4554674
297,total length of implanted stents  mm  mean ( sd ),C0021102;C0439175;C0439810;C0444504;C0449462;C2347634;C2348143;C2699239;C2828363;C4330985;C4554674
297,total back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd,C0004600;C0042815;C0205095;C0439175;C0439810;C0444504;C0460009;C1995000;C2347634;C2348143;C2699239;C4330985;C4554674
297,subcortical wml load diameter  mm  mean ( sd ),C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674
297,subcortical wml load diameter  mm   mean ( sd ),C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674
297,stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ ),C0184666;C0809949;C4330985;C4554674
297,sokolow - lyon voltage  mm,C0598352;C4330985;C4554674
297,sokolow - lyon ( mm ) *,C4330985;C4554674
297,sokolow - lyon  mm,C4330985;C4554674
297,r wave in avl ( mm ),C0429091;C0449216;C4330985;C4554674
297,ptgada ( mm ),C4330985;C4554674
297,platelets xlooo / mm ^,C0005821;C0443116;C1963076;C4330985;C4554674
297,platelet count  x $nmbr$ mm $nmbr$,C0032181;C1287267;C4330985;C4554674
297,phgada ( mm ),C4330985;C4554674
297,patient global assessment of pain ( vas $nmbr$ - $nmbr$ mm ),C0042815;C4054229;C4330985;C4554674
297,pain vas  $nmbr$ - $nmbr$ mm,C0042815;C4330985;C4554674
297,pain ( $nmbr$ mm vas ),C0042815;C4330985;C4554674
297,pain ( $nmbr$ - $nmbr$ mm vas ),C0042815;C4330985;C4554674
297,pain  mm,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
297,pain  $nmbr$ - $nmbr$ mm vas,C0042815;C4330985;C4554674
297,nocturnal back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd,C0042815;C0444504;C1970122;C2347634;C2348143;C2699239;C3536884;C3827561;C4330985;C4554674
297,no stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ ),C0184666;C0809949;C4330985;C4554674
297,mssbp  mm hga,C4330985;C4554674
297,msdbp  mm hga,C4330985;C4554674
297,mean of mean cimt  mean ( sd )  mm,C0444504;C2347634;C2348143;C2699239;C4330985;C4554674
297,mean of jsw ( mm ),C0444504;C2347634;C2348143;C4330985;C4554674
297,lvdd ( mm ),C4330985;C4554674
297,esr — mm / hr,C3811131;C4330985;C4554674
297,esr ( mm / hour ) git config - - global user . name  your name,C0027365;C0205246;C0439227;C0564385;C1418224;C1547383;C1548600;C1706077;C2348867;C2827597;C3811131;C4330985;C4522128;C4554674
297,esr ( mm / hour ),C0439227;C0564385;C3811131;C4330985;C4554674
297,esr ( mm / hour  per unit ),C0456685;C3811131;C4330985;C4554674
297,esr  mm / hour,C0439227;C0564385;C3811131;C4330985;C4554674
297,esr  median ( range ) mm / hour,C0439227;C0549183;C0564385;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3811131;C4330985;C4554674
297,esr  $nmbr$ - $nmbr$ mm / hour,C0439227;C0564385;C3811131;C4330985;C4554674
297,erythrocyte sedimentation rate  mm / hour,C0439227;C0564385;C1176468;C1619634;C4330985;C4554674
297,elevation of cardiac biomarker levels or st - seg - ment deviation > $nmbr$ mm — no . / total no . ( % ),C0084844;C0439175;C0439775;C0439810;C0441889;C0702240;C1114722;C1116089;C1271630;C1519133;C1538994;C1705293;C4330985;C4554674
297,deviation  mm,C0012727;C0205419;C1705236;C4330985;C4554674
297,blood pressure  mean ( sd )  mm hgt,C0428886;C2699239;C4330985;C4554674
297,baseline £ std  mm,C0168634;C1442488;C4330985;C4554674
297,baseline ste in worst lead  mm,C0023175;C0168634;C0181586;C1420459;C1442488;C1442948;C1522166;C1522538;C2348269;C3275067;C3811127;C4330985;C4554674
297,baseline sbp ( mm ),C0085805;C0168634;C1442488;C4330985;C4554674
297,baseline ^ ste  mm,C0168634;C1420459;C1442488;C3811127;C4330985;C4554674
297,arterial area ( mm $nmbr$ ),C0003842;C0017446;C0205146;C0221464;C4330985;C4554674
297,> $nmbr$ mm ( n = $nmbr$ ),C4330985;C4554674
297,> $nmbr$ mm,C4330985;C4554674
297,> $nmbr$ . $nmbr$ mm,C4330985;C4554674
297,< = $nmbr$ . $nmbr$ mm,C4330985;C4554674
297,< $nmbr$ mm,C4330985;C4554674
297,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mm,C4330985;C4554674
297,$nmbr$ - $nmbr$ mm,C4330985;C4554674
297,$nmbr$ - $nmbr$ . $nmbr$ mm,C4330985;C4554674
296,prednisone use  %,C0032952;C0042153;C0457083;C1947944
296,prednisone,C0032952
296,pre fvc % pred,C0032952;C0044955;C0332152;C0740175;C2257086;C3669034;C3714541
296,pre fev $nmbr$   % pred,C0032952;C0044955;C0332152;C0740175;C2257086;C3669034;C3714541
296,post fev $nmbr$   % pred,C0032952;C0044955;C0687676;C1704687;C3469826;C3714541
296,fev $nmbr$ % pred,C0032952;C0044955;C3714541
296,% pred,C0032952;C0044955
296,$nmbr$ ( fev $nmbr$ < $nmbr$ % pred ),C0032952;C0044955;C3714541
295,study medication  pre - dose,C0013227;C0439565;C0557651;C2603343;C3244316;C3812758;C4284232
295,predose fvc ( l ) *,C0439565;C3714541;C3812758
295,predose fvc ( l ),C0439565;C3714541;C3812758
295,predose fev ^ at screening,C0220908;C0220909;C0439565;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541;C3812758
295,predose fev / fvc,C0439565;C3714541;C3812758
295,predose fev -  at randomization,C0034656;C0439565;C3714541;C3812758
295,predose fev $nmbr$ ( l ) *,C0439565;C3714541;C3812758
295,pre - dose,C0439565;C3812758
294,with prior mi / stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C3810814;C4554100
294,ticagrelor pre ‐ hosp ( n = $nmbr$ ),C0332152;C0740175;C1999375;C2257086;C3669034
294,st ‐ str ≥ $nmbr$ % pre ‐ ci,C0008107;C0036056;C0332152;C0740175;C2257086;C3259781;C3272372;C3669034
294,received > $nmbr$ prior anti - tnf therapies  n,C0279936;C0332152;C0432633;C1514756;C2826257
294,received $nmbr$ prior anti - tnf therapy  n,C0279936;C0332152;C0432633;C1514756;C2826257
294,prior vka use for > $nmbr$ d  %,C0042153;C0332152;C0457083;C1947944;C2826257
294,prior use of systemic,C0205373;C0332152;C1524063;C2826257
294,prior use of synthetic dmards  n ( % ),C0242708;C0332152;C1524063;C1883254;C2826257
294,prior use of synthetic dmards,C0242708;C0332152;C1524063;C1883254;C2826257
294,prior use of conventional dmards only ( biologic - nai ' ve )  n ( % ),C0042469;C0205171;C0332152;C0439858;C1524063;C1720467;C2826257;C3537218;C3714652;C4055380;C4321495
294,prior use of $ $nmbr$ systemic therapies,C0205373;C0332152;C1514463;C1515119;C1524063;C2826257
294,prior upper gi clinical event,C0203057;C0205210;C0332152;C0441471;C2826257;C4019010
294,prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
294,prior transient ischemic attack,C0007787;C0332152;C0917805;C2826257
294,prior tnfi  n ( % ),C0332152;C2826257
294,prior tnf antagonist failure - yes,C0231174;C0231491;C0332152;C0680095;C1448177;C1549445;C1705108;C1710701;C2826257
294,prior tnf antagonist failure - no,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
294,prior tnf antagonist failure  n [ % ],C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
294,prior tnf antagonist failure  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
294,prior tnf antagonist  n [ % ] ‘ *,C0231491;C0332152;C1448177;C2826257
294,prior tia,C0007787;C0332152;C0917805;C1054154;C2826257
294,prior therapy with tnf antagonist  n ( % ),C0231491;C0279936;C0332152;C1448177;C1514463;C2826257
294,prior stroke — no . ( % ),C0038454;C0332152;C2826257;C4554100
294,prior stroke or tza,C0038454;C0039298;C0332152;C2826257;C4554100
294,prior stroke or tia  %,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
294,prior stroke or tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
294,prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
294,prior stroke / mi  n ( % ),C0038454;C0332152;C2826257;C3810814;C4554100
294,prior stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C4554100
294,prior stroke ( before index event ),C0332152;C0441471;C0456712;C2826257;C4019010
294,prior stroke ( % ),C0038454;C0332152;C2826257;C4554100
294,prior stroke,C0038454;C0332152;C2826257;C4554100
294,prior statin ( n = $nmbr$  $nmbr$ ),C0332152;C0360714;C2826257
294,prior ptca or pci,C0332152;C2826257;C2936173;C4049621
294,prior ptca / pci,C0332152;C2826257;C2936173;C4049621
294,prior peripheralarterialdisease,C0332152;C2826257
294,prior pci or cabg,C0010055;C0332152;C2826257;C4049621
294,prior pci  %,C0332152;C2826257;C4049621
294,prior pci,C0332152;C2826257;C4049621
294,prior pad,C0182158;C0332152;C0332568;C2826257;C3540603;C3669270;C3814046;C4319657
294,prior oma use ( n = $nmbr$ ),C0042153;C0332152;C0457083;C1947944;C2826257
294,prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
294,prior om,C0028971;C0332152;C1705272;C2826257
294,prior oad :,C0332152;C2826257
294,prior oac,C0332152;C2826257
294,prior non - cns se,C0036919;C0332152;C1518422;C2826257;C3714787
294,prior ml or stroke at baseline,C0038454;C0168634;C0332152;C0439526;C1442488;C1705224;C2826257;C3887665;C4554100
294,prior mi / stroke,C0038454;C0332152;C2826257;C3810814;C4554100
294,prior medication use  n ( % ),C0240320;C0332152;C2826257
294,prior lower gi clinical event,C0205210;C0332152;C0441471;C0441994;C1548802;C1708130;C2003888;C2826257;C3539617;C4019010;C4050121
294,prior llt,C0332152;C2347090;C2826257
294,prior lipid - lowering agent use,C0042153;C0086440;C0332152;C0457083;C1947944;C2826257
294,prior lgi event,C0332152;C0441471;C2826257;C4019010
294,prior lev use,C0023556;C0042153;C0332152;C0457083;C1947944;C2826257
294,prior lev,C0023556;C0332152;C2826257
294,prior implantable cardiodefibrillator  n ( % ),C0021102;C0332152;C2826257
294,prior immunosuppressive exposure  n ( % ),C0021081;C0274281;C0332152;C0332157;C2826257
294,prior immunosuppressant failurec,C0021081;C0332152;C2826257
294,prior immunosuppressant failure,C0021081;C0231174;C0332152;C0680095;C2826257
294,prior hospitalizations  n ( % ),C0019993;C0332152;C2826257
294,prior history of bleeding on oac,C0019080;C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257
294,prior failure of anti - tnf therapy — no . ( % ),C0231174;C0281481;C0332152;C0680095;C2826257
294,prior exposure to topiramate,C0076829;C0274281;C0332152;C0332157;C2826257
294,prior corticosteroid failure only,C0001617;C0205171;C0231174;C0332152;C0680095;C1720467;C2826257;C3536709
294,prior conventional synthetic dmards  n ( % ),C0242708;C0332152;C0439858;C1883254;C2826257
294,prior cardiovascular history,C0332152;C1880008;C2826257
294,prior cardiovascular event — no . ( % ) - j -,C0332152;C1320716;C2826257
294,prior cardiovascular event — no . ( % ),C0332152;C1320716;C2826257
294,prior cardiovascular event  ',C0332152;C1320716;C2826257
294,prior cardiovascular event,C0332152;C1320716;C2826257
294,prior brachytherapy,C0006098;C0332152;C2826257
294,prior bp use,C0037623;C0042153;C0332152;C0457083;C1415692;C1708288;C1947944;C2826257;C4318478
294,prior bisphosphonate usage,C0012544;C0332152;C0457083;C2267018;C2826257
294,prior biologic use,C0005515;C0042153;C0205460;C0332152;C0457083;C1947944;C2826257
294,prior biologic exposure,C0005515;C0205460;C0274281;C0332152;C0332157;C2826257
294,prior aspirin use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257
294,prior aspirin,C0004057;C0332152;C2826257
294,prior antiinflammatory / antirheumatic products  n ( % ),C0003191;C0003209;C0332152;C1514468;C1515999;C2826257
294,prior anti - tnf therapy — no . ( % ),C0281481;C0332152;C2826257
294,prior anti - tnf therapy,C0281481;C0332152;C2826257
294,prior anti - tnf exposure,C0274281;C0332152;C0332157;C1448177;C2826257
294,prior aeds  ≥ $nmbr$  n ( % ),C0180309;C0332152;C2826257
294,prior admb,C0332152;C2826257
294,prior,C0332152;C2826257
294,pre svc,C0231957;C0332152;C0740175;C2257086;C3669034
294,pre hospital ticagrelor,C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
294,pre fvc,C0332152;C0740175;C2257086;C3669034;C3714541
294,pre - treatedforhypertension [ n ( % ) ],C0332152;C0740175;C2257086;C3669034
294,pre - hospital ticagrelor ( n = $nmbr$ ),C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
294,pre - hospital,C0019994;C0332152;C0740175;C1510665;C2257086;C3669034
294,pre - h,C0033727;C0332152;C0369286;C0441932;C0564385;C0740175;C2257086;C3669034;C4528284
294,pre - bd fvc s $nmbr$ % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
294,pre - bd fvc < $nmbr$ % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
294,patients without a prior mi or stroke at baseline,C0030705;C0038454;C0168634;C0332152;C1442488;C2826257;C3810814;C4554100
294,patients with a prior mi or stroke at baseline,C0030705;C0038454;C0168634;C0332152;C1442488;C2826257;C3810814;C4554100
294,no prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
294,no prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
294,no prior stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C4554100
294,no prior stroke,C0038454;C0332152;C2826257;C4554100
294,no prior statin ( n = $nmbr$  $nmbr$ ),C0332152;C0360714;C2826257
294,no prior oma use ( n = $nmbr$ ),C0042153;C0332152;C0457083;C1947944;C2826257
294,no prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
294,no prior llt,C0332152;C2347090;C2826257
294,no prior lgi event,C0332152;C0441471;C2826257;C4019010
294,no prior aspirin,C0004057;C0332152;C2826257
294,no prior admc,C0332152;C2826257
294,no . of prior tnfi,C0332152;C2826257
294,no . of prior aedsd,C0332152;C2826257
294,no . of prior aeds  n ( % ) $nmbr$ - $nmbr$,C0180309;C0332152;C2826257
294,no . of prior aeds  n ( % ),C0180309;C0332152;C2826257
294,no . of prior aeds  c n ( % ),C0180309;C0332152;C2826257
294,heparin pre - randomization,C0019134;C0034656;C0332152;C0740175;C0770546;C2257086;C3669034
294,enrollment strata : prior hospitalization,C0019993;C0332152;C1516879;C1696073;C2826257;C3888021
294,duration of prior statin therapy ^,C0332152;C0360714;C0444917;C2826257
294,duration of pre - randomization anticoagulant therapy,C0034656;C0332152;C0740175;C2257086;C2711563;C3669034
294,dissatisfied with / stopped $ $nmbr$ prior systemic therapy because of side effects,C0001688;C0205373;C0332152;C0870433;C0877248;C0879626;C1272691;C1514463;C1515119;C2826257;C4085546
294,dissatisfied with / stopped $ $nmbr$ prior systemic therapies because of side effects,C0001688;C0205373;C0332152;C0870433;C0877248;C0879626;C1272691;C1514463;C1515119;C2826257;C4085546
294,% predicted pre - bd,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C4050145
294,$nmbr$ prior tnf antagonist failures  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
294,$nmbr$ prior tnf antagonist failure  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
294,# of prior non - tnfi bdmards *,C0332152;C1518422;C2826257
294,# of prior bdmards,C0332152;C2826257
293,presence of tophi  n ( % ),C0150312;C0221248;C0392148;C3854307
293,presence of tophi,C0150312;C0221248;C0392148;C3854307
293,presence of honeycombing  $nmbr$ n ( % ),C0150312;C0332468;C0349384;C0392148;C3854307
293,presence of erosions  n ( % ),C0150312;C0333307;C0392148;C1959609;C3854307
293,presence of enthesitis  n ( % ),C0150312;C0392148;C1282952;C3854307
293,presence of enthesitis,C0150312;C0392148;C1282952;C3854307
293,presence of dactylitis  n ( % ),C0150312;C0239161;C0392148;C3854307
293,presence of dactylitis,C0150312;C0239161;C0392148;C3854307
293,presence of angioedema at baseline,C0002994;C0150312;C0168634;C0392148;C1442488;C3854307
293,pregnancy,C0032961
293,history / presence of tophi,C0019664;C0019665;C0150312;C0221248;C0262512;C0262926;C0392148;C1705255;C2004062;C3854307
293,baseline presence of nasal polyps,C0027430;C0150312;C0168634;C0392148;C1442488;C3854307
292,scarring on renal biopsy,C0005558;C0008767;C0194073;C0220797;C1700247;C2004491
292,prostate biopsy,C0194804
291,proportion of days without heartburn at week $nmbr$  percentage,C0018834;C0332174;C0439165;C0439228;C0439230;C1549488;C1561533;C1709707
291,percentages of patients with event,C0030705;C0439165;C0441471;C1549488;C1561533;C4019010
291,percentages,C0439165;C1549488;C1561533
291,percentage points,C0439165;C1549488;C1552961;C1561533;C2347617;C3714763
291,percentage of patients with event,C0030705;C0439165;C0441471;C1549488;C1561533;C4019010
291,percentage of p,C0439165;C1549488;C1561533
291,percentage of fevj reversibility,C0439165;C0449261;C1549488;C1561533
291,percentage of females,C0086287;C0439165;C1549488;C1561533
291,percentage of days without heartburn,C0018834;C0439165;C0439228;C1549488;C1561533
291,percentage of bsa involved,C0439165;C1314939;C1549488;C1561533
291,percentage,C0439165;C1549488;C1561533
291,mean percentage of nights without heartburn,C0018834;C0240526;C0439165;C0444504;C1549488;C1561533;C2347634;C2348143
290,within $nmbr$ h after first procedure,C0033727;C0184661;C0205435;C0369286;C0441932;C0564385;C1279901;C2700391;C3274430;C3539779;C4528284
290,with dm ( n proactive intervention ( n = $nmbr$ a ),C0011816;C0184661;C0886296;C1273869;C3250443
290,unsuccessful procedure,C0184661;C1272705;C2700391;C3274430;C3539779
290,time  mean ( sd )  min procedure,C0040223;C0184661;C0444504;C0702093;C1524029;C2347634;C2348143;C2699239;C2700391;C3274430;C3539779;C3541383;C3813700
290,procedures in the hospital — no . ( % ),C0019994;C0025664;C0184661;C1510665;C2700391;C3538935
290,procedures after discharge — no . ( % ),C0012621;C0025664;C0030685;C0184661;C2700391;C2926602;C3538935
290,procedure * *,C0184661;C2700391;C3274430;C3539779
290,procedure,C0184661;C2700391;C3274430;C3539779
290,proactive intervention ( n = $nmbr$ a ),C0184661;C0886296;C1273869
290,pro - active intervention,C0033382;C0184661;C0205177;C0523852;C0886296;C1273869;C2987124;C3853793;C3888249
290,prior carotid intervention,C0184661;C0332152;C0741968;C0886296;C1273869;C2826257
290,previous intervention ( % ),C0184661;C0205156;C0886296;C1273869;C1552607
290,previous coronary intervention,C0018787;C0184661;C0205156;C0886296;C1273869;C1552607
290,percutaneous intervention,C0184661;C0522523;C0886296;C1273869
290,pci procedure,C0184661;C2700391;C3274430;C3539779;C4049621
290,non pci procedure,C0184661;C1518422;C2700391;C3274430;C3539779;C4049621
290,multivessel intervention  n ( % ),C0184661;C0886296;C1273869
290,intervention group ( n = $nmbr$ ),C0184661;C0441848;C0886296;C1273869
290,intervention .,C0184661;C0886296;C1273869
290,intervention ( n = $nmbr$ ),C0184661;C0886296;C1273869
290,intervention,C0184661;C0886296;C1273869
290,interaction p values are as follows : amlodipine vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . lisinopril vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . peripheral arterial disease refers to in - trial hospitalization or lower extremity revascularization procedure .,C0001779;C0008294;C0008976;C0011847;C0011849;C0015385;C0019664;C0019665;C0019993;C0034510;C0040363;C0041260;C0051696;C0065374;C0079399;C0085096;C0184661;C0205543;C0262512;C0262926;C0280604;C0332283;C0369773;C0441994;C0581603;C1522384;C1548802;C1704436;C1704675;C1705255;C1706779;C1709380;C1719822;C1883351;C2003888;C2004062;C2603361;C2700391;C3274430;C3539779;C3542407;C3853635;C4281991
290,first procedure,C0184661;C0205435;C1279901;C2700391;C3274430;C3539779
290,experimental intervention group ( n = $nmbr$ ),C0184661;C0441848;C0886296;C1273869;C1517586
290,cystoscopic procedure,C0184661;C0560573;C2700391;C3274430;C3539779
290,coronary intervention,C0018787;C0184661;C0886296;C1273869
290,coronary angiography and intervention,C0085532;C0184661;C0886296;C1273869;C1548829
290,carotid artery intervention *,C0007272;C0162859;C0184661;C0397581;C0741968;C0886296;C1273869
290,baseline procedure  n ( % ),C0168634;C0184661;C1442488;C2700391;C3274430;C3539779
-10,potential predictor,C2698872;C3245505
288,pulmonary function tests  % of predicted,C0024119;C0681842;C1882327;C2598152
288,predicted normal ) t,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
288,predicted normal ( % ),C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
288,prebronchodilator fev $nmbr$ ( % predicted normal ) t,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C2599602;C3714541;C4553972
288,postbronchodilator fevj ( % predicted ),C0681842;C1882327;C2599594
288,pef  post - bronchodilator  % predicted normal,C0030771;C0205307;C0231683;C0439166;C0681842;C1518922;C1542834;C1882327;C2347086;C2599594;C4553972
288,mean ( sd ) % of predicted normal fev $nmbr$,C0444504;C0520835;C0681842;C1882327;C2347634;C2348143;C2699239
288,mean ( sd ) % of predicted normal eevi,C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2699239;C4553972
288,fevj % predicted !  t,C0681842;C1882327
288,fev $nmbr$   % of predicted normal post - bronchodilator,C0520835;C0681842;C1882327;C2599594
288,fev $nmbr$ ( % predicted normal ),C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C3714541;C4553972
288,fev $nmbr$ % predicted normal,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C3714541;C4553972
288,diffusion capacity of the lung for carbon monoxide  % predicted !,C0007018;C0231971;C0681842;C1882327;C4520712
288,b postbronchodilator fevl ( % predicted ),C0681842;C1882327;C2599594
288,> $nmbr$ % predicted to < $nmbr$ % predicted,C0681842;C1882327
288,> $nmbr$ % predicted,C0681842;C1882327
288,< $nmbr$ % predicted,C0681842;C1882327
288,% predicted value ( sd ),C0681842;C1522609;C1882327;C2699239
288,% predicted,C0681842;C1882327
288,% of predicted normal value *,C0086715;C0681842;C1882327
288,% of predicted,C0681842;C1882327
287,time from onset of symptoms to presentation — hr,C0449450;C1320528
287,syndesmophyte present  n ( % ),C0150312;C0221690;C0449450
287,presentation to tertiary care hospital — %,C0337954;C0449450
287,presentation *,C0449450
287,present smokerc,C0150312;C0449450
287,present at screening,C0150312;C0220908;C0220909;C0449450;C1698960;C1710031;C1710032;C1710477;C2348164
287,present ( £ $nmbr$ mg / dl ),C0150312;C0439269;C0449450
287,present ( > $nmbr$ mg / dl ),C0150312;C0439269;C0449450
287,present,C0150312;C0449450
287,number ( s ) of features present,C0150312;C0237753;C0449450;C0449788;C1521970;C1706388;C2346469;C2348519
287,not present at screening  but within previous year,C0150312;C0205156;C0220908;C0220909;C0439234;C0439508;C0449450;C1518422;C1552607;C1698960;C1710031;C1710032;C1710477;C2348164
287,factor present,C0150312;C0449450;C1521761;C2827422
287,dx at presentation  n ( % ),C0449450;C3538936
287,dm present,C0011816;C0150312;C0449450;C3250443
287,angioedema present  n ( % ) {,C0002994;C0150312;C0449450
287,angioedema present  n ( % ) $nmbr$,C0002994;C0150312;C0449450
286,probenecid,C0033209
286,high - sensitivityc - reactive protein  mg / l,C0033684;C0205250;C0205332;C0439268;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
286,high - sensitivity c - reactive protein — mg / liter |,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
286,high - sensitivity c - reactive protein stratification,C0006560;C1413716;C1441604;C1514983;C4048285
286,high - sensitivity c - reactive protein  mg / ltt,C0006560;C0024671;C0026410;C0439269;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
286,das $nmbr$ ( c - reactive protein ),C0006560;C0051767;C0057671;C1413716;C4048285
286,c - reactive proteinc,C0205332
286,c - reactive protein — mg / literj,C0006560;C0024671;C0026410;C0439269;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
286,c - reactive protein ( mg / dl_ ),C0006560;C0439269;C1413716;C4048285
286,c - reactive protein ( mg / dl ),C0006560;C0439269;C1413716;C4048285
286,c - reactive protein  u / l,C0006560;C0439339;C1413716;C4048285
286,c - reactive protein,C0006560;C1413716;C4048285
286,batellna c - reective protein,C0033684
285,proteinuria ( > $nmbr$ g / $nmbr$ h )  %,C0033687;C0560020;C1962972;C4554346
285,proteinuria $nmbr$ ( g / day ),C0033687;C0439417;C1962972;C4554346
285,protein in urine    ≥ $nmbr$ +,C0033687
284,oriental,C0078988;C0699027
284,oretal,
284,asian or oriental,C0078988;C0699027
284,asian / oriental,C0078988;C0699027
283,stroke of atherosclerotic origin,C0038454;C0079946;C0333482;C0439659;C1550512;C4554100
283,origin [ n ( % ) ],C0079946;C0439659;C1550512
282,worsened,C1457868;C4084902
282,incident or worsening nephropathy,C0022658;C0332271;C1457868;C1546960;C1551358
282,hf symptom worsened,C0018488;C1313497;C1457868;C1457887;C1538440;C3273279;C3854129;C4084902
282,copd worsening,C0024117;C0332271;C1412502;C1457868;C1546960;C3714496
281,thyroid hormone,C0040135;C4522017
281,post - menopausal without hormone replacement,C0019930
281,post - menopausal with hormone replacement,C0019930
280,hormones,C0019932
280,estrogen - containing hormones,C0014939;C0019932;C0332256;C2700400;C2936882;C4542544
279,orthopnea  frequent / continuous,C0085619;C0332183;C0549178
279,orthopnea  ( % ),C0085619
279,orthopnea,C0085619
279,orthopaedic,C0029355
278,lipid trial participants - n ( % ),C0023779;C1997894;C2242969
278,lipid trial participants #,C0023779;C1997894;C2242969
278,lipid trial participants  no . ( % ),C0023779;C1997894;C2242969
278,lipid trial participants,C0023779;C1997894;C2242969
278,lioid trial participants,C1997894;C2242969
278,limited i -,C0021966;C0221138;C0439801;C2674459;C3542948;C4050251
278,limited,C0439801;C2674459;C3542948;C4050251
277,albiglutide events / patients ( %,C0030705;C0441471;C2607479;C3541888
277,albiglutide ( n = $nmbr$ ),C2607479
276,visits $nmbr$ e $nmbr$,C0545082;C1512346;C2826704
276,visit $nmbr$ blood pressures :,C0545082;C1272641;C1512346;C2826704
276,visit,C0545082;C1512346;C2826704
276,types of antihypertensive medications at last visit   §,C0003364;C0332307;C0545082;C1512346;C1517741;C2826704
276,sbp at visit $nmbr$,C0085805;C0545082;C1512346;C2826704
276,randomisation visit ( baseline ),C0034656;C0168634;C0545082;C1442488;C1512346;C2826704
276,number of er visits in last year prior to baseline,C0168634;C0237753;C0439234;C0439508;C0449788;C0545082;C1442488;C1512346;C2826704;C3810541;C3811131
276,no . with visit,C0545082;C1512346;C2826704
276,mean number of antihypertensive medication at last visit   ‡,C0003364;C0237753;C0444504;C0449788;C0545082;C1512346;C1517741;C2347634;C2348143;C2826704
276,last study visit,C0545082;C0557651;C1512346;C1517741;C2603343;C2826704
276,er visit,C0545082;C1512346;C2826704;C3810541;C3811131
276,ed visit related to exacerbation  n ( % ),C0439849;C0445223;C0545082;C1512346;C2826704;C3538926;C4086268
276,ed severity  visit $nmbr$ * *,C0439793;C0522510;C0545082;C1512346;C2826704;C3538926
276,ed duration  visit $nmbr$ * *,C0449238;C0545082;C1512346;C2826704;C2926735;C3538926
276,dbp at visit $nmbr$,C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
275,spondylitis with peripheral arthritis,C0038012;C0238694
275,asymmetric peripheral arthritis,C0238694;C0332514
274,dip joint arthritis,C0003864;C0932510;C4552845
274,arthritis type *,C0003864;C0332307;C1547052;C4552845
274,arthritis characteristics,C0003864;C1521970;C4552845
274,arthritis,C0003864;C4552845
273,pharyngitis,C0031350;C4553308
273,nasopharyngitis,C0027441
272,rhinitis,C0035455
272,osteitis,C0029400
272,cystitis,C0010692;C0600041;C1963088
272,allergic rhinitis — no . ( % ),C1334103;C2607914;C4552864
272,allergic rhinitis duration  mean ± sd  y *,C0444504;C0449238;C1334103;C2347634;C2348143;C2607914;C2699239;C2926735;C4552864
272,allergic rhinitis,C1334103;C2607914;C4552864
271,uveitis,C0042164;C1963266
271,uniti - $nmbr$ and uniti - $nmbr$ im - uniti,
271,uniti - $nmbr$,
271,randomised patients with enthesitis at baselinet,C0030705;C1282952
271,patients with enthesitis at week $nmbr$  n ( % ),C0030705;C0332174;C0439230;C1282952
271,patients with enthesitis at baseline  no .,C0030705;C0168634;C1282952;C1442488
271,patients with enthesitis  no . ( % ),C0030705;C1282952
271,patients with enthesitis  n ( % ),C0030705;C1282952
271,patients with enthesitis,C0030705;C1282952
271,patients with $ $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C0030705;C0332174;C0439230;C1282952;C3863761
271,im - uniti,
271,enthesitis score at baseline  median ( iqr ) week $nmbr$,C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1282952;C1442488;C2347635;C2348144;C2939193;C4050231
271,enthesitis score *,C0449820;C1282952;C4050231
271,enthesitis  n ( % ),C1282952
271,enthesitis  % §,C1282952
271,enthesitis,C1282952
271,bursitis,C0006444
271,% improvement in enthesitis score at week $nmbr$  n,C0332174;C0439230;C0449820;C1282952;C2986411;C4050231
270,tendonitis,C0039503
270,pancolitis,C0868908
270,extensive / pancolitis,C0205231;C0868908
269,spondylitis,C0038012
269,randomised patients with spondylitis at baseline  n,C0030705;C0038012;C0168634;C1442488
268,synovitis,C0039103
268,sinusitis,C0037199;C4553555
268,chronic sinusitis + nasal polypsd  n ( % ),C0028429;C0149516;C4520890
268,chronic bronchitis ( n = $nmbr$ ),C0008677
268,chronic bronchitis ( itt ) ( n = $nmbr$ ),C0008677
268,chronic bronchitis ( % ),C0008677
268,chronic bronchitis !,C0008677
268,chronic bronchitis,C0008677
268,bronchitis,C0006277
267,diagnostic catheterization,C0596429
267,cardiac catheterization,C0018795
267,cardiac catheterisation or pci for index event,C0018795;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
266,infliximab combination therapy,C0009429;C0205195;C0556895;C0666743;C1947911;C3811910;C4076075
266,combination therapy * *,C0009429;C0556895
266,combination therapy ( n = $nmbr$ ),C0009429;C0556895
266,combination therapy  n = $nmbr$,C0009429;C0556895
266,ambition,C0870128
265,toast classification,C1710306;C4521230
265,patient classification,C0008902;C0008903;C0030705;C0678229
265,pah classification — no . ( % ),C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
265,pah classification,C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
265,gold classification,C0008902;C0008903;C0018026;C0678229;C1304897
265,diabetes mellitus classification,C0008902;C0008903;C0011849;C0678229
265,classification of epilepsy type  n ( % ),C0008902;C0008903;C0014544;C0332307;C0678229;C1547052
265,classification of af  no . ( % ),C0008902;C0008903;C0344434;C0678229;C4049859
264,heavy calcification,C0006660;C0006663;C0175895;C0439539;C1533591;C1879982;C2242558
264,calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
264,calcification  n ( % ),C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
263,intermittent claudication,C0021775
263,claudication only,C0021775;C0205171;C0311395;C1456822;C1720467
263,claudication ( fontaine class > $nmbr$ ),C0021775;C0311395;C0456387;C1456822;C1518526;C1705943
263,claudication,C0021775;C0311395;C1456822
262,dcct a $nmbr$ c,
262,ccv history / condition at baseline,C0168634;C0683519;C1442488
262,ccv history / condition,C0683519
261,pci - hospital,C0019994;C1510665;C4049621
261,medications in the hospital after randomization — no . ( % ),C0013227;C0019994;C0034656;C0802604;C1510665;C2598133;C4284232
261,in - hospital medication,C0013227;C0019994;C1510665;C3244316;C4284232
261,in - hospital,C0019994;C1510665
261,community hospital ( % ),C0020003
261,community hospital  n ( % ),C0020003
261,community hospital,C0020003
260,hospitalized pneumonia events  n,C0032285;C0441471;C0701159;C3541888
260,hospitalized angina,C0002962;C0701159
260,hospitalized !,C0701159
260,hospitalized,C0701159
259,required hospitalization,C1708385
259,previous hospitalization for heart failure,C0205156;C1552607;C3898876
259,hospitalization for heart failure within previous $nmbr$ mo — no . ( % ),C0026544;C0205156;C0332177;C1552607;C3898876
259,hospitalization for heart failure within $nmbr$ mo,C0026544;C0332177;C3898876
259,hospitalization for heart failure n ( % ),C3898876
259,hospitalization for heart failure,C3898876
259,hospitalisation for heart failure,C3898876
259,heart failure hospitalizations,C3898876
259,cardiovascular death / hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775
258,time to death due to pah or hospitalization due to pah up to the end of the treatment periodd,C0019993;C0030123;C0039798;C0087111;C0444930;C0547043;C0678226;C1301931;C1522326;C1533734;C1705169;C2746065;C3203102;C3538994;C3887704;C4284467
258,prior hospitalization for hf  %,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
258,prior hf hospitalization ( n = $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
258,prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
258,previous hospitalization for unstable angina,C0002965;C0019993;C0205156;C1552607
258,pci during index hospitalization,C0019993;C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
258,no prior hf hospitalization ( n = $nmbr$  $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
258,no prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
258,medical therapy during index hospitalization — %,C0019993;C0418981;C0600653;C0918012;C1552854;C1637833;C2986546
258,hospitalizations  n,C0019993
258,hospitalizations,C0019993
258,hospitalization stratum  n ( % ),C0019993
258,hospitalization for unstable ap,C0002680;C0019993;C0443343;C1883468;C3887950
258,hospitalization for hf,C0018488;C0019993;C1313497;C1538440;C3273279
258,hospitalization for / due to,C0019993
258,hospitalization for,C0019993
258,hospitalization  n ( % ),C0019993
258,hospitalization,C0019993
258,hospitalisation for chf within $nmbr$ years of randomisation,C0018802;C0019993;C0034656;C0439234
258,hospitalisation,C0019993
258,hf hospitalizations  median ( iqr ),C0018488;C0019993;C0549183;C0876920;C1313497;C1538440;C2347635;C2348144;C2939193;C3273279
258,hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
258,cabg performed during index hospitalization,C0010055;C0019993;C0600653;C0884358;C0918012;C1552854;C1637833;C2986546
258,cabg during index hospitalization,C0010055;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
257,ct ratio > $nmbr$ . $nmbr$,C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
257,ct ratio ( % ),C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
257,ct or mr scan of the brain *,C0007673;C0024485;C0034606;C0441633;C0596217;C0881827;C1417249;C2347167;C2826292;C3254418;C3540513;C3813556;C3888140;C4050513
257,ct findings,C0007673;C2607943;C2926606;C3539655;C3540513;C3813556;C3888140
257,ct + tt,C0007673;C1452561;C3540513;C3813556;C3888140;C4554543
257,ct,C0007673;C3540513;C3813556;C3888140
256,icd or crt - d,C0021122
256,icd / crt - d  n ( % ),C0021122
256,crt - p + d  n ( % ),
256,crt - p,
256,crt - d,
256,crt,
255,it $nmbr$ . $nmbr$,
255,copd assessment test ( cat ) score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
255,comparison : cat . $nmbr$ vs . cat . $nmbr$,C0007450;C0325090;C0524517;C1443200;C1707455;C3665481;C4050461;C4284282
255,cat total score $nmbr$,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
255,cat total score,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
255,cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
255,cat score category,C0007450;C0325090;C0449820;C0524517;C0683312;C1443200;C3665481;C3889287;C4050231;C4050461;C4284282
255,cat score  mean ( sd ),C0007450;C0325090;C0444504;C0449820;C0524517;C1443200;C2347634;C2348143;C2699239;C3665481;C4050231;C4050461;C4284282
255,cat score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
255,cat > = $nmbr$ ( n = $nmbr$  $nmbr$ ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
255,cat > = $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
255,cat > $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
255,cat < $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
255,cat . $nmbr$ n / n ( % ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
255,$nmbr$ % cit,C0008864;C0523573;C1427027;C4553421
254,p value ( on vs off omt ),C1709380
254,on omt ( n = $nmbr$ ),
254,on omt,
254,oma / oat ( n   =   $nmbr$ ),C0028753;C0331496;C0939905;C3539067;C3897364
254,oma / oat,C0028753;C0331496;C0939905;C3539067;C3897364
254,oat ( n   =   $nmbr$ ),C0028753;C0331496;C0939905;C3539067;C3897364
254,oat,C0028753;C0331496;C0939905;C3539067;C3897364
253,zt = $nmbr$,
253,ra ndosii zat ion,C0022023;C1700702;C3538806;C4048756
252,without dvt dvt alone,C0149871;C0205171;C0439044;C0679994;C2926618;C3899446
252,treatment period index dvt : event,C0039798;C0087111;C0149871;C0439531;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1948053;C2926618;C2986546;C3538994;C3887704;C3899446;C4019010
252,only dvt,C0149871;C0205171;C1720467;C2926618;C3899446
252,locafon of index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
252,kheeatne index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
252,dvt only,C0149871;C0205171;C1720467;C2926618;C3899446
252,dvt,C0149871;C2926618;C3899446
252,concomitant dvt — no . ( % ) baseline nt - probnp — no . ( % ),C0149871;C0168634;C0521115;C0669479;C0754710;C1442488;C2926618;C3899446
252,concomitant dvt  n ( % ),C0149871;C0521115;C2926618;C3899446
252,acute dvt study,C0149871;C0205178;C0557651;C2603343;C2926618;C3899446
251,tt,C1452561;C4554543
251,tgt,C1421391;C1428265;C4321338
251,low tt < $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205251;C1452561;C1550472;C3890211;C4048187;C4321351;C4522223;C4554543
250,p value by gt,C1435727;C1704693;C1709380;C2697657
250,gt + tt,C1435727;C1452561;C1704693;C2697657;C4554543
250,gt,C1435727;C1704693;C2697657
249,psa ‐ modified shs of hands and feet,C0016504;C0018563;C0347981;C0392747;C1552914;C3810537;C3813209;C3889737
249,psa - modified shs of hands & feet $nmbr$ ( $nmbr$ - $nmbr$ ),C0016504;C0018563;C0347981;C0392747;C1552914;C3810537;C3813209;C3889737
249,msfc timed $nmbr$ - foot walk test .,C0016504;C0347981;C0392761;C2346504;C2348613;C2348704;C4277740
249,feet,C0016504;C0347981
248,patients ( ft ),C0030705;C1881534;C3890579
248,> $nmbr$ ft,C1881534;C3890579
248,< $nmbr$ ft,C1881534;C3890579
248,$nmbr$ - $nmbr$ ft,C1881534;C3890579
247,rest ofworld,C0035253;C1622890
247,rest ofthe world,C0035253;C1622890;C2700280
247,rest of world n z $nmbr$,C0035253;C1622890;C2700280
247,rest of world,C0035253;C1622890;C2700280
247,rest of the world,C0035253;C1622890;C2700280
247,rest - of - world ( n = $nmbr$ ),C0035253;C1622890;C2700280
247,pao $nmbr$ at rest  mm hg,C0035253;C0232555;C0439475;C1423784;C1427155;C1622890;C4318615
247,aapo $nmbr$ at rest  mm hg,C0035253;C0439475;C1622890
246,triglycerides $nmbr$ st third,C0036056;C0041004;C0205437;C3272372
246,st ‐ str ≥ $nmbr$ % post pci,C0036056;C0687676;C1704687;C3272372;C3469826;C4049621
246,st change > $nmbr$ mm,C0036056;C0392747;C0443172;C1705241;C3272372;C4319952;C4330985;C4554674
246,st / t wave,C0036056;C0429103;C3272372
246,st - t wavett,C0036056;C3272372
246,st - t waveft,C0036056;C3272372
246,st - t wave changes,C0036056;C0392747;C0429103;C0443172;C1705241;C3272372;C4319952
246,st - t wave abnormality d,C0036056;C1839341;C3272372
246,st - t wave  no . ( % ),C0036056;C0429103;C3272372
246,st - t wave  n ( % ),C0036056;C0429103;C3272372
246,st - t wave,C0036056;C0429103;C3272372
246,st - segment deviation > $nmbr$ mm — no . / total no . ( % ),C0012727;C0036056;C0205419;C0429029;C0429066;C0439175;C0439810;C0441635;C1114722;C1116089;C1705236;C3272372;C4330985;C4554674
246,st - $nmbr$ ( ng / ml ),C0036056;C0439275;C3272372
246,st -,C0036056;C3272372
246,st +,C0036056;C3272372
246,st ( arc definite only ),C0036056;C0205171;C0439544;C1704787;C1720467;C3272372
246,st,C0036056;C3272372
246,key secondary end point : st,C0036056;C3272372;C4528314
246,death / st,C0011065;C0036056;C1306577;C3272372;C4082313;C4552775
246,death / mi / idr / st,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
246,death  mi  idr  st  or gusto mod / sev bleeding,C0011065;C0011860;C0019080;C0036056;C0439793;C0458216;C1306577;C2983285;C3272372;C3810814;C4082313;C4552775
246,death  mi  idr  st  or any timi bleeding,C0011065;C0019080;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
246,death  mi  idr  or st,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
246,copd medication taken for at least $nmbr$ months before st,C0013227;C0024117;C0036056;C0439231;C1412502;C1883727;C3244316;C3272372;C3714496;C4284232
246,> $nmbr$ st and < $nmbr$ nd quartile,C0036056;C2828255;C3272372
246,< $nmbr$ st quartile,C0036056;C2828255;C3272372
246,$nmbr$ st < $nmbr$ . $nmbr$,C0036056;C3272372
246,$nmbr$ st : $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0036056;C0439284;C3272372
246,$nmbr$ days definite st,C0036056;C0439228;C0439544;C1704787;C3272372
246,$nmbr$ days composite of death / new mi / urgent revascularization and definite st,C0011065;C0036056;C0205199;C0439544;C0439609;C0581603;C1306577;C1547335;C1704787;C3272275;C3272372;C3810814;C4082313;C4552775;C4689466
245,post svc,C0231957;C0687676;C1704687;C3469826
245,post hoc analysis,C0002778;C0687676;C0936012;C1524024;C1704687;C3469826
245,post fvc % pred,C0032952;C0044955;C0687676;C1704687;C3469826;C3714541
245,post fvc,C0687676;C1704687;C3469826;C3714541
245,post - cabg,C0010055;C0687676;C1704687;C3469826
245,fev $nmbr$ / fvc ( post - albuterol ),C0001927;C0687676;C1704687;C3469826;C3714541
245,fev $nmbr$ / fvc  post - albuterol  %,C0001927;C0687676;C1704687;C3469826;C3714541
244,timi flow grade $nmbr$ of mi culprit vessel post ‐ pci,C0005847;C0441800;C0856742;C0919553;C3244287;C3272266;C4049621
244,post - mi,C0856742
243,mostly satisfied,C0205393;C0242428;C0750554;C4049977;C4084799
243,mostly dissatisfied,C0205393;C0750554;C0870433;C4085546
243,most frequent serious teaes,C0205393;C0205404;C0332183
243,most frequent non - infectious teaesb,C0205393;C0239998;C1518422
243,most frequent infections,C0205393;C0239998
243,most frequent aesa,C0205393;C0332183
242,trend / het . test,C0022885;C0039593;C0392366;C0456984;C0898753;C1335803;C1515976;C1521798;C1704827;C3831328;C4318744;C4554533
242,test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
242,test for interaction between treatment and race,C0022885;C0034510;C0039593;C0039798;C0087111;C0392366;C0456984;C1515976;C1522326;C1533734;C1704675;C1705169;C1706779;C3538994;C3831328;C3853635;C3887704;C4318744
242,test for interaction,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
242,ppg post - meal test  mmol / l,C0022885;C0039593;C0376674;C0392366;C0456984;C1418888;C1515976;C1532563;C3831328;C4318744
242,positive orthostatic test },C0022885;C0039593;C0231472;C0392366;C0439178;C0456984;C1446409;C1514241;C1515976;C2825490;C3812269;C3831328;C4318744
242,positive cu index test  z n ( % ),C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
242,positive cu index test,C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
242,orthostatic test *,C0022885;C0039593;C0231472;C0392366;C0456984;C1515976;C3831328;C4318744
242,likelihood test,C0022885;C0033204;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
242,laboratory tests,C0022885
242,laboratory testing,C0022885
242,heterogeneity test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C3831328;C4318744
242,heterogeneity / trend test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
242,dfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
242,cu index test  n ( % ) $nmbr$,C0022885;C0039593;C0392366;C0456984;C0600653;C0918012;C1177210;C1515976;C1552854;C1637833;C2347872;C2986546;C3831328;C4318744
242,cfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
242,atopy by phadiatop test  n ( % ),C0022885;C0039593;C0392366;C0392707;C0456984;C1441070;C1515976;C3539705;C3831328;C4318744
242,atopic ( based on phadiatop test ),C0022885;C0039593;C0392366;C0392707;C0456984;C1441070;C1515976;C1527178;C1705938;C3831328;C4318744
241,ratio to baseline in total ige at week $nmbr$  geometric mean ( se on loge scale ) u / ml,C0036919;C0168634;C0175659;C0332174;C0349674;C0439230;C0439340;C0456603;C0806481;C1442488;C1547037;C1880521;C1947916;C2697934;C2945590;C2986759
241,gm  geometric mean  gmr  geometric mean ratio over baseline  uacr  urinary albumimcreatinine ratio . % reduction : $nmbr$ x ( $nmbr$ — ratio of gmr for losartan versus gmr for placebo ) . amean of change  with change calculated as difference between time indicated and baseline as measured for each participant  difference of changes between treatment groups . cp - values compare differences from no change .,C0006938;C0017480;C0032042;C0039798;C0042295;C0087111;C0126174;C0168634;C0301630;C0392747;C0392756;C0441833;C0443172;C0444686;C0444706;C0456603;C0679646;C0687744;C1257890;C1273442;C1293152;C1441506;C1442103;C1442488;C1444656;C1519504;C1522326;C1522544;C1533734;C1547037;C1547049;C1552839;C1696465;C1704695;C1705169;C1705241;C1705242;C1705428;C1705429;C1706408;C1707455;C2698741;C2986759;C3538994;C3541902;C3854019;C3887704;C4050020;C4319952;C4551656;C4554048
241,geometric mean uacr,C2986759
241,geometric mean of baseline,C0168634;C1442488;C2986759
241,geometric mean ige on loge scale — u / ml,C0175659;C0349674;C0439340;C1880521;C1947916;C2697934;C2945590;C2986759
241,geometric mean blood eosinophil count on loge scale — cells / ^ ljj,C0175659;C0200638;C0349674;C1947916;C2697934;C2986759
241,geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mm $nmbr$,C0175659;C0200638;C0349674;C1947916;C2697934;C2699239;C2986759;C4330985;C4554674
241,geometric mean,C2986759
241,baseline geometric mean ( $nmbr$ ® / l ),C0168634;C1442488;C2986759
240,mean hbaic = • = s . d .  %,C0444504;C2347634;C2348143
240,mean ( s . d . ) hbalc  %,C0444504;C2347634;C2348143
240,hbalc > = $nmbr$ % ( n - $nmbr$ ),
240,hbalc ( % )  mean ( sd ) ^,C0444504;C2347634;C2348143;C2699239
240,hbalc ( % ),
240,hbalc  mean ( s . d . ),C0444504;C2347634;C2348143
240,hbalc  %  mean ( sd ),C0444504;C2347634;C2348143;C2699239
240,hbalc  %,
240,hbaie ( % ) mean ± sd,C0444504;C2347634;C2348143;C2699239
240,hbaie ( % ),
240,hbaie  %,
240,hbaic — %,
240,hbaic ( % )  mean ± s . d .,C0444504;C2347634;C2348143
240,hbaic ( % ),
240,hbai,
239,no mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
239,mra use,C0042153;C0243032;C0457083;C1609165;C1947944;C3891069
239,mra regimen ( n - $nmbr$ ),C0040808;C0243032;C1609165;C2945654;C3891069
239,mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
239,mra  ( % ),C0243032;C1609165;C3891069
239,mra,C0243032;C1609165;C3891069
239,magnetic resonance angiography,C0243032
238,riva roxa ban n / n { % ) $nmbr$ ( $nmbr$ . $nmbr$ ),C0683610;C4553947
238,poba  n ( % ),
238,cuban,C1553379
237,ukraine,C0041580
237,ua ( n = $nmbr$ ),C0041580;C0042014
237,ua,C0041580;C0042014
237,serum ua < $nmbr$ mg / dl by month $nmbr$,C0041580;C0042014;C0229671;C0332177;C0439231;C0439269;C1546774;C1550100
237,russia / ukraine / belarus,C0006539;C0035970;C0041580
236,with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,with corticosteroid treatment > $nmbr$,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
236,with corticosteroid treatment < $nmbr$,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
236,vka therapy,C0039798;C0087111;C1363945
236,treatment   ×   lipid interaction,C0023779;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
236,treatment with sulphonylurea + biguanide  n { % ),C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
236,treatment with sulphonylurea + biguanide  n ( % ),C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
236,treatment with sulphonylurea  n ( % ),C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3538994;C3887704
236,treatment with drugeluting stent,C0039798;C0087111;C1322815;C1522326;C1533734;C1705169;C3538994;C3887704
236,treatment with candesartan,C0039798;C0087111;C0717550;C1522326;C1533734;C1705169;C3538994;C3887704
236,treatment with anti - platelet drugs,C0039798;C0087111;C1522326;C1533734;C1705169;C2963157;C3538994;C3887704
236,treatment groups [ n / nb ( % ) ],C0028101;C0039798;C0087111;C0441848;C0919442;C1522326;C1533734;C1705169;C1705347;C3538994;C3887704;C4553907
236,treatment groups  n ( % ),C0039798;C0087111;C0441848;C1522326;C1533734;C1705169;C3538994;C3887704
236,treatment group,C0039798;C0087111;C0441833;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
236,treatment glargine,C0039798;C0087111;C0907402;C1522326;C1533734;C1705169;C3538994;C3887704
236,treatment for latent tuberculosis ^,C0039798;C0087111;C0205275;C0749724;C1522326;C1533734;C1609538;C1705169;C3538994;C3887704
236,treatment difference  ml,C0039798;C0087111;C0439526;C1522326;C1533734;C1705169;C1705224;C1705241;C1705242;C3538994;C3887665;C3887704
236,treatment difference,C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
236,treatment characteristics,C0039798;C0087111;C1521970;C1522326;C1533734;C1705169;C3538994;C3887704
236,treatment by subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
236,treatment before randomization  %,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,treatment before catheterization,C0007430;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,treatment at baseline,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538994;C3887704
236,treatment and parameter,C0039798;C0087111;C0549193;C1522326;C1533734;C1704769;C1705169;C2350001;C3538994;C3887704
236,treatment - by - subgroup interaction  p = $nmbr$ . $nmbr$,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
236,treatment - by - subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
236,treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,total by treatment,C0039798;C0087111;C0439175;C0439810;C1522326;C1533734;C1705169;C3538994;C3887704
236,topical therapy,C0039798;C0087111;C0332237;C1363945
236,time since cessation of full - dose warfarin therapy,C0039798;C0040223;C0087111;C0178602;C0366686;C0443225;C0869039;C1114758;C1363945;C1880019;C3541383;C4303340
236,time from symptoms to treatment,C0039798;C0040223;C0087111;C0683368;C1457887;C1522326;C1533734;C1705169;C3538994;C3541383;C3887704
236,time between cessation of full - dose warfarin therapy and enrollment ( mo ),C0026544;C0039798;C0087111;C0178602;C0332177;C0366686;C0682295;C0869039;C1114758;C1363945;C1516879;C1696073;C1880019;C3888021;C4303340
236,thrombolytic treatment before randomization,C0016018;C0034656;C0039798;C0087111;C0520997;C1522326;C1533734;C1705169;C3538994;C3887704
236,therapy,C0039798;C0087111;C1363945
236,therapies,C0087111
236,taking antihypertensive treatment at,C0003364;C0039798;C0087111;C1515187;C1522326;C1533734;C1705169;C3538994;C3887704
236,table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C0039224;C0039601;C0039798;C0087111;C0168634;C0205363;C0370003;C0947343;C1315074;C1442488;C1516050;C1522326;C1533734;C1705169;C1706074;C2347026;C3538994;C3887704;C4684572
236,sulfasalazine treatment,C0036078;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,subgroup treatment,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1705169;C3538994;C3887704
236,refractory to such therapy — no . ( % ),C0039798;C0087111;C0205269;C1363945
236,receiving insulin therapy,C0021641;C0039798;C0087111;C1363945;C1514756;C1533581;C1579433;C3714501
236,randomized treatment  % ( n ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
236,randomized treatment,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
236,randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,previous treatment with tnf antagonist — no . ( % ) §,C0039798;C0087111;C0205156;C0231491;C1448177;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
236,previous treatment ?,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
236,previous treatment,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
236,pretreatment / concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1550147;C1705169;C2709094;C3538994;C3539075;C3539076;C3887704
236,prestudy treatment ( % ) a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,other treatment assignment,C0039798;C0087111;C1516050;C1522326;C1533734;C1705169;C3538994;C3887704
236,oab therapy,C0039798;C0087111;C1363945
236,noninsulin therapy,C0039798;C0087111;C1363945
236,no pah therapy,C0030123;C0039798;C0087111;C1363945;C3203102;C4284467
236,no pah - specific therapy,C0030123;C0039798;C0087111;C0205369;C1363945;C1552740;C3203102;C4284467
236,no . of background glucose - lowering therapies  no . ( % ),C0017725;C0087111;C0441994;C1706907;C2003888
236,naive to antihyperglycemic agent therapy,C0020616;C0039798;C0087111;C0450442;C1254351;C1363945;C1521826
236,month $nmbr$ subgroup x treatment interaction p - value,C0039798;C0087111;C0332177;C0439231;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
236,mean treatment exposure  wk,C0039798;C0087111;C0274281;C0332157;C0332174;C0439230;C0444504;C1522326;C1533734;C1705169;C2347634;C2348143;C3538994;C3887704
236,long term vka therapy,C0039798;C0087111;C0443252;C1363945
236,long - term vka therapy,C0039798;C0087111;C0443252;C1363945
236,lipid treatment,C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,ldl cholesterol - lowering therapy,C0023824;C0039798;C0087111;C0202117;C0441994;C1363945;C2003888
236,insulin therapy  n ( % ) 本,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
236,insulin therapy  n ( % ),C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
236,insulin therapy,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
236,initial treatment randomization,C0034656;C0039798;C0087111;C0205265;C1279901;C1522326;C1533734;C1555582;C1705169;C1705685;C3538994;C3887704
236,ineffective therapy,C0039798;C0087111;C1363945;C3242229
236,ics / laba therapy  n ( % ),C0039798;C0087111;C0815320;C1363945;C4551720
236,icd therapy vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl ),C0021122;C0032042;C0039798;C0087111;C0596019;C1363945;C1696465;C1706408;C2985465
236,icd therapy ( n =,C0021122;C0039798;C0087111;C1363945
236,hypoglycaemic therapy,C0020616;C0039798;C0087111;C1363945
236,h $nmbr$ blocker ( n  % ) long - term vka therapy,C0033727;C0039798;C0087111;C0369286;C0441932;C0443252;C0564385;C1363945;C4528284
236,glucose - lowering therapy - no . ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
236,glucose - lowering therapy  n ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
236,glucose - lowering therapy,C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
236,glucose - lowering therapies — no . { % ),C0017725;C0087111;C0441994;C2003888
236,glucose - lowering therapies,C0017725;C0087111;C0441994;C2003888
236,epa treatment ( n = $nmbr$ ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
236,currently on aha therapy,C0039798;C0050451;C0087111;C0521116;C0772110;C1363945
236,concomitant treatment 一 no . ( % ),C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
236,concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
236,chronic treatment with aspirin,C0004057;C0039798;C0087111;C0205191;C1522326;C1533734;C1705169;C3538994;C3887704
236,characteristic and treatment,C0039798;C0087111;C1521970;C1522326;C1533734;C1705169;C3538994;C3887704
236,background treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C1706907;C3538994;C3887704
236,background therapy,C0039798;C0087111;C1363945;C1706907
236,background lipid therapy per acc / aha definition    n   ( % ) a,C0023767;C0039798;C0087111;C1363945;C1550452;C1704788;C1706907;C3539107;C3888054;C4072694
236,background aha therapy at screening  n ( % ) §,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
236,background aha therapy at screening  n ( % ),C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
236,background aha therapy at screening  n,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
236,background aha therapy at screening  a   n ( % ),C0039798;C0050451;C0087111;C0220908;C0220909;C0369718;C0441922;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
236,background aha therapy at screening  a,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
236,asian itt population by treatment group,C0032659;C0039798;C0078988;C0087111;C0374505;C1257890;C1522326;C1533734;C1705169;C3538994;C3887704
236,any treatment - emergent ae,C0039798;C0087111;C0750573;C1522326;C1533734;C1705169;C3538994;C3887670;C3887704
236,any therapy — no . ( % ),C0039798;C0087111;C1363945
236,antithrombotic therapy,C0039798;C0087111;C1363945
236,anti platelet therapy,C0005821;C0039798;C0087111;C1363945
236,anti - platelet therapy,C0005821;C0039798;C0087111;C1363945
236,actual treatment strategy,C0039798;C0087111;C0237400;C0679199;C1522326;C1533734;C1705169;C3538994;C3887704
236,ace inhibitor treatment,C0003015;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C4541021
235,tests for categoric,C0589061
235,pfor heterogeneity,C0019409;C0242960;C1151635
235,pfor,C1151635
234,poor  tried previous glucocorticoid / non - laba,C0017710;C0032854;C0205156;C0542537;C1518422;C1552607;C2700379
234,poor  tried previous glucocorticoid + laba,C0017710;C0032854;C0205156;C0542537;C1552607;C2700379
234,poor,C0032854;C0542537;C2700379
234,fair or poor,C0032854;C0542537;C2700379;C2911689
234,fair / poor,C0032854;C0542537;C2700379;C2911689
233,pneumonia in past year,C0032285;C4086728
233,pack - years ( iqr ),C1277691
233,over past $nmbr$ years  n ( % ),C4086728
233,no . of exacerbations in past year,C4086268;C4086728
233,exacerbations requiring hospitalisation ( past year ) ( % ),C0019993;C4086268;C4086728
233,( iqr ),
232,war,C0043027
232,mar imputation ( random . ) ( n = $nmbr$ ),C0034656;C0439605;C2699638;C3829202;C4255469
232,mar ( itt ) ( n = $nmbr$ ),C3829202;C4255469
231,previously taken any other dmards  n ( % ),C0242708;C1883727
231,other dmards,C0242708
231,other dmard use,C0042153;C0242708;C0457083;C1947944
231,dmard − ( n   =   $nmbr$ ),C0242708
231,dmard | |,C0242708
231,dmard + ( n   =   $nmbr$ ),C0242708
231,concomitant use of conventional synthetic dmard up to $nmbr$ mo — no . { % ) methotrexate,C0025677;C0026544;C0242708;C0332177;C0439858;C0521115;C1524063;C1883254
231,concomitant conventional dmard use,C0042153;C0242708;C0439858;C0457083;C0521115;C1947944
230,primary trial end point,C0008976;C2986535
230,primary safety end point : severe / life - threatening,C0036043;C0205082;C1546953;C1705187;C2826244;C2986535;C3537125;C4050465;C4050466
230,primary indication,C1549995
230,primary endpoint ’,C2986535
230,primary endpoint death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
230,primary endpoint at $nmbr$ months,C0439231;C2986535
230,primary endpoint at $nmbr$ days,C0439228;C2986535
230,primary endpoint ^,C2986535
230,primary endpoint :,C2986535
230,primary endpoint $nmbr$,C2986535
230,primary endpoint,C2986535
230,primary end point |,C2986535
230,primary end point kaplan - meier rate  %,C0871208;C1521828;C2986535
230,primary end point : death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
230,primary end point *,C2986535
230,primary end point,C2986535
230,primary end - point,C2986535
230,primary cv endpoint,C2986535;C3538987;C4048877;C4318503
230,nace ( primary endpoint ),C2986535
229,year of publication of primary results,C0034036;C0034037;C0205225;C0439234;C0439508;C0439612;C0439631;C1274040;C1546471;C1704324;C2825142
229,third primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ ),C0205225;C0205437;C0332174;C0392747;C0439230;C0439612;C0439631;C0443172;C0449820;C1705241;C3639721;C4050231;C4319952
229,second primary composite outcome,C0205199;C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1547335;C1561503;C1705190
229,second co - primary outcome,C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1561503;C1705190;C3245499
229,second co - primary,C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1561503;C1705190;C3245499
229,primary target vessel ( % ),C0205225;C0439612;C0439631;C0449618
229,primary study joint  n ( % ),C0022417;C0205225;C0392905;C0439612;C0439631;C0557651;C1706309;C2603343
229,primary pcit,C0205225;C0439612;C0439631
229,primary pci no .,C0205225;C0439612;C0439631;C4049621
229,primary pci n = $nmbr$,C0205225;C0439612;C0439631;C4049621
229,primary pci ( n = $nmbr$ ),C0205225;C0439612;C0439631;C4049621
229,primary pci,C0205225;C0439612;C0439631;C4049621
229,primary outcomes,C0205225;C0439612;C0439631;C1274040
229,primary outcome plus revascularization or nonfatal hf,C0018488;C0205225;C0332287;C0439612;C0439631;C0581603;C1274040;C1313497;C1538440;C3273279
229,primary outcome : $nmbr$ % decrease in womac pain score,C0205225;C0392756;C0439612;C0439631;C0547047;C0582148;C1274040
229,primary outcome ! ( n = $nmbr$ ),C0205225;C0439612;C0439631;C1274040
229,primary outcome !,C0205225;C0439612;C0439631;C1274040
229,primary outcome,C0205225;C0439612;C0439631;C1274040
229,primary nonresponse,C0205225;C0439612;C0439631
229,primary ischemic stroke,C0205225;C0439612;C0439631;C0948008
229,primary end points,C0205225;C0439612;C0439631;C2349179
229,primary efficacy outcome,C0205225;C0439612;C0439631;C1274040;C1280519;C1707887
229,primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
229,primary composite end points,C0205199;C0205225;C0439612;C0439631;C1547335;C2349179
229,primary composite ^,C0205199;C0205225;C0439612;C0439631;C1547335
229,primary cause of heart failure,C0015127;C0018801;C0018802;C0205225;C0439612;C0439631;C1524003;C4554158
229,primary cause of chf,C0015127;C0018802;C0205225;C0439612;C0439631;C1524003
229,primary angioplasty ( n = $nmbr$ ),C0162577;C0205225;C0439612;C0439631;C1548817
229,primary analysis,C0002778;C0205225;C0439612;C0439631;C0936012;C1524024
229,primary *,C0205225;C0439612;C0439631
229,primary,C0205225;C0439612;C0439631
229,overall cohort ( primary analysis ),C0086027;C0205225;C0282416;C0439612;C0439631;C1561607
229,or primary outcome,C0205225;C0439612;C0439631;C1274040
229,medical history duration of heart failure ( years ) primary cause of heart failure,C0015127;C0199168;C0205225;C0205476;C0439234;C0439612;C0439631;C0449238;C0455531;C1524003;C2926735
229,first primary composite outcome,C0205199;C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C1547335
229,first co - primary outcome,C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C3245499
229,first co - primary,C0205225;C0205435;C0439612;C0439631;C1279901;C3245499
229,fibrinolysis primary pci ( n = $nmbr$ ) ( n = $nmbr$ ) no . of patients / total no . ( % ),C0016017;C0030705;C0205225;C0439175;C0439612;C0439631;C0439810;C1305868;C4049621
229,combo vs . primary,C0205225;C0439612;C0439631
229,chd ( primary outcome ),C0205225;C0280604;C0439612;C0439631;C1274040;C3542407
229,accord primary  n ( % ),C0205225;C0439612;C0439631;C0680240
229,a . primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
228,native coronary - artery lesions,C0205042;C0221198;C0302891
228,left main coronary artery bifurcation,C3898614
228,coronary artery stenosis > $nmbr$ %,C0242231
228,coronary artery osteochondrosis,C0029376;C0029429;C0205042;C0729346
228,coronary artery,C0205042
228,> $nmbr$ % coronary stenosis,C0242231
227,previous coronary artery bypass surgery  no . ( % ),C2144990
227,previous coronary artery bypass grafting,C2144990
227,previous coronary artery bypass graft,C2144990
227,previous coronary angioplasty  n ( % ),C2114427
227,previous coronary - artery bypass grafting,C2144990
226,• death from coronary heart disease,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
226,voluntary,C0439656;C3543419
226,stable coronary artery disease,C0010054;C0010068;C0205360;C1547311;C1956346
226,prior coronary artery disease yes,C0010054;C0010068;C0332152;C1549445;C1705108;C1710701;C1956346;C2826257
226,previous coronary heart disease,C0010054;C0010068;C0205156;C1552607;C1956346
226,previous coronary artery disease  n ( % ),C0010054;C0010068;C0205156;C1552607;C1956346
226,only coronary artery disease,C0010054;C0010068;C0205171;C1720467;C1956346
226,multivessel coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C0439175;C0439810;C1956346
226,multivessel coronary artery disease,C0010054;C0010068;C1956346
226,hope patients with coronary - artery disease ( n = $nmbr$ ),C0010054;C0010068;C0030705;C0392347;C1956346
226,documented coronary artery disease,C0010054;C0010068;C1301725;C1609436;C1956346
226,coronary heart disease — no . ( % ),C0010054;C0010068;C1956346
226,coronary heart disease death,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
226,coronary heart disease ( % ),C0010054;C0010068;C1956346
226,coronary heart disease  n ( % ) t,C0010054;C0010068;C1956346
226,coronary heart disease  n ( % ) b,C0010054;C0010068;C1956346
226,coronary heart disease,C0010054;C0010068;C1956346
226,coronary disease,C0010068;C1956346
226,coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C0439175;C0439810;C1956346
226,coronary artery disease — no . ( % ) : c,C0010054;C0010068;C1956346
226,coronary artery disease — no . ( % ) : ! :,C0010054;C0010068;C1956346
226,coronary artery disease — no . ( % ),C0010054;C0010068;C1956346
226,coronary artery disease — %,C0010054;C0010068;C1956346
226,coronary artery disease §,C0010054;C0010068;C1956346
226,coronary artery disease history,C0010054;C0010068;C0019664;C0019665;C0262512;C0262926;C1705255;C1956346;C2004062
226,coronary artery disease ^,C0010054;C0010068;C1956346
226,coronary artery disease *,C0010054;C0010068;C1956346
226,coronary artery disease ( n = $nmbr$ $nmbr$ ),C0010054;C0010068;C1956346
226,coronary artery disease ( % ),C0010054;C0010068;C1956346
226,coronary artery disease    n   ( % ),C0010054;C0010068;C1956346
226,coronary artery disease  n ( % ),C0010054;C0010068;C1956346
226,coronary artery disease  %,C0010054;C0010068;C1956346
226,coronary artery disease,C0010054;C0010068;C1956346
226,any established coronary artery disease,C0010054;C0010068;C0443211;C1272684;C1956346
226,any coronary artery disease,C0010054;C0010068;C1956346
226,* atherosclerotic coronary heart disease  ischaemic stroke or peripheral arterial disease . † n / n = number of people in phase $nmbr$ studies only . ‡ high ‐ intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg  rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily .,C0003842;C0010054;C0010068;C0012634;C0018787;C0024671;C0026410;C0027361;C0074554;C0205100;C0205171;C0205390;C0221464;C0237753;C0286651;C0332173;C0333482;C0360714;C0439269;C0449788;C0557651;C0947630;C0948008;C0965129;C1704788;C1710475;C1720467;C1956346;C1960952;C2346927;C2603343;C3539106;C4081854;C4321396;C4521761
225,time from acute coronary syndrome to randomization ( days ),C0034656;C0040223;C0439228;C0948089;C3541383
225,median time from index acute coronary syndrome to randomization ( iqr ) — mo,C0026544;C0034656;C0040223;C0332177;C0549183;C0600653;C0876920;C0918012;C0948089;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C3541383
225,coronary events $nmbr$,C0741923
225,acute coronary syndrome $nmbr$,C0948089
225,acute coronary syndrome,C0948089
225,acute coronary event,C0205178;C0741923
224,right coronary artery  n ( % ),C1261316
224,right coronary artery,C1261316
224,right coronary,C0225808
224,coronary risk factors — no . ( % ),C2024776
223,prior coronary revascularization — no . { % ),C0332152;C0877341;C2826257
223,prior coronary revascularization ( pci or cabg ),C0010055;C0332152;C0877341;C2826257;C4049621
223,prior coronary revascularization  no . ( % ),C0332152;C0877341;C2826257
223,prior coronary revascularization  n / n ( % ),C0332152;C0877341;C2826257
223,prior coronary revascularization  n ( % ),C0332152;C0877341;C2826257
223,prior coronary revascularization,C0332152;C0877341;C2826257
223,previous coronary revascularization — no . ( % ),C0205156;C0877341;C1552607
223,previous coronary revascularization,C0205156;C0877341;C1552607
223,previous coronary revascularisation,C0205156;C0877341;C1552607
223,history ol coronary revascularization *,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
223,history of coronary revascularization  no . ( % ),C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
223,coronary revascularization procedure,C0877341
223,coronary revascularization,C0877341
223,coronary revascularisation §,C0877341
223,coronary revascularisation,C0877341
223,any coronary revascularization,C0877341
222,rr *,
222,rr $nmbr$ . $nmbr$ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *,
222,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
222,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ },
222,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) * *,
222,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *,
222,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),
222,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$,
222,rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$ . $nmbr$ . $nmbr$ ) *,
222,rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$  $nmbr$ . $nmbr$ ),
222,rr $nmbr$ . $nmbr$,
222,hr * or rr †,
222,aml / val  $nmbr$ / $nmbr$ mg rr = $nmbr$ *,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761;C4554402
221,unadjusted irr,C1439367;C4082285
221,irr = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$,C4082285
220,upcr  n ( % ),
220,ucr,
220,idr,
220,death / udmi / idr,C0011065;C1306577;C4082313;C4552775
220,death / q - mi / idr,C0011065;C1306577;C3810814;C4082313;C4552775
220,death  mi  idr  st or gusto severe bleeding,C0011065;C0019080;C0036056;C0205082;C1306577;C3272372;C3810814;C4050465;C4050466;C4082313;C4552775
220,cv death / mi / stroke / ucr,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
219,prior surgery : no,C0455610
219,prior oabg surgery,C0455610
219,prior cabg surgery,C0010055;C0455610
219,prior aortocoronary bypass surgery 一 no . ( % ),C0010055;C0455610
219,prior aortocoronary bypass surgery — no . ( % ),C0010055;C0455610
219,prior aortocoronary bypass surgery,C0010055;C0455610
219,previous bypass surgery  n ( % ),C0205156;C1536078;C1552607
219,lower - limb angioplasty or bypass surgery,C0745788;C1536078
219,hungary,C0020174
219,bypass surgery,C1536078
218,urgent surgery,C2188405
218,undergoing major vascular surgery,C0005847;C0042381;C0205082;C0205164;C0679637;C1558950;C1801960;C3714645;C4318856;C4521762
218,otherb,
218,other cardiac surgery  n ( % ),C0018821;C0524727
218,minor surgery,C0038904
218,major surgery,C0679637
218,emergent / urgent surgery,C0750573;C2188405
218,cancer surgery,C0920424
217,use of clopidogrel,C0070166;C1524063
217,timing of clopidogrel loading dose,C0070166;C0449243;C1704250;C3714444
217,open - label clopidogrel after completion of study drug,C0013227;C0070166;C0205197;C1254351;C1554962;C1709323
217,interval from clopidogrel loading  h,C0033727;C0070166;C0369286;C0441932;C0564385;C1272706;C1552654;C1552713;C1708715;C4528284
217,interval clopidogrel to pci,C0070166;C1272706;C1552654;C1552713;C4049621
217,duration of clopidogrel pretreatment 一 hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
217,clopiodogrel,
217,clopidogrel pretreatment duration,C0070166;C0449238;C1550147;C2709094;C2926735;C3539075;C3539076
217,clopidogrel plus aspirin ( n = $nmbr$ ),C0004057;C0070166;C0332287
217,clopidogrel plus aspirin % / yr,C0004057;C0070166;C0332287;C0439234
217,clopidogrel plus aspirin,C0004057;C0070166;C0332287
217,clopidogrel no . of patients % ),C0030705;C0070166
217,clopidogrel n / n { % ),C0070166
217,clopidogrel n / n ( % ),C0070166
217,clopidogrel given before procedure,C0070166;C0184661;C1442162;C1550718;C1947971;C2700391;C3244317;C3274430;C3539779
217,clopidogrel / total no . of patients % %,C0030705;C0070166;C0439175;C0439810
217,clopidogrel + aspirin ( n = $nmbr$ ),C0004057;C0070166
217,clopidogrel ( n = $nmbr$ ) n / n ( % ),C0070166
217,clopidogrel ( n = $nmbr$ ),C0070166
217,clopidogrel ( n = $nmbr$ $nmbr$ ),C0070166
217,clopidogrel ( n = $nmbr$  $nmbr$ ),C0070166
217,clopidogrel %,C0070166
217,clopidogrel  %,C0070166
217,clopidogrel,C0070166
217,aspirin plus clopidogrel ( n = $nmbr$ ),C0004057;C0070166;C0332287
217,aspirin i clopidogrel ( n = $nmbr$  $nmbr$ ),C0004057;C0021966;C0070166;C0221138
217,aspirin + clopidogrel ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0004057;C0070166
217,aspirin $nmbr$ clopidogrel,C0004057;C0070166
216,ticlopidine after completion of study drug,C0013175;C0013227;C0040207;C0205197;C1254351;C1554962;C2348557
216,ticlopidine ( n = $nmbr$ ),C0040207
216,ticlopidine,C0040207
216,ticlopidin,
216,loading dose of clopidogrel or ticlopidine,C0040207;C0070166;C3714444
216,clopidogrel or ticlopidine,C0040207;C0070166
216,clopidogrel / ticlopidine,C0040207;C0070166
216,clopidogrel  ticlopidine  or prasugrel,C0040207;C0070166;C1620287
215,piroxicam,C0031990
215,non - biological systemic,C0205373;C0445097
215,meloxicam,C0083381
215,biological,C0005532;C0205460
214,prior use of biologics  n ( % ),C0005515;C0005522;C0332152;C1524063;C2826257;C4553887
214,prior use of biologic agents,C0005515;C0332152;C1524063;C2826257
214,prior biologic therapeutic failures  n ( % ),C0005515;C0087111;C0205460;C0231174;C0302350;C0332152;C0680095;C2826257
214,other biologic agent,C0005515
214,biologic therapeutic failure,C0005515;C0087111;C0205460;C0231174;C0302350;C0680095
214,biologic naive,C0005515;C0205460
214,biologic agents,C0005515
214,biologic,C0005515;C0205460
213,severity ofcopd ( gold $nmbr$ )  n ( % ),C0018026;C0439793;C0522510;C1304897
213,severity of the disease ( gold $nmbr$ )  n ( % ),C0018026;C0521117;C1304897
213,severity of copd  n ( % ) ( gold $nmbr$ ) : moderate,C0018026;C0024117;C0205081;C0439793;C0522510;C1304897;C1412502;C1881878;C3714496;C4049705;C4049706;C4085643;C4321335
213,severity of airflow limitation ( gold $nmbr$ - $nmbr$ )  n ( % ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
213,severity of airflow limitation ( gold $nmbr$ )  n ( % ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
213,severe ( gold $nmbr$ ),C0018026;C0205082;C1304897;C4050465;C4050466
213,severe  gold $nmbr$,C0018026;C0205082;C1304897;C4050465;C4050466
213,moderate ( gold $nmbr$ ),C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
213,moderate  gold $nmbr$,C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
213,gold stage ( % ) : c,C0018026;C0441785;C1304897
213,gold ii,C0018026;C1304897;C1710602;C4082587
213,gold groups a - d using mmrcb,C0018026;C0441833;C0687744;C0718133;C1257890;C1304897;C1519504;C1524063;C1552839;C1705428;C1705429
213,gold group d — no . ( % ) | |,C0018026;C0441838;C1304897
213,gold group d,C0018026;C0441838;C1304897
213,gold group b,C0018026;C1304897;C4522078
213,gold group  n ( % ),C0018026;C0441848;C1304897
213,gold group,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1705428;C1705429
213,gold d,C0018026;C1304897
213,gold c,C0018026;C1304897
213,gold b,C0018026;C1304897
213,gold a,C0018026;C1304897
213,gold $nmbr$ groups  n ( % ),C0018026;C0369718;C0441833;C0441922;C0687744;C1257890;C1304897;C1519504;C1552839;C1705428;C1705429
213,gold $nmbr$ groups,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1552839;C1705428;C1705429
213,gold $nmbr$ - $nmbr$ ( « = $nmbr$ ),C0018026;C1304897
213,gold $nmbr$ - $nmbr$ ( n = $nmbr$ ),C0018026;C1304897
213,gold $nmbr$ - $nmbr$,C0018026;C1304897
213,gold $nmbr$ ( « = $nmbr$ ),C0018026;C1304897
213,gold $nmbr$,C0018026;C1304897
213,gold  n ( % ),C0018026;C1304897
212,good / moderate response,C0205170;C4085643
212,good  tried previous glucocorticoid + laba,C0017710;C0205156;C0205170;C1552607
212,good  tried previous glucocorticoid,C0017710;C0205156;C0205170;C1552607
212,good,C0205170
211,tnt and ideal ( pooled ),C1512612;C1709595;C2349200;C4522255
211,secukinumab pooled †   ( n   = $nmbr$ ),C1709595;C2349200;C3179547;C4522255
211,pooled simva,C1709595;C2349200;C4522255
211,pooled secukinumab,C1709595;C2349200;C3179547;C4522255
211,pooled itt,C1709595;C2349200;C4522255
211,pooled eze / simva,C1709595;C2349200;C4522255
211,pooled empagliflozin ( n = $nmbr$ ),C1709595;C2349200;C3490348;C4522255
211,pooled analysis sample,C0002778;C0936012;C1303103;C1524024;C1709595;C2349200;C4522255
211,pooled analysis of sustain $nmbr$ — $nmbr$ trials,C0002778;C0008976;C0443318;C0936012;C1524024;C1709595;C2349200;C2732140;C4522255
211,pooled analysis,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
211,pooled,C1709595;C2349200;C4522255
211,empagliflozin pooled ( n = $nmbr$ ),C1709595;C2349200;C3490348;C4522255
210,ltg subgroup  n = $nmbr$,C1079230;C1420817;C1515021;C4521367;C4521846
210,ltg - naive,C1420817;C4521367;C4521846
210,lrg,C1428862
209,tg ’,C0337445
209,tg §,C0337445
209,tg > $nmbr$ . $nmbr$,C0337445
209,tg < = $nmbr$ . $nmbr$,C0337445
209,tg < $nmbr$  hdl > $nmbr$ ( n = $nmbr$ ),C0337445;C3715113
209,tg +,C0337445
209,tg *,C0337445
209,tg ( mmol / l ) c,C0337445;C1532563
209,tg ( mmol / l ),C0337445;C1532563
209,tg  median ( min  max ),C0337445;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
209,tg,C0337445
209,middle tg tertile,C0337445;C0444598;C0549183;C1552826
209,median ( q $nmbr$ : q $nmbr$ ) tg - rich lipoprotein cholesterol,C0065055;C0337445;C0549183;C0699759;C0876920;C2347635;C2348144;C2939193
209,lowest tg tertile,C0337445;C1708760
209,highest tg tertile,C0337445;C1522410
209,hdl - c   high - density lipoprotein cholesterol    ldl - c   low - density lipoprotein cholesterol    sestandard error    tg   triglycerides .,C0023822;C0337445;C0743559;C0858892;C1608199
209,elevated tg,C0205250;C0337445;C3163633
209,change in tg,C0337445;C0392747;C0443172;C1705241;C4319952
209,baseline tg level { n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
209,baseline tg level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
209,baseline tg level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
209,baseline tg level ( n = $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
209,baseline tg > $nmbr$ . $nmbr$ mmol / l,C0168634;C0337445;C1442488;C1532563
209,baseline tg < $nmbr$ . $nmbr$ mmol / l,C0168634;C0337445;C1442488;C1532563
209,baseline tg,C0168634;C0337445;C1442488
209,* p < $nmbr$ . $nmbr$ for eze / simva ( pooled across doses ) vs . simva ( pooled across doses ) for the entire cohort data are presented as least squares mean ± standard error ( † median ± se for tg ) for the entire cohort and also for each selected subgroup simva = simvastatin  eze = ezetimibe  tc = total cholesterol  tg = triglycerides  hdl - c = high - density lipoprotein - cholesterol  non - hdl - c = non - high - density lipoprotein cholesterol  apo = apolipoprotein,C0003591;C0008377;C0009247;C0023189;C0023821;C0023822;C0036919;C0039411;C0040642;C0041004;C0041405;C0041698;C0062152;C0065055;C0074554;C0178587;C0178602;C0201950;C0205250;C0337445;C0369773;C0439175;C0439751;C0439810;C0444504;C0444667;C0449450;C0543421;C0549183;C0599755;C0729627;C0876920;C1079230;C1142985;C1299351;C1511726;C1515021;C1518422;C1707391;C1708438;C1709595;C1710181;C1824670;C2347634;C2347635;C2348143;C2348144;C2349200;C2603361;C2700149;C2939193;C3245479;C3272447;C3714741;C3715113;C3887512;C3889660;C4321237;C4522122;C4522209;C4522255
208,sfc $nmbr$ / $nmbr$ pg twice daily ( n = $nmbr$ ),C0030827;C0072225;C0585361;C1266240;C4521536
208,sfc $nmbr$ / $nmbr$ pg b . i . d . n = $nmbr$,C0021966;C0030827;C0072225;C0152277;C0221138;C1266240;C2827928;C4521536
208,qva $nmbr$ / $nmbr$ pg once daily ( n = $nmbr$ ),C0030827;C0072225;C0332173;C1266240
208,nt - probnp  pg / mlt,C0030827;C0072225;C0669479;C0754710;C1266240;C4553833
208,indacaterol $nmbr$ pg,C0030827;C0072225;C1266240;C1722260
208,gly ( $nmbr$ . $nmbr$ pg b . i . d . ) n = $nmbr$,C0030827;C0072225;C0152277;C1266240;C1415124
208,formoterol $nmbr$ pg vs placebo,C0030827;C0032042;C0060657;C0072225;C1266240;C1696465;C1706408
208,formoterol $nmbr$ pg,C0030827;C0060657;C0072225;C1266240
208,ff $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240;C4554348
208,fdc $nmbr$ / $nmbr$ pg vs placebo,C0030827;C0032042;C0072225;C0340427;C1266240;C1413520;C1696465;C1706408;C3539652
208,fdc $nmbr$ / $nmbr$ pg vs formoterol $nmbr$ pg,C0030827;C0060657;C0072225;C0340427;C1266240;C1413520;C3539652
208,fdc $nmbr$ / $nmbr$ pg vs aclidinium $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C2699757;C3539652
208,fdc $nmbr$ / $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
208,difference vs ff $nmbr$ pg ( $nmbr$ % ci ),C0008107;C0030827;C0072225;C1266240;C1705241;C1705242;C3259781;C4554348
208,aclidinium / formoterol $nmbr$ / $nmbr$ pg twice daily,C0030827;C0060657;C0072225;C0585361;C1266240;C2699757
208,aclidinium $nmbr$ pg vs placebo,C0030827;C0032042;C0072225;C1266240;C1696465;C1706408;C2699757
208,aclidinium $nmbr$ pg,C0030827;C0072225;C1266240;C2699757
208,ab / ff $nmbr$ / $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240;C4554348
208,ab $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240
208,$nmbr$ - h pg ( mmol / l ),C0030827;C0072225;C0439190;C1266240;C2827798;C2827804
207,≤ $nmbr$ ug / g,C0439272
207,≤ $nmbr$ u / kg / day,C1532634
207,£ l $nmbr$ kg,C1637390
207,tcz $nmbr$ mg / kg n = $nmbr$,C0439272
207,mean ( sd )  mg / kg $nmbr$,C0439272;C0444504;C2347634;C2348143;C2699239
207,infliximab ( combined $nmbr$ mg / kg and $nmbr$ mg / kg )  n ( % ),C0205195;C0439272;C0666743
207,infliximab $nmbr$ mg / kg,C0439272;C0666743
207,golimumab $nmbr$ mg / kg + mtx,C0025677;C0439272;C1417487;C2353893
207,> $nmbr$ ug / g,C0439272
207,> $nmbr$ u / kg / day,C1532634
207,$nmbr$ mg / kg ( n = $nmbr$ ),C0439272
207,$nmbr$ mg / kg,C0439272
206,≥ $nmbr$ kg / m $nmbr$,C1532718
206,≥ $nmbr$  kg / m $nmbr$,C1532718
206,£ $nmbr$ kg / m $nmbr$,C1532718
206,values are presented as mean sd unless stated otherwise . data shown are for the randomized population . * body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group . † obesity was defined as body mass index $nmbr$ kg / m $nmbr$ . ‡ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection  evaluation  and treatment of high blood cholesterol in adults ( adult treatment panel iii ) criteria $nmbr$ as any $nmbr$ of the following : waist circumference $nmbr$ cm for men or $nmbr$ cm for women  triglycerides $nmbr$ mg / dl  high - density lipoprotein cholesterol $nmbr$ mg / dl for men or $nmbr$ mg / dl for women  mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg  fasting glucose $nmbr$ mg / dl . § by medical history . aliskiren  n $nmbr$  hydrochlorothiazide  n $nmbr$ .,C0001675;C0005893;C0008377;C0015663;C0017725;C0020261;C0023822;C0024671;C0025266;C0026410;C0028754;C0030705;C0032659;C0034656;C0039798;C0041004;C0042295;C0043210;C0086858;C0087111;C0150375;C0205437;C0220825;C0231290;C0243161;C0262926;C0332282;C0376691;C0439070;C0439269;C0439475;C0441833;C0444504;C0449450;C0455829;C0518010;C0524620;C0578022;C0600653;C0680240;C0684224;C0687744;C0700287;C0918012;C1120110;C1257890;C1261322;C1301808;C1305855;C1442792;C1511726;C1511790;C1519504;C1522326;C1532718;C1533734;C1547282;C1551393;C1552854;C1637833;C1704706;C1704788;C1705160;C1705169;C1705428;C1705429;C1705492;C1706365;C1709697;C1960952;C1963185;C1999270;C2241628;C2346927;C2347634;C2348143;C2699239;C2728259;C2986546;C3245479;C3245503;C3272743;C3273238;C3484370;C3538994;C3539106;C3539687;C3714741;C3815594;C3842522;C3887704;C4068104;C4255046;C4321396;C4521761
206,s $nmbr$ kg / m ^,C0565930;C1532718;C2603362
206,s $nmbr$ kg / m $nmbr$,C0565930;C1532718;C2603362
206,patients with bw decrease of $ $nmbr$ % in patients with baseline bmi of $ $nmbr$ kg / m $nmbr$ +,C0005910;C0006041;C0030705;C0168634;C0392756;C0547047;C0578022;C1442488;C1532718;C2986891
206,obesity ( body mass index > $nmbr$ kg / m $nmbr$ ),C0005893;C0028754;C0578022;C1305855;C1532718;C1963185
206,obesity ( bmi £ $nmbr$ kg / m $nmbr$ ),C0028754;C0578022;C1532718;C1963185
206,obesity ( bmi > $nmbr$ kg / m $nmbr$ )  %,C0028754;C0578022;C1532718;C1963185
206,obese ( bmi > $nmbr$ kg / m $nmbr$ ),C0028754;C0578022;C1532718
206,obese ( > $nmbr$ kg / m ^ $nmbr$ ),C0028754;C1532718
206,mean total ipss mean ipss by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0439175;C0439810;C0444504;C0578022;C1019118;C1532718;C1998280;C2347634;C2348143;C2827405;C3811063
206,mean qmax score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0578022;C1532718;C3533236
206,mean iief ef score mean iief domain score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0578022;C1532718;C1880389;C1883221;C3533236;C3541951;C3641331
206,mean bmii 士 s . d .  kg / m $nmbr$,C0444504;C1532718;C2347634;C2348143
206,mean bmi ± sd ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,mean bmi ± s . d .  kg / m ^,C0444504;C0578022;C1532718;C2347634;C2348143
206,mean bmi ± s . d .  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
206,mean bmi ( sd )  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,mean bmi  kg / m $nmbr$ ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,mean ( sd ) bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,low ( < $nmbr$ kg / m ^ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
206,low ( < $nmbr$ kg / m $nmbr$ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
206,lean ( < $nmbr$ kg / m $nmbr$ ),C1532718
206,kg / m $nmbr$ ),C1532718
206,kg / m $nmbr$,C1532718
206,high ( i $nmbr$ kg / m $nmbr$ ) baseline bmi,C0021966;C0168634;C0205250;C0221138;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
206,high ( > $nmbr$ kg / m ^ ) baseline bmi,C0168634;C0205250;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
206,egfr  ml / kg per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439526;C0441923;C1300574;C1532718;C1705224;C1739039;C3811844;C3812682;C3887665
206,bodymass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
206,body mass index group ( ≥ $nmbr$ kg / m $nmbr$ ) — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1305855;C1519504;C1532718;C1705428;C1705429;C4054209
206,body mass index > $nmbr$ kg / m $nmbr$ *,C0005893;C0578022;C1305855;C1532718
206,body mass index > $nmbr$ kg / m $nmbr$  n ( % ),C0005893;C0578022;C1305855;C1532718
206,body mass index < $nmbr$ kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
206,body mass index ( range ) ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1514721;C1532718;C2348147;C3542016
206,body mass index ( kg / m ^ ),C0005893;C0578022;C1305855;C1532718
206,body mass index ( kg / m $nmbr$ ) ∗,C0005893;C0578022;C1305855;C1532718
206,body mass index  kg / m ^ ^,C0005893;C0578022;C1305855;C1532718
206,body - mass index ( kg / m ’ ),C0005893;C0578022;C1305855;C1532718
206,body - mass index ( kg / m - ) !,C0005893;C0578022;C1305855;C1532718
206,body - mass index  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
206,bmp kg - m “ $nmbr$,C0053932;C0279266;C1532718;C4281808
206,bmi kg - m - $nmbr$,C0578022;C1532718
206,bmi group ( kg / m ^ ),C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1519504;C1532718;C1705428;C1705429;C4054209
206,bmi at baseline ( kg / m $nmbr$ ),C0168634;C0578022;C1442488;C1532718
206,bmi > = $nmbr$ kg / m $nmbr$ population ( n = $nmbr$ ),C0032659;C0578022;C1257890;C1532718
206,bmi > $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
206,bmi > $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
206,bmi > $nmbr$ kg / m $nmbr$ ( % ),C0578022;C1532718
206,bmi ( sd )  kg / m $nmbr$,C0578022;C1532718;C2699239
206,bmi ( kg / m $nmbr$ ) < $nmbr$,C0578022;C1532718
206,bmi ( kg / m $nmbr$ ) ( sd ),C0578022;C1532718;C2699239
206,bmi ( kg / m $nmbr$ )  median ( range ),C0549183;C0578022;C0876920;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016
206,bmi # kg - m “ $nmbr$,C0578022;C1532718
206,bmi  median ( iqr )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
206,bmi  mean ± sd kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,bmi  mean ± sd  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,bmi  mean ( sd ) kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,bmi  mean ( sd ) ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,bmi  mean ( sd )  kg / m ^,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,bmi  mean ( sd )  kg / m $nmbr$ c,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,bmi  mean  kg / m $nmbr$ ( ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,bmi  kg / m ^ *,C0578022;C1532718
206,bmi  kg / m ^,C0578022;C1532718
206,bmi  kg / m $nmbr$ cholesterol  mg / dl,C0008377;C0439269;C0578022;C1532718
206,bmi  kg / m $nmbr$ ( sd ),C0578022;C1532718;C2699239
206,bmi  kg / m $nmbr$ ( mean $nmbr$ sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
206,bmi  kg / m $nmbr$  n ( % ),C0578022;C1532718
206,bmi  kg / m $nmbr$  mean,C0444504;C0578022;C1532718;C2347634;C2348143
206,bm $nmbr$ ( kg / m $nmbr$ ),C0006416;C1532718
206,bl bm $nmbr$ < $nmbr$ kg / m ^,C0005918;C0006413;C0006416;C1532718;C1552663;C2827109
206,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0439230;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
206,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$,C0168634;C0578022;C1442488;C1532718
206,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$,C0168634;C0578022;C1442488;C1532718
206,baseline bmi > $nmbr$ kg / m $nmbr$,C0168634;C0578022;C1442488;C1532718
206,baseline bmi < $nmbr$ kg / m $nmbr$,C0168634;C0578022;C1442488;C1532718
206,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0439230;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
206,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0439230;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
206,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$,C0168634;C0578022;C1442488;C1532718
206,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$,C0168634;C0578022;C1442488;C1532718
206,a $nmbr$ kg / m $nmbr$,C1532718
206,[ kg / m ^ ],C1532718
206,> = $nmbr$ kg / m $nmbr$,C1532718
206,> $nmbr$ kg / m ’,C1532718
206,> $nmbr$ kg / m ^ ( obesity ),C0028754;C1532718;C1963185
206,> $nmbr$ kg / m ^,C1532718
206,> $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),C1532718
206,> $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
206,> $nmbr$ kg / m $nmbr$,C1532718
206,> $nmbr$ . $nmbr$ kg / m $nmbr$ hypertension :,C0020538;C1532718;C1963138
206,> $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
206,> $nmbr$ - s $nmbr$ kg / m ’,C0565930;C1532718;C2603362
206,> $nmbr$ - ^ $nmbr$ kg / m ’,C1532718
206,> $nmbr$ - < s $nmbr$ kg / m ’,C0565930;C1532718;C2603362
206,> $nmbr$ - < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
206,< $nmbr$ kg / m ^,C1532718
206,< $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),C1532718
206,< $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
206,< $nmbr$ kg / m $nmbr$,C1532718
206,< $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
206,< $nmbr$  kg / m $nmbr$,C1532718
206,$nmbr$ to < $nmbr$ kg / m $nmbr$,C1532718
206,$nmbr$ kg / m ’,C1532718
206,$nmbr$ kg / m $nmbr$ or more,C0205172;C1532718
206,$nmbr$ kg / m $nmbr$,C1532718
206,$nmbr$ bmi  kg / m,C0578022;C1532718
206,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
206,$nmbr$ - < $nmbr$ kg / m $nmbr$,C1532718
206,$nmbr$ - $nmbr$ kg / m $nmbr$,C1532718
206,$nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
206,$nmbr$ $nmbr$ to < $nmbr$ kg / m $nmbr$,C1532718
205,« $nmbr$ kg,C0022718;C0439209;C4054209
205,£ $nmbr$ kg,C0022718;C0439209;C4054209
205,weight 一 kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight — kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight at randomization ( kg ),C0022718;C0439209;C2985844;C4054209
205,weight [ kg ],C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight > $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight < $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight - kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight ( kg ) 十,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight ( kg ) a,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight ( kg ) ( mean ± sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight ( kg )  mean   ±   sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight ( kg )  mean ± sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight  median ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2699239;C2939193;C4054209
205,weight  mean ± sd kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight  mean ( sd ) ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight  mean ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight  kg mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight  kg *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,weight  kg ( mean $nmbr$ sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight  kg  mean ± sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight  kg  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
205,weight  kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
205,total daily insulin dose ( lu / kg ),C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
205,q $nmbr$ : > $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
205,q $nmbr$ : < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
205,o $nmbr$ kg  n ( % ),C0022718;C0439209;C0483204;C4054209
205,median weight  kg ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
205,median m / kg $nmbr$ ( iqr ),C0022718;C0369637;C0439209;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
205,median body weight — kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
205,median body weight ( kg ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
205,mean body weight ( sd )  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
205,mean body weight  kg ( range ),C0005910;C0022718;C0439209;C0444504;C1305866;C1514721;C2347634;C2348143;C2348147;C3542016;C4054209
205,mean body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C4054209
205,lu / kg,C0022718;C0024171;C0024176;C0439209;C2697939;C4054209
205,low body weight ( < $nmbr$ kg ),C0022718;C0041667;C0439209;C4054209
205,kg,C0022718;C0439209;C4054209
205,grip strength ( kg ),C0022718;C0429271;C0439209;C2598165;C4054209
205,dose adjustment reason < $nmbr$ kg,C0022718;C0439209;C2826286;C4054209
205,difference vs . placebo  kg ( $nmbr$ % cl ),C0022718;C0032042;C0439209;C0596019;C1696465;C1705241;C1705242;C1706408;C4054209
205,daily total dose of insulin — lu / kg,C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
205,bw at $nmbr$ weeks  kg +,C0005910;C0006041;C0022718;C0439209;C0439230;C2986891;C4054209
205,bw  kg,C0005910;C0006041;C0022718;C0439209;C2986891;C4054209
205,bodyweight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
205,bodyweight  kg,C0005910;C0022718;C0439209;C1305866;C4054209
205,body weight — kg,C0005910;C0022718;C0439209;C1305866;C4054209
205,body weight ( kg ) *,C0005910;C0022718;C0439209;C1305866;C4054209
205,body weight ( kg )  n ( % ),C0005910;C0022718;C0439209;C1305866;C4054209
205,body weight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
205,body weight  mean = sd  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
205,body weight  kg ^,C0005910;C0022718;C0439209;C1305866;C4054209
205,body weight  kg ( sd ),C0005910;C0022718;C0439209;C1305866;C2699239;C4054209
205,body weight  kg,C0005910;C0022718;C0439209;C1305866;C4054209
205,body mass index ( kg / nr ),C0005893;C0022718;C0027496;C0439209;C0578022;C1305855;C3844738;C4054209
205,body mass index ( bmi  kg / m $nmbr$ )  n ( % ) < $nmbr$ kg / m $nmbr$,C0005893;C0022718;C0439209;C0578022;C1305855;C1709500;C4054209
205,body mass  kg,C0022718;C0439209;C0518010;C4054209
205,body - mass index > $nmbr$ kg / nrn,C0005893;C0022718;C0439209;C0578022;C1305855;C1425210;C4054209
205,body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0578022;C1305855;C4054209
205,body - mass index ( kg / mj ) previous diagnosis,C0005893;C0022718;C0332132;C0439209;C0439254;C0578022;C1305855;C4054209;C4284025
205,bmi : < $nmbr$ kg / nr,C0022718;C0027496;C0439209;C0578022;C3844738;C4054209
205,bmi ( kg / rrr ),C0022718;C0439209;C0578022;C4054209
205,bmi $nmbr$ - < $nmbr$ kg / ni - ( n = $nmbr$ / $nmbr$ ),C0022718;C0028075;C0439209;C0578022;C2348274;C3869926;C3869927;C4054209
205,bmi  mean ( sd )  kg / rn $nmbr$,C0022718;C0439209;C0444504;C0578022;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819
205,baseline weight  kg,C0022718;C0439209;C1303013;C4054209
205,adjusted mean change ( kg ),C0022718;C0392747;C0439209;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4054209;C4319952
205,actual or estimated weight  kg,C0022718;C0237400;C0439209;C4054209;C4329797
205,> = $nmbr$ kg,C0022718;C0439209;C4054209
205,> $nmbr$ kg — no . ( % ),C0022718;C0439209;C4054209
205,> $nmbr$ kg nr,C0022718;C0027496;C0439209;C3844738;C4054209
205,> $nmbr$ kg / nr,C0022718;C0027496;C0439209;C3844738;C4054209
205,> $nmbr$ kg,C0022718;C0439209;C4054209
205,> $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
205,> $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
205,> $nmbr$ - $nmbr$ kg,C0022718;C0439209;C4054209
205,< = € $nmbr$ kg,C0022718;C0439209;C4054209
205,< = $nmbr$ kg,C0022718;C0439209;C4054209
205,< $nmbr$ kg ' i ',C0021966;C0022718;C0221138;C0439209;C4054209
205,< $nmbr$ kg  n ( % ),C0022718;C0439209;C4054209
205,< $nmbr$ kg,C0022718;C0439209;C4054209
205,< $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
205,. $nmbr$ kg mtx use,C0022718;C0025677;C0042153;C0439209;C0457083;C1417487;C1947944;C4054209
205,. $nmbr$ kg,C0022718;C0439209;C4054209
205,$nmbr$ to < $nmbr$ kg,C0022718;C0439209;C4054209
205,$nmbr$ kg,C0022718;C0439209;C4054209
205,$nmbr$ - < $nmbr$ kg,C0022718;C0439209;C4054209
205,$nmbr$ - $nmbr$ kg,C0022718;C0439209;C4054209
205,# $nmbr$ kg,C0022718;C0439209;C4054209
204,≥ $nmbr$ ng / ml,C0439275
204,wap $nmbr$ c ( ng / ml ),C0439275
204,vegfr ( ng / ml ),C0439275;C1568520
204,troy ( ng / ml ),C0439275;C1420811;C1883402
204,tnf - r $nmbr$ a ( ng / ml ),C0439275;C1363984;C1706001
204,tertile $nmbr$ ( < $nmbr$ . $nmbr$ ng / ml ) n - $nmbr$,C0439275
204,t $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml ),C0439275;C2603360
204,syndecan - $nmbr$ ( ng / ml ),C0075691;C0439275;C1419891
204,sdc ( ng / ml ),C0439275;C1419891;C3273112
204,sdc ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml ),C0439275;C1419891;C3273112
204,sdc $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml,C0439275;C1419891;C3273112
204,rage ( ng / ml ),C0034634;C0439275;C3539760;C3815186
204,ptx $nmbr$ ( ng / ml ),C0030899;C0439275
204,psap - b ( ng / ml ),C0439275;C1418975;C1420002;C1425004
204,psa level  ng / ml,C0439275;C4086720
204,psa ( ng / ml ),C0439275;C3810537;C3813209
204,psa  ng / ml  mean ( sd ),C0439275;C0444504;C2347634;C2348143;C2699239;C3810537;C3813209
204,proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - > = median ( n = $nmbr$  $nmbr$ ),C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
204,proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - < median ( n = $nmbr$  $nmbr$ ),C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
204,procalcitonin ( ng / ml ),C0072027;C0439275
204,proadm ( ng / ml ),C0439275
204,pigr ( ng / ml ),C0439275;C1418569
204,pentraxin - $nmbr$ ( ng / ml ),C0439275
204,osteopontin ( ng / ml ),C0069676;C0439275;C1420369;C1505427;C4084879
204,opg  ( ng / ml ),C0439275;C1262886;C1336645;C1412836;C1710303
204,ntpro - cnp ( ng / ml ),C0439275;C3889729
204,nt probnp > $nmbr$ ng / ml n ( % ) §,C0439275;C1317554;C2825907;C4284038
204,ngal ( ng / ml ),C0215955;C0439275;C1416806;C2346625
204,neuropilin ( ng / ml ),C0287275;C0439275
204,mpo ( ng / ml ),C0439275
204,mmp - $nmbr$ ( ng / ml ) *,C0439275;C0623362;C0919336
204,mmp - $nmbr$ ( ng / ml ),C0439275;C0623362;C0919336
204,mesothelin ( ng / ml ),C0380162;C0439275;C1334533
204,ltbr ( ng / ml ),C0439275;C1416931
204,gdf - $nmbr$ ( ng / ml ),C0439275;C1418244
204,galectin - $nmbr$ ( ng / ml ),C0439275;C0607430
204,fasting c - peptide ( ng / ml ),C0006558;C0015663;C0439275
204,fasting c - peptide  ng / ml,C0006558;C0015663;C0439275
204,esam ( ng / ml ),C0439275;C1424976
204,ctn - l  ng / ml,C0439275;C0917591
204,ctn - i  ng / ml,C0021966;C0221138;C0439275;C0917591
204,crp ( ng / ml ),C0439275;C3890735;C4048285
204,ck - mb  ng / ml,C0010290;C0439275
204,cholesterol ( ng / ml ),C0008377;C0439275
204,biomarker low ( periostin < $nmbr$ ng / ml or blood eosinophils < $nmbr$ cells per pl )  na,C0005516;C0005773;C0007584;C0007634;C0014467;C0200638;C0205251;C0219433;C0439275;C0597484;C1272460;C1424662;C1546968;C1550472;C1879645;C3812270;C3890211;C3897966;C4048187;C4049765;C4049872;C4321351;C4522223;C4552882
204,angiogenin ( ng / ml ),C0051844;C0439275;C1367482
204,> $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ ),C0439275
204,> $nmbr$ . $nmbr$ ng / ml,C0439275
204,< $nmbr$ ng / ml,C0439275
204,< $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ ),C0439275
204,< $nmbr$ . $nmbr$ ng / ml,C0439275
203,ng ( n = $nmbr$  $nmbr$ ),C0017887;C0028074
203,ng,C0017887;C0028074
203,median serum periostin  ng / mla,C0017887;C0028074;C0219433;C0229671;C0549183;C0599973;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
203,d - dimer level  mean ( sd )  ng / mld,C0017887;C0023522;C0028074;C0060323;C0441889;C0444504;C0456079;C1539265;C1547707;C2347634;C2348143;C2699239;C2946261;C3539688;C3539689
202,troponin t ( pg / ml ),C0077404;C0439297;C1420827
202,troponin i ( pg / ml ),C0077401;C0439297
202,tnf - alpha ( pg / ml ),C0439297;C1448177;C1456820;C1522669
202,n - terminal pro - brain natriuretic peptide  pg / ml,C0439297;C3272900
202,kim $nmbr$ ( pg / ml ),C0439297
202,interleukin - $nmbr$ ( ng / l ),C0021764;C0439297;C1527200
202,interleukin $nmbr$ ( pg / ml ),C0021764;C0439297;C1527200
202,endothelin $nmbr$ ( pg / ml ),C0079284;C0439297
202,b - natriuretic peptide . pg / ml,C0070338;C0439297;C0597421
202,avp pg / ml,C0439297;C1098706;C1568204;C1708407
202,> ulnand < $nmbr$ ng / l,C0439297
202,> = $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
202,> = $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
202,> = $nmbr$ ng / l ( n = $nmbr$ ),C0439297
202,> = $nmbr$ . $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
202,> $nmbr$ ng / l,C0439297
202,< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
202,< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ),C0439297
202,% phg,
202,$nmbr$ . $nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ ),C0439297
202,$nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ ),C0439297
201,mmp - $nmbr$  median ( iqr )  gg / l,C0017454;C0018370;C0549183;C0623362;C0876920;C0919336;C2347635;C2348144;C2939193
201,ind $nmbr$ gg q . d . n / n ( % ),C0017454;C0018370;C4049864
201,gly $nmbr$ . $nmbr$ gg b . i . d n / n ( % ),C0017454;C0018370;C0152277;C1415124
201,gg,C0017454;C0018370
200,urine acr ( mg / mmol ),C0042036;C0042037;C0567349;C1412134;C1515941;C2348885;C2963137
200,urinary acr ( mg / mmol ),C0042027;C0567349;C1412134;C1515941;C1524119;C2348885
200,uacr   ≥ $nmbr$   mg / mmol ∗,C0567349;C2348885
200,uacr   < $nmbr$   mg / mmol ∗,C0567349;C2348885
200,s $nmbr$ mg / mmol,C0565930;C0567349;C2348885;C2603362
200,s $nmbr$ . $nmbr$ mg / mmol,C0565930;C0567349;C2348885;C2603362
200,mg / mmol,C0567349;C2348885
200,median ( sd )  mg / mmol,C0549183;C0567349;C0876920;C2347635;C2348144;C2348885;C2699239;C2939193
200,mean a ± sd  mg / dl ( mmol / $nmbr$ ),C0439190;C0439269;C0444504;C0567349;C2347634;C2348143;C2348885;C2699239;C3642216
200,bl mean  mg / dl ( mmol / $nmbr$ ),C0005918;C0006413;C0439190;C0439269;C0444504;C0567349;C1552663;C2347634;C2348143;C2348885;C2827109;C3642216
200,albumin / creatinine ratio - mg / mmol  median ( iqr ),C0486293;C0549183;C0567349;C0876920;C1318293;C2347635;C2348144;C2348885;C2939193
200,acr  mg / mmol,C0567349;C1412134;C1515941;C2348885
200,> $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
200,< $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
200,. $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
200,$nmbr$ . $nmbr$ to # $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
200,$nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
200,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
199,umec $nmbr$ . $nmbr$ mcg ( n = $nmbr$ ),C0439211;C3463985
199,tio i $nmbr$ mcg ( n = $nmbr$ ),C0021966;C0221138;C0439211;C3463985
198,steroid use at baseline ( mg / day ),C0168634;C0281991;C0439422;C1442488
198,simvastatin ( $nmbr$ / $nmbr$ mg / d ) ( n = $nmbr$ ),C0074554;C0439422
198,simvastatin ( $nmbr$ / $nmbr$ mg / d ),C0074554;C0439422
198,rsg $nmbr$ mg / day,C0439422
198,rasagiline  $nmbr$ mg / day,C0439422;C0525678
198,placebo + $nmbr$ mg / d of simvastatin ( n = $nmbr$ ),C0032042;C0074554;C0439422;C1696465;C1706408
198,no . of $nmbr$ - mg acetaminophen tablets / day,C0439422;C1243102
198,mg / day,C0439422
198,methotrexate dose on day $nmbr$ — mg per wl < $nmbr$,C0025677;C0178602;C0332173;C0439228;C0439422;C0439505;C0869039;C1114758;C4086581
198,mean dose ( sd ) ( mg / day ),C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
198,levodopa dose  mean ± sd  mg / day,C0023570;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
198,leflunomide ( mean dose : $nmbr$ . $nmbr$ mg / day ),C0063041;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
198,itca $nmbr$ $nmbr$ mg / day ( n = $nmbr$ ),C0165330;C0439422
198,ind $nmbr$ mg q . d . n = $nmbr$,C0439422;C4049864
198,dose ( mg / day ),C0178602;C0439422;C0869039;C1114758
198,dietary epa - dha intake ( mg / day ) *,C0142831;C0439422;C1286104;C2348308
198,dapagliflozin $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C2353951
198,brv dosage  mg / d,C0155502;C0178602;C0439422;C2986497
198,brv > $nmbr$ mg / day,C0155502;C0439422
198,brv $nmbr$   mg / day,C0155502;C0439422
198,brv $nmbr$ mg / day ( n = $nmbr$ ),C0155502;C0439422
198,brv $nmbr$ mg / day ( n =,C0155502;C0439422
198,baseline corticosteroidst ( mean dose : $nmbr$ . $nmbr$ mg / day )  n ( % ),C0168634;C0178602;C0439422;C0444504;C0869039;C1114758;C1442488;C2347634;C2348143
198,> $nmbr$ mg / day,C0439422
198,> $nmbr$ mg / d peq,C0439422
198,> $nmbr$ . $nmbr$ mg / day  %,C0439422
198,< $nmbr$ mg / day,C0439422
198,< $nmbr$ mg / d peq,C0439422
198,$nmbr$ mg / day,C0439422
198,$nmbr$ mg / d ( n = $nmbr$ ),C0439422
197,urinary protein : creatinine ratioa ( mg / mg ),C0042027;C0369901;C0428627;C1319635;C1524119
197,urinary albumin : creatinine ratio ( pg / mg )  median ( iqr ),C0455271;C0549183;C0876920;C1318330;C1627892;C2347635;C2348144;C2939193
197,uacr  pg / mg,C1627892
197,( pg / mg ),C1627892
197,$nmbr$ baricitinib $nmbr$ mg ■ baricitinib $nmbr$ mg,C1319635;C4044947
196,≥ $nmbr$ to < $nmbr$ mg / g,C1300563
196,≥ $nmbr$ mg / g,C1300563
196,urine acr geometric mean ( cv % )  a  b mg / g,C0042036;C0042037;C1300563;C1412134;C1515941;C2963137;C2986759;C3538987;C4048877;C4318503
196,urine acr ( mg / g ),C0042036;C0042037;C1300563;C1412134;C1515941;C2963137
196,uacra  mg / g  n ( % ),C1300563
196,uacra  mg / g  gmean = gcv,C0017066;C1300563
196,uacr — mg / g  median ( iqr ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
196,uacr *  mg / g ( q $nmbr$  q $nmbr$ ),C1300563
196,uacr ( mg / g ),C1300563
196,uacr ( mg / g  median [ iqr ] ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
196,uacr  mg / g  median ( iqr ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
196,uacr  median ( iqr )  mg / g,C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
196,uac > $nmbr$ mg / g,C1300563
196,uac $nmbr$ - $nmbr$ mg / g,C1300563
196,prevalent kidney disease ( egfr < $nmbr$ ml / min / usm ^ or maeroalbuminuria uacr > $nmbr$ mg / g ),C0022658;C0033105;C0220900;C0439445;C1300563;C1739039;C3811844;C3812682
196,normoalbuminuria ( uacr < $nmbr$ mg / g ),C1300563
196,normal acr ( < $nmbr$ mg / mg ) at baseline to albuminuria ( acr > $nmbr$ mg / g ),C0001925;C0168634;C0205307;C0231683;C0439166;C1300563;C1319635;C1412134;C1442488;C1515941;C2347086;C4553972
196,microalbuminuria  mg / g cr,C0201975;C0730345;C1300563;C3539604;C3711669;C4084730;C4553336;C4553337
196,mg / g,C1300563
196,mean fecal calprotectin level  mg / g stool ( sd ),C0015733;C0183622;C0441889;C0444504;C0456079;C0950624;C1300563;C1335798;C1366582;C1547707;C2347634;C2348143;C2699239;C2946261
196,fcal  mg / g  mean ± sd,C0444504;C1300563;C2347634;C2348143;C2699239
196,cohort $nmbr$ ( uacr > $nmbr$ . $nmbr$ mg / g ),C0009247;C0599755;C1300563
196,cohort $nmbr$ ( uacr < $nmbr$ . $nmbr$ mg / g ),C0009247;C0599755;C1300563
196,baseline uacr > $nmbr$ mg / g,C0168634;C1300563;C1442488
196,baseline uacr < $nmbr$ mg / g,C0168634;C1300563;C1442488
196,acr > $nmbr$ mg / g,C1300563;C1412134;C1515941
196,acr ( mg / g )  mean ( sd ),C0444504;C1300563;C1412134;C1515941;C2347634;C2348143;C2699239
196,^ $nmbr$ mg / g  n ( % ),C1300563
196,> = $nmbr$ mg / g,C1300563
196,> $nmbr$ to $nmbr$ mg / g,C1300563
196,> $nmbr$ mg / g,C1300563
196,< $nmbr$ mg / g  n ( % ),C1300563
196,< $nmbr$ mg / g,C1300563
196,- median urine acr ( mg / g ) ( iqr ),C0042036;C0042037;C0549183;C0876920;C1300563;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
196,$nmbr$ − $nmbr$ mg / g,C1300563
196,$nmbr$ to $nmbr$ mg / g,C1300563
196,$nmbr$ mg / g  n ( % ),C1300563
196,$nmbr$ mg / g,C1300563
196,$nmbr$ - $nmbr$ mg / g,C1300563
195,serum fg  mg / dl,C0016703;C0229671;C0439214;C0439269;C1546774;C1550100;C1638318;C2348814;C3642216
195,serum cholesterol ( mg / l ) *,C0439268;C0587184
195,serum cholesterol  mg / dl,C0439269;C0587184
195,serum cholesterol  median ( iqr )  mg / dl,C0439269;C0549183;C0587184;C0876920;C2347635;C2348144;C2939193
195,fg > $nmbr$,C0016703;C0439214;C2348814
194,mtx ( mean dose : $nmbr$ . $nmbr$ mg / wk ),C0366550;C0444504;C1881833;C2347634;C2348143
194,$nmbr$ mg / $nmbr$ wk ( n = $nmbr$ ),C1881833
193,≤ $nmbr$ mg / l,C0439268
193,upadacitinib $nmbr$ mg ( n = l $nmbr$ ),C0439268
193,mean hscrp  mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239
193,mean crp level  mg / l ( sd ),C0439268;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285
193,mean baseline ibdq score ( sd ) § crp concentration  mg / l,C0086045;C0168634;C0439268;C1442488;C1446561;C2699239;C3533236;C3827302;C3890735;C4048285
193,mean ( sd ) crp  mg / l *,C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
193,hscrp > $nmbr$ to < $nmbr$ mg / l,C0439268
193,hscrp > $nmbr$ mg / l,C0439268
193,hscrp > $nmbr$ . $nmbr$ mg / l,C0439268
193,hscrp < $nmbr$ . $nmbr$ mg / l,C0439268
193,hscrp ( mg / l ) c,C0439268
193,hscrp ( mg / l )  median ( minimum ‒ maximum ),C0439268;C0549183;C0806909;C0876920;C1524031;C1552614;C1552615;C2347635;C2348144;C2826545;C2826546;C2939193
193,hscrp ( mg / l )  median ( first  third quartiles ),C0205435;C0205437;C0439268;C0549183;C0876920;C1279901;C2347635;C2348144;C2828255;C2939193
193,hscrp ( mg / l ),C0439268
193,hscrp  mg / l,C0439268
193,hscrp  median ( iqr )  mg / l,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193
193,high sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
193,high - sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
193,high - sensitivity c - reactive protein  mg / l,C0006560;C0439268;C1413716;C1441604;C4048285
193,high - density lipoprotein cholesterol  mg / l,C0023822;C0439268
193,geometric mean crp concentration ( mg / l ),C0086045;C0439268;C1446561;C2986759;C3827302;C3890735;C4048285
193,final median  mg / l,C0205088;C0439268;C0549183;C0876920;C1546485;C2347635;C2348144;C2939193;C3853528
193,crp — mg / l,C0439268;C3890735;C4048285
193,crp < $nmbr$ mg / l  n,C0439268;C3890735;C4048285
193,crp ( mg / l ) : < $nmbr$,C0439268;C3890735;C4048285
193,crp ( mg / l )  n,C0439268;C3890735;C4048285
193,crp ( mg / l )  median ± sd,C0439268;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3890735;C4048285
193,crp ( mg / l )  mean ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
193,crp $ $nmbr$ mg / l  n,C0439268;C3890735;C4048285
193,crp  mg / l : median ( range ),C0439268;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
193,crp  mg / l *,C0439268;C3890735;C4048285
193,crp  mg / l,C0439268;C3890735;C4048285
193,crp  mean mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
193,cld $nmbr$ mg ( n = l $nmbr$ ),C0439268
193,canakinumab  hscrp > $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0439231;C0439268;C2718773
193,canakinumab  hscrp < $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0439231;C0439268;C2718773
193,c - reactive protein concentration ( mg / l ),C0006560;C0086045;C0439268;C1413716;C1446561;C3827302;C4048285
193,c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C4048285
193,c - reactive protein  mg / l,C0006560;C0439268;C1413716;C4048285
193,c - reactive protein  * mg / l,C0006560;C0439268;C1413716;C4048285
193,baseline serum mg > = $nmbr$ . $nmbr$ mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
193,baseline serum mg < $nmbr$ . $nmbr$ mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
193,baseline median  mg / l,C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
193,baseline crp levels ≥ $nmbr$ mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
193,baseline crp levels < $nmbr$ mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
193,baseline crp category ( mg / l ),C0168634;C0439268;C0683312;C1442488;C3889287;C3890735;C4048285
193,about $nmbr$ mg / l or more,C0205172;C0439268
193,about $nmbr$ mg / l,C0439268
193,> $nmbr$ mg / l ( n = $nmbr$ ),C0439268
193,> $nmbr$ mg / l,C0439268
193,> $nmbr$ . $nmbr$ mg / l,C0439268
193,< $nmbr$ mg / l ( n = $nmbr$ ),C0439268
193,< $nmbr$ mg / l,C0439268
193,< $nmbr$ . $nmbr$ mg / l,C0439268
193,( ≥ $nmbr$ mg / l ),C0439268
193,( < $nmbr$ mg / l ),C0439268
193,% change median baseline crp > $nmbr$ mg / l,C0168634;C0392747;C0439268;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C3890735;C4048285;C4319952
193,$nmbr$ to $nmbr$ mg / l ( n = $nmbr$ ),C0439268
193,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / l,C0439268
192,≥ $nmbr$ to < $nmbr$ mg / dl,C0439269
192,≥ $nmbr$ mg / dl,C0439269
192,£ $nmbr$ mg / dl,C0439269
192,with baseline crp level of > $nmbr$ mg / liter,C0024671;C0026410;C0168634;C0439269;C0441889;C0456079;C0475211;C1442488;C1547707;C1960952;C2346927;C2946261;C3890735;C4048285;C4321396;C4521761
192,week $nmbr$ ertugliflozin $nmbr$   mg vs . placebo,C0024671;C0026410;C0032042;C0332174;C0439230;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761
192,week $nmbr$ ertugliflozin $nmbr$ mg vs placebo,C0024671;C0026410;C0032042;C0332174;C0439230;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761
192,week $nmbr$ ertugliflozin $nmbr$ mg vs . placebo,C0024671;C0026410;C0032042;C0332174;C0439230;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761
192,week $nmbr$ czp $nmbr$ mg q $nmbr$ w ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,week $nmbr$ czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,vonoprazan $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4080009;C4321396;C4521761
192,viidagliptin $nmbr$ mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
192,uric acid tertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
192,uric acid tertile $nmbr$ ( < $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
192,uric acid tertile $nmbr$ ( $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
192,uric acid fertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl ),C0015895;C0041980;C0439269
192,uric acid ( mg / dl ) creatinine clearance ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0024671;C0026410;C0041980;C0151280;C0369637;C0439269;C0441923;C1960952;C2346927;C3642208;C4321396;C4521761
192,uric acid ( mg / dl ),C0041980;C0439269
192,upa $nmbr$ mg qd,C0024671;C0026410;C0042071;C0332173;C0439269;C1706177;C1960952;C2346927;C4321396;C4521761
192,u » c » ( mg / g ),C0024671;C0026410;C0439148;C0439267;C0439269;C1300563;C1532633;C1638407;C1960952;C2346927;C2608091;C4321396;C4521761
192,triglycerides level  mg / dl,C0428475;C0439269
192,triglycerides ( sd )  mg / dl,C0041004;C0439269;C2699239
192,triglycerides  mg / dl,C0041004;C0439269
192,triglyceride ( mg / dl ),C0041004;C0439269
192,triglyceride  mg / dl  mean ( sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
192,total intravenous loop diuretic ( mg ) median,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C0549183;C0876920;C1960952;C2346927;C2347635;C2348144;C2939193;C3536704;C4321396;C4521761
192,total glucose mg / dl,C0017725;C0439175;C0439269;C0439810
192,total cholesterol level  mg / dl,C0439269;C0878805;C1445957
192,total chol  mg / dl,C0201950;C0439175;C0439269;C0439810
192,total c ( mg / dl ) *,C0439175;C0439269;C0439810
192,toricoxib $nmbr$ mg n = $nmbr$ ) ( % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,toial cholcsierol ( mg / dl ),C0439269
192,tofacitinib $nmbr$ mg twice daily n = $nmbr$,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
192,tofacitinib  $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
192,tiotropium / olodaterol $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
192,tiotropium / olodaterol $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
192,tiotropium / olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
192,tiotropium + olodaterol $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
192,tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
192,tiotropium $nmbr$ mg respimat ® ( n z $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
192,tiotropium $nmbr$ mg respimat ® ( n = $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
192,tiotropium $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
192,tiotropium $nmbr$ mg ( n = $nmbr$,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
192,tiotropium $nmbr$ mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
192,tiotropium $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
192,ticagrelor $nmbr$ mg no diabetes n = $nmbr$,C0011847;C0011849;C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
192,ticagrelor $nmbr$ mg km %,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
192,ticagrelor $nmbr$ mg diabetes n = $nmbr$,C0011847;C0011849;C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
192,ticagrelor $nmbr$ mg $nmbr$ year km ( % ),C0024671;C0026410;C0439234;C0439269;C0439508;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
192,ticagrelor $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
192,ticagrelor  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
192,tg mg / dl  median ( sd ),C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
192,tg > $nmbr$ mg / dl  n ( ° / o ),C0337445;C0439269
192,tg > $nmbr$ . hdl < $nmbr$ ( mg / dl ) ( / ? = $nmbr$ ),C0337445;C0439269;C3715113
192,tg ( mg / dl )  median ± sd,C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
192,tg ( mg / dl ),C0337445;C0439269
192,tg  mg / dl  mean ± sd,C0337445;C0439269;C0444504;C2347634;C2348143;C2699239
192,tanezumab $nmbr$ mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
192,tanezumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
192,tanezumab $nmbr$ . $nmbr$ mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
192,tanezumab $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
192,t $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2603360;C4321396;C4521761
192,sita $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,sirukumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
192,silodosin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1870115;C1960952;C2346927;C4321396;C4521761
192,serum uric acid ( mg / dl ),C0439269;C0455272;C0700634
192,serum uric acid  mg / dl,C0439269;C0455272;C0700634
192,serum urea nitrogen  mg / dl,C0028158;C0229671;C0439269;C0600137;C0856666;C1291218;C1546774;C1550100;C1550581;C3683557
192,serum urate ( mg / dl )  n ( % ),C0439269;C0455272
192,serum urate ( mg / dl ),C0439269;C0455272
192,serum triglycerides  mg / dle,C0024138;C0024671;C0026410;C0439269;C0542495;C1960952;C2346927;C3542918;C4321396;C4521761
192,serum glucose ( mg / dl ),C0202041;C0439269;C3534430
192,serum creatinine level  mean ( sd )  mg / dl,C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
192,serum creatinine  mg / dlb,C0024671;C0026410;C0201976;C0439269;C0600061;C0752347;C1960952;C2346927;C3890365;C4321396;C4521761
192,serum cholesterol  mg / dld,C0024671;C0026410;C0439269;C0587184;C1414063;C1960952;C2346927;C2826331;C4321396;C4521761
192,serum cholesterol  mean ( sd ) mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143;C2699239
192,serum cholesterol  mean ( sd )  mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143;C2699239
192,secukinumab intravenous $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0348016;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
192,secukinumab $nmbr$   mg no load ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1550025;C1704782;C1708715;C1960952;C2346927;C3179547;C4321396;C4521761
192,secukinumab $nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
192,secukinumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
192,secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
192,sc belimumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
192,saxa $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,saxa $nmbr$ mg $nmbr$ metformin ( n $nmbr$ $nmbr$ ),C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,saxa $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,rosuva $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,rosuva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,rosiglitazone $nmbr$ mg daily,C0024671;C0026410;C0289313;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
192,rosiglitazone $nmbr$ mg daik,C0024671;C0026410;C0289313;C0439269;C1960952;C2346927;C4321396;C4521761
192,randomized to canakinumab $nmbr$ mg,C0024671;C0026410;C0034656;C0040363;C0041260;C0439269;C1883351;C1960952;C2346927;C2718773;C3815594;C4321396;C4521761
192,r $nmbr$ mg + fa ( « = $nmbr$ ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
192,r $nmbr$ mg + fa,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
192,r $nmbr$ mg ( « = $nmbr$ ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
192,r $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0687673;C1960952;C2346927;C4321396;C4521761
192,r $nmbr$ mg,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
192,prednisone - equivalent dose — mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
192,ppg  mg / dl,C0439269;C1418888
192,plasma lipids ( mg / dl ) $nmbr$ total cholesterol mean,C0023779;C0439269;C0444504;C0858034;C2347634;C2348143
192,plasma cholesterol — mg / dl,C0439269;C0858034
192,placebofigolimumab $nmbr$ mg / $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,pitavastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1101838;C1960952;C2346927;C4321396;C4521761
192,periprocedural medications  n ( % ) clopidogrel  $nmbr$ mg *,C0013227;C0024671;C0026410;C0070166;C0439269;C0802604;C1960952;C2346927;C2598133;C4284232;C4321396;C4521761
192,pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ ( n = $nmbr$ ),C0024671;C0026410;C0031962;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,patients receiving $nmbr$ mg of edoxaban at randomization — no . ( % ) f,C0016327;C0024671;C0026410;C0030705;C0034656;C0439269;C1514756;C1960952;C2346927;C2975435;C4321396;C4521761
192,p - value d $nmbr$ mg vs . warfarin,C0024671;C0026410;C0043031;C0439269;C1709380;C1960952;C2346927;C4321396;C4521761
192,oral glucocorticoid dose  mg ( prednisone equivalent ),C0017710;C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0442027;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761;C4521986
192,on maximum tolerated medications ( % ) median ( $nmbr$ th to $nmbr$ th quartile ) sua ( mg / dl ),C0013227;C0039725;C0039738;C0439269;C0549183;C0802604;C0806909;C0876920;C1420718;C1552615;C2347635;C2348144;C2598133;C2826546;C2828255;C2939193;C4282123;C4284232;C4285344
192,omalizumab $nmbr$ mg ( n [ $nmbr$ ),C0024671;C0026410;C0439269;C0966225;C1960952;C2346927;C4321396;C4521761
192,olodaterol $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
192,olodaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
192,olmesartan medoxomil $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0386393;C0439269;C1960952;C2346927;C4321396;C4521761
192,non - hdl - c ( mg / dl ) * *,C0439269;C1518422;C3715113
192,non - hdl - c ( mg / dl ),C0439269;C1518422;C3715113
192,non - hdl - c  mg / dl,C0439269;C1518422;C3715113
192,non - hdl ( mg / dl ) < $nmbr$,C0439269;C1518422;C3715113
192,no . of $nmbr$ - mg tablets of acetaminophen,C0024671;C0026410;C0439269;C1243102;C1960952;C2346927;C4321396;C4521761
192,mtx ≤ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
192,mtx dose > $nmbr$ mg / week  %,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
192,mtx average weekly dose  mg / week  mean ( sd ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1510992;C1960952;C2346927;C2347634;C2348143;C2699239;C2825518;C4321396;C4521761
192,mtx > $nmbr$ – $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
192,mtx > $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
192,mtx > $nmbr$ and £ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
192,mtx > $nmbr$ and si $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
192,mtx < $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
192,mg daily ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
192,mg / dl,C0439269
192,metsyn with ldl > $nmbr$ . $nmbr$ mg / dl,C0439269
192,methotrexate dose | |  mg,C0024671;C0025677;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
192,metformin dose  mg,C0024671;C0025598;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
192,mepolizumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
192,mepolizumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
192,median c - reactive protein — mg / liter,C0006560;C0024671;C0026410;C0439269;C0475211;C0549183;C0876920;C1413716;C1960952;C2346927;C2347635;C2348144;C2939193;C4048285;C4321396;C4521761
192,mean — mg / dl level — no . ( % ),C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
192,mean — mg / dl,C0439269;C0444504;C2347634;C2348143
192,mean ± sd triglycerides  mg / dl,C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
192,mean serum potassium  mg / dl,C0302353;C0439269;C0444504;C0543465;C2347634;C2348143
192,mean serum glucose  mg / dl  mean = sd,C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430
192,mean serum cholesterol  mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143
192,mean sd ldl - c  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
192,mean sd hdl - c  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
192,mean sd fpg  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
192,mean lipid difference ( mg / dl ) hdl - c,C0023779;C0439269;C0444504;C1705241;C1705242;C2347634;C2348143;C3715113
192,mean dose ( sd ) ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
192,mean daily dose ( range ) — mg  i,C0021966;C0024671;C0026410;C0221138;C0439269;C0444504;C1514721;C1960952;C2346927;C2347634;C2348070;C2348143;C2348147;C3542016;C4321396;C4521761
192,mean change in dbp from baseline  mg / dl  mean ( sd ),C0168634;C0392747;C0439269;C0443172;C0444504;C0536221;C1442488;C1705241;C2347634;C2348143;C2699239;C3813197;C4281799;C4319952
192,mean ( sd ) mtx dose  mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
192,mean ( sd ) calcium intake in mg daily,C0024671;C0026410;C0332173;C0439269;C0444504;C0489458;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
192,mean ( s . d . ) apoc - ll $nmbr$  mg / dl,C0003594;C0439269;C0444504;C2347634;C2348143
192,mean ( s . d . ) apob  mg / dl,C0003593;C0439269;C0444504;C2347634;C2348143;C3252643
192,mean ( median ) mtx dose  mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C0549183;C0876920;C1960952;C2346927;C2347634;C2347635;C2348143;C2348144;C2939193;C4321396;C4521761
192,mean  mg / dl,C0439269;C0444504;C2347634;C2348143
192,male acr definition  ^ . g / mg,C0024671;C0026410;C0086582;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1706180;C1706428;C1706429;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761
192,lpa  mg / dl,C0439269;C1096202;C1439335;C3539666;C4049711;C4553379
192,low density lipoprotein cholesterol - mg / dltt,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,low density lipoprotein cholesterol  mg / dl * *,C0023824;C0439269
192,low - density lipoprotein cholesterol — mg / dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,low - density lipoprotein cholesterol  mg / dl,C0023824;C0439269
192,low - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl,C0023824;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
192,lovastatin $nmbr$ mg,C0024027;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,llraglutide $nmbr$ - $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
192,lipids  mean ( sd )  mg / dlt,C0023779;C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
192,lipids  mean ( sd )  mg / dlf,C0023779;C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
192,lipid parameters  mg / dl  mean ( sd ),C0023779;C0439269;C0444504;C0449381;C2347634;C2348143;C2699239
192,lipid measures at baseline — mg / dl,C0023779;C0079809;C0168634;C0242485;C0439269;C1442488;C1879489
192,lipid levels — mg / dlj total cholesterol,C0024671;C0026410;C0201950;C0428460;C0439269;C0543421;C1960952;C2346927;C4321396;C4521761
192,lipid levels — mg / dl,C0428460;C0439269
192,lipid difference ( mg / dl ),C0023779;C0439269;C1705241;C1705242
192,lipid and lipoprotein values ( mg / dl ),C0023779;C0023820;C0042295;C0439269
192,lebrikizumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
192,lebrikizumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
192,lebrikizumab $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
192,lebrikizumab $nmbr$ - $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
192,ldl cholesterol — mg / dl | |,C0023824;C0202117;C0439269
192,ldl cholesterol — mg / dl,C0023824;C0202117;C0439269
192,ldl cholesterol ( sd )  mg / dl,C0023824;C0202117;C0439269;C2699239
192,ldl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0023824;C0030705;C0202117;C0439269;C0444504;C0470187;C2347634;C2348143;C2699239
192,ldl cholesterol ( mg / dl ),C0023824;C0202117;C0439269
192,ldl cholesterol  mg / dl,C0023824;C0202117;C0439269
192,ldl cholesterol  mean ( sd )  mg / dl,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
192,ldl - cholesterol ( mg / dl ),C0023824;C0202117;C0439269
192,ldl - cholesterol  mg / dl  mean ( sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
192,ldl - cholesterol  mean ( sd ) mg / dl,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
192,ldl - c level  mg / dl,C0439269;C0441889;C0456079;C1547707;C2946261
192,ldl - c level  mean ( sd )  mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261
192,ldl - c > $nmbr$ mg / dl,C0439269
192,ldl - c < $nmbr$ mg / dl  no . ( % ),C0439269
192,ldl - c < $nmbr$ mg / dl,C0439269
192,ldl - c ( mg / dl ) < $nmbr$,C0439269
192,ldl - c ( mg / dl ) * *,C0439269
192,ldl - c ( mg / dl ),C0439269
192,ldl - c ( calculated )  mg / dl  mean ( sd ),C0439269;C0444504;C0444686;C1441506;C2347634;C2348143;C2699239
192,ldl - c ( bq ) ( mg / dl ) - mean ± sd,C0439269;C0444504;C0560038;C2346983;C2347634;C2348143;C2699239;C3541236;C3642216
192,ldl - c $nmbr$ - $nmbr$ mg / dl,C0439269
192,ldl - c  mg / dl *,C0439269
192,ldl - c  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
192,ldl - c  mg / dl  mean + sd,C0439269;C0444504;C2347634;C2348143;C2699239
192,ldl - c  mg / dl,C0439269
192,ldl - c  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
192,lansoprazole $nmbr$ mg qd,C0024671;C0026410;C0050940;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
192,iv - $nmbr$ mg,C0022326;C0024671;C0026410;C0439269;C1960952;C2346927;C4265176;C4321396;C4521761
192,initiation of dialysis  renal transplantation  or creatinine . $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mmol / l ),C0010294;C0011945;C0011946;C0019004;C0022671;C0040732;C0040733;C0439269;C0589507;C1059964;C1158830;C1532563;C1561535;C1704686;C4551529
192,indacaterol $nmbr$ mg [ n z $nmbr$ ],C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
192,indacaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
192,ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$ ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
192,ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$  $nmbr$ ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
192,increase creatinine  > $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C0442805;C1561535
192,increase creatinine  < $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C0442805;C1561535
192,impaired fasting glucose ( > $nmbr$ mg / dl ) ( % ),C0439269;C1272092
192,i intensive  $nmbr$ mg of atorvastatin ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0162425;C0221138;C0286651;C0439269;C0522510;C1283828;C1550453;C1960952;C2346927;C4321396;C4521761
192,i - $nmbr$ mg / d ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C4321396;C4521761
192,hscrp — mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
192,hscrp  mg / dl,C0439269
192,high - sensitivity crp — mg / liter | |,C0024671;C0026410;C0439269;C0475211;C1441604;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
192,hdl cholesterol — mg / dl triglycerides — mg / dl,C0023822;C0024671;C0026410;C0041004;C0392885;C0439269;C1960952;C2346927;C3539687;C4321396;C4521761
192,hdl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0023822;C0030705;C0392885;C0439269;C0444504;C0470187;C2347634;C2348143;C2699239
192,hdl cholesterol  mean ( sd )  mg / dl,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
192,hdl < $nmbr$ mg / dl,C0439269;C3715113
192,hdl - cholesterol  mg / dl  mean ( sd ),C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
192,hdl - cholesterol  mean ( sd ) mg / dl,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
192,hdl - c level  mg / dl,C0439269;C0441889;C0456079;C1547707;C2946261;C3715113
192,hdl - c level  mean ( sd )  mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3715113
192,hdl - c level  < $nmbr$ mg / dld,C0024671;C0026410;C0439269;C0441889;C0456079;C1414063;C1547707;C1960952;C2346927;C2826331;C2946261;C3715113;C4321396;C4521761
192,hdl - c < $nmbr$ mg / dl_,C0439269;C3715113
192,hdl - c < $nmbr$ mg / dl . n ( % ),C0439269;C3715113
192,hdl - c < $nmbr$ mg / dl  no . ( % ),C0439269;C3715113
192,hdl - c < $nmbr$ mg / dl,C0439269;C3715113
192,hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
192,hdl - c ( mg / dl ) *,C0439269;C3715113
192,hdl - c ( mg / dl ),C0439269;C3715113
192,hdl - c ( median  iqr )  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3715113
192,hdl - c  mg / dl  mean + sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
192,hdl - c  mg / dl,C0439269;C3715113
192,hdl - c  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
192,hdl - c  $nmbr$ mg / dl  n ( % ),C0439269;C3715113
192,hdl ( mg / dl ),C0439269;C3715113
192,h dl cholesterol < $nmbr$ mg / dl,C0008377;C0024671;C0026410;C0033727;C0369286;C0439269;C0441932;C0564385;C1960952;C2346927;C3539687;C4321396;C4521761;C4528284
192,glycopyrronium $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3814772;C4321396;C4521761
192,glycemia  mg / dl,C0005802;C0439269
192,gly $nmbr$ . $nmbr$ mg b . i . d . n = $nmbr$,C0024671;C0026410;C0152277;C0439269;C1415124;C1960952;C2346927;C4321396;C4521761
192,glucose — mg / dl,C0017725;C0439269
192,glucose ( mg / dl ),C0017725;C0439269
192,glucose  mg / dl  mean,C0017725;C0439269;C0444504;C2347634;C2348143
192,geometric mean ofcrp — mg / liter ( range ),C0024671;C0026410;C0439269;C0475211;C1514721;C1960952;C2346927;C2348147;C2986759;C3542016;C4321396;C4521761
192,fsg ( mg / dl ),C0439269
192,fsg  mg / dl ( mean ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239
192,fpg month $nmbr$ ( mg / dl ),C0332177;C0439231;C0439269
192,fpg change ( mg / dl ) *,C0392747;C0439269;C0443172;C1705241;C4319952
192,fpg ( mg / dl ) x,C0439269
192,fpg ( mg / dl ),C0439269
192,fpg  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
192,fpg  mg / dl,C0439269
192,fpg  mean ( sd )  mg / dlt,C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
192,fpg  mean ( sd )  mg / dlf,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
192,fpg  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
192,fpg  ( mg / dl ),C0439269
192,feno $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,feno  $nmbr$ mg dn = $nmbr$ ),C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761
192,female acr definition  ^ g / mg,C0024671;C0026410;C0043210;C0086287;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1705497;C1705498;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761
192,febuxostat $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
192,febuxostat $nmbr$ mg daily n = $nmbr$ n ( % ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
192,febuxostat $nmbr$ mg daily n = $nmbr$ % ( n / n ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
192,febuxostat $nmbr$ mg daily n = $nmbr$,C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
192,febuxostat $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
192,febuxostat $nmbr$ mg,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
192,fc - ldl - c  mg / dl,C0439269;C2983605
192,fbs > = $nmbr$ mg / dl,C0439269;C3812213
192,fbs < $nmbr$ mg / dl,C0439269;C3812213
192,fbg ( mg / dl ),C0439269
192,fasting triglycerides  mean ( sd ) mg / dl,C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
192,fasting triglyceride level  mean ( sd )  mg / dl,C0015663;C0428475;C0439269;C0444504;C2347634;C2348143;C2699239
192,fasting serum glucose — mg / dl * *,C0015663;C0202041;C0439269;C3534430
192,fasting serum glucose level  mean ( sd )  mg / dl,C0015663;C0202045;C0229671;C0439269;C0444504;C0583332;C1546774;C1550100;C2347634;C2348143;C2699239
192,fasting serum glucose ( mg / dl )  median ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
192,fasting serum glucose ( mg / dl ),C0015663;C0202041;C0439269;C3534430
192,fasting serum glucose  mg / dl,C0015663;C0202041;C0439269;C3534430
192,fasting serum glucose  median ( sd )  mg / dl,C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3534430
192,fasting serum glucose  mean ( sd ) mg / dl,C0015663;C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430
192,fasting glucose — mg / dl,C0015663;C0017725;C0439269
192,fasting glucose mg / dl diabetes classification,C0008902;C0008903;C0011847;C0011849;C0015663;C0017725;C0439269;C0678229
192,fasting glucose level  mg / dl,C0202045;C0439269
192,fasting glucose > $nmbr$ mg / dl *,C0015663;C0017725;C0439269
192,fasting glucose > $nmbr$ mg / dl  n ( % ),C0015663;C0017725;C0439269
192,fasting glucose ( mg / dl ),C0015663;C0017725;C0439269
192,fasting glucose  mg / dl ',C0015663;C0017725;C0439269
192,fasting glucose  mg / dl  mean ( sd ) §,C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239
192,fasting glucose  mg / dl,C0015663;C0017725;C0439269
192,fasting glucose  mean ( sd )  mg / dl,C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239
192,fasting cholesterol — mg / dl,C0008377;C0015663;C0439269
192,famotidine $nmbr$ mg ( n = $nmbr$ ),C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,fa $nmbr$ mg ( « = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,fa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,ezetimibe / simvastatin $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1532737;C1960952;C2346927;C4321396;C4521761
192,ezetimibe $nmbr$ mg ( n — $nmbr$ ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
192,ezetimibe $nmbr$ mg ( n = $nmbr$ * ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
192,ezetimibe $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
192,eze = ezetimibe $nmbr$ mg  pooled sinva = simvastatin pooled across doses  pooled eze / sinva = ezetimibe / simvastatin tablet pooled across doses  bni = body mass index  ldl - c = low - density lipoprotein cholesterol  t g = triglycerides  t c = total cholesterol  hdl - c = high - density lipoprotein cholesterol  apo — apolipoprotein  c rp — c - neactive protein  rlp - c = remnant - like particle - cholesterol .,C0003591;C0003594;C0008377;C0023821;C0023824;C0024671;C0026410;C0031529;C0033684;C0039225;C0041004;C0074554;C0178602;C0201950;C0242821;C0439267;C0439269;C0460148;C0543421;C0577559;C0577573;C0600653;C0674390;C0918012;C1096155;C1142985;C1268086;C1306372;C1532737;C1538326;C1552854;C1637833;C1705223;C1709595;C1960952;C2346927;C2349200;C2986546;C3152252;C3539882;C3541325;C3891451;C4054077;C4082212;C4283905;C4319774;C4321396;C4521761;C4522255
192,eze $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,eze $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,esrd saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0022661;C0024671;C0026410;C0035078;C0439269;C1960952;C2316810;C2346927;C4321396;C4521761
192,esr  mean ± sd mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3811131
192,ertuglifldzin $nmbr$ mg vs placebo / glinepiride,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
192,erlugliflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0032042;C0061323;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
192,empaglifiozin $nmbr$ mg ( w = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,empaglifiozin $nmbr$ . $nmbr$ mg ( w = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,empagiiflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,elevated symptomatic serum creatinine  hypotension > $nmbr$ . $nmbr$ mg / dl,C0020649;C0231220;C0439269;C0700225;C3163620
192,elevated serum creatinine ( > $nmbr$ . $nmbr$ mg / dl_ ),C0439269;C0700225
192,elevated serum creatinine  > $nmbr$ . $nmbr$ mg / dl,C0439269;C0700225
192,dupiiumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,dulaglutide $nmbr$ · $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
192,dulaglutide $nmbr$ . $nmbr$ mg *,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
192,dulaglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
192,dulaglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
192,dose equivalent  mg ( sd ) ),C0024671;C0026410;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C2699239;C4321396;C4521761
192,dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
192,dose  mg,C0024671;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
192,dbp $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) baseline lipid profile  mg / dl  mean ( sd ),C0023779;C0168634;C0439269;C0444504;C0536221;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239;C3813197;C4281799
192,dapagliflozin $nmbr$ mg group ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0441848;C1960952;C2346927;C2353951;C4321396;C4521761
192,dapagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
192,dapagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
192,daily dose > $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
192,daily dose $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
192,daily dose $nmbr$ - $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
192,dabigatran $nmbr$   mg b . i . d .,C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran $nmbr$ mg versus warfarin,C0024671;C0026410;C0043031;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran $nmbr$ mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran $nmbr$ mg bid vs warfarin,C0024671;C0026410;C0043031;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran $nmbr$ mg bid events / n ( % / y ),C0024671;C0026410;C0439269;C0441471;C1960952;C2346927;C2348066;C3541888;C4321396;C4521761
192,dabigatran $nmbr$ mg bid ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran  $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran  $nmbr$ mg  vs . warfarin,C0024671;C0026410;C0043031;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,dabigatran  $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
192,d $nmbr$ mg vs . warfarin,C0024671;C0026410;C0043031;C0073187;C0332173;C0439269;C1960952;C2346927;C4321396;C4484261;C4521761
192,czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,czp $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,czp $nmbr$ mg ( n = lll ),C0024671;C0026410;C0054841;C0439269;C1261077;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,czp $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,czp $nmbr$ mg ( n $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,czp $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,czp $nmbr$ mg  % ( n / n ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,czp $nmbr$ mg,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
192,crp — mg / liter ^,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
192,crp mean ( mg / dl ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
192,crp level  mean ± sd mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285
192,crp > $nmbr$ mg / $nmbr$  n [ % ],C0024671;C0026410;C0439269;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
192,crp > $nmbr$ . $nmbr$ mg / dl  n ( % ),C0439269;C3890735;C4048285
192,crp ( normal range : $nmbr$ - $nmbr$ . $nmbr$ )  mg / dl  mean ( sd ),C0086715;C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
192,crp ( normal < $nmbr$ . $nmbr$ mg / dl ),C0205307;C0231683;C0439166;C0439269;C2347086;C3890735;C4048285;C4553972
192,crp ( mg / dl ) < $nmbr$ . $nmbr$,C0439269;C3890735;C4048285
192,crp ( mg / dl ) * *,C0439269;C3890735;C4048285
192,crp ( mg / dl ),C0439269;C3890735;C4048285
192,crp ( mg / dl  per unit ),C0024671;C0026410;C0439148;C0439269;C0439453;C1509845;C1519795;C1532632;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C3890735;C4048285;C4321396;C4521761
192,crp  mg / dl  median,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
192,crp  mg / dl  mean ( sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
192,crp  mg / dl,C0439269;C3890735;C4048285
192,crp  median  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
192,crp  mean [ sd ] mg / $nmbr$,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C3890735;C4048285;C4321396;C4521761
192,creatinine ≥ $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C1561535
192,creatinine — mg / dl urinary albumin - to - creatinine ratio §,C0010294;C0439269;C0456603;C1547037;C1561535;C2362049
192,creatinine — mg / dl,C0010294;C0439269;C1561535
192,creatinine ( mg / dl )  mean ( sd ),C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
192,creatinine ( mg / dl ),C0010294;C0439269;C1561535
192,creatinine $nmbr$ . $nmbr$ mg / dl medications,C0010294;C0013227;C0439269;C0802604;C1561535;C2598133;C4284232
192,creatinine  mg / dl_,C0010294;C0439269;C1561535
192,creatinine  mg / dl ( sd ),C0010294;C0439269;C1561535;C2699239
192,creatinine  mg / dl  mean,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143
192,creatinine  mg / dl,C0010294;C0439269;C1561535
192,creatinine  mean ( sd )  mg / dl,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
192,clopidogrel loading dose $nmbr$ mg,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C3714444;C4321396;C4521761
192,clopidogrel  $nmbr$ mg loading doset,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C4321396;C4521761
192,clopidogrel  $nmbr$ mg loading dose !,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761
192,clopidogrel  $nmbr$ mg *,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C4321396;C4521761
192,clopidogrel  $nmbr$ - mg loading dose,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761
192,cld $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,cholesterol — mg / dl,C0008377;C0439269
192,cholesterol ( mg / dl ),C0008377;C0439269
192,cholesterol  mg / dl,C0008377;C0439269
192,change in fpg $nmbr$ to month $nmbr$ ( mg / dl ),C0332177;C0392747;C0439231;C0439269;C0443172;C1705241;C4319952
192,change from baseline to eos  mg / dl,C0168634;C0392747;C0439269;C0443172;C1442488;C1623465;C1705241;C1861303;C4319952
192,change from baseline  mg / dl  mean ( sd ),C0168634;C0392747;C0439269;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2699239;C4319952
192,carisbamate $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
192,carisbamate $nmbr$  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
192,canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2718773;C4321396;C4521761
192,cana $nmbr$ mg ( n = $nmbr$ ) *,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
192,cana $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
192,cana $nmbr$ mg ( n - $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
192,cana $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
192,cana $nmbr$ mg,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
192,c - reactive protein — mg / liter * *,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
192,bun ( mg / dl ),C0439269
192,bun  mg / dl,C0439269
192,body mass index ( mg / m $nmbr$ ),C0005893;C0024671;C0026410;C0369637;C0439269;C0441923;C0578022;C1305855;C1960952;C2346927;C4321396;C4521761
192,blood urea nitrogen ( mg / dl ),C0005845;C0439269;C0600137
192,blood urea nitrogen  mg / dl,C0005845;C0439269;C0600137
192,belimumab $nmbr$ mg sc ( n $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
192,baseline sildenafil dose mg,C0024671;C0026410;C0168634;C0178602;C0439269;C0529793;C0869039;C1114758;C1442488;C1960952;C2346927;C4321396;C4521761
192,baseline serum urate ( mg / dl ) a,C0168634;C0439269;C0455272;C1442488
192,baseline mean ( mg / dl ],C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
192,baseline mean  mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
192,baseline lp ( a )  mg / dl,C0065058;C0168634;C0439269;C1439335;C1442488;C4553379
192,baseline low - density lipoprotein cholesterol ( mg / dl ),C0023824;C0168634;C0439269;C1442488
192,baseline ldlc level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
192,baseline ldlc level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
192,baseline ldlc level ( n = $nmbr$  $nmbr$ ) ^ $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
192,baseline ldl ‐ c  mg / dl,C0168634;C0439269;C1442488
192,baseline ldl - c > $nmbr$ mg / dl,C0168634;C0439269;C1442488
192,baseline ldl - c  mg / dl,C0168634;C0439269;C1442488
192,baseline ldl ( mg % ),C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
192,baseline hdl ‐ c  mg / dl,C0168634;C0439269;C1442488;C3715113
192,baseline hdl - c level ( n = s $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
192,baseline hdl - c level ( n = $nmbr$ » $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
192,baseline hdl - c level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
192,baseline hdl - c level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
192,baseline hdl - c  mg / dl,C0168634;C0439269;C1442488;C3715113
192,baseline fpg  mg / dl,C0168634;C0439269;C1442488
192,baseline crp ( mg / dl ),C0168634;C0439269;C1442488;C3890735;C4048285
192,baseline aspirin dose < $nmbr$ mg,C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761;C4696290
192,baseline . mean _ sd . mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
192,baseline . mean _ sd  mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
192,baseline  mg / dl ( mmol / l ),C0168634;C0439269;C1442488;C1532563
192,baricitinib $nmbr$ mg qd ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
192,baricitinib $nmbr$ mg qd,C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
192,baricitinib $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
192,baricitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
192,baricitinib $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
192,baricitinib  $nmbr$ mg daily ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
192,azl - m $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0369637;C0439269;C0441923;C1960952;C2346927;C4321396;C4521761
192,average weekly mtx dose ( mg / week ) t,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
192,average weekly mtx dose ( mg / week ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
192,average dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
192,ato $nmbr$ mg and sim $nmbr$ ^ $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1420068;C1960952;C2346927;C4321396;C4521761
192,ato $nmbr$ mg and sim $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1420068;C1960952;C2346927;C4321396;C4521761
192,ato $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,aspirin use ( > $nmbr$ mg ),C0004057;C0024671;C0026410;C0042153;C0439269;C0457083;C1947944;C1960952;C2346927;C4321396;C4521761
192,aspirin dose at baseline  mg,C0004057;C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4086581;C4321396;C4521761;C4696290
192,aspirin $nmbr$ mg ( n = $nmbr$ ),C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,aspirin $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,asa > $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
192,asa < $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
192,apremilast $nmbr$ mg bid n = $nmbr$,C0024671;C0026410;C0439269;C1678805;C1960952;C2346927;C4321396;C4521761
192,apolipoprotein b ( mg / dl ),C0003593;C0439269
192,apolipoprotein b $nmbr$  mg / dl,C0003593;C0439269
192,apolipoprotein b  mg / dl,C0003593;C0439269
192,apolipoprotein a $nmbr$ ( mg / dl ),C0003592;C0439269;C0523508
192,apob ( mg / dl ),C0003593;C0439269;C3252643
192,apob  mg / dl,C0003593;C0439269;C3252643
192,apoal ( mg / dl ) *,C0439269
192,apoal  mg / dl,C0439269
192,apoa $nmbr$  mg / dl,C0003592;C0439269;C0523508;C4553344;C4553379
192,apo a $nmbr$ ( mg / dl ),C0003592;C0439269;C0523508;C4553344;C4553379
192,aplxaban $nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,apixaban $nmbr$ mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
192,apixaban $nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
192,apixaban  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
192,apixaban  $nmbr$ mg,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
192,apixaban  $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
192,apixaban  $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
192,amlodipine / valsartan $nmbr$ to $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
192,amlodipine / valsartan $nmbr$ / $nmbr$ vs $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
192,amlodipine / valsartan $nmbr$ / $nmbr$ mg / v = $nmbr$,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
192,amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ i ),C0021966;C0024671;C0026410;C0221138;C0369718;C0439269;C0441922;C1960952;C1962523;C2346927;C4321396;C4521761
192,amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
192,amlodipine / valsartan $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
192,amlodipine $nmbr$ to $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
192,amlodipine $nmbr$ mg / v = $nmbr$,C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
192,ami $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
192,ami $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
192,alogliptin $nmbr$ mg + pioglitazone ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
192,alogliptin $nmbr$ . $nmbr$ mg + pioglitazone ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
192,all dulaglutide $nmbr$ . $nmbr$ mg + insulin lispro / insulin glargine ( n = $nmbr$ ),C0024671;C0026410;C0293359;C0439269;C0907402;C1960952;C2346927;C3179549;C4321396;C4521761
192,> = $nmbr$ mg / dl,C0439269
192,> $nmbr$ to < $nmbr$ mg dl,C0439269
192,> $nmbr$ to < $nmbr$ mg / dl,C0439269
192,> $nmbr$ to < $nmbr$ - $nmbr$ mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
192,> $nmbr$ mg dl,C0439269
192,> $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
192,> $nmbr$ mg / dl — %,C0439269
192,> $nmbr$ mg / dl simva ( „ = $nmbr$ ),C0439269
192,> $nmbr$ mg / dl simva $nmbr$ = $nmbr$ ],C0439269
192,> $nmbr$ mg / dl simva,C0439269
192,> $nmbr$ mg / dl eze / simva ( „ = $nmbr$ ),C0439269
192,> $nmbr$ mg / dl eze / simva $nmbr$ = $nmbr$ },C0439269
192,> $nmbr$ mg / dl eze / simva,C0439269
192,> $nmbr$ mg / dl,C0439269
192,> $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,> $nmbr$ but < $nmbr$ mg / dl,C0439269
192,> $nmbr$ and < $nmbr$ mg / dl,C0439269
192,> $nmbr$ . $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
192,> $nmbr$ . $nmbr$ mg / dl,C0439269
192,> $nmbr$ & < $nmbr$ mg / dl,C0439269
192,> $nmbr$  < $nmbr$ mg / dl,C0439269
192,< $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
192,< $nmbr$ mg / dl simva ( n = $nmbr$ ],C0439269
192,< $nmbr$ mg / dl simva ( n = $nmbr$ ),C0439269
192,< $nmbr$ mg / dl simva,C0439269
192,< $nmbr$ mg / dl eze / simva ( n = $nmbr$ },C0439269
192,< $nmbr$ mg / dl eze / simva ( n = $nmbr$ ),C0439269
192,< $nmbr$ mg / dl eze / simva,C0439269
192,< $nmbr$ mg / dl *,C0439269
192,< $nmbr$ mg / dl,C0439269
192,< $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,< $nmbr$ / $nmbr$ mmhg  ldl - c < $nmbr$ mg / dl,C0439269;C0439475
192,< $nmbr$ . $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
192,< $nmbr$ . $nmbr$ mg / dl,C0439269
192,- median fasting serum glucose ( mg / dl ) ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
192,( sd )  mg / dl,C0439269;C2699239
192,( mg / dl ± sd ),C0439269;C2699239
192,( mg / dl ),C0439269
192,$nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ to < $nmbr$ mg / dl,C0439269
192,$nmbr$ mg vs placebo,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg twice daily n = $nmbr$,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg sirukumab every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0439230;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
192,$nmbr$ mg qw $nmbr$ . $nmbr$ pt yrs,C0024671;C0026410;C0032743;C0043011;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg qd ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg ew n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg eow n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg cohort,C0009247;C0024671;C0026410;C0439269;C0599755;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg clopidogrel load,C0024671;C0026410;C0070166;C0439269;C1550025;C1704782;C1708715;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg biw $nmbr$ . $nmbr$ pt yrs,C0024671;C0026410;C0032743;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg / kgf ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg / dl ldl cholesterol | |,C0023824;C0202117;C0439269
192,$nmbr$ mg / dl,C0439269
192,$nmbr$ mg / $nmbr$ mgc,C0024671;C0026410;C0439269;C1960952;C2346927;C3888239;C4321396;C4521761
192,$nmbr$ mg / $nmbr$ mgb,C0024671;C0026410;C0373680;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg + mtx,C0024671;C0025677;C0026410;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg ( $nmbr$  $nmbr$ . $nmbr$ % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
192,$nmbr$ - h pmg ( mg / dl ),C0033727;C0369286;C0439269;C0441932;C0564385;C4528284
192,$nmbr$ - $nmbr$ mg / dl *,C0439269
192,$nmbr$ - $nmbr$ mg / dl,C0439269
192,$nmbr$ $nmbr$ mg / dl,C0439269
191,symptom onset to first medical contact : ambulance or emergency department,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C0562508;C1279901;C1705415;C3812666;C3846685;C4086878
191,non - pci hospital / ambulance,C0002422;C0019994;C1510665;C1518422;C3846685;C4049621
191,in emergency department before ambulance transfer,C0002422;C0040671;C0562508;C1705822;C3846685;C4319192
191,in ambulance,C0002422;C3846685
191,first medical contact in ambulance,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685
191,ambulance ( % ),C0002422;C3846685
191,ambulance  n ( % ),C0002422;C3846685
191,ambulance,C0002422;C3846685
190,locally advanced,C0205179;C1517927
190,advanced  n ( % ),C0205179
190,advanced,C0205179
189,poland,C0032356
189,north america plus australia and new zealand,C0004340;C0027978;C0028405;C0324547;C0332287
189,north america ( plus australia and new zealand ),C0004340;C0027978;C0028405;C0324547;C0332287
189,new zealand,C0027978;C0324547
189,australia and new zealand,C0004340;C0027978;C0324547
189,austrafca and new zealand,C0027978;C0324547
188,worldwide non - black patients,C0005680;C0027567;C0085756;C0439541;C1829939
188,u . s . non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541;C1829939
188,race  black or african - american  n ( % ),C0005680;C0027567;C0034510;C0085756;C0439541;C1706779;C3853635
188,non - hispanic black or african - american,C0005680;C0027567;C0085756;C0439541;C1518424
188,non - hispanic black,C0005680;C0027567;C0085756;C0439541;C1518424
188,non - black participants,C0005680;C0027567;C0085756;C0439541;C0679646;C1518422
188,non - black ( n = $nmbr$ ),C0005680;C0027567;C0085756;C0439541;C1518422
188,non - black  worldwide,C0005680;C0027567;C0085756;C0439541;C1518422
188,hispanic black,C0005680;C0027567;C0085756;C0086409;C0439541
188,black participants,C0005680;C0027567;C0085756;C0439541;C0679646
188,black or african ‐ american,C0005680;C0027567;C0085756;C0439541
188,black or african heritage,C0005680;C0027567;C0085756;C0439541;C2986513
188,black or african american,C0005680;C0027567;C0085756;C0439541
188,black or african america,C0005680;C0027567;C0085756;C0439541
188,black or african - american,C0005680;C0027567;C0085756;C0439541
188,black or african,C0005680;C0027567;C0085756;C0439541
188,black non - hispanic - n ( % ),C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
188,black non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
188,black / non - black,C0005680;C0027567;C0085756;C0439541;C1518422
188,black / african american *,C0085756
188,black / african american,C0085756
188,black / african - american ( $nmbr$ . $nmbr$ % ),C0085756
188,black / african - american,C0085756
188,black *,C0005680;C0027567;C0085756;C0439541
188,black ( n — $nmbr$ ),C0005680;C0027567;C0085756;C0439541
188,black ( n   = $nmbr$ ),C0005680;C0027567;C0085756;C0439541
188,black  worldwide,C0005680;C0027567;C0085756;C0439541
188,black  us,C0005680;C0027567;C0085756;C0439541
188,black  no . ( % ),C0005680;C0027567;C0085756;C0439541
188,black  n ( % ),C0005680;C0027567;C0085756;C0439541
188,black,C0005680;C0027567;C0085756;C0439541
188,b : u . s . black and non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541;C1829939
188,african americans,C0085756
188,african american n = $nmbr$,C0085756
188,african american / black,C0005680;C0027567;C0085756;C0439541
188,african american  n ( % ),C0085756
188,african american,C0085756
188,african america,C0085756
188,african - latin american,C0085756
188,african - american / african heritage ( n = $nmbr$ ),C0085756;C2986513
188,african - american,C0085756
188,african,C0027567
188,a : worldwide black and non - black patients,C0005680;C0027567;C0085756;C0439541;C1829939
188,* non - black *,C0005680;C0027567;C0085756;C0439541;C1518422
187,uacr ( mgg - $nmbr$ ),
187,uacr  n ( % ) †,
187,uacr  mgg $nmbr$ ( gm ),C0017480;C3854019
187,uacr  mg / mmol ( interquartile range ) b,C0567349;C1711350;C2348885
187,uacr,
187,scr  gmol / l,C1539487;C4050416
186,om $nmbr$ mg / aml $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
186,om $nmbr$ mg / aml $nmbr$ mg ( n = $nmbr$ ),C0023465;C0023467;C0028971;C1319635;C1705272
186,om $nmbr$ mg / aml $nmbr$ mg,C0023465;C0023467;C0028971;C1319635;C1705272
186,om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
186,om $nmbr$ / aml $nmbr$ /,C0023465;C0023467;C0028971;C1705272
186,aml / val $nmbr$ / $nmbr$ mg,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761
186,aml ( n = $nmbr$ ),C0023465;C0023467
186,aml $nmbr$ /,C0023465;C0023467
186,aml,C0023465;C0023467
186,a / aml ( n = $nmbr$ ),C0023465;C0023467
185,ppi or h $nmbr$ receptor antagonist  n ( % ),C0033727;C0358591;C0369286;C0441932;C0564385;C0871125;C3811894;C4528284;C4543207
185,mineralocorticoid receptor antagonists,C1373021;C1579268
185,mineralocorticoid receptor antagonist n ( % ),C1579268
185,mineralocorticoid receptor antagonist,C1579268
185,mineralcorticoid receptor antagonist,C4543207
185,leukotriene receptor antagonists,C0595726;C2757015;C3542962
185,leukotriene - receptor antagonist,C0595726;C3537183;C4521995
185,h $nmbr$ receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
185,h $nmbr$ - receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
185,endothelin - receptor antagonists plus phosphodiesterase type $nmbr$ inhibitors,C0031638;C0332307;C1134681;C1547052;C1656262;C2266875;C3539996
185,endothelin - receptor antagonists,C1134681;C2266875
185,aldosterone receptor antagonists,C1579268
184,tnf antagonist,C0231491;C1448177
184,ras antagonist  %,C0034678;C0231491;C0525678
184,no history of tnf antagonist treatment — no . ( % ),C0019664;C0019665;C0039798;C0087111;C0231491;C0262512;C0262926;C1448177;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
184,miami k antagonist received,C0231491;C0597277;C1514756;C1551421;C1708601
184,history of disease refractory to treatment with tnf antagonist — no . ( % ),C0039798;C0087111;C0205269;C0231491;C0683519;C0730226;C0850708;C0944983;C1448177;C1522326;C1533734;C1705169;C3538994;C3887704
184,antagonist,C0231491
184,adp antagonist,C0231491;C0523452
183,total included in combined analysis,C0002778;C0205195;C0332257;C0439175;C0439810;C0936012;C1524024
183,stratified analyses,C0002778;C0205363;C0936012;C1524024
183,sensitivity analyses,C0002778;C0020517;C0036667;C0312418;C0427965;C0936012;C1511883;C1522640;C1524024;C2346484;C2349185
183,responder analyses ( achieving alc < $nmbr$ . $nmbr$ % ),C0002778;C0936012;C1424945;C1524024;C3811058
183,prespecified analysis,C0002778;C0936012;C1524024
183,patients included in analysis,C0002778;C0030705;C0332257;C0936012;C1524024
183,patients in analysis  n,C0002778;C0030705;C0936012;C1524024
183,patients ( full analysis sety )  n,C0002778;C0030705;C0443225;C0936012;C1524024
183,overall analysis,C0002778;C0282416;C0936012;C1524024;C1561607
183,integrated analysis set ( n = $nmbr$ ),C0002778;C0036849;C0369718;C0441922;C0936012;C1158478;C1442518;C1524024;C1705195;C1705422
183,included in analysis,C0002778;C0332257;C0936012;C1524024
183,full analysis set  n,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
183,full analysis set,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
183,final analysis ( all patients ),C0002778;C0030705;C0205088;C0936012;C1524024;C1546485;C3853528
183,analysis,C0002778;C0936012;C1524024
183,$nmbr$ days until end of study ( landmark analysis ),C0002778;C0444930;C0936012;C1524024;C2746065;C2826182
182,interim analysis ( all patients ),C0030705;C4684691
182,interim analysis,C4684691
181,subgroup statistics,C0038215;C0600673;C1079230;C1515021
181,statistics,C0038215;C0600673
181,statisticd,
181,statistic * *,C2348149;C2828391
181,sample statistics,C2348149
181,parameter statistics,C0681933
180,ugt induction status : as randomizeda  n ( % ),C0205263;C0449438;C0857127;C1420188;C4284131
180,ish status  n ( % ),C0449438
180,ish,
180,as,
179,established renal disease ( egfr $nmbr$ - < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ with any uacr mg / g or egfr > $nmbr$ - $nmbr$ ml / inin / l $nmbr$ m $nmbr$ with an uacr > $nmbr$ mg / g ) without previous maerovaseular and albuminuria disease,C0001925;C0012634;C0022658;C0205156;C0369637;C0439445;C0439526;C0441923;C0443211;C0456616;C1272684;C1300563;C1552607;C1705224;C1739039;C3811844;C3812682;C3887665
179,established maerovaseular disease and albuminuria,C0001925;C0012634;C0443211;C1272684
179,established disease,C0012634;C0443211;C1272684
179,established atherosclerotic disease  n ( % ),C0012634;C0333482;C0443211;C1272684
179,established atherosclerotic,C0333482;C0443211;C1272684
179,established ascvd or > $nmbr$ cv risk factors,C0035648;C0443211;C1272684;C1553898;C3538987;C3665365;C4048877;C4318503
179,established ascvd,C0443211;C1272684;C3665365
179,established ( n = $nmbr$ ),C0443211;C1272684
179,established,C0443211;C1272684
179,> $nmbr$ cv risk factors 咐 or established atherosclerotic cv disease,C0007222;C0035648;C0333482;C0443211;C1272684;C1553898;C3538987;C4048877;C4318503
178,drinker ( $nmbr$ to $nmbr$ drinks / week ),C0332174;C0439230;C0452428;C0556338
178,drinker ( $nmbr$ - $nmbr$ drinks / week ),C0332174;C0439230;C0452428;C0556338
178,alcohol use  drinks / wk *,C0001948;C0332174;C0439230;C0452428
178,alcohol use  drinks / wk,C0001948;C0332174;C0439230;C0452428
178,> $nmbr$ drinks / wk,C0332174;C0439230;C0452428
178,> $nmbr$ drinks / week,C0332174;C0439230;C0452428
178,> $nmbr$ drinks / dav,C0452428
178,> $nmbr$ drinks,C0452428
178,> $nmbr$ ( $nmbr$ ) drinks / day if male ( female ),C0043210;C0086287;C0086582;C0332173;C0439228;C0439505;C0452428;C1705497;C1705498;C1706180;C1706428;C1706429
178,$nmbr$ drinks / wk,C0332174;C0439230;C0452428
178,$nmbr$ drinks,C0452428
178,$nmbr$ - $nmbr$ drinks / wk,C0332174;C0439230;C0452428
178,$nmbr$ - $nmbr$ drinks / dav,C0452428
178,$nmbr$ - $nmbr$ drinks,C0452428
178,$nmbr$ + drinks / wk,C0332174;C0439230;C0452428
177,handihaler and diskus  n,C1553480
177,diskus only  n,C0205171;C1553480;C1720467
176,non - / ex - drinker,C0457801
176,former / non - drinker,C0205156;C0457801;C0750523
176,ex - drinker,C0337679
176,drinker ( % ) a,C0556338
176,drinker ( % ),C0556338
176,drinker  n ( % ),C0556338
176,alcohol drinker  n ( % ),C0001962;C0001975;C0556338
176,alcohol drinker,C0001962;C0001975;C0556338
175,three of seven risk factors,C0035648;C0205449;C0205453;C1553898
175,temporary risk factor,C0035648;C0205374;C1548539;C3245481
175,risk factors — no . ( % ),C0035648;C1553898
175,risk factors specified as inclusion criteria — no . ( % ) f,C0016327;C0035648;C0205369;C1512693;C1553898
175,risk factors only,C0035648;C0205171;C1553898;C1720467
175,risk factors for stroke  no . ( % ),C0035648;C0038454;C1553898;C4554100
175,risk factors for stroke,C0035648;C0038454;C1553898;C4554100
175,risk factors for recurrent vte — no . ( % ) f,C0016327;C0035648;C0630906;C1455761;C1553898;C2945760
175,risk factors ( % ),C0035648;C1553898
175,risk factors  no . ( % ),C0035648;C1553898
175,risk factors  %,C0035648;C1553898
175,risk factors,C0035648;C1553898
175,risk factor profile index event,C0035648;C0441471;C0600653;C0918012;C1552854;C1637833;C1979963;C2003903;C2986546;C4019010
175,risk factor,C0035648
175,qualifying risk factors — no . ( % ),C0035648;C1514624;C1553898
175,qualifying risk factor — no . ( % ),C0035648;C1514624
175,qualifying risk factor  n ( % ),C0035648;C1514624
175,qualifying risk factor,C0035648;C1514624
175,psychosocial risk factors,C0033963;C0035647;C0035648;C0542298;C1458132;C1553898;C4552904
175,other risk factors,C0035648;C1553898
175,other major risk factors,C0035648;C0205082;C0205164;C1553898;C4318856;C4521762
175,non - transient risk factors for recurrent vte  n ( % ),C0035648;C0040704;C0205374;C0439597;C0630906;C1553898
175,no . of risk factors for venous thromboembolism  no . ( % ),C0035648;C1553898;C1861172
175,no . of risk factors ( % ) | |,C0035648;C1553898
175,multiple risk factors,C0035648;C0439064;C1553898
175,multiple ( > $nmbr$ ) chd risk factors that confer a $nmbr$ - year risk of chd > $nmbr$ %,C0035648;C0280604;C0439064;C0439234;C0439508;C1282512;C1553898;C3542407
175,male sex — no . ( % ) risk factors,C0035648;C0086582;C1553898
175,history of cvd and of cv risk factors - no . ( % ),C0007222;C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503
175,diagnoses / risk factors  n ( % ],C0011900;C0035648;C1553898
175,diagnoses / risk factors  n ( % ),C0011900;C0035648;C1553898
175,cv risk factors  % of patients,C0030705;C0035648;C1553898;C3538987;C4048877;C4318503
175,chd risk factors #,C0035648;C0280604;C1553898;C3542407
175,baseline risk factors,C0035648;C0168634;C1442488;C1553898
175,any risk factor for stent thrombosis,C0035648;C3897493
175,> $nmbr$ chd risk factors,C0035648;C0280604;C1553898;C3542407
174,pci delay due to low risk,C0205421;C0678226;C3272281;C3538919;C4049621
174,lower risk ( n = $nmbr$ ),C3272281;C3538919
174,lower risk,C3272281;C3538919
174,low risk and fewer symptoms ( group a ),C0205388;C0441835;C0683368;C1457887;C3272281;C3538919;C4522145
174,low risk ( ri = $nmbr$ - $nmbr$ ),C0035487;C1826843;C3272281;C3538919
174,low risk ( n $nmbr$ $nmbr$ ),C3272281;C3538919
174,low risk ( ? ics ),C0815320;C3272281;C3538919;C4551720
174,low risk ( - ics ),C0815320;C3272281;C3538919;C4551720
174,low risk ( $nmbr$ - $nmbr$ ),C3272281;C3538919
174,low risk,C3272281;C3538919
174,group b ( low risk  more symptoms )  n ( % ),C0441848;C0683368;C1457887;C3272281;C3538919
174,$nmbr$ - $nmbr$ ( low risk ),C3272281;C3538919
173,vascular risk score — no . { % ) ^,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
173,vascular risk score |,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
173,vascular risk score *,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
173,timi risk scoret,C0035647;C4552904
173,timi risk score — no . / total no . ( % ) : c,C0035647;C0439175;C0439810;C0449820;C4050231;C4552904
173,timi risk score category — no . ( % ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
173,timi risk score > $nmbr$  n ( % ),C0035647;C0449820;C4050231;C4552904
173,timi risk score $nmbr$ - $nmbr$,C0035647;C0449820;C4050231;C4552904
173,timi risk score  n / n ( % ),C0035647;C0449820;C4050231;C4552904
173,shock risk indext,C0035647;C0036974;C4552904
173,risk stratum,C0035647;C4552904
173,risk score category ( points ),C0035647;C0449820;C0683312;C1552961;C2347617;C3714763;C3889287;C4050231;C4552904
173,risk category ( points ),C0035647;C0683312;C1552961;C2347617;C3714763;C3889287;C4552904
173,risk categories,C0035647;C0683312;C4552904
173,risk at,C0035647;C4552904
173,risk *,C0035647;C4552904
173,risk,C0035647;C4552904
173,no increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
173,ncep risk category at study entry  n ( % ),C0035647;C1705654;C2983287;C2983669;C4552904
173,moderate risk ( > $nmbr$ - $nmbr$ ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
173,increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
173,framingham risk score *,C0035647;C0449820;C3166866;C4050231;C4552904
173,framingham risk score ( % ),C0035647;C0449820;C3166866;C4050231;C4552904
173,framingham risk score  arbitrary units,C0035647;C0439183;C0449820;C3166866;C4050231;C4552904
173,framingham risk score,C0035647;C0449820;C3166866;C4050231;C4552904
173,cardio - renal risk,C0018787;C0022646;C0035647;C4552904
173,cardiac risk,C0018787;C0035647;C1522601;C4552904
173,> $nmbr$ ( moderate or high bleeding risk )  no . / total ( % ),C0019080;C0035647;C0205081;C0205250;C0439175;C0439810;C1299351;C1881878;C2700149;C3887512;C3889660;C4049705;C4049706;C4085643;C4321237;C4321335;C4522209;C4552904
172,unadjusted $nmbr$ - y risk per $nmbr$ population = se ( adjusted rate ),C0036919;C0242444;C0456081;C0871208;C1439367;C1521828;C2987720
172,risk group,C0242444
172,intermediate risk ( ri = $nmbr$ ),C0035487;C1826843;C3640764
172,intermediate risk,C3640764
171,risk reduction ( %  $nmbr$ % ci ),C0008107;C1137094;C3259781
171,risk reduction  %,C1137094
171,reduction in risk ( $nmbr$ % ci ) %,C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
171,reduction in risk % ( $nmbr$ % ci ),C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
171,absolute risk reductions,C3179139
171,absolute risk reduction ( $nmbr$ % cl ) *,C0596019;C3179139
171,absolute risk reduction ( $nmbr$ % ci )  % / y,C0008107;C3179139;C3259781
171,* risk reduction  $nmbr$ percent confidence interval ( ci )  and p value are derived from cox models . for risk reductions  negative numbers indicate an increase in risk . † diabetes and hypertension were defined by clinical history . ‡ a family history was defined as having one or more first - degree relatives with either myocardial infarction or sudden death before the age of $nmbr$ . § hdl cholesterol levels are shown according to the median value ( $nmbr$ . $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¶ triglyceride levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¿ ldl cholesterol levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) and according to the values that divide the subjects into three equal groups ( < $nmbr$  $nmbr$ to $nmbr$  and > $nmbr$ mg per deciliter [ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$  and > $nmbr$ . $nmbr$ mmol per liter ] ) .,C0008107;C0009667;C0010234;C0019664;C0019665;C0020538;C0023824;C0024671;C0026410;C0027051;C0042295;C0202069;C0202117;C0205163;C0205172;C0205210;C0205447;C0205449;C0241889;C0262512;C0262926;C0332849;C0392885;C0428475;C0428953;C0439165;C0439190;C0439241;C0439269;C0441833;C0441889;C0442805;C0475211;C0549183;C0567349;C0680240;C0681850;C0687744;C0876920;C1137094;C1171304;C1257890;C1276802;C1441547;C1518469;C1519504;C1522609;C1546180;C1547282;C1549782;C1550501;C1552839;C1704788;C1705255;C1705428;C1705429;C1706203;C1709380;C1960952;C1963138;C2004062;C2346927;C2347285;C2347635;C2348144;C2348885;C2349001;C2697811;C2825415;C2926063;C2939193;C3245521;C3259781;C3539106;C3810814;C4321396;C4521761;C4552959
171,% risk reduction ( $nmbr$ % ci ),C0008107;C1137094;C3259781
170,sk . $nmbr$,
170,rash,C0015230
170,heart disease risk factors,C0741920
170,coronary heart disease risk equivalents  n ( % ) c,C0439185;C1277690;C4049980
170,$nmbr$ - yr risk of coronary heart disease ( % ) ^ |,C0439234;C1277690
169,nih stroke scale,C1697238;C3484372
169,$nmbr$ nil,C0442734
168,india,C0021201;C2700456
168,* other - europe ( n = $nmbr$ )  australia ( n = $nmbr$ ) and india ( n = $nmbr$ ) - the data from these regions were collapsed due to the small numbers,C0004340;C0015176;C0017446;C0021201;C0205147;C0237753;C0344329;C0392748;C0449788;C0678226;C0700321;C1511726;C2700456;C3245479;C3714741
167,use of high - dose inhaled glucocorticoid — no . { % ),C0004048;C0017710;C0444956;C1524063
167,laba ( inhaled )  d   n ( % ),C0004048;C0073187;C0332173;C4484261
167,inhaledb,
167,inhaled §,C0004048
167,inhaled j $nmbr$ - agonist §,C0004048;C2987634
167,inhaled anticholinergic §,C0004048;C0242896;C3537004
167,inhaled ^,C0004048
167,daily dose of inhaled glucocorticoid — no . ( % ) §,C0004048;C0017710;C2348070
167,a ) those receiving no inhaled pre - treatment maintenance medication,C0004048;C0013227;C0021459;C0024501;C0039798;C0087111;C0332152;C0740175;C1514756;C1522326;C1533734;C1705169;C2257086;C2347660;C3244316;C3469597;C3538994;C3669034;C3887704;C4284232
-10,unhappy,C1688635
-10,nap,C0870935;C1423800;C4283878
164,enalapril lcz $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),C0014025
164,enalapril dm = $nmbr$ non - dm = $nmbr$,C0011816;C0014025;C1518422;C3250443
164,enalapril + aliskiren ( n = $nmbr$ ),C0014025;C1120110
164,enalapril ( n = $nmbr$ ),C0014025
164,enalapril,C0014025
163,insulin detemir,C0537270
163,insulin aspart ( mealtime ),C0123677;C0587119;C1708521
163,insulin aspart,C0123677;C1708521
163,detemir / insulin glargine  %,C0537270;C0907402
162,type of insulin therapy — no . ( % ) $nmbr$,C0039798;C0087111;C0457592;C1363945
162,type of insulin,C0457592
162,type of basal insulin  n ( % ),C0205112;C0332307;C0457592;C0650607;C1547052
162,method of insulin administration,C0025663;C0199782;C0449851;C0871511
162,insulin type  n ( % ),C0457592
162,insulin administration,C0199782
161,insulins and analogs,C0021641;C0243071;C3537244;C4049919
161,insulins,C0021641;C3537244;C4049919
161,insulin sensitivity — % §,C0920563;C4049919
161,composite index of insulin sensitivity ( isi ),C0205199;C0600653;C0918012;C0920563;C1547335;C1552854;C1637833;C2986546;C4049919
160,insulin - dependent diabetes mellitus,C0011854
160,insulin - dependent diabetes,C0011854
159,oral antidiabetes combination therapy without insulina  n ( % ),C0009429;C0442027;C0556895;C4521986
159,insulina  n ( % ),
159,insulina,
158,octave induction $nmbr$ and $nmbr$,C0205263;C0857127
158,octave induction $nmbr$,C0205263;C0857127
158,noninducing,
158,non - enzyme inducing,C0014442;C0205263;C1518422;C4521602
158,induction - trial group assignment — no . ( % ),C0205263;C0857127;C1320290;C1516050
158,inducing,C0205263
158,enzyme inducing,C0014442;C0205263;C4521602
157,yes  non - insulin - treated,C0021641;C1518422;C1522326;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
157,yes  insulin - treated,C0021641;C1522326;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
157,without insulin or insulin - modifying therapy,C0021641;C0039798;C0087111;C0392747;C1363945;C1533581;C1579433;C3714501
157,treated with insulin,C0021641;C0332293;C1533581;C1579433;C3714501
157,total daily insulin dose ( u / day ),C0021641;C0456683;C1533581;C1579433;C2348070;C3714501
157,total daily insulin dose  units / kgt,C0021641;C0439148;C1519795;C1533581;C1579433;C2348070;C3714501;C3853603
157,total daily insulin dose  u,C0021641;C0439148;C1533581;C1579433;C2348070;C3714501
157,total baseline insulin dose,C0021641;C0168634;C0366513;C0439175;C0439810;C1442488;C1533581;C1579433;C2986497;C3714501
157,sustain $nmbr$ : semaglutide add ‐ on to insulin vs . placebo,C0021641;C0032042;C0443318;C1533581;C1579433;C1696465;C1706408;C1883712;C2732140;C3714501;C3885068
157,premixed insulin with oads ( % ),C0021641;C1533581;C1579433;C3714501
157,premixed insulin only ( % ),C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
157,pre - mixed insulin,C0021641;C0205430;C0332152;C0740175;C1533581;C1579433;C2257086;C3160715;C3669034;C3714501
157,placebo + insulin ( n   = $nmbr$ ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
157,placebo + insulin ( n = $nmbr$ ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
157,patients treated with insulin,C0021641;C0030705;C0332293;C1533581;C1579433;C3714501
157,participants taking insulin,C0021641;C0679646;C1515187;C1533581;C1579433;C3714501
157,oad plus insulin,C0021641;C1533581;C1579433;C3714501
157,median fasting insulin ( iqr ) — pu per milliliter,C0015663;C0018387;C0021641;C0439242;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
157,mean ± sd fasting insulin  uu / ml,C0015663;C0021641;C0439342;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
157,insulin 一 no . ( % ),C0021641;C1533581;C1579433;C3714501
157,insulin — iu,C0021641;C0049272;C0439453;C0694756;C1533581;C1579433;C3714501
157,insulin — / tu / ml,C0021641;C0041400;C0439526;C1532464;C1533581;C1579433;C1705224;C2700314;C3714501;C3811255;C3887665
157,insulin yes,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
157,insulin treated,C0021641;C1522326;C1533581;C1579433;C3714501
157,insulin secretagogue,C0021641;C1533581;C1579433;C3714501;C4704833
157,insulin plus oral,C0021641;C0442027;C1533581;C1579433;C3714501;C4521986
157,insulin plus > $nmbr$ oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
157,insulin plus $nmbr$ oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
157,insulin only,C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
157,insulin glargin arm,C0021641;C0446516;C1533581;C1579433;C3714501;C3715044;C4553528
157,insulin dependentc,C0021641;C1533581;C1579433;C3714501
157,insulin based,C0021641;C1527178;C1533581;C1579433;C1705938;C3714501
157,insulin at baseline,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
157,insulin alone,C0021641;C0205171;C0439044;C0679994;C1533581;C1579433;C3714501
157,insulin : glucose ratio,C0017725;C0021641;C0456603;C1533581;C1547037;C1579433;C3714501
157,insulin - treated dm,C0011816;C0021641;C1522326;C1533581;C1579433;C3250443;C3714501
157,insulin - treated diabetes  %,C0011847;C0011849;C0021641;C1522326;C1533581;C1579433;C3714501
157,insulin - treated diabetes,C0011847;C0011849;C0021641;C1522326;C1533581;C1579433;C3714501
157,insulin - treated,C0021641;C1522326;C1533581;C1579433;C3714501
157,insulin - requiring diabetes,C0011847;C0011849;C0021641;C1533581;C1579433;C3714501
157,insulin - requiring,C0021641;C1533581;C1579433;C3714501
157,insulin - naive  n ( % ),C0021641;C1533581;C1579433;C3714501
157,insulin - dependent,C0021641;C0429964;C0429986;C0851827;C1533581;C1579433;C1701901;C3244310;C3714501;C4321395
157,insulin + oad,C0021641;C1533581;C1579433;C3714501
157,insulin + metformin,C0021641;C0025598;C1533581;C1579433;C3714501
157,insulin ( pmol / l ) t vital signs,C0021641;C0150404;C0439284;C0518766;C1533581;C1579433;C3714501
157,insulin ( pmol / l ),C0021641;C0439284;C1533581;C1579433;C3714501
157,insulin ( mu / ml ),C0021641;C0439339;C1533581;C1579433;C3714501
157,insulin ( % ),C0021641;C1533581;C1579433;C3714501
157,insulin  pmol / l,C0021641;C0439284;C1533581;C1579433;C3714501
157,insulin  n ( % ),C0021641;C1533581;C1579433;C3714501
157,insulin  iu / ml  median ( q $nmbr$  q $nmbr$ ),C0021641;C0439458;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
157,insulin,C0021641;C1533581;C1579433;C3714501
157,initiation of insulin,C0021641;C0589507;C1158830;C1533581;C1579433;C1704686;C3714501
157,fasting insulin — pmol / liter,C0015663;C0021641;C0439192;C0475211;C1533581;C1579433;C3714501
157,fasting insulin — / tiu / ml §,C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
157,fasting insulin ( pmol / l ),C0015663;C0021641;C0439284;C1533581;C1579433;C3714501
157,fasting insulin ( miu / ml ),C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
157,fasting insulin ( giu / ml ),C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
157,fasting insulin  pmol / l ( mean ± sd ),C0015663;C0021641;C0439284;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
157,fasting insulin  iiiu / ml  mean ± sd,C0015663;C0021641;C0439526;C0444504;C1533581;C1579433;C1705224;C2347634;C2348143;C2699239;C3714501;C3887665
157,fasting insulin  * median ( iqr )  gu / ml,C0015663;C0021641;C0120446;C0439526;C0549183;C0876920;C1533581;C1579433;C1705224;C2347635;C2348144;C2939193;C3714501;C3887515;C3887665
157,fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
157,daily insulin dose  mean ( sd )  iu,C0021641;C0049272;C0332173;C0366513;C0439453;C0444504;C0694756;C1533581;C1579433;C2347634;C2348070;C2348143;C2699239;C3714501
157,bolus insulin doseh,C0021641;C1186706;C1511237;C1533581;C1579433;C1705509;C3714501;C3812160
157,baseline insulin,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
157,$nmbr$ - h postprandial insulin ( miu / ml ),C0021641;C0033727;C0369286;C0376674;C0439457;C0441932;C0564385;C1533581;C1579433;C3714501;C4528284
156,values are expressed as percentages unless otherwise indicated . bmi  body mass index  cabg  coronary artery bypass ischemic attack  nsaids  nonsteroidal anti - inflammatory drugs  sbp  systolic bp  dbp  diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications .,C0003209;C0003211;C0010055;C0012000;C0013227;C0019664;C0019665;C0023779;C0042295;C0085805;C0242821;C0262512;C0262926;C0439165;C0441994;C0460148;C0521116;C0536221;C0577559;C0577573;C0578022;C0600653;C0745413;C0802604;C0871470;C0918012;C0935929;C1096155;C1268086;C1306372;C1444656;C1515187;C1549488;C1552854;C1561533;C1637833;C1705255;C2003888;C2004062;C2598133;C2986546;C3152252;C3539882;C3813197;C4082212;C4281799;C4283905;C4284232
156,previous anti - inflammatory / antirheumatic products n ( % ),C0003191;C0205156;C0333348;C0432633;C1514468;C1552607
156,inflammatory,C0333348
156,antiplatelet or anti - inflammatory drugs,C0003209
156,anti - inflammatory drugs,C0003209
155,inflammation,C0021368
155,baseline inflammation markers,C0005516;C0021368;C0168634;C1442488
154,previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
154,no previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
154,infliximab monotherapy,C0666743
154,infliximab - naive ( n = $nmbr$ ),C0666743
154,infliximab - experienced ( n = $nmbr$ ),C0666743
154,infliximab ( n = $nmbr$ ),C0666743
154,infliximab,C0666743
154,inflix  yes,C0666743;C1549445;C1705108;C1710701
154,inflix  no,C0666743
154,combined infliximab,C0205195;C0666743
153,npi,C1412208;C1549728;C3539727
153,ni,C0028075;C2348274;C3869926;C3869927
153,> $nmbr$ ml / niin / l $nmbr$ ni -,C0028075;C1635169;C2348274;C3869926;C3869927
153,< $nmbr$ ml / min / $nmbr$ . $nmbr$ ni -,C0028075;C0439445;C2348274;C3869926;C3869927
152,no anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
152,new anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0205314;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
152,improving anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1272745;C1319635;C1549954;C4554633
152,anemia — no . ( % ) | |,C0002871;C1000483;C4554633
152,anemia ( % ),C0002871;C1000483;C4554633
152,anemia  no . / total ( % ) ”,C0002871;C0439175;C0439810;C1000483;C4554633
152,anemia  %,C0002871;C1000483;C4554633
152,anemia,C0002871;C1000483;C4554633
151,nyhaii,
151,nyha iv  n ( % ),C0022326;C1275491;C4265176
151,nyha iv  %,C0022326;C1275491;C4265176
151,nyha iii or iv § ( n = $nmbr$ $nmbr$ ),C0022326;C0439070;C1275491;C1705160;C4265176
151,nyha iii or iv,C0022326;C0439070;C1275491;C1705160;C4265176
151,nyha iii  n ( % ),C0439070;C1275491;C1705160
151,nyha ii  n ( % ),C1275491;C1710602;C4082587
151,nyha ii,C1275491;C1710602;C4082587
151,nyha,C1275491
151,nph,C0020258;C0027442
151,heart failure nyha ii - iii,C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
151,heart failure ( nyha ii ‐ iii )  n ( % ),C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
151,dyspnea at rest ( nyha iv )  ( % ),C0022326;C0743330;C1275491;C4265176
151,( nyha grade iii or iv ),C0022326;C0205617;C0450094;C0475271;C0687697;C1275491;C3889290;C4050000;C4265176;C4283820;C4283821;C4283822
-10,has - bledo,C1019275
149,less than $nmbr$ y ears,C0013443;C0439092;C0521421
149,< $nmbr$ y ears,C0013443;C0521421
148,≥ $nmbr$ yearsa,
148,£ $nmbr$ . $nmbr$ yrs,
148,younger subjects ( aged < $nmbr$ years ),C0001779;C0001792;C0332239;C0439234;C0681850;C1550501;C1706203;C1999167;C2349001;C2697811
148,younger patients ( aged $nmbr$ years ),C0001779;C0001792;C0030705;C0332239;C0439234;C1999167
148,older subjects ( aged > $nmbr$ years ',C0001779;C0001792;C0439234;C0580836;C0681850;C1550501;C1706203;C1999167;C2349001;C2697811
148,older patients ( aged > $nmbr$ years ),C0001779;C0001792;C0030705;C0439234;C0580836;C1999167
148,aged ≥ $nmbr$ years,C0001779;C0001792;C0439234;C1999167
148,aged a $nmbr$ years,C0001779;C0001792;C0439234;C1999167
148,aged ^ $nmbr$ years,C0001779;C0001792;C0439234;C1999167
148,aged < $nmbr$ years,C0001779;C0001792;C0439234;C1999167
148,age ≥ $nmbr$ yearsa,C0001779
148,age ± sd ( yrs ),C0001779;C2699239
148,age ^ $nmbr$ yrs  n ( % ),C0001779
148,age > $nmbr$ yrs  n ( % ),C0001779
148,age ( yrs ) < $nmbr$,C0001779
148,age ( yrs ) $nmbr$ - $nmbr$,C0001779
148,age $nmbr$ + yrs,C0001779
148,age  yrs  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
148,age  yrs  median ( $nmbr$ th  $nmbr$ th ),C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
148,< $nmbr$ yrs,
148,< $nmbr$ . $nmbr$ yrs,
147,yes vs . no,C1549445;C1705108;C1710701
147,yes *,C1549445;C1705108;C1710701
147,yes ( stopped for trial ),C0008976;C1272691;C1549445;C1705108;C1710701
147,yes ( n = $nmbr$ ),C1549445;C1705108;C1710701
147,yes ( n  % ),C1549445;C1705108;C1710701
147,yes ( any ),C1549445;C1705108;C1710701
147,yes ( % ),C1549445;C1705108;C1710701
147,yes ',C1549445;C1705108;C1710701
147,yes  z $nmbr$ cm,C1549445;C1705108;C1710701
147,yes  yes,C1549445;C1705108;C1710701
147,yes  unknown,C0439673;C1549445;C1705108;C1710701;C3541433;C4050014
147,yes  r $nmbr$ y,C0205090;C0684010;C1549445;C1705108;C1710701;C2603358
147,yes  proliferative,C0334094;C1549445;C1705108;C1710701
147,yes  o $nmbr$ cm,C1549445;C1705108;C1710701
147,yes  non - proliferative,C0334094;C1518422;C1549445;C1705108;C1710701
147,yes  n ( % ),C1549445;C1705108;C1710701
147,yes  $nmbr$ $nmbr$ y,C1549445;C1705108;C1710701
147,yes,C1549445;C1705108;C1710701
147,use of cgm ( yes ),C1524063;C1549445;C1705108;C1710701
147,thiazolidinedione yes,C0289779;C1257987;C1549445;C1705108;C1710701;C3537039
147,prior tnf antagonist treatment - yes,C0231491;C1448177;C1514463;C1549445;C1705108;C1710701
147,prior hypertensiona yes,C0332152;C1549445;C1705108;C1710701;C2826257
147,partner  n ( % yes ),C0682323;C1549445;C1705108;C1710701;C3887537
147,parental history of ml before age $nmbr$ y yes,C0001779;C0019664;C0019665;C0030551;C0262512;C0262926;C0439526;C1549445;C1705108;C1705224;C1705255;C1710701;C2004062;C3887665
147,no  yes,C1549445;C1705108;C1710701
147,naive : yes,C1549445;C1705108;C1710701
147,metformin : no / yes  %,C0025598;C1549445;C1705108;C1710701
147,long ( > $nmbr$ mm ) stenting yes ( n = $nmbr$ ),C0038257;C0205166;C1549445;C1705108;C1706317;C1710701;C2348535;C4330985;C4554674
147,ics use yes,C0042153;C0457083;C0815320;C1549445;C1705108;C1710701;C1947944;C4551720
147,ics : yes,C0815320;C1549445;C1705108;C1710701;C4551720
147,etn  yes,C0014758;C0717758;C1549445;C1705108;C1710701
147,ed history  n ( % yes ),C0019664;C0019665;C0262512;C0262926;C1549445;C1705108;C1705255;C1710701;C2004062;C3538926
147,diabetics - yes ( n = $nmbr$  $nmbr$ ),C0241863;C1549445;C1705108;C1710701
147,diabetic yes,C0241863;C1549445;C1705108;C1710701
147,diabetic ( yes ),C0241863;C1549445;C1705108;C1710701
147,diabetesh yes,C1549445;C1705108;C1710701
147,diabetes | | yes,C0011847;C0011849;C1549445;C1705108;C1710701
147,diabetes mellitus yes ( n  % ) hypertension,C0011849;C0020538;C1549445;C1705108;C1710701;C1963138
147,diabetes mellitus  n ( % ) yes,C0011849;C1549445;C1705108;C1710701
147,current smoker yes,C1549445;C1705108;C1710701;C3173209;C3241966
147,corticosteroid use at baseline - yes,C0168634;C0239126;C1442488;C1549445;C1705108;C1710701
147,copd exacerbation : yes,C0740304;C1549445;C1705108;C1710701
147,concomitant medications ( yes )  n ( % },C0013227;C0521115;C0802604;C1549445;C1705108;C1710701;C2598133;C4284232
147,cardiac rhythm disorder at baseline yes,C0168634;C0264886;C1442488;C1549445;C1705108;C1710701
147,baseline sulfonylurea yes,C0038766;C0168634;C1442488;C1549445;C1705108;C1710701;C3536898
147,baseline ocs use : yes,C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944
147,baseline ics use : yes,C0042153;C0168634;C0457083;C0815320;C1442488;C1549445;C1705108;C1710701;C1947944;C4551720
147,baseline calcium yes,C0006675;C0006726;C0168634;C1442488;C1549445;C1705108;C1710701;C2936886;C3540037;C3714611
147,amiodarone use at baseline yes $nmbr$  $nmbr$,C0002598;C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944
147,ace inhibitor yes,C0003015;C1549445;C1705108;C1710701;C4541021
147,[ no / yes ] ( % ),C1549445;C1705108;C1710701
146,tass ’,C0559483
146,mean body - mass indexj,C0444504;C0518010;C2347634;C2348143
146,lv mass index ( mg / m $nmbr$ ),C0024671;C0026410;C0369637;C0439269;C0441923;C0455825;C0600653;C0918012;C1552854;C1637833;C1960952;C2346927;C2986546;C4321396;C4521761
146,lv mass,C0455825
146,body mass indext,C0518010
146,body mass indexf  < $nmbr$,C0518010
146,body mass indexf,C0518010
146,body mass indexc,C0518010
146,body mass indexb,C0518010
146,body mass indexa < median,C0518010;C0549183;C0876920;C2347635;C2348144;C2939193
146,body mass indexa,C0518010
146,body - mass indexj,C0518010
146,body - mass indexf,C0518010
145,vdhmtss,
145,mtss cfb mean ± sd,C0009002;C0444504;C1824728;C2347634;C2348143;C2699239
145,mtss cfb,C0009002;C1824728
-10,( fxs ),C0016667
143,mean score on das $nmbr$ - $nmbr$ ( crp ) ^,C0051767;C0057671;C3533236;C3890735;C4048285
143,das - $nmbr$ ( crp ) < $nmbr$ . $nmbr$  n ( % ),C0051767;C0057671;C3890735;C4048285
143,das - $nmbr$ ( crp )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
143,das $nmbr$ ‐ crp,C0051767;C0057671;C3890735;C4048285
143,das $nmbr$ score,C0051767;C0057671;C0449820;C4050231
143,das $nmbr$ - hscrp,C0051767;C0057671
143,das $nmbr$ - crp §,C0051767;C0057671;C3890735;C4048285
143,das $nmbr$ - crp  ls mean change from baseline ( se ) ¥,C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952
143,das $nmbr$ - crp,C0051767;C0057671;C3890735;C4048285
143,das $nmbr$ ( crp )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
143,das $nmbr$ ( crp ),C0051767;C0057671;C3890735;C4048285
143,das $nmbr$,C0051767;C0057671
143,c . das $nmbr$ - crp < $nmbr$ . $nmbr$,C0051767;C0057671;C3890735;C4048285
142,time of symptom onset to randomization ( hrs ),C0034656;C1320528;C1568891
142,time of symptom onset to balloon inflation ( hrs ),C0021398;C0336867;C0441144;C1318493;C1320528;C1568891
142,time of qualifying ecg to balloon inflation ( hrs ),C0021398;C0040223;C0336867;C0441144;C1318493;C1514624;C1568891;C1623258;C3541383
142,hps,C0242994
142,^ $nmbr$ hrs,C1568891
142,> $nmbr$ hrs,C1568891
142,< $nmbr$ hrs,C1568891
141,qrs interval > $nmbr$ msec — no . ( % ),C0439223;C0520880
141,qrs < $nmbr$ msec,C0439223
140,time since first af diagnosis  yrs,C0011900;C0040223;C0205435;C0344434;C1279901;C1704338;C1704656;C3541383;C4049859
140,time since copd diagnosis ( yrs ),C0011900;C0024117;C0040223;C1412502;C1704338;C1704656;C3541383;C3714496
140,mras,C1335594;C1367476
140,> $nmbr$ . $nmbr$ yrs,
140,$nmbr$ yrs l,
139,total pack - yrs,C0439175;C0439810;C1968515;C2825051;C2828395
139,grs,C1412761;C3539564
139,$nmbr$ yrs,
138,psoriasis duration  yrs *,C0033860;C0449238;C2926735
138,duration of ra  mean ( min - max ) ( yrs ),C0444504;C0449238;C0702093;C1524029;C2347634;C2348143;C2926735;C3538806;C3813700;C4048756
138,duration of crohn ’ s disease ( yrs ),C0010346;C0449238;C2926735
138,duration of crohn ' s disease ( yrs ),C0010346;C0449238;C2926735
138,disease duration  yrs  mean ( sd ),C0444504;C0872146;C2347634;C2348143;C2699239
138,> $nmbr$ yrs,
138,$nmbr$ . $nmbr$ yrs,
138,$nmbr$ - < $nmbr$ yrs,
138,$nmbr$ - $nmbr$ yrs,
137,previous ics only,C0205156;C0205171;C0815320;C1552607;C1720467;C4551720
137,is only,C0205171;C1720467
137,ics only,C0205171;C0815320;C1720467;C4551720
137,ibs ( $nmbr$ . $nmbr$ ),C0022104;C0432306
137,$nmbr$ is ( $nmbr$ . $nmbr$ ),
136,previous or current use of im or cs : no,C0010182;C0205156;C0271160;C0521116;C1524063;C1552607;C1705970;C3540510;C4085345
136,previous or current use of im and cs : no,C0010182;C0205156;C0271160;C0521116;C1524063;C1552607;C1705970;C3540510;C4085345
136,previous or current cs use : no,C0010182;C0042153;C0205156;C0271160;C0457083;C0521116;C1552607;C1705970;C1947944;C3540510;C4085345
136,no cs and is,C0010182;C0271160;C3540510;C4085345
136,no cs and imm,C0010182;C0205470;C0271160;C3540510;C4085345
136,neither cs nor imm,C0010182;C0205470;C0271160;C3540510;C4085345
136,im or cs use : no,C0010182;C0042153;C0271160;C0457083;C1947944;C3540510;C4085345
136,im and cs use : no,C0010182;C0042153;C0271160;C0457083;C1947944;C3540510;C4085345
136,glycopyrrolate / glycopyrrolate / eflow cs $nmbr$ meg eflow cs $nmbr$ meg ( n = $nmbr$ ) ( n = $nmbr$ ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
136,glycopyrrolate / eflow cs $nmbr$ meg ( n = $nmbr$ ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
136,cs use : no,C0010182;C0042153;C0271160;C0457083;C1947944;C3540510;C4085345
136,cs only,C0010182;C0205171;C0271160;C1720467;C3540510;C4085345
136,cs and is,C0010182;C0271160;C3540510;C4085345
136,cs and imm,C0010182;C0205470;C0271160;C3540510;C4085345
136,cs and im,C0010182;C0271160;C3540510;C4085345
136,cs,C0010182;C0271160;C3540510;C4085345
135,p $nmbr$ vs no treatment $nmbr$,C0039798;C0087111;C0369773;C1522326;C1533734;C1705169;C2603361;C3538994;C3887704
135,p  all vs all,C0369773;C2603361
135,a vs . c,
134,women ( n = $nmbr$ vs $nmbr$ ),C0043210
134,male vs . female,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
134,> $nmbr$   vs .   ≤   $nmbr$,
134,$nmbr$ . $nmbr$ % vs . $nmbr$ . $nmbr$ %,
133,lisinopril vs chlorthalidone obese,C0008294;C0028754;C0065374
133,lisinopril vs amlodipineb,C0065374
133,chlorthalidone vs lisinopril,C0008294;C0065374
133,$nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$,
132,tp vs no tp,C0036183;C3541334
132,q $nmbr$ : $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
132,ith vs . without ),
132,e $nmbr$ / s $nmbr$ vs s $nmbr$,C0565930;C2603362;C3846405
132,e $nmbr$ / s $nmbr$ vs e $nmbr$,C3846405
132,> $nmbr$ to   ≤   $nmbr$   vs .   ≤   $nmbr$,
132,> $nmbr$ and   ≤   $nmbr$   vs   ≤   $nmbr$,
132,> $nmbr$ and   ≤   $nmbr$   vs .   ≤   $nmbr$,
132,> $nmbr$ . $nmbr$   vs .   >   $nmbr$ . $nmbr$ and   ≤   $nmbr$ . $nmbr$,
131,notes :,C1317574
131,nos $nmbr$ glu $nmbr$ asp g . t  n ( % ),C0125690;C0326287;C0439267;C1518425;C2986835
131,nos $nmbr$ $nmbr$ c . t  n ( % ),C0326287;C1518425
131,nos $nmbr$ $nmbr$ a . g  n ( % ),C0326287;C0439267;C1518425
130,tion  os = overall satisfaction  qmax = maximal urinary flow rate .,C0229090;C0230028;C0262950;C0393706;C0429784;C1561953;C4086680
130,os domain,C0229090;C0230028;C0262950;C0393706;C1561953;C1880389;C1883221;C3541951
130,ocs  n ( % ),
130,no ocs,
130,- o . os,C2673162
130,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . os ),C0229090;C0230028;C0262950;C0393706;C1561953
129,sys : ns dia : < $nmbr$ . $nmbr$,C0038944;C1112705;C1425041;C1705982;C1706546
129,ns cardiac cisease,C0018787;C0038944;C1112705;C1522601;C1705982
129,ns,C0038944;C1112705;C1705982
128,tgs ( mg / dl ),C0439269;C1156212;C1537574
128,fasting tgs §,C0015663;C1156212;C1537574
128,baseline fasting tgs  mg / dl,C0015663;C0168634;C0439269;C1156212;C1442488;C1537574
127,ssed as ls means,C0023668;C1704970
127,ls / ul $nmbr$ $nmbr$,C0023668;C1300557
127,lis,C2247545
127,lips,C0023759
127,aml vs . lis,C0023465;C0023467;C2247545
126,qrs width  ms,C0487742;C2349943;C3539704;C3713294
126,qrs duration > $nmbr$ ms  n ( % ),C0429025;C0488377;C2349943;C3539704;C3713294
126,qrs duration  ms,C0429025;C0488377;C2349943;C3539704;C3713294
126,qrs > $nmbr$ ms *,C2349943;C3539704;C3713294
126,qrs > $nmbr$ ms  n ( % )  available for $nmbr$ patients,C0030705;C0470187;C2349943;C3539704;C3713294
126,qrs > $nmbr$ ms  % ( n ),C2349943;C3539704;C3713294
126,qrs < $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$  $nmbr$ ),C0596019;C2349943;C3539704;C3713294
126,qrs $ $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$ ),C0596019;C2349943;C3539704;C3713294
126,ms < $nmbr$  n [ % ],C2349943;C3539704;C3713294
126,ms & ng,C0017887;C0028074;C2349943;C3539704;C3713294
126,ms $nmbr$ - $nmbr$  n [ % ],C2349943;C3539704;C3713294
126,ms  mean [ sd ],C0444504;C2347634;C2348143;C2349943;C2699239;C3539704;C3713294
126,cornell voltage x duration product  mm x ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
126,cornell voltage - duration product  mm × ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
126,cornell voltage - duration product  mm x ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
126,corneii product  mm - ms,C1514468;C1704444;C2349943;C3539704;C3713294;C4330985;C4554674
126,( n = ms ),C0369718;C0441922;C2349943;C3539704;C3713294
126,$nmbr$ ms score †,C0449820;C2349943;C3539704;C3713294;C4050231
125,psa ‐ modified mases score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0392747;C0449820;C1947916;C3810537;C3813209;C3889737;C4050231
125,psa subtypes  n ( % ),C0449560;C3810537;C3813209
125,psa reported  n ( % ),C0369718;C0441922;C0684224;C0700287;C3810537;C3813209;C4319718
125,psa pain ( vas ),C0042815;C3810537;C3813209
125,psa - modified total shs,C0392747;C0439175;C0439810;C3810537;C3813209;C3889737
125,psa - modified shs ( $nmbr$ - $nmbr$ ),C0392747;C3810537;C3813209;C3889737
125,psa - modified mases score ( $nmbr$ - $nmbr$ ),C0392747;C0449820;C3810537;C3813209;C3889737;C4050231
125,psa ( n = $nmbr$ ),C3810537;C3813209
125,psa,C3810537;C3813209
125,patients with change from baseline in psa - modified total shs score # $nmbr$,C0030705;C0168634;C0392747;C0439175;C0439810;C0443172;C0449820;C1442488;C1705241;C3810537;C3813209;C3889737;C4050231;C4319952
125,no psa ( n = $nmbr$ ),C3810537;C3813209
125,no psa,C3810537;C3813209
125,no . of patients with psa,C0030705;C3810537;C3813209
124,total ipss,C0439175;C0439810;C1019118;C1998280;C2827405;C3811063
124,severe ( ipss > $nmbr$ ) age group,C0027362;C0205082;C1019118;C1998280;C2348001;C2827405;C3811063;C4050465;C4050466
124,severe ( ipss > $nmbr$ ) ( n = $nmbr$ ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
124,severe ( ipss > $nmbr$ ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
124,moderate ( ipss < $nmbr$ ) ( n = $nmbr$ ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
124,moderate ( $nmbr$ < ipss < $nmbr$ ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
124,mild / moderate ( ipss < $nmbr$ ),C1019118;C1299392;C1998280;C2827405;C3811063
124,mild - to - moderate ( ipss < $nmbr$ ),C1019118;C1299392;C1998280;C2827405;C3811063
124,mild ( ipss < $nmbr$ ),C1019118;C1998280;C2827405;C2945599;C3811063
124,ipss total score,C1019118;C1998280;C2827405;C2964552;C3811063
124,ipss hrql,C1019118;C1998280;C2827405;C3811063
124,ipss categories,C0683312;C1019118;C1998280;C2827405;C3811063
124,ipss - v,C1019118;C1998280;C2827405;C3811063
124,ipss - s,C1019118;C1998280;C2827405;C3811063
124,ipss ( unit ),C0439148;C0439453;C1019118;C1509845;C1519795;C1704753;C1880519;C1998280;C2827405;C3811063;C3853603
124,ipss  “ / o,C1019118;C1998280;C2827405;C3811063
124,ipss,C1019118;C1998280;C2827405;C3811063
124,erectile function  ipss,C0030847;C0031843;C0542341;C0700205;C1019118;C1705273;C1998280;C2827405;C3811063
124,baseline total ipss,C0168634;C0439175;C0439810;C1019118;C1442488;C1998280;C2827405;C3811063
124,= international prostate symptom score,C1998280
124,( ngml ' ' ) total mean ipss score,C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C2964552;C3533236;C3811063
123,russia and georgia,C0017452;C0017454;C0035970
123,russia / georgia ( n = $nmbr$ ),C0017452;C0017454;C0035970
123,russia / georgia,C0017452;C0017454;C0035970
123,russia,C0035970
123,rs - totala,C0035970;C3714753;C3813325
123,rs - chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
123,rs - breathlessnessb,C0035970;C3714753;C3813325
123,rs $nmbr$ ( ac ) & rs $nmbr$,C0001246;C0003354;C0035970;C1412573;C2000891;C3539770;C3714753;C3813325
123,rs $nmbr$ ( aa ) & rs $nmbr$,C0035970;C0282379;C1235746;C1882141;C3714753;C3813325;C4554792
123,rs $nmbr$ & rs $nmbr$,C0035970;C3714753;C3813325
123,rs $nmbr$,C0035970;C3714753;C3813325
123,europe and russia,C0015176;C0035970
123,enrolled in russia or georgia,C0017452;C0017454;C0035970;C4684790
123,e - rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
122,prior insulin use ( years ),C0240016;C0332152;C0439234;C2826257
122,insulin use at baseline,C0168634;C0240016;C1442488
122,insulin use    n   ( % ),C0240016
122,insulin use,C0240016
122,heparin use,C0239945
121,us w = $nmbr$,
121,us resident,C1320928;C1549439;C2347958;C3835651
120,systemic corticosteroid use,C0042153;C0205373;C0239126;C0457083;C1947944;C4053960
120,steroid use at baseline  n ( % ),C0168634;C0281991;C1442488
120,steroid use at baseline,C0168634;C0281991;C1442488
120,steroid use  %,C0281991
120,no steroid use at baseline ( ref ),C0168634;C0281991;C1425988;C1442488
120,corticosteroid use at randomization    n   ( % ),C0034656;C0239126
120,corticosteroid use at randomization,C0034656;C0239126
120,corticosteroid use at baseline - no,C0168634;C0239126;C1442488
120,corticosteroid use at baseline,C0168634;C0239126;C1442488
120,corticosteroid use  n ( % ),C0239126
120,corticosteroid use  %,C0239126
120,corticosteroid use  $nmbr$ n ( % ),C0239126
120,corticosteroid use,C0239126
120,concomitant corticosteroid use  n ( % ),C0239126;C0521115
120,concomitant corticosteroid use,C0239126;C0521115
120,baseline corticosteroid use ( mg ),C0024671;C0026410;C0168634;C0239126;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
119,use of rescue medication,C0240320
119,rescue medication use  inh / d {,C0022209;C0240320
119,no use ofdiabetes drugs — no . ( % ),C0240320
119,medication use before enrollment  no . ( % ),C0240320;C1516879;C1696073;C3888021
119,medication use at entry ( % ),C0240320;C1705654
119,medication use ( % ) aspirin,C0004057;C0240320
119,medication use ( % ),C0240320
119,medication use  n ( % ),C0240320
119,medication use,C0240320
119,current medication use,C0042153;C0240320;C0457083;C0521116;C0746467;C1705970;C1947944
119,concomitant medication use,C0240320;C0521115
119,blood pressure lowering medication use,C0005823;C0240320;C0441994;C1271104;C1272641;C2003888
118,use oforal glucose - lowering agent — no . ( % ),C0017725;C0042153;C0441994;C0450442;C0457083;C1254351;C1521826;C1947944;C2003888
118,use ( % ),C0042153;C0457083;C1947944
118,use,C0042153;C0457083;C1947944
118,triple therapy use at screening  n ( % ),C0039798;C0042153;C0087111;C0457083;C1363945;C1947944;C2121434
118,therapy use,C0039798;C0042153;C0087111;C0457083;C1363945;C1947944
118,sulfasalazine use at randomization    n   ( % ),C0034656;C0036078;C0042153;C0457083;C1947944
118,sulfasalazine use at randomization,C0034656;C0036078;C0042153;C0457083;C1947944
118,statin use — no . { % ),C0042153;C0360714;C0457083;C1947944
118,statin use ( % ),C0042153;C0360714;C0457083;C1947944
118,statin use,C0042153;C0360714;C0457083;C1947944
118,saba use in past $nmbr$ days,C0042153;C0439228;C0457083;C1444637;C1947944;C4284302
118,saba use  occasions / weekt,C0042153;C0457083;C1947944
118,rotablator use  n ( % ),C0042153;C0457083;C1260867;C1947944
118,regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
118,recurrent vte ( statin use vs non - use ),C0042153;C0360714;C0457083;C0630906;C1455761;C1518422;C1947944;C2945760
118,prior statin use ( n = $nmbr$ ),C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
118,prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
118,prior mesalazine use *,C0042153;C0127615;C0332152;C0457083;C1947944;C2826257
118,previous or current im use : no,C0042153;C0205156;C0457083;C0521116;C1552607;C1705970;C1947944
118,p - gp use,C0042153;C0369773;C0457083;C1705010;C1947944;C2603361;C3811116
118,no use,C0042153;C0457083;C1947944
118,no statin use,C0042153;C0360714;C0457083;C1947944
118,no regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
118,no prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
118,no concomitant cortcosteroid use,C0042153;C0457083;C0521115;C1947944
118,methotrexate use at randomization    n   ( % ),C0025677;C0034656;C0042153;C0457083;C1947944
118,methotrexate use at randomization,C0025677;C0034656;C0042153;C0457083;C1947944
118,methotrexate use at randomisation,C0025677;C0034656;C0042153;C0457083;C1947944
118,methotrexate use,C0025677;C0042153;C0457083;C1947944
118,mesalamine use  n ( % ) a,C0042153;C0127615;C0457083;C1947944
118,major bleeding ( statin use vs non - use ),C0019080;C0042153;C0205082;C0205164;C0360714;C0457083;C1518422;C1947944;C4318856;C4521762
118,maintenance use — no . ( % ),C0024501;C0042153;C0457083;C1947944
118,low - dose aspirin use strata * n ( % ),C0042153;C0457083;C1947944;C2608320
118,low - dose aspirin use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944;C2608320
118,low - dose aspirin use . strata *  n ( % ),C0042153;C0457083;C1947944;C2608320
118,low - dose aspirin use,C0042153;C0457083;C1947944;C2608320
118,laba use at enrolment,C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
118,initiated use during double - blind treatment period,C0013072;C0039798;C0042153;C0087111;C0439531;C0457083;C1522326;C1533734;C1548602;C1704686;C1705169;C1947944;C1948053;C3538994;C3887704
118,im use : no,C0042153;C0457083;C1947944
118,ezetimibe use,C0042153;C0457083;C1142985;C1947944
118,dopamine agonist use  no . ( % ),C0042153;C0178601;C0457083;C1947944;C3536925
118,days without albuterol use  * %,C0001927;C0042153;C0439228;C0457083;C1947944
118,current lra use,C0042153;C0457083;C0521116;C1705970;C1947944
118,current laba use,C0042153;C0457083;C0521116;C1705970;C1947944
118,cse ] +,
118,cox - $nmbr$ selective inhibitor use,C0036576;C0042153;C0085387;C0457083;C1707391;C1947944
118,concomitant statin use,C0042153;C0360714;C0457083;C0521115;C1947944
118,concomitant methotrexate use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1947944
118,concomitant mao - b inhibitor use,C0042153;C0457083;C0521115;C0595265;C1947944;C2917433
118,concomitant aspirin use,C0004057;C0042153;C0457083;C0521115;C1947944
118,concomitant antibiotic use  n [ % ],C0003232;C0042153;C0457083;C0521115;C1947944
118,cholinesterase inhibitor use at baseline  no . ( % ),C0008425;C0042153;C0168634;C0457083;C1442488;C1947944;C3536756;C4521309
118,cholinesterase inhibitor use,C0008425;C0042153;C0457083;C1947944;C3536756;C4521309
118,cgm use,C0042153;C0457083;C1947944
118,before bronchodilator use,C0006280;C0042153;C0457083;C1947944
118,baseline aspirin use strata,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
118,baseline aspirin use,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
118,background laba use - yes  n ( % ),C0042153;C0457083;C1549445;C1705108;C1706907;C1710701;C1947944
118,background laba use,C0042153;C0457083;C1706907;C1947944
118,aspirin use n ( % ),C0004057;C0042153;C0457083;C1947944
118,aspirin use at randomization - n ( % ),C0004057;C0034656;C0042153;C0457083;C1947944
118,aspirin use at randomization,C0004057;C0034656;C0042153;C0457083;C1947944
118,aspirin use ( p = $nmbr$ . $nmbr$ t ),C0004057;C0042153;C0457083;C1947944
118,aspirin use ( p = $nmbr$ - $nmbr$ 十 ),C0004057;C0042153;C0457083;C1947944
118,aspirin use ( p = $nmbr$ - $nmbr$ t ),C0004057;C0042153;C0457083;C1947944
118,aspirin use ( % ),C0004057;C0042153;C0457083;C1947944
118,aspirin use,C0004057;C0042153;C0457083;C1947944
118,any use,C0042153;C0457083;C1947944
118,any glycoprotein iib / iiia inhibitor use,C0016011;C0042153;C0457083;C1947944;C1999216
118,antithrombotic use before enrollment  no . ( % ),C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
118,antithrombotic use,C0042153;C0457083;C1947944
118,antiplatelet use,C0042153;C0457083;C1947944
118,anorexigen use,C0042153;C0457083;C1947944
118,aldosterone use,C0002006;C0042153;C0457083;C1947944
118,albuterol use,C0001927;C0042153;C0457083;C1947944
118,after bronchodilator use,C0006280;C0042153;C0457083;C1947944
117,ssi - $nmbr$,
117,ss at baseline,C0168634;C1442488;C2699257;C3891295;C4551874
117,ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C2699257;C3891295;C4551874
117,ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C2699257;C3891295;C4551874
116,js $nmbr$ - agonists,C0243192;C1552154;C2987634
116,$nmbr$ [ $nmbr$ - $nmbr$ js,C1552154
115,observed case,C0868928;C1441672;C1706255;C1706256
115,observed,C1441672
115,mbesc  n / n ( % ),
115,mbesb  n / n ( % ),
115,mbes / crbesc,
115,mbes / crbesb  n / n ( % ),
115,$nmbr$ - $nmbr$ . $nmbr$ : obese class i,C3853264
114,teaes  cases per $nmbr$ - patient years ( ci ),C0008107;C0030705;C0439234;C0868928;C1533148;C3259781
114,no cases,C0868928;C1533148
114,mtss at baseline observed case,C0168634;C0868928;C1441672;C1442488;C1706255;C1706256
114,mtss at,
114,mtss ( $nmbr$ - $nmbr$ ),
114,mtss,
114,cases,C0868928;C1533148
113,post - dose,C0439568
113,percentage of patients receiving dose adjustment,C0030705;C0439165;C1514756;C1549488;C1561533;C2826232
113,first dose admin . $nmbr$ - $nmbr$ h / $nmbr$ - $nmbr$ h post onset of symptoms,C0033727;C0205435;C0369286;C0439568;C0441932;C0564385;C1279901;C4084955;C4086878;C4528284
113,dose adjustment n ( % ),C2826232
112,lower dose,C0445550;C1708745
112,lower - dose,C0445550;C1708745
112,low dose combination therapy,C0009429;C0445550;C0556895;C1708745
112,low dose,C0445550;C1708745
112,low - dose statin,C0360714;C0445550;C1708745
112,fenofibric acid - i - low - dose statin,C0021966;C0060179;C0221138;C0360714;C0445550;C1708745
112,fenofibric acid - $nmbr$ - low - dose statin,C0060179;C0360714;C0445550;C1708745
112,fenofibric acid + low - dose statin,C0060179;C0360714;C0445550;C1708745
112,edoxaban lower dose vs warfarin,C0043031;C0445550;C1708745;C2975435
111,higher dose,C0444956
111,higher - dose edoxaban vs warfarin,C0043031;C0444956;C2975435
111,higher - dose edoxaban ( n = $nmbr$ )  n ( % / y ),C0444956;C2975435
111,higher - dose,C0444956
111,high dose statin ( n = $nmbr$  $nmbr$ ),C0360714;C0444956
111,high dose,C0444956
111,high - dose statin use at screening *,C0042153;C0220908;C0220909;C0360714;C0444956;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
111,high - dose statin use  n ( % ) e,C0042153;C0360714;C0444956;C0457083;C1947944
111,high - dose statin,C0360714;C0444956
111,high - dose edoxaban vs warfarin,C0043031;C0444956;C2975435
111,high - dose edoxaban ( n = $nmbr$ ),C0444956;C2975435
111,high - dose edoxaban,C0444956;C2975435
111,high - dose arb ( n = $nmbr$ ),C0444956;C3888198
111,edoxaban higher dose vs warfarin,C0043031;C0444956;C2975435
110,tanezumab ( all doses combined ) + nsaida,C0178602;C0205195;C2346819
110,tanezumab ( all doses combined ),C0178602;C0205195;C2346819
110,smedian prednisone dose  n ( % ),C0032952;C0178602;C0869039;C1114758
110,ras % target dose,C0034678;C0178602;C0525678;C0869039;C1114758;C1521840;C2986546
110,ptrend across doses,C0178602
110,prednisone or equivalent dose ( mg / day ),C0032952;C0178602;C0205163;C0439185;C0439422;C0869039;C1114758
110,prednisone - equivalent dose  mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
110,patients with supplemental vitamin d dose of $nmbr$ iu / day starting at screeningc    n   ( % ),C0030705;C0178602;C0420176;C0439465;C0439659;C0869039;C1114758;C3541352
110,oral corticosteroid dose ( mg / day ),C0001617;C0178602;C0439422;C0442027;C0869039;C1114758;C3536709;C4521986
110,need for $nmbr$ ng edoxaban dose at,C0017887;C0027552;C0028074;C0178602;C0686904;C0869039;C1114758;C2975435
110,metformin dose,C0025598;C0178602;C0869039;C1114758
110,metformin - dose,C0025598;C0178602;C0869039;C1114758
110,mean ( s . d . ) metformin dose †  mg / day,C0025598;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
110,intended clopidogrel dose $nmbr$ mg,C0024671;C0026410;C0070166;C0178602;C0439269;C0869039;C1114758;C1283828;C1551357;C1960952;C2346927;C4321396;C4521761
110,edoxaban dose adjusted at randomisation  n ( % ) *,C0034656;C0178602;C0456081;C0869039;C1114758;C2975435
110,doubling statin dose,C0178602;C0205173;C0360714;C0869039;C1114758;C1705764
110,dose reduction at randomization — no . ( % )  i,C0021966;C0034656;C0178602;C0221138;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
110,dose reduction at randomization  %,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
110,dose reduction at randomization,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
110,dose reduction  n ( % ),C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
110,dose reduced at randomization *,C0034656;C0178602;C0392756;C0869039;C1114758
110,dose adjusted,C0178602;C0456081;C0869039;C1114758
110,dose ( n ),C0178602;C0869039;C1114758
110,corticosteroid dose ( prednisone,C0001617;C0032952;C0178602;C0869039;C1114758;C3536709
110,clopidogrel dose,C0070166;C0178602;C0869039;C1114758
110,canakinumab dose ( per month ),C0178602;C0332177;C0439231;C0869039;C1114758;C2718773
110,canakinumab dose ( per mo ),C0026544;C0178602;C0332177;C0869039;C1114758;C2718773
110,canakinumab dose,C0178602;C0869039;C1114758;C2718773
110,aspirin ( any dose ),C0004057;C0178602;C0869039;C1114758
110,any dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
110,all doses ( n = $nmbr$ ),C0178602
110,all doses,C0178602
110,< median prednisone dose  n ( % ),C0032952;C0178602;C0549183;C0869039;C0876920;C1114758;C2347635;C2348144;C2939193
110,( phase $nmbr$ dose - finding trial ),C0008976;C0037088;C0178602;C0205390;C0243095;C0869039;C1114758;C1710475;C2825141
-10,decreased appetite,C0232462
108,connective tissue disease,C0009782
108,connective - tissue disease,C0009782
108,associated with connective tissue disease,C0009782;C0332281
108,assoc  with connective tissue disease,C0009782
107,inflammatory disease,C1290884
107,inflammatory bowel disease,C0021390
107,chronic inflammatory disease,C1290886
107,active inflammatory bowel disease,C0021390;C0205177;C3853793;C3888249
106,pulmonary disease — no . ( % ),C0024115
106,pulmonary disease,C0024115
106,chronic pulmonary disease,C0746102
106,b . i . d .  twice daily  cat  copd assessment test  copd  chronic obstructive pulmonary disease  fev $nmbr$    forced expiratory volume in $nmbr$   s  fvc  forced vital capacity  gold  global initiative for chronic obstructive lung disease  ics  inhaled corticosteroid  mcid  minimum clinically important difference  mmrc  modified medical research council  o . d .  once daily  sd  standard deviation  sgrq - c  st . george ’ s respiratory questionnaire for copd,C0001617;C0004048;C0007450;C0016529;C0018026;C0024115;C0024117;C0034394;C0079816;C0152277;C0205191;C0205246;C0325090;C0332173;C0392747;C0424093;C0521346;C0524517;C0549186;C0585361;C0815320;C0871420;C1304897;C1306036;C1412502;C1443200;C1546767;C1551807;C1553316;C2348867;C2699239;C3536709;C3665481;C3714496;C3714541;C3826872;C3826977;C3889737;C4050461;C4277733;C4284282;C4551720
105,thyroid disease,C0040128
105,patient history of disease n ( % ),C0030705;C0683519;C0730226;C0850708;C0944983
105,patient history of disease,C0030705;C0683519;C0730226;C0850708;C0944983
105,microvascular disease history  no . ( % ),C0443258;C0683519
105,microvascular disease history  n ( % ),C0443258;C0683519
105,microvascular disease history,C0443258;C0683519
105,history of thyroid disease  n ( % ),C0040132;C0683519;C0730226;C0850708;C0944983;C3540038
105,history of peripheral arterial disease ( % ),C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
105,history of peripheral arterial disease,C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
105,history of microvascular eye disease 本  n ( % ),C0015392;C0015397;C0019664;C0019665;C0262512;C0262926;C0443258;C0683519;C0700042;C0730226;C0850708;C0944983;C1705255;C2004062
105,history of microvascular disease — no . ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
105,history of microvascular disease ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
105,history of microvascular disease,C0443258;C0683519;C0730226;C0850708;C0944983
105,history of major microvascular disease — no . ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
105,history of major microvascular disease  n ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
105,history of major macrovascular disease — no . ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
105,history of major macrovascular disease  n ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
105,history of macrovascular disease at baseline  n ( % ),C0168634;C0683519;C0730226;C0850708;C0944983;C1442488
105,history of macrovascular disease ( % ),C0683519;C0730226;C0850708;C0944983
105,history of macrovascular disease,C0683519;C0730226;C0850708;C0944983
105,history of ischemic heart disease — no . ( % ),C0018787;C0475224;C0683519;C0730226;C0850708;C0944983
105,history of fistullzing disease  n ( % ),C0683519;C0730226;C0850708;C0944983
105,history of fistulizing disease  n ( % ),C0683519;C0730226;C0850708;C0944983
105,history of fistulising disease  n [ % ],C0683519;C0730226;C0850708;C0944983
105,history of cv disease,C0683519;C0730226;C0850708;C0944983;C3538987;C4048877;C4318503
105,history of crohn ' s disease surgery  n ( % ),C0010346;C0455610
105,history of coronary heart disease at,C0018787;C0683519;C0730226;C0850708;C0944983
105,history of coronary heart disease  no . ( % ),C0018787;C0683519;C0730226;C0850708;C0944983
105,history of coronary arteiy disease,C0018787;C0683519;C0730226;C0850708;C0944983
105,history of carotid disease - n ( % ),C0683519;C0730226;C0741968;C0850708;C0944983
105,history of carotid artery disease,C0007273;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
105,history of bone disease ( predefined )  n ( % ),C0005940;C0019664;C0019665;C0262512;C0262926;C0262950;C0369718;C0441922;C0683519;C0730226;C0850708;C0944983;C1705255;C2004062
105,history of atherosclerotic vascular disease — no . ( % ) §,C0005847;C0333482;C0683519;C0730226;C0850708;C0944983;C1558950;C1801960
105,disease history,C0683519
105,crohn ' s disease,C0010346
105,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,C0010346;C0030705;C0039798;C0087111;C0205420;C0557651;C1522326;C1533734;C1705169;C1705654;C2603343;C3538994;C3887704;C4554348
105,carotid artery disease,C0007273
105,baseline history of vascular disease ( % ),C0005847;C0168634;C0683519;C0730226;C0850708;C0944983;C1442488;C1558950;C1801960
104,kidney disease ( usrds ),C0022658
104,duration of chronic kidney disease * ( years ),C0022658;C0205191;C0439234;C0449238;C2926735
104,diabetic kidney disease,C0011881
104,chronic kidney diseased,C2364010
103,valvular heart disease — no . ( % ),C0018824;C1963123
103,valvular heart disease  n ( % ),C0018824;C1963123
103,valvular heart disease,C0018824;C1963123
103,valvular disease ( % ),C3258293
103,valvular disease  mitral,C0746591;C3258293
103,valvular disease,C3258293
103,mitral valve disease ( n = $nmbr$ $nmbr$ ),C0026265;C4553832
103,cardiac valvular disease,C0018824
102,vessel disease,C0042373
102,vascular disease indicator no ( n = $nmbr$ ),C0021212;C0042373;C0369718;C0441922;C1235732;C1522602
102,vascular disease,C0042373
102,single vessel disease,C0037179;C0042373;C0087136;C0205171
102,single - vessel disease  n ( % ),C0037179;C0042373;C0087136;C0205171
102,single - vessel disease,C0037179;C0042373;C0087136;C0205171
102,other vascular disease — no . ( % ),C0042373
102,double - vessel disease  n ( % ),C0042373;C0205173;C1705764;C1705765
102,any vascular disease,C0042373
101,simplified disease activity index score ( $nmbr$ - $nmbr$ ),C0449820;C3869582;C4050231
101,simplified disease activity index score,C0449820;C3869582;C4050231
101,simplified disease activity index,C3869582
101,ptga of disease activity ( $nmbr$ ‒ $nmbr$ mm )  mean ( sd ) †,C0444504;C1292728;C2347634;C2348143;C2699239;C4330985;C4554674
101,high disease activity : > $nmbr$ . $nmbr$  n ( % ),C0012634;C0205250;C1292728;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C4699623
101,disease activity ],C1292728
101,disease activity ( n ( % ) ),C1292728
101,disease activity,C1292728
101,clinical disease activity index score ( $nmbr$ - $nmbr$ ),C0449820;C3869583;C4050231
101,clinical disease activity index,C3869583
100,ease activity ],C0205177;C0439167;C0441655;C1331418;C1561536;C3668946;C4049938;C4049939
100,ease - $nmbr$,C1331418
100,base,C0002055;C0178499;C1880279
99,type of reflux disease,C0232483;C0457464;C1882919;C4317146
99,gastrooesophageal reflux disease,C0017168;C4553201
99,gastroesophageal reflux disease,C0017168;C4553201
99,erosive reflux disease,C0012634;C0232483;C0439679;C1882919;C4317146
98,polyvascular disease * status,C3176928
98,physician ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4050369
98,global assessment of disease status score,C0281858;C0449820;C3176928;C4050231
98,disease stage,C0699749
97,severe disease,C1836348
97,self - reported disease severity  $nmbr$ - $nmbr$ scale *,C0175659;C0349674;C0521117;C0681906;C1947916;C2700446
97,rheumatic heart disease,C0035439
97,moderate or severe renal disease  n ( % ),C0022646;C0022658;C0205081;C0205082;C1836348;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
97,moderate or severe renal disease  b   n ( % ),C0022646;C0022658;C0205081;C0205082;C1836348;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335
97,endoscopic disease severity,C0014245;C0442418;C0521117
97,disease severity,C0521117
97,congenital heart disease,C0152021
97,component . for all instruments  higher scores indicate more severe disease . ara denotes american rheumatism association ( now called,C0004083;C0009326;C0035435;C0205172;C0205250;C0325983;C0439849;C0449432;C0449820;C0596070;C0596306;C0679006;C0699792;C1705248;C1836348;C1947967;C1948052;C2316832;C3890184;C4282437;C4321455;C4551823
97,$nmbr$ ( severe disease ),C1836348
96,cigarettesmoking  %,
96,cigarette users,C0677453;C1704760;C1706077;C3890423
95,unspecified,C0205370;C1549663;C2983689;C4048188
95,unified parkinson disease,C0030567;C1521736;C1548174;C1706076
95,unclassified,C0205426;C1546437;C2347854;C4085229
94,or per unit for continuous variables,C0439148;C0439453;C0439828;C0549178;C1509845;C1519795;C1704753;C1880519;C3853603
94,mtss units,C0439148;C1519795;C3853603
94,insulin dose ( u ),C0366513;C0439148
94,insulin dose  u,C0366513;C0439148
94,ae / e ' ratio ( per $nmbr$ unit ),C0439148;C0439453;C0456603;C1509845;C1519795;C1547037;C1704753;C1880519;C3853603;C3887670
94,ae / a ratio ( per $nmbr$ . $nmbr$ unit ),C0439148;C0439453;C0456603;C1509845;C1519795;C1547037;C1704753;C1880519;C3853603;C3887670
94,% anti - ccp + ( > $nmbr$ units ),C0439148;C1519795;C3853603;C4318437
93,unknown — no . { % ),C0439673;C3541433;C4050014
93,unknown type,C0332307;C0439673;C1547052;C3541433;C4050014
93,unknown ( none of the above ),C0439673;C1282910;C1552828;C3541433;C4050014
93,unknown ( % ),C0439673;C3541433;C4050014
93,unknown,C0439673;C3541433;C4050014
93,non - detectable / unknown  n ( % ),C0439673;C1518422;C3541433;C3830527;C4050014
93,non - detectable / unknown,C0439673;C1518422;C3541433;C3830527;C4050014
93,no or unknown,C0439673;C3541433;C4050014
93,no / unknown,C0439673;C3541433;C4050014
93,mi type unknown ( % ),C0332307;C0439673;C1547052;C3541433;C3810814;C4050014
93,ischaemic or unknown stroke,C0038454;C0439673;C0475224;C3541433;C4050014;C4554100
93,indeterminate or unknown,C0205258;C0439673;C3541433;C4050014
93,a excludes two randomized patients with unknown diabetes status at baseline .,C0034656;C0168634;C0205448;C0332196;C0439673;C1315719;C1442488;C2828389;C3541433;C3815594;C4050014
92,uacr not available,C0686905
92,not severe,C4316743
92,not available,C0686905
92,not assessable,C1883425
92,nnt,C1417750
91,p - value ( ■ nt ),C0332126;C1449832;C1709380;C3889152;C4050156;C4283901;C4284038
91,nt estimated,C0332126;C0750572;C1449832;C3889152;C4050156;C4283901;C4284038
91,n nt,C0332126;C0369718;C0441922;C1449832;C3889152;C4050156;C4283901;C4284038
90,new - onset atrial fibrillation,C0741281
90,ne,C0027608;C0028219;C3538705
90,lone atrial fibrillation — no . ( % ) §,C0340489
90,duration of qualifying atrial fibrillation » $nmbr$ days — no . ( % ),C0004238;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
90,atrial fibrillation  duration — no . ( % ),C0004238;C0344434;C0449238;C1963067;C2926735
90,< $nmbr$ no . ( % ),
90,( ne  ne ),C0027608;C0028219;C3538705
90,$nmbr$ . $nmbr$ ( ne  ne ),C0027608;C0028219;C3538705
89,nx *,C0445085
89,no . ( % ) $nmbr$ ( $nmbr$ ),
89,modified rankin scale — no . ( % ) |,C2984908;C3854213
88,traditional chinese medicine for respiratory disease — no . ( % ),C0025124;C0035204;C0035242;C1515884
88,no po,C0032729;C0442027
88,fluindione  no . ( % ),C0117899
88,chronic cardiovascular disease  no . ( % ),C1290380
88,associatedproximaldeep - veinthrombosisatdiagnosis  no . ( % ),
87,onsetofaf  no . ( % ),
87,nonsustained ventricular tachycardia — no . ( % ) - j -,C0750194;C2919575
87,enox,C3147679
86,no ( $nmbr$ . $nmbr$ ),
86,family history of cad ( diagnosed at < $nmbr$ yr of age ) — no . ( % ) cigarette smoker — no . ( % ),C0001779;C0011900;C0241889;C0337667;C0439234;C1504769;C2239547;C3813548;C4284121
86,diagnosis at study entry — no . ( % ),C1704656;C1705654;C4068481
86,age > $nmbr$ yr  no . ( % ),C0001779;C0439234
86,> $nmbr$  no . ( % ),
86,< $nmbr$ yr — no . { % ),C0439234
86,< $nmbr$ vr — no . ( % ),C3476815
86,$nmbr$ - $nmbr$ vr — no . ( % ),C3476815
85,on non ‐ metformin aha,C0025598;C0050451;C0772110;C1518422
85,not tested,C0392366;C1518422
85,not reported / unknown,C0439673;C0684224;C0700287;C1518422;C3541433;C4050014;C4319718
85,not reported,C0684224;C0700287;C1518422;C4319718
85,not provided,C1518422;C1999230
85,not perfused,C1518422;C1549542
85,not on metformin,C0025598;C1518422
85,not on an aha,C0050451;C0772110;C1518422
85,not localized,C0392752;C1518422
85,not estimable,C1518422
85,not collected ^,C1516695;C1516698;C1518422
85,non diuretics,C0012798;C1518422
85,non - united states,C0041703;C1518422
85,non - u . s .,C0041703;C1518422
85,non - spondylitis,C0038012;C1518422
85,non - severe hypoglycaemia,C0020615;C0205082;C1518422;C4050465;C4050466;C4553659
85,non - rollover,C0517067;C0543436;C1518422
85,non - rheumatic valvular heart disease,C0264757;C1518422
85,non - hispanicwhite,C1518422
85,non - hishnic,C1518422
85,non - epa number of <,C0237753;C0449788;C1518422
85,non - epa ( n = $nmbr$ ),C1518422
85,non - cabg or combined,C0010055;C0205195;C1518422
85,non - c,C1518422
85,no . of tnfi among non - tnfi naive,C1518422
85,no . of non - tnfi,C1518422
85,nct $nmbr$,
85,major or clinically relevant non - major bleeding,C0019080;C0205082;C0205164;C1518422;C2347946;C4318856;C4521762
85,major or clinically relevant non - major bleed,C0019080;C0205082;C0205164;C1518422;C2347946;C4318856;C4521762
85,infarction  date not reported,C0011008;C0021308;C0684224;C0700287;C1518422;C2348077;C4319718
85,did not enrol into osler,C1518422
85,clinically relevant non,C1518422;C2347946
84,white tcz + mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
84,tx $nmbr$,C0041403
84,tx,C0041403
84,tcz + mtx ( n ),C0025677;C1417487
84,$nmbr$ tcz + mtx mtx,C0025677;C1417487
84,$nmbr$ tcz + mtx,C0025677;C1417487
84,$nmbr$ tcz,
83,qtc > $nmbr$ n = $nmbr$,
83,qtc < $nmbr$ n = $nmbr$,
83,freedom from gtc seizures  n ( % ),C1299590
82,ratio of urinary albumin ( mg ) to creatinine ( g ) median,C0010294;C0024671;C0026410;C0439267;C0439269;C0456603;C0549183;C0876920;C1547037;C1561535;C1960952;C2346927;C2347635;C2348144;C2362049;C2939193;C4321396;C4521761
82,ratio of urinary albumin ( mg ) to creatinine ( g ),C0010294;C0024671;C0026410;C0439267;C0439269;C0456603;C1547037;C1561535;C1960952;C2346927;C2362049;C4321396;C4521761
82,estimated creatinine clearancet,C0010294;C0750572;C1561535
82,doubling of creatinine †,C0010294;C0205173;C1561535;C1705764
82,doubling of creatinine,C0010294;C0205173;C1561535;C1705764
82,creatinine ratio $nmbr$ - $nmbr$,C0010294;C0456603;C1547037;C1561535
82,creatinine ratio,C0010294;C0456603;C1547037;C1561535
82,creatinine clearanceb  ml / min,C0010294;C0439445;C1561535
82,creatinine ciearance,C0010294;C1561535
82,creatinine ( µ mol / l ),C0010294;C0347982;C1561535
82,creatinine ( p  mol / l ),C0010294;C0347982;C1561535
82,creatinine ( ^ mol / l ) ( median  iqr ),C0010294;C0347982;C0549183;C0876920;C1561535;C2347635;C2348144;C2939193
82,creatinine  pmol / l,C0010294;C0439284;C1561535
82,creatinine  mmol 八,C0010294;C0439190;C1561535
82,creatinine,C0010294;C1561535
81,no colchicine ( n = $nmbr$ ),C0009262
81,colchicine ( n = $nmbr$ ),C0009262
80,urine albumin / creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
80,urine albumin / creatinine ratio  mg / mmol,C0455271;C0567349;C1318330;C2348885
80,urine albumin / creatinine ( mg / mmol ),C0455271;C0567349;C1318330;C2348885
80,urine albumin - to - ereatinine ratio,C0001924;C0042038;C0456603;C0587185;C1273442;C1547037;C2362049
80,urine albumin - to - creatinine ratio - no . ( % ) § §,C0455271;C1318330
80,urine albumin - to - creatinine ratio,C0455271;C1318330
80,urinary protein - to - creatinine ratio | |,C1096054
80,urinary albumin : creatinine ratioa ( mg / g ),C0455271;C1300563;C1318330
80,urinary albumin : creatinine ratio ^,C0455271;C1318330
80,urinary albumin : creatinine ratio *,C0455271;C1318330
80,urinary albumin : creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
80,urinary albumin - to - creatinine ratio — no . ( % ) §,C0455271;C1318330
80,urinary albumin - to - creatinine ratio §,C0455271;C1318330
80,urinary albumin - to - creatinine ratio ^,C0455271;C1318330
80,urinary albumimcreatinine ratio,C1273442
80,median albumin - to - creatinine ratio ( interquartile range ),C0486293;C0549183;C0876920;C1318293;C1711350;C2347635;C2348144;C2939193
80,mean ( sd ) values are presented for all variables  except medical history  race or ethnic group  and sex ( n  % ) and urinary albumin / creatinine ratio ( median ( range ) ) . abody mass index is the weight in kilograms divided by the square of the height in meters . bto convert values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . estimated using the modified equation from the modification of diet in renal disease study . dto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . eto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ^ to convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005910;C0009253;C0015031;C0019664;C0019665;C0034510;C0036864;C0040363;C0041260;C0042027;C0042295;C0043100;C0079399;C0199168;C0205120;C0205476;C0262512;C0262926;C0332849;C0392747;C0439190;C0439194;C0439209;C0439828;C0441074;C0444504;C0449450;C0457987;C0475211;C0486293;C0489786;C0549183;C0552449;C0557651;C0577559;C0577573;C0600653;C0724655;C0750572;C0804628;C0876920;C0918012;C1096155;C1305866;C1306372;C1314687;C1318293;C1514721;C1522384;C1524063;C1524119;C1552595;C1552854;C1554963;C1637833;C1705104;C1705255;C1706779;C1719797;C1879937;C1883351;C2004062;C2347634;C2347635;C2348143;C2348144;C2348147;C2603343;C2699239;C2911648;C2939193;C2986546;C3152252;C3539882;C3542016;C3840684;C3853635;C3889737;C4283905
80,baseline albumin / creatinine ratio in $nmbr$ classes,C0168634;C0456387;C0486293;C1318293;C1442488;C1518526;C1705943;C4019422
80,albumin creatinine ratio,C0486293;C1318293
80,albumin / creatinine ratio  n ( % ),C0486293;C1318293
80,albumin - to - creatinine ratio ( acr ),C0486293;C1318293;C1412134;C1515941
80,albumin - to - creatinine ratio,C0486293;C1318293
79,renal fmclicn : creatntoe clearance,C0232813;C0699829
79,estimated creatinine clearance < $nmbr$ rmb ' mint,C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C3890003
79,estimated creatinine clearance < $nmbr$ ml / mint,C0439526;C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C1705224;C3887665;C3890003
79,estimated creatinine clearance  !,C0750572;C0812399
79,estimated * creatinine clearance < $nmbr$ mlvmin  %,C0750572;C0812399
79,data are expressed as n / total ( % ) unless otherwise specified . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation,C0040363;C0041260;C0205369;C0439175;C0439390;C0439453;C0439810;C0439836;C0552449;C0750572;C0812399;C1511726;C1719797;C1883351;C2911648;C3245479;C3714741
79,creatinine clearance ， : : $nmbr$ ml / min  %,C0439445;C0812399
79,creatinine clearance — no . ( % ),C0812399
79,creatinine clearance category [ ml / min ],C0439445;C0683312;C0812399;C3889287
79,creatinine clearance category  ml / min  no . ( % ) b,C0439445;C0683312;C0812399;C3889287
79,creatinine clearance at randomization ( ixrs ),C0034656;C0812399
79,creatinine clearance at randomization,C0034656;C0812399
79,creatinine clearance < $nmbr$ ml / min — no . ( % ) weight < $nmbr$ kg — no . ( % ),C0005910;C0022718;C0043100;C0439209;C0439445;C0812399;C1305866;C1705104;C4054209
79,creatinine clearance < $nmbr$ ml / min  no . / total ( % ),C0439175;C0439445;C0439810;C0812399
79,creatinine clearance  no . ( % ),C0812399
79,creatinine clearance  n ( % ),C0812399
79,creatinine clearance  an   ( % ),C0812399
79,creatinine clearance,C0812399
78,nilvadipine,C0132512
78,chlorthalidone vs amlodipine,C0008294;C0051696
78,chlorthalidone - amlodipine - lisinopril,C0008294;C0051696;C0065374
78,benazepril / hydrochlorothiazide - benazepril / amlodipine,C0051696;C0717481
78,amlodipine vs chlorthalidone overweight,C0008294;C0051696;C0497406
78,amlodipine vs chlorthalidone obese,C0008294;C0028754;C0051696
78,amlodipine / wlsartan i $nmbr$ / $nmbr$ mg,C0021966;C0024671;C0026410;C0051696;C0221138;C0439269;C1960952;C2346927;C4321396;C4521761
78,amlodipine / vaisartan ( n = $nmbr$ ),C0051696
78,amlodipine / lisinopril $nmbr$,C0051696;C0065374
78,amlodipine - amlodipine / valsartan,C1962523
78,amlodipine ( n = $nmbr$ ),C0051696
78,amlodipine,C0051696
78,! amlodipine,C0051696
77,mercaptopurine,C0000618
77,corticosteroid - azathioprine / $nmbr$ - mercaptopurine,C0000618;C0001617;C0004482;C3536709
77,$nmbr$ - mercaptopurine / azathioprine,C0000618;C0004482
77,$nmbr$ - mercaptopurine,C0000618
-10,leukotriene modifier,C0023545;C0205349;C1514623;C1516451;C3542952
75,prior exposure to lamotrigine,C0064636;C0274281;C0332152;C0332157;C0524166;C2826257
75,lamotrigine,C0064636;C0524166
74,placebo - famotidine $nmbr$ - famotidine $nmbr$,C0015620;C0032042;C1696465;C1706408
74,placebo - famotidine $nmbr$,C0015620;C0032042;C1696465;C1706408
74,famotidine $nmbr$ - famotidine $nmbr$,C0015620
73,thienopyridine use,C0042153;C0457083;C1120149;C1947944
73,thienopyridine type,C0332307;C1120149;C1547052
73,thienopyridine n = $nmbr$,C1120149
73,thienopyridine + dipyridamole,C0012582;C1120149
73,thienopyridine ( n = $nmbr$ ),C1120149
73,thienopyridine,C1120149
73,prior thienopyridine ( - ),C0332152;C1120149;C2826257
73,prior thienopyridine ( + ),C0332152;C1120149;C2826257
73,planned thienopyridine at enrollment,C1120149;C1709561
73,no thienopyridine,C1120149
73,aspirin and thienopyridine therapy,C0004057;C0039798;C0087111;C1120149;C1363945
73,aspirin + thienopyridine,C0004057;C1120149
73,- thienopyridine,C1120149
73,+ thienopyridine,C1120149
72,thiazolidinedionesc,
72,thiazolidinediones *,C1257987;C3541957
72,thiazolidinediones,C1257987;C3541957
72,thiazolidinedioneb,
72,thiazolidinedione 一 no . ( % ),C0289779;C1257987;C3537039
72,thiazolidinedione use at baseline,C0042153;C0168634;C0289779;C0457083;C1257987;C1442488;C1947944;C3537039
72,thiazolidinedione no,C0289779;C1257987;C3537039
72,thiazolidinedione based,C0289779;C1257987;C1527178;C1705938;C3537039
72,thiazolidinedione ( includes pioglitazone ),C0071097;C0289779;C0332257;C1257987;C1552866;C2700399;C3537039
72,thiazolidinedione,C0289779;C1257987;C3537039
72,any thiazolidinedione,C0289779;C1257987;C3537039
71,sulfasalazine,C0036078
71,ranozaline,
71,ranolazine n = $nmbr$,C0073633
71,ranolazine ( n = $nmbr$ ),C0073633
71,ranolazine ( n = $nmbr$  $nmbr$ ),C0073633
71,ranolazine ( n $nmbr$ $nmbr$ ),C0073633
71,ranolazine  n   =   $nmbr$,C0073633
71,ranolazine  n = i $nmbr$ i $nmbr$,C0021966;C0073633;C0221138
71,ranolazine,C0073633
71,prior sulfasalazine use *,C0036078;C0042153;C0332152;C0457083;C1947944;C2826257
71,hydralazine,C0020223
70,lisinopril vs chlorthalidone normal,C0008294;C0065374;C0205307;C0231683;C0439166;C2347086;C4553972
70,lisinopril vs chlorthalidone,C0008294;C0065374
70,lisinopril / chlorthalidone,C0008294;C0065374
70,lisinopril - chlorthalidone,C0008294;C0065374
70,favors lisinopril favors chlorthalidone,C0008294;C0065374;C0309049
70,favors favors lisinopril chlorthalidone,C0008294;C0065374;C0309049
70,favors favors amlodipine chlorthalidone,C0008294;C0051696;C0309049
70,favors amlodipine favors chlorthalidone,C0008294;C0051696;C0309049
70,chlorthalidone vs doxazosin,C0008294;C0114873
70,chlorthalidone group,C0008294;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
70,chlorthalidone ( n = $nmbr$ ),C0008294
70,chlorthalidone $nmbr$,C0008294
70,chlorthalidone,C0008294
70,amlodipione - chlorthalidone,C0008294
70,amlodipine vs chlorthalidone normal,C0008294;C0051696;C0205307;C0231683;C0439166;C2347086;C4553972
70,amlodipine / lisinopril / chlorthalidone comparison,C0008294;C0051696;C0065374;C1707455
70,amlodipine / chlorthalidone,C0008294;C0051696
70,$nmbr$ lisinopril - chlorthalidone,C0008294;C0065374
70,$nmbr$ chlorthalidone amlodipine,C0008294;C0051696
70,$nmbr$ chlorthalidone ( n = $nmbr$ ),C0008294
70,$nmbr$ chlorthalidone,C0008294
70,$nmbr$ amlodipine - chlorthalidone,C0008294;C0051696
69,placebo + insulin glargine ( award - $nmbr$  n = $nmbr$ ),C0004446;C0032042;C0907402;C1696465;C1706408
69,insulin glargine   ±   oad   +   od prandial,C0229089;C0439164;C0907402;C1512019;C1998602;C3273373;C3665488;C4553624
69,insulin glargine   ±   oad   +   bd prandial,C0005126;C0907402;C1998602;C2344255;C4050145;C4553624
69,insulin glargine   ±   oad   +   > bd prandial,C0005126;C0907402;C1998602;C2344255;C4050145;C4553624
69,insulin glargine   ±   oad,C0907402
69,insulin glargine n ( x ),C0907402
69,insulin glargine allocation,C0907402;C1706778
69,insulin glargine + insulin lispro ( award - $nmbr$  n = $nmbr$ ),C0004446;C0293359;C0907402
69,insulin glargine ( n = $nmbr$ ),C0907402
69,insulin glargine,C0907402
69,insuiin giargine ± oad,
69,iglar ( n   =   $nmbr$ ),
69,iglar ( insulin glargine l $nmbr$ u ),C0439148;C0907402
69,glargine allocation,C0907402;C1706778
69,glargine $nmbr$,C0907402
69,glargine,C0907402
69,giargine,
68,ivabradine group ( n = $nmbr$ ),C0257190;C0441848
68,ivabradine group,C0257190;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
68,ivabradine ( n = $nmbr$ ),C0257190
68,ivabradine,C0257190
67,rolofylline rx,C0166128;C1425688;C1521941;C2709207
67,rolofylline n,C0166128
67,rolofylline dose,C0166128;C0178602;C0869039;C1114758
67,rolofylline ( n = $nmbr$ ),C0166128
67,rolofylline ( n = $nmbr$  $nmbr$ ),C0166128
67,rolofylline $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0166128;C0439269;C1960952;C2346927;C4321396;C4521761
67,rolofylline,C0166128
66,theophyllines,C0039771
66,theophylline compound,C0039771;C0205198;C1706082
65,prior angina pectoris — no . / total no . ( % ),C0002962;C0332152;C0439175;C0439810;C2826257
65,prior angina pectoris,C0002962;C0332152;C2826257
65,prior angina ( n = $nmbr$  $nmbr$ ),C0002962;C0332152;C2826257
65,prior angina  n / n ( % ),C0002962;C0332152;C2826257
65,prior angina,C0002962;C0332152;C2826257
65,previous angina pectoris,C0002962;C0205156;C1552607
65,previous angina  n ( % ),C0002962;C0205156;C1552607
65,no prior angina ( n = $nmbr$  $nmbr$ ),C0002962;C0332152;C2826257
65,myocardial infarction or angina,C0002962;C0027051;C0428953;C2926063;C3810814;C4552959
65,hospitaiization for angina,C0002962
65,angina symptoms ^,C0858277
65,angina pectorisf,C0002962
65,angina pectoris 本,C0002962
65,angina pectoris — no . ( % ),C0002962
65,angina pectoris *,C0002962
65,angina pectoris  ( % ),C0002962
65,angina pectoris,C0002962
65,angina or acute mi,C0002962;C0155626
65,angina .,C0002962
65,angina  n ( % ),C0002962
65,angina,C0002962
64,worsening angina,C0002965
64,unstable but no rest angina,C0002965;C0152172;C0443343;C1883468
64,unstable angina — no . ( % ),C0002965
64,unstable angina ( n = $nmbr$  $nmbr$ ),C0002965
64,unstable angina,C0002965
64,rest angina past $nmbr$ h,C0002965;C0033727;C0152172;C0369286;C0441932;C0564385;C1444637;C4284302;C4528284
64,rest angina but not past $nmbr$ h,C0002965;C0033727;C0152172;C0369286;C0441932;C0564385;C1444637;C1518422;C4284302;C4528284
64,rest angina,C0002965;C0152172
64,rec . ischemia due worsening angina,C0002965;C0022116;C0678226;C1424025;C2606415;C3146286;C4321499
64,no rest angina,C0002965;C0152172
64,due worsening angina,C0002965;C0678226;C3146286
63,aii patients ( n = $nmbr$ ),C0030705;C1424250;C2698414
63,aii participants ( n = $nmbr$ ),C0679646;C1424250;C2698414
63,ai $nmbr$,C0003504;C4551710
63,$nmbr$ i - $nmbr$ - $nmbr$ ai,C0003504;C0021966;C0221138;C4551710
62,flex ain ' ’,C0347129
62,ain  no . ( % ) “ *,C0347129
62,ain  no . ( % ) * *,C0347129
61,insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
61,air insulin - insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
61,air insulin - air insulin / insulin glargine,C0001861;C0907402;C3536832
61,air ( n = $nmbr$ ),C0001861;C3536832
60,s - asa compounds at baseline,C0004057;C0010139;C0043474;C0168634;C1442488;C3853627
60,prior asa use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257;C3853627
60,pfo + asa,C0004057;C3853627
60,no asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
60,no asa,C0004057;C3853627
60,high - dose aspirin,C0004057;C0444956
60,baseline $nmbr$ - asa,C0004057;C0168634;C1442488;C3853627
60,baseiine aspirin,C0004057
60,aspirin group ( n = $nmbr$ ),C0004057;C0441848
60,aspirin group,C0004057;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
60,aspirin at last follow - up,C0004057;C0589120;C1522577;C1704685;C3274571
60,aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
60,aspirin ( n = $nmbr$ ),C0004057
60,aspirin ( asa ) ( » = $nmbr$ $nmbr$ ),C0004057;C3853627
60,aspirin $nmbr$  $nmbr$,C0004057
60,aspirin $nmbr$,C0004057
60,asas partial remission    n   ( % ),C0004057;C1521726;C3853627;C4552913;C4552914
60,asas partial remission  %,C0004057;C1521726;C3853627;C4552913;C4552914
60,asas $nmbr$ / $nmbr$    n   ( % ),C0004057;C3853627
60,asas $nmbr$ / $nmbr$    %,C0004057;C3853627
60,asas $nmbr$    %,C0004057;C3853627
60,asas $nmbr$  %,C0004057;C3853627
60,asas $nmbr$,C0004057;C3853627
60,asa use at baseline  n ( % ),C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
60,asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
60,asa  n ( % ),C0004057;C3853627
60,asa,C0004057;C3853627
60,acetylsalicylic acid,C0004057
60,acetyl - salicylic acid,C0004057
59,myalgia,C0231528;C4552646
59,malaysia,C0024552
58,prior analgesic products  n ( % ),C0002771;C0332152;C2826257
58,analgesic medication  n ( % ),C0002771
57,alpha reductase inhibitors,C0439095;C0597153;C1655741;C2003941;C2350010
57,alpha receptor antagonist,C0439095;C2003941;C2350010;C4543207
56,corticosteroid or azathioprine / $nmbr$ - mercaptopurine,C0000618;C0001617;C0004482;C3536709
56,azathioprine monotherapy,C0004482
56,azathioprine / $nmbr$ - mercaptopurine,C0000618;C0004482
56,azathioprine ( n = $nmbr$ ),C0004482
56,azathioprine,C0004482
56,aza ( n = $nmbr$ ),C0004482
56,and / or aza at baseline,C0004482;C0168634;C1442488
56,$nmbr$ - up and / or aza at baseline,C0004482;C0168634;C1442488
55,the netherlands  australia  new zealand  and south africa,C0027778;C0037712;C4289954
55,austria,C0004348
55,australia / new zealand / south africa,C0037712;C4289954
55,australia / new zealand,C4289954
55,asia / australia / new zealand,C0003980;C4289954
54,western european includinq australia  israel  and south africa,C0004340;C0022271;C0037712;C0043128;C0239307;C0239312;C1535514
54,western europe and australia,C0004340;C0043129
54,australia / nz,C0004340;C0027978
54,australia,C0004340
54,australasia,C0282279;C1257882
53,regional anaesthesia,C0002911
53,paresthesia,C0030554;C4553220
53,general anaesthesia,C0002915;C2930406
53,anesthesiad  n ( % ),
53,anaesthesia / analgesia,C0002905
52,urinary acr,C0042027;C1412134;C1515941;C1524119
52,sprint acr > $nmbr$ - $nmbr$,C1412134;C1515941
52,sprint acr < $nmbr$ - $nmbr$,C1412134;C1515941
52,categories of urinary acr  ^ g / mg,C0042027;C0683312;C1300563;C1412134;C1515941;C1524119
52,b . acr $nmbr$,C1412134;C1515941
52,albuminuria ( acr > $nmbr$ m . g / g ) at baseline to normoalbuminuria,C0001925;C0168634;C0369637;C0441923;C1319635;C1412134;C1442488;C1515941
52,acr response by baseline weight,C0871261;C1303013;C1412134;C1515941;C1704632;C1706817;C2911692
52,acr response by baseline mtx use  no . / total no . ( % ) acr $nmbr$,C0025677;C0042153;C0168634;C0439175;C0439810;C0457083;C0871261;C1412134;C1417487;C1442488;C1515941;C1704632;C1706817;C1947944;C2911692
52,acr response  % acr $nmbr$,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
52,acr response  %,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
52,acr functional class  n ( % ),C0205245;C0456387;C0542341;C1412134;C1515941;C1518526;C1705943;C2700217
52,acr deciles,C1412134;C1515941
52,acr $nmbr$ response at week $nmbr$  n ( % ),C0332174;C0439230;C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
52,acr $nmbr$ response  n / n ( % ),C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
52,acr $nmbr$ response,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
52,acr $nmbr$,C1412134;C1515941
52,acr,C1412134;C1515941
52,accord acr > $nmbr$ - $nmbr$,C0680240;C1412134;C1515941
52,accord acr < $nmbr$ - $nmbr$,C0680240;C1412134;C1515941
52,a . acr $nmbr$,C1412134;C1515941
51,arr ( % ),C2170357;C4084934
51,arr ( $nmbr$ % cl ),C0596019;C2170357;C4084934
51,arr ( $nmbr$ % ci ),C0008107;C2170357;C3259781;C4084934
51,arr,C2170357;C4084934
51,> $nmbr$ % predicted arr ( n = $nmbr$ ),C0681842;C1882327;C2170357;C4084934
51,> $nmbr$ % and < $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ ),C0681842;C1882327;C2170357;C4084934
51,< $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ ),C0681842;C1882327;C2170357;C4084934
50,diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
50,diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
49,married,C0024841;C0555047
49,marital status  married,C0024819;C0024841;C0555047;C1716536;C3172566
48,middle east  africa  or asia - pacific,C0001737;C0001741;C0003980;C0026068;C0444598;C0549183;C1552826
48,asia pacific and africa,C0001737;C0003980
48,africa or near east,C0001737;C0205674
48,africa *,C0001737
48,africa ! near east,C0001737;C1707877
48,africa  asia  or the middle east,C0001737;C0003980;C0026068
48,africa,C0001737
47,≥ $nmbr$ ae,C3887670
47,laboratory ae  n ( % },C0022877;C3244292;C3887670;C4283904
47,drug - related ae *,C0013227;C0439849;C0445223;C1254351;C3887670
47,clinical ae  n ( % },C0205210;C3887670
47,because of ae,C3887670
47,any drug - related ae  n ( % ),C0013227;C0439849;C0445223;C1254351;C3887670
47,any clinical ae,C0205210;C3887670
47,any ae  n ( % ) ‡,C3887670
47,any ae,C3887670
47,any adverse event ( ae ),C0877248;C3887670
46,randomly assigned to ace,C1452534;C1516050;C1552601;C4284014
46,no ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
46,neither ace - i nor arb use,C0021966;C0042153;C0221138;C0457083;C1452534;C1947944;C3888198;C4284014
46,arb / ace,C1452534;C3888198;C4284014
46,ace ‐ i or arb,C0021966;C0221138;C1452534;C3888198;C4284014
46,ace or arb,C1452534;C3888198;C4284014
46,ace / arb users,C1452534;C1706077;C3888198;C4284014
46,ace / arb medication ( % ),C0013227;C1452534;C3244316;C3888198;C4284014;C4284232
46,ace / arb,C1452534;C3888198;C4284014
46,ace - lorarb,C1452534;C4284014
46,ace - l / arbs,C1452534;C3888198;C4284014
46,ace - i or arb use at baseline,C0021966;C0042153;C0168634;C0221138;C0457083;C1442488;C1452534;C1947944;C3888198;C4284014
46,ace - i or arb use,C0021966;C0042153;C0221138;C0457083;C1452534;C1947944;C3888198;C4284014
46,ace - i or arb  % ( n ),C0021966;C0221138;C1452534;C3888198;C4284014
46,ace - i or arb,C0021966;C0221138;C1452534;C3888198;C4284014
46,ace - i / arb  ( % ),C0021966;C0221138;C1452534;C3888198;C4284014
46,ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
46,ace - i ( n  % ),C0021966;C0221138;C1452534;C4284014
46,ace,C1452534;C4284014
45,age — yr age group — no . ( % ),C0027362;C0439234;C2348001
45,age group 一 ％,C0027362;C2348001
45,age group — no . ( % ),C0027362;C2348001
45,age group ( ≥ $nmbr$ ) — no . ( % ),C0027362;C2348001
45,age group ( years ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
45,age group $nmbr$,C0027362;C2348001
45,age group  no . ( % )  y,C0027362;C2348001
45,age group  no . ( % ),C0027362;C2348001
45,age group,C0027362;C2348001
45,age cohort  no . ( % ),C2348001
44,without acei / arb,C3888198
44,with acei / arb,C3888198
44,use of ace inhibitors / arbs  n ( % ),C0003015;C1524063;C3888198
44,use of ace inhibitor  arb  or both — no . ( % ),C0003015;C1524063;C3888198;C4541021
44,prior bb plus acbi plus arb use,C0004739;C0042153;C0332152;C0332287;C0332297;C0457083;C1947944;C2826257;C3888198
44,prior acbi or arb use,C0042153;C0332152;C0457083;C1947944;C2826257;C3888198
44,previously on acei + arb,C3888198
44,peri - op ace - inhibitors / arbs : no ( n = $nmbr$ ),C0003015;C0347985;C0369718;C0441922;C3888198
44,no ace inhibitor / arb,C0003015;C3888198;C4541021
44,neither ace inhibitor nor arb,C0003015;C3888198;C4541021
44,both ace inhibitor and arb,C0003015;C3888198;C4541021
44,baseiine acei / arb,C3888198
44,arbs or ace inhibitors,C0003015;C3888198
44,arbs,C3888198
44,arb or ace inhibitor  n ( % ),C0003015;C3888198;C4541021
44,arb or ace inhibitor,C0003015;C3888198;C4541021
44,arb monotherapy,C3888198
44,arb at enrollment,C1516879;C1696073;C3888021;C3888198
44,arb ( n  % ),C3888198
44,arb  n ( % ),C3888198
44,arb  %,C3888198
44,arb,C3888198
44,aceis / arbs,C3888198
44,aceis  n ( % ),
44,aceis,
44,acei or arb pre - randomisation,C0034656;C0332152;C0740175;C2257086;C3669034;C3888198
44,acei or arb post - randomisation,C0034656;C0687676;C1704687;C3469826;C3888198
44,acei or arb,C3888198
44,acei and / or arb,C3888198
44,acei / arb therapy  n ( % ),C0039798;C0087111;C1363945;C3888198
44,acei / arb,C3888198
44,ace inhibitors or arbs,C0003015;C3888198
44,ace inhibitors or arb,C0003015;C3888198
44,ace inhibitors and arb,C0003015;C3888198
44,ace inhibitors / arbs  n ( % ),C0003015;C3888198
44,ace inhibitors / arbs,C0003015;C3888198
44,ace inhibitors / arb,C0003015;C3888198
44,ace inhibitor or arb at enrollment,C0003015;C1516879;C1696073;C3888021;C3888198;C4541021
44,ace inhibitor or arb,C0003015;C3888198;C4541021
44,ace inhibitor and / or arb,C0003015;C3888198;C4541021
44,ace inhibitor / arb therapy,C1444755;C3888198
44,ace inhibitor / arb  %,C0003015;C3888198;C4541021
44,ace inhibitor / arb,C0003015;C3888198;C4541021
44,ace inhibitor  arb  or both,C0003015;C3888198;C4541021
44,ace / arb use,C0042153;C0457083;C1452534;C1947944;C3888198;C4284014
44,ace - inhibitors / arbs  n ( % ),C0003015;C3888198
44,ace - inhibitor or arb ( % ),C0003015;C3888198;C4541021
43,limited to left side of colon,C0227388;C0439801;C2674459;C3542948;C4050251
43,left sided colitis,C2887821
43,left side only,C3842976
43,left side of colon,C0227388
43,left shoulder,C0524469
43,left - sided disease only,C0012634;C3842976
43,left - sided colitis,C2887821
42,unprotected left main stented,C0038257;C0205091;C0205225;C0443246;C1542147;C1552822
42,multivessel ( two vessel  three vessel  or left main ),C0205091;C0205225;C0205449;C0443246;C1542147;C1552822;C4012475;C4037954
42,left side  n ( % ),C0205091
42,left main treated,C0205091;C0205225;C0443246;C1522326;C1542147;C1552822
42,left main disease  n ( % ),C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
42,left main disease,C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
42,left main artery,C0003842;C0205091;C0205225;C0226004;C0443246;C1542147;C1552822
42,left main,C0205091;C0205225;C0443246;C1542147;C1552822
42,left - sided colitisz,C0205091;C0443246
42,left,C0205091;C0443246;C1552822
41,left atrial dimension  cm,C0018792;C0439534;C2950135
41,alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014
41,$nmbr$ s = scandinavian simvastatin survival study . $nmbr$ woscops = west of scotland coronary prevention study . $nmbr$ care = cholesterol and recurrent events . $nmbr$ post - cabg = post - coronary artery bypass graft . $nmbr$ afcaps / texcaps = air force / texas coronary atherosclerosis prevention study . $nmbr$ lipid = long - term intervention with pravastatin in ischaemic disease . $nmbr$ gissi prevention = gruppo italiano per lo studio della sopravvivenza nell ’ infarto miocardico . $nmbr$ lips = lescol intervention prevention study . $nmbr$ hps = heart protection study . $nmbr$ prosper = prospective study of pravastatin in the elderly at risk . $nmbr$ allhat - llt = antihypertensive and lipid - lowering treatment to prevent heart attack trial . $nmbr$ ascot - lla = anglo - scandinavian cardiac outcomes trial - lipid lowering arm . $nmbr$ alert = assessment of lescol in renal transplantation . $nmbr$ cards = collaborative atorvastatin diabetes study . $nmbr$ s = simvastatin . l = lovastatin . p = pravastatin . f = ﬂ uvastatin . a = atorvastatin . * mean duration of follow - up based on survival times within each trial . overall mean is weighted by trial - speci ﬁ c variances of logrank ( o – e ) for major vascular events . † all trials included dietary intervention : woscops  gissi prevention  lipid  $nmbr$ s  lips  and hps provided dietary advice  afcaps / texcaps  post - cabg  care  allhat  alert  cards  and prosper used american heart association ( aha ) step $nmbr$ diet and care intensi ﬁ ed to step $nmbr$ diet if ldl cholesterol $nmbr$ · $nmbr$ mmol / l ( $nmbr$ mg / dl ) . ‡ other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi ( as already counted in mi column ) . § other vascular includes history of intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  and peripheral artery disease . ¶ none includes individuals without a history of mi  symptomatic chd  intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  or peripheral artery disease,C0001792;C0002458;C0003364;C0005847;C0005910;C0008377;C0008976;C0010054;C0010055;C0011847;C0011849;C0012155;C0012159;C0012171;C0016327;C0018787;C0019664;C0019665;C0022671;C0023759;C0023779;C0023824;C0023981;C0024027;C0027051;C0027361;C0030705;C0033522;C0035647;C0036453;C0038454;C0038952;C0039711;C0039798;C0040363;C0040704;C0041260;C0043100;C0050451;C0074554;C0085542;C0085565;C0086153;C0087111;C0150158;C0184661;C0199176;C0202117;C0204932;C0205082;C0205164;C0205374;C0206579;C0220921;C0231220;C0237401;C0239110;C0240951;C0242994;C0262512;C0262926;C0277793;C0280604;C0282416;C0286651;C0309872;C0332196;C0332257;C0420180;C0439394;C0439673;C0441471;C0441994;C0444504;C0446516;C0449238;C0455536;C0475224;C0489835;C0557651;C0565930;C0589120;C0591720;C0679698;C0680782;C0681804;C0687676;C0718674;C0745413;C0750480;C0772110;C0870136;C0886296;C0948008;C1096775;C1185738;C1232424;C1260596;C1261512;C1261552;C1273517;C1273869;C1304680;C1305866;C1455761;C1519433;C1522326;C1522577;C1522601;C1527178;C1533734;C1545588;C1552866;C1558950;C1561607;C1704379;C1704436;C1704685;C1704687;C1705117;C1705169;C1705255;C1705493;C1705566;C1705938;C1706132;C1706420;C1706495;C1709709;C1711260;C1736144;C1801960;C1883351;C1947933;C1999167;C1999230;C2003888;C2004062;C2004580;C2347090;C2347634;C2348143;C2348152;C2603343;C2603362;C2700399;C2700409;C2825408;C2828389;C2919552;C2926735;C2930619;C2937358;C2945760;C2983588;C3274571;C3275277;C3469826;C3538926;C3538994;C3541433;C3541888;C3542407;C3642216;C3642217;C3665546;C3668949;C3669039;C3715044;C3810814;C3814463;C3887704;C3889123;C3898312;C4025272;C4050014;C4084853;C4318856;C4521762;C4552904;C4553014;C4553528;C4554100
40,left ventricular systolic or diastolic dysfunction,C0039155;C0225897;C0520863
40,left ventricular systolic dysfunction  n ( % ),C1277187;C1963159;C4553199
40,left ventricular ejection,C2733342
40,left ventricular dysfunction,C0242698
40,ecg left ventricular,C0225897;C1623258
40,af alone refers to atrial fi - brillation without coexisting cardiovascular conditions but with left atrial dilatation . ace denotes angiotensin - con - verting enzyme  hf heart failure  and lvd left ventricular dysfunction .,C0003018;C0007226;C0012634;C0014442;C0018792;C0018801;C0205171;C0205543;C0242698;C0344434;C0344720;C0348080;C0387288;C0439044;C0679994;C1452534;C1705253;C3864998;C3887460;C4049859;C4050619;C4284014;C4521302;C4521602
39,saxa + met n = $nmbr$,C0369718;C0428210;C0441922;C1550543;C4317104
39,saxa + dapa + met n = $nmbr$,C0369718;C0428210;C0441922;C1550543;C4317104
39,no longer met study criteria,C0205166;C0243161;C0428210;C0557651;C1550543;C1706317;C2603343;C4317104
39,met criterion at finalt,C0243161;C0428210;C1550543;C4317104
39,met criterion at final ( n [ % ] ),C0205088;C0243161;C0428210;C1546485;C1550543;C3853528;C4317104
39,met criterion at blt ( n [ % ] ),C0243161;C0428210;C1550543;C1563149;C1708627;C4317104
39,met criterion at bl ( n [ % ] ),C0005918;C0006413;C0243161;C0428210;C1550543;C1552663;C2827109;C4317104
39,met ( n = $nmbr$ ),C0428210;C1550543;C4317104
39,met % △ ( se ),C0036919;C0428210;C1550543;C4317104
39,mean ( $nmbr$ % ci ) difference vs saxa + dapa + met,C0008107;C0428210;C0444504;C1550543;C1705241;C1705242;C2347634;C2348143;C3259781;C4317104
39,dapa + met n = $nmbr$,C0369718;C0428210;C0441922;C1550543;C4317104
39,cana $nmbr$ / met ( n = $nmbr$ ),C0369718;C0428210;C0441922;C1418845;C1550543;C4317104
39,add - on to met + su $nmbr$,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
39,add - on to met + su,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
39,add - on to met $nmbr$,C0428210;C1550543;C1883712;C4317104
39,add - on to met,C0428210;C1550543;C1883712;C4317104
38,placeboa,
38,mean_delta,C0439097;C0444504;C1705241;C2347634;C2348143;C3146239;C3538806;C3540585;C3815527
38,difference from placeboa,C1705241;C1705242
38,am_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
38,am_ % delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
37,★ reported by physicians . tdata are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C0237753;C0444504;C0449788;C0549183;C0876920;C1444656;C1511726;C1709908;C2347634;C2347635;C2348143;C2348144;C2699239;C2939193;C3245479;C3714741
37,years ( mean ± sd ),C0439234;C0444504;C2347634;C2348143;C2699239
37,years  mean ( sd ),C0439234;C0444504;C2347634;C2348143;C2699239
37,weight in kg ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] ),C0022718;C0036919;C0332174;C0392747;C0439209;C0439230;C0443172;C0444504;C1303013;C1705241;C2347634;C2348143;C2699239;C4054209;C4319952
37,weight in kg  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,weight ( kg )  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,weight ( kg )  mean ( s . e . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
37,weight ( kg )  mean ( s . d . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
37,weight  mean ± sd ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,weight  mean ( sd ) kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,weight  mean $nmbr$ sd kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,weight  kg : mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,weight  kg ( mean ± s . d . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
37,week $nmbr$ fpg  mean ( s . e . ),C0332174;C0439230;C0444504;C2347634;C2348143
37,van der heijde mtss  mean ( sd ),C0444504;C0557775;C1511780;C2347634;C2348143;C2699239
37,ups score  mean ( sd ),C0334463;C0444504;C0449820;C2347634;C2348143;C2699239;C3542434;C4050231
37,units per week  mean ( sd ),C0444504;C0560588;C2347634;C2348143;C2699239
37,type $nmbr$ collagen  mean ( sd )  ng / ml £,C0009325;C0332307;C0439275;C0444504;C1547052;C2347634;C2348143;C2699239
37,triglycerides mean ( mg / dl ± sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
37,triglycerides mean,C0041004;C0444504;C2347634;C2348143
37,triglycerides ( mg / dl )  mean + sd  available for $nmbr$ patients,C0030705;C0041004;C0439269;C0444504;C0470187;C2347634;C2348143;C2699239
37,treatment duration mean ( sd ),C0444504;C0444921;C2347634;C2348143;C2699239;C3259042
37,total updrs score ( baseline )  mean ( sd ),C0168634;C0439175;C0439810;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C3639721;C4050231
37,total pack - years mean ( sd ),C0439175;C0439810;C0444504;C1277691;C2347634;C2348143;C2699239
37,total daily dose of ics  mean  μ gc,C0444504;C0815320;C2347634;C2348070;C2348143;C3537453;C4281799;C4551720
37,total cigarette pack - years  mean ( sd ),C0439175;C0439810;C0444504;C1303175;C2347634;C2348143;C2699239
37,total basdai score  mean   ±   sd,C0439175;C0439810;C0444504;C0449820;C1998004;C2347634;C2348143;C2699239;C4050231
37,time since start of fit  mean ( sd )  y,C0036572;C0040223;C0439659;C0444504;C1711239;C2347634;C2348143;C2349186;C2699239;C3541383;C4048158;C4553125
37,time since pd diagnosis  mean ± sd,C0011900;C0040223;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383;C4553228;C4553229
37,time since first psoriasis diagnosis ( y )  mean ( sd ),C0011900;C0033860;C0040223;C0205435;C0444504;C1279901;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383
37,time since end of fit  mean ( sd )  y,C0036572;C0040223;C0444504;C0444930;C1711239;C2347634;C2348143;C2349186;C2699239;C2746065;C3541383;C4048158;C4553125
37,time since diagnosis of diabetes  mean ( sd ),C0011847;C0011849;C0011900;C0040223;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383
37,time since as diagnosis ( years )  mean ( sd ),C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383
37,time since as diagnosis  mean ( sd ) years,C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383
37,tchdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,tc level  mean ( sd ) mg / dl,C0039411;C0040642;C0041405;C0041698;C0439269;C0441889;C0444504;C0456079;C1547707;C1824670;C2347634;C2348143;C2699239;C2946261;C3272447;C4522122
37,tc  mg / dl  mean ± sd,C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
37,tc  mg / dl  mean + sd,C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
37,tc  mean ( sd )  rrig / dl,C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C3642216;C4522122
37,tc  mean ( sd ),C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
37,symptoms mean ( sd ),C0444504;C0683368;C1457887;C2347634;C2348143;C2699239
37,sulfasalazine ( mean dose : $nmbr$ . $nmbr$ g / day ),C0036078;C0178602;C0439417;C0444504;C0869039;C1114758;C2347634;C2348143
37,standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
37,smoking history  pack - years  mean ( sd ),C0444504;C1277691;C1519384;C2347634;C2348143;C2699239
37,smoking  mean,C0037369;C0444504;C0453996;C1881674;C2347634;C2348143
37,shs  mean ± sd,C0444504;C2347634;C2348143;C2699239
37,shs  mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239
37,sgrq scores  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
37,sgrq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
37,ses - cd  mean ( sd ),C0007928;C0034283;C0444504;C2347634;C2348143;C2699239;C4552032
37,serum $nmbr$ ( oh ) d concentrations  ng / ml  mean ( sd ),C0220853;C0439275;C0444504;C0683149;C2347634;C2348143;C2699239
37,sbp  mm hg ( mean $nmbr$ h )  mean ( sd ),C0025424;C0085805;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239
37,sbp  mm hg  mean ± sdc,C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112
37,sbp  mm hg  mean + sdc,C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112
37,rescue use : mean no . of inhalations / d,C0004048;C0042153;C0354922;C0444504;C0457083;C1947944;C2347634;C2348143
37,rescue medication use  mean inhalations / previous $nmbr$ d,C0004048;C0205156;C0240320;C0354922;C0444504;C1552607;C2347634;C2348143
37,pulse in beats / minute  mean ( sd ),C0232117;C0391850;C0439385;C0444504;C1947910;C2347634;C2348143;C2699239
37,previous dmards  mean ± sd,C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239
37,plp - c  mean ( sd )  mg / dl,C0034266;C0439269;C0444504;C1175541;C1257874;C1705623;C2347634;C2348143;C2699239
37,placebo estimated mean,C0032042;C0444504;C0750572;C1696465;C1706408;C2347634;C2348143
37,phosphatase  mean ( sd )  ng / ' mlf,C0017887;C0028074;C0031678;C0066495;C0444504;C1149880;C2347634;C2348143;C2699239;C4522024
37,pasi score ( $nmbr$ - $nmbr$ ) t  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
37,pasi score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
37,pasi score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
37,pasi score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
37,pasi  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4528685
37,pain vas ( range $nmbr$ - $nmbr$ )  mean ± sd,C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
37,pain vas  range $nmbr$ - $nmbr$ mm  mean ( sd ),C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C4330985;C4554674
37,pack - years  mean ( sd ),C0444504;C1277691;C2347634;C2348143;C2699239
37,ocs dose *  mean ( sd ),C0178602;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
37,number of visits  mean ± sd,C0444504;C1549755;C2347634;C2348143;C2699239
37,number of implanted stents  n  mean ( sd ),C0237753;C0444504;C0449788;C0522776;C2347634;C2348143;C2699239
37,number of exacerbations in previous year  mean ( sd ),C0205156;C0237753;C0439234;C0439508;C0444504;C0449788;C1552607;C2347634;C2348143;C2699239;C4086268
37,non - hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
37,non - hdl - c  mg / dl  mean ( sd ),C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
37,no . previous dmard  mean ( sd ),C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239
37,mtss  mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,msasss  mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,months since first ra symptom  mean ( sd ) f,C0016327;C0205435;C0439231;C0444504;C1279901;C1457887;C2347634;C2348143;C2699239;C3538806;C3854129;C4048756
37,modified hachinski ischemia scale  mean ( sd ) c,C0022116;C0175659;C0349674;C0392747;C0444504;C1947916;C2347634;C2348143;C2699239;C3889737;C4321499
37,mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
37,mean — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
37,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area,C0017446;C0205146;C0369637;C0439445;C0441923;C0444504;C0489451;C2347634;C2348143
37,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
37,mean — ml / min,C0439445;C0444504;C2347634;C2348143
37,mean — kg,C0022718;C0439209;C0444504;C2347634;C2348143;C4054209
37,mean — g / dl,C0439267;C0444504;C2347634;C2348143
37,mean — %,C0444504;C2347634;C2348143
37,mean ±   sd,C0444504;C2347634;C2348143;C2699239
37,mean ± sd unless otherwise indicated,C0444504;C1444656;C2347634;C2348143;C2699239
37,mean ± sd mg ( n = $nmbr$  $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
37,mean ± sd ( n ),C0444504;C2347634;C2348143;C2699239
37,mean ± sd  n,C0444504;C2347634;C2348143;C2699239
37,mean ± sd,C0444504;C2347634;C2348143;C2699239
37,mean ± s . d . weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209
37,mean ± s . d . fpg,C0444504;C2347634;C2348143
37,mean ± s . d .,C0444504;C2347634;C2348143
37,mean yearly decline,C0332181;C0439508;C0444504;C2347634;C2348143
37,mean weight ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,mean weight  kg ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,mean weight  kg  mean = sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,mean time since diagnosis  y,C0011900;C0040223;C0444504;C1704338;C1704656;C2347634;C2348143;C3541383
37,mean time since as diagnosis  years  mean ± sd,C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383
37,mean sitting systolic blood pressure,C0277814;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2584297;C4050224
37,mean sitting diastolic blood pressure,C0444504;C1319894;C2347634;C2348143
37,mean score,C3533236
37,mean prebronchodilation ( l ),C0444504;C2347634;C2348143
37,mean or n,C0369718;C0441922;C0444504;C2347634;C2348143
37,mean number of puffs per day,C0237753;C0332173;C0439228;C0439505;C0444504;C0449788;C1533107;C2347634;C2348143
37,mean number of exacerbations in previous y ( sd ),C0205156;C0237753;C0444504;C0449788;C1552607;C2347634;C2348143;C2699239;C4086268
37,mean number of exacerbations in previous $nmbr$ months ( sd ),C0205156;C0237753;C0439231;C0444504;C0449788;C1552607;C2347634;C2348143;C2699239;C4086268
37,mean number of combined visits / hospitalizations †,C0205195;C0444504;C0545082;C1512346;C2347634;C2348143;C4086639
37,mean number of caes in past $nmbr$ months ( number per patient ) ] |,C0030705;C0237753;C0444504;C0449788;C2347634;C2348143;C4331910
37,mean iglar dose ± sd ( u / day ),C0178602;C0444504;C0456683;C0869039;C1114758;C2347634;C2348143;C2699239
37,mean ics ( fluticasone propionate dpi or equivalent  pg per day ),C0117996;C0205163;C0439185;C0444504;C0815320;C2347634;C2348143;C2827928;C4551720
37,mean eosinophil count  per ml,C0200638;C0439526;C0444504;C0750879;C1705224;C2347634;C2348143;C3887665
37,mean doseb,C0444504;C2347634;C2348143
37,mean dose ' ’,C0178602;C0444504;C0869039;C1114758;C2347634;C2348143
37,mean dlco ± sd,C0444504;C1516251;C2347634;C2348143;C2699239
37,mean difference = seb,C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
37,mean change in total updrs scores adjusted according to baseline updrs,C0168634;C0392747;C0439175;C0439810;C0443172;C0444504;C0456081;C0680240;C1442488;C1705241;C2347634;C2348143;C2964552;C3533236;C3639721;C4319952
37,mean change in radiographic end points shs  mean ± sd,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C2699239;C4319952
37,mean bm $nmbr$ ± s . d .  kg / m $nmbr$,C0006416;C0444504;C1532718;C2347634;C2348143
37,mean blood eosinophil count ( cells per pl ),C0200638;C0444504;C2347634;C2348143;C3897966;C4049765
37,mean asui scored,C0444504;C0449820;C2347634;C2348143
37,mean annualized exacerbation rate,C0444504;C0871208;C1521828;C2347634;C2348143;C4086268
37,mean age ( y ) ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
37,mean age ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
37,mean age  years ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
37,mean age  y ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
37,mean age  y  mean = sd,C0001779;C0444504;C2347634;C2348143;C2699239
37,mean acrn,C0444504;C2347634;C2348143
37,mean acq - $nmbr$ scores,C0444504;C0449820;C2347634;C2348143;C2919686;C4050231
37,mean acq - $nmbr$ score at randomization  !,C0034656;C0444504;C0449820;C2347634;C2348143;C2919686;C4050231
37,mean a ± sdt,C0444504;C2347634;C2348143
37,mean = sd,C0444504;C2347634;C2348143;C2699239
37,mean *,C0444504;C2347634;C2348143
37,mean ( ± s . d . ),C0444504;C2347634;C2348143
37,mean ( sd on loge scale ) u / ml,C0175659;C0349674;C0439340;C0444504;C1880521;C1947916;C2347634;C2348143;C2697934;C2699239;C2945590
37,mean ( sd ) years daily ocs use  n ( % ),C0042153;C0332173;C0369718;C0439234;C0441922;C0444504;C0457083;C1947944;C2347634;C2348143;C2699239
37,mean ( sd ) weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
37,mean ( sd ) total asthma symptom scores,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
37,mean ( sd ) periostin  ng / ml,C0219433;C0439275;C0444504;C1424662;C2347634;C2348143;C2699239;C3812270
37,mean ( sd ) number of exacerbations *,C0237753;C0444504;C0449788;C2347634;C2348143;C2699239;C4086268
37,mean ( sd ) number of albuterol per day  puff,C0001927;C0237753;C0332173;C0439228;C0439505;C0444504;C0449788;C1533107;C1882376;C2347634;C2348143;C2699239
37,mean ( sd ) hba $nmbr$ c  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
37,mean ( sd ) duration of smoking  pack years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
37,mean ( sd ) duration of smoking  pack - years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
37,mean ( sd ) das $nmbr$ - $nmbr$ ( esr ) *,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
37,mean ( sd ) d,C0444504;C2347634;C2348143;C2699239
37,mean ( sd ) anthropometry,C0003188;C0444504;C2347634;C2348143;C2699239
37,mean ( sd ) age in years,C0444504;C1510829;C2347634;C2348143;C2699239
37,mean ( sd ) age ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
37,mean ( sd ) age  years,C0444504;C1510829;C2347634;C2348143;C2699239
37,mean ( sd ) age,C0001779;C0444504;C2347634;C2348143;C2699239
37,mean ( sd ) [ range ],C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
37,mean ( sd ) ( years ),C0439234;C0444504;C2347634;C2348143;C2699239
37,mean ( sd ) % of predicted normal fevi,C0205307;C0231683;C0429706;C0439166;C0444504;C0681842;C0849974;C1561566;C1882327;C2347086;C2347634;C2348143;C2699239;C4528367;C4553972
37,mean ( sd ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C0444504;C2347634;C2348143;C2699239
37,mean ( sd )  ng / ml £,C0439275;C0444504;C2347634;C2348143;C2699239
37,mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,mean ( s . e . ) t,C0444504;C2347634;C2348143
37,mean ( s . e . ),C0444504;C2347634;C2348143
37,mean ( s . d . ) weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209
37,mean ( s . d . ) total pcsk $nmbr$  ng / ml,C0439175;C0439275;C0439810;C0444504;C2347634;C2348143
37,mean ( s . d . ) non - hdl cholesterol,C0444504;C0729627;C1535899;C2347634;C2348143
37,mean ( s . d . ) ldl particle number  nmol / l,C0237753;C0439282;C0444504;C0449788;C2347634;C2348143;C2612459
37,mean ( s . d . ) hdl cholesterol,C0023822;C0392885;C0444504;C2347634;C2348143
37,mean ( s . d . ) free pcsk $nmbr$  ng / ml,C0332296;C0439275;C0444504;C1880497;C1996904;C2347634;C2348143
37,mean ( s . d . ) fpg,C0444504;C2347634;C2348143
37,mean ( s . d . ),C0444504;C2347634;C2348143
37,mean ( = sd ) days since,C0439228;C0444504;C2347634;C2348143;C2699239
37,mean % predicted value prebronchodilation,C0444504;C0681842;C1522609;C1882327;C2347634;C2348143
37,mean % predicted dlco * ( sd ),C0444504;C0681842;C1516251;C1882327;C2347634;C2348143;C2699239
37,mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239
37,mean $nmbr$ mwd *  m ( sd ),C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
37,mean $nmbr$ - h sbp *,C0033727;C0085805;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
37,mean  ml ( sd ),C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665
37,mean,C0444504;C2347634;C2348143
37,mases ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,lv ejection fraction  mean ( sd ) [ range ]  %,C0023128;C0444504;C0489482;C0731033;C1514721;C1881413;C2347634;C2348143;C2348147;C2699239;C2700378;C3542016
37,lung function  mean,C0035245;C0444504;C2347634;C2348143
37,ls mean difference ± seb,C0023668;C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
37,ls mean change ± sea,C0023668;C0036493;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
37,ls mean change,C0023668;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
37,ls mean ( s . e . ) primary endpoint : % change from baseline to week $nmbr$,C0023668;C0168634;C0332174;C0392747;C0439230;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2986535;C4319952
37,ls mean,C0023668;C0444504;C2347634;C2348143
37,lp ( a )  nmol / l  mean ( sd ),C0065058;C0439282;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
37,lp ( a )  mean ( sd ),C0065058;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
37,lowest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1708760;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
37,leeds enthesitis index  mean ( sd ) ’ ’ * ’,C0444504;C0451148;C2347634;C2348143;C2699239
37,leeds dactylitis index - basic  mean ( sd ) ’ ' ^,C0239161;C0444504;C0600653;C0918012;C1527178;C1552854;C1637833;C2347634;C2348143;C2699239;C2986546
37,least square mean ( se ),C0023189;C0036919;C0444504;C2347634;C2348143
37,ldl cholesterol mean ( mg / dl ± sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
37,ldl - cihdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,ldl - c ( calculated )  mean ( sd ),C0444504;C0444686;C1441506;C2347634;C2348143;C2699239
37,ldl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,insulin glargine vs standard care least - squares mean ( $nmbr$ % cl ),C0023189;C0444504;C0596019;C0907402;C1442989;C1947933;C2347634;C2348143;C2828392
37,in previous year  mean ( sd ),C0205156;C0439234;C0439508;C0444504;C1552607;C2347634;C2348143;C2699239
37,imaging data  mean ( sd ),C0011923;C0079595;C0444504;C1511726;C2347634;C2348143;C2699239;C3245479;C3714741
37,ileum ses - cd score  mean ( sd ),C0007928;C0020885;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4552032
37,ics use at enrollment  mean  mg / d,C0042153;C0439422;C0444504;C0457083;C0815320;C1516879;C1696073;C1947944;C2347634;C2348143;C3888021;C4551720
37,hscrp  mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,highest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1522410;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
37,hemoglobin a $nmbr$ c  mean ( sd )  % b,C0062248;C0444504;C2347634;C2348143;C2699239
37,hemoglobin a $nmbr$ c  mean ( sd )  %,C0019020;C0444504;C2347634;C2348143;C2699239;C3889898
37,hdl cholesterol mean,C0023822;C0392885;C0444504;C2347634;C2348143
37,hdl cholesterol  mmol / l  women  mean ± sd,C0023822;C0043210;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
37,hdl - c  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
37,hdl - c  mg / dl  mean ( sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
37,hdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3715113
37,hdl  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
37,hba $nmbr$ ca  %  mean ± sd,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3887642
37,haq pain scale  mean,C0102923;C0444504;C0451208;C1504479;C2347634;C2348143
37,haemoglobin ( g / dl )  mean + sd  available for $nmbr$ patients,C0019046;C0030705;C0439267;C0444504;C0470187;C1319312;C2347634;C2348143;C2699239;C3642216
37,glycated hemoglobin  mean ( sd )  %,C0017853;C0444504;C2347634;C2348143;C2699239
37,fpg ( mmol / l )  mean ± s . d .,C0439433;C0444504;C2347634;C2348143
37,fevi  l  mean ( sd ) $nmbr$,C0429706;C0444504;C0849974;C1561566;C2347634;C2348143;C2699239;C4528367
37,fevi  % predicted  mean ( sd ) $nmbr$,C0444504;C0681842;C0849974;C1561566;C1882327;C2347634;C2348143;C2699239;C4528367
37,fas  range $nmbr$ - $nmbr$  mean ( sd ),C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
37,estimated mean,C0444504;C0750572;C2347634;C2348143
37,enthesitis score ( mases  $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C1282952;C2347634;C2348143;C2699239;C4050231
37,ejection fraction ( mean ),C0444504;C0489482;C2347634;C2348143;C2700378
37,egfr — mean ( sd  n ),C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
37,egfr  mean ± sd,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
37,duration of alendronate use  mean ( sd )  y,C0102118;C0444504;C1881378;C2347634;C2348143;C2699239;C2826775
37,duration  mean ( sd )  years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
37,diagnosis ( y )  mean ( sd ),C0011900;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239
37,diabetesduration  mean ( sd )  y,C0444504;C2347634;C2348143;C2699239
37,das $nmbr$ - hscrp  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
37,das $nmbr$ ( esr )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
37,das $nmbr$  range $nmbr$ - $nmbr$  mean ( sd ),C0051767;C0057671;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
37,das $nmbr$  mean ± sd,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
37,das $nmbr$  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
37,daily “ off ” time  mean ± sd  h / dayf,C0033727;C0040223;C0332173;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C3541383;C4528284
37,crcb - ( ml / min )  mean ( s . e . ),C0439390;C0439445;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
37,colon ' ses - cd score  mean ( sd ),C0007928;C0009368;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C3888384;C4050231;C4552032
37,cognitive subscale on alzheimer ' s disease assessment scale  mean ( sd ) e,C0444504;C0450989;C1516691;C2347634;C2348143;C2699239
37,clinical dementia rating sum of boxes  mean ( sd ) f,C0444504;C0451074;C1515051;C1517104;C2347634;C2348143;C2699239
37,clean  n ( % ) a,C1947930
37,cigarette smoking  mean pack - years ( sd ),C0037369;C0444504;C0453996;C1303175;C1881674;C2347634;C2348143;C2699239
37,cholesterol - mean ( sd  n ),C0008377;C0444504;C2347634;C2348143;C2699239
37,cholesterol  mg / dl  mean ( sd ) §,C0008377;C0439269;C0444504;C2347634;C2348143;C2699239
37,change from baseline in das $nmbr$ - esr  mean $nmbr$ sd,C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2699239;C3811131;C4319952
37,cclear < $nmbr$,
37,cclear $nmbr$ - $nmbr$,
37,cclear $nmbr$ +,
37,calculated annual decline  mean ± se,C0036919;C0332181;C0444504;C0444686;C1441506;C2347634;C2348143
37,body weight ( kg )  mean ± sd,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
37,body weight  kg ( mean ± sd ),C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
37,body massindex  mean ( sd ) a,C0242821;C0444504;C0460148;C1268086;C2347634;C2348143;C2699239;C4082212
37,bm $nmbr$  kg / m $nmbr$ ( mean ± s . d . ),C0006416;C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C1275571;C1513009;C2347634;C2348143;C4054209
37,blood eosinophils  mean ( range )  cells / ml,C0014467;C0444504;C1514721;C2347634;C2348143;C2348147;C2699156;C3542016
37,biochemical parameters at randomization  mean,C0034656;C0205474;C0444504;C0449381;C2347634;C2348143
37,beam values ( mg / dl )  mean ( sd ),C0042295;C0338248;C0439269;C0444504;C2347634;C2347880;C2348143;C2699239;C4521565
37,baseline haq mean ( s . e . ),C0102923;C0168634;C0444504;C0451208;C1442488;C2347634;C2348143
37,baseline dyspnea index  mean total score,C0439175;C0439810;C0444504;C1511069;C2347634;C2348143;C2964552;C3533236
37,baseline daytime nasal symptoms score  mean ± sd,C0168634;C0231918;C0332169;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C4050231
37,basdai score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C1998004;C2347634;C2348143;C2699239;C4050231
37,basdai score  mean ( sd ),C0444504;C0449820;C1998004;C2347634;C2348143;C2699239;C4050231
37,basdai question $nmbr$ score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C1522634;C1998004;C2347634;C2348143;C2699239;C4050231
37,basdai  total  mean ± sd,C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239
37,asui score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
37,asui score  mean,C0444504;C0449820;C2347634;C2348143;C4050231
37,as duration  y  mean ( sd ),C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
37,apob  g / l  mean ( sd ),C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239;C3252643
37,apo b  mg / dl  mean ( sd ),C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
37,apo b  mean ( sd ),C0003593;C0444504;C2347634;C2348143;C2699239;C3252643
37,apo a - l ( mg / dl ) - mean ± sd,C0439269;C0444504;C1447574;C2347634;C2348143;C2699239;C4521365
37,apo a - $nmbr$  mean ( sd )  mg / dl,C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
37,apo a $nmbr$  mg / dl  mean ( sd ),C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
37,anthropometry : mean ( sd ),C0003188;C0444504;C2347634;C2348143;C2699239
37,anthropometrics  mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,age — mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
37,age when diabetes first diagnosed ( years )  mean ( sd ),C0001779;C0011847;C0011849;C0011900;C0205435;C0439234;C0444504;C1279901;C2347634;C2348143;C2699239
37,age at first seizure  years  mean ( sd ),C0036572;C0205435;C0444504;C1279901;C1510829;C1959629;C2347634;C2348143;C2699239;C4553401
37,age at enrollment ( years )  mean ( sd ),C0444504;C1510829;C1516879;C1696073;C2347634;C2348143;C2699239;C3888021
37,age at baseline in years  mean ( sd ),C0001779;C0168634;C0439234;C0444504;C1442488;C2347634;C2348143;C2699239
37,age ( years ) mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
37,age ( years ) mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
37,age  years  mean + sd,C0444504;C1510829;C2347634;C2348143;C2699239
37,age  y mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
37,age  y ( mean ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
37,age  y  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
37,age  mean ± sd years,C0444504;C1510829;C2347634;C2348143;C2699239
37,age  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
37,age  mean years ( sd ) ’ gender  n ( % ),C0079399;C0444504;C1510829;C1522384;C2347634;C2348143;C2699239
37,age  mean years  [ sd ],C0444504;C1510829;C2347634;C2348143;C2699239
37,age  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
37,age  mean $nmbr$ sd years,C0444504;C1510829;C2347634;C2348143;C2699239
37,adjusted ∗   mean of difference ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C1705241;C1705242;C2347634;C2348143;C3887665
37,adjusted mean ± se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
37,adjusted mean change,C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
37,adjusted mean ( se ),C0036919;C0444504;C0456081;C2347634;C2348143
37,> mean,C0444504;C2347634;C2348143
37,> $nmbr$ months  mean ( sd ),C0439231;C0444504;C2347634;C2348143;C2699239
37,< mean,C0444504;C2347634;C2348143
37,< $nmbr$ months  mean ( sd ),C0439231;C0444504;C2347634;C2348143;C2699239
37,* reported by physicians . † data are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C0237753;C0444504;C0449788;C0549183;C0876920;C1444656;C1511726;C1709908;C2347634;C2347635;C2348143;C2348144;C2699239;C2939193;C3245479;C3714741
37,( % )  $nmbr$ mean ( sd ),C0444504;C2347634;C2348143;C2699239
37,% \mean ± sd,C0444504;C2347634;C2348143;C2699239
36,weeko mean + sem,C0444504;C2347634;C2348143
36,week $nmbr$ mean ± sem,C0332174;C0439230;C0444504;C2347634;C2348143
36,week $nmbr$ mean + sem,C0332174;C0439230;C0444504;C2347634;C2348143
36,percent change from baseline to week $nmbr$ in auc ( mean  sem ),C0332174;C0376690;C0439230;C0444504;C2347634;C2348143;C3272907
36,mean a ± sem ( % ),C0444504;C2347634;C2348143
36,left ventricular ef  mean ( sd )  %,C0225897;C0444504;C2347634;C2348143;C2699239
36,hab $nmbr$ c ( mean ± sem )  %,C0444504;C2347634;C2348143
36,ef > $nmbr$ % n = $nmbr$,
36,ef < $nmbr$ %,
36,ef ( % )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
36,( sem ),
35,nonsevere hypoglycemia,C0020615;C4553659
35,no nonsevere hypoglycemia,C0020615;C4553659
35,major hypoglycemia,C0020615;C0205082;C0205164;C4318856;C4521762;C4553659
35,investigator - reported hypoglycaemia *,C0020615;C0035173;C0684224;C0700287;C4319718;C4553659
35,investigator - reported hypoglycaemia,C0020615;C0035173;C0684224;C0700287;C4319718;C4553659
35,hypoglycemiat,
35,hypoglycemia ^,C0020615;C4553659
35,hypoglycemia,C0020615;C4553659
35,hosji fcrhypoglycemia,
35,b nonsevere hypoglycemia,C0020615;C4553659
34,normoglycemic {,C0580545
34,normoglycemic ^,C0580545
34,normoglycemic $nmbr$,C0580545
34,normoglycemic,C0580545
34,normoglycemia ^,C0580545
34,normoglycemia,C0580545
34,baseline normoglycemia,C0168634;C0580545;C1442488
33,took prior antihyperglycemic agent ( any ),C0020616;C0332152;C0450442;C1254351;C1515187;C1521826;C2826257
33,other hypoglycemic agent  n ( % ),C0020616
33,hypoglycemic agent,C0020616
33,hypoglycaemic agents,C0020616
33,antihyperglycemictherapies  %,
33,antihyperglycemic medication usage,C0013227;C0020616;C0457083;C3244316;C4284232
33,antihyperglycemic,C0020616
32,olaemia  n ( % ),
32,hypovolaemia,C0546884
32,hypokalemia ‡   ( potassium < $nmbr$ . $nmbr$ mmol / l ),C0020621;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4553966
32,hypokalemia,C0020621;C4553966
32,hypokalaemia,C0020621;C4553966
32,hvookalemia,
31,p value *  placebo group p value *  hyponatremia normonatremic group  tolvaptan vs hyponatremic vs placebo,C0020625;C0032042;C0441833;C0687744;C0857122;C1176308;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408;C1709380;C4553967
31,hyponatremia,C0020625;C4553967
30,hyperkalemiab,
30,hyperkalemia * ’,C0020461;C4552983
30,hyperkalemia ( > $nmbr$ . $nmbr$ meq / l ),C0020461;C0439375;C4552983
30,hyperkalemia  n ( % ),C0020461;C4552983
30,hyperkalaemia ( investigator reported ),C0020461;C0035173;C0684224;C0700287;C4319718;C4552983
30,hyperkalaemia,C0020461;C4552983
29,hyperlipidemia — no . / total no . ( % ),C0020473;C0428465;C0439175;C0439810;C4555212
29,hyperlipidemia — no . ( % ),C0020473;C0428465;C4555212
29,hyperlipidemia § yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
29,hyperlipidemia §,C0020473;C0428465;C4555212
29,hyperlipidemia | | yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
29,hyperlipidemia | |,C0020473;C0428465;C4555212
29,hyperlipidemia ^,C0020473;C0428465;C4555212
29,hyperlipidemia ( % ) §,C0020473;C0428465;C4555212
29,hyperlipidemia ( % ),C0020473;C0428465;C4555212
29,hyperlipidemia  n / n ( % ),C0020473;C0428465;C4555212
29,hyperlipidemia  n ( % ),C0020473;C0428465;C4555212
29,hyperlipidemia  %,C0020473;C0428465;C4555212
29,hyperlipidemia,C0020473;C0428465;C4555212
29,hyperlipidaemia ( % ),C0020473;C0428465;C4555212
29,hyperlipidaemia  n ( % ) yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
29,hyperlipidaemia,C0020473;C0428465;C4555212
28,with placebo ( n $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
28,with placebo,C0032042;C1696465;C1706408
28,we recorded no significant interactions for any subgroup analysis . pufa = polyunsaturated fatty acids . nyha = new york heart association . lvef = left ventricular ejection fraction . * $nmbr$ % cl was calculated with a cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .,C0004083;C0018623;C0018787;C0027976;C0030705;C0032042;C0032615;C0034869;C0042508;C0201950;C0205091;C0205351;C0237688;C0237881;C0428772;C0439849;C0443246;C0444686;C0470187;C0488728;C0543421;C0596019;C0596306;C0699792;C0750502;C1079230;C1275491;C1441506;C1515021;C1546944;C1552822;C1565830;C1696465;C1704610;C1704675;C1706408;C2986480;C3853788
28,we recorded no significant interactions for any subgroup analysis . nyha = new york heart association . lvef = left ventricular ejection fraction . ' $nmbr$ % cl was calculated by cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .,C0004083;C0018787;C0027976;C0030705;C0032042;C0033489;C0034869;C0201950;C0237688;C0237881;C0428772;C0439849;C0444686;C0470187;C0543421;C0596019;C0596306;C0699792;C0750502;C0965129;C1079230;C1275491;C1441506;C1515021;C1546944;C1565830;C1696465;C1704610;C1704675;C1706408;C2986480;C3853788
28,vs . placebo,C0032042;C1696465;C1706408
28,vorapaxar placebo $nmbr$ - yr . km %,C0032042;C0439234;C1696465;C1706408;C2974521;C3887676
28,tiotropium + placebo ( n [ $nmbr$ ),C0032042;C0213771;C1696465;C1706408
28,therapy ( asa $nmbr$ / placebo $nmbr$ ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
28,therapy ( asa $nmbr$  $nmbr$ / placebo $nmbr$ ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
28,statin + placebo ( n = $nmbr$ ),C0032042;C0360714;C1696465;C1706408
28,serum uric acid  difference vs placebo ( $nmbr$ % cl ),C0032042;C0455272;C0596019;C0700634;C1696465;C1705241;C1705242;C1706408
28,sbp  difference vs placebo ( $nmbr$ % cl ),C0032042;C0085805;C0596019;C1696465;C1705241;C1705242;C1706408
28,s $nmbr$ vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
28,s $nmbr$ - $nmbr$ vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
28,rerandomization to placebo ( n = $nmbr$ ) f,C0016327;C0032042;C1696465;C1706408
28,rate ratio vs placebo ( $nmbr$ % ci ),C0008107;C0032042;C0456603;C0871208;C1521828;C1547037;C1696465;C1706408;C3259781
28,ranolazine vs . placebo km failure rate,C0032042;C0073633;C0231174;C0680095;C0871208;C1521828;C1696465;C1706408;C3887676
28,ranolazine ( n = $nmbr$ ) placebo ( n = $nmbr$ ),C0032042;C0073633;C1696465;C1706408
28,proportion ( % ) of individuals a alirocumab • placebo,C0027361;C0032042;C0237401;C1696465;C1706408;C1709707;C3491162
28,pooled placebo,C0032042;C1696465;C1706408;C1709595;C2349200;C4522255
28,plaeebo,
28,placebo §,C0032042;C1696465;C1706408
28,placebo |,C0032042;C1696465;C1706408
28,placebo to ustekinumab $nmbr$ mgt,C0032042;C1608841;C1696465;C1706408
28,placebo tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0032042;C0213771;C1518422;C1696465;C1706408
28,placebo slope lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C0807955;C1696465;C1706408;C4330985;C4554674
28,placebo secukinumab pooled,C0032042;C1696465;C1706408;C1709595;C2349200;C3179547;C4522255
28,placebo r %,C0032042;C0205090;C0684010;C1696465;C1706408;C2603358
28,placebo plus statin ( n = $nmbr$ ),C0032042;C0332287;C0360714;C1696465;C1706408
28,placebo plus aspirin,C0004057;C0032042;C0332287;C1696465;C1706408
28,placebo patients with events / total,C0030705;C0032042;C0439175;C0439810;C0441471;C1696465;C1706408;C3541888
28,placebo patients with events,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
28,placebo patients / events n,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
28,placebo no diabetes n = $nmbr$,C0011847;C0011849;C0032042;C1696465;C1706408
28,placebo no . of events / total no . ( % ),C0032042;C0439175;C0439810;C0441471;C1696465;C1706408;C3541888
28,placebo no . of events / no .,C0032042;C0441471;C1696465;C1706408;C3541888
28,placebo no . / total no .,C0032042;C0439175;C0439810;C1696465;C1706408
28,placebo no . / total ( % ),C0032042;C0439175;C0439810;C1696465;C1706408
28,placebo no . ( $nmbr$ - y km % ),C0032042;C1696465;C1706408;C3887676
28,placebo n [ $nmbr$,C0032042;C1696465;C1706408
28,placebo n = $nmbr$ subjects,C0032042;C0681850;C1550501;C1696465;C1706203;C1706408;C2349001;C2697811
28,placebo n = $nmbr$ n ( % ),C0032042;C1696465;C1706408
28,placebo n = $nmbr$,C0032042;C1696465;C1706408
28,placebo n / n ( % ),C0032042;C1696465;C1706408
28,placebo n / n,C0032042;C1696465;C1706408
28,placebo n ( rate ) *,C0032042;C0871208;C1521828;C1696465;C1706408
28,placebo n ( rate ) $nmbr$,C0032042;C0871208;C1521828;C1696465;C1706408
28,placebo n ( % ),C0032042;C1696465;C1706408
28,placebo n,C0032042;C1696465;C1706408
28,placebo mortality rate  events per $nmbr$ person - y,C0026565;C0027361;C0032042;C0205848;C0441471;C1696465;C1706408;C2347489;C3541888
28,placebo mean change ( sd ),C0032042;C0392747;C0443172;C0444504;C1696465;C1705241;C1706408;C2347634;C2348143;C2699239;C4319952
28,placebo mean ( n ),C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
28,placebo mean,C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
28,placebo mdi,C0032042;C0993596;C1696465;C1706408;C1839839;C4049613
28,placebo ls means ( n ),C0023668;C0032042;C1696465;C1704970;C1706408
28,placebo km %,C0032042;C1696465;C1706408;C3887676
28,placebo group ( n = $nmbr$ ) ’ j ',C0032042;C0441844;C1696465;C1706408
28,placebo group ( n = $nmbr$ ) f,C0016327;C0032042;C0441848;C1696465;C1706408
28,placebo group ( n = $nmbr$ ),C0032042;C0441848;C1696465;C1706408
28,placebo group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years ),C0027361;C0032042;C0439234;C0441848;C1696465;C1706408;C2347489
28,placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
28,placebo every $nmbr$ weeks ( n = $nmbr$ ),C0032042;C0439230;C1696465;C1706408
28,placebo events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
28,placebo events / patients (,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
28,placebo events / n ( % ),C0032042;C0441471;C1696465;C1706408;C3541888
28,placebo event rate ( n = $nmbr$ )  %,C0032042;C0441471;C0871208;C1521828;C1696465;C1706408;C4019010
28,placebo dr = $nmbr$ ),C0013014;C0031831;C0032042;C1696465;C1706408;C1707664;C2348314;C3540849
28,placebo dn = $nmbr$ ),C0032042;C1333964;C1696465;C1706408;C1707618
28,placebo diabetes n = $nmbr$,C0011847;C0011849;C0032042;C1696465;C1706408
28,placebo croup  n / n ( % ),C0010380;C0032042;C1696465;C1706408
28,placebo arm,C0032042;C0446516;C1696465;C1706408;C3715044;C4553528
28,placebo analysed ( % ),C0032042;C1696465;C1706408
28,placebo allocation,C0032042;C1696465;C1706408;C1706778
28,placebo [ n z $nmbr$ ],C0032042;C1696465;C1706408
28,placebo [ n = $nmbr$ |,C0032042;C1696465;C1706408
28,placebo [ n = $nmbr$ ],C0032042;C1696465;C1706408
28,placebo / simva,C0032042;C1696465;C1706408
28,placebo / rosu vastatin,C0032042;C1099881;C1696465;C1706408
28,placebo /,C0032042;C1696465;C1706408
28,placebo - vonoprazan $nmbr$ - vonoprazan $nmbr$,C0032042;C1696465;C1706408;C4080009
28,placebo - vonoprazan $nmbr$,C0032042;C1696465;C1706408;C4080009
28,placebo - dexlansoprazole,C0032042;C1696465;C1706408;C2348248
28,placebo - carisbamate $nmbr$ mg - carisbamate $nmbr$ mg,C0032042;C1319635;C1696465;C1706408;C1871983
28,placebo + statin ( n = $nmbr$  $nmbr$ ),C0032042;C0360714;C1696465;C1706408
28,placebo + statin,C0032042;C0360714;C1696465;C1706408
28,placebo + pioglitazone ( n = $nmbr$ ),C0032042;C0071097;C1696465;C1706408
28,placebo + mtx ( n = $nmbr$ ),C0025677;C0032042;C1417487;C1696465;C1706408
28,placebo + mtx,C0025677;C0032042;C1417487;C1696465;C1706408
28,placebo ( » = $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( « = $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( w = $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n — $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n   =   $nmbr$ ) b,C0032042;C1696465;C1706408
28,placebo ( n   =   $nmbr$ ) a,C0032042;C1696465;C1706408
28,placebo ( n   =   $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n   =   $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n   =   $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n   = $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n   = $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n z $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n [ $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n = l $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ o ),C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ l ),C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ i $nmbr$ ),C0021966;C0032042;C0221138;C0369718;C0441922;C1696465;C1706408
28,placebo ( n = $nmbr$ * ),C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ ) †,C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ ) n ( % ),C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ ) i -,C0021966;C0032042;C0221138;C0369718;C0441922;C1696465;C1706408
28,placebo ( n = $nmbr$ ) ',C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ )  n ( % ),C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n = $nmbr$,C0032042;C1696465;C1706408
28,placebo ( n : $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n - $nmbr$ . $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n - $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( n $nmbr$ $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( lsm ),C0032042;C1696465;C1706408
28,placebo ( events / n ( % ) ),C0032042;C0441471;C1696465;C1706408;C3541888
28,placebo ( dm - vs . dm + ),C0011816;C0032042;C1696465;C1706408;C3250443
28,placebo ( % ),C0032042;C1696465;C1706408
28,placebo ( $nmbr$ = $nmbr$ ),C0032042;C1696465;C1706408
28,placebo ( $nmbr$  $nmbr$ . $nmbr$ % ),C0032042;C1696465;C1706408
28,placebo %,C0032042;C1696465;C1706408
28,placebo $nmbr$ yr km %,C0032042;C0439234;C1696465;C1706408;C3887676
28,placebo $nmbr$ year km ( % ),C0032042;C0439234;C0439508;C1696465;C1706408;C3887676
28,placebo $nmbr$ o $nmbr$,C0032042;C1696465;C1706408
28,placebo $nmbr$ / $nmbr$,C0032042;C1696465;C1706408
28,placebo $nmbr$ . $nmbr$ pt yrs,C0032042;C0032743;C0699718;C1696465;C1706408
28,placebo $nmbr$ . $nmbr$,C0032042;C1696465;C1706408
28,placebo $nmbr$  $nmbr$,C0032042;C1696465;C1706408
28,placebo $nmbr$,C0032042;C1696465;C1706408
28,placebo  n   =   $nmbr$,C0032042;C1696465;C1706408
28,placebo  n = l $nmbr$,C0032042;C1696465;C1706408
28,placebo  n = i $nmbr$,C0021966;C0032042;C0221138;C0369718;C0441922;C1696465;C1706408
28,placebo  n = $nmbr$,C0032042;C1696465;C1706408
28,placebo  n / n ( % ),C0032042;C1696465;C1706408
28,placebo  n *,C0032042;C1696465;C1706408
28,placebo  n ( rate ),C0032042;C0871208;C1521828;C1696465;C1706408
28,placebo  n ( % ),C0032042;C1696465;C1706408
28,placebo  n,C0032042;C1696465;C1706408
28,placebo  events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
28,placebo  ( n = $nmbr$ ),C0032042;C1696465;C1706408
28,placebo  % > ( n / n ),C0032042;C1696465;C1706408
28,placebo  % ( n / n ),C0032042;C1696465;C1706408
28,placebo,C0032042;C1696465;C1706408
28,patients in the placebo group  nt - probnp values were reported for $nmbr$ patients,C0030705;C0032042;C0042295;C0441833;C0588446;C0669479;C0687744;C0754710;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
28,p   vs . placebo,C0032042;C0369773;C1696465;C1706408;C2603361
28,p vs placebo,C0032042;C0369773;C1696465;C1706408;C2603361
28,p value versus placebo,C0032042;C1696465;C1706408;C1709380
28,p $nmbr$ vs placebo,C0032042;C0369773;C1696465;C1706408;C2603361
28,or placebo treatment,C0032042;C0039798;C0087111;C1522326;C1533734;C1696465;C1705169;C1706408;C3538994;C3887704
28,omega - $nmbr$ fatty acid vs placebo least - squares mean ( $nmbr$ % cl ),C0015684;C0023189;C0032042;C0444504;C0596019;C1696465;C1706408;C1719844;C2347634;C2348143
28,nominal p vs placebo,C0032042;C1696465;C1706408
28,no laba  no ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0815320;C1696465;C1706408;C4551720
28,no . of patients ( indacaterol / placebo ),C0030705;C0032042;C1696465;C1706408;C1722260
28,n ( indacaterol $nmbr$ ug / indacaterol $nmbr$ ug / placebo ),C0032042;C0369718;C0441922;C1319635;C1696465;C1706408;C1722260
28,mtx plus placebo,C0025677;C0032042;C0332287;C1417487;C1696465;C1706408
28,ls mean difference vs placebo ( $nmbr$ % ci ),C0008107;C0023668;C0032042;C0444504;C1696465;C1705241;C1705242;C1706408;C2347634;C2348143;C3259781
28,ls mean difference ( se ) vs placebo,C0023668;C0032042;C0036919;C0444504;C1696465;C1705241;C1705242;C1706408;C2347634;C2348143
28,ls mean [ $nmbr$ % ci ] treatment difference vs placebo,C0008107;C0023668;C0032042;C0039798;C0087111;C0444504;C1522326;C1533734;C1696465;C1705169;C1705241;C1705242;C1706408;C2347634;C2348143;C3259781;C3538994;C3887704
28,laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C1696465;C1706408
28,ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0815320;C1696465;C1706408;C4551720
28,i placebo ( n = $nmbr$ ),C0021966;C0032042;C0221138;C1696465;C1706408
28,i placebo,C0021966;C0032042;C0221138;C1696465;C1706408
28,hba $nmbr$ c  difference vs placebo ( $nmbr$ % cl ),C0019016;C0032042;C0596019;C1696465;C1705241;C1705242;C1706408;C1825777;C3538758
28,figure $nmbr$ least squares ( ls ) mean differences between ro ﬂ umilast and placebo in ( a ) pre - and ( b ) postbronchodilator fev $nmbr$ in the itt population and subpopulations . copd  chronic obstructive pulmonary disease  fev $nmbr$  forced expiratory volume in $nmbr$ s  ics  inhaled corticosteroid  itt  intent to treat  laba  long - acting b $nmbr$ - agonist .,C0001617;C0004048;C0016529;C0023189;C0023668;C0024117;C0032042;C0032659;C0035826;C0040363;C0041260;C0079613;C0087111;C0162425;C0205166;C0332152;C0444504;C0740175;C0815320;C1257890;C1283828;C1292734;C1306036;C1413096;C1522326;C1550453;C1696465;C1704930;C1705241;C1705242;C1706317;C1706408;C1869853;C1883351;C2257086;C2347634;C2348143;C2599594;C2987048;C2987634;C3536709;C3669034;C3714541;C3890007;C4048375;C4551720
28,feno placebo ( lsm ),C0032042;C1696465;C1706408
28,feno,
28,favors ffa / i favors placebo,C0015688;C0021966;C0032042;C0221138;C0309049;C1696465;C1706408
28,f $nmbr$ vs placebo,C0016327;C0032042;C1696465;C1706408
28,esrd on placebo ( % ),C0022661;C0032042;C0035078;C1696465;C1706408;C2316810
28,duration from clopidogrel / placebo to pci  min ( median  iqr ),C0032042;C0070166;C0449238;C0549183;C0702093;C0876920;C1524029;C1696465;C1706408;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
28,dm - ( aliskiren vs . placebo ),C0011816;C0032042;C1120110;C1696465;C1706408;C3250443
28,dm + ( aliskiren vs . placebo ),C0011816;C0032042;C1120110;C1696465;C1706408;C3250443
28,differences between indacaterol + tiotropium versus tiotropium + placebo,C0032042;C0213771;C1696465;C1705241;C1705242;C1706408;C1722260
28,difference vs placebo * *,C0032042;C1696465;C1705241;C1705242;C1706408
28,difference vs placebo ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
28,difference vs placebo ',C0032042;C1696465;C1705241;C1705242;C1706408
28,difference vs placebo  % [ $nmbr$ % cl ]  p,C0032042;C0596019;C1696465;C1705241;C1705242;C1706408
28,difference vs placebo,C0032042;C1696465;C1705241;C1705242;C1706408
28,difference vs . placebo  % ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408
28,difference vs . placebo,C0032042;C1696465;C1705241;C1705242;C1706408
28,difference from placebo ¥,C0032042;C1696465;C1705241;C1705242;C1706408
28,difference from placebo * ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
28,difference from placebo ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408
28,difference from placebo ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
28,difference from placebo,C0032042;C1696465;C1705241;C1705242;C1706408
28,difference ( n - $nmbr$ fa - placebo ) lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C1696465;C1705241;C1705242;C1706408;C4330985;C4554674
28,difference ( a ) vs placebo ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408
28,dapagliflozin placebo no . of events / no . of patients,C0030705;C0032042;C0441471;C1696465;C1706408;C2353951;C3541888
28,copd - placebo ( n = $nmbr$ ),C0024117;C0032042;C1412502;C1696465;C1706408;C3714496
28,copd - placebo ( $nmbr$ pt ) n . ( % ),C0024117;C0032042;C0032743;C0699718;C1412502;C1696465;C1706408;C3714496
28,comparison with placebo ( mean,C0032042;C0444504;C1696465;C1706408;C1707455;C2347634;C2348143
28,comparison with placebo,C0032042;C1696465;C1706408;C1707455
28,chf on placebo ( % ),C0018802;C0032042;C1696465;C1706408
28,baseline to eom placebo ( n = $nmbr$ ),C0032042;C0168634;C0241886;C1442488;C1696465;C1706408
28,b digit symbol substitution  omega - $nmbr$ fatty acids vs placebo,C0015684;C0032042;C0582802;C0679214;C1555721;C1696465;C1698987;C1706204;C1706408;C1719844;C3241971
28,assigned to placebo,C0032042;C1516050;C1552601;C1696465;C1706408
28,aspirin plus placebo ( n = $nmbr$ ),C0004057;C0032042;C0332287;C1696465;C1706408
28,any placebo,C0032042;C1696465;C1706408
28,ambulatory sbp  difference vs placebo ( $nmbr$ % cl ),C0032042;C0085805;C0439841;C0596019;C1696465;C1705241;C1705242;C1706408
28,active   versus   placebo,C0032042;C0205177;C1696465;C1706408;C3853793;C3888249
28,active vs placebo,C0032042;C0205177;C1696465;C1706408;C3853793;C3888249
28,absolutedifferenceestimate vs placebo ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1706408;C3259781
28,absolute difference estimate vs placebo ( $nmbr$ % ci ),C0008107;C0032042;C0750572;C1549031;C1696465;C1706408;C3259781
28,abbreviations : ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by height in meters squared )  dm  diabetes mellitus  hba $nmbr$ c  hemoglobin a $nmbr$ c  hmg - coa  $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a . asome subjects took more than $nmbr$ oral anti - dm drug in addition to metformin  and thus the total number of concomitant oral anti - dm drugs in the columns exceed the “ n ” values in the colesevelam hydrochloride and placebo group headings . bsulfonylureas include chlorpropamide  glibenclamide  glimepiride  glipizide  and tolazamide . cthiazolidinediones include pioglitazone  pioglitazone hydrochloride  rosiglitazone  and rosiglitazone maleate . d - glucosidase inhibitors include acarbose or miglitol .,C0000723;C0005910;C0008287;C0009226;C0011816;C0011849;C0013227;C0017628;C0017642;C0019016;C0019046;C0022709;C0025598;C0029167;C0032042;C0040372;C0042295;C0043100;C0050393;C0061323;C0066535;C0073187;C0175795;C0205120;C0205172;C0289313;C0304289;C0332173;C0332257;C0332287;C0332849;C0369718;C0439209;C0441074;C0441833;C0441922;C0442027;C0444686;C0489786;C0521115;C0541154;C0681850;C0687744;C0700307;C0795660;C0872972;C1185738;C1254351;C1257890;C1305855;C1305866;C1441506;C1512211;C1515187;C1519504;C1550501;C1552595;C1552866;C1696465;C1705104;C1705428;C1705429;C1706132;C1706203;C1706408;C1825777;C2349001;C2697811;C2700399;C3250443;C3538758;C4288115;C4484261;C4521986;C4553328
28,a $nmbr$ vs placebo,C0032042;C1696465;C1706408
28,[ } ifrerence vs . placebo  % ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1706408
28,= placebo  eze : tes ( fc j > $nmbr$ rr $nmbr$ definition ) .,C0032042;C0076172;C1422793;C1550452;C1696465;C1704788;C1706408;C2983605;C3539107;C3888054;C4554402
28,- $nmbr$ placebo,C0032042;C1696465;C1706408
28,* plus – minus values are means ± sd . percentages may not total $nmbr$ because of rounding . the body - mass index is the weight in kilograms divided by the square of the height in meters . to convert the values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ace denotes angiotensin - converting enzyme  cabg coronary - artery bypass grafting  nt - probnp n - terminal pro - b – type natriuretic peptide  nyha new york heart association  and pci percutaneous coro - nary intervention . † race was reported by the investigators . ‡ one patient in nyha class i was mistakenly included in the placebo group . § this category includes any angina - like symptoms at any time in the past  with no confirmation of diagnosis of coro - nary heart disease required . ¶ possible scores range from $nmbr$ to $nmbr$  with lower scores indicating a better quality of life . ∥ anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women . * * nt - probnp levels are influenced by a variety of factors  including age  sex  body - mass index  and renal function . no clinically useful normal range has been established . † † some patients were taking both loop and thiazide diuretics .,C0001779;C0002871;C0004083;C0005893;C0005910;C0009253;C0010055;C0010294;C0012802;C0018787;C0022709;C0025266;C0027976;C0030705;C0032042;C0034510;C0035173;C0036864;C0040223;C0040363;C0041260;C0042295;C0043100;C0043210;C0043237;C0079399;C0086715;C0184661;C0205088;C0205120;C0205447;C0232804;C0243161;C0332126;C0332149;C0332257;C0332272;C0332288;C0332306;C0332307;C0332490;C0332849;C0376558;C0439092;C0439165;C0439175;C0439194;C0439209;C0439241;C0439267;C0439810;C0439849;C0441074;C0441833;C0441889;C0441994;C0443211;C0445022;C0449820;C0475211;C0489786;C0521091;C0522523;C0578022;C0596306;C0596672;C0683312;C0687744;C0699792;C0804628;C0814287;C0858277;C0886296;C1000483;C1144709;C1257890;C1272684;C1273869;C1275491;C1281911;C1292769;C1305855;C1305866;C1314687;C1317554;C1444637;C1449832;C1452534;C1514721;C1514873;C1515187;C1518422;C1519504;C1522384;C1547052;C1548802;C1549488;C1552595;C1552866;C1561533;C1561535;C1696465;C1704788;C1704970;C1705104;C1705314;C1705315;C1705428;C1705429;C1705910;C1706408;C1706779;C1709908;C1719797;C1882084;C1883351;C1883525;C2003888;C2346866;C2348147;C2362652;C2699239;C2700399;C2709270;C2825907;C2911648;C3537020;C3539106;C3541383;C3542016;C3827682;C3853635;C3889152;C3889287;C4049621;C4050156;C4283901;C4284014;C4284038;C4284302;C4522046;C4554633
28,( tiotropium n = $nmbr$  placebo n =,C0032042;C0213771;C1696465;C1706408
28,( tiotropium n = $nmbr$  placebo n,C0032042;C0213771;C1696465;C1706408
28,$nmbr$ placebo n = $nmbr$,C0032042;C1696465;C1706408
28,$nmbr$ placebo ( n = $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
28,$nmbr$ placebo,C0032042;C1696465;C1706408
28,$nmbr$ mg / day - placebo,C0032042;C0439422;C1696465;C1706408
28,$nmbr$ - year rates in placebo groups,C0032042;C0439234;C0439508;C0441833;C0687744;C0871208;C1257890;C1519504;C1521828;C1552839;C1696465;C1705428;C1705429;C1706408
27,tnfi exposed,C0332157
27,tnfi - exposed †,C0332157
27,tnf antagonist - exposed,C0231491;C0332157;C1448177
27,previous tnf antagonist exposure  n ( % ),C0205156;C0231491;C0274281;C0332157;C1448177;C1552607
27,ltg - exposed,C0332157;C1420817;C4521367;C4521846
27,exposure,C0274281;C0332157
27,exposed ( n = $nmbr$ ),C0332157
27,exposed,C0332157
26,participated in a previous febuxostat studyb  n ( % ),C0205156;C0249529;C1552607
26,febuxostat - febuxostat / lesinurad $nmbr$ - febuxostat / lesinurad $nmbr$,C0249529;C3886073
26,febuxostat - febuxostat / lesinurad $nmbr$,C0249529;C3886073
26,febuxostat,C0249529
26,completed prior febuxostat studya,C0205197;C0249529;C0332152;C2826257;C3854010
26,completed previous febuxostat study,C0205156;C0249529;C1552607;C2348557
25,use of ticagrelor,C1524063;C1999375
25,use of systemic glucocorticoid at random -,C0017710;C0034656;C0205373;C0439605;C1524063
25,use of proton inhibitors  n ( % ),C0033727;C0243077;C1524063
25,use of parenteral antithrombotic,C0030547;C1524063;C4522267
25,use of methotrexate at randomization —,C0025677;C0034656;C1524063
25,use of low - dose aspirin ( < $nmbr$ mg daily ),C0024671;C0026410;C0332173;C0439269;C1524063;C1960952;C2346927;C2608320;C4321396;C4521761
25,use of low - dose aspirin ( < $nmbr$,C1524063;C2608320
25,use of diuretics  n ( % ),C0012798;C1524063
25,postoperative use of p - blocker,C0032790;C1524063
25,new use of gpa,C0205314;C1524063;C3495801;C4553145
25,menopausal status and use of ht,C0018510;C0677607;C1513126;C1524063
25,menopausal status and use of hrt ( % ) y,C0282402;C1513126;C1524063
25,diabetes with use of oral diabetes drugs,C0011847;C0011849;C0020616;C0029167;C0175795;C0304289;C0442027;C1524063;C4521986
25,diabetes with no use of diabetes drugs,C0020616;C1524063
25,continued use of gpa,C0549178;C1524063;C3495801;C4553145
24,ocs use,C0042153;C0457083;C1947944
24,ocs,
24,oam use [ n ( % ) ],C0042153;C0457083;C1947944
24,oad use  n ( % ),C0042153;C0457083;C1947944
24,maintenance ocs use  n ( % ),C0024501;C0042153;C0369718;C0441922;C0457083;C1947944
24,$nmbr$ oam,
24,$nmbr$ oad,
23,tobacco user,C3853727
23,tobacco use — no . ( % ),C0040335;C0543414;C0841002;C3853727
23,tobacco use ( % ),C0040335;C0543414;C0841002;C3853727
23,tobacco use  yes  n ( % ),C0040335;C0543414;C0841002;C1549445;C1705108;C1710701;C3853727
23,tobacco use  n ( % ),C0040335;C0543414;C0841002;C3853727
23,tobacco use,C0040335;C0543414;C0841002;C3853727
23,tobacco abuse,C0040336
23,prior tobacco use  n ( % ),C0040335;C0332152;C0543414;C0841002;C2826257;C3853727
23,non - / ex - tobacco user,C1518422;C3853727
23,no current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
23,current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
23,baseline tobacco use,C0040335;C0168634;C0543414;C0841002;C1442488;C3853727
22,glucose in urine    ≥ $nmbr$ +,C0004076
22,dosing,
22,$nmbr$ - h plasma glucose during ogtt ( mmol / l ),C0029161;C0202042;C0455280;C2827804
21,fasting plasma glucose — mg / dl,C0015663;C0202042;C0439269;C0455280
21,fasting plasma glucose categories  n ( % ),C0015663;C0202042;C0455280;C0683312
21,fasting plasma glucose *,C0015663;C0202042;C0455280
21,fasting plasma glucose ( mg / dl ) $nmbr$,C0015663;C0202042;C0439269;C0455280
21,fasting plasma glucose ( mg / dl ),C0015663;C0202042;C0439269;C0455280
21,fasting plasma glucose $nmbr$ medan,C0015663;C0202042;C0455280
21,fasting plasma glucose  mg / dl  mean ( sd ) b,C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
21,fasting plasma glucose  mg / dl  mean ( sd ),C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
21,fasting plasma glucose  mg / dl,C0015663;C0202042;C0439269;C0455280
21,fasting plasma glucose,C0015663;C0202042;C0455280
21,fascng plasma glucose a medan,C0202042;C0455280
21,casual plasma glucose ( mg / dl ),C0202042;C0439269;C0455280
21,baseline fasting plasma glucose,C0015663;C0168634;C0202042;C0455280;C1442488
21,$nmbr$ - hr plasma glucose — mg / dl,C0202042;C0439269;C0455280
20,who / idf impaired fasting glucose,C1272092
20,impaired glucose tolerance or impaired fasting glucose — no . ( % ),C0271650;C1272092
20,impaired glucose tolerance or impaired fasting glucose,C0271650;C1272092
20,impaired fasting glucose §,C1272092
20,impaired fasting glucose level ( n = $nmbr$ ),C0202045;C0221099;C0441889;C0456079;C1272092;C1547707;C2946261
20,impaired fasting glucose,C1272092
20,glucose test,C0337438;C0595310
20,both impaired glucose tolerance and impaired fasting glucose tolerance — no .,C0013220;C0015663;C0020963;C0220929;C0231197;C0271650;C1272092;C1704410
19,salmeterol / fluticasone $nmbr$ / $nmbr$   μ g b . i . d .,C0086706;C0939232
19,salmeterol / fluticasone $nmbr$ / $nmbr$ pg twice daily,C0030827;C0072225;C0585361;C0939232;C1266240
19,salmeterol - fluticasone group ( n = $nmbr$ ),C0441848;C0939232
19,fluticasone furoate  n = $nmbr$,C1948374
19,fluticasone - salmeterol ( n = $nmbr$ ),C0939232
19,fluticasone - fluticasone / salmeterol,C0939232
18,fasting blood glucose > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ),C0428568;C0439269;C1261430;C1532563
18,fasting blood glucose > $nmbr$ mg / dl,C0428568;C0439269;C1261430
18,fasting blood glucose ( mg / dl ),C0428568;C0439269;C1261430
18,fasting blood glucose  mean ( sd )  mg / dlt,C0024671;C0026410;C0428568;C0439269;C0444504;C1261430;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
18,fasting blood glucose,C0428568;C1261430
18,blood - glucose control,C3267174
17,red blood cell counting  $nmbr$ / l,C0005767;C0005768;C0022827;C0229664;C0332575;C0750480;C1260956;C1705566;C4049926
17,blood pressure at baseline :,C0005767;C0005768;C0005823;C0168634;C0229664;C0443150;C1271104;C1272641;C1442488
17,blood bilirubin increased,C0005437;C0005767;C0005768;C0205217;C0229664;C0442805
17,baseline diastolic blood,C0005767;C0005768;C0012000;C0168634;C0229664;C1442488
17,any blood,C0005767;C0005768;C0229664
16,systolic blood pressure ( change from baseline ),C0392747;C0443172;C1705241;C4274438;C4319952
16,pulsed blood pressure,C0232108
16,baseline systolic blood pressure,C4274438
15,weight  kg blood pressure  mm hg,C0005823;C0005910;C0022718;C0043100;C0439209;C0439475;C1271104;C1272641;C1305866;C1705104;C4054209
15,treatment with any blood - pressure -,C0005823;C0033095;C0039798;C0087111;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C3538994;C3887704;C4284008
15,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0005823;C0030705;C0439475;C0445204;C1271104;C1272641;C1512693;C1550543
15,lvh by ecgt blood pressure  mm hg,C0005823;C0149721;C0439475;C1271104;C1272641
15,body - mass index : ! : blood pressure — mm hg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
15,blood pressure — mmhg,C0005823;C0439475;C1271104;C1272641
15,blood pressure — mm hg,C0005823;C0439475;C1271104;C1272641
15,blood pressure while seated — mm hg,C0005823;C0277814;C0439475;C1271104;C1272641;C1283233
15,blood pressure eontrolt,C0005823;C1271104;C1272641
15,blood pressure at target level ( % ) §,C0005823;C0441889;C0456079;C1271104;C1272641;C1521840;C1547707;C2946261;C2986546
15,blood pressure at entry ( mm   hg ),C0005823;C0439475;C1271104;C1272641;C1705654
15,blood pressure > $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
15,blood pressure < $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
15,blood pressure < $nmbr$ / $nmbr$ mmhg  n ( % ),C0005823;C0439475;C1271104;C1272641
15,blood pressure - lowering treatment,C0005823;C0033095;C0039798;C0087111;C0441994;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704;C4284008
15,blood pressure ( mmhg ),C0005823;C0439475;C1271104;C1272641
15,blood pressure ( mm hg ) *,C0005823;C0439475;C1271104;C1272641
15,blood pressure ( mm hg ),C0005823;C0439475;C1271104;C1272641
15,blood pressure ( % ),C0005823;C1271104;C1272641
15,blood pressure  mmhg systolic,C0005823;C0039155;C0439475;C1271104;C1272641
15,blood pressure  mmhg,C0005823;C0439475;C1271104;C1272641
15,blood pressure  mm hg,C0005823;C0439475;C1271104;C1272641
15,blood pressure  mm,C0005823;C1271104;C1272641;C4330985;C4554674
15,blood pressure,C0005823;C1271104;C1272641
15,arterial blood pressure  mm hg,C0439475;C1272641
14,rosigiitazone ± oad,
14,previous oral glucose - lowering agents  % of patients,C0205156;C0441994;C0600419;C1552607;C1955477;C2003888
14,previous oad ( % ),C0205156;C1552607
14,previous limb or foot amputation,C0015385;C0188605;C0205156;C1552607
14,previous aorta - femoral or lower extremity bypass surgery  pta of iliac  or infrainguinal artery,C0003483;C0003842;C0015811;C0020889;C0187763;C0205156;C0226004;C0741847;C1552607;C3274435
14,oralb,
14,or $nmbr$,
14,oad,
14,glulisine + oad,
14,giimepiride ± oad,
13,smoking status  n ( % ) former,C0205156;C0750523;C1519386
13,smoker ( current / former ),C0205156;C0337664;C0521116;C0750523;C1705970
13,previous exposure to a vitamin k antagonist — no . ( % ) current or former never,C0042839;C0087161;C0205156;C0231491;C0332157;C0521116;C0597277;C0750523;C1552607;C1705970;C1708601;C2003901;C2825076;C3714656
13,previous a - blocker use,C0042153;C0205156;C0457083;C1552607;C1947944
13,previous a - blocker,C0205156;C1552607
13,former smoking,C0037369;C0205156;C0453996;C0750523;C1881674
13,former or never diabetes,C0011847;C0011849;C0205156;C0750523;C2003901
13,former or never,C0205156;C0750523;C2003901
13,former n z $nmbr$,C0205156;C0750523
13,former / current smoker ( n = $nmbr$ $nmbr$ ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
13,former / current smoker  n ( % ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
13,former ( n   = $nmbr$  $nmbr$ ),C0205156;C0750523
13,former  n ( % ),C0205156;C0750523
13,former,C0205156;C0750523
13,ever smoked ( current / former ),C0037366;C0205156;C0439994;C0521116;C0750523;C1705970;C1881674
13,b - blocker,
13,a - blocker,
12,worsening heart failure,C0018801;C0018802;C0332271;C1457868;C1546960;C4554158
12,time since diagnosis of heart failure,C0011900;C0018801;C0018802;C0040223;C1704338;C1704656;C3541383;C4554158
12,score on the minnesota living with heart failure scaled,C0018801;C0018802;C0026183;C0175659;C0349674;C0449820;C0595998;C1947916;C4050231;C4520849;C4551704;C4554158
12,recurrent heart failure,C0018801;C0018802;C1455761;C2945760;C4554158
12,priorheartfailure  %,
12,prior heart failure — no . { % ),C0018801;C0018802;C0332152;C2826257;C4554158
12,prior heart failure yes,C0018801;C0018802;C0332152;C1549445;C1705108;C1710701;C2826257;C4554158
12,prior heart failure ( n = $nmbr$  $nmbr$ ),C0018801;C0018802;C0332152;C2826257;C4554158
12,prior heart failure  n / n ( % ),C0018801;C0018802;C0332152;C2826257;C4554158
12,prior heart failure  n ( % ),C0018801;C0018802;C0332152;C2826257;C4554158
12,prior heart failure  %,C0018801;C0018802;C0332152;C2826257;C4554158
12,prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
12,previous hospital admission for heart failure,C0018801;C0018802;C0184666;C0205156;C1552607;C4554158
12,participants without heart failure,C0018801;C0018802;C0679646;C4554158
12,participants with heart failure,C0018801;C0018802;C0679646;C4554158
12,not hospitalized for heart failure in the year prior to study enrollment,C0018801;C0018802;C0332152;C0701159;C1516879;C1518422;C1696073;C3258203;C3888021;C4554158
12,no prior heart failure ( n = $nmbr$  $nmbr$ ),C0018801;C0018802;C0332152;C2826257;C4554158
12,no prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
12,no heart failure,C0018801;C0018802;C4554158
12,mortality  shock or congestive heart failure within $nmbr$ days,C0018802;C0026565;C0026566;C0036974;C0439228
12,medical history of cv disease or heart failure  n ( % ),C0007222;C0018801;C0018802;C0262926;C4554158
12,hospitalized heart failure,C0018801;C0018802;C0701159;C4554158
12,hospitalized for heart failure during that time period,C0018801;C0018802;C0701159;C1948053;C4554158
12,hospitalized / fatal heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
12,hospital admission for heart failure,C0018801;C0018802;C0184666;C4554158
12,histor y of heart failure,C0018801;C0018802;C4554158
12,histor y of congestive heart failure — no . ( % ),C0018802
12,heart failure ‡,C0018801;C0018802;C4554158
12,heart failure — no . / total no . ( % ),C0018801;C0018802;C0439175;C0439810;C4554158
12,heart failure — no . ( % ),C0018801;C0018802;C4554158
12,heart failure history,C0018801;C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4554158
12,heart failure criteria met,C0018801;C0018802;C0243161;C0428210;C1550543;C4317104;C4554158
12,heart failure cause,C0015127;C0018801;C0018802;C1524003;C4554158
12,heart failure at entry  no . ( % ),C0018801;C0018802;C1705654;C4554158
12,heart failure *,C0018801;C0018802;C4554158
12,heart failure ( treated / hospitalized / fatal ),C0018801;C0018802;C0701159;C1302234;C1522326;C1705232;C4554158
12,heart failure  no . / total no . ( % ),C0018801;C0018802;C0439175;C0439810;C4554158
12,heart failure  n ( % ),C0018801;C0018802;C4554158
12,heart failure  hospitalized or fatal,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
12,heart failure,C0018801;C0018802;C4554158
12,fatal & nonfatal hospitalized heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
12,data are mean ( sd ) or n ( % ) . ace = angiotensin - converting enzyme  arb = angiotensin - receptor blocker . chf = congestive heart failure . * any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery .,C0004057;C0018802;C0022709;C0033727;C0034787;C0038894;C0038895;C0042153;C0205171;C0369286;C0369718;C0439228;C0441922;C0441932;C0444504;C0457083;C0543467;C0564385;C1274039;C1511726;C1514873;C1622222;C1720467;C1947944;C2347634;C2348143;C2699239;C3245479;C3714741;C3888198;C4528284
12,congestive heart failure †,C0018802
12,congestive heart failure — no . ( % ) | |,C0018802
12,congestive heart failure — no . ( % ) |,C0018802
12,congestive heart failure — no . ( % ),C0018802
12,congestive heart failure — %,C0018802
12,congestive heart failure §,C0018802
12,congestive heart failure at randomisation,C0018802;C0034656
12,congestive heart failure ( definite ),C0018802;C0439544;C1704787
12,congestive heart failure ( chf ) ( in past $nmbr$ weeks ),C0018802;C2987125
12,congestive heart failure ( < $nmbr$ wk ),C0018802;C0332174;C0439230
12,congestive heart failure  n ( % ),C0018802
12,congestive heart failure,C0018802
12,combined cardiac failure  cardiomyopathy or other cardiac disorder  n ( % ) luts severity  n ( % ),C0018787;C0018799;C0018801;C0018802;C0205195;C0439793;C0521117;C0522510;C0574785;C0878544;C1292730;C1522601
12,chronic heart failure class ii - iii,C0018802;C0264716;C0439070;C0441886;C0441887;C1705160;C1710602;C2698968;C2698969;C4082587
12,chronic heart failure,C0018802;C0264716
12,cause of heart failure — no . ( % ),C0015127;C0018801;C0018802;C1524003;C4554158
12,cause of heart failure,C0015127;C0018801;C0018802;C1524003;C4554158
12,cardiac failure —,C0018801;C0018802
12,cardiac failure §,C0018801;C0018802
12,cardiac failure *,C0018801;C0018802
12,cardiac failure  n ( % ),C0018801;C0018802
12,cardiac failure,C0018801;C0018802
12,baseline heart failure severity amongthose with priorheartfailure  %,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C4554158
11,type of tnf failure  n ( % ) b,C0231174;C0332307;C0680095;C1547052;C3887647
11,type of tnf antagonist failure  n ( “ / o ) ”,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
11,type of tnf antagonist failure  n ( % ) ' ’,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
11,tnf antagonist - failure population ( n - $nmbr$ ),C0032659;C0231174;C0231491;C0680095;C1257890;C1448177
11,tnf - failure patientsa,C0231174;C0680095;C1448177
11,prior immunnosupressive failure but no anti - tnf failure,C0231174;C0332152;C0680095;C1448177;C2826257
11,prior anti - tnf failure,C0231174;C0332152;C0680095;C1448177;C2826257
11,heat failure,C0018837;C0231174;C0680095
11,failure,C0231174;C0680095
11,any prior anti - tnf treatment failure,C0162643;C0231174;C0235828;C0332152;C0521983;C0680095;C1448177;C1514463;C1547544;C2826257
11,> $nmbr$ failure,C0231174;C0680095
10,question $nmbr$ ( fatigue / tiredness ),C0015672;C1522634;C3463815;C4050243;C4553152;C4554645
10,fatigue ( range $nmbr$ - $nmbr$ ),C0015672;C1514721;C2348147;C3463815;C3542016;C4050243;C4554645
10,fatigue,C0015672;C3463815;C4050243;C4554645
10,facit - fatigue . mean $nmbr$ sd ( range $nmbr$ - $nmbr$ ),C0015672;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3463815;C3476791;C3542016;C4050243;C4554645
10,energy / fatigue,C0015672;C0424589;C0542479;C1442080;C3463815;C4050243;C4330907;C4554645
9,value for nteraction,C1522609
9,value *,C1522609
9,value,C1522609
9,troponin or ckmb value,C0010290;C0041199;C0523584;C1522609
9,proportion of predicted normal fev $nmbr$ value   §,C0086715;C0520835;C0681842;C1522609;C1709707;C1882327;C3714541
9,post - bronchodilator fev $nmbr$  reversibility percentage of baseline value,C0168634;C0439165;C0449261;C1442488;C1522609;C1549488;C1561533;C2599594;C3714541
9,or_value,C1522609
9,or $nmbr$ _value,C1522609
9,l ’ - value ’,C0439394;C1522609;C1706495;C3642217
9,fev $nmbr$ — % of predicted value,C0681842;C1522609;C1882327;C3714541
9,fev $nmbr$ ( % of predicted value ),C0681842;C1522609;C1882327;C3714541
9,d - value,C1522609
9,baseline value,C0168634;C1442488;C1522609
9,/ ’ - value $nmbr$ ’,C1522609
9,/ ’ - value,C1522609
8,valve replacement / repair with or without cabg,C0010055;C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
8,valve repair / replacement with or without cabg,C0010055;C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
8,valve repair / replacement only,C0035139;C0043240;C0184252;C0205171;C0374711;C0559956;C1186983;C1555302;C1704414;C1720467;C3888056;C4319951;C4553149
8,cabg or valve,C0010055;C0184252;C1186983;C1704414;C3888056
7,use of cgm interaction test p - value ^ =,C0022885;C0039593;C0392366;C0456984;C1515976;C1524063;C1704675;C1709380;C3831328;C4318744
7,univariate p - value,C1709380
7,test for interaction ( p value ),C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C1709380;C3831328;C4318744
7,subgroup p value 本,C1079230;C1515021;C1709380
7,subgroup p value !,C1079230;C1515021;C1709380
7,subgroup p - value $nmbr$,C1079230;C1515021;C1709380
7,subgroup by treatment interaction p - value,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
7,strata modelb hr  $nmbr$ % ci  p value,C0008107;C1709380;C3259781
7,rr ( $nmbr$ aci ) [ p value ],C0814206;C1510682;C1709380;C2346870;C4050575;C4554402
7,p — value for interaction,C1704675;C1709380
7,p ‐ value *,C1709380
7,p ‐ value,C1709380
7,p   values of interaction,C1704675;C1709380
7,p   value for interaction,C1704675;C1709380
7,p   value,C1709380
7,p values,C1709380
7,p value 十,C1709380
7,p value ∥,C1709380
7,p value § ® ( w,C1709380
7,p value § ( < $nmbr$ vs . > = $nmbr$ years ),C0439234;C1709380
7,p value interaction,C1704675;C1709380
7,p value heart failure vs no heart failure,C0018801;C0018802;C1709380;C4554158
7,p value for trend across tertiles,C1521798;C1709380;C4554533
7,p value for trend *,C1521798;C1709380;C4554533
7,p value for trend,C1521798;C1709380;C4554533
7,p value for mra vs no mra,C0243032;C1609165;C1709380;C3891069
7,p value for interactiont,C1709380
7,p value for interaction ® vertebral fracture at flex baseline :,C0080179;C0168634;C1442488;C1704675;C1709380
7,p value for interaction ®,C1704675;C1709380
7,p value for interaction by region,C0017446;C0205147;C1704675;C1709380
7,p value for interaction ^,C1704675;C1709380
7,p value for interaction ( age groups ) *,C0027362;C1704675;C1709380
7,p value for interaction,C1704675;C1709380
7,p value for,C1709380
7,p value fo interactio,C1709380
7,p value f,C0016327;C1709380
7,p value c,C1709380
7,p value * $nmbr$,C1709380
7,p value *,C1709380
7,p value ( nominal ),C1709380
7,p value ( interaction ),C1704675;C1709380
7,p value $nmbr$ . $nmbr$,C1709380
7,p value $nmbr$,C1709380
7,p value,C1709380
7,p - value ‘ ’,C1709380
7,p - value ¶,C1709380
7,p - value },C1709380
7,p - value vs . placebo,C0032042;C1696465;C1706408;C1709380
7,p - value n / n ( % ),C1709380
7,p - value interaction,C1704675;C1709380
7,p - value for variance,C1709380;C1711260;C2348152
7,p - value for trend across categories,C0683312;C1521798;C1709380;C4554533
7,p - value for trend *,C1521798;C1709380;C4554533
7,p - value for interaction *,C1704675;C1709380
7,p - value for interaction $nmbr$ :,C1704675;C1709380
7,p - value for interaction $nmbr$ . $nmbr$,C1704675;C1709380
7,p - value for interaction,C1704675;C1709380
7,p - value for,C1709380
7,p - value * ' ',C1709380
7,p - value *,C1709380
7,p - value ( vs placebo ),C0032042;C1696465;C1706408;C1709380
7,p - value ( trend ),C1521798;C1709380;C4554533
7,p - value ( overall ),C0282416;C1561607;C1709380
7,p - value ( lnteraction ),C1709380
7,p - value ( interaction ) ≠,C1704675;C1709380
7,p - value ( anova ),C0753802;C1709380
7,p - value ( ancova treatment difference ) a,C0039798;C0087111;C0814908;C1522326;C1533734;C1705169;C1705241;C1705242;C1709380;C3538994;C3887704
7,p - value $nmbr$,C1709380
7,p - value,C1709380
7,p ' value,C1709380
7,nteraction p value,C1709380
7,multivariate p - value,C1709380
7,multivariable or ( $nmbr$ % ci )  p value *,C0008107;C1709380;C3259781
7,interaction p value 中,C1704675;C1709380
7,interaction p value ∗,C1704675;C1709380
7,interaction p value §,C1704675;C1709380
7,interaction p value *,C1704675;C1709380
7,interaction p value $nmbr$ . $nmbr$,C1704675;C1709380
7,interaction p value !,C1704675;C1709380
7,interaction p value,C1704675;C1709380
7,interaction p - value *,C1704675;C1709380
7,interaction p - value $nmbr$,C1704675;C1709380
7,interaction p - value,C1704675;C1709380
7,interaction : treatment by psoriasis p value $nmbr$,C1704675;C1709380;C3258078
7,heterogeneity p value,C0019409;C0242960;C1709380
7,heterogeneity or trend p value,C0019409;C0242960;C1521798;C1709380;C4554533
7,genotype - by - treatment interaction p values *,C0017431;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
7,chi - square p value,C1552646;C1709380
7,bonferroni - adjusted p value  d vs a,C1709380;C1879894
7,bonferroni - adjusted p value  c vs a,C1709380;C1879894
7,bonferroni - adjusted p value  b vs a,C1709380;C1879894
7,adjusted p - value for interaction,C0456081;C1704675;C1709380
7,* the p ‐ value is from the test statistic for testing the interaction between the treatment group and diabetes group .,C0011847;C0011849;C0039593;C0237913;C0374505;C0392366;C0441833;C0687744;C1257890;C1519504;C1704675;C1705428;C1705429;C1709380
7,* p value,C1709380
7,$nmbr$ p value,C1709380
6,plaque score ( $nmbr$ - $nmbr$ ),C0429153
6,plaque ( n  % ),C0011389;C0241148;C0332461;C0333463;C4316797
6,percent of predicted value before bronchodilation ^,C1371299;C1882327;C3537072
6,/ j - valuc ! l,
5,pvalue ∗,
5,pvalue for heterogeneity,C0019409;C0242960
5,pvalue,
5,p value for heterogeneity （ rosiglitazone versus metformin ）,C0019409;C0025598;C0242960;C0289313;C1709380
5,p value for heterogeneity,C0019409;C0242960;C1709380
4,prasugrel or ticagrelor,C1620287;C1999375
4,prasugrel,C1620287
3,outcome measure,C0086749
3,leisure,C0086542
2,physiological measures,C0079809;C0205463;C1879489
2,measures of lung function,C0035245;C0079809;C1879489
2,measures ( mmol / l ),C0079809;C0242485;C1532563;C1879489
2,measures ( % ),C0079809;C1879489
2,measures,C0079809;C1879489
2,measure,C0079809;C0242485
2,lipid measure *,C0023779;C0079809;C0242485
2,efficacy measures,C0079809;C0242485;C1280519;C1707887;C1879489
2,diff_measure,C0079809;C0242485
2,biochemical measures  mean ( sd ),C0079809;C0205474;C0444504;C1879489;C2347634;C2348143;C2699239
1,weeks_measured,C0439230;C0444706;C3541902
1,ldl - c ( measured ) *,C0444706;C3541902
1,ldl - c ( measured )  mean ( sd ),C0444504;C0444706;C2347634;C2348143;C2699239;C3541902
